FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Sawada, H
   Narumi, T
   Kiyohara, M
   Baba, M
AF Sawada, Hideo
   Narumi, Tamikazu
   Kiyohara, Makiko
   Baba, Masanori
TI Preparation of fluoroalkyl end-capped cooligomers/silica nanoparticles:
   A new approach to fluorinated nanoparticle inhibitors of Human
   Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus (SIVmac)
SO JOURNAL OF FLUORINE CHEMISTRY
LA English
DT Article
DE fluorinated oligomer; silica nanoparticle; hybrid; Anti-HIV-1 activity;
   Anti-SIVmac activity
ID SURFACTANT PROPERTIES; OLIGOMERS; INFECTION; PEROXIDES
AB Fluoroalkyl end-capped acrylic acid and sulfonic acid cooligomers reacted with tetraethoxysilane (TEOS) and silica/nanoparticles under alkaline conditions to afford the corresponding cooligomers/silica nanoparticles (mean diameters: 32-173 nm) with a good dispersibility and stability in aqueous and organic media. Interestingly, fluorinated nanoparticles containing carboxy groups were found to exhibit a potent and selective anti-HIV-1 activity in vitro. In contrast, fluorinated cooligomers containing sulfo groups were shown to have a potent and selective anti-SIVmac activity in vitro. (c) 2007 Published by Elsevier B.V.
C1 Hirosaki Univ, Grad Sch Sci & Technol, Dept Frontier Mat Chem, Hirosaki, Aomori 0368561, Japan.
   Kagoshima Univ, Ctr Chron Viral Dis, Grad Sch Med & Dental Sci, Kagoshima 8908520, Japan.
RP Sawada, H (reprint author), Hirosaki Univ, Grad Sch Sci & Technol, Dept Frontier Mat Chem, Hirosaki, Aomori 0368561, Japan.
EM hideosaw@cc.hirosaki-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Ameduri B, 2000, J FLUORINE CHEM, V104, P53, DOI 10.1016/S0022-1139(00)00227-X                                                   
   BABA M, 1994, J ACQ IMMUN DEF SYND, V7, P24
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Johns K, 2000, J FLUORINE CHEM, V104, P5, DOI 10.1016/S0022-1139(00)00251-7                                                   
   NAIDU YM, 1988, J VIROL, V62, P4691
   POPOVIC M, 1984, SCIENCE, V224, P500
   Sawada H, 1996, CHEM REV, V96, P1779, DOI 10.1021/cr9411482                                                               
   Sawada H, 2003, J FLUORINE CHEM, V121, P111, DOI 10.1016/S0022-1139(03)00040-X
   Sawada H, 2001, KOBUNSHI RONBUNSHU, V58, P255, DOI 10.1295/koron.58.255                                                            
   Sawada H, 2001, KOBUNSHI RONBUNSHU, V58, P147, DOI 10.1295/koron.58.147                                                            
   Sawada H, 1996, J FLUORINE CHEM, V77, P51, DOI 10.1016/0022-1139(95)03378-5                                                    
   Sawada H, 1996, J FLUORINE CHEM, V79, P149, DOI 10.1016/S0022-1139(96)03476-8                                                   
   SAWADA H, 1994, LANGMUIR, V10, P994, DOI 10.1021/la00016a005                                                             
NR 13
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0022-1139
J9 J FLUORINE CHEM
JI J. Fluor. Chem.
PD NOV
PY 2007
VL 128
IS 11
BP 1416
EP 1420
DI 10.1016/j.jfluchem.2007.05.023
PG 5
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
SC Chemistry
GA 229OU
UT WOS:000250814700012
DA 2018-01-05
ER

PT J
AU Mai, A
   Artico, M
   Rotili, D
   Tarantino, D
   Clotet-Codina, I
   Armand-Ugoon, M
   Ragno, R
   Simeoni, S
   Sbardella, G
   Nawrozkij, MB
   Samuele, A
   Maga, G
   Estee, JA
AF Mai, Antonello
   Artico, Marino
   Rotili, Dante
   Tarantino, Domenico
   Clotet-Codina, Imma
   Armand-Ugon, Mercedes
   Ragno, Rino
   Simeoni, Silvia
   Sbardella, Gianluca
   Nawrozkij, Maxim B.
   Samuele, Alberta
   Maga, Giovanni
   Este, Jose A.
TI Synthesis and biological properties of novel 2-Aminopyrimidin-4(3H)-ones
   highly potent against HIV-1 mutant strains
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; IMMUNODEFICIENCY-VIRUS TYPE-1;
   STRUCTURE-BASED DESIGN; S-DABO SERIES; PROTEIN DATA-BANK; ANTI-HIV-1
   ACTIVITY; 3,4-DIHYDRO-2-ALKOXY-6-BENZYL-4-OXOPYRIMIDINES DABOS;
   NONNUCLEOSIDE INHIBITORS; BINDING MODE; ANTIVIRAL ACTIVITY
AB Following the disclosure of dihydro-alkoxy-, dihydro-alkylthio-, and dihydro-alkylamino-benzyl-oxopyrimidines (DABOs, S-DABOs, and NH-DABOs) as potent and selective anti-HIV-1 agents belonging to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, we report here the synthesis and biological evaluation of a novel series of DABOs bearing a NN-disubstituted amino group or a cyclic amine at the pyrimidine-C, position, a hydrogen atom or a small alkyl group at C-5 and/or at the benzylic position, and the favorable 2,6-difluorobenzyl moiety at the C-6 position (F,NN-DABOs). The new compounds were highly active up to the subnanomolar level against both wt HIV-1 and the Y181C mutant and at the submicromolar to nanomolar range against the K103N and Y188L mutant strains. Such derivatives were more potent than S-DABOs, NH-DABOs, and nevirapine and efavirenz were chosen as reference drugs. The higher inhibitor adaptability to the HIV- I RT non-nucleoside binding site (NNBS) may account for the higher inhibitory effect exerted by the new molecules against the mutated RTs.
C1 Univ Roma La Sapienza, Dipartimento Farmaceut, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy.
   Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Retrovirol Lab IrsiCaixa, Badalona 08916, Spain.
   Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, SA, Italy.
   Volgograd State Tech Univ, Volgograd 400131, Russia.
   CNR, IGM, I-27100 Pavia, Italy.
RP Mai, A (reprint author), Univ Roma La Sapienza, Dipartimento Farmaceut, Ist Pasteur Fdn Cenci Bolognetti, P le A Moro 5, I-00185 Rome, Italy.
EM antonello.mai@uniromal.it
RI Este, Jose/B-5509-2008; Rotili, Dante/J-9157-2016; Sbardella,
   Gianluca/E-2823-2010; Nawrozkij, Maxim/N-6646-2015; Maga,
   Giovanni/C-5409-2009
OI Este, Jose/0000-0002-1436-5823; Sbardella, Gianluca/0000-0003-0748-1145;
   Nawrozkij, Maxim/0000-0001-5432-1326; Maga,
   Giovanni/0000-0001-8092-1552; Ragno, Rino/0000-0001-5399-975X; Rotili,
   Dante/0000-0002-8428-8763; Mai, Antonello/0000-0001-9176-2382
CR Armand-Ugon M, 2005, VIROLOGY, V343, P141, DOI 10.1016/j.virol.2005.08.007
   ARTICO M, 1993, ANTIVIR CHEM CHEMOTH, V4, P361, DOI 10.1177/095632029300400608                                                      
   Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   Balzarini J, 2004, CURR TOP MED CHEM, V4, P921, DOI 10.2174/1568026043388420                                                        
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   Berman HM, 2003, PROTEIN STRUCTURE: DETERMINATION, ANALYSIS, AND APPLICATIONS FOR DRUG DISCOVERY, P389
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BOTTA M, 1992, EUR J MED CHEM, V27, P251, DOI 10.1016/0223-5234(92)90009-P
   Cabana M, 1999, J MED VIROL, V59, P480, DOI 10.1002/(SICI)1096-9071(199912)59:4<480::AID-JMV10>3.0.CO;2-8                   
   Campiani G, 2002, CURR PHARM DESIGN, V8, P615, DOI 10.2174/1381612024607207                                                        
   Cancio R, 2007, CHEMMEDCHEM, V2, P445, DOI 10.1002/cmdc.200600310
   Danel K, 1998, J MED CHEM, V41, P191, DOI 10.1021/jm970443m
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   Deshpande N, 2005, NUCLEIC ACIDS RES, V33, pD233
   Ettorre A, 1996, ACTA CRYSTALLOGR C, V52, P2115, DOI 10.1107/S0108270196006117                                                       
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   He YP, 2004, BIOORG MED CHEM LETT, V14, P3173, DOI 10.1016/j.bmcl.2004.04.008
   HUANG CC, 1996, CHIMERA EXTENSIBLE M, P724
   Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm.020406h
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Ji L, 2007, J MED CHEM, V50, P1778, DOI 10.1021/jm061167r
   Lather V, 2005, BIOORGAN MED CHEM, V13, P1599, DOI 10.1016/j.bmc.2004.12.014
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mai A, 2005, BIOORGAN MED CHEM, V13, P2065, DOI 10.1016/j.bmc.2005.01.005
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   MAI A, 1995, J MED CHEM, V38, P3258, DOI 10.1021/jm00017a010
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   MARONGIU ME, 2001, RRD MED CHE, V1, P65
   MARTIN ACR, PROFIT 2 2
   MASSA S, 1995, ANTIVIR CHEM CHEMOTH, V6, P1
   MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806
   Motakis D, 2002, ANTIMICROB AGENTS CH, V46, P1851, DOI 10.1128/AAC.46.6.1851-1856.2002
   Pani Alessandra, 2001, Antiviral Chemistry and Chemotherapy, V12, P51
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Quaglia MG, 2001, CHIRALITY, V13, P75, DOI 10.1002/1520-636X(2001)13:2<75::AID-CHIR1001>3.0.CO;2-W                         
   Ragno R, 2005, J MED CHEM, V48, P213, DOI 10.1021/jm040854k
   Ragno R, 2005, J MED CHEM, V48, P200, DOI 10.1021/jm0493921
   Ragno R, 2004, J MED CHEM, V47, P1351, DOI 10.1021/jm031036f
   Ragno R, 2004, J MED CHEM, V47, P928, DOI 10.1021/jm0309856
   Ragno R, 2007, J MED CHEM, V50, P1241, DOI 10.1021/jm061213n
   Sankatsing SUC, 2003, AIDS, V17, P2623, DOI 10.1097/01.aids.0000096860.36052.03
   Sbardella G, 2001, ANTIVIR CHEM CHEMOTH, V12, P37, DOI 10.1177/095632020101200102                                                      
   Sbardella G, 2000, MED CHEM RES, V10, P30
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Sorbera LA, 2003, DRUG FUTURE, V28, P1149, DOI 10.1358/dof.2003.028.12.772681                                                  
   Sudbeck EA, 1998, ANTIMICROB AGENTS CH, V42, P3225
   TRAMONTANO E, 1994, MICROBIOLOGICA, V17, P269
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
   Wainberg MA, 2003, JAIDS-J ACQ IMM DEF, V34, pS2, DOI 10.1097/00126334-200309011-00002
   *WHO UNAIDS, 2003, AIDS EP UPD
   Williams IG, 2003, INT J CLIN PRACT, V57, P890
NR 62
TC 50
Z9 51
U1 2
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 1
PY 2007
VL 50
IS 22
BP 5412
EP 5424
DI 10.1021/jm070811e
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 225ZO
UT WOS:000250557100019
PM 17910429
DA 2018-01-05
ER

PT J
AU Patel, LN
   Zaro, JL
   Shen, WC
AF Patel, Leena N.
   Zaro, Jennica L.
   Shen, Wei-Chiang
TI Cell penetrating peptides: Intracellular pathways and pharmaceutical
   perspectives
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE cell penetrating peptides; endocytosis; intracellular pathways; membrane
   transduction peptides; protein transduction domains; transduction
ID HIV-1 TAT PROTEIN; HUMAN-IMMUNODEFICIENCY-VIRUS; ARGININE-RICH PEPTIDES;
   HEPARAN-SULFATE PROTEOGLYCANS; MEMBRANE-PERMEABLE PEPTIDES;
   VECTOR-MEDIATED STRATEGY; BLOOD-BRAIN-BARRIER; IN-VIVO; TRANSDUCTION
   DOMAIN; FUSION PROTEINS
AB Cell penetrating peptides, generally categorized as amphipathic or cationic depending on their sequence, are increasingly drawing attention as a non-invasive delivery technology for macromolecules. Delivery of a diverse set of cargo in terms of size and nature ranging from small molecules to particulate cargo has been attempted using different types of cell penetrating peptides (CPPs) in vitro and in vivo. However, the internalization mechanism of CPPs is an unresolved issue to date, with dramatic changes in view regarding the involvement of endocytosis as a pathway of internalization. A key reason for the lack of consensus on the mechanism can be attributed to the methodology in deciphering the internalization mechanism. In this review, we highlight some of the methodology concerns, focus more on the internalization pathway and also provide a novel perspective about the intracellular processing of CPPs, which is a crucial aspect to consider when selecting a cell penetrating peptide as a drug delivery system. In addition, recent applications of cell penetrating peptides for the delivery of small molecules, peptides, proteins, oligonucleotides, nanoparticles and liposomes have been reviewed.
C1 Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA.
RP Shen, WC (reprint author), Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA.
EM weishen@usc.edu
RI Zaro, Jennica/E-3536-2010; Zaro, Jennica/B-4899-2011
FU NIGMS NIH HHS [GM070777]; NHLBI NIH HHS [HL64365]
CR Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873
   ADAM T, 2003, COST EFFECTIVENESS R, V1, DOI DOI 10.1186/1478-7547-1-3
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Binder H, 2003, BIOPHYS J, V85, P982, DOI 10.1016/S0006-3495(03)74537-8
   Brunner J, 2006, BIOCHEMISTRY-US, V45, P12295, DOI 10.1021/bi061198o
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Cao LM, 2006, MOL CELLS, V21, P104
   Chaloin L, 2001, BIOCONJUGATE CHEM, V12, P691, DOI 10.1021/bc000125t
   Chen BX, 2002, IMMUNOL LETT, V84, P63, DOI 10.1016/S0165-2478(02)00146-3
   Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547                                                    
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Diem R, 2005, NEUROBIOL DIS, V20, P218, DOI 10.1016/j.nbd.2005.03.003
   Dietz GPH, 2006, BRAIN RES, V1082, P61, DOI 10.1016/j.brainres.2006.01.083
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Elmquist A, 2003, BIOL CHEM, V384, P387, DOI 10.1515/BC.2003.044                                                             
   Fahraeus R, 1998, ONCOGENE, V16, P587, DOI 10.1038/sj.onc.1201580                                                          
   Falnes PO, 2001, BIOCHEMISTRY-US, V40, P4349, DOI 10.1021/bi002443l
   Fernandez-Carneado J, 2004, BIOPOLYMERS, V76, P196, DOI 10.1002/bip.10585
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fretz M, 2006, J CONTROL RELEASE, V116, P247, DOI 10.1016/j.jconrel.2006.07.009
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   Garden OA, 2006, J IMMUNOL METHODS, V314, P123, DOI 10.1016/j.jim.2006.06.010
   GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5                                                    
   Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001
   GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245
   Goncalves E, 2005, BIOCHEMISTRY-US, V44, P2692, DOI 10.1021/bi048046i
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hakansson S, 2003, BIOCHEMISTRY-US, V42, P8999, DOI 10.1021/bi020715+
   Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1
   Ho A, 2001, CANCER RES, V61, P474
   Hosotani R, 2002, CLIN CANCER RES, V8, P1271
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Inoue M, 2004, INT J ONCOL, V25, P713
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200
   Khalil IA, 2004, GENE THER, V11, P636, DOI 10.1038/sj.gt.3302128
   Kilk K, 2005, J CONTROL RELEASE, V103, P511, DOI 10.1016/j.jconrel.2004.12.006
   Kim WL, 2006, MOL THER, V14, P343, DOI 10.1016/j.ymthe.2006.03.022
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   KOLSON DL, 1994, J GEN VIROL, V75, P1927, DOI 10.1099/0022-1317-75-8-1927
   Law B, 2006, MOL CANCER THER, V5, P1944, DOI 10.1158/1535-7163.MCT-05-0509
   Lechardeur D, 2006, HUM GENE THER, V17, P882, DOI 10.1089/hum.2006.17.882
   Lee HJ, 2001, BIOCONJUGATE CHEM, V12, P995, DOI 10.1021/bc0155061
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Liang JF, 2005, BIOCHEM BIOPH RES CO, V335, P734, DOI 10.1016/j.bbrc.2005.07.142
   Lindgren M, 2006, BIOCHEM PHARMACOL, V71, P416, DOI 10.1016/j.bcp.2005.10.048
   Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760
   Liu ZH, 2005, J CONTROL RELEASE, V102, P699, DOI 10.1016/j.jconrel.2004.10.013
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Maiolo JR, 2004, J AM CHEM SOC, V126, P15376, DOI 10.1021/ja044867z
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Muratovska A, 2004, FEBS LETT, V558, P63, DOI 10.1016/S0014-5793(03)01505-9
   Myou S, 2003, J EXP MED, V198, P1573, DOI 10.1084/jem.20030298
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x                                              
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Ross MF, 2004, BIOCHEM SOC T, V32, P1072, DOI 10.1042/BST0321072                                                              
   Ross MF, 2004, BIOCHEM J, V383, P457, DOI 10.1042/BJ20041095
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   RYSER HJP, 1978, P NATL ACAD SCI USA, V75, P3867, DOI 10.1073/pnas.75.8.3867                                                          
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Sakai N, 2005, CHEMBIOCHEM, V6, P114, DOI 10.1002/cbic.200400256
   Sakai N, 2003, J AM CHEM SOC, V125, P14348, DOI 10.1021/ja0376011
   Salamon Z, 2003, BIOPHYS J, V84, P1796, DOI 10.1016/S0006-3495(03)74987-X                                                   
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Scheller A, 1999, J PEPT SCI, V5, P185, DOI 10.1002/(SICI)1099-1387(199904)5:4<185::AID-PSC184>3.0.CO;2-9
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SHEN WC, 1978, P NATL ACAD SCI USA, V75, P1872, DOI 10.1073/pnas.75.4.1872
   Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Shokolenko IN, 2005, DNA REPAIR, V4, P511, DOI 10.1016/j.dnarep.2004.11.009
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Snyder Eric L, 2005, Expert Opin Drug Deliv, V2, P43, DOI 10.1517/17425247.2.1.43
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1
   Takeuchi T, 2006, ACS CHEM BIOL, V1, P299, DOI 10.1021/cb600127m
   Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Trehin R, 2004, BIOCHEM J, V382, P945, DOI 10.1042/BJ20040238                                                              
   Trehin R, 2004, EUR J PHARM BIOPHARM, V58, P209, DOI 10.1016/j.ejpb.2004.02.018
   Trehin R, 2004, PHARM RES, V21, P1248, DOI 10.1023/B:PHAM.0000033013.45204.c3
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Tung CH, 2003, ADV DRUG DELIVER REV, V55, P281, DOI 10.1016/S0169-409X(02)00183-7
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2002, J AM CHEM SOC, V124, P13382, DOI 10.1021/ja0275109
   Wu HY, 2003, NEUROSCI RES, V47, P131, DOI 10.1016/S0168-0102(03)00195-0
   Yan H, 2006, ONCOGENE, V25, P6968, DOI 10.1038/sj.onc.1209676
   YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451
   Yang LL, 2003, CANCER RES, V63, P831
   Zaro JL, 2006, MOL PHARMACEUT, V3, P181, DOI 10.1021/mp0500869
   Zaro JL, 2005, J CONTROL RELEASE, V108, P409, DOI 10.1016/j.jconrel.2005.08.028
   Zaro JL, 2005, EXP CELL RES, V307, P164, DOI 10.1016/j.yexcr.2005.02.024
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
   Zielinski J, 2006, P NATL ACAD SCI USA, V103, P1557, DOI 10.1073/pnas.0510611103
   Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010
NR 145
TC 286
Z9 293
U1 7
U2 94
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD NOV
PY 2007
VL 24
IS 11
BP 1977
EP 1992
DI 10.1007/s11095-007-9303-7
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 215IS
UT WOS:000249802500001
PM 17443399
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Wan, L
   Pooyan, S
   Hu, P
   Leibowitz, MJ
   Stein, S
   Sinko, PJ
AF Wan, Li
   Pooyan, Shahriar
   Hu, Peidi
   Leibowitz, Michael J.
   Stein, Stanley
   Sinko, Patrick J.
TI Peritoneal macrophage uptake, pharmacokinetics and biodistribution of
   macrophage-targeted PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine)
   nanocarriers for improving HIV drug delivery
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE biodistribution; HIV; PEG-fMLF nanocarrier; peritoneal macrophage;
   pharmacokinetic
ID ACTIVE ANTIRETROVIRAL THERAPY; PEGYLATED INTERFERONS; PROTEIN
   PEGYLATION; INFECTION; RESERVOIR; CELLS; REPLICATION; MONOCYTES;
   GLYCOL); PEPTIDE
AB To assess in vivo macrophage targeting potential of PEG-fMLF nanocarriers and to investigate their biodistribution, peritoneal macrophage uptake, and pharmacokinetics.
   Multiple copies of fMLF were conjugated to purchased and novel (branched, peptide-based) PEG nanocarriers. Peritoneal macrophage uptake was evaluated in mice 4 hours after IP administration of fluorescence-labeled PEG-fMLF nanocarriers. Pharmacokinetics and biodistribution were determined in rats after IV administration of tritiated PEG-fMLF nanocarriers.
   Attachment of one, two, or four fMLF copies increased uptake in macrophages by 3.8-, 11.3-, and 23.6-fold compared to PEG without fMLF. Pharmacokinetic properties and tissue distribution also differed between nanocarriers with and without fMLF. Attachment of fMLF residues increased the t(1/2) of PEG(5K) by threefold but decreased the t(1/2) of PEG(20K) by 40%. Attachment of fMLF increased accumulation of nanocarriers into macrophages of liver, kidneys and spleen. However, on a molar basis, penetration was equivalent suggesting nanocarrier size and targeting moieties are important determinants.
   These results demonstrate the feasibility for targeting macrophages, a primary HIV reservoir site. However, these studies also suggest that balancing peripheral tissue penetration (a size-dependent phenomenon) versus target cell uptake specificity remains a challenge to overcome.
C1 Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA.
   Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA.
   Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
   Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA.
RP Sinko, PJ (reprint author), Rutgers State Univ, Dept Pharmaceut, Ernest Mario Sch Pharm, 160 Frelinghuysen Rd, Piscataway, NJ 08854 USA.
EM sinko@rci.rutgers.edu
FU NIAID NIH HHS [R37 AI051214-07, R37 AI051214-06, AI51214, R37
   AI051214-05, AI33789, R01 AI051214, R37 AI051214-08, R37 AI051214]
CR Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Aquaro S, 2002, ANTIVIR RES, V55, P209, DOI 10.1016/S0166-3542(02)00052-9
   Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008                                                
   Burke B, 2002, MACROPHAGE, pxxvii
   Caliceti P, 2003, ADV DRUG DELIVER REV, V55, P1261, DOI 10.1016/S0169-409X(03)00108-X
   Caliceti P, 1999, BIOCONJUGATE CHEM, V10, P638, DOI 10.1021/bc980155k                                                               
   Conover CD, 1998, CANCER CHEMOTH PHARM, V42, P407, DOI 10.1007/s002800050837
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Crowe SM, 2000, J LEUKOCYTE BIOL, V68, P345
   Greenwald RB, 2003, ADV DRUG DELIVER REV, V55, P217, DOI 10.1016/S0169-409X(02)00180-1                                                   
   Greenwald RB, 2001, J CONTROL RELEASE, V74, P159, DOI 10.1016/S0168-3659(01)00331-5                                                   
   Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005
   HARRIS JM, 1991, POLY ETHYLENE GLYCOL
   HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401                                                     
   Hu JH, 2000, J CONTROL RELEASE, V69, P327, DOI 10.1016/S0168-3659(00)00319-9                                                   
   Igarashi T, 2001, P NATL ACAD SCI USA, V98, P658, DOI 10.1073/pnas.021551798
   Koumenis IL, 2000, INT J PHARM, V198, P83, DOI 10.1016/S0378-5173(99)00458-5
   Kozlowski A, 2001, BIODRUGS, V15, P419, DOI 10.2165/00063030-200115070-00001                                                
   Kozlowski A, 2001, J CONTROL RELEASE, V72, P217, DOI 10.1016/S0168-3659(01)00277-2
   Langer R, 2001, SCIENCE, V293, P58, DOI 10.1126/science.1063273                                                         
   Langer R, 1998, NATURE, V392, P5
   LEIJH PCJ, 1984, INFECT IMMUN, V46, P448
   Maesaki S, 2002, CURR PHARM DESIGN, V8, P433, DOI 10.2174/1381612023395916
   Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522
   MONFARDINI C, 1995, BIOCONJUGATE CHEM, V6, P62, DOI 10.1021/bc00031a006
   Pooyan S, 2002, BIOCONJUGATE CHEM, V13, P216, DOI 10.1021/bc0100657
   PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272
   Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3                                                   
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Schrager LK, 1998, JAMA-J AM MED ASSOC, V280, P67, DOI 10.1001/jama.280.1.67                                                           
   SCHUITEMAKER H, 1991, J VIROL, V65, P356
   SHERMAN MR, 1997, CONJUGATION HIGH MOL
   Sonza S, 2001, AIDS, V15, P17, DOI 10.1097/00002030-200101050-00005
   Stebbing J, 2004, NEW ENGL J MED, V350, P1872, DOI 10.1056/NEJMra032395
   Torchilin VP, 2000, EUR J PHARM SCI, V11, pS81, DOI 10.1016/S0928-0987(00)00166-4
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
   VERNONROBERTS B, 1972, MACROPHAGE
   Veronese FM, 1997, J BIOACT COMPAT POL, V12, P196, DOI 10.1177/088391159701200303                                                      
NR 39
TC 23
Z9 23
U1 0
U2 10
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD NOV
PY 2007
VL 24
IS 11
BP 2110
EP 2119
DI 10.1007/s11095-007-9402-5
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 215IS
UT WOS:000249802500016
PM 17701325
OA green_accepted
DA 2018-01-05
ER

PT J
AU Miranda, LP
   Shao, HY
   Williams, J
   Chen, SY
   Kong, T
   Garcia, R
   Chinn, Y
   Fraud, N
   O'Dwyer, B
   Ye, J
   Wilken, J
   Low, DE
   Cagle, EN
   Carnevali, M
   Lee, A
   Song, D
   Kung, A
   Bradburne, JA
   Paliard, X
   Kochendoerfer, GG
AF Miranda, Les P.
   Shao, Haiyan
   Williams, Jason
   Chen, Shiah-Yun
   Kong, Ting
   Garcia, Rod
   Chinn, Yvonne
   Fraud, Nathalie
   O'Dwyer, Bill
   Ye, Jay
   Wilken, Jill
   Low, Donald E.
   Cagle, E. Neil
   Carnevali, Maia
   Lee, Alexander
   Song, Di
   Kung, Ada
   Bradburne, James A.
   Paliard, Xavier
   Kochendoerfer, Gerd G.
TI A chemical approach to the pharmaceutical optimization of an anti-HIV
   protein
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID AMINO-ACIDS; CRYSTAL-STRUCTURE; ENTRY INHIBITORS; CC-CHEMOKINES; RANTES;
   AGGREGATION; ANTAGONIST; CHEMISTRY; PEPTIDE; OLIGOMERIZATION
AB Chemical protein synthesis is important for dissecting the molecular basis of protein function. Here we advance its scope by demonstrating the significant improvement of the multifaceted pharmaceutical profile of small proteins exclusively via a chemical-based approach. The focus of this work centered on CCL-5 (RANTES) derivatives with potent anti-HIV activity. The overall chemical strategy involved a combination of coded and noncoded amino acid mutagenesis, peptide backbone engineering, and site-specific polymer attachment. The ability to alter specific protein residues, as well as precise control of the position and type of polymer attachment, allows for the exploration of specific molecular designs and resulted in novel CCL-5 analogues with significant differences in their respective biochemical and pharmaceutical properties. Using this approach, the complex-interplay of variables contributing to the noncovalent self-association (aggregation) state, CCR-5 specificity, in vivo elimination half-life, and anti-HIV activity of CCL-5-based protein analogues could be empirically evaluated via total chemical synthesis. This work has led to the identification of potent (sub-nanomolar) anti-HIV proteins with significantly improved pharmaceutical profiles, and illustrates the increasing value of protein chemical synthesis in contemporary therapeutic discovery. These antiviral molecules provide a novel mechanism of action for the development of a new generation of anti-HIV therapeutics which are still desperately needed.
C1 Amgen Inc, Thousand Oaks, CA 91320 USA.
   Gryphon Therapeut, San Francisco, CA 94080 USA.
RP Miranda, LP (reprint author), Amgen Inc, 1 Amgen Ctr Dr,MS 29-M-B, Thousand Oaks, CA 91320 USA.
EM lesm@amgen.com
CR Appay V, 1999, J BIOL CHEM, V274, P27505, DOI 10.1074/jbc.274.39.27505
   Bartkowski R, 2002, J PROTEIN CHEM, V21, P137, DOI 10.1023/A:1015364431227
   Blanpain C, 1999, BLOOD, V94, P1899
   CAMARERO JA, 1999, CURRENT PROTOCOLS PR, V18, P1
   CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   CORNISHBOWDEN A, 1984, BIOCHEM J, V219, P345
   Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077
   DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629                                                         
   Hartley O, 2005, CURR PROTEIN PEPT SC, V6, P207, DOI 10.2174/1389203054065400                                                        
   Hartley O, 2004, P NATL ACAD SCI USA, V101, P16460, DOI 10.1073/pnas.0404802101
   Hendrickson TL, 2004, ANNU REV BIOCHEM, V73, P147, DOI 10.1146/annurev.biochem.73.012803.092429
   Hermeling S, 2004, PHARM RES, V21, P897, DOI 10.1023/B:PHAM.0000029275.41323.a6                                              
   Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Kochendoerfer GG, 2003, SCIENCE, V299, P884, DOI 10.1126/science.1079085
   Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288                                                         
   Merrifield Bruce, 1963, J AM CHEM SOC, V85, P2149
   Michael NL, 1999, NAT MED, V5, P740, DOI 10.1038/10462                                                                   
   Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157                                                        
   Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599                                                          
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   Roberts MJ, 2002, ADV DRUG DELIVER REV, V54, P459, DOI 10.1016/S0169-409X(02)00022-4
   Robertson D, 2003, NAT BIOTECHNOL, V21, P470, DOI 10.1038/nbt0503-470                                                             
   Ryu YH, 2006, NAT METHODS, V3, P263, DOI 10.1038/NMETH864
   SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180
   Shao HY, 2005, J AM CHEM SOC, V127, P1350, DOI 10.1021/ja043095w
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004
   SYED R, 1993, BIOCHEMISTRY-US, V32, P6157, DOI 10.1021/bi00075a007
   Tumelty D, 2003, J AM CHEM SOC, V125, P14238, DOI 10.1021/ja037357y
   *UN AIDS WHO, 2003, AIDS EP UPD
   Wilken J, 1999, CHEM BIOL, V6, P43, DOI 10.1016/S1074-5521(99)80019-2
NR 34
TC 6
Z9 6
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 31
PY 2007
VL 129
IS 43
BP 13153
EP 13159
DI 10.1021/ja073982h
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 229QK
UT WOS:000250818900050
PM 17915868
DA 2018-01-05
ER

PT J
AU Savarino, A
   Pistello, M
   D'Ostilio, D
   Zabogli, E
   Taglia, F
   Mancini, F
   Ferro, S
   Matteucci, D
   De Luca, L
   Barreca, ML
   Ciervo, A
   Chimirri, A
   Ciccozzi, M
   Bendinelli, M
AF Savarino, Andrea
   Pistello, Mauro
   D'Ostilio, Daniela
   Zabogli, Elisa
   Taglia, Fabiana
   Mancini, Fabiola
   Ferro, Stefania
   Matteucci, Donatella
   De Luca, Laura
   Barreca, Maria Letizia
   Ciervo, Alessandra
   Chimirri, Alba
   Ciccozzi, Massimo
   Bendinelli, Mauro
TI Human immunodeficiency virus integrase inhibitors efficiently suppress
   feline immunodeficiency virus replication in vitro and provide a
   rationale to redesign antiretroviral treatment for feline AIDS
SO RETROVIROLOGY
LA English
DT Article
ID HIV-1 INTEGRASE; PROTEASE INHIBITORS; CATALYTIC DOMAIN; MODEL; FIV;
   CHLOROQUINE; TRANSPOSASE; RESISTANCE; INFECTION; DESIGN
AB Background: Treatment of feline immunodeficiency virus (FIV) infection has been hampered by the absence of a specific combination antiretroviral treatment (ART). Integrase strand transfer inhibitors (INSTIs) are emerging as a promising new drug class for HIV-1 treatment, and we evaluated the possibility of inhibiting FIV replication using INSTIs.
   Methods: Phylogenetic analysis of lentiviral integrase (IN) sequences was carried out using the PAUP* software. A theoretical three-dimensional structure of the FIV IN catalytic core domain (CCD) was obtained by homology modeling based on a crystal structure of HIV-1 IN CCD. The interaction of the transferred strand of viral DNA with the catalytic cavity of FIV IN was deduced from a crystal structure of a structurally similar transposase complexed with transposable DNA. Molecular docking simulations were conducted using a genetic algorithm (GOLD). Antiviral activity was tested in feline lymphoblastoid MBM cells acutely infected with the FIV Petaluma strain. Circular and total proviral DNA was quantified by real-time PCR.
   Results: The calculated INSTI-binding sites were found to be nearly identical in FIV and HIV-1 IN CCDs. The close similarity of primate and feline lentivirus IN CCDs was also supported by phylogenetic analysis. In line with these bioinformatic analyses, FIV replication was efficiently inhibited in acutely infected cell cultures by three investigational INSTIs, designed for HIV-1 and belonging to different classes. Of note, the naphthyridine carboxamide INSTI, L-870,810 displayed an EC(50) in the low nanomolar range. Inhibition of FIV integration in situ was shown by real-time PCR experiments that revealed accumulation of circular forms of FIV DNA within cells treated with L-870,810.
   Conclusion: We report a drug class (other than nucleosidic reverse transcriptase inhibitors) that is capable of inhibiting FIV replication in vitro. The present study helped establish L-870,810, a compound successfully tested in human clinical trials, as one of the most potent anti-FIV agents ever tested in vitro. This finding may provide new avenues for treating FIV infection and contribute to the development of a small animal model mimicking the effects of ART in humans.
C1 [Savarino, Andrea; D'Ostilio, Daniela; Taglia, Fabiana; Mancini, Fabiola; Ciervo, Alessandra; Ciccozzi, Massimo] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy.
   [Pistello, Mauro; Zabogli, Elisa; Matteucci, Donatella; Bendinelli, Mauro] Univ Pisa, Dept Expt Pathol, I-56127 Pisa, Italy.
   [Ferro, Stefania; De Luca, Laura; Barreca, Maria Letizia; Chimirri, Alba] Univ Messina, Pharmaco Chem Dept, I-98168 Messina, Italy.
RP Savarino, A (reprint author), Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Viale Regina Elena 299, I-00161 Rome, Italy.
EM andrea.savarino@iss.it; pistello@biomed.unipi.it;
   danieladostilio@hotmail.it; elisazabogli@biomed.unipi.it;
   fabina.taglia@gmail.com; fabiola.mancini@iss.it; sferro@pharma.unime.it;
   domatt@biomed.unipi.it; ldeluca@pharma.unime.it;
   barrecal@pharma.unime.it; alessandra.ciervo@iss.it;
   chimirri@pharma.unime.it; cicozzi@issi.it; bendinelli@biomed.unipi.it
RI CIERVO, ALESSANDRA/C-8812-2016; CICCOZZI, MASSIMO/C-6484-2016; De Luca,
   Laura/D-8532-2011; MANCINI, FABIOLA/C-8818-2016
OI CICCOZZI, MASSIMO/0000-0003-3866-9239; De Luca,
   Laura/0000-0003-0614-5713; Barreca, Maria Letizia/0000-0003-3530-5042
CR Auwerx J, 2004, MOL PHARMACOL, V65, P244, DOI 10.1124/mol.65.1.244
   Barreca ML, 2006, J MED CHEM, V49, P3994, DOI 10.1021/jm060323r
   Barreca ML, 2005, J MED CHEM, V48, P7084, DOI 10.1021/jm050549e
   Bisset LR, 2002, ANTIVIR RES, V53, P35, DOI 10.1016/S0166-3542(01)00190-5                                                   
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   *C REP NATAP, 2007, 14 CROI C RETR OPP I
   Cassone A, 2002, TRENDS MICROBIOL, V10, P177, DOI 10.1016/S0966-842X(02)02341-7
   Ciervo A, 2003, MOL CELL PROBE, V17, P107, DOI 10.1016/S0890-8508(03)00028-8
   Cyranoski D, 2006, NATURE, V444, P812, DOI 10.1038/444812a
   Dayam Raveendra, 2007, Drugs R D, V8, P155, DOI 10.2165/00126839-200708030-00003
   Del Mauro D, 1998, J VIROL, V72, P2199
   DICKER IB, 2007, IN PRESS J BIOL CHEM
   Driscoll CA, 2007, SCIENCE, V317, P519, DOI 10.1126/science.1139518
   Dunham S, 2006, INFEC AGENT, P293
   *EXPASY, EXPASY PROT SERV
   Foley BT., 2000, HIV SEQUENCE COMPEND, P35
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040                                                        
   Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2
   Hall T.A., 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008
   Hartmann K, 2006, INFEC AGENT, P333
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Johnson AA, 2007, MOL PHARMACOL, V71, P893, DOI 10.1124/mol.106.030817
   Lin YC, 2003, J VIROL, V77, P6589, DOI 10.1128/JVI.77.12.6589-6600.2003
   Lombardi S, 1996, VIROLOGY, V220, P274, DOI 10.1006/viro.1996.0315
   Lucia MB, 2005, JAIDS-J ACQ IMM DEF, V40, P257, DOI 10.1097/01.qai.0000181280.68046.23
   Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002
   MATTEUCCI D, 1995, VET IMMUNOL IMMUNOP, V46, P71, DOI 10.1016/0165-2427(94)07007-T
   O'Brien SJ, 2006, BIOL CONSERV, V131, P255, DOI 10.1016/j.biocon.2006.05.001
   Pistello M, 1997, J GEN VIROL, V78, P2247, DOI 10.1099/0022-1317-78-9-2247                                                     
   RCSB, RCSB PROT DAT BANK
   Renoux-Elbe C, 2002, J MOL EVOL, V54, P376, DOI 10.1007/s00239-001-0028-7
   Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166
   Savarino A, 2005, J CLIN VIROL, V34, P170, DOI 10.1016/j.jcv.2005.03.005
   Savarino A, 2004, JAIDS-J ACQ IMM DEF, V35, P223, DOI 10.1097/00126334-200403010-00002
   Savarino A, 2001, AIDS, V15, P2221, DOI 10.1097/00002030-200111230-00002                                                
   Savarino A, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-21
   Savarino A, 2006, EXPERT OPIN INV DRUG, V15, P1507, DOI 10.1517/13543784.15.12.1507
   Shibagaki Y, 1997, VIROLOGY, V230, P1, DOI 10.1006/viro.1997.8466
   Sparger EE, 2006, INFEC AGENT, P149
   Swofford D, PAUP 4 0 PHYLOGENETI
   Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876
   Vahlenkamp TW, 2006, INFEC AGENT, P239
   VINK C, 1994, J VIROL, V68, P1468
   YAMAMOTO JK, 1991, INTERVIROLOGY, V32, P361, DOI 10.1159/000150220                                                               
NR 44
TC 24
Z9 27
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-4690
J9 RETROVIROLOGY
JI Retrovirology
PD OCT 30
PY 2007
VL 4
AR 79
DI 10.1186/1742-4690-4-79
PG 13
WC Virology
SC Virology
GA 265HI
UT WOS:000253349300001
PM 17971219
OA gold
DA 2018-01-05
ER

PT J
AU Guillon, C
   Mayol, K
   Terrat, C
   Compagnon, C
   Primard, C
   Charles, MH
   Delair, T
   Munier, S
   Verrier, B
AF Guillon, Christophe
   Mayol, Katia
   Terrat, Celine
   Compagnon, Christelle
   Primard, Charlotte
   Charles, Marie-Helene
   Delair, Thierry
   Munier, Severine
   Verrier, Bernard
TI Formulation of HIV-1 Tat and p24 antigens by PLA nanoparticles or MF59
   impacts the breadth, but not the magnitude, of serum and faecal antibody
   responses in rabbits
SO VACCINE
LA English
DT Article
DE HIV-1; p24; Tat; PLA nanoparticles; adjuvant
ID HUMORAL IMMUNE-RESPONSES; COATED NANOPARTICLES; VACCINE ANTIGENS;
   DELIVERY SYSTEMS; GUINEA-PIGS; PROTEIN; IMMUNOGENICITY; MICROPARTICLES;
   MICROSPHERES; CELL
AB Biodegradable nanoparticles coated with proteins represent a promising method for in vivo delivery of vaccines. Here we used a rabbit model to compare quantitatively and qualitatively the antibody responses induced by poly(D,L-lactide) nanoparticles (PLA) and by emulsion adjuvant MF59 using three HIV-1 antigens: p24gag, WT Tat and a mutated, detoxified form of Tat. We could show that all antigens and adjuvants lead to the induction of similar level of IgG titres in serum when injected subcutaneously. p24, but not Tat, could also induce faecal IgG in rabbits when formulated with PLA or MF59. The nature of the adjuvant had consequences on the spectrum of specificity induced, depending on the antigen: PLA adjuvant focussed the anti-p24 response to an immunodominant domain when compared to MF59. With wild-type Tat, no difference between adjuvants was observed in the spectrum of specificity induced. On the opposite, detoxified Tat coated on PLA increased the number of epitopes recognized by serum IgG compared to MF59 adjuvantation. The impact of these qualitative differences depending on the antigen/adjuvant associations will be important to take into account for further designs of vaccinal formulation using particulate adjuvants. (c) 2007 Elsevier Ltd. All rights reserved.
C1 CNRS BioMerieux, FRE2736, IFR BioSci Gerland Lyon Sud 128, F-69007 Lyon, France.
   CNRS BioMerieux, UMR2714, IFR BioSci Gerland Lyon Sud 128, F-69007 Lyon, France.
RP Guillon, C (reprint author), Univ Lyon 1, CNRS, Lab Biocristallog,UMR 5086, IBCP,IFR Biosci Gerland Lyon Sud 128, 7 Passage Vercors, F-69007 Lyon, France.
EM c.guillon@ibcp.fr
RI Delair, Thierry/E-7896-2012; guillon, christophe/A-4084-2015
OI guillon, christophe/0000-0001-6378-3303
CR ALMEIDA AJ, 1993, J PHARM PHARMACOL, V45, P198, DOI 10.1111/j.2042-7158.1993.tb05532.x                                              
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Cherkasova EA, 2002, J VIROL, V76, P6791, DOI 10.1128/JVI.76.13.6791-6799.2002
   CHEYNET V, 1993, PROTEIN EXPRES PURIF, V4, P367, DOI 10.1006/prep.1993.1048                                                          
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Donnelly S, 2001, INFECT IMMUN, V69, P4217, DOI 10.1128/IAI.69.7.4217-4223.2001
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Guillon C, 2006, AIDS RES HUM RETROV, V22, P1283, DOI 10.1089/aid.2006.22.1283
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Johansen P, 1999, VACCINE, V18, P209, DOI 10.1016/S0264-410X(99)00191-7                                                   
   KORBER BTM, 2005, HIV MOL IMMUNOLOGY 2
   Lamalle-Bernard D, 2006, J CONTROL RELEASE, V115, P57, DOI 10.1016/j.jconrel.2006.07.006
   MALOY KJ, 1994, IMMUNOLOGY, V81, P661
   Marciani DJ, 2003, DRUG DISCOV TODAY, V8, P934, DOI 10.1016/S1359-6446(03)02864-2
   Mayol K, 2007, VACCINE, V25, P6047, DOI 10.1016/j.vaccine.2007.05.048
   Moreau E, 2004, J GEN VIROL, V85, P2893, DOI 10.1099/vir.0.80365-0
   Moyle P. M., 2004, Current Drug Delivery, V1, P385, DOI 10.2174/1567201043334588
   OHAGAN DT, 1991, IMMUNOLOGY, V73, P239
   Opi S, 2004, VACCINE, V22, P3105, DOI 10.1016/j.vaccine.2004.01.057
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Podda Audino, 2003, Expert Rev Vaccines, V2, P197, DOI 10.1586/14760584.2.2.197
   Shojania S, 2006, J BIOL CHEM, V281, P8347, DOI 10.1074/jbc.M510748200
   Singh M, 2006, VACCINE, V24, P1680, DOI 10.1016/j.vaccine.2005.09.046
   SINGH M, 1991, PHARMACEUT RES, V8, P958, DOI 10.1023/A:1015832302605
   Singh Manmohan, 2006, Current Drug Delivery, V3, P115, DOI 10.2174/156720106775197565
   Storni T, 2005, ADV DRUG DELIVER REV, V57, P333, DOI 10.1016/j.addr.2004.09.008
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
NR 28
TC 29
Z9 29
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD OCT 23
PY 2007
VL 25
IS 43
BP 7491
EP 7501
DI 10.1016/j.vaccine.2007.08.060
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 230QV
UT WOS:000250891900002
PM 17904700
DA 2018-01-05
ER

PT J
AU Zhang, CY
   Johnson, LW
AF Zhang, Chun-Yang
   Johnson, Lawrence W.
TI Quantifying RNA - Peptide interaction by single-quantum dot-based
   nanosensor: An approach fair drug screening
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID RESONANCE ENERGY-TRANSFER; REV-RESPONSIVE ELEMENT; ALPHA-HELIX; RRE RNA;
   FLUORESCENCE; BINDING; PROTEIN; HIV-1; DNA; BIOMOLECULES
AB The sequence-specific RRE RNA-Rev binding is essential for HIV-1 replication and provides a useful in vitro system for real-time evaluating the inhibitory effect of drugs on the RRE-Rev interaction. The rapid and sensitive detection of RRE-Rev interaction in complex biological systems represents a fundamental challenge. Here we report the development of a single-quantum-dot (QD)-based nanosensor for sensitively quantifying Rev peptide-RRE interaction and characterizing the potential inhibitors by virtue of single-molecule detection and QD-based fluorescence resonance energy transfer (FRET). We demonstrate that the stoichiometry of Rev peptide binding to RRE can be accurately determined by using this single-QD-based nanosensor. Importantly, this single-QD-based nanosensor can sensitively quantify the inhibitory efficacy of proflavin on the Rev peptide-RRE binding, even in the presence of substantial levels of interference fluorescence from high-concentration proflavin, which usually prevents the discrimination of FRET signals in ensemble measurements. The application of this nanosensor in the screening of libraries of small-molecule drugs mill facilitate the development of new drugs against various diseases, cancers, and HIV.
C1 CUNY, Dept Chem, CUNY York Coll, Jamaica, NY 11451 USA.
   CUNY, Grad Ctr, Jamaica, NY 11451 USA.
RP Johnson, LW (reprint author), CUNY, Dept Chem, CUNY York Coll, Jamaica, NY 11451 USA.
EM lwj@york.cuny.edu
FU NIGMS NIH HHS [GM08153]
CR Agrawal A, 2006, ANAL CHEM, V78, P1061, DOI 10.1021/ac051801t
   ALIVISATOS AP, 2004, NAT BIOTECHNOL, V22, P47, DOI DOI 10.1038/NBT927
   Anni M, 2004, APPL PHYS LETT, V85, P4169, DOI 10.1063/1.1814795
   Bakalova R, 2005, J AM CHEM SOC, V127, P11328, DOI 10.1021/ja051089h
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   Billinton N, 2001, ANAL BIOCHEM, V291, P175, DOI 10.1006/abio.2000.5006
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Charbonniere LJ, 2006, J AM CHEM SOC, V128, P12800, DOI 10.1021/ja062693a
   Cho JH, 1999, BIOCHEMISTRY-US, V38, P8548, DOI 10.1021/bi990273a                                                               
   Clapp AR, 2004, J AM CHEM SOC, V126, P301, DOI 10.1021/ja037088b
   Clapp AR, 2005, J AM CHEM SOC, V127, P1242, DOI 10.1021/ja045676z
   COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577
   DeJong ES, 2003, BIOCHEMISTRY-US, V42, P8035, DOI 10.1021/bi0345252z
   Goldman ER, 2004, ANAL CHEM, V76, P684, DOI 10.1021/ac035083r
   GULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346
   Hendrix M, 1997, J AM CHEM SOC, V119, P3641, DOI 10.1021/ja964290o                                                               
   Hildebrandt N, 2005, ANGEW CHEM INT EDIT, V44, P7612, DOI 10.1002/anie.200501552
   Hohng S, 2005, CHEMPHYSCHEM, V6, P956, DOI 10.1002/cphc.200400557
   Kagan CR, 1996, PHYS REV LETT, V76, P1517, DOI 10.1103/PhysRevLett.76.1517                                                     
   Kirk SR, 2000, J AM CHEM SOC, V122, P980, DOI 10.1021/ja993387i                                                               
   KJERNS J, 1991, CELL, V67, P169
   Lacourciere KA, 2000, BIOCHEMISTRY-US, V39, P5630, DOI 10.1021/bi992932p
   Medintz IL, 2006, NAT MATER, V5, P581, DOI 10.1038/nmat1676
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   MEDINTZ IL, 2005, NAT MATER, V4, P437
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Myong S, 2005, NATURE, V437, P1321, DOI 10.1038/nature04049
   NIE S, 1997, ANNU REV BIOPH BIOM, V26, P565
   Patolsky F, 2003, J AM CHEM SOC, V125, P13918, DOI 10.1021/ja035848c
   Pons T, 2006, J AM CHEM SOC, V128, P15324, DOI 10.1021/ja0657253
   SHI L, 2007, Z ANAL CHEM, V79, P208
   Shi LF, 2006, J AM CHEM SOC, V128, P10378, DOI 10.1021/ja063509o
   Smith AM, 2006, ANN BIOMED ENG, V34, P3, DOI 10.1007/s10439-005-9000-9
   TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4
   *UNAIDS, 2006, UNAIDA 2006 REP GLOB
   Wang Y, 1997, BIOCHEMISTRY-US, V36, P768, DOI 10.1021/bi962095g
   Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676
   Werstuck G, 1996, CHEM BIOL, V3, P129, DOI 10.1016/S1074-5521(96)90289-6
   Xu XH, 1997, SCIENCE, V275, P1106, DOI 10.1126/science.275.5303.1106
   Yeung ES, 2004, ANNU REV PHYS CHEM, V55, P97, DOI 10.1146/annurev.physchem.54.011002.103820
   ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B
   Zhang CY, 2007, ANGEW CHEM INT EDIT, V46, P3482, DOI 10.1002/anie.200604861
   Zhang CY, 2006, ANAL CHEM, V78, P5532, DOI 10.1021/ac0605389
   Zhang CY, 2005, NAT MATER, V4, P826, DOI 10.1038/nmat1508
   Zhang CY, 2006, J AM CHEM SOC, V128, P5324, DOI 10.1021/ja060537y
   Zhang CY, 2006, ANALYST, V131, P484, DOI 10.1039/b514309h
   Zhou DJ, 2005, CHEM COMMUN, P4807, DOI 10.1039/b508911e
NR 48
TC 32
Z9 33
U1 5
U2 32
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD OCT 15
PY 2007
VL 79
IS 20
BP 7775
EP 7781
DI 10.1021/ac071225w
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 220QW
UT WOS:000250173200024
PM 17877365
DA 2018-01-05
ER

PT J
AU Cullen, MD
   Deng, BL
   Hartman, TL
   Watson, KM
   Buckheit, RW
   Pannecouque, C
   De Clercq, E
   Cushman, M
AF Cullen, Matthew D.
   Deng, Bo-Liang
   Hartman, Tracy L.
   Watson, Karen M.
   Buckheit, Robert W., Jr.
   Pannecouque, Christophe
   De Clercq, Erik
   Cushman, Mark
TI Synthesis and biological evaluation of alkenyldiarylmethane HIV-1
   non-nucleoside reverse transcriptase inhibitors that possess increased
   hydrolytic stability
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ADAM SERIES; AIDS DRUGS; NNRTIS; REPLICATION; MECHANISM; THERAPY;
   DMP-266; ALKENYL; DESIGN; AGENTS
AB Non-nucleoside inhibitors of HIV reverse transcriptase (NNRTIs), albeit not the mainstays of HIV/AIDS treatment, have become increasingly important in highly active antiretroviral therapy (HAART) due to their unique mechanism of action. Several years ago our group identified the alkenyldiarylmethanes (ADAMs) as a potent and novel class of NNRTIs; however, the most active compounds were found to be metabolically unstable. Subsequent work has led to the synthesis of 33 analogues, with improved metabolic profiles, through the replacement of labile esters with various heterocycles, nitriles, and thioesters. As a result, a number of hydrolytically stable NNRTIs were identified with anti-HIV activity in the nanomolar concentration range. Furthermore, an improved pharmacophore model has been developed based on the new ADAM series, in which a salicylic acid-derived aryl ring is oriented cis to the side chain and the aryl ring that is trans to the side chain contains a hydrogen bond acceptor site within the plane of the ring
C1 Purdue Univ, Sch Pharm & Pharmaceut Sci, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.
   Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA.
   Imquest Biosci, Frederick, MD 21704 USA.
   Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Cushman, M (reprint author), Purdue Univ, Sch Pharm & Pharmaceut Sci, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.
EM cushman@pharmacy.purdue.edu
FU NIAID NIH HHS [R01-AI-43637]
CR Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200
   Bean Pamela, 2002, Am Clin Lab, V21, P12
   Casimiro-Garcia A, 1999, J MED CHEM, V42, P4861, DOI 10.1021/jm990343b
   Cushman M, 1998, J MED CHEM, V41, P2076, DOI 10.1021/jm9800595                                                               
   CUSHMAN M, 1995, BIOORG MED CHEM LETT, V5, P2713, DOI 10.1016/0960-894X(95)00465-6
   Cushman M, 1996, J MED CHEM, V39, P3217, DOI 10.1021/jm960082v                                                               
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   Deng BL, 2006, BIOORGAN MED CHEM, V14, P2366, DOI 10.1016/j.bmc.2005.11.014
   Deng BL, 2005, J MED CHEM, V48, P6140, DOI 10.1021/jm050452s
   Deng BL, 2006, J MED CHEM, V49, P5316, DOI 10.1021/jm060449o
   DUEWEKE TJ, 1993, ANTIMICROB AGENTS CH, V37, P1127, DOI 10.1128/AAC.37.5.1127                                                           
   Gottlieb HE, 1997, J ORG CHEM, V62, P7512, DOI 10.1021/jo971176v
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   Keyes RF, 1996, J MED CHEM, V39, P508, DOI 10.1021/jm950666h
   Lindberg J, 2002, EUR J BIOCHEM, V269, P1670, DOI 10.1046/j.1432-1327.2002.02811.x
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   Montaner JSG, 2001, AIDS, V15, P61, DOI 10.1097/00002030-200101050-00010
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   POWDERLY WG, 2002, J ACQ IMMUN DEF SYND, V31, P3
   Rice W G, 1995, Adv Pharmacol, V33, P389, DOI 10.1016/S1054-3589(08)60675-4
   Silvestri MA, 2004, J MED CHEM, V47, P3149, DOI 10.1021/jm049916x
   UNAIDS/ WHO, 2005, AIDS EP UPD, P1
   Walker U A, 2001, J HIV Ther, V6, P17
   Xu GZ, 2001, J MED CHEM, V44, P4092, DOI 10.1021/jm010212m
   Xu GZ, 2001, J ORG CHEM, V66, P5958, DOI 10.1021/jo0100291
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
NR 29
TC 23
Z9 23
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD OCT 4
PY 2007
VL 50
IS 20
BP 4854
EP 4867
DI 10.1021/jm070382k
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 216II
UT WOS:000249871300007
PM 17803290
DA 2018-01-05
ER

PT J
AU La Regina, G
   Coluccia, A
   Piscitelli, F
   Bergamini, A
   Sinistro, A
   Cavazza, A
   Maga, G
   Samuele, A
   Zanoli, S
   Novellino, E
   Artico, M
   Silvestri, R
AF La Regina, Giuseppe
   Coluccia, Antonio
   Piscitelli, Francesco
   Bergamini, Alberto
   Sinistro, Anna
   Cavazza, Antonella
   Maga, Giovanni
   Samuele, Alberta
   Zanoli, Samantha
   Novellino, Ettore
   Artico, Marino
   Silvestri, Romano
TI Indolyl aryl Sulfones as HIV-1 non-nucleoside reverse transcriptase
   inhibitors: Role of two halogen atoms at the indole ring in developing
   new analogues with improved antiviral activity
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RESISTANCE MUTATIONS; DESIGN;
   DERIVATIVES; STRATEGIES; VARIANTS; THERAPY
AB Indolyl aryl sulfones bearing the 4,5-difluoro (10) or 5-chloro-4-fluoro (16) substitution pattern at the indole ring were potent inhibitors of HIV-1 WT and the NNRTI-resistant strains Y181C and K103N-Y181C. These compounds were highly effective against the 112 and the AB1 strains in lymphocytes and inhibited at nanomolar concentration the multiplication of the IIIBBa-L strain in macrophages. Compound 16 was exceptionally potent against RT WT and RTs carrying the K103N, Y181I, and L100I mutations.
C1 Univ Roma La Sapienza, Dipartimento Farmaceut, Inst Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy.
   Univ Naples Federico 2, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy.
   CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   Univ Roma Tor Vergata, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy.
RP Silvestri, R (reprint author), Univ Roma La Sapienza, Dipartimento Farmaceut, Inst Pasteur, Fdn Cenci Bolognetti, Piazzle Aldo Moro 5, I-00185 Rome, Italy.
EM romano.silvestri@uniromal.it
RI La Regina, Giuseppe/I-2161-2012; Maga, Giovanni/C-5409-2009
OI La Regina, Giuseppe/0000-0003-3252-1161; Maga,
   Giovanni/0000-0001-8092-1552; Silvestri, Romano/0000-0003-2489-0178;
   /0000-0002-7940-8206; Novellino, Ettore/0000-0002-2181-2142; Cavazza,
   Antonella/0000-0002-2885-4839
CR Artico M, 1996, BIOORGAN MED CHEM, V4, P837, DOI 10.1016/0968-0896(96)00075-2                                                    
   Artico M, 2000, J MED CHEM, V43, P1886, DOI 10.1021/jm9901125
   Artico M, 1996, J MED CHEM, V39, P522, DOI 10.1021/jm950568w
   Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1
   Corbett JW, 1999, ANTIMICROB AGENTS CH, V43, P2893
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   De Clercq E, 2002, MINI-REV MED CHEM, V2, P163, DOI 10.2174/1389557024605474
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DEMARTINO G, 2006, ANTIVIR CHEM CHEMOTH, V57, P59
   Gagliardi S, 1998, J MED CHEM, V41, P1568, DOI 10.1021/jm9800144
   HEARHBROWN B, 1965, J CHEM SOC, P7185
   Li XH, 2005, JAIDS-J ACQ IMM DEF, V38, P320
   Opar A, 2007, NAT REV DRUG DISCOV, V6, P258, DOI 10.1038/nrd2294
   Orkin C, 2005, J ANTIMICROB CHEMOTH, V55, P246, DOI 10.1093/jac/dkh515
   Ragno R, 2005, J MED CHEM, V48, P213, DOI 10.1021/jm040854k
   Ragno R, 2006, J MED CHEM, V49, P3172, DOI 10.1021/jm0512490
   Robinson B., 1982, FISCHER INDOLE SYNTH
   Silvestri R, 2004, J MED CHEM, V47, P3892, DOI 10.1021/jm031147e
   Silvestri R, 2004, ARKIVOC, P26
   Silvestri R, 2003, J MED CHEM, V46, P2482, DOI 10.1021/jm0211063
   SILVESTRI R, 2002, ORG PREP PROCED INT, V34, P507
   UNAIDS: Joint United Nations Programme on HIV/AIDS, 2006, REP GLOB AIDS EP 200
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
   Wang LX, 2007, CURR PHARM DESIGN, V13, P127, DOI 10.2174/138161207779313641                                                      
   Williams IG, 2003, INT J CLIN PRACT, V57, P890
   LACOLLA P, 2002, Patent No. 20020831296
NR 26
TC 21
Z9 22
U1 1
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD OCT 4
PY 2007
VL 50
IS 20
BP 5034
EP 5038
DI 10.1021/jm070488f
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 216II
UT WOS:000249871300022
DA 2018-01-05
ER

PT J
AU Lisziewicz, J
   Calarota, SA
   Lori, F
AF Lisziewicz, Julianna
   Calarota, Sandra A.
   Lori, Franco
TI The potential of topical DNA vaccines adjuvanted by cytokines
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE cellular immunity; cytokine adjuvant; dendritic cells; DermaVir; HIV-1;
   Langerhans cells; topical DNA vaccines
ID COLONY-STIMULATING FACTOR; CELLULAR IMMUNE-RESPONSES; MEMORY T-CELLS;
   IMMUNODEFICIENCY-VIRUS TYPE-1; PROLONGED VIRAL SUPPRESSION; EPIDERMAL
   LANGERHANS CELLS; ANTIGEN-PRESENTING CELLS; HERPES-SIMPLEX VIRUS-2;
   IN-VIVO; RHESUS MACAQUES
AB To improve the efficacy of DNA immunization epidermal Langerhans cells are attractive targets to deliver antigen-encoding plasmid DNA. Topical vaccination with naked plasmid DNA has been shown to induce immune responses, and their potency might be improved by chemical and physical methods aimed to enhance the efficiency of plasmid DNA delivery into the skin. Cytokines have also been evaluated as adjuvants for DNA vaccines because they influence the host immune response. This review focuses on the action of several cytokines tested as molecular adjuvants for DNA vaccines and the combination of them with the DermaVir Patch vaccine. DermaVir vaccine, topically administered under a patch, consists of a plasmid DNA that is chemically formulated into a nanoparticle to support vaccine delivery into epidermal Langerhans cells and to induce antigen-specific memory T cells.
C1 Fdn IRCCS Policlin, Res Inst Genet & Human Therapy, I-27100 Pavia, Italy.
RP Lori, F (reprint author), Fdn IRCCS Policlin, Res Inst Genet & Human Therapy, San Matteo Ple Golgi 2, I-27100 Pavia, Italy.
EM rightpv@tin.it
CR ARMITAGE RJ, 1995, J IMMUNOL, V154, P483
   Babiuk S, 2004, J BIOTECHNOL, V110, P1, DOI 10.1016/j.biotec.2004.01.015
   Babiuk S, 2000, J CONTROL RELEASE, V66, P199, DOI 10.1016/S0168-3659(99)00274-6
   Babiuk S, 2003, MOL THER, V8, P992, DOI 10.1016/j.ymthe.2003.09.008
   Babiuk S, 2002, VACCINE, V20, P3399, DOI 10.1016/S0264-410X(02)00269-4
   Bachy M, 2001, VACCINE, V19, P1688, DOI 10.1016/S0264-410X(00)00406-0
   Barouch DH, 2000, P NATL ACAD SCI USA, V97, P4192, DOI 10.1073/pnas.050417697
   Barouch DH, 2004, IMMUNOL REV, V202, P266, DOI 10.1111/j.0105-2896.2004.00200.x
   Barouch DH, 2004, VACCINE, V22, P3092, DOI 10.1016/j.vaccine.2004.01.065
   Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Barouch DH, 1998, J IMMUNOL, V161, P1875
   Barouch DH, 2002, J IMMUNOL, V168, P562, DOI 10.4049/jimmunol.168.2.562                                                      
   Berry LJ, 2004, INFECT IMMUN, V72, P1019, DOI 10.1128/IAI.72.2.1019-1028.2004
   Bieber T, 2002, J CONTROL RELEASE, V82, P441, DOI 10.1016/S0168-3659(02)00129-3
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Boyer JD, 2005, J MED PRIMATOL, V34, P262, DOI 10.1111/j.1600-0684.2005.00124.x
   Calarota SA, 2004, IMMUNOL REV, V199, P84, DOI 10.1111/j.0105-2896.2004.00150.x
   Calarota SA, 2007, VACCINE, V25, P3070, DOI 10.1016/j.vaccine.2007.01.024
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   Chabalgoity JA, 2007, CYTOKINE GROWTH F R, V18, P195, DOI 10.1016/j.cytogfr.2007.01.016
   Chattergoon MA, 2004, VACCINE, V22, P1744, DOI 10.1016/j.vaccine.2004.01.036
   Chong SY, 2007, VACCINE, V25, P4967, DOI 10.1016/j.vaccine.2006.11.070
   Chow YH, 1998, J IMMUNOL, V160, P1320
   Chow YH, 1997, J VIROL, V71, P169
   Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122
   Coulman Sion A., 2006, Current Drug Delivery, V3, P65, DOI 10.2174/156720106775197510
   Cristillo AD, 2007, VIROLOGY, V366, P197, DOI 10.1016/j.virol.2007.04.012
   Cumberbatch M, 2000, CLIN EXP DERMATOL, V25, P413, DOI 10.1046/j.1365-2230.2000.00678.x
   Drabick JJ, 2001, MOL THER, V3, P249, DOI 10.1006/mthe.2000.0257
   Dujardin N, 2001, PHARMACEUT RES, V18, P61, DOI 10.1023/A:1011026726938                                                         
   Fan HR, 1999, NAT BIOTECHNOL, V17, P870
   Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14                                                          
   Finzi D, 1999, NAT MED, V5, P512
   Geissler M, 1997, J IMMUNOL, V158, P1231
   Gherardi MM, 2000, J VIROL, V74, P6278, DOI 10.1128/JVI.74.14.6278-6286.2000
   Giri M, 2004, CLIN MICROBIOL REV, V17, P370, DOI 10.1128/CMR.17.2.370-389.2004
   HEUFLER C, 1993, J EXP MED, V178, P1109, DOI 10.1084/jem.178.3.1109                                                          
   HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700
   Hooper JW, 2007, VACCINE, V25, P1814, DOI 10.1016/j.vaccine.2006.11.017
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   Kamiya H, 2001, ADV DRUG DELIVER REV, V52, P153, DOI 10.1016/S0169-409X(01)00216-2
   Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433                                                                
   Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714                                                                
   Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675                                                     
   Kendall M, 2004, J BIOMECH, V37, P1733, DOI 10.1016/j.jbiomech.2004.01.032
   Kieper WC, 2002, J EXP MED, V195, P1533, DOI 10.1084/jem.20020067
   Kim JJ, 1997, J IMMUNOL, V158, P816
   Kim JJ, 1999, J MED PRIMATOL, V28, P214, DOI 10.1111/j.1600-0684.1999.tb00272.x                                              
   Kim JJ, 1999, J INTERF CYTOK RES, V19, P77, DOI 10.1089/107999099314441
   Kim JJ, 2000, J VIROL, V74, P3427, DOI 10.1128/JVI.74.7.3427-3429.2000
   Kim JJ, 1998, EUR J IMMUNOL, V28, P1089, DOI 10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L
   Kim JJ, 2001, VACCINE, V19, P2496, DOI 10.1016/S0264-410X(00)00479-5                                                   
   Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675
   Kumar S, 2002, IMMUNOL LETT, V81, P13, DOI 10.1016/S0165-2478(01)00316-9                                                   
   Kutzler MA, 2005, J IMMUNOL, V175, P112, DOI 10.4049/jimmunol.175.1.112                                                      
   LabatMoleur F, 1996, GENE THER, V3, P1010
   Larregina AT, 2001, GENE THER, V8, P608, DOI 10.1038/sj.gt.3301404                                                           
   LENZ A, 1993, J CLIN INVEST, V92, P2587, DOI 10.1172/JCI116873
   Letvin NL, 2006, SCIENCE, V312, P1530, DOI 10.1126/science.1124226
   Lin MTS, 2000, INT J DERMATOL, V39, P161, DOI 10.1046/j.1365-4362.2000.00925.x                                                
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Lisziewicz Julianna, 2006, Current Drug Delivery, V3, P83, DOI 10.2174/156720106775197574
   Liu ZH, 2001, CHINESE J STRUC CHEM, V20, P1
   Lori F, 2005, VACCINE, V23, P2030, DOI 10.1016/j.vaccine.2005.01.004
   Lori Franco, 2004, Expert Rev Vaccines, V3, pS189, DOI 10.1586/14760584.3.4.S189
   Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727
   Mattapallil JJ, 2006, J EXP MED, V203, P1533, DOI 10.1084/jem.20060657
   McCluskie MJ, 2000, VACCINE, V19, P413, DOI 10.1016/S0264-410X(00)00208-5
   Melchionda F, 2005, J CLIN INVEST, V115, P1177, DOI 10.1172/JCI200523134
   Mikszta JA, 2002, NAT MED, V8, P415, DOI 10.1038/nm0402-415
   Mohamadzadeh M, 2001, J EXP MED, V194, P1013, DOI 10.1084/jem.194.7.1013                                                          
   Moore AC, 2002, J VIROL, V76, P243, DOI 10.1128/JVI.76.1.243-250.2002
   MORRISSEY PJ, 1987, J IMMUNOL, V139, P1113
   Mueller YM, 2003, BLOOD, V101, P1024, DOI 10.1182/blood-2002-07-1957
   NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077
   O'Neill E, 2002, J MED PRIMATOL, V31, P217, DOI 10.1034/j.1600-0684.2002.02008.x
   Oh S, 2003, P NATL ACAD SCI USA, V100, P3392, DOI 10.1073/pnas.0630592100
   Okada E, 1997, J IMMUNOL, V159, P3638
   Orenstein JM, 2000, AIDS, V14, P1709, DOI 10.1097/00002030-200008180-00004
   Otten G, 2004, VACCINE, V22, P2489, DOI 10.1016/j.vaccine.2003.11.073
   Ozaki T, 2005, VIRAL IMMUNOL, V18, P373, DOI 10.1089/vim.2005.18.373
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402                                                     
   Parker SE, 2001, GENE THER, V8, P1011, DOI 10.1038/sj.gt.3301491
   PERTMER TM, 1995, VACCINE, V13, P1427, DOI 10.1016/0264-410X(95)00069-D                                                    
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Prausnitz MR, 2004, ADV DRUG DELIVER REV, V56, P581, DOI 10.1016/j.addr.2003.10.023
   Premenko-Lanier M, 2003, VIROLOGY, V307, P67, DOI 10.1016/S0042-6822(02)00036-3
   RAZ E, 1994, P NATL ACAD SCI USA, V91, P9519, DOI 10.1073/pnas.91.20.9519                                                         
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   Roos AK, 2005, PROSTATE, V62, P217, DOI 10.1002/pros.20135
   Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314
   Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9                                                   
   Rubinstein MP, 2002, J IMMUNOL, V169, P4928, DOI 10.4049/jimmunol.169.9.4928                                                     
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Schadeck EB, 2006, VACCINE, V24, P4677, DOI 10.1016/j.vaccine.2005.10.035
   Scheule RK, 2000, ADV DRUG DELIVER REV, V44, P119, DOI 10.1016/S0169-409X(00)00090-9                                                   
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Seaman MS, 2004, J VIROL, V78, P206, DOI 10.1128/JVI.78.1.206-215.2004
   Sedegah M, 2000, J IMMUNOL, V164, P5905, DOI 10.4049/jimmunol.164.11.5905                                                    
   Sin JI, 2000, CLIN DIAGN LAB IMMUN, V7, P751, DOI 10.1128/CDLI.7.5.751-758.2000
   Sin JI, 1999, J IMMUNOL, V162, P2912
   Sin JI, 1999, J VIROL, V73, P501
   Sin JI, 1998, EUR J IMMUNOL, V28, P3530, DOI 10.1002/(SICI)1521-4141(199811)28:11<3530::AID-IMMU3530>3.0.CO;2-C
   Stoecklinger A, 2007, J IMMUNOL, V179, P886, DOI 10.4049/jimmunol.179.2.886                                                      
   Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179
   Svanholm C, 1997, SCAND J IMMUNOL, V46, P298, DOI 10.1046/j.1365-3083.1997.d01-130.x
   Tang DC, 1997, NATURE, V388, P729, DOI 10.1038/41917                                                                   
   TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G                                                    
   Trimble C, 2003, VACCINE, V21, P4036, DOI 10.1016/S0264-410X(03)00275-5
   TRINCHIERI G, 1994, BLOOD, V84, P4008
   Tsuji T, 1997, J IMMUNOL, V158, P4008
   Vaccari M, 2005, J IMMUNOL, V175, P3502, DOI 10.4049/jimmunol.175.6.3502                                                     
   Villinger F, 2004, VACCINE, V22, P3510, DOI 10.1016/j.vaccine.2003.07.022
   WALDMANN TA, 1991, J BIOL CHEM, V266, P2681
   Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(09)00091-0
   Waldmann TA, 2006, NAT REV IMMUNOL, V6, P595, DOI 10.1038/nri1901
   Watabe S, 2001, VACCINE, V19, P4434, DOI 10.1016/S0264-410X(01)00194-3
   WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002
   Webster DP, 2005, P NATL ACAD SCI USA, V102, P4836, DOI 10.1073/pnas.0406381102
   Weiss WR, 1998, J IMMUNOL, V161, P2325
   Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889
   Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635                                                     
   Xin KQ, 1999, VACCINE, V17, P858, DOI 10.1016/S0264-410X(98)00271-0
   Xin KQ, 1998, IMMUNOLOGY, V94, P438, DOI 10.1046/j.1365-2567.1998.00533.x
   Zhang L, 2002, BBA-GEN SUBJECTS, V1572, P1, DOI 10.1016/S0304-4165(02)00270-2                                                   
   Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6
   Zhao YG, 2006, VACCINE, V24, P897, DOI 10.1016/j.vaccine.2005.093
NR 132
TC 10
Z9 10
U1 2
U2 4
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1471-2598
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD OCT
PY 2007
VL 7
IS 10
BP 1563
EP 1574
DI 10.1517/14712598.7.10.1563                                              
          
PG 12
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 224DM
UT WOS:000250426200009
PM 17916048
DA 2018-01-05
ER

PT J
AU Tang, SX
   Zhao, JQ
   Storhoff, JJ
   Norris, PJ
   Little, RF
   Yarchoan, R
   Stramer, SL
   Patno, T
   Domanus, M
   Dhar, A
   Mirkin, CA
   Hewlett, IK
AF Tang, Shixing
   Zhao, Jiangqin
   Storhoff, James J.
   Norris, Philip J.
   Little, Richard F.
   Yarchoan, Robert
   Stramer, Susan L.
   Patno, Tim
   Domanus, Marc
   Dhar, Arindam
   Mirkin, Chad A.
   Hewlett, Indira K.
TI Nanoparticle-based biobarcode amplification assay (BCA) for sensitive
   and early detection of human immunodeficiency type 1 capsid (p24)
   antigen
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV-1; p24 antigen; nanoparticle; biobarcode; detection
ID HEAT-DENATURED PLASMA; VIRUS TYPE-1; HIV-1 P24; ANTIRETROVIRAL THERAPY;
   SIGNAL AMPLIFICATION; DNA DETECTION; VIRAL-RNA; PROBES; PROTEINS;
   ANTIBODY
AB Nanotechnology-based techniques are being widely evaluated in medical testing and could provide a new generation of diagnostic assays due to their high degrees of sensitivity, high specificity, multiplexing capabilities, and ability to operate without enzymes. In this article, we have modified a nanoparticle-based biobarcode amplification (BCA) assay for early and sensitive detection of HIV-1 capsid (p24) antigen by using antip24 antibody-coated microplates to capture viral antigen (p24) and streptavidin-coated nanoparticle-based biobarcode DNAs for signal amplification, followed by detection using a chip-based scanometric method. The modified BCA assay exhibited a linear dose-dependent pattern within the detection range of 0.1 to 500 pg/ml and was approximately 150-fold more sensitive than conventional enzyme-linked immunosorbent assay (ELISA). No false positive results were observed in 30 HIV-1-negative samples, while all 45 HIV-1 RNA positive samples were found HIV-1 p24 antigen positive by the BCA assay. In addition, the BCA assay detected HIV-1 infection 3 days earlier than ELISA in seroconversion samples. Preliminary evaluation based on testing a small number of samples indicates that the HIV-1 p24 antigen BCA may provide a new tool for sensitive and early detection of HIV 1 p24 antigen in settings where HIV-1 RNA testing is currently not routinely performed.
C1 US FDA, Ctr Biol Evaluat & Res, Mol Virol Lab, Bethesda, MD 20892 USA.
   Nanosphere, N Brook, IL USA.
   Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
   NCI, Natl Inst Hlth, HIV & AIDS Malilgnancy Branch, Bethesda, MD 20892 USA.
   Amer Red Cross, Biomed Serv Sci Support Off, Gaithersburg, MD USA.
   US FDA, NCI, Interagcy Oncol Task Force, Bethesda, MD 20014 USA.
   Northwestern Univ, Dept Chem, Evanston, IL USA.
   Northwestern Univ, Int Inst Nanotechnol, Evanston, IL USA.
RP Tang, SX (reprint author), US FDA, Ctr Biol Evaluat & Res, Mol Virol Lab, Bldg 29B,Rm 4NN16,8800 Rcokville Pike, Bethesda, MD 20892 USA.
EM shixing.tang@fda.hhs.gov; indira.hewlett@fda.hhs.gov
RI Mirkin, Chad/E-3911-2010
CR Bao YP, 2006, ANAL CHEM, V78, P2055, DOI 10.1021/ac051798d
   Barletta JM, 2004, AM J CLIN PATHOL, V122, P20, DOI 10.1309/529T2WDNEB6X8VUN
   BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X                                                    
   Bounou S, 2002, J VIROL, V76, P1004, DOI 10.1128/JVI.76.3.1004-1014.2002
   FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617
   Fiebig EW, 2003, AIDS, V17, P1871, DOI 10.1097/01.aids.0000076308.76477.b8
   Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102
   Kolk DP, 2002, J CLIN MICROBIOL, V40, P1761, DOI 10.1128/JCM.40.5.1761-1766.2002
   LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E
   Ledergerber B, 2000, J INFECT DIS, V181, P1280, DOI 10.1086/315366
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Nam JM, 2005, ANAL CHEM, V77, P6985, DOI 10.1021/ac0513764
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Nam JM, 2003, SCIENCE, V301, P1884, DOI 10.1126/science.1088755
   NISHANIAN P, 1990, J INFECT DIS, V162, P21, DOI 10.1093/infdis/162.1.21                                                         
   Oh BK, 2006, SMALL, V2, P103, DOI 10.1002/smll.200500260
   PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x
   Piwowar-Manning EM, 2003, AM J CLIN PATHOL, V120, P268, DOI 10.1309/TRROFWM9LE9H427M
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Saviranta P, 2004, CLIN CHEM, V50, P1907, DOI 10.1373/clinchem.2004.037929
   Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598
   SCHUPBACH J, 1994, J INFECT DIS, V170, P318, DOI 10.1093/infdis/170.2.318                                                        
   Schupbach J, 2006, J MED VIROL, V78, P1003, DOI 10.1002/jmv.20655
   Schupbach J, 2003, INT ARCH ALLERGY IMM, V132, P196, DOI 10.1159/000074552
   Schupbach J, 2003, JAIDS-J ACQ IMM DEF, V33, P292, DOI 10.1097/00126334-200307010-00002                                                
   Schupbach J, 1996, AIDS, V10, P1085
   Simon JHM, 1997, J VIROL, V71, P5259
   Stoeva SI, 2006, J AM CHEM SOC, V128, P8378, DOI 10.1021/ja0613106
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Storhoff JJ, 2004, BIOSENS BIOELECTRON, V19, P875, DOI 10.1016/j.bios.2003.08.014
   Stramer SL, 2000, TRANSFUSION, V40, P1165, DOI 10.1046/j.1537-2995.2000.40101165.x
   SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502                                                          
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   TERWILLIGER EF, 1989, P NATL ACAD SCI USA, V86, P5163, DOI 10.1073/pnas.86.13.5163
   Thaxton CS, 2006, CLIN CHIM ACTA, V363, P120, DOI 10.1016/j.cccn.2005.05.042
   Vogt VM, 1999, J VIROL, V73, P7050
   Wehrly K, 1997, METHODS, V12, P288, DOI 10.1006/meth.1997.0481
   Yerly S, 2000, AIDS, V14, P243, DOI 10.1097/00002030-200002180-00006
NR 39
TC 55
Z9 60
U1 4
U2 32
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD OCT 1
PY 2007
VL 46
IS 2
BP 231
EP 237
DI 10.1097/QAI.0b013e31814a554b
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 215LO
UT WOS:000249810100015
PM 17693896
OA gold
DA 2018-01-05
ER

PT J
AU Bramer, T
   Dew, N
   Edsman, K
AF Bramer, Tobias
   Dew, Noel
   Edsman, Katarina
TI Pharmaceutical applications for catanionic mixtures
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Review
ID SODIUM DODECYL-SULFATE; ION-PAIR AMPHIPHILE; ANTI-HIV ACTIVITY;
   DODECYLTRIMETHYLAMMONIUM BROMIDE DTAB; PENNIFORM BAWO4 NANOSTRUCTURES;
   SPONTANEOUS VESICLE FORMATION; CATIONIC-ANIONIC SURFACTANTS;
   SINGLE-CHAIN AMPHIPHILES; NEUTRON-SCATTERING SANS; CONTROLLED
   DRUG-RELEASE
AB Mixtures of oppositely charged surfactants, so called catanionic mixtures, are a growing area of research. These mixtures have been shown to form several different types of surfactant aggregates, such as micelles of various forms and sizes, and lamellar structures, such as vesicles. In this review, a short introduction to the field of catanionic mixtures is presented and the pharmaceutical possibilities offered by such mixtures are reviewed. There are several interesting ideas on how to apply catanionic mixtures to improve the delivery of, for example, drug compounds and DNA, or for HIV treatment.
C1 Uppsala Univ, Dept Pharm, SE-75123 Uppsala, Sweden.
RP Edsman, K (reprint author), Q Med AB, Seminariegatan 21, SE-75228 Uppsala, Sweden.
EM k.edsman@q-med.com
CR Almgren M, 2004, LANGMUIR, V20, P6611, DOI 10.1021/la049211y
   AMBUHL M, 1993, LANGMUIR, V9, P36, DOI 10.1021/la00025a011                                                             
   ANACKER EW, 1953, J COLL SCI IMP U TOK, V8, P402, DOI 10.1016/0095-8522(53)90024-5                                                    
   Antunes FE, 2004, LANGMUIR, V20, P4647, DOI 10.1021/la049783i
   Ashbaugh HS, 2002, COLLOID POLYM SCI, V280, P783, DOI 10.1007/s00396-002-0702-3
   Backlund S, 1997, COLLOID SURFACE A, V123, P125, DOI 10.1016/S0927-7757(96)03796-X                                                   
   BARKER CA, 1974, J CHEM SOC FARAD T 1, V70, P154, DOI 10.1039/f19747000154                                                            
   Bergstrom M, 1999, LANGMUIR, V15, P2250, DOI 10.1021/la981495x                                                               
   Bergstrom M, 1998, LANGMUIR, V14, P3754, DOI 10.1021/la980107o                                                               
   Bergstrom M, 2001, J COLLOID INTERF SCI, V240, P294, DOI 10.1006/jcis.2001.7624
   Bhattacharya S, 1998, J ORG CHEM, V63, P7640, DOI 10.1021/jo980315l                                                               
   Blanzat M, 2005, CHEMBIOCHEM, V6, P2207, DOI 10.1002/cbic.200500203
   Blanzat M, 2003, CHEM COMMUN, P244, DOI 10.1039/b210392n
   Blanzat M, 2002, CHEM COMMUN, P1864, DOI 10.1039/b204287h
   Blanzat M, 2001, LANGMUIR, V17, P3512, DOI 10.1021/la001744t
   Blanzat M, 1999, NEW J CHEM, V23, P1063, DOI 10.1039/a905417k                                                                
   Blanzat M, 1999, LANGMUIR, V15, P6163, DOI 10.1021/la990300y                                                               
   Bramer T, 2006, J PHARM SCI-US, V95, P769, DOI 10.1002/jps.20582
   Bramer T, 2003, PHARMACEUT RES, V20, P1661, DOI 10.1023/A:1026103805283                                                         
   BRAMER T, 2007, IN PRESS J DRUG SCI
   BRASHER LL, 1995, LANGMUIR, V11, P4267, DOI 10.1021/la00011a017                                                             
   Brohede U, 2005, J PHYS CHEM B, V109, P15250, DOI 10.1021/jp0511350
   Brun A, 2003, COLLOID SURFACE A, V228, P3, DOI 10.1016/j.colsurfa.2003.08.008
   Caillet C, 2000, LANGMUIR, V16, P9099, DOI 10.1021/la000810o
   Chen L, 2002, LANGMUIR, V18, P7250, DOI 10.1021/la025878d
   Chung MH, 2004, COLLOID SURFACE B, V39, P165, DOI 10.1016/j.colsurfb.2004.06.012
   Chung MH, 2004, COLLOID SURFACE B, V34, P179, DOI 10.1016/j.colsurfb.2003.12.014
   Chung MH, 2003, COLLOID SURFACE B, V29, P75, DOI 10.1016/S0927-7765(02)00183-2                                                   
   Chung MH, 2003, COLLOID SURFACE B, V28, P83, DOI 10.1016/S0927-7765(02)00138-8                                                   
   Chung MH, 2002, COLLOID SURFACE B, V24, P111, DOI 10.1016/S0927-7765(01)00223-5                                                   
   Chung YC, 1999, B KOR CHEM SOC, V20, P838
   Chung YC, 2000, B KOR CHEM SOC, V21, P1257
   CHUNG YC, 1992, LANGMUIR, V8, P2843, DOI 10.1021/la00047a042                                                             
   Chung YC, 1998, B KOR CHEM SOC, V19, P1249
   Coldren B, 2003, LANGMUIR, V19, P5632, DOI 10.1021/la034311+
   Collins L, 2006, METH MOL B, V333, P201
   COLLISON R, 1959, T FARADAY SOC, V55, P662, DOI 10.1039/tf9595500662
   Delorme N, 2006, J PHYS CHEM B, V110, P1752, DOI 10.1021/jp054473+
   Dias R, 2002, BRAZ J MED BIOL RES, V35, P509, DOI 10.1590/S0100-879X2002000500002
   Dias RS, 2004, COLLOID SURFACE A, V250, P115, DOI 10.1016/j.colsurfa.2004.07.026
   Dias RS, 2002, J PHYS CHEM B, V106, P12600, DOI 10.1021/jp020391z
   Dias RS, 2002, J PHYS CHEM B, V106, P12608, DOI 10.1021/jp020392r
   DROBECK HP, 1994, SURF SCI SER, V53, P61
   Dubois M, 2001, NATURE, V411, P672, DOI 10.1038/35079541                                                                
   FILIPOVICVINCEKOVIC N, 1995, COLLOID POLYM SCI, V273, P182, DOI 10.1007/BF00654016
   Fischer A, 2002, J COLLOID INTERF SCI, V248, P163, DOI 10.1006/jcis.2001.8187
   FUKUDA H, 1990, J AM CHEM SOC, V112, P1635, DOI 10.1021/ja00160a057                                                             
   Gradzielski M, 2003, J PHYS-CONDENS MAT, V15, pR655, DOI 10.1088/0953-8984/15/19/202
   Hao JC, 2004, CURR OPIN COLLOID IN, V9, P279, DOI 10.1016/j.cocis.2004.06.004
   Hao JC, 2000, J PHYS CHEM B, V104, P10144, DOI 10.1021/jp000394g
   HARGREAVES WR, 1978, BIOCHEMISTRY-US, V17, P3759, DOI 10.1021/bi00611a014
   Hassan PA, 2002, LANGMUIR, V18, P2543, DOI 10.1021/la011435i
   HAYER HW, 1961, J PHYS CHEM-US, V65, P1804
   HERRINGTON KL, 1993, J PHYS CHEM-US, V97, P13792, DOI 10.1021/j100153a058                                                             
   HIRANO K, 1991, LANGMUIR, V7, P1045, DOI 10.1021/la00054a003                                                             
   HOFFMANN H, 1982, COLLOID POLYM SCI, V260, P1042, DOI 10.1007/BF01451652                                                              
   JOKELA P, 1987, J PHYS CHEM-US, V91, P3291, DOI 10.1021/j100296a037
   Jung HT, 2001, P NATL ACAD SCI USA, V98, P1353, DOI 10.1073/pnas.041420998
   KALER EW, 1992, J PHYS CHEM-US, V96, P6698, DOI 10.1021/j100195a033                                                             
   KALER EW, 1989, SCIENCE, V245, P1371, DOI 10.1126/science.2781283
   Kepczynski M, 2004, ADV MATER, V16, P1861, DOI 10.1002/adma.200400537
   KHATORY A, 1993, LANGMUIR, V9, P1456, DOI 10.1021/la00030a005                                                             
   KONDO Y, 1995, LANGMUIR, V11, P2380, DOI 10.1021/la00007a011                                                             
   Kuo JHS, 2005, COLLOID SURFACE B, V41, P189, DOI 10.1016/j.colsurfb.2004.12.008
   Laughlin RG, 1997, COLLOID SURFACE A, V128, P27, DOI 10.1016/S0927-7757(97)03899-5                                                   
   Lee JH, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.048102
   Lee JH, 2005, LANGMUIR, V21, P26, DOI 10.1021/la048194+
   Li HG, 2006, J PHYS CHEM B, V110, P68, DOI 10.1021/jp054637m
   Lindman B, 2002, PROG COLL POL SCI S, V120, P52
   Liu SY, 2003, LANGMUIR, V19, P10732, DOI 10.1021/la035409r
   Lootens D, 2003, J MATER CHEM, V13, P2072, DOI 10.1039/b305808p
   Marques EF, 2000, LANGMUIR, V16, P8255, DOI 10.1021/la0002278
   Marques EF, 1999, MACROMOLECULES, V32, P6626, DOI 10.1021/ma990350+                                                               
   Marques EF, 1999, J PHYS CHEM B, V103, P8353, DOI 10.1021/jp990852p                                                               
   Marques EF, 1998, J PHYS CHEM B, V102, P6746, DOI 10.1021/jp980355t                                                               
   Marques EF, 2000, LANGMUIR, V16, P4798, DOI 10.1021/la9908135                                                               
   MAZER NA, 1976, J PHYS CHEM-US, V80, P1075, DOI 10.1021/j100551a011                                                             
   McKelvey CA, 2002, J COLLOID INTERF SCI, V245, P68, DOI 10.1006/jcis.2001.7999
   McKelvey CA, 2000, LANGMUIR, V16, P8285, DOI 10.1021/la000569d
   Medronho B, 2006, J DISPER SCI TECHNOL, V27, P83, DOI 10.1081/DIS-200066744
   Mel'nikov SM, 1999, FEBS LETT, V453, P113, DOI 10.1016/S0014-5793(99)00699-7
   Miguel MG, 2003, COLLOID SURFACE A, V228, P43, DOI 10.1016/S0927-7757(03)00334-0
   Morgan JD, 1997, LANGMUIR, V13, P6447, DOI 10.1021/la970495e                                                               
   Mueller A, 2002, CHEM REV, V102, P727, DOI 10.1021/cr000071g
   Nilsson S, 2000, LANGMUIR, V16, P6825, DOI 10.1021/la991379+
   Osth K, 2002, J CONTROL RELEASE, V83, P377, DOI 10.1016/S0168-3659(02)00209-2
   Paulsson M, 2002, J COLLOID INTERF SCI, V248, P194, DOI 10.1006/jcis.2001.8182
   Paulsson M, 2001, PHARMACEUT RES, V18, P1586, DOI 10.1023/A:1013086632302
   Raghavan SR, 2002, LANGMUIR, V18, P1056, DOI 10.1021/la011148e
   Raghavan SR, 2002, LANGMUIR, V18, P3797, DOI 10.1021/la0115583
   Regev O, 1996, J COLLOID INTERF SCI, V182, P95, DOI 10.1006/jcis.1996.0440                                                          
   Regev O, 1999, LANGMUIR, V15, P642, DOI 10.1021/la9803474                                                               
   Rico-Lattes I, 2005, CR CHIM, V8, P807, DOI 10.1016/j.crci.2005.02.015
   Rosa M, 2006, LANGMUIR, V22, P5588, DOI 10.1021/la053464p
   Salkar RA, 1998, LANGMUIR, V14, P3778, DOI 10.1021/la971024v                                                               
   Schulz PC, 1999, COLLOID POLYM SCI, V277, P837, DOI 10.1007/s003960050460                                                           
   Segota S, 2005, SOFT MATER, V3, P51, DOI 10.1080/15394450600683477
   Shi HT, 2006, J PHYS CHEM B, V110, P748, DOI 10.1021/jp0545694
   Shi HT, 2002, CHEM COMMUN, P1704, DOI 10.1039/b204995c
   Shi HT, 2003, J AM CHEM SOC, V125, P3450, DOI 10.1021/ja029958f
   Shioi A, 2002, LANGMUIR, V18, P7341, DOI 10.1021/la020268z
   Sterzel W, 1995, TOXICOLOGY OF INDUSTRIAL COMPOUNDS, P341
   STERZEL W, 1997, SURFACTANTS COSMETIC, P557
   Tondre C, 2001, ADV COLLOID INTERFAC, V93, P115, DOI 10.1016/S0001-8686(00)00081-6                                                   
   Villeneuve M, 1999, LANGMUIR, V15, P2029, DOI 10.1021/la980925g                                                               
   WAN LSC, 1969, J PHARM SCI, V58, P1562, DOI 10.1002/jps.2600581238
   Wang CZ, 2004, ELECTROPHORESIS, V25, P825, DOI 10.1002/elps.200305760
   Wang X, 2006, LANGMUIR, V22, P6461, DOI 10.1021/la0605135
   Yadava P, 2006, ACS SYM SER, V923, P198
   Yan P, 2005, COLLOID SURFACE A, V259, P55, DOI 10.1016/j.colsurfa.2005.02.021
   Zemb T, 1999, SCIENCE, V283, P816, DOI 10.1126/science.283.5403.816                                                    
   Zhu C, 2006, LANGMUIR, V22, P2951, DOI 10.1021/la053475i
NR 112
TC 76
Z9 76
U1 0
U2 33
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0022-3573
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD OCT
PY 2007
VL 59
IS 10
BP 1319
EP 1334
DI 10.1211/jpp.59.10.0001
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 226RI
UT WOS:000250605800001
PM 17910806
OA gold
DA 2018-01-05
ER

PT J
AU Lawtrakul, L
   Hannongbua, S
AF Lawtrakul, Luckhana
   Hannongbua, Supa
TI Molecular dynamics study on the unbinding of HBY 097 in the K103N mutant
   RT
SO MONATSHEFTE FUR CHEMIE
LA English
DT Article
DE molecular dynamics simulations; HIV-1 reverse transcriptase;
   non-nucleoside inhibitor; virus mutation
ID HIV-1 REVERSE-TRANSCRIPTASE; HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIBODY FAB
   FRAGMENT; BINDING FREE-ENERGIES; ANGSTROM RESOLUTION; RESISTANCE
   MUTATIONS; CRYSTAL-STRUCTURES; WILD-TYPE; HBY 097; INHIBITOR
AB The structural rearrangement due to the unbinding of HBY 097 in K103N mutant HIV-1 reverse transcriptase (RT) was studied using two nanosecond molecular dynamics simulations. The simulations showed the dynamics of an open or upright position of the p66 thumb subdomain moving to a closed configuration together with the dynamic correction of protein residues around the non-nucleoside inhibitor binding pocket (NNIBP) and its putative entrance.
C1 Thammasat Univ, SIIT, Dept Common & Grad Studies, Pathum Thani, Thailand.
   Kasetdart Univ, Fac Sci, Dept Chem, Bangkok, Thailand.
RP Lawtrakul, L (reprint author), Thammasat Univ, SIIT, Dept Common & Grad Studies, Pathum Thani, Thailand.
EM luckhana@siit.tu.ac.th
RI Lawtrakul, Luckhana/A-4054-2009
OI Hannongbua, Supa/0000-0002-9901-4466
CR Balzarini J, 1998, BIOCHEM PHARMACOL, V55, P617, DOI 10.1016/S0006-2952(97)00506-6
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BYRNES VW, 1994, ANTIMICROB AGENTS CH, V38, P1404, DOI 10.1128/AAC.38.6.1404                                                           
   CASE DA, 2002, AMBER7
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   Das K, 2007, J MOL BIOL, V365, P77, DOI 10.1016/j.jmb.2006.08.097
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740
   Eriksson MAL, 1999, J MED CHEM, V42, P868, DOI 10.1021/jm980277y                                                               
   GARNER J, 2007, J MOL GRAPH MODEL
   Hansson T, 2002, CURR OPIN STRUC BIOL, V12, P190, DOI 10.1016/S0959-440X(02)00308-1
   Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   JACOBOMOLINA A, 1991, P NATL ACAD SCI USA, V88, P10895, DOI 10.1073/pnas.88.23.10895
   Kleim JP, 1999, J INFECT DIS, V179, P709, DOI 10.1086/314633                                                                  
   KLEIM JP, 1995, ANTIMICROB AGENTS CH, V39, P2253, DOI 10.1128/AAC.39.10.2253                                                          
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   MCCAMMON JA, 1977, NATURE, V267, P585, DOI 10.1038/267585a0
   *MOL SIM INC, 2000, WEBLAB VIEWERPRO 4 0
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207                                                           
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   Rubsamen-Waigmann H, 1999, ANTIVIR RES, V42, P15, DOI 10.1016/S0166-3542(99)00010-8
   Shen LL, 2003, BIOPHYS J, V84, P3547, DOI 10.1016/S0006-3495(03)75088-7                                                   
   Smith RH, 1998, J MED CHEM, V41, P5272, DOI 10.1021/jm9804174                                                               
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Weinzinger P, 2005, J ENZYM INHIB MED CH, V20, P129, DOI 10.1080/14756360400020520
   Zhou ZG, 2005, J AM CHEM SOC, V127, P17253, DOI 10.1021/ja053973d
NR 33
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0026-9247
J9 MONATSH CHEM
JI Mon. Chem.
PD OCT
PY 2007
VL 138
IS 10
BP 1029
EP 1034
DI 10.1007/s00706-007-0704-4
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 215FO
UT WOS:000249793900014
DA 2018-01-05
ER

PT J
AU Sha, MY
   Xu, H
   Penn, SG
   Cromer, R
AF Sha, Michael Y.
   Xu, Hongxia
   Penn, Sharron G.
   Cromer, Remy
TI SERS nanoparticles: a new optical detection modality for cancer
   diagnosis
SO NANOMEDICINE
LA English
DT Article
DE diagnostics; HIV; nanoparticles; oncology; Raman; surface-enhanced Raman
   scattering
ID ENHANCED RAMAN-SCATTERING; ORGANIC-INORGANIC NANOPARTICLES; COATED
   MAGNETIC NANOPARTICLES; MOLECULAR DIAGNOSTICS; CARBON NANOTUBES;
   SEPARATION TOOLS; BREAST-CANCER; QUANTUM DOTS; NANOTECHNOLOGY; GENE
AB Surface-enhanced Raman scattering. (SERS) is an optical detection technique that offers advantages over traditional assay detection technologies, such as fluorescence and chemiluminescence. These advantages include sensitivity, high levels of multiplexing, robustness and ability to perform detection in blood and other biological matrices. Here, we report on the growing field of SERS-active nanoparticles as a novel method for detection, with special emphasis on their use in the field of oncology. We discuss examples of SERS-active nanoparticles used in an assay for PSA, BRCA1 and Her-2, along with examples of nucleic-acid detection. We present data on a novel homogeneous, single-tube, rapid assay for nucleic acid detection and show how it will benefit the oncology community.
C1 Oxonica Inc, Mountain View, CA 94043 USA.
RP Cromer, R (reprint author), Oxonica Inc, 665 Clyde Ave,Suite A, Mountain View, CA 94043 USA.
EM remy.cromer@oxonica.com
FU NCI NIH HHS [U54 CA 119338]
CR Banerjee HN, 2006, EXPERT REV MOL DIAGN, V6, P679, DOI 10.1586/14737159.6.5.679
   Cao YC, 2003, J AM CHEM SOC, V125, P14676, DOI 10.1021/ja0366235
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Cho SJ, 2007, LANGMUIR, V23, P1974, DOI 10.1021/la060093j
   Cohen J, 2005, SCIENCE, V308, P618, DOI 10.1126/science.308.5722.618                                                    
   Cuenca AG, 2006, CANCER, V107, P459, DOI 10.1002/cncr.22035
   Culha M, 2003, EXPERT REV MOL DIAGN, V3, P669, DOI 10.1586/14737159.3.5.669                                                        
   Culha M, 2003, ANAL CHEM, V75, P6196, DOI 10.1021/ac0346003
   Dieringer JA, 2006, FARADAY DISCUSS, V132, P9, DOI 10.1039/b513431p
   Driskell JD, 2005, ANAL CHEM, V77, P6147, DOI 10.1021/ac0504159
   Driskell JD, 2007, ANAL CHEM, V79, P4141, DOI 10.1021/ac0701031
   Eastman PS, 2006, NANO LETT, V6, P1059, DOI 10.1021/nl060795t
   Eggeling C, 2003, DRUG DISCOV TODAY, V8, P632, DOI 10.1016/S1359-6446(03)02752-1
   Emerich DF, 2007, J DRUG TARGET, V15, P163, DOI 10.1080/10611860701231810
   FERRARI M, 2007, NAT REV CANCER, V5, P161
   Freeman RG, 2005, P SOC PHOTO-OPT INS, V5705, P114, DOI 10.1117/12.591114
   Gong JL, 2007, BIOSENS BIOELECTRON, V22, P1501, DOI 10.1016/j.bios.2006.07.004
   Grubisha DS, 2003, ANAL CHEM, V75, P5936, DOI 10.1021/ac034356f
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Huang XH, 2007, NANO LETT, V7, P1591, DOI 10.1021/nl070472c
   Ioannidis JPA, 2007, ONCOLOGIST, V12, P301, DOI 10.1634/theoncologist.12-3-301
   Jager S, 2003, Curr Pharm Biotechnol, V4, P463, DOI 10.2174/1389201033377382
   Jain KK, 2005, CLIN CHIM ACTA, V358, P37, DOI 10.1016/j.cccn.2005.03.014
   Jain KK, 2003, EXPERT REV MOL DIAGN, V3, P153, DOI 10.1586/14737159.3.2.153                                                        
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V1, P84
   Kim JH, 2006, ANAL CHEM, V78, P6967, DOI 10.1021/ac0607663
   Kneipp K, 2005, BIOPHYS J, V88, p365A
   Kneipp K, 2004, PHILOS T ROY SOC A, V362, P2361, DOI 10.1098/rsta.2004.1445
   Kneipp K., 2006, SURFACE ENHANCED RAM, P261
   Kneipp K, 2006, APPL SPECTROSC, V60, p322A, DOI 10.1366/000370206779321418                                                      
   LASERNA J, 1996, MODERN TECHNIQUES RA
   Lee S, 2007, ANAL CHEM, V79, P916, DOI 10.1021/ac061246a
   Li YG, 2006, EXPERT REV MOL DIAGN, V6, P567, DOI 10.1386/14737159.6.4.-567
   Liang Y, 2007, TALANTA, V72, P443, DOI 10.1016/j.talanta.2006.11.002
   Long D. A., 2002, RAMAN EFFECT UNIFIED
   Mazumder A, 2006, PHARMACOGENOMICS, V7, P1167, DOI 10.2217/14622416.7.8.1167
   McCabe AF, 2006, FARADAY DISCUSS, V132, P303, DOI 10.1039/b506942d
   MOSKOVITS M, 1985, REV MOD PHYS, V57, P783, DOI 10.1103/RevModPhys.57.783
   Moskovits M., 2002, OPTICAL PROPERTIES N, P215
   Mulvaney SP, 2003, LANGMUIR, V19, P4784, DOI 10.1021/la026706j
   Mycek M. A., 2003, HDB BIOMEDICAL FLUOR
   Natan MJ, 2006, FARADAY DISCUSS, V132, P321, DOI 10.1039/b601494c
   NATAN MJ, 2006, PAP AM CHEM SOC, P231
   Ni J, 1999, ANAL CHEM, V71, P4903, DOI 10.1021/ac990616a                                                               
   Nie SM, 2007, ANNU REV BIOMED ENG, V9, P257, DOI 10.1146/annurev.bioeng.9.060906.152025
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   Niu ZQ, 2006, J COLLOID INTERF SCI, V303, P224, DOI 10.1016/j.jcis.2006.07.039
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Pal A, 2006, FARADAY DISCUSS, V132, P293, DOI 10.1039/b506341h
   Pelletier M. J., 1999, ANAL APPL RAMAN SPEC
   Penn SG, 2003, CURR OPIN CHEM BIOL, V7, P609, DOI 10.1016/j.cbpa.2003.08.013
   Perrin D, 2006, ASSAY DRUG DEV TECHN, V4, P185, DOI 10.1089/adt.2006.4.185
   Raja S, 2002, CLIN CHEM, V48, P1329
   Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f
   Schwartzberg AM, 2006, J PHYS CHEM B, V110, P19935, DOI 10.1021/jp062136a
   Schwartzberg AM, 2006, ANAL CHEM, V78, P4732, DOI 10.1021/ac060220g
   Sha MY, 2007, NANOBIOTECHNOLOGY, V3, P23
   Sha M. Y., 2005, NANOBIOTECHNOLOGY, V1, P327
   Shanmukh S, 2006, NANO LETT, V6, P2630, DOI 10.1021/nl061666f
   Smith AM, 2006, EXPERT REV MOL DIAGN, V6, P231, DOI 10.1586/14737159.6.2.231
   Sobek J, 2006, COMB CHEM HIGH T SCR, V9, P365, DOI 10.2174/138620706777452429
   STOKES RJ, 2006, NANO LETT, V1, P57
   Stone N, 2007, ANAL BIOANAL CHEM, V387, P1657, DOI 10.1007/s00216-006-0937-9
   *STRAT DIR INT INC, 2002, MARK FORC 2001 2006
   Su X, 2005, NANO LETT, V5, P49, DOI 10.1021/nl0484088
   Sun L, 2007, NANO LETT, V7, P351, DOI 10.1021/nl062453t
   T Perelman L, 2006, EXPERT REV MED DEVIC, V3, P787, DOI 10.1586/17434440.3.6.787
   Thaxton CS, 2006, CLIN CHIM ACTA, V363, P120, DOI 10.1016/j.cccn.2005.05.042
   Vo-Dinh T, 2005, METH MOL B, V300, P255
   VODINH T, 2006, SURFACE ENHANCED RAM, V103, P409
   Young Andrew, 2005, Conf Proc IEEE Eng Med Biol Soc, V1, P723
   Zhang X., 2005, IEE Proceedings Nanobiotechnology, V152, P195, DOI 10.1049/ip-nbt:20050009
   Zhang XY, 2006, VIB SPECTROSC, V42, P2, DOI 10.1016/j.vibspec.2006.02.001
NR 73
TC 64
Z9 65
U1 5
U2 46
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
EI 1748-6963
J9 NANOMEDICINE-UK
JI Nanomedicine
PD OCT
PY 2007
VL 2
IS 5
BP 725
EP 734
DI 10.2217/17435889.2.5.725
PG 10
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 232RX
UT WOS:000251038200019
PM 17976033
DA 2018-01-05
ER

PT J
AU Voltan, R
   Castaldello, A
   Brocca-Cofano, E
   Altavilla, G
   Caputo, A
   Laus, M
   Sparnacci, K
   Ensoli, B
   Spaccasassi, S
   Ballestri, M
   Tondelli, L
AF Voltan, Rebecca
   Castaldello, Arianna
   Brocca-Cofano, Egidio
   Altavilla, Giuseppe
   Caputo, Antonella
   Laus, Michele
   Sparnacci, Katia
   Ensoli, Barbara
   Spaccasassi, Silvia
   Ballestri, Marco
   Tondelli, Luisa
TI Preparation and characterization of innovative protein-coated
   Poly(Methylmethacrylate) core-shell nanoparticles for vaccine purposes
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE carboxyl groups; core-shell nanoparticles; poly(methylmethacrylate);
   proteins; vaccines
ID HIV-1 TAT PROTEIN; POLY(LACTIC-CO-GLYCOLIC ACID) MICROPARTICLES; HUMORAL
   IMMUNE-RESPONSES; T-CELL RESPONSES; DELIVERY-SYSTEMS; CYNOMOLGUS
   MONKEYS; DNA VACCINES; POLYMERIC MICROSPHERES; VIRAL-INFECTIONS;
   ANTIGEN-DELIVERY
AB Purpose. This study aims at developing novel core-shell poly(methylmethacrylate) (PMMA) nanoparticles as a delivery system for protein vaccine candidates.
   Materials and Methods. Anionic nanoparticles consisting of a core of PMMA and a shell deriving from Eudragit L100/55 were prepared by an innovative synthetic method based on emulsion polymerization. The formed nanoparticles were characterized for size, surface charge and ability to reversibly bind two basic model proteins (Lysozyme, Trypsin) and a vaccine relevant antigen (HIV-1 Tat), by means of cell-free studies. Their in vitro toxicity and capability to preserve the biological activity of the HIV-1 Tat protein were studied in cell culture systems. Finally, their safety and immunogenicity were investigated in the mouse model.
   Results. The nanoparticles had smooth surface, spherical shape and uniform size distribution with a mean diameter of 220 nm. The shell is characterized by covalently bound carboxyl groups negatively charged at physiological pH, able to reversibly adsorb large amounts (up to 20% w/w) of basic proteins (Lysozyme, Trypsin and HIV-1 Tat), mainly through specific electrostatic interactions. The nanoparticles were stable, not toxic to the cells, protected the HIV-1 Tat protein from oxidation, thus preserving its biological activity and increasing its shelf-life, and efficiently delivered and released it intracellularly. In vivo experiments showed that they are well tolerated and elicit strong immune responses against the delivered antigen in mice.
   Conclusions. This study demonstrates that these new nanoparticles provide a versatile platform for protein surface adsorption and a promising delivery system particularly when the maintenance of the biologically active conformation is required for vaccine efficacy.
C1 Univ Padua, Dept Histol Microbiol & Med Biotechnol, Microbiol Sect, I-35122 Padua, Italy.
   Univ Padua, Inst Pathol Anat, I-35122 Padua, Italy.
   Univ Piemonte Orientale, INSTM, Dept Life & Ambient Sci, I-15100 Alessandria, Italy.
   Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
   ISOF, Consiglio Nazl Ric, I-40129 Bologna, Italy.
RP Caputo, A (reprint author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Microbiol Sect, Via A Gabelli 63, I-35122 Padua, Italy.
EM antonella.caputo@unipd.it
RI tondelli, luisa/C-1414-2012; Sparnacci, Katia/C-1138-2009; Ballestri,
   Marco/E-6697-2012; Ensoli, Barbara/J-9169-2016
OI tondelli, luisa/0000-0002-3971-3361; Sparnacci,
   Katia/0000-0003-2102-9649; Ensoli, Barbara/0000-0002-0545-8737;
   ballestri, marco/0000-0001-7336-2131; Laus, Michele/0000-0002-4296-3732
CR Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Berzofsky JA, 2004, J CLIN INVEST, V114, P450, DOI 10.1172/JCI200422674
   Berzofsky JA, 2004, J CLIN INVEST, V113, P1515, DOI 10.1172/JCI200-421926
   Betti M, 2001, VACCINE, V19, P3408, DOI 10.1016/S0264-410X(01)00067-6                                                   
   Borchard G, 1993, J DRUG TARGET, V1, P15, DOI 10.3109/10611869308998760
   Borchard G, 1996, PHARMACEUT RES, V13, P1055, DOI 10.1023/A:1016010808522
   Brehm MA, 2004, CELL MICROBIOL, V6, P411, DOI 10.1111/j.1462-5822.2004.00390.x
   Cafaro A, 1999, NAT MED, V5, P643
   Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0
   Caputo A, 2004, CURR HIV RES, V2, P357, DOI 10.2174/1570162043350986
   Caputo A, 2004, VACCINE, V22, P2910, DOI 10.1016/j.vaccine.2003.12.025
   Caputo A, 2003, VACCINE, V21, P1103, DOI 10.1016/S0264-410X(02)00555-8                                                   
   Caselli E, 1999, J IMMUNOL, V162, P5631
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Cui ZR, 2003, CRIT REV THER DRUG, V20, P103, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10                                   
   Ensoli B, 2005, MICROBES INFECT, V7, P1385, DOI 10.1016/j.micinf.2005.07.022
   Ensoli B, 2005, MICROBES INFECT, V7, P1445, DOI 10.1016/j.micinf.2005.07.024
   Ensoli B, 2005, MICROBES INFECT, V7, P1433, DOI 10.1016/j.micinf.2005.07.019
   ENSOLI B, 1993, J VIROL, V67, P277
   Ensoli B, 2005, MICROBES INFECT, V7, P1392, DOI 10.1016/j.micinf.2005.07.016
   Ensoli B, 2006, AIDS, V20, P2245, DOI 10.1097/QAD.0b013e3280112cd1
   Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197                                                      
   Felnerova D, 2004, CURR OPIN BIOTECH, V15, P518, DOI 10.1016/j.copbio.2004.10.005
   Ferrantelli F, 2004, CURR OPIN BIOTECH, V15, P543, DOI 10.1016/j.copbio.2004.10.008
   Frazer Robert Q, 2005, J Long Term Eff Med Implants, V15, P629
   Gavioli R, 2004, J IMMUNOL, V173, P3838, DOI 10.4049/jimmunol.173.6.3838                                                     
   Hanson HL, 2000, IMMUNITY, V13, P265, DOI 10.1016/S1074-7613(00)00026-1                                                   
   Jabbal-Gill I, 1999, VACCINE, V18, P238, DOI 10.1016/S0264-410X(99)00195-4
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8                                                    
   Kasturi SP, 2005, BIOMATERIALS, V26, P6375, DOI 10.1016/j.biomaterials.2005.03.043
   KREUTER J, 1976, EXP CELL BIOL, V44, P12
   KREUTER J, 1976, J PHARM SCI, V65, P1624, DOI 10.1002/jps.2600651115                                                          
   KREUTER J, 1976, INFECT IMMUN, V13, P204
   Lemperle G, 2004, PLAST RECONSTR SURG, V113, P1380, DOI 10.1097/01.PRS.0000112764.22839.7A
   Levine MM, 2004, NAT IMMUNOL, V5, P460, DOI 10.1038/ni0504-465
   Liang XP, 2005, J VIROL, V79, P12321, DOI 10.1128/JVI.79.19.12321-12331.2005
   Maggiorella MT, 2004, VACCINE, V22, P3258, DOI 10.1016/j.vaccine.2004.03.009
   Mandal B, 2004, INT J PHARM, V269, P259, DOI 10.1016/j.ijpharm.2003.09.023
   Matano T, 2003, AIDS, V17, P1392, DOI 10.1097/01.aids.0000072665.21517.e4
   Mooij P, 2001, VACCINE, V20, P304, DOI 10.1016/S0264-410X(01)00373-5
   O'Hagan D. T., 2001, Current Drug Targets - Infectious Disorders, V1, P273, DOI 10.2174/1568005014606008
   O'Hagan Derek T, 2003, Expert Rev Vaccines, V2, P269, DOI 10.1586/14760584.2.2.269
   O'Hagan DT, 2004, IMMUNOL REV, V199, P191, DOI 10.1111/j.0105-2896.2004.00153.x                                                
   O'Hagan DT, 2002, AIDS, V16, pS115, DOI 10.1097/00002030-200216004-00016                                                
   Otten G, 2003, J VIROL, V77, P6087, DOI 10.1128/JVI.77.10.6087-6092.2003
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Sesardic D, 2004, VACCINE, V22, P2452, DOI 10.1016/j.vaccine.2003.11.071
   Silvera P, 2002, J VIROL, V76, P3800, DOI 10.1128/JVI.76.8.3800-3809.2002
   Singh Manmohan, 2006, Current Drug Delivery, V3, P115, DOI 10.2174/156720106775197565
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7
   Sparnacci K, 2005, J BIOMAT SCI-POLYM E, V16, P1557, DOI 10.1163/156856205774576673
   Storni T, 2005, ADV DRUG DELIVER REV, V57, P333, DOI 10.1016/j.addr.2004.09.008
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
   Titti F, 2007, EXPERT OPIN EMERG DR, V12, P23, DOI 10.1517/14728214.12.1.23
   van de Weert M, 2000, PHARMACEUT RES, V17, P1159, DOI 10.1023/A:1026498209874                                                         
   Watkins JD, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-8
   Zhao J, 2005, VIROLOGY, V342, P1, DOI 10.1016/j.virol.2005.07.016
   ENSOLI B, Patent No. 2004012420
   ENSOLI B, Patent No. 2005048997
NR 63
TC 22
Z9 23
U1 0
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD OCT
PY 2007
VL 24
IS 10
BP 1870
EP 1882
DI 10.1007/s11095-007-9310-8
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 209SI
UT WOS:000249407900008
PM 17476465
DA 2018-01-05
ER

PT J
AU Hazen, R
   Harvey, R
   Ferris, R
   Craig, C
   Yates, P
   Griffin, P
   Miller, J
   Kaldor, I
   Ray, J
   Samano, V
   Furfine, E
   Spaltenstein, A
   Michael, HT
   Tung, R
   Clair, MS
   Hanlon, M
   Boone, L
AF Hazen, Richard
   Harvey, Robert
   Ferris, Robert
   Craig, Charles
   Yates, Phillip
   Griffin, Philip
   Miller, John
   Kaldor, Istvan
   Ray, John
   Samano, Vincente
   Furfine, Eric
   Spaltenstein, Andrew
   Hale, Michael
   Tung, Roger
   Clair, Marty St.
   Hanlon, Mary
   Boone, Lawrence
TI In vitro antiviral activity of the novel, tyrosyl-based human
   immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir
   (GW640385) in combination with other antiretrovirals and against a panel
   of protease inhibitor-resistant HIV
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID WILD-TYPE; CELL-LINE; POTENT; ARYLSULFONAMIDES; REPLICATION; MUTATIONS;
   INFECTION; DISCOVERY; STRAINS; GW0385
AB Brecanavir, a novel tyrosyl-based arylsulfonamide, high-affinity, human immunodeficiency virus type I (HIV-1) protease inhibitor (PI), has been evaluated for anti-HIV activity in several in vitro assays. Preclinical assessment of brecanavir indicated that this compound potently inhibited HIV-1 in cell culture assays with 50% effective concentrations (EC(50)s) of 0.2 to 0.53 nM and was equally active against HIV strains utilizing either the CXCR4 or CCR5 coreceptor, as was found with other PIs. The presence of up to 40% human serum decreased the anti-HIV-1 activity of brecanavir by 5.2-fold, but under these conditions the compound retained single-digit nanomolar EC(50)s. When brecanavir was tested in combination with nucleoside reverse transcriptase inhibitors, the antiviral activity of brecanavir was synergistic with the effects of stavudine and additive to the effects of zidovudine, tenofovir, dideoxycytidine, didanosine, adefovir, abacavir, lamivudine, and emtricitabine. Brecanavir was synergistic with the nonnucleoside reverse transcriptase inhibitor nevirapine or delavirdine and was additive to the effects of efavirenz. In combination with other PIs, brecanavir was additive to the activities of indinavir, lopinavir, nelfinavir, ritonavir, amprenavir, saquinavir, and atazanavir. Clinical HIV isolates from PI-experienced patients were evaluated for sensitivity to brecanavir and other PIs in a recombinant virus assay. Brecanavir had a <5-fold increase in EC(50)s against 80% of patient isolates tested and had a greater mean in vitro potency than amprenavir, indinavir, lopinavir, atazanavir, tipranavir, and darunavir. Brecanavir is by a substantial margin the most potent and broadly active antiviral agent among the PIs tested in vitro.
C1 AstraZeneca, Waltham, MA USA.
   Vertex Pharmaceut, Cambridge, MA USA.
   GlaxoSmithKline Inc, Dept Virol, Res Triangle Pk, NC 27709 USA.
   GlaxoSmithKline Inc, Dept Med Chem, Res Triangle Pk, NC 27709 USA.
   GlaxoSmithKline Inc, Dept Biochem & Analyt Pharmacol, Res Triangle Pk, NC 27709 USA.
   GlaxoSmithKline Inc, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA.
RP Hazen, R (reprint author), GlazoSmithKline, Dept Virol, Metab & Viral Dis CEDD, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA.
EM richard.j.hazen@gsk.com
CR Ammaranond P, 2003, J CLIN VIROL, V26, P153, DOI 10.1016/S1386-6532(02)00114-2
   Boden D, 1998, ANTIMICROB AGENTS CH, V42, P2775
   DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590                                                           
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.62314-2321.2005
   Panel on Antiretroviral Guidelines for Adults and Adolescents, 2006, GUID US ANT AG HIV 1
   Dumans AT, 2002, ANTIMICROB AGENTS CH, V46, P3075, DOI 10.1128/AAC.46.9.3075-3079.2002
   Ferris RG, 2005, ANTIMICROB AGENTS CH, V49, P4046, DOI 10.1128/AAC.49.10.4046-4051.2005
   FISHER AG, 1985, NATURE, V316, P262, DOI 10.1038/316262a0
   Ford SL, 2006, ANTIMICROB AGENTS CH, V50, P2201, DOI 10.1128/AAC.01490-05
   Hanlon MH, 2004, BIOCHEMISTRY-US, V43, P14500, DOI 10.1021/bi0488799
   Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192                                                                  
   HILL AV, 1910, J PHYSIOL-LONDON, V40, P4
   Johnson Victoria A, 2005, Top HIV Med, V13, P51
   KIMPTON J, 1992, J VIROL, V66, P2232
   Little SJ, 1999, JAMA-J AM MED ASSOC, V282, P1142, DOI 10.1001/jama.282.12.1142                                                        
   MAGER ME, 1972, DATA ANAL BIOCH BIOP
   Miller JF, 2006, BIOORG MED CHEM LETT, V16, P1788, DOI 10.1016/j.bmcl.2006.01.035
   Miller JF, 2004, BIOORG MED CHEM LETT, V14, P959, DOI 10.1016/j.bmc.2003.12.008
   MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0                                                                
   Molla A, 1998, VIROLOGY, V250, P255, DOI 10.1006/viro.1998.9383
   Molla A, 2002, ANTIMICROB AGENTS CH, V46, P2249, DOI 10.1128/AAC.46.7.2249-2253.2002
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   SCHWARTZ O, 1988, AIDS RES HUM RETROV, V4, P441, DOI 10.1089/aid.1988.4.441                                                          
   Selleseth DW, 2003, ANTIMICROB AGENTS CH, V47, P1468, DOI 10.1128/AAC.47.4.1468-1471.2003
   Thaisrivongs S, 1999, BIOPOLYMERS, V51, P51
   Yates PJ, 2006, ANTIMICROB AGENTS CH, V50, P1092, DOI 10.1128/AAC.50.3.1093-1095.2006
NR 26
TC 18
Z9 18
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2007
VL 51
IS 9
BP 3147
EP 3154
DI 10.1128/AAC.00401-07
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 206HV
UT WOS:000249175400015
PM 17620375
OA gold
DA 2018-01-05
ER

PT J
AU Keyaerts, E
   Vijgen, L
   Pannecouque, C
   Van Damme, E
   Peumans, W
   Egberink, H
   Balzarini, J
   Van Ranst, M
AF Keyaerts, Els
   Vijgen, Leen
   Pannecouque, Christophe
   Van Damme, Els
   Peumans, Willy
   Egberink, Herman
   Balzarini, Jan
   Van Ranst, Marc
TI Plant lectins are potent inhibitors of coronaviruses by interfering with
   two targets in the viral replication cycle
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE coronavirus; plant lectins; antiviral; SARS-CoV; mannose
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE RESPIRATORY SYNDROME;
   SARS-CORONAVIRUS; RT-PCR; INFECTION; HKU1; PROTEINS; CHILDREN; SEQUENCE;
   INVITRO
AB We describe the antiviral activity of plant lectins with specificity for different glycan structures against the severe acute respiratory syndrome coronavirus (SARS-CoV) and the feline infectious peritonitis virus (FIPV) in vitro. The SARS-CoV emerged in 2002 as an important cause of severe lower respiratory tract infection in humans, and FIPV infection causes a chronic and often fatal peritonitis in cats. A unique collection of 33 plant lectins with different specificities were evaluated. The plant lectins possessed marked antiviral properties against both coronaviruses with EC50 values in the lower microgram/ml range (middle nanomolar range), being non-toxic (CC50) at 50-100 mu g/ml. The strongest anti -coronavirus activity was found predominantly among the mannose-binding lectins. In addition, a number of galactose-, N-acetylgalactosamine-, glucose-, and N-acetylglucosamine-specific plant agglutinines exhibited anti -coronaviral activity. A significant correlation (with an r-value of 0.70) between the EC50 values of the 10 mannose-specific plant lectins effective against the two coronaviruses was found. In contrast, little correlation was seen between the activity of other types of lectins. Two targets of possible antiviral intervention were identified in the replication cycle of SARS-CoV. The first target is located early in the replication cycle, most probably viral attachment, and the second target is located at the end of the infectious virus cycle. (C) 2007 Elsevier B.V. All rights reserved.
C1 Katholieke Univ Leuven, Dept Mol Biotechnol, B-3000 Louvain, Belgium.
   Katholieke Univ Leuven, Lab Clin & Epidemiol Virol, Dept Microbiol & Immunol, Rega Inst Med Res, B-3000 Louvain, Belgium.
   Univ Ghent, Dept Mol Biotechnol, Ghent, Belgium.
   Fac Vet, Dept Infect Dis & Immunol, Utrecht, Netherlands.
RP Balzarini, J (reprint author), Katholieke Univ Leuven, Dept Mol Biotechnol, B-3000 Louvain, Belgium.
EM jan.balzarini@rega.kuleuven.be; marc.vanranst@uz.kuleuven.ac.be
OI Van Damme, Els/0000-0001-9848-766X; Van Ranst, Marc/0000-0002-1674-4157
CR Arden KE, 2005, J MED VIROL, V75, P455, DOI 10.1002/jmv.20288
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   BALZARINI J, 1992, ANTIVIR RES, V18, P191, DOI 10.1016/0166-3542(92)90038-7                                                    
   Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004
   Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200
   Bastien N, 2005, J INFECT DIS, V191, P503, DOI 10.1086/426869                                                                  
   Chen Y, 2002, FASEB J, V16, P905, DOI 10.1096/fj.01-0598fje
   Doms RW, 2004, NEW ENGL J MED, V351, P743, DOI 10.1056/NEJMp048058                                                             
   Gonzaalez JM, 2003, ARCH VIROL, V148, P2207, DOI 10.1007/s00705-003-0162-1
   HAMMAR L, 1989, AIDS RES HUM RETROV, V5, P495, DOI 10.1089/aid.1989.5.495
   HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003                                                
   Herman P, 2004, APPL BIOSAFETY, V9, P128
   Huang Y, 2004, J VIROL, V78, P12557, DOI 10.1128/JVI.78.22.12557-12565.2004
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Keyaerts E, 2006, INT J INFECT DIS, V10, P32, DOI 10.1016/j.ijid.2005.02.003
   Keyaerts E, 2005, BIOCHEM BIOPH RES CO, V329, P1147, DOI 10.1016/j.bbrc.2005.02.085
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Krokhin O, 2003, MOL CELL PROTEOMICS, V2, P346, DOI 10.1074/mcp.M300048-MCP200
   LARSON HE, 1980, J MED VIROL, V5, P221, DOI 10.1002/jmv.1890050306
   MATSUI T, 1990, MED MICROBIOL IMMUN, V179, P225
   MCKEIRNAN AJ, 1981, FELINE PRACT, V11, P17
   Moes E, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-6
   Muller-Schwarze D, 2001, CHEM SIGNAL, V9, P1
   PEDERSEN NC, 1981, AM J VET RES, V42, P368
   Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.108952
   Sloots TP, 2006, J CLIN VIROL, V35, P99, DOI 10.1016/j.jcv.2005.09.008
   Vabret A, 2006, CLIN INFECT DIS, V42, P634, DOI 10.1086/500136
   Van Damme EJM, 2002, PLANT PHYSIOL, V130, P757, DOI 10.1104/pp.005892
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Van Damme E. J., 1998, HDB PLANT LECTINS PR
   Wang WF, 2003, PLANT J, V33, P293, DOI 10.1046/j.1365-313X.2003.01623.x
   Woo PCY, 2005, J VIROL, V79, P884, DOI 10.1128/JVI.79.2.884-895.2005
NR 32
TC 48
Z9 49
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD SEP
PY 2007
VL 75
IS 3
BP 179
EP 187
DI 10.1016/j.antiviral.2007.03.003
PG 9
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 207AS
UT WOS:000249224600001
PM 17428553
DA 2018-01-05
ER

PT J
AU Costa, MJL
   Pedro, L
   de Matos, APA
   Aires-Barros, MR
   Belo, JA
   Goncalves, J
   Ferreira, GNM
AF Costa, Maria J. L.
   Pedro, Luisa
   Alves de Matos, Antonio P.
   Aires-Barros, Maria R.
   Belo, Jose A.
   Goncalves, Joao
   Ferreira, Guilherme N. M.
TI Molecular construction of bionanoparticles: chimaeric SIV p17-HIV 1 p6
   nanoparticles with minimal viral protein content
SO BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
LA English
DT Article
DE bionanoparticle; delivery vector; gene therapy; human and simian;
   immunodeficiency virus (HIV and SIV); molecular therapy; virus-like
   particle
ID VIRUS-LIKE PARTICLES; PSEUDOTYPED RETROVIRAL VECTORS; SIMIAN
   IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS-VIRUS; MATRIX PROTEIN;
   GENE-TRANSFER; GAG PROTEIN; ENVELOPE GLYCOPROTEIN; LATE-DOMAIN;
   HIGH-TITER
AB VLPs (virus-like particles) are promising delivery vectors for molecular therapy, since they combine the major advantages of viral vectors with significantly fewer viral vector disadvantages. The present paper describes the molecular construction of chimaeric VLPs based on minimal SIV (simian immunodeficiency virus) and HIVI components. A chimaeric protein was constructed byfusion of SIV matrix protein (p17) and HIVI p6 protein, and we demonstrated that the chimaeric proteins assemble as 80 nm nanciparticles containing similar to 7700 chimaeric protein units. Chimaeric VLPs are released from HEK-293T cells (human embryonic kidney cells expressing the large T-antigen of simian virus 40) and are fully encapsulated with lipid membrane. Chimaeric VLPs are produced at 3.7-fold higher levels when compared with SIV p17 VLPs owing to duplication of a PTAP (Pro-Thr-Ala-Pro) domain previously shown as essential for virus particle release. The chimaeric VLPs constructed in the present paper were efficiently pseudotyped with vesicular-stomatitis-virus glycoprotein, as shown by immunciprecipitation assays.
C1 Univ Algarve, FERN, Ctr Biomed Mol & Estrutural, IBB, P-8005139 Faro, Portugal.
   Univ Lisbon, Fac Farm, URIA, Lisbon, Portugal.
   Inst Super Tecn, Ctr Engn Biol & Quim, Lisbon, Portugal.
   Hosp Curry Cabral, Dept Anat Patol, Lisbon, Portugal.
   Univ Lisbon, Dept Biomat, Escola Med Dent, Lisbon, Portugal.
   Gulbenkian Inst Sci, Oeiras, Portugal.
RP Ferreira, GNM (reprint author), Univ Algarve, FERN, Ctr Biomed Mol & Estrutural, IBB, Campus Gambelas, P-8005139 Faro, Portugal.
EM gferrei@ualg.pt
RI Matos, Antonio/A-4539-2013; Ferreira, Guilherme/J-3310-2013;
   Aires-Barros, Maria Raquel/E-6021-2010; iMed.ULisboa, M2B/B-5277-2014;
   Goncalves, Joao/B-2013-2008; Belo, Jose A./F-4444-2012; iMed.ULisboa,
   iMed.ULisboa/C-6292-2014
OI Matos, Antonio/0000-0001-9386-0349; Ferreira,
   Guilherme/0000-0002-0210-0211; Aires-Barros, Maria
   Raquel/0000-0002-1813-4280; Goncalves, Joao/0000-0002-1245-3715; Belo,
   Jose A./0000-0001-7384-0949; 
CR Accola MA, 2000, J VIROL, V74, P5395, DOI 10.1128/JVI.74.12.5395-5402.2000
   Adamson CS, 2004, REV MED VIROL, V14, P107, DOI 10.1002/rmv.418
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033
   Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635
   Demirov DG, 2004, VIRUS RES, V106, P87, DOI 10.1016/j.virusres.2004.08.007
   Demirov DG, 2002, J VIROL, V76, P105, DOI 10.1128/JVI.76.1.105-117.2002
   DORFMAN T, 1994, J VIROL, V68, P1689
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   Gariepy J, 2001, TRENDS BIOTECHNOL, V19, P21, DOI 10.1016/S0167-7799(00)01520-1                                                   
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Giddings AM, 1998, VIROLOGY, V248, P108, DOI 10.1006/viro.1998.9284
   Gonzalez SA, 1996, J VIROL, V70, P6384
   GONZALEZ SA, 1993, VIROLOGY, V194, P548, DOI 10.1006/viro.1993.1293
   GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195
   Hu WS, 2000, PHARMACOL REV, V52, P493
   HUANG MJ, 1995, J VIROL, V69, P6810
   Jaffray A, 2004, J GEN VIROL, V85, P409, DOI 10.1099/vir.0.19396-0
   Kang CY, 1999, BIOL CHEM, V380, P353, DOI 10.1515/BC.1999.047                                                             
   Kondo E, 1996, J VIROL, V70, P159
   Kuate S, 2006, VIROLOGY, V351, P133, DOI 10.1016/j.virol.2006.03.009
   Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702
   Mountain A, 2000, TRENDS BIOTECHNOL, V18, P119, DOI 10.1016/S0167-7799(99)01416-X                                                   
   Muller B, 2002, J VIROL, V76, P1015, DOI 10.1128/JVI.76.3.1015-1024.2002
   Nermut MV, 2003, VIROLOGY, V305, P219, DOI 10.1006/viro.2002.1692
   PARENT LJ, 1995, J VIROL, V69, P5455
   Perletti G, 2004, J Cell Mol Med, V8, P142, DOI 10.1111/j.1582-4934.2004.tb00269.x
   Petry H, 2003, CURR OPIN MOL THER, V5, P524
   Romano G, 2000, STEM CELLS, V18, P19, DOI 10.1634/stemcells.18-1-19                                                       
   Sakuragi S, 2002, P NATL ACAD SCI USA, V99, P7956, DOI 10.1073/pnas.082281199
   Schaffer DV, 2000, CURR OPIN MOL THER, V2, P155
   Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063
   Wang X, 1999, MOL CELL PROBE, V13, P1, DOI 10.1006/mcpr.1998.0204                                                          
   Yamada T, 2003, NAT BIOTECHNOL, V21, P885, DOI 10.1038/nbt843
   YEE JK, 1994, METHOD CELL BIOL, V43, P99
   Yu XF, 1998, J VIROL, V72, P3412
NR 36
TC 5
Z9 5
U1 0
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0885-4513
J9 BIOTECHNOL APPL BIOC
JI Biotechnol. Appl. Biochem.
PD SEP
PY 2007
VL 48
BP 35
EP 43
DI 10.1042/BA20060208
PN 1
PG 9
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 212NY
UT WOS:000249605300005
PM 17391101
DA 2018-01-05
ER

PT J
AU Sidorov, IA
   Prabakaran, P
   Dimitrov, DS
AF Sidorov, Igor A.
   Prabakaran, Ponraj
   Dimitrov, Dirniter S.
TI Non-covalent conjugation of nanoparticles to antibodies via
   electrostatic interactions - A computational model
SO JOURNAL OF COMPUTATIONAL AND THEORETICAL NANOSCIENCE
LA English
DT Article
DE nanoparticle; antibody; liposome; electrostatics; non-covalent
   interaction; targeted delivery
ID CIRCULATION TIME; LIPOSOMES; TUMORS; BLOOD; CELLS
AB Conjugation of antibodies to nanoparticles is important for the development of vehicles with targeting specificity which can be used for diagnosis and treatment of cancer and other diseases. The antibody association with nanoliposomes and other nanoparticles is achieved mostly by generation of covalent bonds based on their chemical and structural properties. Here we describe a theoretical approach that may have implications for non-covalent conjugation of antibodies to nanoparticles based on their electrostatic properties. We analyzed in detail the crystal structure of the anti-HIV antibody Fab m18 and identified basic residues in the constant domain of the light chain. Some of these residues including four lysines at the positions 126, 183, 188, and 190, histidine 189 and agrinine 211 are highly exposed and form clusters. The electrostatic potential of the antibody surface was calculated by solving the Poisson-Boltzmann equation. The results suggest the existence of a dominant positively charged surface overlapping with the basic residues. We hypothesized that these conserved charges on the constant domain of antibody may facilitate binding to a negatively charged nanoparticle surface. Our computational analysis of the electrostatic energy of antibody-nanoparticle interactions provided evidence supporting this hypothesis and the possibility to design antibodies that can be non-covalently associated with nanoparticles via electrostatic interactions. These results may provide a framework for the development of novel approaches for the generation of antibody-nanoparticle conjugates.
C1 NCI, Prot Interact Grp, CCRNP, CCR,NIH, Frederick, MD 21702 USA.
RP Sidorov, IA (reprint author), NCI, Prot Interact Grp, CCRNP, CCR,NIH, Frederick, MD 21702 USA.
RI Ponraj, Prabakaran/D-6325-2011
CR BAKKERWOUDENBERG IAJM, 1992, BIOCHIM BIOPHYS ACTA, V1138, P318, DOI 10.1016/0925-4439(92)90010-K
   Dukhin S.S., 1986, COAGULATION DYNAMICS
   GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949                                                         
   GRAY AG, 1988, CLIN EXP IMMUNOL, V72, P168
   Harasym TO, 1997, CANCER CHEMOTH PHARM, V40, P309, DOI 10.1007/s002800050662
   Harasym TO, 1998, ADV DRUG DELIVER REV, V32, P99, DOI 10.1016/S0169-409X(97)00134-8                                                   
   Huang CC, 2004, P NATL ACAD SCI USA, V101, P2706, DOI 10.1073/pnas.0308527100
   JONES MN, 1995, ADV COLLOID INTERFAC, V54, P93, DOI 10.1016/0001-8686(94)00223-Y
   LEE KD, 1993, BIOPHYS J, V64, P905, DOI 10.1016/S0006-3495(93)81453-X                                                   
   Liu Y, 2001, LANGMUIR, V17, P2063, DOI 10.1021/la0011634
   MACHY P, 1984, EMBO J, V3, P1971
   Nobs L, 2004, J PHARM SCI-US, V93, P1980, DOI 10.1002/jps.20098
   Park JW, 1997, CANCER LETT, V118, P153, DOI 10.1016/S0304-3835(97)00326-1                                                   
   Prabakaran P, 2006, J MOL BIOL, V357, P82, DOI 10.1016/j.jmb.2005.062
NR 14
TC 12
Z9 12
U1 1
U2 9
PU AMER SCIENTIFIC PUBLISHERS
PI STEVENSON RANCH
PA 25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA
SN 1546-1955
J9 J COMPUT THEOR NANOS
JI J. Comput. Theor. Nanosci.
PD SEP
PY 2007
VL 4
IS 6
BP 1103
EP 1107
PG 5
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 224ML
UT WOS:000250451000002
DA 2018-01-05
ER

PT J
AU Wang, X
   Uto, T
   Akagi, T
   Akashi, M
   Baba, M
AF Wang, Xin
   Uto, Tomofumi
   Akagi, Takami
   Akashi, Mitsuru
   Baba, Masanori
TI Induction of potent CD8(+) T-Cell responses by novel biodegradable
   nanoparticles carrying human immunodeficiency virus type 1 gp120
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; HUMAN DENDRITIC CELLS;
   IMMUNE-RESPONSES; POLY(GAMMA-GLUTAMIC ACID); CAPTURING NANOSPHERES;
   ANTIBODY-RESPONSE; RHESUS MACAQUES; IMMUNIZATION; VACCINE;
   MICROPARTICLES
AB The mainstream of recent anti-AIDS vaccines is a prime/boost approach with multiple doses of the target DNA of human immunodeficiency virus type I (HIV-1) and recombinant viral vectors. In this study, we have attempted to construct an efficient protein-based vaccine using biodegradable poly (gamma-glutamic acid) (7-PGA) nanoparticles (NPs), which are capable of inducing potent cellular immunity. A significant expansion of CD8(+) T cells specific to the major histocompatibility complex class I-restricted gp120 epitope was observed in mice intranasally immunized once with gp120-carrying NPs but not with gp120 alone or gp120 together with the B-subunit of cholera toxin. Both the gp120-encapsulating and -immobilizing forms of NI's could induce antigen-specific spleen CD8(+) T cells having a functional profile of cytotoxic T lymphocytes. Long-lived memory CD8(+) T cells could also be elicited. Although a substantial decay in the effector memory T cells was observed over time in the immunized mice, the central memory T cells remained relatively constant from day 30 to day 238 after immunization. Furthermore, the memory CD8(+) T cells rapidly expanded with boosting with the same immunogen. In addition,,y-PGA NI's were found to be a much stronger inducer of antigen-specific CD8(+) T-cell responses than nonbiodegradable polystyrene NPs. Thus, gamma-PGA NPs carrying various HIV-1 antigens may have great potential as a novel priming and/or boosting tool in current vaccination regimens for the induction of cellular immune responses.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
   Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   JST, CREST, Tokyo 1500002, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, 8-35-1,Sakuragaoka, Kagoshima 8908544, Japan.
EM m-baba@vanilla.ocn.ne.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Badovinac VP, 2005, NAT MED, V11, P748, DOI 10.1038/n/nm1257
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Borroto R J, 1997, Rev Panam Salud Publica, V1, P3
   Fonteneau JF, 2003, BLOOD, V102, P4448, DOI 10.1182/bloo-2003-06-1801
   Goonetilleke N, 2006, J VIROL, V80, P4717, DOI 10.1128/JVI.80.10.4717-4728.2006
   Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Klein M, 2003, VACCINE, V21, P616, DOI 10.1016/S0264-410X(02)00568-6                                                   
   LETVIN N, 2006, RETROVIROLOGY S1, V3, pS20
   Letvin NL, 2004, J VIROL, V78, P7490, DOI 10.1128/JVI.78.14.7490-7497.2004
   Letvin NL, 2002, J CLIN INVEST, V110, P15, DOI 10.1172/JCI200215985
   Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828                                                         
   MALOY KJ, 1994, IMMUNOLOGY, V81, P661
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   Otten G, 2003, J VIROL, V77, P6087, DOI 10.1128/JVI.77.10.6087-6092.2003
   Otten GR, 2005, J VIROL, V79, P8189, DOI 10.1128/JVI.79.13.8189-8200.2005
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Seaman MS, 2005, J VIROL, V79, P2956, DOI 10.1128/JVI.79.5.2956-2963.2005
   Sun Y, 2006, J VIROL, V80, P10950, DOI 10.1128/JVI.01458-06
   TAKAHASHI H, 1992, SCIENCE, V255, P333, DOI 10.1126/science.1372448
   Uto T, 2007, J IMMUNOL, V178, P2979, DOI 10.4049/jimmunol.178.5.2979                                                     
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Wang X, 2007, MINI-REV ORG CHEM, V4, P51, DOI 10.2174/157019307779815857                                                      
   Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889
NR 29
TC 39
Z9 42
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 2007
VL 81
IS 18
BP 10009
EP 10016
DI 10.1128/JVI.00489-07
PG 8
WC Virology
SC Virology
GA 208JI
UT WOS:000249315200038
PM 17609261
OA gold
DA 2018-01-05
ER

PT J
AU Klostranec, JM
   Xiang, Q
   Farcas, GA
   Lee, JA
   Rhee, A
   Lafferty, EI
   Perrault, SD
   Kain, KC
   Chan, WCW
AF Klostranec, Jesse M.
   Xiang, Qing
   Farcas, Gabriella A.
   Lee, Jeongjin A.
   Rhee, Alex
   Lafferty, Erin I.
   Perrault, Steven D.
   Kain, Kevin C.
   Chan, Warren C. W.
TI Convergence of quantum dot barcodes with microfluidics and signal
   processing for multiplexed high-throughput infectious disease
   diagnostics
SO NANO LETTERS
LA English
DT Article
ID BIOBARCODED NANOPARTICLE PROBES; SOFT LITHOGRAPHY; NANOCRYSTALS; CHIP;
   BIOMOLECULES; PARTICLES; CHEMISTRY; DEVICE; CELLS; ASSAY
AB Through the convergence of nano- and microtechnologies (quantum dots and microfluidics), we have created a diagnostic system capable of multiplexed, high-throughput analysis of infectious agents in human serum samples. We demonstrate, as a proof-of-concept, the ability to detect serum biomarkers of the most globally prevalent blood-borne infectious diseases (i.e., hepatitis B, hepatitis C, and HIV) with low sample volume (< 100 mu L), rapidity (< 1 h), and 50 times greater sensitivity than that of currently available FDA-approved methods. We further show precision for detecting multiple biomarkers simultaneously in serum with minimal cross-reactivity. This device could be further developed into a portable handheld point-of-care diagnostic system, which would represent a major advance in detecting, monitoring, treating, and preventing infectious disease spread in the developed and developing worlds.
C1 Univ Toronto, Terrence Donnelly Ctr Cellular & Mol Res, Inst Biomat & Biomed Engn, Toronto, ON M5S 3E1, Canada.
   Univ Toronto, McLaughlin Ctr Mol Med, Inst Med Sci, Toronto, ON M5S 3E1, Canada.
   Univ Toronto, Dept Mat Sci, Toronto, ON, Canada.
   UHN, Toronto Gen Hosp, McLaughlin Rotman Ctr Global Hlth, Trop Dis Unit, Toronto, ON M5M 1M1, Canada.
RP Chan, WCW (reprint author), Univ Toronto, Terrence Donnelly Ctr Cellular & Mol Res, Inst Biomat & Biomed Engn, 160 Coll St, Toronto, ON M5S 3E1, Canada.
EM warren.chan@utoronto.ca
RI Perrault, Steven/A-9457-2009
CR Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506                                                               
   Bailey RE, 2003, J AM CHEM SOC, V125, P7100, DOI 10.1021/ja035000o
   Burda C, 2005, CHEM REV, V105, P1025, DOI 10.1021/cr030063a
   Burns MA, 1998, SCIENCE, V282, P484, DOI 10.1126/science.282.5388.484
   Erickson D, 2004, LAB CHIP, V4, P87, DOI 10.1039/b316916b
   Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711
   Ghazani AA, 2006, NANO LETT, V6, P2881, DOI 10.1021/nl062111n
   Ghosal S, 2006, ANNU REV FLUID MECH, V38, P309, DOI 10.1146/annurev.fluid.38.050304.092053                                          
   Goluch ED, 2006, LAB CHIP, V6, P1293, DOI 10.1039/b606294f
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   Huang B, 2007, SCIENCE, V315, P81, DOI 10.1126/science.1133992
   Jiang W, 2004, TRENDS BIOTECHNOL, V22, P607, DOI 10.1016/j.tibtech.2004.10.012
   Jiang W, 2006, CHEM MATER, V18, P4845, DOI 10.1021/cm061311x
   Klostranec JM, 2006, ADV MATER, V18, P1953, DOI 10.1002/adma.200500786
   Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046
   Lai CL, 2003, LANCET, V362, P2089, DOI 10.1016/S0140-6736(03)15108-2
   Liu WT, 2005, LAB CHIP, V5, P1327, DOI 10.1039/b509086e
   Poynard T, 2003, LANCET, V362, P2095, DOI 10.1016/S0140-6736(03)15109-4
   Pregibon DC, 2007, SCIENCE, V315, P1393, DOI 10.1126/science.1134929
   Rogers PH, 2005, LANGMUIR, V21, P5562, DOI 10.1021/la046790y
   Shatz G. C., 2007, P NATL ACAD SCI USA, V104, P6885
   Squires TM, 2005, REV MOD PHYS, V77, P977, DOI 10.1103/RevModPhys.77.977                                                       
   Steigert J., 2005, JALA, V10, P331, DOI DOI 10.1016/JJALA.2005.07.002
   STENBERG M, 1986, J THEOR BIOL, V120, P129, DOI 10.1016/S0022-5193(86)80169-2                                                   
   STENBERG M, 1988, J IMMUNOL METHODS, V113, P3, DOI 10.1016/0022-1759(88)90376-6
   Stoeva SI, 2006, J AM CHEM SOC, V128, P8378, DOI 10.1021/ja0613106
   Stoeva SI, 2006, ANGEW CHEM INT EDIT, V45, P3303, DOI 10.1002/anie.200600124
   Tate Jill, 2004, Clin Biochem Rev, V25, P105
   Toepke MW, 2006, LAB CHIP, V6, P1484, DOI 10.1039/b612140c
   Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113
   Weissleder R, 2001, NAT BIOTECHNOL, V19, P316, DOI 10.1038/86684                                                                   
   Xia YN, 1998, ANNU REV MATER SCI, V28, P153, DOI 10.1146/annurev.matsci.28.1.153                                                 
   Xing Y, 2007, NAT PROTOC, V2, P1152, DOI 10.1038/nprot.2007.107
   Xuan XC, 2005, ELECTROPHORESIS, V26, P3552, DOI 10.1002/elps.200500298
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yotter RA, 2003, IEEE SENS J, V3, P288, DOI 10.1109/JSEN.2003.814651
   Yun KS, 2006, MEAS SCI TECHNOL, V17, P3178, DOI 10.1088/0957-0233/17/12/S10
NR 37
TC 117
Z9 119
U1 1
U2 57
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD SEP
PY 2007
VL 7
IS 9
BP 2812
EP 2818
DI 10.1021/nl071415m
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 211CM
UT WOS:000249501900049
PM 17705551
DA 2018-01-05
ER

PT J
AU Rawat, A
   Vaidya, B
   Khatri, K
   Goyal, AK
   Gupta, PN
   Mahor, S
   Paliwal, R
   Rai, S
   Vyas, SP
AF Rawat, A.
   Vaidya, B.
   Khatri, K.
   Goyal, A. K.
   Gupta, P. N.
   Mahor, S.
   Paliwal, R.
   Rai, S.
   Vyas, S. P.
TI Targeted intracellular delivery of therapeutics: an overview
SO PHARMAZIE
LA English
DT Review
ID PH-SENSITIVE LIPOSOMES; RECEPTOR-MEDIATED ENDOCYTOSIS; EFFICIENT
   GENE-TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS; VASCULAR ENDOTHELIAL-CELLS;
   POLYLYSINE DNA COMPLEXES; CATIONIC LIPOSOMES; FOLATE RECEPTOR;
   DRUG-DELIVERY; IN-VIVO
AB During the last decade, intracellular drug delivery has become an emerging area of research in the medical and pharmaceutical field. Many therapeutic agents such as drugs and DNA/oligonucleotides can be delivered not just to the cell but also to a particular compartment of that cell to achieve better activity e.g. proapoptotic drugs to the mitochondria, antibiotics and enzymes to the lysosomes and various anticancer drugs and gene to the nucleus. The lipidic nature of biological membrans is the major obstacle to the intracellular delivery of macromolecular and ionic drugs. Additionally, after endocytosis, the lysosome, the major degradation compartment, needs to be avoided for better activity. To avoid these problems, various carriers have been investigated for efficient intracellular delivery, either by direct entry to cytoplasm or by escaping the endosomal compartment. These include cell penetrating peptides, and carrier systems such as liposomes, cationic lipids and polymers, polymeric nanoparticles, etc. Various properties of these carriers, including size, surface charge, composition and the presence of cell specific ligands, alter their efficacy and specificity towards particular cells. This review summarizes various aspects of targeted intracellular delivery of therapeutics including pathways, mechanisms and approaches. Various carrier constructs having potential for targeted intracellular delivery are also been discussed.
C1 Dept Pharmaceut Sci, Drug Delivery Res Lab, Sagar 470003, Madhya Pradesh, India.
RP Vyas, SP (reprint author), Dept Pharmaceut Sci, Drug Delivery Res Lab, Sagar 470003, Madhya Pradesh, India.
EM vyas_sp@rediffmail.com
CR Ahmed OAA, 2005, PHARM RES, V22, P972, DOI 10.1007/s11095-005-4592-1
   Almofti MR, 2003, ARCH BIOCHEM BIOPHYS, V410, P246, DOI 10.1016/S0003-9861(02)00725-7
   Azzam T, 2004, J CONTROL RELEASE, V96, P309, DOI 10.1016/j.jconrel.2004.01.022
   BAGAI S, 1993, FEBS LETT, V326, P183, DOI 10.1016/0014-5793(93)81787-Z                                                    
   Bailey AL, 1997, BIOCHEMISTRY-US, V36, P1628, DOI 10.1021/bi961173x
   BEHR JP, 1989, P NATL ACAD SCI USA, V86, P6982, DOI 10.1073/pnas.86.18.6982
   BELCHETZ PE, 1977, LANCET, V2, P116
   Belting M, 2005, ADV DRUG DELIVER REV, V57, P505, DOI 10.1016/j.addr.2004.10.004
   BENACHIR T, 1995, BBA-BIOMEMBRANES, V1235, P452, DOI 10.1016/0005-2736(95)80035-E                                                    
   BERTLING WM, 1991, BIOTECHNOL APPL BIOC, V13, P390
   Blau S, 2000, CRIT REV THER DRUG, V17, P425
   BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0                                                                
   Boddapati SV, 2005, J LIPOSOME RES, V15, P49, DOI 10.1081/LPR-200064958
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   BRON R, 1994, BIOCHEMISTRY-US, V33, P9110, DOI 10.1021/bi00197a013
   BRON R, 1993, METHOD ENZYMOL, V220, P313, DOI 10.1016/0076-6879(93)20091-G
   BROWN LF, 1993, AM J PATHOL, V143, P1255
   BROWN MS, 1983, CELL, V32, P663, DOI 10.1016/0092-8674(83)90052-1
   Bulmus V, 2005, AUST J CHEM, V58, P411, DOI 10.1071/CH05066
   Bulmus V, 2003, J CONTROL RELEASE, V93, P105, DOI 10.1016/j.jconrel.2003.06.001
   Burrows FJ, 1995, CLIN CANCER RES, V1, P1623
   CHAVANY C, 1994, PHARMACEUT RES, V11, P1370, DOI 10.1023/A:1018923301967
   CHAVANY C, 1992, PHARMACEUT RES, V9, P441, DOI 10.1023/A:1015871809313
   Cheng SM, 2005, J DRUG DELIV SCI TEC, V15, P81, DOI 10.1016/S1773-2247(05)50010-8                                                   
   Chiu SJ, 2006, ANTICANCER RES, V26, P1049
   Cho YW, 2003, J PHARM PHARMACOL, V55, P721, DOI 10.1211/0022357021206
   Choi Y, 2005, CHEM BIOL, V12, P35, DOI 10.1016/j.chembiol.2004.10.016
   CHU CJ, 1990, PHARMACEUT RES, V7, P824, DOI 10.1023/A:1015908831507                                                         
   Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
   COLLINS D, 1989, BIOCHIM BIOPHYS ACTA, V987, P47, DOI 10.1016/0005-2736(89)90453-7                                                    
   COLLINS DS, 1992, J IMMUNOL, V148, P3336
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   COUVREUR P, 1993, ADV DRUG DELIVER REV, V10, P141, DOI 10.1016/0169-409X(93)90046-7                                                    
   Csaba N, 2005, BIOMACROMOLECULES, V6, P271, DOI 10.1021/bm049577p
   CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1                                                    
   Curnis F, 2000, NAT BIOTECHNOL, V18, P1185
   D'Souza GGM, 2003, J CONTROL RELEASE, V92, P189, DOI 10.1016/S0168-3659(03)00297-9
   DEGOLS G, 1989, NUCLEIC ACIDS RES, V17, P9341, DOI 10.1093/nar/17.22.9341
   DeLong R, 1997, J PHARM SCI, V86, P762, DOI 10.1021/js960409f                                                               
   Deshayes S, 2005, CELL MOL LIFE SCI, V62, P1839, DOI 10.1007/s00018-005-5109-0
   Dias N, 2005, BIOCHEM PHARMACOL, V70, P1, DOI 10.1016/j.bcp.2005.03.021
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Dubey PK, 2004, J DRUG TARGET, V12, P257, DOI 10.1080/10611860410001728040
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Emile C, 1996, Drug Deliv, V3, P187, DOI 10.3109/10717549609029449
   EUM K M, 1989, Biochemistry, V28, P8206, DOI 10.1021/bi00446a036
   Fattal E, 1998, J CONTROL RELEASE, V53, P137, DOI 10.1016/S0168-3659(97)00246-0                                                   
   Feener EP, 1998, ADV DRUG DELIVER REV, V29, P197, DOI 10.1016/S0169-409X(97)00079-3
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Felnerova D, 2004, CURR OPIN BIOTECH, V15, P518, DOI 10.1016/j.copbio.2004.10.005
   Fonseca C, 2005, EUR J PHARM BIOPHARM, V59, P359, DOI 10.1016/j.ejpb.2004.08.012
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Funhoff AM, 2004, BIOMACROMOLECULES, V5, P32, DOI 10.1021/bm034041+
   Gabizon A, 2003, CLIN CANCER RES, V9, P6551
   Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124                                                               
   Gao X, 1995, GENE THER, V2, P710
   Gosk T, 2004, J CEREBR BLOOD F MET, V24, P1193, DOI 10.1097/01.WCB.0000135592.28823.47
   Gottschalk S, 1996, GENE THER, V3, P448
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GREGORIADIS G, 1978, NATURE, V275, P695, DOI 10.1038/275695a0
   Griffiths PC, 2004, BIOMACROMOLECULES, V5, P1422, DOI 10.1021/bm049936g
   Guo WJ, 1999, AAPS PHARMSCI, V1
   Gupta AK, 2003, IEEE T NANOBIOSCI, V2, P255, DOI 10.1109/TNB.2003.820279
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B
   GUTOWSKA A, 1992, J CONTROL RELEASE, V22, P95, DOI 10.1016/0168-3659(92)90194-V                                                    
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89
   HANSEN SH, 1991, J CELL BIOL, V113, P731, DOI 10.1083/jcb.113.4.731
   Harris J, 2002, TRENDS IMMUNOL, V23, P158, DOI 10.1016/S1471-4906(01)02161-5
   HEGE KM, 1989, BLOOD, V74, P2043
   Hu Y, 2004, DRUG DEV IND PHARM, V30, P135, DOI 10.1081/DDC-120028708
   Ishida E, 2004, PHARM RES, V21, P932, DOI 10.1023/B:PHAM.0000029280.39882.ff
   Ishida K, 1997, J MOL EVOL, V45, P682, DOI 10.1007/PL00006272
   JAASKELAINEN I, 1994, BBA-BIOMEMBRANES, V1195, P115, DOI 10.1016/0005-2736(94)90017-5
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   KAMATA H, 1994, NUCLEIC ACIDS RES, V22, P536, DOI 10.1093/nar/22.3.536
   KAMIYA H, 2002, NUCL ACIDS RES S, V2, P85
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   KARP G, 1999, CELL MOL BIOL CONCEP, P323
   Kaul G, 2002, PHARMACEUT RES, V19, P1061, DOI 10.1023/A:1016486910719                                                         
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kiang T, 2004, J BIOMAT SCI-POLYM E, V15, P1405, DOI 10.1163/1568562042368112
   Kichler A, 2003, P NATL ACAD SCI USA, V100, P1564, DOI 10.1073/pnas.0337677100
   Kichler A, 2001, J GENE MED, V3, P135, DOI 10.1002/jgm.173                                                                 
   Kim T, 2004, BIOMACROMOLECULES, V5, P2487, DOI 10.1021/bm049563j
   KIM YH, 1994, J CONTROL RELEASE, V28, P143
   Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   Lackey CA, 1999, BIOCONJUGATE CHEM, V10, P401, DOI 10.1021/bc980109k                                                               
   Langner M, 2000, CELL MOL BIOL LETT, V5, P295
   Lappalainen K, 1997, J HISTOCHEM CYTOCHEM, V45, P265, DOI 10.1177/002215549704500211                                                      
   LAPPALAINEN K, 1994, PHARMACEUT RES, V11, P1127, DOI 10.1023/A:1018932714745
   LEAR JD, 1987, J BIOL CHEM, V262, P6500
   Lechardeur D, 2005, ADV DRUG DELIVER REV, V57, P755, DOI 10.1016/j.addr.2004.12.008
   LEE RJ, 1994, J BIOL CHEM, V269, P3198
   Leroux JC, 2001, J CONTROL RELEASE, V72, P71, DOI 10.1016/S0168-3659(01)00263-2                                                   
   Levchenko TS, 2003, METHOD ENZYMOL, V372, P339
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li YC, 2002, LIFE SCI, V71, P2729, DOI 10.1016/S0024-3205(02)02103-3
   Lim YB, 2002, BIOCONJUGATE CHEM, V13, P952, DOI 10.1021/bc025541n
   LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Lloyd JB, 2000, ADV DRUG DELIVER REV, V41, P189, DOI 10.1016/S0169-409X(99)00065-4
   Majoros IJ, 2006, BIOMACROMOLECULES, V7, P572, DOI 10.1021/bm0506142
   Martin B, 2005, CURR PHARM DESIGN, V11, P375, DOI 10.2174/1381612053382133
   Maruyama A, 1997, BIOCONJUGATE CHEM, V8, P735, DOI 10.1021/bc9701048
   Maruyama K, 2004, J CONTROL RELEASE, V98, P195, DOI 10.1016/j.jconrel.2004.04.018
   MATTEO PD, 2006, MOL IMMUNOL, V43, P1509
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   Meyer O, 1998, FEBS LETT, V421, P61, DOI 10.1016/S0014-5793(97)01520-2
   Midoux P, 1998, BIOCONJUGATE CHEM, V9, P260, DOI 10.1021/bc9701611
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   Mishra V, 2006, J DRUG TARGET, V14, P45, DOI 10.1080/10611860600612953
   MISLICK KA, 1995, BIOCONJUGATE CHEM, V6, P512, DOI 10.1021/bc00035a002
   Mitra A, 2005, J CONTROL RELEASE, V102, P191, DOI 10.1016/j.jconrel.2004.09.023
   Mizoue T, 2002, INT J PHARM, V237, P129, DOI 10.1016/S0378-5173(02)00044-3                                                   
   MODICANAPOLITAN.JS, 2002, EXP REV MOL MED
   Moghimi SM, 2000, ADV DRUG DELIVER REV, V41, P129, DOI 10.1016/S0169-409X(99)00060-5                                                   
   MOLEMA G, 1994, ADV DRUG DELIVER REV, V14, P25, DOI 10.1016/0169-409X(94)90004-3
   Mukherjee S, 1997, PHYSIOL REV, V77, P759
   Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1
   Murthy N, 1999, J CONTROL RELEASE, V61, P137, DOI 10.1016/S0168-3659(99)00114-5
   Murthy N, 2003, BIOCONJUGATE CHEM, V14, P412, DOI 10.1021/bc020056d
   Murthy N, 2003, J CONTROL RELEASE, V89, P365, DOI 10.1016/S0168-3659(03)00099-3
   Nakada Y, 1996, PHARMACEUT RES, V13, P38, DOI 10.1023/A:1016017014573
   Nakanishi M, 2001, ADV DRUG DELIVER REV, V52, P197, DOI 10.1016/S0169-409X(01)00207-1                                                   
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257
   Ni S, 2002, ANTICANCER RES, V22, P2131
   Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   PALIWAL R, IN PRESS CURR DRUG D
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Panyam J, 2003, PHARMACEUT RES, V20, P212, DOI 10.1023/A:1022219003551                                                         
   Panyam J, 2003, INT J PHARM, V262, P1, DOI 10.1016/S0378-5173(03)00295-3
   PANYAM J, 2004, CURR DRUG DELIV, V1, P1
   PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8713, DOI 10.1021/bi00489a030
   Park JS, 2006, J CONTROL RELEASE, V115, P37, DOI 10.1016/j.jconrel.2006.07.011
   Pasqualini R, 2000, CANCER RES, V60, P722
   Pastorino F, 2003, CANCER RES, V63, P7400
   Patil SD, 2005, AAPS J, V7, pE61, DOI 10.1208/aapsj070109
   Plank C, 1998, ADV DRUG DELIVER REV, V34, P21, DOI 10.1016/S0169-409X(98)00005-2                                                   
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Podbilewicz B, 1996, MOL BIOL CELL, V7, P1877
   Pooga M, 1998, FASEB J, V12, P67
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Quintana A, 2002, PHARMACEUT RES, V19, P1310, DOI 10.1023/A:1020398624602
   RACOOSIN EL, 1993, J CELL BIOL, V121, P1011, DOI 10.1083/jcb.121.5.1011                                                          
   RACOOSIN EL, 1992, J CELL SCI, V102, P867
   Reddy JA, 2000, J CONTROL RELEASE, V64, P27, DOI 10.1016/S0168-3659(99)00135-2                                                   
   Reddy JA, 2002, GENE THER, V9, P1542, DOI 10.1038/sj.gt.3301833
   Rijnboutt S, 1996, J CELL BIOL, V132, P35, DOI 10.1083/jcb.132.1.35
   Rinne J, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-1
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   RODRIGUEZCRESPO I, 1995, J GEN VIROL, V76, P301, DOI 10.1099/0022-1317-76-2-301                                                      
   Rozenzhak SM, 2005, CHEM COMMUN, P2217, DOI 10.1039/b418454h
   Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977
   Sanchez G, 2002, BIOL RES, V35, P39, DOI 10.4067/S0716-97602002000100007
   Sarti P, 1996, BIOTECHNOL APPL BIOC, V24, P269
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Seow WY, 2007, BIOMATERIALS, V28, P1730, DOI 10.1016/j.biomaterials.2006.11.039
   Shao K, 2006, J CONTROL RELEASE, V115, P150, DOI 10.1016/j.jconrel.2006.07.024
   Shi GF, 2002, J CONTROL RELEASE, V80, P309, DOI 10.1016/S0168-3659(02)00017-2
   Simkiss K, 1998, COMP BIOCHEM PHYS A, V120, P17, DOI 10.1016/S1095-6433(98)10004-1                                                   
   Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038
   Singla AK, 2001, J PHARM PHARMACOL, V53, P1047, DOI 10.1211/0022357011776441                                                        
   Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x
   Spagnou S, 2004, BIOCHEMISTRY-US, V43, P13348, DOI 10.1021/bi048950a
   Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795
   Sudimack JJ, 2002, BBA-BIOMEMBRANES, V1564, P31, DOI 10.1016/S0005-2736(02)00399-1
   Suk JS, 2006, BIOMATERIALS, V27, P5143, DOI 10.1016/j.biomaterials.2006.05.013
   Sweeney P, 2003, CANCER RES, V63, P4017
   TAKAKURA K, 1994, EUR J PHARMACOL, V271, P367
   Takei K, 2001, TRENDS CELL BIOL, V11, P385, DOI 10.1016/S0962-8924(01)02082-7
   Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin V. P., 1993, J LIPOSOME RES, V3, P201
   TROUNG VL, 1998, HUM GENE THER, V9, P1706
   Turner C, 2002, J LIPOSOME RES, V12, P311, DOI 10.1081/LPR-120016197
   van de Wetering P, 1999, BIOCONJUGATE CHEM, V10, P589, DOI 10.1021/bc980148w                                                               
   van Rossenberg SMW, 2002, J BIOL CHEM, V277, P45803, DOI 10.1074/jbc.M203510200
   van Steenis JH, 2003, J CONTROL RELEASE, V87, P167, DOI 10.1016/S0168-3659(02)00361-9
   Varga CM, 2000, BIOTECHNOL BIOENG, V70, P593, DOI 10.1002/1097-0290(20001220)70:6<593::AID-BIT1>3.0.CO;2-N
   Vasir JK, 2006, EXPERT OPIN DRUG DEL, V3, P325, DOI 10.1517/17425247.3.3.325
   Venugopalan P, 2002, PHARMAZIE, V57, P659
   Vinogradov SV, 2004, BIOCONJUGATE CHEM, V15, P50, DOI 10.1021/bc034164r
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vyas SP, 2000, ADV DRUG DELIVER REV, V43, P101, DOI 10.1016/S0169-409X(00)00067-3                                                   
   Vyas SP, 2001, CRIT REV THER DRUG, V18, P1
   VYAS SP, 2002, TRAGETED CONTROLLED, P217
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   WANG CY, 1987, P NATL ACAD SCI USA, V84, P7851, DOI 10.1073/pnas.84.22.7851
   WATTS C, 1992, J CELL SCI, V103, P1
   Weissig V, 2004, MITOCHONDRION, V3, P229, DOI 10.1016/j.mito.2003.11.002
   Weissig V, 1998, PHARMACEUT RES, V15, P334, DOI 10.1023/A:1011991307631
   Weissig V, 2001, J CONTROL RELEASE, V75, P401, DOI 10.1016/S0168-3659(01)00392-3
   Weissig V, 2006, J LIPOSOME RES, V16, P249, DOI 10.1080/08982100600851169
   Weyermann J, 2004, EUR J PHARM BIOPHARM, V58, P25, DOI 10.1016/j.ejpb.2004.02.011
   Wiethoff CM, 2003, J PHARM SCI, V92, P203, DOI 10.1002/jps.10286
   WILEMAN T, 1985, BIOCHEM J, V232, P1
   WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A
   WU GY, 1988, BIOCHEMISTRY-US, V27, P887, DOI 10.1021/bi00403a008                                                             
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Xi KL, 1996, PHARMACEUT RES, V13, P1846, DOI 10.1023/A:1016037225728
   Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019
   XUE FL, 2007, IN PRESS J FLUORESC
   Yamada Y, 2005, INT J PHARM, V303, P1, DOI 10.1016/j.ijpharm.2005.06.009
   YAMASHIRO DJ, 1984, J CELL BIOCHEM, V26, P231, DOI 10.1002/jcb.240260404
   Zanta MA, 1997, BIOCONJUGATE CHEM, V8, P839, DOI 10.1021/bc970098f                                                               
   Zareie HM, 2000, POLYMER, V41, P6723, DOI 10.1016/S0032-3861(00)00008-2
   Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493
   ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655
   Zhang LK, 2004, INT J PHARMACEUT, V287, P155, DOI 10.1016/j.ijpharm.2004.08.015
   ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3                                                    
   ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073
   Zignani M, 2000, BBA-BIOMEMBRANES, V1463, P383, DOI 10.1016/S0005-2736(99)00234-5
   Zobel HP, 1997, ANTISENSE NUCLEIC A, V7, P483, DOI 10.1089/oli.1.1997.7.483                                                        
NR 220
TC 20
Z9 22
U1 1
U2 23
PU GOVI-VERLAG  PHARMAZEUTISCHER VERLAG GMBH
PI ESCHBORN
PA PHARMAZEUTISCCARL MANNICH STR 26, D-65760 ESCHBORN, GERMANY
SN 0031-7144
J9 PHARMAZIE
JI Pharmazie
PD SEP
PY 2007
VL 62
IS 9
BP 643
EP 658
DI 10.1691/ph.2007.9.7072
PG 16
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 217JC
UT WOS:000249943200001
PM 17944316
DA 2018-01-05
ER

PT J
AU Morningstar, ML
   Roth, T
   Farnsworth, DW
   Smith, MK
   Watson, K
   Buckheit, RW
   Das, K
   Zhang, WY
   Arnold, E
   Julias, JG
   Hughes, SH
   Michejda, CJ
AF Morningstar, Marshall L.
   Roth, Thomas
   Farnsworth, David W.
   Smith, Marilyn Kroeger
   Watson, Karen
   Buckheit, Robert W., Jr.
   Das, Kalyan
   Zhang, Wanyi
   Arnold, Eddy
   Julias, John G.
   Hughes, Stephen H.
   Michejda, Christopher J.
TI Synthesis, biological activity, and crystal structure of potent
   nonnucleoside inhibitors of HIV-1 reverse transcriptase that retain
   activity against mutant forms of the enzyme
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID POSITIONAL ADAPTABILITY; HIGHLY POTENT; WILD-TYPE; DRUG;
   THIAZOLOBENZIMIDAZOLE; REPLICATION; DERIVATIVES; DISCOVERY; INVITRO;
   BINDING
AB In an ongoing effort to develop novel and potent nonnucleoside HIV-1 reverse transcriptase (RT) inhibitors that are effective against the wild type (WT) virus and clinically observed mutants, 1,2-bis-substituted benzimidazoles were synthesized and tested. Optimization of the N1 and C2 positions of benzimidazole led to the development of 1-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)-4-methylbenzimidazole (1) (IC50 = 0.2 mu M, EC50 = 0.44 mu M, and TC50 >= 100 against WT). This paper describes how substitution on the benzimidazole ring profoundly affects activity. Substituents at the benzimidazole C4 dramatically enhanced potency, while at C5 or C6 substituents were generally detrimental or neutral to activity, respectively. A 7-methyl analogue did not inhibit HIV-1 RT. Determination of the crystal structure of 1 bound to RT provided the basis for accurate modeling of additional analogues, which were synthesized and tested. Several derivatives were nanomolar inhibitors of wild-type virus and were effective against clinically relevant HIV-1 mutants.
C1 NCI, Mol Aspects Drug Design Sect, Frederick, MD 21702 USA.
   NCI, Retroviral Replicat Lab, Frederick, MD 21702 USA.
   McDaniel Coll, Westminster, MD 21157 USA.
   So Res Inst, Frederick Res Ctr, Frederick, MD 21701 USA.
   Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.
   Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.
RP Farnsworth, DW (reprint author), NCI, Mol Aspects Drug Design Sect, POB B, Frederick, MD 21702 USA.
EM farnswor@ncifcrf.gov
FU NIGMS NIH HHS [P01 GM066671-04, P01 GM066671, P01 GM 56671]; Intramural
   NIH HHS; NIAID NIH HHS [R37 AI027690-18, R37 AI027690, AI 27690]
CR Brunger AT, 1998, CURR OPIN STRUC BIOL, V8, P606, DOI 10.1016/S0959-440X(98)80152-8
   BUCKHEIT RW, 1993, ANTIVIR RES, V21, P247, DOI 10.1016/0166-3542(93)90031-D                                                    
   Campiani G, 2002, CURR PHARM DESIGN, V8, P615, DOI 10.2174/1381612024607207                                                        
   CHIMIRRI A, 1991, FARMACO, V46, P817
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   De Clercq E, 2002, MINI-REV MED CHEM, V2, P163, DOI 10.2174/1389557024605474
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   ELDAREER SM, 1993, DRUG METAB DISPOS, V21, P231
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   JORGENSEN WL, MCPRO VERSION 2 0
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   OTWINOWSKI Z, 2001, INT TABLES CRYSTALLO, P226
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   ROMERO DL, 1994, J MED CHEM, V37, P999, DOI 10.1021/jm00033a018
   Roth T, 1997, J MED CHEM, V40, P4199, DOI 10.1021/jm970096g
   Smith MBK, 2003, J MED CHEM, V46, P1940, DOI 10.1021/jm020271f
   WEISLOW OS, 1989, J NATL CANCER I, V81, P557
   WOOD JL, 1979, TETRAHEDRON LETT, V51, P4907
   YANG S, 1995, LEUKEMIA S1, pS75
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
NR 24
TC 67
Z9 70
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 23
PY 2007
VL 50
IS 17
BP 4003
EP 4015
DI 10.1021/jm060103d
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 200JB
UT WOS:000248758600006
PM 17663538
OA green_accepted
DA 2018-01-05
ER

PT J
AU Zhang, K
   Chen, ZY
   Germack, DS
   Zhang, YM
   Fang, HF
   Taylor, JSA
   Wooley, KL
AF Zhang, Ke
   Chen, Zhiyun
   Germack, David S.
   Zhang, Yanming
   Fang, Huafeng
   Taylor, John-Stephen A.
   Wooley, Karen L.
TI Shape effects of nanoparticles conjugated with cell-penetrating peptide
   (HIV Tat PTD) on CHO cell uptake
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Zhang, Ke; Chen, Zhiyun; Germack, David S.; Wooley, Karen L.] Washington Univ, Ctr Mat Innovat, Dept Chem, St Louis, MO 63130 USA.
   [Zhang, Ke; Chen, Zhiyun; Germack, David S.; Wooley, Karen L.] Washington Univ, Dept Radiol, St Louis, MO 63130 USA.
EM kzhang@artsci.wustl.edu; zchenb@artsci.wustl.edu;
   dsgermac@artsci.wustl.edu; hfang@artsci.wustl.edu;
   taylor@wuchem.wustl.edu; klwooley@artsci.wustl.edu
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD AUG 19
PY 2007
VL 234
MA 465-PMSE
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V12IW
UT WOS:000207593905732
DA 2018-01-05
ER

PT J
AU Vasir, JK
   Labhasetwar, V
AF Vasir, Jaspreet K.
   Labhasetwar, Vinod
TI Biodegradable nanoparticles for cytosolic delivery of therapeutics
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE biodegradable polymers; nanoparticles; sustained release; gene delivery;
   drug delivery; cellular uptake; endocytosis
ID CELL-PENETRATING PEPTIDES; PH-SENSITIVE LIPOSOMES; HIV-1 TAT-PEPTIDE;
   GENE DELIVERY; IN-VITRO; INTRACELLULAR DELIVERY; CYTOPLASMIC DELIVERY;
   MEDIATED DELIVERY; POLY(DL-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES; INDUCED
   DESTABILIZATION
AB Many therapeutics require efficient cytosolic delivery either because the receptors for those drugs are located in the cytosol or their site of action is an intracellular organelle that requires transport through the cytosolic compartment. To achieve efficient cytosolic delivery of therapeutics, different nanomaterials have been developed that consider the diverse physicochemical nature of therapeutics (macromolecule to small molecule; water soluble to water insoluble) and various membrane associated and intracellular barriers that these systems need to overcome to efficiently deliver and retain therapeutics in the cytoplasmic compartment. Our interest is in investigating PLGA and PLA-based nanoparticles for intracellular delivery of drugs and genes. The present review discusses the various aspects of our studies and emphasizes the need for understanding of the molecular mechanisms of intracellular trafficking of nanoparticles in order to develop an efficient cytosolic delivery system. (C) 2007 Elsevier B.V. All rights reserved.
C1 Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA.
RP Labhasetwar, V (reprint author), Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA.
EM labhasv@ccf.org
FU NCI NIH HHS [CA121751]; NIBIB NIH HHS [R01 EB003975, R01 EB003975-01A1];
   NIMH NIH HHS [R21 MH67525]
CR Al-Taei S, 2006, BIOCONJUGATE CHEM, V17, P90, DOI 10.1021/bc050274h
   Alexeyev Mikhail F, 2004, Methods Mol Biol, V267, P91
   Arangoa MA, 2003, GENE THER, V10, P5, DOI 10.1038/sj.gt.3301840
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Bailey AL, 1997, BBA-BIOMEMBRANES, V1324, P232, DOI 10.1016/S0005-2736(96)00228-3
   Bengali Z, 2005, BIOTECHNOL BIOENG, V90, P290, DOI 10.1002/bit.20393
   Benns JM, 2000, J DRUG TARGET, V8, P1, DOI 10.3109/10611860009009205
   Chu Chun-Jung, 1994, Journal of Liposome Research, V4, P361, DOI 10.3109/08982109409037050
   CHU CJ, 1990, PHARMACEUT RES, V7, P824, DOI 10.1023/A:1015908831507                                                         
   Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
   COLLINS D, 1990, BIOCHIM BIOPHYS ACTA, V1025, P234, DOI 10.1016/0005-2736(90)90102-T
   Collins D, 1995, LIPOSOMES TOOLS BASI, P201
   CONNOR J, 1986, BIOCHIM BIOPHYS ACTA, V884, P474, DOI 10.1016/0304-4165(86)90197-2
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dincer S, 2005, GENE THER, V12, pS139, DOI 10.1038/sj.gt.3302628
   Dodart JC, 2005, P NATL ACAD SCI USA, V102, P1211, DOI 10.1073/pnas.0409072102
   ELLENS H, 1984, BIOCHEMISTRY-US, V23, P1532, DOI 10.1021/bi00302a029                                                             
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1                                                             
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Fotin-Mleczek M, 2005, J CELL SCI, V118, P3339, DOI 10.1242/jcs.02460
   Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607
   Hawley AE, 1997, PHARMACEUT RES, V14, P657, DOI 10.1023/A:1012117531448
   HO RJY, 1986, BIOCHEMISTRY-US, V25, P5500, DOI 10.1021/bi00367a023
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Kono K, 1997, BBA-BIOMEMBRANES, V1325, P143, DOI 10.1016/S0005-2736(96)00244-1
   Koul S, 2005, AM J NEPHROL, V25, P176, DOI 10.1159/000085410
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   LIU DX, 1990, BIOCHIM BIOPHYS ACTA, V1022, P348, DOI 10.1016/0005-2736(90)90284-U
   LIU DX, 1989, BIOCHIM BIOPHYS ACTA, V981, P254, DOI 10.1016/0005-2736(89)90035-7                                                    
   LIU DX, 1989, BIOCHEMISTRY-US, V28, P7700, DOI 10.1021/bi00445a027
   LIU DX, 1991, BIOCHIM BIOPHYS ACTA, V1066, P159, DOI 10.1016/0005-2736(91)90182-8                                                    
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   Murakami H, 1999, INT J PHARM, V187, P143, DOI 10.1016/S0378-5173(99)00187-8
   Murthy N, 2003, BIOCONJUGATE CHEM, V14, P412, DOI 10.1021/bc020056d
   Nakanishi M, 2001, EUR J PHARM SCI, V13, P17, DOI 10.1016/S0928-0987(00)00203-7
   Neal JC, 1998, J PHARM SCI, V87, P1242, DOI 10.1021/js970462j                                                               
   Nir S, 1999, MOL MEMBR BIOL, V16, P95, DOI 10.1080/096876899294814                                                         
   NITTIN N, 2004, NUCLEIC ACIDS RES, V32, pE58
   Otsuka H, 2003, ADV DRUG DELIVER REV, V55, P403, DOI 10.1016/S0169-409X(02)00226-0
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Panyam J, 2003, PHARMACEUT RES, V20, P212, DOI 10.1023/A:1022219003551                                                         
   Panyam Jayanth, 2004, Current Drug Delivery, V1, P235, DOI 10.2174/1567201043334768
   Panyam J, 2004, MOL PHARMACEUT, V1, P77, DOI 10.1021/mp034002c
   Park YJ, 2003, J GENE MED, V5, P700, DOI 10.1002/jgm.402
   Perez C, 2001, J CONTROL RELEASE, V75, P211, DOI 10.1016/S0168-3659(01)00397-2                                                   
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Prabha S, 2004, PHARM RES, V21, P354, DOI 10.1023/B:PHAM.0000016250.56402.99
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0
   Prabha S, 2004, MOL PHARMACEUT, V1, P211, DOI 10.1021/mp049970+
   Provoda CJ, 2003, J BIOL CHEM, V278, P35102, DOI 10.1074/jbc.M305411200
   Qu BX, 2006, J NEUROL SCI, V244, P151, DOI 10.1016/j.jns.2006.02.006
   Redhead HM, 2001, J CONTROL RELEASE, V70, P353, DOI 10.1016/S0168-3659(00)00367-9                                                   
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   ROPERT C, 1995, STRATEGIES OLIGONUCL, P151
   Rudolph C, 2004, PHARM RES, V21, P1662, DOI 10.1023/B:PHAM.0000041463.56768.ec                                              
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Sahoo SK, 2005, MOL PHARMACEUT, V2, P373, DOI 10.1021/mp050032z
   Sahoo SK, 2004, INT J CANCER, V112, P335, DOI 10.1002/ijc.20405
   SCHROIT AJ, 1986, CHEM PHYS LIPIDS, V40, P373, DOI 10.1016/0009-3084(86)90080-0
   Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038
   STOLNIK S, 1994, PHARMACEUT RES, V11, P1800, DOI 10.1023/A:1018931820564
   STRAUBINGER RM, 1985, FEBS LETT, V179, P148, DOI 10.1016/0014-5793(85)80210-6                                                    
   Subramanian A, 1999, NAT BIOTECHNOL, V17, P873
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Tobio M, 1999, PHARMACEUT RES, V16, P682, DOI 10.1023/A:1018820507379
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Turk MJ, 2002, BBA-BIOMEMBRANES, V1559, P56, DOI 10.1016/S0005-2736(01)00441-2
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wagner E, 1999, ADV DRUG DELIVER REV, V38, P279, DOI 10.1016/S0169-409X(99)00033-2                                                   
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Ziegler A, 2005, BIOCHEMISTRY-US, V44, P138, DOI 10.1021/bi0491604
NR 75
TC 280
Z9 294
U1 6
U2 84
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD AUG 10
PY 2007
VL 59
IS 8
BP 718
EP 728
DI 10.1016/j.addr.2007.06.003
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 217FY
UT WOS:000249935000003
PM 17683826
OA green_accepted
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Howl, J
   Nicholl, ID
   Jones, S
AF Howl, J.
   Nicholl, I. D.
   Jones, S.
TI The many futures for cell-penetrating peptides: how soon is now?
SO BIOCHEMICAL SOCIETY TRANSACTIONS
LA English
DT Article
DE endocytosis; oligonucleotide; penetratin; transactivator of
   transcription (Tat); therapeutics; translocation
ID IN-VIVO; DELIVERY; INTERNALIZATION
AB Studies of CPPs (cell-penetrating peptides), sequences that are also commonly designated as protein transduction domains, now extend to a second decade of exciting and far-reaching discoveries. CPPs are proven vehicles for the intracellular delivery of macromolecules that include oligonucleotides, peptides and proteins, low-molecular-mass drugs, nanoparticles and liposomes. The biochemical properties of different classes of CPP, including various sequences derived from the HIV-1 Tat (transactivator of transcription) [e.g. Tat-(48-60), GRKKRRQRRRPPQ], and the homeodomain of the Drosophila homeoprotein Antennapaedia (residues 43-58, commonly named penetratin, RQIKIWFQNRRMKWKK), also provide novel insights into the fundamental mechanisms of translocation across biological membranes. Thus the efficacy of CPP-mediated cargo delivery continues to provide valuable tools for biomedical research and, as witnessed in 2007, candidate and emerging therapeutics. Thus it is anticipated that the further refinement of CPP technologies will provide drug-delivery vectors, cellular imaging tools, nanoparticulate devices and molecular therapeutics that will have a positive impact on the healthcare arena. The intention of this article is to provide both a succinct overview of current developments and applications of CPP technologies, and to illustrate key developments that the concerted efforts of the many researchers contributing to the Biochemical Society's Focused Meeting in Telford predict for the future. The accompanying papers in this issue of Biochemical Society Transactions provide additional details and appropriate references. Hopefully, the important and eagerly anticipated biomedical and clinical developments within the CPP field will occur sooner rather than later.
C1 Wolverhampton Univ, Res Inst Healthcare Sci, Mol Pharmacol Res Grp, Wolverhampton WV1 1SB, England.
   Wolverhampton Univ, Res Inst Healthcare Sci, Canc Res Grp, Wolverhampton WV1 1SB, England.
RP Howl, J (reprint author), Wolverhampton Univ, Res Inst Healthcare Sci, Mol Pharmacol Res Grp, Wolverhampton WV1 1SB, England.
EM J.Howl@wlv.ac.uk
CR Abes R, 2007, BIOCHEM SOC T, V35, P775, DOI 10.1042/BST0350775                                                              
   Chen L, 2007, BIOCHEM SOC T, V35, P821, DOI 10.1042/BST0350821                                                              
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Enback J, 2007, BIOCHEM SOC T, V35, P780, DOI 10.1042/BST0350780                                                              
   Futaki S, 2007, BIOCHEM SOC T, V35, P784, DOI 10.1042/BST0350784                                                              
   Gomez JA, 2007, BIOCHEM SOC T, V35, P797, DOI 10.1042/BST0350797                                                              
   Hallbrink M, 2005, INT J PEPT RES THER, V11, P249, DOI 10.1007/s10989-005-9393-1
   Jarvert P, 2007, BIOCHEM SOC T, V35, P770
   Melnick A, 2007, BIOCHEM SOC T, V35, P802, DOI 10.1042/BST0350802                                                              
   Moschos SA, 2007, BIOCHEM SOC T, V35, P807, DOI 10.1042/BST0350807                                                              
   Moulton HM, 2007, BIOCHEM SOC T, V35, P826, DOI 10.1042/BST0350826                                                              
   PIPKORN P, 2007, BIOCHEM SOC T, V35, P829
   Pooga M, 1998, FASEB J, V12, P67
   Poon GMK, 2007, BIOCHEM SOC T, V35, P788, DOI 10.1042/BST0350788                                                              
   Pujals S, 2007, BIOCHEM SOC T, V35, P794, DOI 10.1042/BST0350794                                                              
   Rhyner C, 2007, BIOCHEM SOC T, V35, P833, DOI 10.1042/BST0350833                                                              
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Tilstra J, 2007, BIOCHEM SOC T, V35, P811, DOI 10.1042/BST0350811                                                              
   Torchilin VP, 2007, BIOCHEM SOC T, V35, P816, DOI 10.1042/BST0350816                                                              
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
NR 20
TC 28
Z9 29
U1 0
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0300-5127
J9 BIOCHEM SOC T
JI Biochem. Soc. Trans.
PD AUG
PY 2007
VL 35
BP 767
EP 769
DI 10.1042/BST0350767                                                      
          
PN 4
PG 3
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 204OG
UT WOS:000249053300034
PM 17635144
OA gold
DA 2018-01-05
ER

PT J
AU Akagi, T
   Wang, X
   Uto, T
   Baba, M
   Akashi, M
AF Akagi, Takami
   Wang, Xin
   Uto, Tomofumi
   Baba, Masanori
   Akashi, Mitsuru
TI Protein direct delivery to dendritic cells using nanoparticles based on
   amphiphilic poly(amino acid) derivatives
SO BIOMATERIALS
LA English
DT Article
DE nanoparticles; vaccine; protein delivery; dendritic cells;
   poly(gamma-glutamic acid)
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO; BIODEGRADABLE NANOPARTICLES;
   POLY(GAMMA-GLUTAMIC ACID); ANTIGEN PRESENTATION; ENZYMATIC DEGRADATION;
   IMMUNE-RESPONSES; PARTICLE UPTAKE; SURFACE-CHARGE; GENE DELIVERY
AB Induction of an adaptive immune response by vaccination is possible for a broad range of infectious diseases or cancers. Antigen-loaded polymeric nanoparticles have recently been shown to possess significant potential as vaccine delivery systems and adjuvants. Here we demonstrate the use of nanoparticles composed of amphiphilic poly(amino acid) derivatives as vaccine adjuvants. We prepared protein-loaded, biodegradable nanoparticles composed of hydrophobically modified poly(gamma-glutamic acid) (gamma-PGA). gamma-PGA hydrophobic derivatives (gamma-hPGA) formed 200 nm-sized nanoparticles in water. The protein-encapsulated gamma-hPGA nanoparticles were efficiently taken up by immature dendritic cells (iDCs). Interestingly, the nanoparticle uptake by iDCs induced DC maturation. The immunization with human immunodeficiency virus (HIV)-1 gp120-encapsulated nanoparticles strongly induced antigen-specific cellular immunity. These results suggest that antigen-loaded gamma-hPGA nanoparticles provide a novel delivery tool for vaccination against viral infections or tumors. This system has potential application as a universal delivery system for protein-based vaccines capable of inducing cytotoxic T lymphocyte (CTL). (c) 2007 Elsevier Ltd. All rights reserved.
C1 Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   Kagoshima Univ, Gard Sch Med & Dent Sci, Ctr Chron Viral dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
   Japn Sci & Technol Agcy, Core Res Evolut Sci & technol, Kawaguchi 3320012, Japan.
RP Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM akashi@chem.eng.osaka-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2006, BIOMACROMOLECULES, V7, P297, DOI 10.1021/bm050657i
   Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2006, J BIOMAT SCI-POLYM E, V17, P875, DOI 10.1163/156856206777996871
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Copland MJ, 2003, VACCINE, V21, P883, DOI 10.1016/S0264-410X(02)00536-4                                                   
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Fischer S, 2007, BIOMATERIALS, V28, P994, DOI 10.1016/j.biomaterials.2006.10.034
   Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035                                                   
   Fowke KR, 2000, IMMUNOL CELL BIOL, V78, P586, DOI 10.1046/j.1440-1711.2000.00944.x
   Gamvrellis A, 2004, IMMUNOL CELL BIOL, V82, P506, DOI 10.1111/j.1440-1711.2004.01271.x
   HARDING CV, 1994, J IMMUNOL, V153, P4925
   Huth US, 2006, J CONTROL RELEASE, V110, P490, DOI 10.1016/j.jconrel.2005.10.018
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Jilek S, 2004, PHARM RES, V21, P1240, DOI 10.1023/B:PHAM.0000033012.16152.5d                                              
   Jilek S, 2005, ADV DRUG DELIVER REV, V57, P377, DOI 10.1016/j.addr.2004.09.010
   Kaneko T, 2005, CHEM MATER, V17, P2484, DOI 10.1021/cm048196f
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   KLIKS SC, 1993, P NATL ACAD SCI USA, V90, P11518, DOI 10.1073/pnas.90.24.11518                                                        
   Kono K, 2005, BIOCONJUGATE CHEM, V16, P208, DOI 10.1021/bc049785e
   Kusonwiriyawong C, 2003, EUR J PHARM BIOPHARM, V56, P237, DOI 10.1016/S0939-6411(03)00093-6
   Kwon YJ, 2005, J CONTROL RELEASE, V105, P199, DOI 10.1016/j.jconrel.2005.02.027
   Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758
   Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828                                                         
   Matsusaki M, 2005, NANO LETT, V5, P2168, DOI 10.1021/nl050541s
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   Nixon DF, 1996, VACCINE, V14, P1523, DOI 10.1016/S0264-410X(96)00099-0
   Obst M, 2004, BIOMACROMOLECULES, V5, P1166, DOI 10.1021/bm049949u
   Ohmori N, 1998, BIOCHEM BIOPH RES CO, V245, P259, DOI 10.1006/bbrc.1998.8408                                                          
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Prodhomme EJF, 2003, BIOCONJUGATE CHEM, V14, P1148, DOI 10.1021/bc020019m
   ROBINSON WE, 1989, P NATL ACAD SCI USA, V86, P4710, DOI 10.1073/pnas.86.12.4710
   Shen H, 2006, IMMUNOLOGY, V117, P78, DOI 10.1111/j.1365-2567.2005.02268.x
   Shih IL, 2001, BIORESOURCE TECHNOL, V79, P207, DOI 10.1016/S0960-8524(01)00074-8
   Sun HF, 2003, VACCINE, V21, P849, DOI 10.1016/S0264-410X(02)00531-5                                                   
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
   Thiele L, 2003, PHARMACEUT RES, V20, P221, DOI 10.1023/A:1022271020390
   Thiele L, 2001, J CONTROL RELEASE, V76, P59, DOI 10.1016/S0168-3659(01)00412-6
   van de Weert M, 2000, PHARMACEUT RES, V17, P1159, DOI 10.1023/A:1026498209874                                                         
   Waeckerle-Men Y, 2006, VACCINE, V24, P1847, DOI 10.1016/j.vaccine.2005.10.032
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Yessine MA, 2006, EUR J PHARM BIOPHARM, V63, P1, DOI 10.1016/j.ejpb.2005.10.010
   Yih TC, 2006, J CELL BIOCHEM, V97, P1184, DOI 10.1002/jcb.20796
   Yoshida M, 2004, J BIOMED MATER RES A, V71A, P45, DOI 10.1002/jbm.a.30131
   Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777                                                   
NR 46
TC 123
Z9 126
U1 6
U2 59
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2007
VL 28
IS 23
BP 3427
EP 3436
DI 10.1016/j.biomaterials.2007.04.023
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 180KT
UT WOS:000247362700007
PM 17482261
DA 2018-01-05
ER

PT J
AU Kuo, YC
   Su, FL
AF Kuo, Yung-Chih
   Su, Fu-Lung
TI Transport of stavudine, delavirdine, and saquinavir across the
   blood-brain barrier by polybutylcyanoacrylate,
   methylmethacrylate-sulfopropylmethacrylate, and solid lipid
   nanoparticles
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE polybutylcyanoacrylate; methylmethacrylate-sulfopropylmethacrylate;
   solid lipid nanoparticle; blood-brain barrier; Anti-HIV agent; AIDS
ID IN-VITRO RELEASE; DRUG-DELIVERY; COPOLYMER NANOPARTICLES;
   ENDOTHELIAL-CELLS; PERMEABILITY; CARRIER; VIVO; PHARMACOKINETICS;
   DEGRADATION; ZIDOVUDINE
AB Permeability of the anti-human immunodeficiency virus (HIV) agents, including stavudine (D4T), delavirdine (DLV), and saquinavir (SQV), across the in vitro blood-brain barrier (BBB) was studied. Here, the anti-HIV agents were incorporated with polybutylcyanoacrylate (PBCA) nanoparticles (NPs), methyl methacrylate-sulfopropylmethacrylate (MMA-SPM) NPs, and solid lipid nanoparticles (SLNs). Transport of the anti-HIV agents across BBB is a key factor in their applications to the therapy of the acquired immunodeficiency syndrome (AIDS). Experimental results revealed that the drug order of the loading efficiency (LE) on PBCA and MMA-SPM was D4T > DLV > SQV. For the entrapment efficiency (EE) in SLNs, this order was reversed. Also, LE of D4T on MMA-SPM was larger than that on PBCA; however, the reverse was true for DLV and SQV. As the particle size increased, LE decreased and EE increased. For a fixed drug carrier, an increase in the particle size yielded a decrease in the BBB permeability coefficient of the anti-HIV agents. Moreover, enhancement in the BBB permeability was on the carrier order of PBCA > MMA-SPM > SLNs for D4T, and for DLV and SQV the order became PBCA > SLNs > MMA-SPM. PBCA, MMA-SPM, and SLNs were efficacious carriers of D4T, DLV and SQV to meliorate BBB permeability by 3-16 folds, indicating the clinical potential of the present NP formulations for the AIDS treatment. (c) 2007 Elsevier B.V. All rights reserved.
C1 Natl Chung Cheng Univ, Dept Chem Engn, Chiayi 62102, Taiwan.
RP Kuo, YC (reprint author), Natl Chung Cheng Univ, Dept Chem Engn, Chiayi 62102, Taiwan.
EM chmyek@eeu.edu.tw
CR Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824
   Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X
   Alyaudtin RN, 2001, J DRUG TARGET, V9, P209, DOI 10.3109/10611860108997929                                                       
   Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016
   Bargoni A, 1998, PHARMACEUT RES, V15, P745, DOI 10.1023/A:1011975120776
   BETZ AL, 1978, SCIENCE, V202, P225, DOI 10.1126/science.211586                                                          
   BRUCE A, 2002, MOL BIOL CELL, P749
   Cavalli R, 2000, EUR J PHARM SCI, V10, P305, DOI 10.1016/S0928-0987(00)00081-6                                                   
   Enanga B, 2002, CELL MOL LIFE SCI, V59, P845, DOI 10.1007/s00018-002-8472-0
   Fundaro A, 2000, PHARMACOL RES, V42, P337, DOI 10.1006/phrs.2000.0695
   Gaillard PJ, 2000, EUR J PHARM SCI, V12, P95, DOI 10.1016/S0928-0987(00)00152-4
   GERALD KM, 2003, AM HOSP FORMULARY SE, P698
   Glynn SL, 1998, J PHARM SCI, V87, P306, DOI 10.1021/js970291i
   Guicheux J, 1997, J BIOMED MATER RES, V34, P165, DOI 10.1002/(SICI)1097-4636(199702)34:2<165::AID-JBM4>3.0.CO;2-O
   HARMIA T, 1986, INT J PHARM, V33, P45, DOI 10.1016/0378-5173(86)90037-2
   Hopkins AM, 2000, ADV DRUG DELIVER REV, V41, P329, DOI 10.1016/S0169-409X(00)00050-8
   HORSTMANN BJ, 1986, J CHROMATOGR, V361, P179, DOI 10.1016/S0021-9673(01)86905-3                                                   
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164
   JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470
   Kreuter J, 2005, INT CONGR SER, V1277, P85, DOI 10.1016/j.ics.2005.02.014
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   KREUTER J, 2002, J DRUG TARGET, V10, P371
   Kuo YC, 2006, J PHYS CHEM B, V110, P2202, DOI 10.1021/jp056266f
   Kuo YC, 2005, J CHIN INST CHEM ENG, V36, P627
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Kuo YC, 2006, INT J PHARM, V327, P160, DOI 10.1016/j.ijpharm.2006.07.044
   Langer K, 1996, INT J PHARM, V137, P67, DOI 10.1016/0378-5173(96)89589-5
   Langer K, 1997, INT J PHARM, V158, P211, DOI 10.1016/S0378-5173(97)00256-1
   LAPIN GD, 1996, IEEE ENG MED BIOL, V4, P57
   Miyazaki Y, 2006, J CONTROL RELEASE, V114, P47, DOI 10.1016/j.jconrel.2006.05.015
   MULLER RH, 1990, BIOMATERIALS, V11, P590, DOI 10.1016/0142-9612(90)90084-4
   Mullin JM, 2005, DRUG DISCOV TODAY, V10, P395, DOI 10.1016/S1359-6446(05)03379-9
   PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0
   PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66
   Ramge P, 2000, EUR J NEUROSCI, V12, P1931, DOI 10.1046/j.1460-9568.2000.00078.x
   Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804
   RIDDLER SA, 1995, ANTIVIR RES, V27, P189, DOI 10.1016/0166-3542(95)00016-F
   Scherrmann JM, 2002, VASC PHARMACOL, V38, P349, DOI 10.1016/S1537-1891(02)00202-1                                                   
   SHAH MV, 1989, PHARMACEUT RES, V6, P624, DOI 10.1023/A:1015913817221
   Sullivan CO, 2004, BIOMATERIALS, V25, P4375, DOI 10.1016/j.biomaterials.2003.11.001
   Sun WQ, 2004, BIOMATERIALS, V25, P3065, DOI 10.1016/j.biomaterials.2003.09.087
   Tran JQ, 2001, CLIN PHARMACOKINET, V40, P207, DOI 10.2165/00003088-200140030-00005
   Vauthier C, 2003, ADV DRUG DELIVER REV, V55, P519, DOI 10.1016/S0169-409X(03)00041-3
   Vila A, 2004, BIOCHEMISTRY-US, V43, P12592, DOI 10.1021/bi0491200
   WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348
   Wissing SA, 2002, J CONTROL RELEASE, V81, P225, DOI 10.1016/S0168-3659(02)00056-1
   Xiaoling L., 1999, ADV DRUG DELIV REV, V39, P81
   Yang SC, 1999, J CONTROL RELEASE, V59, P299, DOI 10.1016/S0168-3659(99)00007-3
NR 48
TC 95
Z9 102
U1 0
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD AUG 1
PY 2007
VL 340
IS 1-2
BP 143
EP 152
DI 10.1016/j.ijpharm.2007.03.012
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 202KZ
UT WOS:000248901800020
PM 17418986
DA 2018-01-05
ER

PT J
AU Kissel, JD
   Held, DM
   Hardy, RW
   Burke, DH
AF Kissel, Jay D.
   Held, Daniel M.
   Hardy, Richard W.
   Burke, Donald H.
TI Active site binding and sequence requirements for inhibition of HIV-1
   reverse transcriptase by the RT1 family of single-stranded DNA aptamers
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RNA PSEUDOKNOT INHIBITOR; NONNUCLEOSIDE
   INHIBITORS; ANGSTROM RESOLUTION; ANTIVIRAL ACTIVITY; ANALOG INHIBITORS;
   CRYSTAL-STRUCTURE; H DOMAIN; TYPE-1; REPLICATION
AB Nucleic acid aptamers can potentially be developed as broad-spectrum antiviral agents. Single-stranded DNA (ssDNA) aptamer RT1t49 inhibits reverse transcriptases (RT) from HIV-1 and diverse lentiviral subtypes with low nanomolar values of Kd and IC50. To dissect the structural requirements for inhibition, RT-catalyzed DNA polymerization was measured in the presence of RT1t49 variants. Three structural domains were found to be essential for RT inhibition by RT1t49: a 50 stem ( stem I), a connector and a 30 stem ( stem II) capable of forming multiple secondary structures. Stem I tolerates considerable sequence plasticity, suggesting that it is recognized by RT more by structure than by sequence-specific contacts. Truncating five nucleotides from the 30 end prevents formation of the most stable stem II structure, yet has little effect on IC50 across diverse HIV-1, HIV-2 and SIVCPZ RT. When bound to wild-type RT or an RNase H active site mutant, site-specifically generated hydroxyl radicals cleave after nucleotide A32. Cleavage is eliminated by either of two polymerase (pol)-active site mutants, strongly suggesting that A32 lies within the RT pol-active site. These data suggest a model of ssDNA aptamer-RT interactions and provide an improved molecular understanding of a potent, broad-spectrum ssDNA aptamer.
C1 Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Life Sci Ctr 471h, Columbia, MO 65211 USA.
   Univ Missouri, Sch Med, Dept Biochem, Life Sci Ctr 471h, Columbia, MO 65211 USA.
RP Burke, DH (reprint author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Life Sci Ctr 471h, Columbia, MO 65211 USA.
EM burkedh@missouri.edu
FU PHS HHS [A162513]
CR Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   ANTAO VP, 1991, NUCLEIC ACIDS RES, V19, P5901, DOI 10.1093/nar/19.21.5901
   Bai JR, 2002, MOL THER, V6, P770, DOI 10.1006/mthe.2002.0800
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   Chaloin L, 2002, NUCLEIC ACIDS RES, V30, P4001, DOI 10.1093/nar/gkf522
   Ding Jianping, 1994, Journal of Molecular Recognition, V7, P157, DOI 10.1002/jmr.300070212
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Fisher Timothy S, 2005, AIDS Res Ther, V2, P8, DOI 10.1186/1742-6405-2-8
   Fisher TS, 2003, J VIROL, V77, P5837, DOI 10.1128/JVI.77.10.5837-5845.2003
   Fisher TS, 2002, J VIROL, V76, P4068, DOI 10.1128/JVI.76.8.4068-4072.2002
   Fu H, 2006, ELECTROPHORESIS, V27, P433, DOI 10.1002/elps.200500460
   FURFINE ES, 1991, J BIOL CHEM, V266, P406
   Gonzales MJ, 2003, AIDS, V17, P791, DOI 10.1097/01.aids.0000050860.71999.23
   Gonzales MJ, 2001, J INFECT DIS, V184, P998, DOI 10.1086/323601
   Good PD, 1997, GENE THER, V4, P45, DOI 10.1038/sj.gt.3300354
   Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139                                                        
   GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122
   Hannoush RN, 2004, CHEMBIOCHEM, V5, P527, DOI 10.1002/cbic.200300831
   Held DM, 2007, J VIROL, V81, P5375, DOI 10.1128/JVI.01923-06
   Held DM, 2006, J BIOL CHEM, V281, P25712, DOI 10.1074/jbc.M604460200
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   Jaeger J, 1998, EMBO J, V17, P4535, DOI 10.1093/emboj/17.15.4535
   Johnson Victoria A, 2003, Top HIV Med, V11, P215
   Johnson Victoria A, 2004, Top HIV Med, V12, P119
   Joshi P, 2002, J VIROL, V76, P6545, DOI 10.1128/JVI.76.13.6545-6557.2002
   Joshi PJ, 2005, MOL THER, V11, P677, DOI 10.1016/j.ymthe.2005.01.013
   KENSCH O, 2000, J BIOL CHEM, V275, P18275
   Kissel JD, 2007, AIDS RES HUM RETROV, V23, P699, DOI 10.1089/aid.2006.0262
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Smith CM, 1999, J VIROL, V73, P6573
   Somasunderam A, 2005, BIOCHEMISTRY-US, V44, P10388, DOI 10.1021/bi0507074
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469                                                         
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 37
TC 17
Z9 19
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD AUG
PY 2007
VL 35
IS 15
BP 5039
EP 5050
DI 10.1093/nar/gkm420
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 212QQ
UT WOS:000249612300010
PM 17644816
OA gold
DA 2018-01-05
ER

PT J
AU van Vlerken, LE
   Vyas, TK
   Amiji, MM
AF van Vlerken, Lilian E.
   Vyas, Tushar K.
   Amiji, Mansoor M.
TI Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and
   intracellular delivery
SO PHARMACEUTICAL RESEARCH
LA English
DT Review
DE intracellular delivery; long-circulation; poly(ethylene glycol);
   polymeric nanocarriers; tumor targeting
ID COATED GADOLINIUM NANOPARTICLES; VITRO DNA TRANSFECTION; STAR
   BLOCK-COPOLYMERS; HIV-1 TAT PROTEIN; GELATIN NANOPARTICLES; GENE
   DELIVERY; DRUG-DELIVERY; IN-VITRO; POLYMERIC NANOPARTICLES;
   CANCER-CHEMOTHERAPY
AB The success of anti-cancer therapies largely depends on the ability of the therapeutics to reach their designated cellular and intracellular target sites, while minimizing accumulation and action at nonspecific sites. Surface modification of nanoparticulate carriers with poly(ethylene glycol) (PEG)/ poly(ethylene oxide) (PEO) has emerged as a strategy to enhance solubility of hydrophobic drugs, prolong circulation time, minimize non-specific uptake, and allow for specific tumor-targeting through the enhanced permeability and retention effect. Furthermore, PEG/PEO modification has emerged as a platform for incorporation of active targeting ligands, thereby providing the drug and gene carriers with specific tumor-targeting properties through a flexible tether. This review focuses on the recent developments surrounding such PEG/PEO-surface modification of polymeric nanocarriers to promote tumor-targeting capabilities, thereby enhancing efficacy of anti-cancer therapeutic strategies.
C1 Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA.
RP Amiji, MM (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, 110 Mugar Life Sci Bldg, Boston, MA 02115 USA.
EM m.amiji@neu.edu
RI Amiji, Mansoor/A-4365-2014
OI Amiji, Mansoor/0000-0001-6170-881X
CR Adams ML, 2003, J PHARM SCI, V92, P1343, DOI 10.1002/jps.10397
   American Cancer Society, 2006, CANC FACTS FIG
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bellocq NC, 2003, BIOCONJUGATE CHEM, V14, P1122, DOI 10.1021/bc034125f
   Bibby DC, 2005, INT J PHARM, V293, P281, DOI 10.1016/j.ijpharm.2004.12.021
   Brigger I, 2004, J CONTROL RELEASE, V100, P29, DOI 10.1016/j.jconrel.2004.07.019
   Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0                                                   
   Del Gaizo V, 2003, MOL GENET METAB, V80, P170, DOI 10.1016/j.ymgme.2003.08.017
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Elbayoumi TA, 2006, EUR J NUCL MED MOL I, V33, P1196, DOI 10.1007/s00259-006-0139-x
   Fang C, 2006, EUR J PHARM SCI, V27, P27, DOI 10.1016/j.ejps.2005.08.002
   Farokhzad OC, 2006, P NATL ACAD SCI USA, V103, P6315, DOI 10.1073/pnas.0601755103
   Forrest ML, 2006, J CONTROL RELEASE, V116, P139, DOI 10.1016/j.jconrel.2006.07.003
   Fustin CA, 2006, LANGMUIR, V22, P6690, DOI 10.1021/la060758h
   Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169-409X(95)00026-4
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Hafez IM, 2001, GENE THER, V8, P1188, DOI 10.1038/sj.gt.3301506
   Hamidi M, 2006, DRUG DELIV, V13, P399, DOI 10.1080/10717540600814402
   Harada Hisashi, 2003, Rev Clin Exp Hematol, V7, P117
   Harris J.M., 1992, POLYETHYLENE GLYCOL
   Hatakeyama H, 2007, GENE THER, V14, P68, DOI 10.1038/sj.gt.3302843
   Hattoni Y, 2004, J CONTROL RELEASE, V97, P173, DOI 10.1016/j.jconrel.2004.03.007
   Hayes ME, 2006, MOL PHARMACEUT, V3, P726, DOI 10.1021/mp060040v
   Hiemstra C, 2006, BIOMACROMOLECULES, V7, P2790, DOI 10.1021/bm060630e
   Jang SH, 2003, PHARM RES-DORDR, V20, P1337, DOI 10.1023/A:1025785505977
   Jeong YI, 2005, INT J PHARM, V296, P151, DOI 10.1016/j.ijpharm.2005.02.027
   Jongpaiboonkit L, 2006, J BIOMAT SCI-POLYM E, V17, P747, DOI 10.1163/156856206777656553
   Kaul G, 2002, PHARMACEUT RES, V19, P1061, DOI 10.1023/A:1016486910719                                                         
   Kaul G, 2005, PHARM RES, V22, P951, DOI 10.1007/s11095-005-4590-3
   Kaul G, 2004, J DRUG TARGET, V12, P585, DOI 10.1080/10611860400013451
   Kaul G, 2005, J PHARM SCI-US, V94, P184, DOI 10.1002/jps.20216
   Kim SH, 2005, LANGMUIR, V21, P8852, DOI 10.1021/la0502084
   Kleemann E, 2005, J CONTROL RELEASE, V109, P299, DOI 10.1016/j.jconrel.2005.09.036
   Kommareddy S, 2005, TECHNOL CANCER RES T, V4, P615, DOI 10.1177/153303460500400605                                                      
   Kommareddy S, 2005, BIOCONJUGATE CHEM, V16, P1423, DOI 10.1021/bc050146t
   Kommareddy S, 2007, J PHARM SCI-US, V96, P397, DOI 10.1002/jps.20813
   Kubetzko S, 2006, J BIOL CHEM, V281, P35186, DOI 10.1074/jbc.M604127200
   Kumar N, 2001, ADV DRUG DELIVER REV, V53, P23, DOI 10.1016/S0169-409X(01)00219-8
   Kushibiki T, 2005, J BIOMAT SCI-POLYM E, V16, P1447, DOI 10.1163/156856205774472326
   Li WJ, 2005, J GENE MED, V7, P67, DOI 10.1002/jgm.634
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   MANN DA, 1991, EMBO J, V10, P1733
   Mao SR, 2006, BIOCONJUGATE CHEM, V17, P1209, DOI 10.1021/bc060129j
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Mishra S, 2004, EUR J CELL BIOL, V83, P97, DOI 10.1078/0171-9335-00363
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   MOGHIMI SM, 1993, BIOCHIM BIOPHYS ACTA, V1157, P233, DOI 10.1016/0304-4165(93)90105-H                                                    
   MONFARDINI C, 1995, BIOCONJUGATE CHEM, V6, P62, DOI 10.1021/bc00031a006
   MURAKAMI Y, 2006, J BIOMED MATER RES A, V80, P421
   Nielsen UB, 2002, BBA-MOL CELL RES, V1591, P109, DOI 10.1016/S0167-4889(02)00256-2
   Nori A, 2005, ADV DRUG DELIVER REV, V57, P609, DOI 10.1016/j.addr.2004.10.006
   Oishi M, 2006, BIOCONJUGATE CHEM, V17, P677, DOI 10.1021/bc050364m
   Owens DE, 2006, INT J PHARM, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Oyewumi MO, 2004, J CONTROL RELEASE, V95, P613, DOI 10.1016/j.jconrel.2004.01.002
   Oyewumi MO, 2003, BIOCONJUGATE CHEM, V14, P404, DOI 10.1021/bc0340013
   Park TG, 2006, INT J PHARM, V326, P169, DOI 10.1016/j.ijpharm.2006.06.041
   Prabhutendolkar A, 2006, DRUG DELIV, V13, P433, DOI 10.1080/10717540600559452
   Pun SH, 2004, CANCER BIOL THER, V3, P641, DOI 10.4161/cbt.3.7.918                                                             
   Russell-Jones G, 2004, J INORG BIOCHEM, V98, P1625, DOI 10.1016/j.jinorgbio.2004.07.009
   Satomi T, 2006, J NANOSCI NANOTECHNO, V6, P1792, DOI 10.1166/jnn.2006.234
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Schiffelers R. M., 2004, NUCLEIC ACIDS RES, V32, P149
   SEZGIN S, 2006, EUR J PHARM BIOPHARM, V64, P261
   Shah LK, 2006, PHARM RES, V23, P2638, DOI 10.1007/s11095-006-9101-7
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Shenoy DB, 2005, INT J PHARM, V293, P261, DOI 10.1016/j.ijpharm.2004.12.010
   Shenoy D, 2005, MOL PHARMACEUT, V2, P357, DOI 10.1021/mp0500420
   Simberg D, 2007, P NATL ACAD SCI USA, V104, P932, DOI 10.1073/pnas.0610298104
   Sun C, 2006, J BIOMED MATER RES A, V78A, P550, DOI 10.1002/jbm.a.30781
   Torchilin VP, 2006, ANNU REV BIOMED ENG, V8, P343, DOI 10.1146/annurev.bioeng.8.061505.095735
   Uhrich KE, 1999, CHEM REV, V99, P3181, DOI 10.1021/cr940351u                                                               
   *US NIH, CANC STAT
   *USFDA, 1996, INT INGR GUID RED
   *USFDA CTR DRUG EV, GUID IND SCAL UP POS
   Utreja S, 1999, Pharm Acta Helv, V73, P275, DOI 10.1016/S0031-6865(99)00002-3
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0                                                   
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wang J, 2005, J DRUG TARGET, V13, P73, DOI 10.1080/10611860400011935
   Xu ZH, 2005, INT J PHARM, V288, P361, DOI 10.1016/j.ijpharm.2004.10.009
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   YOKOYAMA M, 1992, CRIT REV THER DRUG, V9, P213
NR 82
TC 287
Z9 293
U1 6
U2 93
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD AUG
PY 2007
VL 24
IS 8
BP 1405
EP 1414
DI 10.1007/s11095-007-9284-6
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 181YS
UT WOS:000247472900001
PM 17393074
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Wang, ZQ
   Bennett, EM
   Wilson, DJ
   Salomon, C
   Vince, R
AF Wang, Zhengqiang
   Bennett, Eric M.
   Wilson, Daniel J.
   Salomon, Christine
   Vince, Robert
TI Rationally designed dual inhibitors of HIV reverse transcriptase and
   integrase
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID MULTIPLE LIGANDS; NONNUCLEOSIDE INHIBITORS; VIRAL REPLICATION; HIGHLY
   POTENT; DISCOVERY; HEPT; NUCLEOSIDES; ANTAGONISTS; RESISTANCE; ANALOGS
AB Bifunctional inhibitors were designed and synthesized based on 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)(a1) non-nucleoside reverse transcriptase (RT) inhibitors and diketoacid (DKA) integrase (IN) inhibitors. Biochemical studies revealed activity against RT and IN at low nanomolar and low micromolar concentrations, respectively. Exceptionally low IC50 values from a cell-based assay were achieved along with remarkably high therapeutic indices. Compound 7 was identified as the best compound of the series (IC50: 24 nM against RT, 4.4 mu M against IN, and 10 nM against HIV-1).
C1 Univ Minnesota, Ctr Drug Design, Acad Hlth Ctr, Minneapolis, MN 55455 USA.
RP Vince, R (reprint author), Univ Minnesota, Ctr Drug Design, Acad Hlth Ctr, 308 Harvard St SE, Minneapolis, MN 55455 USA.
EM vince001@umn.edu
CR BABA M, 1994, ANTIMICROB AGENTS CH, V38, P688, DOI 10.1128/AAC.38.4.688                                                            
   Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064                                                          
   Carroll L., 1871, LOOKING GLASS
   Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773                                                      
   Dayam R, 2005, J MED CHEM, V48, P111, DOI 10.1021/jm0496077
   Didierjean J, 2005, ANTIMICROB AGENTS CH, V49, P4884, DOI 10.1128/AAC.49.12.4884-4894.2005
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Fokunang C. N., 2006, INT J PHARMACEUT, V2, P152
   Gemma S, 2006, J MED CHEM, V49, P3421, DOI 10.1021/jm060257t
   Groneberg RD, 1999, J MED CHEM, V42, P541, DOI 10.1021/jm980567e
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hehl EA, 2004, J VIROL, V78, P5056, DOI 10.1128/JVI.78.10.5056-5067.2004
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Kawanishi Y, 1996, BIOORG MED CHEM LETT, V6, P1427, DOI 10.1016/S0960-894X(96)00249-1                                                   
   Lewis WG, 2002, ANGEW CHEM INT EDIT, V41, P1053, DOI 10.1002/1521-3773(20020315)41:6<1053::AID-ANIE1053>3.0.CO;2-4
   Maurer K, 2000, BIOORG CHEM, V28, P140, DOI 10.1006/bioo.2000.1166
   Morphy R, 2004, DRUG DISCOV TODAY, V9, P641, DOI 10.1016/S1359-6446(04)03163-0                                                   
   Morphy R, 2005, J MED CHEM, V48, P6523, DOI 10.1021/jm.058225d
   Morphy R, 2006, J MED CHEM, V49, P4961, DOI 10.1021/jm0603015
   Munoz-Torrero D, 2006, CURR MED CHEM, V13, P399, DOI 10.2174/092986706775527974                                                      
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Pannecouque C, 2002, CURR BIOL, V12, P1169, DOI 10.1016/S0960-9822(02)00952-1
   Ryckmans T, 2002, BIOORG MED CHEM LETT, V12, P261, DOI 10.1016/S0960-894X(01)00727-2
   Schinazi RF, 2006, ANTIVIR RES, V71, P322, DOI 10.1016/j.antiviral.2006.03.012
   SHIPOV AG, 1989, ZH OBSHCH KHIM+, V59, P1204
   Skillman AG, 2002, BIOORG CHEM, V30, P443, DOI 10.1016/S0045-2068(02)00502-3
   TANAKA H, 1995, J MED CHEM, V38, P2860, DOI 10.1021/jm00015a008
   TANAKA H, 1999, ADV ANTIV D, V3, P93
   Tasara T, 2001, FEBS LETT, V507, P39, DOI 10.1016/S0014-5793(01)02945-3
   Wai JS, 2000, J MED CHEM, V43, P4923, DOI 10.1021/jm000176b
   Wilhelm M, 2006, EUKARYOT CELL, V5, P1760, DOI 10.1128/EC.00159-06
   Yamamoto M, 2002, BIOORG MED CHEM LETT, V12, P375, DOI 10.1016/S0960-894X(01)00755-7                                                   
   Yeni P, 2006, J HEPATOL, V44, pS100, DOI 10.1016/j.jhep.2005.11.021
   Young B, 2002, INFECT DIS THER, V25, P257
   Zawahir Z, 2006, BIOORG MED CHEM LETT, V16, P5199, DOI 10.1016/j.bmcl.2006.07.022
   KENYON GL, 1998, Patent No. 9850347
   ADRIAN G, 2000, Patent No. 200000
NR 38
TC 58
Z9 63
U1 1
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 26
PY 2007
VL 50
IS 15
BP 3416
EP 3419
DI 10.1021/jm070512p
PG 4
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 191HD
UT WOS:000248121300003
PM 17608468
DA 2018-01-05
ER

PT J
AU Takahashi, K
   Saito, K
   Masuda, J
   Fujigaki, S
   Takemura, M
   Ito, H
   Seishima, M
AF Takahashi, Kanako
   Saito, Kuniaki
   Masuda, Junichi
   Fujigaki, Suwako
   Takemura, Masao
   Ito, Hiroyasu
   Seishima, Mitsuru
TI Changes in neuronal protein expression in LP-BM5-infected mice
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE murine acquired immunodeficiency syndrome; neurologic dysfunction;
   two-dimensional polyacrylamide gel electrophoresis
ID MURINE LEUKEMIA-VIRUS; IMMUNODEFICIENCY-SYNDROME; CEREBROSPINAL-FLUID;
   ANIMAL-MODEL; LP-BM5; AIDS
AB Murine acquired immunodeficiency syndrome (MAIDS) induced by LP-BM5 murine leukemia virus is used as a model of human immunodeficiency virus (HIV)-related neurologic dysfunction. Mice infected with LP-BM5 have mnemonic abnormalities (i.e., spontaneous alternation behavior in the Y-maze and performance in the Morris water maze) and biochemical alternations (i.e., cytokines, platelet- activating factor, quinolinate, glutamate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) that produce neurologic symptoms similar to those observed in HIV-related neurologic dysfunction. To identify proteins associated with dysmnesia in the MAIDS model, we examined the expression of neuronal proteins in LP-BM5-infected mice using two-dimensional polyacrylamide gel electrophoresis (2-DE). Neuronal protein expression in LP-BM5-infected mice was compared with that in non-infected mice using the Image Master 2D. We detected approximately 800 protein spots, of which 35 were distinguishable between non-infected and LP-BM5-infected mice. Most of these spots were downregulated in LP-BM5-infected mice. Three of the spots were identified as 14-3-3 protein zeta/delta, synapsin 2 and protein disulfide isomerase using a capillary nanoliquid chromatography tandem mass spectrometric system. We verified the expression levels of these proteins by Western blot. Analysis of these 35 spots could provide insight into mechanisms of dysmnesia in the MAIDS model of HIV-related neuronal dysfunction. (c) 2007 Published by Elsevier Ireland Ltd.
C1 Gifu Univ, Grad Sch Med, Dept Informat Clin Med, Gifu, Japan.
   Kyoto Univ, Grad Sch Med, Human Hlth Sci, Kyoto, Japan.
   Kyoto Univ, Fac Med, Kyoto, Japan.
RP Saito, K (reprint author), Gifu Univ, Grad Sch Med, Dept Informat Clin Med, Gifu, Japan.
EM saito@gifu-u.acjp
CR BROWNING MD, 1993, BIOL PSYCHIAT, V34, P529, DOI 10.1016/0006-3223(93)90195-J
   HA JH, 1995, J NEUROCHEM, V64, P1896
   Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303
   Iida R, 2000, FASEB J, V14, P1023
   Iida R, 1999, J NEUROIMMUNOL, V95, P65, DOI 10.1016/S0165-5728(98)00259-8
   JOLICOEUR P, 1991, FASEB J, V5, P2398
   Kustova Y, 1998, MOL CHEM NEUROPATHOL, V35, P39, DOI 10.1007/BF02815115
   Kustova Y, 1998, BRAIN RES, V793, P119, DOI 10.1016/S0006-8993(98)00167-X                                                   
   Kustova Y, 1996, BRAIN RES, V742, P271, DOI 10.1016/S0006-8993(96)01014-1
   Markovic I, 2004, BLOOD, V103, P1586, DOI 10.1182/blood-2003-05-1390                                                      
   Nishida K, 1996, J NEUROCHEM, V66, P433
   Sei Y, 1996, J NEUROCHEM, V66, P296
   Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782
   Wakabayashi H, 2001, CLIN CHIM ACTA, V312, P97, DOI 10.1016/S0009-8981(01)00595-2
NR 14
TC 2
Z9 3
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JUL 11
PY 2007
VL 422
IS 2
BP 114
EP 118
DI 10.1016/j.neulet.2007.05.059
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 203MU
UT WOS:000248979500006
PM 17602838
DA 2018-01-05
ER

PT J
AU Wang, Y
   Nakamura, K
   Liu, XR
   Kitamura, N
   Kubo, A
   Hnatowich, DJ
AF Wang, Yi
   Nakamura, Kayoko
   Liu, Xinrong
   Kitamura, Naoto
   Kubo, Atsushi
   Hnatowich, Donald J.
TI Simplified preparation via streptavidin of antisense oligomers/carriers
   nanoparticles showing improved cellular delivery in culture
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID PEPTIDE; OLIGONUCLEOTIDE; TAT; EXPRESSION; DNA; TECHNOLOGY; MECHANISM;
   MODEL
AB Objective: Carriers are increasingly now viewed as helpful or even essential to improve cellular uptake in connection with antisense tumor targeting and other applications requiring transmembrane delivery of oligomers. Evaluation of many of the large number of available and potentially useful carriers is limited only by the complexities of preparing the oligomer/carriers by covalent conjugation. However, using streptavidin as a linker between biotinylated carriers and biotinylated antisense oligomers would require only simple mixing for preparation. The goal of this study was to evaluate the preparation and cell accumulation in culture of carrier/streptavidin nanoparticle of an antisense phosphorodiamide morpholino (MORF) oligomer. Methods: The model carriers were cholesterol, a 10 mer HIV-tat peptide, and a 10 mer polyarginine, each having been reported elsewhere to improve cellular delivery of oligomers. The model antisense oligomer was the 25 mer MORF targeting the survivin mRNA. The accumulations of the antisense MORF/carrier nanoparticle were compared to the sense MORF/carrier, to the carrier-free nanoparticles, and to the naked antisense MORF in the survivin-expressing MCF-7 cells. The MORFs and peptides were purchased biotinylated, while the cholesterol was biotinylated in-house. In all cases, the Tc-99m radiolabel was placed on the oligomers. Cell studies were performed at low nM concentration as required for antisense imaging applications and at 37 degrees C primarily in 1% FBS. Results: Each radiolabeled oligomer/streptavidin/carrier nanoparticle was successfully prepared by careful mixing at a 1:1 molar ratio. As evidence of carrier participation, the radiolabeled MORF showed increased accumulation in cells when incubated as the nanoparticle compared to the carrier-free nanoparticle and by as much as a factor of 11. Accumulation of the antisense MORF/streptavidin/tat nanoparticle was significantly higher than the sense MORF/streptavidin/tat nanoparticle as evidence of specific antisense targeting. Conclusions: The preparation of oligomer/carrier nanoparticles was greatly simplified over covalent conjugations by using streptavidin as a linker. Furthermore, our results suggest that the addition of streptavidin did not interfere with the cellular delivery function of the tat, polyarginine, or cholesterol carriers nor with the specific antisense mRNA binding function of the MORF oligomer.
C1 Univ Massachusetts, Sch Med, Dept Radiol, Div Nucl Med, Worcester, MA 01655 USA.
   Keio Univ, Sch Med, Dept Radiol, Tokyo 1608582, Japan.
RP Hnatowich, DJ (reprint author), Univ Massachusetts, Sch Med, Dept Radiol, Div Nucl Med, 55 Lake Ave N,H2-579, Worcester, MA 01655 USA.
EM donald.hnatowich@umassmed.edu
FU NCI NIH HHS [SR21CA100092-02]
CR Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   BEHLKE MA, 2005, MOL THER, V12, P644
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Chen CP, 2003, BIOCONJUGATE CHEM, V14, P532, DOI 10.1021/bc034004f
   CHU TC, 2006, NUCLEIC ACIDS RES, V34, pS73
   Hnatowich DJ, 2006, CURR OPIN MOL THER, V8, P136
   Iversen PL, 2003, CLIN CANCER RES, V9, P2510
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Lee HJ, 2002, J NUCL MED, V43, P948
   Lee HJ, 2001, BIOCONJUGATE CHEM, V12, P995, DOI 10.1021/bc0155061
   Li FZ, 2005, ONCOGENE, V24, P1385, DOI 10.1038/sj.onc.1208330
   Manoharan M, 2002, ANTISENSE NUCLEIC A, V12, P103, DOI 10.1089/108729002760070849                                                      
   MOCK DM, 1986, ANAL BIOCHEM, V153, P272, DOI 10.1016/0003-2697(86)90092-8
   Moulton HM, 2003, ANTISENSE NUCLEIC A, V13, P31, DOI 10.1089/108729003764097322
   Nakamura K, 2006, MOL IMAGING BIOL, V8, P188, DOI 10.1007/s11037-006-0035-6
   NAKAMURA K, 2006, J NUCL MED S, V47
   Noguchi H, 2006, ACTA MED OKAYAMA, V60, P1
   Shiraishi T, 2006, FEBS LETT, V580, P1451, DOI 10.1016/j.febslet.2006.01.077
   Tung CH, 2000, BIOCONJUGATE CHEM, V11, P605, DOI 10.1021/bc0000334
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wang Y, 2006, NAT PROTOC, V1, P1477, DOI 10.1038/nprot.2006.262
   Wang Y, 2007, NUCL MED BIOL, V34, P47, DOI 10.1016/j.nucmedbio.2006.10.007
   Winnard P, 1997, NUCL MED BIOL, V24, P425, DOI 10.1016/S0969-8051(97)00027-9
   ZHANG Y, 2002, J NUCL MED S, V43
   ZHANG Y, 2001, CAN BIOTHER RADIOPHA, V6, P411
   Zhang Yu-Min, 2003, Mol Imaging Biol, V5, P240, DOI 10.1016/S1536-1632(03)00106-9
NR 26
TC 19
Z9 19
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL-AUG
PY 2007
VL 18
IS 4
BP 1338
EP 1343
DI 10.1021/bc070032c
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 190UI
UT WOS:000248085700040
PM 17605463
DA 2018-01-05
ER

PT J
AU Van Eerdenbrugh, B
   Froyen, L
   Martens, JA
   Blaton, N
   Augustijns, P
   Brewster, M
   Van den Mooter, G
AF Van Eerdenbrugh, B.
   Froyen, L.
   Martens, J. A.
   Blaton, N.
   Augustijns, P.
   Brewster, M.
   Van den Mooter, G.
TI Characterization of physico-chemical properties and pharmaceutical
   performance of sucrose co-freeze-dried solid nanoparticulate powders of
   the anti-HIV agent loviride prepared by media milling
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE media milling; nanosuspensions; nanoparticles; dissolution rate;
   co-freeze-drying; sucrose
ID CRYSTALLIZATION; PRECIPITATION
AB In order to improve the dissolution and absorption properties of loviride, a poorly soluble antiviral agent, sucrose co-freeze-dried nanopowders were prepared, characterized and evaluated. Tween 80/poloxamer 188-stabilized nanosuspensions were produced on a laboratory scale using media milling. The milling process was monitored by dynamic light scattering (DLS) and resulted in particles with a mean size of 264 +/- 14 nm and a distribution width of 59 +/- 6 nm after 4 h of milling. Co-freeze-drying of the nanosuspensions with sucrose had an inhibiting effect on nanoparticle agglomeration and yielded solid "nanopowders" that were resuspendable and homogeneous with respect to loviride content. X-ray powder diffraction (XRPD) confirmed the presence of small loviride crystallites and indicated that sucrose and poloxamer 188 were crystalline. Differential scanning calorimetry (DSC) showed melting peaks of poloxamer 188, sucrose and loviride. Time-resolved XRPD indicated that sucrose crystallization was complete within 24 h of storage. Scanning electron microscopy (SEM) suggested the formation of sheet-like matrix structures. The dissolution rate of loviride from the nanopowders was excellent. A Caco-2 experiment on the nanopowder showed a significantly higher cumulative amount transported after 120 min (1.59 +/- 0.02 mu g) compared to the physical mixture (0.93 +/- 0.01 mu g) and the untreated loviride (0.74 +/- 0.03 mu g). (c) 2007 Elsevier B.V. All rights reserved.
C1 Katholieke Univ Leuven, Lab Pharmacotechnol & Biopharm, B-3000 Louvain, Belgium.
   Katholieke Univ Leuven, Dept Met & Mat Engn, B-3001 Louvain, Belgium.
   Katholieke Univ Leuven, Ctr Surface Chem & Catalysis, B-3001 Louvain, Belgium.
   Katholieke Univ Leuven, Lab Biocrystallog, B-3000 Louvain, Belgium.
   Johnson & Johnson Pharmaceut Res & Dev, B-2340 Beerse, Belgium.
RP Van den Mooter, G (reprint author), Katholieke Univ Leuven, Lab Pharmacotechnol & Biopharm, Gasthuisberg O&N2,Herestr 49,Box 921, B-3000 Louvain, Belgium.
EM Guy.vandenmooter@pharm.kuleuven.be
OI Martens, Johan/0000-0002-9292-2357
CR BREWSTER ME, 2004, EUR J PHARM SCI S, V23, P47
   BROUWERS J, 2005, J PHARM SCI, V95, P372
   CARSTENSEN JT, 1990, PHARMACEUT RES, V7, P1278, DOI 10.1023/A:1015942022789
   Chen JF, 2004, INT J PHARM, V269, P267, DOI 10.1016/j.ijpharm.2003.09.044
   Eerikainen H, 2003, EUR J PHARM BIOPHARM, V55, P357, DOI 10.1016/S0939-6411(03)00005-5
   Kawakami K, 2006, J PHARM SCI-US, V95, P1354, DOI 10.1002/jps.20458
   Kedward CJ, 2000, CARBOHYD RES, V329, P423, DOI 10.1016/S0008-6215(00)00179-8
   Kockbek P, 2006, INT J PHARMACEUT, V312, P179
   Konan YN, 2002, INT J PHARM, V233, P239, DOI 10.1016/S0378-5173(01)00944-9                                                   
   Lipinski C. A., 2002, AM PHARM REV, V5, P82
   Liversidge GG, 1994, United States patent, Patent No. [5302401 A, 5302401, US 5,302,401 1994]
   Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8
   Moschwitzer J, 2004, EUR J PHARM BIOPHARM, V58, P615, DOI 10.1016/j.ejpb.2004.03.022
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Rogers TL, 2004, PHARM RES, V21, P2048, DOI 10.1023/B:PHAM.0000048196.61887.e5                                              
   Thakur R, 2006, INT J PHARM, V308, P190, DOI 10.1016/j.ijpharm.2005.11.005
   Trotta M, 2003, INT J PHARM, V254, P235, DOI 10.1016/S0378-5173(03)00029-2
   Witvrouw M, 2000, ANTIVIR RES, V46, P215, DOI 10.1016/S0166-3542(00)00084-X
   YALKOWKSI SH, 1981, TECHNIQUES SOLUBILIS, V12, P1
NR 19
TC 78
Z9 83
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD JUN 29
PY 2007
VL 338
IS 1-2
BP 198
EP 206
DI 10.1016/j.ijpharm.2007.02.005
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 182HB
UT WOS:000247494600027
PM 17363200
DA 2018-01-05
ER

PT J
AU Terpstra, FG
   Kleijn, M
   Koenderman, AHL
   Over, J
   van Engelenburg, FAC
   Schuitemaker, H
   van't Wout, AB
AF Terpstra, F. G.
   Kleijn, M.
   Koenderman, A. H. L.
   Over, J.
   van Engelenburg, F. A. C.
   Schuitemaker, H.
   van't Wout, A. B.
TI Viral safety of C1-inhibitor NF
SO BIOLOGICALS
LA English
DT Article
DE C1-inhibitor; nanofiltration; viral safety; pasteurization; PEG
   precipitation
ID PATHOGENIC PRION PROTEIN; HEPATITIS-A VIRUS; HUMAN PLASMA; HEREDITARY
   ANGIOEDEMA; MANUFACTURING PROCESS; PARVOVIRUS B19; RESIDUAL RISK;
   INACTIVATION; REMOVAL; NANOFILTRATION
AB We studied the efficacy of virus reduction by three process steps (polyethylene glycol 4000 (PEG) precipitation, pasteurization, and 15 nm virus filtration) in the manufacturing of C1-inhibitor NF. The potential prion removing capacity in this process was estimated based on data from the literature. Virus studies were performed using hepatitis A virus (HAV) and human immunodeficiency virus (HIV) as relevant viruses and bovine viral diarrhea virus (BVDV), canine parvovirus (CPV) and pseudorabies virus (PRV) as model viruses, respectively. In the PEG precipitation step, an average reduction in infectious titer of 4.5 log(10) was obtained for all five viruses tested. Pasteurization resulted in reduction of infectious virus of > 6 log(10) for BVDV, HIV, and PRV; for HAV the reduction factor was limited to 2.8 log(10) and for CPV it was zero. Virus filtration (15 nm) reduced the infectious titer of all viruses by more than 4.5 log(10). The overall virus reducing capacity was > 16 log(10) for the LE viruses. For the NLE viruses CPV and HAV, the overall virus reducing capacities were > 8.7 and > 10.5 log(10), respectively. Based on literature and theoretical assumptions, the prion reducing capacity of the Cl-inhibitor NF process was estimated to be > 9 log(10). (c) 2006 The International Association for Biologicals. Published by Elsevier Ltd. All rights reserved.
C1 Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands.
   Sanquin Plasma Prod, Amsterdam, Netherlands.
   Kinesis Pharma, Breda, Netherlands.
RP Terpstra, FG (reprint author), Sanquin, Virus Safety Serv, Plesmanlaan 125, NL-1006 AD Amsterdam, Netherlands.
EM f.terpstra@sanquin.nl
CR Blumel J, 2002, TRANSFUSION, V42, P1011, DOI 10.1046/j.1537-2995.2002.00158.x                                                
   Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x
   Caliezi C, 2000, PHARMACOL REV, V52, P91
   Chiavetta JA, 2003, CAN MED ASSOC J, V169, P767
   Farrugia A, 2006, BEST PRACT RES CL HA, V19, P243, DOI 10.1016/J.BEHA.2005.01.002
   Foster PR, 2000, VOX SANG, V78, P86, DOI 10.1159/000031156
   Golker CF, 1996, BIOLOGICALS, V24, P103
   HILFENHAUS J, 1994, VOX SANG, V67, P62, DOI 10.1111/j.1423-0410.1994.tb00980.x                                              
   Lee DC, 2001, TRANSFUSION, V41, P449, DOI 10.1046/j.1537-2995.2001.41040449.x
   Mazurier C, 2004, VOX SANG, V86, P100, DOI 10.1111/j.0042-9007.2004.00398.x                                                
   Montgomery D.C., 1996, DESIGN ANAL EXPT
   MURPHY P, 1993, J MED VIROL, V41, P61, DOI 10.1002/jmv.1890410113
   NOWAK T, 1993, DEV BIOL STAND, V81, P169
   OGrady J, 1996, DEV BIOL STAND, V88, P319
   Pillonel J, 2004, TRANSFUS CLIN BIOL, V11, P81, DOI 10.1016/j.tracli.2004.02.004
   Stenland CJ, 2002, TRANSFUSION, V42, P1497, DOI 10.1046/j.1537-2995.2002.00216.x                                                
   Tateishi J, 2001, BIOLOGICALS, V29, P17, DOI 10.1006/biol.2001.0269
   Tateishi Jun, 1993, Membrane, V18, P357
   Terpstra FG, 2006, VOX SANG, V90, P21, DOI 10.1111/j.1423-0410.2005.00710.x
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   Van Holten RW, 2002, VOX SANG, V83, P227, DOI 10.1046/j.1423-0410.2002.00224.x
   *WHO, 2006, CONS M TISS INF DIST
   Yunoki M, 2003, VOX SANG, V84, P164, DOI 10.1046/j.1423-0410.2003.00280.x                                                
   Zuraw BL, 2005, CLIN IMMUNOL, V114, P10, DOI 10.1016/j.clim.2004.08.001
NR 24
TC 22
Z9 22
U1 0
U2 1
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
J9 BIOLOGICALS
JI Biologicals
PD JUN
PY 2007
VL 35
IS 3
BP 173
EP 181
DI 10.1016/j.biologicals.2006.08.005
PG 9
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA 181VA
UT WOS:000247463000004
PM 17071103
DA 2018-01-05
ER

PT J
AU Zhao, XW
   Bailey, MR
   Emery, WR
   Lambooy, PK
   Chen, DY
AF Zhao, Xiaowen
   Bailey, Mark R.
   Emery, Warren R.
   Lambooy, Peter K.
   Chen, Dayue
TI Evaluation of viral removal by nanofiltration using real-time
   quantitative polymerase chain reaction
SO BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY
LA English
DT Article
DE infectivity assays; model viruses; nanofiltration; nuclease treatment;
   quantitative polymerase chain reaction (quantitative PCR); virus removal
ID REVERSE TRANSCRIPTION-PCR; SECRETING MONOCLONAL-ANTIBODIES;
   RETROVIRUS-LIKE PARTICLES; CELL-CULTURE; ARMORED RNA; VIRUS; CLEARANCE;
   CONTAMINATION; CHO; QUANTIFICATION
AB Nanofiltration is commonly introduced into purification processes of biologics produced in mammalian cells to serve as a designated step for removal of potential exogenous viral contaminants and endogenous retrovirus-like particles. The LRV (log reduction value) achieved by nanofiltration is often determined by cell-based infectivity assay, which is time-consuming and labour-intensive. We have explored the possibility of employing QPCR (quantitative Pill to evaluate LRV achieved by nanofiltration in scaled-down studies using two model viruses, namely xenotropic murine leukemia virus and murine minute virus. We report here the successful development of a QPCR-based method suitable for quantification of virus removal by nanofiltration. The method includes a nuclease treatment step to remove free viral nucleic acids, while viral genome associated with intact virus particles is shielded from the nuclease. In addition, HIV Armored RNA (R) was included as an internal control to ensure the accuracy and reliability of the method. The QPCR- based method described here provides several advantages such as better sensitivity, faster turnaround time, reduced cost and higher throughput over the traditional cell-based infectivity assays.
C1 Eli Lilly & Co, Bioproc Res & Dev, Indianapolis, IN 46221 USA.
RP Chen, DY (reprint author), Eli Lilly & Co, Bioproc Res & Dev, 1223 W Morris St, Indianapolis, IN 46221 USA.
EM chen_dayue@lilly.com
CR Abe H, 2000, ARTIF CELL BLOOD SUB, V28, P375, DOI 10.3109/10731190009118582                                                       
   Adamson SR, 1998, DEV BIOL STAND, V93, P89
   ANDERSON KP, 1991, VIROLOGY, V181, P305, DOI 10.1016/0042-6822(91)90496-X
   ANDERSON KP, 1991, DEV BIOLOGICALS, V75, P123
   ANDERSON KP, 1990, J VIROL, V64, P2021
   BARTAL AH, 1986, MED MICROBIOL IMMUN, V174, P325, DOI 10.1007/BF02123685
   Beld M, 2004, J CLIN MICROBIOL, V42, P3059, DOI 10.1128/JCM.42.7.3059-3064.2004
   Bolton G, 2005, BIOTECHNOL APPL BIOC, V42, P133, DOI 10.1042/BA20050056
   Bressler AM, 2004, J CLIN MICROBIOL, V42, P987, DOI 10.1128/JCM.42.3.987-991.2004
   BROUGH H, 2002, BIOTECHNOL PROGR, V18, P781
   Curtis S, 2003, BIOTECHNOL BIOENG, V84, P179, DOI 10.1002/bit.10746
   de Wit C, 2000, BIOLOGICALS, V28, P137, DOI 10.1006/biol.2000.0250
   DINOWITZ M, 1992, DEV BIOLOGICALS, V76, P201
   *EUR UN BIOT GUID, 1995, PROD Q CONTR MON ANT
   [Anonymous], 1997, POINTS CONS MAN TEST
   Garnick RL, 1998, DEV BIOL STAND, V93, P21
   Garnick RL, 1996, DEV BIOL STAND, V88, P49
   International Conference on Harmonization (ICH), 1998, GUID VIR SAF EV BIOT, DOI Geneva
   Kreil TR, 2006, TRANSFUSION, V46, P1143, DOI 10.1111/j.1537-2995.2006.00864.x
   LIE YS, 1994, J VIROL, V68, P7840
   NICKLAS W, 1993, LAB ANIM SCI, V43, P296
   Pasloske BL, 1998, J CLIN MICROBIOL, V36, P3590
   *PDA, 2005, PDA J PHARM SCI TECH, V59, pS2
   ROZMAN C, 1982, LANCET, V2, P445
   Shi LM, 1999, BIOLOGICALS, V27, P241, DOI 10.1006/biol.1999.0212
   Shi LM, 2004, BIOTECHNOL BIOENG, V87, P884, DOI 10.1002/bit.20198
   Valdes R, 2002, J BIOTECHNOL, V96, P251, DOI 10.1016/S0168-1656(02)00047-0
   Valera CR, 2003, BIOTECHNOL BIOENG, V84, P714, DOI 10.1002/bit.10825
   Van Holten RW, 2002, VOX SANG, V83, P227, DOI 10.1046/j.1423-0410.2002.00224.x
   WalkerPeach CR, 1999, CLIN CHEM, V45, P2079
   Walsh G, 2003, NAT BIOTECHNOL, V21, P865, DOI 10.1038/nbt0803-865
   WEISS RA, 1982, NEW ENGL J MED, V307, P1587
   Xu Y, 2003, Dev Biol (Basel), V113, P89
   Zhan DJ, 2002, BIOLOGICALS, V30, P259, DOI 10.1006/biol.2001.0284
NR 34
TC 5
Z9 5
U1 4
U2 7
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0885-4513
J9 BIOTECHNOL APPL BIOC
JI Biotechnol. Appl. Biochem.
PD JUN
PY 2007
VL 47
BP 97
EP 104
DI 10.1042/BA20060195
PN 2
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 174MQ
UT WOS:000246946800003
PM 17233631
DA 2018-01-05
ER

PT J
AU Feng, JA
   Tessler, LA
   Marshall, GR
AF Feng, Jianwen A.
   Tessler, Lee A.
   Marshall, Garland R.
TI Chimeric protein engineering
SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
LA English
DT Article
DE protein engineering; helix mimetic; peptidomimetic; chimeric protein
ID MOLECULAR-DYNAMICS; DESIGN; PEPTIDES; SIMULATIONS; CONSTRAINTS;
   SOLVATION; MIMETICS; GROMACS
AB Protein stability can be enhanced by the incorporation of non-natural amino acids and semi-rigid peptidomimetics to lower the entropic penalty upon protein folding through preorganization. An example is the incorporation of aminoisobutyric acid (Aib, alpha-methylalanine) into proteins to restrict the Phi and Psi backbone angles adjacent to Aib to those associated with helix formation. Reverse-turn analogs were introduced into the sequences of HIV protease and ribonuclease A that enhanced their stability and retained their native enzymatic activity. In this work, a chimeric protein, design_4, was engineered, in silico, by replacing the C-terminal helix of full sequence design protein (FSD-1) with a semi-rigid helix mimetic. Residues 1-16 of FSD-1 was ligated in silico with the N-terminus of a phenylbipyridyl-based helix mimetic to form design_4. The designed chimeric protein was stable and maintained the designed fold in a 100-nanosecond molecular dynamics simulation at 280 K. Its beta-hairpin adopted conformations that formed three additional hydrogen bonds. Compared to FSD-1, design_4 contained fewer peptide bonds and internal degrees of freedom; it should, therefore, be more resistant to proteolytic degradation and denaturation.
C1 Washington Univ, Ctr Computat Biol, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.
RP Marshall, GR (reprint author), Washington Univ, Ctr Computat Biol, Dept Biochem & Mol Biophys, 700 S Euclid Ave, St Louis, MO 63110 USA.
EM garland@pcg.wustl.edu
RI Tessler, Lee/A-5154-2009
OI Marshall, Garland/0000-0002-3098-0332
CR Arnold U, 2002, J AM CHEM SOC, V124, P8522, DOI 10.1021/ja026114n
   BACA M, 1993, PROTEIN SCI, V2, P1085, DOI 10.1002/pro.5560020702                                                          
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   Che Y, 2006, J COMPUT AID MOL DES, V20, P109, DOI 10.1007/s10822-006-9040-8
   Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117                                                                
   Gupta R, 2002, APPL MICROBIOL BIOT, V59, P15, DOI 10.1007/s00253-002-0975-y
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.3.CO;2-L
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Jang S, 2006, PROTEINS, V62, P663, DOI 10.1002/prot.20771
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kaminski GA, 2001, J PHYS CHEM B, V105, P6474, DOI 10.1021/jp003919d
   Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427
   Lei HX, 2006, J PHYS CHEM B, V110, P22001, DOI 10.1021/jp063716a
   Lei HX, 2004, J CHEM PHYS, V121, P12104, DOI 10.1063/1.1822916
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045                                                           
   MARSHALL GR, 1990, P NATL ACAD SCI USA, V87, P487, DOI 10.1073/pnas.87.1.487
   Marshall G. R., 1972, CIRC RES          S2, V31, P143
   MERRIFIELD B. M., 1993, LIFE GOLDEN AGE PEPT
   Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h                                                               
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Snow CD, 2002, NATURE, V420, P102, DOI 10.1038/nature01160
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038                                                             
   Struthers M, 1998, FOLD DES, V3, P95, DOI 10.1016/S1359-0278(98)00015-7                                                   
   Struthers MD, 1996, SCIENCE, V271, P342, DOI 10.1126/science.271.5247.342
   Sugita Y, 1999, CHEM PHYS LETT, V314, P141, DOI 10.1016/S0009-2614(99)01123-9
   Takeuchi Y, 1998, J AM CHEM SOC, V120, P5363, DOI 10.1021/ja970855k                                                               
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Yin H, 2005, J AM CHEM SOC, V127, P10191, DOI 10.1021/ja050122x
   Yin H, 2005, ANGEW CHEM INT EDIT, V44, P2704, DOI 10.1002/anie.200462316
NR 31
TC 6
Z9 6
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1573-3149
J9 INT J PEPT RES THER
JI Int. J. Pept. Res. Ther.
PD JUN
PY 2007
VL 13
IS 1-2
BP 151
EP 160
DI 10.1007/s10989-006-9058-8
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 178QZ
UT WOS:000247236500017
DA 2018-01-05
ER

PT J
AU Gomez-Jeria, JS
AF Gomez-Jeria, Juan S.
TI On the metallicity of some carbon nanotubes
SO JOURNAL OF THE CHILEAN CHEMICAL SOCIETY
LA English
DT Article
DE HIV Reverse Transcriptase; thiazolidenebenzenesulfonamide derivatives;
   structure-activity relationships; klopman-peradejordi; Gomez model;
   zindo/I
ID EXTENDED HUCKEL THEORY; HYDROCARBONS; GAPS
AB Some zigzag and all armchair single-walled carbon nanotubes are believed to behave as metals. However, recent experimental results suggest that only armchair single-walled carbon nanotubes show typically metallic behavior. It has been suggested that metallic zigzag nanotubes are not true metals but small-gap semiconductors. Here we show, through simple quantum chemical calculations, that these zigzag nanotubes exhibit less metallic character than armchair ones because in the former, fewer electrons can flow freely between the valence and conduction bands. Therefore, they can be considered semimetals and not small-gap semiconductors.
C1 Univ Chile, Fac Sci, Santiago 21, Chile.
   Univ Andres Bello, Programa Dr Fisicoquim Mol, Santiago, Chile.
RP Gomez-Jeria, JS (reprint author), Univ Chile, Fac Sci, POB 653, Santiago 21, Chile.
EM facien03@uchile.cl
OI Gomez-Jeria, Juan S./0000-0003-1753-6701
CR Dresselhaus M. S., 1996, SCI FULLERENES CARBO
   Gomez-Jeria JS, 2003, J CHIL CHEM SOC, V48, P85, DOI 10.4067/S0717-97072003000300017
   Gomez-Jeria JS, 2006, J CHIL CHEM SOC, V51, P905, DOI 10.4067/S0717-97072006000200014
   Gomez-Jeria JS, 2006, J CHIL CHEM SOC, V51, P1061, DOI 10.4067/S0717-97072006000400016
   GOMEZJERIA JS, 2005, J CHIL CHEM SOC, V50, P597
   HOFFMANN R, 1963, J CHEM PHYS, V39, P1397, DOI 10.1063/1.1734456                                                               
   IIJIMA S, 1993, NATURE, V363, P603, DOI 10.1038/363603a0                                                                
   IIJIMA S, 1992, NATURE, V356, P776
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0                                                                
   Leyton P, 2006, J PHYS CHEM B, V110, P6470, DOI 10.1021/jp056379z
   O'Keeffe J, 2002, APPL PHYS LETT, V80, P676, DOI 10.1063/1.1432441
   Ouyang M, 2001, SCIENCE, V292, P702, DOI 10.1126/science.1058853                                                         
   Zhu HW, 2002, SCIENCE, V296, P884, DOI 10.1126/science.1066996
NR 13
TC 2
Z9 2
U1 0
U2 1
PU SOCIEDAD CHILENA DE QUIMICA
PI CONCEPCION
PA CASILLA 2613, CONCEPCION, CHILE
SN 0717-9324
J9 J CHIL CHEM SOC
JI J. Chil. Chem. Soc.
PD JUN
PY 2007
VL 52
IS 2
BP 1198
EP 1199
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 176IS
UT WOS:000247078800018
DA 2018-01-05
ER

PT J
AU Asasutjarit, R
   Lorenzen, SI
   Sirivichayakul, S
   Ruxrungtham, K
   Ruktanonchai, U
   Ritthidej, GC
AF Asasutjarit, Rathapon
   Lorenzen, Sven-Iver
   Sirivichayakul, Sunee
   Ruxrungtham, Kiat
   Ruktanonchai, Uracha
   Ritthidej, Garnpimol C.
TI Effect of solid lipid nanoparticles formulation compositions on their
   size, zeta potential and potential for in vitro type pHIS-HIV-Hugag
   transfection
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE face-centered central composite design; HIV plasmid DNA vaccine
   delivery; size; solid lipid nanoparticles; zeta potential
ID GENE DELIVERY; PLASMID DNA; DESIGN
AB Purpose. This work was conducted to determine model equations describing the effect of solid lipid nanoparticles (SLN) formulation compositions on their size and zeta potential using the face-centered central composite design and to determine the effect of SLN formulation compositions on the potential for in vitro pHIS-HIV-hugag transfection.
   Materials and Methods. SLN were prepared by the hot high pressure homogenization technique using cetylpalmitate as lipid matrix at varying concentrations of Tween 80 and Span 85 mixture, dimethyldioctadecyl ammonium bromide (DDAB) and cholesterol. Size and zeta potential used as responses of the design were measured at pH 7.0. The model equations were accepted as statistical significance at p value of less than 0.05. Ability of SLN to form complex with pHIS-HIV-hugag was evaluated by electrophoretic mobility shift assay. In vitro cytotoxicity of SLN was studied in HeLa cells using alamar blue bioassay. The potential of SLN for in vitro pHIS-HIV-hugag transfection was also determined in HeLa cells by western blot technique.
   Results. SLN possessed diameter in a range of 136-191 nm and zeta potential 11-61 mV depending on the concentrations of surfactant mixture, DDAB and cholesterol. The regression analysis showed that the model equations of responses fitted well with quadratic equations. The ability of SLN to form complex with pHIS-HIV-hugag was also affected by formulation compositions. In vitro cytotoxicity results demonstrated that HeLa cells were not well tolerant of high concentrations of SLN but still survived in a range of 100-200 mg/ml of SLN in culture medium. The results of transfection study showed ability of SLN to use as a vector for in vitro pHIS-HIV-hugag transfection. However, their potential for in vitro transfection was lower than the established transfection reagent.
   Conclusions. Size and zeta potential of SLN could be predicted from their quadratic model equations achieved by combination of three variables surfactant, DDAB and cholesterol concentrations. In addition, these variables also affected the potential of SLN as a vector for in vitro pHIS-HIV-hugag transfection. The results here provide the framework for further study involving the SLN formulation design for DNA delivery.
C1 Chulalongkorn Univ, Fac Pharmaceut Sci, Bangkok 10330, Thailand.
   Chulalongkorn Univ, Fac Med, Bangkok 10330, Thailand.
   NSTDA, Natl Nanotechnol Ctr, Pathum Thani 12120, Thailand.
RP Ritthidej, GC (reprint author), Chulalongkorn Univ, Fac Pharmaceut Sci, Bangkok 10330, Thailand.
EM rgarnpim@chula.ac.th
RI Ruktanonchai, Uracha/E-8893-2010
CR Ahlin Pegi, 1998, Acta Pharmaceutica (Zagreb), V48, P259
   Alonso MJ, 2004, BIOMED PHARMACOTHER, V58, P168, DOI 10.1016/j.biopha.2004.01.007
   Calvo P, 1996, J PHARM PHARMACOL, V48, P1147, DOI 10.1111/j.2042-7158.1996.tb03911.x                                              
   Chacon M, 1996, INT J PHARM, V141, P81, DOI 10.1016/0378-5173(96)04618-2
   Cui Z, 2002, J CONTROL RELEASE, V81, P173, DOI 10.1016/S0168-3659(02)00051-2
   Davoren M, 2005, TOXICOL IN VITRO, V19, P421, DOI 10.1016/j.tiv.2004.12.002
   de Souza EF, 2003, REV ADV MATER SCI, V5, P34
   Egan MA, 2006, VACCINE, V24, P4510, DOI 10.1016/j.vaccine.2005.08.024
   Goloub TP, 2005, J COLLOID INTERF SCI, V291, P256, DOI 10.1016/j.jcis.2005.02.035
   Gu Y, 1998, J COLLOID INTERF SCI, V206, P346
   Hung CF, 2005, INT J PHARM, V289, P197, DOI 10.1016/j.ijpharm.2004.11.008
   Jain SK, 2005, DRUG DELIV, V12, P207, DOI 10.1080/10717540590952591
   Locher CP, 2003, IMMUNOL LETT, V90, P67, DOI 10.1016/j.imlet.2003.02.001
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Olbrich C, 2001, J CONTROL RELEASE, V77, P345, DOI 10.1016/S0168-3659(01)00506-5
   Pang SW, 2002, COLLOID SURFACE B, V26, P213, DOI 10.1016/S0927-7765(01)00335-6
   ROLAND A, 2003, PHARM GENE DELIVERY
   Schubert MA, 2005, EUR J PHARM BIOPHARM, V61, P77, DOI 10.1016/j.ejpb.2005.03.006
   Sierra S, 2005, J CLIN VIROL, V34, P233, DOI 10.1016/j.jcv.2005.09.004
   Tabatt K, 2004, J CONTROL RELEASE, V97, P321, DOI 10.1016/j.jconrel.2004.02.029
   Tabatt K, 2004, EUR J PHARM BIOPHARM, V57, P155, DOI 10.1016/j.ejpb.2003.10.015
   Vandervoort J, 2002, INT J PHARM, V238, P77, DOI 10.1016/S0378-5173(02)00058-3
   Wiethoff CM, 2001, J BIOL CHEM, V276, P32806, DOI 10.1074/jbc.M007940200
NR 23
TC 39
Z9 41
U1 1
U2 20
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD JUN
PY 2007
VL 24
IS 6
BP 1098
EP 1107
DI 10.1007/s11095-007-9234-3
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 169VH
UT WOS:000246619700007
PM 17385021
DA 2018-01-05
ER

PT J
AU Sommer, AP
AF Sommer, Andrei P.
TI Antiinfectives and low-level light: A new chapter in photomedicine
SO PHOTOMEDICINE AND LASER SURGERY
LA English
DT Article
ID OPTICAL ANALYSIS; FOOT INFECTIONS; LASER-LIGHT; NANOBACTERIA; HIV;
   BACTERIA; BIOMIMETICS; THERAPY
AB Objective: The purpose of this study was to identify synergistic effects in the interaction of light with biosystems in the presence of chemical agents. Their systematic analysis promises therapeutic strategies. Background Data: Light intensities around 1000 W m(-2) potentially induce density variations in nanoscopic water layers adhering to surfaces in air or subaquatically. In permeable nanoscopic compartments in the interior of biosystems, this could result in powerful flow processes and bidirectional flows for repetitive applications of light. Consequently, external stimulation with light will force microorganisms and cells to incorporate a suitable antiinfective. Nanoscale biosystems, which respond to both light stimulation and antibiotics, are nanobacteria. Responses include growth, inhibition, and slime secretion. Slime secretion was provoked in vitro by gentamycin, an agent proposed for in vivo eradication, and blocked by light. Depending on the field of action, cooperative effects between light and an antiinfective can be exploited by considering two properties of the drug: transmission of light and resorption by the tissue. Antiinfectives can be administered in an active form or via drug delivery systems. In the latter case, a double action of the light could be exploited: stimulated release from the carrier and subsequent uptake by the targeted biosystem. Methods: The attenuation of laser light ( 670 nm) by antiinfectives was measured in films of different thickness of a vaginal suppository. The effect of 670-nm laser light - not absorbed by water - on nanoscopic water layers was examined by comparing the evaporation time of irradiated drops of water-based nanosuspensions with non-irradiated controls. Results: The 6-mu m-thick suppository films were virtually transparent to the laser light, and the 1-mm-thick films totally attenuated it. Nanosuspension drops irradiated with 670-nm light needed more time to evaporate than controls. Conclusion: Low-level light (LLL) therapy is compatible with antiinfectives, and even capable of boosting effects of superficially applied and/or absorbed antiinfectives. Temporal coordination between light treatment and drug administration maximizes drug effects and minimizes possible adverse effects. Irradiation should start when the drug concentration has reached its maximum in the desired field of action. Light-induced flow in nanoscale cavities could represent one mechanism of LLL therapy.
C1 Univ Ulm, Div Mat, D-89081 Ulm, Germany.
RP Sommer, AP (reprint author), Univ Ulm, Div Mat, Albert Einstein Allee 47, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Abdulrazak A, 2005, J DIABETES COMPLICAT, V19, P138, DOI 10.1016/j.jdiacomp.2004.06.001
   Bjorklund M, 1998, P SOC PHOTO-OPT INS, V3441, P123, DOI 10.1117/12.319827
   Brown ED, 2006, NATURE, V441, P293, DOI 10.1038/441293a
   Chincholikar Dipali A, 2002, Indian J Pathol Microbiol, V45, P15
   Chukwu GA, 2004, AFR J ORAL HLTH, V1, P31
   Culligan Patrick, 2003, Infect Dis Obstet Gynecol, V11, P161, DOI 10.1080/10647440300025515
   Fredricks DN, 2005, NEW ENGL J MED, V353, P1899, DOI 10.1056/NEJMoa043802
   GERDING DN, 1995, CLIN INFECT DIS, V20, pS283, DOI 10.1093/clinids/20.Supplement_2.S283                                            
   Candel Gonzalez FJ, 2003, EUR J INTERN MED, V14, P341
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Jinesh KB, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.166103
   Kajander EO, 2006, LETT APPL MICROBIOL, V42, P549, DOI 10.1111/j.1472-765X.2006.01945.x
   KAJANDER EO, 1998, P SOC PHOTO-OPT INS, V3755, P106
   Kolter R, 2006, NATURE, V441, P300, DOI 10.1038/441300a
   Long TC, 2006, ENVIRON SCI TECHNOL, V40, P4346, DOI 10.1021/es060589n
   LOUIE TJ, 1976, ANN INTERN MED, V85, P461, DOI 10.7326/0003-4819-85-4-461
   LUBART R, 1993, 5 C EUR SOC PHOT MAR
   Maiman T, 1960, NATURE, V187, P494
   MESTER AR, 2001, J CLIN LASER MED SUR, V19, P110
   Mester E, 1966, Orv Hetil, V107, P1012
   MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105
   MILLER VM, 2004, AM J PHYSIOL-HEART C, V287, P1115
   Pinheiro A, 2002, J CLIN LASER MED SUR, V20, P279
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   Rao N, 2005, CLIN ORTHOP RELAT R, P87, DOI 10.1097/01.blo.0000181497.42117.fa
   Shoskes DA, 2005, J UROLOGY, V173, P474, DOI 10.1097/01.ju.0000150062.60633.b2
   Sommer AP, 2006, ENERG FUEL, V20, P2189, DOI 10.1021/ef0602325
   Sommer AP, 2006, CHEMOTHERAPY, V52, P95, DOI 10.1159/000092475
   Sommer AP, 2006, NATURWISSENSCHAFTEN, V93, P334, DOI 10.1007/s00114-006-0108-z
   Sommer AP, 2006, J PROTEOME RES, V5, P611, DOI 10.1021/pr050370s
   Sommer AP, 2005, CRYST GROWTH DES, V5, P559, DOI 10.1021/cg049805z
   Sommer AP, 2005, CRYST GROWTH DES, V5, P21, DOI 10.1021/cg049812n
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
   Sommer AP, 2003, NANO LETT, V3, P19, DOI 10.1021/nl025839m
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   Sommer AP, 2002, J PROTEOME RES, V1, P111, DOI 10.1021/pr025501t
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   Taylor PW, 2005, INT J ANTIMICROB AG, V26, P183, DOI 10.1016/j.ijantimicag.2005.06.002
   Tegos GP, 2006, ANTIMICROB AGENTS CH, V50, P196, DOI 10.1128/AAC.50.1.196-203.2006
   Wainwright M, 2004, MICROBIOL-SGM, V150, P756, DOI 10.1099/mic.0.26907-0
   KAJANDER OE, 2004, Patent No. 6706290
   SOMMER AP, 2005, Patent No. 102005045654554
   MILANKOVITS M, 2005, Patent No. 20050208152A1
   2001, NASA PUBL
   2001, J CLIN LASER MED SUR, V19, P109
   SOMMER AP, 2001, Patent No. 4308474C2
NR 49
TC 6
Z9 6
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1549-5418
J9 PHOTOMED LASER SURG
JI Photomed. Laser Surg.
PD JUN
PY 2007
VL 25
IS 3
BP 150
EP 158
DI 10.1089/pho.2007.2058
PG 9
WC Surgery
SC Surgery
GA 185NL
UT WOS:000247717600004
PM 17603854
DA 2018-01-05
ER

PT J
AU Shlyahovsky, B
   Li, D
   Katz, E
   Willner, I
AF Shlyahovsky, Bella
   Li, Di
   Katz, Eugenii
   Willner, Itamar
TI Proteins modified with DNAzymes or aptamers act as biosensors or
   biosensor labels
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE DNAzyme; aptamer; glucose oxidase; thrombin; biosensor;
   chemiluminescence
ID FUNCTIONALIZED AU NANOPARTICLES; AMPLIFIED OPTICAL-DETECTION;
   NUCLEIC-ACID LABELS; IN-VITRO SELECTION; HIV-1 TAT PROTEIN; TELOMERASE
   ACTIVITY; ELECTROCHEMICAL DETECTION; IMPEDANCE SPECTROSCOPY;
   PEROXIDASE-ACTIVITY; MOLECULAR BEACON
AB Hybrid systems composed of a glucose oxidase (GOx)/peroxidase-mimicking DNAzyme, and of microperoxidase-11 (MP-11)/anti-thrombin aptamer were synthesized. The hybrid systems were employed as amplifying labels for the colorimetric or chemiluminescence detection of an enzyme functions, and thrombin analysis, respectively. In the GOx/DNAzyme system, the GOx-mediated oxidation of glucose led to the formation of H2O2, and this activated the oxidation of ABTS to a colored product, or to the generation of chemiluminescence in the presence of luminol. The MP-11/anti-thrombin aptamer enabled the amplified analysis of thrombin by the MP-11-mediated generation of chemiluminescence in the presence of luminol/H2O2. (c) 2006 Elsevier B.V. All rights reserved.
C1 Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel.
RP Willner, I (reprint author), Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel.
EM willnea@vms.huji.ac.il
RI Li, Di/F-2468-2012
OI Li, Di/0000-0003-1674-0110
CR ADAMS P.A., 1991, PEROXIDASES CHEM BIO, V2, P171
   Baron R, 2006, ANGEW CHEM INT EDIT, V45, P1572, DOI 10.1002/anie.200503314
   Breaker RR, 2002, CURR OPIN BIOTECH, V13, P31, DOI 10.1016/S0958-1669(02)00281-1
   BURGSTALLER P, 1995, ANGEW CHEM INT EDIT, V34, P1189, DOI 10.1002/anie.199511891                                                          
   Cao ZJ, 2006, ANAL CHIM ACTA, V557, P152, DOI 10.1016/j.aca.2005.10.048
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   FAMULOK M, 1992, ANGEW CHEM INT EDIT, V31, P979, DOI 10.1002/anie.199209791
   FAMULOK M, 1993, NUCLEIC ACIDS MOL BI, V7, P271
   Gill R, 2006, SMALL, V2, P1037, DOI 10.1002/smll.200600133
   Hamaguchi N, 2001, ANAL BIOCHEM, V294, P126, DOI 10.1006/abio.2001.5169
   Ho HA, 2004, J AM CHEM SOC, V126, P1384, DOI 10.1021/ja037289f
   Jhaveri S, 2000, NAT BIOTECHNOL, V18, P1293, DOI 10.1038/82414
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Katz E, 2004, ELECTROANAL, V16, P19, DOI 10.1002/elan.200302930
   KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358
   Le Floch F, 2006, ANAL CHEM, V78, P4727, DOI 10.1021/ac0521955
   Liu JW, 2006, ANGEW CHEM INT EDIT, V45, P90, DOI 10.1002/anie.200502589
   Lu Y, 2002, CHEM-EUR J, V8, P4589
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Niazov T, 2004, NANO LETT, V4, P1683, DOI 10.1021/nl0491428
   Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003
   Patolsky F, 1999, ANAL CHEM, V71, P3171, DOI 10.1021/ac9901541                                                               
   Patolsky F, 2002, J AM CHEM SOC, V124, P770, DOI 10.1021/ja0119752
   Pavlov V, 2005, J AM CHEM SOC, V127, P6522, DOI 10.1021/ja050678k
   Pavlov V, 2004, ANAL CHEM, V76, P2152, DOI 10.1021/ac0352191
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Radi AE, 2006, J AM CHEM SOC, V128, P117, DOI 10.1021/ja053121d
   RIKLIN A, 1995, ANAL CHEM, V67, P4118, DOI 10.1021/ac00118a014                                                             
   Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723                                                                   
   Shlyahovsky B, 2006, ANGEW CHEM INT EDIT, V45, P4815, DOI 10.1002/anie.200600073
   Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q                                                               
   Swearingen CB, 2005, ANAL CHEM, V77, P442, DOI 10.1021/ac0401016
   Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275                                                          
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   Travascio P, 1998, CHEM BIOL, V5, P505, DOI 10.1016/S1074-5521(98)90006-0
   Travascio P, 1999, CHEM BIOL, V6, P779, DOI 10.1016/S1074-5521(99)80125-2
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Weizmann Y, 2006, ANGEW CHEM INT EDIT, V45, P2238, DOI 10.1002/anie.200503810
   Xiao Y, 2004, J AM CHEM SOC, V126, P7430, DOI 10.1021/ja031875r
   Xiao Y, 2005, J AM CHEM SOC, V127, P17990, DOI 10.1021/ja056555h
NR 41
TC 88
Z9 88
U1 9
U2 86
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD MAY 15
PY 2007
VL 22
IS 11
BP 2570
EP 2576
DI 10.1016/j.bios.2006.10.009
PG 7
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA 166MH
UT WOS:000246382500025
PM 17098412
DA 2018-01-05
ER

PT J
AU Elson-Schwab, L
   Garner, OB
   Schuksz, M
   Crawford, BE
   Esko, JD
   Tor, Y
AF Elson-Schwab, Lev
   Garner, Omai B.
   Schuksz, Manuela
   Crawford, Brett E.
   Esko, Jeffrey D.
   Tor, Yitzhak
TI Guanidinylated neomycin delivers large, bioactive cargo into cells
   through a heparan sulfate-dependent pathway
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; CELLULAR-UPTAKE; FIBROBLAST-GROWTH; RICH
   PEPTIDES; TAT PEPTIDE; TRANSLOCATION; MOLECULES; PROTEIN; MEMBRANES;
   ARGININE
AB Facilitating the uptake of molecules into living cells is of substantial interest for basic research and drug delivery applications. Arginine-rich peptides have been shown to facilitate uptake of high molecular mass cargos into cells, but the mechanism of uptake is complex and may involve multiple receptors. In this report, we show that a derivative of the aminoglycoside antibiotic neomycin, in which all of the ammonium groups have been converted into guanidinium groups, can carry large (> 300 kDa) bioactive molecules across cell membranes. Delivery occurs at nanomolar transporter concentrations and under these conditions depends entirely on cell surface heparan sulfate proteoglycans. Conjugation of guanidinoneomycin to the plant toxin saporin, a ribosome-inactivating agent, results in proteoglycan-dependent cell toxicity. In contrast, an arginine-rich peptide shows both heparan sulfate-dependent and -independent cellular uptake. The high selectivity of guanidi-noneomycin for heparan sulfate suggests the possibility of exploiting differences in proteoglycan compositions to target delivery to different cell types.
C1 Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA.
   Zacharon Pharmaceut Inc, La Jolla, CA 92037 USA.
RP Esko, JD (reprint author), Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.
EM jesko@ucsd.edu; ytor@ucsd.edu
FU NINDS NIH HHS [NS047101]; NCI NIH HHS [CA11227, CA67754]; NIGMS NIH HHS
   [GM77471, GM33063]; NIAID NIH HHS [AI47673, 5F31AI05891602]
CR Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017                                                        
   Caesar CEB, 2006, BIOCHEMISTRY-US, V45, P7682, DOI 10.1021/bi052095t
   Chambers H. F., 2006, GOODMAN GILMANS PHAR, P1155
   Chung HH, 2004, BIOPOLYMERS, V76, P83, DOI 10.1002/bip.10597
   DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2                                                    
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197
   Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458
   Fernandex-Carneado J, 2005, J AM CHEM SOC, V127, P869, DOI 10.1021/ja044006q
   Fillon YA, 2005, J AM CHEM SOC, V127, P11798, DOI 10.1021/ja052377g
   Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2006, BIOPOLYMERS, V84, P241, DOI 10.1002/hip.20421
   Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hitz T, 2006, BIOCHEMISTRY-US, V45, P5817, DOI 10.1021/bi060285d
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8
   LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267                                                          
   Luedtke NW, 2003, J AM CHEM SOC, V125, P12374, DOI 10.1021/ja0360135
   Luedtke NW, 2000, J AM CHEM SOC, V122, P12035, DOI 10.1021/ja002421m
   RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   RYSER HJP, 1968, SCIENCE, V159, P390, DOI 10.1126/science.159.3813.390
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857                                                         
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253
   YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W
NR 35
TC 47
Z9 47
U1 1
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 4
PY 2007
VL 282
IS 18
BP 13585
EP 13591
DI 10.1074/jbc.M700463200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 162BC
UT WOS:000246060300047
PM 17311923
OA gold
DA 2018-01-05
ER

PT J
AU Kissel, JD
   Held, DM
   Hardy, RW
   Burke, DH
AF Kissel, Jay D.
   Held, Daniel M.
   Hardy, Richard W.
   Burke, Donald H.
TI Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H
   functions of HIV type 1, HIV type 2, and SIVCPZ RTs
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS;
   GROOVE-BINDING TRACK; NONNUCLEOSIDE INHIBITORS; ANTIVIRAL ACTIVITY;
   DRUG-RESISTANCE; HIGH-AFFINITY; SUBTYPE-C; EXPONENTIAL ENRICHMENT;
   ANTIRETROVIRAL THERAPY
AB Natural and selected resistance of HIV-1 to current anti-HIV drugs continues to pose serious problems to the development of HIV-1 antivirals. The viral reverse transcriptase (RT) is a proven therapeutic target. Single-stranded RNA and DNA (ssRNA and ssDNA) aptamers have been selected that specifically and potently inhibit RT function. In particular, the ssDNA aptamer RT1t49 was previously selected to recognize the RT from a subtype B strain of HIV-1 and binds with a reported K-d of 4 nM. In the present work, we show that RT1t49 inhibits recombinant RT cloned from diverse branches of the primate lentiviral family. Aptamer concentrations required for half-maximal inhibition of all HIV-1, HIV-2, and SIVCPZ RTs assayed were in the low- to mid-nanomolar range for both polymerase and RNase H activities. Using pre-steady-state and order-of-addition kinetic analyses, we also established that this ssDNA aptamer competes with primer-template for access to RT, and that addition of a nucleoside analog RT inhibitor (NRTI) to the in vitro reaction enhanced the overall effectiveness of both drugs, while nonnucleoside analog RT inhibitors (NNRTIs) exhibited simple additivity. This is the first demonstration of universal inhibition of HIV and SIVcpz RTs by a nucleic acid aptamer and supports previous reports suggesting that resistance to RT1t49 may be exceptionally infrequent.
C1 Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA.
   Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA.
   Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.
RP Burke, DH (reprint author), Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, 1201 E Rollins St, Columbia, MO 65211 USA.
EM burkedh@missouri.edu
FU NIAID NIH HHS [AI62513]
CR Adje C, 2001, J ACQ IMMUN DEF SYND, V26, P501
   Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200
   Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194
   BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1
   Bitko V, 2005, NAT MED, V11, P50, DOI 10.1038/nm1164
   Bitko V, 2001, BMC Microbiol, V1, P34, DOI 10.1186/1471-2180-1-34
   Boyer PL, 2006, PLOS PATHOG, V2, P101, DOI 10.1371/journal.ppat0020010
   Brenner B, 2003, AIDS, V17, pF1, DOI 10.1097/01.aids.0000042957.95433.6c
   Brenner BG, 2006, AIDS, V20, pF9, DOI 10.1097/01.aids.0000232228.88511.0b                                             
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   Chaloin L, 2002, NUCLEIC ACIDS RES, V30, P4001, DOI 10.1093/nar/gkf522
   CHONG KT, 1994, ANTIMICROB AGENTS CH, V38, P288, DOI 10.1128/AAC.38.2.288                                                            
   Cruchaga C, 2005, BIOCHEMISTRY-US, V44, P3535, DOI 10.1021/bi048129z
   DAQUILA RT, 2002, TOPICS HIV MED, V10, P21
   DeStefano JJ, 2006, NUCLEIC ACIDS RES, V34, P130, DOI 10.1093/nar/gkj426
   Este JA, 1998, MOL PHARMACOL, V53, P340
   Ferguson MR, 2006, BIOCHEM BIOPH RES CO, V344, P792, DOI 10.1016/j.bbrc.2006.03.201
   Fisher Timothy S, 2005, AIDS Res Ther, V2, P8, DOI 10.1186/1742-6405-2-8
   Fisher TS, 2003, J VIROL, V77, P5837, DOI 10.1128/JVI.77.10.5837-5845.2003
   Fisher TS, 2002, J VIROL, V76, P4068, DOI 10.1128/JVI.76.8.4068-4072.2002
   Frost SDW, 2001, VIROLOGY, V284, P250, DOI 10.1006/viro.2000.0887
   Gonzales MJ, 2003, AIDS, V17, P791, DOI 10.1097/01.aids.0000050860.71999.23
   Gonzales MJ, 2001, J INFECT DIS, V184, P998, DOI 10.1086/323601
   Grossman Z, 2004, AIDS, V18, P909, DOI 10.1097/01.aids.0000111402.02002.49
   GURTLER LG, 1994, J VIROL, V68, P1581
   Hannoush RN, 2004, CHEMBIOCHEM, V5, P527, DOI 10.1002/cbic.200300831
   Held DM, 2006, J BIOL CHEM, V281, P25712, DOI 10.1074/jbc.M604460200
   Held DM, 2006, FRONT BIOSCI, V11, P89, DOI 10.2741/1782
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   Jaeger J, 1998, EMBO J, V17, P4535, DOI 10.1093/emboj/17.15.4535
   Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000
   Jobb G, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-18                                                          
   Johnson Victoria A, 2003, Top HIV Med, V11, P215
   Johnson Victoria A, 2004, Top HIV Med, V12, P119
   Joshi P, 2002, J VIROL, V76, P6545, DOI 10.1128/JVI.76.13.6545-6557.2002
   Joshi P. J., 2003, Current Drug Targets - Infectious Disorders, V3, P383, DOI 10.2174/1568005033481060
   Julg B, 2005, INFECTION, V33, P299, DOI 10.1007/s15010-005-6405-1
   Kensch O, 2000, J BIOL CHEM, V275, P18271, DOI 10.1074/jbc.M001309200                                                          
   Lal RB, 2005, INDIAN J MED RES, V121, P287
   Lanchy JM, 1996, EMBO J, V15, P7178
   Loemba H, 2002, ANTIMICROB AGENTS CH, V46, P2087, DOI 10.1128/AAC.46.7.2087-2094.2002
   Maga G, 2001, J BIOL CHEM, V276, P44653, DOI 10.1074/jbc.M106702200
   Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184
   Palliser D, 2006, NATURE, V439, P89, DOI 10.1038/nature04263
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924
   Quan YD, 2003, AIDS RES HUM RETROV, V19, P743, DOI 10.1089/088922203769232548                                                      
   ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925
   Robertson DL, 2000, SCIENCE, V288, P55
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017
   Somasunderam A, 2005, BIOCHEMISTRY-US, V44, P10388, DOI 10.1021/bi0507074
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wainberg MA, 2004, AIDS, V18, pS63, DOI 10.1097/01.aids.0000131319.67773.8e
   Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537
   Zhuang JL, 2002, J VIROL, V76, P11273, DOI 10.1128/JVI.76.22.11273-11282.2002
NR 59
TC 19
Z9 20
U1 2
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD MAY
PY 2007
VL 23
IS 5
BP 699
EP 708
DI 10.1089/aid.2006.0262
PG 10
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 172JJ
UT WOS:000246799900006
PM 17530996
DA 2018-01-05
ER

PT J
AU Urbano, P
   Urbano, F
AF Urbano, Pasquale
   Urbano, Francesco
TI Nanobacteria: Facts or fancies?
SO PLOS PATHOGENS
LA English
DT Editorial Material
ID POLYCYSTIC KIDNEY-DISEASE; STONE FORMATION; PARTICLES;
   BIOMINERALIZATION; CALCIFICATION; CANCER; BLOOD; SERUM; CELL; HIV
C1 Univ Florence, Sch Med, Florence, Italy.
   Univ Florence, Dept Publ Hlth, Florence, Italy.
   Italian Army Med Corps, Logist Headquarters, Med Branch, Rome, Italy.
RP Urbano, P (reprint author), Univ Florence, Sch Med, Florence, Italy.
EM pasquale.urbano@unifi.it
RI Urbano, Pasquale/A-7354-2010
CR Aho K, 2003, J CLIN MICROBIOL, V41, P3460, DOI 10.1128/JCM.41.7.3460-3461.2003
   Altundag K, 2006, BREAST J, V12, P287, DOI 10.1111/j.1075-122X.2006.00264.x                                                
   Barr SC, 2003, AM J VET RES, V64, P176, DOI 10.2460/ajvr.2003.64.176
   Benzerara K, 2003, P NATL ACAD SCI USA, V100, P7438, DOI 10.1073/pnas.0832464100
   Breitschwerdt EB, 2001, J CLIN MICROBIOL, V39, P879, DOI 10.1128/JCM.39.3.879-882.2001
   Ciftcioglu N, 2005, KIDNEY INT, V67, P483, DOI 10.1111/j.1523-1755.2005.67105.x                                                
   Ciftcioglu N, 2003, CIRCULATION, V108, pE58, DOI 10.1161/01.CIR.0000086781.16968.2D                                              
   Ciftcioglu N, 1999, KIDNEY INT, V56, P1893, DOI 10.1046/j.1523-1755.1999.00755.x
   CIFTCIOGLU N, 1998, PATHOPHYSIOLOGY, V4, P259
   Cisar JO, 2000, P NATL ACAD SCI USA, V97, P11511, DOI 10.1073/pnas.97.21.11511
   Drancourt M, 2003, J CLIN MICROBIOL, V41, P368, DOI 10.1128/JCM.41.1.368-372.2003
   Eskandary H, 2005, MED HYPOTHESES, V65, P997, DOI 10.1016/j.mehy.2004.11.016
   Gundeslioglu O, 2005, AESTHET PLAST SURG, V29, P582, DOI 10.1007/s00266-005-0094-0
   Hjelle JT, 2000, KIDNEY INT, V57, P2360, DOI 10.1046/j.1523-1755.2000.00096.x                                                
   Hudelist G, 2004, HISTOPATHOLOGY, V45, P633, DOI 10.1111/j.1365-2559.2004.02030.x                                                
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kajander EO, 2006, LETT APPL MICROBIOL, V42, P549, DOI 10.1111/j.1472-765X.2006.01945.x
   Kajander EO, 1997, P SOC PHOTO-OPT INS, V3111, P420, DOI 10.1117/12.278796
   KAJANDER EO, 1994, ZBL BAKT S, V26, P147
   Kajander EO, 2003, UROL RES, V31, P47, DOI 10.1007/s002440-003-0304-7
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   Kajander EO, 2001, CURR OPIN NEPHROL HY, V10, P445, DOI 10.1097/00041552-200105000-00023                                                
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   Kim BH, 2004, APPL MICROBIOL BIOT, V63, P672, DOI 10.1007/s00253-003-1412-6
   KNOLL A, 1998, SIZE LIMITS VERY SMA
   Li Yongguo, 2002, Zhonghua Yi Xue Za Zhi, V82, P1557
   Maniloff J, 1997, SCIENCE, V276, P1776
   Maniscalco Benedict S., 2004, Pathophysiology, V11, P95, DOI 10.1016/j.pathophys.2004.06.001
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   Mushegian AR, 1996, P NATL ACAD SCI USA, V93, P10268, DOI 10.1073/pnas.93.19.10268
   Puskas LG, 2005, ACTA BIOL HUNG, V56, P233, DOI 10.1556/ABiol.56.2005.3-4.7
   Shiekh FA, 2006, UROL RES, V34, P53, DOI 10.1007/s00240-005-0034-0
   Shoskes DA, 2005, J UROLOGY, V173, P474, DOI 10.1097/01.ju.0000150062.60633.b2
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Travis J, 1998, SCI NEWS, V154, P75
   Tsurumoto T, 2006, J PROTEOME RES, V5, P1276, DOI 10.1021/pr050450w
   *US SEC EXCH COMM, 2006, NAN PHARM INC ANN RE
   Wainwright M., 2004, Aerobiologia, V20, P237, DOI 10.1007/s10453-004-1188-x
   WAINWRIGHT M, 1999, MICROBIOLOGY, V145, P10
   Wang Xue-Jun, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P492
   Wen Y, 2005, CHINESE MED J-PEKING, V118, P421
NR 42
TC 27
Z9 30
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD MAY
PY 2007
VL 3
IS 5
BP 567
EP 570
AR e55
DI 10.1371/journal.ppat.0030055
PG 4
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 196VU
UT WOS:000248511100001
PM 17530922
OA gold
DA 2018-01-05
ER

PT J
AU Liang, Y
   Gong, JL
   Huang, Y
   Zheng, Y
   Jiang, JH
   Shen, GL
   Yu, RQ
AF Liang, Yi
   Gong, Ji-Lai
   Huang, Yong
   Zheng, Yue
   Jiang, Jian-Hui
   Shen, Guo-Li
   Yu, Ru-Qin
TI Biocompatible core-shell nanoparticle-based surface-enhanced Raman
   scattering probes for detection of DNA related to HIV gene using
   silica-coated magnetic nanoparticles as separation tools
SO TALANTA
LA English
DT Article
DE surface-enhanced Raman scattering; Raman tags; magnetic nanoparticles;
   hybridization
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ELECTROCHEMICAL DETECTION; BIOLOGICAL
   APPLICATIONS; IMMUNOASSAY; HYBRIDIZATION; TECHNOLOGY; TAGS;
   SPECTROSCOPY; ELECTRODE; SYSTEM
AB A novel, highly selective DNA hybridization assay has been developed based on surface-enhanced Raman scattering (SERS) for DNA sequences related to HIV. This strategy employs the Ag/SiO2 core-shell nanoparticle-based Raman tags and the amino group modified silica-coated magnetic nanoparticles as immobilization matrix and separation too]. The hybridization reaction was performed between Raman tags functionalized with 3'-amino-labeled oligonucleotides as detection probes and the amino group modified silica-coated magnetic nanoparticles functionalized with 5'-amino-labeled oligonucleotides as capture probes. The Raman spectra of Raman tags can be used to monitor the presence of target oligonucleotides. The utilization of silica-coated magnetic nanoparticles not only avoided time-consuming washing, but also amplified the signal of hybridization assay. Additionally, the results of control experiments show that no or very low signal would be obtained if the hybridization assay is conducted in the presence of DNA sequences other than complementary oligonucleotides related to HIV gene such as non-complementary oligonucleotides, four bases mismatch oligonucleotides, two bases mismatch oligonucleotides and even single base mismatch oligonucleotides. It was demonstrated that the method developed in this work has high selectivity and sensitivity for DNA detection related to HIV gene. (c) 2006 Published by Elsevier B.V.
C1 Hunan Univ, State Key Lab Chemo Biosensing & Chemometr, Coll Chem & Chem Engn, Changsha 410082, Peoples R China.
RP Jiang, JH (reprint author), Hunan Univ, State Key Lab Chemo Biosensing & Chemometr, Coll Chem & Chem Engn, Changsha 410082, Peoples R China.
EM jianhuijiang@hnu.cn; rqyu@hnu.cn
RI Jiang, Jian-Hui/K-2054-2012
CR Allain LR, 2002, ANAL CHIM ACTA, V469, P149, DOI 10.1016/S0003-2670(01)01537-9                                                   
   Campion A, 1998, CHEM SOC REV, V27, P241, DOI 10.1039/a827241z                                                                
   Cao YC, 2005, TALANTA, V67, P449, DOI 10.1016/j.talanta.2005.06.063
   Cao YC, 2003, J AM CHEM SOC, V125, P14676, DOI 10.1021/ja0366235
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Dou X, 1997, ANAL CHEM, V69, P1492, DOI 10.1021/ac960995x                                                               
   Faulds K, 2004, ANAL CHEM, V76, P412, DOI 10.1021/ac035060c
   FLEISCHMANN M, 1974, CHEM PHYS LETT, V26, P163, DOI 10.1016/0009-2614(74)85388-1                                                    
   Gabl R, 2004, BIOSENS BIOELECTRON, V19, P615, DOI 10.1016/S0956-5663(03)00259-8
   Gao XH, 2004, ANAL CHEM, V76, P2406, DOI 10.1021/ac0354600
   Gong JL, 2006, J COLLOID INTERF SCI, V298, P752, DOI 10.1016/j.jcis.2006.01.024
   Gong JL, 2006, ANAL CHIM ACTA, V564, P151, DOI 10.1016/j.aca.2006.01.055
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   Ito A, 2005, J BIOSCI BIOENG, V100, P1, DOI 10.1263/jbb.100.1
   Kang YS, 1996, CHEM MATER, V8, P2209, DOI 10.1021/cm960157j                                                               
   Kneipp J, 2005, ANAL CHEM, V77, P2381, DOI 10.1021/ac050109v
   Lee KB, 2004, NANO LETT, V4, P1869, DOI 10.1021/nl049002y
   Levy L, 2002, CHEM MATER, V14, P3715, DOI 10.1021/cm0203013
   Li JH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gnil163
   Liu ZM, 2005, ANAL CHIM ACTA, V533, P3, DOI 10.1016/j.aca.2004.10.077
   Mulvaney SP, 2003, LANGMUIR, V19, P4784, DOI 10.1021/la026706j
   Neuberger T, 2005, J MAGN MAGN MATER, V293, P483, DOI 10.1016/j.jmmm.2005.01.064
   Oldenburg SJ, 2002, ANAL BIOCHEM, V309, P109, DOI 10.1016/S0003-2697(02)00410-4
   Pappas D, 2000, TALANTA, V51, P131, DOI 10.1016/S0039-9140(99)00254-4
   PROFFITT MR, 1993, ANAL CHEM, V65, pR396
   Qhobosheane M, 2001, ANALYST, V126, P1274, DOI 10.1039/b101489g                                                                
   ROHR TE, 1989, ANAL BIOCHEM, V182, P388, DOI 10.1016/0003-2697(89)90613-1                                                    
   Santra S, 2001, LANGMUIR, V17, P2900, DOI 10.1021/la0008636
   Talley CE, 2004, ANAL CHEM, V76, P7064, DOI 10.1021/ac049093j
   Tanaka T, 2000, ANAL CHEM, V72, P3518, DOI 10.1021/ac9912505
   Tlili C, 2005, TALANTA, V68, P131, DOI 10.1016/j.talanta.2005.04.069
   Wabuyele MB, 2005, ANAL CHEM, V77, P7810, DOI 10.1021/ac0514671
   Wang J, 2003, ELECTROCHEM COMMUN, V5, P1000, DOI 10.1016/j.elecom.2003.09.010
   Wang J, 2003, J AM CHEM SOC, V125, P3214, DOI 10.1021/ja029668z
   Wu W, 2006, J APPL PHYS, V99, DOI 10.1063/1.2165915
   Yang HH, 2004, ANAL CHEM, V76, P1316, DOI 10.1021/ac034920m
   Yeh HC, 2005, NANOMED-NANOTECHNOL, V1, P115, DOI 10.1016/j.nano.2005.03.004
   Zhu NN, 2003, ANAL CHIM ACTA, V481, P181, DOI 10.1016/S0003-2670(03)00123-5
NR 38
TC 70
Z9 72
U1 6
U2 77
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD APR 30
PY 2007
VL 72
IS 2
BP 443
EP 449
DI 10.1016/j.talanta.2006.11.002
PG 7
WC Chemistry, Analytical
SC Chemistry
GA 165QU
UT WOS:000246321200017
PM 19071638
DA 2018-01-05
ER

PT J
AU Hyun, S
   Kim, HJ
   Lee, NJ
   Lee, KH
   Lee, Y
   Ahn, DR
   Kim, K
   Jeong, S
   Yu, J
AF Hyun, Soonsil
   Kim, Hyun Jin
   Lee, Nam Ju
   Lee, Kyung Hyun
   Lee, Yeongran
   Ahn, Dae Ro
   Kim, Keysun
   Jeong, Sunjoo
   Yu, Jaehoon
TI alpha-helical peptide containing N,N-dimethyl lysine residues displays
   low-nanomolar and highly specific binding to RRE RNA
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID BETA-HAIRPIN PEPTIDE; CATION-PI INTERACTION; ARGININE METHYLATION; HIV-1
   REV; AMPHIPHILIC PEPTIDES; AMINO-ACIDS; PROTEIN; CONSTRUCTION; SEQUENCE;
   AFFINITY
AB The combinatorial introduction of N,N-dimethyl-Lys groups into Lys-rich alpha-helical peptides and measuring affinities against RRE RNA were carried out. Peptide-g, in which two Lys were replaced by N,N-dimethyl-Lys at 3 and 9 positions, showed low-nanomolar affinity, which is almost the same value as Rev peptide, the natural RRE ligand. Moreover, peptide-g displays a compatible binding specificity as Rev peptide. The effects of the positions of Lys N,N-dimethylation on the specificity of RNA binding could serve as the basis of a new strategy for the design of novel agents against RNAs. The results support that nature may use N-methylation as a post-translational modification to enhance specific peptide-RNA interactions.
C1 Seoul Natl Univ, Dept Chem & Educ, Seoul 151742, South Korea.
   Korea Inst Sci & Technol, Div Life Sci, Seoul 130650, South Korea.
   Dankook Univ, Dept Mol Biol, Seoul 140714, South Korea.
RP Yu, J (reprint author), Seoul Natl Univ, Dept Chem & Educ, Seoul 151742, South Korea.
EM jhoonyu@snu.ac.kr
OI Lee, Kyung Hyun/0000-0001-8246-7592
CR Ahn DR, 2005, BIOORGAN MED CHEM, V13, P1177, DOI 10.1016/j.bmc.2004.11.021
   Banister A. J., 2005, NATURE, V436, P1103
   Calabro V, 2005, P NATL ACAD SCI USA, V102, P6849, DOI 10.1073/pnas.0409282102
   COX JA, 1985, J BIOL CHEM, V260, P2527
   Das C, 2003, BIOPOLYMERS, V70, P80, DOI 10.1002/bip.10429
   Friesen WJ, 1998, NAT STRUCT BIOL, V5, P543, DOI 10.1038/794
   Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459
   Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9
   HAYNIE SL, 1995, ANTIMICROB AGENTS CH, V39, P301, DOI 10.1128/AAC.39.2.301                                                            
   Hendrickson EL, 2004, J BACTERIOL, V186, P6956, DOI 10.1128/JB.186.20.6956-6969.2004
   Hughes RM, 2005, J AM CHEM SOC, V127, P6518, DOI 10.1021/ja0507259
   Hughes RM, 2006, J AM CHEM SOC, V128, P13586, DOI 10.1021/ja0648460
   Hughes RM, 2006, J AM CHEM SOC, V128, P12735, DOI 10.1021/ja061656g
   Ippolito JA, 2000, J MOL BIOL, V295, P711, DOI 10.1006/jmbi.1999.3405
   Kirk SR, 1999, BIOORGAN MED CHEM, V7, P1979, DOI 10.1016/S0968-0896(99)00170-4
   Lee JK, 2004, J AM CHEM SOC, V126, P1956, DOI 10.1021/ja038937y
   LIU Q, 1995, MOL CELL BIOL, V15, P2800
   Luedtke NW, 2003, BIOCHEMISTRY-US, V42, P11391, DOI 10.1021/bi034766y
   McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mills NL, 2006, J AM CHEM SOC, V128, P3496, DOI 10.1021/ja0582051
   Pain A, 2005, SCIENCE, V309, P131, DOI 10.1126/science.1110418
   Sathyapriya R, 2004, NUCLEIC ACIDS RES, V32, P4109, DOI 10.1093/nar/gkh733
   SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304
   Takahashi T, 2001, BIOORGAN MED CHEM, V9, P991, DOI 10.1016/S0968-0896(00)00324-2                                                   
   Tan RY, 1998, P NATL ACAD SCI USA, V95, P4247, DOI 10.1073/pnas.95.8.4247
   TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025
   Usui K, 2004, BIOPOLYMERS, V76, P129, DOI 10.1002/bip.10568
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
NR 29
TC 19
Z9 19
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD APR 18
PY 2007
VL 129
IS 15
BP 4514
EP +
DI 10.1021/ja068265m
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 157RZ
UT WOS:000245739700005
PM 17378563
DA 2018-01-05
ER

PT J
AU Goyal, RN
   Oyama, M
   Tyagi, A
   Singh, SP
AF Goyal, Rajendra N.
   Oyama, Munetaka
   Tyagi, Anuradha
   Singh, Sudhanshu P.
TI Voltammetric determination of anabolic steroid nandrolone at gold
   nanoparticles modified ITO electrode in biological fluids
SO TALANTA
LA English
DT Article
DE gold nanoparticles modified ITO electrode; nandrolone decanoate;
   voltammetric detection; biological fluids
ID DECANOATE TREATMENT; DOPING CONTROL; BODY-COMPOSITION; CLINICAL-TRIAL;
   DOUBLE-BLIND; WEIGHT-LOSS; RATS; OSTEOPOROSIS; PLACEBO; HIV
AB The electrochemical behavior of nandrolone decanoate (ND) at gold nanoparticles modified indium tin oxide (ITO) electrode was investigated. Oxidation of ND has been carried out in phosphate containing supporting electrolyte in the pH range 2.1-9.2 and a well-defined oxidation peak was noticed. The peak potential (E-p) of the oxidation peak decreases linearly with increasing pH. Linear calibration curve is obtained over the nandrolone decanoate concentration range of 50 nM to 1.5 mu M at pH 7.2 with a detection limit of 1.36 x 10(-7) M. The proposed method is effectively applied to detect the concentration of ND in human blood serum and urine samples after 24 and 72 h of intramuscular injection. The method is rapid and does not require any pre-treatment. (C) 2006 Elsevier B.V.. All rights reserved.
C1 Indian Inst Technol, Dept Chem, Roorkee 247667, Uttar Pradesh, India.
   Int Innovat Ctr, Div Res Initiat, Nishikyo Ku, Kyoto 6158520, Japan.
RP Goyal, RN (reprint author), Indian Inst Technol, Dept Chem, Roorkee 247667, Uttar Pradesh, India.
EM rngeyfcy@iitr.ernet.in
RI Oyama, Munetaka/D-6541-2014
OI Oyama, Munetaka/0000-0001-7422-9914; Goyal, Rajendra
   N/0000-0002-3416-8640
CR Umar A. Ali, 2005, CRYST GROWTH DES, V5, P599
   Batterham MJ, 2001, INT J ANDROL, V24, P232, DOI 10.1046/j.1365-2605.2001.00291.x
   Bisschop A, 1997, J APPL PHYSIOL, V82, P1112
   Cavalcante WLG, 2004, COMP BIOCHEM PHYS C, V139, P219, DOI 10.1016/j.cca.2004.11.004
   Christian G. D., 1962, J ELECTROANAL CHEM, V3, P363
   CRIST DM, 1983, J APPL PHYSIOL, V54, P366
   DURBECK HW, 1982, FRESEN Z ANAL CHEM, V311, P404, DOI 10.1007/BF00481771
   Flicker L, 1997, OSTEOPOROSIS INT, V7, P29, DOI 10.1007/BF01623456
   Frisoli A, 2005, J GERONTOL A-BIOL, V60, P648, DOI 10.1093/gerona/60.5.648                                                         
   Gerez JR, 2005, CONTRACEPTION, V72, P77, DOI 10.1016/j.contraception.2005.02.001
   Ghorbanihaghjo Amir, 2004, Lipids Health Dis, V3, P16, DOI 10.1186/1476-511X-3-16
   Gold J, 2006, HIV MED, V7, P146, DOI 10.1111/j.1468-1293.2006.00358.x                                                
   GOLD J, 2004, P 7 INT C DRUG THER
   Goyal RN, 2006, ELECTROCHEM COMMUN, V8, P65, DOI 10.1016/j.elecom.2005.10.011
   GOYAL RN, IN PRESS ANAL CHIM A
   Hemmersbach P, 1996, J CHROMATOGR B, V687, P221, DOI 10.1016/S0378-4347(96)00276-9
   Huang RY, 2002, BONE, V30, P492, DOI 10.1016/S8756-3282(01)00691-3
   Jin WR, 1997, ELECTROANAL, V9, P498, DOI 10.1002/elan.1140090613                                                         
   Kurling S, 2005, BRAIN RES, V1044, P67, DOI 10.1016/j.brainres.2005.02.071
   Lichtenbelt WDV, 2004, MED SCI SPORT EXER, V36, P484, DOI 10.1249/01.MSS.0000117157.06455.B0
   Lippi G, 1997, SCAND J CLIN LAB INV, V57, P507, DOI 10.3109/00365519709084601
   LYRITIS GP, 1994, BONE MINER, V27, P209, DOI 10.1016/S0169-6009(08)80194-8
   MCDOWALL RD, 1989, J CHROMATOGR-BIOMED, V492, P3, DOI 10.1016/S0378-4347(00)84463-1                                                   
   Noorafshan A, 2005, APMIS, V113, P122, DOI 10.1111/j.1600-0463.2005.apm1130205.x                                           
   Perez Regina Raquel, 2005, Cienc. Rural, V35, P589, DOI 10.1590/S0103-84782005000300015
   Sattler FR, 2002, AM J PHYSIOL-ENDOC M, V283, pE1214, DOI 10.1152/ajpendo.00189.2002
   SEGURA J, 1998, DRUG ABUSE HDB, P641
   Sheashaa H, 2005, NEPHRON CLIN PRACT, V99, pC102, DOI 10.1159/000083891
   SOLANS A, 1995, J ANAL TOXICOL, V19, P104, DOI 10.1093/jat/19.2.104                                                            
   STEENSLAND PJ, 2002, EUR J NEUROSCI, V15, P539
   Storer TW, 2005, J CLIN ENDOCR METAB, V90, P4474, DOI 10.1210/jc.2005-0275
   Teruel JL, 1997, AM J KIDNEY DIS, V29, P569, DOI 10.1016/S0272-6386(97)90340-1
   Tsivou M, 2006, ANAL CHIM ACTA, V555, P1, DOI 10.1016/j.aca.2005.08.068
   Ventura R, 1996, J CHROMATOGR B, V687, P127, DOI 10.1016/S0378-4347(96)00279-4
   WIJNAND HP, 1985, ACTA ENDOCRINOL-COP, V110, P19
NR 35
TC 17
Z9 18
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0039-9140
J9 TALANTA
JI Talanta
PD APR 15
PY 2007
VL 72
IS 1
BP 140
EP 144
DI 10.1016/j.talanta.2006.10.004
PG 5
WC Chemistry, Analytical
SC Chemistry
GA 164IB
UT WOS:000246225900019
PM 19071594
DA 2018-01-05
ER

PT J
AU Deng, YQ
   Zheng, Q
   Ketas, TJ
   Moore, JP
   Lu, M
AF Deng, Yiqun
   Zheng, Qi
   Ketas, Thomas J.
   Moore, John P.
   Lu, Min
TI Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor
SO BIOCHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PEPTIDE INHIBITOR; ENTRY INHIBITORS;
   MEMBRANE-FUSION; CELL-FUSION; TRANSMEMBRANE GLYCOPROTEIN; NEUTRALIZING
   ANTIBODY; ENVELOPE GLYCOPROTEIN; ATOMIC-STRUCTURE; BINDING-SITE
AB Peptides derived from the carboxyl-terminal heptad repeat of the gp41 envelope glycoprotein ectodomain (C-peptides) can inhibit HIV-1 membrane fusion by binding to the amino-terminal trimeric coiled coil of the same protein. The fusion inhibitory peptide T-20 contains an additional tryptophan-rich sequence motif whose binding site extends beyond the gp41 coiled-coil region yet provides the key determinant of inhibitory activity in T-20. Here we report the design of a recombinant peptide inhibitor (called C52L) that includes both the C-peptide and tryptophan-rich regions. By calorimetry, C52L binds to a peptide mimic of the amino-terminal coiled coil with a K-d of 80 nM, reflecting the large degree of helicity in C52L as measured by circular dichroism spectroscopy. The C52L peptide potently inhibits in vitro infection of human T cells by diverse primary HIV-1 isolates irrespective of coreceptor preference, with nanomolar IC50 values. Significantly, C52L is fully active against T-20-resistant variants in a single-cycle HIV-1 infectivity assay. Moreover, because it can be expressed in bacteria, the C52L peptide might be more economical to manufacture on a large scale than T-20-like peptides produced by chemical synthesis. Hence the C52L fusion inhibitor may find a practical application, for example as a vaginal or rectal microbicide to prevent HIV-1 infection in the developing world.
C1 Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA.
   Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.
RP Lu, M (reprint author), Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA.
EM mlu@med.cornell.edu
RI Deng, Yiqun/K-7709-2013
FU NIAID NIH HHS [R01 AI68591, U19 AI65413]
CR Abrahamyan LG, 2005, J VIROL, V79, P106, DOI 10.1128/JVI.79.1.106-115.2005
   Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428.12437.2004
   Beddows S, 2005, J VIROL, V79, P8812, DOI 10.1128/JVI.79.14.8812-8827.2005
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Cao W, 2004, PROTEIN SCI, V13, P177, DOI 10.1110/ps.03383004
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   CHEN W, 1995, THEOR PRACT OBJ SYST, V1, P41
   CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027                                                             
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699                                                               
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   Eron JJ, 2004, J INFECT DIS, V189, P1075, DOI 10.1086/381707                                                                  
   Ferrer M, 1999, NAT STRUCT BIOL, V6, P953
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Gordon CJ, 1999, J VIROL, V73, P684
   HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0
   Harrison SC, 2005, ADV VIRUS RES, V64, P231, DOI 10.1016/S0065-3527(05)64007-9
   Herrera C, 2003, J VIROL, V77, P1084, DOI 10.1128/JVI.77.2.1084-1091.2003
   HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Jin BS, 2000, AIDS RES HUM RETROV, V16, P1797, DOI 10.1089/08892220050195757
   JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4                                                   
   Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426
   KETAS T, 2007, IN PRESS VIROLOGY
   Ketas TJ, 2003, AIDS RES HUM RETROV, V19, P177, DOI 10.1089/088922203763315678
   Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294                                                      
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   KLASSE PJ, 2006, PLOS MED, V3
   KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395
   Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200                                                          
   KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163
   KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367
   Kuritzkes DR, 1996, AIDS, V10, pS27, DOI 10.1097/00002030-199612005-00005                                                
   Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P90
   Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M41141200
   Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958                                                  
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Mansky LM, 2002, J VIROL, V76, P9253, DOI 10.1128/JVI.76.18.9253-9259.2002
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Moore R A, 2000, BMC Fam Pract, V1, P1, DOI 10.1186/1471-2296-1-1
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Pillay D, 2000, REV MED VIROL, V10, P231, DOI 10.1002/1099-1654(200007/08)10:4<231::AID-RMV290>3.3.CO;2-G
   Poveda E, 2002, AIDS, V16, P1959, DOI 10.1097/00002030-200209270-00014
   Reeves JD, 2004, J VIROL, V78, P5476, DOI 10.1128/JVI.78.10.5476-5485.2004
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Rimsky LT, 1998, J VIROL, V72, P986
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687
   Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w
   Sia SK, 2003, P NATL ACAD SCI USA, V100, P9756, DOI 10.1073/pnas.1733910100
   Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Trkola A, 1999, J VIROL, V73, P8966
   Trkola A, 1998, J VIROL, V72, P396
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Zhou GF, 2000, BIOORGAN MED CHEM, V8, P2219, DOI 10.1016/S0968-0896(00)00155-3                                                   
   Zwick MB, 2005, J VIROL, V79, P1252, DOI 10.1128/JVI.79.2.1252-1261.2005
NR 68
TC 38
Z9 41
U1 2
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD APR 10
PY 2007
VL 46
IS 14
BP 4360
EP 4369
DI 10.1021/bi7001289
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 152OD
UT WOS:000245370400014
PM 17371053
DA 2018-01-05
ER

PT J
AU Dutta, T
   Jain, NK
AF Dutta, Tathagata
   Jain, Narendra K.
TI Targeting potential and anti-HIV activity of lamivudine loaded
   mannosylated poly (propyleneimine) dendrimer
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Article
DE poly (propyleneimine) dendrimer; mannosylated dendrimer; anti HIV
   activity; macrophage targeting; lamivudine
ID IN-VITRO; INFECTION; MACROPHAGES; NANOPARTICLES; LIPOSOMES; MONOCYTES;
   DELIVERY; TUFTSIN; INVITRO; SYSTEM
AB T-lymphocytes, dendritic cells and macrophages are the target cells for HIV. The infected macrophages are considered as reservoirs for spreading the virus. Treatment of HIV infection therefore must reach these cells in addition to the organs like brain, liver and bone marrow. Lectin receptors, which act as molecular targets for sugar molecules, are found on the surface of these cells of the phagocytic system. The purpose of the present study is to investigate the targeting potential and anti HIV activity of lamivudine (3TC) loaded mannosylated fifth generation Poly (propyleneimine) dendrimers (MPPI). The entrapment efficiency of 3TC loaded MPPI and 5th generation poly(propyleneimine) dendrimer (PPI) were found to be 43.27 +/- 0.13% and 35.69 +/- 0.2% respectively. The in vitro drug release profile shows that while PPI releases the drug by 24 h, the MPPI slows down and hence prolongs the release up to 144 h (96.89 +/- 1.8% in case of MPPI). The results of in vitro ligand agglutination assay indicated that even after conjugation with PPI, mannose displayed binding specificity towards Con A. The subtoxic concentrations of free 3TC, blank PPI, blank MPPI, drug loaded PPI and drug loaded MPPI, determined on MT2 cells, were found to be 0.625, 0.039, 0.156, 0.039 and 0.156 nM/ml respectively. Significant increase in cellular uptake of 3TC was observed when MPPI was used, which was 21 and 8.3 times higher than that of free drug (p < 0.001) and PPI (p < 0.001) at 48 h respectively. Antiretroviral activity was determined using MT2 cell lines by estimating p24 antigen by ELISA. 3TC loaded PPI and MPPI formulations were found to possess higher anti-HIV activity at a concentration as low as 0.019 nM/ml, as compared to that of free drug, which was found to be extremely significant (p < 0.001). The significantly higher anti-HIV activity of PPI and MPPI is due to the enhanced cellular uptake of 3TC in formulation as compared to that of free drug Results suggest that the proposed carrier hold potential to increase the efficacy and reduce the toxicity of antiretroviral therapy. (c) 2006 Elsevier B.V. All rights reserved.
C1 Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
RP Jain, NK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
EM duttatathababu@yahoo.com; jnarendr@yahoo.co.in
CR Ashton PR, 1997, CHEM-EUR J, V3, P974, DOI 10.1002/chem.19970030620                                                        
   Auge M., 1992, NATURAL IMMUNE SYSTE, P2
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   BERNSTEIN DI, 2003, ANTIVIR RES, V57, P89
   BETAGERI GV, 1993, J PHARM PHARMACOL, V45, P48, DOI 10.1111/j.2042-7158.1993.tb03678.x                                              
   Bhadra D, 2005, INT J PHARM, V295, P221, DOI 10.1016/j.ijpharm.2005.01.026
   BORGES AR, 2005, DISORDERS, V5, P247
   Copland MJ, 2003, VACCINE, V21, P883, DOI 10.1016/S0264-410X(02)00536-4                                                   
   DUTTA T, 2007, J DRUG TARGET, V15, P1
   FISCHER D, 2003, BIOMATERIALS, V24, P114
   Fridkin M, 2005, J PEPT SCI, V11, P37, DOI 10.1002/psc.587
   FRIDKIN M, 1989, CRIT REV BIOCHEM MOL, V24, P1, DOI 10.3109/10409238909082550                                                       
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   JANSEN JFG, 1994, SCIENCE, V226, P1226
   Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3                                                   
   KONOPKA K, 1990, J GEN VIROL, V71, P2899, DOI 10.1099/0022-1317-71-12-2899
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   Liu MJ, 1999, PHARM SCI TECHNOL TO, V2, P393, DOI 10.1016/S1461-5347(99)00203-5                                                   
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Mankertz J, 1996, BBA-MOL BASIS DIS, V1317, P233, DOI 10.1016/S0925-4439(96)00059-2
   Miklis P, 1997, J AM CHEM SOC, V119, P7458, DOI 10.1021/ja964230i                                                               
   NICHOLSON JKA, 1986, J IMMUNOL, V137, P323
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SHAKTHIVEL T, 2003, DRUG DELIV TECHNOL, V3, P73
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Tomalia DA, 2004, ALDRICHIM ACTA, V37, P39
   de Brabander van den Berg E. M. M., 1993, ANGEW CHEM INT EDIT, V32, P1308
   VIRAD M, 2004, GLYCOCONJUGATE J, V20, P213
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   Zhao H, 2004, FEBS LETT, V563, P241, DOI 10.1016/S0014-5793(04)00284-4
   2004, AUGUST, V24, P1
NR 33
TC 107
Z9 110
U1 2
U2 21
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4165
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD APR
PY 2007
VL 1770
IS 4
BP 681
EP 686
DI 10.1016/j.bbagen.2006.12.007
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 149SC
UT WOS:000245165900022
PM 17276009
DA 2018-01-05
ER

PT J
AU Jiang, L
   Qian, F
   He, XW
   Wang, F
   Ren, D
   He, Y
   Li, K
   Sun, S
   Yin, C
AF Jiang, Lei
   Qian, Feng
   he, Xiaowen
   Wang, Fang
   Ren, Ding
   He, Ying
   Li, Ka
   Sun, Shuhan
   Yin, Chunhua
TI Novel chitosan derivative nanopartictes enhance the immunogenicity of a
   DNA vaccine encoding hepatitis B virus core antigen in mice
SO JOURNAL OF GENE MEDICINE
LA English
DT Article
ID GENE DELIVERY; CATIONIC MICROPARTICLES; TRANSFECTION EFFICIENCY; PEPTIDE
   DELIVERY; IMMUNE-RESPONSES; HIV-1 TAT; IN-VITRO; T-CELL; IMMUNIZATION;
   CARRIERS
AB Background Chitosan has been shown to possess useful properties such as non-toxicity, high biocompatibility and non-antigenicity that offer advantages for vaccine delivery systems. In this study, we prepared novel chitosan derivative nanoparticles as DNA vaccine carriers and the potential and mechanism of the DNA-nanoparticle complexes in inducing augmented immune responses were explored.
   Methods The pVAX(HBc)DNA-nanoparticle complexes as vaccine delivery systems were studied in several aspects: the protection against DNase I degradation was measured by an in vitro inhibition assay; the sustained expression of the plasmid in vivo was determined by RT-PCR; the elevated uptake efficiency by phagocytes was observed with confocal microscopy; the biocompatibility was evaluated by cytotoxicity and histology assay; the complexes were administrated to C57BL/6 mice and the humoral and cellular immune responses were evaluated by ELISA, IFN-gamma production and cytolytic T lymphocyte (CTL)-specific lysis assay.
   Results The remaining relative activity of DNase I after inhibition varied from 32.3% to 77.6%. The Complexes were observed with higher uptake efficiency by phagocytes than naked DNA. Three types of nanoparticles did not induce significant cyLotoxicity at concentrations <= 400 mu g/ml. No specific histological alteration related to the injection of the complexes was observed. The formulations of DNA-nanoparticle complexes significantly enhanced the immunogenicity in several parameters: elevated antibody production, higher level of IFN-gamma secretion, and augmented specific cell lysis.
   Conclusions This study demonstrated the potential of the novel chitosan derivative nanoparticles for safe and effective DNA vaccine delivery. (c) Copyright 2007 John Wiley & Sons, Ltd.
C1 Second Mil Med Univ, Dept Med Genet, Shanghai 200433, Peoples R China.
   Fudan Univ, State Key Lab Genet Engn, Dept Pharmaceut Sci, Sch Life Sci, Shanghai 200433, Peoples R China.
   Fudan Univ, Dept Biochem, Sch Life Sci, Shanghai 200433, Peoples R China.
RP Sun, S (reprint author), Second Mil Med Univ, Dept Med Genet, Shanghai 200433, Peoples R China.
EM shsun@vip.sina.com; chyin@fudan.edu.cn
RI He, Xiaowen/C-9632-2010
CR Caputo A, 2003, VACCINE, V21, P1103, DOI 10.1016/S0264-410X(02)00555-8                                                   
   Castaldello A, 2006, VACCINE, V24, P5655, DOI 10.1016/j.vaccine.2006.05.058
   CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333
   Cui ZR, 2001, J CONTROL RELEASE, V75, P409, DOI 10.1016/S0168-3659(01)00407-2                                                   
   Davis HL, 1996, P NATL ACAD SCI USA, V93, P7213, DOI 10.1073/pnas.93.14.7213
   Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633                                                      
   El-Din ANMN, 2006, VACCINE, V24, P1997, DOI 10.1016/j.vaccine.2005.11.033
   Erbacher P, 1998, PHARMACEUT RES, V15, P1332, DOI 10.1023/A:1011981000671
   Fifis T, 2004, J IMMUNOL, V173, P3148, DOI 10.4049/jimmunol.173.5.3148                                                     
   He XW, 2005, J CONTROL RELEASE, V107, P357, DOI 10.1016/j.jconrel.2005.06.020
   He XW, 2005, VACCINE, V23, P1649, DOI 10.1016/j.vaccine.2004.10.013
   He XW, 2005, J GEN VIROL, V86, P601, DOI 10.1099/vir.0.80575-0
   Hedley ML, 2003, EXPERT OPIN BIOL TH, V3, P903, DOI 10.1517/eobt.3.6.903.21268
   Ishiyama M, 1996, BIOL PHARM BULL, V19, P1518
   Kai E, 2004, PHARM RES, V21, P838, DOI 10.1023/B:PHAM.0000026437.32238.6f
   Kim TH, 2004, BIOMATERIALS, V25, P3783, DOI 10.1016/j.biomaterials.2003.10.063
   Kotze AF, 1999, EUR J PHARM SCI, V7, P145, DOI 10.1016/S0928-0987(98)00016-5                                                   
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168-3659(98)00097-2
   Mancini-Bourgine M, 2004, HEPATOLOGY, V40, P874, DOI 10.1002/hep.20408
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Moret-Tatay I, 2006, VACCINE, V24, P3937, DOI 10.1016/j.vaccine.2006.02.019
   Onal S, 2002, ARTIF CELL BLOOD SUB, V30, P229, DOI 10.1081/BIO-120004343
   Qian F, 2006, BIOMACROMOLECULES, V7, P2722, DOI 10.1021/bm060065f
   Sakuma S, 2001, ADV DRUG DELIVER REV, V47, P21, DOI 10.1016/S0169-409X(00)00119-8
   SEYMOUR L, 1991, CELL BIOL INT REP, V15, P277, DOI 10.1016/0309-1651(91)90166-G
   Singh M, 2004, EXPERT OPIN BIOL TH, V4, P483, DOI 10.1517/14712598.4.4.483
   Singh M, 2001, VACCINE, V20, P594, DOI 10.1016/S0264-410X(01)00321-8                                                   
   Thanou M, 2002, BIOMATERIALS, V23, P153, DOI 10.1016/S0142-9612(01)00090-4
   Thomas SM, 2003, CANCER GENE THER, V10, P518, DOI 10.1038/sj.cgt.7700567
   Wang F, 2006, VACCINE, V24, P2017, DOI 10.1016/j.vaccine.2005.11.042
   Wong K, 2006, BIOCONJUGATE CHEM, V17, P152, DOI 10.1021/bc0501597
   Xu W, 2004, VACCINE, V22, P3603, DOI 10.1016/j.vaccine.2004.03.033
NR 32
TC 34
Z9 38
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1099-498X
EI 1521-2254
J9 J GENE MED
JI J. Gene. Med.
PD APR
PY 2007
VL 9
IS 4
BP 253
EP 264
DI 10.1002/jgm.1017
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 166LW
UT WOS:000246381400003
PM 17397104
DA 2018-01-05
ER

PT J
AU Tang, J
   Xing, GM
   Zhao, F
   Yuan, H
   Zhao, YL
AF Tang, Jun
   Xing, Gengmei
   Zhao, Feng
   Yuan, Hui
   Zhao, Yuliang
TI Modulation of structural and electronic properties of fullerene and
   metallofullerenes by surface chemical modifications
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE fullerene; metallofullerene; nanotube; electronic properties;
   modulation; chemical modification
ID WALLED CARBON NANOTUBES; RESONANT PHOTOEMISSION; IN-VIVO; GD-AT-C-82
   METALLOFULLERENES; FLUORINATED FULLERENES; EXOHEDRAL ADDITION;
   OPTICAL-PROPERTIES; HIV-1 PROTEASE; C-60; DERIVATIVES
AB Many applications of fullerene, metallofullerene, and carbon nanotubes request the chemical modifications. But how the modification influences the stability, structural, and electronic properties that directly relate to the practical functions of the carbon nanomaterials, this issue is discussed in this paper. The outer chemical modifications can sensitively influence the stability of final derivatives of fullerenes, depending on parameters such as the number of the modified groups, the unintended impurity groups on the cage surface, and chemical conditions in synthesizing processes. The outer chemical modification can induce alteration in electronic properties of metallofullerene. Gd@C-82 is taken as a model to show how the electronic properties of the encaged metal atom are modulated by the cage surface modification. There exist sandwich-type electronic interactions along pathway: [outer modification group]-[cage surface]-[inner atom], and their synergistic effects are discussed. Beside the number of the modified groups, whose distribution patterns on the cage surface also play crucial roles in determining how the electronic interactions are modulated. Their synergistic effects dominate the electronic, optical, or magnetic properties of functionalized fullerenic nanomaterials. As the surface of nanotube is chemically more inert as compared to that of fullerene or metallofullerene, to achieve desirable modulations of nanotubes is probably more difficult. The research aimed to explore the changes in their structural or electronic property after the outer chemical functionalization was few, though this is of special significant and needs investigations because the chemical modifications are widely applying to the carbon nanotubes in applications.
C1 Chinese Acad Sci, Lab Bioenvironm Hlth Sci Nanoscale Mat, Inst High Energy Phys, Beijing 100049, Peoples R China.
   Natl Ctr Nanosci & Nanotechnol, Beijing 100080, Peoples R China.
   Grad Univ, Chinese Acad Sci, Coll Chem, Beijing 100049, Peoples R China.
RP Zhao, YL (reprint author), Chinese Acad Sci, Lab Bioenvironm Hlth Sci Nanoscale Mat, Inst High Energy Phys, Beijing 100049, Peoples R China.
RI Tang, Jun/D-6863-2015
CR AKASAKA T, 1995, NATURE, V374, P600, DOI 10.1038/374600a0                                                                
   Al-Matar H, 2001, ORG LETT, V3, P1669, DOI 10.1021/ol0100531
   Bahr JL, 2001, J AM CHEM SOC, V123, P6536, DOI 10.1021/ja010462s                                                               
   Banerjee IA, 2003, J AM CHEM SOC, V125, P9542, DOI 10.1021/ja0344011
   Bolskar RD, 2003, J AM CHEM SOC, V125, P5471, DOI 10.1021/ja03400984
   BOS DT, 1999, CHEM COMMUN, P663
   BOUTORINE AS, 1994, ANGEW CHEM INT EDIT, V33, P2462
   Cagle DW, 1996, J AM CHEM SOC, V118, P8043, DOI 10.1021/ja960841z                                                               
   Cagle DW, 1999, P NATL ACAD SCI USA, V96, P5182, DOI 10.1073/pnas.96.9.5182                                                          
   Chen CY, 2005, NANO LETT, V5, P2050, DOI 10.1021/nl051624b
   Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95                                                     
   Chen Z, 2006, TOXICOL LETT, V163, P109, DOI 10.1016/j.toxlet.2005.10.003
   Chen ZF, 2000, J MOL STRUC-THEOCHEM, V498, P227, DOI 10.1016/S0166-1280(99)00264-X                                                   
   CHIANG LY, 1993, J AM CHEM SOC, V115, P5453, DOI 10.1021/ja00066a014                                                             
   CHIANG LY, 1992, J AM CHEM SOC, V114, P10154, DOI 10.1021/ja00052a010                                                             
   CHIANG LY, 1994, J CHEM SOC CHEM COMM, P2675, DOI 10.1039/c39940002675                                                            
   CHIANG LY, 1995, SYNTHETIC MET, V70, P1477, DOI 10.1016/0379-6779(94)02925-O
   CHIANG LY, 1995, MATER RES SOC SYMP P, V359, P327
   CHIANG LY, 1995, CHEM FULLERENES, P67
   CHIANG LY, 1994, J CHEM SOC CHEM COMM, P1283
   Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434                                                         
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Fu KF, 2002, J NANOSCI NANOTECHNO, V2, P457, DOI 10.1166/jnn.2002.135
   Georgakilas V, 2002, J AM CHEM SOC, V124, P760, DOI 10.1021/ja016954m
   GERKEN F, 1981, PHYS REV LETT, V47, P993, DOI 10.1103/PhysRevLett.47.993                                                      
   GOSIVAMI TH, 2003, POLYMER, V44, P3209
   Goswami TH, 2004, THERMOCHIM ACTA, V419, P97, DOI 10.1016/j.tca.2004.02.001
   Hinokuma K, 2001, CHEM PHYS LETT, V341, P442, DOI 10.1016/S0009-2614(01)00549-8
   HIRSCH A, 1994, ANGEW CHEM INT EDIT, V33, P437, DOI 10.1002/anie.199404371                                                          
   HIRSCH A, 1999, TOP CURR CHEM, V199, P33
   HOLLOWAY JH, 1991, J CHEM SOC CHEM COMM, P966, DOI 10.1039/c39910000966                                                            
   Huang WJ, 2002, NANO LETT, V2, P311, DOI 10.1021/n1010095i
   HUMMELEN JC, 1995, J AM CHEM SOC, V117, P7003, DOI 10.1021/ja00131a024                                                             
   Iezzi EB, 2002, SYNTHETIC MET, V128, P289, DOI 10.1016/S0379-6779(02)00034-6                                                   
   Iiduka Y, 2005, J AM CHEM SOC, V127, P12500, DOI 10.1021/ja054209u
   Jia G, 2005, ENVIRON SCI TECHNOL, V39, P1378, DOI 10.1021/es048729l
   Jin ZX, 2000, CHEM PHYS LETT, V318, P505, DOI 10.1016/S0009-2614(00)00091-9
   JOHNSON RD, 1992, NATURE, V355, P239, DOI 10.1038/355239a0
   Bubnov V. P., 2005, ANGEW CHEM, V117, P1880
   KATO T, 1995, J PHYS CHEM-US, V99, P856, DOI 10.1021/j100003a002                                                             
   KESHAVARZ M, 1995, J AM CHEM SOC, V117, P11371, DOI 10.1021/ja00150a048                                                             
   Khairallah G, 1997, CHEM PHYS LETT, V268, P218, DOI 10.1016/S0009-2614(97)00190-5
   KIKUCHI K, 1994, J AM CHEM SOC, V116, P9367, DOI 10.1021/ja00099a079                                                             
   KNIAZ K, 1993, J AM CHEM SOC, V115, P6060, DOI 10.1021/ja00067a022                                                             
   Kobayashi K, 2003, CHEM PHYS LETT, V374, P562, DOI 10.1016/S0009-2614(03)00750-4
   KUTZLER FW, 1984, PHYS REV B, V29, P1008, DOI 10.1103/PhysRevB.29.1008
   LAMPARTH I, 1994, J CHEM SOC CHEM COMM, P1727, DOI 10.1039/c39940001727                                                            
   Leiro JA, 2003, J ELECTRON SPECTROSC, V128, P205, DOI 10.1016/S0368-2048(02)00284-0
   Li QN, 2002, NUCL MED BIOL, V29, P707
   Li YM, 2002, SOLID STATE IONICS, V150, P309, DOI 10.1016/S0167-2738(02)00449-6
   Lin Y, 2002, J PHYS CHEM B, V106, P1294, DOI 10.1021/jp013501v
   Marcorin GL, 2000, ORG LETT, V2, P3955, DOI 10.1021/ol000217y
   Meier MS, 2001, ORG LETT, V3, P1717, DOI 10.1021/ol0159120
   MICHELSON ET, 1998, CHEM PHYS LETT, V296, P188
   MICHELSON ET, 1999, J PHYS CHEM B, V103, P4318
   Mikawa M, 2001, BIOCONJUGATE CHEM, V12, P510, DOI 10.1021/bc000136m
   Mishra SR, 1998, PHYS REV LETT, V81, P1306, DOI 10.1103/PhysRevLett.81.1306                                                     
   NAGASE S, 1994, CHEM PHYS LETT, V228, P106, DOI 10.1016/0009-2614(94)00911-2
   NAIM A, 1992, TETRAHEDRON LETT, V33, P7097, DOI 10.1016/S0040-4039(00)60845-6                                                   
   Nishibori E, 1998, CHEM PHYS LETT, V298, P79, DOI 10.1016/S0009-2614(98)01133-6
   Nishibori E, 2000, CHEM PHYS LETT, V330, P497, DOI 10.1016/S0009-2614(00)01079-4
   Nishibori E, 2001, ANGEW CHEM INT EDIT, V40, P2998, DOI 10.1002/1521-3773(20010817)40:16<2998::AID-ANIE2998>3.0.CO;2-4
   NSIHIBORI E, 2004, PHYS REV B, V69
   Okada EJ, 2004, TETRAHEDRON LETT, V45, P527, DOI 10.1016/j.tetlet.2003.10.212
   Park N, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.125401                                                      
   Pekker S, 2001, J PHYS CHEM B, V105, P7938, DOI 10.1021/jp010642o
   POIRIER DM, 1994, PHYS REV B, V49, P17403, DOI 10.1103/PhysRevB.49.17403
   Qu L, 2006, J ALLOY COMPD, V408, P400, DOI 10.1016/j.jallcom.2004.12.101
   Riggs JE, 2000, J AM CHEM SOC, V122, P5879, DOI 10.1021/ja9942282
   Rincon ME, 2003, J PHYS CHEM B, V107, P4111, DOI 10.1021/jp022159z
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   Schuster DI, 1996, BIOORG MED CHEM LETT, V6, P1253, DOI 10.1016/0960-894X(96)00210-7
   SELIG H, 1991, J AM CHEM SOC, V113, P5475, DOI 10.1021/ja00014a061                                                             
   Senapati L, 2005, NANO LETT, V5, P2341, DOI 10.1021/nl0518831
   Senapati L, 2004, NANO LETT, V4, P2073, DOI 10.1021/nl049164u
   SHINOHARA H, 1992, NATURE, V357, P52, DOI 10.1038/357052a0                                                                
   SHINOHARA H, 1992, J PHYS CHEM-US, V96, P3571, DOI 10.1021/j100188a004                                                             
   SHINOHARA H, 1995, J PHYS CHEM-US, V99, P1369
   Slanina Z, 1999, INT J QUANTUM CHEM, V74, P343, DOI 10.1002/(SICI)1097-461X(1999)74:3<343::AID-QUA7>3.0.CO;2-S                      
   SLANINA Z, 1996, CHEM PHYS FULLERENES, V3, P987
   SLANINA Z, 1997, CHEM PHYSICS FULLERE, V4, P721
   Starke K, 1997, PHYS REV B, V55, P2672, DOI 10.1103/PhysRevB.55.2672
   Sun BY, 2005, ANGEW CHEM INT EDIT, V44, P4568, DOI 10.1002/anie.200500876
   Sun YP, 2001, CHEM MATER, V13, P2864, DOI 10.1021/cm0100691
   Sun YP, 2002, CHEM PHYS LETT, V351, P349, DOI 10.1016/S0009-2614(01)01404-X
   Szade J, 1999, J ALLOY COMPD, V286, P153, DOI 10.1016/S0925-8388(98)00997-9
   Szade J, 2002, SURF SCI, V497, P29, DOI 10.1016/S0039-6028(01)01622-3
   Tagmatarchis N, 2002, CHEM PHYS LETT, V355, P226, DOI 10.1016/S0009-2614(02)00207-5
   Takata M, 1997, PHYS REV LETT, V78, P3330, DOI 10.1103/PhysRevLett.78.3330
   Takata M, 1999, PHYS REV LETT, V83, P2214, DOI 10.1103/PhysRevLett.83.2214                                                     
   TAKATA M, 1995, NATURE, V377, P46, DOI 10.1038/377046a0
   Tang J, 2005, J PHYS CHEM B, V109, P8779, DOI 10.1021/jp050374k
   Tobin JG, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.155109
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
   Trajmar S, 1996, CHEM PHYS LETT, V262, P241, DOI 10.1016/0009-2614(96)01090-1
   Tsang SC, 1997, ANGEW CHEM INT EDIT, V36, P2198, DOI 10.1002/anie.199721981                                                          
   Wang B, 2006, TOXICOL LETT, V161, P115, DOI 10.1016/j.toxlet.2005.08.007
   WANG BC, 1997, J MOL STRUC-THEOCHEM, V391, P179, DOI DOI 10.1016/S0166-1280(96)04800-2
   Wang H, 2005, J MOL ENDOCRINOL, V35, P1, DOI 10.1677/jme.1.01738                                                             
   Wang HF, 2004, ACTA PHYS-CHIM SIN, V20, P673, DOI 10.3866/PKU.WHXB20040701
   Wang HF, 2004, J NANOSCI NANOTECHNO, V4, P1019, DOI 10.1166/jnn.2004.146
   Wang JX, 2006, BIOCHEM PHARMACOL, V71, P872, DOI 10.1016/j.bcp.2005.12.001
   Wang KD, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.185504
   Wang QH, 1997, APPL PHYS LETT, V70, P3308, DOI 10.1063/1.119146
   WANG TC, 2005, ENV OCCUPATIONAL MED, V21, P434
   WEAVER JH, 1992, CHEM PHYS LETT, V190, P460, DOI 10.1016/0009-2614(92)85173-8                                                    
   Xing GM, 2004, J PHYS CHEM B, V108, P11473, DOI 10.1021/jp0487962
   Yamada M, 2006, J AM CHEM SOC, V128, P1400, DOI 10.1021/ja055882m
   Yamada M, 2005, J AM CHEM SOC, V127, P14570, DOI 10.1021/ja054346r
   YAMAMOTO K, 1994, J PHYS CHEM-US, V98, P2008, DOI 10.1021/j100059a004                                                             
   YAMAMOTO K, 1994, J PHYS CHEM-US, V98, P12831, DOI 10.1021/j100100a006                                                             
   YANNONI CS, 1992, SCIENCE, V256, P1191, DOI 10.1126/science.256.5060.1191
   Ye C, 2006, CHINESE SCI BULL, V51, P1060, DOI 10.1007/s11434-006-1060-1
   Yoon BJ, 2005, J AM CHEM SOC, V127, P8234, DOI 10.1021/ja043823n
   Zhang YZ, 2005, CHEM LETT, V34, P1264, DOI 10.1246/cl.2005.1264
   ZHAO YL, 2005, B CHIN ACAD SCI, V20, P194
   Zhu W, 1999, APPL PHYS LETT, V75, P873, DOI 10.1063/1.124541
NR 118
TC 20
Z9 20
U1 2
U2 23
PU AMER SCIENTIFIC PUBLISHERS
PI VALENCIA
PA 26650 THE OLD RD, STE 208, VALENCIA, CA 91381-0751 USA
SN 1533-4880
EI 1533-4899
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD APR-MAY
PY 2007
VL 7
IS 4-5
BP 1085
EP 1101
DI 10.1166/jnn.2007.301
PG 17
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 149JC
UT WOS:000245142200002
PM 17450881
DA 2018-01-05
ER

PT J
AU Cambi, A
   Lidke, DS
   Arndt-Jovin, DJ
   Figdor, CG
   Jovin, TM
AF Cambi, Alessandra
   Lidke, Diane S.
   Arndt-Jovin, Donna J.
   Figdor, Carl G.
   Jovin, Thomas M.
TI Ligand-conjugated quantum dots monitor antigen uptake and processing by
   dendritic cells
SO NANO LETTERS
LA English
DT Article
ID LECTIN DC-SIGN; T-CELLS; LIVE CELLS; RECEPTOR; VIRUS; INFECTION; TRANS;
   VACCINATION; ANISOTROPY; RESPONSES
AB The dendritic cell (DC) specific pathogen-uptake receptor (DC-SIGN) internalizes antigens for degradation and presentation onto MHC molecules. At the cell membrane, DC-SIGN forms nanoclusters that facilitate virus capture. However, internalized viruses, such as HIV-1, escape degradation. Here, we exploit ligand-conjugated, virus-sized, highly photostable quantum dots (QDs) to monitor in living cells antigen binding, entry, and trafficking. The antigen-coated QDs specific uptake and persistence in live DCs open the possibility for tracking antigen-presenting cells in vivo.
C1 Max Planck Inst Biophys Chem, Dept Mol Biol, D-37077 Gottingen, Germany.
   Radboud Univ Nijmegen Med Ctr, Dept Tumor Immunol, Ctr Mol Life Sci, Nijmegen, Netherlands.
RP Cambi, A (reprint author), Max Planck Inst Biophys Chem, Dept Mol Biol, D-37077 Gottingen, Germany.
EM a.cambi@ncmls.ru.nl; tjovin@gwdg.de
RI Cambi, A./L-4242-2015; Figdor, Carl/A-4232-2010
OI Cambi, A./0000-0003-1597-1582; Figdor, Carl/0000-0002-2366-9212
CR Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Appelmelk BJ, 2003, J IMMUNOL, V170, P1635, DOI 10.4049/jimmunol.170.4.1635                                                     
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Bergman MP, 2004, J EXP MED, V200, P979, DOI 10.1084/jem.20041061
   Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598
   Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Cambi A, 2004, J CELL BIOL, V164, P145, DOI 10.1083/jcb.200306112                                                           
   Cambi A, 2003, EUR J IMMUNOL, V33, P532, DOI 10.1002/immu.200310029
   Caparros E, 2006, BLOOD, V107, P3950, DOI 10.1182/blood-2005-03-1252
   Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118                                                     
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723
   Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   Grecco HE, 2004, MICROSC RES TECHNIQ, V65, P169, DOI 10.1002/jemt.20129
   Keler T, 2004, EXPERT OPIN BIOL TH, V4, P1953, DOI 10.1517/14712598.4.12.1953
   Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5
   Lidke DS, 2005, J CELL BIOL, V170, P619, DOI 10.1083/jcb.200503140                                                           
   Lidke DS, 2003, BIOCHEM SOC T, V31, P1020
   Lidke DS, 2004, NAT BIOTECHNOL, V22, P198, DOI 10.1038/nbt929
   Ludewig B, 2003, CURR TOP MICROBIOL, V276, P199
   Ludwig IS, 2004, J VIROL, V78, P8322, DOI 10.1128/jvi.78.15.8322-8332.2004
   Martinez O, 2005, INT IMMUNOL, V17, P769, DOI 10.1093/intimm/dxh258
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Mousavi SA, 2004, BIOCHEM J, V377, P1, DOI 10.1042/BJ20031000
   Nichols BJ, 2003, CURR BIOL, V13, P686, DOI 10.1016/S0960-9822(03)00209-4
   Pohlmann S, 2001, J VIROL, V75, P4664, DOI 10.1128/JVI.75.10.4664-4672.2001
   Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961                                                            
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83                                                            
   Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318
   van Gisbergen KPJM, 2005, IMMUNOL LETT, V97, P199, DOI 10.1016/j.imlet.2004.11.008
   YUASA T, 1991, J GEN VIROL, V72, P2021, DOI 10.1099/0022-1317-72-8-2021
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055                                                                
NR 37
TC 75
Z9 77
U1 0
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD APR
PY 2007
VL 7
IS 4
BP 970
EP 977
DI 10.1021/nl0700503
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 155TG
UT WOS:000245600500022
PM 17388641
DA 2018-01-05
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Carbon nanotubes and siRNA battle HIV
SO NANOMEDICINE
LA English
DT News Item
CR Dai H., 2007, ANGEW CHEM, V119, P2069
NR 1
TC 0
Z9 0
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1743-5889
J9 NANOMEDICINE-UK
JI Nanomedicine
PD APR
PY 2007
VL 2
IS 2
BP 150
EP 150
PG 1
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 159IR
UT WOS:000245859500004
DA 2018-01-05
ER

PT J
AU Foerg, C
   Ziegler, U
   Fernandez-Carneado, J
   Giralt, E
   Merkle, HP
AF Foerg, Christina
   Ziegler, Urs
   Fernandez-Carneado, Jimena
   Giralt, Ernest
   Merkle, Hans P.
TI Differentiation restricted endocytosis of cell penetrating peptides in
   MDCK cells corresponds with activities of Rho-GTPases
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE cell penetrating peptides; cellular internalization; endocytosis; MDCK;
   Rho-GTPases
ID INFLAMMATORY-BOWEL-DISEASE; EPITHELIAL BARRIER FUNCTION;
   NECROSIS-FACTOR-ALPHA; HIV-1 TAT PROTEIN; TIGHT JUNCTIONS; IN-VIVO;
   PLASMA-MEMBRANE; PROINFLAMMATORY CYTOKINES; MAGNETIC NANOPARTICLES;
   SURFACE POLARITY
AB Cellular entry of biomacromolecules is restricted by the barrier function of cell membranes. Tethering such molecules to cell penetrating peptides (CPPs) that can translocate cell membranes has opened new horizons in biomedical research. Here, we investigate the cellular internalization of hCT(9-32)-br, a human calcitonin derived branched CPP, and SAP, a gamma-zein related sequence.
   Internalization of fluorescence labelled CPPs was performed with both proliferating and confluent MDCK cells by means of confocal laser scanning microscopy (CLSM) and fluorescence activated cell sorting (FACS) using appropriate controls. Internalization was further elaborated in an inflammatory, IFN-gamma/TNF-alpha a induced confluent MDCK model mimicking inflammatory epithelial pathologies. Activities of active form Rho-GTPases (Rho-A and Rac-1) in proliferating and confluent MDCK cells were monitored by pull-down assay and Western blot analysis.
   We observed marked endocytic uptake of the peptides into proliferating MDCK by a process suggesting both lipid rafts and clathrin-coated pits. In confluent MDCK, however, we noted a massive but compound-unspecific slow-down of endocytosis. This corresponded with a down-regulation of endocytosis by Rho-GTPases, previously identified to be intimately involved in endocytic traffic. In fact, we found endocytic internalization to relate with active Rho-A; vice versa, MDCK cell density, degree of cellular differentiation and endocytic slow-down were found to relate with active Rac-1. To our knowledge, this is the first study to cast light on the previously observed differentiation restricted internalization of CPPs into epithelial cell models. In the inflammatory IFN-gamma/TNF-alpha a induced confluent MDCK model mimicking inflammatory epithelial pathologies, CPP internalization was enhanced in a cytokine concentration-dependent way resulting in maximum enhancement rates of up to 90%. We suggest a cytokine induced redistribution of lipid rafts in confluent MDCK to cause this enhancement.
   Our findings emphasize the significance of differentiated cell models in the study of CPP internalization and point towards inflammatory epithelial pathologies as potential niche for the application of CPPs for cellular delivery.
C1 ETH, Inst Pharmaceut Sci, Zurich, Switzerland.
   Univ Zurich, Inst Anat, Zurich, Switzerland.
   Inst Rec Biomed Barcelona, Barcelona, Spain.
   Univ Barcelona, Dept Quim Organ, Barcelona, Spain.
   ETH, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland.
RP Merkle, HP (reprint author), ETH, Inst Pharmaceut Sci, Zurich, Switzerland.
EM hmerkle@pharma.ethz.ch
RI giralt, ernest/N-1669-2014; Merkle, Hans/A-4381-2014
OI giralt, ernest/0000-0001-8381-1797; 
CR Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   BALCAROVASTANDER J, 1984, EMBO J, V3, P2687
   Bonfield TL, 1999, J ALLERGY CLIN IMMUN, V104, P72, DOI 10.1016/S0091-6749(99)70116-8
   BOURNE HR, 1993, NATURE, V366, P628, DOI 10.1038/366628a0                                                                
   Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164                                                    
   Bucci M, 2000, NAT MED, V6, P1362
   CEREIJIDO M, 1984, J MEMBRANE BIOL, V81, P41, DOI 10.1007/BF01868808
   Cereijido M, 1998, ANNU REV PHYSIOL, V60, P161, DOI 10.1146/annurev.physiol.60.1.161
   CHO MJ, 1989, PHARMACEUT RES, V6, P71, DOI 10.1023/A:1015807904558
   Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134
   Crespo L, 2002, J AM CHEM SOC, V124, P8876, DOI 10.1021/ja020364m
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9
   Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148
   Fernandez-Carneado J, 2004, BIOPOLYMERS, V76, P196, DOI 10.1002/bip.10585
   Fernandez-Carneado J, 2004, ANGEW CHEM INT EDIT, V43, P1811, DOI 10.1002/anie.200352540
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Fish SM, 1999, GUT, V45, P191, DOI 10.1136/gut.45.2.191                                                            
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   Gassler N, 2001, AM J PHYSIOL-GASTR L, V281, pG216
   Gitter AH, 2000, FASEB J, V14, P1749, DOI 10.1096/fj.99-0898com
   Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509
   Hallbrink M, 2004, BBA-BIOMEMBRANES, V1667, P222, DOI 10.1016/j.bbamem.2004.10.009
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Hemmings DG, 2001, PLACENTA, V22, P70, DOI 10.1053/plac.2000.0587
   Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300
   Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287                                                            
   Karp G., 1999, CELL MOL BIOL
   Krauss U, 2004, BIOORG MED CHEM LETT, V14, P51, DOI 10.1016/j.bmcl.2003.10.014
   Kucharzik T, 2001, AM J PATHOL, V159, P2001, DOI 10.1016/S0002-9440(10)63051-9
   Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675
   Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X
   Letoha T, 2003, J MOL RECOGNIT, V16, P272, DOI 10.1002/jmr.637
   Leung SM, 1999, MOL BIOL CELL, V10, P4369, DOI 10.1091/mbc.10.12.4369                                                          
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   MANN DA, 1991, EMBO J, V10, P1733
   Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2
   Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655
   Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529
   NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4
   Nusrat A, 2000, J CELL SCI, V113, P1771
   Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905
   Orlando Roy C, 2002, Rev Gastroenterol Disord, V2 Suppl 2, pS2
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x                                                
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X
   Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084
   Qualmann B, 2003, BIOCHEM J, V371, P233, DOI 10.1042/BJ20030139
   Qualmann B., 2000, J CELL BIOL, V150, P111
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rivero F, 2002, J MUSCLE RES CELL M, V23, P737, DOI 10.1023/A:1024423611223
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rothen-Rutishauser B, 1998, PHARMACEUT RES, V15, P964, DOI 10.1023/A:1011953405272                                                         
   Sanders DSA, 2005, J CLIN PATHOL, V58, P568, DOI 10.1136/jcp.2004.021840                                                         
   Schmitz H, 2000, ANN NY ACAD SCI, V915, P312
   Schmitz H, 1999, J CELL SCI, V112, P137
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Siccardi D, 2005, ADV DRUG DELIVER REV, V57, P219, DOI 10.1016/j.addr.2004.08.005
   SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331                                             
   Singh D, 1999, BIOCONJUGATE CHEM, V10, P745, DOI 10.1021/bc980131d
   Symons M, 2003, CURR BIOL, V13, pR409, DOI 10.1016/S0960-9822(03)00324-5
   Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047
   Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436
   Trehin R, 2004, PHARM RES, V21, P33, DOI 10.1023/B:PHAM.0000012149.83119.bf
   Trehin R, 2004, PHARM RES, V21, P1248, DOI 10.1023/B:PHAM.0000033013.45204.c3
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   VAN AL, 1997, GENE DEV, V11, P2295
   VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0                                                                
   VAN MEER G, 1986, EMBO J, V5, P1455
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289                                                        
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Zhang XP, 2004, MOL PHARMACEUT, V1, P145, DOI 10.1021/mp034014y
NR 79
TC 35
Z9 35
U1 1
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD APR
PY 2007
VL 24
IS 4
BP 628
EP 642
DI 10.1007/s11095-006-9212-1
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 145UF
UT WOS:000244890100002
PM 17334941
DA 2018-01-05
ER

PT J
AU Lee-Huang, S
   Huang, PL
   Zhang, DW
   Lee, JW
   Bao, J
   Sun, YT
   Chang, YT
   Zhang, J
   Huang, PL
AF Lee-Huang, Sylvia
   Huang, Philip Lin
   Zhang, Dawei
   Lee, Jae Wook
   Bao, Ju
   Sun, Yongtao
   Chang, Young-Tae
   Zhang, John
   Huang, Paul Lee
TI Discovery of small-molecule HIV-1 fusion and integrase inhibitors
   oleuropein and hydroxytyrosol: Part II. Integrase inhibition
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE HIV-1; AIDS; natural product; small molecule HIV-1 inhibitors; HIV-1
   integrase inhibitor; olive leaf extract (OLE); oleuropein (Ole);
   hydroxytyrosol (HT); structure-function; molecular modeling
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ESCHERICHIA-COLI; TYPE-1; MUTATIONS;
   MUTANT; SITE
AB We report molecular modeling and functional confirmation of Ole and HT binding to HIV-1 integrase. Docking simulations identified two binding regions for Ole within the integrase active site. Region I encompasses the conserved D64-116-E152 motif, while region II involves the flexible loop region formed by amino acid residues 140-149. HT, on the other hand, binds to region II. Both Ole and HT exhibit favorable interactions with important amino acid residues through strong H-bonding and van der Waals contacts, predicting integrase inhibition. To test and confirm modeling predictions, we examined the effect of Ole and HT on HIV-1 integrase activities including 3'-processing, strand transfer, and disintegration. Ole and HT exhibit dose-dependent inhibition on all three activities, with EC(50)s in the nanomolar range. These studies demonstrate that molecular modeling of target-ligand interaction coupled with structural-activity analysis should facilitate the design and identification of innovative integrase inhibitors and other therapeutics. (c) 2007 Elsevier Inc. All rights reserved.
C1 NYU, Sch Med, Dept Biochem, New York, NY 10016 USA.
   Amer Biosci, Boston, MA 02114 USA.
   NYU, Dept Chem, New York, NY 10003 USA.
   Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Lee-Huang, S (reprint author), NYU, Sch Med, Dept Biochem, 550 1St Ave, New York, NY 10016 USA.
EM sylvia.lee-huang@med.nyu.edu
RI Zhang, Dawei/C-5981-2008; Bao, Ju/E-6242-2012; Chang,
   Young-Tae/B-2780-2010
OI Chang, Young-Tae/0000-0002-1927-3688; Lee-Huang,
   Sylvia/0000-0003-3302-241X
FU NCCIH NIH HHS [R01-AT01383, R01 AT001383]
CR Al-Mawsawi LQ, 2006, P NATL ACAD SCI USA, V103, P10080, DOI 10.1073/pnas.0511254103
   BLOMMERS MJJ, 1989, BIOCHEMISTRY-US, V28, P7491, DOI 10.1021/bi00444a049
   BROWN PO, 1998, RETROVIRUSES, P161
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547
   CHOW SA, 1994, J VIROL, V68, P3896
   CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845                                                         
   Duan Y, 2003, J COMPUT CHEM, V24, P1999, DOI 10.1002/jcc.10349
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040                                                        
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   HAERTLE T, 1988, J BIOL CHEM, V263, P5870
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712                                                         
   Lee-Huang S, 2005, BIOCHEMISTRY-US, V44, P4648, DOI 10.1021/bi0477081
   LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818                                                         
   Li M, 2005, J BIOL CHEM, V280, P29334, DOI 10.1074/jbc.M505367200
   MANN DL, 1989, AIDS RES HUM RETROV, V5, P253, DOI 10.1089/aid.1989.5.253
   Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119
   Sotriffer CA, 2000, J MED CHEM, V43, P4109, DOI 10.1021/jm000194t
   VINCENT KA, 1993, J VIROL, V67, P425
   Zhu K, 2004, J VIROL, V78, P5045, DOI 10.1128/JVI.78.10.5045-5055.2004
NR 24
TC 41
Z9 43
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 23
PY 2007
VL 354
IS 4
BP 879
EP 884
DI 10.1016/j.bbrc.2007.01.058
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 139DF
UT WOS:000244411800007
PM 17261269
OA green_accepted
DA 2018-01-05
ER

PT J
AU Hamada, K
   Kaneko, T
   Chen, MQ
   Akashi, M
AF Hamada, Kazuhiro
   Kaneko, Tatsuo
   Chen, Ming Qing
   Akashi, Mitsuru
TI Size-selective material adsorption property of polymeric nanoparticles
   with projection coronas
SO CHEMISTRY OF MATERIALS
LA English
DT Article
ID POLY(ETHYLENE GLYCOL); HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES;
   GRAFT-COPOLYMERS; POLYSTYRENE NANOPARTICLES; RESISTANT SURFACES;
   CHAIN-LENGTH; PEG; RECOGNITION; NANOSPHERES
AB We prepared irregularly shaped nanoparticles with carboxyl groups on the surface of nanoparticles in a "confetti"-like arrangement by dispersion copolymerization in the presence of the functional macromonomers methacryloyl-endcapped poly(methacrylic acid) (PMAA), poly(ethylene glycol) monomethoxymonomethacrylate (PEGm) with styrene (St), and acrylonitrile (AN), in the presence of 2,2'-azobis(isobutyronitrile) (AIBN) in a polar solvent. Concanavalin A (Con A) can be immobilized on the surface of these confetti nanoparticles, which showed a higher efficiency of Con A immobilization than the corresponding spherical nanoparticles (PMAA-PEGm-St nanoparticles and PMAA-St nanoparticles). Moreover, these Con A-immobilized confetti nanoparticles were able to capture HIV-1 virions (100 nm), even in the presence of erythrocytes (10 mu m). This size-selective material adsorption property of the confetti nanoparticles is expected to be useful for various separation materials by changing the projection morphologies.
C1 Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   Yangtze Univ, Sch Chem & Mat Engn, Wuxi 214036, Peoples R China.
   Japan Sci & Technol Agcy, CREST, Tokyo, Japan.
RP Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM akashi@chem.eng.osaka-u.ac.jp
CR Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Albertorio F, 2006, J AM CHEM SOC, V128, P7168, DOI 10.1021/ja062010r
   Chen CW, 2002, CHEM MATER, V14, P2232, DOI 10.1021/cm011634n
   Chen MQ, 1999, J POLYM SCI POL CHEM, V37, P2155, DOI 10.1002/(SICI)1099-0518(19990701)37:13<2155::AID-POLA31>3.0.CO;2-G              
   Chen MQ, 2001, CHEM LETT, P1306
   DRUMHELLER PD, 1995, J BIOMED MATER RES, V29, P207, DOI 10.1002/jbm.820290211
   Green RJ, 1998, J BIOMED MATER RES, V42, P165, DOI 10.1002/(SICI)1097-4636(199811)42:2<165::AID-JBM1>3.0.CO;2-N
   Groll J, 2005, BIOMACROMOLECULES, V6, P956, DOI 10.1021/bm049350u
   Hamada K, 2005, POLYMER, V46, P12166, DOI 10.1016/j.polymer.2005.10.085
   Harada A, 1999, SCIENCE, V283, P65, DOI 10.1126/science.283.5398.65
   Kaneko T, 2004, MACROMOLECULES, V37, P501, DOI 10.1021/ma035276g
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Lazos D, 2005, LANGMUIR, V21, P8774, DOI 10.1021/la051049r
   LEE JH, 1989, J BIOMED MATER RES, V23, P351, DOI 10.1002/jbm.820230306                                                           
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   MORROW WGW, 1993, HIV MOL ORG PATHOLOG, P29
   Otsuka H, 2004, LANGMUIR, V20, P11285, DOI 10.1021/la0483414
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   Sakuma S, 1999, INT J PHARM, V177, P161, DOI 10.1016/S0378-5173(98)00346-9
   Serizawa T, 2001, BIOMACROMOLECULES, V2, P469, DOI 10.1021/bm000131s
   Takae S, 2005, BIOMACROMOLECULES, V6, P818, DOI 10.1021/bm049427e
   Thom VH, 2000, LANGMUIR, V16, P2756, DOI 10.1021/la990303a                                                               
   Yu C, 1999, BIOMATERIALS, V20, P253, DOI 10.1016/S0142-9612(98)00169-0
NR 23
TC 13
Z9 16
U1 1
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0897-4756
J9 CHEM MATER
JI Chem. Mat.
PD MAR 6
PY 2007
VL 19
IS 5
BP 1044
EP 1052
DI 10.1021/cm0624217
PG 9
WC Chemistry, Physical; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA 139YC
UT WOS:000244467800017
DA 2018-01-05
ER

PT J
AU Kol, N
   Shi, Y
   Tsvitov, M
   Barlam, D
   Shneck, RZ
   Kay, MS
   Rousso, I
AF Kol, Nitzan
   Shi, Yu
   Tsvitov, Marianna
   Barlam, David
   Shneck, Roni Z.
   Kay, Michael S.
   Rousso, Itay
TI A stiffness switch in human immunodeficiency virus
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID GP41 CYTOPLASMIC TAIL; ENVELOPE GLYCOPROTEIN; CLATHRIN ADAPTER; TYPE-1
   MATRIX; HIV; FUSION; ORGANIZATION; MATURATION; PROTEIN; SURFACE
AB After budding from the cell, human immunodeficiency virus (HIV) and other retrovirus particles undergo a maturation process that is required for their infectivity. During maturation, HIV particles undergo a significant internal morphological reorganization, changing from a roughly spherically symmetric immature particle with a thick protein shell to a mature particle with a thin protein shell and conical core. However, the physical principles underlying viral particle production, maturation, and entry into cells remain poorly understood. Here, using nanoindentation experiments conducted by an atomic force microscope (AFM), we report the mechanical measurements of HIV particles. We find that immature particles are more than 14-fold stiff er than mature particles and that this large difference is primarily mediated by the HIV envelope cytoplasmic tail domain. Finite element simulation shows that for immature virions the average Young's modulus drops more than eightfold when the cytoplasmic tail domain is deleted (930 vs. 115 MPa). We also find a striking correlation between the softening of viruses during maturation and their ability to enter cells, providing the first evidence, to our knowledge, for a prominent role for virus mechanical properties in the infection process. These results show that HIV regulates its mechanical properties at different stages of its life cycle (i.e., stiff during viral budding versus soft during entry) and that this regulation may be important for efficient infectivity. Our report of this maturation-induced "stiffness switch" in HIV establishes the groundwork for mechanistic studies of how retroviral particles can regulate their mechanical properties to affect biological function.
C1 Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.
   Ben Gurion Univ Negev, Dept Mech Engn, IL-84105 Beer Sheva, Israel.
   Ben Gurion Univ Negev, Dept Mat Engn, IL-84105 Beer Sheva, Israel.
   Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84112 USA.
RP Rousso, I (reprint author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.
EM kay@biochem.utah.edu; itay.rousso@weizmann.ac.il
RI Rousso, Itay/A-7662-2013
OI Rousso, Itay/0000-0002-4399-9171
CR Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Berlioz-Torrent C, 1999, J VIROL, V73, P1350
   Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773
   Bueckle H, 1973, SCI HARDNESS TESTING
   Carrasco C, 2006, P NATL ACAD SCI USA, V103, P13706, DOI 10.1073/pnas.0601881103
   Cavrois M, 2002, NAT BIOTECHNOL, V20, P1151, DOI 10.1038/nbt745
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   CHEN BK, 1994, J VIROL, V68, P654
   Chertova E, 2002, J VIROL, V76, P5315, DOI 10.1128/JVI.76.11.5315-5325.2002
   COFFIN JM, 1997, RETROVIRUSES
   DeHart JL, 2005, J VIROL, V79, P1389, DOI 10.1128/JVI.79.3.1389-1396.2005
   DUBAY JW, 1992, J VIROL, V66, P6616
   FREED EO, 1995, J VIROL, V69, P1984
   Freed EO, 1996, J VIROL, V70, P341
   FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883                                                        
   GELDERBLOM HR, 1991, AIDS, V5, P617, DOI 10.1097/00002030-199106000-00001                                                
   HOCKLEY DJ, 1988, J GEN VIROL, V69, P2455, DOI 10.1099/0022-1317-69-10-2455
   HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970
   Ivanovska IL, 2004, P NATL ACAD SCI USA, V101, P7600, DOI 10.1073/pnas.0308198101
   Jiang JY, 2006, VIROLOGY, V346, P460, DOI 10.1016/j.virol.2005.11.008
   Kol N, 2006, BIOPHYS J, V91, P767, DOI 10.1529/biophysj.105.079657
   Michel JP, 2006, P NATL ACAD SCI USA, V103, P6184, DOI 10.1073/pnas.0601744103
   Moore JP, 1998, NATURE, V393, P630, DOI 10.1038/31359
   Murakami T, 2004, J VIROL, V78, P1026, DOI 10.1128/JVI.78.2.1026-1031.2004
   OZEL M, 1988, ARCH VIROL, V100, P255, DOI 10.1007/BF01487688
   ROWELL JF, 1995, J IMMUNOL, V155, P473
   SPIES CP, 1994, J VIROL, V68, P585
   Swanstrom R., 1997, P263
   Wilk T, 2001, J VIROL, V75, P759, DOI 10.1128/JVI.75.2.759-771.2001
   WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002
   Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004
   Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299
   Zhu P, 2003, P NATL ACAD SCI USA, V100, P15812, DOI 10.1073/pnas.26334931100
   Zhu P, 2006, NATURE, V441, P847, DOI 10.1038/nature04817
NR 34
TC 108
Z9 109
U1 0
U2 17
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD MAR 1
PY 2007
VL 92
IS 5
BP 1777
EP 1783
DI 10.1529/biophysj.106.093914
PG 7
WC Biophysics
SC Biophysics
GA 138PD
UT WOS:000244373800032
PM 17158573
OA gold
DA 2018-01-05
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Ceramic nanotubes could be cure for HIV
SO FILTRATION & SEPARATION
LA English
DT News Item
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0015-1882
J9 FILTR SEPARAT
JI Filtr. Sep.
PD MAR
PY 2007
VL 44
IS 2
BP 9
EP 9
PG 1
WC Engineering, Chemical
SC Engineering
GA 154AL
UT WOS:000245479100002
DA 2018-01-05
ER

PT J
AU Uto, T
   Wang, X
   Sato, K
   Haraguchi, M
   Akagi, T
   Akashi, M
   Baba, M
AF Uto, Tomofumi
   Wang, Xin
   Sato, Katsuaki
   Haraguchi, Misako
   Akagi, Takami
   Akashi, Mitsuru
   Baba, Masanori
TI Targeting of antigen to dendritic cells with poly(gamma-glutamic acid)
   nanoparticles induces antigen-specific humoral and cellular immunity
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; HIV-1 GAG PROTEIN; NF-KAPPA-B;
   IN-VIVO; T-CELLS; ANTIBODY-RESPONSE; BACTERIAL-DNA; IMMUNIZATION;
   INDUCTION; ACTIVATION
AB Nanoparticles are considered to be efficient tools for inducing potent immune responses by an Ag carrier. In this study, we examined the effect of Ag-carrying biodegradable poly(gamma-glutamic acid) (gamma-PGA) nanoparticles (NPs) on the induction of immune responses in mice. The NPs were efficiently taken up by dendritic cells (DCs) and subsequently localized in the lysosomal compartments. gamma-PGA NPs strongly induced cytokine production, up-regulation of costimulatory molecules, and the enhancement of T cell stimulatory capacity in DCs. These maturational changes of DCs involved the MyD88-mediated NF-kappa B signaling pathway. In vivo, gamma-PGA NPs were preferentially internalized by APCs (DCs and macrophages) and induced the production of IL-12p40 and IL-6. The immunization of mice with OVA-carrying NPs induced Ag-specific CTL activity and Ag-specific production of IFN-gamma in splenocytes as well as potent production of Ag-specific IgG1 and IgG2a Abs in serum. Furthermore, immunization with NPs carrying a CD8(+) T cell epitope peptide of Listeria monocytogenes significantly protected the infected mice from death. These results suggest that Ag-carrying gamma-PGA NPs are capable of inducing strong cellular and humoral immune responses and might be potentially useful as effective vaccine adjuvants for the therapy of infectious diseases.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima, Japan.
   Yokohama Inst, Lab Dendrit Cell Immunol, Res Ctr Allergy & Immunol, Inst Phys & Chem Res Japan, Kanagawa, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 890, Japan.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Osaka, Japan.
   Japan Sci & Technol Agcy, CREST, Tokyo, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, 8-35-1 Sakuragaoka, Kagoshima, Japan.
EM m-baba@vanilla.ocn.ne.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Badovinac VP, 2005, NAT MED, V11, P748, DOI 10.1038/n/nm1257
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Becker PD, 2006, VACCINE, V24, P5269, DOI 10.1016/j.vaccine.2005.11.008
   Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298                                                          
   Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5
   Coester C, 2006, EUR J PHARM BIOPHARM, V62, P306, DOI 10.1016/j.ejpb.2005.09.009
   den Haan JMM, 2000, J EXP MED, V192, P1685, DOI 10.1084/jem.192.12.1685
   Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038
   Freund J, 1937, P SOC EXP BIOL MED, V37, P509
   Fujita M, 2004, ORAL ONCOL, V40, P199, DOI 10.1016/S1368-8375(03)00152-0
   GENINAT G, 2001, J IMMUNOL, V166, P1877
   Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57
   Hanke T, 2002, VACCINE, V20, P1995, DOI 10.1016/S0264-410X(02)00085-3
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Hutchings CL, 2005, J IMMUNOL, V175, P599, DOI 10.4049/jimmunol.175.1.599                                                      
   Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200
   Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842
   Letvin NL, 2002, ANNU REV IMMUNOL, V20, P73, DOI 10.1146/annurev.immunol.20.081501.094854                                        
   Lizee G, 2003, NAT IMMUNOL, V4, P1065, DOI 10.1038/ni989
   Loiarro M, 2005, J BIOL CHEM, V280, P15809, DOI 10.1074/jbc.C400613200
   Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320                                                     
   Luci C, 2006, J IMMUNOL, V176, P2749, DOI 10.4049/jimmunol.176.5.2749                                                     
   Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587
   Manickasingham SR, 2003, EUR J IMMUNOL, V33, P101, DOI 10.1002/immu.200390001                                                          
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moore AC, 2004, IMMUNOL REV, V199, P126, DOI 10.1111/j.0105-2896.2004.00138.x
   Nagata T, 2002, INFECT IMMUN, V70, P2676, DOI 10.1128/IAI.70.5.2676-2680.2002
   Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x
   PORGADOR A, 1995, J EXP MED, V182, P255, DOI 10.1084/jem.182.1.255
   Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4
   Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397                                                              
   Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8              
   Suzue K, 2003, EUR J IMMUNOL, V33, P2666, DOI 10.1002/eji.200323292
   Tritel M, 2003, J IMMUNOL, V171, P2538, DOI 10.4049/jimmunol.171.5.2538                                                     
   Wan T, 2004, BLOOD, V103, P1747, DOI 10.1182/blood-2003-08-2828
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Wille-Reece U, 2005, J IMMUNOL, V174, P7676, DOI 10.4049/jimmunol.174.12.7676                                                    
NR 43
TC 144
Z9 148
U1 1
U2 35
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD MAR 1
PY 2007
VL 178
IS 5
BP 2979
EP 2986
DI 10.4049/jimmunol.178.5.2979                                             
          
PG 8
WC Immunology
SC Immunology
GA 143PH
UT WOS:000244734500052
PM 17312143
OA gold
DA 2018-01-05
ER

PT J
AU Zink, MC
AF Zink, M. Christine
TI Translational research models and novel adjunctive therapies for
   neuroAIDS
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article; Proceedings Paper
CT NIMH HIV Preclinical/Clinical Therapeutics Research Meeting
CY MAY 15-16, 2006
CL Bethesda, MD
SP NIMH
DE anti-inflammatory; microglia; mononuclear phagocytes; lentiviruses;
   blood-brain barrier; neuroAIDS therapeutics; antioxidants; gene
   delivery; HIV-1 proteins
ID DELIVERY
AB The goal of this component of the meeting was to discuss novel therapeutics that attenuate inflammatory pathways, enhance drug delivery into the brain and/or bypass the blood-brain barrier (131313). Presentations included discussions of (i) antiretroviral drugs packaged into nanoparticles by Howard Gendelman, (ii) how to engage the nasal epithelium and its closely associated neural fibers as a route for drug entry to the brain, by William H. Frey and Lynn Pulliam, and (iii) antioxidant gene delivery to neurons using vector systems that can protect neurons against HIV-associated toxicity, by David Strayer. The session was capped by active discourse among leaders in the field of adjunctive therapies in a broad range of scientific disciplines.
C1 Johns Hopkins Med Inst, Dept Mol & Comparat Pathobiol, Baltimore, MD 21205 USA.
RP Zink, MC (reprint author), Johns Hopkins Med Inst, Dept Mol & Comparat Pathobiol, Broadway Res Bldg,Suite 839,733 N Broadway, Baltimore, MD 21205 USA.
EM mczink@jhmi.edu
CR Agrawal L, 2006, GENE THER, V13, P1645, DOI 10.1038/sj.gt.3302821
   Ciborowski P, 2006, CURR HIV RES, V4, P279, DOI 10.2174/157016206777709474
   Dou H, 2006, BLOOD, V108, P2827, DOI 10.1182/blood-2006-03-012534
   HANSON LR, 2007, J NEUROIMMUNE PHARM
   Kingsley JD, 2006, J NEUROIMMUNE PHARM, V1, P340, DOI 10.1007/s11481-006-9032-4
   Rempel HC, 2005, AIDS, V19, P127, DOI 10.1097/00002030-200501280-00004
NR 6
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD MAR
PY 2007
VL 2
IS 1
BP 14
EP 19
DI 10.1007/s11481-006-9062-y
PG 6
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 201YW
UT WOS:000248869500004
PM 18040821
DA 2018-01-05
ER

PT J
AU Dou, HY
   Morehead, J
   Destache, CJ
   Kingsley, JD
   Shlyakhtenko, L
   Zhou, Y
   Chaubal, M
   Werling, J
   Kipp, J
   Rabinow, BE
   Gendelman, HE
AF Dou, Huanyu
   Morehead, Justin
   Destache, Christopher J.
   Kingsley, Jeffrey D.
   Shlyakhtenko, Lyudmila
   Zhou, You
   Chaubal, Mahesh
   Werling, Jane
   Kipp, James
   Rabinow, Barrett E.
   Gendelman, Howard E.
TI Laboratory investigations for the morphologic, pharmacokinetic, and
   anti-retroviral properties of indinavir nanoparticles in human
   nomocyte-derived macrophages
SO VIROLOGY
LA English
DT Article
DE macrophages; nanoparticles; anti-retroviral efficacy; human
   immunodeficiency virus; indinavir
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-DELIVERY SYSTEMS; HIV-1 INFECTION;
   TREATMENT INTERRUPTION; MEDIATED DELIVERY; IN-VITRO; THERAPY; MONOCYTES;
   FAILURE; NEUROPATHOGENESIS
AB The effectiveness of anti-retroviral therapies (ART) depends on its ultimate ability to clear reservoirs of continuous human immunodeficiency virus (HIV) infection. We reasoned that a principal vehicle for viral dissemination, the mononuclear phagocytes could also serve as an ART transporter and as such improve therapeutic indices. A nanoparticle-indinavir (NP-IDV) formulation was made and taken up into and released from vacuoles of human monocyte-derived macrophages (MDM). Following a single NP-IDV dose, drug levels within and outside MDM remained constant for 6 days without cytotoxicity. Administration of NP-IDV when compared to equal drug levels of free soluble IDV significantly blocked induction of multinucleated giant cells, production of reverse transcriptase activity in culture fluids and cell-associated HIV-1p24 antigens after HIV-1 infection. These data provide "proof of concept" for the use of macrophage-based NP delivery systems for human HIV-1 infections. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Omaha, NE 68198 USA.
   Univ Nebraska, Dept Vet & Biomed Sci, Lincoln, NE 68588 USA.
   Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   Baxter Healthcare Corp, Round Lake, IL 60073 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Destache, Christopher/0000-0001-7923-3939
FU NCRR NIH HHS [20 RR15635]; NINDS NIH HHS [P01 NS11766-28, 5
   P01NS31492-11, 5 R01 NS034239-10, 1 P01 NS43985-01A1, 5 R37 NS36126-07,
   1 T32 NS07488-01]; NIMH NIH HHS [5 P01 MH64570-03]
CR ALIAUTDIN RN, 2003, EKSP KLIN FARMAKOL, V66, P25
   Aweeka F, 1999, J ACQ IMMUN DEF SYND, V20, P39, DOI 10.1097/00042560-199901010-00006                                                
   AYRE SG, 1989, MED HYPOTHESES, V29, P283, DOI 10.1016/0306-9877(89)90113-8
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20                                    
   Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186                                                        
   Berton M, 2001, PHARMACEUT RES, V18, P1096, DOI 10.1023/A:1010962507273                                                         
   Boffito M, 2003, AIDS RES HUM RETROV, V19, P825, DOI 10.1089/088922203769232629
   Chan WCW, 2006, BIOL BLOOD MARROW TR, V12, P87, DOI 10.1016/j.bbmt.2005.10.004
   Chen HB, 2006, J CONTROL RELEASE, V110, P296, DOI 10.1016/jjconrel.2005.09.052
   Chen RY, 2002, AIDS RES HUM RETROV, V18, P909, DOI 10.1089/088922202760265588
   Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270
   Collman RG, 2003, J LEUKOCYTE BIOL, V74, P631, DOI 10.1189/jlb.0703357
   Dailey LA, 2003, J CONTROL RELEASE, V86, P131, DOI 10.1016/S0168-3659(02)00370-X                                                   
   De Rossi A, 2004, MICROBIOLOGICA, V27, P45
   Delaugerre C, 2005, J MED VIROL, V77, P345, DOI 10.1002/jmv.20462
   Delaugerre C, 2005, J CLIN VIROL, V32, P241, DOI 10.1016/j.jcv.2004.05.020                                                       
   DOU H, IN PRESS BLOOD
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Feng SS, 2004, CURR MED CHEM, V11, P413, DOI 10.2174/0929867043455909
   GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   Griese M, 1998, J DRUG TARGET, V5, P471, DOI 10.3109/10611869808997873                                                       
   Horisawa E, 2002, PHARMACEUT RES, V19, P132, DOI 10.1023/A:1014260513728                                                         
   Jain KK, 2005, TECHNOL CANCER RES T, V4, P645, DOI 10.1177/153303460500400608                                                      
   Jain KK, 2005, DRUG DISCOV TODAY, V10, P1435, DOI 10.1016/S1359-6446(05)03573-7                                                   
   Jin YG, 2006, INT J PHARM, V309, P199, DOI 10.1016/j.ijpharm.2005.11.025
   Kadiu I, 2005, NEUROTOX RES, V8, P25, DOI 10.1007/BF03033818                                                              
   KALTER DC, 1991, J IMMUNOL, V146, P146
   Kim WK, 2005, NEUROTOX RES, V8, P107, DOI 10.1007/BF03033823                                                              
   Koblet H, 1998, SCHWEIZ MED WSCHR, V128, P586
   Kotwal GJ, 1997, J LEUKOCYTE BIOL, V62, P415
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   Liu CM, 1998, HUM GENE THER, V9, P2375, DOI 10.1089/hum.1998.9.16-2375                                                      
   MARSHALL DW, 1988, NEUROLOGY, V38, P1000, DOI 10.1212/WNL.38.6.1000-b                                                         
   Maslin CLV, 2005, CURR HIV RES, V3, P303, DOI 10.2174/157016205774370401
   MELTZER MS, 1988, IMMUNOL LETT, V19, P193, DOI 10.1016/0165-2478(88)90142-3
   Michaelis M, 2000, ANTI-CANCER DRUG, V11, P369, DOI 10.1097/00001813-200006000-00007
   Miller JF, 2004, BIOORG MED CHEM LETT, V14, P959, DOI 10.1016/j.bmc.2003.12.008
   MONKKONEN J, 1993, PHARMACEUT RES, V10, P1130, DOI 10.1023/A:1018955915848
   Murri R, 2006, JAIDS-J ACQ IMM DEF, V41, P23, DOI 10.1097/01.qai.0000188337.76164.7a
   Pandey R, 2005, INT J PHARM, V301, P268, DOI 10.1016/j.ijpharm.2005.05.027
   Perno CF, 1998, J INFECT DIS, V178, P413, DOI 10.1086/515642                                                                  
   Persidsky Y, 2003, J LEUKOCYTE BIOL, V74, P691, DOI 10.1189/jlb.0503205
   Pezzotti P, 1999, AIDS, V13, P249, DOI 10.1097/00002030-199902040-00013
   Prejdova Jana, 2004, Current Drug Targets - Infectious Disorders, V4, P137, DOI 10.2174/1568005043340984
   Rossi L, 1998, AIDS RES HUM RETROV, V14, P435, DOI 10.1089/aid.1998.14.435                                                         
   Rowe KA, 2005, INT J TUBERC LUNG D, V9, P263
   Shahgaldian P, 2002, CHEM COMMUN, P326, DOI 10.1039/b111367b                                                                
   Shehu-Xhilaga M, 2005, CURR MED CHEM, V12, P1705, DOI 10.2174/0929867054367211
   Singh B, 2003, J PHARM PHARMACOL, V55, P1635, DOI 10.1211/0022357022368
   Smit TK, 2004, J VIROL, V78, P10133, DOI 10.1128/JVI.78.18.10133-10148.2004
   Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006
   Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5                                                   
   SWINDELLS S, 2005, NEUROLOGY AIDS
   Thomas SA, 2004, CURR PHARM DESIGN, V10, P1313, DOI 10.2174/1381612043384835                                                        
   Tonnesen HH, 2002, DRUG DEV IND PHARM, V28, P621, DOI 10.1081/DDC-120003853                                                           
   Verani A, 2005, MOL IMMUNOL, V42, P195, DOI 10.1016/j.molimm.2004.06.020
   WEYAND CM, 1992, Z RHEUMATOL, V51, P55
   ZENGER E, 1994, FRONT BIOSCI, V2, pD527
   Zhang L, 2006, J PHYS CHEM B, V110, P6615, DOI 10.1021/jp0570216
NR 60
TC 64
Z9 66
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD FEB 5
PY 2007
VL 358
IS 1
BP 148
EP 158
DI 10.1016/j.virol.2006.08.012
PG 11
WC Virology
SC Virology
GA 131LS
UT WOS:000243871100015
PM 16997345
OA gold
DA 2018-01-05
ER

PT J
AU Ma, DW
   Yu, SH
   Li, B
   Chen, L
   Chen, RH
   Yu, KQ
   Zhang, LQ
   Chen, ZW
   Zhong, DF
   Gong, Z
   Wang, RX
   Jiang, HL
   Pei, G
AF Ma, Dawei
   Yu, Shanghai
   Li, Ben
   Chen, Li
   Chen, Renhai
   Yu, Kunqian
   Zhang, Linqi
   Chen, Zhiwei
   Zhong, Dafang
   Gong, Zheng
   Wang, Renxiao
   Jiang, Hualiang
   Pei, Gang
TI Synthesis and biological evaluation of 1,3,3,4-tetrasubstituted
   pyrrolidine CCR5 receptor antagonists. Discovery of a potent and orally
   bioavailable anti-HIV agent
SO CHEMMEDCHEM
LA English
DT Article
AB A series of 1,3,3,4-tetrasubstituted pyrrolidine containing CCR5 receptor antagonists were designed, which were elaborated either by condensation of a lithium salt of 3-(N,N-dibenzyl)aminopropionic acid methyl ester with ethyl benzoformate or by Baylis-Hillman reaction of ethyl acrylate with ethyl benzoformate and subsequent 1,4-addition of benzylamine, in the key steps. These compounds bearing 4-(N,N-disubstituted)amino piperidine units showed low nanomolor potency against the CCR5 receptor, whereas molecules with a 4-phenylpiperidine moiety displayed poor activity. Asymmetric synthesis of the most potent compound 23 a gave rise to the (3R,4S)-enantiomer 30 and the (3S,4R)-enantiomer 31, which showed IC50 values of 2.9 and 385.9 nm, respectively. These results indicated that (3 R,4S)-configuration in the series of compounds is favored for their interaction with the CCR5 receptor. The possible binding mode of these antagonists with the CCR5 receptor was discussed using a computer-modeling method. Compound 30 displayed excellent replication inhibition of seven genetically diverse R5 HIV-1 strains in the PBMC model, in a concentration-dependent manner with EC50 values ranging from 0.3 nm to 30 nm. This molecule showed oral bioavailabilities of 41.2% and 27.6% in rats and dogs, respectively. Thus, compound 30 is a promising candidate for the treatment of HIV-1 infection.
RP Ma, DW (reprint author), Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, 345 Lingling Lu, Shanghai 200032, Peoples R China.
EM madw@mail.sioc.ac.cn
CR Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   BASAVAIAH D, 1987, TETRAHEDRON LETT, V28, P4351, DOI 10.1016/S0040-4039(00)96506-7                                                   
   CLERCQ ED, 2005, J MED CHEM, V48, P1297
   Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697
   Finke PE, 2001, BIOORG MED CHEM LETT, V11, P265, DOI 10.1016/S0960-894X(00)00639-9
   Gao ZL, 2003, CHEM REV, V103, P3733, DOI 10.1021/cr020474b
   Hale JJ, 2001, BIOORG MED CHEM LETT, V11, P2741, DOI 10.1016/S0960-894X(01)00545-5
   Hale JJ, 2001, BIOORG MED CHEM LETT, V11, P1437, DOI 10.1016/S0960-894X(01)00232-3                                                   
   Huang XQ, 2000, ACTA PHARMACOL SIN, V21, P521
   Lynch CL, 2002, BIOORG MED CHEM LETT, V12, P3001, DOI 10.1016/S0960-894X(02)00606-6
   Ma DW, 1998, TETRAHEDRON-ASYMMETR, V9, P575, DOI 10.1016/S0957-4166(98)00016-0                                                   
   Maeda K, 2001, J BIOL CHEM, V276, P35194, DOI 10.1074/jbc.M105670200
   MEADOWS DC, 2006, CHEMEDCHEM, V1, P17
   Nishikawa M, 2005, ANTIMICROB AGENTS CH, V49, P4708, DOI 10.1128/AAC.49.11.4708-4715.2005
   Palani A, 2006, J MED CHEM, V49, P2851, DOI 10.1021/jm0600009x
   *SCHROD INC, 2003, GLID VERS 2 5 1 DISC
   Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005
   Takashima K, 2005, ANTIMICROB AGENTS CH, V49, P3474, DOI 10.1128/AAC.49.8.3474-3482.2005
   Tsamis F, 2003, J VIROL, V77, P5201, DOI 10.1128/JVI.77.9.5201-5208.2003
   Wood A, 2005, PROGR MED CHEM, V43, P239, DOI 10.1016/S0079-6468(05)43007-6
   Xu Y, 2004, BIOORGAN MED CHEM, V12, P6193, DOI 10.1016/j.bmc.2004.08.045
   Zhang WB, 2002, J BIOL CHEM, V277, P24515, DOI 10.1074/jbc.M200889200
NR 22
TC 17
Z9 20
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD FEB
PY 2007
VL 2
IS 2
BP 187
EP 193
DI 10.1002/cmdc.200600182
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA V43PJ
UT WOS:000202946700006
PM 17163560
DA 2018-01-05
ER

PT J
AU Wang, X
   Akagi, T
   Akashi, M
   Baba, M
AF Wang, Xin
   Akagi, Takami
   Akashi, Mitsuru
   Baba, Masanori
TI Development of core-corona type polymeric nanoparticles as an anti-HIV-1
   vaccine
SO MINI-REVIEWS IN ORGANIC CHEMISTRY
LA English
DT Article
DE polystyrene nanoparticles; concanavalin A; HIV-1; mucosal vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INACTIVATED HIV-1-CAPTURING NANOSPHERES;
   IMMOBILIZED POLYSTYRENE NANOSPHERES; POLY(ETHYLENE OXIDE) MACROMONOMERS;
   WATER-DISPERSIBLE MICROSPHERES; CROSS-SECTIONAL MORPHOLOGIES;
   SALTING-OUT PROCESS; HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES;
   GRAFT-COPOLYMERS
AB We developed a novel technology for core-corona polymeric nanoparticles having hydrophilic polymer chains with functional groups. Polystyrene nanoparticles immobilized with the mannose-specific lectin concanavalin A could efficiently capture human immunodeficiency virus type 1 (HIV-1) particles and gp120 antigens on their surface. Since the antigen-capturing nanoparticles were capable of inducing humoral and cellular immune responses to HIV-1, they could be developed as a mucosal vaccine against HIV-1 infection.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka 5650871, Japan.
   Japan Sci & Technol Corp, CREST, Tokyo 1500002, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
EM baba@m.kufm.kagoshima-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   AKASHI M, 1989, J POLYM SCI POL LETT, V27, P377, DOI 10.1002/pol.1989.140271005                                                      
   AKASHI M, 1985, ANGEW MAKROMOL CHEM, V132, P81, DOI 10.1002/apmc.1985.051320107                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   AKASHI M, 1990, J APPL POLYM SCI, V39, P2027, DOI 10.1002/app.1990.070390917                                                      
   AKASHI M, 1992, BIOCONJUGATE CHEM, V3, P363, DOI 10.1021/bc00017a002
   ALLEMANN E, 1992, INT J PHARM, V87, P247, DOI 10.1016/0378-5173(92)90249-2                                                    
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Chen CW, 1999, LANGMUIR, V15, P7998, DOI 10.1021/la9817462                                                               
   Chen CW, 1998, CHEM COMMUN, P831, DOI 10.1039/a800203g                                                                
   Chen CW, 1998, ADV MATER, V10, P1122, DOI 10.1002/(SICI)1521-4095(199810)10:14<1122::AID-ADMA1122>3.3.CO;2-E
   Chen CW, 1999, CHEM MATER, V11, P1381, DOI 10.1021/cm9900047                                                               
   Chen MQ, 1999, J POLYM SCI POL CHEM, V37, P2155, DOI 10.1002/(SICI)1099-0518(19990701)37:13<2155::AID-POLA31>3.0.CO;2-G              
   Chen MQ, 2001, CHEM LETT, P1306
   Chen MQ, 1996, J POLYM SCI POL CHEM, V34, P2213
   Chen MQ, 2000, J POLYM SCI POL CHEM, V38, P1811, DOI 10.1002/(SICI)1099-0518(20000515)38:10<1811::AID-POLA660>3.0.CO;2-V             
   EVANS LA, 1993, HIV MOL ORG PATHOGEN, P29
   FALLOUH NA, 1986, INT J PHARM, V28, P125
   Gazzard B, 1999, Int J Clin Pract Suppl, V103, P45
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   IBRAHIM H, 1992, INT J PHARM, V87, P239, DOI 10.1016/0378-5173(92)90248-Z
   Kaneko T, 2004, MACROMOLECULES, V37, P501, DOI 10.1021/ma035276g
   Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004
   Kawaguchi H., 1993, BIOMEDICAL APPL POLY, P299
   KAWAGUCHI S, 1995, MACROMOLECULES, V28, P1159, DOI 10.1021/ma00108a051                                                             
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Klein M, 1999, VACCINE, V17, pS65, DOI 10.1016/S0264-410X(99)00236-4                                                   
   KOBAYASHI S, 1993, J POLYM SCI POL CHEM, V31, P3133, DOI 10.1002/pola.1993.080311229                                                     
   KREUTER J, 1989, INT J PHARM, V55, P39, DOI 10.1016/0378-5173(89)90274-3
   LERAY AM, 1994, J PHARM SCI, V83, P845, DOI 10.1002/jps.2600830618
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   Liu J, 1997, J POLYM SCI POL CHEM, V35, P3575
   Matsusaki M, 2005, NANO LETT, V5, P2168, DOI 10.1021/nl050541s
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   Mbemba E, 1996, AIDS RES HUM RETROV, V12, P47, DOI 10.1089/aid.1996.12.47
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   MIYAUCHI N, 1988, J POLYM SCI POL CHEM, V26, P1561, DOI 10.1002/pola.1988.080260607                                                     
   NUGROHO MB, 1995, MACROMOL REP A S5, V32, P593
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   RIZA M, 1994, NEW POLYM MAT, V4, P189
   Sakuma S, 1999, INT J PHARM, V177, P161, DOI 10.1016/S0378-5173(98)00346-9
   Sakuma S, 2002, J CONTROL RELEASE, V81, P281, DOI 10.1016/S0168-3659(02)00072-X                                                   
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   Sakuma S, 2002, INT J PHARM, V239, P185, DOI 10.1016/S0378-5173(02)00113-8
   SCHULZ GO, 1982, J APPL POLYM SCI, V27, P4773, DOI 10.1002/app.1982.070271222                                                      
   Serizawa T, 2000, COLLOID SURFACE A, V169, P95, DOI 10.1016/S0927-7757(00)00421-0                                                   
   Serizawa T, 2005, POLYM J, V37, P39, DOI 10.1295/polymj.37.39
   Serizawa T, 1999, J BIOMAT SCI-POLYM E, V10, P391, DOI 10.1163/156856299X00441                                                         
   Serizawa T, 2000, MACROMOLECULES, V33, P1759, DOI 10.1021/ma9907486                                                               
   Serizawa T, 1998, J POLYM SCI POL CHEM, V36, P2581, DOI 10.1002/(SICI)1099-0518(199810)36:14<2581::AID-POLA17>3.0.CO;2-E
   SINGER JM, 1956, AM J MED, V21, P888, DOI 10.1016/0002-9343(56)90103-6                                                    
   SUGIYAMA K, 1993, POLYM J, V25, P521, DOI 10.1295/polymj.25.521                                                           
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Wu C, 1997, MACROMOLECULES, V30, P2187, DOI 10.1021/ma9608333                                                               
NR 57
TC 12
Z9 12
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-193X
J9 MINI-REV ORG CHEM
JI Mini-Rev. Org. Chem.
PD FEB
PY 2007
VL 4
IS 1
BP 51
EP 59
DI 10.2174/157019307779815857                                              
          
PG 9
WC Chemistry, Organic
SC Chemistry
GA 133IK
UT WOS:000244006400004
DA 2018-01-05
ER

PT J
AU Patel, JD
   O'Carra, R
   Jones, J
   Woodward, JG
   Mumper, RJ
AF Patel, Jigna D.
   O'Carra, Ronan
   Jones, Julia
   Woodward, Jerold G.
   Mumper, Russell J.
TI Preparation and characterization of nickel nanoparticles for binding to
   his-tag proteins and antigens
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE nanoparticles; nickel; histidine tagged proteins; HIV-1 Gag p24
ID CYTOTOXIC T-LYMPHOCYTES; CO-GLYCOLIDE MICROPARTICLES; IMMUNE-RESPONSES;
   COATED NANOPARTICLES; PLG MICROPARTICLES; SYSTEMIC ANTIBODY; VACCINE
   ADJUVANTS; DENDRITIC CELLS; IN-VITRO; IMMUNIZATION
AB Purpose. The purpose of these studies was to prepare nanoparticles (NPs) with a small amount of surface-chelated nickel for obtaining enhanced binding of histidine-tagged (his-tag) proteins compared to non-histidine-tagged protein binding to charged nanoparticles.
   Materials and Methods. NPs were prepared from oil-in-water microemulsion precursors using emulsifying wax, 3 mM Brij 78 and 0.1 mM DOGS-NTA-Ni lipid (referred to as Ni-NPs). The amount of lipid entrapped in the NPs was quantitated by atomic emission spectroscopy (AES). The Ni-NPs were investigated for binding to two his-tag proteins, green fluorescent protein (GFP) and his-tag HIV-1 Gag p24. In vivo studies in mice were carried out to evaluate the immune responses obtained to his-tag Gag p24 bound to Ni-NPs.
   Results. AES studies demonstrated that approximately 5% of the DOGS-NTA-Ni lipid used was entrapped in the NPs. The optimal binding ratio his-tag GFP and his-tag Gag p24 to Ni-NPs was found to be 1:33.7 and 1:35.4 w/w, respectively. This interaction was stable at 37 degrees C in PBS, pH 7.4 over 4 h and the interaction of his-tag GFP with the Ni-NPs was enhanced compared to control NPs prepared with no Ni on the surface (NTA-NPs). The in vivo studies demonstrated enhanced serum IgG and IgG2a responses to his-tag Gag p24 bound to Ni-NPs compared to protein adjuvanted with Alum or adsorbed on the surface of control NTA-NPs.
   Conclusions. Ni-NPs can be used to bind strongly to his-tag proteins. This system was demonstrated to have potential applications in vaccine delivery for enhancing immune responses to protein-based vaccines.
C1 Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA.
RP Mumper, RJ (reprint author), Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA.
EM rjmump2@email.uky.edu
FU NIAID NIH HHS [AI058842]
CR Bix M, 1998, J EXP MED, V188, P2289, DOI 10.1084/jem.188.12.2289
   Bot AI, 2001, PHARM RES-DORDR, V18, P971, DOI 10.1023/A:1010988311640                                                         
   BROEKHOVENVAN CL, 2004, CANCER RES, V64, P4357
   BUSEYNE F, 1993, J VIROL, V67, P694
   Carcaboso AM, 2004, VACCINE, V22, P1423, DOI 10.1016/j.vaccine.2003.10.020
   Celia H, 1999, P NATL ACAD SCI USA, V96, P5634, DOI 10.1073/pnas.96.10.5634                                                         
   Chikh GG, 2002, BBA-BIOMEMBRANES, V1567, P204, DOI 10.1016/S0005-2736(02)00618-1                                                   
   Coombes AGA, 1996, VACCINE, V14, P1429, DOI 10.1016/S0264-410X(96)00077-1                                                   
   Crowe J, 1996, Methods Mol Biol, V58, P491
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Cui ZR, 2002, INT J PHARM, V238, P229, DOI 10.1016/S0378-5173(02)00079-0
   Cui ZR, 2002, PHARMACEUT RES, V19, P939, DOI 10.1023/A:1016402019380
   Debin A, 2002, VACCINE, V20, P2752, DOI 10.1016/S0264-410X(02)00191-3
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398
   GRAHAM JA, 1978, ENVIRON RES, V16, P77, DOI 10.1016/0013-9351(78)90144-5
   Guler ML, 1997, J IMMUNOL, V159, P1767
   GUPTA RK, 1995, VACCINE, V13, P1263, DOI 10.1016/0264-410X(95)00011-O
   Gupta RK, 1998, ADV DRUG DELIV REV, V32, P225
   HEATH TD, 1986, CHEM PHYS LIPIDS, V40, P347, DOI 10.1016/0009-3084(86)90078-2
   HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Kazzaz J, 2006, J CONTROL RELEASE, V110, P566, DOI 10.1016/j.jconrel.2005.10.010
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   Kersten GFA, 2003, VACCINE, V21, P915, DOI 10.1016/S0264-410X(02)00540-6
   Lauer SA, 2002, CYTOMETRY, V48, P136, DOI 10.1002/cyto.10124
   Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828                                                         
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   Novitsky V, 2002, J VIROL, V76, P10155, DOI 10.1128/JVI.76.20.10155-10168.2002
   *NPER ASS ND I, 1997, SAF US NICK WORKPL
   O'Hagan Derek T, 2003, Expert Rev Vaccines, V2, P269, DOI 10.1586/14760584.2.2.269
   O'Hagan DT, 1998, ADV DRUG DELIVER REV, V34, P305, DOI 10.1016/S0169-409X(98)00045-3                                                   
   O'Hagan DT, 2001, BIOMOL ENG, V18, P69, DOI 10.1016/S1389-0344(01)00101-0                                                   
   Oyewumi MO, 2002, DRUG DEV IND PHARM, V28, P317, DOI 10.1081/DDC-120002847                                                           
   Patel J, 2006, VACCINE, V24, P3564, DOI 10.1016/j.vaccine.2006.01.065
   Pink J Richard, 2004, Vaccine, V22, P2097, DOI 10.1016/j.vaccine.2004.01.021
   PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0                                                                
   SCHMITT J, 1993, MOL BIOL REP, V18, P223, DOI 10.1007/BF01674434
   Singh M, 2004, PHARM RES, V21, P2148, DOI 10.1007/s11095-004-7666-6
   Singh M, 2004, EXPERT OPIN BIOL TH, V4, P483, DOI 10.1517/14712598.4.4.483
   Singh M, 2002, PHARMACEUT RES, V19, P715, DOI 10.1023/A:1016104910582
   SMIALOWICZ RJ, 1984, ENVIRON RES, V33, P413, DOI 10.1016/0013-9351(84)90039-2
   SUGIMOTO M, 1995, FEBS LETT, V363, P53, DOI 10.1016/0014-5793(95)00279-I
   Sun HF, 2003, VACCINE, V21, P849, DOI 10.1016/S0264-410X(02)00531-5                                                   
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   WEISSIG V, 1986, FEBS LETT, V202, P86, DOI 10.1016/0014-5793(86)80654-8
   Xie H, 2005, INFECT IMMUN, V73, P828, DOI 10.1028/IAI.73.2.828-833.2005
   Zuniga R, 2006, J VIROL, V80, P3122, DOI 10.1128/JVI.80.6.3122-3125.2006
NR 48
TC 35
Z9 35
U1 0
U2 19
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD FEB
PY 2007
VL 24
IS 2
BP 343
EP 352
DI 10.1007/s11095-006-9154-7
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 124VP
UT WOS:000243398900014
PM 17180725
DA 2018-01-05
ER

PT J
AU Getz, MM
   Andrews, AJ
   Fierke, CA
   Al-Hashimi, HM
AF Getz, Melissa M.
   Andrews, Andy J.
   Fierke, Carol A.
   Al-Hashimi, Hashim M.
TI Structural plasticity and Mg2+ binding properties of RNase PP4 from
   combined analysis of NMR residual dipolar couplings and motionally
   decoupled spin relaxation
SO RNA-A PUBLICATION OF THE RNA SOCIETY
LA English
DT Article
DE RNA dynamics; electrostatics; collective motions; catalysis; RNP folding
ID BACTERIAL RIBONUCLEASE-P; METAL-ION BINDING; MODEL-FREE APPROACH; HIV-1
   TAR RNA; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; HYDROGEN-BONDS;
   MODIFICATION-INTERFERENCE; PROTEIN RECOGNITION; TELOMERASE RNA
AB The P4 helix is an essential element of ribonuclease P (RNase P) that is believed to bind catalytically important metals. Here, we applied a combination of NMR residual dipolar couplings (RDCs) and a recently introduced domain-elongation strategy for measuring "motionally decoupled'' relaxation data to characterize the structural dynamics of the P4 helix from Bacillus subtilis RNase P. In the absence of divalent ions, the two P4 helical domains undergo small amplitude (similar to 13 degrees) collective motions about an average interhelical angle of 10. The highly conserved U7 bulge and helical residue C8, which are proposed to be important for substrate recognition and metal binding, are locally mobile at pico- to nanosecond timescales and together form the pivot point for the collective domain motions. Chemical shift mapping reveals significant association of Mg2+ ions at the P4 major groove near the flexible pivot point at residues (A5, G22, G23) previously identified to bind catalytically important metals. The Mg2+ ions do not, however, significantly alter the structure or dynamics of P4. Analysis of results in the context of available Xray structures of the RNA component of RNase P and structural models that include the pre-tRNA substrate suggest that the internal motions observed in P4 likely facilitate adaptive changes in conformation that take place during folding and substrate recognition, possibly aided by interactions with Mg2+ ions. Our results add to a growing view supporting the existence of functionally important internal motions in RNA occurring at nanosecond timescales.
C1 Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
   Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.
   Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.
RP Al-Hashimi, HM (reprint author), Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
EM hashimi@umich.edu
FU NIGMS NIH HHS [R01 GM55387, R01 GM055387]; NIAID NIH HHS [R01 AI066975]
CR *ACC INC, 2002, FELIX US GUID
   Al-Hashimi HM, 2005, CHEMBIOCHEM, V6, P1506, DOI 10.1002/cbic.200500002
   Al-Hashimi HM, 2002, J MOL BIOL, V315, P95, DOI 10.1006/jmbi.2001.5235
   Al-Hashimi HM, 2002, J MOL BIOL, V318, P637, DOI 10.1016/S0022-2836(02)00160-2
   Beebe JA, 1996, BIOCHEMISTRY-US, V35, P10493, DOI 10.1021/bi960870m
   Chen JL, 1997, RNA, V3, P557
   Chin K, 1999, NAT STRUCT BIOL, V6, P1055
   Christian EL, 1998, BIOCHEMISTRY-US, V37, P17618, DOI 10.1021/bi982050a                                                               
   Christian EL, 2000, RNA, V6, P511, DOI 10.1017/S1355838200000042                                                       
   Christian EL, 2006, RNA, V12, P1463, DOI 10.1261/rna.158606
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f                                                               
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5197
   Crary SM, 2002, RNA, V8, P933, DOI 10.1017/S1355838202025025
   de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dingley AJ, 1999, J AM CHEM SOC, V121, P6019, DOI 10.1021/ja9908321                                                               
   Dingley AJ, 1998, J AM CHEM SOC, V120, P8293, DOI 10.1021/ja981513x                                                               
   Duchardt E, 2005, J BIOMOL NMR, V32, P295, DOI 10.1007/s10858-005-0659-x
   Ennifar E, 2000, J MOL BIOL, V304, P35, DOI 10.1006/jmbi.2000.4204
   Frank DN, 1997, P NATL ACAD SCI USA, V94, P14355, DOI 10.1073/pnas.94.26.14355                                                        
   Furtig B, 2003, CHEMBIOCHEM, V4, P936, DOI 10.1002/cbic.200300700
   Ghosh S, 2005, RNA, V11, P657, DOI 10.1261/rna.7224305
   Glemarec C, 1996, NUCLEIC ACIDS RES, V24, P2022, DOI 10.1093/nar/24.11.2022
   Goddard T., 2004, SPARKY 3
   Gonzalez RL, 1999, J MOL BIOL, V289, P1267, DOI 10.1006/jmbi.1999.2841
   GUERRIERTAKADA C, 1986, BIOCHEMISTRY-US, V25, P1509, DOI 10.1021/bi00355a006
   GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4
   Hansen AL, 2006, J MAGN RESON, V179, P299, DOI 10.1016/j.jmr.2005.12.012
   Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176                                                                    
   HARDT WD, 1995, EMBO J, V14, P2935
   Hardt WD, 1996, RNA, V2, P1189
   HARRIS ME, 1995, RNA, V1, P210
   Heide C, 1999, RNA, V5, P102, DOI 10.1017/S1355838299981499
   JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272
   Kaye NM, 2002, J MOL BIOL, V324, P429, DOI 10.1016/S0022-2836(02)01094-X
   Kaye NM, 2002, BIOCHEMISTRY-US, V41, P4533, DOI 10.1021/bi012158h
   Kazantsev AV, 2005, P NATL ACAD SCI USA, V102, P13392, DOI 10.1073/pnas.0506662102
   Kazantsev AV, 1998, RNA, V4, P937, DOI 10.1017/S1355838298980384
   Krummel DAP, 1999, RNA, V5, P1021, DOI 10.1017/S1355838299990416                                                       
   Kurz JC, 2000, CURR OPIN CHEM BIOL, V4, P553, DOI 10.1016/S1367-5931(00)00131-9
   Latham MP, 2005, CHEMBIOCHEM, V6, P1492, DOI 10.1002/cbic.200500123
   Leeper TC, 2005, RNA, V11, P394, DOI 10.1261/rna.7222505
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754
   MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073                                                          
   Meissner A, 1999, J MAGN RESON, V139, P439, DOI 10.1006/jmre.1999.1788
   Meissner A, 1997, J MAGN RESON, V128, P92, DOI 10.1006/jmre.1997.1213
   MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51
   Mollova ET, 2000, J AM CHEM SOC, V122, P11561, DOI 10.1021/ja0027822
   Musselman C, 2006, J BIOMOL NMR, V36, P235, DOI 10.1007/s10858-006-9087-9
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t
   PAN T, 1995, BIOCHEMISTRY-US, V34, P902, DOI 10.1021/bi00003a024
   Pervushin K, 1998, P NATL ACAD SCI USA, V95, P14147, DOI 10.1073/pnas.95.24.14147                                                        
   Pitt SW, 2005, ANGEW CHEM INT EDIT, V44, P3412, DOI 10.1002/anie.200500075
   Pitt SW, 2004, J MOL BIOL, V338, P7, DOI 10.1016/j.jmb.2004.02.031
   Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656
   Richards RJ, 2006, RNA, V12, P1475, DOI 10.1261/rna.112306
   Schmitz M, 2000, RNA, V6, P1212, DOI 10.1017/S1355838200000881
   Serganov A, 2006, NATURE, V441, P1167, DOI 10.1038/nature04740
   Shajani Z, 2005, J MOL BIOL, V349, P699, DOI 10.1016/j.jmb.2005.04.012
   SHOWALTER SA, 2005, METHOD ENZYMOL, V394, P465
   Sibille N, 2001, J AM CHEM SOC, V123, P12135, DOI 10.1021/ja011646+
   Siew D, 1999, BIOCHEMISTRY-US, V38, P1873, DOI 10.1021/bi982329r
   SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279
   Tolman JR, 1997, NAT STRUCT BIOL, V4, P292, DOI 10.1038/nsb0497-292                                                             
   Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y
   Torres-Larios A, 2005, NATURE, V437, P584, DOI 10.1038/nature04074
   Torres-Larios A, 2006, CURR OPIN STRUC BIOL, V16, P327, DOI 10.1016/j.sbi.2006.04.002
   Tsai HY, 2003, J MOL BIOL, V325, P661, DOI 10.1016/S0022-2836(02)01267-6
   Vallurupalli P, 2005, J AM CHEM SOC, V127, P6893, DOI 10.1021/ja0427799
   Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   Yip GNB, 2005, J MAGN RESON, V176, P171, DOI 10.1016/j.jmr.2005.06.003
   Yip GNB, 2004, J MAGN RESON, V171, P25, DOI 10.1016/j.jmr.2004.06.021
   ZACHARIAS M, 1995, J MOL BIOL, V247, P486, DOI 10.1006/jmbi.1995.0155
   Zacharias M, 1996, J MOL BIOL, V257, P276, DOI 10.1006/jmbi.1996.0162
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2003, J AM CHEM SOC, V125, P10530, DOI 10.1021/ja0363056
   Zweckstetter M, 2004, BIOPHYS J, V86, P3444, DOI 10.1529/biophysj.103.035790
NR 84
TC 33
Z9 34
U1 0
U2 4
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1355-8382
J9 RNA
JI RNA-Publ. RNA Soc.
PD FEB
PY 2007
VL 13
IS 2
BP 251
EP 266
DI 10.1261/rna.264207
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 129TR
UT WOS:000243753500008
PM 17194721
OA gold
DA 2018-01-05
ER

PT J
AU Gill, DJ
   Teo, H
   Sun, J
   Perisic, O
   Veprintsev, DB
   Emr, SD
   Williams, RL
AF Gill, David J.
   Teo, Hsiangling
   Sun, Ji
   Perisic, Olga
   Veprintsev, Dmitry B.
   Emr, Scott D.
   Williams, Roger L.
TI Structural insight into the ESCRT-I/-II link and its role in MVB
   trafficking
SO EMBO JOURNAL
LA English
DT Article
DE CHMP; ESCRT; HIV budding; MVB; NZF finger
ID YEAST SACCHAROMYCES-CEREVISIAE; ENDOSOME-ASSOCIATED COMPLEX;
   MULTIVESICULAR BODY; SORTING COMPLEX; UBIQUITIN INTERACTIONS; PROTEIN
   COMPLEXES; CRYSTAL-STRUCTURE; ZINC FINGERS; GLUE DOMAIN; MEMBRANES
AB ESCRT (endosomal sorting complex required for transport) complexes orchestrate efficient sorting of ubiquitinated transmembrane receptors to lysosomes via multivesicular bodies (MVBs). Yeast ESCRT-I and ESCRT-II interact directly in vitro; however, this association is not detected in yeast cytosol. To gain understanding of the molecular mechanisms of this link, we have characterised the ESCRT-I/-II supercomplex and determined the crystal structure of its interface. The link is formed by the vacuolar protein sorting (Vps) 28 C-terminus (ESCRT-I) binding with nanomolar affinity to the Vps36-NZF-N zinc-finger domain (ESCRT-II). A hydrophobic patch on the Vps28-CT four-helix bundle contacts the hydrophobic knuckles of Vps36-NZF-N. Mutation of the ESCRT-I/-II link results in a cargo-sorting defect in yeast. Interestingly, the two Vps36 NZF domains, NZF-N and NZF-C, despite having the same core fold, use distinct surfaces to bind ESCRT-I or ubiquitinated cargo. We also show that a new component of ESCRT-I, Mvb12 (YGR206W), engages ESCRT-I directly with nanomolar affinity to form a 1: 1: 1: 1 heterotetramer. Mvb12 does not affect the affinity of ESCRT-I for ESCRT-II in vitro. Our data suggest a complex regulatory mechanism for the ESCRT-I/-II link in yeast.
C1 MRC, Mol Biol Lab, Prot & Nucl Acid Chem, Cambridge CB2 2QH, England.
   Univ Calif San Diego, Howard Hughes Med Inst, Dept Cellular & Mol Med, Sch Med, San Diego, CA 92103 USA.
   MRC Ctr, Ctr Prot Engn, Cambridge, England.
RP Gill, DJ (reprint author), MRC, Mol Biol Lab, Prot & Nucl Acid Chem, Hills Rd, Cambridge CB2 2QH, England.
EM djg38@mrc-lmb.cam.ac.uk
RI Gill, David/H-7691-2013; Veprintsev, Dmitry/H-2228-2012
OI Gill, David/0000-0002-0937-9737; Veprintsev, Dmitry/0000-0002-3583-5409
FU Medical Research Council [MC_U105184308]
CR Adams SR, 2002, J AM CHEM SOC, V124, P6063, DOI 10.1021/ja017687n
   Alam SL, 2004, EMBO J, V23, P1411, DOI 10.1038/sj.emboj.7600114
   Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8
   Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4
   Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915
   Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007
   Bonangelino CJ, 2002, MOL BIOL CELL, V13, P2486, DOI 10.1091/mbc.02-01-0005
   Bowers K, 2004, TRAFFIC, V5, P194, DOI 10.1111/j.1600-0854.2004.00169.x
   Chu T, 2006, J CELL BIOL, V175, P815, DOI 10.1083/jcb.200608053
   Doyotte A, 2005, J CELL SCI, V118, P3003, DOI 10.1242/jcs.02421
   FIELD MG, 2006, ORIGINS EVOLUTION EU, P309
   Hierro A, 2004, NATURE, V431, P221, DOI 10.1038/nature02914
   Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026
   Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126
   Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2
   Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jbc.00302136
   Kostelansky MS, 2006, CELL, V125, P113, DOI 10.1016/j.cell.2006.01.049
   Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161
   Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670
   Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370
   Lin Y, 2005, J BIOL CHEM, V280, P12799, DOI 10.1074/jbc.M413968200
   Muziol T, 2006, DEV CELL, V10, P821, DOI 10.1016/j.devcel.2006.03.013
   Pineda-Molina E, 2006, TRAFFIC, V7, P1007, DOI 10.1111/j.1600-0854.2006.00440.x
   Praefcke GJK, 2004, EMBO J, V23, P4371, DOI 10.1038/sj.emboj.7600445
   Raiborg C, 2006, J CELL SCI, V119, P2414, DOI 10.1242/jcs.02978
   Razi M, 2006, MOL BIOL CELL, V17, P3469, DOI 10.1091/mbc.E05-11-1054
   Shim JH, 2006, J CELL BIOL, V172, P1045, DOI 10.1083/jcb.200509041                                                           
   Slagsvold T, 2005, J BIOL CHEM, V280, P19600, DOI 10.1074/jbc.M501510200
   Slagsvold T, 2006, TRENDS CELL BIOL, V16, P317, DOI 10.1016/j.tcb.2006.04.004
   Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363
   Teo H, 2004, DEV CELL, V7, P559, DOI 10.1016/j.devcel.2004.09.003                                                    
   Teo HL, 2006, CELL, V125, P99, DOI 10.1016/j.cell.2006.01.047
   Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200
   Whitley P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200
   Yorikawa C, 2005, BIOCHEM J, V387, P17, DOI 10.1042/BJ20041227
NR 35
TC 60
Z9 64
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD JAN 24
PY 2007
VL 26
IS 2
BP 600
EP 612
DI 10.1038/sj.emboj.7601501
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 129LJ
UT WOS:000243730700030
PM 17215868
OA gold
DA 2018-01-05
ER

PT J
AU Athanassiou, Z
   Patora, K
   Dias, RLA
   Moehle, K
   Robinson, JA
   Varani, G
AF Athanassiou, Zafiria
   Patora, Krystyna
   Dias, Ricardo L. A.
   Moehle, Kerstin
   Robinson, John A.
   Varani, Gabriele
TI Structure-guided peptidomimetic design leads to nanomolar beta-hairpin
   inhibitors of the Tat-TAR interaction of bovine immunodeficiency Virus
SO BIOCHEMISTRY
LA English
DT Article
ID PROTEIN SECONDARY STRUCTURE; SMALL-MOLECULE; RNA RECOGNITION;
   CHEMICAL-SHIFT; TARGETING RNA; HUMAN-CELLS; PEPTIDE; NMR; PROGRAM;
   COMPLEX
AB The Tat protein of immunodeficiency viruses is the main activator of viral gene expression. By binding specifically to its cognate site, the transactivator response element (TAR), Tat mediates a strong induction of the production of all viral transcripts. In seeking a new chemical solution to inhibiting viral protein-RNA interactions, we recently identified inhibitors of the viral Tat protein from the bovine immunodeficiency virus (BIV) using conformationally constrained beta-hairpin peptidomimetics. We identified a micromolar ligand, called BIV2, and the structure of its complex with BIV TAR was determined by NMR. In this work, we demonstrate that this chemistry can rapidly yield highly potent and selective ligands. On the basis of the structure, we synthesized and assayed libraries of mutant peptidomimetics. Remarkably, we were able in just a few rounds of design and synthesis to discover nanomolar inhibitors of the Tat-TAR interaction in BIV that selectively bind the BIV TAR RNA compared to RNA structures as closely related as the HIV-1 TAR or RRE elements. The molecular recognition principles developed in this study have been exploited in discovering related peptidomimetic inhibitors of the Tat-TAR interaction in HIV-1.
C1 Univ Washington, Dept Chem, Seattle, WA 98195 USA.
   Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   Univ Zurich, Dept Chem, CH-8057 Zurich, Switzerland.
RP Robinson, JA (reprint author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.
EM robinson@oci.unizh.ch
FU NIAID NIH HHS [AI 60410]
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Arzumanov A, 2001, NUCLEOS NUCLEOT NUCL, V20, P471, DOI 10.1081/NCN-100002321
   Arzumanov A, 2001, BIOCHEMISTRY-US, V40, P14645, DOI 10.1021/bi011279e
   Athanassiou Z, 2004, J AM CHEM SOC, V126, P6906, DOI 10.1021/ja0497680
   Atherton E., 1989, SOLID PHASE PEPTIDE
   BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486
   CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077
   CUNDLIFFE E, 1981, EUR J BIOCHEM, V118, P47, DOI 10.1111/j.1432-1033.1981.tb05484.x
   Gadek TR, 2003, DRUG DISCOV TODAY, V8, P545, DOI 10.1016/S1359-6446(03)02735-1
   Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086                                                   
   Gallego J, 2001, ACCOUNTS CHEM RES, V34, P836, DOI 10.1021/ar000118k
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   Griffiths-Jones SR, 1999, J MOL BIOL, V292, P1051, DOI 10.1006/jmbi.1999.3119                                                          
   Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284
   Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   HWANG S, 2003, J BIOL CHEM, V40, P39092
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   KREBS A, 2003, CHEMBIOCHEM, V6, P972
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Leeper TC, 2005, BIOCHEMISTRY-US, V44, P12362, DOI 10.1021/bi0510532
   Maynard AJ, 1998, J AM CHEM SOC, V120, P1996, DOI 10.1021/ja9726769                                                               
   MEI HY, 1995, BIOORG MED CHEM LETT, V5, P2755, DOI 10.1016/0960-894X(95)00467-8
   MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8733
   PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680
   PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200
   Searle MS, 2004, CURR OPIN STRUC BIOL, V14, P458, DOI 10.1016/j.sbi.2004.06.001
   Surabhi RM, 2002, J VIROL, V76, P12963, DOI 10.1128/JVI.76.24.12963-12973.2002
   Tamilarasu N, 2001, BIOORG MED CHEM LETT, V11, P505, DOI 10.1016/S0960-894X(00)00709-5
   Wang SH, 1998, BIOCHEMISTRY-US, V37, P5549, DOI 10.1021/bi972808a
   West MJ, 2001, J VIROL, V75, P8524, DOI 10.1128/JVI.75.18.8524-8537.2001
   Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900
   WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q
   WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010
   Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6
NR 38
TC 53
Z9 54
U1 1
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 23
PY 2007
VL 46
IS 3
BP 741
EP 751
DI 10.1021/bi0619371
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 125ZX
UT WOS:000243483100012
PM 17223695
DA 2018-01-05
ER

PT J
AU Maehashi, K
   Katsura, T
   Kerman, K
   Takamura, Y
   Matsumoto, K
   Tamiya, E
AF Maehashi, Kenzo
   Katsura, Taiji
   Kerman, Kagan
   Takamura, Yuzuru
   Matsumoto, Kazuhiko
   Tamiya, Eiichi
TI Label-free protein biosensor based on aptamer-modified carbon nanotube
   field-effect transistors
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID PROBE CAPILLARY-ELECTROPHORESIS; HIV-1 TAT PROTEIN; BINDING PROTEINS;
   DNA; SELECTION; LIGANDS; ANTIBODIES; SEPARATION; COMPLEXES; MOLECULES
AB We have fabricated label-free protein biosensors based on aptamer-modified carbon nanotube field-effect transistors (CNT-FETs) for the detection of immunoglobulin E (IgE). After the covalent immobilization of 5'-amino-modified 45-mer aptamers on the CNT channels, the electrical properties of the CNT-FETs were monitored in real time. The introduction of target IgE at various concentrations caused a sharp decrease in the source-drain current, and a gradual saturation was observed at lower concentrations. The amount of the net source-drain current before and after IgE introduction on the aptamer-modified CNT-FETs increased as a function of IgE concentration. The detection limit for IgE was determined as 250 pM. We have also prepared CNT-FET biosensors using a monoclonal antibody against IgE (IgE-mAb). The electrical properties of the aptamer- and antibody-modified CNT-FETs were compared. The performance of aptamer-modified CNT-FETs provided better results than the ones obtained using IgE-mAb-modified CNT-FETs under similar conditions. Thus, we suggest that the aptamer-modified CNT-FETs are promising candidates for the development of label-free protein biosensors.
C1 Osaka Univ, Inst Sci & Ind Res, Osaka 5670047, Japan.
   Japan Adv Inst Sci & Technol, Sch Mat Sci, Nomi, Ishikawa 9231292, Japan.
   Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan.
RP Maehashi, K (reprint author), Osaka Univ, Inst Sci & Ind Res, 8-1 Mihogaoka, Osaka 5670047, Japan.
EM maehashi@sanken.osaka-u.ac.jp; tamiya@jaist.ac.jp
RI Maehashi, Kenzo/A-7426-2015; Zhou, Feng/E-9510-2011; Takamura,
   Yuzuru/A-3450-2009; 李, 府中/H-4357-2011
OI Maehashi, Kenzo/0000-0002-9925-8874; 
CR Berezovski M, 2003, J AM CHEM SOC, V125, P13451, DOI 10.1021/ja037186x
   Buchanan DD, 2003, ELECTROPHORESIS, V24, P1375, DOI 10.1002/elps.200390176
   Byon HR, 2006, J AM CHEM SOC, V128, P2188, DOI 10.1021/ja056897n
   Chen RJ, 2004, J AM CHEM SOC, V126, P1563, DOI 10.1021/ja038702m
   Chen ZH, 2005, NANO LETT, V5, P1497, DOI 10.1021/nl0508624
   Debye P, 1936, CHEM REV, V19, P171, DOI 10.1021/cr60064a002                                                             
   DeWitt CA, 2006, J AM ACAD DERMATOL, V54, P855, DOI 10.1016/j.jaad.2005.10.022
   Drummond TG, 2003, NAT BIOTECHNOL, V21, P1192, DOI 10.1038/nbt873
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   German I, 1998, ANAL CHEM, V70, P4540, DOI 10.1021/ac980638h                                                               
   Gruner G, 2006, ANAL BIOANAL CHEM, V384, P322, DOI 10.1007/s00216-005-3400-4
   Guo XF, 2005, J AM CHEM SOC, V127, P15045, DOI 10.1021/ja054335y                                                               
   Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   Jiang YX, 2004, ANAL CHEM, V76, P5230, DOI 10.1021/ac049565u
   Jiang YX, 2003, ANAL CHEM, V75, P2112, DOI 10.1021/ac026182s
   KAMINISHI D, 2005, APPL PHYS LETT, V86, P113
   KANE PM, 1988, J CELL BIOL, V107, P969, DOI 10.1083/jcb.107.3.969
   Kerman K, 2004, MEAS SCI TECHNOL, V15, pR1, DOI 10.1088/0957-0233/15/2/R01
   Kerman K, 2005, NANOBIOTECHNOLOGY, V1, P65
   Li C, 2005, J AM CHEM SOC, V127, P12484, DOI 10.1021/ja053761g
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Luzi E, 2003, TRAC-TREND ANAL CHEM, V22, P810, DOI 10.1016/S0165-9936(03)01208-1
   Maehashi K, 2004, JPN J APPL PHYS 2, V43, pL1558, DOI 10.1143/JJAP.43.L1558
   Maehashi K, 2004, APPL PHYS LETT, V85, P858, DOI 10.1063/1.1778471
   Michaud M, 2004, ANAL CHEM, V76, P1015, DOI 10.1021/ac035090f
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   O'Sullivan CK, 2002, ANAL BIOANAL CHEM, V372, P44, DOI 10.1007/s00216-001-1189-3
   POOLE JA, 2005, J ALLERGY CLIN IMMUN, V115, pS375
   Rajendran M, 2003, NUCLEIC ACIDS RES, V31, P5700, DOI 10.1093/nar/gkg764
   Rancinan C, 1998, J ALLERGY CLIN IMMUN, V102, P329, DOI 10.1016/S0091-6749(98)70107-1
   RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325                                             
   Rehder-Silinski MA, 2003, J CHROMATOGR A, V1008, P233, DOI 10.1016/S0021-9673(03)00973-7
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   RUDIKOFF S, 1976, P NATL ACAD SCI USA, V73, P2109, DOI 10.1073/pnas.73.6.2109
   So HM, 2005, J AM CHEM SOC, V127, P11906, DOI 10.1021/ja053094r
   SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0
   TEILLAUD JL, 1983, SCIENCE, V222, P721, DOI 10.1126/science.6356353
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wiegand TW, 1996, J IMMUNOL, V157, P221
   Xu DK, 2005, ANAL CHEM, V77, P5107, DOI 10.1021/ac050192m
NR 43
TC 418
Z9 426
U1 24
U2 234
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD JAN 15
PY 2007
VL 79
IS 2
BP 782
EP 787
DI 10.1021/ac060830g
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 125BF
UT WOS:000243415800052
PM 17222052
HC Y
HP N
DA 2018-01-05
ER

PT S
AU Narasimha, R
   Bennett, A
   Zabransky, D
   Sougrat, R
   McLaughlin, S
   Subramaniam, S
AF Narasimha, Rajesh
   Bennett, Adam
   Zabransky, Daniel
   Sougrat, Rachid
   McLaughlin, Steven
   Subramaniam, Sriram
GP IEEE
TI Gigabytes to bytes: Automated denoising and feature extraction as
   applied to the analysis of hiv architecture and variability using
   electron tomography
SO 2007 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH, AND SIGNAL
   PROCESSING, VOL I, PTS 1-3, PROCEEDINGS
SE International Conference on Acoustics Speech and Signal Processing
   ICASSP
LA English
DT Proceedings Paper
CT 32nd IEEE International Conference on Acoustics, Speech and Signal
   Processing
CY APR 15-20, 2007
CL Honolulu, HI
SP IEEE Signal Proc Soc
DE electron tomography; denoising; feature extraction; HIV; dual-axis SIRT
   and automated techniques
ID IMAGE; DIFFUSION
AB Advances in automated data acquisition in electron tomography have led to an explosion in the amount of data that can be obtained about the spatial architecture of a variety of biologically and medically relevant objects with sizes in the "nano" range of 10-1000nm. The development of methods to analyze the vast amounts of information contained in these tomograms is a major challenge since the electron tomograms are intrinsically noisy. A fundamental step in the automatic analysis of large amounts of data for statistical inference is to segment 3D features in cellular tomograms that can work robustly and rapidly despite of low signal to noise ratios inherent to biological electron microscopy. This work evaluates various denoising techniques on tomograms obtained using dual-axis simultaneous iterative reconstruction (SIRT) technique. Using three-dimensional images of HIV in infected human macrophages as an example, we demonstrate that transform domain-denoising techniques significantly improve the fidelity of automated feature extraction. Importantly, our approaches represent an vital step in automating the efficient extraction of useful information from large datasets in biological tomography, and facilitate the overall goal of speeding up the process of reducing gigabyte-sized tomograms to byte-sized data.
C1 [Narasimha, Rajesh; Bennett, Adam; Zabransky, Daniel; Sougrat, Rachid; Subramaniam, Sriram] NCI, Cell Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Narasimha, Rajesh; McLaughlin, Steven] Georgia Inst Technol, Atlanta, GA USA.
RP Narasimha, R (reprint author), NCI, Cell Biol Lab, Ctr Canc Res, Bethesda, MD 20892 USA.
EM rajesh@ece.gatech.edu; bennettad@mail.nih.gov; djzabr@wm.edu;
   sougrat@mail.nih.gov; ssl@nih.gov; swm@ece.gatech.edu
CR DONOHO DL, 1995, IEEE T INFORM THEORY, V41, P613, DOI 10.1109/18.382009
   Frangakis AS, 2004, CURR OPIN STRUC BIOL, V14, P325, DOI 10.1016/j.sbi.2004.04.003
   Frank J, 2006, 3 DIMENSIONAL ELECT
   GILBERT P, 1972, J THEOR BIOL, V36, P105, DOI 10.1016/0022-5193(72)90180-4
   Gilboa G, 2004, IEEE T PATTERN ANAL, V26, P1020, DOI 10.1109/TPAMI.2004.47
   KOVESI P, 1999, DICTA 99, P212
   Kremer JR, 1996, J STRUCT BIOL, V116, P71, DOI 10.1006/jsbi.1996.0013
   PENCZEK P, 1995, ULTRAMICROSCOPY, V60, P393, DOI 10.1016/0304-3991(95)00078-X
   PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205
   Portilla J, 2003, IEEE T IMAGE PROCESS, V12, P1338, DOI 10.1109/TIP.2003.818640
   Subramaniam S, 2004, ANNU REV BIOPH BIOM, V33, P141, DOI 10.1146/annurev.biophys.33.110502.140339
   Thong JTL, 2001, SCANNING, V23, P328
NR 12
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
SN 1520-6149
BN 978-1-4244-0728-6
J9 INT CONF ACOUST SPEE
PY 2007
BP 301
EP +
PG 3
WC Acoustics; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology
SC Acoustics; Engineering; Imaging Science & Photographic Technology
GA BGO60
UT WOS:000249040000076
DA 2018-01-05
ER

PT J
AU Torchilin, VP
AF Torchilin, Vladimir P.
TI Targeted pharmaceutical nanocarriers for cancer therapy and Imaging
SO AAPS JOURNAL
LA English
DT Review
DE nanoparticles; nanocarriers; targeted delivery; cancer therapy; imaging
ID PEGYLATED-LIPOSOMAL DOXORUBICIN; STERICALLY STABILIZED LIPOSOMES;
   BLOCK-COPOLYMER MICELLES; LARGE UNILAMELLAR LIPOSOMES; LONG-CIRCULATING
   LIPOSOMES; PH-SENSITIVE LIPOSOMES; HIGH INTRATUMORAL ACCUMULATION;
   GADOLINIUM-LABELED LIPOSOMES; HUMAN IMMUNODEFICIENCY VIRUS; CONTRAST
   ENHANCEMENT AGENTS
AB The use of various pharmaceutical nanocarriers has become one of the most important areas of nanomedicine. Ideally, such carriers should be specifically delivered (targeted) to the pathological area to provide the maximum therapeutic efficacy. Among the many potential targets for such nanocarriers, tumors have been most often investigated. This review attempts to summarize currently available information regarding targeted pharmaceutical nanocarriers for cancer therapy and imaging. Certain issues related to some popular pharmaceutical nanocarriers, such as liposomes and polymeric micelles, are addressed, as are different ways to target tumors via specific ligands and via the stimuli sensitivity of the carriers. The importance of intracellular targeting of drug- and DNA-loaded pharmaceutical nanocarriers is specifically discussed, including intracellular delivery with cell-penetrating peptides.
C1 Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
   Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
EM torchilin@neu.edu
CR ALLEN TM, 1995, ADV DRUG DELIVER REV, V16, P267, DOI 10.1016/0169-409X(95)00029-7
   ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7                                                    
   ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5
   ASAI T, 2002, FEBS LETT, V520, P165
   Asokan A, 2003, BBA-BIOMEMBRANES, V1611, P151, DOI 10.1016/S0005-2736(03)00050-6
   Bae Y, 2005, MOL BIOSYST, V1, P242, DOI 10.1039/b500266d
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   BAO A, 2003, J PHARMACOL EXP THER, V308, P419
   Belhaj-Tayeb H, 2003, EUR J NUCL MED MOL I, V30, P502, DOI 10.1007/s00259-002-1038-4
   Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7
   BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3
   BOMAN NL, 1994, CANCER RES, V54, P2830
   Boomer JA, 1999, CHEM PHYS LIPIDS, V99, P145, DOI 10.1016/S0009-3084(99)00033-X
   Bourre L, 2003, PHARMACOL RES, V47, P253, DOI 10.1016/S1043-6618(02)00312-2
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Brignole C, 2003, CANCER LETT, V197, P231, DOI 10.1016/S0304-3835(03)00107-1
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   Cammas S, 1997, J CONTROL RELEASE, V48, P157, DOI 10.1016/S0168-3659(97)00040-0
   CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0
   Choi H, 2004, ACAD RADIOL, V11, P996, DOI 10.1016/j.acra.2004.04.018
   CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7
   CHONN A, 1992, J BIOL CHEM, V267, P18759
   Chung JE, 1999, J CONTROL RELEASE, V62, P115, DOI 10.1016/S0168-3659(99)00029-2                                                   
   Cohen S, 1996, MICROPARTICULATE SYS
   Dagar S, 2003, J CONTROL RELEASE, V91, P123, DOI 10.1016/S0168-3659(03)00242-6
   Dash PR, 2000, J BIOL CHEM, V275, P3793, DOI 10.1074/jbc.275.6.3793
   Derycke ASL, 2004, ADV DRUG DELIVER REV, V56, P17, DOI 10.1016/j.addr.2003.07.014
   Derycke ASL, 2002, INT J ONCOL, V20, P181
   Drummond D C, 2000, Vitam Horm, V60, P285, DOI 10.1016/S0083-6729(00)60022-5
   Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8
   Elbayoumi TA, 2007, J LIPOSOME RES, V17, P1, DOI 10.1080/08982100601186474
   Elbayoumi TA, 2006, EUR J NUCL MED MOL I, V33, P1196, DOI 10.1007/s00259-006-0139-x
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Ewer MS, 2004, SEMIN ONCOL, V31, P161, DOI 10.1053/j.seminoncol.2004.08.006
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fernandez AM, 2001, J MED CHEM, V44, P3750, DOI 10.1021/jm0108754
   Fonseca MJ, 2003, PHARMACEUT RES, V20, P423, DOI 10.1023/A:1022608321861
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GABIZON A, 1994, CANCER RES, V54, P987
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   GABIZON A, 1992, BIOCHIM BIOPHYS ACTA, V1103, P94, DOI 10.1016/0005-2736(92)90061-P
   GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949                                                         
   GABIZON AA, 1995, ADV DRUG DELIVER REV, V16, P285, DOI 10.1016/0169-409X(95)00030-B                                                    
   Gao ZG, 2005, J DRUG TARGET, V13, P391, DOI 10.1080/10611860500376741
   Gaspar MM, 1996, CANCER CHEMOTH PHARM, V38, P373, DOI 10.1007/s002800050497                                                           
   GEISERT EE, 1995, NEUROSCI LETT, V184, P40, DOI 10.1016/0304-3940(94)11163-D
   Gijsens Antoon, 2002, International Journal of Cancer, V101, P78, DOI 10.1002/ijc.10548
   Glogard C, 2002, INT J PHARM, V233, P131, DOI 10.1016/S0378-5173(01)00935-8
   Goins Beth A., 2003, P319
   GRANT CWM, 1989, MAGNET RESON MED, V11, P236, DOI 10.1002/mrm.1910110211
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169-409X(95)00026-4
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Guo X, 2001, BIOCONJUGATE CHEM, V12, P291, DOI 10.1021/bc000110v
   Hafez IM, 2001, GENE THER, V8, P1188, DOI 10.1038/sj.gt.3301506
   HAGELUKEN A, 1994, BIOCHEM PHARMACOL, V47, P1789, DOI 10.1016/0006-2952(94)90307-7
   Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341                                                    
   HARPER GR, 1991, BIOMATERIALS, V12, P695, DOI 10.1016/0142-9612(91)90119-U
   Harrington KJ, 2000, BRIT J CANCER, V83, P684, DOI 10.1054/bjoc.2000.1320
   Harrington KJ, 2000, CLIN CANCER RES, V6, P2528
   Harrington KJ, 2001, CLIN CANCER RES, V7, P243
   Harrington KJ, 2001, EUR J CANCER, V37, P2015, DOI 10.1016/S0959-8049(01)00216-7                                                   
   Hatakeyama H, 2004, INT J PHARM, V281, P25, DOI 10.1016/j.ijpharm.2004.05.025
   Hilger I, 2002, INVEST RADIOL, V37, P580, DOI 10.1097/00004424-200210000-00008                                                
   Hlrano K., 1985, J PHARM SCI, V74, P915
   HUANG SK, 1994, CANCER RES, V54, P2186
   Huang XH, 2006, J AM CHEM SOC, V128, P2115, DOI 10.1021/ja057254a
   Huh YM, 2005, J AM CHEM SOC, V127, P12387, DOI 10.1021/ja052337c
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164
   Hwang K. J., 1987, LIPOSOMES BIOPHYSICS, P109
   Iinuma H, 2002, INT J CANCER, V99, P130, DOI 10.1002/ijc.10242
   Ishida O, 2001, PHARMACEUT RES, V18, P1042, DOI 10.1023/A:1010960900254
   Ivkov R, 2005, CLIN CANCER RES, V11, p7093S, DOI 10.1158/1078-0432.CCR-1004-0016
   Johannsen M, 2006, PROSTATE, V66, P97, DOI 10.1002/pros.20324
   Johannsen M, 2005, PROSTATE, V64, P283, DOI 10.1002/pros.20213
   Johannsen M, 2005, INT J HYPERTHER, V21, P637, DOI 10.1080/02656730500158360
   Johnson PK, 2001, INT J POWDER METALL, V37, P8
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Jordan A, 2006, J NEURO-ONCOL, V78, P7, DOI 10.1007/s11060-005-9059-z
   Joshee N, 2002, HUM GENE THER, V13, P1991, DOI 10.1089/10430340260355392
   Jule E, 2003, BIOCONJUGATE CHEM, V14, P177, DOI 10.1021/bc025598+
   KABALKA GW, 1991, MAGN RESON IMAGING, V9, P373, DOI 10.1016/0730-725X(91)90425-L                                                    
   KABALKA GW, 1991, MAGNET RESON MED, V19, P406, DOI 10.1002/mrm.1910190231
   Kakudo T, 2004, BIOCHEMISTRY-US, V43, P5618, DOI 10.1021/bi035802w
   Kamps JAAM, 2000, J DRUG TARGET, V8, P235, DOI 10.3109/10611860008997902                                                       
   Kato K, 2004, BIOTECHNOL PROGR, V20, P897, DOI 10.1021/bp0342093
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kisel MA, 2001, INT J PHARM, V216, P105, DOI 10.1016/S0378-5173(01)00579-8
   KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H
   Koukourakis MI, 2000, BRIT J CANCER, V83, P1281, DOI 10.1054/bjoc.2000.1459
   Koukourakis MI, 1999, J CLIN ONCOL, V17, P3512, DOI 10.1200/JCO.1999.17.11.3512                                                     
   Koukourakis MI, 2000, ACTA ONCOL, V39, P207
   Kratz F, 1999, CRIT REV THER DRUG, V16, P245, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i3.10                                    
   KRAUSE HJ, 1985, INT J PHARM, V27, P145, DOI 10.1016/0378-5173(85)90064-X
   KWON GS, 1995, ADV DRUG DELIVER REV, V16, P295, DOI 10.1016/0169-409X(95)00031-2                                                    
   Lasic D, 1995, STEALTH LIPOSOMES
   LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2
   Lasic D. D., 1993, LIPOSOMES PHYS APPL
   Le Garrec D, 2002, J DRUG TARGET, V10, P429, DOI 10.1080/1061186021000001887
   Leamon CP, 1999, BIOCONJUGATE CHEM, V10, P947, DOI 10.1021/bc990066n
   LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572
   Leamon CP, 2001, DRUG DISCOV TODAY, V6, P44, DOI 10.1016/S1359-6446(00)01594-4
   Lee CM, 2002, CANCER RES, V62, P4282
   Lee ES, 2005, J CONTROL RELEASE, V103, P405, DOI 10.1016/j.jconrel.2004.12.018
   Lee ES, 2003, J CONTROL RELEASE, V91, P103, DOI 10.1016/S0168-3659(03)00239-6
   Lee ES, 2003, J CONTROL RELEASE, V90, P363, DOI 10.1016/S0168-3659(03)00205-0
   LEE RJ, 1994, J BIOL CHEM, V269, P3198
   Leroux JC, 2001, J CONTROL RELEASE, V72, P71, DOI 10.1016/S0168-3659(01)00263-2                                                   
   LIN AW, 2005, J BIOMED OPT, V10, P64044
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu C, 2001, J GENE MED, V3, P145, DOI 10.1002/jgm.164
   Liu SQ, 2005, BIOMATERIALS, V26, P5064, DOI 10.1016/j.biomaterials.2005.01.030
   Lu YJ, 2002, ADV DRUG DELIVER REV, V54, P675, DOI 10.1016/S0169-409X(02)00042-X
   Lu YJ, 2002, CANCER IMMUNOL IMMUN, V51, P153, DOI 10.1007/s00262-002-0266-6
   Lukyanov AN, 2004, J CONTROL RELEASE, V100, P135, DOI 10.1016/j.jconrel.2004.08.007
   Lukyanov AN, 2004, J CONTROL RELEASE, V94, P187, DOI 10.1016/j.jconrel.2003.10.008
   Maeda H, 2001, J CONTROL RELEASE, V74, P47, DOI 10.1016/S0168-3659(01)00309-1
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Maeda H, 2001, ADV DRUG DELIVER REV, V46, P169, DOI 10.1016/S0169-409X(00)00134-4
   Mamot C, 2003, CANCER RES, V63, P3154
   Marty C, 2005, METH MOLEC MED, V109, P389
   MARUYAMA K, 1991, CHEM PHARM BULL, V39, P1620
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   Matsuda I, 2001, SURG TODAY, V31, P414, DOI 10.1007/s005950170132                                                           
   Meyer O, 1998, FEBS LETT, V421, P61, DOI 10.1016/S0014-5793(97)01520-2
   Morawski AM, 2005, CURR OPIN BIOTECH, V16, P89, DOI 10.1016/j.copbio.2004.11.001
   Muller M, 2003, J BIOMED MATER RES A, V66A, P55, DOI 10.1002/jbm.a.10502
   Muller R.H., 1991, COLLOIDAL CARRIERS C
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nagasaki Y, 2001, BIOMACROMOLECULES, V2, P1067, DOI 10.1021/bm015574q
   Napper D. H., 1983, POLYM STABILIZATION
   NEEDHAM D, 1992, BIOCHIM BIOPHYS ACTA, V1108, P40, DOI 10.1016/0005-2736(92)90112-Y
   Ni S, 2002, ANTICANCER RES, V22, P2131
   Nori A, 2003, J CONTROL RELEASE, V91, P53, DOI 10.1016/S0168-3659(03)00213-X
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   O'Shaughnessy Joyce A, 2003, Clin Breast Cancer, V4, P318, DOI 10.3816/CBC.2003.n.037
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814
   Opanasopit P, 2002, J CONTROL RELEASE, V80, P283, DOI 10.1016/S0168-3659(02)00006-8
   Pan XQ, 2003, PHARMACEUT RES, V20, P417, DOI 10.1023/A:1022656105022
   PANG SNJ, 1993, J AM COLL TOXICOL, V12, P429
   PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460
   Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200                                                          
   Park EK, 2005, BIOMATERIALS, V26, P1053, DOI 10.1016/j.biomaterials.2004.04.008
   Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7
   PATEL HM, 1984, BIOCHIM BIOPHYS ACTA, V801, P76, DOI 10.1016/0304-4165(84)90214-9
   Peer D, 2004, INT J CANCER, V108, P780, DOI 10.1002/ijc.11615
   Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2
   Perez AT, 2002, CANCER INVEST, V20, P22, DOI 10.1081/CNV-120014883
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Phillips WT, 1995, HANDB PHARM TOX, P149
   Powel G.M., 1980, HDB WATER SOLUBLE GU, P1
   Raffaghello L, 2003, CANCER LETT, V197, P151, DOI 10.1016/S0304-3835(03)00097-1
   Roby A, 2006, EUR J PHARM BIOPHARM, V62, P235, DOI 10.1016/j.ejpb.2005.09.010
   Roeder GE, 2004, BIOTECHNOL APPL BIOC, V40, P157, DOI 10.1042/BA20030172
   Rose PG, 2005, ONCOLOGIST, V10, P205, DOI 10.1634/theoncologist.10-3-205                                                  
   Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003
   Roux E, 2004, J CONTROL RELEASE, V94, P447, DOI 10.1016/j.jconrel.2003.10.024
   Roux E, 2002, INT J PHARM, V242, P25, DOI 10.1016/S0378-5173(02)00183-7                                                   
   Roux E, 2002, J PHARM SCI, V91, P1795, DOI 10.1002/jps.10172
   RUBAS W, 1986, INT J CANCER, V37, P149, DOI 10.1002/ijc.2910370123
   Sapra P, 2002, CANCER RES, V62, P7190
   Sawant RM, 2006, BIOCONJUGATE CHEM, V17, P943, DOI 10.1021/bc060080h
   Schmidinger M, 2001, BRIT J CANCER, V85, P1850, DOI 10.1054/bjoc.2001.2149
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   SCHWENDENER RA, 1990, INVEST RADIOL, V25, P922, DOI 10.1097/00004424-199008000-00009                                                
   Seiden MV, 2004, GYNECOL ONCOL, V93, P229, DOI 10.1016/j.ygyno.2003.12.037
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   SENIOR JH, 1987, CRIT REV THER DRUG, V3, P123
   SHABNER BA, 1990, CANC CHEMOTHERAPY PR
   Shalaev EY, 1999, BBA-BIOMEMBRANES, V1419, P229, DOI 10.1016/S0005-2736(99)00068-1
   Sheff D, 2004, ADV DRUG DELIVER REV, V56, P927, DOI 10.1016/j.addr.2003.11.005
   Shi GF, 2002, J CONTROL RELEASE, V80, P309, DOI 10.1016/S0168-3659(02)00017-2
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Shokolenko IN, 2005, DNA REPAIR, V4, P511, DOI 10.1016/j.dnarep.2004.11.009
   Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038
   Skubitz KM, 2003, CANCER INVEST, V21, P167, DOI 10.1081/CNV-120016412
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   Stephenson SM, 2003, ANTICANCER RES, V23, P3341
   Stewart S., 1997, ONCOLOGY S11, V11, P33
   Stroh M, 2005, NAT MED, V11, P678, DOI 10.1038/nm1247
   Sudimack JJ, 2002, BBA-BIOMEMBRANES, V1564, P31, DOI 10.1016/S0005-2736(02)00399-1
   Sullivan DC, 2004, MOL IMAGING, V3, P364, DOI 10.1162/1535350042973526
   Symon Z, 1999, CANCER, V86, P72, DOI 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.3.CO;2-T
   Takeuchi Y, 2004, J CONTROL RELEASE, V97, P231, DOI 10.1016/j.jconrel.2004.03.030
   Tan PH, 2003, J GENE MED, V5, P311, DOI 10.1002/jgm.358
   Tasciotti E, 2003, CANCER GENE THER, V10, P64, DOI 10.1038/sj.cgt.7700526
   TILCOCK C, 1989, RADIOLOGY, V171, P77, DOI 10.1148/radiology.171.1.2928549                                                 
   TILCOCK C, 1993, LIPOSOME TECHNOLOGY, P65
   Torchilin V, 1991, IMMOBILIZED ENZYMES
   Torchilin V P, 1985, Crit Rev Ther Drug Carrier Syst, V2, P65
   Torchilin Vladimir P., 1995, Journal of Liposome Research, V5, P795, DOI 10.3109/08982109509012682
   Torchilin Vladimir P., 2000, Current Pharmaceutical Biotechnology, V1, P183, DOI 10.2174/1389201003378960
   Torchilin Vladimir P., 1996, Journal of Liposome Research, V6, P99, DOI 10.3109/08982109609037204
   Torchilin VP, 2002, BIOMEDICAL ASPECTS OF DRUG TARGETING, P3
   TORCHILIN VP, 1995, ADV DRUG DELIVER REV, V16, P141, DOI 10.1016/0169-409X(95)00022-Y                                                    
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5
   Torchilin VP, 1999, CHEMTECH, V29, P27
   Torchilin VP, 1997, ADV DRUG DELIVER REV, V24, P301, DOI 10.1016/S0169-409X(96)00472-3
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Torchilin VP, 1998, J MICROENCAPSUL, V15, P1, DOI 10.3109/02652049809006831                                                       
   Torchilin VP, 1996, BBA-BIOMEMBRANES, V1279, P75, DOI 10.1016/0005-2736(95)00248-0
   TORCHILIN VP, 2000, CONTROLLED DRUG DELI, P297
   Torchilin VP, 2000, 27 INT S CONTR REL B
   Torchilin V.P, 1995, HANDB PHARM TOX, P403
   Torchilin V.P, 1995, STEALTH LIPOSOMES, P225
   TORCHILIN VP, 1995, HDB TARGETED DELIVER
   Torchilin V. P., 1993, J LIPOSOME RES, V3, P201
   Torchilin VP, 2006, NANOPARTICULATES PHA
   TORCHILIN VP, 2001, BIOCHIM BIOPHYS ACTA, V1511, P391
   Trubetskoy Vladimir S., 1994, Journal of Liposome Research, V4, P961, DOI 10.3109/08982109409018613
   TRUBETSKOY VS, 1995, ADV DRUG DELIVER REV, V16, P311, DOI 10.1016/0169-409X(95)00032-3
   TRUBETSKOY VS, 1995, MAGN RESON IMAGING, V13, P31, DOI 10.1016/0730-725X(94)00083-F
   Trubetskoy VS, 1996, STP PHARMA SCI, V6, P79
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Turk MJ, 2002, BBA-BIOMEMBRANES, V1559, P56, DOI 10.1016/S0005-2736(01)00441-2
   UNGER EC, 1989, RADIOLOGY, V171, P81, DOI 10.1148/radiology.171.1.2928550                                                 
   Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9
   Vinogradov S, 1999, BIOCONJUGATE CHEM, V10, P851, DOI 10.1021/bc990037c                                                               
   Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wang HY, 2002, J CLIN INVEST, V109, P1463, DOI 10.1172/JCI200215399
   Wang J, 2005, J DRUG TARGET, V13, P73, DOI 10.1080/10611860400011935
   Wollina U, 2003, CANCER, V98, P993, DOI 10.1002/cncr.11593
   WOODLE MC, 1993, CHEM PHYS LIPIDS, V64, P249, DOI 10.1016/0009-3084(93)90069-F
   Xu L, 2002, MOL CANCER THER, V1, P337
   Yalkowsky S.H., 1981, TECHNIQUES SOLUBILIZ
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yessine MA, 2004, ADV DRUG DELIVER REV, V56, P999, DOI 10.1016/j.addr.2003.10.039
   YOKOGAWA K, 1990, PHARMACEUT RES, V7, P691, DOI 10.1023/A:1015803202857
   YUAN F, 1995, CANCER RES, V55, P3752
   ZALIPSKY S, 1995, ADV DRUG DELIVER REV, V16, P157, DOI 10.1016/0169-409X(95)00023-Z
   Zalipsky S, 1999, BIOCONJUGATE CHEM, V10, P703, DOI 10.1021/bc990031n                                                               
   ZALIPSKY S, 1998, TARGETING DRUGS, V6, P131
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   Zavaglia D, 2003, MOL THER, V8, P840, DOI 10.1016/S1525-0016(03)00278-8
   Zhang JX, 2004, PHARMACOL RES, V49, P185, DOI 10.1016/j.phrs.2003.09.003
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142-9612(01)00267-8
NR 244
TC 393
Z9 402
U1 13
U2 101
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1550-7416
J9 AAPS J
JI AAPS J.
PY 2007
VL 9
IS 2
BP E128
EP E147
AR 15
DI 10.1208/aapsj0902015
PG 20
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 200DQ
UT WOS:000248744500004
PM 17614355
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Liu, Z
   Winters, M
   Holodniy, M
   Dai, HJ
AF Liu, Zhuang
   Winters, Mark
   Holodniy, Mark
   Dai, Hongjie
TI siRNA delivery into human T cells and primary cells with carbon-nanotube
   transporters
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Article
DE carbon nanotubes; drug delivery; nanobiotechnology; RNA interference; T
   cells
ID SMALL INTERFERING RNA; HIV-1 INFECTION; GENE DELIVERY;
   FUNCTIONALIZATION; INHIBITION; EXPRESSION
C1 Stanford Univ, Dept Chem, Stanford, CA 94305 USA.
   Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.
   Palo Alto Hlth Care Syst, Stanford, CA 94305 USA.
RP Dai, HJ (reprint author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.
EM hdai@stanford.edu
RI Liu, Zhuang/H-4352-2011
OI Liu, Zhuang/0000-0002-1629-1039; Holodniy, Mark/0000-0002-6655-7982
CR Bianco A, 2005, CHEM COMMUN, P571, DOI 10.1039/b410943k
   Chen RJ, 2003, P NATL ACAD SCI USA, V100, P4984, DOI 10.1073/pnas.0837064100
   Chen X, 2006, J AM CHEM SOC, V128, P6292, DOI 10.1021/ja060276s
   Cherukuri P, 2004, J AM CHEM SOC, V126, P15638, DOI 10.1021/ja0466311
   DRESSELHAUS M, 2004, MRS BULL, P29
   Dresselhaus M. S., 1996, SCI FULLERENES CARBO
   Dumortier H, 2006, NANO LETT, V6, P1522, DOI 10.1021/nl061160x
   Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129
   Harris J. M., 1997, POLYETHYLENE GLYCOL
   Heller DA, 2005, ADV MATER, V17, P2793, DOI 10.1002/adma.200500477                                                          
   Henry CM, 2004, CHEM ENG NEWS, V82, P37
   KAM NSW, 2005, P NATL ACAD SCI USA, V1102, P11600
   Kam NWS, 2004, J AM CHEM SOC, V126, P6850, DOI 10.1021/ja0486059
   Kam NWS, 2005, J AM CHEM SOC, V127, P12492, DOI 10.1021/ja053962k
   Kam N. W. S., 2006, ANGEW CHEM, V118, P591, DOI DOI 10.1002/ANGE.200503389
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Latchman DS, 2001, GENE, V264, P1, DOI 10.1016/S0378-1119(01)00322-5
   Martinez MA, 2002, AIDS, V16, P2385, DOI 10.1097/00002030-200212060-00002
   McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754                                                    
   Mukherjee S, 1997, PHYSIOL REV, V77, P759
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Pantarotto D, 2004, CHEM COMMUN, P16, DOI 10.1039/b311254c
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Sayes CM, 2006, TOXICOL LETT, V161, P135, DOI 10.1016/j.toxlet.2005.08.011
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Spagnou S, 2004, BIOCHEMISTRY-US, V43, P13348, DOI 10.1021/bi048950a
NR 26
TC 433
Z9 445
U1 2
U2 83
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1433-7851
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2007
VL 46
IS 12
BP 2023
EP 2027
DI 10.1002/anie.200604295
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 148JP
UT WOS:000245071000016
PM 17290476
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Willner, I
   Zayats, M
AF Willner, Itamar
   Zayats, Maya
TI Electronic aptamer-based sensors
SO ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
LA English
DT Review
DE aptamers; biosensors; electrochemistry; nanostructures; proteins
ID ANTIGEN-ANTIBODY INTERACTIONS; STRANDED-DNA MOLECULES; HIV-1 TAT
   PROTEIN; LABEL-FREE; ELECTROCHEMICAL DETECTION; IMPEDANCE SPECTROSCOPY;
   INSOLUBLE PRODUCT; NUCLEIC-ACIDS; BIOCATALYZED PRECIPITATION; ENZYME
   BIOSENSORS
C1 Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel.
RP Willner, I (reprint author), Hebrew Univ Jerusalem, Inst Chem, IL-91904 Jerusalem, Israel.
EM willnea@vms.huji.ac.il
CR Alfonta L, 2001, BIOSENS BIOELECTRON, V16, P675, DOI 10.1016/S0956-5663(01)00231-7
   Baker BR, 2006, J AM CHEM SOC, V128, P3138, DOI 10.1021/ja056957p
   Bang GS, 2005, BIOSENS BIOELECTRON, V21, P863, DOI 10.1016/j.bios.2005.02.002
   Bardea A, 1999, CHEM COMMUN, P21, DOI 10.1039/a808319c                                                                
   Bardea A, 2000, ELECTROANAL, V12, P1097, DOI 10.1002/1521-4109(200010)12:14<1097::AID-ELAN1097>3.0.CO;2-X
   BERGVELD P, 2003, SENSOR ACTUAT B-CHEM, V88, P20
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Brody E.N., 2000, REV MOL BIOTECHNOL, V74, P5, DOI DOI 10.1016/S1389-0352(99)00004-5
   BUTTRY DA, 1992, CHEM REV, V92, P1355, DOI 10.1021/cr00014a006                                                             
   Cai H, 2006, SENSOR ACTUAT B-CHEM, V114, P433, DOI 10.1016/j.snb.2005.06.017
   Clark SL, 2003, ANAL CHEM, V75, P5692, DOI 10.1021/ac030156s
   Clark SL, 2002, ELECTROPHORESIS, V23, P1335, DOI 10.1002/1522-2683(200205)23:9<1335::AID-ELPS1335>3.0.CO;2-E                     
   Deng Q, 2003, J CHROMATOGR A, V1005, P123, DOI 10.1016/S0021-9673(03)00812-4
   Dzyadevych SV, 2006, ANAL CHIM ACTA, V568, P248, DOI 10.1016/j.aca.2005.11.057
   ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0                                                                
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Famulok M, 2000, ACCOUNTS CHEM RES, V33, P591, DOI 10.1021/ar960167q
   Famulok M, 1999, CURR OPIN STRUC BIOL, V9, P324, DOI 10.1016/S0959-440X(99)80043-8                                                   
   Fan CH, 2003, P NATL ACAD SCI USA, V100, P9134, DOI 10.1073/pnas.1633515100
   Feigon J, 1996, CHEM BIOL, V3, P611, DOI 10.1016/S1074-5521(96)90127-1
   Fiammengo R, 2005, CURR OPIN BIOTECH, V16, P614, DOI 10.1016/j.copbio.2005.10.006
   Floch F.L., 2006, ANAL CHEM, V78, P4727
   Fritz J, 2002, P NATL ACAD SCI USA, V99, P14142, DOI 10.1073/pnas.232276699                                                          
   GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555
   Gronewold TMA, 2005, BIOSENS BIOELECTRON, V20, P2044, DOI 10.1016/j.bios.2004.09.007
   Hansen JA, 2006, J AM CHEM SOC, V128, P2228, DOI 10.1021/ja060005h
   HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904
   Hianik T, 2005, BIOORG MED CHEM LETT, V15, P291, DOI 10.1016/j.bmcl.2004.10.083
   Ho HA, 2005, J AM CHEM SOC, V127, P12673, DOI 10.1021/ja053417j
   Ho HA, 2004, J AM CHEM SOC, V126, P1384, DOI 10.1021/ja037289f
   Ikebukuro K, 2005, BIOSENS BIOELECTRON, V20, P2168, DOI 10.1016/j.bios.2004.09.002
   Immoos CE, 2004, CHEMBIOCHEM, V5, P1100, DOI 10.1002/cbic.200400045
   Jayasena SD, 1999, CLIN CHEM, V45, P1628
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   Josse F, 2001, ANAL CHEM, V73, P5937, DOI 10.1021/ac010859e
   Katz E, 2003, ELECTROANAL, V15, P913, DOI 10.1002/elan.200390114
   Kim DS, 2004, BIOSENS BIOELECTRON, V20, P69, DOI 10.1016/j.bios.2004.01.025
   Kirby R, 2004, ANAL CHEM, V76, P4066, DOI 10.1021/ac049858n
   Kusser W, 2000, J Biotechnol, V74, P27
   Lee M, 2000, ANAL BIOCHEM, V282, P142, DOI 10.1006/abio.2000.4595                                                          
   Levy M, 2005, CHEMBIOCHEM, V6, P2163, DOI 10.1002/cbic.200500218
   Li JWJ, 2002, BIOCHEM BIOPH RES CO, V292, P31, DOI 10.1006/bbrc.2002.6581
   Lilley DMJ, 2005, CURR OPIN STRUC BIOL, V15, P313, DOI 10.1016/j.sbi.2005.05.002
   Liss M, 2002, ANAL CHEM, V74, P4488, DOI 10.1021/ac011294p
   Liu J, 2005, J AM CHEM SOC, V127, P12677, DOI 10.1021/ja053567u
   Lu Y., 2002, CHEM-EUR J, V8, P4588
   Mao YD, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng108
   Michaud M, 2003, J AM CHEM SOC, V125, P8672, DOI 10.1021/ja034483t
   Minunni M, 2004, BIOSENS BIOELECTRON, V20, P1149, DOI 10.1016/j.bios.2004.03.037
   Mir M, 2006, ELECTROCHEM COMMUN, V8, P505, DOI 10.1016/j.elecom.2005.12.022
   O'Sullivan CK, 2002, ANAL BIOANAL CHEM, V372, P44, DOI 10.1007/s00216-001-1189-3
   PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651
   Patel DJ, 2000, REV MOL BIOTECHNOL, V74, P39
   Patolsky F, 2003, CHEM-EUR J, V9, P1137, DOI 10.1002/chem.200390131
   Patolsky F, 2002, ANGEW CHEM INT EDIT, V41, P3398, DOI 10.1002/1521-3773(20020916)41:18<3398::AID-ANIE3398>3.0.CO;2-W                  
   Patolsky F, 2001, NAT BIOTECHNOL, V19, P253, DOI 10.1038/85704                                                                   
   Pavlov V, 2005, J AM CHEM SOC, V127, P6522, DOI 10.1021/ja050678k
   Pavlov V, 2004, J AM CHEM SOC, V126, P11768, DOI 10.1021/ja046970u
   Pei RJ, 2001, BIOSENS BIOELECTRON, V16, P355, DOI 10.1016/S0956-5663(01)00150-6
   PIEKEN WA, 1991, SCIENCE, V253, P314, DOI 10.1126/science.1857967
   Polsky R, 2006, ANAL CHEM, V78, P2268, DOI 10.1021/ac0519864
   Radi AE, 2006, J AM CHEM SOC, V128, P117, DOI 10.1021/ja053121d
   Radi AE, 2005, ANAL CHEM, V77, P6320, DOI 10.1021/ac0505775
   Rodriguez MC, 2005, CHEM COMMUN, P4267, DOI 10.1039/b506571b
   Sakata T, 2005, BIOSENS BIOELECTRON, V21, P827, DOI 10.1016/j.bios.2005.01.018
   SCHCNING MJ, 2002, ANALYST, V127, P1137
   Schcning M. J., 2006, ELECTROANAL, V18, P1893
   Schlensog MD, 2004, SENSOR ACTUAT B-CHEM, V101, P308, DOI 10.1016/j.snb.2004.03.015
   Shin JK, 2004, ELECTROANAL, V16, P1912, DOI 10.1002/elan.200403080
   Silverman SK, 2004, ORG BIOMOL CHEM, V2, P2701, DOI 10.1039/b411910j
   So HM, 2005, J AM CHEM SOC, V127, P11906, DOI 10.1021/ja053094r
   TANG HT, 1988, ANAL CHIM ACTA, V214, P187, DOI 10.1016/S0003-2670(00)80440-7                                                   
   Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275                                                          
   Tombelli S, 2005, BIOSENS BIOELECTRON, V20, P2424, DOI 10.1016/j.bios.2004.11.006
   Tombelli S, 2005, BIOELECTROCHEMISTRY, V67, P135, DOI 10.1016/j.bioelechem.2004.04.011
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Uslu F, 2004, BIOSENS BIOELECTRON, V19, P1723, DOI 10.1016/j.bios.2004.01.019
   Vagin MY, 2002, BIOELECTROCHEMISTRY, V56, P91, DOI 10.1016/S1567-5394(01)00142-6
   Wang J, 2003, J AM CHEM SOC, V125, P3214, DOI 10.1021/ja029668z
   Wang J, 2001, ANAL CHEM, V73, P5576, DOI 10.1021/ac0107148
   White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325
   Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611
   Xiao Y, 2004, ANGEW CHEM INT EDIT, V43, P4519, DOI 10.1002/anie.200460608
   Xiao Y, 2005, J AM CHEM SOC, V127, P17990, DOI 10.1021/ja056555h
   Xiao Y, 2005, ANGEW CHEM INT EDIT, V44, P5456, DOI 10.1002/anie.200500989
   XIAO Y, 2004, ANGEW CHEM, V116, P4619
   Xu DK, 2005, ANAL CHEM, V77, P5107, DOI 10.1021/ac050192m
   Zayats M, 2006, J AM CHEM SOC, V128, P13666, DOI 10.1021/ja0651456
NR 88
TC 482
Z9 494
U1 51
U2 409
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1433-7851
J9 ANGEW CHEM INT EDIT
JI Angew. Chem.-Int. Edit.
PY 2007
VL 46
IS 34
BP 6408
EP 6418
DI 10.1002/anie.200604524
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 208CH
UT WOS:000249296900005
PM 17600802
HC Y
HP N
DA 2018-01-05
ER

PT J
AU Uckun, FM
   DuMez, D
   Qazi, S
   Tibbles, H
   Venkatachalam, TK
AF Uckun, Fatih M.
   DuMez, Darin
   Qazi, Sanjive
   Tibbles, Heather
   Venkatachalam, Taracad K.
TI Anti-retroviral activity of GMP-grade stampidine against genotypically
   and phenotypically nucleoside reverse transcriptase inhibitor resistant
   recombinant human immunodeficiency virus - An in vitro study
SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
LA English
DT Article
DE AIDS; CAS 217178-62-6; human immunodeficiency virus; nucleoside reverse
   transcriptase inhibitors; stampidine, antiretroviral activity,
   GMP-grade, in vitro study
ID THYMIDINE ANALOG; NAIVE PATIENTS; STAVUDINE; HIV; ZIDOVUDINE; MUTATIONS;
   THERAPY; DRUGS; TYPE-1; DIDANOSINE
AB The in vitro potency of GMP-grade stampidine (CAS 217178-62-6) was examined against 3 clinical HIV-1 isolates and 6 recombinant HIV-1 clones with multi-NRTI resistance (NRTI: nucleoside reverse transcriptase inhibitors). GMP-grade stampidine active drug substance (Lot #s MPR-M0008.00-01 and MPR-M0008.01-01) as well as GMP-grade stampidine extracted from the clinical stampidine capsules (GMP-Grade Clinical Batch, Pharmaceutical Service Lot Number 15910601) were highly potent and exhibited nanomolar IC50 values against clinical HIV-1 isolates as well as recombinant HIV-1 clones with multi-NRTI resistance containing common patterns of reverse transcriptase mutations responsible for NRTI resistance.
C1 Paradigm Pharmaceut, White Bear Lake, MN 55110 USA.
   Parker Hughes Inst, Roseville, MN USA.
   Ikaros Enterprises Inc, Hudson, WI USA.
RP Uckun, FM (reprint author), Paradigm Pharmaceut, 2139 4th St, White Bear Lake, MN 55110 USA.
EM fatih_uckun@tmo.blackberry.net
CR Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002
   DuMez D, 2006, ARZNEIMITTEL-FORSCH, V56, P136
   Duwe S, 2001, J ACQ IMMUN DEF SYND, V26, P266, DOI 10.1097/00126334-200103010-00010                                                
   Gottlieb MS, 2001, NEW ENGL J MED, V344, P1788, DOI 10.1056/NEJM200106073442312                                                     
   Gutierrez F, 2000, MED CLIN-BARCELONA, V115, P401, DOI 10.1016/S0025-7753(00)71574-0                                                   
   Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210                                                          
   Izopet J, 1999, J MED VIROL, V59, P507, DOI 10.1002/(SICI)1096-9071(199912)59:4<507::AID-JMV14>3.3.CO;2-3
   JOHNSON VA, 1995, J INFECT DIS, V171, pS140, DOI 10.1093/infdis/171.Supplement_2.S140                                            
   Johnston E, 2005, AIDS, V19, P731, DOI 10.1097/01.aids.0000166098.54564.0c
   Lin PF, 1999, ANTIVIR THER, V4, P21
   Palmer S, 1999, AIDS, V13, P661
   Picard V, 2001, J INFECT DIS, V184, P781, DOI 10.1086/323088                                                                  
   Pillay D, 2000, REV MED VIROL, V10, P231, DOI 10.1002/1099-1654(200007/08)10:4<231::AID-RMV290>3.3.CO;2-G
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Ross L, 2001, AIDS RES HUM RETROV, V17, P1107, DOI 10.1089/088922201316912718
   Rousseau MN, 2001, J ACQ IMMUN DEF SYND, V26, P36
   Salomon H, 2000, AIDS, V14, pF17, DOI 10.1097/00002030-200001280-00003                                                
   SCHAFER R, 2000, AIDS REV, V2, P221
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Shulman NS, 2001, J ACQ IMMUN DEF SYND, V27, P377
   Uckun F.M., 2002, U.S. Patent, Patent No. [6,350.736, 6350736]
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P193
   Uckun FM, 2006, ARZNEIMITTEL-FORSCH, V56, P117
   Uckun FM, 2005, ARZNEIMITTEL-FORSCH, V55, P223
   Uckun FM, 2004, ARZNEIMITTEL-FORSCH, V54, P69
   Uckun FM, 2003, ANTIMICROB AGENTS CH, V47, P1233, DOI 10.1128/AAC.47.4.1233-1240.2003
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3613, DOI 10.1128/AAC.46.11.3613-3616.2002
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3428, DOI 10.1128/AAC.46.11.3428-3436.2002
   FATIH M, Patent No. 1090018
   PARADIGM PHARM, 2004, Patent No. 6825177
   PARADIGM PHARM, 2003, Patent No. 6528495
   UCKUN FM, 2006, Patent No. 7071176
   2003, Patent No. 6670336
   Uckun F.M., 2000, US Patent, Patent No. [6030957, 6,030,957]
   PARADIGM PHARM, 2003, Patent No. 6537975
   UCKUN FM, 2003, Patent No. 6503890
NR 36
TC 5
Z9 6
U1 0
U2 0
PU ECV-EDITIO CANTOR VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI AULENDORF
PA BANDELSTOCKWEG 20, POSTFACH 1255, D-88322 AULENDORF, GERMANY
SN 0004-4172
J9 ARZNEIMITTEL-FORSCH
JI Arzneimittelforschung
PY 2007
VL 57
IS 2
BP 112
EP 121
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 152SA
UT WOS:000245380900006
PM 17396622
DA 2018-01-05
ER

PT J
AU Uckun, FM
   Erbeck, D
   Tibbles, H
   Qazi, S
   Venkatachalam, TK
AF Uckun, Fatih M.
   Erbeck, Douglas
   Tibbles, Heather
   Qazi, Sanjive
   Venkatachalam, Taracad K.
TI Improved oral bioavailability of anti-HIV agent N
   '-[2-(2-thiophene)ethyl] N '-[2-(5-bromopyridyl)]-thiourea (HI-443) in a
   novel lipophilic formulation
SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
LA English
DT Article
DE anti-HIV agent; CAS 258340-15-7; HI-443; N '-[2-(2-thiophene)ethyl]-N
   '[2-(5-bromopyridyl)]-thiourea; non-nucleoside reverse transcriptase
   inhibitor
AB N'- [2- (2-Thiophene)ethyl]-N'-[2-(5-bromopyridyl)] -thiourea (CAS 258340-15-7, HI-443) is a rationally designed non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent anti-HIV activity at nanomolar concentrations but poor oral bioavailability. Here the identification of a novel oleic acid containing lead formulation of HI-443 is described which resulted in a similar to 10-fold improvement of oral bioavailability yielding 10-fold higher systemic exposure levels in mice. Formulated HI-443 exhibited a favorable pharmacokinetics and toxicity profile in mice.
C1 Paradigm Pharmaceut, White Bear Lake, MN 55110 USA.
   Parker Hughes Inst, St Paul, MN USA.
RP Uckun, FM (reprint author), Paradigm Pharmaceut, 2139 4th St, White Bear Lake, MN 55110 USA.
EM fatih_uckun@tmo.blackberry.net
FU NIAID NIH HHS [1R43AI052633-01]
CR Gibaldi M., 1982, PHARMACOKINETICS, P494
   UCKIN FM, 2007, IN PRESS ARZNEIMITTE
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   UCKUN FM, 2007, IN PRESS ARZNEIMITTE
   UCKUN FM, 2000, Patent No. 6124324
NR 5
TC 4
Z9 4
U1 0
U2 0
PU ECV-EDITIO CANTOR VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI AULENDORF
PA BANDELSTOCKWEG 20, POSTFACH 1255, D-88322 AULENDORF, GERMANY
SN 0004-4172
J9 ARZNEIMITTEL-FORSCH
JI Arzneimittelforschung
PY 2007
VL 57
IS 3
BP 164
EP 170
PG 7
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 163AV
UT WOS:000246131700006
PM 17469651
DA 2018-01-05
ER

PT S
AU Yun, H
   Bang, H
   Lee, WG
   Lim, H
   Park, J
   Lee, J
   Riaz, A
   Cho, KC
   Chung, CI
   Han, DC
   Chang, JK
AF Yun, Hoyoung
   Bang, Hyunwoo
   Lee, Won Gu
   Lim, Hyunchang
   Park, Junha
   Lee, Joonmo
   Riaz, Asif
   Cho, Keunchang
   Chung, Chanil
   Han, Dong-Chul
   Chang, Jun Keun
BE Nicolau, DV
TI Fluorescent intensity-based differential counting of FITC-doped silica
   nanoparticles: Applications of CD4+T-cell detection in microchip-type
   flowcytometers
SO BIOMEDICAL APPLICATIONS OF MICRO- AND NANOENGINEERING III
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Biomedical Applications of Micro- and Nanoengineering
CY DEC 11-13, 2006
CL Adelaide, AUSTRALIA
SP SPIE, Australian Govt Dept Defence, Defence Sci & Technol Org, Global Off Naval Res Sci & Technol, Off Naval Res, Asian Off Aerosp Res Dev, AF Off Sci Res, COSNet-ARC Complex Open Syst Res Network, Australian Res Council Nanotechnol Network
DE fluorescent dye-doped silica nanoparticles; CD4+T-cell counting;
   differential counting; microchip-type flowcytometer
ID COST
AB Although CD4+ T-cells are an important target of HIV detection, there have been still major problems in making a diagnosis and monitoring in the third world and the region with few medical facilities. Then, it is necessary to use portable diagnosis devices at low cost when you put an enumeration of CD4+ T-cells. In general, the counting of CD4 below 200cells/mu L makes it necessary to initiate antiretroviral treatment in adults (over 13 years old). However, lymphocyte subsets (including CD4 counts) of infants and young children are higher than those of adults. This fact shows the percentage of CD4+ T-cells of blood subsets, i.e., CD4/CD45%, CD4/CD8% or CD4/CD3% means a more reliable indicator of HIV infection than absolute counts in children. To know the percentage of CD4+ T-cell by using two fluorescent dyes of different emission wavelength, at least, one laser and two PMT detectors are in general needed. Then, it is so hard to develop a portable device like a 'toaster size' because this makes such a device more complex including many peripheral modules. In this study, we developed a novel technique to control the intensity of fluorescent dye-doped silica nanoparticles. I synthesized FITC-doped silica nanoparticles conjugated CD4 antibody 10 times brighter than FITC-conjugated CD45 antibody. With the difference of intensity of two fluorescent dyes, we measured two parameters by using only a single detector and laser. Most experiments were achieved with mu FACS (microfabricated fluorescence-activated cell sorter) on an inverted microscope (IX71, Olympus). In conclusion, this method enables us to discriminate the difference between CD4 and CD45 in an intensity domain simultaneously. Furthermore, this technique would make it possible develop much cheaper and smaller devices which can count the number of CD4 T-cells.
C1 [Yun, Hoyoung; Bang, Hyunwoo; Lee, Won Gu; Lee, Joonmo; Han, Dong-Chul] Seoul Natl Univ, Sch Mech & Aerosp Engn, Seoul 151, South Korea.
   [Lim, Hyunchang] Seoul Natl Univ, Dept Chem, Seoul, South Korea.
   [Park, Junha; Cho, Keunchang; Chung, Chanil; Chang, Jun Keun] Inc, Digital Bio Technol, Seoul, South Korea.
   [Riaz, Asif] Univ Calif, Dept Bioengn, Berkeley, CA 94607 USA.
RP Yun, H (reprint author), Seoul Natl Univ, Sch Mech & Aerosp Engn, Seoul 151, South Korea.
OI Lee, Won Gu/0000-0003-1473-0672
FU Intelligent Microsystem Center; Korea Ministry Of Commerce, Industry and
   Energy
FX This research has been supported by the Intelligent Microsystem Center
   (IMC; http://www.microsystem.re.kr), which carries out one of the 21st
   century's Frontier R&D Projects sponsored by the Korea Ministry Of
   Commerce, Industry and Energy
CR Bang HW, 2006, MICROSYST TECHNOL, V12, P746, DOI 10.1007/s00542-005-0076-9
   Bentwich Z, 2005, PLOS MED, V2, P595, DOI 10.1371/journal.pmed.0020214
   Bindhu CV, 1996, J PHYS D APPL PHYS, V29, P1074, DOI 10.1088/0022-3727/29/4/022
   Cohen J, 2004, SCIENCE, V304, P1936, DOI 10.1126/science.304.5679.1936
   COPPETA JR, 1996, 960539 AIAA, P1
   Glencross D, 2002, CYTOMETRY, V50, P69, DOI 10.1002/cyto.10068
   GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D
   GREVE B, 2004, BUSINESS BRIEFING LO, P32
   GREVE B, 2004, BUSINESS BRIEFING LO, P34
   HUGHES J, 2003, CURR ALLERGY CLIN IM, V16
   Janossy G, 2002, CYTOMETRY, V50, P78, DOI 10.1002/cyto.10082
   Janossy G, 2002, CLIN DIAGN LAB IMMUN, V9, P1085, DOI 10.1128/CDLI.9.5.1085-1094.2002
   Janossy G, 2000, BRIT J HAEMATOL, V111, P1198, DOI 10.1046/j.1365-2141.2000.02433.x
   Qhobosheane M, 2001, ANALYST, V126, P1274, DOI 10.1039/b101489g                                                                
   Rodriguez WR, 2005, PLOS MED, V2, P663, DOI 10.1371/journal.pmed.0020182
   Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+
   Santra S, 2004, CHEM COMMUN, P2810, DOI 10.1039/b411916a
   Santra S, 2006, J LUMIN, V117, P75, DOI 10.1016/j.jlumin.2005.04.008
   STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4
   Xu H, 2003, J BIOMED MATER RES A, V66A, P870, DOI 10.1002/jbm.a.10057
   ZHAO XJ, 2004, ADV MAT, V16
   Zhu NN, 2003, ANAL CHIM ACTA, V481, P181, DOI 10.1016/S0003-2670(03)00123-5
NR 22
TC 0
Z9 0
U1 1
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 978-0-8194-6524-5
J9 PROC SPIE
PY 2007
VL 6416
AR 641605
DI 10.1117/12.695975
PG 8
WC Engineering, Biomedical; Nanoscience & Nanotechnology
SC Engineering; Science & Technology - Other Topics
GA BGB85
UT WOS:000245945900004
DA 2018-01-05
ER

PT J
AU Lam, Y
   Alam, MS
   Zauscher, S
AF Lam, Yee
   Alam, Munir S.
   Zauscher, Stefan
TI Molecular-recognition force spectroscopy of induced-fit antibody binding
   to HIV-1 env gp120 and a nano-mechanical approach to understanding
   neutralizing antibody unbinding behavior
SO BIOPHYSICAL JOURNAL
LA English
DT Meeting Abstract
CT 51st Annual Meeting of the Biophysical-Society
CY MAR 03-07, 2007
CL Baltimore, MD
SP Biophys Soc
C1 Duke Univ, Durham, NC USA.
RI Zauscher, Stefan/C-3947-2008
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD JAN
PY 2007
SU S
BP 514A
EP 514A
PG 1
WC Biophysics
SC Biophysics
GA 132WA
UT WOS:000243972403254
DA 2018-01-05
ER

PT J
AU Zhou, M
   Ghosh, I
AF Zhou, Min
   Ghosh, Indraneel
TI Quantum dots and peptides: A bright future together
SO BIOPOLYMERS
LA English
DT Article
DE quantum dot; peptide; conjugate; imaging
ID RESONANCE ENERGY-TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS; IN-VIVO;
   MAMMALIAN-CELLS; LIVING CELLS; INTRACELLULAR DELIVERY; PHAGE DISPLAY;
   TAT PROTEIN; LONG-TERM; NANOCRYSTALS
AB Nanocrystalline semi-conductor materials, called quantum dots (QDs), exhibit unique optical and spectroscopic properties, which include broad absorption, narrow and tunable emission, resistance to photobleaching, strong luminescence, and long luminescent lifetimes. These remarkable properties of QDs have resulted in their use as an alternative to both small-molecule and protein flurophores in innumerable biological applications. The overlap of QDs with the rich chemistry and biology that is characteristic of the peptide arena is an emerging research area. Peptides engineered with appropriate cysteines or histidines have served as ligands for producing water soluble QDs as well as for tagging protein ligands and biosensors to QD surfaces. Incorporation of cell-penetrating peptides on QD surfaces has allowed for the translocation of functionalized QDs into cells for intracellular imaging applications. QDs containing fluorescently labeled peptide substrates have shown utility in the development of novel protease assays. Moreover, QD labeled peptides that serve as ligands for cellular receptors provide an alternative to antibody mediated imaging at the whole-cell and single molecule level to study receptor distributiona nd trafficking. This review highlights the overlap between QD and peptide chemistry and speculates on future research directions. (c) 2006 Wiley Periodicals, Inc.
C1 Univ Arizona, Dept Chem, Tucson, AZ 85721 USA.
RP Ghosh, I (reprint author), Univ Arizona, Dept Chem, Tucson, AZ 85721 USA.
EM ghosh@email.arizona.edu
CR Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399
   Cai WB, 2006, NANO LETT, V6, P669, DOI 10.1021/nl052405t
   Chan PM, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni162
   Chan WCW, 2000, PROC SPIE, V3924, P2, DOI 10.1117/12.384243
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3                                                   
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chang E, 2005, BIOCHEM BIOPH RES CO, V334, P1317, DOI 10.1016/j.bbrc.2005.07.028
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Choi SH, 2006, J PHOTOCH PHOTOBIO A, V179, P135, DOI 10.1016/j.jphotochem.2005.08.004
   Clapp AR, 2004, J AM CHEM SOC, V126, P301, DOI 10.1021/ja037088b
   Clapp AR, 2005, J AM CHEM SOC, V127, P18212, DOI 10.1021/ja054630i
   Claveria C, 2004, J BIOL CHEM, V279, P1368, DOI 10.1074/jbc.M309819200
   Creaser SP, 2002, J AM CHEM SOC, V124, P2444, DOI 10.1021/ja017671x
   Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525
   de la Fuente JM, 2005, CHEMBIOCHEM, V6, P989, DOI 10.1002/cbic.200500071
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   Ding SY, 2003, NANO LETT, V3, P1581, DOI 10.1021/nl034578t
   Dubertret B, 2002, SCIENCE, V298, P1759, DOI 10.1126/science.1077194
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fillon YA, 2005, J AM CHEM SOC, V127, P11798, DOI 10.1021/ja052377g
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x
   Gao XH, 2002, J BIOMED OPT, V7, P532, DOI 10.1117/1.1506706
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Gerion D, 2001, J PHYS CHEM B, V105, P8861, DOI 10.1021/jp0105488
   GIEBEL LB, 1995, BIOCHEMISTRY-US, V34, P15430, DOI 10.1021/bi00047a006
   Giepmans BNG, 2005, NAT METHODS, V2, P743, DOI 10.1038/NMETH791
   Goldman ER, 2004, ANAL CHEM, V76, P684, DOI 10.1021/ac035083r
   Goldman ER, 2005, J AM CHEM SOC, V127, P6744, DOI 10.1021/ja0436771
   Gomez N, 2005, TALANTA, V67, P462, DOI 10.1016/j.talanta.2005.06.041
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Groc L, 2004, NAT NEUROSCI, V7, P695, DOI 10.1038/nn1270
   Hansen JA, 2006, J AM CHEM SOC, V128, P2228, DOI 10.1021/ja060005h
   HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053                                             
   Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562                                                               
   Hoshino A, 2004, MICROBIOL IMMUNOL, V48, P985, DOI 10.1111/j.1348-0421.2004.tb03621.x                                              
   Howarth M, 2005, P NATL ACAD SCI USA, V102, P7583, DOI 10.1073/pnas.0503125102
   Hussey SL, 2002, J AM CHEM SOC, V124, P6265, DOI 10.1021/ja0258733
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Kim JH, 2004, SENSOR ACTUAT B-CHEM, V102, P315, DOI 10.1016/j.snb.2004.04.107
   Kircher MF, 2004, BIOCONJUGATE CHEM, V15, P242, DOI 10.1021/bc034151d
   Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Lidke DS, 2004, NAT BIOTECHNOL, V22, P198, DOI 10.1038/nbt929
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Mattheakis LC, 2004, ANAL BIOCHEM, V327, P200, DOI 10.1016/j.ab.2004.01.031
   Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y
   Medintz IL, 2006, NAT MATER, V5, P581, DOI 10.1038/nmat1676
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   Meyer SC, 2006, CHEM BIOL DRUG DES, V68, P3, DOI 10.1111/j.1747-0285.2006.00401.x
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025                                                             
   NORRIS DJ, 1994, PHYS REV LETT, V72, P2612, DOI 10.1103/PhysRevLett.72.2612
   Norris DJ, 1996, PHYS REV B, V53, P16338, DOI 10.1103/PhysRevB.53.16338
   Parak WJ, 2003, NANOTECHNOLOGY, V14, pR15, DOI 10.1088/0957-4484/14/7/201
   Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m                                                               
   Pham W, 2004, BIOCONJUGATE CHEM, V15, P1403, DOI 10.1021/bc049924s
   PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0
   Pinaud F, 2004, J AM CHEM SOC, V126, P6115, DOI 10.1021/ja031691c
   Porkka K, 2002, P NATL ACAD SCI USA, V99, P7444, DOI 10.1073/pnas.062189599
   Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593                                                        
   RodriguezViejo J, 1997, APPL PHYS LETT, V70, P2132, DOI 10.1063/1.119043
   ROSENBERG MB, 1986, J NEUROCHEM, V46, P641, DOI 10.1111/j.1471-4159.1986.tb13015.x
   Rosenthal SJ, 2001, NAT BIOTECHNOL, V19, P621, DOI 10.1038/90213                                                                   
   Rozenzhak SM, 2005, CHEM COMMUN, P2217, DOI 10.1039/b418454h
   Sandros MG, 2005, CHEM COMMUN, P2832, DOI 10.1039/b501315a
   Sandros MG, 2005, J AM CHEM SOC, V127, P12198, DOI 10.1021/ja054166h
   Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b
   Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140
   Schlecht S, 2005, CHEM MATER, V17, P809, DOI 10.1021/cm048417h
   Schwartz DA, 2003, J AM CHEM SOC, V125, P13205, DOI 10.1021/ja036811v
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shi LF, 2006, J AM CHEM SOC, V128, P10378, DOI 10.1021/ja063509o
   Silver J, 2005, NANO LETT, V5, P1445, DOI 10.1021/nl050808n
   Skerra A, 1999, BIOMOL ENG, V16, P79, DOI 10.1016/S1050-3862(99)00033-9
   Smith AM, 2004, ANALYST, V129, P672, DOI 10.1039/b404498n
   Stockholm D, 2005, J MOL BIOL, V346, P215, DOI 10.1016/j.jmb.2004.11.039
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vu TQ, 2005, NANO LETT, V5, P603, DOI 10.1021/nl047977c
   Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933                                                                    
   Winter JO, 2001, ADV MATER, V13, P1673, DOI 10.1002/1521-4095(200111)13:22<1673::AID-ADMA1673>3.0.CO;2-6                    
   Wu XY, 2003, NAT BIOTECHNOL, V21, P452
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xu CJ, 2006, BIOCHEM BIOPH RES CO, V344, P931, DOI 10.1016/j.bbrc.2006.030225
   YOSHIHARA T, 1992, INT J CANCER, V51, P620, DOI 10.1002/ijc.2910510419
   Young SH, 2006, AM J PHYSIOL-CELL PH, V290, pC728, DOI 10.1152/ajpcell.00310.2005
   Zhang CY, 2005, NAT MATER, V4, P826, DOI 10.1038/nmat1508
   Zhang CY, 2006, J AM CHEM SOC, V128, P5324, DOI 10.1021/ja060537y
   Zhou M, 2004, ORG LETT, V6, P3561, DOI 10.1021/ol0485262
   Zhou M, 2004, J AM CHEM SOC, V126, P734, DOI 10.1021/ja036634y
   ZHOU M, 2007, IN PRESS BIOCONJUGAT
NR 94
TC 80
Z9 82
U1 1
U2 44
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PY 2007
VL 88
IS 3
BP 325
EP 339
DI 10.1002/bip.20655
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 160JT
UT WOS:000245937400001
PM 17167795
OA gold
DA 2018-01-05
ER

PT J
AU Lee, YR
   Yu, J
AF Lee, Y. R.
   Yu, J.
TI Amphiphilic peptides with acridinylated lysine showed sub-nanomolar
   affinity against Rev responsive element (RRE) RNA of HIV-1
SO BIOPOLYMERS
LA English
DT Meeting Abstract
CT 20th American-Peptide-Society Symposium
CY JUN 26-30, 2007
CL Montreal, CANADA
SP Amer Peptide Soc
C1 Seoul Natl Univ, Dept Chem & Educ, Seoul 151742, South Korea.
EM yiyeong@hanmail.net; jhoonyu@snu.ac.kr
NR 0
TC 0
Z9 0
U1 0
U2 0
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PY 2007
VL 88
IS 4
SI SI
BP 621
EP 621
PG 1
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 181GT
UT WOS:000247425900430
DA 2018-01-05
ER

PT J
AU Winters-Hilt, S
   Davis, A
   Amin, I
   Morales, E
AF Winters-Hilt, Stephen
   Davis, Amanda
   Amin, Iftekhar
   Morales, Eric
TI Nanopore current transduction analysis of protein binding to
   non-terminal and terminal DNA regions: analysis of transcription factor
   binding, retroviral DNA terminus dynamics, and retroviral integrase-DNA
   binding
SO BMC BIOINFORMATICS
LA English
DT Article
AB Background: Synthetic transcription factors (STFs) promise to offer a powerful new therapeutic against Cancer, AIDS, and genetic disease. Currently, 10% of drugs are of this type, including salicylate and tamoxifen. STFs that can appropriately target (and release) their transcription factor binding sites on native genomic DNA provide a means to directly influence cellular mRNA production. An effective mechanism for screening amongst transcription factor (TF) candidates would itself be highly valued, and such may be possible with nanopore cheminformatics methods.
   Results: It is hypothesized that binding targets on channel-captured molecules, that are well away from the channel-captured region, can be monitored insofar as their binding status, or history, is concerned. The first set of experiments we perform to explore this "transduction" hypothesis involve non-terminal dsDNA binding to protein (DNA TATA box receptor binding to TBP), where we show new experimental results and application of a new cheminformatics data analysis method. In the second series of experiments to explore the transduction hypothesis we examine terminal (blunt-ended) dsDNA binding to protein. We show experimental results before and after introduction of HIV's DNA integrase to a solution of bifunctional "Y" shaped aptamers that have an HIV consensus terminus exposed for interaction.
   Conclusion: X-ray crystallographic studies have guided our understanding of DNA structure for almost a century. It is still difficult, however, to translate the sequence-directed curvature information obtained through these tools to actual systems found in solution. With a nanopore detector the sequence-dependent conformation kinetics of DNA, especially at the DNA terminus, can be studied in a new way while still in solution and on a single molecule basis.
C1 [Winters-Hilt, Stephen; Amin, Iftekhar] Univ New Orleans, Dept Comp Sci, New Orleans, LA 70148 USA.
   [Winters-Hilt, Stephen; Davis, Amanda; Morales, Eric] Childrens Hosp, Res Inst Children, New Orleans, LA 70118 USA.
RP Winters-Hilt, S (reprint author), Univ New Orleans, Dept Comp Sci, New Orleans, LA 70148 USA.
EM winters@cs.uno.edu; adavis@chnola-research.org; iftekhar.amin@gmail.com;
   emorales@chnola-research.org
FU NLM NIH HHS [5K22LM008794, K22 LM008794]
CR Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5                                                   
   Apel PY, 2001, NUCL INSTRUM METH B, V184, P337, DOI 10.1016/S0168-583X(01)00722-4                                                   
   Bezrukov SM, 2000, J MEMBRANE BIOL, V174, P1, DOI 10.1007/s002320001026                                                           
   BEZRUKOV SM, 1994, NATURE, V370, P279, DOI 10.1038/370279a0
   Branton D, 2002, NATO SCI S PRT 3 HI, V87, P177
   Chen P, 2004, NANO LETT, V4, P1333, DOI 10.1021/nl0494001
   Cormen TH, 1989, INTRO ALGORITHMS
   Coulter WH, 1957, P NAT EL C, P1034
   Deamer DW, 2000, TRENDS BIOTECHNOL, V18, P147, DOI 10.1016/S0167-7799(00)01426-8
   Durbin R, 1998, BIOL SEQUENCE ANAL P, Vxi, P356
   Ken Healy K, 2006, THESIS NATL U IRELAN
   Heins E, 2005, 49 BIOPH SOC M LONG
   Heng J, 2003, P IEDM 8 10 DEC, P3221
   Henrickson SE, 2000, PHYS REV LETT, V85, P3057, DOI 10.1103/PhysRevLett.85.3057
   Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836
   Howorka S, 2001, NAT BIOTECHNOL, V19, P636, DOI 10.1038/90236
   Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770                                                        
   Landry M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S7-S12
   Latchman DS, 1998, GENE REGULATION EUKA
   Latchman DS, 2000, TRANSCRIPTION FACTOR
   Latchman DS, 1998, EUKARYOTIC TRANSCRIP
   Li J, 2001, NATURE, V412, P166, DOI 10.1038/35084037
   Mara A, 2004, NANO LETT, V4, P497, DOI 10.1021/nl035141o
   Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079
   Meller A, 2002, ELECTROPHORESIS, V23, P2583, DOI 10.1002/1522-2683(200208)23:16<2583::AID-ELPS2583>3.0.CO;2-H
   Meller A, 2001, PHYS REV LETT, V86, P3435, DOI 10.1103/PhysRevLett.86.3435
   Mitsui D, 2006, PHYS REV LETT, V96
   Siwy Z, 2003, APPL PHYS A-MATER, V76, P781, DOI 10.1007/s00339-002-1982-7
   Stein D, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.276106
   Stein DM, 2004, REV SCI INSTRUM, V75, P900, DOI 10.1063/1.1666986
   Storm AJ, 2003, NAT MATER, V2, P537, DOI 10.1038/nmat941
   Thomson K, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S7-S11
   Vercoutere W, 2001, NAT BIOTECHNOL, V19, P248, DOI 10.1038/85696
   Vercoutere WA, 2003, NUCLEIC ACIDS RES, V31, P1311, DOI 10.1093/nar/gkg218
   Winters-Hilt S, 2003, BIOPHYS J, V84, P967, DOI 10.1016/S0006-3495(03)74913-3                                                   
   Winters-Hilt S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S14
   Winters-Hilt S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S22
   Winters-Hilt S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S21
   Winters-Hilt S, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S7-S9
   Winters-Hilt S, 2004, DNA CELL BIOL
   Winters-Hilt S, 2003, 3 INT C UNS PROBL NO, P355
   Winters-Hilt S, 2004, SPIE 2 INT S FLUCT N
NR 42
TC 5
Z9 5
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PY 2007
VL 8
SU 7
AR S10
DI 10.1186/1471-2105-8-S7-S10
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA V23BB
UT WOS:000208317200010
PM 18047709
OA gold
DA 2018-01-05
ER

PT S
AU Delehanty, JB
   Medintz, IL
   Pons, T
   Dawson, PE
   Brunel, FM
   Mattoussi, H
AF Delehanty, James B.
   Medintz, Igor L.
   Pons, Thomas
   Dawson, Philip E.
   Brunel, Florence M.
   Mattoussi, Hedi
BE Osinski, M
   Jovin, TM
   Yamamoto, K
TI Selective cellular delivery of self-assembled quantum dot-peptide
   bioconjugates
SO COLLOIDAL QUANTUM DOTS FOR BIOMEDICAL APPLICATIONS II
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Conference on Colloidal Quantum Dots for Biomedical Applications II
CY JAN 20-23, 2007
CL San Jose, CA
SP SPIE
DE quantum dot; fluorophore; peptide; HIV-1 Tat; cellular labeling;
   transmembrane; endocytosis; translocation
ID RESONANCE ENERGY-TRANSFER; ARGININE-RICH PEPTIDES; TAT-FUSION PROTEINS;
   PENETRATING PEPTIDES; INTRACELLULAR DELIVERY; LONG-TERM; CELLS;
   NANOCRYSTALS; DONORS; MACROPINOCYTOSIS
AB We demonstrate the selective delivery of self-assembled luminescent semiconductor quantum dot (QD)-peptide bioconjugates into several eukaryotic cell lines. A 23-mer hetero-bifunctional peptide bearing a positively-charged oligoarginine domain and a terminal polyhistidine tract was synthesized and used to mediate the cellular internalization of the QD-bioconjugates. The polyhistidine tract allows the peptide to self-assemble onto the QD surface via metal-ion coordination while the oligoarginine domain mediates the specific uptake of the QD-bioconjugates via electrostatic interactions with cell surface receptors. In both HEK 293T/17 and COS-1 cells, this peptide-mediated delivery is concentration-dependent in terms of both the QD concentration and the peptide:QD ratio. Intracellularly, the QD signal is punctate in appearance and some, but not all, of the QDs are located within recycling endosomes as evidenced by their colocalization with transferrin. In both cell lines, the QD-bioconjugates elicit minimal cytotoxicity within the timeframe required for adequate cellular uptake. The specificity of this delivery strategy is demonstrated by performing a multicolor QD labeling, wherein the presence or absence of the peptide on the QD surface controls cellular uptake.
C1 [Delehanty, James B.; Medintz, Igor L.] US Naval Res Lab, Ctr Bio Mol Sci & Engn, Code 6900, Washington, DC 20375 USA.
   [Pons, Thomas; Mattoussi, Hedi] US Naval Res Lab, Opt Sci Div, Washington, DC 20375 USA.
   [Dawson, Philip E.; Brunel, Florence M.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.
   [Dawson, Philip E.; Brunel, Florence M.] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   [Dawson, Philip E.; Brunel, Florence M.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   [Pons, Thomas] Johns Hopkins Univ, Chem & Biomol Engn Dept, Baltimore, MD 21218 USA.
RP Delehanty, JB (reprint author), US Naval Res Lab, Ctr Bio Mol Sci & Engn, Code 6900, Washington, DC 20375 USA.
EM jdelehanty@cbmse.nrl.navy.mil; hedimat@ccs.nrl.navy.mil
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Alivisatos P, 2004, NAT BIOTECHNOL, V22, P47, DOI 10.1038/nbt927
   Bentzen EL, 2005, BIOCONJUGATE CHEM, V16, P1488, DOI 10.1021/bc0502006
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Clapp AR, 2004, J AM CHEM SOC, V126, P301, DOI 10.1021/ja037088b
   Clapp AR, 2005, J AM CHEM SOC, V127, P1242, DOI 10.1021/ja045676z
   Delehanty JB, 2006, BIOCONJUGATE CHEM, V17, P920, DOI 10.1021/bc060044i
   Delehanty JB, 2004, ANAL CHEM, V76, P7323, DOI 10.1021/ac049259g
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Goldman ER, 2005, J AM CHEM SOC, V127, P6744, DOI 10.1021/ja0436771
   Goldman ER, 2005, ANAL CHIM ACTA, V534, P63, DOI 10.1016/j.aca.2004.03.079
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9
   Lovric J, 2005, J MOL MED-JMM, V83, P377, DOI 10.1007/s00109-004-0629-x
   Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y
   Medintz IL, 2005, ADV MATER, V17, P2450, DOI 10.1002/adma.200500722
   Medintz IL, 2004, P NATL ACAD SCI USA, V101, P9612, DOI 10.1073/pnas.0403343101
   Medintz IL, 2004, J AM CHEM SOC, V126, P30, DOI 10.1021/ja037970h
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Parak WJ, 2003, NANOTECHNOLOGY, V14, pR15, DOI 10.1088/0957-4484/14/7/201
   Parak WJ, 2005, NANOTECHNOLOGY, V16, pR9, DOI 10.1088/0957-4484/16/2/R01
   PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253
   Pooga M, 1998, FASEB J, V12, P67
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Saar K, 2005, ANAL BIOCHEM, V345, P55, DOI 10.1016/j.ab.2005.07.033
   Sapsford KE, 2004, LANGMUIR, V20, P7720, DOI 10.1021/la049263n
   SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180
   Shiohara A, 2004, MICROBIOL IMMUNOL, V48, P669, DOI 10.1111/j.1348-0421.2004.tb03478.x                                              
   Voura EB, 2004, NAT MED, V10, P993, DOI 10.1038/nm1096
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
NR 41
TC 0
Z9 0
U1 0
U2 3
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
EI 1996-756X
BN 978-0-8194-6561-0
J9 PROC SPIE
PY 2007
VL 6448
AR 64480U
DI 10.1117/12.700768
PG 10
WC Engineering, Biomedical; Nanoscience & Nanotechnology
SC Engineering; Science & Technology - Other Topics
GA BGF77
UT WOS:000246495800015
DA 2018-01-05
ER

PT J
AU Lori, F
   Calarota, SA
   Lisziewicz, J
AF Lori, F.
   Calarota, S. A.
   Lisziewicz, J.
TI Nanochemistry-based immunotherapy for HIV-1
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE HIV-1; DermaVir; topical vaccine administration; dendritic cells;
   cellular immunity; cytokines; molecular adjuvants
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR IMMUNE-RESPONSES; MEMORY T-CELLS;
   STRUCTURED TREATMENT INTERRUPTIONS; ACTIVE ANTIRETROVIRAL THERAPY;
   PROLONGED VIRAL SUPPRESSION; IN-VIVO; DNA VACCINE; RHESUS MACAQUES;
   MEDIATED-IMMUNITY
AB Highly active antiretroviral treatment (HAART), i.e. the combination of three or more drugs against human immunodeficiency virus type 1 (HIV-1), has greatly improved the clinical outcome of HIV-1-infected individuals. However, HAART is unable to reconstitute HIV-specific immunity and eradicate the virus. Several observations in primate models and in humans support the notion that cell-mediated immunity can control viral replication and slow disease progression. Thus, besides drugs, an immunotherapy that induces long-lasting HIV-specific T-cell responses could play a role in the treatment of HIV/AIDS. To induce such immune responses, DermaVir Patch has been developed. DermaVir consists of an HIV-1 antigenen-coding plasmid DNA that is chemically formulated in a nanoparticle. DermaVir is administered under a patch after a skin preparation that supports the delivery of the nanoparticle to Langerhans cells (LC). Epidermal LC trap and transport the nanomedicine to draining lymph nodes. While in transit, LC mature into dendritic cells (DC), which can efficiently present the DNA-encoded antigens to naive T-cells for the induction of cellular immunity. Pre-clinical studies and Phase I clinical testing of DermaVir in HIV-1-infected individuals have demonstrated the safety and tolerability of DermaVir Patch. To further modulate cellular immunity, molecular adjuvants might be added into the nanoparticle. DermaVir Patch represents a new nanomedicine platform for immunotherapy of HIV/AIDS. In this review, the antiviral activity of Derma-Vir-induced cellular immunity is discussed. Furthermore, the action of some cytokines currently being tested as adjuvants are highlighted and the adjuvant effect of cytokine plasmid DNA included in the DennaVir nanoparteile is reviewed.
C1 Genet Immun, H-1027 Budapest, Hungary.
   Genet Immun, Washington, DC USA.
   RIGHT, Pavia, Italy.
   RIGHT, Bethesda, MD USA.
RP Lisziewicz, J (reprint author), Genet Immun, Fo Utca 68, H-1027 Budapest, Hungary.
EM lisziewj@geneticimmunity.com
CR Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486
   Barouch DH, 1998, J IMMUNOL, V161, P1875
   Bieber T, 2002, J CONTROL RELEASE, V82, P441, DOI 10.1016/S0168-3659(02)00129-3
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Boyer JD, 2005, J MED PRIMATOL, V34, P262, DOI 10.1111/j.1600-0684.2005.00124.x
   Boyer JD, 2000, AIDS, V14, P1515, DOI 10.1097/00002030-200007280-00007
   Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874
   Calarota SA, 2004, IMMUNOL REV, V199, P84, DOI 10.1111/j.0105-2896.2004.00150.x
   CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401
   CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395
   Fehervari Z, 2004, J CLIN INVEST, V114, P1209, DOI 10.1172/JCI200434495
   Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14                                                          
   Finzi D, 1999, NAT MED, V5, P512
   Garcia F, 2005, J INFECT DIS, V191, P1680, DOI 10.1086/429340                                                                  
   Giri M, 2004, CLIN MICROBIOL REV, V17, P370, DOI 10.1128/CMR.17.2.370-389.2004
   Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828                                        
   Gurunathan S, 1998, J IMMUNOL, V161, P4563
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Huster KM, 2004, P NATL ACAD SCI USA, V101, P5610, DOI 10.1073/pnas.0308054101
   Jacobson EL, 1996, P NATL ACAD SCI USA, V93, P10405, DOI 10.1073/pnas.93.19.10405
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Kaech SM, 2002, NAT REV IMMUNOL, V2, P251, DOI 10.1038/nri778
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   Kaufmann DE, 2004, PLOS MED, V1, P137, DOI 10.1371/journal.pmed.0010036
   Kaul R, 2001, J CLIN INVEST, V107, P1303, DOI 10.1172/JCI12433                                                                
   Kaul R, 2001, J CLIN INVEST, V107, P341, DOI 10.1172/JCI10714                                                                
   Keating SM, 2005, J IMMUNOL, V175, P5675, DOI 10.4049/jimmunol.175.9.5675                                                     
   Kim JJ, 1997, J IMMUNOL, V158, P816
   Kim JJ, 1999, J MED PRIMATOL, V28, P214, DOI 10.1111/j.1600-0684.1999.tb00272.x                                              
   Kim JJ, 2000, J VIROL, V74, P3427, DOI 10.1128/JVI.74.7.3427-3429.2000
   Kim JJ, 1997, NAT BIOTECHNOL, V15, P641
   Kim JJ, 1998, EUR J IMMUNOL, V28, P1089, DOI 10.1002/(SICI)1521-4141(199803)28:03<1089::AID-IMMU1089>3.0.CO;2-L
   Kim JJ, 2001, VACCINE, V19, P2496, DOI 10.1016/S0264-410X(00)00479-5                                                   
   Kim JJ, 2000, J INTERF CYTOK RES, V20, P311
   KINTER AL, 1995, J IMMUNOL, V154, P2448
   Kovacs JA, 1996, NEW ENGL J MED, V335, P1350, DOI 10.1056/NEJM199610313351803                                                     
   Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675
   Kursar M, 2002, J EXP MED, V196, P1585, DOI 10.1084/jem.20011347
   Kutzler MA, 2005, J IMMUNOL, V175, P112, DOI 10.4049/jimmunol.175.1.112                                                      
   LabatMoleur F, 1996, GENE THER, V3, P1010
   Lisziewicz J, 2005, AIDS, V19, P35, DOI 10.1097/00002030-200501030-00004
   Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114
   Lisziewicz J, 2005, J INVEST DERMATOL, V124, P160, DOI 10.1111/j.0022-202X.2004.23535.x
   Lisziewicz J, 2001, J VIROL, V75, P7621, DOI 10.1128/JVI.75.16.7621-7628.2001
   Lori F, 2000, SCIENCE, V290, P1591, DOI 10.1126/science.290.5496.1591                                                   
   Lori F, 2005, VACCINE, V23, P2030, DOI 10.1016/j.vaccine.2005.01.004
   Lori F, 2001, JAMA-J AM MED ASSOC, V286, P2981, DOI 10.1001/jama.286.23.2981
   Lu W, 2004, NAT MED, V10, P1359, DOI 10.1038/nm1147
   Lu W, 2003, NAT MED, V9, P27, DOI 10.1038/nm806
   Mendoza RB, 1997, J IMMUNOL, V159, P5777
   Mohamadzadeh M, 2001, J EXP MED, V194, P1013, DOI 10.1084/jem.194.7.1013                                                          
   Moore AC, 2002, J VIROL, V76, P243, DOI 10.1128/JVI.76.1.243-250.2002
   Mueller YM, 2003, BLOOD, V101, P1024, DOI 10.1182/blood-2002-07-1957
   Orenstein JM, 2000, AIDS, V14, P1709, DOI 10.1097/00002030-200008180-00004
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402                                                     
   Perales MA, 1996, AIDS RES HUM RETROV, V12, P659, DOI 10.1089/aid.1996.12.659
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Prayaga SK, 1997, VACCINE, V15, P1349, DOI 10.1016/S0264-410X(97)00036-4
   Reece WHH, 2004, NAT MED, V10, P406, DOI 10.1038/nm1009
   Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314
   ROWLANDJONES SL, 1999, CURR BIOL, V9, P248
   SAKATA T, 1990, J LEUKOCYTE BIOL, V48, P205
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Santra S, 2000, EUR J IMMUNOL, V30, P2650, DOI 10.1002/1521-4141(200009)30:9<2650::AID-IMMU2650>3.0.CO;2-K                     
   Schadeck EB, 2006, VACCINE, V24, P4677, DOI 10.1016/j.vaccine.2005.10.035
   Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857                                                    
   Seaman MS, 2004, J VIROL, V78, P206, DOI 10.1128/JVI.78.1.206-215.2004
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a                                                                 
   Sin JI, 2000, CLIN DIAGN LAB IMMUN, V7, P751, DOI 10.1128/CDLI.7.5.751-758.2000
   SMARA RR, 2001, SCIENCE, V292, P69
   Stellbrink HJ, 1998, ANTIVIR THER, V3, P209
   Stellbrink HJ, 2002, AIDS, V16, P1479, DOI 10.1097/00002030-200207260-00004
   Stone GW, 2006, J VIROL, V80, P1762, DOI 10.1128/JVI.80.4.1762-1772.2006
   Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098
   TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343
   Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9
   Tsuji T, 1997, J IMMUNOL, V158, P4008
   Tsuji T, 1997, EUR J IMMUNOL, V27, P782, DOI 10.1002/eji.1830270329                                                          
   WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002
   Wee EGT, 2002, J GEN VIROL, V83, P75, DOI 10.1099/0022-1317-83-1-75                                                       
   Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889
   Wherry EJ, 2004, J VIROL, V78, P5535, DOI 10.1128/JVI.78.11.5335-5545.2004
   WILES MV, 1992, EUR J IMMUNOL, V22, P1037, DOI 10.1002/eji.1830220424
   Xin KQ, 1999, VACCINE, V17, P858, DOI 10.1016/S0264-410X(98)00271-0
   Xin KQ, 1998, IMMUNOLOGY, V94, P438, DOI 10.1046/j.1365-2567.1998.00533.x
   Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6
NR 89
TC 23
Z9 25
U1 1
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2007
VL 14
IS 18
BP 1911
EP 1919
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 192LM
UT WOS:000248203300001
PM 17691933
DA 2018-01-05
ER

PT J
AU Fabris, D
   Chaudhari, P
   Hagan, N
   Turner, K
AF Fabris, Daniele
   Chaudhari, Prajakta
   Hagan, Nathan
   Turner, Kevin
TI Functional investigations of retroviral protein-ribonucleic acid
   complexes by nanospray Fourier transform ion cyclotron resonance mass
   spectrometry
SO EUROPEAN JOURNAL OF MASS SPECTROMETRY
LA English
DT Article; Proceedings Paper
CT 17th International Mass Spectrometry Conference
CY AUG 27-SEP 01, 2006
CL Prague, CZECH REPUBLIC
SP Czech Spectroscop Soc, Mass Spectrometry Grp, Acad Sci Czech Republic, Inst Microbiol
DE hIV-1; RNA isomerization; RNA conformation; ribonucleoprotein;
   protein-nucleic acids assembly; non-covalent complex; protein binding;
   chaperone; competitive binding; ESI-FT-ICR
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 NUCLEOCAPSID PROTEIN; CHAPERONE
   ACTIVITY; RNA DIMERIZATION; ELEMENTS; SITE
AB Nanospray-FT-ICR has been employed to investigate the processes of genome dimerization, selection, and packaging in human immunodifficiency virus type 1, which are mediated by specific interactions between the nucleocapsid protein (NQ and the structural elements formed by the genome's packaging signal (Psi-ribonucleic acid (RNA)]. This analytical platform allowed for the unambiguous characterization of all the non-covalent complexes formed in vitro by simultaneous RNA-RNA and protein-RNA binding equilibria. Competitive binding experiments involving the isolated RNA elements were completed to evaluate their ability to sustain specific protein interactions. In similar fashion, ad hoc RNA mutants were used to locate two distinct binding sites on the apical loop and stem-bulge of the monomeric stemloop 1 (SL1) domain, which is responsible for initiating the dimerization process. The stem-bulge motifs provided viable binding sites in both the kissing-loop (KL) and the extended duplex forms of dimeric SL1, whereas the latter included additional sites corresponding to the A-bulge motifs that flank the annealed palindromes. A cross-linking approach using pre-derivatized, photo - cross-linkable NC demonstrated that the SL3 domain was the preferred site for protein binding in the context of full-length Psi-RNA. This concerted strategy is expected to provide new valuable insight into the effects induced by the global folding of Psi-RNA on its ability to interact with the NC protein during genome dimerization, selection and packaging.
C1 Univ Maryland, Dept Chem & Biochem, Baltimore, MD 21250 USA.
RP Fabris, D (reprint author), Univ Maryland, Dept Chem & Biochem, 1000 Hilltop Circle, Baltimore, MD 21250 USA.
FU NIGMS NIH HHS [R01-GM643208]
CR Aleksandrov M.L., 1984, DOKL AKAD NAUK SSSR, V277, P379
   CLEVER J, 1995, J VIROL, V69, P2101
   COFFIN JM, 1997, RETROVIRUSES
   COMISAROW MB, 1974, CHEM PHYS LETT, V25, P282, DOI 10.1016/0009-2614(74)89137-2
   DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y
   Fisher RJ, 2006, NUCLEIC ACIDS RES, V34, P472, DOI 10.1093/nar/gkj442
   GANEM B, 1991, J AM CHEM SOC, V113, P6294, DOI 10.1021/ja00016a069                                                             
   Hagan N, 2003, BIOCHEMISTRY-US, V42, P10736, DOI 10.1021/bi0348922
   Hagan NA, 2007, J MOL BIOL, V365, P396, DOI 10.1016/j.mb.2006.09.081
   Hendrickson CL, 1999, ANNU REV PHYS CHEM, V50, P517, DOI 10.1146/annurev.physchem.50.1.517                                               
   LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035
   Levin JG, 2005, PROG NUCLEIC ACID RE, V80, P217, DOI 10.1016/S0079-6603(05)80006-6
   Loo JA, 1997, MASS SPECTROM REV, V16, P1
   McBride MS, 1996, J VIROL, V70, P2963
   MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945
   Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635
   Turner KB, 2006, NUCLEIC ACIDS RES, V34, P1305, DOI 10.1093/nar/gkl004
   YAMASHITA M, 1984, J PHYS CHEM-US, V88, P4671, DOI 10.1021/j150664a046
NR 20
TC 7
Z9 7
U1 0
U2 3
PU IM PUBLICATIONS
PI W SUSSEX
PA 6 CHARLTON MILL, CHARLTON, CHICHESTER,, W SUSSEX PO18 0HY, ENGLAND
SN 1469-0667
J9 EUR J MASS SPECTROM
JI Eur. J. Mass Spectrom.
PY 2007
VL 13
IS 1
BP 29
EP 33
DI 10.1255/ejms.839
PG 5
WC Physics, Atomic, Molecular & Chemical; Spectroscopy
SC Physics; Spectroscopy
GA 200ZR
UT WOS:000248801800013
PM 17878535
DA 2018-01-05
ER

PT J
AU Udhrain, A
   Skubitz, KM
   Northfelt, DW
AF Udhrain, Ashish
   Skubitz, Keith M.
   Northfelt, Donald W.
TI Pegylated liposomal doxorubicin in the treatment of AIDS-related
   Kaposi's sarcoma
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE liposomal doxorubicin; pegylated liposomal doxorubicin; Kaposi's
   sarcoma; liposomal daunorubicin; liposomal anthracyclinces
ID HIV TAT GENE; TRANSGENIC MICE; DERMAL LESIONS; PHASE-II; CHEMOTHERAPY;
   VINCRISTINE; BLEOMYCIN; EFFICACY; SAFETY; TRIAL
AB Kaposi's sarcoma is a vascular tumor of skin and viscera first described in 1872. Prior to the 1980s, this disease was rarely seen in the Western world, but was quite prevalent in Sub-Saharan African countries. Since the onset of the HIV pandemic in the 1980s, the incidence of Kaposi's sarcoma has increased markedly in Africa and continues to be a significant problem in association with AIDS in Western countries. Many therapies have been demonstrated to be effective in the treatment of HIV-related Kaposi's sarcoma, including alitretinoin gel, interferon alpha, and various forms of cytotoxic chemotherapy. Antiretroviral therapy combined with cytotoxic agents has yielded significantly greater efficacy than chemotherapy alone. However, as reviewed in this report, pegylated liposomal doxorubicin has been established as the treatment of choice for patients with AIDS-associated Kaposi's sarcoma in Western countries. Compelling preclinical and clinical evidence, reviewed herein, has demonstrated that the nanoparticle (pegylated liposome) delivery system of this formulation leads to greater tumor localization of doxorubicin and consequent improved efficacy, as well as reduced toxicity.
C1 [Northfelt, Donald W.] Mayo Clin Arizona, Div Hematol Med Oncol, Phoenix, AZ USA.
   [Udhrain, Ashish] Mayo Clin Arizona, Dept Med, Phoenix, AZ USA.
   [Skubitz, Keith M.] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA.
RP Northfelt, DW (reprint author), Mayo Clin Arizona, Div Hematol Med Oncol, Phoenix, AZ USA.
EM northfelt.donald@mayo.edu
CR Allen TM, 2004, SEMIN ONCOL, V31, P5, DOI 10.1053/j.seminoncol.2004.08.004
   BERGIN C, 1995, AM J HEALTH-SYST PH, V52, P2001
   BOGNER JR, 1994, J ACQ IMMUN DEF SYND, V7, P463
   Cheung TW, 1999, CLIN CANCER RES, V5, P3432
   *DAUNOXOME, 1996, PRESCR INF
   *DOXIL, 2001, PRESCR INF
   Goebel FD, 1996, BRIT J CANCER, V73, P989, DOI 10.1038/bjc.1996.193
   Grunaug M, 1998, Eur J Med Res, V3, P13
   HARRISON M, 1995, J CLIN ONCOL, V13, P914, DOI 10.1200/JCO.1995.13.4.914                                                       
   HENGGE UR, 1993, LANCET, V342, P497, DOI 10.1016/0140-6736(93)91624-U
   Hengge UR, 2001, EUR J CANCER, V37, P878, DOI 10.1016/S0959-8049(01)00053-3                                                   
   Henry D, 2002, P AN M AM SOC CLIN, V21, p411a
   HUANG SK, 1993, AM J PATHOL, V143, P10
   James N D, 1994, Clin Oncol (R Coll Radiol), V6, P294, DOI 10.1016/S0936-6555(05)80269-9
   Krown SE, 2004, J CLIN ONCOL, V22, P399, DOI 10.1200/JCO.2004.08.064
   LOGAN DM, 1991, INT C AIDS, V7, P99
   MITSUYASU R, 1997, P AN M AM SOC CLIN, V16, pA55
   Mitsuyasu RT, 2000, ONCOLOGY-NY, V14, P867
   Newell M, 1998, AUST NZ J MED, V28, P777, DOI 10.1111/j.1445-5994.1998.tb01553.x
   Northfelt DW, 1996, J CLIN PHARMACOL, V36, P55, DOI 10.1002/j.1552-4604.1996.tb04152.x                                              
   Northfelt DW, 1997, J CLIN ONCOL, V15, P653, DOI 10.1200/JCO.1997.15.2.653                                                       
   NORTHFELT DW, 1998, STEALTH LIPOSOMES, V16, P2445
   Nunez M, 2001, HIV Clin Trials, V2, P429
   Osoba D, 2001, CANCER INVEST, V19, P573, DOI 10.1081/CNV-100104284
   PETERS BS, 1991, BRIT MED J, V302, P203, DOI 10.1136/bmj.302.6770.203                                                        
   Simpson JK, 1993, CLIN ONCOL, V5, P372, DOI 10.1016/S0936-6555(05)80089-5
   Stewart S, 1998, J CLIN ONCOL, V16, P683, DOI 10.1200/JCO.1998.16.2.683                                                       
   STURZL M, 1994, RES VIROLOGY, V145, P261, DOI 10.1016/S0923-2516(07)80031-8
   Vail DM, 2004, SEMIN ONCOL, V31, P16, DOI 10.1053/j.seminoncol.2004.08.002
   VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0
   WAGNER D, 1994, CLIN INVESTIGATOR, V72, P417
   WANG CYE, 1995, MAYO CLIN PROC, V70, P869
NR 32
TC 30
Z9 30
U1 1
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9114
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2007
VL 2
IS 3
BP 345
EP 352
PG 8
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 247BK
UT WOS:000252051900007
PM 18019833
DA 2018-01-05
ER

PT J
AU Rupp, R
   Rosenthal, SL
   Stanberry, LR
AF Rupp, Richard
   Rosenthal, Susan L.
   Stanberry, Lawrence R.
TI VivaGel (TM) (SPL7013 Gel): A candidate dendrimer microbicide for the
   prevention of HIV and HSV infection
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE microbicide; dendrimer; SPL7013; VivaGel (TM)
ID TOPICAL MICROBICIDES; TRANSMISSION; HERPES
AB Microbicides are compounds that applied vaginally or rectally, protect the user from sexually transmitted infections. Although no commercial product is yet available, many candidates are under development. A leading candidate, VivaGel (TM) (SPL7013 Gel) is the product of nanotechnology. The active ingredient is SPL7013, a dendrimer that was designed specifically with HIV and HSV antiviral activity and human safety in mind. SPL7013 has demonstrated efficacy against human immunodeficiency virus and herpes simplex virus in in vitro and animal models. VivaGeIT (TM) appears to be well tolerated in both animals and humans. This review summarizes the studies of VivaGel (TM) and its active ingredient, SPL7013.
C1 [Rupp, Richard; Rosenthal, Susan L.; Stanberry, Lawrence R.] Univ Texas Galveston, Med Branch, Dept Pediat, Galveston, TX 77555 USA.
   [Rupp, Richard; Rosenthal, Susan L.; Stanberry, Lawrence R.] Univ Texas Galveston, Med Branch, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA.
RP Rupp, R (reprint author), Univ Texas Galveston, Med Branch, Dept Pediat, 301 Univ Blvd, Galveston, TX 77555 USA.
EM rrupp@utmb.edu
CR Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424                                                                  
   Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004
   Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q
   Patton DL, 2006, ANTIMICROB AGENTS CH, V50, P1696, DOI 10.1128/AAC.50.5.1696-1700.2006
   *STARPH, 2006, VIV IS POT CONTR AN
   *STARPH, 2006, VIV IND GEN HERP TRI
   *STARPH, 2006, VIV FAST TRACK STAT
   Turpin JA, 2002, EXPERT OPIN INV DRUG, V11, P1077, DOI 10.1517/13543784.11.8.1077                                                      
   *UNAIDS, 2006, REP GLOB AIDS EP
NR 12
TC 145
Z9 149
U1 1
U2 10
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9114
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2007
VL 2
IS 4
BP 561
EP 566
PG 6
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 251FO
UT WOS:000252357400005
PM 18203424
DA 2018-01-05
ER

PT J
AU Lanao, JM
   Briones, E
   Colino, CI
AF Lanao, Jose M.
   Briones, Elsa
   Colino, Clara I.
TI Recent advances in delivery systems for anti-HIV1 therapy
SO JOURNAL OF DRUG TARGETING
LA English
DT Review
DE HIV1 therapy; carrier systems; drug delivery; gene therapy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; ERYTHROCYTE-MEDIATED
   DELIVERY; INHIBIT HIV-1 REPLICATION; GENE-THERAPY; IN-VITRO; BACTERIAL
   GHOSTS; ANTISENSE OLIGONUCLEOTIDES; LENTIVIRAL VECTOR; DNA VACCINES
AB In the last years, different non-biological and biological carrier systems have been developed for anti-HIV1 therapy. Liposomes are excellent potential anti-HIVI carriers that have been tested with drugs, antisense oligonucleotides, ribozymes and therapeutic genes. Nanoparticles and low-density lipoproteins (LDLs) are cell-specific transporters of drugs against macrophage-specific infections such as HIV1. Through a process of protein transduction, cell-permeable peptides of natural origin or designed artificially allow the delivery of drugs and genetic material inside the cell. Erythrocyte ghosts and bacterial ghosts are a promising delivery system for therapeutic peptides and HIV vaccines. Of interest are the advances made in the field of HIV gene therapy by the use of autologous haematopoietic stem cells and viral vectors for HIV vaccines. Although important milestones have been reached in the development of carrier systems for the treatment of HIV, especially in the field of gene therapy, further clinical trials are required so that the efficiency and safety of these new systems can be guaranteed in HIV patients.
C1 Univ Salamanca, Fac Pharm, Dept Pharm & Pharmaceut Technol, Salamanca 37007, Spain.
RP Lanao, JM (reprint author), Univ Salamanca, Fac Pharm, Dept Pharm & Pharmaceut Technol, Salamanca 37007, Spain.
EM jmlanao@usal.es
RI 2007, Secribsal/A-1556-2012
CR Agrawal AK, 2000, ADV DRUG DELIVER REV, V41, P135, DOI 10.1016/S0169-409X(99)00061-7                                                   
   Ahsan FL, 2002, J CONTROL RELEASE, V79, P29, DOI 10.1016/S0168-3659(01)00549-1
   Akkina R, 2003, ANTICANCER RES, V23, P1997
   Altmeyer R, 2004, CURR PHARM DESIGN, V10, P3701, DOI 10.2174/1381612043382729
   ALVAREZ FE, 1995, ANN CLIN LAB SCI, V25, P283
   Amado RG, 1999, HUM GENE THER, V10, P2255, DOI 10.1089/10430349950017239                                                       
   Bai Y, 2003, GENE THER, V10, P1446, DOI 10.1038/sj.gt.3302026
   Bauer G, 2000, ANN NY ACAD SCI, V918, P318
   Bax BE, 1999, CLIN SCI, V96, P171, DOI 10.1042/CS19980229                                                              
   Becker PS, 2005, ACTA HAEMATOL-BASEL, V114, P188, DOI 10.1159/000088409
   Benatti U, 1996, BIOCHEM BIOPH RES CO, V220, P20, DOI 10.1006/bbrc.1996.0349
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Bestman-Smith J, 2000, BBA-BIOMEMBRANES, V1468, P161, DOI 10.1016/S0005-2736(00)00254-6
   BOHJANENE PR, 1997, FRONT BIOSCI, V2, P619
   Bonyhadi ML, 1997, J VIROL, V71, P4707
   Brenner S, 2003, BBA-MOL CELL RES, V1640, P1, DOI 10.1016/S0167-4889(03)00024-7
   Casimiro DR, 2003, J VIROL, V77, P7663, DOI 10.1128/JVI.77.13.7663-7668.2003
   Cavallaro G, 2004, J DRUG TARGET, V12, P593, DOI 10.1080/10611860400013477
   Chan J, 2005, STEM CELLS, V23, P93, DOI 10.1634/stemcells.2004-0138                                                     
   Cockrell AS, 2003, CURR HIV RES, V1, P419, DOI 10.2174/1570162033485104
   Coupar BEH, 2006, VACCINE, V24, P1378, DOI 10.1016/j.vaccine.2005.09.044
   Cui ZR, 2003, CRIT REV THER DRUG, V20, P103, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10                                   
   Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7                                                   
   Dinauer N, 2004, J CONTROL RELEASE, V96, P497, DOI 10.1016/j.jconrel.02.020
   Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617
   Dorr P, 2005, ANTIMICROB AGENTS CH, V49, P4721, DOI 10.1128/AAC.49.11.4721-4732.2005
   Dorrell L, 2005, EXPERT REV VACCINES, V4, P513, DOI 10.1586/14760584.4.4.513
   Dropulic B, 2006, HUM GENE THER, V17, P577, DOI 10.1089/hum.2006.17.577
   Duerr A, 2006, CLIN INFECT DIS, V43, P500, DOI 10.1086/505979
   Duzgunes N, 2001, EXPERT OPIN BIOL TH, V1, P949
   Ebensen T, 2004, J IMMUNOL, V172, P6858, DOI 10.4049/jimmunol.172.11.6858                                                    
   El-Aneed A, 2004, J CONTROL RELEASE, V94, P1, DOI 10.1016/j.jconrel.2003.09.013
   Exceler JL, 2005, INDIAN J MED RES, V121, P568
   Falkner FG, 2004, CURR GENE THER, V4, P417
   Fanning G, 2003, J GENE MED, V5, P645, DOI 10.1002/jgm.436
   Felnerova D, 2004, MED SCI MONITOR, V10, pBR362
   Franchetti P, 2000, ANTIVIR RES, V47, P149, DOI 10.1016/S0166-3542(00)00101-7
   Fraternale A, 2003, J ANTIMICROB CHEMOTH, V52, P551, DOI 10.1093/jac/dkg428
   Fraternale A, 2002, ANTIVIR RES, V56, P263, DOI 10.1016/S0166-3542(02)00128-6
   Fraternale A, 2001, EUR J CLIN INVEST, V31, P248, DOI 10.1046/j.1365-2362.2001.00806.x
   Fridkin M, 2005, J PEPT SCI, V11, P37, DOI 10.1002/psc.587
   Fruh K, 2001, DRUG DISCOV TODAY, V6, P621, DOI 10.1016/S1359-6446(01)01808-6
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gerber D, 2004, J BIOL CHEM, V279, P48224, DOI 10.1074/jbc.M403436200
   Gherardi MM, 2005, J GEN VIROL, V86, P2925, DOI 10.1099/vir.0.81181-0
   Giammona G, 1998, J CONTROL RELEASE, V54, P321, DOI 10.1016/S0168-3659(98)00020-0
   Giammona G, 1999, ADV DRUG DELIVER REV, V39, P153, DOI 10.1016/S0169-409X(99)00024-1                                                   
   Gibbs MA, 2000, ANN PHARMACOTHER, V34, P89
   Goepfert PA, 2005, J INFECT DIS, V192, P1249, DOI 10.1086/432915                                                                  
   GOTTFREDSSON M, 1997, FRONT BIOSCI, V2, P619
   Grimaldi S, 1997, RES VIROLOGY, V148, P177, DOI 10.1016/S0923-2516(97)89906-2
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   Hamidi M, 2003, DRUG DELIV, V10, P9, DOI 10.1080/10717540390169520
   Hamm TE, 1999, J VIROL, V73, P5741
   Hatziioannou T, 2004, P NATL ACAD SCI USA, V101, P10774, DOI 10.1073/pnas.0402361101
   Hu JH, 2000, J CONTROL RELEASE, V69, P327, DOI 10.1016/S0168-3659(00)00319-9                                                   
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240                                                             
   Humeau LM, 2004, MOL THER, V9, P902, DOI 10.1016/j.ymthe.2004.03.005
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Ikeda M, 2006, NUCLEOS NUCLEOT NUCL, V25, P427, DOI 10.1080/01457630600684120
   Jain RA, 2000, BIOMATERIALS, V21, P2475, DOI 10.1016/S0142-9612(00)00115-0
   Jain Sanjay, 1997, Indian Journal of Pharmaceutical Sciences, V59, P275
   Jason TLH, 2004, TOXICOL APPL PHARM, V201, P66, DOI 10.1016/j.taap.2004.04.017
   Jin SX, 2005, PHARMAZIE, V60, P840
   Johnson PR, 2005, J VIROL, V79, P955, DOI 10.1128/JVI.79.2.955-965.2005
   Kader A, 1998, J CONTROL RELEASE, V55, P231, DOI 10.1016/S0168-3659(98)00052-2
   Kalkut G, 2005, CURR OPIN ONCOL, V17, P479, DOI 10.1097/01.cco.0000174035.39161.d8                                              
   KARLOWSKY JA, 1992, CLIN INFECT DIS, V15, P654, DOI 10.1093/clind/15.4.654                                                          
   Katragadda A, 2000, CELL MOL BIOL LETT, V5, P483
   Keckesova Z, 2004, P NATL ACAD SCI USA, V101, P10780, DOI 10.1073/pnas.0402474101
   Kitajima I, 1997, J BIOL CHEM, V272, P27099, DOI 10.1074/jbc.272.43.27099
   Klink Daniel, 2004, J Cyst Fibros, V3 Suppl 2, P203, DOI 10.1016/j.jcf.2004.05.042
   Kohn DB, 1999, BLOOD, V94, P368
   Konopka K, 1998, BBA-BIOMEMBRANES, V1372, P55, DOI 10.1016/S0005-2736(98)00046-7
   Konopka K, 1998, J DRUG TARGET, V5, P247, DOI 10.3109/10611869808995879                                                       
   Kozubek A, 2000, ACTA BIOCHIM POL, V47, P639
   Lambert John S, 2005, Paediatr Drugs, V7, P267, DOI 10.2165/00148581-200507050-00001
   Lamothe B, 2000, FRONT BIOSCI, V5, pD527, DOI 10.2741/Lamothe
   LANAO JM, 2006, NANOPARTICULATES DRU, P329
   Lee YH, 2005, GENE THER, V12, P625, DOI 10.1038/sj.gt.3302444
   Levy JA, 2002, LANCET, V359, P2212, DOI 10.1016/S0140-6736(02)09314-5
   Li MJ, 2005, MOL THER, V12, P900, DOI 10.1016/j.ymthe.2005.07.524
   Liang WS, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-20
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lochmann D, 2004, EUR J PHARM BIOPHARM, V58, P237, DOI 10.1016/j.ejpb.2004.03.031
   Luque F, 2005, CELL MOL BIOL, V51, P93, DOI 10.1170/T601
   MAGNANI M, 1992, P NATL ACAD SCI USA, V89, P6477, DOI 10.1073/pnas.89.14.6477                                                         
   Magnani M, 2002, GENE THER, V9, P749, DOI 10.1038/sj.gt.3301758
   MAGNANI M, 1995, VET IMMUNOL IMMUNOP, V46, P151, DOI 10.1016/0165-2427(94)07014-X
   Mankertz J, 1996, BBA-MOL BASIS DIS, V1317, P233, DOI 10.1016/S0925-4439(96)00059-2
   Mankertz J, 1997, BIOCHEM BIOPH RES CO, V240, P112, DOI 10.1006/bbrc.1997.7625
   Marchart J, 2003, VACCINE, V21, P3988, DOI 10.1016/S0264-410X(03)00383-9
   Marusich EI, 2005, VIROLOGY, V332, P258, DOI 10.1016/j.virol.2004.11.012
   MAUTINO MR, 2001, REV J VIROL, V75, P3590
   Mayr UB, 2005, ADV DRUG DELIVER REV, V57, P1381, DOI 10.1016/j.addr.2005.01.027
   Millan CG, 2004, J CONTROL RELEASE, V95, P27, DOI 10.1016/j.jconrel.2003.11.018
   Miyano-Kurosaki Naoko, 2004, Antiviral Chemistry & Chemotherapy, V15, P93
   Morel F, 1999, HUM GENE THER, V10, P2779, DOI 10.1089/10430349950016519
   Moroziewicz D, 2005, CURR OPIN MOL THER, V7, P317
   Moss HA, 2000, EUR J ANAESTH, V17, P680, DOI 10.1046/j.1365-2346.2000.00741.x
   Nielsen MH, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-10
   Noguchi H, 2006, J HEPATO-BILIARY-PAN, V13, P306, DOI 10.1007/s00534-005-1038-4
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000                                              
   Oehlke J, 2002, EUR J BIOCHEM, V269, P4025, DOI 10.1046/j.1432-1033.2002.03093.x
   Oussoren C, 1999, INT J PHARM, V180, P261, DOI 10.1016/S0378-5173(99)00016-2                                                   
   Perno CF, 1997, ANTIVIR RES, V33, P153, DOI 10.1016/S0166-3542(96)01011-X
   Phillips MI, 2005, METH MOLEC MED, V106, P3
   Plavec I, 1997, GENE THER, V4, P128, DOI 10.1038/sj.gt.3300369
   Podsakoff GM, 2005, MOL THER, V12, P77, DOI 10.1016/j.ymthe.2005.02.024
   Poeschla E, 1996, P NATL ACAD SCI USA, V93, P11395, DOI 10.1073/pnas.93.21.11395
   Pollard VW, 1998, ANNU REV MICROBIOL, V52, P491, DOI 10.1146/annurev.micro.52.1.491                                                  
   Prior S, 2002, EUR J PHARM SCI, V15, P197, DOI 10.1016/S0928-0987(01)00218-4
   Putnam DA, 1996, AM J HEALTH-SYST PH, V53, P151
   Quintana FJ, 2005, J CLIN INVEST, V115, P2149, DOI 10.1172/JCI23956
   Ramezani A, 2006, FRONT BIOSCI, V11, P2940, DOI 10.2741/2023
   Ranade V. V., 2004, DRUG DELIVERY SYSTEM
   Raulin J, 2002, PROG LIPID RES, V41, P27, DOI 10.1016/S0163-7827(01)00019-4                                                   
   Reeves JD, 2005, DRUGS, V65, P1747, DOI 10.2165/00003495-200565130-00002
   Remeta DP, 2002, BIOCHEMISTRY-US, V41, P2044, DOI 10.1021/bi015614a
   RENNEISEN K, 1990, J BIOL CHEM, V265, P16337
   Rossi L, 2001, J ANTIMICROB CHEMOTH, V47, P819, DOI 10.1093/jac/47.6.819
   Rossi Luiga, 2005, Expert Opin Drug Deliv, V2, P311, DOI 10.1517/17425247.2.2.311
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Schang LM, 2002, J ANTIMICROB CHEMOTH, V50, P779, DOI 10.1093/jac/dkf227
   Selvam MP, 1996, ANTIVIR RES, V33, P11, DOI 10.1016/S0166-3542(96)00993-X
   Siapati EK, 2005, MOL THER, V12, P537, DOI 10.1016/j.ymthe.2005.01.022
   Slyker JA, 2005, VACCINE, V23, P4711, DOI 10.1016/j.vaccine.2005.01.145
   Sokolskaja E, 2006, CURR OPIN MICROBIOL, V9, P404, DOI [10.1016/j.mib.2006.06.011, 10.1016/j.mib.2006.06.001]
   Song EW, 2003, J VIROL, V77, P7174, DOI 10.1128/JVI.77.13.7174-7181.2003
   Strizki JM, 2005, ANTIMICROB AGENTS CH, V49, P4911, DOI 10.1128/AAC.49.12.4911-4919.2005
   Su LS, 1997, BLOOD, V89, P2283
   Sugai Y, 2001, TRANSFUS APHER SCI, V24, P255, DOI 10.1016/S1473-0502(01)00067-2
   Szostak MP, 1996, J BIOTECHNOL, V44, P161, DOI 10.1016/0168-1656(95)00123-9
   SZOSTAK MP, 1993, VACCINE, V93, P419
   Tabrizi CA, 2004, CURR OPIN BIOTECH, V15, P530, DOI 10.1016/j.copbio.2004.10.004
   Tam RC, 2001, ANTIVIR CHEM CHEMOTH, V12, P261, DOI 10.1177/095632020101200501                                                      
   Tomanin R, 2004, CURR GENE THER, V4, P357
   Tubiana R, 2005, VACCINE, V23, P4292, DOI 10.1016/j.vaccine.2005.04.013
   Valbonesi M, 2001, TRANSFUS APHER SCI, V24, P91, DOI 10.1016/S0955-3886(00)00128-4
   van Griensven J, 2005, AIDS REV, V7, P44
   Vaysse L, 2000, BBA-GEN SUBJECTS, V1475, P369, DOI 10.1016/S0304-4165(00)00093-3                                                   
   Veres G, 1998, J VIROL, V72, P1894
   Vitas AI, 1996, ANTIMICROB AGENTS CH, V40, P146
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   von Laer D, 2006, J GENE MED, V8, P658, DOI 10.1002/jgm.908
   VONBRIESEN H, 2000, AIDS REV, V2, P31
   Walcher Petra, 2004, Expert Rev Vaccines, V3, P681, DOI 10.1586/14760584.3.6.681
   Xin KQ, 2005, GENE THER, V12, P1769, DOI 10.1038/sj.gt.3302590
   Yap MW, 2004, P NATL ACAD SCI USA, V101, P10786, DOI 10.1073/pnas.0402876101
   Zala C, 2000, CLIN INFECT DIS, V30, pS143, DOI 10.1086/313856
   Zelphati O, 1993, Antisense Res Dev, V3, P323
   ZELPHATI O, 1994, NUCLEIC ACIDS RES, V22, P4307, DOI 10.1093/nar/22.20.4307
   Zheng JY, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-79
NR 156
TC 35
Z9 38
U1 1
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1061-186X
EI 1029-2330
J9 J DRUG TARGET
JI J. Drug Target.
PY 2007
VL 15
IS 1
BP 21
EP 36
DI 10.1080/10611860600942178
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 134GE
UT WOS:000244070700002
PM 17365271
DA 2018-01-05
ER

PT J
AU Dutta, T
   Agashe, HB
   Garg, M
   Balasubramanium, P
   Kabra, M
   Jain, NK
AF Dutta, Tathagata
   Agashe, Hrushikesh B.
   Garg, Minakshi
   Balasubramanium, Prahlad
   Kabra, Madhulika
   Jain, Narendra K.
TI Poly (propyleneimine) dendrimer based nanocontainers for targeting of
   efavirenz to human monocytes/macrophages in vitro
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE poly (propyleneimine) dendrimer; nanocontainers; macrophage targeting;
   efavirenz; antiretroviral; monocytes/macrophages
ID POLY(PROPYLENE IMINE) DENDRIMERS; PLASMA-LEVELS; MACROPHAGES; INFECTION;
   NANOPARTICLES; LIPOSOMES; MONOCYTES; CULTURES; INVITRO; SYSTEM
AB Cells of the mononuclear phagocytic system, in particular mono cytes/macrophages (Mo/Mac) serve as a reservoir for human immunodeficiency virus (HIV) and are believed to be responsible for its dissemination throughout the body and especially into the brain. Treatment of HIV infection, therefore, must reach these cells in addition to the lymphocytes. The purpose of the present study is to develop poly(propyleneimine) (PPI) dendrimer-based nanocontainers for targeting of efavirenz (EFV) to Mo/Mac. Fifth generation PPI dendrimer, t-Boc-glycine conjugated PPI dendrimer (TPPI) and mannose conjugated dendrimers were synthesized and characterized. While the haemolytic activity and cytotoxicity of PPI dendrimer was found to be very high, the toxicity of t-Boc-glycine conjugated dendrimer and mannose conjugated dendrimers were found to be negligible. The entrapment efficiency of mannose conjugated dendrimer was found to be 47.4%, followed by that of PPI dendrimer (32.15%) and t-Boc-glycine conjugated dendrimer (23.1%). The in vitro drug release profile shows that while PPI dendrimer releases the drug by 24 h, the dendrimer-based nanocontainers prolong the release rate up to 144 h (83 +/- 0.4% in case of t-Boc-glycine conjugated dendrimer and 91 +/- 0.3% in mannose conjugated dendrimer). The cellular uptake of EFV was found to be both concentration and time dependent. Significant increase in cellular uptake of EFV by Mo/Mac cells were observed in case of mannose conjugated dendrimer which is 12 times higher than that of free drug and 5.5 times higher than that of t-Boc-glycine conjugated dendrimer. While mannose conjugated dendrimer was taken up by the lectin receptors of the cells, phagocytosis of t-Boc-glycine conjugated dendrimer might be responsible for its enhanced uptake. Results suggest that the proposed carriers hold potential to increase the efficacy and reduce the toxicity of antiretroviral therapy.
C1 Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar 470003, MP, India.
   All India Inst Med Sci, Dept Pediat, Div Genet, New Delhi, India.
RP Jain, NK (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar 470003, MP, India.
EM duttatathababu@yahoo.com; jnarendr@yahoo.co.in
OI kabra, madhulika/0000-0003-3315-9782
CR ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2                                                   
   Ashton PR, 1997, CHEM-EUR J, V3, P974, DOI 10.1002/chem.19970030620                                                        
   Auge M., 1992, NATURAL IMMUNE SYSTE, P2
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   BETAGERI GV, 1993, J PHARM PHARMACOL, V45, P48, DOI 10.1111/j.2042-7158.1993.tb03678.x                                              
   Bhadra D, 2005, INT J PHARM, V295, P221, DOI 10.1016/j.ijpharm.2005.01.026
   DEBRABANDERVANDENBERG EMM, 1993, ANGEW CHEM INT EDIT, V32, P1308, DOI 10.1002/anie.199313081                                                          
   FISCHER D, 2003, BIOMATERIALS, V24, P114
   Fridkin M, 2005, J PEPT SCI, V11, P37, DOI 10.1002/psc.587
   GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648
   GORDON S, 2001, IMMUNOLOGY, P153
   JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226                                                   
   Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3                                                   
   LEE YC, 1983, J BIOL CHEM, V258, P199
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   Liu MJ, 1999, PHARM SCI TECHNOL TO, V2, P393, DOI 10.1016/S1461-5347(99)00203-5                                                   
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011                                                
   MCGANN KA, 1994, J INFECT DIS, V169, P746, DOI 10.1093/infdis/169.4.746                                                        
   Miklis P, 1997, J AM CHEM SOC, V119, P7458, DOI 10.1021/ja964230i                                                               
   MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305
   MULLER CD, 1989, BIOCHIM BIOPHYS ACTA, V986, P97, DOI 10.1016/0005-2736(89)90277-0
   NICHOLSON JKA, 1986, J IMMUNOL, V137, P323
   Nunez M, 2001, J ACQ IMMUN DEF SYND, V28, P399
   Sarasa-Nacenta M, 2001, J CHROMATOGR B, V763, P53, DOI 10.1016/S0378-4347(01)00357-7
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SHAKTHIVEL T, 2003, DRUG DELIV TECHNOL, V3, P73
   Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501
   Tomalia DA, 2004, ALDRICHIM ACTA, V37, P39
   VONBRIESEN H, 1990, RES VIROLOGY, V141, P225, DOI 10.1016/0923-2516(90)90025-E
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
NR 31
TC 98
Z9 101
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PY 2007
VL 15
IS 1
BP 89
EP 98
DI 10.1080/10611860600965914
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 134GE
UT WOS:000244070700009
PM 17365278
DA 2018-01-05
ER

PT J
AU Dutta, T
   Agashe, HB
   Garg, M
   Balasubramanium, P
   Kabra, M
   Jain, NK
AF Dutta, Tathagata
   Agashe, Hrushikesh B.
   Garg, Minakshi
   Balasubramanium, Prahlad
   Kabra, Madhulika
   Jain, Narendra K.
TI Poly (propyleneimine) dendrimer based nanocontainers for targeting of
   efavirenz to human inonocytes/macrophages in vitro (vol 15, pg 89, 2007)
SO JOURNAL OF DRUG TARGETING
LA English
DT Correction
DE poly (propyleneimine) dendrimer; nanocontainers; macrophage targeting;
   efavirenz; antiretroviral; monocytes/macrophages
AB Cells of the mononuclear phagocytic system, in particular monocytes/macrophages (Mo/Mac) serve as a reservoir for human immunodeficiency virus (HIV) and are believed to be responsible for its dissemination throughout the body and especially into the brain. Treatment of HIV infection, therefore, must reach these cells in addition to the lymphocytes. The purpose of the present study is to develop poly(propyleneimine) (PPI) dendrimer-based nanocontainers for targeting of efavirenz (EFV) to Mo/Mac. Fifth generation PPI dendrimer, t-Boc-glycine conjugated PPI dendrimer (TPPI) and mannose conjugated dendrimers were synthesized and characterized. While the haemolytic activity and cytotoxicity of PPI dendrimer was found to be very high, the toxicity of t-Boc-glycine conjugated dendrimer and mannose conjugated dendrimers were found to be negligible. The entrapment efficiency of mannose conjugated dendrimer was found to be 47.4%, followed by that of PPI dendrimer (32.15%) and t-Boc-glycine conjugated dendrimer (23.1%). The in vitro drug release profile shows that while PPI dendrimer releases the drug by 24 h, the dendrimer-based nanocontainers prolong the release rate up to 144 h (83 +/- 0.4% in case of t-Boc-glycine conjugated dendrimer and 91 +/- 0.3% in mannose conjugated dendrimer). The cellular uptake of EFV was found to be both concentration and time dependent, Significant increase in cellular uptake of EFV by Mo/Mac cells were observed in case of mannose conjugated dendrimer which is 12 times higher than that of free drug and 5.5 times higher than that of t-Boc-glycine conjugated dendrimer. While mannose conjugated dendrimer was taken up by the lectin receptors of the cells, phagocytosis of t-Boc-glycine conjugated dendrimer might be responsible for its enhanced uptake. Results suggest that the proposed carriers hold potential to increase the efficacy and reduce the toxicity of antiretroviral therapy.
C1 [Dutta, Tathagata; Agashe, Hrushikesh B.; Garg, Minakshi; Jain, Narendra K.] Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
   [Balasubramanium, Prahlad; Kabra, Madhulika] All India Inst Med Sci, Dept Pediat, Div Genet, New Delhi, India.
RP Dutta, T (reprint author), Dr Hari Singh Gour Vishwavidyalaya, Dept Pharmaceut Sci, Sagar 470003, Madhya Pradesh, India.
CR Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914
NR 1
TC 0
Z9 0
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PY 2007
VL 15
IS 10
BP 721
EP 722
DI 10.1080/10611860600965914
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 248JT
UT WOS:000252150300008
DA 2018-01-05
ER

PT J
AU Jelic, TM
   Chang, HH
   Roque, R
   Malas, AM
   Warren, SG
   Sommer, AP
AF Jelic, Tomislav M.
   Chang, Ho-Huang
   Roque, Rod
   Malas, Amer M.
   Warren, Stafford G.
   Sommer, Andrei P.
TI Nanobacteria-associated calcific aortic valve stenosis
SO JOURNAL OF HEART VALVE DISEASE
LA English
DT Article
ID HIV; SURVIVAL; DISEASE; STONES
AB Calcific aortic valve stenosis is the most common valvular disease in developed countries, and the major reason for operative valve replacement. In the US, the current annual cost of this surgery is approximately $1 billion. Despite increasing morbidity and mortality, little is known of the cellular basis of the calcifications, which occur in high-perfusion zones of the heart. The case is presented of a patient with calcific aortic valve stenosis and colonies of progressively mineralized nanobacteria in the fibrocalcific nodules of the aortic cusps, as revealed by transmission electron microscopy. Consistent with their outstanding bioadhesivity, nanobacteria might serve as causative agents in the development of calcific aortic valve stenosis.
C1 W Virginia Univ, Charleston Area Med Ctr, Dept Pathol & Lab Med, Charleston, WV 25304 USA.
   W Virginia Univ, Robert C Byrd Hlth Sci Ctr, Dept Internal Med, Charleston Div, Charleston, WV 25304 USA.
   Charleston Area Med Ctr, Charleston, WV USA.
   Univ Ulm, Div Mat, D-89069 Ulm, Germany.
RP Jelic, TM (reprint author), Mem Hosp, Charleston Area Med Ctr, 3200 MacCorkle Ave, Charleston, WV 25304 USA.
EM tomislav.jelic@camc.org
CR Abbott A, 1999, NATURE, V401, P105, DOI 10.1038/43525
   Bjorklund M, 1998, P SOC PHOTO-OPT INS, V3441, P123, DOI 10.1117/12.319827
   Ciftcioglu N, 2002, ANTIMICROB AGENTS CH, V46, P2077, DOI 10.1128/AAC.46.7.2007-2086.2002
   HOGAN J, 2004, NEW SCI         0519
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kajander EO, 2006, LETT APPL MICROBIOL, V42, P549, DOI 10.1111/j.1472-765X.2006.01945.x
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   King RHM, 2001, J CLIN PATHOL-MOL PA, V54, P400
   Kurz DJ, 2006, ARTERIOSCL THROM VAS, V26, pE114, DOI 10.1161/01.ATV.0000222961.24912.69
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   OTTO CM, 1994, CIRCULATION, V90, P844
   Pace NR, 2006, NATURE, V441, P289, DOI 10.1038/441289a
   Piper C, 2006, J HEART VALVE DIS, V15, P499
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   Puskas LG, 2005, ACTA BIOL HUNG, V56, P233, DOI 10.1556/ABiol.56.2005.3-4.7
   Rajamannan NM, 2003, HEART, V89, P801, DOI 10.1136/heart.89.7.801
   Shiekh FA, 2006, UROL RES, V34, P53, DOI 10.1007/s00240-005-0034-0
   Shoskes DA, 2005, J UROLOGY, V173, P474, DOI 10.1097/01.ju.0000150062.60633.b2
   Sommer AP, 2006, CHEMOTHERAPY, V52, P95, DOI 10.1159/000092475
   Sommer AP, 2006, J PROTEOME RES, V5, P611, DOI 10.1021/pr050370s
   Sommer AP, 2006, J ENVIRON MONITOR, V8, P341, DOI 10.1039/b512496d
   Sommer AP, 2005, CRYST GROWTH DES, V5, P551, DOI 10.1021/cg0496989
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   TOMAZIC BB, 1995, ANN THORAC SURG, V60, pS322, DOI 10.1016/0003-4975(95)00205-Y
   TSURMOTO T, 2006, PROTEOME RES, V5, P1276
   Wang Xue-Jun, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P492
   ZHOU HD, 2000, MOL IMMUNOL, V43, P1864
NR 31
TC 11
Z9 16
U1 0
U2 6
PU I C R PUBLISHERS
PI NORTHWOOD
PA CRISPIN HOUSE, 12/A SOUTH APPROACH, MOOR PARK, NORTHWOOD HA6 2ET,
   ENGLAND
SN 0966-8519
J9 J HEART VALVE DIS
JI J. Heart Valve Dis.
PD JAN
PY 2007
VL 16
IS 1
BP 101
EP 105
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 126MP
UT WOS:000243517300017
PM 17315391
DA 2018-01-05
ER

PT J
AU Sun, XY
   Zhang, Q
   Al-Hashimi, HM
AF Sun, Xiaoyan
   Zhang, Qi
   Al-Hashimi, Hashim M.
TI Resolving fast and slow motions in the internal loop containing
   stem-loop 1 of HIV-1 that are modulated by Mg2+ binding: role in the
   kissing-duplex structural transition
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DIMERIZATION INITIATION SITE; RESIDUAL
   DIPOLAR COUPLINGS; MODEL-FREE APPROACH; RNA DIMERIZATION; NUCLEOCAPSID
   PROTEIN; MOLECULAR-DYNAMICS; GENOMIC RNA; STEM-LOOP; IN-VITRO
AB Stem loop 1 (SL1) is a highly conserved hairpin in the 5 '-leader of the human immunodeficiency virus type I that forms a metastable kissing dimer that is converted during viral maturation into a stable duplex with the aid of the nucleocapsid (NC) protein. SL1 contains a highly conserved internal loop that promotes the kissing-duplex transition by a mechanism that remains poorly understood. Using NMR, we characterized internal motions induced by the internal loop in an SL1 monomer that may promote the kissing-duplex transition. This includes micro-to-millisecond secondary structural transitions that cause partial melting of three base-pairs above the internal loop making them key nucleation sites for exchanging strands and nanosecond rigid-body stem motions that can help bring strands into spatial register. We show that while Mg2+ binds to the internal loop and arrests these internal motions, it preserves and/or activates local mobility at internal loop residues G272 and G273 which are implicated in NC binding. By stabilizing SL1 without compromising the accessibility of G272 and G273 for NC binding, Mg-2+ may increase the dependence of the kissing-duplex transition on NC binding thus preventing spontaneous transitions from taking place and ensuring that viral RNA and protein maturation occur in concert.
C1 Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
   Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.
RP Al-Hashimi, HM (reprint author), Univ Michigan, Dept Chem, 930 N Univ Ave, Ann Arbor, MI 48109 USA.
EM hashimi@umich.edu
RI Zhang, Qi/E-1722-2011; Zhang, Qi/F-3323-2010; Zhang, Qi/B-5869-2014
OI Zhang, Qi/0000-0003-1754-4058
FU NIAID NIH HHS [R01 AI066975]
CR Abbink TEM, 2005, BIOCHEMISTRY-US, V44, P9058, DOI 10.1021/bi0502588
   Aci S, 2005, J MOL BIOL, V351, P520, DOI 10.1016/j.jmb.2005.06.009
   Aci S, 2004, BIOPOLYMERS, V74, P177, DOI 10.1002/bip.20032
   Al-Hashimi HM, 2000, J MAGN RESON, V143, P402, DOI 10.1006/jmre.2000.2049
   Al-Hashimi HM, 2002, J MOL BIOL, V315, P95, DOI 10.1006/jmbi.2001.5235
   Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979
   Baba S, 2005, J BIOCHEM, V138, P583, DOI 10.1093/jb/mvi158
   Beaurain F, 2003, OLIGONUCLEOTIDES, V13, P501, DOI 10.1089/154545703322860816
   Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1
   Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684
   Chin K, 1999, NAT STRUCT BIOL, V6, P1055
   CLEVER J, 1995, J VIROL, V69, P2101
   Clever JL, 1997, J VIROL, V71, P3407
   Clever JL, 1996, J VIROL, V70, P5902
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Clore GM, 1998, J AM CHEM SOC, V120, P10571, DOI 10.1021/ja982592f                                                               
   D'Souza V, 2005, NAT REV MICROBIOL, V3, P643, DOI 10.1038/nrmicro1210
   Damgaard CK, 1998, NUCLEIC ACIDS RES, V26, P3667, DOI 10.1093/nar/26.16.3667
   DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dingley AJ, 1998, J AM CHEM SOC, V120, P8293, DOI 10.1021/ja981513x                                                               
   Ennifar E, 2006, J MOL BIOL, V356, P771, DOI 10.1016/j.jmb.2005.12.022
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577
   Fosse P, 1996, BIOCHEMISTRY-US, V35, P16601, DOI 10.1021/bi9613786
   FU W, 1994, J VIROL, V68, P5013
   FU W, 1993, J VIROL, V67, P5443
   GODDARD TD, SPARKY, V34, P936
   Gonzalez RL, 1999, J MOL BIOL, V289, P1267, DOI 10.1006/jmbi.1999.2841
   Greatorex J, 2002, J MOL BIOL, V322, P543, DOI 10.1016/S0022-2836(02)00776-3
   Hansen AL, 2006, J MAGN RESON, V179, P299, DOI 10.1016/j.jmr.2005.12.012
   Hansen MR, 1998, NAT STRUCT BIOL, V5, P1065, DOI 10.1038/4176                                                                    
   Hoglund S, 1997, VIROLOGY, V233, P271, DOI 10.1006/viro.1997.8585
   Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881                                                       
   JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272
   Latham MP, 2005, CHEMBIOCHEM, V6, P1492, DOI 10.1002/cbic.200500123
   LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035
   Lawrence DC, 2003, J MOL BIOL, V326, P529, DOI 10.1016/S0022-2836(02)01305-0
   Liang C, 1999, J VIROL, V73, P7014
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754
   MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073                                                          
   MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349
   Meissner A, 1999, J MAGN RESON, V139, P439, DOI 10.1006/jmre.1999.1788
   Meissner A, 1997, J MAGN RESON, V128, P92, DOI 10.1006/jmre.1997.1213
   Mihailescu MR, 2004, P NATL ACAD SCI USA, V101, P1189, DOI 10.1073/pnas.0307966100
   Mirambeau G, 2006, J MOL BIOL, V364, P496, DOI 10.1016/j.jmb.2006.08.065
   Mollova ET, 2000, J AM CHEM SOC, V122, P11561, DOI 10.1021/ja0027822
   Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686                                                        
   Musselman C, 2006, J BIOMOL NMR, V36, P235, DOI 10.1007/s10858-006-9087-9
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Ooms M, 2004, J VIROL, V78, P10814, DOI 10.1128/JVI.78.19.10814-10819.2004
   Paillart JC, 2004, NAT REV MICROBIOL, V2, P461, DOI 10.1038/nrmicro903
   Paillart JC, 1996, BIOCHIMIE, V78, P639, DOI 10.1016/S0300-9084(96)80010-1
   Pervushin K, 1998, P NATL ACAD SCI USA, V95, P14147, DOI 10.1073/pnas.95.24.14147                                                        
   Pitt SW, 2005, ANGEW CHEM INT EDIT, V44, P3412, DOI 10.1002/anie.200500075
   Pitt SW, 2004, J MOL BIOL, V338, P7, DOI 10.1016/j.jmb.2004.02.031
   Reblova K, 2003, NUCLEIC ACIDS RES, V31, P6942, DOI 10.1093/nar/gkg880
   Rist MJ, 2002, BIOCHEMISTRY-US, V41, P14762, DOI 10.1021/bi0267240
   SAUPE A, 1963, PHYS REV LETT, V11, P462, DOI 10.1103/PhysRevLett.11.462                                                      
   SAUPE A, 1968, ANGEW CHEM INT EDIT, V7, P97, DOI 10.1002/anie.196800971                                                          
   Shehu-Xhilaga M, 2001, J VIROL, V75, P9156, DOI 10.1128/JVI.75.19.9156-9164.2001
   Sheng NJ, 1997, J VIROL, V71, P5723
   SHENG NJ, 1994, J VIROL, V68, P6207
   Shubsda MF, 2002, BIOCHEMISTRY-US, V41, P5276, DOI 10.1021/bi016045+
   Sibille N, 2001, J AM CHEM SOC, V123, P12135, DOI 10.1021/ja011646+
   SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945
   Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P681, DOI 10.1093/oxfordjournals.jbchem.a022657                                           
   Takahashi K, 2001, J BIOL CHEM, V276, P31274, DOI 10.1074/jbc.M104577200
   Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635
   Theilleux-Delalande V, 2000, EUR J BIOCHEM, V267, P2711, DOI 10.1046/j.1432-1327.2000.01292.x
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279
   Tolman JR, 1997, NAT STRUCT BIOL, V4, P292, DOI 10.1038/nsb0497-292                                                             
   Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y
   Ulyanov NB, 2006, J BIOL CHEM, V281, P16168, DOI 10.1074/jbc.M601711200
   Windbichler N, 2003, NUCLEIC ACIDS RES, V31, P6419, DOI 10.1093/nar/gkg873
   Yip GNB, 2005, J MAGN RESON, V176, P171, DOI 10.1016/j.jmr.2005.06.003
   Yip GNB, 2004, J MAGN RESON, V171, P25, DOI 10.1016/j.jmr.2004.06.021
   Yuan YQ, 2003, BIOCHEMISTRY-US, V42, P5259, DOI 10.1021/bi034084a
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2003, J AM CHEM SOC, V125, P10530, DOI 10.1021/ja0363056
   Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908                                                               
NR 84
TC 37
Z9 38
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PY 2007
VL 35
IS 5
BP 1698
EP 1713
DI 10.1093/nar/gkm020
PG 16
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 166IA
UT WOS:000246371200028
PM 17311812
OA gold
DA 2018-01-05
ER

PT J
AU Metifiot, M
   Faure, A
   Guyonnet-Duperat, V
   Bellecave, P
   Litvak, S
   Ventura, M
   Andreola, ML
AF Metifiot, Mathieu
   Faure, Aurelie
   Guyonnet-Duperat, Veronique
   Bellecave, Pantxika
   Litvak, Simon
   Ventura, Michel
   Andreola, Marie-Line
TI Cellular uptake of ODNs in HIV-1 human-infected cells: A role for viral
   particles in DNA delivery?
SO OLIGONUCLEOTIDES
LA English
DT Article
ID ANTISENSE OLIGONUCLEOTIDES; IN-VITRO; INITIATION COMPLEX; PLASMID DNA;
   VIRUS; INTEGRASE; APTAMERS; INHIBITION; VECTOR; REPLICATION
AB We have previously described how a 16 nucleotides ODN (termed 93del) is capable of inhibiting the activity of recombinant integrase in a cell-free system as well as HIV-1 replication in human-infected cells With IC50 in the low nanomolar range. Intracellular HIV-1 replication was inhibited when the ODN was added at the onset of infection. These results raise several questions. Is a naked ODN able to enter the cell? Does the virus play a role in ODN entry? The uptake of several ODNs (93del, 60del(sc), TBA, T30923) was evaluated and then tracked by labeling the ODN with a fluorescent dye and assessing its intracellular localization by confocal microscopy. A significant level of cellular uptake of free ODN was observed in several cell lines: HeLa epithelial cells, Huh7 hepatic cells, and H9 lymphocytes, and was detected for all ODNs tested except for TBA. Striking differences were observed when naked ODNs were added to cell in the presence or absence of the virus. When HIV-1 virions were present a sharp increase in cellular fluorescence was observed. These results strongly suggest a role for HIV-1 virions in the uptake of certain ODNs.
C1 Univ Victor Segalen Bordeaux 2, CNRS, UMR 5097, F-33076 Bordeaux, France.
   Inst Fed Rec Pathol Infect Canc IFR 66, Bordeaux, France.
   INSERM 217, Bordeaux, France.
RP Andreola, ML (reprint author), Univ Victor Segalen Bordeaux 2, CNRS, UMR 5097, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM Marie-line.andreola@reger.u-bordeaux2.fr
CR Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
   Boulme F, 2000, EUR J BIOCHEM, V267, P2803, DOI 10.1046/j.1432-1327.2000.01310.x                                                
   Braun H, 1999, BIOTECHNOL APPL BIOC, V29, P31
   CAMPBELL S, 1995, J VIROL, V69, P487
   CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   Ehrlich LS, 2001, BIOPHYS J, V81, P586, DOI 10.1016/S0006-3495(01)75725-6                                                   
   Freund F, 2001, ANTISENSE NUCLEIC A, V11, P301, DOI 10.1089/108729001753231687                                                      
   GAIT MJ, 2003, CELL MOL LIFE SCI, V60, P1
   Galderisi U, 1999, J CELL PHYSIOL, V181, P251, DOI 10.1002/(SICI)1097-4652(199911)181:2<251::AID-JCP7>3.0.CO;2-D                   
   Garcia-Chaumont C, 2000, PHARMACOL THERAPEUT, V87, P255, DOI 10.1016/S0163-7258(00)00062-0
   Goldmann C, 1999, J VIROL, V73, P4465
   Held DM, 2006, FRONT BIOSCI, V11, P89, DOI 10.2741/1782
   Jing Naijie, 2001, Current Drug Targets - Infectious Disorders, V1, P79, DOI 10.2174/1568005013343173
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 2001, DNA CELL BIOL, V20, P499, DOI 10.1089/104454901316976136
   Johnson AA, 2004, CURR TOP MED CHEM, V4, P1059, DOI 10.2174/1568026043388394                                                        
   Kaneda Y, 2003, CURR DRUG TARGETS, V4, P599, DOI 10.2174/1389450033490740                                                        
   Kaneda Y, 2002, MOL THER, V6, P219, DOI 10.1006/mthe.2002.0647
   Kaneda Y, 2005, ADV GENET, V53, P307, DOI 10.1016/S0065-2660(05)53012-8
   Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u
   Metifiot M, 2005, BIOCHIMIE, V87, P911, DOI 10.1016/j.biochi.2005.03.013
   Nimjee SM, 2005, ANNU REV MED, V56, P555, DOI 10.1146/annurev.med.56.062904.144915
   Oehlke J, 2002, EUR J BIOCHEM, V269, P4025, DOI 10.1046/j.1432-1033.2002.03093.x
   OJWANG J, 1994, J ACQ IMMUN DEF SYND, V7, P560
   Okimoto T, 2001, MOL THER, V4, P232, DOI 10.1006/mthe.2001.0443
   Parissi V, 2000, J MOL BIOL, V295, P755, DOI 10.1006/jmbi.1999.3416                                                          
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Richard E, 2001, MOL THER, V4, P331, DOI 10.1006/mthe.2001.0467
   ROCANCOURT D, 1990, J VIROL, V64, P2660
   Schubert S, 2006, HANDB EXP PHARM, V173, P261
   SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105
   SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0
   SMITH CC, 1986, P NATL ACAD SCI USA, V83, P2787, DOI 10.1073/pnas.83.9.2787
   Stritzker J, 2004, MOL GENET GENOMICS, V272, P497, DOI 10.1007/s00438-004-1080-y
   Thierry AR, 2003, CURR OPIN MOL THER, V5, P133
   Ventura M, 1999, ARCH VIROL, V144, P513, DOI 10.1007/s007050050522
   Wiznerowicz M, 2005, TRENDS BIOTECHNOL, V23, P42, DOI 10.1016/j.tibtech.2004.11.001
NR 39
TC 16
Z9 16
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1545-4576
J9 OLIGONUCLEOTIDES
JI Oligonucleotides
PY 2007
VL 17
IS 2
BP 151
EP 165
DI 10.1089/oli.2006.0061
PG 15
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 193QO
UT WOS:000248289400001
PM 17638520
DA 2018-01-05
ER

PT J
AU Akagi, T
   Baba, M
   Akashi, M
AF Akagi, Takami
   Baba, Masanori
   Akashi, Mitsuru
TI Development of vaccine adjuvants using polymeric nanoparticles and their
   potential applications for anti-HIV vaccine
SO YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN
LA Japanese
DT Review
DE polymeric nanoparticles; vaccine; drug delivery system; HIV-1
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; IMMOBILIZED POLYSTYRENE
   NANOSPHERES; IMMUNODEFICIENCY-VIRUS TYPE-1; HYDROPHOBIC BACKBONE;
   HYDROPHILIC BRANCHES; GRAFT-COPOLYMERS; POLY(GAMMA-GLUTAMIC ACID);
   DENDRITIC CELLS; BIODEGRADABLE NANOPARTICLES; INTRANASAL IMMUNIZATION
AB The development of a prophylactic/therapeutic HIV-1 vaccine based on recombinant proteins is needed for the control of the worldwide AIDS epidemic. Subunit protein and peptide vaccines are generally very safe, with well-defined components. However, these antigens are often poorly immunogenic, and thus require the use of adjuvants to induce adequate immunity. Particulate adjuvants (e.g. micro/nanoparticles, emulsions, ISCOMS, liposomes, virosomes, and virus-like particles) have been widely investigated as HIV-1 vaccine delivery systems. Antigen uptake by antigen-presenting cells (APC) is enhanced by the association of the antigens with polymeric micro/nanoparticles. The adjuvant effect of micro/nanoparticles appears to largely be a consequence of their uptake into APC. More importantly, particulate antigens have been shown to be more efficient than soluble antigens for the induction of immune responses. Over the past two decades, we have studied the synthesis and clinical applications of core-corona polymeric nanospheres composed of hydrophobic polystyrene and hydrophilic macromonomers. Core-corona type polymeric nanospheres have applications in various technological and biomedical fields, because their chemical structures and particle size can be easily controlled. In this study, we focused on the development of a HIV-1 vaccine using polymeric nanoparticles. We evaluated the immunization strategies for HIV-1-capturing core-corona type polystyrene nanospheres that would efficiently induce HIV-1-specific IgA responses in female mice and the macaque genital tract. Moreover, based on this research, we attempted to develop novel biodegradable nanoparticles composed of poly (gamma-glutamic acid) (gamma-PGA) for protein-based vaccine delivery. These HIV-1-capturing nanospheres and protein-loaded gamma-PGA nanoparticles have shown unique potential as vaccine carriers.
C1 Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Div Antiviral Chemotherapy, Ctr Chron Viral Dis, Kagoshima 8908544, Japan.
   Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan.
RP Akagi, T (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM akagit@chem.eng.osaka-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2005, J CONTROL RELEASE, V109, P49, DOI 10.1016/j.jconrel.2005.09.014
   Akagi T, 2006, BIOMACROMOLECULES, V7, P297, DOI 10.1021/bm050657i
   Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akagi T, 2006, J BIOMAT SCI-POLYM E, V17, P875, DOI 10.1163/156856206777996871
   AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Baba TW, 1999, NAT MED, V5, P194
   Chen MQ, 1999, J POLYM SCI POL CHEM, V37, P2155, DOI 10.1002/(SICI)1099-0518(19990701)37:13<2155::AID-POLA31>3.0.CO;2-G              
   Chen MQ, 1996, J POLYM SCI POL CHEM, V34, P2213
   DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917                                                         
   Elamanchili P, 2004, VACCINE, V22, P2406, DOI 10.1016/j.vaccine.2003.12.032
   Flynn MN, 2005, J INFECT DIS, V191, P654
   GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27
   Greenough TC, 1999, J INFECT DIS, V180, P1790, DOI 10.1086/315128
   Hanes J, 1997, ADV DRUG DELIVER REV, V28, P97, DOI 10.1016/S0169-409X(97)00053-7                                                   
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Ikuta Y, 2002, BLOOD, V99, P3717, DOI 10.1182/blood.V99.10.3717                                                       
   Kakizawa Y, 2002, ADV DRUG DELIVER REV, V54, P203, DOI 10.1016/S0169-409X(02)00017-0
   Kaneko T, 2005, CHEM MATER, V17, P2484, DOI 10.1021/cm048196f
   Kaul R, 2000, J IMMUNOL, V164, P1602, DOI 10.4049/jimmunol.164.3.1602                                                     
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Matsusaki M, 2005, NANO LETT, V5, P2168, DOI 10.1021/nl050541s
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   OHAGAN DT, 2002, AIDS, V16, P115
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   Serizawa T, 2000, COLLOID SURFACE A, V169, P95, DOI 10.1016/S0927-7757(00)00421-0                                                   
   Serizawa T, 2000, MACROMOLECULES, V33, P1759, DOI 10.1021/ma9907486                                                               
   Serizawa T, 1998, J POLYM SCI POL CHEM, V36, P2581, DOI 10.1002/(SICI)1099-0518(199810)36:14<2581::AID-POLA17>3.0.CO;2-E
   Singh M, 2002, PHARMACEUT RES, V19, P715, DOI 10.1023/A:1016104910582
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Zhang LF, 1996, SCIENCE, V272, P1777, DOI 10.1126/science.272.5269.1777                                                   
   Zhao Z, 1996, J PHARM SCI-US, V85, P1261, DOI 10.1021/js9602812
   ZHAO Z, 1996, J PHARM SCI, V85, P261
NR 40
TC 5
Z9 5
U1 0
U2 10
PU PHARMACEUTICAL SOC JAPAN
PI TOKYO
PA 2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN
SN 0031-6903
J9 YAKUGAKU ZASSHI
JI Yakugaku Zasshi-J. Pharm. Soc. Jpn.
PY 2007
VL 127
IS 2
BP 307
EP 317
DI 10.1248/yakushi.127.307
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 155NF
UT WOS:000245583400015
PM 17268151
OA gold
DA 2018-01-05
ER

PT J
AU Wedekind, JE
   Gillilan, R
   Janda, A
   Krucinska, J
   Salter, JD
   Bennett, RP
   Raina, J
   Smith, HC
AF Wedekind, Joseph E.
   Gillilan, Richard
   Janda, Alena
   Krucinska, Jolanta
   Salter, Jason D.
   Bennett, Ryan P.
   Raina, Jay
   Smith, Harold C.
TI Nanostructures of APOBEC3G support a hierarchical assembly model of high
   molecular mass ribonucleoprotein particles from dimeric subunits
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SMALL-ANGLE SCATTERING; CD4 T-CELLS; CYTIDINE DEAMINASE; BIOLOGICAL
   MACROMOLECULES; RETROVIRAL INFECTION; ANTIVIRAL ACTIVITY;
   CRYSTAL-STRUCTURE; HIV-1 INFECTION; VIF PROTEIN; RNA
AB Human APOBEC3G ( hA3G) is a cytidine deaminase that restricts human immunodeficiency virus (HIV)-1 infection in a vif ( the virion infectivity factor from HIV)-dependent manner. hA3G from HIV-permissive activated CD4+ T-cells exists as an inactive, high molecular mass (HMM) complex that can be transformed in vitro into an active, low molecular mass (LMM) variant comparable with that of HIV-non-permissive CD4+ T-cells. Here we present low resolution structures of hA3G in HMM and LMM forms determined by small angle x-ray scattering and advanced shape reconstruction methods. The results show that LMM particles have an extended shape, dissimilar to known cytidine deaminases, featuring novel tail-to-tail dimerization. Shape analysis of LMM and HMM structures revealed how symmetric association of dimers could lead to minimal HMM variants. These observations imply that the disruption of cellular HMM particles may require regulation of protein-RNA, as well as protein-protein interactions, which has implications for therapeutic development.
C1 Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA.
   Cornell Univ, MacCHESS, Macromol Struct Facil, Cornell High Energy Synchrotron Source, Ithaca, NY 14853 USA.
   Immunodiagnostics Inc, Woburn, MA 01801 USA.
RP Smith, HC (reprint author), Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.
EM harold.smith@rochester.edu
OI Smith, Harold/0000-0001-6257-6791
FU NIAID NIH HHS [R21 AI058789, T32 AI049815, T32 AI 49815]; NCRR NIH HHS
   [P41 RR001646, RR 01646]; NIGMS NIH HHS [DMR0225180]
CR BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018
   Chacon P, 2002, J MOL BIOL, V317, P375, DOI 10.1006/jmbi.2002.5438
   Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086
   Chen KY, 2006, J VIROL, V80, P7645, DOI 10.1128/JVI.00206-06
   Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493
   Chung SJ, 2005, J MED CHEM, V48, P658, DOI 10.1021/jm0496279
   Creighton T.E., 1993, PROTEINS STRUCTURES
   DeLano W. L, 2002, PYMOL
   Feigin L. A., 1987, STRUCTURE ANAL SMALL
   GLATTER O, 1977, J APPL CRYSTALLOGR, V10, P415, DOI 10.1107/S0021889877013879                                                       
   Guinier A., 1955, SMALL ANGLE SCATTERI
   Hammel M, 2005, J BIOL CHEM, V280, P38562, DOI 10.1074/jbc.M503168200
   Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9                                                   
   HEINEY P, 2006, DATA SQUEEZE 2 07
   Huthoff H, 2005, VIROLOGY, V334, P147, DOI 10.1016/j.virol.2005.01.038
   Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05
   Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718
   Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a
   Johs A, 2006, J BIOL CHEM, V281, P19732, DOI 10.1074/jbc.M601688200
   Kozak SL, 2006, J BIOL CHEM, V281, P29105, DOI 10.1074/jbc.M601901200
   Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126
   Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856
   Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4                                                   
   Navaratnam N, 1998, J MOL BIOL, V275, P695, DOI 10.1006/jmbi.1997.1506
   Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011
   Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068
   Opi S, 2006, J VIROL, V80, P4673, DOI 10.1128/JVI.80.10.4673-4682.2006
   Petoukhov MV, 2006, STRUCTURE, V14, P1021, DOI 10.1016/j.str.2006.04.005
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00969
   SMITH HC, 2005, TOPICS CURRENT GENET, P1610
   Sowden MP, 2002, J CELL SCI, V115, P1027
   Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8
   Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047
   Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6                                                   
   SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663                                                       
   Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268
   Wedekind JE, 2003, TRENDS GENET, V19, P207, DOI 10.1016/S0168-9525(03)00054-4
   Xie KF, 2004, P NATL ACAD SCI USA, V101, P8114, DOI 10.1073/pnas.0400493101
   Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758
   Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707
NR 42
TC 65
Z9 66
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 15
PY 2006
VL 281
IS 50
BP 38122
EP 38126
DI 10.1074/jbc.C600253200
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 115BL
UT WOS:000242709500003
PM 17079235
OA gold
DA 2018-01-05
ER

PT J
AU Ali, A
   Reddy, GSKK
   Cao, H
   Anjum, SG
   Nalam, MNL
   Schiffer, CA
   Rana, TM
AF Ali, Akbar
   Reddy, G. S. Kiran Kumar
   Cao, Hong
   Anjum, Saima Ghafoor
   Nalam, Madhavi N. L.
   Schiffer, Celia A.
   Rana, Tariq M.
TI Discovery of HIV-1 protease inhibitors with picomolar affinities
   incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 Ligands
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS PROTEASE; STRUCTURE-BASED DESIGN; ORALLY
   BIOAVAILABLE INHIBITOR; POTENT INHIBITORS; DRUG-RESISTANCE; TMC114;
   MODEL; COMBINATION; SUBSTRATE; THERAPY
AB Here, we describe the design, synthesis, and biological evaluation of novel HIV-1 protease inhibitors incorporating N-phenyloxazolidinone-5-carboxamides into the (hydroxyethylamino) sulfonamide scaffold as P2 ligands. Series of inhibitors with variations at the P2 phenyloxazolidinone and the P2' phenylsulfonamide moieties were synthesized. Compounds with the (S)-enantiomer of substituted phenyloxazolidinones at P2 show highly potent inhibitory activities against HIV-1 protease. The inhibitors possessing 3-acetyl, 4-acetyl, and 3-trifluoromethyl groups at the phenyl ring of the oxazolidinone fragment are the most potent in each series, with K-i values in the low picomolar (pM) range. The electron-donating groups 4-methoxy and 1,3-dioxolane are preferred at P2' phenyl ring, as compounds with other substitutions show lower binding affinities. Attempts to replace the isobutyl group at P1' with small cyclic moieties caused significant loss of affinities in the resulting compounds. Crystal structure analysis of the two most potent inhibitors in complex with the HIV-1 protease provided valuable information on the interactions between the inhibitor and the protease enzyme. In both inhibitor-enzyme complexes, the carbonyl group of the oxazolidinone ring makes hydrogen-bond interactions with relatively conserved Asp29 residue of the protease. Potent inhibitors from each series incorporating various phenyloxazolidinone based P2 ligands were selected and their activities against a panel of multidrug-resistant (MDR) protease variants were determined. Interestingly, the most potent protease inhibitor starts out with extremely tight affinity for the wild-type enzyme (K-i = 0.8 pM), and even against the MDR variants it retains picomolar to low nanomolar Ki, which is highly comparable with the best FDA-approved protease inhibitors.
C1 Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Chem Biol Program, Worcester, MA 01605 USA.
RP Rana, TM (reprint author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Chem Biol Program, Worcester, MA 01605 USA.
EM tariq.rana@umassmed.edu
FU NIGMS NIH HHS [GM66524]
CR Barbachyn MR, 2003, ANGEW CHEM INT EDIT, V42, P2010, DOI 10.1002/anie.200200528
   Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006
   Brickner SJ, 1996, J MED CHEM, V39, P673, DOI 10.1021/jm9509556
   Cheng TJ, 2004, ANTIMICROB AGENTS CH, V48, P2437, DOI 10.1128/AAC.48.7.2437-2447.2004
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.62314-2321.2005
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7                                                    
   Freskos JN, 1996, BIOORG MED CHEM LETT, V6, P445, DOI 10.1016/0960-894X(96)00035-2
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P979, DOI 10.1016/S0960-894X(98)00139-5                                                   
   Ghosh AK, 2005, J MED CHEM, V48, P3576, DOI 10.1021/jm050019i
   Ghosh AK, 2001, FARMACO, V56, P29, DOI 10.1016/S0014-827X(01)01025-4
   GRECO WR, 1979, J BIOL CHEM, V254, P2104
   Gulick RM, 2000, ANN INTERN MED, V133, P35, DOI 10.7326/0003-4819-133-1-200007040-00007
   Jones T. A., 1990, CRYSTALLOGRAPHIC MOD, P189
   Kaldor SW, 1997, J MED CHEM, V40, P3979, DOI 10.1021/jm9704098
   Kazmierski WM, 2004, BIOORG MED CHEM LETT, V14, P5685, DOI 10.1016/j.bmcl.2004.08.038
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   King NM, 2004, J VIROL, V78, P12012, DOI 10.1128/JVI.78.21.12012-12021.2004
   King NM, 2004, CHEM BIOL, V11, P1333, DOI 10.1016/j.chembiol.2004.08.010
   King NM, 2002, PROTEIN SCI, V11, P418, DOI 10.1110/ps.25502
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   Kovalevsky AY, 2006, J MED CHEM, V49, P1379, DOI 10.1021/jm050943c
   KURIYAN J, 1991, P NATL ACAD SCI USA, V88, P2773, DOI 10.1073/pnas.88.7.2773
   Manninen P. R., 2005, ORG SYNTH, V81, P112
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   Miller JF, 2006, BIOORG MED CHEM LETT, V16, P1788, DOI 10.1016/j.bmcl.2006.01.035
   MINOR W, 1993, XDISPLAYF PROGRAM
   Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255                                                       
   Nagarajan SR, 2003, BIOORGAN MED CHEM, V11, P4769, DOI 10.1016/j.bmc.2003.07.001
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597                                                       
   Otwinowski Z., 1997, MACROMOLECULAR CRYST, P307
   Prabu-Jeyabalan M, 2000, J MOL BIOL, V301, P1207, DOI 10.1006/jmbi.2000.4018
   Prabu-Jeyabalan M, 2003, J VIROL, V77, P1306, DOI 10.1128/JVI.77.2.1306-1315.2003
   Prabu-Jeyabalan M, 2002, STRUCTURE, V10, P369, DOI 10.1016/S0969-2126(02)00720-7
   Randolph JT, 2006, BIOORGAN MED CHEM, V14, P4035, DOI 10.1016/j.bmc.2006.02.013
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   Robinson BS, 2000, ANTIMICROB AGENTS CH, V44, P2093, DOI 10.1128/AAC.44.8.2093-2099.2000                                                 
   Salituro FG, 1998, BIOORG MED CHEM LETT, V8, P3637, DOI 10.1016/S0960-894X(98)00670-2                                                   
   SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218
   Surleraux DLNG, 2005, J MED CHEM, V48, P1965, DOI 10.1021/jm049454m
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   THOSH AK, 2006, J MED CHEM, V49, P5252
   TICKLE IJ, 1999, IUCR99 COMP SCH LOND
   Turner SR, 1998, J MED CHEM, V41, P3467, DOI 10.1021/jm9802158
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Wu TD, 2003, J VIROL, V77, P4836, DOI 10.1128/JVI.77.8.4836-4847.2003
   Yeung CM, 2005, BIOORG MED CHEM LETT, V15, P2275, DOI 10.1016/j.bmcl.2005.03.008
   VAZQUEZ ML, 2000, Patent No. 6046190
   HESTER JB, 2003, Patent No. 2003006440
   THOMAS RC, 2003, Patent No. 2003072553
NR 56
TC 68
Z9 70
U1 2
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 14
PY 2006
VL 49
IS 25
BP 7342
EP 7356
DI 10.1021/jm060666p
PG 15
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 113VJ
UT WOS:000242625800010
PM 17149864
DA 2018-01-05
ER

PT J
AU Torchilin, VP
AF Torchilin, Vladimir P.
TI Multifunctional nanocarriers
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE nanomedicine; pharmaceutical carriers; drug delivery; drug targeting;
   long-circulating drug carriers; imaging; intracellular drug; delivery;
   liposomes; micelles; polymeric nanoparticles
ID STERICALLY STABILIZED LIPOSOMES; HUMAN-IMMUNODEFICIENCY-VIRUS; LARGE
   UNILAMELLAR LIPOSOMES; PROLONGED CIRCULATION TIME; PH-SENSITIVE
   LIPOSOMES; PEGYLATED POLYCYANOACRYLATE NANOPARTICLES; POLY(ETHYLENE
   GLYCOL)-GRAFTED LIPOSOMES; GADOLINIUM-LABELED LIPOSOMES; CONTRAST
   ENHANCEMENT AGENTS; RECEPTOR-TARGETED DELIVERY
AB Currently used pharmaceutical nanocarriers, such as liposomes, micelles, nanoemulsions, polymeric nanoparticles and many others demonstrate a broad variety of useful properties, such as longevity in the blood allowing for their accumulation in pathological areas with compromised vasculature; specific targeting to certain disease sites due to various targeting ligands attached to the surface of the nanocarriers; enhanced intracellular penetration with the help of surface-attahced cell-penetrating molecules; contrast properties due to the carrier loading with various contrast materials allowing for direct carrier visualization in vivo; stimuli-sensitivity allowing for drug release from the carriers under certain physiological conditions, and others. Some of those pharmaceutical carriers have already made their way into clinic, while others are still under preclinical development. What could be seen much more rare, however, are the pharmaceutical nanocarriers combining several from the listed abilities. Long-circulating immunoliposomes capable of prolonged residence in the blood and specific target recognition represent one of few examples of this kind. At the same time, the enginnering of multifunctional pharmaceutical nanocarriers combinig several useful preoperties in one particle can significantly enhance the efficacy of many therapeutic and diagnostic protocols. This paper considers current status and possible future directions in the emerging area of multifunctional nanocarriers with primary attention on the combination of such properties as longevity, targetability, intracellular penetration and contrast loading. (c) 2006 Elsevier B.V. All rights reserved.
C1 Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Mugar Bldg,Room 312,360 Huntington Ave, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
CR ALLEN TM, 1995, ADV DRUG DELIVER REV, V16, P267, DOI 10.1016/0169-409X(95)00029-7
   ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7                                                    
   ALLEN TM, 1992, CANCER RES, V52, P2431
   ALLEN TM, 1991, BIOCHIM BIOPHYS ACTA, V1066, P29, DOI 10.1016/0005-2736(91)90246-5
   Alonso MJ, 2004, BIOMED PHARMACOTHER, V58, P168, DOI 10.1016/j.biopha.2004.01.007
   Asai T, 2002, FEBS LETT, V520, P167, DOI 10.1016/S0014-5793(02)02821-1
   Bae Y, 2005, BIOCONJUGATE CHEM, V16, P122, DOI 10.1021/bc0498166
   Balthasar S, 2005, BIOMATERIALS, V26, P2723, DOI 10.1016/j.biomaterials.2004.07.047
   Barsky D, 1992, MAGN RESON MED, V21, P1
   BENHAR I, 1994, P NATL ACAD SCI USA, V91, P12051, DOI 10.1073/pnas.91.25.12051                                                        
   Bernkop-Schnurch A, 2001, CRIT REV THER DRUG, V18, P459
   Bhadra D, 2003, INT J PHARM, V257, P111, DOI 10.1016/S0378-5173(03)00132-7
   BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3
   BOGDANOV AA, 1988, FEBS LETT, V231, P381, DOI 10.1016/0014-5793(88)80854-8                                                    
   BOMAN NL, 1994, CANCER RES, V54, P2830
   Boomer JA, 1999, CHEM PHYS LIPIDS, V99, P145, DOI 10.1016/S0009-3084(99)00033-X
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Branden LJ, 1999, NAT BIOTECHNOL, V17, P784, DOI 10.1038/11726                                                                   
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745
   CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0
   Choi H, 2004, ACAD RADIOL, V11, P996, DOI 10.1016/j.acra.2004.04.018
   Choi Y, 2005, CELL CYCLE, V4, P669, DOI 10.4161/cc.4.5.1684
   CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7
   CHONN A, 1992, J BIOL CHEM, V267, P18759
   Cohen S, 1996, MICROPARTICULATE SYS
   Dagar S, 2003, J CONTROL RELEASE, V91, P123, DOI 10.1016/S0168-3659(03)00242-6
   DAVIS SS, 1993, J CONTROL RELEASE, V24, P157, DOI 10.1016/0168-3659(93)90175-5
   DeFrees SA, 1996, J AM CHEM SOC, V118, P6101, DOI 10.1021/ja954122g                                                               
   Delgado AD, 2000, J BIOMAT SCI-POLYM E, V11, P1395, DOI 10.1163/156856200744309                                                         
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derycke ASL, 2002, INT J ONCOL, V20, P181
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   DUNNICK JK, 1975, J NUCL MED, V16, P483
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006
   ENOCH HG, 1979, P NATL ACAD SCI USA, V76, P145, DOI 10.1073/pnas.76.1.145
   Ewer MS, 2004, SEMIN ONCOL, V31, P161, DOI 10.1053/j.seminoncol.2004.08.006
   FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GABIZON A, 1994, CANCER RES, V54, P987
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   GABIZON A, 1992, BIOCHIM BIOPHYS ACTA, V1103, P94, DOI 10.1016/0005-2736(92)90061-P
   GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949                                                         
   Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124                                                               
   GABIZON AA, 1995, ADV DRUG DELIVER REV, V16, P285, DOI 10.1016/0169-409X(95)00030-B                                                    
   Gaspar MM, 1996, CANCER CHEMOTH PHARM, V38, P373, DOI 10.1007/s002800050497                                                           
   GEISERT EE, 1995, NEUROSCI LETT, V184, P40, DOI 10.1016/0304-3940(94)11163-D
   Gijsens Antoon, 2002, International Journal of Cancer, V101, P78, DOI 10.1002/ijc.10548
   Glogard C, 2002, INT J PHARM, V233, P131, DOI 10.1016/S0378-5173(01)00935-8
   GRANT CWM, 1989, MAGNET RESON MED, V11, P236, DOI 10.1002/mrm.1910110211
   GREF R, 1995, ADV DRUG DELIVER REV, V16, P215, DOI 10.1016/0169-409X(95)00026-4
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   Gregoriadis G., 1988, LIPOSOMES DRUG CARRI
   Guo X, 2001, BIOCONJUGATE CHEM, V12, P291, DOI 10.1021/bc000110v
   Gupta AK, 2004, J MATER SCI-MATER M, V15, P493, DOI 10.1023/B:JMSM.0000021126.32934.20                                              
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Hafez IM, 2001, GENE THER, V8, P1188, DOI 10.1038/sj.gt.3301506
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   HARPER GR, 1991, BIOMATERIALS, V12, P695, DOI 10.1016/0142-9612(91)90119-U
   Hatakeyama H, 2004, INT J PHARM, V281, P25, DOI 10.1016/j.ijpharm.2004.05.025
   HEATH TD, 1980, BIOCHIM BIOPHYS ACTA, V599, P42, DOI 10.1016/0005-2736(80)90055-3
   HEEREMANS JLM, 1995, THROMB HAEMOSTASIS, V73, P488
   HIRANO K, 1985, J PHARM SCI, V74, P915, DOI 10.1002/jps.2600740902                                                          
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   HUANG SK, 1994, CANCER RES, V54, P2186
   Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164
   Hwang K. J., 1987, LIPOSOMES BIOPHYSICS, P109
   Iinuma H, 2002, INT J CANCER, V99, P130, DOI 10.1002/ijc.10242
   ILLUM L, 1983, J PHARM SCI, V72, P1086, DOI 10.1002/jps.2600720933                                                          
   Illum L, 2001, PHARMACEUT RES, V18, P640, DOI 10.1023/A:1011081210142
   Ishida O, 2001, PHARMACEUT RES, V18, P1042, DOI 10.1023/A:1010960900254
   JAMSHAID M, 1988, INT J PHARM, V48, P125, DOI 10.1016/0378-5173(88)90255-4                                                    
   Jeong JH, 2003, BIOCONJUGATE CHEM, V14, P473, DOI 10.1021/bc025632k
   Joshee N, 2002, HUM GENE THER, V13, P1991, DOI 10.1089/10430340260355392
   KABALKA GW, 1991, MAGN RESON IMAGING, V9, P373, DOI 10.1016/0730-725X(91)90425-L                                                    
   KABALKA GW, 1991, MAGNET RESON MED, V19, P406, DOI 10.1002/mrm.1910190231
   Kakudo T, 2004, BIOCHEMISTRY-US, V43, P5618, DOI 10.1021/bi035802w
   Kamps JAAM, 2000, J DRUG TARGET, V8, P235, DOI 10.3109/10611860008997902                                                       
   Kato K, 2004, BIOTECHNOL PROGR, V20, P897, DOI 10.1021/bp0342093
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   Kellam B, 2003, CHEM SOC REV, V32, P327, DOI 10.1039/b211643j
   KHAW BA, 1991, J NUCL MED, V32, P1742
   KLIBANOV AL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P142, DOI 10.1016/0005-2736(91)90385-L
   KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H
   Klibanov A.L, 1998, LONG CIRCULATING LIP, P269
   Klibanov Alexander L., 2003, P231
   Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78                                                     
   Kratz F, 1999, CRIT REV THER DRUG, V16, P245, DOI 10.1615/CritRevTherDrugCarrierSyst.v16.i3.10                                    
   KRAUSE HJ, 1985, INT J PHARM, V27, P145, DOI 10.1016/0378-5173(85)90064-X
   Kunath K, 2003, J CONTROL RELEASE, V89, P113, DOI 10.1016/S0168-3659(03)00076-2
   KUNG VT, 1986, BIOCHIM BIOPHYS ACTA, V862, P435, DOI 10.1016/0005-2736(86)90247-6
   Lasic D, 1995, STEALTH LIPOSOMES
   LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2
   LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572
   Lee ES, 2005, NANO LETT, V5, P325, DOI 10.1021/nl0479987
   Lee ES, 2003, J CONTROL RELEASE, V91, P103, DOI 10.1016/S0168-3659(03)00239-6
   Lee ES, 2003, J CONTROL RELEASE, V90, P363, DOI 10.1016/S0168-3659(03)00205-0
   LEE RJ, 1994, J BIOL CHEM, V269, P3198
   Leroux JC, 2001, J CONTROL RELEASE, V72, P71, DOI 10.1016/S0168-3659(01)00263-2                                                   
   LESERMAN LD, 1980, NATURE, V288, P602, DOI 10.1038/288602a0
   Lestini BJ, 2002, J CONTROL RELEASE, V78, P235, DOI 10.1016/S0168-3659(01)00505-3                                                   
   Levchenko TS, 2003, METHOD ENZYMOL, V372, P339
   LISZIEWICZ J, 1995, GENE THER, V2, P218
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Lu YJ, 2002, ADV DRUG DELIVER REV, V54, P675, DOI 10.1016/S0169-409X(02)00042-X
   Lu YJ, 2002, CANCER IMMUNOL IMMUN, V51, P153, DOI 10.1007/s00262-002-0266-6
   Lukyanov AN, 2004, J CONTROL RELEASE, V100, P135, DOI 10.1016/j.jconrel.2004.08.007
   Lukyanov AN, 2004, J CONTROL RELEASE, V94, P187, DOI 10.1016/j.jconrel.2003.10.008
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Majoros IJ, 2005, J MED CHEM, V48, P5892, DOI 10.1021/jm0401863
   MARTIN FJ, 1982, J BIOL CHEM, V257, P286
   Marty C, 2005, METH MOLEC MED, V109, P389
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   MARUYAMA K, 1991, CHEM PHARM BULL, V39, P1620
   MARUYAMA K, 1994, INT J PHARM, V111, P103, DOI 10.1016/0378-5173(94)90407-3
   MARUYAMA K, 1995, BBA-BIOMEMBRANES, V1234, P74, DOI 10.1016/0005-2736(94)00263-O
   Mastrobattista E, 2002, J BIOL CHEM, V277, P27135, DOI 10.1074/jbc.M200429200
   MOGHIMI SM, 1991, INT J PHARM, V68, P121, DOI 10.1016/0378-5173(91)90134-A
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   MONFARDINI C, 1995, BIOCONJUGATE CHEM, V6, P62, DOI 10.1021/bc00031a006
   Monsky WL, 1999, CANCER RES, V59, P4129
   Morawski AM, 2005, CURR OPIN BIOTECH, V16, P89, DOI 10.1016/j.copbio.2004.11.001
   Muller M, 2003, J BIOMED MATER RES A, V66A, P55, DOI 10.1002/jbm.a.10502
   Muller R, 1991, CARRIERS CONTROLLED
   Murad KT, 1999, BLOOD, V93, P2121
   NAPER DH, 1983, POLYM STABILIZATION
   NEEDHAM D, 1992, BIOCHIM BIOPHYS ACTA, V1108, P40, DOI 10.1016/0005-2736(92)90112-Y
   Ni S, 2002, ANTICANCER RES, V22, P2131
   Nobs L, 2004, J PHARM SCI-US, V93, P1980, DOI 10.1002/jps.20098
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Ogris M, 2001, AAPS PHARMSCI, V3, part. no.
   Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814
   Paleos CM, 2004, BIOMACROMOLECULES, V5, P524, DOI 10.1021/bm030068h
   Pan XQ, 2003, PHARMACEUT RES, V20, P417, DOI 10.1023/A:1022656105022
   PANG SNJ, 1993, J AM COLL TOXICOL, V12, P429
   PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460
   Park EK, 2005, BIOMATERIALS, V26, P1053, DOI 10.1016/j.biomaterials.2004.04.008
   Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7
   Patel H, 1990, TARGETING DRUGS OPTI, P87
   PATEL HM, 1984, BIOCHIM BIOPHYS ACTA, V801, P76, DOI 10.1016/0304-4165(84)90214-9
   Peer D, 2004, INT J CANCER, V108, P780, DOI 10.1002/ijc.11615
   Peracchia MT, 1999, J CONTROL RELEASE, V60, P121, DOI 10.1016/S0168-3659(99)00063-2
   Phillips WT, 1995, HANDB PHARM TOX, P149
   Pollard H, 2001, J GENE MED, V3, P153, DOI 10.1002/jgm.160
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Pooga M, 1998, FASEB J, V12, P67
   PORTER CJH, 1992, FEBS LETT, V305, P62, DOI 10.1016/0014-5793(92)80655-Z
   Powel G.M., 1980, HDB WATER SOLUBLE GU, P1
   Putz B., 1994, Journal of Liposome Research, V4, P771, DOI 10.3109/08982109409018599
   Raffaghello L, 2003, CANCER LETT, V197, P151, DOI 10.1016/S0304-3835(03)00097-1
   RANUCCI E, 1994, MACROMOL CHEM PHYSIC, V195, P3469, DOI 10.1002/macp.1994.021951015                                                     
   Rolland A., 1993, PHARM PARTICULATE CA
   Rose PG, 2005, ONCOLOGIST, V10, P205, DOI 10.1634/theoncologist.10-3-205                                                  
   Roth JA, 1998, SEMIN ONCOL, V25, P33
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Roux E, 2004, J CONTROL RELEASE, V94, P447, DOI 10.1016/j.jconrel.2003.10.024
   Roux E, 2002, INT J PHARM, V242, P25, DOI 10.1016/S0378-5173(02)00183-7                                                   
   Roux E, 2002, J PHARM SCI, V91, P1795, DOI 10.1002/jps.10172
   RUBAS W, 1986, INT J CANCER, V37, P149, DOI 10.1002/ijc.2910370123
   RUBEN S, 1989, J VIROL, V63, P1
   Sakurai F, 2000, J CONTROL RELEASE, V66, P255, DOI 10.1016/S0168-3659(99)00280-1
   Salem AK, 2003, NAT MATER, V2, P668, DOI 10.1038/nmat974
   Sapra P, 2002, CANCER RES, V62, P7190
   SARTORE L, 1994, J BIOACT COMPAT POL, V9, P411, DOI 10.1177/088391159400900404
   Sawant R.M, 2005, P 32 INT S CONTR REL
   Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689                                                        
   Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2
   SCHWAHN D, 1994, J PHYS II, V4, P837, DOI 10.1051/jp2:1994168
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwendener R, 1990, INVEST RADIOL, V23, P922
   Scott MD, 2004, TRANSFUS CLIN BIOL, V11, P40, DOI 10.1016/j.tracli.2003.12.005
   Scott MD, 1998, CURR PHARM DESIGN, V4, P423
   SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8
   SENIOR JH, 1987, CRIT REV THER DRUG, V3, P123
   Shalaev EY, 1999, BBA-BIOMEMBRANES, V1419, P229, DOI 10.1016/S0005-2736(99)00068-1
   Sheff D, 2004, ADV DRUG DELIVER REV, V56, P927, DOI 10.1016/j.addr.2003.11.005
   Shi GF, 2002, J CONTROL RELEASE, V80, P309, DOI 10.1016/S0168-3659(02)00017-2
   Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038
   SIOMI H, 1990, J VIROL, V64, P1803
   STANIMIROVIC DB, 1994, NEUROCHEM RES, V19, P1473, DOI 10.1007/BF00968993
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   Stephenson SM, 2003, ANTICANCER RES, V23, P3341
   Sudimack JJ, 2002, BBA-BIOMEMBRANES, V1564, P31, DOI 10.1016/S0005-2736(02)00399-1
   Sullivan DC, 2004, MOL IMAGING, V3, P364, DOI 10.1162/1535350042973526
   Takeuchi H, 1999, EUR J PHARM BIOPHARM, V48, P123, DOI 10.1016/S0939-6411(99)00029-6
   Tan PH, 2003, J GENE MED, V5, P311, DOI 10.1002/jgm.358
   Tang FX, 1999, BIOCONJUGATE CHEM, V10, P791, DOI 10.1021/bc990016i                                                               
   Thomas TP, 2004, BIOMACROMOLECULES, V5, P2269, DOI 10.1021/bm049704h
   TILCOCK C, 1989, RADIOLOGY, V171, P77, DOI 10.1148/radiology.171.1.2928549                                                 
   Tilcock C, 1993, LIPOSOME TECHNOLOGY, V2, P65
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Torchilin V, 1993, PHOSPHOLIPID HDB, P293
   Torchilin V P, 1985, Crit Rev Ther Drug Carrier Syst, V2, P65
   Torchilin Vladimir P., 1995, Journal of Liposome Research, V5, P795, DOI 10.3109/08982109509012682
   Torchilin Vladimir P., 2003, P193
   Torchilin Vladimir P., 2000, Current Pharmaceutical Biotechnology, V1, P183, DOI 10.2174/1389201003378960
   Torchilin Vladimir P., 1996, Journal of Liposome Research, V6, P99, DOI 10.3109/08982109609037204
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P181, DOI 10.1016/0005-2736(94)90025-6
   Torchilin VP, 2002, BIOMEDICAL ASPECTS OF DRUG TARGETING, P3
   TORCHILIN VP, 1995, ADV DRUG DELIVER REV, V16, P141, DOI 10.1016/0169-409X(95)00022-Y                                                    
   TORCHILIN VP, 1995, J PHARM SCI, V84, P1049, DOI 10.1002/jps.2600840904
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   TORCHILIN VP, 1982, FEBS LETT, V138, P117, DOI 10.1016/0014-5793(82)80408-0                                                    
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100
   TORCHILIN VP, 1994, BBA-BIOMEMBRANES, V1195, P11, DOI 10.1016/0005-2736(94)90003-5
   Torchilin VP, 1999, CHEMTECH, V29, P27
   TORCHILIN VP, 1992, FASEB J, V6, P2716
   Torchilin VP, 1997, ADV DRUG DELIVER REV, V24, P301, DOI 10.1016/S0169-409X(96)00472-3
   TORCHILIN VP, 1980, BIOCHIM BIOPHYS ACTA, V602, P511, DOI 10.1016/0005-2736(80)90330-2                                                    
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   Torchilin VP, 2001, BIOMATERIALS, V22, P3035, DOI 10.1016/S0142-9612(01)00050-3                                                   
   Torchilin VP, 2001, J CONTROL RELEASE, V73, P137, DOI 10.1016/S0168-3659(01)00299-1
   Torchilin VP, 1998, J MICROENCAPSUL, V15, P1, DOI 10.3109/02652049809006831                                                       
   Torchilin V.P, 1995, HANDB PHARM TOX, P403
   Torchilin VP., 1984, LIPOSOME TECHNOLOGY, V3, P75
   Torchilin V.P, 1991, IMMOBILIZED ENZYMES, P206
   Torchilin V.P, 1995, STEALTH LIPOSOMES, P225
   TORCHILIN VP, 1997, J NUCL MED, V41, P141
   TORCHILIN VP, 1995, HDB TARGETED DELIVER
   Torchilin V. P., 1993, J LIPOSOME RES, V3, P201
   Torchilin V.P, 2000, P 27 INT S CONTR REL, P217
   Trubetskoy Vladimir S., 1994, Journal of Liposome Research, V4, P961, DOI 10.3109/08982109409018613
   TRUBETSKOY VS, 1995, ADV DRUG DELIVER REV, V16, P311, DOI 10.1016/0169-409X(95)00032-3
   TRUBETSKOY VS, 1995, MAGN RESON IMAGING, V13, P31, DOI 10.1016/0730-725X(94)00083-F
   Trubetskoy VS, 1996, ACAD RADIOL, V3, P232, DOI 10.1016/S1076-6332(96)80448-X                                                   
   Trubetskoy VS, 1996, STP PHARMA SCI, V6, P79
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Turk MJ, 2002, BBA-BIOMEMBRANES, V1559, P56, DOI 10.1016/S0005-2736(01)00441-2
   UNGER E, 1990, INVEST RADIOL, V25, P638, DOI 10.1097/00004424-199006000-00004                                                
   UNGER EC, 1989, RADIOLOGY, V171, P81, DOI 10.1148/radiology.171.1.2928550                                                 
   van Vlerken Lilian E, 2006, Expert Opin Drug Deliv, V3, P205, DOI 10.1517/17425247.3.2.205
   Varga CM, 2000, BIOTECHNOL BIOENG, V70, P593, DOI 10.1002/1097-0290(20001220)70:6<593::AID-BIT1>3.0.CO;2-N
   Veronese FM, 2001, BIOMATERIALS, V22, P405, DOI 10.1016/S0142-9612(00)00193-9
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang J, 2005, J DRUG TARGET, V13, P73, DOI 10.1080/10611860400011935
   Wartlick H, 2004, J DRUG TARGET, V12, P461, DOI 10.1080/10611860400010697
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   WEISSIG V, 1986, FEBS LETT, V202, P86, DOI 10.1016/0014-5793(86)80654-8
   WEISSIG V, 1990, PHARMAZIE, V45, P849
   Gregoriadis G, 1992, LIPOSOME TECHNOLOGY, V3, P231
   Wong JY, 1997, SCIENCE, V275, P820, DOI 10.1126/science.275.5301.820
   WOODLE MC, 1994, BIOCONJUGATE CHEM, V5, P493, DOI 10.1021/bc00030a001                                                             
   WOODLE MC, 1992, INT J PHARMACEUT, V88, P327, DOI 10.1016/0378-5173(92)90331-U                                                    
   WOODLE MC, 1993, CHEM PHYS LIPIDS, V64, P249, DOI 10.1016/0009-3084(93)90069-F
   WU GY, 1987, J BIOL CHEM, V262, P4429
   Xu L, 2002, MOL CANCER THER, V1, P337
   Xu YH, 1996, BIOCHEMISTRY-US, V35, P5616, DOI 10.1021/bi9602019
   YAMAOKA T, 1994, J PHARM SCI, V83, P601, DOI 10.1002/jps.2600830432
   Yessine MA, 2004, ADV DRUG DELIVER REV, V56, P999, DOI 10.1016/j.addr.2003.10.039
   YOSHIOKA H, 1991, BIOMATERIALS, V12, P861, DOI 10.1016/0142-9612(91)90075-L
   YUAN F, 1995, CANCER RES, V55, P3752
   Zalipsky S, 1997, BIOCONJUGATE CHEM, V8, P111, DOI 10.1021/bc9600832                                                               
   ZALIPSKY S, 1995, ADV DRUG DELIVER REV, V16, P157, DOI 10.1016/0169-409X(95)00023-Z
   Zalipsky S, 1999, BIOCONJUGATE CHEM, V10, P703, DOI 10.1021/bc990031n                                                               
   ZALIPSKY S, 1998, TARGETING DRUGS, V6, P131
   Zhang F, 2001, J BIOMAT SCI-POLYM E, V12, P515, DOI 10.1163/156856201300194252
   Zhang JX, 2004, PHARMACOL RES, V49, P185, DOI 10.1016/j.phrs.2003.09.003
   Zhang Y, 2002, BIOMATERIALS, V23, P1553, DOI 10.1016/S0142-9612(01)00267-8
NR 264
TC 803
Z9 822
U1 14
U2 349
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 1
PY 2006
VL 58
IS 14
BP 1532
EP 1555
DI 10.1016/j.addr.2006.09.009
PG 24
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 122GE
UT WOS:000243212900007
PM 17092599
DA 2018-01-05
ER

PT J
AU Musselman, C
   Pitt, SW
   Gulati, K
   Foster, LL
   Andricioaei, I
   Al-Hashimi, HM
AF Musselman, Catherine
   Pitt, Stephen W.
   Gulati, Kush
   Foster, Lesley L.
   Andricioaei, Ioan
   Al-Hashimi, Hashim M.
TI Impact of static and dynamic A-form heterogeneity on the determination
   of RNA global structural dynamics using NMR residual dipolar couplings
SO JOURNAL OF BIOMOLECULAR NMR
LA English
DT Article
DE adaptive recognition; alignment tensor error; idealized A-form helix;
   rdc; RNA structure; spin relaxation
ID HIV-1 TAR RNA; LIQUID-CRYSTALLINE MEDIUM; NUCLEIC-ACID;
   MOLECULAR-DYNAMICS; RESONANCE ASSIGNMENT; ALIGNMENT TENSORS; FIELD;
   CONFORMATION; MOTIONS; RELAXATION
AB We examined how static and dynamic deviations from the idealized A-form helix propagate into errors in the principal order tensor parameters determined using residual dipolar couplings (rdcs). A 20-ns molecular dynamics (MD) simulation of the HIV-1 transactivation response element (TAR) RNA together with a survey of spin relaxation studies of RNA dynamics reveals that pico-to-nanosecond local motions in nonterminal Watson-Crick base-pairs will uniformly attenuate base and sugar one bond rdcs by similar to 7%. Gaussian distributions were generated for base and sugar torsion angles through statistical comparison of 40 RNA X-ray structures solved to < 3.0 angstrom resolution. For a typical number (>= 11) of one bond C-H base and sugar rdcs, these structural deviations together with rdc uncertainty (1.5 Hz) lead to average errors in the magnitude and orientation of the principal axis of order that are < 9% and < 4 degrees, respectively. The errors decrease to < 5% and < 4 degrees for <= 17 rdcs. A protocol that allows for estimation of error in A-form order tensors due to both angular deviations and rdc uncertainty (Aform-RDC) is validated using theoretical simulations and used to analyze rdcs measured previously in TAR in the free state and bound to four distinct ligands. Results confirm earlier findings that the two TAR helices undergo large changes in both their mean relative orientation and dynamics upon binding to different targets.
C1 Univ Michigan, Dept Chem, Div Biophys Res, Ann Arbor, MI 48109 USA.
   Univ Michigan, Program Bioinformat, Ann Arbor, MI 48109 USA.
   Johnson & Johnson Consumer Prod Inc, Skillman, NJ 08558 USA.
RP Al-Hashimi, HM (reprint author), Univ Michigan, Dept Chem, Div Biophys Res, 930 N Univ Ave, Ann Arbor, MI 48109 USA.
EM hashimi@umich.edu
OI Musselman, Catherine/0000-0002-8356-7971
FU NIAID NIH HHS [R01 AI066975-01]
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Al-Hashimi HM, 2005, CHEMBIOCHEM, V6, P1506, DOI 10.1002/cbic.200500002
   Al-Hashimi HM, 2003, J MOL BIOL, V329, P867, DOI 10.1016/S0022-2836(03)00517-5
   Al-Hashimi HM, 2002, J MOL BIOL, V315, P95, DOI 10.1006/jmbi.2001.5235
   Al-Hashimi HM, 2002, J MOL BIOL, V318, P637, DOI 10.1016/S0022-2836(02)00160-2
   BERMAN HM, 1992, BIOPHYS J, V63, P751, DOI 10.1016/S0006-3495(92)81649-1                                                   
   Boisbouvier J, 2004, J BIOMOL NMR, V30, P287, DOI 10.1007/s10858-005-1846-5
   Bondensgaard K, 2002, BIOCHEMISTRY-US, V41, P11532, DOI 10.1021/bi012167q
   BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724
   Bruschweiler R, 2003, CURR OPIN STRUC BIOL, V13, P175, DOI 10.1016/S0959-440X(03)00036-8
   Bryce DL, 2004, J AM CHEM SOC, V126, P10820, DOI 10.1021/ja047179o
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   DICKERSON RE, 1989, NUCLEIC ACIDS RES, V17, P1797, DOI 10.1093/nar/17.5.1797
   Du ZH, 2002, CHEM BIOL, V9, P707, DOI 10.1016/S1074-5521(02)00151-5
   Duchardt E, 2005, J BIOMOL NMR, V32, P295, DOI 10.1007/s10858-005-0659-x
   Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200                                                          
   Gelbin A, 1996, J AM CHEM SOC, V118, P519, DOI 10.1021/ja9528846                                                               
   Hansen AL, 2006, J MAGN RESON, V179, P299, DOI 10.1016/j.jmr.2005.12.012
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695                                                        
   Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819
   Jaroniec CP, 2005, J BIOMOL NMR, V31, P231, DOI 10.1007/s10858-005-0646-2
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Klein DJ, 2001, EMBO J, V20, P4214, DOI 10.1093/emboj/20.15.4214                                                        
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   Lilley David M J, 2004, Methods Mol Biol, V252, P77
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754
   Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680
   MacKerell Alexander D. Jr., 2000, Biopolymers, V56, P257, DOI 10.1002/1097-0282(2000)56:4<257::AID-BIP10029>3.0.CO;2-W
   McCallum SA, 2003, J MOL BIOL, V326, P1037, DOI 10.1016/S0022-2836(02)01431-6
   Mollova ET, 2000, J AM CHEM SOC, V122, P11561, DOI 10.1021/ja0027822
   Moore PB, 1999, ANNU REV BIOCHEM, V68, P287, DOI 10.1146/annurev.biochem.68.1.287                                                
   NEIDLE S, 1999, OXFORD HDB NUCL ACID
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334                                                                
   O'Neil-Cabello E, 2004, J AM CHEM SOC, V126, P66, DOI 10.1021/ja038314k
   Olson WK, 2001, J MOL BIOL, V313, P229, DOI 10.1006/jmbi.2001.4987
   Pitt SW, 2005, ANGEW CHEM INT EDIT, V44, P3412, DOI 10.1002/anie.200500075
   Pitt SW, 2004, J MOL BIOL, V338, P7, DOI 10.1016/j.jmb.2004.02.031
   Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Ramirez BE, 1998, J AM CHEM SOC, V120, P9106, DOI 10.1021/ja982310b                                                               
   Reiter NJ, 2004, BIOCHEMISTRY-US, V43, P13739, DOI 10.1021/bi048815y
   SAUPE A, 1968, ANGEW CHEM INT EDIT, V7, P97, DOI 10.1002/anie.196800971                                                          
   Shajani Z, 2005, J MOL BIOL, V349, P699, DOI 10.1016/j.jmb.2005.04.012
   Showalter SA, 2005, J BIOMOL NMR, V32, P179, DOI 10.1007/s10858-005-7948-2
   Sibille N, 2001, J AM CHEM SOC, V123, P12135, DOI 10.1021/ja011646+
   Sun G, 2004, J CHEM INF COMP SCI, V44, P1752, DOI 10.1021/ci049881+
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279
   Tolman JR, 1997, NAT STRUCT BIOL, V4, P292, DOI 10.1038/nsb0497-292                                                             
   Tolman JR, 2001, J AM CHEM SOC, V123, P1416, DOI 10.1021/ja002500y
   Trantirek L, 2000, J AM CHEM SOC, V122, P10454, DOI 10.1021/ja0015702
   Vallurupalli P, 2005, J AM CHEM SOC, V127, P6893, DOI 10.1021/ja0427799
   van Buuren BNM, 2004, ANGEW CHEM INT EDIT, V43, P187, DOI 10.1002/anie.200351632
   Warren JJ, 2001, J BIOMOL NMR, V20, P311, DOI 10.1023/A:1011214214552
   Zhang Q, 2006, SCIENCE, V311, P653, DOI 10.1126/science.1119488
   Zhang Q, 2003, J AM CHEM SOC, V125, P10530, DOI 10.1021/ja0363056
   Zweckstetter M, 2003, J BIOMOL NMR, V27, P41, DOI 10.1023/A:1024768328860                                                         
   Zweckstetter M, 2002, J BIOMOL NMR, V23, P127, DOI 10.1023/A:1016316415261
NR 60
TC 48
Z9 49
U1 1
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0925-2738
J9 J BIOMOL NMR
JI J. Biomol. NMR
PD DEC
PY 2006
VL 36
IS 4
BP 235
EP 249
DI 10.1007/s10858-006-9087-9
PG 15
WC Biochemistry & Molecular Biology; Spectroscopy
SC Biochemistry & Molecular Biology; Spectroscopy
GA 124JS
UT WOS:000243364700004
PM 17077936
DA 2018-01-05
ER

PT J
AU Veldhoen, S
   Laufer, SD
   Trampe, A
   Restle, T
AF Veldhoen, Sandra
   Laufer, Sandra D.
   Trampe, Alexander
   Restle, Tobias
TI Cellular delivery of small interfering RNA by a non-covalently attached
   cell-penetrating peptide: quantitative analysis of uptake and biological
   effect
SO NUCLEIC ACIDS RESEARCH
LA English
DT Review
ID TAT-DEPENDENT TRANSACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS; IN-VIVO;
   MAMMALIAN-CELLS; GENE DELIVERY; HELA-CELLS; REVERSE-TRANSCRIPTASE;
   MEDIATED ENDOCYTOSIS; PROTEIN TRANSDUCTION; EFFICIENT DELIVERY
AB Cell-penetrating peptides (CPPs) have evolved as promising new tools to deliver nucleic acids into cells. So far, the majority of these delivery systems require a covalent linkage between carrier and cargo. To exploit the higher flexibility of a non-covalent strategy, we focused on the characterisation of a novel carrier peptide termed MPG alpha, which spontaneously forms complexes with nucleic acids. Using a luciferase-targeted small interfering RNA (siRNA) as cargo, we optimised the conditions for MPG alpha-mediated transfection of mammalian cells. In this system, reporter gene activity could be inhibited up to 90% with an IC50 value in the sub-nanomolar range. As a key issue, we addressed the cellular uptake mechanism of MPG alpha/siRNA complexes applying various approaches. First, transfection of HeLa cells with MPG alpha/siRNA complexes in the presence of several inhibitors of endocytosis showed a significant reduction of the RNA interference (RNAi) effect. Second, confocal laser microscopy revealed a punctual intracellular pattern rather than a diffuse distribution of fluorescently labelled RNA-cargo. These data provide strong evidence of an endocytotic pathway contributing significantly to the uptake of MPG alpha/siRNA complexes. Finally, we quantified the intracellular number of siRNA molecules after MPG alpha-mediated transfection. The amount of siRNA required to induce half maximal RNAi was 10 000 molecules per cell. Together, the combination of methods provided allows for a detailed side by side quantitative analysis of cargo internalisation and related biological effects. Thus, the overall efficiency of a given delivery technique as well as the mechanism of uptake can be assessed.
C1 Univ Lubeck, Univ Klinikum Schleswig Holstein, Inst Mol Med, D-23538 Lubeck, Germany.
RP Restle, T (reprint author), Univ Lubeck, Univ Klinikum Schleswig Holstein, Inst Mol Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM restle@imm.uni-luebeck.de
CR Abes S, 2006, J CONTROL RELEASE, V110, P595, DOI 10.1016/j.jconrel.2005.10.026
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   Almofti MR, 2003, ARCH BIOCHEM BIOPHYS, V410, P246, DOI 10.1016/S0003-9861(02)00725-7
   Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Barany-Wallje E, 2005, BIOPHYS J, V89, P2513, DOI 10.1529/biophysj.105.067694
   Berezhna SY, 2006, P NATL ACAD SCI USA, V103, P7682, DOI 10.1073/pnas.0600148103
   BREZIS M, 1984, SCIENCE, V224, P66, DOI 10.1126/science.6322305                                                         
   Burlina F, 2005, ANGEW CHEM INT EDIT, V44, P4244, DOI 10.1002/anie.200500477
   Check E, 2005, NATURE, V433, P561, DOI 10.1038/433561a
   Chien PY, 2005, CANCER GENE THER, V12, P321, DOI 10.1038/sj.cgt.7700793
   Ciftci K, 2001, INT J PHARM, V218, P81, DOI 10.1016/S0378-5173(01)00623-8
   COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   De Coupade C, 2005, BIOCHEM J, V390, P407, DOI 10.1042/BJ20050401
   Deshayes S, 2004, BIOCHEMISTRY-US, V43, P7698, DOI 10.1021/bi049298m
   Deshayes S, 2004, BBA-BIOMEMBRANES, V1667, P141, DOI 10.1016/j.bbamem.2004.09.010
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   DUNN WA, 1980, J BIOL CHEM, V255, P5971
   El-Andaloussi S, 2005, J CONTROL RELEASE, V110, P189, DOI 10.1016/j.jconrel.2005.09.012
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3                                                   
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fedorov Y, 2006, RNA, V12, P1188, DOI 10.1261/rna.28106
   Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044
   Foerg C, 2005, BIOCHEMISTRY-US, V44, P72, DOI 10.1021/bi048330+
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Grzelinski M, 2006, HUM GENE THER, V17, P751, DOI 10.1089/hum.2006.17.751                                                         
   Gumbleton M, 2000, PHARMACEUT RES, V17, P1035, DOI 10.1023/A:1026464526074
   GURNEY T, 1980, J CELL BIOL, V87, P398, DOI 10.1083/jcb.87.2.398
   Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   HAYLETT T, 1991, J BIOL CHEM, V266, P8322
   Hellgren I, 2004, J DRUG TARGET, V12, P39, DOI 10.1080/106118604200041403
   Henriques ST, 2005, BIOCHEMISTRY-US, V44, P10189, DOI 10.1021/bi0502644
   Innes NPT, 1999, ARCH ORAL BIOL, V44, P519, DOI 10.1016/S0003-9969(99)00027-8
   Jarmy G, 2001, J MED VIROL, V64, P223, DOI 10.1002/jmv.1040
   Jiang M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni144
   JOLIOT AH, 1991, NEW BIOL, V3, P1121
   JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146                                                            
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kensch O, 2000, J BIOL CHEM, V275, P18271, DOI 10.1074/jbc.M001309200                                                          
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kootstra NA, 2003, ANNU REV PHARMACOL, V43, P413, DOI 10.1146/annurev.pharmtox.43.100901.140257
   Kretschmer-Kazemi Far R, 2003, NUCLEIC ACIDS RES, V31, P4417
   LAMB JF, 1987, Q J EXP PHYSIOL CMS, V72, P189, DOI 10.1113/expphysiol.1987.sp003063                                                
   Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571
   LINDGREN M, 2002, CELL PENETRATING PEP, P263
   LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295
   Maiolo JR, 2005, BBA-BIOMEMBRANES, V1712, P161, DOI 10.1016/j.bbamem.2005.04.010
   Mano M, 2006, BBA-BIOMEMBRANES, V1758, P336, DOI 10.1016/j.bbamem.2006.01.014
   Mano M, 2005, BIOCHEM J, V390, P603, DOI 10.1042/BJ20050577
   MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715
   MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676
   Minakuchi Y, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh093
   Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Oehlke J, 2005, J MOL RECOGNIT, V18, P50, DOI 10.1002/jmr.691
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Overhoff M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh168
   Padari K, 2005, BIOCONJUGATE CHEM, V16, P1399, DOI 10.1021/bc050125z
   PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199
   Pooga M, 1998, FASEB J, V12, P67
   Prasad TK, 2005, FEBS LETT, V579, P2635, DOI 10.1016/j.febslet.2005.03.083
   Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016
   Rejman J, 2004, BIOCHEM J, V377, P159, DOI 10.1042/BJ20031253
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Robb GB, 2005, NAT STRUCT MOL BIOL, V12, P133, DOI 10.1038/nsmb886
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Sato SB, 1996, J BIOCHEM, V119, P887
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100
   Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/vir.O.18346-O
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   SILVERSTEIN SC, 1977, AM J TROP MED HYG, V26, P161, DOI 10.4269/ajtmh.1977.26.161                                                       
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5
   Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121
   Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325                                                            
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1
   Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102
   Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317
   Thoren PEG, 2005, BIOPHYS CHEM, V114, P169, DOI 10.1016/j.bpc.2004.11.016
   Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049
   Tripathi S, 2005, NUCLEIC ACIDS RES, V33, P4345, DOI 10.1093/nar/gki743
   Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P27, DOI 10.1093/nar/gki142
   Turner JJ, 2005, NUCLEIC ACIDS RES, V33, P6837, DOI 10.1093/nar/gki991
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
   Verma IM, 2005, ANNU REV BIOCHEM, V74, P711, DOI 10.1146/annurev.biochem.74.050304.091637
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WASSARMAN DA, 1991, MOL CELL BIOL, V11, P3432, DOI 10.1128/MCB.11.7.3432                                                           
   Zatsepin TS, 2005, CURR PHARM DESIGN, V11, P3639, DOI 10.2174/138161205774580769
   Zhang AY, 2006, HYPERTENSION, V47, P74, DOI 10.1161/01.HYP.0000196727.53300.62
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 105
TC 140
Z9 145
U1 2
U2 35
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC
PY 2006
VL 34
IS 22
BP 6561
EP 6573
DI 10.1093/nar/gkl941
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 121XY
UT WOS:000243191500022
PM 17135188
OA gold
DA 2018-01-05
ER

PT J
AU Barrientos, LG
   Matei, E
   Lasala, F
   Delgado, R
   Gronenborn, AM
AF Barrientos, Laura G.
   Matei, Elena
   Lasala, Fatima
   Delgado, Rafael
   Gronenborn, Angela M.
TI Dissecting carbohydrate-Cyanovirin-N binding by structure-guided
   mutagenesis: functional implications for viral entry inhibition
SO PROTEIN ENGINEERING DESIGN & SELECTION
LA English
DT Article
DE Cyanovirin-N; high-mannose oligosaccharides; mutant design; viral env
   glycoprotein; virucidal agent
ID HIV-INACTIVATING PROTEIN; DOMAIN-SWAPPED DIMER; CIRCULAR-PERMUTED
   VARIANT; ANTIVIRAL ACTIVITY; CONTAINS 2; VIRUS; AFFINITY; GP120; SITES;
   NMR
AB The HIV-inactivating protein Cyanovirin-N (CV-N) is a cyanobacterial lectin that exhibits potent antiviral activity at nanomolar concentrations by interacting with high-mannose carbohydrates on viral glycoproteins. To date there is no molecular explanation for this potent virucidal activity, given the experimentally measured micromolar affinities for small sugars and the problems encountered with aggregation and precipitation of high-mannose/CV-N complexes. Here, we present results for two CV-N variants, CV-N-mutDA and CV-N-mutDB, compare their binding properties with monomeric [P51G]CV-N (a stabilized version of wtCV-N) and test their in vitro activities. The mutations in CV-N-mutDA and CV-N-mutDB comprise changes in amino acids that alter the trimannose specificity of domain A(M) and abolish the sugar binding site on domain B-M, respectively. We demonstrate that carbohydrate binding via domain B-M is essential for antiviral activity, whereas alterations in sugar binding specificity on domain A(M) have little effect on envelope glycoprotein recognition and antiviral activity. Changes in A(M), however, affect the cross-linking activity of CV-N. Our findings augment and clarify the existing models of CV-N binding to N-linked glycans on viral glycoproteins, and demonstrate that the nanomolar antiviral potency of CV-N is related to the constricted and spatially crowded arrangement of the mannoses in the glycan clusters on viral glycoproteins and not due to CV-N induced virus particle agglutination, making CV-N a true viral entry inhibitor.
C1 NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
   Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.
   Hosp Univ 12 Octubre, Mol Microbiol Lab, Madrid, Spain.
   Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15260 USA.
RP Barrientos, LG (reprint author), NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
EM lbarrientos1@cdc.gov; amg100@pitt.edu
RI Delgado, Rafael/C-4910-2016
OI Delgado, Rafael/0000-0002-6912-4736; Gronenborn, Angela
   M/0000-0001-9072-3525
CR Barrientos LG, 2004, STRUCTURE, V12, P1799, DOI 10.1016/j.str.2004.07.019
   Barrientos LG, 2004, J INFECT DIS, V189, P1440, DOI 10.1086/382658
   Barrientos LG, 2003, J MOL BIOL, V325, P211, DOI 10.1016/S0022-2836(02)01205-6
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Barrientos LG, 2002, PROTEINS, V46, P153, DOI 10.1002/prot.10024
   Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X                                                   
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Barrientos LG, 2002, BIOCHEM BIOPH RES CO, V298, P598, DOI 10.1016/S0006-291X(02)02489-0                                                   
   Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0
   Bewley CA, 2002, J MOL BIOL, V322, P881, DOI 10.1016/S0022-2836(02)00842-2
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   HE JL, 1995, J VIROL, V69, P6705
   Hong PWP, 2002, J VIROL, V76, P12855, DOI 10.1128/JVI.76.24.12855-12865.2002
   Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m
   Lee RT, 2000, GLYCOCONJUGATE J, V17, P543, DOI 10.1023/A:1011070425430                                                         
   Leikina E, 2005, NAT IMMUNOL, V6, P995, DOI 10.1038/ni1248
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2
   Mori T, 1998, PROTEIN EXPRES PURIF, V12, P151, DOI 10.1006/prep.1997.0838
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Sandstrom C, 2004, BIOCHEMISTRY-US, V43, P13926, DOI 10.1021/bi048676k
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
   Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255                                                       
NR 31
TC 36
Z9 37
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1741-0126
J9 PROTEIN ENG DES SEL
JI Protein Eng. Des. Sel.
PD DEC
PY 2006
VL 19
IS 12
BP 525
EP 535
DI 10.1093/protein/gzl040
PG 11
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 115EK
UT WOS:000242717400001
PM 17012344
OA gold
DA 2018-01-05
ER

PT J
AU Summa, V
   Petrocchi, A
   Matassa, VG
   Gardelli, C
   Muraglia, E
   Rowley, M
   Paz, OG
   Laufer, R
   Monteagudo, E
   Pace, P
AF Summa, Vincenzo
   Petrocchi, Alessia
   Matassa, Victor G.
   Gardelli, Cristina
   Muraglia, Ester
   Rowley, Michael
   Paz, Odalys Gonzalez
   Laufer, Ralph
   Monteagudo, Edith
   Pace, Paola
TI 4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone
   carboxamides are potent, selective HIV integrase inhibitors with good
   pharmacokinetic profiles in preclinical species
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DEPENDENT RNA-POLYMERASE; ACTIVE-SITE; DESIGN; ACID; REPLICATION;
   DISCOVERY; ESTER; CELLS; SAR
AB The dihydroxypyrimidine carboxamide 4a was discovered as a potent and selective HIV integrase strand transfer inhibitor. The optimization of physicochemical properties, pharmacokinetic profiles, and potency led to the identification of 13 in the dihydroxypyrimidine series and 18 in the N-methylpyrimidinone series having low nanomolar activity in the cellular HIV spread assay in the presence of 50% normal human serum and very good pharmacokinetics in preclinical species.
C1 IRBM MRL Rome, Dept Med Chem, I-00040 Monte Porzio Catone, Italy.
   IRBM MRL Rome, Dept Drug Metab, I-00040 Monte Porzio Catone, Italy.
RP Summa, V (reprint author), IRBM MRL Rome, Dept Med Chem, Via Pontina,Km 30-600, I-00040 Monte Porzio Catone, Italy.
EM Vincenzo_summa@merck.com
RI Laufer, Ralph/H-9336-2013
CR CULBERTSON TP, 1979, J HETEROCYCLIC CHEM, V16, P1423, DOI 10.1002/jhet.5570160726                                                         
   Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199
   Hazuda DJ, 1997, J VIROL, V71, P7005
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632
   Jin HL, 2006, BIOORG MED CHEM LETT, V16, P3989, DOI 10.1016/j.bcml.2006.05.016
   Koch U, 2006, J MED CHEM, V49, P1693, DOI 10.1021/jm051064t
   Pace P, 2004, BIOORG MED CHEM LETT, V14, P3257, DOI 10.1016/j.bmcl.2004.03.087
   RAMIREZ M, 2006, 10 EUR AIDS C DUBL I
   Sato M, 2006, J MED CHEM, V49, P1506, DOI 10.1021/jm0600139
   Summa V, 2004, J MED CHEM, V47, P5336, DOI 10.1021/jm0494669
   Summa V, 2004, J MED CHEM, V47, P14, DOI 10.1021/jm0342109
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Zhuang LC, 2003, J MED CHEM, V46, P453, DOI 10.1021/jm025553u
NR 15
TC 70
Z9 73
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 16
PY 2006
VL 49
IS 23
BP 6646
EP 6649
DI 10.1021/jm060854f
PG 4
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 103NP
UT WOS:000241894000005
PM 17154493
DA 2018-01-05
ER

PT J
AU Wu, PL
   Hsu, YL
   Wu, TS
   Bastow, KF
   Lee, KH
AF Wu, Pei-Lin
   Hsu, Yu-Lin
   Wu, Tian-Shung
   Bastow, K. F.
   Lee, Kuo-Hsiung
TI Kalanchosides A-C, new cytotoxic bufadienolides from the aerial parts of
   Kalanchoe gracilis
SO ORGANIC LETTERS
LA English
DT Article
ID CYTO-TOXIC BUFADIENOLIDE; BRYOPHYLLUM-PINNATUM; DERIVATIVES; AGENTS
AB Three new compounds, kalanchosides A-C (1-3), as well as five known compounds, were isolated from the aerial parts of Kalanchoe gracilis. The compound structures were determined by spectroscopic methods. All eight isolated compounds showed significant cytotoxic activity against a panel of human tumor cell lines, with potency reaching the nanomolar range. However, only bryophyllin B (8) inhibited HIV replication in H9 lymphocyte cells.
C1 Chung Hwa Coll Med Technol, Dept Cosmet Sci, Tainan 717, Taiwan.
   Natl Cheng Kung Univ, Dept Chem, Tainan 701, Taiwan.
   Natl Res Inst Chinese Med, Taipei 112, Taiwan.
   Univ N Carolina, Sch Pharm, Nat Prod Lab, Chapel Hill, NC 27599 USA.
RP Wu, PL (reprint author), Chung Hwa Coll Med Technol, Dept Cosmet Sci, Tainan 717, Taiwan.
EM wupl@mail.ncku.edu.tw
FU NIAID NIH HHS [AI33066]; NCI NIH HHS [CA17625]
CR Almeida AP, 2000, PLANTA MED, V66, P134, DOI 10.1055/s-2000-11131
   ANDERSON LAP, 1984, J CHEM SOC PERK T 1, P1573, DOI 10.1039/p19840001573                                                            
   Costa SS, 1996, J NAT PROD, V59, P327, DOI 10.1021/np960203u                                                               
   DURRWACHTER JR, 1986, J AM CHEM SOC, V108, P7812, DOI 10.1021/ja00284a053
   GAIND KN, 1976, PHYTOCHEMISTRY, V15, P1999, DOI 10.1016/S0031-9422(00)88875-5                                                   
   Hanniffy OM, 1999, CARBOHYD RES, V319, P124, DOI 10.1016/S0008-6215(99)00129-9
   Kamano Y, 2002, J MED CHEM, V45, P5440, DOI 10.1021/jm0202066
   KEFURT K, 1984, COLLECT CZECH CHEM C, V49, P2130, DOI 10.1135/cccc19842130                                                            
   LIAO JUC, 1993, FLORA TAIWAN, V3, P14
   LIU KCS, 1989, J NAT PROD, V52, P970, DOI 10.1021/np50065a009
   LIU KCS, 1989, PHYTOCHEMISTRY, V28, P2813
   Supratman U, 2001, BIOSCI BIOTECH BIOCH, V65, P947, DOI 10.1271/bbb.65.947
   VAN HEERDEN FR, 1988, MAGN RESON CHEM, V26, P464, DOI 10.1002/mrc.1260260605                                                          
   VANHEERDEN FR, 1988, AFR J CHEM, V41, P39
   WAGNER H, 1986, HELV CHIM ACTA, V69, P359, DOI 10.1002/hlca.19860690215
   Wu PL, 2003, J NAT PROD, V66, P996, DOI 10.1021/np0301238
   Xie L, 2004, J MED CHEM, V47, P756, DOI 10.1021/jm030416y
   YAMAGISHI T, 1988, CHEM PHARM BULL, V36, P1615
   YAMAGISHI T, 1989, J NAT PROD, V52, P1071, DOI 10.1021/np50065a025
NR 19
TC 24
Z9 25
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1523-7060
J9 ORG LETT
JI Org. Lett.
PD NOV 9
PY 2006
VL 8
IS 23
BP 5207
EP 5210
DI 10.1021/ol061873m
PG 4
WC Chemistry, Organic
SC Chemistry
GA 101GQ
UT WOS:000241729500008
PM 17078679
DA 2018-01-05
ER

PT J
AU Couvreur, P
   Stella, B
   Reddy, LH
   Hillaireau, H
   Dubernet, C
   Desmaele, D
   Lepetre-Mouelhi, S
   Rocco, F
   Dereuddre-Bosquet, N
   Clayette, P
   Rosilio, V
   Marsaud, V
   Renoir, JM
   Cattel, L
AF Couvreur, Patrick
   Stella, Barbara
   Reddy, L. Harivardhan
   Hillaireau, Herve
   Dubernet, Catherine
   Desmaele, Didier
   Lepetre-Mouelhi, Sinda
   Rocco, Flavio
   Dereuddre-Bosquet, Nathalie
   Clayette, Pascal
   Rosilio, Veronique
   Marsaud, Veronique
   Renoir, Jack-Michel
   Cattel, Luigi
TI Squalenoyl nanomedicines as potential therapeutics
SO NANO LETTERS
LA English
DT Article
ID CELLULAR PHARMACOLOGY; ANTITUMOR-ACTIVITY; GEMCITABINE; LEUKEMIA;
   ELIMINATION; NUCLEOSIDES; MECHANISMS; ANALOGS; PLASMA
AB Nucleoside analogues display significant anticancer or antiviral activity by interfering with DNA synthesis. However, there are some serious restrictions to their use, including their rapid metabolism and the induction of resistance. We have discovered that the linkage of nucleoside analogues to squalene leads to amphiphilic molecules that self-organize in water as nanoassemblies of 100-300 nm, irrespective of the nucleoside analogue used. The squalenoyl gemcitabine exhibited superior anticancer activity in vitro in human cancer cells and gemcitabine-resistant murine leukemia cells, and in vivo in experimental leukemia both after intravenous and oral administration. The squalenoylation of other antiretroviral nucleosides also led to more potent drugs when tested in primary cultures of HIV-infected lymphocytes. Thus, the squalenoylation is an original technology platform for generating more potent anticancer and antiviral nanomedicines.
C1 Univ Paris Sud, Fac Pharm, CNRS, UMR 8612,IFR 141, F-92296 Chatenay Malabry, France.
   Univ Turin, Fac Farm, Dipartimento Sci & Tecnol Farm, I-10125 Turin, Italy.
   Univ Paris Sud, Fac Pharm, CNRS, UMR 8076, F-92296 Chatenay Malabry, France.
   CEA, Lab Neurovirol, SPI BIO, F-92265 Fontenay Aux Roses, France.
RP Couvreur, P (reprint author), Univ Paris Sud, Fac Pharm, CNRS, UMR 8612,IFR 141, F-92296 Chatenay Malabry, France.
EM patrick.couvreur@cep.u-psud.fr
RI Hillaireau, Herve/U-7781-2017; Lepetre-Mouelhi, Sinda/J-7176-2012;
   COUVREUR, Patrick/G-4844-2011
OI Hillaireau, Herve/0000-0002-0628-7618; COUVREUR,
   Patrick/0000-0001-7961-5443; Stella, Barbara/0000-0001-8266-6604
CR ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491                                                        
   BOUFFARD DY, 1993, BIOCHEM PHARMACOL, V45, P1857, DOI 10.1016/0006-2952(93)90444-2
   CATTEL L, 1992, ACS SYM SER, V497, P174
   CERUTI M, 1992, J MED CHEM, V35, P3050, DOI 10.1021/jm00094a020
   Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114
   GRUNEWALD R, 1992, J CLIN ONCOL, V10, P406, DOI 10.1200/JCO.1992.10.3.406                                                       
   HEINEMANN V, 1992, CANCER RES, V52, P533
   HERTEL LW, 1990, CANCER RES, V50, P4417
   HERTEL LW, 1988, J ORG CHEM, V53, P2406, DOI 10.1021/jo00246a002
   Japour A J, 1995, AIDS Clin Care, V7, P63
   JOLY V, 1995, PRESSE MED, V24, P103
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   LISTER TA, 1982, SEMIN HEMATOL, V19, P172
   Matsuda A, 2004, CANCER SCI, V95, P105, DOI 10.1111/j.1349-7006.2004.tb03189.x
   McComsey Grace, 2003, AIDS Read, V13, P539
   Plunkett W, 1995, ANTI-CANCER DRUG, V6, P7, DOI 10.1097/00001813-199512006-00002
   POGLIANI L, 1994, CHEM PHYS LIPIDS, V70, P21, DOI 10.1016/0009-3084(94)90044-2
   RUSTUM YM, 1992, PHARMACOL THERAPEUT, V56, P307, DOI 10.1016/0163-7258(92)90022-R
   MYHREN F, 2000, Patent No. 0986570
NR 19
TC 178
Z9 182
U1 3
U2 50
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD NOV 8
PY 2006
VL 6
IS 11
BP 2544
EP 2548
DI 10.1021/nl061942q
PG 5
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 103AT
UT WOS:000241856700027
PM 17090088
DA 2018-01-05
ER

PT J
AU Mishra, SH
   Shelley, CM
   Barrow, DJ
   Darby, MK
   Germann, MW
AF Mishra, Subrata H.
   Shelley, Christopher M.
   Barrow, Doyle J., Jr.
   Darby, Martyn K.
   Germann, Markus W.
TI Solution structures and characterization of human immunodeficiency virus
   Rev responsive element IIB RNA targeting zinc finger proteins
SO BIOPOLYMERS
LA English
DT Article
DE Rev responsive element; human immunodeficiency virus; RNA; zinc finger
   proteins; binding; phage display
ID MESSENGER-RNA; CRYSTAL-STRUCTURE; GENE-EXPRESSION; DNA RECOGNITION;
   CHEMICAL-SHIFTS; BINDING-SITE; TYPE-1; COMPLEX; PEPTIDE; NMR
AB The Rev responsive element (RRE), a part of unspliced human immunodeficiency virus (HIV) RNA, serves a crucial role in the production of infectious HIV virions. The viral protein Rev binds to RRE and facilitates transport of mRNA to the cytoplasm. Inhibition of the Rev-RRE interaction disrupts the viral life cycle. Using a phage display protocol, dual zinc finger proteins (ZNFs) were generated that bind specifically to RREIIB at the high affinity Rev binding site. These proteins were farther shortened and simplified, and they still retained their RNA binding affinity. The solution structures of ZNF29 and a mutant, ZNF29G29R, have been determined by nuclear magnetic resonance (NMR) spectroscopy. Both proteins form C2H2-type zinc fingers with essentially identical structures. RNA protein interactions were evaluated quantitatively by isothermal titration calorimetry, which revealed dissociation constants (K-d'S) in the nanomolar range. The interaction with the RNA is dependent upon the zinc finger structure; in the presence of EDTA, RNA binding is abolished. For both proteins, RNA binding is mediated by the a-helical portion of the zinc fingers and target the bulge region of RREIIB-TR. However, ZNF29G29R exhibits significantly stronger binding to the RNA target than ZNF29; this illustrates that the binding of the zinc finger scaffold is amenable to further improvements. (c) 2006 Wiley Periodicals, Inc.
C1 Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
   Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA.
   NIEHS, Res Triangle Pk, NC 27709 USA.
RP Germann, MW (reprint author), Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
EM mwg@gsu.edu
RI German, Markus/L-1531-2013
FU NIAID NIH HHS [R01 AI047459-06, R01 AI047459]
CR ARRIGO SJ, 1990, J VIROL, V64, P4585
   BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6
   BEK A, 1995, INT J BIOCHEM CELL B, V27, P1317, DOI 10.1016/1357-2725(95)00098-A                                                    
   Buonomo SBC, 1999, RNA, V5, P993, DOI 10.1017/S1355838299990064
   Clore GM, 1998, TRENDS BIOTECHNOL, V16, P22, DOI 10.1016/S0167-7799(97)01135-9
   COOK KS, 1991, NUCLEIC ACIDS RES, V19, P1577, DOI 10.1093/nar/19.7.1577
   DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375                                                           
   DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q
   Elrod-Erickson M, 1998, STRUCT FOLD DES, V6, P451, DOI 10.1016/S0969-2126(98)00047-1
   Fischer U, 1999, NUCLEIC ACIDS RES, V27, P4128, DOI 10.1093/nar/27.21.4128
   Friesen WJ, 1998, NAT STRUCT BIOL, V5, P543, DOI 10.1038/794
   Friesen WJ, 2001, J BIOL CHEM, V276, P1968, DOI 10.1074/jbc.M008927200
   FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5
   Goddard TD, 1999, SPARKY 3
   Gosser Y, 2001, NAT STRUCT BIOL, V8, P146, DOI 10.1038/84138
   GRIESINGER C, 1985, J AM CHEM SOC, V107, P6394, DOI 10.1021/ja00308a042                                                             
   GRONENBORN AM, 1989, FEBS LETT, V243, P93, DOI 10.1016/0014-5793(89)81224-4
   GUATELLI JC, 1990, J VIROL, V64, P4093
   Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284
   HADZOPOULOUCLADARAS M, 1989, J VIROL, V63, P1265
   Hennig L, 1999, BIOTECHNIQUES, V26, P1170
   HOPE T, 1995, CURR TOP MICROBIOL, V193, P91
   IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465
   Kim CA, 1996, NAT STRUCT BIOL, V3, P940, DOI 10.1038/nsb1196-940
   KIM SY, 1989, J VIROL, V63, P3708
   Kingsman SM, 1996, EUR J BIOCHEM, V240, P491, DOI 10.1111/j.1432-1033.1996.0491h.x                                                
   KJEMS J, 1991, P NATL ACAD SCI USA, V88, P683, DOI 10.1073/pnas.88.3.683
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   LEE MS, 1992, FEBS LETT, V309, P29, DOI 10.1016/0014-5793(92)80732-V
   Lu D, 2003, NATURE, V426, P96, DOI 10.1038/nature02088
   MADORE SJ, 1994, VIROLOGY, V202, P186, DOI 10.1006/viro.1994.1334
   MALIM MH, 1993, MOL CELL BIOL, V13, P6180, DOI 10.1128/MCB.13.10.6180                                                          
   MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U                                                    
   MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8
   McColl DJ, 1999, P NATL ACAD SCI USA, V96, P9521, DOI 10.1073/pnas.96.17.9521                                                         
   Moller HM, 2005, J MOL BIOL, V351, P718, DOI 10.1016/j.jmb.2005.06.032
   OREILLY MM, 1995, VIROLOGY, V213, P373, DOI 10.1006/viro.1995.0010                                                          
   PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256
   PELTON JG, 1993, PROTEIN SCI, V2, P543
   POMERANTZ RJ, 1992, J VIROL, V66, P1809
   PURCELL DFJ, 1993, J VIROL, V67, P6365
   Sambrook J, 1989, MOL CLONING LAB MANU
   SCHWARTZ S, 1990, J VIROL, V64, P2519
   SHAKA AJ, 1988, J MAGN RESON, V77, P274, DOI 10.1016/0022-2364(88)90178-3
   TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758
   Van Ryk DI, 1999, J BIOL CHEM, V274, P17452, DOI 10.1074/jbc.274.25.17452                                                        
   WIDER G, 1993, J MAGN RESON SER B, V102, P239, DOI 10.1006/jmrb.1993.1092
   WISHART DS, 1994, METHOD ENZYMOL, V239, P363
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   Zhang Q, 2001, CHEM BIOL, V8, P511, DOI 10.1016/S1074-5521(01)00027-8
NR 52
TC 4
Z9 4
U1 0
U2 3
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PD NOV
PY 2006
VL 83
IS 4
BP 352
EP 364
DI 10.1002/bip.20565
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 095YK
UT WOS:000241344000003
PM 16826557
DA 2018-01-05
ER

PT J
AU Mares, J
   Muller, JU
   Skirgailiene, A
   Neumoin, A
   Bewley, CA
   Schmidt, RR
   Zerbe, O
AF Mares, Jiri
   Mueller, Jan U.
   Skirgailiene, Audrone
   Neumoin, Alexey
   Bewley, Carole A.
   Schmidt, Richard R.
   Zerbe, Oliver
TI A model for cell-surface-exposed carbohydrate moieties suitable for
   structural studies bv NMR spectroscopy
SO CHEMBIOCHEM
LA English
DT Article
DE carbohydrates; glycolipids; membranes; micelles; NMR spectroscopy
ID HIV-INACTIVATING PROTEIN; PULSED-FIELD GRADIENTS; CYANOVIRIN-N;
   MEMBRANE-PROTEINS; BIOLOGICAL MACROMOLECULES; BINDING; INHIBITION;
   DIFFUSION; AFFINITY; COMPLEX
AB In the present study a synthetic glycolipid system is presented that can be readily incorporated into phospholipid micelles and that allows the study of cell-surface-exposed carbohydrate units by high-resolution NMR techniques. Here, we present an efficient route for the synthesis of glycolipid compounds that contain mannose, mannobiose, or mannotriose coupled either directly to an alkyl chain or through a poly(ethylene glycol) linker. Furthermore, we hove validated our model system by measuring the binding of cyanovirin N (CV-N), a cyanobacterial protein that binds with nanomolar affinity to the terminal arms of high-mannose structures of the HIV surface-envelope glycoprotein gp120, to glycolipids the carbohydrate portions of which comprise the corresponding high-mannose moieties. From the results of chemical-shift mapping with uniformly N-15-labelled CV-N, we conclude that binding to the protein occurs at sites similar to those involved in binding the nonconjugated carbohydrates. We characterized the insertion of the glycolipids into dodecylphosphocholine (DPC) micelles by measuring translational diffusion, and we observed that the diffusion constants of the glycolipids were very similar to those of the DPC micelles themselves, but significantly deviated from those of the free glycolipids. We also present experimental proof that the glycolipids remain inserted in the micelles while binding to CV-N. Finally, by addition of a ligand that had a higher affinity to CV-N but which was not attached did not couple to a lipid anchor, CV-N could be released from the glycolipid and, hence, from the micelle-associated state.
C1 Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland.
   Univ Konstanz, Dept Chem, D-78457 Constance, Germany.
   NIDDKD, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Zerbe, O (reprint author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.
EM oliver.zerbe@oci.unizh.ch
CR BADER R, 2002, BIONMR DRUG RES, P95
   Baleja JD, 2001, ANAL BIOCHEM, V288, P1, DOI 10.1006/abio.2000.4815
   BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486
   BAX A, 1989, ANNU REV BIOCHEM, V58, P223
   Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0
   Bewley CA, 2002, J MOL BIOL, V322, P881, DOI 10.1016/S0022-2836(02)00842-2
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+
   BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Brandley B K, 1991, Semin Cell Biol, V2, P281
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Chang LC, 2002, J MOL BIOL, V318, P1, DOI 10.1016/S0022-2836(02)00045-1
   Damberg P, 2001, METHOD ENZYMOL, V339, P271, DOI 10.1016/S0076-6879(01)39318-7                                                   
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Ferentz AE, 2000, Q REV BIOPHYS, V33, P29, DOI 10.1017/S0033583500003589                                                       
   Gao XF, 1998, BIOPHYS J, V74, P1871, DOI 10.1016/S0006-3495(98)77897-X                                                   
   Goddard T. D, SPARKY3
   Jerschow A, 1997, J MAGN RESON, V125, P372, DOI 10.1006/jmre.1997.1123                                                          
   KEELER J, 1994, METHOD ENZYMOL, V239, P145
   Keller R., 2004, COMPUTER AIDED RESON
   Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1                                                   
   Kruger-Koplin R.D., 2004, J BIOMOL NMR, V28, P43
   LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4
   Lis H, 1998, CHEM REV, V98, P637, DOI 10.1021/cr940413g                                                               
   MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066
   MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004
   MAYER TG, 1994, ANGEW CHEM INT EDIT, V33, P2177, DOI 10.1002/anie.199421771                                                          
   Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399
   Opella SJ, 1997, NAT STRUCT BIOL, V4, P845
   OPELLA SJ, 1994, METHOD ENZYMOL, V239, P536
   PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S                                                    
   Rademann J, 1997, J ORG CHEM, V62, P3650, DOI 10.1021/jo970087f                                                               
   Rudd PM, 2004, TRENDS BIOTECHNOL, V22, P524, DOI 10.1016/j.tibtech.2004.07.012
   Sanders CR, 2000, BBA-BIOMEMBRANES, V1508, P129, DOI 10.1016/S0005-2736(00)00308-4                                                   
   Sandstrom C, 2004, BIOCHEMISTRY-US, V43, P13926, DOI 10.1021/bi048676k
   Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9                                                   
   SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581
   TAYLOR ME, 2003, INTRO GLYCOBIOLOGY
   Tugarinov V, 2004, ANNU REV BIOCHEM, V73, P107, DOI 10.1146/annurev.biochem.73.011303.074004
   Vinogradova O, 1998, J BIOMOL NMR, V11, P381, DOI 10.1023/A:1008289624496
   Wider G, 2005, METHOD ENZYMOL, V394, P382, DOI 10.1016/S0076-6879(05)94015-9                                                   
   Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842
   WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176
   Wuthrich K, 2003, ANGEW CHEM INT EDIT, V42, P3340, DOI 10.1002/anie.200300595
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   [Anonymous], 2003, ANGEW CHEM
   YAMAZAKI F, 1990, CARBOHYD RES, V201, P31, DOI 10.1016/0008-6215(90)84223-H
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
NR 51
TC 2
Z9 2
U1 0
U2 4
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1439-4227
J9 CHEMBIOCHEM
JI ChemBioChem
PD NOV
PY 2006
VL 7
IS 11
BP 1764
EP 1773
DI 10.1002/cbic.200600219
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 105TG
UT WOS:000242054600022
PM 16952190
DA 2018-01-05
ER

PT J
AU Gorantla, S
   Dou, HY
   Boska, M
   Destache, CJ
   Nelson, J
   Poluektova, L
   Rabinow, BE
   Gendelman, HE
   Mosley, RL
AF Gorantla, Santhi
   Dou, Huanyu
   Boska, Michael
   Destache, Chris J.
   Nelson, Jay
   Poluektova, Larisa
   Rabinow, Barett E.
   Gendelman, Howard E.
   Mosley, R. Lee
TI Quantitative magnetic resonance and SPECT imaging for macrophage tissue
   migration and nanoformulated drug delivery
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE monocytes; cell trafficking; mouse; indinavir
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEASE INHIBITOR; MONONUCLEAR-CELLS;
   GENE-THERAPY; MOUSE MODEL; IN-VIVO; MONOCYTES; TOXICITY; HIV-1;
   BIODISTRIBUTION
AB We posit that the same mononuclear phagocytes (MP) [bone marrow (BM) and blood monocytes, tissue macrophages, microglia, and dendritic cells] which serve as targets, reservoirs, and vehicles for HIV dissemination, can be used as vehicles for antiretroviral therapy (ART). Toward this end, BM macrophages (BMM) were used as carriers for nanoparticle-formulated indinavir (NP-IDV), and the cell distribution was monitored by single photon emission computed tomography (SPECT), transverse relation time (T-2)* weighted magnetic resonance imaging (MRI), histology, and T-scintillation spectrometry. BMM labeled with super paramagnetic iron oxide and/or (111)indium oxine were infused i.v. into naive mice. During the first 7 h, greater than 86% of cell label was recorded within the lungs. On Days 1, 3, 5, and 7, less than 10% of BMM were in lungs, and 74-81% and 13-18% were in liver and spleen, respectively. On a tissue volume basis, as determined by SPECT and MRI, BMM densities in spleen and liver were significantly greater than other tissues. Migration into the lymph nodes on Days I and 7 accounted for 1.5-2% of the total BMM. Adoptive transfer of BMM loaded with NP-IDV produced drug levels in lymphoid and nonlymphoid tissues that exceeded reported therapeutic concentrations by 200- to 350-fold on Day 1 and remained in excess of 100- to 300-fold on Day 14. These data show real-time kinetics and destinations of macrophage trafficking and demonstrate the feasibility of monitoring macrophage-based, nanoformulated ART. J. Leukoc. Biol. 80: 1165-1174; 2006.
C1 Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Radiol, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA.
   Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   Baxter Healthcare Corp, Round Lake, IL 60073 USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 985880 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM begendel@unmc.edu
OI Destache, Christopher/0000-0001-7923-3939; Poluektova,
   Larisa/0000-0001-7339-8732
FU NIAID NIH HHS [P30 AI42845]; NIMH NIH HHS [P01 MH64570]; NINDS NIH HHS
   [P01 NS43985, T32 NS07488, NS 43011, R37 NS36126, P01 NS31492, P01
   NS11766, R01 NS34239]; PHS HHS [R1049264]; NCRR NIH HHS [P20 RR15635]
CR ABREO K, 1985, INT J NUCL MED BIOL, V12, P53, DOI 10.1016/0047-0740(85)90013-0                                                    
   Anderson SA, 2005, BLOOD, V105, P420, DOI 10.1182/blood-2004-06-2222
   Anderson SA, 2004, ANN NEUROL, V55, P654, DOI 10.1002/ana.20066
   Andreesen R, 1998, J LEUKOCYTE BIOL, V64, P419
   ASCHER NL, 1979, ARCH SURG-CHICAGO, V114, P386
   Basu MK, 2004, CURR MOL MED, V4, P681, DOI 10.2174/1566524043360186                                                        
   Becker W, 2001, Lancet Infect Dis, V1, P326, DOI 10.1016/S1473-3099(01)00146-3
   Bennink RJ, 2004, NUCL MED BIOL, V31, P93, DOI 10.1016/S0969-8051(03)00109-4
   Bossi P, 2003, AIDS, V17, P1108, DOI 10.1097/01.aids.0000060373.78202.6b
   BULTE JWM, 1993, MAGNET RESON MED, V29, P32, DOI 10.1002/mrm.1910290108                                                          
   Burke B, 2003, EXPERT OPIN BIOL TH, V3, P919, DOI 10.1517/14712598.3.6.919
   Casau NC, 2003, JAIDS-J ACQ IMM DEF, V32, P494, DOI 10.1097/00126334-200304150-00005
   Cohen OJ, 1997, SPRINGER SEMIN IMMUN, V18, P305, DOI 10.1007/BF00813500
   Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204
   Cui ZR, 2003, DRUG DEV IND PHARM, V29, P689, DOI 10.1081/DDC-120021318
   DOU H, 2006, BLOOD
   DOU H, IN PRESS VIROLOGY
   Eggert AAO, 1999, CANCER RES, V59, P3340
   EMBRETSON J, 1993, P NATL ACAD SCI USA, V90, P357, DOI 10.1073/pnas.90.1.357
   FARADJI A, 1991, CANCER IMMUNOL IMMUN, V33, P319, DOI 10.1007/BF01756597
   Fontana G, 2001, BIOMATERIALS, V22, P2857, DOI 10.1016/S0142-9612(01)00030-8                                                   
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   GENDELMAN HE, 1990, CURR OPIN IMMUNOL, V2, P414, DOI 10.1016/0952-7915(89)90152-0
   Germinario RJ, 2003, IN VITRO CELL DEV-AN, V39, P275
   Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058                                                           
   Hoetelmans RMW, 1999, ANTIVIR THER, V4, P29
   Jayewardene AL, 1998, J CHROMATOGR B, V707, P203, DOI 10.1016/S0378-4347(97)00607-5
   Kedzierska K, 2002, CURR MED CHEM, V9, P1893, DOI 10.2174/0929867023368935                                                        
   Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944                                                        
   LAMOTTE C, 2002, INT WORKSH CLIN PHAR
   OLUWOLE SF, 1990, PROG CLIN BIOL RES, V355, P247
   Owen MR, 2004, J THEOR BIOL, V226, P377, DOI 10.1016/j.jtbi.2003.09.004
   Pautler RG, 2004, PHYSIOLOGY, V19, P168, DOI 10.1152/physiol.00016.2004                                                      
   Quillien V, 2001, CANCER IMMUNOL IMMUN, V50, P477, DOI 10.1007/s002620100224                                                           
   Scherberich JE, 2003, INT J CLIN PHARM TH, V41, P459
   SCHRAGER LK, 1995, NATURE, V377, P680, DOI 10.1038/377680a0                                                                
   Tanaka S, 2004, STROKE, V35, P1968, DOI 10.1161/01.STR.0000133685.59556.a7
   TERRIER F, 1995, ACAD RADIOL, V2, P565, DOI 10.1016/S1076-6332(05)80116-3
   VANDERMEER JWM, 1978, J EXP MED, V147, P271, DOI 10.1084/jem.147.1.271                                                           
   VANFURTH R, 1992, DEV DISTRIBUTION MON
   Verani A, 2005, MOL IMMUNOL, V42, P195, DOI 10.1016/j.molimm.2004.06.020
   Verma Indu, 2004, Indian Journal of Experimental Biology, V42, P949
   WILTROUT RH, 1983, J RETICULOENDOTH SOC, V34, P253
   Yeager MP, 2000, CRIT CARE MED, V28, P1477, DOI 10.1097/00003246-200005000-00037                                                
   Zelivyanskaya ML, 2003, J NEUROSCI RES, V73, P284, DOI 10.1002/jnr.10693
NR 45
TC 40
Z9 43
U1 0
U2 6
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD NOV
PY 2006
VL 80
IS 5
BP 1165
EP 1174
DI 10.1189/jlb.0206110
PG 10
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA 119MJ
UT WOS:000243016100022
PM 16908517
DA 2018-01-05
ER

PT J
AU Zhang, QR
   Yu, ET
   Kellersberger, KA
   Crosland, E
   Fabris, D
AF Zhang, Qingrong
   Yu, Eizadora T.
   Kellersberger, Katherine A.
   Crosland, Elizabeth
   Fabris, Daniele
TI Toward building a database of bifunctional probes for the MS3D
   investigation of nucleic acids structures
SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
LA English
DT Article; Proceedings Paper
CT 18th Sanibel Conference on Mass Spectrometry
CY JAN, 2006
CL Sanibel Island, FL
ID TANDEM MASS-SPECTROMETRY; CHEMICAL CROSS-LINKING; ELECTRON-CAPTURE
   DISSOCIATION; ESCHERICHIA-COLI RIBOSOME; CHARGED PROTEIN CATIONS; COMMON
   BUFFER SYSTEMS; DRUG-DNA ADDUCTS; COLLISIONAL ACTIVATION; ALKYLATING
   AGENTS; GENOMIC RNA
AB This report illustrates the approaches employed to investigate critical aspects of the activity of crosslinking reagents toward nucleic acid substrates, which should be evaluated to identify candidate probes for mass spectrometric 3D (MS3D) investigations of biomolecules and macromolecular complexes. Representative members of different classes of bifunctional reagents were taken into consideration, including bikethoxal and phenyl-diglyoxal [bis-(1,2-dicarbonyls)], cisplatin (coordinative binding agents), chlorambucil and nitrogen mustard [bis-(2-chdoroethyl)amines], and sym-triazine trichloride (triazines). Nanospray-Fourier transform mass spectrometry (FTMS) was applied without desalting or separation procedures to characterize the covalent products obtained by probing dinucleotide and trinucleotide substrates under a variety of experimental conditions in vitro. The carefully controlled composition of these substrates enabled us to obtain valid comparisons of probe activity toward individual nucleotides and evaluate possible base-specific effects, including the stability of the different adducts in solution under the selected reaction conditions. The gas-phase behavior of the observed products was investigated using sustained off-resonance irradiation collision-induced dissociation (SORI-CID) to obtain valuable information for guiding the design of sequencing experiments and helping the data interpretation. Structured RNA substrates, such as HIV-1 stemloop 1, were finally employed to investigate the structural determinant of adduct formation and highlight the different nature of the spatial information provided by the various candidate probes.
C1 Univ Maryland, Dept Chem & Biochem, Marlene & Stewart Greenbaum Canc Ctr, Baltimore, MD 21250 USA.
   Villa Julie Coll, Stevenson, MD USA.
   Univ Maryland Baltimore Cty, Baltimore, MD 21228 USA.
RP Fabris, D (reprint author), Univ Maryland, Dept Chem & Biochem, Marlene & Stewart Greenbaum Canc Ctr, 1000 Hilltop Circle, Baltimore, MD 21250 USA.
EM fabris@umbc.edu
RI Yu, Eizadora/A-8971-2011
FU NIGMS NIH HHS [R01-GM643208]
CR Akinsiku OT, 2005, J MASS SPECTROM, V40, P1372, DOI 10.1002/jms.932
   Back JW, 2003, J MOL BIOL, V331, P303, DOI 10.1016/S0022-2836(03)00721-6
   BARRY JP, 1995, J MASS SPECTROM, V30, P993, DOI 10.1002/jms.1190300709                                                          
   Beck JL, 2001, MASS SPECTROM REV, V20, P61, DOI 10.1002/mas.1003
   BREWER LA, 1983, BIOCHEMISTRY-US, V22, P4303, DOI 10.1021/bi00287a022
   BRIMACOMBE R, 1988, METHOD ENZYMOL, V164, P287
   BROOKES P, 1961, BIOCHEM J, V80, P496, DOI 10.1042/bj0800496                                                               
   Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s                                                               
   Chaudhary AK, 1996, CARCINOGENESIS, V17, P1167, DOI 10.1093/carcin/17.5.1167                                                        
   CHRISTIANSEN J, 1988, METHOD ENZYMOL, V164, P456
   COMISAROW MB, 1974, CHEM PHYS LETT, V25, P282, DOI 10.1016/0009-2614(74)89137-2
   DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y
   de Koning LJ, 1997, INT J MASS SPECTROM, V165, P209, DOI 10.1016/S0168-1176(97)00186-9
   Deforce DLD, 1996, ANAL CHEM, V68, P3575, DOI 10.1021/ac9600013                                                               
   EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109                                                          
   EXPERTBEZANCON A, 1988, METHOD ENZYMOL, V164, P310
   FARMER PB, 1995, J MASS SPECTROM, V30, P1369, DOI 10.1002/jms.1190301002                                                          
   FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315
   FICHTINGERSCHEPMAN AMJ, 1985, BIOCHEMISTRY-US, V24, P707, DOI 10.1021/bi00324a025
   GAUTHIER JW, 1991, ANAL CHIM ACTA, V246, P221
   HABIBIGOUDARZI S, 1995, J AM SOC MASS SPECTR, V6, P102, DOI 10.1016/S1044-0305(94)00108-C
   Hagemeister T, 2002, J MASS SPECTROM, V37, P731, DOI 10.1002/jms.333
   Hendrickson CL, 1999, ANNU REV PHYS CHEM, V50, P517, DOI 10.1146/annurev.physchem.50.1.517                                               
   Iannitti P, 1997, J AM CHEM SOC, V119, P1490, DOI 10.1021/ja962439q                                                               
   Iannitti-Tito P, 2000, ANALYST, V125, P627, DOI 10.1039/a908920i                                                                
   Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n                                                               
   Kellersberger KA, 2004, ANAL CHEM, V76, P2438, DOI 10.1021/ac0355045
   Kieken F, 2002, EUR BIOPHYS J BIOPHY, V31, P521, DOI 10.1007/s00249-002-0251-1
   Kirpekar F, 2001, RAPID COMMUN MASS SP, V15, P8, DOI 10.1002/1097-0231(20010115)15:1<8::AID-RCM185>3.0.CO;2-S
   Kruppa GH, 2003, RAPID COMMUN MASS SP, V17, P155, DOI 10.1002/rcm.885
   KUNDU GC, 1994, PHARMACOL BIOCHEM BE, V49, P621, DOI 10.1016/0091-3057(94)90078-7                                                    
   LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035
   LAWLEY PD, 1965, NATURE, V206, P480, DOI 10.1038/206480a0                                                                
   Lawrence DC, 2003, J MOL BIOL, V326, P529, DOI 10.1016/S0022-2836(02)01305-0
   LIPPARD SJ, 1982, SCIENCE, V218, P1075, DOI 10.1126/science.6890712
   LITTLE DP, 1994, ANAL CHEM, V66, P2809, DOI 10.1021/ac00090a004
   Luce RA, 2001, METHOD ENZYMOL, V340, P396
   MARTIN LB, 1991, ANAL BIOCHEM, V193, P6, DOI 10.1016/0003-2697(91)90035-R                                                    
   MCCLOSKEY JA, 1992, INT J MASS SPECTROM, V118, P593, DOI 10.1016/0168-1176(92)85077-D                                                    
   MCLUCKEY SA, 1993, J AM CHEM SOC, V115, P12085, DOI 10.1021/ja00078a054
   MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783
   MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023
   NOLLER HF, 1972, P NATL ACAD SCI USA, V69, P3115, DOI 10.1073/pnas.69.11.3115                                                         
   Nordhoff E, 1996, MASS SPECTROM REV, V15, P67, DOI 10.1002/(SICI)1098-2787(1996)15:2<67::AID-MAS1>3.0.CO;2-8
   Novak P, 2004, J MASS SPECTROM, V39, P322, DOI 10.1002/jms.587
   Null AP, 2003, ANAL CHEM, V75, P1331, DOI 10.1021/ac026217o
   OSTE C, 1979, MOL GEN GENET, V168, P81, DOI 10.1007/BF00267936
   PANCERELLA C, 2005, P 19 PROT SOC M BOST
   RAJSKI SR, 1998, CHEM REV, V98, P2733
   Richter S, 2004, CHEM RES TOXICOL, V17, P492, DOI 10.1021/tx034210b
   Richter SN, 2005, CHEM RES TOXICOL, V18, P35, DOI 10.1021/tx049858i
   RODGERS MT, 1994, INT J MASS SPECTROM, V137, P121, DOI 10.1016/0168-1176(94)04029-X                                                    
   SENKO MW, 1994, ANAL CHEM, V66, P2801, DOI 10.1021/ac00090a003
   Sinz A, 2003, J MASS SPECTROM, V38, P1225, DOI 10.1002/JMS.559
   STAEHELIN M, 1959, BIOCHIM BIOPHYS ACTA, V31, P448, DOI 10.1016/0006-3002(59)90019-8
   Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519                                                               
   WOODIN RL, 1978, J AM CHEM SOC, V100, P3248, DOI 10.1021/ja00478a065                                                             
   Young MM, 2000, P NATL ACAD SCI USA, V97, P5802, DOI 10.1073/pnas.090099097
   Yu E, 2003, J MOL BIOL, V330, P211, DOI 10.1016/S0022-2836(03)00589-8
   Yu ET, 2005, J MOL BIOL, V345, P69, DOI 10.1016/j.jmb.2004.10.014
   YU ET, 2004, ANAL BIOCHEM, V344, P356
   Zubarev RA, 1998, J AM CHEM SOC, V120, P3265, DOI 10.1021/ja973478k                                                               
   Zubarev RA, 2000, ANAL CHEM, V72, P563, DOI 10.1021/ac990811p                                                               
   ZWIEB C, 1978, NUCLEIC ACIDS RES, V5, P2705, DOI 10.1093/nar/5.8.2705                                                            
NR 64
TC 23
Z9 23
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1044-0305
J9 J AM SOC MASS SPECTR
JI J. Am. Soc. Mass Spectrom.
PD NOV
PY 2006
VL 17
IS 11
BP 1570
EP 1581
DI 10.1016/j.jasms.2006.06.002
PG 12
WC Biochemical Research Methods; Chemistry, Analytical; Chemistry,
   Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA 108MC
UT WOS:000242242900012
PM 16875836
OA gold
DA 2018-01-05
ER

PT J
AU Winum, JY
   Scozzafava, A
   Montero, JL
   Supuran, CT
AF Winum, Jean-Yves
   Scozzafava, Andrea
   Montero, Jean-Lonis
   Supuran, Claudiu T.
TI Therapeutic potential of sulfamides as enzyme inhibitors
SO MEDICINAL RESEARCH REVIEWS
LA English
DT Review
DE sulfamide; enzyme-inhibitor adduct; protease inhibitors; carbonic
   anhydrase inhibitors; steroid sulfatase inhibitors; HIV protease;
   gamma-secretase; elastase; chymase; tryptase; thrombin; carboxypeptidase
   A; matrix metalloproteinase; protein tyrosine phosphatase
ID CARBONIC-ANHYDRASE INHIBITORS; 1,2,5-THIADIAZOLIDIN-3-ONE 1,1 DIOXIDE;
   STEROID SULFATASE INHIBITORS; HUMAN-LEUKOCYTE ELASTASE; GAMMA-SECRETASE
   INHIBITORS; TYROSINE-PHOSPHATASE 1B; STATE ANALOG INHIBITORS; RAY
   CRYSTAL-STRUCTURE; OF-THE-ART; ISOZYME-II
AB Sulfamide, a quite simple molecule incorporating the sulfonamide functionality, widely used by medicinal chemists for the design of a host of biologically active derivatives with pharmacological applications, may give rise to at least five types of derivatives, by substituting one to four hydrogen atoms present in it, which show specific biological activities. Recently, some of these compounds started to be exploited for the design of many types of therapeutic agents. Among the enzymes for which sulfamide-based inhibitors were designed, are the carbonic anhydrases (CAs), a large number of proteases belonging to the aspartic protease (HIV-1 protease, gamma-secretase), serine protease (elastase, chymase, tryptase, and thrombin among others), and metalloprotease (carboxypeptidase A (CPA) and matrix metalloproteinases (MMP)) families. Some steroid sulfatase (STS) and protein tyrosine phosphatase inhibitors belonging to the sulfamide class of derivatives have also been reported. In all these compounds, many of which show low nanomolar affinity for the target enzymes for which they have been designed, the free or substituted sulfamide moiety plays important roles for the binding of the inhibitor to the active site cavity, either by directly coordinating to a metal ion found in some metalloenzymes (CAs, CPA, STS), usually by means of one of the nitrogen atoms present in the sulfamide motif, or as in the case of the cyclic sulfamides acting as HIV protease inhibitors, interacting with the catalytically critical aspartic acid residues of the active site by means of an oxygen atom belonging to the HN-SO2-NH motif, which substitutes a catalytically essential water molecule. In other cases, the sulfamide moiety is important for inducing desired physico-chemical properties to the drug-like compounds incorporating it, such as enhanced water solubility, better bioavailability, etc., because of the intrinsic properties of this highly polarized moiety when attached to an organic scaffold. This interesting motif is thus of great value for the design of pharmacological agents with a lot of applications. (c) 2006 Wiley Periodicals, Inc.
C1 Univ Florence, Dipartimento Chim, Lab Chim Bioinorgan, I-50019 Florence, Italy.
   Univ Montpellier 2, Lab Chim Biomol, UMR 5032, Ecole Natl Super Chim, F-34296 Montpellier, France.
RP Winum, JY (reprint author), Univ Florence, Dipartimento Chim, Lab Chim Bioinorgan, Via Lastruccia 3,Rm 188,Polo Sci, I-50019 Florence, Italy.
EM winumj@univ-montp2.fr; claudiu.supuran@unifi.it
RI WINUM, Jean-Yves/P-3387-2016; Supuran, Claudiu/A-5151-2008
OI WINUM, Jean-Yves/0000-0003-3197-3414; 
CR Abbate F, 2002, J MED CHEM, V45, P3583, DOI 10.1021/jm011131t
   ALA PJ, 2002, PROTEINASE PEPTIDASE, P367
   Backbro K, 1997, J MED CHEM, V40, P898, DOI 10.1021/jm960588d
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Black E, 2005, BIOORG MED CHEM LETT, V15, P2503, DOI 10.1016/j.bmcl.2005.03.068
   Briganti F, 1997, BIOCHEMISTRY-US, V36, P10384, DOI 10.1021/bi970760v
   Briganti F, 1996, EUR J MED CHEM, V31, P1001, DOI 10.1016/S0223-5234(97)86179-X                                                   
   Cairns JA, 2005, PULM PHARMACOL THER, V18, P55, DOI 10.1016/j.pupt.2004.09.032
   Casini A, 2003, BIOORG MED CHEM LETT, V13, P837, DOI 10.1016/S0960-894X(03)00028-3
   Casini A, 2002, EXPERT OPIN THER PAT, V12, P1307, DOI 10.1517/13543776.12.9.1307                                                      
   Casini A, 2003, BIOORG MED CHEM LETT, V13, P841, DOI 10.1016/S0960-894X(03)00029-5
   CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003                                                             
   Dadke Shrikrishna, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P299, DOI 10.2174/1568008033340108
   De Simone G, 2005, BIOORG MED CHEM LETT, V15, P2315, DOI 10.1016/j.bmcl.2005.03.032
   Dewang PM, 2005, CURR MED CHEM, V12, P1
   Di Fiore A, 2005, BIOORG MED CHEM LETT, V15, P1937, DOI 10.1016/j.bmcl.2005.01.086
   Doggrell SA, 2004, CARDIOVASC RES, V61, P653, DOI 10.1016/j.cardiores.2003.11.029
   Doherty TM, 2002, EXPERT OPIN THER PAT, V12, P665
   Dorsey B. D., 2001, PROTEASE INHIBITORS, P65
   DUNCAN IB, 2001, PROTEASE INHIBITORS, P27
   ERICKSON JW, 2001, PROTEASE INHIBITORS, P1
   Groutas WC, 1999, BIOORG MED CHEM LETT, V9, P2199, DOI 10.1016/S0960-894X(99)00377-7
   Groutas WC, 2001, BIOORGAN MED CHEM, V9, P1543, DOI 10.1016/S0968-0896(01)00037-2                                                   
   Groutas WC, 2001, ARCH BIOCHEM BIOPHYS, V385, P162, DOI 10.1006/abbi.2000.2139                                                          
   Groutas WC, 1998, BIOORGAN MED CHEM, V6, P661, DOI 10.1016/S0968-0896(98)00006-6
   HE S, 2000, POTENT INHIBITION SE, P1713
   HOWARTH NM, 1994, J MED CHEM, V37, P219, DOI 10.1021/jm00028a002
   Hulten J, 1999, J MED CHEM, V42, P4054, DOI 10.1021/jm991054q                                                               
   Hulten J, 1997, J MED CHEM, V40, P885, DOI 10.1021/jm960728j                                                               
   Ilies MA, 2002, EXPERT OPIN THER PAT, V12, P1181, DOI 10.1517/13543776.12.8.1181                                                      
   KEMPF DJ, 2001, PROTEASE INHIBITORS, P49
   Kim DH, 2004, CURR TOP MED CHEM, V4, P1217, DOI 10.2174/1568026043387908
   KONTOGIORGIS GA, 2005, CURR MED CHEM, V12, P339
   Kuang RZ, 1998, BIOORG MED CHEM LETT, V8, P539, DOI 10.1016/S0960-894X(98)00067-5
   Kuang RZ, 2000, BIOORGAN MED CHEM, V8, P1005, DOI 10.1016/S0968-0896(00)00038-9                                                   
   Lai Z, 2004, ARCH BIOCHEM BIOPHYS, V429, P191, DOI 10.1016/j.abb.2004.06.014
   Lee K, 2003, J MED CHEM, V46, P3612, DOI 10.1021/jm030025j
   Lee K, 2002, BIOORG MED CHEM LETT, V12, P1017, DOI 10.1016/S0960-894X(02)00093-8
   Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m
   Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j                                                               
   Matter H, 2004, CURR OPIN DRUG DISC, V7, P513
   Menchise V, 2005, J MED CHEM, V48, P5721, DOI 10.1021/jm050333c
   NIESTROJ AJ, 2005, ENZYMES THEIR INHIBI, P88
   Nussbaumer P, 2003, EXPERT OPIN THER PAT, V13, P605, DOI 10.1517/13543776.13.5.605
   Ogden R. C., 2001, PROTEASE INHIBITORS, P1
   Park JD, 2004, BIOORGAN MED CHEM, V12, P2349, DOI 10.1016/j.bmc.2004.02.012
   Park JD, 2002, J MED CHEM, V45, P5295, DOI 10.1021/jm020258v
   Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540
   PASTOREKOVA S, 2004, CARBONIC ANHYDRASE I, P253
   Pei ZH, 2004, CURR PHARM DESIGN, V10, P3481, DOI 10.2174/1381612043382954
   Poirier D, 1999, EXPERT OPIN THER PAT, V9, P1083, DOI 10.1517/13543776.9.8.1083                                                       
   Pollack Scott J, 2005, Curr Opin Investig Drugs, V6, P35
   Purohit A, 2003, J STEROID BIOCHEM, V86, P423, DOI 10.1016/S0960-0760(03)00353-4
   Reich S.H., 2001, PROTEASE INHIBITORS, P85
   Roberts SB, 2002, ADV DRUG DELIVER REV, V54, P1579, DOI 10.1016/S0169-409X(02)00155-2
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X                                                   
   Schmidt B, 2003, CHEMBIOCHEM, V4, P366, DOI 10.1002/cbic.200200532
   Scozzafava A, 2000, J ENZYM INHIB, V15, P443, DOI 10.3109/14756360009040700                                                       
   Scozzafava A, 2003, CURR MED CHEM, V10, P925, DOI 10.2174/0929867033457647                                                        
   Scozzafava A, 2004, EXPERT OPIN THER PAT, V14, P667, DOI 10.1517/eotp.14.5.667.31276
   Smith HJ, 2001, EXPERT OPIN THER PAT, V11, P789, DOI 10.1517/13543776.11.5.789                                                       
   Smith H. J., 2002, PROTEASE PEPTIDASE I, P1
   Sparey T, 2005, BIOORG MED CHEM LETT, V15, P4212, DOI 10.1016/j.bmcl.2005.06.084
   Srivastava S, 2005, MED RES REV, V25, P66, DOI 10.1002/med.20016                                                               
   STEINMETZER T, 2005, ENZYMES THEIR INHIBI, P254
   Supuran Claudiu T., 2001, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V1, P61, DOI 10.2174/1568013013359131
   Supuran CT, 2003, MED RES REV, V23, P535, DOI 10.1002/med.10047
   Supuran CT, 2003, EXPERT OPIN INV DRUG, V12, P283, DOI 10.1517/13543784.12.2.283
   Supuran CT, 2002, MED RES REV, V22, P329, DOI 10.1002/med.10007                                                               
   Supuran CT, 2000, EXPERT OPIN THER PAT, V10, P575, DOI 10.1517/13543776.10.5.575                                                       
   Supuran CT, 2002, EXPERT OPIN THER PAT, V12, P217, DOI 10.1517/13543776.12.2.217                                                       
   Supuran CT, 2003, EXPERT OPIN THER PAT, V13, P1545, DOI 10.1517/13543776.13.10.1545
   Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025
   Supuran CT, 2004, CRC ENZYM INHIB SER, P1, DOI 10.1201/9780203475300.ch1
   Supuran CT, 2004, CRC ENZYM INHIB SER, P67
   SUPURAN CT, 2005, ENZYMES THEIR INHIBI, P292
   Supuran C. T., 2004, EXPERT OPIN THER PAT, V14, P25
   SUPURAN CT, 2002, PROTEINASE PEPTIDASE, P35
   Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043
   Takai S, 2004, EUR J PHARMACOL, V501, P1, DOI 10.1016/j.ejphar.2004.08.040
   TAKAI S, 2004, TRENDS PHARMACOL SCI, V25, P519
   Taylor SD, 2004, EXPERT OPIN INV DRUG, V13, P199, DOI 10.1517/13543784.13.3.199
   Tomita T, 2004, DRUG NEWS PERSPECT, V17, P321, DOI 10.1358/dnp.2004.17.5.829036                                                    
   Tsai JY, 2002, CURR MED CHEM, V9, P1087, DOI 10.2174/0929867023370185                                                        
   Tung R D., 2001, PROTEASE INHIBITORS, P101
   VACCA JP, 2000, CURR OPIN CHEM BIOL, V25, P369
   Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543                                                               
   Winum JY, 2004, EXPERT OPIN THER PAT, V14, P1273, DOI 10.1517/13543776.14.9.1273                                                      
   Winum JY, 2005, BIOORG MED CHEM LETT, V15, P2353, DOI 10.1016/j.bmcl.2005.02.091
   Winum JY, 2005, BIOORG MED CHEM LETT, V15, P3302, DOI 10.1016/j.bmcl.2005.04.058
   Winum JY, 2005, MED RES REV, V25, P186, DOI 10.1002/med.20021
   Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897
   Wong TS, 2005, ARCH BIOCHEM BIOPHYS, V436, P1, DOI 10.1016/j.abb.2005.01.022
   Woo LWL, 1996, J STEROID BIOCHEM, V57, P79, DOI 10.1016/0960-0760(95)00244-8
   Woo LWL, 1996, J MED CHEM, V39, P1349, DOI 10.1021/jm950931z
   Zhong JY, 2004, J COMB CHEM, V6, P556, DOI 10.1021/cc030047r
   Zhong JY, 2004, CURR TOP MED CHEM, V4, P1203, DOI 10.2174/1568026043387971
   Zhong JY, 2004, BIOORGAN MED CHEM, V12, P589, DOI 10.1016/j.bmc.2003.10.059
   MERCK SHARP DOHME LT, 2005, Patent No. 2005014553
   MERCK SHARP DOHME LT, 2004, Patent No. 2004039800
   Kenny P. W., 2004, Patent No. 2004050646
   GROUTAS WC, 2001, Patent No. 2001081561
   HOFFMANNLAROCHE, 1998, Patent No. 9832748
   GROUTAS WC, 1999, Patent No. 990997
   NOVARTIS, 2004, Patent No. 20040023974
   NOVARTIS AG, 2003, Patent No. 20030382842
   MADIN A, 2004, Patent No. 2004039370
NR 107
TC 117
Z9 117
U1 4
U2 22
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0198-6325
J9 MED RES REV
JI Med. Res. Rev.
PD NOV
PY 2006
VL 26
IS 6
BP 767
EP 792
DI 10.1002/med.20068
PG 26
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 100QR
UT WOS:000241684200003
PM 16710859
DA 2018-01-05
ER

PT J
AU Shah, LK
   Amiji, MM
AF Shah, Lipa K.
   Amiji, Mansoor M.
TI Intracellular delivery of saquinavir in biodegradable polymeric
   nanoparticles for HIV/AIDS
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE intracellular delivery; nanoparticles; poly(ethylene oxide)-modified
   poly(epsilon-caprolactone); saquivanir; THP-1 monocytes/macrophages
ID BLOOD-BRAIN-BARRIER; POLY(EPSILON-CAPROLACTONE) NANOPARTICLES; TARGETED
   DELIVERY; P-GLYCOPROTEIN; DRUG-DELIVERY; TAMOXIFEN; MECHANISMS;
   RITONAVIR; INFECTION; TRANSPORT
AB Purpose: This study aims at developing poly(ethylene oxide)-modified poly(epsilon-caprolactone) (PEO-PCL) nanoparticulate system as an intracellular delivery vehicle for saquinavir, an anti-HIV protease inhibitor.
   Materials and Methods: Saquinavir-loaded PEO-PCL nanoparticles were prepared by a solvent displacement process. The formed nanoparticles were characterized for size, surface charge, and surface presence of PEO chains. Cellular uptake and distribution of the nanoparticle was examined in THP-1 human monocyte/macrophage (Mo/Mac) cell line. Intracellular saquinavir concentrations were measured as a function of dose and duration of incubation.
   Results: The PEO-PCL nanoparticles had a smooth surface and spherical shape and showed a relatively uniform size distribution with a mean particle diameter of approximately 200 nm. The surface presence of PEO chains was confirmed by an increase in the -C-O-(ether) signature of the C1s spectra in electron spectroscopy for chemical analysis. Rapid cellular uptake of rhodamine-123 encapsulated PEO-PCL nanoparticles was observed in THP-1 cells. Intracellular saquinavir concentrations when administered in the nanoparticle formulation were significantly higher than from aqueous solution.
   Conclusions: This study shows that PEO-PCL nanoparticles provide a versatile platform for encapsulation of saquinavir and subsequent intracellular delivery in Mo/Mac cells.
C1 Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA.
RP Amiji, MM (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, 110 Mugar Life Sci Bldg, Boston, MA 02115 USA.
EM m.amiji@neu.edu
RI Amiji, Mansoor/A-4365-2014
OI Amiji, Mansoor/0000-0001-6170-881X
FU NIBIB NIH HHS [EB-002027]
CR Batsis J.A., 2000, TRINTITY STUD MED J, V1, P60
   BENDER A, 1996, INT C AIDS, V11, P64
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Boudad H, 2001, INT J PHARM, V218, P113, DOI 10.1016/S0378-5173(01)00622-6
   Chawla JS, 2003, AAPS PHARMSCI, V5
   Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0                                                   
   COSTAS SA, 2006, AZOJONO J NANOTECHNO, V2, P1
   Femia RA, 2005, BIODRUGS, V19, P179, DOI 10.2165/00063030-200519030-00004
   Flexner C, 2000, ANNU REV PHARMACOL, V40, P649, DOI 10.1146/annurev.pharmtox.40.1.649
   Gimenez F, 2004, JAIDS-J ACQ IMM DEF, V36, P649, DOI 10.1097/00126334-200406010-00001                                                
   Gunaseelan S, 2004, BIOCONJUGATE CHEM, V15, P1322, DOI 10.1021/bc0498875
   Huang X, 2001, J CONTROL RELEASE, V73, P121, DOI 10.1016/S0168-3659(01)00248-6
   Huisman MT, 2001, MOL PHARMACOL, V59, P806
   Janoly A, 2002, J CHROMATOGR B, V780, P155, DOI 10.1016/S1570-0232(02)00465-8
   Kabanov AV, 2004, CURR PHARM DESIGN, V10, P1355, DOI 10.2174/1381612043384826
   Kedzierska K, 2002, CURR MED CHEM, V9, P1893, DOI 10.2174/0929867023368935                                                        
   Kim Richard B, 2003, Top HIV Med, V11, P136
   Lemoine D, 1996, BIOMATERIALS, V17, P2191, DOI 10.1016/0142-9612(96)00049-X
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Noble S, 1996, DRUGS, V52, P93, DOI 10.2165/00003495-199652010-00007                                                
   Panyam Jayanth, 2004, Current Drug Delivery, V1, P235, DOI 10.2174/1567201043334768
   Ponsart S, 2000, BIOMACROMOLECULES, V1, P275, DOI 10.1021/bm005521t                                                               
   Sarker Dipak K., 2005, Current Drug Delivery, V2, P297, DOI 10.2174/156720105774370267
   Shenoy DB, 2005, INT J PHARM, V293, P261, DOI 10.1016/j.ijpharm.2004.12.010
   TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208
NR 25
TC 75
Z9 76
U1 1
U2 21
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD NOV
PY 2006
VL 23
IS 11
BP 2638
EP 2645
DI 10.1007/s11095-006-9101-7
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 102FY
UT WOS:000241797600015
PM 16969696
DA 2018-01-05
ER

PT J
AU Baryshnikova, OK
   Sykes, BD
AF Baryshnikova, Olga K.
   Sykes, Brian D.
TI Backbone dynamics of SDF-1 alpha determined by NMR: Interpretation in
   the presence of monomer-dimer equilibrium
SO PROTEIN SCIENCE
LA English
DT Article
DE backbone dynamics; NMR; chemokine; SDF-1 alpha; monomer dimer
   equilibrium
ID NUCLEAR-MAGNETIC-RESONANCE; MODEL-FREE APPROACH; ANISOTROPIC ROTATIONAL
   DIFFUSION; CHEMOKINE RECEPTOR CXCR4; FACTOR-I; CRYSTAL-STRUCTURE;
   TROPONIN-C; REGULATORY DOMAIN; N-15 RELAXATION; PH DOMAIN
AB SDF-1 alpha is a member of the chemokine family implicated in various reactions in the immune system. The interaction of SDF-1 alpha with its receptor, CXCR4, is responsible for metastasis of a variety of cancers. SDF-1 alpha is also known to play a role in HIV-1 pathogenesis. The structures of SDF-1 alpha determined by NMR spectroscopy have been shown to be monomeric while X-ray structures are dimeric. Biochemical data and in vivo studies suggest that dimerization is likely to be important for the function of chemokines. We report here the dynamics of SDF-1 alpha determined through measurement of main chain N-15 NMR relaxation data. The data were obtained at several concentrations of SDF-1 alpha and used to determine a dimerization constant of similar to 5 mM for a monomer-dimer equilibrium. The dimerization constant was subsequently used to extrapolate values for the relaxation data corresponding to monomeric SDF-1 alpha. The experimental relaxation data and the extrapolated data for monomeric SDF-1 alpha were analyzed using the model free approach. The model free analysis indicated that SDF-1 alpha is rigid on the nano- to picosecond timescale with flexible termini. Several residues involved in the dimer interface display slow micro- to millisecond timescale motions attributable to chemical exchange such as monomer-dimer equilibrium. NMR relaxation measurements are shown to be applicable for studying oligomerization processes such as the dimerization of SDF-1 alpha.
C1 Univ Alberta, Dept Biochem & Prot Engn, Network Ctr Excellence, Heritage Med Res Ctr 713, Edmonton, AB T6G 2S2, Canada.
RP Sykes, BD (reprint author), Univ Alberta, Dept Biochem & Prot Engn, Network Ctr Excellence, Heritage Med Res Ctr 713, Edmonton, AB T6G 2S2, Canada.
EM brian.sykes@ualberta.ca
CR Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340
   BALDO JH, 1975, BIOCHEMISTRY-US, V14, P1893, DOI 10.1021/bi00680a014
   Baryshnikova OK, 2005, J PEPT RES, V66, P12, DOI 10.1111/j.1747-0285.2006.00330.x                                                
   Berson JF, 1996, J VIROL, V70, P6288
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Cooper CR, 2003, CANCER, V97, P739, DOI 10.1002/cncr.11181
   Crump MP, 1999, PROTEIN SCI, V8, P2041, DOI 10.1110/ps.8.10.2041                                                            
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941
   Epstein RJ, 2004, NAT REV CANCER, V4, P901, DOI 10.1038/nrc1473
   Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838                                       
   Fushman D, 1997, J MOL BIOL, V266, P173, DOI 10.1006/jmbi.1996.0771
   Gagne SM, 1998, J MOL BIOL, V278, P667, DOI 10.1006/jmbi.1998.1723
   GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P
   Goodman JL, 2000, J MOL BIOL, V295, P963, DOI 10.1006/jmbi.1999.3419
   Gozansky EK, 2005, J MOL BIOL, V345, P651, DOI 10.1016/j.jmb.2004.11.003
   GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152
   Gryk MR, 1998, J MOL BIOL, V280, P879, DOI 10.1006/jmbi.1998.1731
   Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613                                                          
   Holmes WD, 2001, PROTEIN EXPRES PURIF, V21, P367, DOI 10.1006/prep.2001.1402
   Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963                                                                   
   Korchuganov DS, 2001, J AM CHEM SOC, V123, P2068, DOI 10.1021/ja0025447
   Kunkel Steven L., 2002, Autoimmunity Reviews, V1, P313, DOI 10.1016/S1568-9972(02)00085-X
   Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d                                                               
   Li Monica X, 2002, Methods Mol Biol, V173, P255
   Liao TS, 2005, J ORTHOP RES, V23, P203, DOI 10.1016/j.orthres.2004.06.018
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Luz JG, 2005, J MOL BIOL, V352, P1019, DOI 10.1016/j.jmb.2005.08.011
   LUZ Z, 1963, J CHEM PHYS, V39, P366, DOI 10.1063/1.1734254
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Mayer KL, 2003, PROTEINS, V50, P184, DOI 10.1002/prot.10238
   Mercier P, 2001, BIOCHEMISTRY-US, V40, P10063, DOI 10.1021/bi010748+
   Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113
   Ohnishi Y, 2000, J INTERF CYTOK RES, V20, P691, DOI 10.1089/10799900050116390
   Pfuhl M, 1999, J BIOMOL NMR, V14, P307, DOI 10.1023/A:1008319917267
   Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC
   Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100
   RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420                                                         
   Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100
   SCHURR JM, 1994, J MAGN RESON SER B, V105, P211, DOI 10.1006/jmrb.1994.1127
   Smith Bryan John, 2003, Methods Mol Biol, V211, P63
   Spyracopoulos L, 2001, CURR OPIN STRUC BIOL, V11, P555, DOI 10.1016/S0959-440X(00)00261-X
   Spyracopoulos L, 2001, BIOCHEMISTRY-US, V40, P12541, DOI 10.1021/bi010903k
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Veldkamp CT, 2005, PROTEIN SCI, V14, P1071, DOI 10.1110/ps.041219505
   Ye JQ, 2001, BIOCHEMISTRY-US, V40, P7820, DOI 10.1021/bi010252s
   ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413                                                              
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 51
TC 28
Z9 28
U1 1
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 0961-8368
J9 PROTEIN SCI
JI Protein Sci.
PD NOV
PY 2006
VL 15
IS 11
BP 2568
EP 2578
DI 10.1110/ps.062255806
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 100KC
UT WOS:000241666600012
PM 17075134
OA gold
DA 2018-01-05
ER

PT J
AU Dou, H
   Destache, CJ
   Morehead, JR
   Mosley, RL
   Boska, MD
   Kingsley, J
   Gorantla, S
   Poluektova, L
   Nelson, JA
   Chaubal, M
   Werling, J
   Kipp, J
   Rabinow, BE
   Gendelman, HE
AF Dou, Huanyu
   Destache, Christopher J.
   Morehead, Justin R.
   Mosley, R. Lee
   Boska, Michael D.
   Kingsley, Jeffrey
   Gorantla, Santhi
   Poluektova, Larisa
   Nelson, Jay A.
   Chaubal, Mahesh
   Werling, Jane
   Kipp, James
   Rabinow, Barrett E.
   Gendelman, Howard E.
TI Development of a macrophage-based nanoparticle platform for
   antiretroviral drug delivery
SO BLOOD
LA English
DT Article
ID VIRUS-INFECTED PATIENTS; POLYMERIC NANOPARTICLES; TREATMENT
   INTERRUPTION; VIROLOGICAL RESPONSE; RESISTANCE MUTATIONS; MURINE MODEL;
   IN-VITRO; THERAPY; INDINAVIR; HIV-1
AB Complex dosing regimens, costs, side effects, biodistribution limitations, and variable drug pharmacokinetic patterns have affected the long-term efficacy of antiretroviral medicines. To address these problems, a nanoparticle indinavir (NP-IDV) formulation packaged into carrier bone marrow-derived macrophages (BMMs) was developed. Drug distribution and disease outcomes were assessed in immune-competent and human immunodeficiency virus type 1 (HIV-1)-infected humanized immune-deficient mice, respectively. In the former, NP-IDV formulation contained within BMMs was adoptively transferred. After a single administration, single-photon emission computed tomography, histology, and reverse-phase-high-performance liquid chromatography (RP-HPLC) demonstrated robust lung, liver, and spleen BMMs and drug distribution. Tissue and sera IDV levels were greater than or equal to 50 mu M for 2 weeks. NP-IDV-BMMs administered to HIV-1-challenged humanized mice revealed reduced numbers of virus-infected cells in plasma, lymph nodes, spleen, liver, and lung, as well as, CD4(+) T-cell protection. We conclude that a single dose of NP-IDV, using BMMs as a carrier, is effective and warrants consideration for human testing.
C1 Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Ctr Neurovirol & Neurodegenerat Disorder, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Radiol, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
   Univ Nebraska, Med Ctr, Dept Pediat, Omaha, NE 68198 USA.
   Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   Baxter Healthcare, Round Lake, IL USA.
RP Gendelman, HE (reprint author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Ctr Neurovirol & Neurodegenerat Disorder, 985880 Nebraska Med Ct, Omaha, NE 68198 USA.
EM hegendel@unmc.edu
OI Destache, Christopher/0000-0001-7923-3939; Poluektova,
   Larisa/0000-0001-7339-8732
FU NINDS NIH HHS [P01 NS 31492, P01 NS 43985, 2R37 NS 36126, 2R01 NS
   034239]; NIMH NIH HHS [P01 MH 64570]; NCRR NIH HHS [P20 RR 15635]
CR Ahlin P, 2002, INT J PHARM, V239, P113, DOI 10.1016/S0378-5173(02)00076-5                                                   
   Alos L, 2005, MODERN PATHOL, V18, P127, DOI 10.1038/modpathol.3800267
   Anabwani G, 2005, NUTRITION, V21, P96, DOI 10.1016/j.nut.2004.09.013
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20                                    
   Cavalli R, 2003, J PHARM SCI, V92, P1085, DOI 10.1002/jps.10368
   Chakraborty R, 2005, CURR HIV RES, V3, P31, DOI 10.2174/1570162052773022
   Chan WCW, 2006, BIOL BLOOD MARROW TR, V12, P87, DOI 10.1016/j.bbmt.2005.10.004
   Chen RY, 2002, AIDS RES HUM RETROV, V18, P909, DOI 10.1089/088922202760265588
   Chulamokha L, 2005, J NEUROVIROL, V11, P76, DOI 10.1080/13550280590931270
   Delaugerre C, 2005, J MED VIROL, V77, P345, DOI 10.1002/jmv.20462
   DOU H, 2006, 12 ANN M SOC NEUR PH
   DOU H, IN PRESS VIROLOGY
   Duval X, 2004, HIV MED, V5, P307, DOI 10.1111/j.1468-1293.2004.00226.x                                                
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Feng SS, 2004, CURR MED CHEM, V11, P413, DOI 10.2174/0929867043455909
   Gallego O, 2001, AIDS, V15, P1701, DOI 10.1097/00002030-200109070-00014
   Gonzalez LMF, 2006, J GEN VIROL, V87, P1303, DOI 10.1099/vir.0.81517-0
   Gorantla S, 2005, J VIROL, V79, P2124, DOI 10.1128/JVI.79.4.2124-2132.2005
   Hawkins T, 2006, AIDS PATIENT CARE ST, V20, P6, DOI 10.1089/apc.2006.20.6
   Horisawa E, 2002, PHARMACEUT RES, V19, P132, DOI 10.1023/A:1014260513728                                                         
   Jain KK, 2005, TECHNOL CANCER RES T, V4, P645, DOI 10.1177/153303460500400608                                                      
   Jain KK, 2005, DRUG DISCOV TODAY, V10, P1435, DOI 10.1016/S1359-6446(05)03573-7                                                   
   Jain KK, 2005, TECHNOL CANCER RES T, V4, P407, DOI 10.1177/153303460500400408                                                      
   Jiao YY, 2002, CIRCULATION, V105, P230, DOI 10.1161/hc0202.101988                                                           
   Kabanov AV, 2002, CRIT REV THER DRUG, V19, P1, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i1.10
   KIBUULE D, 2006, 12 ANN M SOC NEUR PH
   Kwon GS, 2003, CRIT REV THER DRUG, V20, P357, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20                                    
   Langmann P., 2002, Infection, V30, P13, DOI 10.1007/s15010-001-1111-0
   Michaelis M, 2000, ANTI-CANCER DRUG, V11, P369, DOI 10.1097/00001813-200006000-00007
   Murri R, 2006, JAIDS-J ACQ IMM DEF, V41, P23, DOI 10.1097/01.qai.0000188337.76164.7a
   Nielsen SD, 1998, J INFECT DIS, V178, P1299
   Pan Sung-Ching, 2005, Journal of Microbiology Immunology and Infection, V38, P31
   Pandey R, 2005, INT J PHARM, V301, P268, DOI 10.1016/j.ijpharm.2005.05.027
   Pandey R, 2003, TUBERCULOSIS, V83, P373, DOI 10.1016/j.tube.2003.07.001
   Petit F, 2005, TRENDS PHARMACOL SCI, V26, P258, DOI 10.1016/j.tips.2005.03.006
   Pezzotti P, 1999, AIDS, V13, P249, DOI 10.1097/00002030-199902040-00013
   Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639
   Poluektova L, 2004, J IMMUNOL, V172, P7610, DOI 10.4049/jimmunol.172.12.7610                                                    
   Poluektova LY, 2002, J IMMUNOL, V168, P3941, DOI 10.4049/jimmunol.168.8.3941                                                     
   Rhame FS, 2004, ANTIMICROB AGENTS CH, V48, P4200, DOI 10.1128/AAC.48.11.4200-4208.2004
   Servais J, 2001, AIDS, V15, P941, DOI 10.1097/00002030-200105040-00019
   Sharland M, 1998, LANCET, V352, P577, DOI 10.1016/S0140-6736(05)79289-8                                                   
   Shehu-Xhilaga M, 2005, CURR MED CHEM, V12, P1705, DOI 10.2174/0929867054367211
   Shukla R, 2005, LANGMUIR, V21, P10644, DOI 10.1021/la0513712
   Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006
   Tonnesen HH, 2002, DRUG DEV IND PHARM, V28, P621, DOI 10.1081/DDC-120003853                                                           
   Varela MC, 2001, EUR J PHARM SCI, V12, P471
   Vasudevachari MB, 1996, ANTIMICROB AGENTS CH, V40, P2535
   Vinogradov Serguei, 2004, Expert Opin Drug Deliv, V1, P181, DOI 10.1517/17425247.1.1.181
   Xing XL, 2005, J NANOSCI NANOTECHNO, V5, P1688, DOI 10.1166/jnn.2005.199
   Zhang YM, 1997, J VIROL, V71, P6662
NR 51
TC 141
Z9 145
U1 0
U2 19
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 15
PY 2006
VL 108
IS 8
BP 2827
EP 2835
DI 10.1182/blood-2006-03-012534
PG 9
WC Hematology
SC Hematology
GA 092XT
UT WOS:000241131700054
PM 16809617
OA gold
DA 2018-01-05
ER

PT J
AU Suk, JS
   Suh, J
   Choy, K
   Lai, SK
   Fu, J
   Hanes, J
AF Suk, Jung Soo
   Suh, Junghae
   Choy, Kokleong
   Lai, Samuel K.
   Fu, Jie
   Hanes, Justin
TI Gene delivery to differentiated neurotypic cells with RGD and HIV Tat
   peptide functionalized polymeric nanoparticles
SO BIOMATERIALS
LA English
DT Article
DE gene therapy; CNS diseases; polymers; polyethylenimine (PEI)
ID GLYCOL-POLYETHYLENIMINE/DNA COMPLEXES; PARKINSONS-DISEASE; IN-VIVO;
   HEPARAN-SULFATE; DRUG-DELIVERY; TRANSFECTION EFFICIENCY; RAT MODEL; DNA;
   ADENOVIRUS; THERAPY
AB A number of neurodegenerative disorders may potentially be treated by the delivery of therapeutic genes to neurons. Nonviral gene delivery systems, however, typically provide low transfection efficiency in post-mitotic differentiated neurons. To uncover mechanistic reasons for this observation, we compared gene transfer to undifferentiated and differentiated SH-SY5Y cells using polyethylenimine (PEI)/DNA nanocomplexes. Differentiated cells exhibited substantially lower uptake of gene vectors. To overcome this bottleneck, RGD or HIV-1 Tat peptides were attached to PEI/DNA nanocomplexes via poly(ethylene glycol) (PEG) spacer molecules. Both RGD and Tat improved the cellular uptake of gene vectors and enhanced gene transfection efficiency of primary neurons up to 14-fold. RGD functionalization resulted in a statistically significant increase in vector escape from endosomes, suggesting it may improve gene delivery by more than one mechanism. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA.
RP Hanes, J (reprint author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.
EM hanes@jhu.edu
RI Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771; Lai, Samuel/0000-0003-4721-528X
FU NIGMS NIH HHS [T32-GM07057]
CR Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947                                                      
   Almeida A, 2005, J NEUROSCI, V25, P8115, DOI 10.1523/JNEUROSCI.1143-05.2005
   Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S095506740200371X
   Behr JP, 1997, CHIMIA, V51, P34
   Ben-Shachar D, 2004, BIOCHEM PHARMACOL, V67, P1965, DOI 10.1016/j.bcp.2004.02.015
   Berry M, 2001, CURR OPIN MOL THER, V3, P338
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409                                                                   
   Burton EA, 2003, GENE THER, V10, P1721, DOI 10.1038/sj.gt.3302116
   Chen XW, 2003, PARKINSONISM RELAT D, V10, P1, DOI 10.1016/S1353-8020(03)00097-X
   Colin M, 1998, GENE THER, V5, P1488, DOI 10.1038/sj.gt.3300760
   Corti O, 1999, P NATL ACAD SCI USA, V96, P12120, DOI 10.1073/pnas.96.21.12120
   Cryan SA, 2003, PHARMACEUT RES, V20, P569, DOI 10.1023/A:1023286413666
   Fiegel J, 2004, J CONTROL RELEASE, V96, P411, DOI 10.1016/j.jconrel.2004.02.018
   Florea Bogdan I, 2002, AAPS PharmSci, V4, pE12
   Forrest ML, 2002, MOL THER, V6, P57, DOI 10.1006/mthe.2002.0631
   Fu J, 2002, BIOMATERIALS, V23, P4425, DOI 10.1016/S0142-9612(02)00182-5
   Gharwan H, 2003, GENE THER, V10, P810, DOI 10.1038/sj.gt.3301954
   Godbey WT, 2000, J BIOMED MATER RES, V51, P321, DOI 10.1002/1097-4636(20000905)51:3<321::AID-JBM5>3.3.CO;2-I
   Guerra-Crespo M, 2003, J NEUROSCI METH, V127, P179, DOI 10.1016/S0165-0270(03)00125-0
   Hara H, 2003, MOL BRAIN RES, V119, P125, DOI 10.1016/j.molbrainres.2003.08.021
   Harvie P, 2003, J LIPOSOME RES, V13, P231, DOI 10.1081/LPR-120026389
   Horbinski C, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-2
   Horellou P, 1997, MOL NEUROBIOL, V15, P241, DOI 10.1007/BF02740636
   Hurelbrink CB, 2004, EXP NEUROL, V185, P1, DOI 10.1016/j.expneurol.2003.09.018
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Kunath K, 2003, J GENE MED, V5, P588, DOI 10.1002/jgm.382
   Kursa M, 2003, BIOCONJUGATE CHEM, V14, P222, DOI 10.1021/bc0256087
   Li EG, 1998, J VIROL, V72, P2055
   Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200
   Lu YY, 2003, NEUROSCI RES, V45, P33, DOI 10.1016/S0168-0102(02)00195-5                                                   
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   MARGOLIS RK, 1987, ARCH BIOCHEM BIOPHYS, V257, P107, DOI 10.1016/0003-9861(87)90548-0                                                    
   Matsui H, 1997, J BIOL CHEM, V272, P1117, DOI 10.1074/jbc.272.2.1117                                                          
   Medeiros GF, 2000, BBA-GEN SUBJECTS, V1475, P287, DOI 10.1016/S0304-4165(00)00079-9
   Medina-Kauwe LK, 2003, ADV DRUG DELIVER REV, V55, P1485, DOI 10.1016/j.addr.2003.07.010
   Ogris M, 2003, J CONTROL RELEASE, V91, P173, DOI 10.1016/S0168-3659(03)00230-X
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Sakhalkar HS, 2003, P NATL ACAD SCI USA, V100, P15895, DOI 10.1073/pnas.2631433100
   Schaffer DV, 1998, J BIOL CHEM, V273, P28004, DOI 10.1074/jbc.273.43.28004
   Simpson PB, 2001, ANAL BIOCHEM, V298, P163, DOI 10.1006/abio.2001.5346
   SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5
   Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200
   Suh J, 2003, P NATL ACAD SCI USA, V100, P3878, DOI 10.1073/pnas.0636277100
   Suh JH, 2004, BIOTECHNOL PROGR, V20, P598, DOI 10.1021/bp034251y
   SUK JS, UNPUB QUANTIFYING IN
   Tamura M, 2004, J VIROL, V78, P3817, DOI 10.1128/JVI.78.8.3817-3826.2004
   TYLLIANAKIS PE, 1994, ANAL BIOCHEM, V219, P335, DOI 10.1006/abio.1994.1273                                                          
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Wang K, 2000, J VIROL, V74, P2731, DOI 10.1128/JVI.74.6.2731-2739.2000
   Watson P, 2005, ADV DRUG DELIVER REV, V57, P43, DOI 10.1016/j.addr.2004.05.003
   WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E
   WITTEKINDT C, 2004, BIOTECHNOL APPL BIOC
   Wu K, 2004, BRAIN RES, V1008, P284, DOI 10.1016/j.brainres.2004.02.051
   Zaric V, 2004, J GENE MED, V6, P176, DOI 10.1002/jgm.484
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Zou SM, 2000, J GENE MED, V2, P128, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W                 
NR 60
TC 101
Z9 104
U1 1
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD OCT
PY 2006
VL 27
IS 29
BP 5143
EP 5150
DI 10.1016/j.biomaterials.2006.05.013
PG 8
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 079HW
UT WOS:000240167500015
PM 16769110
DA 2018-01-05
ER

PT J
AU Vissers, JPC
   Langridge, J
   McKenna, T
   Riley, T
   Vermeire, K
   Schols, D
   Verhaert, PD
AF Vissers, J. P. C.
   Langridge, J.
   McKenna, T.
   Riley, T.
   Vermeire, K.
   Schols, D.
   Verhaert, P. D.
TI Quantitative label-free nanoscale LC-MS analysis of HIV drug-treated
   human T-cell cultures
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Meeting Abstract
C1 Waters Corp, Manchester, Lancs, England.
   Rega Inst, Louvain, Belgium.
   Delft Univ Technol, Delft, Netherlands.
RI Vermeire, Kurt/P-9992-2017; Schols, Dominique/S-9057-2017
OI Vermeire, Kurt/0000-0003-1123-1907; Schols,
   Dominique/0000-0003-3256-5850
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 1535-9476
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD OCT
PY 2006
VL 5
IS 10
SU S
MA 71
BP S13
EP S13
PG 1
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 098FM
UT WOS:000241506400029
DA 2018-01-05
ER

PT J
AU Lamalle-Bernard, D
   Munier, S
   Compagnon, C
   Charles, MH
   Kalyanaraman, VS
   Delair, T
   Verrier, B
   Ataman-Onal, Y
AF Lamalle-Bernard, Delphine
   Munier, Severine
   Compagnon, Christelle
   Charles, Marie-Helene
   Kalyanaraman, Vaniambadi S.
   Delair, Thierry
   Verrier, Bernard
   Ataman-Onal, Yasemin
TI Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic
   PLA nanoparticles preserves antigenicity and immunogenicity
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE surfactant-free PLA nanoparticles; vaccine adjuvant; coadsorption; HIV-1
   p24 and gp120 proteins; antigenicity; immunogenicity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN MONOCLONAL-ANTIBODY;
   IMMUNE-RESPONSES; DENDRITIC CELLS; ANIMAL-MODELS; MICROPARTICLES;
   TYPE-1; VACCINES; NEUTRALIZATION; GLYCOPROTEIN
AB Biodegradable micro- or nanoparticles with surface adsorbed antigens represent a promising method for in vivo delivery of vaccines. Most vaccines, licensed or under development, are based on combined delivery of multiple antigens. Thus, we investigated the feasibility of combining two vaccine antigens, HIV-1 p24 and gp120 proteins, on the surface of surfactant-free anionic PLA nanoparticles obtained by an improved solvent diffusion method. The analysis of adsorption isotherms has shown that both proteins had similar and high affinities for the nanoparticles. Coadsorption of p24 and gp1120 onto the same PLA particle was evidenced by sandwich ELISA, using antibodies directed against one protein for particle capture and the other one for detection. To assess structural integrity, the antigenicity of free and PLA-adsorbed antigens was compared by competition ELISA, using a set of 6 anti-p24 and 7 anti-gp120 antibodies, as well as soluble CD4. The antigenicity of proteins on the nanoparticle surface was well preserved, adsorbed either individually or in combination. Furthermore, both antigens maintained their immunogenicity, since high antibody titres (10(6) for p24 and 10(5) for gp120) were elicited in mice with monovalent and divalent PLA formulations. Taken together our results show that development of multivalent vaccines based on anionic PLA nanoparticles is possible. Moreover, coadsorption of a ligand for cell-specific targeting or of an immunostimulatory molecule will further extend the field of application of delivery systems based on charged micro- and nanoparticles. (c) 2006 Elsevier B.V. All rights reserved.
C1 IFR128 BioSci Lyon Gerland, FRE2736, CNRS BioMerieux, Tour CERVI, F-69365 Lyon 07, France.
   IFR128 BioSci Lyon Gerland, Unite Mixte CNRS BioMerieux, UMR2714, ENS Lyon, F-69364 Lyon, France.
   Adv BioSci Labs Inc, Kensington 20895, MD USA.
RP Ataman-Onal, Y (reprint author), IFR128 BioSci Lyon Gerland, FRE2736, CNRS BioMerieux, Tour CERVI, 21 Ave Tony Garnier, F-69365 Lyon 07, France.
EM Yasemin.Ataman@eu.biomerieux.com
RI Xu, Qingguo/C-1962-2014; Delair, Thierry/E-7896-2012
OI Xu, Qingguo/0000-0003-3191-0771; 
CR Allard L, 2004, BIOCONJUGATE CHEM, V15, P458, DOI 10.1021/bc034146
   Aristegui Javier, 2003, International Journal of Infectious Diseases, V7, P143, DOI 10.1016/S1201-9712(03)90011-7
   Ataman-Onal Y, 2006, J CONTROL RELEASE, V112, P175, DOI 10.1016/j.jconrel.2006.02.006
   Boehm G, 2002, PHARMACEUT RES, V19, P1330, DOI 10.1023/A:1020354809581                                                         
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   Cavacini L, 2003, AIDS, V17, P685, DOI 10.1097/01.aids.0000050822.06065.4a
   Chesko J, 2005, J PHARM SCI-US, V94, P2510, DOI 10.1002/jps.20472
   Cole KS, 1998, J VIROL, V72, P7852
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Haicheur N, 2003, INT IMMUNOL, V15, P1161, DOI 10.1093/intimm/dxg118
   JANVIER B, 1990, J VIROL, V64, P4258
   Jeannin P, 2000, NAT IMMUNOL, V1, P502, DOI 10.1038/82751
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   Kazzaz J, 2006, J CONTROL RELEASE, V110, P566, DOI 10.1016/j.jconrel.2005.10.010
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   Kempf M, 2003, J DRUG TARGET, V11, P11, DOI 10.1080/1061186031000072978
   MOORE JP, 1993, J VIROL, V67, P863
   O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001
   Pal R, 2006, VACCINE, V24, P1225, DOI 10.1016/j.vaccine.2005.07.112
   Peyre M, 2004, J CONTROL RELEASE, V99, P345, DOI 10.1016/j.jconrel.2004.07.014
   REDHEAD K, 1994, VACCINE, V12, P1460, DOI 10.1016/0264-410X(94)90156-2
   Selvarajah S, 2005, J VIROL, V79, P12148, DOI 10.1128/JVI.79.19.12148-12163.2005
   Singh M, 2004, PHARM RES, V21, P2148, DOI 10.1007/s11095-004-7666-6
   Singh M, 1997, INFECT IMMUN, V65, P1716
   Singh Manmohan, 2006, Current Drug Delivery, V3, P115, DOI 10.2174/156720106775197565
   THALI M, 1993, J VIROL, V67, P3978
   Tichmann I, 2005, VACCINE, V23, P3272, DOI 10.1016/j.vaccine.2005.01.087
   Trkola A, 1996, J VIROL, V70, P1100
   Fessi H., 1986, Patents, Patent No. [US 5118528, 5118528]
NR 30
TC 57
Z9 58
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 28
PY 2006
VL 115
IS 1
BP 57
EP 67
DI 10.1016/j.jconrel.2006.07.006
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 098UN
UT WOS:000241548400007
PM 16919350
DA 2018-01-05
ER

PT J
AU Winters-Hilt, S
   Landry, M
   Akeson, M
   Tanase, M
   Amin, I
   Coombs, A
   Morales, E
   Millet, J
   Baribault, C
   Sendamangalam, S
AF Winters-Hilt, Stephen
   Landry, Matthew
   Akeson, Mark
   Tanase, Maria
   Amin, Iftekhar
   Coombs, Amy
   Morales, Eric
   Millet, John
   Baribault, Carl
   Sendamangalam, Srikanth
TI Cheminformatics methods for novel nanopore analysis of HIV DNA termini
SO BMC BIOINFORMATICS
LA English
DT Article
ID SIGNAL-PROCESSING TECHNIQUES; MURINE LEUKEMIA-VIRUS; HIDDEN
   MARKOV-MODELS; B-DNA; MINOR-GROOVE; BASE-PAIRS; CONFORMATIONAL MAPS;
   HAIRPIN MOLECULES; INTEGRATION SITE; SEQUENCE
AB Background: Channel current feature extraction methods, using Hidden Markov Models (HMMs) have been designed for tracking individual-molecule conformational changes. This information is derived from observation of changes in ionic channel current blockade "signal" upon that molecule's interaction with (and occlusion of) a single nanometer-scale channel in a "nanopore detector". In effect, a nanopore detector transduces single molecule events into channel current blockades. HMM analysis tools described are used to help systematically explore DNA dinucleotide flexibility, with particular focus on HIV's highly conserved (and highly flexible/reactive) viral DNA termini. One of the most critical stages in HIV's attack is the binding between viral DNA and the retroviral integrase, which is influenced by the dynamic-coupling induced high flexibility of a CA/TG dinucleotide positioned precisely two base-pairs from the blunt terminus of the duplex viral DNA. This suggests the study of a family of such CA/TG dinucleotide molecules via nanopore measurement and cheminformatics analysis.
   Results: HMMs are used for level identification on the current blockades, HMM/EM with boosted variance emissions are used for level projection pre-processing, and time-domain FSAs are used to parse the level-projected waveform for kinetic information. The observed state kinetics of the DNA hairpins containing the CA/TG dinucleotide provides clear evidence for HIV's selection of a peculiarly flexible/interactive DNA terminus.
C1 [Winters-Hilt, Stephen; Landry, Matthew; Amin, Iftekhar; Millet, John; Baribault, Carl; Sendamangalam, Srikanth] Univ New Orleans, Dept Comp Sci, New Orleans, LA 70148 USA.
   [Winters-Hilt, Stephen; Tanase, Maria; Morales, Eric] Res Inst Children, New Orleans, LA 70118 USA.
   [Akeson, Mark; Coombs, Amy] Univ Calif Santa Cruz, Dept Chem, Santa Cruz, CA 90560 USA.
RP Winters-Hilt, S (reprint author), Univ New Orleans, Dept Comp Sci, New Orleans, LA 70148 USA.
EM winters@cs.uno.edu; mlandry@cs.uno.edu; makeson@chemistry.ucsc.edu;
   metanase@yahoo.com; iftekhar.amin@gmail.com; acoombs@soe.ucsc.edu;
   emorales@chnola-research.org; millet.john@gmail.com;
   cbaribau@uno.cs.edu; s.n.srikanth@gmail.com
CR Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5                                                   
   BASHAM B, 1995, P NATL ACAD SCI USA, V92, P6464, DOI 10.1073/pnas.92.14.6464
   Burges CJC, 1998, DATA MIN KNOWL DISC, V2, P121, DOI 10.1023/A:1009715923555                                                         
   CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7                                                    
   Chung SH, 1998, METHOD ENZYMOL, V293, P420
   CHUNG SH, 1990, PHILOS T R SOC B, V329, P265, DOI 10.1098/rstb.1990.0170                                                          
   COLICELLI J, 1985, CELL, V42, P573, DOI 10.1016/0092-8674(85)90114-X                                                    
   COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6
   Colquhoun D, 1995, FITTING STAT ANAL SI, P483
   Cormen TH, 1989, INTRO ALGORITHMS
   CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y                                                    
   Denisov VP, 2000, P NATL ACAD SCI USA, V97, P629, DOI 10.1073/pnas.97.2.629
   DICKERSON RE, 1981, J MOL BIOL, V149, P761, DOI 10.1016/0022-2836(81)90357-0
   DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67
   Diserbo M, 2000, J NEUROSCI METH, V99, P137, DOI 10.1016/S0165-0270(00)00230-2
   DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7
   DURBIN R, 1998, BIOL SEQUENCE ANAL
   ElHassan MA, 1996, J MOL BIOL, V259, P95, DOI 10.1006/jmbi.1996.0304                                                          
   FROYSTEIN NA, 1993, ACTA CHEM SCAND, V47, P649, DOI 10.3891/acta.chem.scand.47-0649
   Hays FA, 2005, P NATL ACAD SCI USA, V102, P7157, DOI 10.1073/pnas.0409455102
   Howerton SB, 2001, BIOCHEMISTRY-US, V40, P10023, DOI 10.1021/bi010391+
   Hud NV, 2003, BIOPOLYMERS, V69, P144, DOI 10.1002/bip.10364
   Hud NV, 1997, J AM CHEM SOC, V119, P5756, DOI 10.1021/ja9704085                                                               
   Hud NV, 2002, BIOCHEMISTRY-US, V41, P9900, DOI 10.1021/bi020159j
   Hud NV, 1999, J MOL BIOL, V286, P651, DOI 10.1006/jmbi.1998.2513                                                          
   Hud NV, 2001, CURR OPIN STRUC BIOL, V11, P293, DOI 10.1016/S0959-440X(00)00205-0
   Ivanov V.I., 1995, MOL BIOL, V28, P780
   JOACHIMS T, 1998, ADV KERNEL METHODS, V2
   KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3
   Lynch TW, 2003, J MOL BIOL, V330, P493, DOI 10.1016/S0022-2836(03)00529-1
   MACPHERSON A, 2002, INTRO MACROMOL CRYST
   MICHAEL D, 1999, CHEM SITE 3 01 PYRAM
   MINCHENKOVA LE, 1986, J BIOMOL STRUCT DYN, V4, P463, DOI 10.1080/07391102.1986.10506362                                                  
   NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0
   Osuna E, 1997, NEURAL NETWORKS SIGN, P276
   Packer MJ, 2000, J MOL BIOL, V295, P71, DOI 10.1006/jmbi.1999.3236
   Packer MJ, 2000, J MOL BIOL, V295, P85, DOI 10.1006/jmbi.1999.3237
   PETICOLAS WL, 1988, P NATL ACAD SCI USA, V85, P2579, DOI 10.1073/pnas.85.8.2579
   PLATT JC, 1998, ADV KERNEL METHODS, V12
   POLARD P, 1995, MOL MICROBIOL, V15, P13, DOI 10.1111/j.1365-2958.1995.tb02217.x
   Roe T, 1997, J VIROL, V71, P1334
   SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460
   Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371
   SENIOR MM, 1988, P NATL ACAD SCI USA, V85, P6242, DOI 10.1073/pnas.85.17.6242                                                         
   ShatzkySchwartz M, 1997, J MOL BIOL, V267, P595, DOI 10.1006/jmbi.1996.0878
   Shui XQ, 1998, BIOCHEMISTRY-US, V37, P8341, DOI 10.1021/bi973073c
   Shui XQ, 1998, BIOCHEMISTRY-US, V37, P16877, DOI 10.1021/bi982063o
   Sletten E, 1996, MET IONS BIOL SYST, V32, P397
   Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859
   Suzuki M, 1997, J MOL BIOL, V274, P421, DOI 10.1006/jmbi.1997.1406
   Tereshko V, 1999, J AM CHEM SOC, V121, P3590, DOI 10.1021/ja984346+                                                               
   VAPNIK VN, 1998, NATURE STAT LEARNIN
   Vercoutere W, 2001, NAT BIOTECHNOL, V19, P248, DOI 10.1038/85696
   Vercoutere WA, 2003, NUCLEIC ACIDS RES, V31, P1311, DOI 10.1093/nar/gkg218
   Winters-Hilt S, 2004, DNA CELL BIOL, V23, P675, DOI 10.1089/dna.2004.23.675
   Winters-Hilt S, 2003, AIP CONF PROC, V665, P355
   Winters-Hilt S, 2003, BIOPHYS J, V84, P967, DOI 10.1016/S0006-3495(03)74913-3                                                   
   Winters-Hilt S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S14
   Winters-Hilt S, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S4
   Winters-Hilt S, 2004, SPIE 2 INT S FLUCT N
   Wu ZG, 2003, J BIOMOL NMR, V26, P297, DOI 10.1023/A:1024047103398                                                         
   Young MA, 1997, J AM CHEM SOC, V119, P59, DOI 10.1021/ja960459m                                                               
NR 62
TC 14
Z9 14
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD SEP 26
PY 2006
VL 7
SU 2
AR S22
DI 10.1186/1471-2105-7-S2-S22
PG 18
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA 091DY
UT WOS:000241007700023
PM 17118144
OA gold
DA 2018-01-05
ER

PT J
AU Sawada, H
   Narumi, T
   Kiyohara, M
   Baba, M
AF Sawada, Hideo
   Narumi, Tamikazu
   Kiyohara, Makiko
   Baba, Masanori
TI COLL 220-Synthesis and anti-HIV-1 activity of novel fluoroalkyl
   end-capped cooligomers/silica nanoparticles
SO ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Meeting Abstract
C1 [Sawada, Hideo; Narumi, Tamikazu] Hirosaki Univ, Dept Frontier Mat Chem, Hirosaki, Aomori 0368561, Japan.
   [Kiyohara, Makiko; Baba, Masanori] Kagoshima Univ, Ctr Chron Viral Dis, Grad Sch Med & Dent Sci, Kagoshima 8908544, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0065-7727
J9 ABSTR PAP AM CHEM S
JI Abstr. Pap. Am. Chem. Soc.
PD SEP 10
PY 2006
VL 232
MA 220-COLL
PG 1
WC Chemistry, Multidisciplinary
SC Chemistry
GA V15DB
UT WOS:000207781603336
DA 2018-01-05
ER

PT J
AU Balzarini, J
AF Balzarini, J.
TI Inhibition of HIV entry by carbohydrate-binding proteins
SO ANTIVIRAL RESEARCH
LA English
DT Review
DE carbohydrate-binding agents (CBA); carbohydrate-binding proteins (CBP);
   lectins; HIV; virus entry; gp120 envelope
ID HUMAN-IMMUNODEFICIENCY-VIRUS; URTICA-DIOICA AGGLUTININ; ENVELOPE
   GLYCOPROTEIN GP120; MANNOSE-SPECIFIC LECTIN; HAMSTER OVARY CELLS;
   CYANOVIRIN-N; PLANT-LECTINS; INACTIVATING PROTEIN; GLYCOSYLATION SITES;
   STRUCTURAL BASIS
AB Carbohydrate-binding proteins (CBP) can be isolated from a variety of species, including procaryotes (i.e. cyanobacteria), sea corals, algae, plants, invertebrates and, vertebrates. A number of them, in particular those CBP that show specific recognition for mannose (Man) and N-acetylglucosamine (GIcNAc) are endowed with a remarkable anti-HIV activity in cell culture. The smallest CBP occur as monomeric peptides with a molecular weight of similar to 8.5 kDa. Many others are functionally dimers, trimers or tetramers, and their molecular weight can sometimes largely exceed 50 kDa. CBP can contain 2 to up to 12 c.arbohydrate-binding sites per single molecule, depending on the nature of the lectin and its oligornerization state. CBP qualify as potential anti-HIV microbicide drugs because they not only inhibit infection of cells by cell-free vir-us (in some cases in the lower nano- or even sunnanomolar range) but they can also efficiently prevent virus transmission from virus-infected cells to uninfected T-lymphocytes. Their most likely mechanism of antiviral action is the interruption of virus entry (i.e. fusion) into its target cell. CBP presumably act by direct binding to the glycans that are abundantly present on the HIV-1 gp 120 envelope. They may cross-link several glycans during virus/cell interaction and/or freeze the conformation of gp 120 consequently preventing further interaction with the coreceptor. Several CBP were shown to have a high genetic barrier since multiple (>= 5) glycan deletions in the HIV envelope are necessary to provoke a moderate4evel of drug resistance. CBP are the prototypes of conceptionally novel chernotherapeutics with a unique mechanism of antiviral action, drug resistance profile and an intrinsic capacity to trigger a specific immune response against HIV strains after glycan deletions on their envelope occur in an attempt to escape CBP drug pressure. (c) 2006 Elsevier B.V. All rights reserved.
C1 Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Balzarini, J (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Minderbroedersstr 10, B-3000 Louvain, Belgium.
EM jan.balzarini@rega.kuleuven.be
CR Adams EW, 2004, CHEM BIOL, V11, P875, DOI 10.1016/j.chembiol.2004.04.010
   Balzarini J, 2005, MOL PHARMACOL, V67, P1556, DOI 10.1124/mol.104.005082
   Balzarini J, 2005, CAN MED ASSOC J, V172, P461, DOI 10.1503/cmaj.1041462
   Balzarini J, 2004, J VIROL, V78, P10617, DOI 10.1128/JVI.78.19.10617-10627.2004
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   BALZARINI J, 1992, ANTIVIR RES, V18, P191, DOI 10.1016/0166-3542(92)90038-7                                                    
   Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004
   Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200
   Balzarini O, 2005, LANCET INFECT DIS, V5, P726, DOI 10.1016/S1473-3099(05)70271-1                                                   
   Bewley CA, 2004, J MOL BIOL, V339, P901, DOI 10.1016/j.jmb.2004.04.019
   Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Botos I, 2005, PROG BIOPHYS MOL BIO, V88, P233, DOI 10.1016/j.pbiomolbio.2004.05.001
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Bourne Y, 2002, BIOCHEM J, V364, P173, DOI 10.1042/bj3640173                                                               
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   BULGHERESI S, 2006, IN PRESS APPL ENV MI, V72
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102
   Chang TL, 2004, AIDS REV, V6, P161
   CHANG TL, 2005, J CLIN INVEST, V11, P765
   Charan RD, 2000, J NAT PROD, V63, P1170, DOI 10.1021/np000039h
   Chiba H, 2004, BIOCHEM BIOPH RES CO, V316, P203, DOI 10.1016/j.bbrc.2004.02.036
   Chiba H, 2001, BIOCHEM BIOPH RES CO, V282, P595, DOI 10.1006/bbrc.2001.4495
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   GALLAHER WR, 1995, AIDS RES HUM RETROV, V11, P191, DOI 10.1089/aid.1995.11.191
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Giomarelli B, 2002, AIDS, V16, P1351, DOI 10.1097/00002030-200207050-00006
   Hansen S, 1998, IMMUNOBIOLOGY, V199, P165, DOI 10.1016/S0171-2985(98)80025-9                                                   
   Harata K, 2000, J MOL BIOL, V297, P673, DOI 10.1006/jmbi.2000.3594
   Harata K, 2001, ACTA CRYSTALLOGR D, V57, P1513, DOI 10.1107/S090744490101232X
   Heggelund L, 2005, EUR J CLIN INVEST, V35, P765, DOI 10.1111/j.1365-2362.2005.01579.x
   Hester G, 1996, J MOL BIOL, V262, P516, DOI 10.1006/jmbi.1996.0532
   Inokoshi J, 2001, BIOCHEM BIOPH RES CO, V281, P1261, DOI 10.1006/bbrc.2001.4496
   Ji X, 2005, MOL IMMUNOL, V42, P145, DOI 10.1016/j.molimm.2004.06.015
   Kabir S, 1998, J IMMUNOL METHODS, V212, P193, DOI 10.1016/S0022-1759(98)00021-0
   Klein NJ, 2005, MOL IMMUNOL, V42, P919, DOI 10.1016/j.molimm.2004.12.006
   KLJAJIC Z, 1987, EUR J BIOCHEM, V169, P97, DOI 10.1111/j.1432-1033.1987.tb13585.x                                              
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lagenaur L, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-S1-S93
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   Liu W, 2005, J BIOL CHEM, V280, P14865, DOI 10.1074/jbc.M411634200
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Mizuochi T, 1988, Biomed Chromatogr, V2, P260
   Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200
   Muller-Schwarze D, 2001, CHEM SIGNAL, V9, P1
   Nakowitsch S, 2005, AIDS, V19, P1957, DOI 10.1097/01.aids.0000189856.13817.76
   Nguyen DG, 2003, EUR J IMMUNOL, V33, P483, DOI 10.1002/immu.200310024                                                          
   Ouellet M, 2005, J IMMUNOL, V174, P4120, DOI 10.4049/jimmunol.174.7.4120                                                     
   Pashov A, 2005, GLYCOBIOLOGY, V15, P994, DOI 10.1093/glycob/cwi083
   PEUMANS WJ, 1984, FEBS LETT, V177, P99, DOI 10.1016/0014-5793(84)80989-8                                                    
   Saul FA, 2000, STRUCT FOLD DES, V8, P593, DOI 10.1016/S0969-2126(00)00142-8
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Sharon N, 2003, LECTINS, P1
   SHIBUYA N, 1986, ARCH BIOCHEM BIOPHYS, V249, P215, DOI 10.1016/0003-9861(86)90577-1
   Sun LL, 2005, J VIROL, V79, P14318, DOI 10.1128/JVI.79.22.14318-14329.2005
   Takahashi A, 2005, ARCH BIOCHEM BIOPHYS, V437, P233, DOI 10.1016/j.abb.2005.03.017
   Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244
   Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459
   Turville SG, 2005, J VIROL, V79, P13519, DOI 10.1128/JVI.79.21.13519-13527.2005
   Van Damme E. J., 1998, HDB PLANT LECTINS PR
   VANDAMME EJM, 1994, EUR J BIOCHEM, V221, P769
   VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52
   VANDAMME EJM, 1987, PLANT PHYSIOL, V85, P566, DOI 10.1104/pp.85.2.566                                                             
   VANDAMME EJM, 1988, PLANT PHYSIOL, V86, P598, DOI 10.1104/pp.86.2.598
   VANDAMME EJM, 1989, PHYSIOL PLANTARUM, V79, P1
   WANG JH, IN PRESS COMP BIOC C
   Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   XIONG C, IN PRESS PROTEIN EXP
   Yamaguchi M, 1999, BIOCHEM BIOPH RES CO, V265, P703, DOI 10.1006/bbrc.1999.1749
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
   Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m
NR 77
TC 86
Z9 92
U1 1
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD SEP
PY 2006
VL 71
IS 2-3
BP 237
EP 247
DI 10.1016/j.antiviral.2006.02.004
PG 11
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 082IY
UT WOS:000240381200021
PM 16569440
DA 2018-01-05
ER

PT J
AU DeJesus, E
   Berger, D
   Markowitz, M
   Cohen, C
   Hawkins, T
   Ruane, P
   Elion, R
   Farthing, C
   Zhong, L
   Cheng, AK
   McColl, D
   Kearney, BP
AF DeJesus, Edwin
   Berger, Daniel
   Markowitz, Martin
   Cohen, Calvin
   Hawkins, Trevor
   Ruane, Peter
   Elion, Richard
   Farthing, Charles
   Zhong, Lijie
   Cheng, Andrew K.
   McColl, Dainian
   Kearney, Brian P.
CA 183-0101 Study Team
TI Antiviral activity, pharmacokinetics, and dose response of the HIV-1
   integrase inhibitor GS-9137 (JTK-303) in treatment-naive and
   treatment-experienced patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE GS-9137; JTK-303; integrase; pharmacokinetics/pharmacodynamics; HIV
ID TYPE-1 DRUG-RESISTANCE; SAFETY; REPLICATION; MONOTHERAPY; STAVUDINE;
   INFECTION; EFFICACY; ADULTS; CELLS; TRIAL
AB Background: GS-9137 is a potent low-nanomolar strand transfer inhibitor of HIV-1 integrase.
   Methods: The antiviral activity, tolerability, pharmacokinetics, and pharmacodynamics of GS-9137 were evaluated in a randomized, double-blind, placebo-controlled monotherapy study in 40 HIV-1-infected patients not receiving antiretroviral therapy with an HIV-1 RNA between 10;000 and 300,000 copies/mL and a CD4 count of 200 cells/mu L or greater. GS-9137 or matching placebo was administered with food for 10 days at 5 dosage regimens (200, 400, or 800 mg BID, 800 mg QD, or 50 mg + 100 mg ritonavir QD; 6 active, 2 placebo per dose level). The primary end point was the maximum reduction from baseline in logo HIV-1 RNA.
   Results: Forty patients were enrolled, with a mean baseline viral load of 4.75 log(10) copies/mL and a CD4 count of 442 cells/mu L. Each GS-9137 dosing regimen exhibited significant. exposure-dependent (mean reductions. -0.98 to -1.99 logo copies/mL) antiviral activity compared with placebo (P < 0.01). Twice-daily administrations of GS-9137 at doses of 400 or 800 mg or once-daily dosing of 50 mg with ritonavir demonstrated mean reductions from baseline in HIV-1 RNA of 1.91 log(10) copies/mL or greater, with all patients exhibiting 1 log(10) or greater and 50% having 2 log(10) or greater reductions. No patient developed evidence of integrase resistance. GS-9137 showed an adverse event profile similar to placebo, and there were no study drug discontinuations.
   Conclusions: GS-9137 demonstrated substantial short-term antiviral activity and was well tolerated as monotherapy, thus warranting further study.
C1 Ctr Immunol, Orlando, FL USA.
   NorthStar Med Ctr, Chicago, IL USA.
   Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10021 USA.
   Community Res Initiat New England, Boston, MA USA.
   SW Comprehens AIDS Care Res & Educ, Santa Fe, NM USA.
   Light Source Med, Los Angeles, CA USA.
   Clin Alliance Res & Educ Infect Dis, Washington, DC USA.
   AIDS Healthcare Fdn Res Ctr, Beverly Hills, CA USA.
   Gilead Sci Inc, Foster City, CA 94404 USA.
RP Kearney, BP (reprint author), PharmD, 333 Lakeside Dr, Foster City, CA 94404 USA.
EM bkearney@gilead.com
CR Arasteh K, 2005, AIDS, V19, P943, DOI 10.1097/01.aids.0000171408.38490.01                                             
   *DHHS, GUID US ANT AG HIV 1
   Erali M, 2001, J CLIN MICROBIOL, V39, P2157, DOI 10.1128/JCM.39.6.2157-2165.2001
   Gieschke R, 1999, CLIN PHARMACOKINET, V37, P75, DOI 10.2165/00003088-199937010-00005
   GRINSZTEJN B, 13 C RETR OPP INF FE
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   Johnson Victoria A, 2005, Top HIV Med, V13, P51
   Kawaguchi I, 2006, 13 C RETR OPP INF FE
   KEARNEY BP, 7 INT WORKSH CLIN PH
   Lalezari J, 2005, AIDS, V19, P1443, DOI 10.1097/01.aids.0000183633.06580.8a
   Little S., 2005, 12 C RETR OPP INF FE
   Kearney BP, 2006, 7 INT WORKSH CLIN PH
   MATSUZAKI Y, 13 C RETR OPP INF FE
   McCallister S, 2004, JAIDS-J ACQ IMM DEF, V35, P376, DOI 10.1097/00126334-200404010-00007
   MORALESRAMIREZ JO, 2005, 10 EUR AIDS C EACS N
   Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002                                                
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Sanne I, 2003, JAIDS, V32, P18, DOI 10.1097/00126334-200301010-00004                                                
   Shafer RW, 2002, CLIN MICROBIOL REV, V15, P247, DOI 10.1128/CMR.15.2.247-277.2002
   Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005
   Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006
   Wilson JW, 2000, J CLIN MICROBIOL, V38, P3022
NR 24
TC 199
Z9 205
U1 1
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP
PY 2006
VL 43
IS 1
BP 1
EP 5
DI 10.1097/01.qai.0000233308.82860.2f
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 080YK
UT WOS:000240284200001
PM 16936557
OA gold
DA 2018-01-05
ER

PT J
AU Helle, F
   Wychowski, C
   Vu-Dac, N
   Gustafson, KR
   Voisset, C
   Dubuisson, J
AF Helle, Francois
   Wychowski, Czeslaw
   Vu-Dac, Ngoc
   Gustafson, Kirk R.
   Voisset, Cecile
   Dubuisson, Jean
TI Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope
   protein glycans
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ENDOPLASMIC-RETICULUM; INACTIVATING PROTEIN; GLYCOPROTEIN E2; PSEUDOTYPE
   PARTICLES; CELL-CULTURE; GP120; HIV; GLYCOSYLATION; LOCALIZATION;
   COMPLEXES
AB Inhibition of viruses at the stage of viral entry provides a route for therapeutic intervention. Because of difficulties in propagating hepatitis C virus (HCV) in cell culture, entry inhibitors have not yet been reported for this virus. However, with the development of retroviral particles pseudotyped with HCV envelope glycoproteins (HCVpp) and the recent progress in amplification of HCV in cell culture (HCVcc), studying HCV entry is now possible. In addition, these systems are essential for the identification and the characterization of molecules that block HCV entry. The lectin cyanovirin-N (CV-N) has initially been discovered based on its potent activity against human immunodeficiency virus. Because HCV envelope glycoproteins are highly glycosylated, we sought to determine whether CV-N has an antiviral activity against this virus. CV-N inhibited the infectivity of HCVcc and HCVpp at low nanomolar concentrations. This inhibition is attributed to the interaction of CV-N with HCV envelope glycoproteins. In addition, we showed that the carbohydrate binding property of CV-N is involved in the anti-HCV activity. Finally, CV-N bound to HCV envelope glycoproteins and blocked the interaction between the envelope protein E2 and CD81, a cell surface molecule involved in HCV entry. These data demonstrate that targeting the glycans of HCV envelope proteins is a promising approach in the development of antiviral therapies to combat a virus that is a major cause of chronic liver diseases. Furthermore, CV-N is a new invaluable tool to further dissect the early steps of HCV entry into host cells.
C1 Inst Pasteur, Ctr Natl Rech Sci, Inst Biol, Unite Mixt Rech 8161,Hepatitis C Lab,UMR8161, F-59021 Lille, France.
   NCI, Mol Targets Dev Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA.
RP Dubuisson, J (reprint author), Inst Pasteur, Ctr Natl Rech Sci, Inst Biol, Unite Mixt Rech 8161,Hepatitis C Lab,UMR8161, 1 Rue Calmette,BP447, F-59021 Lille, France.
EM jean.dubuisson@ibl.fr
RI HELLE, Francois/G-7427-2011
OI HELLE, Francois/0000-0001-6884-2456; Dubuisson, Jean/0000-0003-1626-7693
CR Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200
   Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3                                                   
   Barrientos LG, 2005, MINI-REV MED CHEM, V5, P21, DOI 10.2174/1389557053402783                                                        
   Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Choukhi A, 1998, J VIROL, V72, P3851
   Ciczora Y, 2005, J GEN VIROL, V86, P2793, DOI 10.1099/vir.0.81140-0
   Cocquerel L, 2006, J GEN VIROL, V87, P1075, DOI 10.1099/vir.0.81646-0
   Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629                                                     
   De Beeck AO, 2004, J VIROL, V78, P2994, DOI 10.1128/JVI.78.6.2994-3002.2004
   De Francesco R, 2005, NATURE, V436, P953, DOI 10.1038/nature04080
   Deleersnyder V, 1997, J VIROL, V71, P697
   Drummer HE, 2003, FEBS LETT, V546, P385, DOI 10.1016/S0014-5793(03)00635-5
   DUBUISSON J, 1994, J VIROL, V68, P6147
   Duvet S, 1998, J BIOL CHEM, V273, P32088, DOI 10.1074/jbc.273.48.32088
   Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082
   Flint M, 2004, J VIROL, V78, P6875, DOI 10.1128/JVI.78.13.6875-6882.2004
   Flint M, 2000, J VIROL, V74, P702, DOI 10.1128/JVI.74.2.702-709.2000
   Flint M, 1999, J VIROL, V73, P6235
   Goffard A, 2005, J VIROL, V79, P8400, DOI 10.1128/JVI.79.13.8400-8409.2005
   Goffard A, 2003, BIOCHIMIE, V85, P295, DOI 10.1016/S0300-9084(03)00004-X
   Heile JM, 2000, J VIROL, V74, P6885, DOI 10.1128/JVI.74.15.6885-6892.2000
   Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000                                                 
   Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100
   Lavillette D, 2005, HEPATOLOGY, V41, P265, DOI 10.1002/hep.20542
   Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016
   Lindenbach BD, 2001, FIELDS VIROLOGY
   Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200
   MAJOR ME, 2001, FIELDS VIROLOGY
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2
   NAKABAYASHI H, 1982, CANCER RES, V42, P3858
   O'Keefe BR, 2000, MOL PHARMACOL, V58, P982
   O'Keefe BR, 2003, ANTIMICROB AGENTS CH, V47, P2518, DOI 10.1128/AAC.47.8.2518-2525.2003
   Pawlotsky Jean-Michel, 2003, Clin Liver Dis, V7, P45, DOI 10.1016/S1089-3261(02)00065-X
   Pawlotsky JM, 2006, HEPATOLOGY, V43, pS207, DOI 10.1002/hep.21064
   Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938
   Rouille Y, 2006, J VIROL, V80, P2832, DOI 10.1128/JVI.80.6.2832-2841.2006
   Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042
   Shenoy SR, 2002, CHEM BIOL, V9, P1109, DOI 10.1016/S1074-5521(02)00237-5
   Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704
   Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268
   Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506                                                             
   Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005
   Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106
   Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102
NR 48
TC 117
Z9 124
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 1
PY 2006
VL 281
IS 35
BP 25177
EP 25183
DI 10.1074/jbc.M602431200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 077LQ
UT WOS:000240031300018
PM 16809348
OA gold
DA 2018-01-05
ER

PT J
AU Held, DM
   Kissel, JD
   Saran, D
   Michalowski, D
   Burke, DH
AF Held, Daniel M.
   Kissel, Jay D.
   Saran, Dayal
   Michalowski, Daniel
   Burke, Donald H.
TI Differential susceptibility of HIV-1 reverse transcriptase to inhibition
   by RNA aptamers in enzymatic reactions monitoring specific steps during
   genome replication
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; STRAND DISPLACEMENT SYNTHESIS;
   NONNUCLEOSIDE INHIBITORS; DNA-SYNTHESIS; STEADY-STATE; IN-VITRO;
   NUCLEOTIDE INCORPORATION; AVIAN-MYELOBLASTOSIS; PSEUDOKNOT INHIBITOR;
   MOLECULAR-MECHANISM
AB Nucleic acid aptamers to HIV-1 reverse transcriptase (RT) are potent inhibitors of DNA polymerase function in vitro, and they have been shown to inhibit viral replication when expressed in cultured T-lymphoid lines. We monitored RT inhibition by five RNA pseudoknot RNA aptamers in a series of biochemical assays designed to mimic discrete steps of viral reverse transcription. Our results demonstrate potent aptamer inhibition (IC50 values in the low nanomolar range) of all RT functions assayed, including RNA- and DNA-primed DNA polymerization, strand displacement synthesis, and polymerase-independent RNase H activity. Additionally, we observe differences in the time dependence of aptamer inhibition. Polymerase-independent RNase H activity is the most resistant to long term aptamer suppression, and RNA- dependent DNA polymerization is the most susceptible. Finally, when DNA polymerization was monitored in the presence of an RNA aptamer in combination with each of four different small molecule inhibitors, significant synergy was observed between the aptamer and the two nucleoside analog RT inhibitors (azidothymidine triphosphate or ddCTP), whereas two non-nucleoside analog RT inhibitors showed either weak synergy (efavirenz) or antagonism (nevirapine). Together, these results support a model wherein aptamers suppress viral replication by cumulative inhibition of RT at every stage of genome replication.
C1 Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.
   Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.
   Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65211 USA.
   Univ Missouri, Sch Med, Dept Biochem, Columbia, MO 65211 USA.
RP Burke, DH (reprint author), 471h Life Sci Ctr, 1201 E Rollins Rd, Columbia, MO 65211 USA.
EM burkedh@missouri.edu
FU NIAID NIH HHS [AI62513]
CR Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   Archer RH, 2000, J VIROL, V74, P8390, DOI 10.1128/JVI.74.18.8390-8401.2000
   Avidan O, 1998, NUCLEIC ACIDS RES, V26, P1713, DOI 10.1093/nar/26.7.1713
   Basavapathruni A, 2004, J BIOL CHEM, V279, P6221, DOI 10.1074/jbc.C300523200
   BATHURST IC, 1990, BIOCHEM BIOPH RES CO, V171, P589, DOI 10.1016/0006-291X(90)91187-W
   BAVAND MR, 1993, BIOCHEMISTRY-US, V32, P10543, DOI 10.1021/bi00091a003
   BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   Chaloin L, 2002, NUCLEIC ACIDS RES, V30, P4001, DOI 10.1093/nar/gkf522
   CHEN H, 1994, BIOCHEMISTRY-US, V33, P8746, DOI 10.1021/bi00195a016                                                             
   Chen H, 1996, BIOCHEMISTRY-US, V35, P6923, DOI 10.1021/bi9600106                                                               
   CHONG KT, 1994, ANTIMICROB AGENTS CH, V38, P288, DOI 10.1128/AAC.38.2.288                                                            
   Cruchaga C, 2005, BIOCHEMISTRY-US, V44, P3535, DOI 10.1021/bi048129z
   DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423
   DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793
   DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Fisher TS, 2002, J VIROL, V76, P4068, DOI 10.1128/JVI.76.8.4068-4072.2002
   Fuentes GM, 1996, J BIOL CHEM, V271, P1966, DOI 10.1074/jbc.271.4.1966                                                          
   Gerondelis P, 1999, J VIROL, V73, P5803
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   GRAVES MC, 1990, BIOCHEM BIOPH RES CO, V168, P30, DOI 10.1016/0006-291X(90)91670-N
   GREEN L, 1995, J MOL BIOL, V247, P60, DOI 10.1006/jmbi.1994.0122
   Hannoush RN, 2004, CHEMBIOCHEM, V5, P527, DOI 10.1002/cbic.200300831
   Held DM, 2006, FRONT BIOSCI, V11, P89, DOI 10.2741/1782
   Hogg RS, 1999, CAN MED ASSOC J, V160, P659
   HUBER HE, 1989, J BIOL CHEM, V264, P4669
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   Jaeger J, 1998, EMBO J, V17, P4535, DOI 10.1093/emboj/17.15.4535
   Joshi P, 2002, J VIROL, V76, P6545, DOI 10.1128/JVI.76.13.6545-6557.2002
   Joshi P. J., 2003, Current Drug Targets - Infectious Disorders, V3, P383, DOI 10.2174/1568005033481060
   Joshi PJ, 2005, MOL THER, V11, P677, DOI 10.1016/j.ymthe.2005.01.013
   KATI WM, 1992, J BIOL CHEM, V267, P25988
   KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793
   Lanchy JM, 1996, EMBO J, V15, P7178
   Maga G, 2001, J BIOL CHEM, V276, P44653, DOI 10.1074/jbc.M106702200
   PAGE KA, 1990, J VIROL, V64, P5270
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Schneider MF, 2005, AIDS, V19, P2009, DOI 10.1097/01.aids.0000189864.90053.22
   Somasunderam A, 2005, BIOCHEMISTRY-US, V44, P10388, DOI 10.1021/bi0507074
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   Temiz NA, 2002, PROTEINS, V49, P61, DOI 10.1002/prot.10183
   Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   Witvrouw M, 1998, ANTIMICROB AGENTS CH, V42, P618
   Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057
   Yazdanpanah Y, 2004, BRIT MED J, V328, P249, DOI 10.1136/bmj.37995.435787.A6
NR 49
TC 24
Z9 24
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 1
PY 2006
VL 281
IS 35
BP 25712
EP 25722
DI 10.1074/jbc.M604460200
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 077LQ
UT WOS:000240031300074
PM 16798747
OA gold
DA 2018-01-05
ER

PT J
AU Steger, HK
   Root, MJ
AF Steger, H. Kirby
   Root, Michael J.
TI Kinetic dependence to HIV-1 entry inhibition
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENVELOPE GLYCOPROTEIN; POTENT INHIBITORS;
   MEMBRANE-FUSION; NONNEUTRALIZING ANTIBODIES; SYNTHETIC PEPTIDE;
   ATOMIC-STRUCTURE; 6-HELIX BUNDLE; HELICAL DOMAIN; COILED-COIL
AB Infection by human immunodeficiency virus type 1 (HIV-1) involves the fusion of viral and cellular membranes mediated by formation of the gp41 trimer-of-hairpins. A designed protein, 5-Helix, targets the C-terminal region of the gp41 ectodomain, disrupting trimer-of-hairpins formation and blocking viral entry. Here we show that the nanomolar inhibitory potency of 5-Helix (IC50 similar to 6 nM) is 4 orders of magnitude larger than its subpicomolar binding affinity (K-D similar to 0.6 pm). This discrepancy results from the transient exposure of the 5-Helix binding site on gp41. As a consequence, inhibitory potency is determined by the association rate, not by binding affinity. For a series of 5-Helix variants with mutations in their gp41 binding sites, the IC50 and KD values poorly correlate. By contrast, an inverse relationship between IC50 values and association rate constants (kon) extends for over 2 orders of magnitude. The kinetic dependence to inhibition places temporal restrictions on an intermediate state of HIV-1 membrane fusion and suggests that access to the C-terminal region of the gp41 ectodomain is largely free from steric hindrance. Our results support the importance of association kinetics in the development of improved HIV-1 fusion inhibitors.
C1 Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA.
RP Root, MJ (reprint author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Kimmel Canc Ctr, 233 S 10th St,Rm 802, Philadelphia, PA 19107 USA.
EM mroot@mail.jci.tju.edu
FU NIGMS NIH HHS [R01 GM66682]
CR Abrahamyan LG, 2005, J VIROL, V79, P106, DOI 10.1128/JVI.79.1.106-115.2005
   Bianchi E, 2005, P NATL ACAD SCI USA, V102, P12903, DOI 10.1073/pnas.0502449102
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dimitrov AS, 2005, BIOCHEMISTRY-US, V44, P12471, DOI 10.1021/bi051092d
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   Follis KE, 2002, J VIROL, V76, P7356, DOI 10.1128/JVI.76.14.7356-7362.2002
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Hamburger AE, 2005, J BIOL CHEM, V280, P12567, DOI 10.1074/jbc.M412770200
   Herrera C, 2003, J VIROL, V77, P1084, DOI 10.1128/JVI.77.2.1084-1091.2003
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Kilgore NR, 2003, J VIROL, V77, P7669, DOI 10.1128/JVI.77.13.7669-7672.2003
   Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200
   Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Markosyan RM, 2003, MOL BIOL CELL, V14, P926, DOI 10.1091/mbc.E02-09-0573
   Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413
   Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   MUSTER T, 1993, J VIROL, V67, P6642
   Ofek G, 2004, J VIROL, V78, P10724, DOI 10.1128/JVI.78.19.10724-10737.2004
   Pierson TC, 2003, CURR TOP MICROBIOL, V281, P1
   Poignard P, 2003, J VIROL, V77, P353, DOI 10.1128/JVI.77.1.353-365.2003
   Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399
   Rimsky LT, 1998, J VIROL, V72, P986
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Root MJ, 2004, CURR PHARM DESIGN, V10, P1805, DOI 10.2174/1381612043384448
   Root MJ, 2003, P NATL ACAD SCI USA, V100, P5016, DOI 10.1073/pnas.0936926100
   Russell CJ, 2001, EMBO J, V20, P4024, DOI 10.1093/emboj/20.15.4024
   Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 41
TC 53
Z9 53
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 1
PY 2006
VL 281
IS 35
BP 25813
EP 25821
DI 10.1074/jbc.M601457200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 077LQ
UT WOS:000240031300083
PM 16803885
OA gold
DA 2018-01-05
ER

PT J
AU Hillaireau, H
   Le Doan, T
   Couvreur, P
AF Hillaireau, Herve
   Le Doan, Trung
   Couvreur, Patrick
TI Polymer-based nanoparticles for the delivery of nucleoside analogues
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE nanoparticles; nucleoside analogues; nucleoticle analogues;
   poly(alkylcyanoacrylate); poly(lactic acid); poly(lactide-co-glycolide);
   albumin; nanogels
ID LOADED ALBUMIN NANOPARTICLES; DRUG-DELIVERY; BIOADHESIVE PROPERTIES;
   PLGA NANOPARTICLES; BODY DISTRIBUTION; IN-VITRO; CYANOACRYLATE
   NANOPARTICLES; PVM/MA NANOPARTICLES; 5-FLUOROURACIL; NANOSPHERES
AB Nucleoside analogues, together with nucleobases and nucleotide analogues, are commonly used in the treatment of cancer and viral infections. In both cases, they act as antimetabolite agents and interfere with the synthesis of cellular or viral nucleic acids. However, the need of high doses due to the rapid elimination of these compounds, to their poor activation, and/or to their nonspecific distribution, often leads to side effects and resistances. The present paper aims to review the different types of polymer nanoparticles which have been designed as drug delivery devices to address these issues. Thus, poly(alkylcyanoacrylate) nanoparticles have been demonstrated as potential carriers for antiviral nucleoside analogues, especially for anti-HIV agents, regarding both intravenous and oral routes. Nanoparticles based on polyesters such as poly(lactic acid) and poly(lactide-co-glycolide) have been used as nanocarriers for nucleosides analogues too, and especially for their ocular delivery. Albumin has shown interesting properties in the design of nanoparticles for the same application, but also for the oral administration of anticancer analogues. Finally, new hydrophilic nanoparticles consisting of cross-linked polymer network ('Nanogels') open the perspective to deliver nucleoside analogues within their active triphosphate form.
C1 Univ Paris 09, Fac Pharm, CNRS, UMR 8612, F-92296 Chatenay Malabry, France.
RP Couvreur, P (reprint author), Univ Paris 09, Fac Pharm, CNRS, UMR 8612, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.
RI COUVREUR, Patrick/G-4844-2011; Hillaireau, Herve/U-7781-2017
OI COUVREUR, Patrick/0000-0001-7961-5443; Hillaireau,
   Herve/0000-0002-0628-7618
CR Adachi M, 2002, ADV DRUG DELIVER REV, V54, P1333, DOI 10.1016/S0169-409X(02)00166-7                                                   
   Arbos P, 2004, J CONTROL RELEASE, V96, P55, DOI 10.1016/j.jconrel.2004.01.006
   Arbos P, 2003, J CONTROL RELEASE, V89, P19, DOI 10.1016/S0168-3659(03)00066-X
   Arbos P, 2002, INT J PHARM, V242, P129, DOI 10.1016/S0378-5173(02)00182-5                                                   
   Arbos P, 2002, J PHARMACEUT BIOMED, V28, P857, DOI 10.1016/S0731-7085(01)00683-5                                                   
   Bala I, 2004, CRIT REV THER DRUG, V21, P387, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.i5.20                                    
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   Barichello JM, 1999, DRUG DEV IND PHARM, V25, P471, DOI 10.1081/DDC-100102197                                                           
   Barratt G., 2002, POLYM BIOMATERIALS, P753
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   BLUM MR, 1988, AM J MED, V85, P189
   Bourlais C L, 1998, Prog Retin Eye Res, V17, P33
   Bozkir Asuman, 2005, Farmaco (Lausanne), V60, P840, DOI 10.1016/j.farmac.2005.06.016
   Chellat F, 2005, BIOMATERIALS, V26, P7260, DOI 10.1016/j.biomaterials.2005.05.044
   Couvreur P, 2002, CRIT REV THER DRUG, V19, P99, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i2.10                                    
   COUVREUR P, 1979, J PHARM PHARMACOL, V31, P331, DOI 10.1111/j.2042-7158.1979.tb13510.x                                              
   Damaraju VL, 2003, ONCOGENE, V22, P7524, DOI 10.1038/sj.onc.1206952
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   Fresta M, 2001, J PHARM SCI, V90, P288, DOI 10.1002/1520-6017(200103)90:3<288::AID-JPS4>3.0.CO;2-5                          
   Galmarini Carlos M, 2003, Expert Rev Anticancer Ther, V3, P717, DOI 10.1586/14737140.3.5.717
   Galmarini CM, 2002, LANCET ONCOL, V3, P415, DOI 10.1016/S1470-2045(02)00788-X
   Giannavola C, 2003, PHARMACEUT RES, V20, P584, DOI 10.1023/A:1023290514575                                                         
   Govender T, 1999, J CONTROL RELEASE, V57, P171, DOI 10.1016/S0168-3659(98)00116-3
   GREF R, 1994, SCIENCE, V263, P1600, DOI 10.1126/science.8128245
   GREF R, 2004, ENCY NANOSCIENCE NAN, V10, P83
   GRISLAIN L, 1983, INT J PHARM, V15, P335, DOI 10.1016/0378-5173(83)90166-7
   GUISE V, 1990, PHARMACEUT RES, V7, P736, DOI 10.1023/A:1015819706491
   Irache JM, 2005, MINI-REV MED CHEM, V5, P293, DOI 10.2174/1389557053175335                                                        
   KATTAN J, 1992, INVEST NEW DRUG, V10, P191, DOI 10.1007/BF00877245
   KLECKER RW, 1988, J CLIN PHARMACOL, V28, P837, DOI 10.1002/j.1552-4604.1988.tb03225.x                                              
   Kukhanova M, 2000, CURR PHARM DESIGN, V6, P585, DOI 10.2174/1381612003400687                                                        
   Kumar MNVR, 2000, J PHARM PHARM SCI, V3, P234
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Lea AP, 1996, DRUGS, V51, P846, DOI 10.2165/00003495-199651050-00009
   LENAERTS V, 1984, J PHARM SCI, V73, P980, DOI 10.1002/jps.2600730730
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lo CL, 2005, J CONTROL RELEASE, V104, P477, DOI 10.1016/j.jconrel.2005.03.004
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J DRUG TARGET, V5, P171
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   McCarron PA, 2000, J PHARM PHARMACOL, V52, P1451, DOI 10.1211/0022357001777658
   Menei P, 2005, NEUROSURGERY, V56, P242, DOI 10.1227/01.neu.0000144982.82068.A2
   Merodio M, 2002, BIOMATERIALS, V23, P1587, DOI 10.1016/S0142-9612(01)00284-8
   Merodio M, 2002, J DRUG TARGET, V10, P231, DOI 10.1080/10611860290022660
   Merodio M, 2001, EUR J PHARM SCI, V12, P251, DOI 10.1016/S0928-0987(00)00169-X                                                   
   Merodio M, 2000, J CHROMATOGR A, V870, P159, DOI 10.1016/S0021-9673(99)01015-8
   MUKHERJI G, 1990, INT J PHARM, V65, P1, DOI 10.1016/0378-5173(90)90002-L
   NIWA T, 1993, J CONTROL RELEASE, V25, P89, DOI 10.1016/0168-3659(93)90097-O
   Parker William B, 2004, Curr Opin Investig Drugs, V5, P592
   PAUSCH J, 1985, ADV ENZYME REGUL, V24, P429, DOI 10.1016/0065-2571(85)90091-3                                                    
   Peracchia MT, 1998, PHARMACEUT RES, V15, P550, DOI 10.1023/A:1011973625803                                                         
   Ropert C, 1996, BBA-MOL CELL RES, V1310, P53, DOI 10.1016/0167-4889(95)00140-9
   Schafer V, 1994, Clin Diagn Virol, V1, P279, DOI 10.1016/0928-0197(94)90058-2
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Simeonova M, 2003, INT J PHARM, V263, P133, DOI 10.1016/S0378-5173(03)00373-9
   Simeonova M, 2004, J DRUG TARGET, V12, P49, DOI 10.1080/1061186042000207011
   Song D, 1997, CLIN CANCER RES, V3, P901
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   TORNEVIK Y, 1995, BIOCHEM PHARMACOL, V49, P829, DOI 10.1016/0006-2952(94)00453-S
   Van Rompay AR, 2003, PHARMACOL THERAPEUT, V100, P119, DOI 10.1016/j.pharmthera.2003.07.001
   Vauthier C, 2003, ADV DRUG DELIVER REV, V55, P519, DOI 10.1016/S0169-409X(03)00041-3
   VAUTHIER C, 2002, HDB BIOPOLYMERS, V9, P457
   Vinogradov S, 1999, COLLOID SURFACE B, V16, P291, DOI 10.1016/S0927-7765(99)00080-6                                                   
   Vinogradov SV, 2005, MOL PHARMACEUT, V2, P449, DOI 10.1021/mp0500364
   Vinogradov SV, 2005, J CONTROL RELEASE, V107, P143, DOI 10.1016/j.jconrel.2005.06.002
   YARCHOAN R, 1987, NEW ENGL J MED, V316, P557, DOI 10.1056/NEJM198702263160925                                                     
NR 70
TC 24
Z9 26
U1 0
U2 19
PU AMER SCIENTIFIC PUBLISHERS
PI STEVENSON RANCH
PA 25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD SEP-OCT
PY 2006
VL 6
IS 9-10
BP 2608
EP 2617
DI 10.1166/jnn.2006.453
PG 10
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 089FO
UT WOS:000240865900003
PM 17048470
DA 2018-01-05
ER

PT J
AU Kingsley, JD
   Dou, HY
   Morehead, J
   Rabinow, B
   Gendelman, HE
   Destache, CJ
AF Kingsley, Jeffrey D.
   Dou, Huanyu
   Morehead, Justin
   Rabinow, Barrett
   Gendelman, Howard E.
   Destache, Christopher J.
TI Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System
SO JOURNAL OF NEUROIMMUNE PHARMACOLOGY
LA English
DT Article
DE nanotechnology; review; indinavir; drug delivery system; cancer; HIV
   treatment
AB This review will provide an in-depth discussion on the previous development of nanoparticle-based drug delivery systems (DDS) and discuss original research data that includes the therapeutic enhancement of antiretroviral therapy. The use of nanoparticle DDS will allow practitioners to use drugs to target specific areas of the body. In the treatment of malignancies, the use of nanoparticles as a DDS is making measurable treatment impact. Medical imaging will also utilize DDS to illuminate tumors, the brain, or other cellular functions in the body. The utility of nanoparticle DDS to improve human health is potentially enormous.
C1 [Destache, Christopher J.] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   [Kingsley, Jeffrey D.; Dou, Huanyu; Morehead, Justin; Gendelman, Howard E.; Destache, Christopher J.] Univ Nebraska Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA.
   [Dou, Huanyu; Morehead, Justin; Gendelman, Howard E.; Destache, Christopher J.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   [Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
   [Kingsley, Jeffrey D.] Univ Nebraska Med Ctr, Dept Pediat, Omaha, NE 68198 USA.
   [Rabinow, Barrett] Baxter Healthcare Corp, Round Lake, IL 60073 USA.
RP Destache, CJ (reprint author), Creighton Univ, Sch Pharm & Hlth Profess, 2500 Calif Pl, Omaha, NE 68178 USA.
EM destache@creighton.edu
OI Destache, Christopher/0000-0001-7923-3939
CR Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593                                                
   Alder-Moore J., 1994, BONE MARROW TRANSPL, V14, pS3
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Allen TM, 1998, DRUGS, V56, P747, DOI 10.2165/00003495-199856050-00001                                                
   Anzai Yoshimi, 2004, Top Magn Reson Imaging, V15, P103, DOI 10.1097/01.rmr.0000130602.65243.87
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BECK P, 1993, J MICROENCAPSUL, V10, P101, DOI 10.3109/02652049309015316                                                       
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   BORY C, 1991, ADV EXP MED BIOL, V309, P173
   Cabanes A, 1998, INT J ONCOL, V12, P1035
   Caliceti P, 2004, DIGEST LIVER DIS, V36, pS334, DOI 10.1016/S1590-8658(04)80002-1
   Ceresoli GL, 2006, J CLIN ONCOL, V24, P1443, DOI 10.1200/JCO.2005.04.3190
   Cheng TL, 2005, BIOCONJUGATE CHEM, V16, P1225, DOI 10.1021/bc050133f
   CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78
   Conway MA, 2001, VACCINE, V19, P1940, DOI 10.1016/S0264-410X(00)00433-3
   COUVREUR P, 1982, J PHARM SCI, V71, P790, DOI 10.1002/jps.2600710717
   CYNAMON MH, 1989, ANTIMICROB AGENTS CH, V33, P1179, DOI 10.1128/AAC.33.8.1179                                                           
   Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525
   Dembri A, 2001, PHARM RES-DORDR, V18, P467, DOI 10.1023/A:1011050209986
   DOU H, 2006, BLOOD IN PRESS
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   Ferrari M, 2005, CURR OPIN CHEM BIOL, V9, P343, DOI 10.1016/j.cbpa.2005.06.001
   Fiegel J, 2004, J CONTROL RELEASE, V96, P411, DOI 10.1016/j.jconrel.2004.02.018
   Fielding RM, 1998, PHARMACEUT RES, V15, P1775, DOI 10.1023/A:1011925132473                                                         
   Fishbein I, 2001, ARTERIOSCL THROM VAS, V21, P1434, DOI 10.1161/hq0901.095567
   Galeska I, 2005, AAPS J, V7, pE231, DOI 10.1208/aapsj070122                                                             
   Gao XH, 2004, NAT BIOTECHNOL, V22, P969, DOI 10.1038/nbt994
   Gbadamosi JK, 2002, FEBS LETT, V532, P338, DOI 10.1016/S0014-5793(02)03710-9
   Gelperina S, 2005, AM J RESP CRIT CARE, V172, P1487, DOI 10.1164/rccm.200504-613PP
   GENSINI GF, 2006, J INFE IN PRESS 0329
   Glantz MJ, 1999, J CLIN ONCOL, V17, P3110, DOI 10.1200/JCO.1999.17.10.3110                                                     
   Glantz MJ, 1999, CLIN CANCER RES, V5, P3394
   Glue P, 2000, HEPATOLOGY, V32, P647, DOI 10.1053/jhep.2000.16661
   Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054
   Gryziewicz L, 2005, ADV DRUG DELIVER REV, V57, P2092, DOI 10.1016/j.addr.2005.09.009
   HENSON PM, 1988, INFLAMMATION BASIC P, P363
   HIRSCH JG, 1962, J EXP MED, V116, P827, DOI 10.1084/jem.116.6.827
   Hitzman CJ, 2006, J PHARM SCI-US, V95, P1114, DOI 10.1002/jps.20591
   Hoag Hannah, 2006, Nature, V440, P1084, DOI 10.1038/nj7087-1084a
   Hofheinz RD, 2005, ANTI-CANCER DRUG, V16, P691, DOI 10.1097/01.cad.0000167902.53039.5a
   Hohng S, 2004, J AM CHEM SOC, V126, P1324, DOI 10.1021/ja039686w
   Jacobson IM, 2005, AM J GASTROENTEROL, V100, P2453, DOI 10.1111/j.1572-0241.2005.00282.x
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Jayewardene AL, 1998, J CHROMATOGR B, V707, P203, DOI 10.1016/S0378-4347(97)00607-5
   Johnson CM, 2005, ANTIMICROB AGENTS CH, V49, P4335, DOI 10.1128/AAC.49.10.4335-4338.2005
   Kamal SM, 2006, GASTROENTEROLOGY, V130, P632, DOI 10.1053/j.gastro.2006.01.034
   KATO T, 1984, APPL BIOCHEM BIOTECH, V10, P199, DOI 10.1007/BF02783752                                                              
   Kim CK, 2002, ARCH PHARM RES, V25, P229, DOI 10.1007/BF02976620                                                              
   KIM S, 1993, J CLIN ONCOL, V11, P2186, DOI 10.1200/JCO.1993.11.11.2186                                                     
   Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920
   Kipp JE, 2004, INT J PHARM, V284, P109, DOI 10.1016/j.ijpharm.2004.07.019
   Kircher MF, 2003, CANCER RES, V63, P6838
   Kontermann RE, 2006, CURR OPIN MOL THER, V8, P39
   KREUTER J, 1978, PHARM ACTA HELV, V53, P33
   KREUTER J, 1983, PHARM ACTA HELV, V58, P242
   Kumar MNVR, 2000, J PHARM PHARM SCI, V3, P234
   Lacoste TD, 2000, P NATL ACAD SCI USA, V97, P9461, DOI 10.1073/pnas.170286097
   Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775
   LaVan DA, 2003, NAT BIOTECHNOL, V21, P1184, DOI 10.1038/nbt876
   Laverman P, 2001, J CONTROL RELEASE, V75, P347, DOI 10.1016/S0168-3659(01)00402-3
   Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   Lidke DS, 2004, NAT BIOTECHNOL, V22, P198, DOI 10.1038/nbt929
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   Luck M, 1998, J BIOMED MATER RES, V39, P478
   Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620
   Lysik MA, 2003, J PHARM SCI, V92, P1559, DOI 10.1002/jps.10399
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Mansson A, 2004, BIOCHEM BIOPH RES CO, V314, P529, DOI 10.1016/j.bbrc.2003.12.133
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   MOGHIMI SM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P157, DOI 10.1016/0167-4889(93)90137-E
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   Moghimi SM, 2001, CRIT REV THER DRUG, V18, P527
   Moghimi S. M., 2005, FASEB J, V19, P11
   Muggia F, 2001, EUR J CANCER, V37, pS15
   Murry DJ, 2000, ANN PHARMACOTHER, V34, P1173
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   NIRMAL M, 1995, PHYS REV LETT, V75, P3728, DOI 10.1103/PhysRevLett.75.3728                                                     
   Nobs L, 2004, J PHARM SCI-US, V93, P1980, DOI 10.1002/jps.20098
   Nobuto H, 2004, INT J CANCER, V109, P627, DOI 10.1002/ijc.20035
   Northfelt DW, 1996, J CLIN PHARMACOL, V36, P55, DOI 10.1002/j.1552-4604.1996.tb04152.x                                              
   Nyman DW, 2005, J CLIN ONCOL, V23, P7785, DOI 10.1200/JCO.2004.00.6148
   Olsen E, 2001, J CLIN ONCOL, V19, P376, DOI 10.1200/JCO.2001.19.2.376                                                       
   Pandey R, 2005, J ANTIMICROB CHEMOTH, V55, P430, DOI 10.1093/jac/dki027
   Pandey R, 2004, J ANTIMICROB CHEMOTH, V54, P266, DOI 10.1093/jac/dkh260
   Pandey R, 2003, J ANTIMICROB CHEMOTH, V52, P981, DOI 10.1093/jac/dkg477
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Paul M, 1998, J DRUG TARGET, V5, P481, DOI 10.3109/10611869808997874                                                       
   Perez AT, 2002, CANCER INVEST, V20, P22, DOI 10.1081/CNV-120014883
   Persson EM, 2005, PHARM RES, V22, P2141, DOI 10.1007/s11095-005-8192-x
   Petersein J, 1996, Magn Reson Imaging Clin N Am, V4, P53
   Pinaud F, 2004, J AM CHEM SOC, V126, P6115, DOI 10.1021/ja031691c
   Pinto-Alphandary H, 2000, INT J ANTIMICROB AG, V13, P155, DOI 10.1016/S0924-8579(99)00121-1
   Rabinow BE, 2004, NAT REV DRUG DISCOV, V3, P785, DOI 10.1038/nrd1494
   Reddy LH, 2004, J DRUG TARGET, V12, P443, DOI 10.1080/10611860400011406
   Rosen O, 2003, BRIT J HAEMATOL, V123, P836, DOI 10.1046/j.1365-2141.2003.04707.x
   Schiffelers R, 2001, J ANTIMICROB CHEMOTH, V48, P333, DOI 10.1093/jac/48.3.333
   Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794
   Sharma A, 2004, INT J ANTIMICROB AG, V24, P599, DOI 10.1016/j.ijantimicag.2004.07.010
   Shenoy D, 2005, PHARM RES, V22, P2107, DOI 10.1007/s11095-005-8343-0
   Siena S, 2003, ONCOL REP, V10, P715
   Singh SS, 2006, CURR DRUG METAB, V7, P165, DOI 10.2174/138920006775541552
   Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971
   Sundar S, 2003, CLIN INFECT DIS, V37, P800, DOI 10.1086/377542
   Symon Z, 1999, CANCER, V86, P72, DOI 10.1002/(SICI)1097-0142(19990701)86:1<72::AID-CNCR12>3.3.CO;2-T
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Torchilin Vladimir P., 2005, Current Drug Delivery, V2, P319, DOI 10.2174/156720105774370221
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torchilin VP, 2000, EUR J PHARM SCI, V11, pS81, DOI 10.1016/S0928-0987(00)00166-4
   Torchilin VP, 1997, ADV DRUG DELIVER REV, V24, P301, DOI 10.1016/S0169-409X(96)00472-3
   Tucker RD, 2000, J ENDOUROL, V14, P511, DOI 10.1089/end.2000.14.511
   Vicent MJ, 2006, TRENDS BIOTECHNOL, V24, P39, DOI 10.1016/j.tibtech.2005.11.006
   Vogel CL, 2005, J CLIN ONCOL, V23, P1178, DOI 10.1200/JCO.2005.09.102
   Volmink J, 2000, COCHRANE DB SYST REV, V4
   Walsh TJ, 2000, MED MYCOL, V38, P335, DOI 10.1080/mmy.38.s1.335.347
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Ye Q, 2000, J CONTROL RELEASE, V64, P155, DOI 10.1016/S0168-3659(99)00146-7
NR 121
TC 128
Z9 133
U1 2
U2 36
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1890
J9 J NEUROIMMUNE PHARM
JI J. Neuroimmune Pharm.
PD SEP
PY 2006
VL 1
IS 3
BP 340
EP 350
DI 10.1007/s11481-006-9032-4
PG 11
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA V04MW
UT WOS:000207063500014
PM 18040810
DA 2018-01-05
ER

PT J
AU Dou, H
   Destache, CJ
   Morehead, JR
   Mosley, RL
   Boska, MD
   Kingsley, J
   Gorantla, S
   Poluektova, L
   Nelson, JA
   Chaubal, M
   Werling, J
   Kipp, J
   Rabinow, BE
   Gendelman, HE
AF Dou, Huanyu
   Destache, Christopher J.
   Morehead, Justin R.
   Mosley, R. Lee
   Boska, Michael D.
   Kingsley, Jeff
   Gorantla, Santhi
   Poluektova, Larisa
   Nelson, Jay A.
   Chaubal, Mahesh
   Werling, Jane
   Kipp, James
   Rabinow, Barrett E.
   Gendelman, Howard E.
TI Pharmacokinetic, immune, and anti-viral responses of nanoparticle
   indinavir in a murine model of HIV-1 encephalitis
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Meeting Abstract
CT 8th International Conference of Neuroimmunology
CY OCT 15-19, 2006
CL Nagoya, JAPAN
C1 Univ Nebraska Med Ctr, Ctr Neuroviral & Neurodegenerat Disorders, Omaha, NE 68198 USA.
   Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
   Univ Nebraska Med Ctr, Dept Radiol, Omaha, NE 68198 USA.
   Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.
   Univ Nebraska Med Ctr, Dept Pediat, Omaha, NE 68198 USA.
   Creighton Univ, Sch Pharm & Allied Hlth Profess, Omaha, NE 68178 USA.
   Baxter Healthcare Corp, Round Lake, IL 60073 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-5728
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD SEP
PY 2006
VL 178
SU 1
BP 70
EP 70
PG 1
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 099YG
UT WOS:000241633100163
DA 2018-01-05
ER

PT J
AU Kuznetsov, YG
   McPherson, A
AF Kuznetsov, Yuri G.
   McPherson, Alexander
TI Identification of DNA and RNA from retroviruses using ribonuclease A
SO SCANNING
LA English
DT Article
ID ATOMIC-FORCE MICROSCOPY; HUMAN-IMMUNODEFICIENCY-VIRUS; MURINE LEUKEMIA
AB Retroviruses, such as human immunodeficiency virus (HIV), can be disrupted with chemical agents and made to disgorge their encapsidated nucleic acid. The products can be visualized by atomic force microscopy (AFM). Retroviruses may contain both viral genomic RNA and reverse transcribed DNA produced prior to integration into the host cell genome. It is necessary to know which molecules are RNA and which are DNA in order to interpret the events that transpire during infection. DNA, when imaged by AFM, is generally between one and two nanometers in thickness, more regular in its contours, and it is relatively uniform in height over its entire length; RNA, on the other hand, is less than a nanometer in thickness within single stranded regions, but varies dramatically in height over its length due to the presence of secondary structural domains. These observations, however, are often not definitive. Nonetheless, we have been able to tell one from the other using AFM, by exposing the molecules, in buffer, to moderate concentrations of RNase A. Upon exposure to the enzyme, the DNA, which cannot be cleaved, becomes coated with the protein, and the nucleic acid-protein complex exhibits a height of about three times that of the native molecule, appearing as thick cords. RNA, however, is degraded by the single strand specific RNase A into short, stable, presumably double-stranded segments, reflecting its pattern of secondary structure. Using this approach, we obtained evidence that reverse transcription of RNA into DNA may occur within the retroviral capsid.
C1 Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.
RP McPherson, A (reprint author), Univ Calif Irvine, Dept Mol Biol & Biochem, Mail Code 3900, Irvine, CA 92697 USA.
EM amcphers@uci.edu
FU NIGMS NIH HHS [GM58868]
CR COFFIN JM, 1997, RETROVIRUSES
   KO TP, 1994, ACTA CRYSTALLOGR D, V50, P813, DOI 10.1107/S0907444994005512                                                       
   KUNITZ M., 1940, JOUR GEN PHYSIOL, V24, P15, DOI 10.1085/jgp.24.1.15
   Kuznetsov YG, 2000, COLLOID SURFACE B, V19, P333, DOI 10.1016/S0927-7765(00)00142-9
   Kuznetsov YG, 2005, J VIROL, V79, P8032, DOI 10.1128/JVI.79.13.8032-8045.2005
   Kuznetsov YG, 2005, J MOL BIOL, V347, P41, DOI 10.1016/j.jmb.2005.01.006
   Kuznetsov YG, 2005, J STRUCT BIOL, V149, P256, DOI 10.1016/j.jsb.2004.10.007
   Kuznetsov YG, 2004, SCANNING, V26, P209
   Kuznetsov YG, 2003, J VIROL, V77, P11896, DOI 10.1128/JVI.77.22.11896-11909.2003
   Kuznetsov YG, 2002, BIOPHYS J, V83, P3665, DOI 10.1016/S0006-3495(02)75366-6                                                   
   Kuznetsov YG, 2001, J GEN VIROL, V82, P2025, DOI 10.1099/0022-1317-82-9-2025                                                     
   Kuznetsov YG, 2006, VIROLOGY, V352, P329, DOI 10.1016/j.virol.2006.04.008
   Malkin AJ, 2003, J VIROL, V77, P6332, DOI 10.1128/JVI.77.11.6332-6340.2003
   Malkin AJ, 2004, VIRUS STRUCTURE IMAG, P85
   Plomp M, 2002, AM J PATHOL, V160, P1959, DOI 10.1016/S0002-9440(10)61145-5
   SANDMEYER SB, 2002, MOBILE DNA, V2
   SEKINE H, 1969, BIOCHIM BIOPHYS ACTA, V174, P202, DOI 10.1016/0005-2787(69)90243-3
NR 17
TC 12
Z9 12
U1 1
U2 3
PU FAMS INC
PI MAHWAH
PA BOX 832, MAHWAH, NJ 07430-0832 USA
SN 0161-0457
J9 SCANNING
JI Scanning
PD SEP-OCT
PY 2006
VL 28
IS 5
BP 278
EP 281
PG 4
WC Instruments & Instrumentation; Microscopy
SC Instruments & Instrumentation; Microscopy
GA 093FK
UT WOS:000241153200006
PM 17063767
DA 2018-01-05
ER

PT J
AU Wang, ZW
   Wu, BG
   Kuhen, KL
   Bursulaya, B
   Nguyen, TN
   Nguyen, DG
   He, Y
AF Wang, Zhiwei
   Wu, Baogen
   Kuhen, Kelli L.
   Bursulaya, Badry
   Nguyen, Truc N.
   Nguyen, Deborah G.
   He, Yun
TI Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1
   non-nucleoside reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID OF-THE-ART; OXINDOLES; DESIGN; AGENTS; DRUGS
AB A novel sulfanyltriazole was discovered as an HIV-1 non-nucleoside reverse transcriptase inhibitor via HTS using a cell-based assay. Chemical modifications and molecular modeling studies were carried out to establish its SAR and understand its interactions with the enzyme. These modifications led to the identification of sulfanyltriazoles with low nanomolar potency for inhibiting HIV-1 replication and promising activities against selected NNRTI resistant mutants. These novel and potent sulfanyltriazoles could serve as advanced leads for further optimization. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.
RP He, Y (reprint author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.
EM yhe@gnf.org
CR Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Chan JH, 2004, J MED CHEM, V47, P1175, DOI 10.1021/jm030255y
   De Clercq E, 2004, MED CHEM RES, V13, P439, DOI 10.1007/s00044-004-0047-1                                                       
   De Clercq Erik, 2005, Expert Opin Emerg Drugs, V10, P241, DOI 10.1517/14728214.10.2.241
   ELKERDAWY M, 1989, SULFUR LETT, V9, P209
   ELLIS D, 2006, BIOORG MED CHEM LETT
   Freimuth WW, 1996, ADV EXP MED BIOL, V394, P279
   Imamichi T, 2004, CURR PHARM DESIGN, V10, P4039, DOI 10.2174/1381612043382440                                                        
   Jiang T, 2006, BIOORG MED CHEM LETT, V16, P2109, DOI 10.1016/j.bmcl.2006.01.066
   Jiang T, 2006, BIOORG MED CHEM LETT, V16, P2105, DOI 10.1016/j.bmcl.2006.01.073
   KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966                                                        
   Pauwels R, 2004, CURR OPIN PHARMACOL, V4, P437, DOI 10.1016/j.coph.2004.07.005
   SHRIMALI M, 1991, J INDIAN CHEM SOC, V68, P466
   SOLIMAN LN, 1990, B FACULTY PHARM CAIR, V28, P53
   Wainberg MA, 2005, ANTIVIR THER, V10, P13
   Wu BG, 2006, BIOORG MED CHEM LETT, V16, P3430, DOI 10.1016/j.bmcl.2006.04.012
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   GIRARDET JL, 2004, Patent No. 200403061U
   Simoneau B, 2004, Non-nucleoside reverse transcriptase inhibitors, Patent No. [WO 2004050643, 2004050643, WO2004050643]
NR 19
TC 58
Z9 60
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 15
PY 2006
VL 16
IS 16
BP 4174
EP 4177
DI 10.1016/j.bmcl.2006.05.096
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 068CI
UT WOS:000239349000003
PM 16781149
DA 2018-01-05
ER

PT J
AU Ellis, D
   Kuhen, KL
   Anaclerio, B
   Wu, B
   Wolff, K
   Yin, H
   Bursulaya, B
   Caldwell, J
   Karanewsky, D
   He, Y
AF Ellis, David
   Kuhen, Kelli L.
   Anaclerio, Beth
   Wu, Baogen
   Wolff, Karen
   Yin, Hong
   Bursulaya, Badry
   Caldwell, Jeremy
   Karanewsky, Donald
   He, Yun
TI Design, synthesis, and biological evaluations of novel quinolones as
   HIV-1 non-nucleoside reverse transcriptase inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE quinolones; HIV-1 non-nucleoside reverse transcriptase inhibitor
   (NNRTI); SAR; molecule modeling; HIV replication
ID OXINDOLES; FUTURE; AGENTS
AB A novel series of quinolones was discovered as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) using a structure-based approach. The lead quinolones exhibited single digit nanomolar potency in the HIV-1 replication assays. The preliminary SAR of these quinolones was also established via systematic structural modifications. These novel and potent quinolones could serve as advanced leads for further optimization. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Novartis Res Fdn GNF, Genom Inst, San Diego, CA 92121 USA.
RP He, Y (reprint author), Novartis Res Fdn GNF, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.
EM yhe@gnf.org
CR Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   Gotte Matthias, 2004, Expert Rev Anti Infect Ther, V2, P707, DOI 10.1586/14789072.2.5.707
   IRIE H, 1990, CHEM PHARM BULL, V38, P1852
   Jiang T, 2006, BIOORG MED CHEM LETT, V16, P2109, DOI 10.1016/j.bmcl.2006.01.066
   Jiang T, 2006, BIOORG MED CHEM LETT, V16, P2105, DOI 10.1016/j.bmcl.2006.01.073
   KLEIM JP, 1995, ANTIMICROB AGENTS CH, V39, P2253, DOI 10.1128/AAC.39.10.2253                                                          
   Locatelli GA, 2004, CURR DRUG METAB, V5, P283, DOI 10.2174/1389200043335504
   MAGGIOLO F, 2005, J ANTIMICROB CHEMOTH, V5, P821
   Marks K, 2005, HIV CHEMOTHERAPY: A CRITICAL REVIEW, P1
   MEYERS AI, 1988, J AM CHEM SOC, V110, P7245, DOI 10.1021/ja00229a067
   Wainberg MA, 2005, ANTIVIR THER, V10, P13
   WANG Z, 2006, BIOORG MED CHEM LETT, V16
   Wu BG, 2006, BIOORG MED CHEM LETT, V16, P3430, DOI 10.1016/j.bmcl.2006.04.012
NR 14
TC 48
Z9 51
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 15
PY 2006
VL 16
IS 16
BP 4246
EP 4251
DI 10.1016/j.bmcl.2006.05.073
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 068CI
UT WOS:000239349000018
PM 16782337
DA 2018-01-05
ER

PT J
AU Kumar, A
   Srivastava, S
   Mishra, RK
   Mittal, R
   Hosur, RV
AF Kumar, Ashutosh
   Srivastava, Sudha
   Mishra, Ram Kumar
   Mittal, Rohit
   Hosur, Ramakrishna V.
TI Residue-level NMR view of the urea-driven equilibrium folding transition
   of SUMO-1 (1-97): Native preferences do not increase monotonously
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE NMR; denatured state; SUMO-1; protein folding; structure and dynamics
ID NUCLEAR-MAGNETIC-RESONANCE; LOCAL STRUCTURAL PREFERENCES; CHARGE-CHARGE
   INTERACTIONS; UNFOLDED PROTEINS; CHEMICAL-SHIFTS; HIV-1 PROTEASE;
   DYNAMIC CHARACTERIZATION; CIRCULAR-DICHROISM; BACKBONE DYNAMICS; LABELED
   PROTEINS
AB SUMO-1 (1-97) is a crucial protein in the machinery of post-translational modifications. We observed by circular dichroism and fluorescence spectroscopy that urea-induced unfolding of this protein is a complex process with the possibility of occurrence of detectable intermediates along the way. The tertiary structure is completely lost around similar to 4.5 M urea. with a transition mid-point at 2.53 M urea, while the secondary structure unfolding seems to show two transitions, with mid-points at 2.42 M and 5.69 M urea. We have elucidated by systematic urea. titration, the equilibrium residue level structural and dynamics changes along the entire folding/unfolding transition by multidimensional NMR. With urea dilution, the protein is seen to progressively lose most of the broad beta-domain structural preferences present at 8 M urea, acquire some helical propensities at 5 M urea, and lose some of them again on further dilution of urea. Between 3 M and 2 M urea, the protein starts afresh to acquire native structural features. These observations are contrary to the conventional notion that proteins fold with monotonously increasing native-type preferences. For folding below similar to 3 M urea, the region around the alpha 1 helix appears to be a potential folding initiation site. The folding seems to start with a collapse into native-like topologies, at least in parts, and is followed by formation of secondary and tertiary structure, perhaps by cooperative rearrangements. The motional characteristics of the protein show sequence-dependent variation as the concentration of urea is progressively reduced. At the sub-nanosecond level, the features are extremely unusual for denatured states, and only certain segments corresponding to the flexible regions in the native protein display these motions at the different concentrations of urea. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India.
   Tata Inst Fundamental Res, Dept Sci Biol, Bombay 400005, Maharashtra, India.
RP Hosur, RV (reprint author), Tata Inst Fundamental Res, Dept Chem Sci, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.
EM hosur@tifr.res.in
CR Barbar E, 1999, BIOPOLYMERS, V51, P191, DOI 10.1002/(SICI)1097-0282(1999)51:3<191::AID-BIP3>3.0.CO;2-B                      
   BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002                                                             
   Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839
   Bhavesh N. S., 2004, PINSA-A (Proceedings of the Indian National Science Academy) Part A (Physical Sciences), V70, P579
   Bhavesh NS, 2004, PROTEIN SCI, V13, P3085, DOI 10.1110/ps.04805204
   Bhavesh NS, 2003, J BIOL CHEM, V278, P19980, DOI 10.1074/jbc.M301615200
   Bhavesh NS, 2001, FEBS LETT, V509, P218, DOI 10.1016/S0014-5793(01)03066-6                                                   
   Bhavesh NS, 2001, BIOCHEMISTRY-US, V40, P14727, DOI 10.1021/bi015683p
   BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017
   BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302
   Cavagnero S, 1999, J MOL BIOL, V285, P269, DOI 10.1006/jmbi.1998.2273                                                          
   Chatterjee A, 2005, J BIOL CHEM, V280, P11369, DOI 10.1074/jbc.M412603200
   Chatterjee A, 2005, J CHEM SCI, V117, P3, DOI 10.1007/BF02704356
   Chatterjee A, 2002, BIOCHEM BIOPH RES CO, V293, P427, DOI 10.1016/S0006-291X(02)00240-1                                                   
   Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10
   Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8                                                   
   Dobson CM, 2001, BIOCHEM SOC SYMP, P1
   Dunker AK, 2002, ADV PROTEIN CHEM, V62, P25
   Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+
   Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8
   Dyson HJ, 2002, ADV PROTEIN CHEM, V62, P311
   Dyson HJ, 2004, CHEM REV, V104, P3607, DOI 10.1021/cr030403s
   Dyson HJ, 2001, METHOD ENZYMOL, V339, P258
   Eliezer D, 1998, NAT STRUCT BIOL, V5, P148
   FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040                                                             
   Feio MJ, 2004, BIOCHEMISTRY-US, V43, P14784, DOI 10.1021/bi048655q
   Fersht A., 1999, STRUCTURE MECH PROTE
   Finke JM, 2005, BIOPHYS J, V89, P488, DOI 10.1529/biophysj.105.059147
   Foguel B, 2004, BIOCHEMISTRY-US, V43, P11361
   Griko Y, 2001, PROTEIN SCI, V10, P845, DOI 10.1110/ps.39701
   Ibarra-Molero B, 1999, BIOCHEMISTRY-US, V38, P8138, DOI 10.1021/bi9905819
   Jamin M, 2005, PROTEIN PEPTIDE LETT, V12, P229, DOI 10.2174/0929866053587174
   Jin CW, 2001, INT J BIOL MACROMOL, V28, P227, DOI 10.1016/S0141-8130(00)00169-0                                                   
   Kay LE, 2005, J MAGN RESON, V173, P193, DOI 10.1016/j.jmr.2004.11.021
   Kumar A, 2006, BIOPHYS J, V90, P2498, DOI 10.1529/biophysj.105.071746
   Li Y, 2005, J MOL BIOL, V349, P839, DOI 10.1016/j.jmb.2005.04.017
   Lindorff-Larsen K, 2005, TRENDS BIOCHEM SCI, V30, P13, DOI 10.1016/j.tibs.2004.11.008
   Loladze VV, 1999, BIOCHEMISTRY-US, V38, P16419, DOI 10.1021/bi992271w
   Mahajani SM, 1997, ORG PROCESS RES DEV, V1, P97, DOI 10.1021/op960002x                                                               
   Matsuura H, 2004, BIOL CHEM, V385, P1157, DOI 10.1515/BC.2004.149
   Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002
   Mishra RK, 2004, J BIOL CHEM, V279, P31445, DOI 10.1074/jbc.M402911200
   Murugan R, 2004, J BIOL INORG CHEM, V9, P477, DOI 10.1007/s00775-004-0544-1
   Ohnishi S, 2003, PROTEIN SCI, V12, P1530, DOI 10.1110/ps.0306403
   Pace C N, 1986, Methods Enzymol, V131, P266
   Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129                                                
   Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1
   Palmer Arthur G. Iii, 1993, Current Opinion in Biotechnology, V4, P385, DOI 10.1016/0958-1669(93)90002-E
   Panchal SC, 2001, J BIOMOL NMR, V20, P135, DOI 10.1023/A:1011239023422                                                         
   Patel S, 2004, BIOCHEMISTRY-US, V43, P1724, DOI 10.1021/bi0347104
   Permi P, 2004, PROG NUCL MAG RES SP, V44, P97, DOI 10.1016/j.pnmrs.2003.12.001
   Pichler A, 2002, TRAFFIC, V3, P381, DOI 10.1034/j.1600-0854.2002.30601.x
   Ross CA, 2004, NAT MED, V10, pS10, DOI 10.1038/nm1066
   Schwalbe H, 1997, BIOCHEMISTRY-US, V36, P8977, DOI 10.1021/bi970049q
   Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521
   Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i
   Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438
   Stefani M, 2004, BBA-MOL BASIS DIS, V1739, P5, DOI 10.1016/j.bbadis.2004.08.004
   Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194                                                         
   Tugarinov V, 2004, ANNU REV BIOCHEM, V73, P107, DOI 10.1146/annurev.biochem.73.011303.074004
   Uversky VN, 2004, BBA-PROTEINS PROTEOM, V1698, P131, DOI 10.1016/j.bbapap.2003.12.008
   Vendruscolo M, 2005, PHILOS T ROY SOC A, V363, P433, DOI 10.1098/rsta.2004.1501
   WINTRODE PL, 1994, PROTEINS, V18, P246, DOI 10.1002/prot.340180305
   WISHART DS, 1995, J BIOMOL NMR, V6, P135
   WISHART DS, 1994, METHOD ENZYMOL, V239, P363
   WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471
   Wishart DS, 1998, BIOCHEM CELL BIOL, V76, P153, DOI 10.1139/bcb-76-2-3-153
   Zhang XC, 2005, BIOCHEMISTRY-US, V44, P8117, DOI 10.1021/bi0501939
NR 68
TC 12
Z9 12
U1 0
U2 1
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD AUG 4
PY 2006
VL 361
IS 1
BP 180
EP 194
DI 10.1016/j.jmt.2006.06.003
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 072LA
UT WOS:000239673700016
PM 16824543
DA 2018-01-05
ER

PT J
AU Hostetler, KY
   Aldern, KA
   Wan, WB
   Ciesla, SL
   Beadle, JR
AF Hostetler, Karl Y.
   Aldern, Kathy A.
   Wan, William B.
   Ciesla, Stephanie L.
   Beadle, James R.
TI Alkoxyakl esters of (S)-9-[3-Hydroxy-2-(phosphonomethoxy)propyl] adenine
   are potent inhibitors of the replication of wild-type and drug-resistant
   human immunodeficiency virus type 1 in vitro
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ACYCLIC NUCLEOSIDE PHOSPHONATES; ANTIVIRAL ACTIVITY; CYCLIC CIDOFOVIR;
   ORAL TREATMENT; LIPID ESTERS; CYTOMEGALOVIRUS; INFECTIONS; ANALOGS;
   DERIVATIVES; PRODRUGS
AB (S)-9-[3-Hydroxy-2-(phosphonomethoxy)propyl]adenine [(S)-HPMPA], is an effective broad-spectrum antiviral against many DNA viruses but has been reported to be inactive against human immunodeficiency virus (HIV). We synthesized several alkoxyalkyl esters of (S)-HPMPA and now report that hexadecyloxypropyl-(S)-HPMPA [HDP-(S)-HPMPA] and octadecyloxyethyl-(S)-HPMPA [ODE-(S)-HPMPA] had 50% effective concentrations of 0.4 to 7.0 nanomolar and were nearly fully active against HIV variants having reverse transcriptase mutations M184V and K103N and against a zidovudine-resistant variant with mutations D67N, K70R, T215Y, and K219Q. Resistance to HDP-(S)-HPMPA and ODE-(S)-HPMPA was noted for a mutant with mutation K65R. HDP-(S)-HPMPA is also active against herpes simplex virus type 1, human cytomegalovirus, hepatitis B virus, adenoviruses, and orthopoxviruses and is worthy of further evaluation as a possibly therapy for HIV infection.
C1 Univ Calif San Diego, Dept Med, Div Infect Dis, La Jolla, CA 92093 USA.
   Vet Med Res Fdn, La Jolla, CA USA.
RP Hostetler, KY (reprint author), Univ Calif San Diego, Dept Med, Div Infect Dis, Mail Code 0676,9500 Gilman Dr, La Jolla, CA 92093 USA.
EM khostetl@ucsd.edu
FU NIAID NIH HHS [R01 AI071803, R01 AI074057, AI-66499, R37 AI029164,
   AI-29614, R01 AI066499]
CR Aldern KA, 2003, MOL PHARMACOL, V63, P678, DOI 10.1124/mol.63.3.678                                                            
   Baker R, 2003, ANTIVIR RES, V57, P13, DOI 10.1016/S0166-3542(02)00196-1
   BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332                                                            
   Beadle JR, 2006, J MED CHEM, V49, P2010, DOI 10.1021/jm050473m
   Beadle JR, 2002, ANTIMICROB AGENTS CH, V46, P2381, DOI 10.1128/AAC.46.8.2381-2386.2002
   Buller RM, 2004, VIROLOGY, V318, P474, DOI 10.1016/j.virol.2003.11.015
   CONNELLY MC, 1993, BIOCHEM PHARMACOL, V46, P1053, DOI 10.1016/0006-2952(93)90670-R
   DECLERCQ E, 1991, INT J IMMUNOPHARMACO, V13, P91, DOI 10.1016/0192-0561(91)90130-Y                                                    
   DECLERCQ E, 1987, ANTIVIR RES, V8, P261
   DECLERCQ E, 1986, NATURE, V323, P464
   Hammond JL, 2001, ANTIMICROB AGENTS CH, V45, P1621, DOI 10.1128/AAC.45.6.1621-1628.2001
   Hartline CB, 2005, J INFECT DIS, V191, P396, DOI 10.1086/426831                                                                  
   Holy A, 2003, CURR PHARM DESIGN, V9, P2567, DOI 10.2174/1381612033453668
   Keith KA, 2003, ANTIMICROB AGENTS CH, V47, P2193, DOI 10.1128/AAC.47.7.2193-2198.2003
   Kern ER, 2002, ANTIMICROB AGENTS CH, V46, P991, DOI 10.1128/AAC.46.4.991-995.2002
   Naesens L, 1995, Postepy Biochem, V41, P347
   Quenelle DC, 2005, ANTIVIR RES, V65, pA81
   Quenelle DC, 2004, ANTIMICROB AGENTS CH, V48, P404, DOI 10.1128/AAC.48.2.404-412.2004
   QUENELLE DC, 2005, ANTIVIR RES, V65, P76
   Wan WB, 2005, ANTIMICROB AGENTS CH, V49, P656, DOI 10.1128/AAC.49.2.656-662.2005
   Williams-Aziz SL, 2005, ANTIMICROB AGENTS CH, V49, P3724, DOI 10.1128/AAC.49.9.3724-3733.2005
   HOLY A, 1987, Patent No. 4659825
NR 22
TC 24
Z9 24
U1 0
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD AUG
PY 2006
VL 50
IS 8
BP 2857
EP 2859
DI 10.1128/AAC.01223-05
PG 3
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 071YS
UT WOS:000239640400040
PM 16870786
OA gold
DA 2018-01-05
ER

PT J
AU Kadow, J
   Wang, HGH
   Lin, PF
AF Kadow, John
   Wang, Hwei-Gene Heidi
   Lin, Pin-Fang
TI Small-molecule HIV-1 gp120 inhibitors to prevent HIV-1 entry: An
   emerging opportunity for drug development
SO CURRENT OPINION IN INVESTIGATIONAL DRUGS
LA English
DT Article
DE antiviral; CD4; glycoprotein; gp120; HIV-1 entry; microbicide
ID CONFORMATIONAL-CHANGES; ENVELOPE GLYCOPROTEIN; ATTACHMENT INHIBITOR; CD4
   RECEPTOR; CELL FUSION; VIRUS-CELL; IN-VITRO; BMS-378806; BINDING;
   RESISTANCE
AB The HIV-1 gp120 envelope protein is an essential component in the multi-tiered viral entry process. Despite the overall genetic heterogeneity of the gp120 glycoprotein, the conserved CD4 binding site provides an attractive antiviral target. Recently, increased efforts aimed at the development of inhibitors of gp120 have been reported. This review focuses primarily on small-molecule gp120 inhibitors and discusses key characteristics of compounds that appear to fall within this class. The preclinical profiles of compounds that prevent gp120 from assuming a conformation favorable for CD4 binding are described in this review. In addition, inhibitors possessing some common structural features, including at least one compound that exhibits sub-nanomolar potency in a cell fusion assay are discussed. A series of compounds that were designed to enhance immune responses to virus via alteration of the gp120 conformation after targeting the CD4 binding pocket are also described. The efficacy of gp120 inhibitors as a microbicide to prevent sexual HIV transmission in the rhesus macaque model is discussed. Results suggest that this class of compounds may have value if included in a microbicide cocktail with inhibitors of alternate mechanisms. Importantly, preliminary results from clinical studies of orally administered BMS-488043 demonstrate that antiviral efficacy can be achieved in humans with a CD4-attachment inhibitor that targets gp120.
C1 Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Virol, Wallingford, CT 06492 USA.
   Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Chem, Wallingford, CT 06492 USA.
   Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Med Commun, Wallingford, CT 06492 USA.
RP Lin, PF (reprint author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Virol, 5 Res Pkwy, Wallingford, CT 06492 USA.
EM PinFang.Lin@bms.com
CR Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Doms Robert W, 2004, Top HIV Med, V12, P100
   GARCIALERMA J, 2006, C RETR OPP INF, V13
   Guo Q, 2003, J VIROL, V77, P10528, DOI 10.1016/JVI.77.19.10528-10536.2003
   HANNA G, 2004, C RETR OPP INF, V11
   Ho HT, 2006, J VIROL, V80, P4017, DOI 10.1128/JVI.80.8.4017-4025.2006
   Idemyor V, 2005, HIV CLIN TRIALS, V6, P272, DOI 10.1310/979L-39QP-NC9G-WFTF                                                     
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   LIN PF, 2004, C RETR OPP INF, V11
   Madani N, 2004, J VIROL, V78, P3742, DOI 10.1128/JVI.78.7.3742-3752.2004
   Moore PL, 2004, AIDS, V18, P2327, DOI 10.1097/00002030-200411190-00015
   Nagashima KA, 2001, J INFECT DIS, V183, P1121, DOI 10.1086/319284                                                                  
   Shearer WT, 2000, J INFECT DIS, V182, P1774, DOI 10.1086/317622
   Si ZH, 2004, P NATL ACAD SCI USA, V101, P5036, DOI 10.1073/pnas.0307953101
   Srivastava I. K., 2005, PCT Patent Application, Patent No. [WO2005121175, 2005121175]
   Towie N, 2005, NATURE, V438, P6, DOI 10.1038/438006b
   Tremblay CL, 2000, J ACQ IMMUN DEF SYND, V25, P99, DOI 10.1097/00126334-200010010-00001
   Veazey RS, 2005, NATURE, V438, P99, DOI 10.1038/nature04055
   Wang T, 2003, J MED CHEM, V46, P4236, DOI 10.1021/jm034082o
   Wang Z, 2003, WORLD J GASTROENTERO, V9, P1786, DOI 10.3748/wjg.v9.i8.1786                                                          
   WATTS C, 2001, AIDS S1, V5, P543
   Yang Z, 2005, BIOPHARM DRUG DISPOS, V26, P387, DOI 10.1002/bdd.471
   Zhao Q, 2005, VIROLOGY, V339, P213, DOI 10.1016/j.virol.2005.06.008
   LIN PF, 2005, Patent No. 20050215543
   WANG T, 2005, Patent No. 2005272734
   WANG T, 2005, Patent No. 20050090522
   Wang T., 2004, U.S. Patent, Patent No. [2,004,018,629,2A1, 20040186292, A20040186292]
   REGUEIROREN A, 2004, Patent No. 20040063746
   Williams D.H., 2005, PCT Int. Appl. Patent, Patent No. [WO2005016344 A1 20050224, 2005016344]
   Wallace O.B., 2003, U.S. Patent, Patent No. [6,573,262, 6573262]
   LIN PF, 2005, Patent No. 20050215544
   KADOW JF, 2004, Patent No. 06900206
   LIN PF, 2005, Patent No. 20050215545
   KADOW JF, 2003, Patent No. 20030236277
   HO HT, 2003, Patent No. 2003072028
   WANG T, 2004, Patent No. 06900323
   BENDER JA, 2005, Patent No. 20050124623
   BRISTOL MYERS SQUIBB, 2002, Patent No. 6469006
   WANG T, 2003, Patent No. 06825201
   Ueda Y., 2005, [No title captured], Patent No. [US 20050209246, 20050209246]
   Williams D.H., 2005, PCT Int. Appl. Patent, Patent No. [WO2005121094 A1 20051222, 2005121094]
   WANG T, 2004, Patent No. 07037913
   RUEDIGER EH, 2005, Patent No. 20050267130
NR 45
TC 47
Z9 51
U1 0
U2 7
PU THOMSON SCIENTIFIC
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND STREET, LONDON, W1T 4JE, ENGLAND
SN 1472-4472
J9 CURR OPIN INVESTIG D
JI Curr. Opin. Investig. Drugs
PD AUG
PY 2006
VL 7
IS 8
BP 721
EP 726
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 069DE
UT WOS:000239425000005
PM 16955683
DA 2018-01-05
ER

PT J
AU Wriggers, W
   Zhang, Z
   Shah, M
   Sorensen, DC
AF Wriggers, W.
   Zhang, Z.
   Shah, M.
   Sorensen, D. C.
TI Simulating nanoscale functional motions of biomolecules
SO MOLECULAR SIMULATION
LA English
DT Article
DE principal component analysis; normal modes; singular value
   decomposition; symmetry constraints; local feature analysis; molecular
   dynamics
ID MOLECULAR-DYNAMICS SIMULATIONS; NORMAL-MODE ANALYSIS; PROTEIN DYNAMICS;
   COLLECTIVE MOTIONS; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE;
   HARMONIC-ANALYSIS; LARGE SYSTEMS; MONTE-CARLO; MYOSIN
AB We are describing efficient dynamics simulation methods for the characterization of functional motion of biomolecules on the nanometer scale. Multivariate statistical methods are widely used to extract and enhance functional collective motions from molecular dynamics (MD) simulations. A dimension reduction in MD is often realized through a principal component analysis (PCA) or a singular value decomposition (SVD) of the trajectory. Normal mode analysis (NMA) is a related collective coordinate space approach, which involves the decomposition of the motion into vibration modes based on an elastic model. Using the myosin motor protein as an example we describe a hybrid technique termed amplified collective motions (ACM) that enhances sampling of conformational space through a combination of normal modes with atomic level MD. Unfortunately, the forced orthogonalization of modes in collective coordinate space leads to complex dependencies that are not necessarily consistent with the symmetry of biological macromolecules and assemblies. In many biological molecules, such as HIV-1 protease, reflective or rotational symmetries are present that are broken using standard orthogonal basis functions. We present a method to compute the plane of reflective symmetry or the axis of rotational symmetry from the trajectory frames. Moreover, we develop an SVD that best approximates the given trajectory while respecting the symmetry. Finally, we describe a local feature analysis (LFA) to construct a topographic representation of functional dynamics in terms of local features. The LFA representations are low-dimensional, and provide a reduced basis set for collective motions, but unlike global collective modes they are sparsely distributed and spatially localized. This yields a more reliable assignment of essential dynamics modes across different MD time windows.
C1 Univ Texas, Hlth Sci Ctr, Lab Biocomp, Sch Hlth Informat Sci, Houston, TX 77030 USA.
   Univ Texas, Hlth Sci Ctr, Lab Imaging, Sch Hlth Informat Sci, Houston, TX 77030 USA.
   Univ Texas, Hlth Sci Ctr, Inst Mol Med, Houston, TX 77030 USA.
   Rice Univ, Dept Computat & Appl Math, Houston, TX 77005 USA.
RP Wriggers, W (reprint author), Univ Texas, Hlth Sci Ctr, Lab Biocomp, Sch Hlth Informat Sci, 7000 Fannin St,Suite 600, Houston, TX 77030 USA.
EM wriggers@biomachina.org
CR Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   Bahar I, 1997, BIOCHEMISTRY-US, V36, P13512, DOI 10.1021/bi971611f                                                               
   Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2
   Balsera MA, 1996, J PHYS CHEM-US, V100, P2567, DOI 10.1021/jp9536920                                                               
   Bartels C, 1998, J PHYS CHEM B, V102, P865, DOI 10.1021/jp972280j                                                               
   Berendsen HJC, 2000, CURR OPIN STRUC BIOL, V10, P165, DOI 10.1016/S0959-440X(00)00061-0
   Berendsen H. J., 1984, J CHEM PHYS, V81, P8
   BERENDSEN HJC, 1981, INTERMOLECULAR FORCE, P331
   BJORKMAN P, 1999, SUPRAMOLECULAR ASSEM
   Block SM, 1996, CELL, V87, P151, DOI 10.1016/S0092-8674(00)81332-X
   Brandstetter H, 2001, NATURE, V414, P466, DOI 10.1038/35106609
   BROOKS BR, 1995, J COMPUT CHEM, V16, P1522, DOI 10.1002/jcc.540161209
   BROOKS CL, 1988, ADV CHEM PHYS, V71
   CASE DA, 1994, CURR OPIN STRUC BIOL, V4, P285, DOI 10.1016/S0959-440X(94)90321-2
   CASE DA, 1997, COMPUTER SIMULATION, P284
   Chacon P, 2003, J MOL BIOL, V326, P485, DOI 10.1016/S0022-2836(02)01426-2
   CLARAGE JB, 1995, P NATL ACAD SCI USA, V92, P3288, DOI 10.1073/pnas.92.8.3288
   Clementi C, 2000, J MOL BIOL, V298, P937, DOI 10.1006/jmbi.2000.3693
   Eastman P, 1998, PROTEINS, V30, P215
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   Falke JJ, 2002, SCIENCE, V295, P1480, DOI 10.1126/science.1069823                                                         
   FANANAPAZIR L, 1993, P NATL ACAD SCI USA, V90, P3993, DOI 10.1073/pnas.90.9.3993
   Feenstra KA, 1999, J COMPUT CHEM, V20, P786
   FERRENBERG AM, 1988, PHYS REV LETT, V61, P2635, DOI 10.1103/PhysRevLett.61.2635
   GARCIA AE, 1992, PHYS REV LETT, V68, P2696, DOI 10.1103/PhysRevLett.68.2696                                                     
   GRUBMULLER H, 1995, PHYS REV E, V52, P2893, DOI 10.1103/PhysRevE.52.2893
   Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697                                                          
   Holmes KC, 2003, NATURE, V425, P423, DOI 10.1038/nature02005
   HORIUCHI T, 1991, PROTEINS, V10, P106, DOI 10.1002/prot.340100204                                                          
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   JAKOBSSON E, 2005, BIOMED COMPUT REV, V1, P11
   JANEZIC D, 1995, J COMPUT CHEM, V16, P1554, DOI 10.1002/jcc.540161211
   JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0
   KARHUNEN K, 1947, ANN ACAD SCI FENNI A, P137
   KARPLUS M, 1990, STUD PHYS THEO CHEM, V71, P427
   KARPLUS M, 1981, MACROMOLECULES, V14, P325, DOI 10.1021/ma50003a019                                                             
   Kitamura K, 1999, NATURE, V397, P129
   Kitao A, 1999, CURR OPIN STRUC BIOL, V9, P164, DOI 10.1016/S0959-440X(99)80023-2                                                   
   KITAO A, 1991, CHEM PHYS, V158, P447, DOI 10.1016/0301-0104(91)87082-7
   Kitao A, 1998, PROTEINS, V33, P496, DOI 10.1002/(SICI)1097-0134(19981201)33:4<496::AID-PROT4>3.0.CO;2-1
   Lehoucq R. B., 1998, ARPACK USERS GUIDE S
   LEVY RM, 1984, BIOPOLYMERS, V23, P1099, DOI 10.1002/bip.360230610                                                           
   Li H, 1996, SCIENCE, V273, P666, DOI 10.1126/science.273.5275.666
   MAZUR AK, 1991, J COMPUT PHYS, V92, P261, DOI 10.1016/0021-9991(91)90210-C
   McQuarrie D., 1976, STAT MECH
   Nakajima N, 1997, J PHYS CHEM B, V101, P817, DOI 10.1021/jp962142e                                                               
   PESKIN CS, 1989, COMMUN PUR APPL MATH, V42, P1001, DOI 10.1002/cpa.3160420706                                                          
   RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857                                                         
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110
   SCHLITTER J, 1993, MOL SIMULAT, V10, P291, DOI 10.1080/08927029308022170                                                       
   Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413
   Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f                                                               
   SHAH M, 2005, TR0501 RIC U DEP COM
   Shakhnovich EI, 1997, CURR OPIN STRUC BIOL, V7, P29, DOI 10.1016/S0959-440X(97)80005-X
   Tama F, 2001, PROTEIN ENG, V14, P1, DOI 10.1093/protein/14.1.1
   VANAALTEN MF, 1995, PROTEINS, V22, P45
   WATANABE M, 1995, J PHYS CHEM-US, V99, P5680, DOI 10.1021/j100015a061                                                             
   Wriggers W, 1999, PROTEINS, V35, P262, DOI 10.1002/(SICI)1097-0134(19990501)35:2<262::AID-PROT11>3.0.CO;2-N
   Wu XW, 1998, J PHYS CHEM B, V102, P7238, DOI 10.1021/jp9817372                                                               
   ZHANG GH, 1994, J CHEM PHYS, V101, P4995, DOI 10.1063/1.467422
   Zhang L, 1996, PROTEINS, V24, P433, DOI 10.1002/(SICI)1097-0134(199604)24:4<433::AID-PROT3>3.0.CO;2-F                   
   ZHANG Z, 2006, IN PRESS PROTEINS ST
   Zhang ZY, 2003, BIOPHYS J, V84, P3583, DOI 10.1016/S0006-3495(03)75090-5                                                   
   Zhou YQ, 1999, NATURE, V401, P400, DOI 10.1038/43937
NR 66
TC 6
Z9 6
U1 1
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0892-7022
J9 MOL SIMULAT
JI Mol. Simul.
PD AUG-SEP
PY 2006
VL 32
IS 10-11
BP 803
EP 815
DI 10.1080/08927020600771415
PG 13
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 099HY
UT WOS:000241585500004
DA 2018-01-05
ER

PT J
AU Snedecor, SJ
   Sullivan, SM
   Ho, RJY
AF Snedecor, Sonya J.
   Sullivan, Sean M.
   Ho, Rodney J. Y.
TI Feasibility of weekly HIV drug delivery to enhance drug localization in
   lymphoid tissues based on pharmacokinetic models of lipid-associated
   indinavir
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE antiviral therapy; HIV; indinavir; liposomes; pharmacokinetics
ID VIRAL LOAD; INFECTION; RESISTANCE; DYNAMICS; THERAPY
AB Purpose. Compare the simulated pharmacokinetics of lipid-associated and soluble indinavir (IDV) to determine the potential for greater control of virus replication in the lymphoid tissues.
   Methods. Two-compartment mathematical models were developed to simulate the human pharmacokinetics of soluble and lipid-associated forms of IDV in the central compartment and the lymphoid tissue. The lipid-associated IDV model was then used to determine the minimum dosing schedule needed to attain central or lymph drug concentrations comparable to the soluble form.
   Results. Association of IDV to lipid nanoparticles has a favorable half-life and tissue distribution and allows comparable minimum drug concentration in the lymph (where the majority of viral replication occurs) to be achieved with a dosing schedule of every 95.5 h (similar to 4 days).
   Conclusions. Presuming pharmacodynamics of lipid-associated IDV are similar to soluble IDV, estimations based on the proposed kinetic model suggest the novel delivery system could have a tremendous impact on the current standard of HIV treatment, particularly for therapy targeted to clear virus sanctuaries in lymphoid tissues. With less frequent and more effective dosing, lipid-associated indinavir delivery as an adjunct to conventional antiviral therapy could lead to better suppression of viral replication, increased immunological benefit, and fewer treatment failures.
C1 Univ Florida, Dept Pharm Hlth Care Adm, Gainesville, FL USA.
   Univ Florida, Dept Pharmaceut, Gainesville, FL USA.
   Let There Be Hope Med Res Inst, Beverly Hills, CA USA.
   Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
   Pharmerit N Amer LLC, Bethesda, MD 20814 USA.
RP Snedecor, SJ (reprint author), Univ Florida, Dept Pharm Hlth Care Adm, Gainesville, FL USA.
EM sonyaj@lycos.com
FU NIAID NIH HHS [AI52663]; NCRR NIH HHS [RR00166]
CR Boyd MA, 2003, JAIDS-J ACQ IMM DEF, V34, P134, DOI 10.1097/00126334-200310010-00003                                                
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   CLOTET B, 2000, GUIDE MANAGEMENT HIV, P94
   Finzi D, 1998, CELL, V93, P665, DOI 10.1016/S0092-8674(00)81427-0
   Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625
   KHOO BDM, 2002, PRACTICAL GUIDELINES
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Lian T, 2001, J PHARM SCI, V90, P667, DOI 10.1002/jps.1023
   Mammano F, 2000, J VIROL, V74, P8524, DOI 10.1128/JVI.74.18.8524-8531.2000                                                
   Martinez-Picado J, 2000, P NATL ACAD SCI USA, V97, P10948, DOI 10.1073/pnas.97.20.10948
   *MERCK CO INC, 2004, CRIX PRESCR INF
   Oussoren C, 1997, BBA-BIOMEMBRANES, V1328, P261, DOI 10.1016/S0005-2736(97)00122-3
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   YOFFEY, 1956, LYMPHATICS LYMPH LYM, P26
NR 15
TC 2
Z9 2
U1 0
U2 5
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD AUG
PY 2006
VL 23
IS 8
BP 1750
EP 1755
DI 10.1007/s11095-006-9026-1
PG 6
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 072IC
UT WOS:000239666100014
PM 16832614
DA 2018-01-05
ER

PT J
AU Garden, OA
   Reynolds, PR
   Yates, J
   Larkman, DJ
   Marelli-Berg, FM
   Haskard, DO
   Edwards, AD
   George, AJT
AF Garden, O. A.
   Reynolds, P. R.
   Yates, J.
   Larkman, D. J.
   Marelli-Berg, F. M.
   Haskard, D. O.
   Edwards, A. D.
   George, A. J. T.
TI A rapid method for labelling CD4(+) T cells with ultrasmall paramagnetic
   iron oxide nanoparticles for magnetic resonance imaging that preserves
   proliferative, regulatory and migratory behaviour in vitro
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE CD4(+) T cell; magnetic resonance; contrast agent; regulatory T cell
ID MAMMALIAN-CELLS; TAT PEPTIDE; CONTRAST AGENTS; VIVO; DELIVERY; TRACKING;
   MICROSCOPY; PROTEINS
AB A number of techniques have been developed to track the migration of T cells in vivo, but they all suffer significant shortcomings, including the examination of selected organs rather than the organism as a whole - thus precluding longitudinal studies - or limitations imposed by poor spatial resolution and the application of ionizing radiation. By conjugating the HIV tat peptide to ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles in a reaction yielding a mean valence of 45, a magnetic resonance (MR) contrast agent was synthesised that allowed T cells to be efficiently labelled within just 5 min. The USPIO nanoparticles were incorporated into both the cytoplasm and nucleus of labelled cells, which retained normal in vitro proliferative responses to a polyclonal stimulus; suppressive responses mediated by labelled CD4(+) CD25(+) regulatory T cells; chemotactic responses to the chemokine CXCL-12; and transmigration of an activated endothelial monolayer. We believe that this rapid, efficient and essentially non-toxic approach to labelling both murine and human T cells for MRI holds considerable promise, paving the way for the wider immunological application of this exciting technology. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ London Imperial Coll Sci Technol & Med, Dept Immunol, London W12 0NN, England.
   Univ London Imperial Coll Sci Technol & Med, Dept Paediat, London W12 0NN, England.
   Univ London Imperial Coll Sci Technol & Med, Dept Imaging Sci, London W12 0NN, England.
   Univ London Imperial Coll Sci Technol & Med, BHF Cardiovasc Med Unit, Natl Heart & Lung Inst, London W12 0NN, England.
   Univ London Royal Vet Coll, Dept Vet Clin Sci, Hatfield AL9 7TA, Herts, England.
   MRC, Ctr Clin Sci, London W12 0NN, England.
RP George, AJT (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Immunol, Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
EM a.george@imperial.ac.uk
OI George, Andrew/0000-0002-2866-0241; Reynolds, Peter/0000-0002-6409-083X
FU Wellcome Trust; Medical Research Council [MC_U120061309]
CR Ahrens ET, 2005, NAT BIOTECHNOL, V23, P983, DOI 10.1038/nbt1121
   Bartz SR, 1999, J VIROL, V73, P1956
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Bulte Jeff W M, 2006, Methods Mol Med, V124, P419
   de Vries IJM, 2005, NAT BIOTECHNOL, V23, P1407, DOI 10.1038/nbt1154
   Delikatny EJ, 2005, RADIOL CLIN N AM, V43, P205, DOI 10.1016/j.rcl.2004.07.004
   DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1                                                   
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Frank JA, 2004, CYTOTHERAPY, V6, P621, DOI 10.1080/14653240410005267
   Gimi Barjor, 2006, Methods Mol Med, V124, P59
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Iparraguirre A, 2003, INT ARCH ALLERGY IMM, V132, P277, DOI 10.1159/000074896
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kircher MF, 2003, CANCER RES, V63, P6838
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1
   MILLS KHG, 2000, LYMPHOCYTES PRACTICA, P121
   Moore A, 2002, MAGNET RESON MED, V47, P751, DOI 10.1002/mrm.10110
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nappi AJ, 2000, CELL MOL BIOL, V46, P637
   Phelps ME, 2000, P NATL ACAD SCI USA, V97, P9226, DOI 10.1073/pnas.97.16.9226                                                         
   PUCK TT, 1958, J EXP MED, V108, P945, DOI 10.1084/jem.108.6.945
   REYNOLDS PR, IN PRESS RADIOLOGY
   Scheinecker C, 2005, ARTHRITIS RES THER, V7, P246, DOI 10.1186/ar1843
   Tung CH, 2003, ADV DRUG DELIVER REV, V55, P281, DOI 10.1016/S0169-409X(02)00183-7
   Wang YXJ, 2001, EUR RADIOL, V11, P2319, DOI 10.1007/s003300100908                                                           
   YEH TC, 1993, MAGNET RESON MED, V30, P617, DOI 10.1002/mrm.1910300513
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 32
TC 22
Z9 25
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD JUL 31
PY 2006
VL 314
IS 1-2
BP 123
EP 133
DI 10.1016/j.jim.2006.06.010
PG 11
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 080KV
UT WOS:000240247500013
PM 16860821
DA 2018-01-05
ER

PT J
AU Delehanty, JB
   Medintz, IL
   Pons, T
   Brunel, FM
   Dawson, PE
   Mattoussi, H
AF Delehanty, James B.
   Medintz, Igor L.
   Pons, Thomas
   Brunel, Florence M.
   Dawson, Philip E.
   Mattoussi, Hedi
TI Self-assembled quantum dot-peptide bioconjugates for selective
   intracellular delivery
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID RESONANCE ENERGY-TRANSFER; CELL-PENETRATING PEPTIDES; ARGININE-RICH
   PEPTIDES; TAT-FUSION PROTEINS; LIVING CELLS; LIVE CELLS; LONG-TERM;
   NANOCRYSTALS; ENDOCYTOSIS; TOXICITY
AB We demonstrate the use of self-assembled luminescent semiconductor quantum dot (QD)-peptide bioconjugates for the selective intracellular labeling of several eukaryotic cell lines. A bifunctional oligoarginine cell penetrating peptide (based on the HIV-1 Tat protein motif) bearing a terminal polyhistidine tract was synthesized and used to facilitate the transmembrane delivery of the QD bioconjugates. The polyhistidine sequence allows the peptide to self-assemble onto the QD surface via metal-affinity interactions while the oligoarginine sequence allows specific QD delivery across the cellular membrane and intracellular labeling as compared to nonconjugated QDs. This peptide-driven delivery is concentration-dependent and thus can be titrated. Upon internalization, QDs display a punctate-like staining pattern in which some, but not all, of the QD signal is colocalized within endosomes. The effects of constant versus limited exposure to QD-peptide conjugates on cellular viability are evaluated by a metabolic specific assay, and clear differences in cytotoxicity are observed. The efficacy of using peptides for selective intracellular delivery is highlighted by performing a multicolor QD labeling, where we found that the presence or absence of peptide on the QD surface controls cellular uptake.
C1 USN, Res Lab, Ctr Biomol Sci & Engn, Washington, DC 20375 USA.
   USN, Res Lab, Div Opt Sci, Washington, DC 20375 USA.
   Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   Johns Hopkins Univ, Chem & Biomol Engn Dept, Baltimore, MD 21218 USA.
RP Delehanty, JB (reprint author), USN, Res Lab, Ctr Biomol Sci & Engn, Code 6900, Washington, DC 20375 USA.
EM jdelehanty@cbmse.nrl.navy.mil; hedimat@ccs.nrl.navy.mil
RI Pons, Thomas/A-8667-2008
OI Pons, Thomas/0000-0001-8800-4302
FU NIGMS NIH HHS [R01 GM059380, R01 GM059380-08, GM06619]
CR Alivisatos AP, 2005, ANNU REV BIOMED ENG, V7, P55, DOI 10.1146/annurev.bioeng.7.060804.100432
   Alivisatos P, 2004, NAT BIOTECHNOL, V22, P47, DOI 10.1038/nbt927
   Bentzen EL, 2005, BIOCONJUGATE CHEM, V16, P1488, DOI 10.1021/bc0502006
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Chen FQ, 2004, NANO LETT, V4, P1827, DOI 10.1021/nl049170q
   Clapp AR, 2004, J AM CHEM SOC, V126, P301, DOI 10.1021/ja037088b
   Clapp AR, 2005, J AM CHEM SOC, V127, P1242, DOI 10.1021/ja045676z
   DELAFUENTE JM, 2006, BIOCONJUGATE CHEM, V16, P1176
   Delehanty JB, 2004, ANAL CHEM, V76, P7323, DOI 10.1021/ac049259g
   Derfus AM, 2004, ADV MATER, V16, P961, DOI 10.1002/adma.200306111
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Goldman ER, 2005, J AM CHEM SOC, V127, P6744, DOI 10.1021/ja0436771
   Goldman ER, 2005, ANAL CHIM ACTA, V534, P63, DOI 10.1016/j.aca.2004.03.079
   Hainfeld JF, 1999, J STRUCT BIOL, V127, P185, DOI 10.1006/jsbi.1999.4149
   HATEFI A, 2006, IN PRESS J GENE MED
   Hoshino A, 2004, MICROBIOL IMMUNOL, V48, P985, DOI 10.1111/j.1348-0421.2004.tb03621.x                                              
   Jaiswal JK, 2003, NAT BIOTECHNOL, V21, P47, DOI 10.1038/nbt.767
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Keminer O, 1999, BIOPHYS J, V77, P217, DOI 10.1016/S0006-3495(99)76883-9
   Lagerholm BC, 2004, NANO LETT, V4, P2019, DOI 10.1021/nl049295v
   Lovric J, 2005, J MOL MED-JMM, V83, P377, DOI 10.1007/s00109-004-0629-x
   Mattoussi H, 2000, J AM CHEM SOC, V122, P12142, DOI 10.1021/ja002535y
   Medintz IL, 2005, ADV MATER, V17, P2450, DOI 10.1002/adma.200500722
   Medintz IL, 2004, P NATL ACAD SCI USA, V101, P9612, DOI 10.1073/pnas.0403343101
   Medintz IL, 2004, J AM CHEM SOC, V126, P30, DOI 10.1021/ja037970h
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   Medintz IL, 2005, NAT MATER, V4, P435, DOI 10.1038/nmat1390
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Midoux P, 1999, BIOCONJUGATE CHEM, V10, P406, DOI 10.1021/bc9801070
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Parak WJ, 2003, NANOTECHNOLOGY, V14, pR15, DOI 10.1088/0957-4484/14/7/201
   Parak WJ, 2005, NANOTECHNOLOGY, V16, pR9, DOI 10.1088/0957-4484/16/2/R01
   PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253
   Pooga M, 1998, FASEB J, V12, P67
   Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rozenzhak SM, 2005, CHEM COMMUN, P2217, DOI 10.1039/b418454h
   Saalik P, 2004, BIOCONJUGATE CHEM, V15, P1246, DOI 10.1021/bc049938y
   Saar K, 2005, ANAL BIOCHEM, V345, P55, DOI 10.1016/j.ab.2005.07.033
   Sapsford KE, 2004, LANGMUIR, V20, P7720, DOI 10.1021/la049263n
   SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180
   Shiohara A, 2004, MICROBIOL IMMUNOL, V48, P669, DOI 10.1111/j.1348-0421.2004.tb03478.x                                              
   Silver J, 2005, NANO LETT, V5, P1445, DOI 10.1021/nl050808n
   Singh RS, 2004, CHEM BIOL, V11, P713, DOI 10.1016/j.chembiol.2004.03.026
   THORSTENSEN K, 1988, J BIOL CHEM, V263, P8844
   Voura EB, 2004, NAT MED, V10, P993, DOI 10.1038/nm1096
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
NR 52
TC 210
Z9 218
U1 3
U2 61
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL 19
PY 2006
VL 17
IS 4
BP 920
EP 927
DI 10.1021/bc060044i
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 064WJ
UT WOS:000239120500009
PM 16848398
OA green_accepted
DA 2018-01-05
ER

PT J
AU Sawant, RM
   Hurley, JP
   Salmaso, S
   Kale, A
   Tolcheva, E
   Levchenko, TS
   Torchilin, VP
AF Sawant, R. M.
   Hurley, J. P.
   Salmaso, S.
   Kale, A.
   Tolcheva, E.
   Levchenko, T. S.
   Torchilin, V. P.
TI "SMART" drug delivery systems: Double-targeted pH-responsive
   pharmaceutical nanocarriers
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID POORLY SOLUBLE DRUGS; HIV-1 TAT PROTEIN; INTRACELLULAR DELIVERY;
   IN-VIVO; LIPOSOMES; PEPTIDE; CELLS; TRANSDUCTION; ATTACHMENT; ANTIBODIES
AB To develop targeted pharmaceutical carriers additionally capable of responding to certain local stimuli, such as decreased pH values in tumors or infarcts, targeted long-circulating PEGylated liposomes and PEG-phosphatidylethanolamine (PEG-PE)-based micelles have been prepared with several functions. First, they are capable of targeting a specific cell or organ by attaching the monoclonal antimyosin antibody 2G4 to their surface via pNP-PEG-PE moieties. Second, these liposomes and micelles were additionally modified with biotin or TAT peptide (TATp) moieties attached to the surface of the nanocarrier by using biotin-PE or TATp-PE or TATp-short PEG-PE derivatives. PEG-PE used for liposome surface modification or for micelle preparation was made degradable by inserting the pH-sensitive hydrazone bond between PEG and PE (PEG-Hz-PE). Under normal pH values, biotin and TATp functions on the surface of nanocarriers were "shielded" by long protecting PEG chains (pH-degradable PEG(2000)-PE or PEG(5000)-PE) or by even longer pNP-PEG-PE moieties used to attach antibodies to the nanocarrier (non-pH-degradable PEG(3400)-PE or PEG(5000)-PE). At pH 7.4-8.0, both liposomes and micelles demonstrated high specific binding with 2G4 antibody substrate, myosin, but very limited binding on an avidin column (biotin-containing nanocarriers) or internalization by NIH/3T3 or U-87 cells (TATp-containing nanocarriers). However, upon brief incubation (15-30 min) at lower pH values (pH 5.0-6.0), nanocarriers lost their protective PEG shell because of acidic hydrolysis of PEG-Hz-PE and acquired the ability to become strongly retained on an avidin column (biotin-containing nanocarriers) or effectively internalized by cells via TATp moieties (TATp-containing nanocarriers). We consider this result as the first step in the development of multifunctional stimuli-sensitive pharmaceutical nanocarriers.
C1 Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
OI Salmaso, Stefano/0000-0003-4705-5909
FU NCI NIH HHS [R01 CA121838-01, R01 CA121838]; NHLBI NIH HHS [R01
   HL055519, R01 HL055519-06, R01 HL55519]; NIBIB NIH HHS [R01 EB001961-07,
   R01 EB001961]
CR Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   HANSEN CB, 1995, BBA-BIOMEMBRANES, V1239, P133, DOI 10.1016/0005-2736(95)00138-S
   Jaracz S, 2005, BIOORGAN MED CHEM, V13, P5043, DOI 10.1016/j.bmc.2005.04.084
   KLIBANOV AL, 1985, ANAL BIOCHEM, V150, P251, DOI 10.1016/0003-2697(85)90507-X
   Liang Wei, 2004, Current Drug Delivery, V1, P1, DOI 10.2174/1567201043480063
   Lochmann D, 2004, EUR J PHARM BIOPHARM, V58, P237, DOI 10.1016/j.ejpb.2004.03.031
   Lukyanov AN, 2004, J CONTROL RELEASE, V100, P135, DOI 10.1016/j.jconrel.2004.08.007
   Lukyanov AN, 2002, PHARMACEUT RES, V19, P1424, DOI 10.1023/A:1020488012264
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Maheshwari A, 2000, MOL THER, V2, P121, DOI 10.1006/mthe.2000.0105
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   PALMER TN, 1984, BIOCHIM BIOPHYS ACTA, V797, P363, DOI 10.1016/0304-4165(84)90258-7
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Santra S, 2005, J AM CHEM SOC, V127, P1656, DOI 10.1021/ja0464140
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Tachibana R, 1998, BIOCHEM BIOPH RES CO, V251, P538, DOI 10.1006/bbrc.1998.9460                                                          
   Torchilin Vladimir P., 2005, Current Drug Delivery, V2, P319, DOI 10.2174/156720105774370221
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632
   Torchilin VP, 2004, CELL MOL LIFE SCI, V61, P2549, DOI 10.1007/s00018-004-4153-5
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wattiaux R, 2000, ADV DRUG DELIVER REV, V41, P201, DOI 10.1016/S0169-409X(99)00066-6
   Widera A, 2003, ADV DRUG DELIVER REV, V55, P1439, DOI 10.1016/j.addr.2003.07.004
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 33
TC 353
Z9 372
U1 16
U2 235
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL 19
PY 2006
VL 17
IS 4
BP 943
EP 949
DI 10.1021/bc060080h
PG 7
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 064WJ
UT WOS:000239120500012
PM 16848401
OA green_accepted
DA 2018-01-05
ER

PT J
AU Castaldello, A
   Brocca-Cofano, E
   Voltan, R
   Triulzi, C
   Altavilla, G
   Laus, M
   Sparnacci, K
   Ballestri, M
   Tondelli, L
   Fortini, C
   Gavioli, R
   Ensoli, B
   Caputo, A
AF Castaldello, Arianna
   Brocca-Cofano, Egidio
   Voltan, Rebecca
   Triulzi, Chiara
   Altavilla, Giuseppe
   Laus, Michele
   Sparnacci, Katia
   Ballestri, Marco
   Tondelli, Luisa
   Fortini, Cinzia
   Gavioli, Riccardo
   Ensoli, Barbara
   Caputo, Antonella
TI DNA prime and protein boost immunization with innovative polymeric
   cationic core-shell nanoparticles elicits broad immune responses and
   strongly enhance cellular responses of HIV-1 tat DNA vaccination
SO VACCINE
LA English
DT Article
DE biocompatible nanoparticles; HIV-1 tat; DNA vaccination; cellular
   responses
ID ANTIGEN DELIVERY-SYSTEMS; BIODEGRADABLE MICROPARTICLES; PLASMID DNA;
   T-CELL; OLIGONUCLEOTIDE DELIVERY; GLYCOLIDE MICROPARTICLES; FUNCTIONAL
   NANOSPHERES; COATED NANOPARTICLES; GENETIC IMMUNIZATION;
   ANTIBODY-RESPONSES
AB Novel biocompatible core-shell cationic nanoparticles, composed of an inner hard core of poly(methylmethacrylate) (PMMA) and a hydrophilic tentacular shell bearing positively charged groups and poly(ethyleneglycol) chains covalently bound to the core, were prepared by emulsion polymerization and characterized in vitro and in vivo for DNA vaccine applications. The nanoparticles reversibly adsorbed large amounts of DNA, mainly through electrostatic interactions, preserved its functional structure, efficiently delivered it intracellularly, and were not toxic in vitro or in mice. Furthermore, two intramuscular (i.m.) immunizations (4 weeks apart) with a very low dose (1 mu g) of the plasmid pCV-tat delivered by these nanoparticles followed by one or two protein boosts induced significant antigen-specific humoral and cellular responses and greatly increased Th1-type T cell responses and CTLs against HIV-1 Tat. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Padua, Microbiol Sect, Dept Histol Microbiol & Med Biotechnol, I-35122 Padua, Italy.
   Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy.
   Univ Padua, Dept Pathol Anat & Histol, I-35122 Padua, Italy.
   Univ Piemonte Orientale, Dept Life & Ambient Sci, Alessandria, Italy.
   INSTM, UdR, Alessandria, Italy.
   CNR, ISOF, I-40126 Bologna, Italy.
   Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy.
RP Caputo, A (reprint author), Univ Padua, Microbiol Sect, Dept Histol Microbiol & Med Biotechnol, Via A Gabelli 63, I-35122 Padua, Italy.
EM antonella.caputo@unipd.it
RI tondelli, luisa/C-1414-2012; Sparnacci, Katia/C-1138-2009; Ensoli,
   Barbara/J-9169-2016; Ballestri, Marco/E-6697-2012; Gavioli,
   Riccardo/K-7594-2016
OI tondelli, luisa/0000-0002-3971-3361; Sparnacci,
   Katia/0000-0003-2102-9649; Ensoli, Barbara/0000-0002-0545-8737; Gavioli,
   Riccardo/0000-0002-7805-4290; Laus, Michele/0000-0002-4296-3732;
   ballestri, marco/0000-0001-7336-2131
CR Alpar H Oya, 2005, Expert Opin Drug Deliv, V2, P829, DOI 10.1517/17425247.2.5.829
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3                                                   
   ARYA SK, 1985, SCIENCE, V229, P69, DOI 10.1126/science.2990040
   Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0
   Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3
   CAPUTO A, 1990, J ACQ IMMUN DEF SYND, V3, P372
   Caputo A, 2004, CURR HIV RES, V2, P357, DOI 10.2174/1570162043350986
   Caputo A, 2004, VACCINE, V22, P2910, DOI 10.1016/j.vaccine.2003.12.025
   Caputo A, 2003, VACCINE, V21, P1103, DOI 10.1016/S0264-410X(02)00555-8                                                   
   Caselli E, 1999, J IMMUNOL, V162, P5631
   Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   Chen WC, 2005, ADV GENET, V54, P315, DOI 10.1016/S0065-2660(05)54013-6
   Crommelin DJA, 1997, J CONTROL RELEASE, V46, P165, DOI 10.1016/S0168-3659(96)01583-0
   Cui Z, 2002, J CONTROL RELEASE, V81, P173, DOI 10.1016/S0168-3659(02)00051-2
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Cui ZR, 2002, PHARMACEUT RES, V19, P939, DOI 10.1023/A:1016402019380
   Cui ZR, 2002, J PHARM PHARMACOL, V54, P1195, DOI 10.1211/002235702320402035                                                      
   Denis-Mize KS, 2003, CELL IMMUNOL, V225, P12, DOI 10.1016/j.cellimm.2003.09.003
   Donnelly JJ, 2005, J IMMUNOL, V175, P633, DOI 10.4049/jimmunol.175.2.633                                                      
   ELDRIDGE JH, 1991, INFECT IMMUN, V59, P2978
   ENSOLI B, 1993, J VIROL, V67, P277
   Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197                                                      
   Ferrantelli F, 2004, CURR OPIN BIOTECH, V15, P543, DOI 10.1016/j.copbio.2004.10.008
   GAVIOLI R, 2000, J IMMUNOL, V173, P3838
   Gupta RK, 1998, DEV BIOLOGICALS, V92, P63
   Gurunathan S, 2000, CURR OPIN IMMUNOL, V12, P442, DOI 10.1016/S0952-7915(00)00118-7
   Hinkula J, 1997, VACCINE, V15, P874, DOI 10.1016/S0264-410X(96)00257-5
   Hinkula J, 1997, J VIROL, V71, P5528
   Jabbal-Gill I, 1999, VACCINE, V18, P238, DOI 10.1016/S0264-410X(99)00195-4
   Jilek S, 2005, ADV DRUG DELIVER REV, V57, P377, DOI 10.1016/j.addr.2004.09.010
   Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5
   Kasturi SP, 2005, BIOMATERIALS, V26, P6375, DOI 10.1016/j.biomaterials.2005.03.043
   Kaur R, 2004, VACCINE, V22, P2776, DOI 10.1016/j.vaccine.2004.01.040
   Kim JH, 2005, J CONTROL RELEASE, V109, P86, DOI 10.1016/j.jconrel.2005.09.016
   KREUTER J, 1976, INFECT IMMUN, V13, P204
   Laus M, 2000, J POLYM SCI POL CHEM, V38, P1110, DOI 10.1002/(SICI)1099-0518(20000401)38:7<1110::AID-POLA8>3.0.CO;2-5                
   Lode K, 2001, PHARMACEUT RES, V18, P1613
   Majeti NV, 2000, J PHARM PHARM SCI, V3, P234
   MEN Y, 1995, VACCINE, V13, P683
   Mollenkopf HJ, 2004, VACCINE, V22, P2690, DOI 10.1016/j.vaccine.2004.05.005
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NEDRUD JG, 1991, TOPICS VACCINE ADJUV, P51
   Nugent J, 1998, J CLIN PHARM THER, V23, P257
   O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001
   O'Hagan D. T., 2001, Current Drug Targets - Infectious Disorders, V1, P273, DOI 10.2174/1568005014606008
   O'Hagan DT, 2004, VACCINE, V23, P672, DOI 10.1016/j.vaccine.2004.06.037
   O'Hagan DT, 2004, IMMUNOL REV, V199, P191, DOI 10.1111/j.0105-2896.2004.00153.x                                                
   OHAGAN DT, 1993, VACCINE, V11, P965, DOI 10.1016/0264-410X(93)90387-D
   OHAGAN DT, 1991, IMMUNOLOGY, V73, P239
   OHAGAN DT, 1998, J PHARM PHARMACOL, V59, P1
   OKUBO M, 1989, COLLOID POLYM SCI, V267, P861, DOI 10.1007/BF01410333                                                              
   Oster CG, 2005, J CONTROL RELEASE, V104, P359, DOI 10.1016/j.jconrel.2005.02.004
   Otten G, 2003, J VIROL, V77, P6087, DOI 10.1128/JVI.77.10.6087-6092.2003
   Ramakrishna L, 2004, J VIROL, V78, P9174, DOI 10.1128/JVI.78.17.9174-9189.2004
   Rihova B, 1996, ADV DRUG DELIVER REV, V21, P157
   ROLLAND A, 1986, J PHARM BELG, V41, P94
   Singh M, 2004, PHARM RES, V21, P2148, DOI 10.1007/s11095-004-7666-6
   Singh M, 2004, EXPERT OPIN BIOL TH, V4, P483, DOI 10.1517/14712598.4.4.483
   Singh M, 2004, J PHARM SCI-US, V93, P273, DOI 10.1002/jps.10538
   SOKAL RR, 1981, BIOMETRY PRINCIPLES, P128
   Sparnacci K, 2005, J BIOMAT SCI-POLYM E, V16, P1557, DOI 10.1163/156856205774576673
   Sparnacci K, 2000, J POLYM SCI POL CHEM, V38, P3347, DOI 10.1002/1099-0518(20000915)38:18<3347::AID-POLA120>3.3.CO;2-Q
   STIENEKER F, 1991, AIDS, V5, P431, DOI 10.1097/00002030-199104000-00012                                                
   Tahtinen M, 2001, VACCINE, V19, P2039, DOI 10.1016/S0264-410X(00)00420-5
   Thierry AR, 1997, GENE THER, V4, P226, DOI 10.1038/sj.gt.3300350                                                           
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693
   Xie H, 2005, INFECT IMMUN, V73, P828, DOI 10.1028/IAI.73.2.828-833.2005
NR 68
TC 39
Z9 41
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUL 17
PY 2006
VL 24
IS 29-30
BP 5655
EP 5669
DI 10.1016/j.vaccine.2006.05.058
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 064IE
UT WOS:000239081600001
PM 16781023
DA 2018-01-05
ER

PT J
AU Crernel, M
   Hamzeh-Cognasse, H
   Genin, C
   Delezay, O
AF Crernel, Magali
   Hamzeh-Cognasse, Hind
   Genin, Christian
   Delezay, Olivier
TI Female genital tract immunization: Evaluation of candidate
   immunoadjuvants on epithelial cell secretion of CCL20 and
   dendritic/Langerhans cell maturation
SO VACCINE
LA English
DT Article
DE female genital tract; local immunization; candidate mucosal
   immunoadjuvants
ID NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; CCL20/MACROPHAGE INFLAMMATORY
   PROTEIN-3-ALPHA; INACTIVATED HIV-1-CAPTURING NANOSPHERES; HUMAN
   DENDRITIC CELLS; TOLL-LIKE RECEPTOR-9; DOUBLE-STRANDED-RNA;
   IMMUNE-RESPONSES; CHOLERA-TOXIN; INTESTINAL EPITHELIUM
AB The female genital tract is an important site. for numerous pathogens entry. Local immunization, generating specific mucosal IgA and systemic IgG, represents an interesting alternative immunization pathway. However, such a vaccine strategy needs mucosal adjuvants to obtain the best immune response. Considering that the immunization process is mainly dependent on the capture and on the transport of the antigen by Langerhans cells, we evaluated potential adjuvant molecules by analysing their effects on the CCL20 secretion by endocervical and exocervical/vaginal epithelial cells as well as on dendritic cell and Langerhans cell maturation. We demonstrated that DC-Chol and Zymosan are the most efficient mucosal candidate immunoadjuvants that generate a strong increase of CCL20 secretion by the two epithelial cell lines and the maturation of dendritic and Langerhans cells, respectively. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ St Etienne, GIMAP, Fac Med, EA 3064, F-42023 St Etienne 2, France.
RP Genin, C (reprint author), Univ St Etienne, GIMAP, Fac Med, EA 3064, 15 Rue Ambroise Pare, F-42023 St Etienne 2, France.
EM Christian.Genin@univ-st-etienne.fr
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Anjuere F, 2004, J IMMUNOL, V173, P5103, DOI 10.4049/jimmunol.173.8.5103                                                     
   Applequist SE, 2005, J IMMUNOL, V175, P3882, DOI 10.4049/jimmunol.175.6.3882                                                     
   Bafica A, 2005, J EXP MED, V202, P1715, DOI 10.1081/jem.20051782
   Bernardi A, 2004, CHEM-EUR J, V10, P4395, DOI 10.1002/chem.20040084
   Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42                                                               
   Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745
   Cao WP, 2005, BIOCHEM J, V385, P85, DOI 10.1042/BJ20040741
   Caux C, 2002, TRANSPLANTATION, V73, pS7, DOI 10.1097/00007890-200201151-00005
   Crane-Godreau MA, 2005, INFECT IMMUN, V73, P4231, DOI 10.1128/IAI.73.7.4231-4237.2005
   Crane-Godreau MA, 2005, INFECT IMMUN, V73, P476, DOI 10.1128/IAI.73.1.476-484.2005
   Crane-Godreau MA, 2004, INFECT IMMUN, V72, P1866, DOI 10.1128/IAI.72.4.1866-1873.2004
   Cremel M, 2005, J LEUKOCYTE BIOL, V78, P158, DOI 10.1189/jlb.0305147
   Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373
   Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705
   Dunne A, 2005, FEBS LETT, V579, P3330, DOI 10.1016/j.febslet.2005.04.024
   Durand V, 2004, IMMUNOL CELL BIOL, V82, P596, DOI 10.1111/j.1440-1711.2004.01285.x
   Eaton-Bassiri A, 2004, INFECT IMMUN, V72, P7202, DOI 10.1128/IAI.72.12.7202-7211.2004
   Espuelas S, 2005, MOL IMMUNOL, V42, P721, DOI 10.1016/j.molimm.2004.09.022
   Fazeli A, 2005, HUM REPROD, V20, P1372, DOI 10.1093/humrep/deh775
   Fichorova RN, 2002, J IMMUNOL, V168, P2424, DOI 10.4049/jimmunol.168.5.2424                                                     
   Fujiie S, 2001, INT IMMUNOL, V13, P1255, DOI 10.1093/intimm/13.10.1255                                                       
   Fujita M, 2003, J IMMUNOL, V171, P3675, DOI 10.4049/jimmunol.171.7.3675                                                     
   Gangloff SC, 2005, J IMMUNOL, V175, P3940, DOI 10.4049/jimmunol.175.6.3940                                                     
   Gervassi A, 2004, INFECT IMMUN, V72, P7231, DOI 10.1128/IAI.72.12.7231-7239.2004
   Hamajima K, 2002, CLIN IMMUNOL, V102, P12, DOI 10.1006/clim.2001.5141
   Harris G, 2006, WORLD J GASTROENTERO, V12, P2149, DOI 10.3748/wjg.v12.i14.2149                                                        
   Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220
   Heil F, 2003, EUR J IMMUNOL, V33, P2987, DOI 10.1002/eji.200324238
   Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253
   Horne AW, 2006, REPRODUCTION, V131, P733, DOI 10.1530/rep.1.00883
   Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788
   Ishii KJ, 2005, J CLIN IMMUNOL, V25, P511, DOI 10.1007/s10875-005-7829-1
   Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710
   Johansson EL, 2001, INFECT IMMUN, V69, P7481, DOI 10.1128/IAI.69.12.7481-7486.2001
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura YI, 2003, EUR J IMMUNOL, V33, P3205, DOI 10.1002/eji.200324135
   Kollisch G, 2005, IMMUNOLOGY, V114, P531, DOI 10.1111/j.1365-2567.2005.02122.x
   Kucharzik T, 2005, GUT, V54, P1565, DOI 10.1136/gut.2004.061168
   Latz E, 2004, J ENDOTOXIN RES, V10, P406, DOI 10.1179/096805104225006525
   Masson M, 2003, J GEN VIROL, V84, P2099, DOI 10.1099/vir.0.18961-0
   Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068
   Minchinton AI, 1997, ACTA ONCOL, V36, P13, DOI 10.3109/02841869709100724                                                       
   Murtaugh MP, 2002, VET IMMUNOL IMMUNOP, V87, P109, DOI 10.1016/S0165-2427(02)00042-9
   Oh YK, 2003, VACCINE, V21, P1980, DOI 10.1016/S0264-410X(02)00779-X
   Okahira S, 2005, DNA CELL BIOL, V24, P614, DOI 10.1089/dna.2005.24.614
   Okusawa T, 2004, INFECT IMMUN, V72, P1657, DOI 10.1128/IAI.72.3.1657-1665.2004
   Omueti KO, 2005, J BIOL CHEM, V280, P36616, DOI 10.1074/jbc.M504320200
   Patel M, 2005, J IMMUNOL, V174, P7558, DOI 10.4049/jimmunol.174.12.7558                                                    
   Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043
   Pivarcsi A, 2005, MICROBES INFECT, V7, P1117, DOI 10.1016/j.micinf.2005.03.016
   Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373
   Rochman I, 2005, J IMMUNOL, V174, P4761, DOI 10.4049/jimmunol.174.8.4761                                                     
   Schaefer TM, 2004, IMMUNOLOGY, V112, P428, DOI 10.1046/j.1365-2567.2004.01898.x
   Scimone ML, 2005, IMMUNOLOGY, V114, P375, DOI 10.1111/j.1365-2567.2005.02104.x
   Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-03880C
   Sierro F, 2001, P NATL ACAD SCI USA, V98, P13722, DOI 10.1073/pnas.241308598
   Smits HH, 2005, TRENDS IMMUNOL, V26, P123, DOI 10.1016/j.it.2005.01.002
   Takeda Kiyoshi, 2002, Tanpakushitsu Kakusan Koso, V47, P2097
   Takeshita F, 2004, SEMIN IMMUNOL, V16, P17, DOI 10.1016/j.smim.2003.10.009
   Tallant T, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-33
   Tchou I, 2003, IMMUNOL LETT, V86, P7, DOI 10.1016/S0165-2478(02)00263-8                                                   
   Thorley AJ, 2005, AM J RESP CELL MOL, V32, P262, DOI 10.1165/rcmb.2004-0196OC
   Toebak MJ, 2006, TOXICOL IN VITRO, V20, P117, DOI 10.1016/j.tiv.2005.06.039
   Underhill DM, 2003, J ENDOTOXIN RES, V9, P176, DOI 10.1179/096805103125001586
   Wadehra M, 2005, DEV BIOL, V287, P336, DOI 10.1016/j.ydbio.2005.09.003
   Wagner H, 2004, TRENDS IMMUNOL, V25, P381, DOI 10.1016/j.it.2004.04.011
   Yang Y, 2005, J IMMUNOL, V174, P2720, DOI 10.4049/jimmunol.174.5.2720                                                     
NR 70
TC 17
Z9 18
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUL 17
PY 2006
VL 24
IS 29-30
BP 5744
EP 5754
DI 10.1016/j.vaccine.2006.04.044
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 064IE
UT WOS:000239081600011
PM 16730865
DA 2018-01-05
ER

PT J
AU Coburn, CA
   Stachel, SJ
   Jones, KG
   Steele, TG
   Rush, DM
   DiMuzio, J
   Pietrak, BL
   Lai, MT
   Huang, Q
   Lineberger, J
   Jin, LX
   Munshi, S
   Holloway, MK
   Espeseth, A
   Simon, A
   Hazuda, D
   Graham, SL
   Vacca, JP
AF Coburn, CA
   Stachel, SJ
   Jones, KG
   Steele, TG
   Rush, DM
   DiMuzio, J
   Pietrak, BL
   Lai, MT
   Huang, Q
   Lineberger, J
   Jin, LX
   Munshi, S
   Holloway, MK
   Espeseth, A
   Simon, A
   Hazuda, D
   Graham, SL
   Vacca, JP
TI BACE-1 inhibition by a series of psi[CH2NH] reduced amide isosteres
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE beta-secretase; reduced amide; isostere
ID RATIONAL DESIGN; PROTEASE; POTENT; PROTEINASES; PEPTIDE; DISEASE; HIV-1;
   RENIN
AB A series of beta-site amyloid precursor protein cleaving enzyme (BALE-1) inhibitors containing psi (CH2NH) reduced amide bond were synthesized. Incorporation of this reduced amide isostere as a non-cleavable peptide surrogate afforded inhibitors possessing low nanomolar potencies in both an enzymatic and cell-based assay. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA.
   Merck Res Labs, Dept Alzheimers Res, West Point, PA 19486 USA.
   Merck Res Labs, Dept Drug Metab, West Point, PA 19486 USA.
   Merck Res Labs, Dept Biol Struct, West Point, PA 19486 USA.
   Merck Res Labs, Dept Mol Syst, West Point, PA 19486 USA.
RP Coburn, CA (reprint author), Merck Res Labs, Dept Med Chem, POB 4, West Point, PA 19486 USA.
EM craig_coburn@merck.com
CR Beher D, 2005, EXPERT OPIN INV DRUG, V14, P1385, DOI 10.1517/1353784.14.11.1385
   BLUNDELL TL, 1987, BIOCHEMISTRY-US, V26, P5585, DOI 10.1021/bi00392a001
   Brady SF, 2004, BIOORG MED CHEM LETT, V14, P601, DOI 10.1016/j.bmcl.2003.11.061
   Cumming JN, 2004, CURR OPIN DRUG DISC, V7, P536
   Golde TE, 2005, BRAIN PATHOL, V15, P84, DOI 10.1111/j.1750-3639.2005.tb00104.x                                              
   Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004
   Pietrak BL, 2005, ANAL BIOCHEM, V342, P144, DOI 10.1016/j.ab.2005.04.019
   Shi XP, 2005, J ALZHEIMERS DIS, V7, P139
   Skrbec D, 2002, BIOCHEM BIOPH RES CO, V297, P1350, DOI 10.1016/S0006-291X(02)02372-0
   Stachel SJ, 2006, BIOORG MED CHEM LETT, V16, P641, DOI 10.1016/j.bmcl.2005.10.032
   Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g
   SUGUNA K, 1987, P NATL ACAD SCI USA, V84, P7009, DOI 10.1073/pnas.84.20.7009
   SZELKE M, 1982, NATURE, V299, P555, DOI 10.1038/299555a0
   Weber J, 1997, ARCH BIOCHEM BIOPHYS, V341, P62, DOI 10.1006/abbi.1997.9945
   Yang WJ, 2006, J MED CHEM, V49, P839, DOI 10.1021/jm0509142
NR 15
TC 42
Z9 44
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUL 15
PY 2006
VL 16
IS 14
BP 3635
EP 3638
DI 10.1016/j.bmcl.2006.04.076
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 058XR
UT WOS:000238698400001
PM 16690314
DA 2018-01-05
ER

PT J
AU Habashita, H
   Kokubo, M
   Hamano, S
   Hamanaka, N
   Toda, M
   Shibayama, S
   Tada, H
   Sagawa, K
   Fukushima, D
   Maeda, K
   Mitsuya, H
AF Habashita, Hiromu
   Kokubo, Masaya
   Hamano, Shin-ichi
   Hamanaka, Nobuyuki
   Toda, Masaaki
   Shibayama, Shiro
   Tada, Hideaki
   Sagawa, Kenji
   Fukushima, Daikichi
   Maeda, Kenji
   Mitsuya, Hiroaki
TI Design, synthesis, and biological evaluation of the combinatorial
   library with a new spirodiketopiperazine scaffold. Discovery of novel
   potent and selective low-molecular-weight CCR5 antagonists
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN INTERLEUKIN-8 RECEPTOR; CHEMOKINE RECEPTOR; HIV-1 ENTRY;
   AMINO-ACIDS; SOLID-PHASE; IDENTIFICATION; PEPTIDE; RESIN;
   1,4-BENZODIAZEPINE-2,5-DIONES; DERIVATIVES
AB We previously reported the discovery of several spirodiketopiperazine derivatives as potent CCR5 antagonists with anti-HIV activity. Herein, we describe in detail the identification of these lead compounds using a combinatorial chemistry approach. A novel spirodiketopiperazine scaffold was designed on the basis of the concept of the privileged structure of G-protein-coupled receptors (GPCRs). This new framework was obtained in acceptable yield with high purity from the readily prepared isonitrile resin through the Ugi reaction, sequential transformations, and cyclative cleavage. By measuring the inhibitory activity of each compound in the initial library against the intracellular calcium mobilization stimulated by MIP-1 alpha, several compounds were found to show modest but selective CCR5 antagonistic activity. After the rapid evaluation of these hit compounds, several single-digit nanomolar, low-molecular-weight CCR5 antagonists that can potently block the infectivity and replication of laboratory and clinical strains of HIV as well as those of highly drug-resistant HIV variants with minimal cytotoxicity have been identified.
C1 Ono Pharmaceut Co Ltd, Med Chem Res Labs, Osaka 6188585, Japan.
   Ono Pharmaceut Co Ltd, Exploratory Res Labs, Ibaraki 3004247, Japan.
   Kumamoto Univ, Sch Med, Dept Internal Med 2, Kumamoto 8600811, Japan.
   NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA.
RP Habashita, H (reprint author), Ono Pharmaceut Co Ltd, Med Chem Res Labs, Osaka 6188585, Japan.
EM habashita@ono.co.jp
CR AbdelMagid AF, 1996, J ORG CHEM, V61, P3849, DOI 10.1021/jo960057x                                                               
   Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Barber Chris G, 2004, Curr Opin Investig Drugs, V5, P851
   Chen JJ, 2002, TETRAHEDRON LETT, V43, P4083, DOI 10.1016/S0040-4039(02)00700-1                                                   
   DANGLES O, 1987, J ORG CHEM, V52, P4984, DOI 10.1021/jo00231a027                                                             
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dolle RE, 2005, J COMB CHEM, V7, P739, DOI 10.1021/cc050082t
   Domling A, 2000, ANGEW CHEM INT EDIT, V39, P3168, DOI 10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fernandez-Forner D, 2001, TETRAHEDRON LETT, V42, P4471, DOI 10.1016/S0040-4039(01)00755-9
   Fischer PM, 2003, J PEPT SCI, V9, P9, DOI 10.1002/psc.446
   Fischereder M, 2001, LANCET, V357, P1758, DOI 10.1016/S0140-6736(00)04898-4
   Golebiowski A, 2002, J COMB CHEM, V4, P584, DOI 10.1021/cc020029u
   GORDON DW, 1995, BIOORG MED CHEM LETT, V5, P47, DOI 10.1016/0960-894X(94)00455-O
   Hall IP, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03425-X                                                   
   Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t
   Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687
   HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701
   Horuk R, 2003, METHODS, V29, P369, DOI 10.1016/S1046-2023(02)00361-4
   Howard OMZ, 1998, J LEUKOCYTE BIOL, V64, P6
   Hulme C, 2000, TETRAHEDRON LETT, V41, P1883, DOI 10.1016/S0040-4039(00)00052-6                                                   
   Hulme C, 2000, TETRAHEDRON LETT, V41, P1509, DOI 10.1016/S0040-4039(99)02326-6                                                   
   HULME C, 1999, TETRAHEDRON LETT, V40, P5296
   Keating TA, 1996, J ORG CHEM, V61, P8935, DOI 10.1021/jo961517p                                                               
   Kennedy AL, 2002, ORG LETT, V4, P1167, DOI 10.1021/ol0256015
   Maeda K, 2001, J BIOL CHEM, V276, P35194, DOI 10.1074/jbc.M105670200
   Muller G, 2003, DRUG DISCOV TODAY, V8, P681, DOI 10.1016/S1359-6446(03)02781-8
   MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716
   Pachett A. A., 2000, ANNU REP MED CHEM, V35, P289
   Schwarz MK, 2002, NAT REV DRUG DISCOV, V1, P347, DOI 10.1038/nrd795
   SHIMANO M, 1995, J ORG CHEM, V60, P7445, DOI 10.1021/jo00128a016                                                             
   Siegel MG, 1997, TETRAHEDRON LETT, V38, P3357, DOI 10.1016/S0040-4039(97)00650-3
   Thoma G, 2004, J MED CHEM, V47, P1939, DOI 10.1021/jm031046g                                                               
   Thompson LA, 1996, CHEM REV, V96, P555, DOI 10.1021/cr9402081                                                               
   VARTANYAN SA, 1972, ARM KHIM ZH, V25, P163
   Vierboom MPM, 2005, ARTHRITIS RHEUM, V52, P627, DOI 10.1002/art.20850
   White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095                                                        
   Zhang AJ, 1998, TETRAHEDRON LETT, V39, P7439, DOI 10.1016/S0040-4039(98)01631-1
NR 39
TC 69
Z9 70
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 13
PY 2006
VL 49
IS 14
BP 4140
EP 4152
DI 10.1021/jm060051s
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 060MH
UT WOS:000238805800017
PM 16821774
DA 2018-01-05
ER

PT J
AU Sechi, M
   Bacchi, A
   Carcelli, M
   Compari, C
   Duce, E
   Fisicaro, E
   Rogolino, D
   Gates, P
   Derudas, M
   Al-Mawsawi, LQ
   Neamati, N
AF Sechi, Mario
   Bacchi, Alessia
   Carcelli, Mauro
   Compari, Carlotta
   Duce, Elenia
   Fisicaro, Emilia
   Rogolino, Dominga
   Gates, Paul
   Derudas, Marco
   Al-Mawsawi, Laith Q.
   Neamati, Nouri
TI From ligand to complexes: Inhibition of human immunodeficiency virus
   type 1 integrase by beta-diketo acid metal complexes
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID DNA STRAND-TRANSFER; HIV-1 INTEGRASE; ACTIVE-SITE; CATALYTIC DOMAIN;
   DESIGN; BINDING; REPLICATION; MECHANISM; TARGET; IONS
AB ss-Diketo acid-containing compounds are a promising class of human immunodeficiency virus type 1 (HIV1) integrase ( IN) inhibitors. Starting from the hypothesis that these inhibitors are able to coordinate ions in solution before interacting on the active site, a series of potentiometric measurements have been performed to understand the coordination ability of the diketo acid pharmacophore toward the biologically relevant Mg2+. Moreover, by using, ss-diketo acid/ester as model ligands with a set of divalent metal ions (Mg, Mn, Ni, Co, Cu, and Zn), we obtained a series of complexes and tested them for anti-HIV-1 IN activity. Results demonstrate that the diketo acid functionality chelates divalent metal ions in solution, and complexes with metals in different stoichiometric ratios are isolated. We postulate that the diketo acids act as complexes in their active form. In particular, they predominantly form species such as Mg2L2+ and Mg2L2 (derived from diketo acids, H2L), and MgL+ and MgL2 (derived from diketo esters, HL) at physiological pH. Furthermore, the synthesized mono- and dimetallic complexes inhibited IN at a high nanomolar to low micromolar range, with metal dependency in the phenyl diketo acid series. Retrospective analysis suggests that the electronic properties of the aromatic framework influence the metal-chelating ability of the diketo acid system. Therefore, the difference in activities is related to the complexes they preferentially form in solution, and these findings are important for the design of a new generation of IN inhibitors.
C1 Univ Sassari, Dipartimento Farmacochim Tossicol, I-07100 Sassari, Italy.
   Univ Parma, Dipartimento Chim Gen & Inorgan, I-43100 Parma, Italy.
   Univ Parma, Dipartimento Sci Farmacol Biol & Chim Applicate, I-43100 Parma, Italy.
   Univ Bristol, Sch Chem, Bristol BS8 1TS, Avon, England.
   Univ So Calif, Sch Pharm, Dept Pharmaceut Sci, Los Angeles, CA 90089 USA.
RP Sechi, M (reprint author), Univ Sassari, Dipartimento Farmacochim Tossicol, Via Muroni 23A, I-07100 Sassari, Italy.
EM mario.sechi@uniss.it; neamati@usc.edu
RI Carcelli, Mauro/I-1616-2015; Rogolino, Dominga/L-6145-2015; Bacchi,
   Alessia/B-6850-2016
OI Carcelli, Mauro/0000-0001-5888-4556; Rogolino,
   Dominga/0000-0003-2295-5783; Bacchi, Alessia/0000-0001-5675-9372; Sechi,
   Mario/0000-0003-2983-6090
CR ALLEN FH, 1983, ACCOUNTS CHEM RES, V16, P146, DOI 10.1021/ar00089a001                                                             
   ALTOMARE A, 1994, J APPL CRYSTALLOGR, V27, P435, DOI 10.1107/S002188989400021X
   Anthony NJ, 2004, CURR TOP MED CHEM, V4, P979, DOI 10.2174/1568026043388448
   Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1
   BARBARO G, 2005, CURR PHARM DESIGN, V11, P1850
   Billich Andreas, 2003, Curr Opin Investig Drugs, V4, P206
   Brecker L, 1999, NEW J CHEM, V23, P437, DOI 10.1039/a807247g                                                                
   BROWN PO, 1999, INTEGRATION
   Chen I.-Jen, 2002, Current Drug Targets - Infectious Disorders, V2, P217, DOI 10.2174/1568005023342380
   CHIU TK, 2004, CURR TOP MED CHEM, V4, P671
   Cohen J, 2002, SCIENCE, V296, P2320, DOI 10.1126/science.296.5577.2320                                                   
   Cowan J. A., 1995, P1
   d'Angelo J, 2001, PATHOL BIOL, V49, P237, DOI 10.1016/S0369-8114(01)00135-3                                                   
   Dayam R, 2003, CURR PHARM DESIGN, V9, P1789, DOI 10.2174/1381612033454469                                                        
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703
   Debyser Z, 2001, Methods Mol Biol, V160, P139
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C
   Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397                                                          
   Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8
   Farrugia L. J., 1999, J APPL CRYSTALLOGR, V32, P837, DOI DOI 10.1107/S0021889899006020
   Feng M, 2004, NAT STRUCT MOL BIOL, V11, P450, DOI 10.1038/nsmb754
   FISICARO E, 1988, TALANTA, V35, P769, DOI 10.1016/0039-9140(88)80181-4                                                    
   Gans P, 1996, TALANTA, V43, P1739, DOI 10.1016/0039-9140(96)01958-3
   GATEHOUSE BM, 1976, ACTA CRYSTALLOGR B, V32, P3145, DOI 10.1107/S0567740876009825                                                       
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040                                                        
   GRAN G, 1952, ANALYST, V77, P661, DOI 10.1039/an9527700661                                                            
   Grobler JA, 2002, P NATL ACAD SCI USA, V99, P6661, DOI 10.1073/pnas.092056199
   Gupta SP, 2003, CURR MED CHEM, V10, P1779, DOI 10.2174/0929867033456972
   HAZUDA DJ, 1994, NUCLEIC ACIDS RES, V22, P1121, DOI 10.1093/nar/22.6.1121
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Hazuda DJ, 2004, SCIENCE, V305, P528, DOI 10.1126/science.1098632
   Horton NC, 2001, NAT STRUCT BIOL, V8, P290, DOI 10.1038/86149
   JOHNSON AA, 2004, CURR TOP MED CHEM, V4, P671
   KAWAI H, 1993, CHEM PHARM BULL, V41, P357
   Lins RD, 2000, PHARMACOL THERAPEUT, V85, P123, DOI 10.1016/S0163-7258(99)00059-5
   Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552
   Long YQ, 2004, J MED CHEM, V47, P2561, DOI 10.1021/jm030559k
   Marchand C, 2003, MOL PHARMACOL, V64, P600, DOI 10.1124/mol.64.3.600
   Marchand C, 2002, J BIOL CHEM, V277, P12596, DOI 10.1074/jbc.M110758200
   Marchand C, 2001, METHOD ENZYMOL, V340, P624
   Maurin C, 2004, TETRAHEDRON, V60, P6479, DOI 10.1016/j.tet.2004.06.030                                                       
   Maurin C, 2004, J MED CHEM, V47, P5583, DOI 10.1021/jm0408464
   Maurin C, 2003, CURR MED CHEM, V10, P1795, DOI 10.2174/0929867033456981                                                        
   MAZUMDER A, 1999, METHODS CELLULAR MOL
   Nardelli M., 1995, J APPL CRYSTALLOGR, V28, P659, DOI [10.1107/S0021889895007138, DOI 10.1107/S0021889895007138]
   Neamati N, 2000, Adv Pharmacol, V49, P147
   Neamati N, 2002, EXPERT OPIN THER PAT, V12, P709, DOI 10.1517/13543776.12.5.709                                                       
   Neamati N, 2001, EXPERT OPIN INV DRUG, V10, P281, DOI 10.1517/13543784.10.2.281                                                       
   Pais GCG, 2002, DRUG FUTURE, V27, P1101
   Pais GCG, 2002, J MED CHEM, V45, P3184, DOI 10.1021/jm020037p
   Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498                                                          
   Pluymers W, 2002, ANTIMICROB AGENTS CH, V46, P3292, DOI 10.1128/AAC.46.10.3292-3297.2002
   Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   ROSSOTTI FJC, 1961, DETERMINATION STABIL, pCH17
   Sechi M, 2004, J MED CHEM, V47, P5298, DOI 10.1021/jm049944f
   Sechi Mario, 2005, Antiviral Chemistry & Chemotherapy, V16, P41
   Sheldrick G. M., 1997, SHELXL97 PROGRAM REF
   Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395
   Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542
   Tanaka A, 1998, J MED CHEM, V41, P2390, DOI 10.1021/jm9800853
   Turpin Jim A, 2003, Expert Rev Anti Infect Ther, V1, P97, DOI 10.1586/14787210.1.1.97
   Wai JS, 2000, J MED CHEM, V43, P4923, DOI 10.1021/jm000176b
   Witvrouw M, 2004, CURR DRUG METAB, V5, P291, DOI 10.2174/1389200043335487
   YOSHINAGA TS, 2002, 9 C RETR OPP INF SEA
   YOUNG SL, 2002, 14 INT AIDS C W POIN
NR 70
TC 66
Z9 71
U1 1
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUL 13
PY 2006
VL 49
IS 14
BP 4248
EP 4260
DI 10.1021/jm060193m
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 060MH
UT WOS:000238805800027
PM 16821784
DA 2018-01-05
ER

PT J
AU Dou, H
   Destache, C
   Nelson, J
   Poluektova, L
   Gorantla, S
   Boska, M
   Rabinow, B
   Mosley, RL
   Gendelman, HE
AF Dou, H.
   Destache, C.
   Nelson, J.
   Poluektova, L.
   Gorantla, S.
   Boska, M.
   Rabinow, Barrett
   Mosley, R. L.
   Gendelman, H. E.
TI Macrophage nanoparticle delivery system for anti-retroviral medicines:
   Treatment of HIV-1 infection in the nervous system & other viral
   reservoirs
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Meeting Abstract
C1 Baxter Healthcare Corp, Round Lake, IL 60073 USA.
   Creighton Univ, Omaha, NE 68178 USA.
   Univ Nebraska, Med Ctr, Omaha, NE USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1671-4083
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD JUL
PY 2006
VL 27
SU 1
BP 28
EP 28
PG 1
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 071HI
UT WOS:000239590000165
DA 2018-01-05
ER

PT J
AU Dou, H
   Destache, C
   Mosley, RL
   Boska, M
   Rabinow, B
   Gendelman, H
AF Dou, Huanyu
   Destache, Christopher
   Mosley, R. Lee
   Boska, Michael
   Rabinow, Barett
   Gendelman, Howard
TI A macrophage-based nanoparticle system for drug delivery:
   Pharmacokinetic and anti-viral activities in a murine model of HIV-1
   infection
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Meeting Abstract
C1 Univ Nebraska, Med Ctr, Dep Pharm Exp Neurosci, Lincoln, NE 68583 USA.
   Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68178 USA.
   Univ Nebraska, Med Ctr, Dep Pharm Exp Neurosci, Lincoln, NE 68583 USA.
   Baxter Healthcare Corp, Deerfield, IL 60015 USA.
   Univ Nebraska, Med Ctr, Dep Pharm Exp Neurosci, Lincoln, NE 68583 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD JUL
PY 2006
VL 27
SU 1
BP 272
EP 272
PG 1
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 071HI
UT WOS:000239590002271
DA 2018-01-05
ER

PT J
AU Joshi, KB
   Verma, S
AF Joshi, K. B.
   Verma, Sandeep
TI Ordered self-assembly of a glycine-rich linear and cyclic hexapeptide:
   Contrasting ultrastructural morphologies of fiber growth
SO SUPRAMOLECULAR CHEMISTRY
LA English
DT Article
DE peptide; aggregation; self-assembly; conjugate; ultrastructure
ID IMMUNODEFICIENCY-VIRUS TYPE-1; AMYLOID FIBRIL FORMATION; V3 LOOP;
   STRUCTURAL ELEMENTS; CRYSTAL-STRUCTURE; IN-VITRO; PEPTIDE; PRION; HIV-1;
   AGGREGATION
AB Self-assembly is a widely occurring phenomenon in chemistry and biology, where nanoscopic building blocks are organized to yield well-defined aggregates and supramolecular structures. One such example is ordered protein aggregation, which is primarily driven by hydrogen bonding, hydrophobic interactions and other non-covalent stabilizing factors. This report describes differing ultrastructural morphologies of a cyclic and linear hexapeptide, possessing the same amino acid sequence. Microscopic studies reveal two dissimilar pathways leading to self-assembly: one with spherical pre-fibrillar intermediate, while another one displaying spherulite-like "Maltese-cross patterns. Detailed analysis provides crucial insight into initiation, propagation and growth of peptide fibers in two constructs.
C1 Indian Inst Technol, Dept Chem, Kanpur 208016, Uttar Pradesh, India.
RP Verma, S (reprint author), Indian Inst Technol, Dept Chem, Kanpur 208016, Uttar Pradesh, India.
EM sverma@iitk.ac.in
CR Balbach JJ, 2002, BIOPHYS J, V83, P1205, DOI 10.1016/S0006-3495(02)75244-2                                                   
   BASAK S, 1988, BIOPHYS J, V54, P829, DOI 10.1016/S0006-3495(88)83020-0                                                   
   Catasti P, 1996, J BIOL CHEM, V271, P8236, DOI 10.1074/jbc.271.14.8236                                                         
   Clark TD, 1998, J AM CHEM SOC, V120, P8949, DOI 10.1021/ja981485i                                                               
   Cormier EG, 2002, J VIROL, V76, P8953, DOI 10.1128/JVI.76.17.8953-8957.2002
   Fay N, 2005, J BIOL CHEM, V280, P37149, DOI 10.1074/jbc.M506917200
   GARDNER GC, 1989, J RHEUMATOL, V16, P394
   Gazit E, 2002, BIOINFORMATICS, V18, P880, DOI 10.1093/bioinformatics/18.6.880
   GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253                                                         
   Gibbs AC, 1998, NAT STRUCT BIOL, V5, P284, DOI 10.1038/nsb0498-284
   GUNASEKARAN K, 1995, INT J PEPT PROT RES, V46, P359
   Jin LW, 2003, P NATL ACAD SCI USA, V100, P15294, DOI 10.1073/pnas.2534647100
   Khurana R, 2001, J BIOL CHEM, V276, P22715, DOI 10.1074/jbc.M011499200
   KOBAYASHI K, 1995, ANGEW CHEM INT EDIT, V34, P95, DOI 10.1002/anie.199500951                                                          
   KOSTANSEK EC, 1979, J AM CHEM SOC, V101, P5811, DOI 10.1021/ja00513a057
   Krebs MRH, 2004, P NATL ACAD SCI USA, V101, P14420, DOI 10.1073/pnas.0405933101
   Krishnan R, 2005, NATURE, V435, P765, DOI 10.1038/nature03679
   LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685                                                         
   Lyon RP, 2001, J AM CHEM SOC, V123, P4408, DOI 10.1021/ja0040417
   Madhavaiah C, 2005, BIOORGAN MED CHEM, V13, P3241, DOI 10.1016/j.bmc.2005.02.029
   Madhavaiah C, 2004, CHEM COMMUN, P638, DOI 10.1039/b316793c
   Makin OS, 2005, P NATL ACAD SCI USA, V102, P315, DOI 10.1073/pnas.0406847102
   MCFARLANE KJ, 1996, INT J PEPT PROT RES, V47, P447
   Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680
   Nilsson MR, 2004, METHODS, V34, P151, DOI 10.1016/j.ymeth.2004.03.012
   Petty SA, 2005, P NATL ACAD SCI USA, V102, P14272, DOI 10.1073/pnas.0502804102
   Prasad KK, 2005, CHEM COMMUN, P2564, DOI 10.1039/b500654f
   Ritter C, 2005, NATURE, V435, P844, DOI 10.1038/nature03793
   SIROIS S, 2005, CURR PROTEIN PEPT SC, V6, P415
   Su J, 2001, J HUMAN VIROL, V4, P1
   Su J, 2000, AIDS RES HUM RETROV, V16, P37, DOI 10.1089/088922200309584
   Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348
NR 32
TC 8
Z9 8
U1 1
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-0278
J9 SUPRAMOL CHEM
JI Supramol. Chem.
PD JUL-AUG
PY 2006
VL 18
IS 5
BP 405
EP 414
DI 10.1080/10615800600658875
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA 068OU
UT WOS:000239385100004
DA 2018-01-05
ER

PT J
AU Kondapi, AK
   Satyanarayana, N
   Saikrishna, AD
AF Kondapi, AK
   Satyanarayana, N
   Saikrishna, AD
TI A study of the Topoisomerase II activity in HIV-1 replication using the
   ferrocene derivatives as probes
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE HIV infection; Topoisomerase II alpha; Topoisomerase II beta; proviral
   DNA; organometallic compounds; ferrocene derivatives; ruthenium
   derivatives; Topoisomerase II poisons; anti proliferation; anti-HIV
   activity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE TRANSCRIPTION; RETROVIRAL DNA;
   PREINTEGRATION COMPLEXES; PROVIRAL INTEGRATION; CLEAVAGE SITES; PROTEIN;
   BETA; ALPHA; CELLS
AB Human Topoisomerase 11 is present in two isoforms, 170 KDa alpha and 180 KDa beta. Both the isoforms play a crucial role in maintenance of topological changes during DNA replication and recombination. It has been shown that Topoisomerase 11 activity is required for HIV-1 replication and the enzyme is phosphorylated during early time points of HIV-1 replication. In the present study, we have studied the molecular action of Topoisomerase 11 inhibitors, azalactone ferrocene (AzaFecp), Thiomorpholide amido methyl ferrocene (ThioFecp), and Ruthenium benzene amino pyridine (Ru(ben)Apy) on cell proliferation and also on various events of HIV-1 replication cycle. The Topoisomerase II beta over-expressing neuroblastoma cell line shows a higher sensitivity to these compounds compared to the Sup-T1 cell line. All the three Topoisomerase 11 inhibitors show significant anti-HIV activity at nanomolar concentrations against an Indian isolate of HIV-1(93IN103) in Sup-T1 cell line. An analysis of action of these compounds on proviral DNA synthesis at 5 h of post-infection shows that they inhibit proviral DNA synthesis as well as the formation of pre-integration complexes completely. Further analysis, using polymerase chain reaction and western blot, showed that both the Topoisomerase 11 alpha and beta isoforms are present in the pre-integration complexes, suggesting their significant role in HIV-1 replication. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India.
RP Kondapi, AK (reprint author), Univ Hyderabad, Sch Life Sci, Dept Biochem, Hyderabad 500046, Andhra Pradesh, India.
EM akksl@uohyd.ernet.in
OI A. DIVAKAR, SAI KRISHNA/0000-0003-0232-4052
CR ALLEY MC, 1988, CANCER RES, V48, P589
   BENSON JD, 1990, J VIROL, V64, P9
   BERKHOUT B, 1995, J MOL BIOL, V252, P59, DOI 10.1006/jmbi.1994.0475                                                          
   Bouille P, 1999, J MOL BIOL, V285, P945, DOI 10.1006/jmbi.1998.2360                                                          
   BROWN PO, 1987, CELL, V49, P347, DOI 10.1016/0092-8674(87)90287-X                                                    
   BUKRINSKY M, 1993, P NATL ACAD SCI USA, V93, P6125
   Cartier C, 2003, J BIOL CHEM, V278, P35211, DOI 10.1074/jbc.M301257200
   Cereseto A, 2004, AIDS REV, V6, P13
   COFFIN JM, 1990, VIROLOGY, P645
   COLE SPC, 1986, CANCER CHEMOTH PHARM, V17, P259
   Devroe E, 2005, VIROLOGY, V331, P181, DOI 10.1016/j.virol.2004.10.023
   FARNET CM, 1991, J VIROL, V65, P1910
   FARNET CM, 1990, P NATL ACAD SCI USA, V87, P4164, DOI 10.1073/pnas.87.11.4164
   Farnet CM, 1996, P NATL ACAD SCI USA, V93, P9742, DOI 10.1073/pnas.93.18.9742
   FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2
   Gopal YNV, 2002, ARCH BIOCHEM BIOPHYS, V401, P53
   Gotte M, 1999, ARCH BIOCHEM BIOPHYS, V365, P199, DOI 10.1006/abbi.1999.1209
   Hansen K, 1997, FEBS LETT, V409, P195, DOI 10.1016/S0014-5793(97)00495-X
   HOWARD MT, 1993, J MOL BIOL, V232, P1060, DOI 10.1006/jmbi.1993.1460                                                          
   HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865
   HUANG ES, 1992, ANTIVIR RES, V17, P17, DOI 10.1016/0166-3542(92)90087-L
   Johnson CN, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-68
   Kilzer JM, 2003, VIROLOGY, V314, P460, DOI 10.1016/S0042-6822(03)00455-0
   Kondapi AK, 2005, ARCH BIOCHEM BIOPHYS, V441, P41, DOI 10.1016/j.abb.2005.06.021
   Kondapi AK, 2004, INT J DEV NEUROSCI, V22, P19, DOI 10.1016/j.ijdevneu.2003.10.006
   Kondapi AK, 2002, ANTIVIR RES, V54, P47, DOI 10.1016/S0166-3542(01)00212-1
   Krishna ADS, 2005, ARCH BIOCHEM BIOPHYS, V438, P206, DOI 10.1016/j.abb.2005.04.014
   Kwan KY, 2001, P NATL ACAD SCI USA, V98, P5717, DOI 10.1073/pnas.101132498
   LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0
   LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612
   LU YL, 1993, J VIROL, V67, P6542
   MATHES E, 1990, ANTIVIR RES, V13, P273
   Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775
   Miller MD, 1997, J VIROL, V71, P5382
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Negroni M, 2001, ANNU REV GENET, V35, P275, DOI 10.1146/annurev.genet.35.102401.090551
   Nielsen MH, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-10
   POMMIER Y, 1994, BIOCHEM BIOPH RES CO, V205, P1601, DOI 10.1006/bbrc.1994.2850
   ROHDEWOHLD H, 1987, J VIROL, V61, P336
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   Sandri MI, 1996, BRIT J CANCER, V73, P1518, DOI 10.1038/bjc.1996.286
   SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119
   Sonza S, 1996, J VIROL, V70, P3863
   STEVENSON M, 1990, EMBO J, V9, P1551
   TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350
   Tremblay MJ, 1998, IMMUNOL TODAY, V19, P346, DOI 10.1016/S0167-5699(98)01286-9
   TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177
   Vologodskii AV, 2001, P NATL ACAD SCI USA, V98, P3045, DOI 10.1073/pnas.061029098                                                          
   Warburton PE, 1997, BIOESSAYS, V19, P97, DOI 10.1002/bies.950190203
   Wu Yuntao, 2004, Retrovirology, V1, P13, DOI 10.1186/1742-4690-1-13
   ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L
   Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4
NR 52
TC 32
Z9 32
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JUN 15
PY 2006
VL 450
IS 2
BP 123
EP 132
DI 10.1016/j.abb.2006.04.003
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 057GI
UT WOS:000238583900001
PM 16712776
DA 2018-01-05
ER

PT J
AU Randolph, JT
   Huang, PP
   Flosi, WJ
   DeGoey, D
   Klein, LL
   Yeung, CM
   Flentge, C
   Sun, MG
   Zhao, C
   Dekhtyar, T
   Mo, HM
   Colletti, L
   Kati, W
   Marsh, KC
   Molla, A
   Kempf, DJ
AF Randolph, JT
   Huang, PP
   Flosi, WJ
   DeGoey, D
   Klein, LL
   Yeung, CM
   Flentge, C
   Sun, MG
   Zhao, C
   Dekhtyar, T
   Mo, HM
   Colletti, L
   Kati, W
   Marsh, KC
   Molla, A
   Kempf, DJ
TI Synthesis, antiviral activity, and pharmacokinetic evaluation of P3
   pyridylmethyl analogs of oximinoarylsulfonyl HIV-1 protease inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV; aspartyl protease inhibitors; lopinavir resistant virus;
   peptidomimetic
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LOPINAVIR/RITONAVIR; RITONAVIR; ISOSTERES
AB As a continuation of the recently communicated discovery of oximinoarylsulfonamides as potent inhibitors of HIV-1 aspartyl protease, compounds bearing pyridylmethyl substituents at P3 were designed and synthesized. Potent analogs in this series provided low single-digit nanomolar EC50 values against both wild-type HIV and resistant mutant virus (A17), attenuated some 3- to 12-fold in the presence of 50% human serum. Pharmacokinetic results for compounds in this series showed good to excellent exposure when co-administered orally with an equal amount of ritonavir (5 mg/kg each) in the rat, with average AUC > 8 mu g h/mL. Similar dosing in dog resulted in significantly lower plasma levels (average AUC < 2 mu g h/mL). The 3-pyridylmethyl analog 30 gave the best overall exposure (rat AUC = 7.1 mu g h/mL and dog AUC = 4.9 mu g h/mL), however, this compound was found to be a potent inhibitor of cytochrome P450 3A (K-i = 2.4 nM). (c) 2006 Elsevier Ltd. All rights reserved.
C1 Abbott Labs, Global Pharmaceut Res & Dev, Dept R4CR, Infect Dis Res, Abbott Pk, IL 60064 USA.
RP Randolph, JT (reprint author), Abbott Labs, Global Pharmaceut Res & Dev, Dept R4CR, Infect Dis Res, Bldg AP52N,200 Abbott Pk Rd, Abbott Pk, IL 60064 USA.
EM john.randolph@abbott.com
CR COOPER CL, 2003, CLIN INFECT DIS, V36, P1582
   Corbett AH, 2002, ANN PHARMACOTHER, V36, P1193
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004                                                
   de Mendoza C, 2004, CURR DRUG METAB, V5, P321
   FLENTGE C, UNPUB
   Ghosh AK, 1998, J ORG CHEM, V63, P6146, DOI 10.1021/jo980159i                                                               
   Kempf DJ, 1998, J MED CHEM, V41, P602, DOI 10.1021/jm970636+
   Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P902
   Mo HM, 2003, ANTIVIR RES, V59, P173, DOI 10.1016/S0166-3542(03)00107-4
   Molla A, 1998, VIROLOGY, V250, P255, DOI 10.1006/viro.1998.9383
   OGDEN R, 2003, INFECT DIS THER, V30, P523
   Qazi Nadeem A, 2002, Expert Opin Pharmacother, V3, P315, DOI 10.1517/14656566.3.3.315
   Randolph JT, 2004, CURR TOP MED CHEM, V4, P1079, DOI 10.2174/1568026043388330                                                        
   RICH DH, 1991, J MED CHEM, V34, P1222, DOI 10.1021/jm00107a049                                                             
   Sham HL, 2002, BIOORG MED CHEM LETT, V12, P1185, DOI 10.1016/S0960-894X(02)00134-8                                                   
   Velazquez-Campoy Adrian, 2003, Current Drug Targets - Infectious Disorders, V3, P311, DOI 10.2174/1568005033481051
   Walmsley Sharon, 2003, Expert Rev Anti Infect Ther, V1, P389, DOI 10.1586/14787210.1.3.389
   Walsky RL, 2004, DRUG METAB DISPOS, V32, P647, DOI 10.1124/dmd.32.6.647
   Yeung CM, 2005, BIOORG MED CHEM LETT, V15, P2275, DOI 10.1016/j.bmcl.2005.03.008
   CIECIUCH RFW, Patent No. 4098783
NR 21
TC 10
Z9 11
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUN 15
PY 2006
VL 14
IS 12
BP 4035
EP 4046
DI 10.1016/j.bmc.2006.02.013
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 045SZ
UT WOS:000237763900005
PM 16504523
DA 2018-01-05
ER

PT J
AU Nydegger, S
   Khurana, S
   Krementsov, DN
   Foti, M
   Thali, M
AF Nydegger, Sascha
   Khurana, Sandhya
   Krementsov, Dimitry N.
   Foti, Michelangelo
   Thali, Markus
TI Mapping of tetraspanin-enriched microdomains that can function as
   gateways for HIV-1
SO JOURNAL OF CELL BIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; LIPID RAFTS; MEMBRANE-PROTEINS;
   PLASMA-MEMBRANE; COMPLEXES; CELLS; GAG; SURFACE; TSG101; FUSION
AB Specific spatial arrangements of proteins and lipids are central to the coordination of many biological processes. Tetraspanins have been proposed to laterally organize cellular membranes via specific associations with each other and with distinct integrins. Here, we reveal the presence of tetraspanin-enriched microdomains (TEMs) containing the tetraspanins CD9, CD63, CD81, and CD82 at the plasma membrane. Fluorescence and immunoelectron microscopic analyses document that the surface of HeLa cells is covered by several hundred TEMs, each extending over a few hundred nanometers and containing predominantly two or more tetraspanins. Further, we reveal that the human immunodeficiency virus type 1 (HIV-1) Gag protein, which directs viral assembly and release, accumulates at surface TEMs together with the HIV-1 envelope glycoprotein. TSG101 and VPS28, components of the mammalian ESCRT1 (endosomal sorting complex required for transport), which is part of the cellular extravesiculation machinery critical for HIV-1 budding, are also recruited to cell surface TEMs upon virus expression, suggesting that HIV-1 egress can be gated through these newly mapped microdomains.
C1 Univ Vermont, Grad Program Microbiol & Mol Genet, Burlington, VT 05405 USA.
   Univ Vermont, Grad Program Cellular & Mol Biol, Burlington, VT 05405 USA.
   Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA.
   Univ Geneva, Dept Cellular Physiol & Metab, CH-1211 Geneva, Switzerland.
RP Thali, M (reprint author), Univ Vermont, Grad Program Microbiol & Mol Genet, Burlington, VT 05405 USA.
EM markus.thali@uvm.edu
OI Krementsov, Dimitry/0000-0003-2709-7466
FU NCRR NIH HHS [P20 RR021905]; NIAID NIH HHS [R03 AI 060679, R03 AI060679,
   R01 AI 47727, R01 AI047727]
CR AZORSA DO, 1991, BLOOD, V78, P280
   Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595                                                          
   Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477
   Berditchevski F, 2001, J CELL SCI, V114, P4143
   Blot G, 2003, J VIROL, V77, P6931, DOI 10.1128/JVI.77.12.6931-6945.2003
   Charrin S, 2003, BIOCHEM BIOPH RES CO, V304, P107, DOI 10.1016/S0006-291X(03)00545-X
   Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899                                                          
   Ding LM, 2003, J VIROL, V77, P1916, DOI 10.1128/JVI.77.3.1916-1926.2003
   Edidin M, 2003, ANNU REV BIOPH BIOM, V32, P257, DOI 10.1146/annurev.biophys.32.110601.142439
   Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121                                                        
   Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100
   Foti M, 1997, J CELL BIOL, V139, P37, DOI 10.1083/jcb.139.1.37
   Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737                                                           
   Gaietta G, 2002, SCIENCE, V296, P503, DOI 10.1126/science.1068793
   Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2                                                   
   GERLICH, 2003, NAT CELL BIOL S, V5, pS14
   Gluschankof P, 1997, VIROLOGY, V230, P125, DOI 10.1006/viro.1997.8453
   Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Hess ST, 2005, J CELL BIOL, V169, P965, DOI 10.1083/jcb.200412058
   Ihrke G, 2004, TRAFFIC, V5, P946, DOI 10.1111/j.1600-0854.2004.00236.x
   Jaiswal JK, 2004, PLOS BIOL, V2, P1224, DOI 10.1371/journal.pbio.0020233
   Janvier K, 2005, MOL BIOL CELL, V16, P4231, DOI 10.1091/mbc.E05-03-0213
   Jolly C, 2004, J EXP MED, V199, P283, DOI 10.1084/jem.20030648
   Kobayashi T, 2000, MOL BIOL CELL, V11, P1829, DOI 10.1091/mbc.11.5.1829                                                           
   Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548
   Lindwasser OW, 2004, J VIROL, V78, P6013, DOI 10.1128/JVI.78.11.6013-6023.2004
   Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001
   Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201
   Martin-Serrano J, 2003, J VIROL, V77, P4794, DOI 10.1128/JVI.77.8.4794-4804.2003
   Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313                                                             
   Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350
   Mukherjee S, 2004, ANNU REV CELL DEV BI, V20, P839, DOI 10.1146/annurev.cellbio.20.010403.095451
   Murk JLAN, 2003, P NATL ACAD SCI USA, V100, P13332, DOI 10.1073/pnas.2232379100
   Murray JL, 2005, J VIROL, V79, P11742, DOI 10.1128/JVI.79.18.11742-11751.2005
   Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000                                                 
   Nydegger S, 2003, TRAFFIC, V4, P902, DOI 10.1046/j.1600-0854.2003.00145.x
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   ORENTAS RJ, 1993, AIDS RES HUM RETROV, V9, P1157, DOI 10.1089/aid.1993.9.1157                                                         
   Ott DE, 2002, REV MED VIROL, V12, P359, DOI 10.1002/rmv.367
   Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008
   PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001
   Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x                                                
   RODRIGUEZBOULAN E, 1983, J CELL BIOL, V96, P866, DOI 10.1083/jcb.96.3.866                                                            
   Rous BA, 2002, MOL BIOL CELL, V13, P1071, DOI 10.1091/mbc.01-08-0409
   Rousso I, 2000, P NATL ACAD SCI USA, V97, P13523, DOI 10.1073/pnas.240459697                                                          
   Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117                                                          
   Rudner L, 2005, J VIROL, V79, P4055, DOI 10.1128/JVI.79.7.4055-4065.2005
   SANAN DA, 1991, J HISTOCHEM CYTOCHEM, V39, P1017, DOI 10.1177/39.8.1906908                                                            
   Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1                                                             
   Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2                                                   
   Takeda M, 2003, P NATL ACAD SCI USA, V100, P14610, DOI 10.1073/pnas.22356210100
   Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011
   VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198
   Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x
   Yang XW, 2004, J CELL BIOL, V167, P1231, DOI 10.1083/jcb.200404100
NR 58
TC 149
Z9 153
U1 0
U2 8
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0021-9525
J9 J CELL BIOL
JI J. Cell Biol.
PD JUN 5
PY 2006
VL 173
IS 5
BP 795
EP 807
DI 10.1083/jcb.200508165
PG 13
WC Cell Biology
SC Cell Biology
GA 050AL
UT WOS:000238059800015
PM 16735575
OA gold
DA 2018-01-05
ER

PT J
AU Lu, SW
   Tager, LA
   Chitale, S
   Riley, LW
AF Lu, SW
   Tager, LA
   Chitale, S
   Riley, LW
TI A cell-penetrating peptide derived from mammalian cell uptake protein of
   Mycobacterium tuberculosis
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE McelA; Mycobacterium tuberculosis; cytoskeletal rearrangement; colloidal
   gold; cell-penetrating peptides; nonviral delivery system
ID HUMAN IMMUNODEFICIENCY VIRUS; INTERCELLULAR TRAFFICKING; INTRACELLULAR
   DELIVERY; TRANSPORTAN; MEMBRANES; ENTRY
AB A Mycobacterium tuberculosis membrane protein called Mycobacterium cell entry protein (Mce1A) was previously shown to mediate the uptake of nonpathogenic Escherichia coli and latex beads by nonphagocytic mammalian cells. Here we characterize further the in vitro invasive activity of Mce1A using colloidal gold nanoparticles and fluorescent latex microspheres. Mce1A-coated colloidal gold particles induced plasma membrane invagination and entered membrane-bound compartments inside HeLa cells. Few of the protein-coated particles were also found in the cytosol compartment. Cytochalasin D and nocodazole inhibited the uptake by HeLa cells, indicating that rearrangement of both microtubules and microfilaments was necessary for the uptake. The functional domain of Mce1A for invasion was narrowed to a highly basic 22-amino acid sequence termed NO. A synthetic Inv3 peptide stimulated uptake of colloidal gold particles as well as latex microspheres by HeLa cells. A chimeric protein composed of Inv3 sequence Lit the N terminus of beta-galactosidase appeared to stain the nuclear membrane, suggesting that it entered the HeLa cell cytoplasm. These observations suggest that the cell uptake activity of Mce1A is confined to a small peptide domain located in the core region of the protein. Inv3 could be used to ferry any protein in fusion with it into mammalian cells and may serve as a potent nonviral delivery system. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Berkeley, CA 94720 USA.
   NYU, Off Technol, New York, NY 10012 USA.
RP Riley, LW (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Berkeley, CA 94720 USA.
EM lwriley@berkeley.edu
FU NIAID NIH HHS [AI35622]
CR ARRUDA S, 1993, SCIENCE, V261, P1454, DOI 10.1126/science.8367727
   Ausubel F.M., 1994, CURRENT PROTOCOLS MO
   BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61
   Casali N, 2002, INFECT IMMUN, V70, P6846, DOI 10.1128/IAI.70.12.6846-6852.2002
   Chitale S, 2001, CELL MICROBIOL, V3, P247, DOI 10.1046/j.1462-5822.2001.00110.x
   Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gupta B, 2005, ADV DRUG DELIVER REV, V57, P637, DOI 10.1016/j.addr.2004.10.007
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Oehlke J, 1997, BBA-BIOMEMBRANES, V1330, P50, DOI 10.1016/S0005-2736(97)00141-7
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M, 1998, ANN NY ACAD SCI, V863, P450, DOI 10.1111/j.1749-6632.1998.tb10721.x
   RYSER HJP, 1978, LIFE SCI, V22, P1253, DOI 10.1016/0024-3205(78)90094-2                                                    
   Sambrook J, 1989, MOL CLONING LAB MANU
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   SEGREST JP, 1991, PROTEINS, V9, P79
   SHEN WC, 1978, P NATL ACAD SCI USA, V75, P1872, DOI 10.1073/pnas.75.4.1872
   SHEPARD CC, 1955, P SOC EXP BIOL MED, V90, P392
   Singh D, 1998, BIOCHEMISTRY-US, V37, P5798, DOI 10.1021/bi972762l
NR 26
TC 19
Z9 23
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD JUN 1
PY 2006
VL 353
IS 1
BP 7
EP 14
DI 10.1016/j.ab.2006.01.044
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 047CF
UT WOS:000237856700002
PM 16620748
DA 2018-01-05
ER

PT J
AU Ford, SL
   Reddy, YS
   Anderson, MT
   Murray, SC
   Fernandez, P
   Stein, DS
   Johnson, MA
AF Ford, SL
   Reddy, YS
   Anderson, MT
   Murray, SC
   Fernandez, P
   Stein, DS
   Johnson, MA
TI Single-dose safety and pharmacokinetics of brecanavir, a novel human
   immunodeficiency virus protease inhibitor
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID RITONAVIR; TPGS
AB Brecanavir (BCV, 640385) is a novel, potent protease inhibitor (PI) with low nanomolar 50% inhibitory concentrations against PI-resistant human immunodeficiency virus (HIV) in vitro. This phase I, double-blind, randomized, placebo-controlled, two-part single-dose study (first time with humans) was conducted to determine the safety, tolerability, and pharmacokinetics of BCV administered at 10 mg/ml in a tocopherol-polyethylene glycol succinate-polyethylene glycol 400-ethanol 50:40:10 solution. In part I of the study, single oral doses of BCV ranged from 25 mg to 800 mg. In part 2, single oral doses of BCV ranged from 10 mg to 300 mg and were coadministered with 100-mg oral ritonavir (RTV) soft gel capsules. Single doses of BCV and BCV/RTV were generally well tolerated. There were no severe adverse events (SAEs), and no subject was withdrawn due to BCV. The most commonly reported drug-related AEs during both parts of the study combined were gastrointestinal disturbances (similar to placebo) and headache. BCV was readily absorbed following oral administration with mean times to maximum concentration from > 1 h to 2.5 h in part 1 and from 1.5 h to 3 h in part 2. Administration of BCV without RTV resulted in BCV exposures predicted to be insufficient to inhibit PI-resistant virus based on in vitro data. Coadministration of 300 mg BCV with 100 mg RTV, however, significantly increased the plasma BCV area under the concentration-time curve and maximum concentration 26-fold and 11-fold, respectively, achieving BCV concentrations predicted to inhibit PI-resistant HIV.
C1 GlaxoSmithKline Inc, Div Clin Pharmacokinet, Res Triangle Pk, NC 27709 USA.
   Sanofi Aventis Pharmaceut, Bridgewater, NJ USA.
RP Ford, SL (reprint author), GlaxoSmithKline Inc, Div Clin Pharmacokinet, Res Triangle Pk, NC 27709 USA.
EM susan.l.ford@gsk.com
CR *ABB LAB, 2003, KAL PROD INF
   *AG PHARM, 2004, VIR PROD INF
   Boffito M, 2002, BRIT J CLIN PHARMACO, V54, P262, DOI 10.1046/j.1365-2125.2002.01663.x
   Casado JL, 2003, AIDS, V17, P262, DOI 10.1097/01.aids.0000050800.28043.4d
   Clotet B, 2004, AIDS, V18, P1137, DOI 10.1097/01.aids.0000125946.88690.5e
   Dintaman JM, 1999, PHARMACEUT RES, V16, P1550, DOI 10.1023/A:1015000503629
   Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808                                                     
   *GLAXOSMITHKLINE, 2004, LEX PROD INF
   Hugen PWH, 2000, J ACQ IMMUN DEF SYND, V25, P236, DOI 10.1097/00126334-200011010-00005
   Kempf DJ, 1997, ANTIMICROB AGENTS CH, V41, P654
   Kumar GN, 1996, J PHARMACOL EXP THER, V277, P423
   Kurowski M, 2002, CLIN PHARMACOL THER, V72, P123, DOI 10.1067/mcp.2002.126178
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218
   Yeh KC, 1999, J PHARM SCI, V88, P568, DOI 10.1021/js9802392
   Yu L, 1999, PHARMACEUT RES, V16, P1812, DOI 10.1023/A:1018939006780                                                         
NR 15
TC 14
Z9 14
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2006
VL 50
IS 6
BP 2201
EP 2206
DI 10.1128/AAC.01490-05
PG 6
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 048FE
UT WOS:000237932200040
PM 16723584
OA gold
DA 2018-01-05
ER

PT J
AU Blanchette, CD
   Lin, WC
   Ratto, TV
   Longo, ML
AF Blanchette, CD
   Lin, WC
   Ratto, TV
   Longo, ML
TI Galactosylceramide domain microstructure: Impact of cholesterol and
   nucleation/growth conditions
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID ATOMIC-FORCE MICROSCOPY; FLUORESCENCE CORRELATION SPECTROSCOPY;
   HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN GP120; SUPPORTED
   LIPID-BILAYERS; BIOLOGICAL-MEMBRANES; PHASE-SEPARATION;
   EPITHELIAL-CELLS; UNILAMELLAR VESICLES; PLASMA-MEMBRANES
AB Galactosylceramide ( GalCer), a glycosphingolipid, is believed to exist in the extracellular lea. et of cell membranes in nanometer-sized domains or rafts. The local clustering of GalCer within rafts is thought to facilitate the initial adhesion of certain viruses, including HIV-1, and bacteria to cells through multivalent interactions between receptor proteins ( gp120 for HIV-1) and GalCer. Here we use atomic force microscopy ( AFM) to study the effects of cholesterol on solid-phase GalCer domain microstructure and miscibility with a fluid lipid 1,2-dilauroyl-sn-glycero-3-phosphocholine ( DLPC) in supported lipid bilayers. Using "slow-cooled vesicle fusion'' to prepare the supported lipid bilayers, we were able to overcome the nonequilibrium effects of the substrate ( verified by comparison to results for giant unilamellar vesicles) and accurately quantify the dramatic effect of cholesterol on the GalCer domain surface area/perimeter ratio ( AD/P) and DLPC-GalCer miscibility. We compare these results to a supported lipid bilayer system in which the bilayer is rapidly cooled ( nonequilibrium conditions), "quenched vesicle fusion'', and find that the microstructures are remarkably similar above a cholesterol mol fraction of similar to 0.06. We determined that GalCer domains were contained in one lea. et distal to the mica substrate through qualitative binding experiments with Trichosanthes kirilowii agglutinin ( TKA), a galactose-specific lectin, and AFM of Langmuir-Blodgett deposited GalCer/DLPC supported lipid bilayers. In addition, GalCer domains in bilayers containing cholesterol rearranged upon tip-sample contact. Our results further serve to clarify why discrepancies exist between different model membrane systems and between model membranes and cell membranes. In addition, these results offer new insight into the effect of cholesterol and surrounding lipid on domain microstructure and behavior. Finally, our observations may be pertinent to cell membrane structure, dynamics, and HIV infection.
C1 Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA.
   Univ Calif Davis, Div Biol Sci, Biophys Grad Grp, Davis, CA 95616 USA.
   Lawrence Livermore Natl Lab, Biophys & Interfacial Sci Grp, Livermore, CA 94550 USA.
RP Longo, ML (reprint author), Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA.
EM mllongo@ucdavis.edu
RI Lin, Wan-Chen/A-4348-2009
CR Akimov SA, 2004, J ELECTROANAL CHEM, V564, P13, DOI 10.1016/j.jelechem.2003.10.030
   ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127
   Arnulphi C, 2005, BIOPHYS J, V89, P285, DOI 10.1529/biophysj.104.047480
   Bagatolli LA, 2000, BIOPHYS J, V78, P290, DOI 10.1016/S0006-3495(00)76592-1                                                   
   Bagatolli LA, 2000, BIOPHYS J, V79, P434, DOI 10.1016/S0006-3495(00)76305-3                                                   
   BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131
   Blanchette C. D., 2006, CELLULAR ENG, P195
   Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111
   Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575
   BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J
   Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397
   Chiang YW, 2004, BIOPHYS J, V87, P2483, DOI 10.1529/biophysj.104.044438
   Clapham PR, 1996, PERSPECT DRUG DISCOV, V5, P83, DOI 10.1007/BF02174004                                                              
   de Almeida RFM, 2002, BIOPHYS J, V82, P823, DOI 10.1016/S0006-3495(02)75444-1                                                   
   FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700
   Fantini J, 2000, GLYCOCONJUGATE J, V17, P173, DOI 10.1023/A:1026580905156
   Feigenson GW, 2001, BIOPHYS J, V80, P2775, DOI 10.1016/S0006-3495(01)76245-5                                                   
   Gadella BM, 1998, J REPROD IMMUNOL, V41, P233, DOI 10.1016/S0165-0378(98)00061-8
   Giocondi MC, 2001, LANGMUIR, V17, P1653, DOI 10.1021/la0012135
   HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969
   Hollars CW, 1998, BIOPHYS J, V75, P342, DOI 10.1016/S0006-3495(98)77518-6                                                   
   Hwang J, 1998, BIOPHYS J, V74, P2184, DOI 10.1016/S0006-3495(98)77927-5                                                   
   Johnson JM, 2002, BIOPHYS J, V83, P3371, DOI 10.1016/S0006-3495(02)75337-X                                                   
   JORGENSEN K, 1995, BIOPHYS J, V69, P942, DOI 10.1016/S0006-3495(95)79968-4                                                   
   Jorgensen K, 2000, J PHYS CHEM B, V104, P11763, DOI 10.1021/jp001801r
   Keller CA, 2000, PHYS REV LETT, V84, P5443, DOI 10.1103/PhysRevLett.84.5443                                                     
   Keller CA, 1998, BIOPHYS J, V75, P1397, DOI 10.1016/S0006-3495(98)74057-3                                                   
   Korlach J, 2005, BBA-BIOMEMBRANES, V1668, P158, DOI 10.1016/j.bbamem.2004.11.016
   Korlach J, 1999, P NATL ACAD SCI USA, V96, P8461, DOI 10.1073/pnas.96.15.8461
   Kuzmin PI, 2005, BIOPHYS J, V88, P1120, DOI 10.1529/biophysj.104.048223
   Lin WC, 2006, BIOPHYS J, V90, P228, DOI 10.1529/biophysj.105.067066
   LUNDKATZ S, 1988, BIOCHEMISTRY-US, V27, P3416, DOI 10.1021/bi00409a044
   Malewicz B, 2005, BIOPHYS J, V88, P2670, DOI 10.1529/biophysj.104.057059
   Mattjus P, 2002, J BIOL CHEM, V277, P19476, DOI 10.1074/jbc.M201305200
   MERKEL R, 1989, J PHYS-PARIS, V50, P1535, DOI 10.1051/jphys:0198900500120153500
   Milhiet PE, 2002, J BIOL CHEM, V277, P875, DOI 10.1074/jbc.C100654200
   Nag K, 2002, BIOPHYS J, V82, P2041, DOI 10.1016/S0006-3495(02)75552-5                                                   
   NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9                                                   
   NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4                                                   
   PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X
   Ratto TV, 2002, BIOPHYS J, V83, P3380, DOI 10.1016/S0006-3495(02)75338-1                                                   
   Reviakine I, 2000, LANGMUIR, V16, P1806, DOI 10.1021/la9903043                                                               
   Shoemaker SD, 2003, BIOPHYS J, V84, P998, DOI 10.1016/S0006-3495(03)74916-9                                                   
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001
   SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720
   SLOTTE JP, 1993, BIOCHEMISTRY-US, V32, P7886, DOI 10.1021/bi00082a008
   Stottrup BL, 2004, BIOPHYS J, V86, P2942, DOI 10.1016/S0006-3495(04)74345-3
   THOMPSON TE, 1985, ANNU REV BIOPHYS BIO, V14, P361, DOI 10.1146/annurev.biophys.14.1.361
   Tokumasu F, 2004, LANGMUIR, V20, P614, DOI 10.1021/la0355388
   Tokumasu F, 2003, BIOPHYS J, V84, P2609, DOI 10.1016/S0006-3495(03)75066-8                                                   
   Veatch SL, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.148101
   Veatch SL, 2003, BIOPHYS J, V85, P3074, DOI 10.1016/S0006-3495(03)74726-2                                                   
   Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101
   YAHI N, 1994, J BIOL CHEM, V269, P24349
   Yuan CB, 2001, BIOPHYS J, V81, P1059, DOI 10.1016/S0006-3495(01)75763-3                                                   
NR 56
TC 52
Z9 52
U1 4
U2 17
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD JUN
PY 2006
VL 90
IS 12
BP 4466
EP 4478
DI 10.1529/biophysj.105.072744
PG 13
WC Biophysics
SC Biophysics
GA 048EX
UT WOS:000237931500017
PM 16565044
OA gold
DA 2018-01-05
ER

PT J
AU Lundberg, P
   Langel, U
AF Lundberg, P
   Langel, U
TI Uptake mechanisms of cell-penetrating peptides derived from the
   Alzheimer's disease associated gamma-secretase complex
SO INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS
LA English
DT Article
DE cell-penetrating peptide; CPP; internalization; endocytosis; Alzheimer's
   disease; gamma-secretase
ID ARGININE-RICH PEPTIDES; HUMAN IMMUNODEFICIENCY VIRUS; TAT PROTEIN;
   FLUID-PHASE; MEMBRANE TRANSLOCATION; METABOLIC-INHIBITORS; FUNCTIONAL
   DOMAINS; LOW-TEMPERATURE; PRESENILIN; ENDOCYTOSIS
AB Basic peptides with vector abilities, so called cell-penetrating peptides (CPPs), have been reported to enter cells, carrying cargoes ranging from oligonucleotides and proteins to nanoparticles. In this study we present novel CPPs derived from the gamma-secretase complex, which is involved in the amyloidogenic processing of the amyloid precursor protein (APP) and one of the major research targets for Alzheimer's disease therapeutics today. In order to examine the uptake efficiency and internalization mechanism of these novel CPPs, side-by-side comparison with the well characterized CPPs penetratin and tat were made. For assessment of the CPP uptake mechanism, endocytosis inhibitors, endosomal markers and cells deficient in the expression of glycosaminoglycans were used. Also, in order to determine the vector ability of the peptides, protein delivery was quantified. We demonstrate the uptake of the gamma-secretase derived CPPs, in accordance to penetratin and tat, to be largely dependent on temperature and initial binding to cell-surface glycosaminoglycans. After this initial step, there is a discrepancy in the mechanism of uptake, where all peptides, except one, is taken up by a PI 3-kinase dependent fluid phase endocytosis, which could be inhibited by wortmannin. Also, by using endosomal markers and protein delivery efficacy, we conclude that the pathway of internalization for different CPPs could determine the possible cargo size for which they can be used as a vector. The, in this study demonstrated, cell-penetrating properties of the gamma-secretase constituents could prove to be of importance for the gamma-secretase function, which is a matter of further investigation.
C1 Stockholm Univ, Dept Neurochem, S-10691 Stockholm, Sweden.
RP Lundberg, P (reprint author), Stockholm Univ, Dept Neurochem, Svante Arrhenius Vag 21A, S-10691 Stockholm, Sweden.
EM pontus@neurochem.su.se
CR ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249
   Backer Jonathan M., 2000, Molecular Cell Biology Research Communications, V3, P193, DOI 10.1006/mcbr.2000.0202
   Bellette BM, 2003, IMMUNOLOGY, V110, P466, DOI 10.1046/j.1365-2567.2003.01759.x
   BERGMAN A, 2004, J BIOL CHEM, V280, P35352
   Cervantes S, 2004, J BIOL CHEM, V279, P36519, DOI 10.1074/jbc.M404832200
   CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U                                                    
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   DUNN WA, 1980, J BIOL CHEM, V255, P5971
   ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197
   ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695                                                           
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hallbrink M, 2005, INT J PEPT RES THER, V11, P249, DOI 10.1007/s10989-005-9393-1
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031                                                               
   Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100
   Laudon H, 2004, J BIOL CHEM, V279, P23925, DOI 10.1074/jbc.M401277200
   Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940
   Li EG, 1998, J VIROL, V72, P2055
   Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7
   LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267                                                          
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630
   Lundberg P, 2002, BIOCHEM BIOPH RES CO, V299, P85, DOI 10.1016/S0006-291X(02)02595-0
   Nakase I, 2004, MOL THER, V10, P1011, DOI 10.1016/j.ymthe.2004.08.010
   PATTERSON S, 1983, J GEN VIROL, V64, P1091, DOI 10.1099/0022-1317-64-5-1091
   PRATTEN MK, 1979, BIOCHEM J, V180, P567, DOI 10.1042/bj1800567                                                               
   Prochiantz A, 2003, NAT REV MOL CELL BIO, V4, P814, DOI 10.1038/nrm1227
   Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x                                              
   Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rosenbluh J, 2005, J MOL BIOL, V345, P387, DOI 10.1016/j.jmb.2004.10.046
   Simeoni F, 2003, NUCLEIC ACIDS RES, V31, P2717, DOI 10.1093/nar/gkg385
   STEELEMORTIMER O, 2000, TRAFFIC1107118
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415                                                        
   Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731
NR 46
TC 13
Z9 13
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1573-3149
J9 INT J PEPT RES THER
JI Int. J. Pept. Res. Ther.
PD JUN
PY 2006
VL 12
IS 2
BP 105
EP 114
DI 10.1007/s10989-005-9007-y
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 056UM
UT WOS:000238550600002
DA 2018-01-05
ER

PT J
AU Kinman, L
   Bui, T
   Larsen, K
   Tsai, CC
   Anderson, D
   Morton, WR
   Hu, SL
   Ho, RJY
AF Kinman, L
   Bui, T
   Larsen, K
   Tsai, CC
   Anderson, D
   Morton, WR
   Hu, SL
   Ho, RJY
TI Optimization of lipid-indinavir complexes for localization in lymphoid
   tissues of HIV-infected macaques
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE antiretroviral therapy; HIV-1; HIV-2; lipid-associated drug; protease
   macaque model
ID IMMUNODEFICIENCY-VIRUS-INFECTION; ANTIRETROVIRAL THERAPY; NUCLEOSIDE
   ANALOGS; VIRAL LOAD; REPLICATION; CELL; SUPPRESSION; RESERVOIRS;
   REDUCTION; MORTALITY
AB In HIV-infected persons on highly active antiretroviral therapy, residual virus is found in lymphoid tissues. Indinavir concentrations in lymph node mononuclear cells of patients on highly active antiretroviral therapy were approximately 25% to 35% of those in blood mononuclear cells, suggesting that drug insufficiency contributes to residual virus in lymphoid tissues. Therefore, we developed novel lipid-indinavir nanoparticles targeted to lymphoid tissues. Given subcutaneously, these nanoparticles provided indinavir concentrations 250% to 2270% higher than plasma indinavir concentrations in both peripheral and visceral lymph nodes. Improved indinavir delivery was reflected in reduced viral RNA and CD4(+) T-cell rebound. This study optimized lipid nanoparticle formulation with respect to indinavir in lymphoid tissues of HIV-infected macaques. Regardless of lipid characteristic tested (charge, fluidity, and steric modification), indinavir binds completely to lipid at pH 7.4 but is reversed at pH 5.5 or lower. Compared with previous formulations, nanoparticles composed of disteroyl phosphatidylcholine and methyl polyethylene glycoldisteroyl phosphatidylethanolamine (DSPC:mPEG-DSPE) provided 6-fold higher indinavir levels in lymph nodes and enhanced drug exposure in blood. Enhanced anti-HIV activity paralleled improved intracellular drug accumulation. Collectively, these data suggest that indinavir nanoparticles composed of DSPC:mPEG-DSPE provided the most effective lymphoid delivery and could maximally suppress the virus in lymphoid tissues.
C1 Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA.
   Univ Washington, Reg Primate Res Ctr, Seattle, WA 98195 USA.
RP Ho, RJY (reprint author), Univ Washington, Dept Pharmaceut, Box 357610, Seattle, WA 98195 USA.
EM rodneyho@u.washington.edu
RI Hu, Shiu-Lok/A-3196-2008
OI Hu, Shiu-Lok/0000-0003-4336-7964
FU NIAID NIH HHS [AI52663]; NIEHS NIH HHS [ES07033]; NIGMS NIH HHS [GM
   62883]; NINDS NIH HHS [NS 39178]; NHLBI NIH HHS [HL56548]; NCRR NIH HHS
   [RR00166]
CR Brodie SJ, 2000, J LEUKOCYTE BIOL, V68, P351
   Brodie SJ, 2000, J CLIN INVEST, V105, P1407, DOI 10.1172/JCI8707
   Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Ho RJY, 1996, J MED PRIMATOL, V25, P218, DOI 10.1111/j.1600-0684.1996.tb00019.x                                              
   Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545                                                         
   Kinman L, 2003, JAIDS-J ACQ IMM DEF, V34, P387, DOI 10.1097/00126334-200312010-00005
   Oussoren C, 2001, ADV DRUG DELIVER REV, V50, P143, DOI 10.1016/S0169-409X(01)00154-5
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Ruiz L, 1999, AIDS, V13, pF1, DOI 10.1097/00002030-199901140-00001                                                
   Solas C, 2003, ANTIMICROB AGENTS CH, V47, P238, DOI 10.1128/AAC.47.1.238-243.2003
   Vittinghoff E, 1999, J INFECT DIS, V179, P717, DOI 10.1086/314623
   Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
NR 14
TC 32
Z9 32
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN
PY 2006
VL 42
IS 2
BP 155
EP 161
DI 10.1097/01.qai.0000214822.33905.87                                      
          
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 047WZ
UT WOS:000237910700004
PM 16760797
OA gold
DA 2018-01-05
ER

PT J
AU Vogt, A
   Combadiere, B
   Hadam, S
   Stieler, KM
   Lademann, J
   Schaefer, H
   Autran, B
   Sterry, W
   Blume-Peytavi, U
AF Vogt, Annika
   Combadiere, Behazine
   Hadam, Sabrina
   Stieler, Karola M.
   Lademann, Juergen
   Schaefer, Hans
   Autran, Brigitte
   Sterry, Wolfram
   Blume-Peytavi, Ulrike
TI 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+
   cells after transcutaneous application on human skin
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID LANGERHANS CELLS; DENDRITIC CELLS; FOLLICULAR PENETRATION;
   HAIR-FOLLICLES; DELIVERY; VACCINE; MICROSPHERES; IMMUNIZATION;
   ACTIVATION; ANTIGENS
AB Although conventional vaccines have generated major successes in the control of infectious diseases, several obstacles remain in their development against chronic diseases (HIV, tuberculosis), against which no current candidate vaccines yet ensure protection. The transcutaneous route of vaccine administration appears to be a promising approach of targeting vaccines toward antigen-presenting cells (APCs) and thus improving immune responses. We investigated the suitability of nanoparticles in this approach. We found a high density of Langerhans cells (LCs) around hair follicles that, when sorted, readily internalized all size particles. However, flow cytometry after transcutaneous application of 40, 750, or 1,500 nm nanoparticles on human skin samples revealed that only 40 nm particles entered epidermal LC. Fluorescence and laser scan microscopies, which were carried out to identify the penetration pathway of transcutaneously applied nanoparticles, revealed that only 40 nm particles deeply penetrate into vellus hair openings and through the follicular epithelium. We conclude that 40 nm nanoparticles, but not 750 or 1,500 nm nanoparticles, may be efficiently used to transcutaneously deliver vaccine compounds via the hair follicle into cutaneous APCs.
C1 Charite Univ Med Berlin, Clin Res Ctr Hair & Skin Physiol, Dept Dermatol & Allergy, Berlin, Germany.
   Univ Paris 06, Hop Pitie Salpetriere, Lab Immunol Cellulaire & Tissulaire, Paris, France.
RP Vogt, A (reprint author), Charite Univ Med Berlin, Clin Res Ctr Hair & Skin Physiol, Dept Dermatol & Allergy, Berlin, Germany.
EM annika.vogt@charite.de
RI Combadiere, Behazine/G-3881-2013
CR CHOY MJ, 2003, SKIN PHARMACOL APPL, V16, P271
   Christoph T, 2000, BRIT J DERMATOL, V142, P862, DOI 10.1046/j.1365-2133.2000.03464.x
   Glenn GM, 2000, NAT MED, V6, P1403, DOI 10.1038/82225
   Guebre-Xabier M, 2003, J VIROL, V77, P5218, DOI 10.1128/JVI.77.9.5218-5225.2003
   Katoh N, 1997, ACTA DERM-VENEREOL, V77, P365
   Kenney RT, 2004, NEW ENGL J MED, V351, P2295, DOI 10.1056/NEJMoa043540
   Lademann J, 2001, SKIN PHARMACOL APPL, V14, P17, DOI 10.1159/000056385
   Macklin MD, 1998, J VIROL, V72, P1491
   MILLS OH, 1983, DERMATOLOGICA, V167, P57
   Mordon S, 2003, LASER SURG MED, V33, P119, DOI 10.1002/lsm.10204
   Partidos CD, 2003, VACCINE, V21, P776, DOI 10.1016/S0264-410X(02)00597-2                                                   
   Peiser M, 2003, J IMMUNOL METHODS, V279, P41, DOI 10.1016/S0022-1759(03)00257-6
   Reece JC, 2001, IMMUNOL CELL BIOL, V79, P255, DOI 10.1046/j.1440-1711.2001.01011.x                                                
   ROLLAND A, 1993, PHARMACEUT RES, V10, P1738, DOI 10.1023/A:1018922114398
   Schaefer H, 2001, SKIN PHARMACOL APPL, V14, P23, DOI 10.1159/000056386
   Scheicher C, 1995, ADV EXP MED BIOL, V378, P253
   Shen ZH, 1997, J IMMUNOL, V158, P2723
   SOUSA CRE, 1993, J EXP MED, V178, P509
   Taira K, 2002, J DERMATOL SCI, V30, P195, DOI 10.1016/S0923-1811(02)00104-4                                                   
   THOMAS JA, 1984, HISTOCHEM J, V16, P507, DOI 10.1007/BF01041351
   Toll R, 2004, J INVEST DERMATOL, V123, P168, DOI 10.1111/j.0022-202X.2004.22717.x
   Vogt A, 2005, J INVEST DERM SYMP P, V10, P252, DOI 10.1111/j.1087-0024.2005.10124.x
NR 22
TC 182
Z9 186
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD JUN
PY 2006
VL 126
IS 6
BP 1316
EP 1322
DI 10.1038/sj.jid.5700226
PG 7
WC Dermatology
SC Dermatology
GA 062TZ
UT WOS:000238968800024
PM 16614727
OA gold
DA 2018-01-05
ER

PT J
AU Ragno, R
   Coluccia, A
   La Regina, G
   De Martino, G
   Piscitelli, F
   Lavecchia, A
   Novellino, E
   Bergamini, A
   Ciaprini, C
   Sinistro, A
   Maga, G
   Crespan, E
   Artico, M
   Silvestri, R
AF Ragno, Rino
   Coluccia, Antonio
   La Regina, Giuseppe
   De Martino, Gabriella
   Piscitelli, Francesco
   Lavecchia, Antonio
   Novellino, Ettore
   Bergamini, Alberto
   Ciaprini, Chiara
   Sinistro, Anna
   Maga, Giovanni
   Crespan, Emanuele
   Artico, Marino
   Silvestri, Romano
TI Design, molecular modeling, synthesis, and anti-HIV-1 activity of new
   indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; RESISTANCE MUTATIONS; BINDING-SITE;
   WILD-TYPE; IN-VITRO; HIV-1; DOCKING; REPLICATION; MECHANICS; MUTANTS
AB Molecular modeling studies and an updated highly predictive 3-D QSAR model led to the discovery of exceptionally potent indolyl aryl sulfones (IASs) characterized by the presence of either a pyrrolidyn-2-one nucleus at the indole-2-carboxamide or some substituents at the indole-2-carbohydrazide. Compounds 7 and 9 were found active in the sub-nanomolar range of concentration in both MT-4 and C8166cell-based anti-HIV assays. These compounds, and in particular compound 9, also showed excellent inhibitory activity against both HIV-112 and HIV-AB1 primary isolates in lymphocytes and against HIV WT in macrophages.
C1 Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy.
   Univ Roma Tor Vergata, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy.
   CNR, Ist Genet Mol, I-27100 Pavia, Italy.
   Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy.
RP Ragno, R (reprint author), Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur, Fdn Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM rino.ragno@uniroma1.it
RI De Martino, Maria Gabriella/I-2357-2012; Maga, Giovanni/C-5409-2009;
   Lavecchia, Antonio/P-9476-2017; La Regina, Giuseppe/I-2161-2012
OI Maga, Giovanni/0000-0001-8092-1552; Lavecchia,
   Antonio/0000-0002-2181-8026; La Regina, Giuseppe/0000-0003-3252-1161;
   Silvestri, Romano/0000-0003-2489-0178; Crespan,
   Emmanuele/0000-0003-0597-6929; Ragno, Rino/0000-0001-5399-975X;
   /0000-0002-7940-8206; Novellino, Ettore/0000-0002-2181-2142
CR ANDREONI M, 1992, J MED VIROL, V38, P207, DOI 10.1002/jmv.1890380310
   Artico M, 1996, BIOORGAN MED CHEM, V4, P837, DOI 10.1016/0968-0896(96)00075-2                                                    
   Artico M, 2000, J MED CHEM, V43, P1886, DOI 10.1021/jm9901125
   Artico M, 1996, J MED CHEM, V39, P522, DOI 10.1021/jm950568w
   BARONI M, 1993, QUANT STRUCT-ACT REL, V12, P9, DOI 10.1002/qsar.19930120103                                                        
   BERGAMINI A, 1994, J CLIN INVEST, V93, P2251, DOI 10.1172/JCI117223
   Berman H, 2003, NAT STRUCT BIOL, V10, P980, DOI 10.1038/nsb1203-980
   BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882
   Chan JH, 2001, J MED CHEM, V44, P1866, DOI 10.1021/jm0004906
   CHOU TC, 1976, J THEOR BIOL, V59, P253, DOI 10.1016/0022-5193(76)90169-7                                                    
   Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   DEMARTINO G, 2003, IN PRESS ANTIVIRAL C
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Hopkins AL, 2004, J MED CHEM, V47, P5912, DOI 10.1021/jm040071z
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405
   Pastor M, 1997, J MED CHEM, V40, P4089, DOI 10.1021/jm970273d
   Pastor M, 1997, J MED CHEM, V40, P1455, DOI 10.1021/jm9608016
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111
   Placido R, 1997, J PATHOL, V181, P31, DOI 10.1002/(SICI)1096-9896(199701)181:1<31::AID-PATH722>3.0.CO;2-G
   Ragno R, 2005, J MED CHEM, V48, P213, DOI 10.1021/jm040854k
   Ragno R, 2005, J MED CHEM, V48, P200, DOI 10.1021/jm0493921
   Ragno R, 2000, BIOORGAN MED CHEM, V8, P1423, DOI 10.1016/S0968-0896(00)00061-4                                                   
   Silvestri R, 2004, J MED CHEM, V47, P3892, DOI 10.1021/jm031147e
   Silvestri R, 2003, J MED CHEM, V46, P2482, DOI 10.1021/jm0211063
   SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891
   Tachedjian Gilda, 2003, Curr Opin Investig Drugs, V4, P966
   Tafi A, 1996, J MED CHEM, V39, P1227, DOI 10.1021/jm950385+                                                               
   Tetko IV, 2001, J CHEM INF COMP SCI, V41, P1488, DOI 10.1021/ci000392t
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
   *WHO UNAIDS, 2005, AIDS EP UPD
   Williams IG, 2003, INT J CLIN PRACT, V57, P890
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
   YOUNG SD, 1995, BIOORG MED CHEM LETT, V5, P491, DOI 10.1016/0960-894X(95)00059-3                                                    
NR 39
TC 77
Z9 79
U1 1
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 1
PY 2006
VL 49
IS 11
BP 3172
EP 3184
DI 10.1021/jm0512490
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 046SX
UT WOS:000237832400018
PM 16722636
DA 2018-01-05
ER

PT J
AU Fuse, T
   Watanabe, K
   Kitazato, K
   Kobayashi, N
AF Fuse, Takayuki
   Watanabe, Ken
   Kitazato, Kaio
   Kobayashi, Nobuyuki
TI Establishment of a new cell line inducibly expressing HIV-1 protease for
   performing safe and highly sensitive screening of HIV protease
   inhibitors
SO MICROBES AND INFECTION
LA English
DT Article
DE HIV-1 protease; cytotoxicity; screening; mammalian cell-based system;
   tet-off system
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ESCHERICHIA-COLI; CLEAVAGE; INFECTION;
   ADHESION; ASSAY; MUTATIONS; PROTEINS; THERAPY; FORM
AB The human immunodeficiency virus type 1 (HIV-1) protease (PR) plays an essential role in processing viral polyproteins into mature proteins. As a result, it is a major target for the development of drugs against AIDS. However, due to the rapid emergence of drug-resistant HIV, the development of novel HIV PR inhibitors is urgently needed. We recently established a new cell line E-PR293 which can be used as a safe, convenient and highly efficient assay system to screen HIV-1 PR inhibitors. In the cells, the HIV-1 PR is expressed in a chimeric protein with the green fluorescence protein (GFP). This assay measures the PR activity as a function of either the fluorescence of GFP or the cytotoxic activity of HIV-1 PR which is expressed in the cell. E-PR293 cells were maintained in the presence of doxycycline, which suppresses the expression of HIV-1 PR. The removal of doxycycline induces the expression of HIV-1 PR, which is used to screen HIV-1 PR inhibitors. In E-PR293 cells, the 50% inhibitory concentration of the cytotoxic effects by nelfinavir and saquinavir were as low as nanomolar levels, almost equal to those found in the HIV-infection assay. (c) 2006 Elsevier SAS. All rights reserved.
C1 Nagasaki Univ, Grad Sch Biomed Sci, Lab Mol Biol Infect Agents, Nagasaki 8528521, Japan.
RP Kobayashi, N (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Lab Mol Biol Infect Agents, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.
EM nobnob@net.nagasaki-u.ac.jp
CR ADAMS LD, 1992, AIDS RES HUM RETROV, V8, P291, DOI 10.1089/aid.1992.8.291
   Blanco R, 2003, J BIOL CHEM, V278, P1086, DOI 10.1074/jbc.M205636200
   BODARY SC, 1990, J BIOL CHEM, V265, P5938
   Cheng TJ, 2004, ANTIMICROB AGENTS CH, V48, P2437, DOI 10.1128/AAC.48.7.2437-2447.2004
   Cote HCF, 2001, J VIROL, V75, P589, DOI 10.1128/JVI.75.2.589-594.2001
   Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9
   Hu K, 2005, J VIROL METHODS, V128, P93, DOI 10.1016/j.jviromet.2005.04.012
   Ishima R, 2001, J BIOL CHEM, V276, P49110, DOI 10.1074/jbc.M108136200
   Kantor R, 2002, ANTIMICROB AGENTS CH, V46, P1086, DOI 10.1128/AAC.46.4.1086-1092.2002
   KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807
   Lindsten K, 2001, ANTIMICROB AGENTS CH, V45, P2616, DOI 10.1128/AAC.45.9.2616-2622.2001
   Louis JM, 1999, J BIOL CHEM, V274, P23437, DOI 10.1074/jbc.274.33.23437                                                        
   Molla A, 1998, VIROLOGY, V250, P255, DOI 10.1006/viro.1998.9383
   Nie Z, 2002, CELL DEATH DIFFER, V9, P1172, DOI 10.1038/sj.cdd.4401094
   OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703                                                     
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PARTALEDIS JA, 1995, J VIROL, V69, P5228
   Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501                                                          
   SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336
   Shoeman RL, 2002, CELL BIOL INT, V26, P529, DOI 10.1006/cbir.2002.0895
   Speck RR, 2000, ANTIMICROB AGENTS CH, V44, P1397, DOI 10.1128/AAC.44.5.1397-1403.2000                                                 
   Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571                                                         
   Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3                                                   
   Ventoso L, 2005, ANTIVIR RES, V66, P47, DOI 10.1016/j.antiviral.2004.12.008
   Vlahov D, 2005, AM J EPIDEMIOL, V161, P999, DOI 10.1093/aje/kwi133
   WALLIN M, 1990, J GEN VIROL, V71, P1985, DOI 10.1099/0022-1317-71-9-1985
   WAN M, 1995, BIOCHEM MOL BIOL INT, V35, P899
   Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007
   Wu TD, 2003, J VIROL, V77, P4836, DOI 10.1128/JVI.77.8.4836-4847.2003
NR 29
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
J9 MICROBES INFECT
JI Microbes Infect.
PD JUN
PY 2006
VL 8
IS 7
BP 1783
EP 1789
DI 10.1016/j.micinf.2006.02.016
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 079CS
UT WOS:000240153700015
PM 16815068
DA 2018-01-05
ER

PT J
AU Muraglia, E
   Kinzel, OD
   Laufer, R
   Miller, MD
   Moyer, G
   Munshi, V
   Orvieto, F
   Palumbi, MC
   Pescatore, G
   Rowley, M
   Williarns, PD
   Summa, V
AF Muraglia, E
   Kinzel, OD
   Laufer, R
   Miller, MD
   Moyer, G
   Munshi, V
   Orvieto, F
   Palumbi, MC
   Pescatore, G
   Rowley, M
   Williarns, PD
   Summa, V
TI Tetrazole thioacetanilides: Potent non-nucleoside inhibitors of WT HIV
   reverse transcriptase and its K103N mutant
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV; non-nucleoside reverse transcriptase inhibitors; tetrazole
   thioacetanilides
ID RESISTANCE
AB A series of aryltetrazolylacetanilides was synthesized and evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors on wild-type virus and on the clinically relevant K103N mutant strain. Extensive SAR investigation led to potent compounds, with nanomolar activity on K103N, and orally bioavailable in rats. (C) 2006 Elsevier Ltd. All rights reserved.
C1 MRL Rome, IRBM, Dept Med Chem, I-00040 Rome, Italy.
   MRL Rome, IRBM, Dept Pharmacol, I-00040 Rome, Italy.
   WP MRL, Dept Antiviral Res, West Point, PA 19486 USA.
   WP MRL, Dept Med Chem, West Point, PA 19486 USA.
RP Muraglia, E (reprint author), MRL Rome, IRBM, Dept Med Chem, Via Pontina Km 30600, I-00040 Rome, Italy.
EM Ester_Muraglia@merck.com
RI Laufer, Ralph/H-9336-2013
CR Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064                                                          
   De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7
   De Clercq E., 2004, ADV ANTIVIRAL DRUG D, V4, P1
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2
   ROSSI S, 1968, TETRAHEDRON, V24, P6395, DOI 10.1016/S0040-4020(01)96831-0
   Sorbera LA, 2002, DRUG FUTURE, V27, P331, DOI 10.1358/dof.2002.027.04.668445
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
NR 8
TC 65
Z9 66
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 15
PY 2006
VL 16
IS 10
BP 2748
EP 2752
DI 10.1016/j.bmcl.2006.02.024
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 033IE
UT WOS:000236839700037
PM 16503141
DA 2018-01-05
ER

PT J
AU Ataman-Onal, Y
   Munier, S
   Ganee, A
   Terrat, C
   Durand, PY
   Battail, N
   Martinon, F
   Le Grand, R
   Charles, MH
   Delair, T
   Verrier, B
AF Ataman-Onal, Y
   Munier, S
   Ganee, A
   Terrat, C
   Durand, PY
   Battail, N
   Martinon, F
   Le Grand, R
   Charles, MH
   Delair, T
   Verrier, B
TI Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein
   induced enhanced cellular and humoral immune responses in various animal
   models
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE PLA nanoparticles; surfactant-free; vaccine adjuvant; HIV-1 p24 protein;
   cellular and humoral immunity
ID ANTIGEN DELIVERY-SYSTEMS; BIODEGRADABLE MICROSPHERES; POLYMERIC
   MICROSPHERES; POLY(D,L-LACTIC ACID); VACCINE ADJUVANTS; PLASMID DNA;
   MICROPARTICLES; INDUCTION; RELEASE; BINDING
AB Microparticles and nanoparticles prepared with poly(D,L-lactide-co-glycolide) (PLGA) or poly(D,L-lactide) (PLA) polymers represent a promising method for in vivo delivery of encapsulated peptide, protein or DNA antigens. However, one major issue that limits the potential of these delivery systems is the instability or the degradation of the entrapped antigen. Charged microparticles carrying surface adsorbed antigen were developed to resolve this problem and appear more suitable for vaccine applications. We describe here new anionic PLA nanoparticles obtained by the dialysis method that are absolutely surfactant-free, which makes them more appropriate for use in humans. The potency of this delivery system as a vaccine carrier was tested in various animal models using HIV-1 p24 protein. p24-coated PLA nanoparticles (p24/PLA) induced high antibody titres (> 10(6)) in mice, rabbits and macaques. Moreover, p24/PLA nanoparticles elicited strong CTL responses and a Th1-biased cytokine release (IFN-gamma, IL-2) in mice. p24 protein seemed to generate a more Th1-oriented response when administered coated onto the surface of PLA nanoparticles than adjuvanted with Freund's adjuvant. Most importantly, the ability of p24/PLA particles to induce Th1 responses was also confirmed in the macaque model, since high levels of IFN-gamma-producing CD4(+) T cells and CD8(+) T cells could be detected by the ELISPOT assay. This protein delivery system confirms the potential of charged nanoparticles in the field of vaccine development. (c) 2006 Elsevier B.V. All rights reserved.
C1 Tour CERVI, IFR128 Biosci Lyon Gerland, CNRS, FRE2736 Biomerieux, F-69365 Lyon 07, France.
   Ecole Normale Super Lyon, IFR128 Biosci Lyon Gerland, UMR2714, CNRS,Unite Mixte Biomerieux, F-69364 Lyon, France.
   Biomerieux, Serv Anticorps Monoclonaux, F-69280 Marcy Letoile, France.
   CEA, Neurol Serv, F-92265 Fontenay Aux Roses, France.
   Inst Cochin Genet Mol, Dept Immunol, F-75014 Paris, France.
   INSERM, U567, F-75014 Paris, France.
   CNRS, UMR 8104, F-75014 Paris, France.
   Univ Paris 05, Fac Med Rene Descartes, UMRS 8104, F-75014 Paris, France.
RP Verrier, B (reprint author), Tour CERVI, IFR128 Biosci Lyon Gerland, CNRS, FRE2736 Biomerieux, 21,Ave Tony Garnier, F-69365 Lyon 07, France.
EM verrier@cervi-lyon.inserm.fr
RI Xu, Qingguo/C-1962-2014; Delair, Thierry/E-7896-2012
OI Xu, Qingguo/0000-0003-3191-0771; 
CR ALMEIDA AJ, 1993, J PHARM PHARMACOL, V45, P198, DOI 10.1111/j.2042-7158.1993.tb05532.x                                              
   Caputo A, 2004, VACCINE, V22, P2910, DOI 10.1016/j.vaccine.2003.12.025
   CHEYNET V, 1993, PROTEIN EXPRES PURIF, V4, P367, DOI 10.1006/prep.1993.1048                                                          
   *CTR DRUG EV RES, 2005, US FDA IN INGR DAT
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Cui ZR, 2002, INT J PHARM, V238, P229, DOI 10.1016/S0378-5173(02)00079-0
   ELDRIDGE JH, 1991, MOL IMMUNOL, V28, P287, DOI 10.1016/0161-5890(91)90076-V
   Govender T, 1999, J CONTROL RELEASE, V57, P171, DOI 10.1016/S0168-3659(98)00116-3
   Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8
   Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365
   Jeon HJ, 2000, INT J PHARM, V207, P99, DOI 10.1016/S0378-5173(00)00537-8
   Jiang WL, 2005, ADV DRUG DELIVER REV, V57, P391, DOI 10.1016/j.addr.2004.09.003
   Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   MALOY KJ, 1994, IMMUNOLOGY, V81, P661
   Mandal B, 2004, INT J PHARM, V269, P259, DOI 10.1016/j.ijpharm.2003.09.023
   Mata M, 1998, J IMMUNOL, V161, P2985
   Messai I, 2005, MACROMOL MATER ENG, V290, P809, DOI 10.1002/mame.200500129
   Messai I, 2005, COLLOID SURFACE A, V255, P65, DOI 10.1016/j.colsurfa.2004.12.023
   Morris CB, 2001, VACCINE, V20, P12, DOI 10.1016/S0264-410X(01)00271-7                                                   
   Munier S, 2005, COLLOID SURFACE B, V43, P163, DOI 10.1016/j.colsurfb.2005.05.001
   O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001
   OHAGAN DT, 1991, IMMUNOLOGY, V73, P239
   OKADA H, 1995, CRIT REV THER DRUG, V12, P1
   Otten G, 2003, J VIROL, V77, P6087, DOI 10.1128/JVI.77.10.6087-6092.2003
   Ouchi T, 2002, BIOMACROMOLECULES, V3, P885, DOI 10.1021/bm0200231
   Sesardic D, 2004, VACCINE, V22, P2452, DOI 10.1016/j.vaccine.2003.11.071
   Singh M, 2004, EXPERT OPIN BIOL TH, V4, P483, DOI 10.1517/14712598.4.4.483
   Singh M, 2004, J PHARM SCI-US, V93, P273, DOI 10.1002/jps.10538
   SINGH M, 1991, PHARMACEUT RES, V8, P958, DOI 10.1023/A:1015832302605
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
NR 32
TC 79
Z9 82
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 15
PY 2006
VL 112
IS 2
BP 175
EP 185
DI 10.1016/j.jconrel.2006.02.006
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 047VZ
UT WOS:000237908100004
PM 16563545
DA 2018-01-05
ER

PT J
AU Ferraz, RM
   Aris, A
   Martinez, MA
   Villaverde, A
AF Ferraz, RM
   Aris, A
   Martinez, MA
   Villaverde, A
TI High-throughput, functional screening of the anti-HIV-1 humoral response
   by an enzymatic nanosensor
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE HIV; antibody; IgG4; immunosensor; viral infections; allosteric
   biosensor; adaptive binding
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ENGINEERED BETA-GALACTOSIDASE;
   MOUTH-DISEASE VIRUS; ANTI-HIV ANTIBODY; NEUTRALIZATION RESISTANCE;
   IMMUNODOMINANT REGION; DISTINCT MECHANISMS; BINDING; GP120; GP41
AB The impact of antibodies on the target's epitope conformation is a major determinant of HIV-1 neutralization and a potential contributor to disease progression. We explore here a conformation-sensitive enzymatic nanosensor for the high-throughput functional screening of human anti-HIV-1 antibodies in sera. When displaying a model epitope from a gp41 immunodominant region (Env residues from 579 to 613), the sensing signal quantitatively distinguishes between adaptive and non-adaptive antibody binding. By using this tool, we have identified IgG4 as the irnmunoglobulin subpopulation most efficient in the structural modification of the target epitope. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.
   Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain.
   Hosp Univ Germans Trias & Pujol, Fundacaio IrsiCaixa, Badalona 08916, Spain.
RP Villaverde, A (reprint author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.
EM avillaverde@servet.uab.es
RI Martinez, Miguel Angel/K-6435-2014
OI Martinez, Miguel Angel/0000-0002-6681-4950; Villaverde,
   Antonio/0000-0002-2615-4521
CR Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x
   Abbas A, 2005, BIOMED PHARMACOTHER, V59, P38, DOI 10.1016/j.biopha.2004.07.001
   BENITO A, 1995, BIO-TECHNOL, V13, P801, DOI 10.1038/nbt0895-801
   Benito A, 1996, J BIOL CHEM, V271, P21251, DOI 10.1074/jbc.271.35.21251                                                        
   BROLIDEN PA, 1992, P NATL ACAD SCI USA, V89, P461, DOI 10.1073/pnas.89.2.461
   Cavacini LA, 1998, AIDS RES HUM RETROV, V14, P1271, DOI 10.1089/aid.1998.14.1271
   de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004
   Feliu JX, 1998, J MOL BIOL, V283, P331, DOI 10.1006/jmbi.1998.2104
   Feliu JX, 1998, FEBS LETT, V438, P267, DOI 10.1016/S0014-5793(98)01315-5                                                   
   Feliu JX, 1998, FEBS LETT, V434, P23, DOI 10.1016/S0014-5793(98)00943-0                                                   
   Feliu JX, 2002, BBA-PROTEIN STRUCT M, V1596, P212, DOI 10.1016/S0167-4838(02)00226-1
   Ferraz RM, 2004, BIOCHEM BIOPH RES CO, V314, P854, DOI 10.1016/j.bbrc.2003.12.169
   Ferrer-Miralles N, 2000, BIOCHEM BIOPH RES CO, V275, P360, DOI 10.1006/bbrc.2000.3309
   Ferrer-Miralles N, 2001, J BIOL CHEM, V276, P40087, DOI 10.1074/jbc.M104704200
   Koch M, 2003, VIROLOGY, V313, P387, DOI 10.1016/S0042-6822(03)00294-0
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Martinez V, 2005, J INFECT DIS, V191, P2053, DOI 10.1086/430320                                                                  
   McCaffrey RA, 2004, J VIROL, V78, P3279, DOI 10.1128/JVI.78.7.3279-3295.2004
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Park EJ, 1998, J VIROL, V72, P7099
   Park EJ, 2000, J VIROL, V74, P4183, DOI 10.1128/JVI.74.9.4183-4191.2000
   Sambrook J, 1989, MOL CLONING LAB MANU
   THALI M, 1994, J VIROL, V68, P674
   ULLMANN A, 1984, GENE, V29, P27, DOI 10.1016/0378-1119(84)90162-8
   Villaverde A, 2003, FEBS LETT, V554, P169, DOI 10.1016/S0014-5793(03)01160-8
   Viveros M, 2000, VIROLOGY, V270, P135, DOI 10.1006/viro.2000.0269
   Watkins BA, 1996, J VIROL, V70, P8431
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Zhang PF, 2002, J VIROL, V76, P644, DOI 10.1128/JVI.76.2.644-655.2002
NR 30
TC 11
Z9 11
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD MAY
PY 2006
VL 43
IS 13
BP 2119
EP 2123
DI 10.1016/j.molimm.2005.12.012
PG 5
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 049HG
UT WOS:000238006400010
PM 16464501
DA 2018-01-05
ER

PT J
AU Zhang, CY
   Johnson, LW
AF Zhang, CY
   Johnson, LW
TI Quantum-dot-based nanosensor for RRE IIB RNA-Rev peptide interaction
   assay
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID RESONANCE ENERGY-TRANSFER; RESPONSIVE ELEMENT; TAT PEPTIDE; ZINC-FINGER;
   BINDING; PROTEIN; FLUORESCENCE; HIV-1; DNA; NEOMYCIN
C1 CUNY York Coll, Dept Chem, Jamaica, NY 11451 USA.
   CUNY, Grad Ctr, Jamaica, NY 11451 USA.
RP Johnson, LW (reprint author), CUNY York Coll, Dept Chem, Jamaica, NY 11451 USA.
EM lwj@york.cuny.edu
FU NIGMS NIH HHS [S06 GM008153, GM08153, S06 GM008153-320024]
CR ALIVISATOS AP, 2004, NAT BIOTECHNOL, V22, P47, DOI DOI 10.1038/NBT927
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Chan WCW, 1998, SCIENCE, V281, P2016, DOI 10.1126/science.281.5385.2016
   Clapp AR, 2004, J AM CHEM SOC, V126, P301, DOI 10.1021/ja037088b
   Clapp AR, 2005, J AM CHEM SOC, V127, P18212, DOI 10.1021/ja054630i
   CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383                                                         
   DeJong ES, 2003, BIOCHEMISTRY-US, V42, P8035, DOI 10.1021/bi0345252z
   Friesen WJ, 2001, J BIOL CHEM, V276, P1968, DOI 10.1074/jbc.M008927200
   GULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346
   Lacourciere KA, 2000, BIOCHEMISTRY-US, V39, P5630, DOI 10.1021/bi992932p
   LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199                                                          
   Medintz IL, 2004, P NATL ACAD SCI USA, V101, P9612, DOI 10.1073/pnas.0403343101
   Medintz IL, 2003, NAT MATER, V2, P630, DOI 10.1038/nmat961
   MEDINTZ IL, 2005, NAT MATER, V4, P437
   Patolsky F, 2003, J AM CHEM SOC, V125, P13918, DOI 10.1021/ja035848c
   Tamilarasu N, 2001, BIOCONJUGATE CHEM, V12, P135, DOI 10.1021/bc000104z
   Tassew N, 2003, BIOPHYS CHEM, V106, P241, DOI 10.1016/S0301-4622(03)00155-8
   Van Ryk DI, 1999, J BIOL CHEM, V274, P17452, DOI 10.1074/jbc.274.25.17452                                                        
   Wang Y, 1997, BIOCHEMISTRY-US, V36, P768, DOI 10.1021/bi962095g
   ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B
   Zhang CY, 2005, NAT MATER, V4, P826, DOI 10.1038/nmat1508
NR 21
TC 77
Z9 78
U1 8
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD APR 26
PY 2006
VL 128
IS 16
BP 5324
EP 5325
DI 10.1021/ja060537y
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 037CU
UT WOS:000237125100012
PM 16620087
OA green_accepted
DA 2018-01-05
ER

PT J
AU Patel, J
   Galey, D
   Jones, J
   Ray, P
   Woodward, JG
   Nath, A
   Mumper, RJ
AF Patel, J
   Galey, D
   Jones, J
   Ray, P
   Woodward, JG
   Nath, A
   Mumper, RJ
TI HIV-1 Tat-coated nanoparticles result in enhanced humoral immune
   responses and neutralizing antibodies compared to alum adjuvant
SO VACCINE
LA English
DT Article
DE HIV-1 Tat; protein; LTR-transactivation; nanoparticles; vaccine;
   adjuvants
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; B-CELL EPITOPES;
   TYPE-1 TAT; AIDS VACCINE; CYNOMOLGUS MONKEYS; RHESUS MACAQUES; DENDRITIC
   CELLS; PROTEIN; PEPTIDES
AB HIV-1 Tat has been identified as an attractive target for vaccine development and is currently under investigation in clinical trials as both a therapeutic and preventative vaccine for HIV-1. It is well known that protein based vaccines produce poor immune responses by themselves and therefore require adjuvants to enhance immune responses. We have previously reported on the use of anionic nanoparticles (NPs) for enhancing cellular and humoral immune responses to Tat (1-72). The purpose of this study was to further evaluate the immune response of HIV-1 Tat (1-72) coated on anionic nanoparticles compared to alum using various doses of Tat (1-72). Nanoparticles were effective at generating comparable antibody titers at both 1 and 5 mu g doses of Tat (1-72), whereas the antibody titers significantly decreased at the lower dose of Tat (1-72) using alum. Anti-sera from Tat (1-72) immunized mice reacted greatest to the N-terminal and basic regions of Tat, with the NP groups showing stronger reactivity to these regions compared to alum. Moreover, the anti-sera from all Tat (1-72) immunized groups contained Tat-neutralizing antibodies and were able to significantly inhibit Tat-mediated long terminal repeat (LTR) transactivation. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
   Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA.
   Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA.
RP Mumper, RJ (reprint author), Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40536 USA.
EM rjmump2@email.uky.edu
FU NIAID NIH HHS [AI058842, AI051147]
CR Addo MM, 2001, P NATL ACAD SCI USA, V98, P1781, DOI 10.1073/pnas.98.4.1781                                                          
   Addo MM, 2002, DNA CELL BIOL, V21, P671, DOI 10.1089/104454902760330219
   Agwale SM, 2002, P NATL ACAD SCI USA, V99, P10037, DOI 10.1073/pnas.152313899
   Allen TM, 2000, NATURE, V407, P386
   Belliard G, 2005, VACCINE, V23, P1399, DOI 10.1016/j.vaceine.2004.08.037
   Butto S, 2003, J INFECT DIS, V188, P1171, DOI 10.1086/378412
   Cafaro A, 1999, NAT MED, V5, P643
   Caputo A, 2004, CURR HIV RES, V2, P357, DOI 10.2174/1570162043350986
   Caselli E, 1999, J IMMUNOL, V162, P5631
   Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   Cohen J, 2003, SCIENCE, V299, P1290, DOI 10.1126/science.299.5611.1290
   Cui Z, 2002, J CONTROL RELEASE, V81, P173, DOI 10.1016/S0168-3659(02)00051-2
   Cui ZR, 2004, VACCINE, V22, P2631, DOI 10.1016/j.vaccine.2003.12.013
   Cui ZR, 2002, INT J PHARM, V238, P229, DOI 10.1016/S0378-5173(02)00079-0
   Cui ZR, 2002, PHARMACEUT RES, V19, P939, DOI 10.1023/A:1016402019380
   Ensoli B, 2002, VIRUS RES, V82, P91
   Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197                                                      
   Fanales-Belasio E, 2002, DNA CELL BIOL, V21, P599, DOI 10.1089/104454902760330138                                                      
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045
   FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0
   FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397                                                         
   Gallo RC, 2002, DNA CELL BIOL, V21, P611, DOI 10.1089/104454902760330147
   Goldstein G, 1996, NAT MED, V2, P960, DOI 10.1038/nm0996-960
   Goldstein G, 2001, VACCINE, V19, P1738, DOI 10.1016/S0264-410X(00)00393-5                                                   
   Huang HW, 1996, BIOCHEM BIOPH RES CO, V227, P615, DOI 10.1006/bbrc.1996.1554                                                          
   Izmailova E, 2003, NAT MED, V9, P191, DOI 10.1038/nm822
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Koziara JM, 2005, PHARM RES, V22, P1821, DOI 10.1007/s11095-005-7547-7
   Ma MH, 1997, J VIROL, V71, P2495
   Maggiorella MT, 2004, VACCINE, V22, P3258, DOI 10.1016/j.vaccine.2004.03.009
   Marinaro M, 2003, VACCINE, V21, P3972, DOI 10.1016/S0264-410X(03)00295-0
   Misumi S, 2004, AIDS RES HUM RETROV, V20, P297, DOI 10.1089/088922204322996536
   Moreau E, 2004, J GEN VIROL, V85, P2893, DOI 10.1099/vir.0.80365-0
   NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0
   Noonan DM, 2003, JAIDS-J ACQ IMM DEF, V33, P47, DOI 10.1097/00126334-200305010-00008                                                
   Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797
   POPIK W, 1993, J VIROL, V67, P1094
   Re M. C., 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P408, DOI 10.1097/00042560-199512000-00003
   Re M C, 2001, New Microbiol, V24, P197
   Re M C, 2001, New Microbiol, V24, P207
   Re MC, 2001, J CLIN VIROL, V21, P81, DOI 10.1016/S1386-6532(00)00189-X
   Rezza G, 2005, J INFECT DIS, V191, P1321, DOI 10.1086/428909                                                                  
   Silvera P, 2002, J VIROL, V76, P3800, DOI 10.1128/JVI.76.8.3800-3809.2002
   SODROSKI J, 1985, SCIENCE, V229, P74, DOI 10.1126/science.2990041                                                         
   Tosi G, 2000, EUR J IMMUNOL, V30, P1120, DOI 10.1002/(SICI)1521-4141(200004)30:4<1120::AID-IMMU1120>3.0.CO;2-4
   vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913                                                     
   Yamada T, 2000, ARCH VIROL, V145, P1021, DOI 10.1007/s007050050692
   Zagury J F, 1998, J Hum Virol, V1, P282
NR 49
TC 22
Z9 23
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD APR 24
PY 2006
VL 24
IS 17
BP 3564
EP 3573
DI 10.1016/j.vaccine.2006.01.065
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 035MM
UT WOS:000237005400021
PM 16516358
DA 2018-01-05
ER

PT J
AU Jiang, T
   Kuhen, KL
   Wolff, K
   Yin, H
   Bieza, K
   Caldwell, J
   Bursulaya, B
   Wu, TYH
   He, Y
AF Jiang, T
   Kuhen, KL
   Wolff, K
   Yin, H
   Bieza, K
   Caldwell, J
   Bursulaya, B
   Wu, TYH
   He, Y
TI Design, synthesis and biological evaluations of novel oxindoles as HIV-1
   non-nucleoside reverse transcriptase inhibitors. Part I
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE AIDS; HIV; reverse transcriptase; inhibitor; oxindole; SAR
ID CHEMOTHERAPY; SYSTEMS
AB A novel oxindole was discovered as an HIV non-nucleoside reverse transcriptase inhibitor via HTS using a cell-based assay. Systematic structural modifications were carried out to establish its SAR. These modifications led to the identification of oxindoles with low nanomolar potency for inhibiting HIV replication. These novel and potent oxindoles could serve as advanced leads for further optimizations. (C) 2006 Elsevier Ltd. All rights reserved.
C1 Novartis Res Fdn, Genom Inst, San Diego, CA 92121 USA.
   Scripps Res Inst, La Jolla, CA 92037 USA.
RP He, Y (reprint author), Novartis Res Fdn, Genom Inst, 10675 John Jay Hopkins Dr, San Diego, CA 92121 USA.
EM yhe@gnf.org
CR Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064                                                          
   BENNETT GB, 1978, J ORG CHEM, V43, P4383, DOI 10.1021/jo00416a034                                                             
   CAVA MP, 1958, J AM CHEM SOC, V80, P2257, DOI 10.1021/ja01542a055                                                             
   De Clercq E, 2005, J MED CHEM, V48, P1297, DOI 10.1021/jm040158k
   De Clercq E, 2002, BBA-MOL BASIS DIS, V1587, P258, DOI 10.1016/S0925-4439(02)00089-3
   Freimuth WW, 1996, ADV EXP MED BIOL, V394, P279
   KOUP RA, 1991, J INFECT DIS, V163, P966, DOI 10.1093/infdis/163.5.966                                                        
   Meyers C, 2003, ANGEW CHEM INT EDIT, V42, P694, DOI 10.1002/anie.200390192                                                          
   Muthusamy S, 2003, SYNLETT, P1599, DOI 10.1055/s-2003-40996
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
NR 11
TC 125
Z9 125
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 15
PY 2006
VL 16
IS 8
BP 2105
EP 2108
DI 10.1016/j.bmcl.2006.01.073
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 026ED
UT WOS:000236319000009
PM 16480865
DA 2018-01-05
ER

PT J
AU Yih, TC
   Al-Fandi, M
AF Yih, TC
   Al-Fandi, M
TI Engineered nanoparticles as precise drug delivery systems
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE nanoparticles; architecture; material; nanotechnology; drug delivery;
   therapeutic agent; therapeutic application
ID BIODEGRADABLE POLYMERIC NANOPARTICLES; HUMAN-IMMUNODEFICIENCY-VIRUS;
   GENE DELIVERY; IN-VIVO; PHOTODYNAMIC THERAPY; ANTICANCER DRUGS;
   BLOCK-COPOLYMER; CANCER-THERAPY; TUMOR; LIPOSOMES
AB With the remarkable development of nanotechnology in recent years, new drug delivery approaches based on the state-of-the-art nanotechnology have been receiving significant attention. Nanoparticles, all evolvement of nanotechnology, are increasingly considered as a potential candidate to carry therapeutic agents safely into a targeted compartment in an organ, particular tissue or cell. These particles are colloidal structures with a diameter smaller than 1,000 nm, and therefore can penetrate through diminutive capillaries into the cell's internal machinery. This innovative delivery technique might be a promising technology to meet the current challenges in drug delivery. When loaded with a gene or drug agent, nanoparticles can become nanopills, which can effectively treat problematical diseases such as cancer. This article summarizes different types of nanoparticles drug delivery systems under investigation and their prospective therapeutic applications. Also, this article presents a closer look at the advances, current challenges, and future direction of nanoparticles drug delivery systems.
C1 Univ Texas, Dept Mech Engn & Biomech, San Antonio, TX 78249 USA.
RP Yih, TC (reprint author), Univ Texas, Dept Mech Engn & Biomech, 6900 N Loop 1604 W, San Antonio, TX 78249 USA.
EM tc.yih@utsa.edu
CR Al Khouri F, 1986, INT J PHARMACEUT, V28, P125
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Chen CZS, 2002, BIOMATERIALS, V23, P3359, DOI 10.1016/S0142-9612(02)00036-4
   Cherian AK, 2000, DRUG DEV IND PHARM, V26, P459, DOI 10.1081/DDC-100101255
   Cohen H, 2000, GENE THER, V7, P1896, DOI 10.1038/sj.gt.3301318
   Cui ZR, 2005, MOL PHARMACEUT, V2, P22, DOI 10.1021/mp049907k
   Davis SS, 1998, INT J PHARM, V176, P1
   DEY S, 2005, P 6 AN CAMBR HLTH I
   Goren D, 1996, BRIT J CANCER, V74, P1749, DOI 10.1038/bjc.1996.625
   Guzman LA, 1996, CIRCULATION, V94, P1441
   HERFFERNAN M, 2005, POLYKETAL NANOPARTIC
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Hofheinz RD, 2005, ANTI-CANCER DRUG, V16, P691, DOI 10.1097/01.cad.0000167902.53039.5a
   Hughes GA, 2005, NANOMED-NANOTECHNOL, V1, P22, DOI 10.1016/j.nano.2004.11.009
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1                                                   
   Kobayashi H, 2001, BIOCONJUGATE CHEM, V12, P587, DOI 10.1021/bc010002o
   Kreuter J, 2003, PHARMACEUT RES, V20, P409, DOI 10.1023/A:1022604120952                                                         
   Labhasetwar V, 1999, COLLOID SURFACE B, V16, P281, DOI 10.1016/S0927-7765(99)00079-X                                                   
   Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775
   Lasic DD, 1999, CURR OPIN MOL THER, V1, P177
   LATALLO J, 2005, CANCER RES, V65, P5317
   Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597
   Panyam J, 2002, J DRUG TARGET, V10, P515, DOI 10.1080/1061186021000038391
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   PAUL W, 2001, TRENDS BIOMATER ARTI, V14, P37
   Plotkin SA, 2003, J INFECT DIS, V187, P1349, DOI 10.1086/374419
   Priyabrata M., 2005, J BIOMD NANOTECH J, V1, P224
   Quintana A, 2002, PHARMACEUT RES, V19, P1310, DOI 10.1023/A:1020398624602
   Raghuvanshi RJ, 2001, J MICROENCAPSUL, V18, P723
   Rao M, 2000, ADV DRUG DELIVER REV, V41, P171, DOI 10.1016/S0169-409X(99)00064-2
   Rapoport N, 2003, J CONTROL RELEASE, V91, P85, DOI 10.1016/S0168-3659(03)00218-9
   Rojo J, 2004, J ANTIMICROB CHEMOTH, V54, P579, DOI 10.1093/jac/dkh399
   Roy I, 2003, J AM CHEM SOC, V125, P7860, DOI 10.1021/ja0343095
   Roy I, 2003, INT J PHARM, V250, P25, DOI 10.1016/S0378-5173(02)00452-0                                                   
   Sahoo SK, 2003, DRUG DISCOV TODAY, V8, P1112, DOI 10.1016/S1359-6446(03)02903-9
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Slepushkin VA, 1996, BIOCHEM BIOPH RES CO, V227, P827, DOI 10.1006/bbrc.1996.1592                                                          
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Sun YG, 2002, NANO LETT, V2, P481, DOI 10.1021/nl025531v
   Unezaki S, 1996, INT J PHARM, V144, P11, DOI 10.1016/S0378-5173(96)04674-1                                                   
   Versluis AJ, 1998, PHARMACEUT RES, V15, P531, DOI 10.1023/A:1011917508056
   Wang SZ, 2004, J MATER CHEM, V14, P487, DOI 10.1039/b311429e
   Watnasirichaikul S, 2000, PHARMACEUT RES, V17, P684, DOI 10.1023/A:1007574030674                                                         
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   YIH T, 2002, DEV MICRO PUMP LOCAL
   YIH T, 2005, NANOTECH BIOL MED, V1, P244
   Yih TC, 2005, NANOMED-NANOTECHNOL, V1, P191, DOI 10.1016/j.nano.2005.04.001
   Yih TC, 2005, NANOMED-NANOTECHNOL, V1, P164, DOI 10.1016/j.nano.2005.01.002
   YOKOYAMA M, 1990, J CONTROL RELEASE, V11, P269
   YU G, 1998, B J CONTROL RELEASE, V53, P131
NR 51
TC 198
Z9 202
U1 3
U2 46
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0730-2312
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR 15
PY 2006
VL 97
IS 6
BP 1184
EP 1190
DI 10.1002/jcb.20796
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 025XT
UT WOS:000236301500003
PM 16440317
OA gold
DA 2018-01-05
ER

PT J
AU Miller, JF
   Andrews, CW
   Brieger, M
   Furfine, ES
   Hale, MR
   Hanlon, MH
   Hazen, RJ
   Kaldor, I
   McLean, EW
   Reynolds, D
   Sarnmond, DM
   Spaltenstein, A
   Tung, R
   Turner, EM
   Xu, RX
   Sherrill, RG
AF Miller, JF
   Andrews, CW
   Brieger, M
   Furfine, ES
   Hale, MR
   Hanlon, MH
   Hazen, RJ
   Kaldor, I
   McLean, EW
   Reynolds, D
   Sarnmond, DM
   Spaltenstein, A
   Tung, R
   Turner, EM
   Xu, RX
   Sherrill, RG
TI Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The
   discovery of GW0385
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE antiviral; antiretroviral; arylsulfonamide; brecanavir; drug resistance;
   GW0385; HIV protease
ID IMMUNODEFICIENCY-VIRUS-INFECTION; RESISTANCE PROFILES; WILD-TYPE;
   SELECTION; TMC114
AB A novel series of P1 modified HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and protease inhibitor-resistant viruses. Optimization of the P1 moiety resulted in compounds with femtomolar enzyme activities and cellular antiviral activities in the low nanomolar range culminating in the identification of clinical candidate GW0385. (C) 2006 Elsevier Ltd. All rights reserved.
C1 GlaxoSmithKline Inc, Res Triangle Pk, NC 27709 USA.
   Vertex Pharmaceut, Cambridge, MA 02139 USA.
RP Miller, JF (reprint author), GlaxoSmithKline Inc, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM john.6.miller@gsk.com; ron.g.sherrill@gsk.com
CR Boden D, 1998, ANTIMICROB AGENTS CH, V42, P2775
   Boffito M, 2005, CURR OPIN INFECT DIS, V18, P1, DOI 10.1097/00001432-200502000-00002
   DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590                                                           
   *DAYL CHEM INF SYS, DAYL V 4 81
   Evans DA, 1998, TETRAHEDRON LETT, V39, P2937, DOI 10.1016/S0040-4039(98)00502-4                                                   
   FISCHER AG, 1985, NATURE, V316, P262
   Ford J, 2004, J ANTIMICROB CHEMOTH, V54, P982, DOI 10.1093/jac/dkh487
   FORD S, 2005, 12 C RETR OPP INF BO
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Hanlon MH, 2004, BIOCHEMISTRY-US, V43, P14500, DOI 10.1021/bi0488799
   *JOINT UN PROGR HI, 2004, 2004 REP GLOB HIV AI
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   Miller JF, 2005, BIOORG MED CHEM LETT, V15, P3496, DOI 10.1016/j.bmcl.2005.05.129
   Miller JF, 2004, BIOORG MED CHEM LETT, V14, P959, DOI 10.1016/j.bmc.2003.12.008
   Moyle G J, 2001, HIV Med, V2, P105, DOI 10.1046/j.1468-1293.2001.00063.x
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Sherrill RG, 2005, BIOORG MED CHEM LETT, V15, P3560, DOI 10.1016/j.bmcl.2005.05.101
   Surleraux DLNG, 2005, J MED CHEM, V48, P1813, DOI 10.1021/jm049560p
   TOTH MV, 1990, INT J PEPT PROT RES, V36, P544
   Turner D, 2004, ANTIVIR THER, V9, P301
   Ventoso L, 2005, ANTIVIR RES, V66, P47, DOI 10.1016/j.antiviral.2004.12.008
NR 22
TC 55
Z9 56
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 1
PY 2006
VL 16
IS 7
BP 1788
EP 1794
DI 10.1016/j.bmcl.2006.01.035
PG 7
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 027GK
UT WOS:000236402500004
PM 16458505
DA 2018-01-05
ER

PT J
AU Ghosh, AK
   Schiltz, G
   Perali, RS
   Leshchenko, S
   Kay, S
   Walters, DE
   Koh, Y
   Maeda, K
   Mitsuya, H
AF Ghosh, AK
   Schiltz, G
   Perali, RS
   Leshchenko, S
   Kay, S
   Walters, DE
   Koh, Y
   Maeda, K
   Mitsuya, H
TI Design and synthesis of novel HIV-1 protease inhibitors incorporating
   oxyindoles as the P-2 '-ligands
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV proptease; inhibitors; oxyindole; TMC-1 14; design; synthesis
ID HIGH-AFFINITY P-2-LIGANDS; BIOLOGICAL EVALUATION; OLEFIN METATHESIS;
   RECEPTOR; RESOLUTION; TEMPLATES; TMC114; AMIDES
AB A series of novel oxyindole-derived HIV-1 protease inhibitors were designed and synthesized based upon our X-ray crystal structure of inhibitor 2 (TMC-114) bound to HIV-1 protease. The effects of substituents, spirocyclic rings, and ring sizes have been investigated. A number of inhibitors exhibited low nanomolar inhibitory potencies against HIV protease. (C) 2006 Elsevier Ltd. All rights reserved.
C1 Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
   Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA.
   Univ Illinois, Dept Chem, Chicago, IL 60607 USA.
   Rosalind Franklin Univ Med & Sci, Dept Biol Chem, N Chicago, IL 60064 USA.
   Kumamoto Univ, Sch Med, Dept Hematol & Infect Dis, Kumamoto 8608556, Japan.
   NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA.
RP Ghosh, AK (reprint author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
EM akghosh@purdue.edu
FU NIGMS NIH HHS [GM 53386]
CR Abbenante G, 1996, BIOORG MED CHEM LETT, V6, P2531, DOI 10.1016/0960-894X(96)00468-4
   Alvarez RG, 2001, TETRAHEDRON, V57, P8581, DOI 10.1016/S0040-4020(01)00837-7
   Cihlar T, 2000, ANNU REP MED CHEM, V35, P177, DOI 10.1016/S0065-7743(00)35017-5
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.62314-2321.2005
   DEMEYERS S, 2004, C RETR OPP INF 11 CR
   Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808                                                     
   GALLAGHER G, 1985, J MED CHEM, V28, P1533, DOI 10.1021/jm00148a028                                                             
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   Ghosh AK, 2005, J MED CHEM, V48, P3576, DOI 10.1021/jm050019i
   Ghosh AK, 2004, J ORG CHEM, V69, P7822, DOI 10.1021/jo049156y
   Ghosh AK, 2002, BIOORG MED CHEM LETT, V12, P1993, DOI 10.1016/S0960-894X(02)00300-1
   GHOSH AK, 1994, J MED CHEM, V37, P2506, DOI 10.1021/jm00042a002                                                             
   GHOSH AK, 1993, J MED CHEM, V36, P2300, DOI 10.1021/jm00068a006
   GHOSH AK, 1995, TETRAHEDRON LETT, V36, P505, DOI 10.1016/0040-4039(94)02296-N                                                    
   GHOSH AK, 2001, IL FARMACO, V56, P29
   Glenn MP, 2002, J MED CHEM, V45, P371, DOI 10.1021/jm010414i
   Grubbs RH, 1998, TETRAHEDRON, V54, P4413, DOI 10.1016/S0040-4020(97)10427-6                                                   
   Gunasekara NS, 2002, DRUGS, V62, P1217, DOI 10.2165/00003495-200262080-00015
   Halgren TA, 1999, J COMPUT CHEM, V20, P720, DOI 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X
   Haynes J, 1999, AM J PHYSIOL-HEART C, V276, pH1877
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   Liu Y, 2002, EUR J PHARMACOL, V435, P153, DOI 10.1016/S0014-2999(01)01590-4                                                   
   POWERS JC, 1966, J ORG CHEM, V31, P2627, DOI 10.1021/jo01346a041                                                             
   Reid RC, 2004, J MED CHEM, V47, P1641, DOI 10.1021/jm030337m
   Reid RC, 1996, J AM CHEM SOC, V118, P8511, DOI 10.1021/ja960433v                                                               
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   Sharma VM, 2002, BIOORG MED CHEM LETT, V12, P2303, DOI 10.1016/S0960-894X(02)00431-6
   SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805
   Tamalet C, 2000, J MED VIROL, V61, P181, DOI 10.1002/(SICI)1096-9071(200006)61:2<181::AID-JMV2>3.0.CO;2-T
   Tie YF, 2004, J MOL BIOL, V338, P341, DOI 10.1016/j.jmb.2004.02.052
   TOTH MV, 1990, INT J PEPT PROT RES, V36, P544
   *UN, 2004, 4 UN
   Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1258.2002
NR 33
TC 48
Z9 49
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD APR 1
PY 2006
VL 16
IS 7
BP 1869
EP 1873
DI 10.1016/j.bmcl.2006.01.011
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 027GK
UT WOS:000236402500021
PM 16480871
DA 2018-01-05
ER

PT J
AU Tang, JJ
   Xie, JW
   Shao, NS
   Yan, Y
AF Tang, JJ
   Xie, JW
   Shao, NS
   Yan, Y
TI The DNA aptamers that specifically recognize ricin toxin are selected by
   two in vitro selection methods
SO ELECTROPHORESIS
LA English
DT Article
DE aptamer; capillary electrophoresis; ricin toxin protein; systematic
   evolution of ligands by exponential enrichment
ID SINGLE-STRANDED-DNA; HUMAN-IMMUNODEFICIENCY-VIRUS; RNA APTAMERS;
   CAPILLARY-ELECTROPHORESIS; EXPONENTIAL ENRICHMENT;
   REVERSE-TRANSCRIPTASE; SYSTEMATIC EVOLUTION; AFFINITY; LIGANDS; BIND
AB Aptamers which specifically recognize cytotoxin ricin were successfully selected using the two different in vitro selection methods. One selection method was used to isolate aptamers, by affinity chromatography. Another selection method, named CE-SELEX, was carried out using CE as a separation approach. The high separation efficiency of CE evidently improved the rate of enrichment and obviously shortened the selection rounds, with near 87.2% binding just after the fourth round of selection. The aptamers A3, C1, and C5, derived from the two selection methods, were found to possess high affinity and specificity for ricin with the K-d values in the low nanomolar range, and did not recognize abrin toxin similar to ricin in the structures and properties, or BSA. Among the aptamers selected, A3 isolated by affinity chromatography shared extensive sequence similarity with C1 and C5 derived from CE-SELEX. They differed by only one base from each other. Their stable secondary structures predicted also had very similar structure motifs, and all folded a long and internal loop-embedded loop stem structure by base pairing. The ELISA and dot-blot analysis also proved that the selected DNA aptamers had the high specificity to ricin toxin.
C1 Beijing Inst Pharmacol & Toxicol, Beijing 100850, Peoples R China.
   Beijing Inst Basic Med Sci, Beijing, Peoples R China.
RP Xie, JW (reprint author), Beijing Inst Pharmacol & Toxicol, 27 Taiping Rd, Beijing 100850, Peoples R China.
EM xiejw@nic.bmi.ac.cn
CR Bae SJ, 2002, BIOCHEM BIOPH RES CO, V298, P486, DOI 10.1016/S0006-291X(02)02490-7
   BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6
   BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0
   Chen Y, 1997, J CHROMATOGR A, V768, P39, DOI 10.1016/S0021-9673(96)01064-3
   CLARKE EGC, 1953, J PHARM PHARMACOL, V5, P458, DOI 10.1111/j.2042-7158.1953.tb14008.x                                              
   Darby SM, 2001, J FORENSIC SCI, V46, P1033
   Davis KA, 1998, NUCLEIC ACIDS RES, V26, P3915, DOI 10.1093/nar/26.17.3915
   Delehanty JB, 2002, ANAL CHEM, V74, P5681, DOI 10.1021/ac025631l
   Drolet DW, 1996, NAT BIOTECHNOL, V14, P1021, DOI 10.1038/nbt0896-1021
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   German I, 1998, ANAL CHEM, V70, P4540, DOI 10.1021/ac980638h                                                               
   Hesselberth JR, 2000, J BIOL CHEM, V275, P4937, DOI 10.1074/jbc.275.7.4937
   Hirao I, 2004, BIOCHEMISTRY-US, V43, P3214, DOI 10.1021/bi0356146
   JELLINEK D, 1994, BIOCHEMISTRY-US, V33, P10450, DOI 10.1021/bi00200a028
   JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417
   Kensch O, 2000, J BIOL CHEM, V275, P18271, DOI 10.1074/jbc.M001309200                                                          
   Kim SJ, 2002, BIOCHEM BIOPH RES CO, V291, P925, DOI 10.1006/bbrc.2002.6521
   Ligler FS, 2003, ANAL BIOANAL CHEM, V377, P469, DOI 10.1007/s00216-003-1992-0
   Liu XM, 2003, J MOL RECOGNIT, V16, P23, DOI 10.1002/jmr.604
   LORD JM, 1994, FASEB J, V8, P201
   Mendonsa SD, 2004, ANAL CHEM, V76, P5387, DOI 10.1021/ac049857v
   Mendonsa SD, 2004, J AM CHEM SOC, V126, P20, DOI 10.1021/ja037832s
   Murphy MB, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng110
   Narang U, 1997, BIOSENS BIOELECTRON, V12, P937, DOI 10.1016/S0956-5663(97)00027-4
   NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029
   POLI MA, 1994, TOXICON, V32, P1371, DOI 10.1016/0041-0101(94)90409-X                                                    
   ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0
   Rusconi CP, 2002, NATURE, V419, P90, DOI 10.1038/nature01058
   SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0                                                                
   SCHNEIDER DJ, 1995, BIOCHEMISTRY-US, V34, P9599, DOI 10.1021/bi00029a037
   Shyu HF, 2002, HYBRIDOMA HYBRIDOM, V21, P69, DOI 10.1089/15368590252917665
   SIMMONS BM, 1985, ANAL BIOCHEM, V146, P206, DOI 10.1016/0003-2697(85)90417-8                                                    
   Stojanovic MN, 2001, J AM CHEM SOC, V123, P4928, DOI 10.1021/ja0038171
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Wang CL, 2003, J BIOTECHNOL, V102, P15, DOI 10.1016/S0168-1656(02)00360-7
   Wiener SL, 1996, MIL MED, V161, P251
   ZHAN JB, 1991, PROG BIOCHEM BIOPHYS, V18, P219
   Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418                                                          
NR 38
TC 86
Z9 95
U1 4
U2 59
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0173-0835
J9 ELECTROPHORESIS
JI Electrophoresis
PD APR
PY 2006
VL 27
IS 7
BP 1303
EP 1311
DI 10.1002/elps.200500489
PG 9
WC Biochemical Research Methods; Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 033KL
UT WOS:000236845800004
PM 16518777
DA 2018-01-05
ER

PT J
AU Muller, S
   Strohbach, D
   Wolf, J
AF Muller, S
   Strohbach, D
   Wolf, J
TI Sensors made of RNA: tailored ribozymes for detection of small organic
   molecules, metals, nucleic acids and proteins
SO IEE PROCEEDINGS-NANOBIOTECHNOLOGY
LA English
DT Article
ID IN-VITRO SELECTION; ALLOSTERIC HAMMERHEAD RIBOZYME; HIV-1
   REVERSE-TRANSCRIPTASE; HAIRPIN RIBOZYME; GOLD NANOPARTICLES; REAL-TIME;
   OLIGONUCLEOTIDE EFFECTOR; ACTIVATED RIBOZYME; CLEAVING RIBOZYMES;
   CHAPERONE ACTIVITY
AB Nucleic acids are well suited to serve as biosensors for the fast and reliable detection of small organic molecules, such as a number of metabolites or antibiotics, specific nucleic acid sequences, peptides, proteins or metal ions. One of the main advantages of using nucleic acids as biosensors is that they can be modulated to respond allosterically to specific effectors. Thus molecular recognition is transformed directly into a catalytic process with observable results. In particular, catalytic RNA structures, such as the hammerhead and hairpin ribozymes, have been used for biosensor engineering. The review reports on the function mode of nucleic acid biosensors and introduces recent developments and applications in the field.
C1 Ruhr Univ Bochum, Fak Chem, D-44780 Bochum, Germany.
RP Muller, S (reprint author), Ruhr Univ Bochum, Fak Chem, D-44780 Bochum, Germany.
EM sabine.w.mueller@rub.de
RI Muller, Sabine/C-1909-2013
OI Muller, Sabine/0000-0002-8385-7274
CR Araki M, 1998, NUCLEIC ACIDS RES, V26, P3379, DOI 10.1093/nar/26.14.3379
   Araki M, 2001, BIOORGAN MED CHEM, V9, P1155, DOI 10.1016/S0968-0896(00)00336-9
   BERZALHERRANZ A, 1993, EMBO J, V12, P2567
   Blount KE, 2005, ANNU REV BIOPH BIOM, V34, P415, DOI 10.1146/annurev.biophys.34.122004.184428
   Bonnet G, 1999, P NATL ACAD SCI USA, V96, P6171, DOI 10.1073/pnas.96.11.6171
   Burke DH, 2002, BIOCHEMISTRY-US, V41, P6588, DOI 10.1021/bi0201522
   Eckstein F, 2001, CHEMBIOCHEM, V2, P629, DOI 10.1002/1439-7633(20010903)2:9<629::AID-CBIC629>3.0.CO;2-3                      
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Ferguson A, 2004, NUCLEIC ACIDS RES, V32, P1756, DOI 10.1093/nar/gkh336
   Frauendorf C, 2001, BIOORGAN MED CHEM, V9, P2521, DOI 10.1016/S0968-0896(01)00027-X
   Hartig JS, 2002, NAT BIOTECHNOL, V20, P717, DOI 10.1038/nbt0702-717
   Hartig JS, 2002, ANGEW CHEM INT EDIT, V41, P4263, DOI 10.1002/1521-3773(20021115)41:22<4263::AID-ANIE4263>3.0.CO;2-7                  
   HERSCHLAG D, 1994, EMBO J, V13, P2913
   Hesselberth JR, 2003, ANAL BIOCHEM, V312, P106, DOI 10.1016/S0003-2697(02)00441-4
   Huang ZS, 1998, J BIOL CHEM, V273, P26455, DOI 10.1074/jbc.273.41.26455
   Jenne A, 1999, ANGEW CHEM INT EDIT, V38, P1300, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1300::AID-ANIE1300>3.0.CO;2-Q             
   Jose AM, 2001, NUCLEIC ACIDS RES, V29, P1631, DOI 10.1093/nar/29.7.1631
   Kensch O, 2000, J BIOL CHEM, V275, P18271, DOI 10.1074/jbc.M001309200                                                          
   Kertsburg A, 2002, NUCLEIC ACIDS RES, V30, P4599, DOI 10.1093/nar/gkf596
   Koizumi M, 1999, NAT STRUCT BIOL, V6, P1062
   Komatsu Y, 2004, BIOL PHARM BULL, V27, P457, DOI 10.1248/bpb.27.457
   Komatsu Y, 2002, BIOCHEMISTRY-US, V41, P9090, DOI 10.1021/bi020012s
   Kuwabara T, 1998, MOL CELL, V2, P617, DOI 10.1016/S1097-2765(00)80160-4
   Lakowicz J. R., 1983, PRINCIPLES FLUORESCE
   Levy M, 2002, CHEM BIOL, V9, P417, DOI 10.1016/S1074-5521(02)00123-0                                                   
   Liu JW, 2003, J AM CHEM SOC, V125, P6642, DOI 10.1021/ja034775u
   Liu JW, 2004, ANAL CHEM, V76, P1627, DOI 10.1021/ac0351769
   LIVAK KJ, 1995, PCR METH APPL, V4, P357
   Lu Y, 2003, BIOSENS BIOELECTRON, V18, P529, DOI 10.1016/S0956-5663(03)00013-7
   Lu Y., 2002, CHEM-EUR J, V8, P4588
   Marshall KA, 1999, NAT STRUCT BIOL, V6, P992
   MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4859, DOI 10.1021/bi00316a007                                                             
   Najafi-Shoushtari SH, 2005, RNA, V11, P1514, DOI 10.1261/rna.2840805
   Najafi-Shoushtari SH, 2004, NUCLEIC ACIDS RES, V32, P3212, DOI 10.1093/nar/gkh643
   Piganeau N, 2000, ANGEW CHEM INT EDIT, V39, P4369, DOI 10.1002/1521-3773(20001201)39:23<4369::AID-ANIE4369>3.0.CO;2-N                  
   Piganeau N, 2001, J MOL BIOL, V312, P1177, DOI 10.1006/jmbi.2001.4981
   PORTA H, 1995, BIO-TECHNOL, V13, P161, DOI 10.1038/nbt0295-161                                                             
   Robertson MP, 2004, RNA, V10, P114, DOI 10.1261/rna.5900204
   Robertson MP, 1999, NAT BIOTECHNOL, V17, P62
   Robertson MP, 2000, NUCLEIC ACIDS RES, V28, P1751, DOI 10.1093/nar/28.8.1751
   Robertson MP, 2001, NAT BIOTECHNOL, V19, P650, DOI 10.1038/90256
   SARGUEIL B, 1995, BIOCHEMISTRY-US, V34, P7739, DOI 10.1021/bi00023a021
   Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723                                                                   
   Sekella PT, 2002, RNA, V8, P1242, DOI 10.1017/S1355838202028066
   Silverman SK, 2003, RNA, V9, P377, DOI 10.1261/rna.2200903
   Soukup GA, 1999, STRUCT FOLD DES, V7, P783, DOI 10.1016/S0969-2126(99)80102-6                                                   
   Soukup GA, 1999, P NATL ACAD SCI USA, V96, P3584, DOI 10.1073/pnas.96.7.3584
   Srinivasan J, 2004, CHEM BIOL, V11, P499, DOI 10.1016/j.chembiol.2004.03.014
   Stojanovic MN, 2001, CHEMBIOCHEM, V2, P411, DOI 10.1002/1439-7633(20010601)2:6<411::AID-CBIC411>3.3.CO;2-9
   Strohbach D, 2006, ANGEW CHEM INT EDIT, V45, P2127, DOI 10.1002/anie.200503820
   Tang J, 1998, NUCLEIC ACIDS RES, V26, P4214, DOI 10.1093/nar/26.18.4214
   Tang J, 1997, RNA, V3, P914
   Tang J, 1997, CHEM BIOL, V4, P453, DOI 10.1016/S1074-5521(97)90197-6
   Tucker BJ, 2005, CURR OPIN STRUC BIOL, V15, P342, DOI 10.1016/j.sbi.2005.05.003
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49
   Vaish NK, 2004, METHODS, V32, P428, DOI 10.1016/j.ymeth.2003.10.005
   Vaish NK, 2002, NAT BIOTECHNOL, V20, P810, DOI 10.1038/nbt719
   Vauleon S, 2003, CHEMBIOCHEM, V4, P220, DOI 10.1002/cbic.200390035                                                          
   Wang DY, 2002, J MOL BIOL, V318, P33, DOI 10.1016/S0022-2836(02)00046-3
   Wang DY, 2002, COMB CHEM HIGH T SCR, V5, P301
   Wang DY, 2002, NUCLEIC ACIDS RES, V30, P1735, DOI 10.1093/nar/30.8.1735
   Wang DY, 2001, J MOL BIOL, V310, P723, DOI 10.1006/jmbi.2001.4811
   Wilson TJ, 2005, BIOCHEM SOC T, V33, P461, DOI 10.1042/BST0330461                                                              
   Zivarts M, 2005, NUCLEIC ACIDS RES, V33, P622, DOI 10.1093/nar/gki182
NR 65
TC 10
Z9 11
U1 1
U2 14
PU INSTITUTION ENGINEERING TECHNOLOGY-IET
PI HERTFORD
PA MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND
SN 1478-1581
J9 IEE PROC-NANOBIOTECH
JI IEE Proc-Nanobiotechnol.
PD APR
PY 2006
VL 153
IS 2
BP 31
EP 40
DI 10.1049/ip-nbt:20050047
PG 10
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA 047UX
UT WOS:000237905300003
PM 16671821
DA 2018-01-05
ER

PT J
AU Tsai, CJ
   Zheng, J
   Nussinov, R
AF Tsai, Chung-Jung
   Zheng, Jie
   Nussinov, Ruth
TI Designing a nanotube using naturally occurring protein building blocks
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID ASSEMBLED PEPTIDE NANOTUBES; SURFACTANT-LIKE PEPTIDES; HIV-1 CAPSID
   PROTEIN; TUBULES; NANOSTRUCTURES; ARCHITECTURE; ENERGY
AB Here our goal is to carry out nanotube design using naturally occurring protein building blocks. Inspection of the protein structural database reveals the richness of the conformations of proteins, their parts, and their chemistry. Given target functional protein nanotube geometry, our strategy involves scanning a library of candidate building blocks, combinatorially assembling them into the shape and testing its stability. Since self-assembly takes place on time scales not affordable for computations, here we propose a strategy for the very first step in protein nanotube design: we map the candidate building blocks onto a planar sheet and wrap the sheet around a cylinder with the target dimensions. We provide examples of three nanotubes, two peptide and one protein, in atomistic model detail for which there are experimental data. The nanotube models can be used to verify a nanostructure observed by low-resolution experiments, and to study the mechanism of tube formation.
C1 Natl Canc Inst, Basic Res Program, SAIC Frederick Inc, Canc Res Ctr,Nanobiol Program, Frederick, MD USA.
   Tel Aviv Univ, Sch Med, IL-69978 Tel Aviv, Israel.
RP Nussinov, R (reprint author), Natl Canc Inst, Basic Res Program, SAIC Frederick Inc, Canc Res Ctr,Nanobiol Program, Frederick, MD USA.
EM ruthn@ncifcrf.gov
RI Zheng, Jie/B-5057-2013
OI Zheng, Jie/0000-0003-1547-3612
FU NCI NIH HHS [N01CO12400, N01-CO-12400]; Intramural NIH HHS
CR Aggeli A, 1997, NATURE, V386, P259, DOI 10.1038/386259a0
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   DAVIDON WC, 1975, MATH PROGRAM, V9, P1, DOI 10.1007/BF01681328
   Fernandez-Lopez S, 2001, NATURE, V412, P452, DOI 10.1038/35086601                                                                
   Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566
   Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849
   Ganser-Pornillos BK, 2004, J VIROL, V78, P2545, DOI 10.1128/JVI.78.5.2545-2552.2004
   GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0
   Gorbitz CH, 2001, CHEM-EUR J, V7, P5153, DOI 10.1002/1521-3765(20011203)7:23<5153::AID-CHEM5153>3.0.CO;2-N
   Haspel N, 2003, PROTEIN SCI, V12, P1177, DOI 10.1110/ps.0232903
   Kim HS, 1998, J AM CHEM SOC, V120, P4417, DOI 10.1021/ja9735315                                                               
   Li S, 2000, NATURE, V407, P409
   Lu K, 2003, J AM CHEM SOC, V125, P6391, DOI 10.1021/ja0341642
   Majoros IJ, 2005, J MED CHEM, V48, P5892, DOI 10.1021/jm0401863
   Martin CR, 2003, NAT REV DRUG DISCOV, V2, P29, DOI 10.1038/nrd988
   Monaco-Malbet S, 2000, STRUCTURE, V8, P1069, DOI 10.1016/S0969-2126(00)00507-4
   Ponder JW, 2004, TINKER SOFTWARE TOOL
   Rajagopal K, 2004, CURR OPIN STRUC BIOL, V14, P480, DOI 10.1016/j.sbi.2004.06.006
   Ray S, 2004, ORG LETT, V6, P4463, DOI 10.1021/ol048253a
   Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387                                                         
   SCHNUR JM, 1993, SCIENCE, V262, P1669, DOI 10.1126/science.262.5140.1669
   Seeman NC, 2002, P NATL ACAD SCI USA, V99, P6451, DOI 10.1073/pnas.221458298
   Selinger JV, 2001, J PHYS CHEM B, V105, P7157, DOI 10.1021/jp010452d
   Song YJ, 2004, CHEM COMMUN, P1044, DOI 10.1039/b402126f
   Tsai CJ, 2000, P NATL ACAD SCI USA, V97, P12038, DOI 10.1073/pnas.97.22.12038
   Tsai HH, 2005, P NATL ACAD SCI USA, V102, P8174, DOI 10.1073/pnas.0408653102
   Tsai HH, 2004, PROTEIN SCI, V13, P2753, DOI 10.1110/ps.04774004
   Vauthey S, 2002, P NATL ACAD SCI USA, V99, P5355, DOI 10.1073/pnas.072089599
   von Maltzahn G, 2003, LANGMUIR, V19, P4332, DOI 10.1021/la026526+
   WHITE CT, 1993, PHYS REV B, V47, P5485, DOI 10.1103/PhysRevB.47.5485
   Yemini M, 2005, NANO LETT, V5, P183, DOI 10.1021/nl0484189
   Yemini M, 2005, ANAL CHEM, V77, P5155, DOI 10.1021/ac050414g
NR 33
TC 27
Z9 29
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1553-734X
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD APR
PY 2006
VL 2
IS 4
BP 311
EP 319
AR e42
DI 10.1371/journal.pcbi.0020042
PG 9
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA 070AX
UT WOS:000239493800010
PM 16683021
OA gold
DA 2018-01-05
ER

PT J
AU Li, XL
   Horiya, S
   Harada, K
AF Li, XL
   Horiya, S
   Harada, K
TI An efficient thermally induced RNA conformational switch as a framework
   for the functionalization of RNA nanostructures
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID KISSING COMPLEX; ANTISENSE RNA; MAJOR GROOVE; HIV-1 RNA; IN-VITRO;
   DIMERIZATION; PEPTIDE; DIMER; SITE; DEVICES
AB RNA offers a variety of interactions and dynamic conformational switches not available with DNA that may be exploited for the construction of nanomolecular structures. Here, we show how the RNA loop-loop, or "kissing", interaction can be used to construct specific circular RNA arrangements that are capable of thermal isomerization to alternative structures. We also show how this thermally induced structural rearrangement can be used to unmask a functional RNA structure, in this case, a peptide-binding RNA structure, the Rev-response element (RRE) of HIV, thereby acting as a functional peptide-binding switch. The relative ease with which the RRE could be engineered into the RNA substrates suggested that a variety of functional RNA structures may be introduced. In addition, the structural rearrangement was extremely efficient, showing that the "kissing" complexes described in this study may provide a useful framework for the construction of functional RNA-based nanostructures, as well as aid in our understanding of the way RNA functions in biological systems.
C1 Tokyo Gakugei Univ, Dept Life Sci, Koganei, Tokyo 1848501, Japan.
RP Harada, K (reprint author), Tokyo Gakugei Univ, Dept Life Sci, Koganei, Tokyo 1848501, Japan.
EM harada@u-gakugei.ac.jp
CR BATEY RT, 1999, ANGEW CHEM INT EDIT, V38, P2326
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077
   Chworos A, 2004, SCIENCE, V306, P2068, DOI 10.1126/science.1104686
   DOUDNA JA, 1995, RNA, V1, P36
   EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215
   Harada K, 1997, P NATL ACAD SCI USA, V94, P11887, DOI 10.1073/pnas.94.22.11887
   Hermann T, 1999, J MOL BIOL, V294, P829, DOI 10.1006/jmbi.1999.3312
   Horiya S, 2003, CHEM BIOL, V10, P645, DOI 10.1016/S1074-5521(03)00146-7
   Ikawa Y, 2002, STRUCTURE, V10, P527, DOI 10.1016/S0969-2126(02)00739-6
   JAEGER L, 1999, ANGEW CHEM INT EDIT, V39, P2521
   Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f                                                               
   Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s
   Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572
   Schroeder R, 2004, NAT REV MOL CELL BIO, V5, P908, DOI 10.1038/nrm1497
   Seeman NC, 2002, P NATL ACAD SCI USA, V99, P6451, DOI 10.1073/pnas.221458298
   Seeman NC, 2005, TRENDS BIOCHEM SCI, V30, P119, DOI 10.1016/j.tibs.2005.01.007
   SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945
   Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3                                                   
   Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635
   WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433                                             
   Windbichler N, 2003, NUCLEIC ACIDS RES, V31, P6419, DOI 10.1093/nar/gkg873
NR 22
TC 12
Z9 13
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAR 29
PY 2006
VL 128
IS 12
BP 4035
EP 4040
DI 10.1021/ja0572093
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA 027GD
UT WOS:000236401600054
PM 16551112
DA 2018-01-05
ER

PT J
AU Chang, R
   Violi, A
AF Chang, R
   Violi, A
TI Insights into the effect of combustion-generated carbon nanoparticles on
   biological membranes: A computer simulation study
SO JOURNAL OF PHYSICAL CHEMISTRY B
LA English
DT Article
ID MOLECULAR-DYNAMICS SIMULATION; SOOT PARTICLE INCEPTION; HIV-1 PROTEASE;
   FULLERENE DERIVATIVES; PHOSPHOLIPID-BILAYERS; PULMONARY TOXICITY;
   NANOTUBE MATERIAL; PROTON TRANSPORT; FORCE-FIELD; CHOLESTEROL
AB Classical molecular dynamics simulations of atomistic models of combustion-generated carbon nanoparticles and lipid bilayers have been performed to explore their possible structural, dynamical, and thermodynamic effects on biological membranes. The DREIDING generic force field is used for the carbonaceous nanoparticles of different morphologies, as produced from combustion sources, and the united atom model was employed for the dimyristoylphosphatidylcholine (DMPC) bilayer. It is observed that particle shape and structure have significant effects on solvation, mobility, adsorption, and permeation behavior of the particles. While combustion-generated carbon nanoparticles with an aspect ratio close to unity prefer to stay near the membrane center, precursors with other shapes mostly reside within the hydrocarbon tail region of the membrane. Carbon nanoparticles are not trapped in a local region even inside the membranes but move freely with a speed depending on their molecular weight. The adsorption of the particles on the surface of the biological membrane is comparable to thermal fluctuations because the weak segregation effect by water molecules is the main driving force to the adsorption behavior. The bigger the precursors are, the strongrer they are bound to the membrane surface. The presence of combustion-generated nanoparticles inside the membrane perturbs local lipid density by pushing the neighboring lipid molecules away from the nanoparticles. This, coupled with thermal fluctuations, can induce an instantaneous membrane pore to allow water protrusion. From the umbrella sampling method, the potential of mean force for the permeation of carbona nanoparticles into the bilayer was also obtained. Surprisingly, elongated particles have a free energy barrier an order of magnitude smaller compared with more round ones. In addition, the round carbon nanoparticles showed strong hysteresis due to the local trapping of water molecules. Although the carbon soot precursors studied in this work are not the well-known carbon nanoparticles such as fullerenes or carbon nanotubes, the qualitative features of this study may be applicable to them as well.
C1 Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA.
   Kwangwoon Univ, Dept Chem, Seoul 139701, South Korea.
RP Violi, A (reprint author), Univ Michigan, Dept Mech Engn, Ann Arbor, MI 48109 USA.
EM violi@eng.utah.edu
FU NCRR NIH HHS [1 S10 RR17214-01]
CR ADELMANN P, 1994, TOXIC CARCINOGENIC E
   Ajayan PM, 1999, P NATL ACAD SCI USA, V96, P14199, DOI 10.1073/pnas.96.25.14199                                                        
   Arnall A.H., 2003, FUTURE TECHNOLOGIES
   BAGLEY ST, 1996, 76 HLTH EFF I BOST
   Ball P, 2001, NATURE, V414, P142, DOI 10.1038/35102721
   Bosi S, 2003, EUR J MED CHEM, V38, P913, DOI 10.1016/j.ejmech.2003.09.005
   Chang R, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1931651
   Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875
   de Jonge N, 2004, PHILOS T R SOC A, V362, P2239, DOI 10.1098/rsta.2004.1438
   de Vries AH, 2004, J AM CHEM SOC, V126, P4488, DOI 10.1021/ja0398417
   Degiorgi L, 1998, ADV PHYS, V47, P207, DOI 10.1080/000187398243555                                                         
   DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401
   Dresselhaus MS, 2004, MRS BULL, V29, P237, DOI 10.1557/mrs2004.74                                                              
   Endo M, 2004, PHILOS T ROY SOC A, V362, P2223, DOI 10.1098/rsta.2004.1437
   EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094                                                     
   Florian J, 2005, P NATL ACAD SCI USA, V102, P6819, DOI 10.1073/pnas.0408173102
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   Gao HJ, 2004, ANNU REV MATER RES, V34, P123, DOI 10.1146/annurev.matsci.34.040203.120402
   Goel A, 2004, CARBON, V42, P1907, DOI 10.1016/j.carbon.2004.03.022
   Goel A, 2002, CARBON, V40, P177, DOI 10.1016/S0008-6223(01)00170-1                                                   
   Hansen J, 2004, P NATL ACAD SCI USA, V101, P423, DOI 10.1073/pnas.2237157100
   *HLTH EFF I BOST, 2002, HEI SPEC REP RES DIR
   Hofsass C, 2003, BIOPHYS J, V84, P2192, DOI 10.1016/S0006-3495(03)75025-5                                                   
   Huczko A, 1999, FULLERENE SCI TECHN, V7, P935, DOI 10.1080/10641229909351390                                                       
   Huczko A, 2001, FULLERENE SCI TECHN, V9, P251, DOI 10.1081/FST-100102973                                                           
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kittelson DB, 1998, J AEROSOL SCI, V29, P575, DOI 10.1016/S0021-8502(97)10037-4                                                   
   Kohl P, 2000, PHILOS T R SOC A, V358, P579, DOI 10.1098/rsta.2000.0547                                                          
   Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243
   Lin Y, 2004, J MATER CHEM, V14, P527, DOI 10.1039/b314481j
   Lindgren LE, 2000, IMECHE SEM, V2000, P1
   Lipowsky R., 1995, P521
   Marrink SJ, 2001, J PHYS CHEM B, V105, P6122, DOI 10.1021/jp0103474
   Maynard AD, 2004, J TOXICOL ENV HEAL A, V67, P87, DOI 10.1080/15287390490253688
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   MERLO DF, 2004, OCCUP ENV MED, V61
   Moraitakis G, 2003, REP PROG PHYS, V66, P383, DOI 10.1088/0034-4885/66/3/203
   Noon WH, 2002, P NATL ACAD SCI USA, V99, P6466, DOI 10.1073/pnas.022532599
   OBERDORSTER G, 1994, ENVIRON HEALTH PERSP, V102, P173, DOI 10.2307/3432080
   Prato M, 1997, J MATER CHEM, V7, P1097, DOI 10.1039/a700080d                                                                
   Prato M, 1999, TOP CURR CHEM, V199, P173
   Redondo A, 2004, ANNU REV MATER RES, V34, P279, DOI 10.1146/annurev.matsci.34.070503.123908
   Ristovski ZD, 1998, ENVIRON SCI TECHNOL, V32, P3845, DOI 10.1021/es980102d                                                               
   ROUX B, 1995, COMPUT PHYS COMMUN, V91, P275, DOI 10.1016/0010-4655(95)00053-I
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Saiz L, 2002, BIOSCIENCE REP, V22, P151, DOI 10.1023/A:1020130420869
   Sayes CM, 2004, NANO LETT, V4, P1881, DOI 10.1021/nl0489586
   Schlick T, 1997, ANNU REV BIOPH BIOM, V26, P181, DOI 10.1146/annurev.biophys.26.1.181
   Service RF, 2005, SCIENCE, V310, P1609, DOI 10.1126/science.310.5754.1609                                                   
   Shvedova AA, 2003, J TOXICOL ENV HEAL A, V66, P1909, DOI 10.1080/15287390390231566
   Smith W, 1996, J MOL GRAPHICS, V14, P136, DOI 10.1016/S0263-7855(96)00043-4                                                   
   Smondyrev AM, 1999, J COMPUT CHEM, V20, P531, DOI 10.1002/(SICI)1096-987X(19990415)20:5<531::AID-JCC5>3.0.CO;2-3                  
   Smondyrev AM, 1999, BIOPHYS J, V77, P2075, DOI 10.1016/S0006-3495(99)77049-9                                                   
   Smondyrev AM, 2002, BIOPHYS J, V82, P1460, DOI 10.1016/S0006-3495(02)75500-8                                                   
   Smondyrev AM, 2000, BIOPHYS J, V78, P1672, DOI 10.1016/S0006-3495(00)76719-1                                                   
   Smondyrev AM, 1999, J CHEM PHYS, V111, P9864, DOI 10.1063/1.480323
   Smondyrev AM, 2001, CHEM PHYS LIPIDS, V112, P31, DOI 10.1016/S0009-3084(01)00160-8                                                   
   Smondyrev AM, 2001, BIOPHYS J, V80, P1649, DOI 10.1016/S0006-3495(01)76137-1                                                   
   Smondyrev AM, 1999, J CHEM PHYS, V110, P3981, DOI 10.1063/1.478278
   Srinivas G, 2004, NANOTECHNOLOGY, V15, P1289, DOI 10.1088/0957-4484/15/9/030
   Steinfeld J. I., 1998, CHEM KINETICS DYNAMI
   SUBRAMONEY S, 1998, ADV MATER, V10, P15
   TORRIE GM, 1977, J COMPUT PHYS, V23, P187, DOI 10.1016/0021-9991(77)90121-8
   Uragoda CG, 1997, OCCUP MED-OXFORD, V47, P269, DOI 10.1093/occmed/47.5.269
   Vander Wal R, 2004, J NANOPART RES, V6, P555, DOI 10.1007/s11051-004-3724-6
   Violi A, 2005, P COMBUST INST, V30, P1343, DOI 10.1016/j.proci.2004.08.226
   Violi A, 2004, COMBUST FLAME, V139, P279, DOI 10.1016/j.combustflame.2004.08.013
   Violi A, 2004, COMBUST SCI TECHNOL, V176, P991, DOI 10.1080/00102200490428594
   Voth GA, 2003, FRONT BIOSCI-LANDMRK, V8, pS1384, DOI 10.2741/1213                                                                    
   Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228
   Warshel A, 2005, P NATL ACAD SCI USA, V102, P1813, DOI 10.1073/pnas.0409788102
   Xie YH, 2005, MATER LETT, V59, P971, DOI 10.1016/j.matlet.2004.10.079
   Yeh IC, 2004, P NATL ACAD SCI USA, V101, P12177, DOI 10.1073/pnas.0402699101
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
NR 75
TC 36
Z9 36
U1 2
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-6106
J9 J PHYS CHEM B
JI J. Phys. Chem. B
PD MAR 16
PY 2006
VL 110
IS 10
BP 5073
EP 5083
DI 10.1021/jp0565148
PG 11
WC Chemistry, Physical
SC Chemistry
GA 022TB
UT WOS:000236077600079
PM 16526750
DA 2018-01-05
ER

PT J
AU Sung, M
   Poon, GMK
   Gariepy, J
AF Sung, M
   Poon, GMK
   Gariepy, J
TI The importance of valency in enhancing the import and cell routing
   potential of protein transduction domain-containing molecules
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article; Proceedings Paper
CT Conference on Mechanisms of Carrier-Mediated Intra-Cellular Delivery of
   Therapeutics
CY AUG 25-26, 2005
CL Montpellier, FRANCE
ID HIV-1 TAT PROTEIN; DIFFERENTIAL SCANNING CALORIMETRY; PEPTIDE-MODIFIED
   LIPOSOMES; ZINC SUPEROXIDE-DISMUTASE; SINGLE-CHAIN FV; POLY-L-LYSINE;
   ED-B DOMAIN; IN-VIVO; MAMMALIAN-CELLS; FUSION PROTEIN
AB Protein transduction domains (PTDs) are peptides that afford the internalization of cargo macromolecules (including plasmid DNA, proteins, liposomes, and nanoparticles). In the case of polycationic peptides, the efficiency of PTDs to promote cellular uptake is directly related to their molecular mass or their polyvalent presentation. Similarly, the efficiency of routing to the nucleus increases with the number of nuclear localization signals (NLS) associated with a cargo. The quantitative enhancement, however, depends on the identity of the PTD sequence as well as the targeted cell type. Thus the choice and multivalent presentation of PTD and NLS sequences are important criteria guiding the design of macromolecules intended for specific intracellular localization. This review outlines synthetic and recombinant strategies whereby PTDs and signal sequences can be assembled into multivalent peptide dendrimers and promote the uptake and routing of their cargoes. In particular, the tetramerization domain of the tumour suppressor p53 (p53(tet)) is emerging as a useful scaffold to present multiple routing and targeting moieties. Short cationic peptides fused to the 31-residue long p53(tet) sequence resulted in tetramers displaying a significant enhancement (up to 1000 fold) in terms of their ability to be imported into cells and delivered to the cell nucleus in relation to their monomeric analogues. The design of future polycationic peptide dendrimers as effective delivering vehicles will need to incorporate selective cell targeting functions and provide solutions to the issue of endosomal entrapment. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.
RP Gariepy, J (reprint author), Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Dept Med Biophys, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.
EM gariepy@uhnres.utoronto.ca
CR Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328
   Albarran B, 2005, PROTEIN ENG DES SEL, V18, P147, DOI 10.1093/protein/gzi014
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299
   Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473
   Barka T, 2000, J HISTOCHEM CYTOCHEM, V48, P1453, DOI 10.1177/002215540004801102                                                      
   Bello RM, 2001, BIOCONJUG CHEM, V12, P92
   BERTINI I, 1994, EUR BIOPHYS J BIOPHY, V23, P167, DOI 10.1007/BF01007608
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Bisland SK, 1999, BIOCONJUGATE CHEM, V10, P982, DOI 10.1021/bc990020u
   Borsi L, 2002, INT J CANCER, V102, P75, DOI 10.1002/ijc.10662
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3                                                    
   Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Dilber MS, 1999, GENE THER, V6, P12, DOI 10.1038/sj.gt.3300838
   DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2
   DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279
   EDWARDS RA, 1992, BIOCHEM CELL BIOL, V70, P63, DOI 10.1139/o92-009                                                                 
   EDWARDS RA, 1990, BIOCHEMISTRY-US, V29, P11001, DOI 10.1021/bi00501a019
   Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998
   Eum WS, 2002, MOL CELLS, V13, P334
   Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699                                                        
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fernandez-Escamilla AM, 2004, NAT BIOTECHNOL, V22, P1302, DOI 10.1038/nbt1012
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Gariepy J, 2001, TRENDS BIOTECHNOL, V19, P21, DOI 10.1016/S0167-7799(00)01520-1                                                   
   Goel A, 2000, CANCER RES, V60, P6964
   GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0
   Gonzalez M, 1997, J BIOL CHEM, V272, P11288
   Harada H, 2002, CANCER RES, V62, P2013
   Hellgren I, 2004, J DRUG TARGET, V12, P39, DOI 10.1080/106118604200041403
   Hu SZ, 1996, CANCER RES, V56, P3055
   Huhalov A, 2004, Q J NUCL MED MOL IM, V48, P279
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879                                                         
   Jin LH, 2001, FREE RADICAL BIO MED, V31, P1509, DOI 10.1016/S0891-5849(01)00734-1
   JOHNSON CR, 1995, BIOCHEMISTRY-US, V34, P5309, DOI 10.1021/bi00016a002
   Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8
   Kawamura KS, 2002, J IMMUNOL, V168, P5709, DOI 10.4049/jimmunol.168.11.5709                                                    
   KAWAMURA KS, IN PRESS BIOCHEMISTR
   Kiessling LL, 2000, CURR OPIN CHEM BIOL, V4, P696, DOI 10.1016/S1367-5931(00)00153-8
   Kilk K, 2001, BIOCONJUGATE CHEM, V12, P911, DOI 10.1021/bc0100298
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kircher MF, 2003, CANCER RES, V63, P6838
   Kitov PI, 2003, J AM CHEM SOC, V125, P16271, DOI 10.1021/ja038223n
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703                                                                   
   Kollen WJW, 1999, AM J RESP CELL MOL, V20, P1081, DOI 10.1165/ajrcmb.20.5.3417                                                        
   Kwon HY, 2000, FEBS LETT, V485, P163, DOI 10.1016/S0014-5793(00)02215-8
   Lea NC, 2003, MOL CELL BIOL, V23, P2351, DOI 10.1128/MCB.23.7.2351-2361.2003
   LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877
   LEE YC, 1983, J BIOL CHEM, V258, P199
   LEPOCK JR, 1985, ARCH BIOCHEM BIOPHYS, V241, P243, DOI 10.1016/0003-9861(85)90380-7
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598
   Li WJ, 2004, ADV DRUG DELIVER REV, V56, P967, DOI 10.1016/j.addr.2003.10.041
   Linding R, 2004, J MOL BIOL, V342, P345, DOI 10.1016/j.jmb.2004.06.088
   Litowski JR, 2001, J PEPT RES, V58, P477, DOI 10.1034/j.1399-3011.2001.10972.x
   Liu C, 2001, J GENE MED, V3, P145, DOI 10.1002/jgm.164
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Matsushita M, 2004, FEBS LETT, V572, P221, DOI 10.1016/j.febslet.2004.07.033
   Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137
   Michiue H, 2005, J BIOL CHEM, V280, P8285, DOI 10.1074/jbc.M412430200
   MIDOUX P, 1993, NUCLEIC ACIDS RES, V21, P871, DOI 10.1093/nar/21.4.871                                                            
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Moriguchi R, 2005, INT J PHARM, V301, P277, DOI 10.1016/j.ijpharm.2005.05.021
   Moy P, 1996, MOL BIOTECHNOL, V6, P105, DOI 10.1007/BF02740767                                                              
   Nakanishi M, 2003, CURR PROTEIN PEPT SC, V4, P141, DOI 10.2174/1389203033487234
   Niemeyer CM, 1999, NUCLEIC ACIDS RES, V27, P4553, DOI 10.1093/nar/27.23.4553                                                          
   Oneda H, 2003, J BIOCHEM, V134, P683, DOI 10.1093/jb/mvg193
   Orii KO, 2005, MOL THER, V12, P345, DOI 10.1016/j.ymthe.2005.02.031
   Ou JS, 2003, BIOCHEM BIOPH RES CO, V305, P605, DOI 10.1016/S0006-291X(03)00803-9
   PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678                                                          
   Park J, 2002, MOL CELLS, V13, P202
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   ROE JA, 1988, BIOCHEMISTRY-US, V27, P950, DOI 10.1021/bi00403a017
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   RYSER HJP, 1965, SCIENCE, V150, P501, DOI 10.1126/science.150.3695.501
   RYSER HJP, 1967, NATURE, V215, P934, DOI 10.1038/215934a0
   RYSER HJP, 1968, SCIENCE, V159, P390, DOI 10.1126/science.159.3813.390
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Santimaria M, 2003, CLIN CANCER RES, V9, P571
   Sarkar T, 2005, NUCLEIC ACIDS RES, V33, P143, DOI 10.1093/nar/gki156
   Schally AV, 2004, TRENDS ENDOCRIN MET, V15, P300, DOI 10.1016/j.tem.2004.07.002
   Schally AV, 2004, CELL MOL LIFE SCI, V61, P1042, DOI 10.1007/s00018-004-3434-3
   Schally AV, 2003, LIFE SCI, V72, P2305, DOI 10.1016/S0024-3205(03)00113-9
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SCHWARZENBACH G, 1952, HELV CHIM ACTA, V35, P2344, DOI 10.1002/hlca.19520350721                                                        
   SHELDON K, 1995, P NATL ACAD SCI USA, V92, P2056, DOI 10.1073/pnas.92.6.2056
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Singh D, 1998, BIOCHEMISTRY-US, V37, P5798, DOI 10.1021/bi972762l
   Singh D, 1999, BIOCONJUGATE CHEM, V10, P745, DOI 10.1021/bc980131d
   Singh RS, 2004, CHEM BIOL, V11, P713, DOI 10.1016/j.chembiol.2004.03.026
   Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647                                                        
   Sparrow J. T., 1998, ADV DRUG DELIV REV, V30, P115, DOI [10.1016/S0169-409X(97)00111-710837606, DOI 10.1016/S0169-409X(97)00111-710837606]
   Tanaka Yoshiyuki, 2003, Journal of Immunology, V170, P1291
   Tasciotti E, 2003, CANCER GENE THER, V10, P64, DOI 10.1038/sj.cgt.7700526
   TOMINO S, 1975, J BIOL CHEM, V250, P7752
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2002, CELL MOL BIOL LETT, V7, P265
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Waner MJ, 2004, BIOPHYS J, V87, P2701, DOI 10.1529/biophysj.104.047266
   Wang J, 1999, MOL CELL BIOL, V19, P6217
   Watanabe N, 2003, BIOCHEM BIOPH RES CO, V303, P287, DOI 10.1016/S0006-291X(03)00335-8
   Willuda J, 2001, J BIOL CHEM, V276, P14385, DOI 10.1074/jbc.M011669200                                                          
   WU CH, 1989, J BIOL CHEM, V264, P16985
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Yoon HY, 2002, NEUROCHEM INT, V41, P37, DOI 10.1016/S0197-0186(01)00138-3
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 114
TC 31
Z9 32
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD MAR
PY 2006
VL 1758
IS 3
BP 355
EP 363
DI 10.1016/j.bbamem.2005.11.016
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 054AF
UT WOS:000238347000012
PM 16442074
OA gold
DA 2018-01-05
ER

PT J
AU Hu, MD
   Chen, P
   Wang, J
   Chan, C
   Scollard, DA
   Reilly, RM
AF Hu, MD
   Chen, P
   Wang, J
   Chan, C
   Scollard, DA
   Reilly, RM
TI Site-specific conjugation of HIV-1 tat peptides to IgG: a potential
   route to construct radioimmunoconjugates for targeting intracellular and
   nuclear epitopes in cancer
SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
LA English
DT Article
DE immunoglobulins; nuclear translocation; HIV-1 tat peptides; iodine-123;
   breast cancer
ID HUMAN IMMUNODEFICIENCY VIRUS; MEMBRANE-PERMEABLE PEPTIDES; IN-VIVO;
   MONOCLONAL-ANTIBODY; CELLULAR UPTAKE; MAGNETIC NANOPARTICLES; PROTEIN
   TRANSDUCTION; MAMMALIAN-CELLS; DELIVERY; INTERNALIZATION
AB Purpose: Our objective was to study the cellular and nuclear uptake of I-123-mouse IgG (I-123-mIgG) linked to peptides [GRKKRRQRRRPPQGYGC] harbouring the membrane-translocating and nuclear import sequences of HIV-1 tat protein.
   Methods: Carbohydrates on mIgG were oxidized by NaIO4, then reacted with a 40-fold excess of peptides. Displacement of binding of anti-mouse IgG (Fab specific; alpha-mFab) to I-123-mIgG by tat-mIgG or mIgG was compared. Internalization and nuclear translocation of I-123-tat-mIgG in MDA-MB-468, MDA-MB-231 or MCF-7 breast cancer cells were measured. The immunoreactivity of imported tat-mIgG was evaluated by measuring binding of I-123-alpha-mFab to cell lysate and by displacement of binding of I-123-mIgG to alpha-mFab by cell lysate. Biodistribution and nuclear uptake of I-123-tat-mIgG, I-123-mIgG and I-123-tat were compared in mice bearing s.c. MDA-MB-468 tumours.
   Results: There was a 15-fold decrease in affinity of alpha-mFab for tat-mIgG compared with mIgG. Internalized radioactivity imported into the nucleus for I-123-tat-mIgG in MDA-MB-468, MDA-MB-231 and MCF-7 cells was 61.5 +/- 0.6%, 60.3 +/- 3.6% and 64.7 +/- 1.0%, respectively. The binding of I-123-alpha-mFab to lysate from MDA-MB-468 cells importing tat-mIgG was 17-fold higher than that for cells not exposed to tat-mIgG. Imported tat-mIgG competed with tat-mIgG for displacement of binding of I-123-mIgG to alpha-mFab. Conjugation of mIgG to tat peptides did not change tissue distribution. Nuclear localization for I-123-tat-mIgG in MDA-MB-468 tumours was 28.1 +/- 5.6%, and for liver, spleen and kidneys it was 41.7 +/- 2.7%, 13.8 +/- 0.8% and 36.9 +/- 3.3%, respectively.
   Conclusion: I-123-tat-mIgG radioimunoconjugates suggest a route to the design of radiopharmaceuticals exploiting intracellular and nuclear epitopes.
C1 Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 2S2, Canada.
   Univ Hlth Network, Div Nucl Med, Toronto, ON, Canada.
   Univ Toronto, Dept Pharmaceut Sci, Toronto, ON, Canada.
   Univ Toronto, Dept Med Imaging, Toronto, ON, Canada.
RP Reilly, RM (reprint author), Univ Toronto, Leslie Dan Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.
EM raymond.reilly@utoronto.ca
CR ALVAREZ VL, 1988, ANTIBODY MEDIATED DE, P283
   ARNHEITER H, 1988, EMBO J, V7, P1315
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   AWWAD M, 1994, CANCER IMMUNOL IMMUN, V38, P23, DOI 10.1007/BF01517166
   CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
   Cohen PA, 1998, ONCOGENE, V17, P2445, DOI 10.1038/sj.onc.1202190
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Divgi C R, 1996, Oncology (Williston Park), V10, P939
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173
   Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   HU M, 2002, EUR J NUCL MED MO S1, V29, pS378
   KHAW BA, 1979, CIRCULATION, V60, P1527
   KING TP, 1986, BIOCHEMISTRY-US, V25, P5774, DOI 10.1021/bi00367a064                                                             
   KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1
   Park JW, 2002, CLIN CANCER RES, V8, P1172
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   RICHTMYER RD, 1978, PRINCIPLES ADV MATH, V1, P90
   RODWELL JD, 1986, P NATL ACAD SCI USA, V83, P2632, DOI 10.1073/pnas.83.8.2632
   Saha G. B., 1992, FUNDAMENTALS NUCL PH
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SHESHBERADARAN H, 1988, P NATL ACAD SCI USA, V85, P1, DOI 10.1073/pnas.85.1.1                                                             
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Urbain JL, 1999, J NUCL MED, V40, P498
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3
   WELT S, 1987, P NATL ACAD SCI USA, V84, P4200, DOI 10.1073/pnas.84.12.4200
   Whiteman M, 2004, FASEB J, V18, P1395, DOI 10.1096/fj.03-1096fje
   Zeng YX, 1996, ONCOGENE, V12, P1557
NR 37
TC 24
Z9 24
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 1619-7070
J9 EUR J NUCL MED MOL I
JI Eur. J. Nucl. Med. Mol. Imaging
PD MAR
PY 2006
VL 33
IS 3
BP 301
EP 310
DI 10.1007/s00259-005-1908-7
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 022CK
UT WOS:000236032100012
PM 16258763
DA 2018-01-05
ER

PT J
AU Vyas, SP
   Subhedar, R
   Jain, S
AF Vyas, SP
   Subhedar, R
   Jain, S
TI Development and characterization of emulsomes for sustained and targeted
   delivery of an antiviral agent to liver
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-SYNDROME AIDS; CATIONIC LIPOSOMES; ZIDOVUDINE;
   PHARMACOKINETICS; ENDOCYTOSIS; INFECTION; MICE
AB In this study we developed emulsomes, a novel lipoidal vesicular system with an internal solid fat core surrounded by a phospholipid bilayer. Plain emulsomal formulations composed of solid lipid (trilaurin or tristearin), cholesterol and soya phosphatidylcholine and stearylamine containing cationic emulsomes loaded with an antiviral drug (zidovudine) were prepared by a simple cast film method followed by sonication to produce emulsomes of nanometric size range. All different types of formulations were optimized for lipid ratios and characterized in-vitro for shape, morphology, size and in-vitro drug release profile. Emulsomal formulations displayed a sufficiently slow drug release profile (12-15% after 24h). in-vivo organ distribution studies in rats demonstrated better uptake of emulsomal formulations by the liver cells. Further, a significantly higher (P < 0.05) liver concentration of drug was estimated over a period of 24 h for cationic emulsomes than for plain neutral emulsomes. We concluded that cationic emulsomes could fuse with the endosomal membrane due to charge-charge interaction and were released in the cytoplasm before lysosomal degradation and could sustain drug release over a prolonged period. The proposed cationicemulsome-based system showed excellent potential for intracellular hepatic targeting and the strategy could play a vital role in the effective treatment of life-threatening viral infections, such as hepatitis, HIV and Epstein-Barr virus infection.
C1 Def Res & Dev Org, Div Radiopharmaceut, NanoTech & Stem Cell Res, Inst Nucl Med & Allied Sci, Delhi 110054, India.
   Dr Hari Singh Gour Univ, Dept Pharmaceut Sci, Drug Delivery Res Lab, Sagar 470003, Madhya Pradesh, India.
RP Jain, S (reprint author), Def Res & Dev Org, Div Radiopharmaceut, NanoTech & Stem Cell Res, Inst Nucl Med & Allied Sci, Brig SK Mazumdar Rd, Delhi 110054, India.
EM sanyogjain@rediffmail.com
OI Jain, Sanyog/0000-0002-0688-9563
CR Amselem AS, 1994, P INT S CONTR REL BI, V21, P1369
   BLUM MR, 1988, AM J MED, V85, P189
   CLOAD PA, 1989, J INFECTION, V18, P15, DOI 10.1016/S0163-4453(89)80076-3
   Erion MD, 2005, J PHARMACOL EXP THER, V312, P554, DOI 10.1124/jpet.104.075903
   Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7
   FRIJUSPLESSEN N, 1990, J CHROMATOGR-BIOMED, V534, P101, DOI 10.1016/S0378-4347(00)82152-0
   FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0
   GILL PS, 1987, ANN INTERN MED, V107, P502, DOI 10.7326/0003-4819-107-4-502
   Heiati H, 1996, PHARMACEUT RES, V13, P1406, DOI 10.1023/A:1016090420759                                                         
   KENDE M, 1985, ANTIMICROB AGENTS CH, V27, P903, DOI 10.1128/AAC.27.6.903                                                            
   Kretschmar M, 2001, MYCOSES, V44, P281, DOI 10.1046/j.1439-0507.2001.00654.x
   Lambros M. Polikandritou, 2002, Research Communications in Molecular Pathology and Pharmacology, V112, P50
   LIANG V, 1977, ANN NY ACAD SCI, V507, P7
   Lowell GH, 1997, J INFECT DIS, V175, P292, DOI 10.1093/infdis/175.2.292                                                        
   MEIJER DKF, 1992, ANTIVIR RES, V18, P215, DOI 10.1016/0166-3542(92)90058-D
   NEW RRC, 1990, LIPOSOMES PRACTICAL, P1
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   Shi Jing, 2004, Yaoxue Xuebao, V39, P551
   VENUGOPALAN P, 2002, PHARM, V56, P659
   WALKER RE, 1988, ANN INTERN MED, V108, P372, DOI 10.7326/0003-4819-108-3-372
   WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A
NR 21
TC 33
Z9 35
U1 0
U2 2
PU PHARMACEUTICAL PRESS-ROYAL PHARMACEUTICAL SOC GREAT BRITIAN
PI LONDON
PA 1 LAMBETH HIGH ST, LONDON SE1 7JN, ENGLAND
SN 0022-3573
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD MAR
PY 2006
VL 58
IS 3
BP 321
EP 326
DI 10.1211/jpp.58.3.0005
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 021TH
UT WOS:000236008100005
PM 16536898
DA 2018-01-05
ER

PT J
AU Sommer, AP
   Gheorghiu, E
AF Sommer, AP
   Gheorghiu, E
TI Proteobionics: Biomimetics in proteomics
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE proteobionics; biomimetics; drug delivery; nanovesicles; nanoparticles;
   HIV
ID PRIMORDIAL PROTEINS; LIVING NANOVESICLES; PART II; POSSIBLE PROVENANCE;
   MODEL SIMULATION; EGYPTIAN MUMMIES; NERVE-FIBERS; NANOBACTERIA; HIV;
   SKIN
AB Proteomics was established 10 years ago by the analysis of microbial genomes via their protein complement or proteome. Bionics is an ancient art, which converts structures optimized by nature into advanced technical products. Previously, we analyzed survival modalities in nanobacteria and converted the interplay between survival-oriented protein functions and nanoscale mineral shells into models-for advanced drug delivery. Exploiting protein functions observed in nature to design biomedical products and therapies could be named proteobionics. Here, we present examples for this new branch of nanoproteomics.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
   Natl Inst Pharmaceut Chem, R&D, Bucharest 031299, Romania.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Akerman KK, 1997, P SOC PHOTO-OPT INS, V3111, P436, DOI 10.1117/12.278798
   Bailey M, 2001, AM J PATHOL, V159, P1981, DOI 10.1016/S0002-9440(10)63048-9
   Bertrand L, 2003, J SYNCHROTRON RADIAT, V10, P387, DOI 10.1107/S0909049503015334
   Breen RAM, 2005, AIDS, V19, P1201, DOI 10.1097/01.aids.0000176221.33237.67                                             
   Brotz-Oesterhelt H, 2005, MASS SPECTROM REV, V24, P549, DOI 10.1002/mas.20030
   CHIN JC, 1992, VET MICROBIOL, V32, P63, DOI 10.1016/0378-1135(92)90007-G                                                    
   CIFTCIOGLU N, 1998, PATHOPHYSIOLOGY, V4, P259
   Ciftcioglu Neva, 1996, Molecular Biology of the Cell, V7, p517A
   Emanuel K, 2005, NATURE, V436, P686, DOI 10.1038/nature03906
   Fahrenkrog B, 2004, TRENDS BIOCHEM SCI, V29, P175, DOI 10.1016/j.tibs.2004.02.006
   Fan R, 2005, NANO LETT, V5, P1633, DOI 10.1021/nl0509677
   FEYNMAN R, 1960, CALTECHS ENG SCI
   Finn J, 2004, GENE THER, V11, P276, DOI 10.1038/sj.gt.3302172
   Ghosh S, 2003, SCIENCE, V299, P1042, DOI 10.1126/science.1079080
   GOLDFARB DS, 2004, NEPHRON PHYSIOL, V98, P48, DOI DOI 10.1159/000080264
   Gregory JM, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023209
   HANCOCK W, 2005, J PROTEOME RES, V3, P657
   HINO H, 1982, ACTA PATH MICRO IM B, V90, P21
   HOGAN J, 2004, NEW SCI          MAY, P19
   HRDY DB, 1987, REV INFECT DIS, V9, P1109
   Jaenicke R, 2005, SCIENCE, V308, P73, DOI 10.1126/science.1106335
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kaiser J, 2005, SCIENCE, V307, P1858
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   KALIBALA S, 1990, AIDS ACTION, V10, P2
   Kim BH, 2004, APPL MICROBIOL BIOT, V63, P672, DOI 10.1007/s00253-003-1412-6
   KIM KM, 1976, FED PROC, V35, P156
   Liepert BG, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019060
   Limbach LK, 2005, ENVIRON SCI TECHNOL, V39, P9370, DOI 10.1021/es051043o
   MERRITT GC, 1978, AUST VET J, V54, P517, DOI 10.1111/j.1751-0813.1978.tb00318.x
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   Mizuno T, 2005, AM J PHYSIOL-HEART C, V288, pH2819, DOI 10.1152/ajpheart.00862.2004
   PERRIN C, 1994, ANN DERMATOL VENER, V121, P470
   Porter AMW, 2001, J ROY SOC MED, V94, P236
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   Puskas LG, 2005, ACTA BIOL HUNG, V56, P233, DOI 10.1556/ABiol.56.2005.3-4.7
   Rieu P, 2005, ANN UROL, V39, P16, DOI 10.1016/j.anuro.2005.01.001                                                     
   Sattler B, 2001, GEOPHYS RES LETT, V28, P239, DOI 10.1029/2000GL011684
   SCHMID K, 1980, ATHEROSCLEROSIS, V37, P199, DOI 10.1016/0021-9150(80)90005-2
   Schmitt O. H., 1969, P 3 INT BIOPH C BOST, P297
   Sommer AP, 2006, J ENVIRON MONITOR, V8, P341, DOI 10.1039/b512496d
   Sommer AP, 2006, CRYST GROWTH DES, V6, P492, DOI 10.1021/cg050418e
   Sommer AP, 2005, J PROTEOME RES, V4, P1022, DOI 10.1021/pr050064e
   Sommer AP, 2005, CRYST GROWTH DES, V5, P551, DOI 10.1021/cg0496989
   Sommer AP, 2005, J PROTEOME RES, V4, P633, DOI 10.1021/pr049795p
   Sommer AP, 2005, J PROTEOME RES, V4, P180, DOI 10.1021/pr0498382
   Sommer AP, 2004, J PROTEOME RES, V3, P1296, DOI 10.1021/pr049861n
   Sommer AP, 2004, J PROTEOME RES, V3, P1086, DOI 10.1021/pr049935v
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2004, J PROTEOME RES, V3, P667, DOI 10.1021/pr034122c
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   SOMMER AP, 2004, P WORLD C DOS ANT MA, pA131
   STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512                                                        
   Stucker M, 2001, HAUTARZT, V52, P316, DOI 10.1007/s001050051314                                                           
   Thomson MM, 2002, LANCET INFECT DIS, V2, P461, DOI 10.1016/S1473-3099(02)00343-2                                                   
   Vinnikov KY, 2003, SCIENCE, V302, P269, DOI 10.1126/science.1087910
   WASINGER VC, 1995, ELECTROPHORESIS, V16, P1090, DOI 10.1002/elps.11501601185
   Welzel T, 2004, J MATER CHEM, V14, P2213, DOI 10.1039/b401644k
   XIE TD, 1990, BIOPHYS J, V58, P13, DOI 10.1016/S0006-3495(90)82349-3                                                   
   Yu S Y, 1974, Adv Exp Med Biol, V43, P403
   Zwiorek Klaus, 2005, J Pharm Pharm Sci, V7, P22
NR 65
TC 4
Z9 4
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR
PY 2006
VL 5
IS 3
BP 611
EP 618
DI 10.1021/pr050370s
PG 8
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 020GP
UT WOS:000235897000017
PM 16512676
DA 2018-01-05
ER

PT J
AU Brugger, B
   Glass, B
   Haberkant, P
   Leibrecht, I
   Wieland, FT
   Krausslich, HG
AF Brugger, B
   Glass, B
   Haberkant, P
   Leibrecht, I
   Wieland, FT
   Krausslich, HG
TI The HIV lipidome: A raft with an unusual composition
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE dihydrosphingomyelin; nano-electrospray ionization tandem mass
   spectrometry; lipid analysis; viral membrane
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TANDEM MASS-SPECTROMETRY; CELL-MEMBRANES;
   QUANTITATIVE-ANALYSIS; PLASMA-MEMBRANE; LENS MEMBRANES; CHOLESTEROL;
   SPHINGOMYELIN; DOMAINS; PROTEIN
AB The lipids of enveloped viruses play critical roles in viral morphogenesis and infectivity. They are derived from the host membranes from which virus budding occurs, but the precise lipid composition has not been determined for any virus. Employing mass spectrometry, this study provides a quantitative analysis of the lipid constituents of HIV and a comprehensive comparison with its host membranes. Both a substantial enrichment of the unusual sphingolipid dihydrosphingomyelin and a loss of viral infectivity upon inhibition of sphingolipid biosynthesis in host cells are reported, establishing a critical role for this lipid class in the HIV replication cycle. Intriguingly, the overall lipid composition of native HIV membranes resembles detergent-resistant membrane microdomains and is strikingly different from that of host cell membranes. With this composition, the HIV lipidome provides strong evidence for the existence of lipid rafts in living cells.
C1 Univ Heidelberg, Ctr Biochem, BZH, D-69120 Heidelberg, Germany.
   Univ Klinikum Heidelberg, Dept Virol, D-69120 Heidelberg, Germany.
RP Krausslich, HG (reprint author), Univ Heidelberg, Ctr Biochem, BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.
EM hans-georg.kraeusslich@med.uni-heidelberg.de
OI Haberkant, Per/0000-0002-5608-9062
CR ABACIOGLU YH, 1994, AIDS RES HUM RETROV, V10, P371, DOI 10.1089/aid.1994.10.371
   ADACHI A, 1986, J VIROL, V59, P284
   ALOIA RC, 1988, P NATL ACAD SCI USA, V85, P900, DOI 10.1073/pnas.85.3.900
   ALOIA RC, 1993, P NATL ACAD SCI USA, V90, P5181, DOI 10.1073/pnas.90.11.5181
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Briggs JAG, 2004, NAT STRUCT MOL BIOL, V11, P672, DOI 10.1038/nsmb785
   Briggs JAG, 2003, EMBO J, V22, P1707, DOI 10.1093/emboj/cdg143                                                            
   Brugger B, 2000, J CELL BIOL, V151, P507, DOI 10.1083/jcb.151.3.507
   Brugger B, 2004, J BIOL CHEM, V279, P7530, DOI 10.1074/jbc.M310207200
   Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339                                                          
   BYRDWELL WC, 1994, INVEST OPHTH VIS SCI, V35, P4333
   Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004
   Epand RM, 2003, BIOPHYS J, V84, P3102, DOI 10.1016/S0006-3495(03)70035-6                                                   
   Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324                                                               
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Koivusalo M, 2001, J LIPID RES, V42, P663
   Kuikka M, 2001, BIOPHYS J, V80, P2327, DOI 10.1016/S0006-3495(01)76203-0                                                   
   Kusumi A, 2004, TRAFFIC, V5, P213, DOI 10.1111/j.1600-0854.2004.0178.x
   Lagerholm BC, 2005, ANNU REV PHYS CHEM, V56, P309, DOI 10.1146/annurev.physchem.56.092503.141211
   Lu YE, 2000, J VIROL, V74, P7708, DOI 10.1128/JVI.74.17.7708-7719.2000                                                
   Matsuo H, 2004, SCIENCE, V303, P531, DOI 10.1126/science.1092425
   Muller B, 2004, J VIROL, V78, P10803, DOI 10.1128/JVI.78.19.10803-10813.2004
   Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1
   Nagan N, 2001, PROG LIPID RES, V40, P199, DOI 10.1016/S0163-7827(01)00003-0
   Nyholm T, 2003, BIOPHYS J, V84, P987, DOI 10.1016/S0006-3495(03)74915-7                                                   
   Ono A, 2005, ADV VIRUS RES, V64, P311, DOI 10.1016/S0065-3527(05)64010-9
   Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298
   Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557
   ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316
   Scheiffele P, 1999, J BIOL CHEM, V274, P2038, DOI 10.1074/jbc.274.4.2038
   Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100
   Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803                                        
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Stuven E, 2003, J BIOL CHEM, V278, P53112, DOI 10.1074/jbc.M300402200
   Sullards MC, 2000, METHOD ENZYMOL, V312, P32
   WANG E, 1991, J BIOL CHEM, V266, P14486
   Wang YZ, 2000, TRAFFIC, V1, P952, DOI 10.1034/j.1600-0854.2000.011205.x
   Welker R, 2000, J VIROL, V74, P1168, DOI 10.1128/JVI.74.3.1168-1177.2000
NR 38
TC 409
Z9 414
U1 5
U2 45
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 21
PY 2006
VL 103
IS 8
BP 2641
EP 2646
DI 10.1073/pnas.0511136103
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015MG
UT WOS:000235554900031
PM 16481622
OA gold
DA 2018-01-05
ER

PT J
AU Cho, YN
   Ivanisevic, A
AF Cho, YN
   Ivanisevic, A
TI Mapping the interaction forces between TAR RNA and TAT peptides on GaAs
   surfaces using chemical force microscopy
SO LANGMUIR
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; DIP-PEN NANOLITHOGRAPHY; ACOUSTIC-WAVE
   SENSOR; BINDING-SPECIFICITY; PERMEABLE PEPTIDES; PROTEINS; GOLD;
   ALKANETHIOLS; RECOGNITION; GAAS(100)
AB The complexation of the HIV transactivation response element (TAR) RNA with the viral regulatory protein TAT is of enormous interest for the design of new sensing and therapeutic strategies. In this work, we anchored TAT peptides on GaAs surfaces using microcontact printing. Atomic force microscopy was used to quantify the interaction between TAR RNA and model TAT peptide sequences. Different pH conditions were utilized in order to assess specific vs nonspecific interactions. AFM tips functionalized with TAR RNA molecules were used to collect adhesion maps that displayed stronger interaction with peptide sequences that contained a greater number of arginine residues. All of the studies consistently showed a pH dependence of the interaction between the surface bound peptides and the TAR RNA on the AFM tips. This work quantifies the TAR RNA/TAT peptide interaction after one of the molecules is anchored on a surface. The conclusions in this paper are consistent with previous work and demonstrate that cationic residues are responsible for the polyelectrolyte-like affinity of TAT peptides for TAR RNA.
C1 Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
   Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.
RP Ivanisevic, A (reprint author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.
EM albena@purdue.edu
CR Adlkofer K, 2003, J PHYS CHEM B, V107, P587, DOI 10.1021/jp0267813
   Akhremitchev BB, 1998, LANGMUIR, V14, P3976, DOI 10.1021/la970911v                                                               
   Bernard A, 2000, ADV MATER, V12, P1067, DOI 10.1002/1521-4095(200007)12:14<1067::AID-ADMA1067>3.3.CO;2-D
   Bernard A, 1998, LANGMUIR, V14, P2225, DOI 10.1021/la980037l                                                               
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   Cho Y, 2005, J PHYS CHEM B, V109, P6225, DOI 10.1021/jp045731q
   Cho Y, 2005, J PHYS CHEM B, V109, P12731, DOI 10.1021/jp0515737
   Cho Y, 2004, J PHYS CHEM B, V108, P15223, DOI 10.1021/jp048359n
   Demers LM, 2002, SCIENCE, V296, P1836, DOI 10.1126/science.1071480
   Enander K, 2005, LANGMUIR, V21, P2480, DOI 10.1021/la048029u
   FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628
   Futaki S, 2003, CURR PROTEIN PEPT SC, V4, P87, DOI 10.2174/1389203033487261                                                        
   Gelman MA, 2003, ORG LETT, V5, P3563, DOI 10.1021/ol034977v
   Goede K, 2004, NANO LETT, V4, P2115, DOI 10.1021/nl048829p
   Grinevich O, 1999, LANGMUIR, V15, P2077, DOI 10.1021/la981107r                                                               
   Hariton-Gazal E, 2002, BIOCHEMISTRY-US, V41, P9208, DOI 10.1021/bi0201466
   Huq I, 1997, NAT STRUCT BIOL, V4, P881, DOI 10.1038/nsb1197-881
   Jennings GK, 2003, J AM CHEM SOC, V125, P2950, DOI 10.1021/ja020233l                                                               
   Kane RS, 1999, BIOMATERIALS, V20, P2363, DOI 10.1016/S0142-9612(99)00165-9
   Kikuta E, 2001, J AM CHEM SOC, V123, P7911, DOI 10.1021/ja0108335
   KUMAR A, 1994, LANGMUIR, V10, P1498, DOI 10.1021/la00017a030                                                             
   LAIBINIS PE, 1991, J AM CHEM SOC, V113, P7152, DOI 10.1021/ja00019a011
   Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h
   LONG KS, 1995, BIOCHEMISTRY-US, V34, P8885, DOI 10.1021/bi00027a041
   NUZZO RG, 1990, J AM CHEM SOC, V112, P558, DOI 10.1021/ja00158a012
   Olsen GL, 2005, NUCLEIC ACIDS RES, V33, P3447, DOI 10.1093/nar/gki626
   Pardo L, 2003, LANGMUIR, V19, P1462, DOI 10.1021/la026171u
   Petroni S, 2004, APPL PHYS LETT, V85, P1039, DOI 10.1063/1.1780598
   Petrovykh DY, 2004, LANGMUIR, V20, P429, DOI 10.1021/la034944o
   Plassard C, 2005, LANGMUIR, V21, P7263, DOI 10.1021/la050440+
   Poggi MA, 2005, CHEM MATER, V17, P4289, DOI 10.1021/cm04834m
   Poggi MA, 2005, ANAL CHEM, V77, P1192, DOI 10.1021/ac048828h
   Runyon ST, 2003, J AM CHEM SOC, V125, P15704, DOI 10.1021/ja036344h
   Shaporenko A, 2004, J PHYS CHEM B, V108, P17964, DOI 10.1021/jp040474a
   Shaporenko A, 2003, LANGMUIR, V19, P4992, DOI 10.1021/la020909q
   SHEEN CW, 1992, J AM CHEM SOC, V114, P1514, DOI 10.1021/ja00030a076                                                             
   Tassew N, 2003, ORG BIOMOL CHEM, V1, P3268, DOI 10.1039/b307620m
   Tassew N, 2002, ANAL CHEM, V74, P5313, DOI 10.1021/ac025924e
   Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049
   Ukita H, 1997, OPT REV, V4, P623, DOI 10.1007/s10043-997-0623-y
   Uvdal K, 2001, LANGMUIR, V17, P2008, DOI 10.1021/la0009184                                                               
   Wang MS, 2004, LANGMUIR, V20, P7753, DOI 10.1021/la049849+
   Wang XF, 2004, J VAC SCI TECHNOL B, V22, P2563, DOI 10.1116/1.1805544                                                               
   Wang ZY, 2001, BIOCHEMISTRY-US, V40, P6458, DOI 10.1021/bi0028744
   Wangsa-Wirawan ND, 2001, BIOTECHNOL PROGR, V17, P963, DOI 10.1021/bp010072+
   Whaley SR, 2000, NATURE, V405, P665
   Xia YN, 1999, CHEM REV, V99, P1823, DOI 10.1021/cr980002q                                                               
   Ye S, 2003, SURF SCI, V529, P163, DOI 10.1016/S0039-6028(03)00239-5
NR 48
TC 7
Z9 7
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD FEB 14
PY 2006
VL 22
IS 4
BP 1768
EP 1774
DI 10.1021/la052729x
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 012QS
UT WOS:000235354800059
PM 16460104
DA 2018-01-05
ER

PT J
AU Zhang, Q
   Sun, XY
   Watt, ED
   Al-Hashimi, HM
AF Zhang, Q
   Sun, XY
   Watt, ED
   Al-Hashimi, HM
TI Resolving the motional modes that code for RNA adaptation
SO SCIENCE
LA English
DT Article
ID HIV-1 TAR RNA; NMR RELAXATION; PROTEIN RECOGNITION; INDUCED FIT;
   CONFORMATION; DYNAMICS; REVEALS; BULGE; MACROMOLECULES; STABILIZATION
AB Using a domain elongation strategy, we decoupled internal motions in RNA from overall rotational diffusion. This allowed us to site-specifically resolve a manifold of motional modes in two regulatory RNAs from HIV-1 with the use of nuclear magnetic resonance spin relaxation methods. Base and sugar librations vary on a picosecond time scale and occur within helical domains that move collectively at diffusion-limited nanosecond time scales. Pivot points are short; functionally important, and highly mobile internal loops. These spontaneous changes in RNA conformation correlate quantitatively with those that follow adaptive recognition of diverse targets. Thus, ligands may stabilize existing RNA conformations rather than inducing new ones.
C1 Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
   Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA.
RP Al-Hashimi, HM (reprint author), Univ Michigan, Dept Chem, 930 N Univ Ave, Ann Arbor, MI 48109 USA.
EM hashimi@umich.edu
RI Watt, Eric/K-9819-2015; Zhang, Qi/B-5869-2014; Zhang, Qi/E-1722-2011;
   Zhang, Qi/F-3323-2010
OI Watt, Eric/0000-0002-1211-0229; Zhang, Qi/0000-0003-1754-4058; 
FU NIAID NIH HHS [R01 AI066975-01]
CR AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974
   ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Baram D, 2005, FEBS LETT, V579, P948, DOI 10.1016/j.febslet.2004.11.063
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Davis B, 2004, J MOL BIOL, V336, P343, DOI 10.1016/j.jmb.2003.12.046
   de la Torre JG, 2000, J MAGN RESON, V147, P138, DOI 10.1006/jmre.2000.2170
   Dingley AJ, 1999, J AM CHEM SOC, V121, P6019, DOI 10.1021/ja9908321                                                               
   Doudna JA, 2005, NAT STRUCT MOL BIOL, V12, P395, DOI 10.1038/nsmb932
   Du ZH, 2002, CHEM BIOL, V9, P707, DOI 10.1016/S1074-5521(02)00151-5
   Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200                                                          
   Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820                                                    
   Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819
   Lawrence DC, 2003, J MOL BIOL, V326, P529, DOI 10.1016/S0022-2836(02)01305-0
   Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y
   Lilley David M J, 2004, Methods Mol Biol, V252, P77
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073                                                          
   MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9                                                    
   Murchie AIH, 2004, J MOL BIOL, V336, P625, DOI 10.1016/j.jmn.2003.12.028
   Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t
   Pitt SW, 2004, J MOL BIOL, V338, P7, DOI 10.1016/j.jmb.2004.02.031
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Schroeder R, 2004, NAT REV MOL CELL BIO, V5, P908, DOI 10.1038/nrm1497
   Tugarinov V, 2001, J AM CHEM SOC, V123, P3055, DOI 10.1021/ja003803v
   Vallurupalli P, 2005, J AM CHEM SOC, V127, P6893, DOI 10.1021/ja0427799
   Vugmeyster L, 2003, J AM CHEM SOC, V125, P8400, DOI 10.1021/ja029480f
   Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575
NR 27
TC 173
Z9 175
U1 2
U2 31
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD FEB 3
PY 2006
VL 311
IS 5761
BP 653
EP 656
DI 10.1126/science.1119488
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 011GY
UT WOS:000235257400046
PM 16456078
DA 2018-01-05
ER

PT J
AU Fu, YZ
   Yuan, R
   Chai, YQ
   Zhou, L
   Zhang, Y
AF Fu, YZ
   Yuan, R
   Chai, YQ
   Zhou, L
   Zhang, Y
TI Coupling of a reagentless electrochemical DNA biosensor with conducting
   polymer film and nanocomposite as matrices for the detection of the HIV
   DNA sequences
SO ANALYTICAL LETTERS
LA English
DT Article
DE nanocomposite; polypyrrole; electrochemical impedance spectroscopy; DNA
   biosensor; human immunodeficiency virus
ID POLYPYRROLE-SILICA NANOCOMPOSITES; QUARTZ-CRYSTAL MICROBALANCE;
   IMPEDANCE SPECTROSCOPY; MODIFIED ELECTRODES; EXCHANGE POLYMERS; DOPED
   POLYPYRROLE; GLUCOSE-OXIDASE; ADSORPTION; OLIGONUCLEOTIDES;
   IMMOBILIZATION
AB This paper describes a reagentless electrochemical DNA biosensor applied to the detection of human immunodeficiency virus (HIV) sequences based on electrochemical impedance spectroscopy (EIS). The novel DNA biosensor has been elaborated by means of an opposite-charged adsorption Au-Ag nanocomposite to a conductive polymer polypyrrole (PPy) modified platinum electrode (Pt) and self-assembly the mercapto oligonucleotide probes onto the surface of modified electrode via the nanocomposite. The duplex formation was detected by measuring the electrochemical impedance signal of nucleic acids in phosphate buffer solution (PBS). Such response is based on the concomitant conductivity changes of the PPy film and nanocomposite. The reagentless scheme has been characterised using 21-mer synthetic oligonucleotides as models: parameters affecting the hybridization assay were explored and optimized. The detection limit is 5.0x10(-10) M of target oligonucleotides at 3 sigma. The potential for development of reagentless DNA hybridization analysis in the clinical diagnosis is being pursued.
C1 SW Univ Chongqing, Coll Chem & Chem Engn, Chongqink Key Lab Analyt Chem, Chongqing 400700, Peoples R China.
RP Yuan, R (reprint author), SW Univ Chongqing, Coll Chem & Chem Engn, Chongqink Key Lab Analyt Chem, Chongqing 400700, Peoples R China.
EM yuanruo@swu.edu.cn
CR ABEL ML, 1994, SYNTHETIC MET, V66, P225, DOI 10.1016/0379-6779(94)90071-X                                                    
   ARMENGAUD C, 1990, J ELECTROANAL CHEM, V277, P197, DOI 10.1016/0022-0728(90)85102-B                                                    
   Arrigan DWM, 1999, ELECTROANAL, V11, P647, DOI 10.1002/(SICI)1521-4109(199907)11:9<647::AID-ELAN647>3.0.CO;2-N                 
   Azioune A, 1999, SYNTHETIC MET, V102, P1419, DOI 10.1016/S0379-6779(98)00982-5                                                   
   Cai H, 2001, J ELECTROANAL CHEM, V510, P78, DOI 10.1016/S0022-0728(01)00548-4                                                   
   CHEHIMI MM, 1993, SYNTHETIC MET, V60, P183, DOI 10.1016/0379-6779(93)91278-A                                                    
   Cho YK, 2001, LANGMUIR, V17, P7732, DOI 10.1021/10113769
   DEINHAMMER RS, 1991, ANAL CHEM, V63, P1889, DOI 10.1021/ac00017a040
   EBATO H, 1994, ANAL CHEM, V66, P1683, DOI 10.1021/ac00082a014
   Farace G, 2002, BIOELECTROCHEMISTRY, V55, P1, DOI 10.1016/S1567-5394(01)00166-9                                                   
   FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0                                                          
   Fu YZ, 2005, BIOCHEM ENG J, V23, P37, DOI 10.1016/j.bej.2004.10.008
   GE H, 1992, REACT POLYM, V18, P133, DOI 10.1016/0923-1137(92)90251-V                                                    
   Gerard M, 2002, BIOSENS BIOELECTRON, V17, P345, DOI 10.1016/S0956-5663(01)00312-8
   Gerton JL, 1999, J BIOL CHEM, V274, P33480, DOI 10.1074/jbc.274.47.33480
   GRIMSHAW J, 1990, J ELECTROANAL CHEM, V281, P125, DOI 10.1016/0022-0728(90)87034-H                                                    
   Gros P, 2000, ELECTROCHIM ACTA, V46, P643
   GUSTAFSSON G, 1989, SYNTHETIC MET, V31, P163, DOI 10.1016/0379-6779(89)90812-6                                                    
   HOSHI T, 1995, ANAL CHEM, V67, P770, DOI 10.1021/ac00100a013                                                             
   KAJIYA Y, 1991, ANAL CHEM, V63, P49, DOI 10.1021/ac00001a009
   KANG ET, 1993, ADV POLYM SCI, V106, P135
   KEITA B, 1990, J ELECTROANAL CHEM, V279, P187, DOI 10.1016/0022-0728(90)85176-6                                                    
   LAIBINIS PE, 1991, J AM CHEM SOC, V113, P7152, DOI 10.1021/ja00019a011
   Lassalle N, 2001, J ELECTROANAL CHEM, V509, P48, DOI 10.1016/S0022-0728(01)00537-X                                                   
   Lassalle N, 2001, BIOSENS BIOELECTRON, V16, P295, DOI 10.1016/S0956-5663(01)00133-6
   Lillie G, 2001, SENSOR ACTUAT B-CHEM, V78, P249, DOI 10.1016/S0925-4005(01)00821-8
   Lin L, 2000, COLLOID SURFACE A, V175, P11, DOI 10.1016/S0927-7757(00)00459-3                                                   
   Livache T, 1998, ANAL BIOCHEM, V255, P188, DOI 10.1006/abio.1997.2462
   LIVACHE T, 1995, SYNTHETIC MET, V71, P2143, DOI 10.1016/0379-6779(94)03199-G
   MAO HY, 1989, J ELECTROANAL CHEM, V265, P127, DOI 10.1016/0022-0728(89)80184-6                                                    
   Martin C. R, 1998, ANAL CHEM, V70, p322A
   Michaels AM, 1999, J AM CHEM SOC, V121, P9932, DOI 10.1021/ja992128q                                                               
   Michalska AJ, 1999, ELECTROANAL, V11, P756, DOI 10.1002/(SICI)1521-4109(199907)11:10/11<756::AID-ELAN756>3.0.CO;2-O
   MIKSA B, 1995, COLLOID POLYM SCI, V273, P47
   MINEHAN DS, 1994, MACROMOLECULES, V27, P777, DOI 10.1021/ma00081a024                                                             
   Okahata Y, 1998, ANAL CHEM, V70, P1288, DOI 10.1021/ac970584w
   Pividori MI, 2000, BIOSENS BIOELECTRON, V15, P291, DOI 10.1016/S0956-5663(00)00071-3
   Saoudi B, 1997, J COLLOID INTERF SCI, V192, P269, DOI 10.1006/jcis.1997.5000                                                          
   Saoudi B, 1997, SYNTHETIC MET, V87, P97, DOI 10.1016/S0379-6779(96)03812-X
   SHIU KK, 1991, J ELECTROANAL CHEM, V309, P115, DOI 10.1016/0022-0728(91)87008-R                                                    
   Tian Y, 2005, SENSOR ACTUAT B-CHEM, V104, P23, DOI 10.1016/j.snb.2004.04.094
   TOLGYESI M, 1995, ELECTROCHIM ACTA, V40, P1127, DOI 10.1016/0013-4686(95)96917-X
   Wang J, 1999, ANAL CHIM ACTA, V402, P7, DOI 10.1016/S0003-2670(99)00531-0                                                   
   Wang J, 2000, LANGMUIR, V16, P2269, DOI 10.1021/la991122b                                                               
   WEITZ DA, 1985, SURF SCI, V158, P147, DOI 10.1016/0039-6028(85)90292-4                                                    
   ZHAO JG, 1992, J ELECTROANAL CHEM, V327, P109, DOI 10.1016/0022-0728(92)80140-Y                                                    
   Zhou F, 2004, SURF SCI, V561, P1, DOI 10.1016/j.susc.2004.05.077
NR 47
TC 23
Z9 24
U1 1
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0003-2719
J9 ANAL LETT
JI Anal. Lett.
PD FEB
PY 2006
VL 39
IS 3
BP 467
EP 482
DI 10.1080/00032710500536102
PG 16
WC Chemistry, Analytical
SC Chemistry
GA 020YV
UT WOS:000235950200003
DA 2018-01-05
ER

PT J
AU Sommer, AP
   Gheorghiu, E
   Cehreli, M
   Mester, AR
   Whelan, HT
AF Sommer, AP
   Gheorghiu, E
   Cehreli, M
   Mester, AR
   Whelan, HT
TI Biosensor for detection of nanobacteria in water
SO CRYSTAL GROWTH & DESIGN
LA English
DT Article
ID EVAPORATING SESSILE DROPLET; PRIMORDIAL PROTEINS; LIVING NANOVESICLES;
   POSSIBLE PROVENANCE; MODEL SIMULATION; RING FORMATION; PART II; LIGHT;
   BIOMINERALIZATION; HIV
AB The presence of nanobacteria in the environment follows from their abundance in humans, apparent abundance in the terrestrial atmosphere and agricultural irrigation with insufficiently treated water containing human excreta. Survivability of nanobacteria and increasing evidence for their implication in disease demand for their detection in environmental samples. Unfortunately, the 60-300 nm nanocrystalline biohazards resemble "harmless" aerosols that are common in the lower atmosphere and water reservoirs. Here we propose a detector for discrimination between biocolloids and nonbiogenic objects of the same size. It exploits deviations from ideal deposition patterns, formed by drops of nanosuspensions evaporating on substrates. Variations in the crystallinity and/or shape of ring patterns, due to differences in the adhesive capacity of nanoparticles contained in the drops, provide principles to design simple and sensitive biosensors, responding to otherwise nondetectable contaminations of both drops and substrates. Patterns can be visualized on mirror-polished optically reflective substrates by a light microscope operating in the reflection mode. For instance, perfect ring structures emerged from water drops which contained polystyrene nanospheres, and uniformly dense deposition patterns formed from those containing hydroxyapatite nanoparticles. The principal difference is due to the interplay between the convective flow, driving suspended material to the periphery of the evaporating drop, and attraction between nanoparticles and substrate, immobilizing them upon contact. Protected by an outer shell of apatite, nanobacteria are predicted to behave completely different from polystyrene (and most other nanospheres): in water drops with contact angles 0 <= alpha <= 90 degrees those landing around the center of the area wetted by the drop will tend to remain fixed, instead of being moved by the convective flow. The biosensor could allow the identification of nanobacteria in precipitation, water reservoirs, or filtered soil, by facilitating their localization on substrates by high-resolution imaging techniques, which are applied complementary to analytical, spectroscopic, and culture methods.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
   Natl Inst Pharmaceut Chem R&D, Bucharest 031299, Romania.
   Hacettepe Univ, Fac Dent, Dept Prosthodont, TR-06100 Ankara, Turkey.
   Semmelweis Univ, Fac Med, Dept Diagnost Radiol & Oncotherapy, H-1082 Budapest, Hungary.
   Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Akerman KK, 1997, P SOC PHOTO-OPT INS, V3111, P436, DOI 10.1117/12.278798
   Cisar JO, 2000, P NATL ACAD SCI USA, V97, P11511, DOI 10.1073/pnas.97.21.11511
   Dai LL, 2005, LANGMUIR, V21, P2641, DOI 10.1021/la047256t
   Dalton LW, 2004, CHEM ENG NEWS, V82, P44, DOI 10.1021/cen-v082n040.p044                                                       
   Deegan RD, 1997, NATURE, V389, P827, DOI 10.1038/39827                                                                   
   Fischer BJ, 2002, LANGMUIR, V18, P60, DOI 10.1021/la015518a
   Helseth LE, 2005, LANGMUIR, V21, P7271, DOI 10.1021/la050247f
   Hu H, 2005, LANGMUIR, V21, P3972, DOI 10.1021/la0475270
   Hu H, 2005, LANGMUIR, V21, P3963, DOI 10.1021/la047528s
   Hudelist G, 2004, HISTOPATHOLOGY, V45, P633, DOI 10.1111/j.1365-2559.2004.02030.x                                                
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   KAJANDER EO, 2001, P 2 INT C NEAR FIELD
   Kargel JS, 2004, SCIENCE, V306, P1689, DOI 10.1126/science.1105533
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   Kim BH, 2004, APPL MICROBIOL BIOT, V63, P672, DOI 10.1007/s00253-003-1412-6
   Lober WB, 2002, J AM MED INFORM ASSN, V9, P105, DOI 10.1197/jamia.M1052                                                             
   Magnuson ML, 2005, ENVIRON SCI TECHNOL, V39, p153A, DOI 10.1021/es053226g
   Maniscalco Benedict S., 2004, Pathophysiology, V11, P95, DOI 10.1016/j.pathophys.2004.06.001
   Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   MURPHY MD, 2005, SCIENCE, V307, P1888
   Poulard C, 2005, LANGMUIR, V21, P8226, DOI 10.1021/la050406v
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   Puskas LG, 2005, ACTA BIOL HUNG, V56, P233, DOI 10.1556/ABiol.56.2005.3-4.7
   Sheehan PE, 2005, NANO LETT, V5, P803, DOI 10.1021/nl050298x
   Shmuylovich L, 2002, LANGMUIR, V18, P3441, DOI 10.1021/la011484v
   Sommer AP, 2004, J PHYS CHEM B, V108, P8, DOI 10.1021/jp0363747
   Sommer AP, 2005, CRYST GROWTH DES, V5, P551, DOI 10.1021/cg0496989
   Sommer AP, 2005, J PROTEOME RES, V4, P633, DOI 10.1021/pr049795p
   Sommer AP, 2005, J PROTEOME RES, V4, P180, DOI 10.1021/pr0498382
   Sommer AP, 2005, CRYST GROWTH DES, V5, P21, DOI 10.1021/cg049812n
   Sommer AP, 2004, J PROTEOME RES, V3, P1296, DOI 10.1021/pr049861n
   Sommer AP, 2004, INT J ANTIMICROB AG, V24, P548, DOI 10.1016/j.ijantimicag.2004.09.006
   Sommer AP, 2004, J PROTEOME RES, V3, P1086, DOI 10.1021/pr049935v
   Sommer AP, 2004, J PHYS CHEM B, V108, P8096, DOI 10.1021/jp0487049
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2003, NANO LETT, V3, P573, DOI 10.1021/nl0258269
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   SOMMER AP, 2001, P 2 INT C NEAR FIELD
NR 44
TC 26
Z9 26
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD FEB
PY 2006
VL 6
IS 2
BP 492
EP 497
DI 10.1021/cg050418e
PG 6
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 010WM
UT WOS:000235228600024
DA 2018-01-05
ER

PT J
AU Karkkainen, S
   Hiipakka, M
   Wang, JH
   Kleino, I
   Vaha-Jaakkola, M
   Renkema, GH
   Liss, M
   Wagner, R
   Saksela, K
AF Karkkainen, S
   Hiipakka, M
   Wang, JH
   Kleino, I
   Vaha-Jaakkola, M
   Renkema, GH
   Liss, M
   Wagner, R
   Saksela, K
TI Identification of preferred protein interactions by phage-display of the
   human Src homology-3 proteome
SO EMBO REPORTS
LA English
DT Article
DE SH3; Nef; PAK2; ADAM15; POSH2; SNX30
ID SH3 DOMAINS; HIV-1 NEF; INTERACTION NETWORKS; ADAPTER PROTEIN;
   HIGH-AFFINITY; FAMILY; SPECIFICITY; P21-ACTIVATED-KINASE-1; ACTIVATION;
   LIGANDS
AB We have determined the human genome to contain 296 different Src homology-3 (SH3) domains and cloned them into a phage-display vector. This provided a powerful and unbiased system for simultaneous assaying of the complete human SH3 proteome for the strongest binding to target proteins of interest, without the limitations posed by short linear peptide ligands or confounding variables of more indirect methods for protein interaction screening. Studies involving three ligand proteins, human immunodeficiency virus-1 Nef, p21-activated kinase (PAK) 2 and ADAM15, showed previously reported as well as novel SH3 partners with nanomolar affinities specific for them. This argues that SH3 domains may have a more dominant role in directing cellular protein interactions than has been assumed. Besides showing potentially important new SH3-directed interactions, these studies also led to the discovery of novel signalling proteins, such as the PAK2-binding adaptor protein POSH2 and the ADAM15-binding sorting nexin family member SNX30.
C1 Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Virol, Helsinki 00029, Finland.
   Univ Regensburg, Inst Med Microbiol & Hyg, D-93053 Regensburg, Germany.
   Geneart GmbH, D-93053 Regensburg, Germany.
   Univ Tampere, Inst Med Technol, Tampere 33014, Finland.
   Tampere Univ Hosp, Tampere 33014, Finland.
RP Saksela, K (reprint author), Univ Helsinki, Haartman Inst, Dept Virol, Haartmaninkatu 3, FIN-00014 Helsinki, Finland.
EM kalle.saksela@helsinki.fi
RI Renkema, Herma/L-1489-2015
OI Renkema, Herma/0000-0002-8174-6538; Saksela, Kalle/0000-0003-0827-122X
CR Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200
   Arold S, 1998, BIOCHEMISTRY-US, V37, P14683, DOI 10.1021/bi980989q
   Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742
   Brannetti B, 2000, J MOL BIOL, V298, P313, DOI 10.1006/jmbi.2000.3670                                                          
   Hiipakka M, 1999, J MOL BIOL, V293, P1097, DOI 10.1006/jmbi.1999.3225                                                          
   Hildebrandt F, 1997, NAT GENET, V17, P149, DOI 10.1038/ng1097-149                                                              
   Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693
   Jacobsson K, 1996, BIOTECHNIQUES, V20, P1070
   Landgraf C, 2004, PLOS BIOL, V2, P94, DOI 10.1371/journal.pbio.0020014
   LEE CH, 1995, EMBO J, V14, P5006
   Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3
   Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2
   Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2
   Mayer B. J., 2004, STRUCTURE FUNCTION M, P37
   McGee AW, 2001, MOL CELL, V8, P1291, DOI 10.1016/S1097-2765(01)00411-7
   Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0                                                                
   Panni S, 2002, J BIOL CHEM, V277, P21666, DOI 10.1074/jbc.M109788200
   Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200
   Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002
   Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986
   Tapon N, 1998, EMBO J, V17, P1395, DOI 10.1093/emboj/17.5.1395
   Tong AHY, 2002, SCIENCE, V295, P321, DOI 10.1126/science.1064987
   Yuan ZQ, 2005, J BIOL CHEM, V280, P21483, DOI 10.1071/jbc.M50097200
   Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000
NR 24
TC 74
Z9 78
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1469-221X
J9 EMBO REP
JI EMBO Rep.
PD FEB
PY 2006
VL 7
IS 2
BP 186
EP 191
DI 10.1038/sj.embor.7400596
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 023QX
UT WOS:000236142400014
PM 16374509
OA gold
DA 2018-01-05
ER

PT J
AU Matejicek, P
   Cigler, P
   Prochazka, K
   Kral, V
AF Matejicek, P
   Cigler, P
   Prochazka, K
   Kral, V
TI Molecular assembly of metallacarboranes in water: Light scattering and
   microscopy study
SO LANGMUIR
LA English
DT Article
ID PROMISCUOUS INHIBITORS; CRYSTAL STRUCTURE; ASSOCIATION; ANIONS; DRUGS;
   METALLOCARBORANE; COUNTERIONS; DISPERSIONS; ADSORPTION; INTERFACE
AB Polyhedral metallacarboranes are used mainly as ion-pairing agents and recently have been recognized as potent inhibitors of HIV protease. They are characterized by exceptional hydrophobicity, rigid geometry, delocalized negative charge, ion-pairing behavior, and strong acidity of their conjugated acids. The completely novel phenomenon, association of these promising pharmaceutical tectons in aqueous solutions, is described here. The behavior of two structural types of metallacarboranes, [bis(1,2-dicarbollide)cobaltate(1-)] and bis[(3)-1,2-dicarbollylcobalt]-(3,6)- 1,2-dicarbacanastide(2-)], in aqueous solution was studied by a combination of static and dynamic light scattering and microscopy methods. Spherical aggregates with radii of ca. 100 nm and fairly monodisperse nanostructures were found in aqueous solutions. The behavior of nanoaggregates is fairly complex and depends on the concentration and aging of the solutions. The particles are stabilized in the solution by counterions. The formation of larger clusters upon dilution of bis(1,2-dicarbollide)cobaltate(1-) solutions was observed. The secondary aggregation can be suppressed by addition of NaCl. Gel permeation chromatography measurements of sodium bis(1,2-dicarbollide)cobaltate(1 -) show that the majority of matallacarborane molecules form nanoaggregates and only a small amount of the metallacarborane remains molecularly soluble or forms small oligomers.
C1 Charles Univ, Dept Phys & Macromol Chem, Prague 12840 2, Czech Republic.
   Inst Chem Technol, Dept Analyt Chem, CR-16628 Prague 6, Czech Republic.
   Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic.
RP Matejicek, P (reprint author), Charles Univ, Dept Phys & Macromol Chem, Hlavona 2030, Prague 12840 2, Czech Republic.
EM matej@vivien.natur.cuni.cz
RI Kral, Vladimir/I-9518-2017; Cigler, Petr/B-1142-2012; Matejicek,
   Pavel/M-6582-2017; Prochazka, Karel/C-3012-2014
OI Kral, Vladimir/0000-0001-5034-4184; Matejicek,
   Pavel/0000-0001-5482-3465; Prochazka, Karel/0000-0003-2144-5378
CR ATTWOOD D, 1995, ADV COLLOID INTERFAC, V55, P271, DOI 10.1016/0001-8686(94)00228-5                                                    
   ATWOOD D, 1983, SUFACTANT SYSTEMS TH, pCH4
   BERNE BJ, 1976, DYNAMIC LIGTHT SCATT
   Bregadze V.I., 2004, RUSS CHEM REV, V73, P433
   BURCHARD W, 1980, MACROMOLECULES, V13, P1265, DOI 10.1021/ma60077a045                                                             
   Burchard W., 1996, LIGHT SCATTERING PRI, P439
   Chaumont A, 2004, RUSS CHEM B+, V53, P1459, DOI 10.1023/B:RUCB.0000046241.03494.0a                                              
   Cigler P, 2005, P NATL ACAD SCI USA, V102, P15394, DOI 10.1073/pnas.0507577102
   CLARK NA, 1983, PHYS REV LETT, V50, P1459, DOI 10.1103/PhysRevLett.50.1459                                                     
   Deryagin B, 1941, ACTA PHYSICOCHIM USS, V14, P633
   DOSHO S, 1993, LANGMUIR, V9, P394, DOI 10.1021/la00026a008                                                             
   Feng BY, 2005, NAT CHEM BIOL, V1, P146, DOI 10.1038/nchembio718
   FRANCIS JN, 1968, J AM CHEM SOC, V90, P1663, DOI 10.1021/ja01008a055                                                             
   FRANCIS JN, 1971, INORG CHEM, V10, P863
   GROEHN F, 2000, MACROMOLECULES, V33, P5938
   HAWTHORNE MF, 1965, J AM CHEM SOC, V87, P1818, DOI 10.1021/ja01086a053                                                             
   Henderson D, 1998, MOL PHYS, V95, P131, DOI 10.1080/002689798167034                                                         
   Hunter RJ., 1995, FDN COLLOID SCI, VI
   ITO K, 1992, LANGMUIR, V8, P2952, DOI 10.1021/la00048a017                                                             
   KLEIN R, 1996, LIGHT SCATTERING PRI, P30
   Kratochvil P., 1987, CLASSICAL LIGHT SCAT, V5
   Langmuir I, 1938, J CHEM PHYS, V6, P873, DOI 10.1063/1.1750183                                                               
   LIN SC, 1978, BIOPOLYMERS, V17, P1041, DOI 10.1002/bip.1978.360170418
   Makrlik E, 1995, J RADIOAN NUCL CH AR, V198, P359, DOI 10.1007/BF02036551                                                              
   McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   Morandi S, 2004, BBA-BIOMEMBRANES, V1664, P53, DOI 10.1016/j.bbamem.2004.04.002
   Nakamura E, 2003, ACCOUNTS CHEM RES, V36, P807, DOI 10.1021/ar030027y
   PLESEK J, 1984, COLLECT CZECH CHEM C, V49, P2776, DOI 10.1135/cccc19842776                                                            
   PLESEK J, 1992, J CHEM REV, V92, P269
   Popov A, 2001, J COLLOID INTERF SCI, V236, P20, DOI 10.1006/jcis.2000.7339
   PROCHAZKA K, 1988, J LIQ CHROMATOGR, V11, P221
   RAIS J, 2005, SOLVENT EXTRACTION, P243
   Schmitz KS, 1997, LANGMUIR, V13, P5849, DOI 10.1021/la970479h                                                               
   Schreier S, 2000, BBA-BIOMEMBRANES, V1508, P210, DOI 10.1016/S0304-4157(00)00012-5                                                   
   Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r
   Sivaev IB, 1999, COLLECT CZECH CHEM C, V64, P783, DOI 10.1135/cccc19990783                                                            
   SOGAMI I, 1984, J CHEM PHYS, V81, P6320, DOI 10.1063/1.447541                                                                
   STCLAIR D, 1969, INORG CHEM, V8, P2080, DOI 10.1021/ic50080a010                                                             
   Tsao CS, 1999, J PHYS CHEM SOLIDS, V60, P1351, DOI 10.1016/S0022-3697(99)00111-0                                                   
   VANMAU ND, 1984, J COLLOID INTERF SCI, V101, P1
   Verwey E. J. W., 1948, THEORY STABILITY LYO
   Wu C, 2004, POLYMER, V45, P1739, DOI 10.1016/j.polymer.2003.11.045
   Xu W, 1997, AICHE J, V43, P3215, DOI 10.1002/aic.690431209                                                           
   YOSHIDA H, 1995, J CHEM PHYS, V103, P10146, DOI 10.1063/1.469916                                                                
   YOSHIDA H, 1995, LANGMUIR, V11, P2853, DOI 10.1021/la00008a002                                                             
   ZALKIN A, 1967, INORG CHEM, V6, P1911, DOI 10.1021/ic50056a033                                                             
NR 47
TC 67
Z9 67
U1 4
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD JAN 17
PY 2006
VL 22
IS 2
BP 575
EP 581
DI 10.1021/la052201s
PG 7
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 002YC
UT WOS:000234647200011
PM 16401104
DA 2018-01-05
ER

PT J
AU Sieburth, SM
   Chen, CA
AF Sieburth, SM
   Chen, CA
TI Silanediol protease inhibitors: From conception to validation
SO EUROPEAN JOURNAL OF ORGANIC CHEMISTRY
LA English
DT Review
DE drug design; hydrolases; inhibitors; peptidomimetics; proteases;
   silanes; silicon
ID ANGIOTENSIN-CONVERTING ENZYME; ALKYL-ALPHA-AMINOSILANES;
   RHODIUM-CATALYZED HYDROSILYLATION; DRUG DESIGN; HIV PROTEASE; SILICON;
   ACID; DERIVATIVES; THERMOLYSIN; CHEMISTRY
AB Silanediols are isosteric with the unstable hydrated carbonyl group, but are most commonly associated with polymerization to give silicone polymers. Placement of a silanediol in a dipeptide analogue yields a new kind of nonhydrolyzable transition-state-analogue protease inhibitor. Both metallo and aspartic protease inhibitors have been prepared using silanediols, with enzyme inhibition in the low nanomolar range. Structure-activity comparisons with known inhibitors, efficacy in whole cell assays, and a crystal structure of a sitanediol inhibitor bound to the thermolysin active site establish these silanediol inhibitors as effective and predictable new protease inhibitor tools. Recent chemistry developments have led to efficient and streamlined preparation of these inhibitors. ((c) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2006).
C1 Temple Univ, Dept Chem, Rosemont, PA 19010 USA.
   Lundbeck Res USA Inc, Dept Chem, Paramus, NJ 07652 USA.
RP Sieburth, SM (reprint author), Temple Univ, Dept Chem, 1901 N 13th St, Rosemont, PA 19010 USA.
EM scott.sieburth@temple.edu; chie@lundbeck.com
CR ALMQUIST RG, 1980, J MED CHEM, V23, P1392, DOI 10.1021/jm00186a020                                                             
   ALMQUIST RG, 1982, J MED CHEM, V25, P1292, DOI 10.1021/jm00353a005
   Azizuddin K, 2001, INT J ONCOL, V18, P411
   Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z                                                               
   Bains W, 2004, ASTROBIOLOGY, V4, P137, DOI 10.1089/153110704323175124                                                      
   Bains W, 2003, CURR OPIN DRUG DI DE, V6, P526
   BARCZA S, 1988, SILICON CHEMISTRY, P135
   Barrett A. J., 1998, HDB PROTEOLYTIC ENZY
   BEAK P, 1984, CHEM REV, V84, P471, DOI 10.1021/cr00063a003                                                             
   Bodanszky M, 1988, PEPTIDE CHEM PRACTIC
   BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061
   Boven E, 2000, ANN NY ACAD SCI, V922, P175
   BROOK AG, 1974, J AM CHEM SOC, V96, P4692, DOI 10.1021/ja00821a065                                                             
   BROOK AG, 1974, ACCOUNTS CHEM RES, V7, P77, DOI 10.1021/ar50075a003                                                             
   BROWN HC, 1982, J ORG CHEM, V47, P5047
   CARPENTER JC, 1995, ENVIRON SCI TECHNOL, V29, P864, DOI 10.1021/es00004a005
   CASSIDY S, 1989, MANUFACTURING CH DEC, P51
   Chen CA, 2001, CHEM BIOL, V8, P1161, DOI 10.1016/S1074-5521(01)00079-5                                                   
   CHOJNOWSKI J, 1993, SILOXANE POLYM, P1
   COLLSTE L, 1981, EUR UROL, V7, P85
   CUSHMAN DW, 1977, BIOCHEMISTRY-US, V16, P5484, DOI 10.1021/bi00644a014                                                             
   CYPRYK M, 1993, J ORGANOMET CHEM, V446, P91, DOI 10.1016/0022-328X(93)80039-E                                                    
   Daud A, 2005, CLIN CANCER RES, V11, P3009, DOI 10.1158/1078-0432.CCR-04-1722
   Dearden MJ, 2002, J AM CHEM SOC, V124, P11870, DOI 10.1021/ja027774v
   DEJAK B, 1969, B ACAD POL SCI-CHIM, V17, P571
   DEPRIEST SA, 1993, J AM CHEM SOC, V115, P5372, DOI 10.1021/ja00066a004
   DILTHEY W, 1904, BER, V37, P1139
   Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734
   DUFF JM, 1977, CAN J CHEM, V55, P2589, DOI 10.1139/v77-358                                                                 
   EABORN C, 1955, J CHEM SOC, P549, DOI 10.1039/jr9550000549                                                            
   EABORN C, 1956, J CHEM SOC, P4858, DOI 10.1039/jr9560004858                                                            
   EABORN C, 1952, J CHEM SOC, P2846, DOI 10.1039/jr9520002846                                                            
   Erickson J.W., 1999, PROTEASES INFECT AGE, P1
   EVANS DA, 1982, J AM CHEM SOC, V104, P1737, DOI 10.1021/ja00370a050                                                             
   Fessenden R J, 1967, Adv Drug Res, V4, P95
   Field RJ, 2001, J NON-CRYST SOLIDS, V285, P194, DOI 10.1016/S0022-3093(01)00453-7                                                   
   Fleming I., 1989, ORG REACTIONS, V37, P57
   Fleming I., 1979, COMPREHENSIVE ORGANI, V3, P541
   GREENE TW, 1999, PROTECTIVE GROUPS OR
   HAKEN JK, 1987, J COATING TECHNOL, V59, P73
   Hewitt GW, 2000, TETRAHEDRON LETT, V41, P10175, DOI 10.1016/S0040-4039(00)01827-X
   HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008
   Jessup P.J., 1988, ORG SYNTH COLL, V6, P95
   JUERS DH, UNPUB
   KEMPF DJ, 1994, METHOD ENZYMOL, V241, P334
   Kim J, 2005, J ORG CHEM, V70, P5781, DOI 10.1021/jo048121v
   Kim J, 2004, J ORG CHEM, V69, P3008, DOI 10.1021/jo049929i
   Kim J, 2004, BIOORG MED CHEM LETT, V14, P2853, DOI 10.1016/j.bmcl.2004.03.042
   LEHMANN RG, 1994, ENVIRON TOXICOL CHEM, V13, P1061, DOI 10.1897/1552-8618(1994)13[1061:DOSPIS]2.0.CO;2
   Leigh WJ, 1998, J AM CHEM SOC, V120, P9504, DOI 10.1021/ja981435d                                                               
   Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m
   Lickiss P. D., 1995, ADV INORG CHEM, V42, P147, DOI DOI 10.1016/S0898-8838(08)60053-7
   Liu GD, 2003, ORG LETT, V5, P4677, DOI 10.1021/ol0358713
   Luo Y.-R., 2003, HDB BOND DISSOCIATIO
   Marciniec B., 1992, COMPREHENSIVE HDB HY
   Martin G, 1909, J CHEM SOC, V95, P302, DOI 10.1039/ct9099500302
   MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003                                                             
   Meals R.N., 1959, SILICONES
   MEYER RF, 1981, J MED CHEM, V24, P964, DOI 10.1021/jm00140a010
   MIGNANI S, 1995, SYNTHETIC COMMUN, V25, P3855, DOI 10.1080/00397919508011460                                                       
   MOBERG WK, 1986, PESTICIDE SCI BIOTEC, P57
   MURAI T, 1994, J CHEM SOC CHEM COMM, P2143, DOI 10.1039/c39940002143                                                            
   Murai T, 1998, ORGANOMETALLICS, V17, P926, DOI 10.1021/om970993i                                                               
   MUTAHI AM, 1996, THESIS SUNY STONY BR
   Mutahi MW, 2002, J AM CHEM SOC, V124, P7363, DOI 10.1021/ja026158w
   Nishiyama H., 2000, CATALYTIC ASYMMETRIC, P111
   Ojima I., 1989, CHEM ORGANIC SILICON, P1479
   Ojima I., 1998, CHEM ORGANIC SILICON, P1687
   Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v
   Raabe G., 1989, CHEM ORGANIC SILICON, P1015
   Ripka AS, 1998, CURR OPIN CHEM BIOL, V2, P441, DOI 10.1016/S1367-5931(98)80119-1
   Rochow E. G., 1987, SILICON SILICONES
   Showell GA, 2003, DRUG DISCOV TODAY, V8, P551, DOI 10.1016/S1359-6446(03)02726-0                                                   
   SIEBURTH SM, 1995, SYNLETT, P928
   Sieburth SM, 2003, ORG LETT, V5, P1859, DOI 10.1021/ol034397y
   SIEBURTH SM, 1990, PESTIC SCI, V28, P289, DOI 10.1002/ps.2780280308                                                           
   Sieburth SM, 1996, TETRAHEDRON, V52, P5669, DOI 10.1016/0040-4020(96)00190-1                                                    
   Sieburth SM, 1996, TETRAHEDRON, V52, P5683, DOI 10.1016/0040-4020(96)00191-3                                                    
   Sieburth SM, 1998, ANGEW CHEM INT EDIT, V37, P812, DOI 10.1002/(SICI)1521-3773(19980403)37:6<812::AID-ANIE812>3.0.CO;2-I               
   Tacke R, 2005, ORGANOMETALLICS, V24, P1780, DOI 10.1021/om040127n
   Tacke R, 2004, ORGANOMETALLICS, V23, P4915, DOI 10.1021/om040084a
   TACKE R, 1987, CHEM BER-RECL, V120, P1229, DOI 10.1002/cber.19871200719
   Tacke R, 1989, CHEM ORGANIC SILIC 2, P1143
   Tacke R., 1998, CHEM ORGANIC SILICON, P2363
   TEMMERMAN I, 1985, J HIGH RES CHROMATOG, V8, P513, DOI 10.1002/jhrc.1240080905                                                         
   Thompson PA, 2004, CANCER CHEMOTH PHARM, V53, P527, DOI 10.1007/s00280-004-0765-6
   TROST BM, 1983, J ORG CHEM, V48, P3252, DOI 10.1021/jo00167a020
   Uhlig W, 1996, CHEM BER, V129, P733, DOI 10.1002/cber.19961290702                                                        
   WANG D, 2002, SCI SYNTHESIS, V4, P481
   Wender PA, 1997, CHEM IND-LONDON, P765
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Wu SD, 1996, J AM CHEM SOC, V118, P715, DOI 10.1021/ja9524661                                                               
   Zbik M, 2000, METEORIT PLANET SCI, V35, P943, DOI 10.1111/j.1945-5100.2000.tb01484.x                                              
NR 93
TC 87
Z9 88
U1 1
U2 11
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1434-193X
J9 EUR J ORG CHEM
JI Eur. J. Org. Chem.
PD JAN 16
PY 2006
IS 2
BP 311
EP 322
DI 10.1002/ejoc.200500508
PG 12
WC Chemistry, Organic
SC Chemistry
GA 006WD
UT WOS:000234927500001
DA 2018-01-05
ER

PT J
AU Petricci, E
   Mugnaini, C
   Radi, M
   Togninelli, A
   Bernardini, C
   Manetti, F
   Parlato, MC
   Renzulli, ML
   Alongi, M
   Falciani, C
   Corelli, F
   Botta, M
AF Petricci, Elena
   Mugnaini, Claudia
   Radi, Marco
   Togninelli, Andrea
   Bernardini, Cesare
   Manetti, Fabrizio
   Parlato, Maria Cristina
   Renzulli, Michela Lucia
   Alongi, Maddalena
   Falciani, Chiara
   Corelli, Federico
   Botta, Maurizio
TI Towards new methodologies for the synthesis of biologically interesting
   6-substituted pyrimidines and 4(3H)-pyrimidinones
SO ARKIVOC
LA English
DT Article; Proceedings Paper
CT 20th International Congress of Heterocyclic Chemistry
CY JUL 31-AUG 05, 2005
CL Univ Palermo, Palermo, ITALY
HO Univ Palermo
DE pyrimidinones; S-DABOs; anti-HIV; solid phase organic synthesis;
   solution phase parallel synthesis; combinatorial chemistry;
   microwave-assisted organic synthesis; virtual libraries
ID SOLID-PHASE SYNTHESIS; REVERSE-TRANSCRIPTASE INHIBITORS; SUPPORTED
   REAGENTS SSRS; IMMUNODEFICIENCY-VIRUS TYPE-1; PARALLEL SOLUTION-PHASE;
   SELECTIVE ACYLATION; COMBINATORIAL CHEMISTRY; MICROWAVE IRRADIATION;
   ANTIVIRAL ACTIVITY; ORGANIC-SYNTHESIS
AB The present paper describes the application of modern combinatorial and microwave assisted techniques for the lead discovery and optimization of novel non-nucleoside HIV-1-RT inhibitors. Starting from the parallel solid phase synthesis of highly substituted pyrimidinone derivatives, compound 12c was identified as interesting lead compound for further structure optimizations. The generation and screening of a small virtual combinatorial library led to the optimization of the lead structure 12c to give highly active derivatives ( against HIV1-RT wild-type and mutant strains) in the nanomolar range. Moreover, a straightforward three-step parallel solution phase approach was developed for the generation of a small library of novel 4-dialkylamino-2-methylsulfonyl- 6-vinylpyrimidines which were obtained in high yield after a simple ethyl acetate extraction with no need of further purification. Surprisingly, some of these derivatives showed a new competitive inhibition of HIV1-RT never reported in the literature for this class of compounds. Molecular modeling calculations were also performed to investigate the binding mode of all synthesized compounds onto the non-nucleoside reverse transcriptase inhibitor binding site and to rationalize the relationships between their chemical structure and activity.
C1 Univ Siena, Dipartimento Farm Chim Tecnol, I-53100 Siena, Italy.
RP Botta, M (reprint author), Univ Siena, Dipartimento Farm Chim Tecnol, Via Aldo Moro, I-53100 Siena, Italy.
EM botta@unisi.it
CR Anzali S, 2001, J MED CHEM, V44, P2432, DOI 10.1021/jm0010670
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   Balkenhohl F., 1996, ANGEW CHEM INT EDIT, V35, P2288, DOI DOI 10.1002/ANIE.199622881
   Bher J. -B., 2003, BIOORG MED CHEM LETT, V13, P1713
   Botta M, 1997, TETRAHEDRON LETT, V38, P8249, DOI 10.1016/S0040-4039(97)10159-9                                                   
   Botta M, 2002, HETEROCYCLES, V56, P369, DOI 10.3987/COM-01-S(K)50                                                           
   BOTTA M, 1988, TETRAHEDRON LETT, V29, P2741, DOI 10.1016/0040-4039(88)85275-4                                                    
   BOTTA M, 1984, TETRAHEDRON, V40, P3313, DOI 10.1016/0040-4020(84)85016-4
   Botta M, 1999, BIOORGAN MED CHEM, V7, P1925, DOI 10.1016/S0968-0896(99)00111-X                                                   
   Botta M, 2001, TETRAHEDRON, V57, P8357, DOI 10.1016/S0040-4020(01)00815-8                                                   
   BOTTA M, UNPUB
   Bruno-Blanch L, 2003, BIOORG MED CHEM LETT, V13, P2749, DOI 10.1016/S0960-894X(03)00535-3
   Chiosis G, 2001, SCIENCE, V293, P1484, DOI 10.1126/science.1060324                                                         
   CLAY RJ, 1993, SYNTHESIS-STUTTGART, P290
   Dal Cin M, 2002, FARMACO, V57, P497, DOI 10.1016/S0014-827X(02)01215-6
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   Dolle RE, 2002, J COMB CHEM, V4, P369, DOI 10.1021/cc020039v
   EDWARDS P, 2003, DRUG DISCOV TODAY, V8, P762
   Faludi Gabor, 2005, Neuropsychopharmacol Hung, V7, P22
   Font D, 2003, J COMB CHEM, V5, P311, DOI 10.1021/cc020019t
   Ganesan A, 2002, DRUG DISCOV TODAY, V7, P47, DOI 10.1016/S1359-6446(01)02087-6
   GREEN TW, 1980, PROTECTIVE GROUPS OR, P193
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   Haslam E., 1993, SHIKIMIC ACID METABO
   He YP, 2004, BIOORG CHEM, V32, P536, DOI 10.1016/j.bioorg.2004.05.007
   Kappe CO, 2002, CURR OPIN CHEM BIOL, V6, P314, DOI 10.1016/S1367-5931(02)00306-X                                                   
   Kramer A, 2003, J COMPUT AID MOL DES, V17, P13, DOI 10.1023/A:1024503712135
   Kumar A, 2002, BIOORG MED CHEM LETT, V12, P667, DOI 10.1016/S0960-894X(01)00829-0                                                   
   KUNDU NG, 1990, SYNTHESIS-STUTTGART, P243
   Langer Corey, 2003, Clin Adv Hematol Oncol, V1, P424
   Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688                                                            
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   Macdonald SJF, 2002, J MED CHEM, V45, P3878, DOI 10.1021/jm020881f
   Mai A, 2005, BIOORGAN MED CHEM, V13, P2065, DOI 10.1016/j.bmc.2005.01.005
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   Manetti F, 2005, J MED CHEM, V48, P8000, DOI 10.1021/jm050744t
   Mugnaini C, 2005, COMB CHEM HIGH T SCR, V8, P387, DOI 10.2174/1386207054546504                                                        
   Nayyar A, 2005, CURR MED CHEM, V12, P1873, DOI 10.2174/0929867054546654
   Nizi E, 1998, TETRAHEDRON LETT, V39, P3307, DOI 10.1016/S0040-4039(97)84377-8
   Parlato MC, 2004, ARKIVOC, P349
   Petricci E, 2004, J ORG CHEM, V69, P7880, DOI 10.1021/jo048837q
   Petricci E, 2002, TETRAHEDRON LETT, V43, P9667, DOI 10.1016/S0040-4039(02)02380-8                                                   
   Petricci E, 2002, TETRAHEDRON LETT, V43, P6507, DOI 10.1016/S0040-4039(02)01478-8                                                   
   Radi M, 2005, J COMB CHEM, V7, P117, DOI 10.1021/cc049880u
   RADI M, 2000, THESIS U SIENA
   RAGAN J, 2002, J MED CHEM, V45, P2994
   Saladino R, 2002, BIOORGAN MED CHEM, V10, P2143, DOI 10.1016/S0968-0896(02)00077-9
   Shapiro MJ, 1999, PROG NUCL MAG RES SP, V35, P153, DOI 10.1016/S0079-6565(99)00008-4                                                   
   Smaniotto D, 2005, TUMORI, V91, P215
   TOGNINELLI A, 2005, TETRAHEDRON LETT, V47, P65
   Walters WP, 1998, DRUG DISCOV TODAY, V3, P160, DOI 10.1016/S1359-6446(97)01163-X                                                   
   WEBB KS, 1994, TETRAHEDRON LETT, V35, P3457, DOI 10.1016/S0040-4039(00)73209-6
   YOUNG RN, 1984, TETRAHEDRON LETT, V25, P1753
   UNPUB J MED CHEM
   BOTTA M, Patent No. 000512
NR 55
TC 25
Z9 25
U1 1
U2 4
PU ARKAT USA INC
PI GAINESVILLE
PA C/O ALAN R KATRITZKY, UNIV FLORIDA, DEPT CHEMISTRY, PO BOX 117200,
   GAINESVILLE, FL 32611 USA
SN 1424-6376
J9 ARKIVOC
JI Arkivoc
PY 2006
BP 452
EP 478
PN 7
PG 27
WC Chemistry, Organic
SC Chemistry
GA 113CA
UT WOS:000242573900032
DA 2018-01-05
ER

PT J
AU Uckun, FM
   Venkatachalam, TK
   Qazi, S
AF Uckun, FM
   Venkatachalam, TK
   Qazi, S
TI Potency of stampidine against multi-nucleoside reverse transcriptase
   inhibitor resistant human immunodeficiency viruses
SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
LA English
DT Article
DE anti-HIV agents; antiretroviral therapy, viral resistance;
   N-[p-(4-bromopheny1)-2 ',3 '-didehydro-3 '-deoxy-5
   '-thymidylyl]-L-alanine methyl ester; CAS 217178-62-6; DDE-113; HI-113;
   stampidine, viral resistance
ID ACTIVE ANTIRETROVIRAL THERAPY; DRUG-RESISTANT; VIROLOGICAL RESPONSE;
   GENOTYPIC RESISTANCE; PHENOTYPIC SUSCEPTIBILITY; COMBINATION THERAPY;
   THYMIDINE ANALOG; NAIVE PATIENTS; TYPE-1; HIV-1
AB The in vitro potency of stampidine (STAMP, DDE-113, HI-113, N-[p-(4-bromophenyl)-2',3'-didehydro-3'-deoxy- 5'-thymidylyl]-L-alanine methyl ester, CAS 217178-62-6) was examined against 8 clinical non-B subtype HIV-1 isolates with resistance to stavudine (STV, d4T), adefovir and tenofovir, 19 clinical zidovudine-resistant HIV-1 isolates, and 6 recombinant HIV-1 clones with multi-resistance against nucleoside reverse transcriptase inhibitors. Stampidine exhibited potent anti-HIV activity against each one of these 33 HIV-1 isolates with subnanomolar to nanomolar IC50 values.
C1 Paradigm Pharmaceut, St Paul, MN 55113 USA.
   Parker Hughes Inst, Roseville, MN USA.
   Ikaros Enterprises, Hudson, WI USA.
RP Uckun, FM (reprint author), Paradigm Pharmaceut, 2685 Patton Rd, St Paul, MN 55113 USA.
EM fatih_uckun@ih.org
CR Albrecht MA, 2001, NEW ENGL J MED, V345, P398, DOI 10.1056/NEJM200108093450602
   Briones C, 2000, AIDS, V14, P1659, DOI 10.1097/00002030-200007280-00024                                                
   Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002
   Duwe S, 2001, J ACQ IMMUN DEF SYND, V26, P266, DOI 10.1097/00126334-200103010-00010                                                
   Garcia-Lerma JG, 2001, J CLIN VIROL, V21, P197
   Gonzales MJ, 2003, AIDS, V17, P791, DOI 10.1097/01.aids.0000050860.71999.23
   Gottlieb MS, 2001, NEW ENGL J MED, V344, P1788, DOI 10.1056/NEJM200106073442312                                                     
   Gutierrez F, 2000, MED CLIN-BARCELONA, V115, P401, DOI 10.1016/S0025-7753(00)71574-0                                                   
   Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210                                                          
   Izopet J, 1999, J MED VIROL, V59, P507, DOI 10.1002/(SICI)1096-9071(199912)59:4<507::AID-JMV14>3.3.CO;2-3
   JOHNSON VA, 1995, J INFECT DIS, V171, pS140, DOI 10.1093/infdis/171.Supplement_2.S140                                            
   Johnston E, 2005, AIDS, V19, P731, DOI 10.1097/01.aids.0000166098.54564.0c
   Kantor R, 2005, PLOS MED, V2, P325, DOI 10.1371/journal.pmed.0020112
   KUIKEN CL, 1999, HUMAN RETROVIRUSES A
   Kuritzkes DR, 2000, J INFECT DIS, V181, P491, DOI 10.1086/315244
   Lin PF, 1999, ANTIVIR THER, V4, P21
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Miller MD, 2001, J ACQ IMMUN DEF SYND, V27, P450
   Miller V, 2000, AIDS, V14, P163, DOI 10.1097/00002030-200001280-00012
   O'Brien WA, 2000, CLIN INFECT DIS, V30, pS185, DOI 10.1086/313858                                                                  
   Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157
   Palmer S, 2001, AIDS RES HUM RETROV, V17, P1167, DOI 10.1089/088922201316912772
   Palmer S, 1999, AIDS, V13, P661
   Picard V, 2001, J INFECT DIS, V184, P781, DOI 10.1086/323088                                                                  
   Pillay D, 2000, REV MED VIROL, V10, P231, DOI 10.1002/1099-1654(200007/08)10:4<231::AID-RMV290>3.3.CO;2-G
   Rhee SY, 2005, J INFECT DIS, V192, P456, DOI 10.1086/431601
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Roge BT, 2003, ANTIVIR THER, V8, P173
   Ross L, 2001, AIDS RES HUM RETROV, V17, P1107, DOI 10.1089/088922201316912718
   Rousseau MN, 2001, J ACQ IMMUN DEF SYND, V26, P36
   Salomon H, 2000, AIDS, V14, pF17, DOI 10.1097/00002030-200001280-00003                                                
   SCHAFER R, 2000, AIDS REV, V2, P221
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Shafer RW, 1997, J VIROL, V71, P5441
   Shulman NS, 2002, JAIDS, V31, P121, DOI 10.1097/01.QAI.0000038335.74605.52
   Shulman NS, 2001, J ACQ IMMUN DEF SYND, V27, P377
   Starr SE, 1999, NEW ENGL J MED, V341, P1874, DOI 10.1056/NEJM199912163412502                                                     
   Suzuki K, 2001, AIDS RES HUM RETROV, V17, P1293, DOI 10.1089/088922201750461366
   Uckun F.M., 2002, U.S. Patent, Patent No. [6,350.736, 6350736]
   Uckun FM, 2005, ARZNEIMITTEL-FORSCH, V55, P223
   Uckun FM, 2004, ARZNEIMITTEL-FORSCH, V54, P69
   Uckun FM, 2003, ANTIMICROB AGENTS CH, V47, P1233, DOI 10.1128/AAC.47.4.1233-1240.2003
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3613, DOI 10.1128/AAC.46.11.3613-3616.2002
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3428, DOI 10.1128/AAC.46.11.3428-3436.2002
   Venturi G, 1999, EUR J CLIN MICROBIOL, V18, P274
   PARADIGM PHARM, 2004, Patent No. 6825177
   PARADIGM PHARM, 2003, Patent No. 6528495
   2003, Patent No. 6670336
   Uckun F.M., 2000, US Patent, Patent No. [6030957, 6,030,957]
   UCKUN FM, 2004, Patent No. 109018
   PARADIGM PHARM, 2003, Patent No. 6537975
   UCKUN F, 2004, Patent No. 20040171577
   UCKUN FM, 2003, Patent No. 6503890
NR 53
TC 7
Z9 8
U1 0
U2 0
PU ECV-EDITIO CANTOR VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI AULENDORF
PA BANDELSTOCKWEG 20, POSTFACH 1255, D-88322 AULENDORF, GERMANY
SN 0004-4172
J9 ARZNEIMITTEL-FORSCH
JI Arzneimittelforschung
PY 2006
VL 56
IS 2A
BP 193
EP 203
PG 11
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 032YK
UT WOS:000236812600008
PM 16570827
DA 2018-01-05
ER

PT J
AU Sommer, AP
   Milankovits, M
   Mester, AR
AF Sommer, AP
   Milankovits, M
   Mester, AR
TI Nanobacteria, HIV and magic bullets - Update of perspectives 2005
SO CHEMOTHERAPY
LA English
DT Article; Proceedings Paper
CT 1st World Conference on Magic Bullets
CY SEP 09-11, 2004
CL Nuremberg, GERMANY
DE nanobacteria; HIV; highly active antiretroviral therapy; heart disease;
   light exposure
AB In 1997 a Finnish group speculated on the presence of nanobacteriain vaccines. In 2001, a report on the identification of nanobacteria in a number of vaccines attracted much attention. Experiments indicated that viable nanobacteria are excreted via urine. Their extreme survivability suggests that prior to discussing any possible contamination of vaccines, sources and routes of natural infection need to be examined. In view of 30,000,000 HIV infections in sub-Saharan Africa, the recently reported occurrence of nanobacteria in HIV-infected patients deserves concern. Clearly, it could indicate the origin of a giant reservoir and dissemination cycle. Here we discuss novel therapeutic strategies to prevent or reduce nano-bacterial infection. In regard of the rapid progress in this field, we start with a brief introductory summary, and analyze possible implications.
C1 Univ Ulm, Cent Inst Biomed Engn, DE-89081 Ulm, Germany.
   Hungarian Natl Inst Genitourinary Med Fdn, Budapest, Hungary.
   Semmelweis Univ, Fac Med, Dept Diagnost Radiol & Oncotherapy, Budapest, Hungary.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, DE-89081 Ulm, Germany.
EM samoan@gmx.net
CR Brouilette S, 2003, ARTERIOSCL THROM VAS, V23, P842, DOI 10.1161/01.ATV.0000067426.96344.32
   Carnevale V, 2004, DIABETES-METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101
   Glesby MJ, 2003, CLIN INFECT DIS, V37, pS91, DOI 10.1086/375884
   Mooser V, 2003, AIDS, V17, pS65, DOI 10.1097/00002030-200304001-00009                                                
   Nakashima H, 2004, HYPERTENS RES, V27, P319, DOI 10.1291/hypres.27.319
   Sommer AP, 2005, J PROTEOME RES, V4, P633, DOI 10.1021/pr049795p
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   SOMMER AP, 2004, WORLD C MAG BULL DOS
   Sorgel F, 2004, CHEMOTHERAPY, V50, P6, DOI 10.1159/000077277
NR 11
TC 10
Z9 12
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0009-3157
J9 CHEMOTHERAPY
JI Chemotherapy
PY 2006
VL 52
IS 2
BP 95
EP 97
DI 10.1159/000092475
PG 3
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 035SH
UT WOS:000237021500009
PM 16582542
DA 2018-01-05
ER

PT J
AU Bonvicini, F
   Gallinella, G
   Gentilomi, GA
   Ambretti, S
   Musiani, M
   Zerbini, M
AF Bonvicini, F
   Gallinella, G
   Gentilomi, GA
   Ambretti, S
   Musiani, M
   Zerbini, M
TI Prevention of iatrogenic transmission of B19 infection: Different
   approaches to detect, remove or inactivate virus contamination
SO CLINICAL LABORATORY
LA English
DT Review
DE parvovirus B19; plasma products; NAT tests; solvent-detergent
   treatments; heat treatments; nanofiltration
ID HUMAN PARVOVIRUS B19; REAL-TIME PCR; PLASMA POOLS; BLOOD-PRODUCTS; DNA;
   ANEMIA; ASSAY; NANOFILTRATION; TRANSFUSION; SENSITIVITY
AB Parvovirus B19 is a frequent contaminant of human blood and plasma derivatives and iatrogenic transmission of B19 infection has been shown to occur through the administration of contaminated products. Manufacturing procedures, generally used for removal or inactivation of enveloped viruses (HIV, HCV and HBV) are not always effective in the elimination of B19 virus. A certain risk of contamination remains for some plasma derivatives due to the high-titer viral load in the starting blood donations and the extreme heat resistance and small size of the virus. This review provides an update on the different approaches currently available to detect, remove or inactivate B19 virus in order to enhance the safety margins of plasma products. Nucleic acid amplification techniques are the methods of choice for the detection of viruses, due to their high specificity and sensitivity. NAT assays are beneficial tools for the identification of contaminated mini-pools or plasma pools and the quantification of B19 contamination. They may also be valuable for testing the removal of B19 virus during manufacturing: since the virus may not be completely inactivated or removed by chemical or physical treatments, residual B19 contamination should always be checked. Solvent-detergent treatments fail to destroy B19 capsids because of the absence of a lipid-envelope, and heat treatments (pasteurization and dry-heat methods) cannot guarantee a complete viral inactivation because of the variable heat sensitivity of the virus.
C1 Univ Bologna, Div Microbiol, Dept Clin & Expt Med, I-40126 Bologna, Italy.
RP Zerbini, M (reprint author), Osp S Orsola, Div Microbiol, Dept Clin & Expt Med, Via Massarenti 9, I-40138 Bologna, Italy.
EM mzerbini@med.unibo.it
RI Gallinella, Giorgio/H-6864-2017
OI Gallinella, Giorgio/0000-0003-1118-6341
CR Abe H, 2000, ARTIF CELL BLOOD SUB, V28, P375, DOI 10.3109/10731190009118582                                                       
   Aberham C, 2001, J VIROL METHODS, V92, P183, DOI 10.1016/S0166-0934(00)00292-5
   Azzi A, 1999, TRANSFUS MED REV, V13, P194, DOI 10.1016/S0887-7963(99)80033-9
   Baylis SA, 2004, J VIROL METHODS, V121, P7, DOI 10.1016/j.jviromet.2004.05.011
   Blumel J, 2002, TRANSFUSION, V42, P1011, DOI 10.1046/j.1537-2995.2002.00158.x                                                
   Bonvicini F, 2004, J MED VIROL, V74, P272, DOI 10.1002/jmv.20180
   Brause W., 1998, Vox Sanguinis, V74, P1120
   Cohen BJ, 1997, TRANSFUSION, V37, P947, DOI 10.1046/j.1537-2995.1997.37997454023.x
   Daly P, 2002, J CLIN MICROBIOL, V40, P1958, DOI 10.1128/JCM.40.6.1958-1962.2002
   Gallinella G, 2003, J CLIN VIROL, V28, P1, DOI 10.1016/S1386-6532(03)00120-3
   Gallinella G, 2002, VOX SANG, V83, P324, DOI 10.1046/j.1423-0410.2002.00227.x                                                
   Gallinella G, 1997, MOL CELL PROBE, V11, P127, DOI 10.1006/mcpr.1996.0095                                                          
   Harder TC, 2001, J CLIN MICROBIOL, V39, P4413, DOI 10.1128/JCM.39.12.4413-4419.2001
   Hokynar K, 2004, J CLIN MICROBIOL, V42, P2013, DOI 10.1128/JCM.42.5.2013-2019.2004
   Just B, 2002, VOX SANG, V83, P167, DOI 10.1046/j.1423-0410.2002.00204.x
   Koenigbauer UF, 2000, TRANSFUSION, V40, P1203, DOI 10.1046/j.1537-2995.2000.40101203.x                                             
   Koppelman MHGM, 2004, TRANSFUSION, V44, P97, DOI 10.1046/j.0041-1132.2004.00610.x                                                
   LAURIAN Y, 1994, NOUV REV FR HEMATOL, V36, P449
   Manaresi E, 2004, EPIDEMIOL INFECT, V132, P857, DOI 10.1017/S0950268804002389
   Manaresi E, 2002, J MED VIROL, V67, P275, DOI 10.1002/jmv.2218
   Nguyen QT, 1998, LANCET, V352, P1524, DOI 10.1016/S0140-6736(05)60330-3                                                   
   Nguyen QT, 1999, J CLIN MICROBIOL, V37, P2483
   Prikhod'ko GG, 2005, TRANSFUSION, V45, P1011, DOI 10.1111/j.1537-2995.2005.04393.x
   Prowse C, 1997, VOX SANG, V72, P1, DOI 10.1046/j.1423-0410.1997.00001.x                                                
   Saldanha J, 1996, BRIT J HAEMATOL, V93, P714, DOI 10.1046/j.1365-2141.1996.d01-1679.x
   Saldanha J, 2002, VOX SANG, V82, P24, DOI 10.1046/j.1423-0410.2002.00132.x
   Sato K, 2000, J CLIN MICROBIOL, V38, P1241
   Schmidt I, 2001, VOX SANG, V81, P228, DOI 10.1046/j.1423-0410.2001.00120.x
   Solheim BG, 2000, TRANSFUSION, V40, P84, DOI 10.1046/j.1537-2995.2000.40010084.x                                             
   Yokoyama T, 2004, VOX SANG, V86, P225, DOI 10.1111/j.0042-9007.2004.00515.x
   Yunoki M, 2003, VOX SANG, V84, P164, DOI 10.1046/j.1423-0410.2003.00280.x                                                
   YUNOKI M, 2001, BJR, V128, P401
   ZERBINI M, 2003, MANUAL CLIN MICROBIO, P1534
   [Anonymous], EUROPEAN PHARMACOPOE
NR 34
TC 13
Z9 13
U1 0
U2 1
PU CLIN LAB PUBLICATIONS
PI HEIDELBERG
PA IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY
SN 1433-6510
J9 CLIN LAB
JI Clin. Lab.
PY 2006
VL 52
IS 5-6
BP 263
EP 268
PG 6
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 055QO
UT WOS:000238465600007
PM 16812953
DA 2018-01-05
ER

PT J
AU Kulkarni, MV
   Kulkarni, GM
   Lin, CH
   Sun, CM
AF Kulkarni, Manohar V.
   Kulkarni, Geeta M.
   Lin, Chao-Hsiung
   Sun, Chung-Ming
TI Recent advances in coumarins and 1-azacoumarins as versatile biodynamic
   agents
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
ID CHANNEL OPENING RELAXANTS; CORPORAL SMOOTH-MUSCLE; RAIN-FOREST TREE;
   TUMOR-CELL LINES; BIOLOGICAL EVALUATION; IN-VITRO; ANTIINFLAMMATORY
   ACTIVITY; ZANTHOXYLUM-SCHINIFOLIUM; ANTIOXIDANT ACTIVITY;
   NATURAL-PRODUCTS
AB Coumarins, also referred as benzopyran-2-ones, and their corresponding nitrogen counterpart, 1-azacoumarins also referred to as carbostyrils, are a family of nature-occurring factories and lactams respectively. The plant extracts containing coumarin-related heterocycles, which were employed as herbal remedies in early days, have now been extensively studied for their biological activities. These investigations have revealed their potentials as versatile biodynamic agents. For example, coumarins with phenolic hydroxyl groups have the ability to scavenge reactive oxygen species and thus prevent the formation of 5-HETE and HHT in the arachidonic pathway of inflammation suppression. Recent in vivo studies have revealed the role of coumarins in hepatotoxicity and also ill depletion of cytochrome P450. Similarly 1-azacoumarins which is part of quinoline alkaloids, are known for their diverse biological activity and recently, a 6-functionalized 1-aza coumarins are undergoing human clinical trials as an orally active anti-tumor drug in view of its farnesyl protein-inhibiting activity in the nanomolar range. Furthermore, several synthetic coumarins with a variety of pharmacophoric groups at C-3, C-4 and C-7 positions have been intensively screened for anti-microbial, anti-HIV, anti-cancer, lipid-lowering, anti-oxidant, and anti-coagulation activities.
   Specifically, coumarin-3-sulfonamides and carboxamides were reported to exhibit selective cytotoxicity against mammalian cancer cell lines. The C4-substituted aryloxymethyl, arylaminomethyl, and dichloroacetamidomethyl coumarins, along with the corresponding 1-azacoumarins, have been demonstrated to be potential anti-microbial and anti-inflammatory agents. To expand the structural diversity of synthetic courmarins for biological functions, attempts have also been made to attach a chloramphenicol side chain at C-3 position of courmarin. In addition, the bi- and tri-heterocyclic coumarins and 1-azacoumarins with benzofuran, furan and thiazole ring systems along with biocompatible fragments like vanillin have shown remarkable potency as anti-inflammatory agents ill animal models.
   Photobiological studies oil pyridine-fused polycyclic coumarins have highlighted their potential as thymine dimer photosensitisers and the structurally related compounds of both coumarin and carbostyrils have also been found to act via the DNA gyrase pathway in their anti-bacterial activity. Apart from the above works, the present review also addresses the potential roles of coumarins and carbostyrils as protease inhibitors, or fluorescent probes in mechanistic investigation of biochemical pathways, and their application for QSAR in theoretical studies. Though 1-Azacoumarins have received less attention as compared to coumarins in the literature, an attempt has been made to compare both the systems at various stages, so that it can spark new thoughts on synthetic methodologies, reactivity pattern and biological activities.
C1 Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 30050, Taiwan.
   Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan.
RP Sun, CM (reprint author), Natl Chiao Tung Univ, Dept Appl Chem, Hsinchu 30050, Taiwan.
EM cmsun@mail.nctu.edu.tw
CR Adamczyk M, 1997, BIOORG MED CHEM LETT, V7, P1985, DOI 10.1016/S0960-894X(97)00345-4
   Adavi HH, 2004, J INDIAN CHEM SOC, V81, P981
   Al Yousuf MH, 1999, PHYTOCHEMISTRY, V51, P95
   Al-Barwani FM, 2004, BIOCHEM SYST ECOL, V32, P1097, DOI 10.1016/j.bse.2004.02.011
   AL-YAHYA M A, 1991, International Journal of Pharmacognosy, V29, P268
   ALBRECHT CF, 1989, LIFE SCI, V45, P1119, DOI 10.1016/0024-3205(89)90169-0
   Ali MS, 2001, PHYTOCHEMISTRY, V57, P1277, DOI 10.1016/S0031-9422(01)00188-1
   Angibaud PR, 2004, EUR J ORG CHEM, P479, DOI 10.1002/ejoc.200300538
   ANKLEKAR KY, 2003, INDIAN J CHEM, V42, P568
   Antoniadou-Vyza E, 1998, ARCH PHARM, V331, P72, DOI 10.1002/(SICI)1521-4184(199802)331:2<72::AID-ARDP72>3.0.CO;2-E
   Aoki S, 2001, CHEM PHARM BULL, V49, P1372, DOI 10.1248/cpb.49.1372
   Attaur R., 1997, PHYTOCHEMISTRY, V44, P683
   Bach T, 2002, J AM CHEM SOC, V124, P7982, DOI 10.1021/ja0122288
   Bailly C, 2003, J MED CHEM, V46, P5437, DOI 10.1021/jm030903d
   BEVINAKATTI HS, 1981, ARCH PHARM, V314, P162, DOI 10.1002/ardp.19813140212
   Bonsignore L, 1998, FARMACO, V53, P425, DOI 10.1016/S0014-827X(98)00047-0
   Born SL, 1998, TOXICOL APPL PHARM, V151, P45, DOI 10.1006/taap.1998.8442                                                          
   Braccio M.D., 2004, EUR J MED CHEM, V39, P397
   Bruhlmann C, 2001, J MED CHEM, V44, P3195, DOI 10.1021/jm010894d
   Budzisz E, 2003, EUR J MED CHEM, V38, P597, DOI 10.1016/S0223-5324(03)00086-2
   Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047
   CastiglioneGertsch M, 1996, EUR J CANCER, V32A, P393, DOI 10.1016/0959-8049(95)00013-5
   Chang CT, 1997, PHYTOCHEMISTRY, V45, P1419, DOI 10.1016/S0031-9422(97)89023-1
   CHEN IS, 1995, PHYTOCHEMISTRY, V39, P1091, DOI 10.1016/0031-9422(95)00054-B
   Chen IS, 2001, J NAT PROD, V64, P1143, DOI 10.1021/np010122k
   Chen SB, 2002, PLANTA MED, V68, P554, DOI 10.1055/s-2002-32555
   Chen SU, 2004, J BIOL CHEM, V279, P48071, DOI 10.1074/jbc.M406847200
   Chilin A, 2002, J MED CHEM, V45, P1146, DOI 10.1021/jm010993r
   Chimichi S, 2002, TETRAHEDRON LETT, V43, P7473, DOI 10.1016/S0040-4039(02)01798-7
   Chowdhury R, 2003, FITOTERAPIA, V74, P155, DOI 10.1016/S0367-326X(02)00322-2
   Chung HS, 2001, J NAT PROD, V64, P1579, DOI 10.1021/np010324g
   Chung H.S., 2002, NUTRACEUTICALS FOOD, V7, P119
   COHEN AJ, 1979, FOOD COSMET TOXICOL, V17, P277, DOI 10.1016/0015-6264(79)90289-X
   Cottrell S, 1996, FUND APPL TOXICOL, V34, P47, DOI 10.1006/faat.1996.0174                                                          
   DACUNHA EVL, 1993, AUST J CHEM, V46, P1507, DOI 10.1071/CH9931507                                                               
   Dalla Via L, 2003, J MED CHEM, V46, P3800, DOI 10.1021/jm0210919
   Dalla Via Lisa, 2001, Current Medicinal Chemistry, V8, P1405
   de Marchi AA, 2004, BIOORGAN MED CHEM, V12, P4823, DOI 10.1016/j.bmc.2004.07.018
   EGAN D, 1990, DRUG METAB REV, V22, P503, DOI 10.3109/03602539008991449                                                       
   Egan D, 1997, CANCER LETT, V118, P201, DOI 10.1016/S0304-3835(97)00331-5
   Erazo S, 1997, J ETHNOPHARMACOL, V57, P81, DOI 10.1016/S0378-8741(97)00048-2
   Fakhouri W, 2001, PHYTOCHEMISTRY, V58, P1297, DOI 10.1016/S0031-9422(01)00344-2
   FENTEM JH, 1993, COMP BIOCHEM PHYS C, V104, P1, DOI 10.1016/0742-8413(93)90102-Q
   FETZNER S, 1998, ANGEW CHEM INT EDIT, V37, P576, DOI DOI 10.1002/(SICI)1521-3773(19980316)37:5<576::AID-ANIE576>3.0.CO;2-L
   Filippini R, 1998, PHYTOCHEMISTRY, V49, P2337, DOI 10.1016/S0031-9422(98)00356-2
   Finn GJ, 2004, CANCER LETT, V214, P43, DOI 10.1016/j.canlet.2004.04.022
   Finn GJ, 2002, CANCER LETT, V183, P61, DOI 10.1016/S0304-3835(02)00102-7
   Finn GJ, 2001, MELANOMA RES, V11, P461, DOI 10.1097/00008390-200110000-00004                                                
   FOKALIAKIS N, 2002, CHEM PHARM BULL, V50, P413
   Franke K, 2002, PHYTOCHEMISTRY, V61, P873, DOI 10.1016/S0031-9422(02)00358-8                                                   
   FULLER RW, 1994, BIOORG MED CHEM LETT, V4, P1961, DOI 10.1016/S0960-894X(01)80543-6
   Fylaktakidou KC, 2004, CURR PHARM DESIGN, V10, P3813, DOI 10.2174/1381612043382710
   GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474                                                         
   Ghate M, 2003, EUR J MED CHEM, V38, P297, DOI 10.1016/S0223-5234(03)00016-3
   GIN G, 2003, EUR J PHARMACOL, V481, P159
   Gnerre C, 2000, J MED CHEM, V43, P4147
   Goddard JP, 2004, TRENDS BIOTECHNOL, V22, P363, DOI 10.1016/j.tibtech.2004.04.005                                                   
   GRAYER RJ, 1994, PHYTOCHEMISTRY, V37, P19, DOI 10.1016/0031-9422(94)85005-4
   GRUNDON MF, 1985, TETRAHEDRON LETT, V26, P4253, DOI 10.1016/S0040-4039(00)99007-5
   Guilet D, 2001, PHYTOCHEMISTRY, V58, P571, DOI 10.1016/S0031-9422(01)00285-0
   Guillo LA, 1996, PHOTOCHEM PHOTOBIOL, V64, P349, DOI 10.1111/j.1751-1097.1996.tb02470.x
   Hadjipavlou-Litina DJ, 2000, ARZNEIMITTEL-FORSCH, V50, P631
   Hanamanthgad S S, 1985, REV ROUM CHIM, V30, P735
   HANAMANTHGAD SS, 1986, INDIAN J CHEM B, V25, P779
   HARDT TJ, 1983, ARZNEIMITTEL-FORSCH, V33-2, P1662
   Heltweg B, 2004, J MED CHEM, V47, P5235, DOI 10.1021/jm0497592
   Hewawasam P, 2004, BIOORG MED CHEM LETT, V14, P4479, DOI 10.1016/j.bmcl.2004.06.051
   Hewawasam P, 2003, J MED CHEM, V46, P2819, DOI 10.1021/jm030005h
   Hewawasam P, 2002, BIOORG MED CHEM LETT, V12, P1779, DOI 10.1016/S0960-894X(02)00240-8
   Heyduk E, 1997, ANAL BIOCHEM, V248, P216, DOI 10.1006/abio.1997.2148
   Hilgert M, 1999, NEUROSCI LETT, V263, P193, DOI 10.1016/S0304-3940(99)00149-4
   Hoffmann K, 1999, NUCLEIC ACIDS RES, V27, P2057, DOI 10.1093/nar/27.9.2057
   Hopkins AL, 2004, J MED CHEM, V47, P5912, DOI 10.1021/jm040071z
   Hoult JRS, 1996, GEN PHARMACOL, V27, P713, DOI 10.1016/0306-3623(95)02112-4                                                    
   HUITINK GM, 1974, TALANTA, V21, P1221, DOI 10.1016/0039-9140(74)80143-8
   JERRIS PJ, 1981, J ORG CHEM, V46, P577, DOI 10.1021/jo00316a018
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Joseph B, 2002, J MED CHEM, V45, P2543, DOI 10.1021/jm010978m
   Jurd DL, 1970, EXPERIENTIA, V26, P1281
   KASHMAN Y, 1992, J MED CHEM, V35, P2735, DOI 10.1021/jm00093a004
   Katerinopoulos HE, 2004, CURR PHARM DESIGN, V10, P3835, DOI 10.2174/1381612043382666                                                        
   KAYSER O, 1995, PHYTOCHEMISTRY, V39, P1181, DOI 10.1016/0031-9422(95)00166-5
   Kempen I, 2003, BRIT J CANCER, V88, P1111, DOI 10.1038/sj.bjc.6600856
   Khan IA, 2005, EUR J MED CHEM, V40, P1168, DOI 10.1016/j.ejmech.2005.05.007
   Khan IA, 2005, BIOORG MED CHEM LETT, V15, P3584, DOI 10.1016/j.bmcl.2005.05.063
   Khan IA, 1999, INDIAN J CHEM B, V38, P491
   Kim KS, 2002, FITOTERAPIA, V73, P266, DOI 10.1016/S0367-326X(02)00070-9
   KIM S H, 1992, Archives of Pharmacal Research (Seoul), V15, P73, DOI 10.1007/BF02973988
   KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P224
   Kirkiacharian S, 2002, FARMACO, V57, P703, DOI 10.1016/S0014-827X(02)01264-8
   Koch K, 2005, J ORG CHEM, V70, P3275, DOI 10.1021/jo050075r
   KOHLI E, 2004, BIOCHIM BIOPHYS ACTA, P55
   Kolodziej H, 1997, Z NATURFORSCH C, V52, P240
   Kontogiorgis CA, 2004, BIOORG MED CHEM LETT, V14, P611, DOI 10.1016/j.bmcl.2003.11.060
   KULKARNI GM, 1991, INDIAN J CHEM B, V30, P970
   KULKARNI GM, 1990, J INDIAN CHEM SOC, V67, P693
   KULKARNI GM, 1990, REV ROUM CHIM, V35, P549
   KULKARNI GM, 1996, J INDIAN CHEM SOC, V73, P496
   KULKARNI MV, 1981, ARCH PHARM, V314, P708, DOI 10.1002/ardp.19813140810
   Kumar RN, 2002, HETEROCYCLES, V57, P357
   Kwon YS, 1997, PHYTOCHEMISTRY, V44, P887, DOI 10.1016/S0031-9422(96)00634-6
   Lacy A, 2004, CURR PHARM DESIGN, V10, P3797, DOI 10.2174/1381612043382693
   Lake BG, 1996, FUND APPL TOXICOL, V34, P105, DOI 10.1006/faat.1996.0181
   LAKE BG, 1989, TOXICOL APPL PHARM, V97, P311, DOI 10.1016/0041-008X(89)90336-0
   Lake BG, 2002, FOOD CHEM TOXICOL, V40, P809, DOI 10.1016/S0278-6915(02)00036-4
   Laurin P, 1999, BIOORG MED CHEM LETT, V9, P2875, DOI 10.1016/S0960-894X(99)00492-8
   Laurin P, 1999, BIOORG MED CHEM LETT, V9, P2079, DOI 10.1016/S0960-894X(99)00329-7
   LAVOIE EJ, 1988, FOOD CHEM TOXICOL, V26, P625, DOI 10.1016/0278-6915(88)90233-5
   Leal LKAM, 1997, PHYTOMEDICINE, V4, P221, DOI 10.1016/S0944-7113(97)80071-2
   Leal LKAM, 2000, J ETHNOPHARMACOL, V70, P151, DOI 10.1016/S0378-8741(99)00165-8
   Lee KH, 2003, PHYTOCHEMISTRY, V64, P535, DOI 10.1016/S0031-9422(03)00243-7
   LI M, 1995, J AM CHEM SOC, V117, P8132, DOI 10.1021/ja00136a010                                                             
   Liao Y, 1999, BIOORG MED CHEM LETT, V9, P1795
   LILY EM, 1980, MED PLANTS E SE ASIA, P367
   Lobnik A, 2001, SENSOR ACTUAT B-CHEM, V74, P200, DOI 10.1016/S0925-4005(00)00734-6
   Lowe NJ, 1997, CLIN DERMATOL, V15, P745, DOI 10.1016/S0738-081X(97)00017-5                                                   
   LUNNEY EA, 1994, J MED CHEM, V37, P2664, DOI 10.1021/jm00043a006                                                             
   MADDI V, 1992, J PHARM SCI, V81, P964, DOI 10.1002/jps.2600810926
   MANSKY LM, 2003, VIROLOGY, V317, P116
   Marquez N, 2005, ANTIVIR RES, V66, P137, DOI 10.1016/j.antiviral.2005.02.006
   Mederski WWKR, 1997, BIOORG MED CHEM LETT, V7, P1883, DOI 10.1016/S0960-894X(97)00319-3                                                   
   Merabet N, 2004, J MED CHEM, V47, P6392, DOI 10.1021/jm040833q
   MERCHANT JR, 1985, CHEM IND, V30, P1
   Michael JP, 2003, NAT PROD REP, V20, P476, DOI 10.1039/b208140g
   Michael JP, 2002, NAT PROD REP, V19, P742, DOI 10.1039/b104971m
   Morita H, 2004, BIOORG MED CHEM LETT, V14, P3665, DOI 10.1016/j.bmcl.2004.05.015
   Murphy EM, 2004, BIOCHEM SYST ECOL, V32, P203, DOI 10.1016/S0305-1978(03)00171-6
   Murray R.D.H., 1991, PROGR CHEM ORGANIC N, V58, P84
   Ng TB, 2000, LIFE SCI, V66, P709, DOI 10.1016/S0024-3205(99)00642-6
   Nicolaides DN, 1998, J HETEROCYCLIC CHEM, V35, P619, DOI 10.1002/jhet.5570350321                                                         
   Nicolaides DN, 1998, EUR J MED CHEM, V33, P715, DOI 10.1016/S0223-5234(98)80030-5                                                   
   NIMLOS MR, 1987, J PHYS CHEM-US, V91, P6610, DOI 10.1021/j100311a011                                                             
   Noda N, 2001, CHEM PHARM BULL, V49, P930, DOI 10.1248/cpb.49.930
   Oketch-Rabah HA, 2000, FITOTERAPIA, V71, P636, DOI 10.1016/S0367-326X(00)00222-7
   Padmawinata K., 1973, ACTA PHARM, V4, P1
   Pandey Vinod Kumar, 2004, Acta Pharmaceutica (Zagreb), V54, P1
   PAYA M, 1992, BIOCHEM PHARMACOL, V44, P205, DOI 10.1016/0006-2952(92)90002-Z
   Periers AM, 2000, BIOORG MED CHEM LETT, V10, P161, DOI 10.1016/S0960-894X(99)00654-X
   Petit G. R., 1995, J MED CHEM, V38, P1666
   Piazzi L, 2003, J MED CHEM, V46, P2279, DOI 10.1021/jm0340602
   Purohit A, 1996, CANCER RES, V56, P4950
   Purohit A, 2001, MOL CELL ENDOCRINOL, V171, P129, DOI 10.1016/S0303-7207(00)00428-7
   Raj HG, 2001, BIOORGAN MED CHEM, V9, P1085, DOI 10.1016/S0968-0896(00)00328-X                                                   
   Rajab MS, 1998, PLANTA MED, V64, P2, DOI 10.1055/s-2006-957354
   Rajanarendar E, 2004, INDIAN J CHEM B, V43, P1790
   Reddy NS, 2005, BIOORGAN MED CHEM, V13, P3141, DOI 10.1016/j.bmc.2005.02.051
   Reddy NS, 2004, BIOORG MED CHEM LETT, V14, P4093, DOI 10.1016/j.bmcl.2004.05.016
   Reutrakul V, 2003, PLANTA MED, V69, P1048, DOI 10.1055/s-2003-45154
   RINEHART KL, 1970, J AM CHEM SOC, V92, P6994, DOI 10.1021/ja00726a060
   Riveiro ME, 2004, CANCER LETT, V210, P179, DOI 10.1016/j.canlet.2004.03.015
   Roma G, 2003, BIOORGAN MED CHEM, V11, P123, DOI 10.1016/S0968-0896(02)00307-3                                                   
   ROSCHE B, 1995, J BIOL CHEM, V270, P17836, DOI 10.1074/jbc.270.30.17836                                                        
   RUGER A, 1993, BIOL CHEM H-S, V374, P479, DOI 10.1515/bchm3.1993.374.7-12.479
   Sah P, 1996, TRENDS NEUROSCI, V19, P150, DOI 10.1016/S0166-2236(96)80026-9
   Saha K, 1997, PHYTOTHER RES, V11, P463, DOI 10.1002/(SICI)1099-1573(199709)11:6<463::AID-PTR130>3.0.CO;2-1
   San Martin A. J., 1983, Economic Botany, V37, P216
   Sardari S, 1999, BIOORGAN MED CHEM, V7, P1933, DOI 10.1016/S0968-0896(99)00138-8
   Sarker SD, 2004, CURR MED CHEM, V11, P1479, DOI 10.2174/0929867043365189                                                        
   Schimanski CC, 2004, J HEPATOL, V41, P67, DOI 10.1016/j.hep.2004.03.010
   SCHWARZ G, 1989, BIOL CHEM H-S, V370, P1183, DOI 10.1515/bchm3.1989.370.2.1183
   Shan B, 1999, P NATL ACAD SCI USA, V96, P5686, DOI 10.1073/pnas.96.10.5686                                                         
   Shastri LA, 2004, INDIAN J CHEM B, V43, P2416
   Shieh CC, 2000, PHARMACOL REV, V52, P557
   SHUKLA OP, 1989, MICROBIOS, V59, P47
   SIMEONRUDOLF R, 1999, CHEM BIOL INTERACT, V119
   So FV, 1997, CANCER LETT, V112, P127, DOI 10.1016/S0304-3835(96)04557-0
   Spino C, 1998, BIOORG MED CHEM LETT, V8, P3475, DOI 10.1016/S0960-894X(98)00628-3                                                   
   Sugimoto H, 2000, CURR MED CHEM, V7, P303, DOI 10.2174/0929867003375191                                                        
   Tang W., 1992, CHINESE DRUGS PLANT, P179
   THORNES RD, 1968, JOHNS HOPKINS MED J, V123, P305
   THORNES RD, 1982, LANCET, V11, P328
   Tournas VH, 2001, J FOOD PROTECT, V64, P528, DOI 10.4315/0362-028X-64.4.528                                                      
   Tsai IL, 1998, J CHIN CHEM SOC-TAIP, V45, P99, DOI 10.1002/jccs.199800017                                                          
   Tyagi YK, 2005, EUR J MED CHEM, V40, P413, DOI 10.1016/j.ejmech.2004.09.002
   ULRAINETS IV, 2002, CHEM HETEROCYCLIC CO, V38, P571
   Uray G, 1999, HELV CHIM ACTA, V82, P1408, DOI 10.1002/(SICI)1522-2675(19990908)82:9<1408::AID-HLCA1408>3.3.CO;2-H
   VANDERWALT JJA, 1988, PELARGONIUMS SO AFRI, V3, P7
   Velasco-Velazquez MA, 2003, CANCER LETT, V198, P179, DOI 10.1016/S0304-3835(03)00333-1
   Wang BH, 1998, BIOORGAN MED CHEM, V6, P417, DOI 10.1016/S0968-0896(98)00014-5
   Wang CJ, 2002, CANCER LETT, V183, P163, DOI 10.1016/S0304-3835(02)00031-9
   Wang W, 2004, TETRAHEDRON LETT, V45, P8479, DOI 10.1016/j.tetlet.2004.09.003
   WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681                                                               
   Weber US, 1998, RES COMMUN MOL PATH, V99, P193
   Wu TS, 2001, BIOORGAN MED CHEM, V9, P77, DOI 10.1016/S0968-0896(00)00225-X
   Xie L, 2001, J MED CHEM, V44, P664, DOI 10.1021/jm000070g
   Yee SW, 2005, J ENZYM INHIB MED CH, V20, P109, DOI 10.1080/14756360400002015
   Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222
   Yu DL, 2003, MED RES REV, V23, P322, DOI 10.1002/med.10034
   Zaha A A, 2002, New Microbiol, V25, P213
   Zhang HY, 2004, J MOL STRUC-THEOCHEM, V673, P199, DOI 10.1016/j.theochem.2003.12.014
   Zych LA, 2004, BIOORG CHEM, V32, P109, DOI 10.1016/j.bioorg.2003.12.002
   Sit S.-Y., 1999, U.S. Patent, Patent No. [5,892,045, 5892045]
   FRIESEN R, 1996, Patent No. 2169231
   BRITTAIN DR, 1977, Patent No. 2611824
   FRIESEN R, 1996, Patent No. 5576338
   YOSHIAZAKI S, 1978, Patent No. 7783379
NR 196
TC 151
Z9 153
U1 4
U2 76
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2006
VL 13
IS 23
BP 2795
EP 2818
DI 10.2174/092986706778521968
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 083JY
UT WOS:000240453400007
PM 17073630
DA 2018-01-05
ER

PT J
AU Christopher, ME
   Wong, JP
AF Christopher, ME
   Wong, JP
TI Recent developments in delivery of nucleic acid-based antiviral agents
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE liposomes; nanoparticles; immunopotentiating reconstituted influenza
   virosomes; viral vectors
ID MEDIATED GENE-TRANSFER; IMMUNODEFICIENCY-VIRUS TYPE-1; PH-SENSITIVE
   LIPOSOMES; IN-VIVO; PLASMID-DNA; ANTISENSE OLIGONUCLEOTIDES; CATIONIC
   LIPOSOMES; IMMUNE-RESPONSES; CELL-LINES; INTRACELLULAR DELIVERY
AB Rapid advances in viral genomics, gene function and regulation, as well as in rational drug design, have led to the development of gene-based drugs that can induce protective antiviral immunity, interfere with viral replication, suppress viral gene expression or cleave viral mRNAs. Several such drug candidates have been developed in recent years against various viruses including HIV. Although gene-based agents show promise as anti-viral agents their therapeutic efficacy may be restricted by limited delivery to intracellular sites of viral replication and in vivo nuclease degradation. Enhancement of the efficacy of gene-based drugs by encapsulation within liposomes or insertion within viral vectors has been evaluated. This review will highlight recent developments in delivery systems used to target nucleic acid-based drugs into sites of viral replication, therefore avoiding potential drug toxicity in non-viral infected organs. Liposome-encapsulation and insertion of nucleic acid-based drugs within viral vectors can significantly enhance antiviral efficacies. Viral vector-mediated therapy usually results in greater expression of the gene-based drug than with liposome delivery, however significant safety concerns have been raised in regards to viral vector therapies. Research is ongoing to increase drug delivery to the desired target cells while eliminating adverse side effects.
C1 Def R&D Canada Suffield, Chem & Biol Def Sect, Ralston, AB, Canada.
RP Wong, JP (reprint author), Chem & Biol Def Sect, Stn Main, Box 4000, Medicine Hat, AB T1A 8K6, Canada.
EM Jonathan.Wong@drdc-rddc.gc.ca
CR Abe T, 2001, EUR J PHARM SCI, V13, P61, DOI 10.1016/S0928-0987(00)00208-6
   Allen TM, 2002, J LIPOSOME RES, V12, P5, DOI 10.1081/LPR-120004771
   ALMOFTI MR, 2002, ARCH BIOCHEM BIOPHYS, V410, P246
   Anchordoquy TJ, 1997, ARCH BIOCHEM BIOPHYS, V348, P199, DOI 10.1006/abbi.1997.0385
   Audouy SAL, 2002, PHARMACEUT RES, V19, P1599, DOI 10.1023/A:1020989709019
   Bainbridge JWB, 2003, GENE THER, V10, P1336, DOI 10.1038/sj.gt.3301990
   Block A, 2003, J GENE MED, V5, P190, DOI 10.1002/jgm.334
   Bruce CB, 1999, J GEN VIROL, V80, P2621, DOI 10.1099/0022-1317-80-10-2621                                                    
   CECH TR, 1986, ANNU REV BIOCHEM, V55, P599, DOI 10.1146/annurev.biochem.55.1.599
   Chang JS, 2001, VACCINE, V19, P3608, DOI 10.1016/S0264-410X(01)00104-9
   Check E, 2003, NATURE, V422, P7, DOI 10.1038/422007a
   Chen Y, 2003, GENE THER, V10, P1345, DOI 10.1038/sj.gt.3301999
   Chu Q, 2001, HUM GENE THER, V12, P455, DOI 10.1089/104303401300042348
   Cryz S, 1996, VACCINE, V14, P665
   Cusi MG, 2000, VIROLOGY, V277, P111, DOI 10.1006/viro.2000.0605
   Dan N, 2002, BBA-BIOMEMBRANES, V1564, P343, DOI 10.1016/S0005-2736(02)00468-6                                                   
   Dass CR, 2002, ANTISENSE NUCLEIC A, V12, P289, DOI 10.1089/108729002761381276
   Dass CR, 2002, J CANCER RES CLIN, V128, P177, DOI 10.1007/s00432-001-0318-x
   Devroe Eric, 2002, BMC Biotechnol, V2, P15, DOI 10.1186/1472-6750-2-15
   Duncan JE, 1997, HUM GENE THER, V8, P431, DOI 10.1089/hum.1997.8.4-431
   Eastman SJ, 1998, HUM GENE THER, V9, P43, DOI 10.1089/hum.1998.9.1-43
   Eastman SJ, 1997, HUM GENE THER, V8, P313, DOI 10.1089/hum.1997.8.3-313
   Eastman SJ, 1997, HUM GENE THER, V8, P765, DOI 10.1089/hum.1997.8.6-765
   Edelstein ML, 2004, J GENE MED, V6, P597, DOI 10.1002/jgm.619
   El-Aneed A, 2004, J CONTROL RELEASE, V94, P1, DOI 10.1016/j.jconrel.2003.09.013
   Elouahabi A, 2003, MOL THER, V7, P81, DOI 10.1016/S1525-0016(02)00032-1
   Fenart L, 1999, J PHARMACOL EXP THER, V291, P1017
   Flanagan B, 1997, J GEN VIROL, V78, P991, DOI 10.1099/0022-1317-78-5-991                                                      
   Flotte TR, 2003, HUM GENE THER, V14, P1079, DOI 10.1089/104303403322124792
   Fooks AR, 1998, J GEN VIROL, V79, P1027, DOI 10.1099/0022-1317-79-5-1027                                                     
   Freimark BD, 1998, J IMMUNOL, V160, P4580
   Gijsens Antoon, 2002, International Journal of Cancer, V101, P78, DOI 10.1002/ijc.10548
   Gluck R, 1999, VACCINE, V17, P1782, DOI 10.1016/S0264-410X(98)00440-X
   Gorman J., 2003, SCI NEWS, V163, P43
   Grimm D., 2003, Current Gene Therapy, V3, P281, DOI 10.2174/1566523034578285
   Gu JL, 1997, MOL CELL BIOCHEM, V172, P47, DOI 10.1023/A:1006855219018
   Hanke T, 1999, J VIROL, V73, P7524
   Hanke T, 2003, J GEN VIROL, V84, P361, DOI 10.1099/vir.0.18738-0
   Hanke T, 1998, J GEN VIROL, V79, P83, DOI 10.1099/0022-1317-79-1-83                                                       
   Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X
   Huard J, 1997, HUM GENE THER, V8, P439, DOI 10.1089/hum.1997.8.4-439
   HUG P, 1994, J BIOL CHEM, V269, P4050
   HUNZIKER IP, 2002, INT IMMUNOL, V16, P615
   Janssen APCA, 2003, INT J PHARM, V254, P55, DOI 10.1016/S0378-5173(02)00682-8
   Jiao XM, 2003, HEPATOLOGY, V37, P452, DOI 10.1053/jhep.2003.50051
   Joseph A, 2002, VACCINE, V20, P3342, DOI 10.1016/S0264-410X(02)00295-5
   Kaner RJ, 1999, AM J RESP CELL MOL, V20, P361, DOI 10.1165/ajrcmb.20.3.3398                                                        
   Kawakami S, 2000, BBA-GEN SUBJECTS, V1524, P258, DOI 10.1016/S0304-4165(00)00163-X
   Kende M, 2002, VACCINE, V20, P1681, DOI 10.1016/S0264-410X(01)00484-4                                                   
   Kersten GFA, 2003, VACCINE, V21, P915, DOI 10.1016/S0264-410X(02)00540-6
   Khuller GK, 2004, CURR PHARM DESIGN, V10, P3263, DOI 10.2174/1381612043383250
   Kitajima I, 1997, J BIOL CHEM, V272, P27099, DOI 10.1074/jbc.272.43.27099
   Kobayashi H, 1999, INT J CANCER, V81, P944, DOI 10.1002/(SICI)1097-0215(19990611)81:6<944::AID-IJC17>3.0.CO;2-Y
   Kono K, 2001, GENE THER, V8, P5, DOI 10.1038/sj.gt.3301365
   Konopka K, 1998, BBA-BIOMEMBRANES, V1372, P55, DOI 10.1016/S0005-2736(98)00046-7
   Kuwabara T, 2001, NUCLEIC ACIDS RES, V29, P2780, DOI 10.1093/nar/29.13.2780
   Lagunoff M, 1996, J VIROL, V70, P1810
   Lai Z, 2002, J NEUROSCI RES, V67, P363, DOI 10.1002/jnr.10137                                                               
   Lambert G, 2000, PHARMACEUT RES, V17, P707, DOI 10.1023/A:1007582332491                                                         
   Lee ER, 1996, HUM GENE THER, V7, P1701, DOI 10.1089/hum.1996.7.14-1701
   Lee JS, 2002, J INFECT DIS, V185, P1192, DOI 10.1086/339677                                                                  
   Loisel S, 2001, HUM GENE THER, V12, P685, DOI 10.1089/104303401300057405                                                      
   Macejak DG, 1999, J VIROL, V73, P7745
   Mahato RI, 1998, HUM GENE THER, V9, P2083, DOI 10.1089/hum.1998.9.14-2083                                                      
   Mamot C, 2003, CANCER RES, V63, P3154
   Mautino MR, 2002, AIDS PATIENT CARE ST, V16, P11, DOI 10.1089/108729102753429361                                                      
   Medina MFC, 1999, CURR OPIN MOL THER, V1, P580
   MITTAL SK, 1995, J GEN VIROL, V76, P93, DOI 10.1099/0022-1317-76-1-93
   MORRIS KV, 2004, CURR HIV RES, V2, P186
   Nag A, 1999, J DRUG TARGET, V6, P427, DOI 10.3109/10611869908996849                                                       
   Neumann G, 2002, J GEN VIROL, V83, P2635, DOI 10.1099/vir.0.18400-0
   Ogasawara Y, 1999, J GEN VIROL, V80, P2477, DOI 10.1099/0022-1317-80-9-2477                                                     
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Opanasopit P, 2001, BBA-BIOMEMBRANES, V1511, P134, DOI 10.1016/S0005-2736(01)00267-X                                                   
   Parker SE, 1997, HUM GENE THER, V8, P393, DOI 10.1089/hum.1997.8.4-393                                                        
   Pelisek J, 2002, J MOL MED-JMM, V80, P724, DOI 10.1007/s00109-002-0368-9
   Perrie Y, 2000, BBA-GEN SUBJECTS, V1475, P125, DOI 10.1016/S0304-4165(00)00055-6
   Perrie Y, 2001, VACCINE, V19, P3301, DOI 10.1016/S0264-410X(00)00432-1
   Ponnappa BC, 2001, J PHARMACOL EXP THER, V297, P1129
   RAMANI K, 1998, P NATL ACAD SCI USA, V29, P11886
   Reszka R, 1997, J PHARMACOL EXP THER, V280, P232
   Ring CJA, 2002, J GEN VIROL, V83, P491, DOI 10.1099/vir.0.18098-0
   Ruiz FE, 2001, HUM GENE THER, V12, P751, DOI 10.1089/104303401750148667
   Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573                                                    
   Sallenave JM, 1998, GENE THER, V5, P352, DOI 10.1038/sj.gt.3300610
   Santiago Fernando S., 2001, Journal of Molecular Medicine (Berlin), V79, P695, DOI 10.1007/s001090100272
   Saravolac EG, 2000, J DRUG TARGET, V7, P423, DOI 10.3109/10611860009102217                                                       
   SARAVOLAC EG, 2001, RD ANTI RES, V1, P117
   Sarkar R, 2003, J THROMB HAEMOST, V1, P220, DOI 10.1046/j.1538-7836.2003.00096.x
   Sato A, 2001, J DRUG TARGET, V9, P201, DOI 10.3109/10611860108997928                                                       
   Schneider J, 1998, NAT MED, V4, P397, DOI 10.1038/nm0498-397                                                              
   SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460                                                        
   Semple SC, 2001, BBA-BIOMEMBRANES, V1510, P152, DOI 10.1016/S0005-2736(00)00343-6
   Sha ZY, 1999, IMMUNOBIOLOGY, V200, P21, DOI 10.1016/S0171-2985(99)80030-8                                                   
   Shering AF, 1997, J GEN VIROL, V78, P445, DOI 10.1099/0022-1317-78-2-445                                                      
   Shoji I, 1997, J GEN VIROL, V78, P2657, DOI 10.1099/0022-1317-78-10-2657                                                    
   Shoji Y, 2004, CURR PHARM DESIGN, V10, P785, DOI 10.2174/1381612043453009
   Simoes S, 2001, BBA-BIOMEMBRANES, V1515, P23, DOI 10.1016/S0005-2736(01)00389-3
   Skalko-Basnet N, 2002, BIOL PHARM BULL, V25, P1583, DOI 10.1248/bpb.25.1583
   Skog J, 2002, J GEN VIROL, V83, P1299, DOI 10.1099/0022-1317-83-6-1299                                                     
   Smaglik P, 1999, NATURE, V402, P707, DOI 10.1038/45321
   Sollerbrant K, 2001, J GEN VIROL, V82, P2051, DOI 10.1099/0022-1317-82-9-2051                                                     
   Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585                                                      
   Sudimack JJ, 2002, BBA-BIOMEMBRANES, V1564, P31, DOI 10.1016/S0005-2736(02)00399-1
   Sun LQ, 2000, PHARMACOL REV, V52, P325
   Tomita N, 2002, J GENE MED, V4, P527, DOI 10.1002/jgm.300
   Torchilin VP, 2005, ADV DRUG DELIVER REV, V57, P95, DOI 10.1016/j.addr.2004.06.002
   Tsan MF, 1997, HUM GENE THER, V8, P817, DOI 10.1089/hum.1997.8.7-817                                                        
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   VandenDriessche T, 2002, BLOOD, V100, P813, DOI 10.1182/blood.V100.3.813                                                        
   Varnavski AN, 2000, J VIROL, V74, P4394, DOI 10.1128/JVI.74.9.4394-4403.2000
   Varnavski AN, 2002, J VIROL, V76, P5711, DOI 10.1128/JVI.76.11.571105719.2002
   Vignuzzi M, 2001, J GEN VIROL, V82, P1737, DOI 10.1099/0022-1317-82-7-1737                                                     
   Von Seggern DJ, 1998, J GEN VIROL, V79, P1461, DOI 10.1099/0022-1317-79-6-1461                                                     
   Walker K, 2001, Curr Issues Mol Biol, V3, P1
   WANG D, 1999, J CONTROL RELEASE, V4, P9
   WEERASINGHE M, 1991, J VIROL, V65, P5531
   Wong JP, 2001, VACCINE, V19, P2461, DOI 10.1016/S0264-410X(00)00474-6                                                   
   WONG JP, 2001, RD ANTI RES, V1, P175
   Xodo LE, 2004, CURR PHARM DESIGN, V10, P805, DOI 10.2174/1381612043452983
   Xu L, 2002, MOL CANCER THER, V1, P337
   Yu RZ, 1999, PHARMACEUT RES, V16, P1309, DOI 10.1023/A:1014822219133
   Zhang Y, 2003, J GENE MED, V5, P157, DOI 10.1002/jgm.333
   Zhou W, 2002, BIOCONJUGATE CHEM, V13, P1220, DOI 10.1021/bc025569z
NR 124
TC 14
Z9 14
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2006
VL 12
IS 16
BP 1995
EP 2006
DI 10.2174/138161206777442146
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 051ZE
UT WOS:000238199400006
PM 16787243
DA 2018-01-05
ER

PT J
AU Winum, JY
   Scozzafava, A
   Montero, JL
   Supuran, CT
AF Winum, JY
   Scozzafava, A
   Montero, JL
   Supuran, CT
TI The sulfamide motif in the design of enzyme inhibitors
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Review
DE gamma-secretase; carbonic anhydrase inhibitor; carboxypepridase A;
   chymase; elastase; enzyme-inhibitor adduct; HIV protease; matrix
   metalloproteinase; protease inhibitor; protein tyrosine phosphatase;
   steroid sulfatase inhibitor; sulfamide; thrombin; tryptase
ID CARBONIC-ANHYDRASE INHIBITORS; 1,2,5-THIADIAZOLIDIN-3-ONE 1,1 DIOXIDE;
   STEROID SULFATASE INHIBITORS; HUMAN-LEUKOCYTE ELASTASE; GAMMA-SECRETASE
   INHIBITORS; STATE ANALOG INHIBITORS; RAY CRYSTAL-STRUCTURE; OF-THE-ART;
   ISOZYME-II; PROTEASE INHIBITORS
AB The sulfamide moiety, similarly to the structurally related sulfonamide and sulfamate ones, is widely employed in medicinal chemistry for the design of biologically active compounds. Amongst the enzymes for which sulfamide-based inhibitors were designed are the carbonic anhydrases (CAs), and a large number of proteases belonging to the aspartic protease (HIV-1 protease, gamma-secretase), serine protease (elastase, chymase, tryptase and thrombin, among others) and metalloproteinase (carboxypeptidase A [CPA] and matrix metalloproteinase [MMP]) families. Some steroid sulfatase (STS) and protein tyrosine phosphatase inhibitors belonging to the sulfamide class of derivatives have also been reported. In all these compounds, many of which show low nanomolar affinity for the target enzymes for which they have been designed, the free or substituted sulfamide moiety plays an important role in the binding of the inhibitor to the active site cavity. This is achieved either by directly coordinating to the metal ion found in some metalloenzymes (CAs, CPA, STS), usually by means of one of the nitrogen atoms present in the sulfamide motif, or, as in the case of the cyclic sulfamides, acting as HIV protease inhibitors interacting with the catalytically critical aspartic acid residues of the active site by means of an oxygen atom belonging to the HN-SO2-NH motif that substitutes a catalytically essential water molecule. In other cases, the sulfamide moiety is important for inducing desired physicochemical properties to the drug-like compounds incorporating it, such as enhanced water solubility, better bioavailability etc., due to the intrinsic properties of this highly polarised moiety when attached to an organic scaffold. This interesting motif is, thus, of great value for the design of pharmacological agents with many applications.
C1 Univ Montpellier 2, Lab Chim Biomol, UMR 5032, Ecole Natl Super Chim Montpellier, F-34296 Montpellier, France.
   Univ Florence, Dipartimento Chim, Chim Bioorgan Lab, I-50019 Sesto Fiorentino, Firenze, Italy.
RP Winum, JY (reprint author), Univ Montpellier 2, Lab Chim Biomol, UMR 5032, Ecole Natl Super Chim Montpellier, 8 Rue Ecole Normale, F-34296 Montpellier, France.
EM winumj@univ-montp2.fr; claudiu.supuran@unifi.it
RI Supuran, Claudiu/A-5151-2008; WINUM, Jean-Yves/P-3387-2016
OI WINUM, Jean-Yves/0000-0003-3197-3414; Scozzafava,
   Andrea/0000-0001-5020-3322
CR Abbate F, 2002, J MED CHEM, V45, P3583, DOI 10.1021/jm011131t
   ALA PJ, 2002, PROTEINASE PEPTIDASE, P367
   Backbro K, 1997, J MED CHEM, V40, P898, DOI 10.1021/jm960588d
   Barbaro G, 2005, CURR PHARM DESIGN, V11, P1805, DOI 10.2174/1381612053764869
   Black E, 2005, BIOORG MED CHEM LETT, V15, P2503, DOI 10.1016/j.bmcl.2005.03.068
   Briganti F, 1997, BIOCHEMISTRY-US, V36, P10384, DOI 10.1021/bi970760v
   Briganti F, 1996, EUR J MED CHEM, V31, P1001, DOI 10.1016/S0223-5234(97)86179-X                                                   
   Cairns JA, 2005, PULM PHARMACOL THER, V18, P55, DOI 10.1016/j.pupt.2004.09.032
   Casini A, 2003, BIOORG MED CHEM LETT, V13, P837, DOI 10.1016/S0960-894X(03)00028-3
   Casini A, 2002, EXPERT OPIN THER PAT, V12, P1307, DOI 10.1517/13543776.12.9.1307                                                      
   Casini A, 2003, BIOORG MED CHEM LETT, V13, P841, DOI 10.1016/S0960-894X(03)00029-5
   CHRISTIANSON DW, 1989, ACCOUNTS CHEM RES, V22, P62, DOI 10.1021/ar00158a003                                                             
   Dadke Shrikrishna, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P299, DOI 10.2174/1568008033340108
   De Simone G, 2005, BIOORG MED CHEM LETT, V15, P2315, DOI 10.1016/j.bmcl.2005.03.032
   Dewang PM, 2005, CURR MED CHEM, V12, P1
   Di Fiore A, 2005, BIOORG MED CHEM LETT, V15, P1937, DOI 10.1016/j.bmcl.2005.01.086
   Doggrell SA, 2004, CARDIOVASC RES, V61, P653, DOI 10.1016/j.cardiores.2003.11.029
   Doherty TM, 2002, EXPERT OPIN THER PAT, V12, P665
   Dorsey B. D., 2001, PROTEASE INHIBITORS, P65
   DUNCAN IB, 2001, PROTEASE INHIBITORS, P27
   ERICKSON JW, 2001, PROTEASE INHIBITORS, P1
   Groutas WC, 1999, BIOORG MED CHEM LETT, V9, P2199, DOI 10.1016/S0960-894X(99)00377-7
   Groutas WC, 2001, BIOORGAN MED CHEM, V9, P1543, DOI 10.1016/S0968-0896(01)00037-2                                                   
   Groutas WC, 2001, ARCH BIOCHEM BIOPHYS, V385, P162, DOI 10.1006/abbi.2000.2139                                                          
   Groutas WC, 1998, BIOORGAN MED CHEM, V6, P661, DOI 10.1016/S0968-0896(98)00006-6
   He S, 2000, BIOORGAN MED CHEM, V8, P1713, DOI 10.1016/S0968-0896(00)00101-2                                                   
   Hilvo M, 2005, BIOCHEM J, V392, P83, DOI 10.1042/BJ20051102
   HOWARTH NM, 1994, J MED CHEM, V37, P219, DOI 10.1021/jm00028a002
   Hulten J, 1999, J MED CHEM, V42, P4054, DOI 10.1021/jm991054q                                                               
   Hulten J, 1997, J MED CHEM, V40, P885, DOI 10.1021/jm960728j                                                               
   Ilies MA, 2002, EXPERT OPIN THER PAT, V12, P1181, DOI 10.1517/13543776.12.8.1181                                                      
   KEMPF DJ, 2001, PROTEASE INHIBITORS, P49
   Kim DH, 2004, CURR TOP MED CHEM, V4, P1217, DOI 10.2174/1568026043387908
   KONTOGIORGIS GA, 2005, CURR MED CHEM, V12, P339
   Kuang RZ, 1998, BIOORG MED CHEM LETT, V8, P539, DOI 10.1016/S0960-894X(98)00067-5
   Kuang RZ, 2000, BIOORGAN MED CHEM, V8, P1005, DOI 10.1016/S0968-0896(00)00038-9                                                   
   Lai Z, 2004, ARCH BIOCHEM BIOPHYS, V429, P191, DOI 10.1016/j.abb.2004.06.014
   Lee K, 2003, J MED CHEM, V46, P3612, DOI 10.1021/jm030025j
   Lee K, 2002, BIOORG MED CHEM LETT, V12, P1017, DOI 10.1016/S0960-894X(02)00093-8
   Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m
   Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j                                                               
   Matthews DE, 2004, CURR OPIN CLIN NUTR, V7, P513, DOI 10.1097/00075197-200409000-00002
   Menchise V, 2005, J MED CHEM, V48, P5721, DOI 10.1021/jm050333c
   NIESTROJ AJ, 2005, ENZYMES THEIR INHIBI, P88
   Nussbaumer P, 2003, EXPERT OPIN THER PAT, V13, P605, DOI 10.1517/13543776.13.5.605
   Ogden R. C., 2001, PROTEASE INHIBITORS, P1
   Park JD, 2004, BIOORGAN MED CHEM, V12, P2349, DOI 10.1016/j.bmc.2004.02.012
   Park JD, 2002, J MED CHEM, V45, P5295, DOI 10.1021/jm020258v
   Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540
   PASTOREKOVA S, 2004, CARBONIC ANHYDRASE I, P253
   Pei ZH, 2004, CURR PHARM DESIGN, V10, P3481, DOI 10.2174/1381612043382954
   Poirier D, 1999, EXPERT OPIN THER PAT, V9, P1083, DOI 10.1517/13543776.9.8.1083                                                       
   Pollack Scott J, 2005, Curr Opin Investig Drugs, V6, P35
   Purohit A, 2003, J STEROID BIOCHEM, V86, P423, DOI 10.1016/S0960-0760(03)00353-4
   Reich S.H., 2001, PROTEASE INHIBITORS, P85
   Roberts SB, 2002, ADV DRUG DELIVER REV, V54, P1579, DOI 10.1016/S0169-409X(02)00155-2
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X                                                   
   Schmidt B, 2003, CHEMBIOCHEM, V4, P366, DOI 10.1002/cbic.200200532
   Scozzafava A, 2000, J ENZYM INHIB, V15, P443, DOI 10.3109/14756360009040700                                                       
   Scozzafava A, 2003, CURR MED CHEM, V10, P925, DOI 10.2174/0929867033457647                                                        
   Scozzafava A, 2004, EXPERT OPIN THER PAT, V14, P667, DOI 10.1517/eotp.14.5.667.31276
   Smith HJ, 2001, EXPERT OPIN THER PAT, V11, P789, DOI 10.1517/13543776.11.5.789                                                       
   Smith H. J., 2002, PROTEASE PEPTIDASE I, P1
   Sparey T, 2005, BIOORG MED CHEM LETT, V15, P4212, DOI 10.1016/j.bmcl.2005.06.084
   Srivastava S, 2005, MED RES REV, V25, P66, DOI 10.1002/med.20016                                                               
   STEINMETZER T, 2005, ENZYMES THEIR INHIBI, P254
   Supuran Claudiu T., 2001, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V1, P61, DOI 10.2174/1568013013359131
   Supuran CT, 2003, MED RES REV, V23, P535, DOI 10.1002/med.10047
   Supuran CT, 2003, EXPERT OPIN INV DRUG, V12, P283, DOI 10.1517/13543784.12.2.283
   Supuran CT, 2002, MED RES REV, V22, P329, DOI 10.1002/med.10007                                                               
   Supuran CT, 2000, EXPERT OPIN THER PAT, V10, P575, DOI 10.1517/13543776.10.5.575                                                       
   Supuran CT, 2002, EXPERT OPIN THER PAT, V12, P217, DOI 10.1517/13543776.12.2.217                                                       
   Supuran CT, 2003, EXPERT OPIN THER PAT, V13, P1545, DOI 10.1517/13543776.13.10.1545
   Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025
   Supuran CT, 2004, CRC ENZYM INHIB SER, P1, DOI 10.1201/9780203475300.ch1
   Supuran CT, 2004, CRC ENZYM INHIB SER, P67
   SUPURAN CT, 2005, ENZYMES THEIR INHIBI, P292
   Supuran C. T., 2004, EXPERT OPIN THER PAT, V14, P25
   SUPURAN CT, 2002, PROTEINASE PEPTIDASE, P35
   Svastova E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043
   Takai S, 2004, EUR J PHARMACOL, V501, P1, DOI 10.1016/j.ejphar.2004.08.040
   TAKAI S, 2004, TRENDS PHARMACOL SCI, V25, P519
   Taylor MA, 2001, EUR J GASTROEN HEPAT, V13, P199, DOI 10.1097/00042737-200102000-00019                                                
   Tomita T, 2004, DRUG NEWS PERSPECT, V17, P321, DOI 10.1358/dnp.2004.17.5.829036                                                    
   Tsai JY, 2002, CURR MED CHEM, V9, P1087, DOI 10.2174/0929867023370185                                                        
   Tung R D., 2001, PROTEASE INHIBITORS, P101
   VACCA JP, 2000, CURR OPIN CHEM BIOL, V25, P369
   Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543                                                               
   Winum JY, 2004, EXPERT OPIN THER PAT, V14, P1273, DOI 10.1517/13543776.14.9.1273                                                      
   Winum JY, 2005, BIOORG MED CHEM LETT, V15, P2353, DOI 10.1016/j.bmcl.2005.02.091
   Winum JY, 2005, BIOORG MED CHEM LETT, V15, P3302, DOI 10.1016/j.bmcl.2005.04.058
   Winum JY, 2005, MED RES REV, V25, P186, DOI 10.1002/med.20021
   Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897
   Wong TS, 2005, ARCH BIOCHEM BIOPHYS, V436, P1, DOI 10.1016/j.abb.2005.01.022
   Woo LWL, 1996, J STEROID BIOCHEM, V57, P79, DOI 10.1016/0960-0760(95)00244-8
   Woo LWL, 1996, J MED CHEM, V39, P1349, DOI 10.1021/jm950931z
   Zhong JY, 2004, J COMB CHEM, V6, P556, DOI 10.1021/cc030047r
   Zhong JY, 2004, CURR TOP MED CHEM, V4, P1203, DOI 10.2174/1568026043387971
   Zhong JY, 2004, BIOORGAN MED CHEM, V12, P589, DOI 10.1016/j.bmc.2003.10.059
   MERCK SHARP DOHME LT, 2005, Patent No. 2005014553
   MERCK SHARP DOHME LT, 2004, Patent No. 2004039800
   Kenny P. W., 2004, Patent No. 2004050646
   NOVARTIS AG, 2003, Patent No. 030382842
   HOFFMANNLAROCHE, 1998, Patent No. 9832748
   GROUTAS WC, 1999, Patent No. 990997
   NOVARTIS, 2004, Patent No. 20040023974
   GROUTAS WC, 2001, Patent No. 01081561
   MADIN A, 2004, Patent No. 2004039370
NR 108
TC 58
Z9 59
U1 2
U2 14
PU ASHLEY PUBLICATIONS LTD
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3776
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD JAN
PY 2006
VL 16
IS 1
BP 27
EP 47
DI 10.1517/13543776.16.1.27
PG 21
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 000OU
UT WOS:000234472500003
PM 20141508
DA 2018-01-05
ER

PT J
AU Pal, A
   Isola, NR
   Alarie, JP
   Stokes, DL
   Vo-Dinh, T
AF Pal, A
   Isola, NR
   Alarie, JP
   Stokes, DL
   Vo-Dinh, T
TI Synthesis and characterization of SERS gene probe for BRCA-1 (breast
   cancer)
SO FARADAY DISCUSSIONS
LA English
DT Article
ID ENHANCED RAMAN-SCATTERING; AQUEOUS TRITON X-100; GOLD NANOPARTICLES;
   SUBSTRATE; SPECTROSCOPY; DNA; POLYNUCLEOTIDES; POLYMER; BIOTIN
AB A protocol for binding cresyl fast violet (CFV), a SERS-active dye ( label) containing an aromatic amino group with a modified oligomer having a carboxy derivatized thymidine moiety using carbodiimide coupling has been achieved for the first time. Covalent coupling between CFV and the oligomer has been confirmed by mass spectral analysis of the labeled oligomer. The fluorescence, SERS and absorption characteristics of the labeled product have been evaluated. The chosen oligomer contains a BRCA-1 ( breast cancer) sequence, and hence has the potential for being used as a gene probe to identify BRCA-1 gene. It has high potential for being used in polymerase chain reaction (PCR) amplification, as has been performed with labeled oligonucleotide for the HIV sequence.
C1 Indian Inst Technol, Dept Civil Engn, Kharagpur 721302, W Bengal, India.
   Oak Ridge Natl Lab, Div Life Sci, Adv Biomed Sci & Technol Grp, Oak Ridge, TN 37831 USA.
RP Pal, A (reprint author), Indian Inst Technol, Dept Civil Engn, Kharagpur 721302, W Bengal, India.
EM anjalipal@civil.iitkgp.ernet.in
CR ALAK AM, 1989, ANAL CHEM, V61, P656, DOI 10.1021/ac00182a004
   Allain LR, 2002, ANAL CHIM ACTA, V469, P149, DOI 10.1016/S0003-2670(01)01537-9                                                   
   BELLO JM, 1989, ANAL CHEM, V61, P1779, DOI 10.1021/ac00190a600                                                             
   Charles C.Y., 2002, SCIENCE, V297, P1536
   CHU BCF, 1983, NUCLEIC ACIDS RES, V11, P6513, DOI 10.1093/nar/11.18.6513
   DRAPER DE, 1984, NUCLEIC ACIDS RES, V12, P989, DOI 10.1093/nar/12.2.989
   DREYER GB, 1985, P NATL ACAD SCI USA, V82, P968, DOI 10.1073/pnas.82.4.968
   ESHAGHPOUR H, 1979, NUCLEIC ACIDS RES, V7, P1485, DOI 10.1093/nar/7.6.1485
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633
   MARCH J, ADV ORGANIC CHEM, P372
   Narayanan VA, 1996, ANALUSIS, V24, P1
   Pal A, 2004, CURR SCI INDIA, V87, P486
   Pal A, 1998, CURR SCI INDIA, V74, P14
   Pal A, 1998, TALANTA, V46, P583, DOI 10.1016/S0039-9140(97)00320-2
   Pal A, 2003, CURR SCI INDIA, V84, P1342
   PAL A, 1995, ANAL CHEM, V67, P3154, DOI 10.1021/ac00114a009                                                             
   RICHTERICH P, 1993, METHOD ENZYMOL, V218, P187
   Staab H. A., 1962, ANGEW CHEM INT EDIT, V1, P351, DOI DOI 10.1002/ANIE.196203511
   TELSER J, 1989, J AM CHEM SOC, V111, P6966, DOI 10.1021/ja00200a011
   VO-DINH T, 1987, APPL SPECTROSC, V41, P605, DOI 10.1366/0003702874448616                                                        
   VO-DINH T, 1994, ANAL CHEM, V66, P3379, DOI 10.1021/ac00092a014
   VODINH T, 1994, ANAL CHEM, V66, P813, DOI 10.1021/ac00078a009
   VODINH T, 1989, CHEM ANAL POLYAROMAT
NR 24
TC 31
Z9 30
U1 1
U2 18
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1364-5498
J9 FARADAY DISCUSS
JI Faraday Discuss.
PY 2006
VL 132
BP 293
EP 301
DI 10.1039/b506341h
PG 9
WC Chemistry, Physical
SC Chemistry
GA 032KF
UT WOS:000236772600024
PM 16833124
DA 2018-01-05
ER

PT J
AU Zoller, H
   Vogel, W
AF Zoller, Heinz
   Vogel, Wolfgang
TI Nanomedicines in the treatment of patients with hepatitis C co-infected
   with HIV focus on pegylated interferon-alpha
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE pegylated interferon-alpha; HIV hepatitis C; ribavirin
ID HUMAN-IMMUNODEFICIENCY-VIRUS; EARLY VIRAL KINETICS; PLUS RIBAVIRIN;
   LIVER-DISEASE; VIROLOGICAL RESPONSE; NUCLEOSIDE ANALOGS; FOLLOW-UP;
   IN-VIVO; THERAPY; PHARMACOKINETICS
AB In immuno-competent individuals, the natural course of chronic hepatitis C virus (HCV) infection is highly variable and 50/o--30% of patients develop cirrhosis over 20 years. Co-infection with HCV and human immunodeficiency virus (HIV) is an important prognostic factor and associated with more frequent and accelerated progression to cirrhosis. Until recently HIV/AIDS-related complications were life limiting in patients co-infected with HCV, the introduction of highly active antiretroviral treatment (HAART) and the better prognosis of HIV infection has made HCV-related complications an emerging health problem in HCV/HIV co-infected individuals. Treatment of chronic HCV infection has also evolved since the introduction of interferon-alpha. Recently, introduction of pegylated interferon-alpha (peginterferon-alpha) has resulted in an increase in sustained virus clearance rates of up to 80% in selected genotypes and patient populations. The safety and efficacy of modem anti HCV treatment regimens - based on peginterferon-alpha in combination with ribavirin - was evaluated in 4 controlled trials. Sustained clearance of hepatitis C virus can be achieved in up to 35% of patients with HIV/HCV co-infection, and novel HCV treatment regimens based on peginterferon-alpha have no negative effect on the control of HIV disease. In conclusion, if HIV infection is well controlled and CD4(+) cell counts >100/mm(3), treatment of chronic hepatitis C with peginterferon in combination with ribavirin is safe and should be given for 48 weeks regardless of the HCV genotype. Introduction of peginterferon-alpha has significantly improved adherence to treatment and treatment efficacy; in particular sustained virologic response in patients with HCV genotype 1 or 4 infection improved, but sustained viral clearance in only 7%-38% of patients infected with genotype 1 and 4 cannot be the final step in development of effective treatments in patients with HCV/HIV co-infection.
C1 [Zoller, Heinz; Vogel, Wolfgang] Innsbruck Med Univ, Univ Innsbruck Hosp, Dept Med, Clin Div Gastroenterol & Hepatol, Innsbruck, Austria.
RP Zoller, H (reprint author), Innsbruck Med Univ, Univ Innsbruck Hosp, Dept Med, Clin Div Gastroenterol & Hepatol, Anichstr 35, Innsbruck, Austria.
EM wolfgang.vogel@uibk.ac.at
CR Abonyi ME, 2005, ANTICANCER RES, V25, P1315
   Akuta N, 2005, SCAND J GASTROENTERO, V40, P688, DOI 10.1080/00365520510015467
   Alter MJ, 2006, J HEPATOL, V44, pS6, DOI 10.1016/j.jhep.2005.11.004
   Belle S H, 1996, Clin Transpl, P15
   Bergamini A, 2001, CLIN EXP IMMUNOL, V123, P459, DOI 10.1046/j.1365-2249.2001.01468.x
   Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501                                                                  
   CALICETI P, 2004, DIGEST LIVER DIS, V36, P334
   Carlsson T, 2005, J VIRAL HEPATITIS, V12, P473, DOI 10.1111/j.1365-2893.2005.00621.x
   Carrat F, 2004, JAMA-J AM MED ASSOC, V292, P2839, DOI 10.1001/jama.292.23.2839
   Chatelut E, 1999, BRIT J CLIN PHARMACO, V47, P365, DOI 10.1046/j.1365-2125.1999.00912.x
   Chen Stephen L, 2006, Int J Med Sci, V3, P47
   Chung RT, 2001, P NATL ACAD SCI USA, V98, P9847, DOI 10.1073/pnas.171319698                                                          
   Chung RT, 2004, NEW ENGL J MED, V351, P451, DOI 10.1056/NEJMoa032653
   Dahari H, 2005, GASTROENTEROLOGY, V128, P1056, DOI 10.1053/j.gastro.2005.01.049
   Darby SC, 1997, LANCET, V350, P1425, DOI 10.1016/S0140-6736(97)05413-5
   De Clercq E, 2004, J CLIN VIROL, V30, P115, DOI 10.1016/j.jvc.2004.02.009
   de Ledinghen V, 2002, J HEPATOL, V36, P819, DOI 10.1016/S0168-8278(02)00071-5
   DIANZANI F, 1993, GUT, V34, P74
   Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300
   Ferenci P, 2005, J HEPATOL, V43, P425, DOI 10.1016/j.jhep.2005.04.009
   Ferenci P, 2004, SEMIN LIVER DIS, V24, P25, DOI 10.1055/s-2004-832925                                                           
   FERENCI P, 2003, MORE EFFECTIVE DESIG
   Gish RG, 2006, J ANTIMICROB CHEMOTH, V57, P8, DOI 10.1093/jac/dki405
   Glue P, 2000, CLIN PHARMACOL THER, V68, P556, DOI 10.1067/mcp.2000.110973
   Glue P, 1999, SEMIN LIVER DIS, V19, P17
   Grace MJ, 2005, J BIOL CHEM, V280, P6327, DOI 10.1074/jbc.M41234200
   Graci JD, 2006, REV MED VIROL, V16, P37, DOI 10.1002/rmv.483
   Gupta SK, 2002, J CLIN PHARMACOL, V42, P1109, DOI 10.1177/009127002237996
   Hadziyannis SJ, 2004, ANN INTERN MED, V140, P346, DOI 10.7326/0003-4819-140-5-200403020-00010
   Harris JM, 2001, CLIN PHARMACOKINET, V40, P539, DOI 10.2165/00003088-200140070-00005
   Heathcote J, 2005, J VIRAL HEPATITIS, V12, P223, DOI 10.1111/j.1365-2893.2005.00600.x
   Hellen CUT, 1999, J VIRAL HEPATITIS, V6, P79, DOI 10.1046/j.1365-2893.1999.00150.x                                                
   Herrmann E, 2006, EUR J GASTROEN HEPAT, V18, P339, DOI 10.1097/00042737-200604000-00006                                                
   Hoofnagle J. H., 2002, HEPATOLOGY, V36, P21
   Ideo G, 2002, CURR PHARM DESIGN, V8, P959, DOI 10.2174/1381612024607009
   Jessner W, 2003, J VIRAL HEPATITIS, V10, P37, DOI 10.1046/j.1365-2893.2003.00396.x                                                
   JESSNER W, 2002, J CLIN VIROL S3, V3, pS31
   Kamal SM, 2002, GASTROENTEROLOGY, V123, P1070, DOI 10.1053/gast.2002.36045
   Kato T, 2005, J CLIN MICROBIOL, V43, P5679, DOI 10.1128/JCM.43.11.5679-5684.2005
   Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602                                                     
   Laguno M, 2004, AIDS, V18, pF27
   Lebray P, 2005, ANTIVIR THER, V10, P769
   Lee WM, 1998, HEPATOLOGY, V28, P1411, DOI 10.1002/hep.510280533
   Lehmann M, 2004, J MED VIROL, V73, P387, DOI 10.1002/jmv.20103
   Leone N, 2005, Minerva Gastroenterol Dietol, V51, P31
   Lesens O, 1999, J INFECT DIS, V179, P1254, DOI 10.1086/314720                                                                  
   Liu XD, 1996, EUR J DRUG METAB PH, V21, P227, DOI 10.1007/BF03189718                                                              
   Manns MP, 2004, JAMA-J AM MED ASSOC, V292, P2909, DOI 10.1001/jama.292.23.2909
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Margot NA, 2005, ANTIVIR THER, V10, P343
   MORSE GD, 1993, CLIN PHARMACOKINET, V24, P101, DOI 10.2165/00003088-199324020-00002                                                
   Murashima S, 2000, J MED VIROL, V62, P185, DOI 10.1002/1096-9071(200010)62:2<185::AID-JMV9>3.0.CO;2-X
   Musselman DL, 2001, NEW ENGL J MED, V344, P961, DOI 10.1056/NEJM200103293441303
   Neumayr G, 1999, QJM-INT J MED, V92, P505, DOI 10.1093/qjmed/92.9.505
   Nunez M, 2005, ANTIVIR THER, V10, P657
   Patel K, 2001, Expert Opin Pharmacother, V2, P1307
   Pawlotsky JM, 2006, HEPATOLOGY, V43, pS207, DOI 10.1002/hep.21064
   Pedder SCJ, 2003, SEMIN LIVER DIS, V23, P19
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Petrenkiene Vitalija, 2004, Medicina (Kaunas), V40, P962
   Rockstroh JK, 2005, J INFECT DIS, V192, P992, DOI 10.1086/432762                                                                  
   Rodriguez-Torres M, 2005, ANTIMICROB AGENTS CH, V49, P3997, DOI 10.1128/AAC.49.10.3997-4008.2005
   Salmon-Ceron D, 2003, CLIN INFECT DIS, V36, P1295, DOI 10.1086/374837                                                                  
   Schaefer M, 2003, HEPATOLOGY, V37, P443, DOI 10.1053/jhep.2003.50031
   Seef LB, 2002, HEPATOLOGY S1, V36, P35, DOI DOI 10.1053/JHEP.2002.36806
   Sherman KE, 2002, CLIN INFECT DIS, V34, P831, DOI 10.1086/339042                                                                  
   Sulkowski MS, 2003, ANN INTERN MED, V138, P197, DOI 10.7326/0003-4819-138-3-200302040-00012
   Tam RC, 1999, J IMMUNOL, V163, P3709
   Terrault NA, 2002, HEPATOLOGY, V36, pS99, DOI 10.1053/jhep.2002.36797
   Thomas HC, 1999, J HEPATOL, V31, P152, DOI 10.1016/S0168-8278(99)80393-6                                                   
   Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842
   Tsubota A, 2005, J MED VIROL, V75, P27, DOI 10.1002/jmv.20232
   Veronese FM, 2005, DRUG DISCOV TODAY, V10, P1451, DOI 10.1016/S1359-6446(05)03575-0                                                   
   Zeuzem S, 2003, SEMIN LIVER DIS, V23, P23
   [Anonymous], 2006, MMWR MORB MORTAL WKL, V55, P121
NR 75
TC 5
Z9 5
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176-9114
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2006
VL 1
IS 4
BP 399
EP 409
DI 10.2147/nano.2006.1.4.399                                               
          
PG 11
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 247AB
UT WOS:000252048400004
PM 17722274
OA green_published
DA 2018-01-05
ER

PT J
AU Akagi, T
   Kaneko, T
   Kida, T
   Akashi, M
AF Akagi, Takami
   Kaneko, Tatsuo
   Kida, Toshiyuki
   Akashi, Mitsuru
TI Multifunctional conjugation of proteins on/into bio-nanoparticles
   prepared by amphiphilic poly(gamma-glutamic acid)
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE poly(gamma-glutamic acid); biodegradable nanoparticles; amphiphilicity;
   encapsulation; protein carrier
ID METHOXY POLY(ETHYLENE GLYCOL); INACTIVATED HIV-1-CAPTURING NANOSPHERES;
   IMMOBILIZED POLYSTYRENE NANOSPHERES; BLOCK COPOLYMERIC MICELLE; IN-VITRO
   RELEASE; D-GLUTAMIC ACID; HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES;
   GRAFT-COPOLYMERS; BIODEGRADABLE MICROPARTICLES
AB The present study focuses on nanoparticles composed of amphiphilic poly(gamma-glutamic acid) (gamma-PGA) as potential protein carriers. Amphiphilic graft co-polymers composed of gamma-PGA as the hydrophilic backbone and L-phenylalanine ethylester (L-PAE) as the hydrophobic segment were synthesized by grafting L-PAE to gamma-PGA using water-soluble carbodiimide (WSC). Due to their amphiphilic properties, the gamma-PGA-graft-L-PAE co-polymer formed monodispersed nanoparticles in water. The particle size of the nanoparticles composed of gamma-PGA-graft-L-PAE (gamma-PGA nanoparticles) was about 200 nm and showed a highly negative zeta potential. To evaluate their potential applications as multifunctional protein carrier, we prepared protein-entrapped gamma-PGA nanoparticles by encapsulation, covalent immobilization or physical adsorption methods. For this purpose, 11 different proteins with various molecular weights and isoelectric points (pI values) were used as model proteins. The encapsulation of the protein into the nanoparticles was observed for all tested proteins. The amount of protein covalently immobilized or adsorbed onto the nanoparticles showed different tends based on the molecular weight and pI of each protein. Positively charged proteins could be adsorbed onto the negatively charged nanoparticles by electrostatic interaction. Moreover, it was found that enzyme-encapsulated nanoparticles showed higher enzymatic activity than surface-immobilized nanoparticles. These results indicated that the enzymatic activity of the enzyme-entrapped nanoparticles was significantly affected by the conjugation method, and that encapsulation was the optimal method for the conjugation of proteins and nanoparticles. It is expected that the gamma-PGA nanoparticle will have great potential as multifunctional carriers in pharmaceutical and biomedical applications, such as drug and vaccine delivery systems.
C1 Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   Japan Sci & Technol Agcy, JST, CREST, Tokyo, Japan.
RP Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM akashi@chem.eng.osaka-u.ac.jp
CR Akagi T, 2005, J CONTROL RELEASE, V108, P226, DOI 10.1016/j.jconrel.2005.08.003
   Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   AKASHI M, 1985, ANGEW MAKROMOL CHEM, V132, P81, DOI 10.1002/apmc.1985.051320107                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Allen C, 2000, J CONTROL RELEASE, V63, P275, DOI 10.1016/S0168-3659(99)00200-X
   Allen C, 1998, BIOCONJUGATE CHEM, V9, P564, DOI 10.1021/bc9702157
   Cetinus SA, 2003, ENZYME MICROB TECH, V32, P889, DOI 10.1016/S0141-0229(03)00065-6
   Chen CW, 1999, CHEM MATER, V11, P1381, DOI 10.1021/cm9900047                                                               
   Chen MQ, 1999, J POLYM SCI POL CHEM, V37, P2155, DOI 10.1002/(SICI)1099-0518(19990701)37:13<2155::AID-POLA31>3.0.CO;2-G              
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Feng SS, 2001, J CONTROL RELEASE, V71, P53, DOI 10.1016/S0168-3659(00)00364-3
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Iijima M, 1999, MACROMOLECULES, V32, P1140, DOI 10.1021/ma9815962                                                               
   Kaneko T, 2005, CHEM MATER, V17, P2484, DOI 10.1021/cm048196f
   Kang K, 2005, MACROMOL BIOSCI, V5, P344, DOI 10.1002/mabi.200400178
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Kesuo F., 1996, J ENVIRON POLYM DEGR, V4, P253
   Kim SY, 1998, J CONTROL RELEASE, V51, P13, DOI 10.1016/S0168-3659(97)00124-7
   Kim SY, 1998, J CONTROL RELEASE, V56, P197, DOI 10.1016/S0168-3659(98)00083-2
   King EC, 1998, J POLYM SCI POL CHEM, V36, P1995, DOI 10.1002/(SICI)1099-0518(19980915)36:12<1995::AID-POLA4>3.0.CO;2-N               
   Kishida A, 1998, J BIOACT COMPAT POL, V13, P270, DOI 10.1177/088391159801300403                                                      
   KUBOTA H, 1993, BIOSCI BIOTECH BIOCH, V57, P1212, DOI 10.1271/bbb.57.1212
   Lavelle EC, 1999, VACCINE, V17, P512, DOI 10.1016/S0264-410X(98)00229-1                                                   
   Lemoine D, 1996, BIOMATERIALS, V17, P2191, DOI 10.1016/0142-9612(96)00049-X
   Li XH, 2000, J APPL POLYM SCI, V78, P140, DOI 10.1002/1097-4628(20001003)78:1<140::AID-APP180>3.0.CO;2-P                      
   Liggins RT, 2001, INT J PHARM, V222, P19, DOI 10.1016/S0378-5173(01)00690-1                                                   
   Matsusaki M, 2002, BIOCONJUGATE CHEM, V13, P23, DOI 10.1021/bc010008d
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Morillo M, 2001, MACROMOLECULES, V34, P7868, DOI 10.1021/ma010510t
   Nagasaki Y, 1998, MACROMOLECULES, V31, P1473, DOI 10.1021/ma971294k                                                               
   ODonnell PB, 1997, ADV DRUG DELIVER REV, V28, P25, DOI 10.1016/S0169-409X(97)00049-5                                                   
   OHAGAN DT, 1994, INT J PHARM, V103, P37, DOI 10.1016/0378-5173(94)90201-1
   Panyam J, 2003, J CONTROL RELEASE, V92, P173, DOI 10.1016/S0168-3659(03)00328-6
   PARK TG, 1995, J CONTROL RELEASE, V33, P211, DOI 10.1016/0168-3659(94)00084-8
   PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4                                                    
   Prodhomme EJF, 2003, BIOCONJUGATE CHEM, V14, P1148, DOI 10.1021/bc020019m
   Quellec P, 1998, J BIOMED MATER RES, V42, P45, DOI 10.1002/(SICI)1097-4636(199810)42:1<45::AID-JBM7>3.0.CO;2-O
   REGINE A, 1998, PHARM RES, V15, P1111
   Sah H, 1999, J CONTROL RELEASE, V58, P143, DOI 10.1016/S0168-3659(98)00148-5
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   Serizawa T, 2000, COLLOID SURFACE A, V169, P95, DOI 10.1016/S0927-7757(00)00421-0                                                   
   Serizawa T, 2005, POLYM J, V37, P39, DOI 10.1295/polymj.37.39
   Shimokuri T, 2004, J POLYM SCI POL CHEM, V42, P4492, DOI 10.1002/pola.20384
   Shin ILG, 1998, J CONTROL RELEASE, V51, P1
   SINGH M, 2004, PHARM RES, V212, P2148
   Tachibana Y, 2003, BIOMACROMOLECULES, V4, P1132, DOI 10.1021/bm034123y
   van de Weert M, 2000, PHARMACEUT RES, V17, P1159, DOI 10.1023/A:1026498209874                                                         
   Wang W, 2000, LANGMUIR, V16, P7859, DOI 10.1021/la000633r
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
NR 55
TC 37
Z9 37
U1 0
U2 18
PU VSP BV
PI LEIDEN
PA BRILL ACADEMIC PUBLISHERS, PO BOX 9000, 2300 PA LEIDEN, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 2006
VL 17
IS 8
BP 875
EP 892
DI 10.1163/156856206777996871
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 090OA
UT WOS:000240959400003
PM 17024878
DA 2018-01-05
ER

PT J
AU Sommer, AP
   Pavlath, AE
AF Sommer, AP
   Pavlath, AE
TI Nanobioaerosols - reconsidering agricultural irrigation in a warming
   world
SO JOURNAL OF ENVIRONMENTAL MONITORING
LA English
DT Article
ID PRIMORDIAL PROTEINS; POSSIBLE PROVENANCE; PART II; NANOBACTERIA; HIV;
   THUNDERCLOUDS; REPLICATION; BIOSYSTEMS
AB Nanobacteria are best described as 60 - 300 nm nanovesicles. In the body they collect calcium and phosphate to form apatite, adhere to cells, or invade them - processes regulated by a slime based on proteins (primordial proteins). A versatile functionality realized with a minimum of properties equips nanobacteria with a unique survival potential. They were identified in humans, animals, wastewater and the stratosphere. In South Africa they were detected in people infected with HIV. Models indicate that they boost the genetic diversity of the HIV-1 virus. Experiments showed that they are excreted via urine, explaining their presence in the environment. Eradication would be virtually impossible if they had an extraterrestrial origin, implying a permanent bombardment from space. Whereas the biological status of nanobacteria is still not clarified, we postulate here that the native habitat of nanobacteria are mammals, suggesting that at least modern species have their origin on Earth. The thesis results from mapping functions and properties of the slime, and could facilitate the localisation of nanobacterial reservoirs, identification of local distribution routes and tracking of global transport cycles. Agricultural irrigation with water containing excreta from humans infected with nanobacteria could be a central disseminator of the nanobioaerosols.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
   USDA, Western Reg Res Ctr, Albany, CA 94710 USA.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR BIGG KE, 1984, FUNDAMENTAL STUDIES, P38
   Burke DS, 1997, EMERG INFECT DIS, V3, P253, DOI 10.3201/eid0303.970301                                                          
   CIFTCIOGLU N, 1998, PATHOPHYSIOLOGY, V4, P259
   Cummer SA, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL022778
   GODFARB DS, 2004, NEPHRON PHYSL, V98, P48
   Griffin Dale W., 2004, Aerobiologia, V20, P135, DOI 10.1023/B:AERO.0000032948.84077.12
   Helseth LE, 2004, OPT EXPRESS, V12, P3428, DOI 10.1364/OPEX.12.003428
   Jaenicke R, 2005, SCIENCE, V308, P73, DOI 10.1126/science.1106335
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kim BH, 2004, APPL MICROBIOL BIOT, V63, P672, DOI 10.1007/s00253-003-1412-6
   LEFRERE JJ, 1987, ANN INTERN MED, V107, P429, DOI 10.7326/0003-4819-107-2-429_2
   Liepert BG, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019060
   Lund M, 2005, LANGMUIR, V21, P8385, DOI 10.1021/la050607z
   Narlikar JV, 2003, ASTROPHYS SPACE SCI, V285, P555, DOI 10.1023/A:1025442021619
   Pasko VP, 2002, NATURE, V416, P152, DOI 10.1038/416152a
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   Rieu P, 2005, ANN UROL, V39, P16, DOI 10.1016/j.anuro.2005.01.001                                                     
   Sattler B, 2001, GEOPHYS RES LETT, V28, P239, DOI 10.1029/2000GL011684
   Sommer AP, 2005, J PROTEOME RES, V4, P1022, DOI 10.1021/pr050064e
   Sommer AP, 2005, J PROTEOME RES, V4, P633, DOI 10.1021/pr049795p
   Sommer AP, 2005, J PROTEOME RES, V4, P180, DOI 10.1021/pr0498382
   Sommer AP, 2004, J PROTEOME RES, V3, P1296, DOI 10.1021/pr049861n
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2002, LANGMUIR, V18, P5040, DOI 10.1021/la025619o
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   Sommer AP, 1999, BIOMED TECH, V44, P290, DOI 10.1515/bmte.1999.44.10.290
   Sommer AP, 2001, ATMOS RES, V58, P129, DOI 10.1016/S0169-8095(01)00086-2
   SOMMER AP, WORLD C DOS ANT MAG, pA131
   SOMMER AP, 2001, P 2 INT C NEAR FIELD, P78
   Vinnikov KY, 2003, SCIENCE, V302, P269, DOI 10.1126/science.1087910
   Wainwright M., 2004, Aerobiologia, V20, P237, DOI 10.1007/s10453-004-1188-x
   Wainwright M, 2004, MICROBIOL-SGM, V150, P756, DOI 10.1099/mic.0.26907-0
   WANG P, 2005, GEOPHYS RES ABS, V7, P10204
   Wickramasinghe C, 2004, CRYOBIOLOGY, V48, P113, DOI 10.1016/j.cryobiol.2004.03.001
   Zhu B, 2003, BIOPHYS J, V84, P4033, DOI 10.1016/S0006-3495(03)75129-7                                                   
NR 40
TC 6
Z9 6
U1 0
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1464-0325
J9 J ENVIRON MONITOR
JI J. Environ. Monit.
PY 2006
VL 8
IS 3
BP 341
EP 346
DI 10.1039/b512496d
PG 6
WC Chemistry, Analytical; Environmental Sciences
SC Chemistry; Environmental Sciences & Ecology
GA 021NN
UT WOS:000235990000002
PM 16528417
DA 2018-01-05
ER

PT J
AU Chen, B
   Colurave, ML
   Wang, CN
   Craik, DJ
AF Chen, B
   Colurave, ML
   Wang, CN
   Craik, DJ
TI Cycloviolacin H4, a hydrophobic cyclotide from Viola hederaceae
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID ANTI-HIV ACTIVITY; CIRCULAR PROTEIN; STRUCTURAL MOTIF; PLANT CYCLOTIDES;
   KNOTTED PROTEINS; KALATA B1; PEPTIDES; EXPRESSION; CHROMATOGRAPHY;
   FRAMEWORK
AB Cycloviolacin H4, a new macrocyclic miniprotein comprising 30 amino acid residues, was isolated from the underground parts of the Australian native violet Viola hederaceae. Its sequence, cyclo-(CAESCVWIPCTVTALLGCSCSNNVCYNGIP), was determined by nanospray tandem mass spectrometry and quantitative amino acid analysis. A knotted disuffide arrangement, which was designated as a cyclic cystine knot motif and characteristic to all known cyclotides, is proposed for stabilizing the molecular structure and folding. The cyclotide is classified in the bracelet subfamily of cyclotides due to the absence of a cis-Pro peptide bond in the circular peptide backbone. A model of its three-dimensional structure was derived based on the template of the homologous cyclotide vhr1 (Trabi et al. Plant Cell 2004, 16, 2204-2216). Cycloviolacin H4 exhibits the most potent hemolytic activity in cyclotides reported so far, and this activity correlates with the size of a surface-exposed hydrophobic patch. This work has thus provided insight into the factors that modulate the cytotoxic properties of cyclotides.
C1 Univ Queensland, Australian Res Council, Special Res Ctr Funct & Appl Genom, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
   Chinese Acad Sci, Chengdu Inst Biol, Ctr Nat Prod, Chengdu 610041, Peoples R China.
RP Craik, DJ (reprint author), Univ Queensland, Australian Res Council, Special Res Ctr Funct & Appl Genom, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
EM d.craik@imb.uq.edu.au
RI Craik, David/B-1695-2010; Colgrave, Michelle/A-5710-2012; Wang,
   Conan/D-1481-2010
OI Craik, David/0000-0003-0007-6796; Colgrave,
   Michelle/0000-0001-8463-805X; Wang, Conan/0000-0002-7973-7632
CR ANDERS JC, 2002, BIOPHARM EUR, P32
   Barry DG, 2004, STRUCTURE, V12, P85, DOI 10.1016/j.str.2003.11.019
   Barry DG, 2003, BIOCHEMISTRY-US, V42, P6688, DOI 10.1021/bi027323n
   Basse CW, 2005, PLANT PHYSIOL, V138, P1774, DOI 10.1104/pp.105.061200
   Chen B, 2005, J BIOL CHEM, V280, P22395, DOI 10.1074/jbc.M501737200
   Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383
   Craik DJ, 2004, CURR PROTEIN PEPT SC, V5, P297, DOI 10.2174/1389203043379512
   Craik DJ, 2002, CURR OPIN DRUG DI DE, V5, P251
   Daly NL, 2004, FEBS LETT, V574, P69, DOI 10.1016/j.febslet.2004.08.007
   Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276
   Goransson U, 2003, ANAL BIOCHEM, V318, P107, DOI 10.1016/S0003-2697(03)00114-3
   GRAN L, 1973, LLOYDIA, V36, P207
   Gustafson KR, 2004, CURR PROTEIN PEPT SC, V5, P331, DOI 10.2174/1389203043379468
   Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756                                                               
   Jennings C, 2001, P NATL ACAD SCI USA, V98, P10614, DOI 10.1073/pnas.191366898
   Jennings CV, 2005, BIOCHEMISTRY-US, V44, P851, DOI 10.1021/bi047837h
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   Lindholm P, 2002, MOL CANCER THER, V1, P365
   Mulvenna JR, 2005, STRUCTURE, V13, P691, DOI 10.1016/j.str.2005.02.013
   Rosengren KJ, 2003, J BIOL CHEM, V278, P8606, DOI 10.1074/jbc.M211147200
   SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Schopke T., 1993, SCI PHARM, V61, P145
   Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X                                                   
   Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913
   Trabi M, 2004, PLANT CELL, V16, P2204, DOI 10.1105/tpc.104.021790
   Trabi M, 2004, J NAT PROD, V67, P806, DOI 10.1021/np034068e
   WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002
NR 29
TC 33
Z9 34
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163-3864
J9 J NAT PROD
JI J. Nat. Prod.
PD JAN
PY 2006
VL 69
IS 1
BP 23
EP 28
DI 10.1021/np050317i
PG 6
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
SC Plant Sciences; Pharmacology & Pharmacy
GA 009IZ
UT WOS:000235106500006
PM 16441062
DA 2018-01-05
ER

PT J
AU Bullok, KE
   Gammon, ST
   Violini, S
   Prantner, AM
   Villalobos, VM
   Sharma, V
   Piwnica-Worms, D
AF Bullok, Kristin E.
   Gammon, Seth T.
   Violini, Stefania
   Prantner, Andrew M.
   Villalobos, Victor M.
   Sharma, Vijay
   Piwnica-Worms, David
TI Permeation peptide conjugates for in vivo molecular imaging applications
SO MOLECULAR IMAGING
LA English
DT Review
DE tat basic domain; permeation peptide; technetium; gadolinium; iron
   oxide; fluorescence; resonance energy transfer; quenching; molecular
   imaging; metal chelation; diagnostic; nuclear medicine; magnetic
   resonance imaging; optical imaging
ID MRI CONTRAST AGENT; HUMAN IMMUNODEFICIENCY VIRUS; CROSS-LINKED
   NANOPARTICLES; CELL-PENETRATING PEPTIDES; TAT BASIC DOMAIN;
   HEPARAN-SULFATE; MAGNETIC NANOPARTICLES; MAMMALIAN-CELLS; HELA-CELLS;
   INTERCELLULAR TRAFFICKING
AB Rapid and efficient delivery of imaging probes to the cell interior using permeation peptides has enabled novel applications in molecular imaging. Membrane permeant peptides based on the HIV-1 Tat basic domain sequence, GRKKRRQRRR, labeled with fluorophores and fluorescent proteins for optical imaging or with appropriate peptide-based motifs or macrocycles to chelate metals, such as technetium for nuclear scintigraphy and gadolinium for magnetic resonance imaging, have been synthesized. In addition, iron oxide complexes have been functionalized with the Tat basic domain peptides for magnetic resonance imaging applications. Herein we review current applications of permeation peptides in molecular imaging and factors influencing permeation peptide internalization. These diagnostic agents show concentrative cell accumulation and rapid kinetics and display cytosolic and focal nuclear accumulation in human cells. Combining methods, dual-labeled permeation peptides incorporating fluorescein maleimide and chelated technetium have allowed for both qualitative and quantitative analysis of cellular uptake. Imaging studies in mice following intravenous administration of prototypic diagnostic permeation peptides show rapid whole-body distribution allowing for various molecular imaging applications. Strategies to develop permeation peptides into molecular imaging probes have included incorporation of targeting motifs such as molecular beacons or protease cleavable domains that enable selective retention, activatable fluorescence, or targeted transduction. These novel permeation peptide conjugates maintain rapid translocation across cell membranes into intracellular compartments and have the potential for targeted in vivo applications in molecular imaging and combination therapy.
C1 Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA.
RP Piwnica-Worms, D (reprint author), Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, 510 S Kingshighway Blvd,Box 8225, St Louis, MO 63110 USA.
EM piwnica-wormsd@mir.wustl.edu
RI Gammon, Seth/C-8778-2014
FU NCI NIH HHS [P50 CA94056, R01 CA82841]
CR Aime S, 1998, CHEM SOC REV, V27, P19, DOI 10.1039/a827019z
   Alberto R, 1998, J AM CHEM SOC, V120, P7987, DOI 10.1021/ja980745t                                                               
   Alberto R, 2001, J AM CHEM SOC, V123, P3135, DOI 10.1021/ja003932b
   Allen MJ, 2004, CHEM BIOL, V11, P301, DOI 10.1016/j.chembiol.2004.03.003
   Anderson CJ, 1999, CHEM REV, V99, P2219, DOI 10.1021/cr980451q                                                               
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P699, DOI 10.1021/bc049946e
   Becker ML, 2004, BIOCONJUGATE CHEM, V15, P710, DOI 10.1021/bc049945m
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349
   Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77                                                        
   Bullok K, 2005, J MED CHEM, V48, P5404, DOI 10.1021/jm050008p
   BULLOK K, 2004, MOL IMAGING, V3, P190
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   Caravan P, 1999, CHEM REV, V99, P2293, DOI 10.1021/cr980440x                                                               
   Caravan P, 2002, J AM CHEM SOC, V124, P3152, DOI 10.1021/ja017168k
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   CHANCE B, 1994, BIOCHEM SOC T, V22, P983, DOI 10.1042/bst0220983                                                              
   CHOI CW, 1995, CANCER RES, V55, P5323
   Daldrup-Link HE, 2005, RADIOLOGY, V234, P197, DOI 10.1148/radiol.2341031236
   De Leon-Rodriguez LM, 2002, J AM CHEM SOC, V124, P3514, DOI 10.1021/ja025511v
   Decristoforo C, 1999, BIOCONJUGATE CHEM, V10, P431, DOI 10.1021/bc980121c
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   DUNCAN JR, 1993, J NUCL MED, V34, P1728
   Eckelman WC, 2002, INVEST RADIOL, V37, P101, DOI 10.1097/00004424-200203000-00001
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Erickson AC, 2001, MATRIX BIOL, V19, P769, DOI 10.1016/S0945-053X(00)00126-8
   Esclatine A, 2001, VIROLOGY, V289, P23, DOI 10.1006/viro.2001.1122
   Falnes PO, 2001, BIOCHEMISTRY-US, V40, P4349, DOI 10.1021/bi002443l
   Fang B, 1998, GENE THER, V5, P1420, DOI 10.1038/sj.gt.3300741                                                           
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5                                                   
   Franc Benjamin L, 2003, Mol Imaging, V2, P313, DOI 10.1162/153535003322750655
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gallazzi F, 2003, BIOCONJUGATE CHEM, V14, P1083, DOI 10.1021/bc034084n
   Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291
   GAUSH CR, 1966, P SOC EXP BIOL MED, V122, P931
   Gerweck LE, 1996, CANCER RES, V56, P1194
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Harada K, 1997, P NATL ACAD SCI USA, V94, P11887, DOI 10.1073/pnas.94.22.11887
   He DY, 2002, MOL PHARMACOL, V62, P272, DOI 10.1124/mol.62.2.272
   HIDALGO IJ, 1989, GASTROENTEROLOGY, V96, P736
   Hoetelmans RWM, 2001, APPL IMMUNOHISTO M M, V9, P346, DOI 10.1097/00022744-200112000-00010
   Hom RK, 1997, NUCL MED BIOL, V24, P485, DOI 10.1016/S0969-8051(97)00066-8                                                   
   Jain M, 2005, CANCER RES, V65, P7840, DOI 10.1158/0008-5472.CAN-05-0662
   Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Jurisson SS, 1999, CHEM REV, V99, P2205, DOI 10.1021/cr980435t                                                               
   Kalra PS, 2000, METHODS, V22, P249, DOI 10.1006/meth.2000.1076
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   Koch AM, 2003, BIOCONJUGATE CHEM, V14, P1115, DOI 10.1021/bc034123v
   KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765                                                              
   KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5
   Kueltzo LA, 2003, J PHARM SCI, V92, P1754, DOI 10.1002/jps.10448
   Lee HJ, 2001, BIOCONJUGATE CHEM, V12, P995, DOI 10.1021/bc0155061
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lewis MR, 2003, J CELL BIOCHEM, V90, P464, DOI 10.1002/jcb.10641
   Li WH, 2002, INORG CHEM, V41, P4018, DOI 10.1021/ic0200390
   Li WP, 2003, Q J NUCL MED, V47, P201
   Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s
   Lister-James J, 1997, Q J Nucl Med, V41, P111
   ListerJames J, 1997, J NUCL MED, V38, P105
   Liu S, 1999, CHEM REV, V99, P2235, DOI 10.1021/cr980436l                                                               
   Louie AY, 2000, NAT BIOTECHNOL, V18, P321
   Luker GD, 2000, BIOCHEMISTRY-US, V39, P7651, DOI 10.1021/bi9928593
   MAREEL M, 1979, HISTOCHEMISTRY, V63, P253, DOI 10.1007/BF00644547
   McGough NNH, 2004, J NEUROSCI, V24, P10542, DOI 10.1523/JNEUROSCI.3714-04.2004
   Moore A, 2002, MAGNET RESON MED, V47, P751, DOI 10.1002/mrm.10110
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Nitin N, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh063
   Nitin N, 2004, J BIOL INORG CHEM, V9, P706, DOI 10.1007/s00775-004-0560-1
   Nivorozhkin AL, 2001, ANGEW CHEM INT EDIT, V40, P2903, DOI 10.1002/1521-3773(20010803)40:15<2903::AID-ANIE2903>3.0.CO;2-N                  
   Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154                                                           
   OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0
   Pearson DA, 1996, J MED CHEM, V39, P1372, DOI 10.1021/jm950112e
   Pietzsch HJ, 2000, BIOCONJUGATE CHEM, V11, P414, DOI 10.1021/bc990162o                                                               
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Polyakov V. R., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P729
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Prantner Andrew M, 2003, Mol Imaging, V2, P333, DOI 10.1162/153535003322750673
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108
   Salmivirta M, 1998, GLYCOBIOLOGY, V8, P1029, DOI 10.1093/glycob/8.10.1029
   Schibli R, 2001, INORG CHEM, V40, P2358, DOI 10.1021/ic001284r
   Schibli R, 2000, BIOCONJUGATE CHEM, V11, P345, DOI 10.1021/bc990127h
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SCHWOCHAU K, 1994, ANGEW CHEM INT EDIT, V33, P2258, DOI 10.1002/anie.199422581                                                          
   SILBERNAGL S, 1988, PHYSIOL REV, V68, P911
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   TAKEUCHI J, 1977, CANCER RES, V37, P1507
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Volkert WA, 1999, CHEM REV, V99, P2269, DOI 10.1021/cr9804386                                                               
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Waibel R, 1999, NAT BIOTECHNOL, V17, P897
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wender PA, 2002, J AM CHEM SOC, V124, P13382, DOI 10.1021/ja0275109
   Wong E, 1997, INORG CHEM, V36, P5799, DOI 10.1021/ic9706562                                                               
   Wu AM, 2000, P NATL ACAD SCI USA, V97, P8495, DOI 10.1073/pnas.150228297
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Zhang SR, 2003, J AM CHEM SOC, V125, P15288, DOI 10.1021/ja038345f                                                               
   Zhang SR, 1999, ANGEW CHEM INT EDIT, V38, P3192
   Zhang Yu-Min, 2003, Mol Imaging Biol, V5, P240, DOI 10.1016/S1536-1632(03)00106-9
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 115
TC 39
Z9 39
U1 0
U2 20
PU B C DECKER INC
PI HAMILTON
PA 50 KING STREET EAST, 2ND FLOOR, PO BOX 620, L C D 1, HAMILTON, ONTARIO
   L8N 3K7, CANADA
SN 1535-3508
J9 MOL IMAGING
JI Mol. Imaging
PD JAN-MAR
PY 2006
VL 5
IS 1
BP 1
EP 15
DI 10.2310/7290.2006.00001
PG 15
WC Biochemical Research Methods; Radiology, Nuclear Medicine & Medical
   Imaging
SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical
   Imaging
GA 064KB
UT WOS:000239086900001
PM 16779965
DA 2018-01-05
ER

PT J
AU Pittet, MJ
   Swirski, FK
   Reynolds, F
   Josephson, L
   Weissleder, R
AF Pittet, Mikael J.
   Swirski, Filip K.
   Reynolds, Frederick
   Josephson, Lee
   Weissleder, Ralph
TI Labeling of immune cells for in vivo imaging using magnetofluorescent
   nanoparticles
SO NATURE PROTOCOLS
LA English
DT Article
ID T-CELLS; DENDRITIC CELLS; TRACKING; CANCER; LYMPHOCYTES; PEPTIDE;
   TRANSDUCTION; PROTAMINE; MIGRATION; PROTEINS
AB Observation of immune and stem cells in their native microenvironments requires the development of imaging agents to allow their in vivo tracking. We describe here the synthesis of magnetofluorescent nanoparticles for cell labeling in vitro and for multimodality imaging of administered cells in vivo. MION-47, a prototype monocrystalline iron oxide nanoparticle, was first converted to an intermediate bearing a fluorochrome and amine groups, then reacted with either HIV-Tat peptide or protamine to yield a nanoparticle with membrane-translocating properties. We describe how to assess optimal cell labeling with tests of cell phenotype and function. Synthesis of magnetofluorescent nanoparticles and cell-labeling optimization can be realized in 48 h, whereas nanoparticle uptakes and retention studies may generally take up to 120 h. Labeled cells can be detected by magnetic resonance imaging, fluorescence reflectance imaging, fluorescence-mediated tomography, confocal microscopy and flow cytometry, and can be purified based on their fluorescent or magnetic properties. The present protocol focuses on T-cell labeling but can be used for labeling a variety of circulating cells.
C1 Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
RP Pittet, MJ (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
EM mpittet@hms.harvard.edu
OI /0000-0003-0828-4143
CR Abou-Montet K, 2005, MOL IMAGING, V4, P165
   Arbab AS, 2004, BLOOD, V104, P1217, DOI 10.1182/blood-2004-02-0655
   Chen ML, 2005, P NATL ACAD SCI USA, V102, P419, DOI 10.1073/pnas.0408197102
   de Vries IJM, 2005, NAT BIOTECHNOL, V23, P1407, DOI 10.1038/nbt1154
   Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
   Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Frangioni JV, 2004, CIRCULATION, V110, P3378, DOI 10.1161/01.CIR.0000149840.46523.FC
   Kircher MF, 2003, CANCER RES, V63, P6838
   Koehne G, 2003, NAT BIOTECHNOL, V21, P405, DOI 10.1038/nbt805
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238
   Murakami T, 2003, J EXP MED, V198, P1337, DOI 10.1084/jem.20030593
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Ntziachristos V, 2005, NAT BIOTECHNOL, V23, P313, DOI 10.1038/nbt1074
   Pittet MJ, 2006, J IMMUNOL, V176, P2330, DOI 10.4049/jimmunol.176.4.2330                                                     
   Pittet MJ, 2001, CLIN CANCER RES, V7, p796S
   Pittet MJ, 2001, J IMMUNOL, V166, P7634, DOI 10.4049/jimmunol.166.12.7634                                                    
   Reynolds F, 2005, BIOCONJUGATE CHEM, V16, P1240, DOI 10.1021/bc0501451
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043
   Shu CYJ, 2005, P NATL ACAD SCI USA, V102, P17412, DOI 10.1073/pnas.0508698102
   Thorne SH, 2006, SCIENCE, V311, P1780, DOI 10.1126/science.1121411
   Vianello F, 2006, J IMMUNOL, V176, P2902, DOI 10.4049/jimmunol.176.5.2902                                                     
   Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159
   Weissleder R, 2002, NAT REV CANCER, V2, P11, DOI 10.1038/nrc701
   Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123
   Yee C, 2001, CURR OPIN IMMUNOL, V13, P141, DOI 10.1016/S0952-7915(00)00196-5
NR 28
TC 118
Z9 119
U1 2
U2 37
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
EI 1750-2799
J9 NAT PROTOC
JI Nat. Protoc.
PY 2006
VL 1
IS 1
BP 73
EP 79
DI 10.1038/nprot.2006.11
PG 7
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 232EX
UT WOS:000251002200011
PM 17406214
OA gold
DA 2018-01-05
ER

PT J
AU Velazquez-Campoy, A
   Freire, E
AF Velazquez-Campoy, Adrian
   Freire, Ernesto
TI Isothermal titration calorimetry to determine association constants for
   high-affinity ligands
SO NATURE PROTOCOLS
LA English
DT Article
ID HIV-1 PROTEASE; DRUG-RESISTANCE; BINDING; DESIGN
AB An important goal in drug development is to engineer inhibitors and ligands that have high binding affinities for their target molecules. In optimizing these interactions, the precise determination of the binding affinity becomes progressively difficult once it approaches and surpasses the nanomolar level. Isothermal titration calorimetry ( ITC) can be used to determine the complete binding thermodynamics of a ligand down to the picomolar range by using an experimental mode called displacement titration. In a displacement titration, the association constant of a high- affinity ligand that cannot be measured directly is artificially lowered to a measurable level by premixing the protein with a weaker competitive ligand. To perform this protocol, two titrations must be carried out: a direct titration of the weak ligand to the target macromolecule and a displacement titration of the high- affinity ligand to the weak ligand - target macromolecule complex. This protocol takes approximately 5 h.
C1 Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.
   Inst Bicomputat & Complex Syst Phys, E-50009 Zaragoza, Spain.
RP Freire, E (reprint author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.
EM ef@jhu.edu
RI Velazquez-Campoy, Adrian/E-7946-2012; Xu, Qingguo/C-1962-2014
OI Velazquez-Campoy, Adrian/0000-0001-5702-4538; Xu,
   Qingguo/0000-0003-3191-0771
FU NIGMS NIH HHS [GM 56550, GM 57144]
CR Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190
   Ohtaka H, 2002, PROTEIN SCI, V11, P1908, DOI 10.1110/ps.0206402
   Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402                                                          
   Todd MJ, 1998, J MOL BIOL, V283, P475, DOI 10.1006/jmbi.1998.2090                                                          
   Velazquez-Campoy A, 2005, BIOPHYS CHEM, V115, P115, DOI 10.1016/j.bpc.2004.12.015
   Velazquez-Campoy A, 2001, J CELL BIOCHEM, V84, P82, DOI 10.1002/jcb.10068                                                               
   Velazquez-Campoy A, 2002, BIOCHEMISTRY-US, V41, P8613, DOI 10.1021/bi020160i
   Velazquez-Campoy A, 2001, ARCH BIOCHEM BIOPHYS, V390, P169, DOI 10.1006/abbi.2001.2333
   Zhang YL, 1998, ANAL BIOCHEM, V261, P139, DOI 10.1006/abio.1998.2738
NR 9
TC 113
Z9 114
U1 2
U2 44
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
J9 NAT PROTOC
JI Nat. Protoc.
PY 2006
VL 1
IS 1
BP 186
EP 191
DI 10.1038/nprot.2006.28
PG 6
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 232EX
UT WOS:000251002200028
PM 17406231
OA gold
DA 2018-01-05
ER

PT J
AU Link, N
   Aubel, C
   Kelm, JM
   Marty, RR
   Greber, D
   Djonov, V
   Bourhis, J
   Weber, W
   Fussenegger, M
AF Link, N
   Aubel, C
   Kelm, JM
   Marty, RR
   Greber, D
   Djonov, V
   Bourhis, J
   Weber, W
   Fussenegger, M
TI Therapeutic protein transduction of mammalian cells and mice by nucleic
   acid-free lentiviral nanoparticles
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-THERAPY; IN-VIVO; EXPRESSION;
   DELIVERY; CYANIDE; VECTOR; INTEGRATION; GENERATION; TRANSGENE
AB The straightforward production and dose-controlled administration of protein therapeutics remain major challenges for the biopharmaceutical manufacturing and gene therapy communities. Transgenes linked to HIV-1-derived vpr and pol-based protease cleavage (PC) sequences were co-produced as chimeric fusion proteins in a lentivirus production setting, encapsidated and processed to fusion peptide-free native protein in pseudotyped lentivirions for intracellular delivery and therapeutic action in target cells. Devoid of viral genome sequences, protein-transducing nanoparticles (PTNs) enabled transient and dose-dependent delivery of therapeutic proteins at functional quantities into a variety of mammalian cells in the absence of host chromosome modifications. PTNs delivering Manihot esculenta linamarase into rodent or human, tumor cell lines and spheroids mediated hydrolysis of the innocuous natural prodrug linamarin to cyanide and resulted in efficient cell killing. Following linamarin injection into nude mice, linamarase-transducing nanoparticles impacted solid tumor development through the bystander effect of cyanide.
C1 ETH Hoenggerberg HCI F115, Swiss Fed Inst Technol, ICB, CH-8093 Zurich, Switzerland.
   Inst Gustave Roussy, F-94805 Villejuif, France.
   Univ Bern, Inst Anat, CH-3009 Bern, Switzerland.
RP Fussenegger, M (reprint author), ETH Hoenggerberg HCI F115, Swiss Fed Inst Technol, ICB, Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.
EM fussenegger@chem.ethz.ch
RI Weber, Wilfried/B-4732-2012
CR Boorsma M, 2000, NAT BIOTECHNOL, V18, P429
   Bushman FD, 2003, CELL, V115, P135, DOI 10.1016/S0092-8674(03)00760-8
   Cavazzana-Calvo M, 2004, NATURE, V427, P779, DOI 10.1038/427779a
   Cavazzana-Calvo M, 2002, CURR OPIN ALLERGY CL, V2, P507, DOI 10.1097/01.all.0000044535.45448.f6
   Cortes ML, 2002, J GENE MED, V4, P407, DOI 10.1002/jgm.280
   Cortes ML, 1998, GENE THER, V5, P1499, DOI 10.1038/sj.gt.3300751
   CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968                                                         
   Fischer A, 2004, M S-MED SCI, V20, P115, DOI 10.1051/medsci/2004201115
   Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123                                                        
   Gentry BG, 2005, GENE THER, V12, P1033, DOI 10.1038/sj.gt.3302487
   Glover DJ, 2005, NAT REV GENET, V6, P299, DOI 10.1038/nrg1577
   Huang MB, 2001, J ACQ IMMUN DEF SYND, V27, P213
   Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655
   Kousparou CA, 2002, INT J CANCER, V99, P138, DOI 10.1002/okc/10266
   Langer R, 1998, NATURE, V392, P5
   LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E
   Liu SL, 2004, J VIROL, V78, P2642, DOI 10.1128/JVI.78.5.2642-2647.2004
   Mitta B, 2005, METAB ENG, V7, P426, DOI 10.1016/j.ymben.2005.06.006
   Mitta B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf112
   Mochizuki H, 1998, J VIROL, V72, P8873
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775
   Prabhakaran K, 2004, TOXICOL APPL PHARM, V195, P194, DOI 10.1016/j.taap.2003.11.012
   Riis L, 2003, J ECON ENTOMOL, V96, P1905, DOI 10.1603/0022-0493-96.6.1905
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Weber W, 2004, NAT BIOTECHNOL, V22, P1440, DOI 10.1038/nbt1021
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026
NR 28
TC 28
Z9 28
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PY 2006
VL 34
IS 2
AR e16
DI 10.1093/nar/gnj014
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 011TO
UT WOS:000235291300009
PM 16449199
OA gold
DA 2018-01-05
ER

PT J
AU Danscher, G
   Stoltenberg, M
AF Danscher, Gorm
   Stoltenberg, Meredin
TI Autometallography (AMG) - Silver enhancement of quantum dots resulting
   from (1) metabolism of toxic metals in animals and humans, (2) in vivo,
   in vitro and immersion created zinc-sulphur/zinc-selenium nanocrystals,
   (3) metal ions liberated from metal implants and particles
SO PROGRESS IN HISTOCHEMISTRY AND CYTOCHEMISTRY
LA English
DT Review
DE autometallography (AMG); silver; gold; zinc; nanocrystals; quantum dots;
   bismuth; mercury; histochemistry
ID ELECTRON-MICROSCOPIC LOCALIZATION; DORSAL-ROOT GANGLIA; COLLOIDAL GOLD
   PARTICLES; TIMM SULFIDE SILVER; RAT SPINAL-CORD;
   HUMAN-IMMUNODEFICIENCY-VIRUS; RETROGRADE AXONAL-TRANSPORT; ENRICHED ZEN
   TERMINALS; ARGYROPHIL-III METHOD; ULTRASTRUCTURAL-LOCALIZATION
AB Autometallographic (AMG) silver enhancement is a potent histochemical tool for tracing a variety of metal containing nanocrystals, e.g. pure gold and silver nanoclusters and quantum dots of silver, mercury, bismuth or zinc, with sulphur and/or selenium.
   These nanocrystals can be created in many different ways, e.g. (1) by manufacturing colloidal gold or silver particles, (2) by treating an organism in vivo with sulphide or selenide ions, (3) as the result of a metabolic decomposition of bismuth-, mercury- or silver-containing macromolecules in cell organelles, or (4) as the end product of histochemical processing of tissue sections. Such nano-sized AMG nanocrystals can then be silver-amplified several times of magnitude by being exposed to an AMG developer, i.e. a normal photographic developer enriched with silver ions.
   The present monograph attempts to provide a review of the autometallographic silver amplification techniques known today and their use in biology. After achieving a stronghold in histochemistry by Timm's introduction of the "silver-sulphide staining" in 1958, the AMG technique has evolved and expanded into several different areas of research, including immunocytochemistry, tracing of enzymes at LM and EM levels, blot staining, retrograde axonal tracing of zinc-enriched (ZEN) neurons, counterstaining of semithin sections, enhancement of histochemical reaction products, marking of phagocytotic cells, staining of myelin, tracing of gold ions released from gold implants, and visualization of capillaries.
   General technical comments, protocols for the current AMG methods and a summary of the most significant scientific results obtained by this wide variety of AMG histochemical approaches are included in the present article. (c) 2006 Elsevier GmbH. All rights reserved.
C1 Univ Aarhus, Inst Anat, Dept Neurobiol, DK-8000 Aarhus, Denmark.
RP Danscher, G (reprint author), Univ Aarhus, Inst Anat, Dept Neurobiol, DK-8000 Aarhus, Denmark.
EM gd@neuro.au.dk
CR AASETH J, 1981, SCAND J CLIN LAB INV, V41, P247, DOI 10.3109/00365518109092041                                                       
   ARENHOLTBINDSLEV D, 1989, ATLA-ALTERN LAB ANIM, V16, P253
   ARVIDSON B, 1992, MUSCLE NERVE, V15, P1089, DOI 10.1002/mus.880151006
   BAATRUP E, 1987, ECOTOX ENVIRON SAFE, V14, P129, DOI 10.1016/0147-6513(87)90055-8
   BENDAYAN M, 1981, J HISTOCHEM CYTOCHEM, V29, P531, DOI 10.1177/29.4.6265546                                                            
   Birinyi A, 2001, J COMP NEUROL, V433, P208, DOI 10.1002/cne.1136
   BOLEWSKA J, 1990, J ORAL PATHOL MED, V19, P39, DOI 10.1111/j.1600-0714.1990.tb00779.x
   BRITTEN JS, 1968, BIOCHIM BIOPHYS ACTA, V159, P160, DOI 10.1016/0005-2744(68)90254-4
   Brown CE, 2003, J NEUROSCI METH, V129, P41, DOI 10.1016/S0165-0270(03)00195-X
   BRUNK U, 1972, HISTOCHEMISTRY, V29, P140, DOI 10.1007/BF00277282
   CASSELL MD, 1984, J COMP NEUROL, V222, P461, DOI 10.1002/cne.902220311
   Chan WCW, 2002, CURR OPIN BIOTECH, V13, P40, DOI 10.1016/S0958-1669(02)00282-3                                                   
   Cheung ALM, 1999, MODERN PATHOL, V12, P689
   Chimienti F, 2003, CURR DRUG TARGETS, V4, P323, DOI 10.2174/1389450033491082
   CHRISTENSEN MK, 1992, J HISTOCHEM CYTOCHEM, V40, P575, DOI 10.1177/40.4.1313065                                                            
   CHRISTENSEN MM, 1992, HISTOCHEMISTRY, V97, P207, DOI 10.1007/BF00267629
   Cohen-Kfir E, 2005, P NATL ACAD SCI USA, V102, P6154, DOI 10.1073/pnas.0501431102
   Dahan M, 2003, SCIENCE, V302, P442, DOI 10.1126/science.1088525
   DANEELS G, 1986, J IMMUNOL METHODS, V89, P89, DOI 10.1016/0022-1759(86)90035-9
   Danscher G, 2000, J HISTOCHEM CYTOCHEM, V48, P1503, DOI 10.1177/002215540004801107                                                      
   DANSCHER G, 1980, J ULTRA MOL STRUCT R, V73, P93
   DANSCHER G, 1988, ACTA NEUROPATHOL, V76, P107, DOI 10.1007/BF00687687                                                              
   DANSCHER G, 1994, MODERN METHODS IN ANALYTICAL MORPHOLOGY, P327
   Danscher G, 2004, J HISTOCHEM CYTOCHEM, V52, P1619, DOI 10.1369/jhc.4A6371.2004
   DANSCHER G, 1985, J HISTOCHEM CYTOCHEM, V33, P219, DOI 10.1177/33.3.2579122                                                            
   DANSCHER G, 1985, J HISTOCHEM CYTOCHEM, V33, P706, DOI 10.1177/33.7.4008918                                                            
   Danscher G, 1997, J NEUROSCI METH, V77, P175, DOI 10.1016/S0165-0270(97)00121-0                                                   
   DANSCHER G, 1981, HISTOCHEMISTRY, V71, P177, DOI 10.1007/BF00507822
   DANSCHER G, 1982, HISTOCHEMISTRY, V76, P281, DOI 10.1007/BF00543951
   DANSCHER G, 1994, NEUROPATH APPL NEURO, V20, P454, DOI 10.1111/j.1365-2990.1994.tb00996.x
   Danscher G, 2005, J HISTOCHEM CYTOCHEM, V53, P141, DOI 10.1369/jhc.4R6460.2005
   DANSCHER G, 1993, J HISTOTECHNOL, V16, P201, DOI 10.1179/his.1993.16.3.201                                                       
   DANSCHER G, 1983, J HISTOCHEM CYTOCHEM, V31, P1394, DOI 10.1177/31.12.6631001                                                           
   Danscher G, 2002, HISTOCHEM CELL BIOL, V117, P447, DOI 10.1007/s00418-002-0400-8
   DANSCHER G, 1984, HISTOCHEMISTRY, V81, P331, DOI 10.1007/BF00514327                                                              
   DANSCHER G, 1984, HISTOCHEMISTRY, V81, P283, DOI 10.1007/BF00495640
   DANSCHER G, 1985, SCI TOTAL ENVIRON, V42, P189, DOI 10.1016/0048-9697(85)90019-1                                                    
   DANSCHER G, 1985, HISTOCHEMISTRY, V83, P419, DOI 10.1007/BF00509203
   Danscher G, 1997, J HISTOCHEM CYTOCHEM, V45, P1503, DOI 10.1177/002215549704501107                                                      
   Danscher G, 1999, J HISTOTECHNOL, V22, P85
   DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566
   DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572                                                              
   Danscher G, 2001, NEUROSCIENCE, V105, P941, DOI 10.1016/S0306-4522(01)00243-3
   Danscher G, 1996, HISTOCHEM J, V28, P361, DOI 10.1007/BF02331399
   DANSCHER G, 1978, HISTOCHEMISTRY, V55, P27, DOI 10.1007/BF00496691
   DANSCHER G, 1983, STAIN TECHNOL, V58, P365, DOI 10.3109/10520298309066814                                                       
   DANSCHER G, 1990, EXP MOL PATHOL, V52, P291, DOI 10.1016/0014-4800(90)90070-T
   DANSCHER G, 1986, HISTOCHEM J, V18, P109, DOI 10.1007/BF01675364
   DANSCHER G, 1994, J HISTOTECHNOL, V17, P15, DOI 10.1179/his.1994.17.1.15                                                        
   DANSCHER G, 1991, PROG HISTOCHEM CYTOC, V23, P273
   DANSCHER G, 1973, EXP BRAIN RES, V16, P521, DOI 10.1007/BF00234478                                                              
   DANSCHER G, 1984, NEUROBIOLOGY ZINC A, P273
   Danscher G., 1995, IMMUNOGOLD SILVER ST, P11
   DANSCHER G, 1984, NEUROBIOLOGY ZINC A, P229
   DANSCHER G, 2002, GOLD SILVER STAINING
   DANSCHER G, 1984, NEUROBIOLOGY ZINC, VB, P177
   DANSCHER G, 1997, CELL VISION, V4, P375
   de la Fuente JM, 2005, BIOCONJUGATE CHEM, V16, P1176, DOI 10.1021/bc050033+
   DEREWENDA U, 1989, BRIT MED BULL, V45, P4, DOI 10.1093/oxfordjournals.bmb.a072320                                              
   Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7                                                   
   Domouhtsidou GP, 2000, ARCH ENVIRON CON TOX, V38, P472, DOI 10.1007/s002449910062                                                           
   DORE JL, 1976, MED LAB SCI, V33, P209
   DORE JL, 1974, THESIS LONDON
   DOUGLAS KT, 1990, INT J BIOCHEM, V22, P429, DOI 10.1016/0020-711X(90)90254-Z
   Duong TQ, 2001, P NATL ACAD SCI USA, V98, P10904, DOI 10.1073/pnas.191101098                                                          
   Empedocles S, 1999, ACCOUNTS CHEM RES, V32, P389, DOI 10.1021/ar9501939                                                               
   FAULK WP, 1971, IMMUNOCHEMISTRY, V8, P1081
   FOWLER BA, 1974, ARCH PATHOL, V98, P297
   FREDERICKSON CJ, 1987, J HISTOCHEM CYTOCHEM, V35, P579, DOI 10.1177/35.5.2435783                                                            
   FREDERICKSON CJ, 1990, PROG BRAIN RES, V83, P71
   Frederickson CJ, 2000, J NUTR, V130, p1471S
   FUJIMORI O, 1992, HISTOCHEM J, V24, P61, DOI 10.1007/BF01082440
   FUJIMORI O, 1988, HISTOCHEM J, V20, P603, DOI 10.1007/BF01324078                                                              
   FUJIMORI O, 1985, ARCH HISTOL JAPON, V48, P449, DOI 10.1679/aohc.48.449
   GALLYAS F, 1979, STAIN TECHNOL, V54, P173, DOI 10.3109/10520297909112679                                                       
   GALLYAS F, 1981, ACTA MORPHOL HUNG, V29, P177
   GALLYAS F, 1979, HISTOCHEMISTRY, V64, P97, DOI 10.1007/BF00493358                                                              
   GALLYAS F, 1971, ACTA MORPHOL HUNG, V19, P57
   GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239                                                              
   GEHRING PJ, 1967, J PHARMACOL EXP THER, V155, P187
   GILG E, 1952, ACTA PSYCH NEUROL, V27, P43, DOI 10.1111/j.1600-0447.1952.tb04639.x                                              
   Goldschmidt J, 2004, NEUROIMAGE, V23, P638, DOI 10.1016/j.neuroimage.2004.05.023
   Goodman CM, 2004, BIOCONJUGATE CHEM, V15, P897, DOI 10.1021/bc049951i
   GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0
   Hacker GW, 1998, EUR J HISTOCHEM, V42, P111
   HACKER GW, 1990, VERH DEUT G, V74, P368
   HACKER GW, 1993, CHINESE MED J-PEKING, V106, P83
   HACKER GW, 1991, PROG HISTOCHEM CYTOC, V23, P286
   HACKER GW, 2002, GOLD SILVER STAINING
   HACKER GW, 2004, MOL MORPHOLOGY HUMAN
   HACKER GW, 2002, GOLD SILVER STAINING, P47
   Hainfeld J F, 1996, Scanning Microsc Suppl, V10, P309
   HAINFELD JF, 1987, SCIENCE, V236, P450, DOI 10.1126/science.3563522
   HAINFELD JF, 1988, NATURE, V333, P281, DOI 10.1038/333281a0
   HAINFELD JF, 1991, J STRUCT BIOL, V107, P1, DOI 10.1016/1047-8477(91)90024-Q
   HAINFELD JF, 1992, J HISTOCHEM CYTOCHEM, V40, P177, DOI 10.1177/40.2.1552162                                                            
   Hainfeld JF, 2000, J HISTOCHEM CYTOCHEM, V48, P471, DOI 10.1177/002215540004800404                                                      
   Hainfeld JF, 1999, P 57 ANN M MICR SOC, P486
   HANSEN JC, 1995, PHARMACOL TOXICOL, V77, P189, DOI 10.1111/j.1600-0773.1995.tb01011.x                                              
   HAUG FMS, 1967, HISTOCHEMISTRY, V8, P355, DOI 10.1007/BF00401978
   HAUG FMS, 1974, Z ANAT ENTWICKLUNGS, V145, P1
   Haug FM, 1973, ADV ANAT EMBRYOL CEL, V47, P1
   HELLING HB, 1967, THESIS GOTTINGEN
   HOLGATE CS, 1983, J HISTOCHEM CYTOCHEM, V31, P938, DOI 10.1177/31.7.6189883                                                            
   HOLM IE, 1988, HISTOCHEMISTRY, V89, P289, DOI 10.1007/BF00493154
   HOLM IE, 1991, HISTOCHEM J, V23, P63, DOI 10.1007/BF01047109
   HORSTEDBINDSLEV P, 1991, PROG HISTOCHEM CYTOC, V23, P321
   Hosie AM, 2003, NAT NEUROSCI, V6, P362, DOI 10.1038/nn1030
   HOWELL GA, 1990, BRAIN RES, V515, P277, DOI 10.1016/0006-8993(90)90607-D
   HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0
   HURTLEY SM, 2003, SCIENCE, V300
   Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951
   JACOBSEN E, 1989, SCAND J RHEUMATOL, V18, P161, DOI 10.3109/03009748909095414                                                       
   Jo SM, 2000, BRAIN RES, V870, P163, DOI 10.1016/S0006-8993(00)02418-5
   Jones A, 1988, Methods Mol Biol, V3, P441, DOI 10.1385/0-89603-126-8:441
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   KENNEDY C, 1976, P NATL ACAD SCI USA, V73, P4230, DOI 10.1073/pnas.73.11.4230
   KEYNES RD, 1965, J PHYSIOL-LONDON, V179, P333, DOI 10.1113/jphysiol.1965.sp007666                                                  
   KEYNES RD, 1951, J PHYSIOL-LONDON, V113, P99, DOI 10.1113/jphysiol.1951.sp004558                                                  
   Kim BJ, 2000, DIABETES, V49, P367, DOI 10.2337/diabetes.49.3.367
   Klippel JH, 1994, RHEUMATOLOGY
   Kristiansen LH, 2001, HISTOCHEM CELL BIOL, V115, P125, DOI 10.1007/s004180000241
   LAH JJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1396
   LAH JJ, 1990, J HISTOCHEM CYTOCHEM, V38, P503, DOI 10.1177/38.4.2319121                                                            
   LANDOWNE D, 1975, J PHYSIOL-LONDON, V252, P79, DOI 10.1113/jphysiol.1975.sp011135                                                  
   Lansdow AB., 2002, J WOUND CARE, V11, P125
   Lansdown Alan B G, 2004, Br J Nurs, V13, pS6
   Larsen M, 2003, HISTOL HISTOPATHOL, V18, P1125, DOI 10.14670/HH-18.1125
   Laube B, 2002, EUR J NEUROSCI, V16, P1025, DOI 10.1046/j.1460-9568.2002.02170.x
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li Y, 2001, J NEUROSCI, V21, P8015
   LIESEGANG RE, 1911, KOLLOIDCHEMISCHE BEI, P1
   LIESEGANG RE, 1921, Z WISS MIKROSK, V38, P334
   Liuzzi JP, 2004, ANNU REV NUTR, V24, P151, DOI 10.1146/annurev.nutr.24.012003.132402
   LONG YY, 1995, NEUROCHEM INT, V27, P95, DOI 10.1016/0197-0186(94)00171-P
   LONG YY, 1994, NEUROREPORT, V5, P2026, DOI 10.1097/00001756-199410270-00009                                                
   LORMEE P, 1989, J HISTOCHEM CYTOCHEM, V37, P203, DOI 10.1177/37.2.2642940                                                            
   LUPPOCRAMER, 1914, PHOTOGRAPHISCHE KORR, V640, P28
   Magnusson NE, 2005, CELL TISSUE RES, V321, P195, DOI 10.1007/s00441-005-1103-y
   MCPARTLIN M, 1969, J CHEM SOC CHEM COMM, P334, DOI 10.1039/c29690000334                                                            
   MEHTA AC, 1966, BRIT J DERMATOL, V78, P175, DOI 10.1111/j.1365-2133.1966.tb12197.x                                              
   Miro-Bernie N, 2003, J NEUROSCI METH, V127, P199, DOI 10.1016/S0165-0270(03)00146-8
   MOEREMANS M, 1984, J IMMUNOL METHODS, V74, P353, DOI 10.1016/0022-1759(84)90303-X
   MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9
   Moller-Madsen Bjarne, 1994, Pharmacology and Toxicology, V75, P1
   MOLLERMADSEN B, 1984, EXP MOL PATHOL, V41, P74, DOI 10.1016/0014-4800(84)90009-1
   MOLLERMADSEN B, 1987, RHEUMATOL INT, V7, P47, DOI 10.1007/BF00267342
   MOLLERMADSEN B, 1990, TOXICOL APPL PHARM, V103, P303, DOI 10.1016/0041-008X(90)90232-J
   MOLLERMADSEN B, 1985, INT J TISSUE REACT, V7, P439
   MOLLERMADSEN B, 1983, EXP MOL PATHOL, V39, P327, DOI 10.1016/0014-4800(83)90061-8
   MOLLERMADSEN B, 1984, EXP MOL PATHOL, V40, P148, DOI 10.1016/0014-4800(84)90072-8
   MOLLERMADSEN B, 1991, TOXICOL APPL PHARM, V108, P457, DOI 10.1016/0041-008X(91)90092-S
   MONTAGNESE CM, 1993, ANAT EMBRYOL, V188, P173
   Nitzan YB, 2004, J HISTOCHEM CYTOCHEM, V52, P529, DOI 10.1177/002215540405200411                                                      
   NORGAARD JOR, 1989, J HISTOCHEM CYTOCHEM, V37, P1545, DOI 10.1177/37.10.2778309                                                           
   NORGAARD JOR, 1991, PROG HISTOCHEM CYTOC, V23, P187
   NORSETH T, 1971, BIOCHEM PHARMACOL, V20, P1101, DOI 10.1016/0006-2952(71)90339-X
   OTOOLE D, 1995, VET DIAGN INVEST, V7, P281
   Palmiter RD, 2004, PFLUG ARCH EUR J PHY, V447, P744, DOI 10.1007/s00424-003-1070-7
   Pamphlett R, 2000, NEUROTOXICOL TERATOL, V22, P559, DOI 10.1016/S0892-0362(00)00083-0
   Pamphlett R, 2000, ENVIRON RES, V82, P258, DOI 10.1006/enrs.1999.4016                                                          
   PATEL N, 1991, J CLIN PATHOL, V44, P334, DOI 10.1136/jcp.44.4.334
   PATEL N, 1992, ANN CLIN BIOCHEM, V29, P283, DOI 10.1177/000456329202900305                                                      
   Pedersen LH, 2003, J APPL TOXICOL, V23, P235, DOI 10.1002/jat.912
   PEREZCLAUSELL J, 1985, BRAIN RES, V337, P91, DOI 10.1016/0006-8993(85)91612-9                                                    
   PEREZCLAUSELL J, 1986, BRAIN RES, V362, P358, DOI 10.1016/0006-8993(86)90463-4
   PEREZCLAUSELL J, 1988, J COMP NEUROL, V267, P153, DOI 10.1002/cne.902670202
   Pohl K, 1998, MICROSC RES TECHNIQ, V42, P59
   POWELL RD, 2002, GOLD SILVER STAINING
   QUERIDO A, 1947, ACTA PSYCHIAT, V12, P151
   Ranaldi G, 2002, AM J PHYSIOL-RENAL, V283, pF1365, DOI 10.1152/ajprenal.00094.2002
   Rau R, 2005, CLIN RHEUMATOL, V24, P189, DOI 10.1007/s10067-004-0869-8
   Roberts WJ, 1935, P K AKAD WET-AMSTERD, V38, P540
   ROCKS BF, 1991, ANN CLIN BIOCHEM, V28, P155, DOI 10.1177/000456329102800206                                                      
   ROCKS BF, 1990, ANN CLIN BIOCHEM, V27, P114, DOI 10.1177/000456329002700205                                                      
   ROHRINGER R, 1985, ANAL BIOCHEM, V144, P118, DOI 10.1016/0003-2697(85)90092-2                                                    
   Ross JF, 1996, BRAIN RES, V725, P137
   ROSS JF, 1994, TOXICOL APPL PHARM, V124, P191, DOI 10.1006/taap.1994.1023
   ROTH J, 1982, HISTOCHEM J, V14, P791, DOI 10.1007/BF01033628
   ROTH J, 1982, J HISTOCHEM CYTOCHEM, V30, P691, DOI 10.1177/30.7.7050239                                                            
   Rubio ME, 1998, J COMP NEUROL, V399, P341, DOI 10.1002/(SICI)1096-9861(19980928)399:3<341::AID-CNE4>3.0.CO;2-0                 
   RUNGBY J, 1990, DAN MED BULL, V37, P442
   RUNGBY J, 1987, ARCH TOXICOL, V61, P40, DOI 10.1007/BF00324546
   RUNGBY J, 1987, TOXICOLOGY, V45, P135, DOI 10.1016/0300-483X(87)90099-0
   RUNGBY J, 1990, HISTOCHEMISTRY, V94, P109
   SCHIONNING J, 1991, ACTA NEUROPATHOL, V81, P434, DOI 10.1007/BF00293465                                                              
   SCHIONNING JD, 1993, TOXICOL APPL PHARM, V121, P43, DOI 10.1006/taap.1993.1127
   Schionning JD, 1999, APMIS, V107, P303, DOI 10.1111/j.1699-0463.1999.tb01558.x                                              
   SCHIONNING JD, 1992, EXP MOL PATHOL, V56, P239, DOI 10.1016/0014-4800(92)90040-I
   SCHIONNING JD, 1993, HISTOCHEM J, V25, P107, DOI 10.1007/BF00157981                                                              
   SCHIONNING JD, 1992, VIRCHOWS ARCH B, V61, P307, DOI 10.1007/BF02890432
   Schionning JD, 1998, ACTA NEUROPATHOL, V96, P191, DOI 10.1007/s004010050881                                                           
   Schionning Jorgen Drasbaek, 2000, APMIS, V108, P1
   Schroder HD, 2000, BRAIN RES, V868, P119, DOI 10.1016/S0006-8993(00)02238-1                                                   
   SCOPSI L, 1986, MED BIOL, V64, P139
   Sensi SL, 1999, NEUROREPORT, V10, P1723, DOI 10.1097/00001756-199906030-00018                                                
   Seress L, 2000, J NEUROSCI METH, V100, P33, DOI 10.1016/S0165-0270(00)00227-2                                                   
   Shirabe T, 1978, Folia Psychiatr Neurol Jpn, V32, P278
   SHIRABE T, 1979, NEUROTOXICOLOGY, V1, P349
   SKUTELSKY E, 1987, HISTOCHEMISTRY, V86, P291, DOI 10.1007/BF00490261
   SKUTELSKY E, 1986, J HISTOCHEM CYTOCHEM, V34, P693, DOI 10.1177/34.5.3701033                                                            
   SLIWATOMCZOK W, 1990, Z MIKROSK ANAT FORSC, V104, P458
   SLOMIANKA L, 1992, NEUROSCIENCE, V48, P325, DOI 10.1016/0306-4522(92)90494-M
   SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6
   Sondergaard LG, 2005, HORM METAB RES, V37, P133, DOI 10.1055/s-2005-861290
   Sondergaard LG, 2003, APMIS, V111, P1147, DOI 10.1111/j.1600-0463.2003.apm1111211.x
   Sorensen FW, 2000, ACTA NEUROPATHOL, V100, P95, DOI 10.1007/s004010051198                                                           
   Sorensen MB, 1998, MOL HUM REPROD, V4, P423, DOI 10.1093/molehr/4.5.423                                                          
   Sorensen MB, 1999, MOL HUM REPROD, V5, P331, DOI 10.1093/molehr/5.4.331
   Sorensen MB, 1997, PROSTATE, V31, P125, DOI 10.1002/(SICI)1097-0045(19970501)31:2<125::AID-PROS8>3.0.CO;2-M
   Soto M, 1996, TISSUE CELL, V28, P557, DOI 10.1016/S0040-8166(96)80058-9
   STIERHOF YD, 1991, J ELECTRON MICR TECH, V17, P336, DOI 10.1002/jemt.1060170307
   Stoll HM, 2001, GEOCHEM GEOPHY GEOSY, V2, DOI 10.1029/2000GC000144
   Stoltenberg M, 2004, J HISTOCHEM CYTOCHEM, V52, P1241, DOI 10.1369/jhc.4B6286.2004
   Stoltenberg M, 2000, REPROD TOXICOL, V14, P65, DOI 10.1016/S0890-6238(99)00060-X
   Stoltenberg M, 1997, HISTOCHEM J, V29, P721, DOI 10.1023/A:1026413101443                                                         
   Stoltenberg M, 2003, HISTOL HISTOPATHOL, V18, P781, DOI 10.14670/HH-18.781
   Stoltenberg M, 2003, ACTA NEUROPATHOL, V105, P351, DOI 10.1007/s00401-002-0650-5
   Stoltenberg M, 2002, APMIS, V110, P396, DOI 10.1034/j.1600-0463.2002.100505.x                                               
   Stoltenberg M, 2002, J APPL TOXICOL, V22, P111, DOI 10.1002/jat.835
   Stoltenberg M, 1996, HISTOCHEM J, V28, P173, DOI 10.1007/BF02331441
   Stoltenberg M, 2001, J NEUROPATH EXP NEUR, V60, P705, DOI 10.1093/jnen/60.7.705                                                           
   Stoltenberg M, 2001, ACTA NEUROPATHOL, V101, P123
   Stoltenberg M, 2000, HISTOCHEM J, V32, P645, DOI 10.1023/A:1004115130843
   Stoltenberg M, 1997, INT J ANDROL, V20, P229, DOI 10.1046/j.1365-2605.1997.00060.x
   STOLTENBERG M, 2004, THESIS U AARHUS
   Suh SW, 2000, BRAIN RES, V852, P274, DOI 10.1016/S0006-8993(99)02096-X
   TAUCK DL, 1985, J NEUROSCI, V5, P1016
   THORLACIUSUSSING O, 1985, EXP MOL PATHOL, V42, P278, DOI 10.1016/0014-4800(85)90034-6
   TIMM F, 1958, Dtsch Z Gesamte Gerichtl Med, V46, P706, DOI 10.1007/BF00665092
   TIMM F, 1961, HISTOCHEMISTRY, V2, P332, DOI 10.1007/BF00848037                                                              
   TIMM F, 1962, ACTA HISTOCHEM JEN S, V3, P142
   Traber KE, 1999, INT IMMUNOL, V11, P143, DOI 10.1093/intimm/11.2.143
   Tubbs R, 2002, AM J PATHOL, V160, P1589, DOI 10.1016/S0002-9440(10)61106-6
   Ueno S, 2002, J CELL BIOL, V158, P215, DOI 10.1083/jcb.200204066
   Valente T, 2002, EXP NEUROL, V174, P215, DOI 10.1006/exnr.2002.7876
   VOIGT GE, 1959, VIRCHOWS ARCH A, V332, P295, DOI 10.1007/BF00956478                                                              
   Wang ZY, 2005, BRAIN RES BULL, V64, P441, DOI 10.1016/j.brainresbull.2004.10.001
   Wang ZY, 2001, BRAIN RES, V900, P80, DOI 10.1016/S0006-8993(01)02261-2
   Wang ZY, 2003, NEUROSCIENCE, V120, P605, DOI 10.1016/S0306-4522(03)00419-6
   Wang ZY, 2002, NEUROSCI LETT, V321, P37, DOI 10.1016/S0304-3940(01)02560-5                                                   
   Wang ZY, 2001, BRAIN RES, V921, P165, DOI 10.1016/S0006-8993(01)03114-6                                                   
   Wang ZZ, 2002, BRAIN RES, V928, P165, DOI 10.1016/S0006-8993(01)03344-3
   Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8
   WEN GY, 1985, ACTA NEUROPATHOL, V68, P175, DOI 10.1007/BF00690191                                                              
   Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676
   Wu XY, 2003, NAT BIOTECHNOL, V21, P41, DOI 10.1038/nbt764
   Xiao Y, 2003, SCIENCE, V299, P1877, DOI 10.1126/science.1080664
   YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5                                                    
   Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151                                                         
   Yuan XM, 1999, FREE RADICAL RES, V30, P221, DOI 10.1080/10715769900300241
   ZDOLSEK JM, 1993, FREE RADICAL BIO MED, V15, P1, DOI 10.1016/0891-5849(93)90120-J
   ZEIGER K, 1938, WISS FORSCHUNGSBER, V48, P55
NR 253
TC 80
Z9 81
U1 2
U2 28
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0079-6336
J9 PROG HISTOCHEM CYTO
JI Prog. Histochem. Cytochem.
PY 2006
VL 41
IS 2
BP 57
EP 139
DI 10.1016/j.proghi.2006.06.001
PG 83
WC Cell Biology
SC Cell Biology
GA 087OE
UT WOS:000240750900001
PM 16949439
DA 2018-01-05
ER

PT J
AU Terpstra, FG
   Parkkinen, J
   Tolo, H
   Koenderman, AHL
   ter Hart, HGJ
   Bonsdorff, L
   Torma, E
   Engelenburg, FAC
AF Terpstra, FG
   Parkkinen, J
   Tolo, H
   Koenderman, AHL
   ter Hart, HGJ
   Bonsdorff, L
   Torma, E
   Engelenburg, FAC
TI Viral safety of Nanogam (R), a new 15 nm-filtered liquid immunoglobulin
   product
SO VOX SANGUINIS
LA English
DT Article
DE B19; immunoglobulin; nanofiltration; neutralization; SD treatment; viral
   safety
ID PARVOVIRUS B19; VIRUS INACTIVATION; INTRAVENOUS IMMUNOGLOBULIN; RESIDUAL
   RISK; IGG SOLUTIONS; BLOOD-DONORS; HEPATITIS-B; NANOFILTRATION; REMOVAL;
   PLASMA
AB Background and Objectives Producers of plasma derivatives continuously improve the viral safety of their products by, for example, introducing additional virus-reducing steps into the manufacturing process. Here we present virus-elimination studies undertaken for a number of steps employed in a new manufacturing process for liquid intravenous immunoglobulin (Nanogam (R)) that comprises two specific virus-reducing steps: a 15-nm filtration step combined with pepsin treatment at pH 4.4 (pH 4.4/15NF); and solvent-detergent (SD) treatment. The manufacturing process also includes precipitation of Cohn fraction III and viral neutralization, which contribute to the total virus-reducing capacity of the manufacturing process. In addition, the mechanism and robustness of the virus-reducing steps were studied.
   Materials and Methods Selected process steps were studied with spiking experiments using a range of lipid enveloped (LE) and non-lipid-enveloped (NLE) viruses. The LE viruses used were bovine viral diarrhoea virus (BVDV), human immunodeficiency virus (HIV) and pseudorabies virus (PRV); the NLE viruses used were parvovirus B19 (B19), canine parvovirus (CPV) and encephalomyocarditis virus (EMC). After spiking, samples were collected and tested for residual infectivity, and the reduction factors were calculated. For B19, however, removal of B19 DNA was measured, not residual infectivity. To reveal the contribution of viral neutralization, bovine parvovirus (BPV) and hepatitis A virus (HAV) were used.
   Results For the pH 4.4/15NF step, complete reduction (> 6 log(10)) was demonstrated for all viruses, including B19, but not for CPV (> 3.4 but <= 4.2 log(10)). Robustness studies of the pH 4.4/15NF step with CPV showed that pH was the dominant process parameter. SD treatment for 10 min resulted in complete inactivation (> 6 log(10)) of all LE viruses tested. Precipitation of Cohn fraction III resulted in the significant removal (3-4 log(10)) of both LE and NLE viruses. Virus-neutralization assays of final product revealed significant reduction (>= 3 log(10)) of both BPV and HAV.
   Conclusions The manufacturing process of Nanogam (R) comprises two effective steps for the reduction of LE viruses and one for NLE viruses. In addition, the precipitation of Cohn fraction III and the presence of neutralizing antibodies contribute to the total virus-reducing capacity of Nanogam (R). The overall virus-reducing capacity was > 15 log(10) for LE viruses. For the NLE viruses B19, CPV and EMC, the overall virus-reducing capacities were > 10, > 7 and > 9 log(10), respectively. Including the contribution of immune neutralization, the overall virus-reducing capacity for B19 and HAV is estimated to be > 10 log(10).
C1 Sanquin, Virus Safety Serv, Div Res & Dev, NL-1006 AD Amsterdam, Netherlands.
   Sanquin, Div Plasma Prod, NL-1006 AD Amsterdam, Netherlands.
   Finnish Red Cross Blood Serv, Helsinki, Finland.
RP Terpstra, FG (reprint author), Sanquin, Virus Safety Serv, Div Res & Dev, Plesmanlaan 125, NL-1006 AD Amsterdam, Netherlands.
EM f.terpstra@sanquin.nl
CR Biesert L., 1998, Vox Sanguinis, V74, P207
   Biesert L, 1996, CLIN EXP RHEUMATOL, V14, pS47
   Blumel J, 2002, TRANSFUSION, V42, P1011, DOI 10.1046/j.1537-2995.2002.00158.x                                                
   Bolt CE, 1998, ARCH VIROL, V143, P549, DOI 10.1007/s007050050310
   Bos OJM, 1998, BIOLOGICALS, V26, P267, DOI 10.1006/biol.1998.0148
   Boschetti N, 2004, TRANSFUSION, V44, P1079, DOI 10.1111/j.1537-2995.2004.03420.x
   BRUMMELHUIS HGJ, 1983, VOX SANG, V45, P205, DOI 10.1111/j.1423-0410.1983.tb01906.x                                              
   Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x
   BURNOUFRADOSEVICH M, 1995, TRANSFUS CLIN BIOL, V2, P167, DOI 10.1016/S1246-7820(05)80044-8
   Caillet-Fauquet P, 2004, TRANSFUSION, V44, P1340, DOI 10.1111/j.0041-1132.2004.04127.x
   Chiavetta JA, 2003, CAN MED ASSOC J, V169, P767
   COCHRAN WG, 1950, BIOMETRICS, V6, P105, DOI 10.2307/3001491
   *CPMP, CPMPBWP26895 EUR AG
   *CPMP, 2001, CPMPBWP26995 EUR AG
   HAMALAINEN E, 1992, VOX SANG, V63, P6
   HIEMSTRA H, 2001, EXPT DESIGNS BASIS V, P37
   HOROWITZ B, 1994, BLOOD COAGUL FIBRIN, V5, P21
   Jacobsen KH, 2004, EPIDEMIOL INFECT, V132, P1005, DOI 10.1017/S0950268804002857
   KEMPF C, 1991, TRANSFUSION, V31, P423, DOI 10.1046/j.1537-2995.1991.31591263197.x
   Koppelman MHGM, 2004, TRANSFUSION, V44, P97, DOI 10.1046/j.0041-1132.2004.00610.x                                                
   Mazurier C, 2004, VOX SANG, V86, P100, DOI 10.1111/j.0042-9007.2004.00398.x                                                
   Montgomery D.C., 1996, DESIGN ANAL EXPT
   OGrady J, 1996, DEV BIOL STAND, V88, P319
   Omar A, 2002, TRANSFUSION, V42, P1005, DOI 10.1046/j.1537-2995.2002.00145.x
   Omar A, 1996, TRANSFUSION, V36, P866, DOI 10.1046/j.1537-2995.1996.361097017171.x
   Pillonel J, 2004, TRANSFUS CLIN BIOL, V11, P81, DOI 10.1016/j.tracli.2004.02.004
   Rollag H, 1998, VOX SANG, V74, P213, DOI 10.1111/j.1423-0410.1998.tb05475.x                                              
   Scheiblauer H, 1996, CLIN THER, V18, P59, DOI 10.1016/S0149-2918(96)80196-2
   Termorshuizen F, 2000, EPIDEMIOL INFECT, V124, P459, DOI 10.1017/S0950268899003842
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   Van Holten RW, 2002, VOX SANG, V83, P227, DOI 10.1046/j.1423-0410.2002.00224.x
   Yokoyama T, 2004, VOX SANG, V86, P225, DOI 10.1111/j.0042-9007.2004.00515.x
   Yunoki M, 2003, VOX SANG, V84, P164, DOI 10.1046/j.1423-0410.2003.00280.x                                                
   ZAAIJER HL, 1993, J MED VIROL, V40, P22, DOI 10.1002/jmv.1890400106
   Zaaijer HL, 2004, EPIDEMIOL INFECT, V132, P1161, DOI 10.1017/S0950268804002730
   1994, GERMAN FEDERAL REQUI
NR 36
TC 25
Z9 26
U1 0
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD JAN
PY 2006
VL 90
IS 1
BP 21
EP 32
DI 10.1111/j.1423-0410.2005.00710.x
PG 12
WC Hematology
SC Hematology
GA 991JG
UT WOS:000233808800003
PM 16359352
DA 2018-01-05
ER

PT B
AU Bhat, TN
AF Bhat, Talapady N.
BE Callaos, N
   Lesso, W
   Tremante, A
   Baralt, J
   Rebielak, J
TI Semantic Web for Chemical Genomics - need, how to, and hurdles
SO WMSCI 2006: 10TH WORLD MULTI-CONFERENCE ON SYSTEMICS, CYBERNETICS AND
   INFORMATICS, VOL VII, PROCEEDINGS
LA English
DT Proceedings Paper
CT 10th World Multi-Conference on Systemics, Cybernetics and
   Informatics/12th International Conference on Information Systems
   Analysis and Synthesis
CY JUL 16-19, 2006
CL Orlando, FL
SP Int Inst Informat & System
DE HIV; AIDS; Semantic Web; OWL; RDF; healthcare; chem-BLAST
AB Semantic Web has been often suggested as the information technology solution to the growing problem in managing the millions of data points generated by modem science such as nanotechnology and high through-put screening for drugs. However, the progress towards this vision envisaged by the W3C has been very limited. Here we discuss -some of the obstacles to the realization of this vision and we make some suggestions as to how one may overcome sonic of these hurdles? Here we discuss some of these issues and present thoughts on an alternative method to Semantic Web that is less drastic in requirements. This method does not require the use of RDF and Protege, and it works in an environment currently used by the chemical and biological database providers. In our method one attempts to use as many components as possible from the tools already used by the database providers and one brings in far fewer new tools and techniques compared to the method that use RDF or Protege. Our method uses a standard database environment and web tools rather than the RDF and Protege to manage user interface and the data is held in a database rather than using RDF. This method shifts the task of building Semantic knowledge-base and ontology from RDF and Protege to a SQL based database environment.
C1 NIST, Chem Sci & Technol Lab, Div Biochem Sci, Gaithersburg, MD 20899 USA.
RP Bhat, TN (reprint author), NIST, Chem Sci & Technol Lab, Div Biochem Sci, 100 Bur Dr, Gaithersburg, MD 20899 USA.
CR Austin CP, 2004, SCIENCE, V306, P1138, DOI 10.1126/science.1105511                                                         
   Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bhat TN, 2001, NUCLEIC ACIDS RES, V29, P214, DOI 10.1093/nar/29.1.214
   BHAT TN, 2005, P 9 WORLD MULT C SYS, V1, P69
   Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095
   CLARK T, 2005, GENOME TECHNOLOGY, P23
   MACNEIL JS, 2005, GENOME TECHNOLOGY, P26
   Neumann E. K., 2006, PAC S BIOC, P176
   Prasanna MD, 2006, PROTEINS, V63, P907, DOI 10.1002/prot.20914
   Prasanna MD, 2005, PROTEINS, V60, P1, DOI 10.1002/prot.20469
   SLAUGHTER LA, 2005, INT J MED INFORM
   Wheeler DL, 2006, NUCLEIC ACIDS RES, V34, pD173, DOI 10.1093/nar/gkj158
NR 13
TC 0
Z9 0
U1 0
U2 0
PU INT INST INFORMATICS & SYSTEMICS
PI ORLANDO
PA 14269 LORD BARCLAY DR, ORLANDO, FL 32837 USA
BN 978-980-6560-72-7
PY 2006
BP 1
EP 6
PG 6
WC Computer Science, Artificial Intelligence; Computer Science,
   Cybernetics; Computer Science, Information Systems
SC Computer Science
GA BHA60
UT WOS:000251939800001
DA 2018-01-05
ER

PT J
AU Manetti, F
   Este, JA
   Clotet-Codina, I
   Armand-Ugon, M
   Maga, G
   Crespan, E
   Cancio, R
   Mugnaini, C
   Bernardini, C
   Togninelli, A
   Carmi, C
   Alongi, M
   Petricci, E
   Massa, S
   Corelli, F
   Botta, M
AF Manetti, F
   Este, JA
   Clotet-Codina, I
   Armand-Ugon, M
   Maga, G
   Crespan, E
   Cancio, R
   Mugnaini, C
   Bernardini, C
   Togninelli, A
   Carmi, C
   Alongi, M
   Petricci, E
   Massa, S
   Corelli, F
   Botta, M
TI Parallel solution-phase and microwave-assisted synthesis of new S-DABO
   derivatives endowed with subnanomolar anti-HIV-1 activity
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; IMMUNODEFICIENCY-VIRUS TYPE-1;
   NONNUCLEOSIDE INHIBITORS; CRYSTAL-STRUCTURES; DRUG CANDIDATES; PETT
   COMPOUNDS; WILD-TYPE; POTENT; RESISTANCE; SERIES
AB A simple and efficient methodology for the parallel solution-phase synthesis has been set up to obtain a series of thiouracils, in turn selectively S-benzylated under microwave irradiation to give new S-DABOs. Biological screening led to the identification of compounds with nanomolar activity toward both the highly purified recombinant human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) enzyme (wild-type and mutants) and wild-type (wt) and mutant HIV-1 strains. In particular, 20 was found to be the most potent S-DABO reported so far (ID50 = 26 nM toward the isolated wt enzyme) with subnanomolar activity toward both the wt and the pluriresistant virus (IRLL98) HIV-1 strain (EC50 < 0.14 nM and EC50 = 0.22 nM, respectively). Molecular modeling calculations were also performed to investigate the binding mode of such compounds onto the non-nucleoside reverse transcriptase inhibitor binding site and to rationalize the relationships between their chemical structure and activity values toward wt RT.
C1 Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
   Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Retrovirol Lab irsiCaixa, E-08916 Badalona, Spain.
   CNR, Ist Genet Mol, IGM, I-27100 Pavia, Italy.
   Univ Parma, Dipartimento Farmaceut, I-43100 Parma, Italy.
RP Botta, M (reprint author), Univ Siena, Dipartimento Farmaco Chim Tecnol, Via Alcide Gasperi 2, I-53100 Siena, Italy.
EM botta@unisi.it
RI Maga, Giovanni/C-5409-2009; Manetti, Fabrizio/B-9852-2011; Este,
   Jose/B-5509-2008
OI Maga, Giovanni/0000-0001-8092-1552; Manetti,
   Fabrizio/0000-0002-9598-2339; Este, Jose/0000-0002-1436-5823; Crespan,
   Emmanuele/0000-0003-0597-6929; Armand-Ugon, Mercedes/0000-0002-4069-9915
CR Armand-Ugon M, 2003, ANTIVIR RES, V59, P137, DOI 10.1016/S0166-3542(03)00071-8
   Arnold E, 1996, Drug Des Discov, V13, P29
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   BOTTA M, 1992, EUR J MED CHEM, V27, P251, DOI 10.1016/0223-5234(92)90009-P
   BOX VGS, 1991, HETEROCYCLES, V32, P245
   Cabana M, 1999, J MED VIROL, V59, P480, DOI 10.1002/(SICI)1096-9071(199912)59:4<480::AID-JMV10>3.0.CO;2-8                   
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CLAY RJ, 1993, SYNTHESIS-STUTTGART, P290
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   Hogberg M, 1999, J MED CHEM, V42, P4150, DOI 10.1021/jm990095j
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2225, DOI 10.1016/S0960-894X(01)00410-3
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2229, DOI 10.1016/S0960-894X(01)00411-5
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   Mai A, 2005, BIOORGAN MED CHEM, V13, P2065, DOI 10.1016/j.bmc.2005.01.005
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405
   Obrecht D, 1997, HELV CHIM ACTA, V80, P65, DOI 10.1002/hlca.19970800106                                                        
   Parlato MC, 2004, ARKIVOC, P349
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   Petricci E, 2004, J ORG CHEM, V69, P7880, DOI 10.1021/jo048837q
   Radi M, 2005, J COMB CHEM, V7, P117, DOI 10.1021/cc049880u
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m                                                               
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972                                                          
NR 38
TC 47
Z9 50
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 15
PY 2005
VL 48
IS 25
BP 8000
EP 8008
DI 10.1021/jm050744t
PG 9
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 992ZR
UT WOS:000233923000010
PM 16335924
DA 2018-01-05
ER

PT J
AU Duncan, R
   Izzo, L
AF Duncan, R
   Izzo, L
TI Dendrimer biocompatibility and toxicity
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE dendrimer; dendron; biocompatibility; toxicity; polymer therapeutic;
   biomedical use
ID NEUTRON-CAPTURE THERAPY; EPIDERMAL-GROWTH-FACTOR; POLY(AMIDOAMINE) PAMAM
   DENDRIMERS; HUMAN-IMMUNODEFICIENCY-VIRUS; DRUG-DELIVERY APPLICATIONS;
   INTRAVENOUS GENE DELIVERY; MRI CONTRAST AGENTS; IN-VITRO; POLYAMIDOAMINE
   DENDRIMERS; ANTISENSE OLIGONUCLEOTIDES
AB The field of biomedical dendrimers is still in its infancy, but the explosion of interest in dendrimers and dendronised polymers as inherently active therapeutic agents, as vectors for targeted delivery of drugs, peptides and oligonucleotides, and as permcability enhancers able to promote oral and transdermal drug delivery makes it timely to review Current knowledge regarding the toxicology of these dendrimer chemistries (currently under development for biomedical applications). Clinical experience with polymeric excipients, plasma expanders, and most recently the development of more 'classical polymer'-derived therapeutics can be used to guide development of "safe" dendritic polymers. Moreover, in future it will only ever be possible to designate a dendruner as "safe" when related to a specific application. The so far limited clinical experience using dendrimers make it impossible to designate any particular chemistry intrinsically "safe" or "toxic". Although there is widespread concern as to the safety of nano-sized particles, preclinical and clinical experience gained during the development of polymeric excipients, biomedical polymers and polymer therapeutics shows that judicious development of dendrimer chemistry for each specific application will ensure development of safe and important materials for biomedical and pharmaceutical use. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Cardiff Wales, Welsh Sch Pharm, Ctr Polymer Therapeut, Cardiff CF10 3XF, Wales.
   Univ Salerno, Dipartimento Chim, I-84081 Baronissi, SA, Italy.
RP Duncan, R (reprint author), Univ Cardiff Wales, Welsh Sch Pharm, Ctr Polymer Therapeut, Cardiff CF10 3XF, Wales.
EM DuncanR@cf.ac.uk
CR Al-Jamal KT, 2003, INT J PHARM, V254, P33, DOI 10.1016/S0378-5173(02)00678-6
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Aulenta F, 2003, EUR POLYM J, V39, P1741, DOI 10.1016/S0014-3057(03)00100-9
   Baigude H, 2004, J POLYM SCI POL CHEM, V42, P1400, DOI 10.1002/pola.11031
   BALOGH LP, 2003, J NUCL MED SS, V44, P1094
   Balzani V, 2003, TOP CURR CHEM, V228, P159, DOI 10.1007/b11010
   Barth RF, 2004, APPL RADIAT ISOTOPES, V61, P899, DOI 10.1016/j.apradiso.2004.05.004
   BARTH RF, 1994, BIOCONJUGATE CHEM, V5, P58, DOI 10.1021/bc00025a008                                                             
   Bay S, 1997, J PEPT RES, V49, P620
   Beezer AE, 2003, TETRAHEDRON, V59, P3873, DOI 10.1016/S0040-4020(03)00437-X
   BERNSTEIN DI, 2003, ANTIVIR RES, V57, P89
   Bielinska A, 1996, NUCLEIC ACIDS RES, V24, P2176, DOI 10.1093/nar/24.11.2176                                                          
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Borm PJA, 2002, INHAL TOXICOL, V14, P311, DOI 10.1080/08958370252809086
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   BRESLOW DS, 1976, PURE APPL CHEM, V46, P103, DOI 10.1351/pac197646020103                                                         
   BUHLEIER E, 1978, SYNTHESIS-STUTTGART, P155
   CAMINADE AM, IN PRESS ADV DRUG DE
   Capala J, 1996, BIOCONJUGATE CHEM, V7, P7, DOI 10.1021/bc950077q
   Chauhan AS, 2003, J CONTROL RELEASE, V90, P335, DOI 10.1016/S0168-3659(03)00200-1
   Chen HT, 2004, J AM CHEM SOC, V126, P10044, DOI 10.1021/ja048548j
   Choi JS, 2004, J CONTROL RELEASE, V99, P445, DOI 10.1016/j.jconrel.2004.07.027
   Cloninger MJ, 2002, CURR OPIN CHEM BIOL, V6, P742, DOI 10.1016/S1367-5931(02)00400-3                                                   
   D'Emanuele A, 2004, J CONTROL RELEASE, V95, P447, DOI 10.1016/j.jconrel.2003.12.006
   De Jesus OLP, 2002, BIOCONJUGATE CHEM, V13, P453, DOI 10.1021/bc010103m
   Devarakonda B, 2004, INT J PHARM, V284, P133, DOI 10.1016/j.ijpharm.2004.07.006
   Du YG, 2004, TETRAHEDRON, V60, P6345, DOI 10.1016/j.tet.2004.05.086
   Duncan R, 1996, STP PHARMA SCI, V6, P237
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Duncan R, 1998, HUM EXP TOXICOL, V17, P93, DOI 10.1191/096032798678908378
   Duncan R, 1991, PROGR MEMBRANE BIOTE, P121
   Duncan R., 2005, POLYM DRUG DELIVERY, P1
   Duncan R., 2003, HDB ANTICANCER DRUG, P239
   DUNCAN R, ENCY MOL CELL BIOL M, P163
   El-Sayed M, 2003, INT J PHARM, V265, P151, DOI 10.1016/S0378-5173(03)00391-0
   El-Sayed M, 2001, PHARMACEUT RES, V18, P23, DOI 10.1023/A:1011066408283                                                         
   Eliyahu H, 2002, GENE THER, V9, P850, DOI 10.1038/sj.gt.3301705
   Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359-6446(01)01757-3
   ESFAND R, 1999, BIOCONJUG CHEM, V10, P271
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   Flanagan P. A., 1990, J BIOACT COMPAT POLY, V5, P151
   Frechet JMJ, 1996, J MACROMOL SCI PURE, VA33, P1399, DOI 10.1080/10601329608014916                                                       
   Frechet J. M. J., 2001, DENDRIMERS OTHER DEN, P647
   Fuchs S, 2004, CHEM-EUR J, V10, P1167, DOI 10.1002/chem.200305386
   Giles J, 2004, NATURE, V430, P599, DOI 10.1038/430599b
   GILLIES ER, 2002, J AM CHEM SOC, V154, P14137
   GITSOV I, 1993, MACROMOLECULES, V26, P5621, DOI 10.1021/ma00073a014                                                             
   GODDARD P, 1991, J BIOACT COMPAT POL, V6, P4, DOI 10.1177/088391159100600102                                                      
   Grayson SM, 2001, CHEM REV, V101, P3819, DOI 10.1021/cr990116h
   Guo CY, 2004, PROG BIOCHEM BIOPHYS, V31, P804
   HAENSLER J, 1993, BIOCONJUGATE CHEM, V4, P372, DOI 10.1021/bc00023a012
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   HAWKER CJ, 1990, J AM CHEM SOC, V112, P7638, DOI 10.1021/ja00177a027                                                             
   Herborn CU, 2003, RADIOLOGY, V229, P217, DOI 10.1148/radiol.2291021033
   Higashiyama S, 2004, KOBUNSHI RONBUNSHU, V61, P587, DOI 10.1295/koron.61.587                                                            
   Hollins AJ, 2004, PHARM RES, V21, P458, DOI 10.1023/B:PHAM.0000019300.04836.51
   Hong SP, 2004, BIOCONJUGATE CHEM, V15, P774, DOI 10.1021/bc049962b
   Hussain M, 2004, J CONTROL RELEASE, V99, P139, DOI 10.1016/j.jconrel.2004.06.009
   Ihre HR, 2002, BIOCONJUGATE CHEM, V13, P443, DOI 10.1021/bc010102u
   JANSEN JFGA, 1994, SCIENCE, V266, P1226, DOI 10.1126/science.266.5188.1226                                                   
   Jevprasesphant R, 2004, J CONTROL RELEASE, V97, P259, DOI 10.1016/j.jconrel.2004.03.022
   Jevprasesphant R, 2003, PHARMACEUT RES, V20, P1543, DOI 10.1023/A:1026166729873                                                         
   Jevprasesphant R, 2003, INT J PHARM, V252, P263, DOI 10.1016/S0378-5173(02)00623-3                                                   
   Kensinger RD, 2004, ANTIMICROB AGENTS CH, V48, P1614, DOI 10.1128/AAC.48.5.1614-1623.2004
   Kihara F, 2003, BIOCONJUGATE CHEM, V14, P342, DOI 10.1021/bc025613a
   KIM HS, 2003, J NUCL MED, V44, P1091
   Kim T, 2004, BIOMACROMOLECULES, V5, P2487, DOI 10.1021/bm049563j
   Kobayashi H, 2001, MAGNET RESON MED, V46, P795, DOI 10.1002/mrm.1259
   Kobayashi H, 2004, CLIN CANCER RES, V10, P7712, DOI 10.1158/1078-0432.CCR-04-1175                                                   
   Kobayashi H, 2004, J MAGN RESON IMAGING, V20, P512, DOI 10.1002/jmri.20147
   Kobayashi H, 2002, KIDNEY INT, V61, P1980, DOI 10.1046/j.1523-1755.2002.00364.x                                                
   Kobayashi H, 2004, J NATL CANCER I, V96, P703, DOI 10.1093/jnci/djh124
   Kobayashi H, 2002, RADIOLOGY, V225, P237
   Kobayashi H, 2001, MAGNET RESON MED, V46, P457, DOI 10.1002/mrm.1214
   Kono K, 1999, BIOCONJUGATE CHEM, V10, P1115, DOI 10.1021/bc990082k
   KukowskaLatallo JF, 1996, P NATL ACAD SCI USA, V93, P4897, DOI 10.1073/pnas.93.10.4897                                                         
   Langereis S, 2004, MACROMOLECULES, V37, P3084, DOI 10.1021/ma035983+
   Lee JH, 2003, BIOCONJUGATE CHEM, V14, P1214, DOI 10.1021/bc034095g
   Li YG, 2004, NAT MATER, V3, P38, DOI 10.1038/nmat1045
   Lloyd JB, 2000, ADV DRUG DELIVER REV, V41, P189, DOI 10.1016/S0169-409X(99)00065-4
   Mackay ME, 2003, CR CHIM, V6, P747, DOI 10.1016/j.crci.2003.05.003
   Malik N, 2000, J CONTROL RELEASE, V65, P133, DOI 10.1016/S0168-3659(99)00246-1                                                   
   Malik N, 1999, ANTI-CANCER DRUG, V10, P767, DOI 10.1097/00001813-199909000-00010
   Manunta M, 2004, NUCLEIC ACIDS RES, V32, P2730, DOI 10.1093/nar/gkh595
   Marano RJ, 2004, EXP EYE RES, V79, P525, DOI 10.1016/j.exer.2004.06.023
   Margerum LD, 1997, J ALLOY COMPD, V249, P185, DOI 10.1016/S0925-8388(96)02830-7                                                   
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   McIntyre JO, 2004, BIOCHEM J, V377, P617, DOI 10.1042/BJ20030582
   Moon WK, 2003, BIOCONJUGATE CHEM, V14, P539, DOI 10.1021/bc0340114
   Nakanishi H, 2003, GENE THER, V10, P434, DOI 10.1038/sj.gt.3301912
   NEWKOME GR, 1996, DENDRITIC MOL CONCEP, P1
   Ohana P., 2004, GENE THER MOL BIOL, V8, P181
   Okuda T, 2003, ORG BIOMOL CHEM, V1, P1270, DOI 10.1039/b212086k
   Ooya T, 2004, BIOCONJUGATE CHEM, V15, P1221, DOI 10.1021/bc049814l
   Ota S, 2002, CANCER RES, V62, P1471
   Patri AK, 2004, BIOCONJUGATE CHEM, V15, P1174, DOI 10.1021/bc0499127
   Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437                                                      
   Pospisil M, 2001, ADV EXP MED BIOL, V495, P343
   RIHOVA B, 1989, BIOMATERIALS, V10, P335, DOI 10.1016/0142-9612(89)90075-6
   RIHOVA B, 1984, BIOMATERIALS, V5, P143, DOI 10.1016/0142-9612(84)90048-6
   Rihova B, 1996, ADV DRUG DELIVER REV, V21, P157
   RIHOVA B, 1983, FOLIA MICROBIOL, V28, P7
   RIHOVA B, 1985, MAKROMOL CHEM S, V9, P13
   Roberts JC, 1996, J BIOMED MATER RES, V30, P53, DOI 10.1002/(SICI)1097-4636(199601)30:1<53::AID-JBM8>3.0.CO;2-Q
   Roesnecker J, 2003, J GENE MED, V5, P49, DOI 10.1002/jgm.291
   Roovers J, 1999, ADV POLYM SCI, V142, P179
   Roy R, 1997, TOP CURR CHEM, V187, P241
   Sanchez-Sancho F, 2002, BIOCONJUGATE CHEM, V13, P647, DOI 10.1021/bc0155824
   Santhakumaran LM, 2004, NUCLEIC ACIDS RES, V32, P2102, DOI 10.1093/nar/gkh526
   Sashiwa H, 2003, BIOMACROMOLECULES, V4, P1244, DOI 10.1021/bm030021w
   Sato N, 2001, MAGNET RESON MED, V46, P1169, DOI 10.1002/mrm.1314
   Schluter AD, 2000, ANGEW CHEM INT EDIT, V39, P864, DOI 10.1002/(SICI)1521-3773(20000303)39:5<864::AID-ANIE864>3.0.CO;2-E               
   SEIB FP, 2004, P INT S CONTR REL BI, V31, P717
   SEIB P, 2005, THESIS CARDIFF U
   SEYMOUR LW, 1987, J BIOMED MATER RES, V21, P1341, DOI 10.1002/jbm.820211106
   SGOURAS D, 1990, J MATER SCI-MATER M, V1, P67
   SHAUNAK S, 2004, NAT BIOTECHNOL, V22, P1
   Simekova J, 1986, J BIOACT COMPAT POLY, V1, P20
   Stiriba SE, 2002, ANGEW CHEM INT EDIT, V41, P1329, DOI 10.1002/1521-3773(20020415)41:8<1329::AID-ANIE1329>3.0.CO;2-P
   SVENSON S, IN PRESS ADV DRUG DE
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   Tang MX, 1996, BIOCONJUGATE CHEM, V7, P703, DOI 10.1021/bc9600630                                                               
   Tansey W, 2004, J CONTROL RELEASE, V94, P39, DOI 10.1016/j.jconrel.2003.09.005
   Thomas TP, 2004, BIOMACROMOLECULES, V5, P2269, DOI 10.1021/bm049704h
   TOMALIA DA, 1991, MACROMOLECULES, V24, P1435, DOI 10.1021/ma00006a039                                                             
   TOMALIA DA, 1985, POLYM J, V17, P117, DOI 10.1295/polymj.17.117                                                           
   TOMALIA DA, 1990, ANGEW CHEM INT EDIT, V29, P138, DOI 10.1002/anie.199001381                                                          
   TOMALIA DA, 2001, SUPRAMOLECULAR POLYM, P359
   Vannucci L, 2003, INT J ONCOL, V23, P285
   Vincent L, 2003, INT J CANCER, V105, P419, DOI 10.1002/ijc.11105
   WAGNER E, IN PRESS ADV POLYM S
   Wang SJ, 2003, INVEST RADIOL, V38, P662, DOI 10.1097/01.rli.0000084887.47427.75
   Wang ZX, 2003, J BIOSCI BIOENG, V96, P537, DOI 10.1016/S1389-1723(04)70146-2
   Wilbur DS, 1998, BIOCONJUGATE CHEM, V9, P813, DOI 10.1021/bc980055e
   WILLIAMS DF, 1989, J BIOMED ENG, V11, P185, DOI 10.1016/0141-5425(89)90138-6
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Wiwattanapatapee R, 2000, PHARMACEUT RES, V17, P991, DOI 10.1023/A:1007587523543
   Xyloyiannis M., 2003, P INT S CONTR REL BI, V30, P149
   Yang WL, 2004, APPL RADIAT ISOTOPES, V61, P981, DOI 10.1016/j.apradiso.2004.05.071
   YEUNG TK, 1991, CANCER CHEMOTH PHARM, V29, P105, DOI 10.1007/BF00687318                                                              
   Yordanov AT, 2003, J MATER CHEM, V13, P1523, DOI 10.1039/b304147f
   Zhao H, 2004, FEBS LETT, V563, P241, DOI 10.1016/S0014-5793(04)00284-4
   Zhou M, 2004, ORG LETT, V6, P3561, DOI 10.1021/ol0485262
NR 144
TC 669
Z9 695
U1 22
U2 284
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD DEC 14
PY 2005
VL 57
IS 15
BP 2215
EP 2237
DI 10.1016/j.addr.2005.09.019
PG 23
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 998ES
UT WOS:000234302000009
PM 16297497
DA 2018-01-05
ER

PT J
AU Jaroniec, CP
   Kaufman, JD
   Stahl, SJ
   Viard, M
   Blumenthal, R
   Wingfield, PT
   Bax, A
AF Jaroniec, CP
   Kaufman, JD
   Stahl, SJ
   Viard, M
   Blumenthal, R
   Wingfield, PT
   Bax, A
TI Structure and dynamics of micelle-associated human immunodeficiency
   virus gp41 fusion domain
SO BIOCHEMISTRY
LA English
DT Review
ID NUCLEAR-MAGNETIC-RESONANCE; RESIDUAL DIPOLAR COUPLINGS; MODEL-FREE
   APPROACH; 3-DIMENSIONAL SOLUTION STRUCTURE; MEDIATED MEMBRANE-FUSION; A
   TRANSMEMBRANE DOMAIN; HIV-1 GP41; ENVELOPE GLYCOPROTEIN;
   NMR-SPECTROSCOPY; INFLUENZA HEMAGGLUTININ
AB The N-terminal fusion domain of the HIV-1 gp4l envelope glycoprotein is responsible for initiating the fusion of viral and cellular membranes, leading to the subsequent infection of the host cell by HIV-1. We have investigated the backbone structure and dynamics of the 30 N-terminal residues of HIV-1 gp4l in membrane-mimicking environments using NMR spectroscopy and N-15- and N-15,C-13,H-2-labeled peptides. Similar N-15-H-1 HSQC spectra were obtained in a variety of detergents, including SDS, DPC, mixed DPC/SDS, and LPPG micelles, indicating that the peptide structure is not strongly influenced by the type of detergent used. Detailed characterization was carried out in SDS micelles, where the longterm sample stability was found to be optimal. In addition to J-coupling and NOE restraints, a nearly complete set of backbone residual dipolar coupling restraints was recorded for the fusion domain-micelle complex aligned with respect to the magnetic field using a stretched polyacrylamide gel. Backbone amide 15N spin relaxation and amide hydrogen exchange rates with the solvent were also measured. The ensemble of NMR structures reveals an uninterrupted alpha-helix for the least mobile residues (S-2 > 0.65), lle-4 to Met- 19, with transient helical character extending up to Ala-22. A 12-residue (Ile-4 to Ala-15) segment is fully shielded from solvent, with Gly-3 and Gly-16 found at micelle-solvent interfaces. Res dues external to the micelle exhibit enhanced picosecond to nanosecond time scale dynamics relative to the residues buried in the micelle, and their mobility increases with the distance from the micelle.
C1 NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
   NIAMSD, Prot Express Lab, NIH, Bethesda, MD 20892 USA.
   NCI, Ctr Canc Res, Nanobiol Program, NIH, Frederick, MD 21702 USA.
RP Jaroniec, CP (reprint author), NIDDKD, Chem Phys Lab, NIH, Bldg 2, Bethesda, MD 20892 USA.
EM jaroniec@speck.niddk.nih.gov; bax@nih.gov
RI Jaroniec, Christopher/A-4948-2008
OI Jaroniec, Christopher/0000-0003-0364-2888
FU Intramural NIH HHS
CR Arora A, 2001, NAT STRUCT BIOL, V8, P334, DOI 10.1038/86214
   Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X                                                   
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8                                                   
   BAX A, 1993, ACCOUNTS CHEM RES, V26, P13
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Blackledge M, 2005, PROG NUCL MAG RES SP, V46, P23, DOI 10.1016/j.pnmrs.2004.11.002
   Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+
   BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0                                                                
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200
   Chang DK, 1997, J VIROL, V71, P6593
   Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863                                                         
   Chou JJ, 2002, J AM CHEM SOC, V124, P2450, DOI 10.1021/ja017875d
   Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740                                                         
   Curtain C, 1999, EUR BIOPHYS J BIOPHY, V28, P427, DOI 10.1007/s002490050225
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Delahunty MD, 1996, VIROLOGY, V218, P94, DOI 10.1006/viro.1996.0169
   Lano De, 2002, PYMOL MOL GRAPHICS S
   Durell SR, 1997, MOL MEMBR BIOL, V14, P97, DOI 10.3109/09687689709048170                                                       
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Epand RM, 2003, BBA-BIOMEMBRANES, V1614, P116, DOI 10.1016/S0005-2736(03)00169-X
   Evenas J, 2001, J AM CHEM SOC, V123, P2858, DOI 10.1021/ja003833y
   FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040                                                             
   Fass D, 1996, NAT STRUCT BIOL, V3, P465, DOI 10.1038/nsb0596-465
   Fernandez C, 2004, J MOL BIOL, V336, P1211, DOI 10.1016/j.jmb.2003.09.014
   Fisher LE, 1999, J MOL BIOL, V293, P639, DOI 10.1006/jmbi.1999.3126
   GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11                                                            
   Goddard T. D., SPARKY 3
   Gordon LM, 2002, BBA-BIOMEMBRANES, V1559, P96, DOI 10.1016/S0005-2736(01)00443-6
   GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S                                                    
   Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002
   Han X, 2000, P NATL ACAD SCI USA, V97, P13097, DOI 10.1073/pnas.230212097
   Han X, 2001, NAT STRUCT BIOL, V8, P715, DOI 10.1038/90434                                                                   
   Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627
   HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8                                                    
   HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204
   Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z                                                               
   Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238
   Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499
   Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0                                                   
   Kamath S, 2002, BIOPHYS J, V83, P135, DOI 10.1016/S0006-3495(02)75155-2                                                   
   KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088                                                             
   KONTAXIS G, 2005, METHOD ENZYMOL, V394, P48
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Krueger-Koplin RD, 2004, J BIOMOL NMR, V28, P43, DOI 10.1023/B:JNMR.0000012875.80898.8f
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   LEAR JD, 1987, J BIOL CHEM, V262, P6500
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Louhivuori M, 2003, J AM CHEM SOC, V125, P15647, DOI 10.1021/ja035427v
   MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131
   Malashkevich VN, 1999, P NATL ACAD SCI USA, V96, P2662, DOI 10.1073/pnas.96.6.2662
   Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134                                                         
   MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073                                                          
   Martin I, 1996, J VIROL, V70, P298
   Mascioni A, 2002, BIOCHEMISTRY-US, V41, P475, DOI 10.1021/bi011243m
   Meier S, 2002, J BIOMOL NMR, V24, P351, DOI 10.1023/A:1021609207024
   Mesleh MF, 2002, J AM CHEM SOC, V124, P4206, DOI 10.1021/ja0178665
   Morris KF, 2004, BBA-BIOMEMBRANES, V1667, P67, DOI 10.1016/j.bbamem.2004.08.014
   NIEVA JL, 1994, BIOCHEMISTRY-US, V33, P3201, DOI 10.1021/bi00177a009
   Nieva JL, 2003, BBA-BIOMEMBRANES, V1614, P104, DOI 10.1016/S0005-2736(03)00168-8
   Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361
   Oxenoid K, 2005, P NATL ACAD SCI USA, V102, P10870, DOI 10.1073/pnas.0504920102
   Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t
   PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001                                                             
   Park SH, 2003, J MOL BIOL, V333, P409, DOI 10.1016/j.jmb.2003.08.048
   PISZKIEW.D, 1970, BIOCHEM BIOPH RES CO, V40, P1173, DOI 10.1016/0006-291X(70)90918-6
   Poulsen SA, 2000, J STRUCT BIOL, V130, P142, DOI 10.1006/jsbi.2000.4267
   Prestegard JH, 2000, Q REV BIOPHYS, V33, P371, DOI 10.1017/S0033583500003656
   Pritsker M, 1999, BIOCHEMISTRY-US, V38, P11359, DOI 10.1021/bi990232e
   Qiao H, 1999, MOL BIOL CELL, V10, P2759, DOI 10.1091/mbc.10.8.2759                                                           
   QUINA FH, 1995, J PHYS CHEM-US, V99, P17028, DOI 10.1021/j100046a031                                                             
   RAFALSKI M, 1990, BIOCHEMISTRY-US, V29, P7917, DOI 10.1021/bi00486a020
   Rastogi VK, 1999, NATURE, V402, P263
   Sackett K, 2005, J MOL BIOL, V350, P790, DOI 10.1016/j.jmb.2005.05.030
   Sass HJ, 2000, J BIOMOL NMR, V18, P303, DOI 10.1023/A:1026703605147
   Sass J, 1999, J AM CHEM SOC, V121, P2047, DOI 10.1021/ja983887w                                                               
   SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561
   Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u
   SCHOCH C, 1993, J BIOL CHEM, V268, P9267
   SCHWIETERS CD, 2003, J MAGN RESON, V1060, P65
   SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227
   STEINHAUER DA, 1995, J VIROL, V69, P6643
   STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023
   Tamm LK, 2002, BIOPOLYMERS, V66, P249, DOI 10.1002/bip.10261
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Tian CL, 2005, J AM CHEM SOC, V127, P8010, DOI 10.1021/ja05116115
   Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q
   Ulmer TS, 2003, J AM CHEM SOC, V125, P9179, DOI 10.1021/ja0350684
   ULMER TS, 2005, J BIOL CHEM, V80, P9595
   VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723
   Viard M, 2002, J VIROL, V76, P11584, DOI 10.1128/JVI.76.22.11584-11595.2002
   VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024
   Wasniewski CM, 2004, CHEM PHYS LIPIDS, V132, P89, DOI 10.1016/j.chemphyslip.2004.09.008
   Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706                                                         
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weissenhorn W, 1998, MOL CELL, V2, P605, DOI 10.1016/S1097-2765(00)80159-8
   Weissenhorn W, 1997, P NATL ACAD SCI USA, V94, P6065, DOI 10.1073/pnas.94.12.6065
   WHARTON SA, 1988, J GEN VIROL, V69, P1847, DOI 10.1099/0022-1317-69-8-1847
   Wuthrich K., 1986, NMR PROTEINS NUCL AC
   Yamazaki T, 1996, PROTEIN SCI, V5, P495
   YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005                                                             
   Yang J, 2001, BIOCHEMISTRY-US, V40, P8126, DOI 10.1021/bi0100283
   Yang J, 2004, BIOPHYS J, V87, P1951, DOI 10.1529/biophysj.103.028530
   Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116
NR 111
TC 100
Z9 102
U1 2
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD DEC 13
PY 2005
VL 44
IS 49
BP 16167
EP 16180
DI 10.1021/bi051672a
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 992QH
UT WOS:000233898400023
PM 16331977
DA 2018-01-05
ER

PT J
AU Akagi, T
   Ueno, M
   Hiraishi, K
   Baba, M
   Akashi, M
AF Akagi, T
   Ueno, M
   Hiraishi, K
   Baba, M
   Akashi, M
TI AIDS vaccine: Intranasal immunization using inactivated HIV-1-capturing
   core-corona type polymeric nanospheres
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 12th International Symposium on Recent Advances in Drug Delivery Systems
CY FEB 21-24, 2005
CL Salt Lake City, UT
SP Abbott Labs, Ind Technol Res Inst, Nitto Denko Corp, Samyang Corp, Shiseido Res Ctr, Watson Labs
DE nanospheres; HIV; vaccine; mucosal immunization; IgA
ID IMMOBILIZED POLYSTYRENE NANOSPHERES; PLUS CPG OLIGODEOXYNUCLEOTIDES;
   HUMAN DENDRITIC CELLS; IMMUNE-RESPONSES; NASAL IMMUNIZATION;
   ANTIBODY-RESPONSE; BIODEGRADABLE MICROPARTICLES; CAPTURING NANOSPHERES;
   MUCOSAL IMMUNIZATION; LOADED NANOSPHERES
AB Polymeric nanospheres have been widely used in biomedical applications, such as drug, gene and vaccine delivery systems. Nanospheres with entrapped antigens have recently been shown to possess significant potential as vaccine delivery systems and adjuvants. We previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and intranasal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody responses in mice. In addition, vaginal washes from intranasally immunized mice were capable of neutralizing HIV-1. Moreover, simian/human immunodeficiency virus KU-2-capturing nanospheres (SHIV-NS) immunized macaques exhibited partial protection when vaginally and systemically challenged with pathogenic viruses. HIV-NS is suggested to be particularly suitable to enhance antigen delivery to dendritic cells (DCs). In this study, we investigated the mucosal antibody response in mice after the intravaginal or intranasal immunization in detail with using different sized (360, 660, 940 and 1230 nm) HIV-NS. The amount of immobilized Con A to NS was dependent on the surface area of the particle. Moreover, Con A-NS with different sizes could equally capture inactivated HIV-1. Intravaginal or intranasal immunization by HIV-NS with diameters ranging 360 to 1230 nm significantly induced vaginal antibody responses. However, significant differences on vaginal anti-HIV-1 gp 120 IgA and IgG antibodies were not found after intravaginal or intranasal immunization with different sized HIV-NS. These results suggest that HIV-NS provides an efficient vaccine delivery system for the induction of a mucosal immune response and the development of a mucosal vaccine. (c) 2005 Elsevier B.V. All rights reserved.
C1 Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan.
   Japan Immunores Labs, Takasaki, Gumma, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 890, Japan.
   Japan Sci & Technol Agcy, JST, CREST, Tokyo, Japan.
RP Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Appl Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM akashi@chem.eng.osaka-u.ac.p
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Baba TW, 2000, NAT MED, V6, P200
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Belyakov IM, 2004, IMMUNITY, V20, P247, DOI 10.1016/S1074-7613(04)00053-6                                                   
   Belyakov IM, 1998, J CLIN INVEST, V102, P2072, DOI 10.1172/JCI5102                                                                 
   Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320
   Bradney CP, 2002, J VIROL, V76, P517, DOI 10.1128/JVI.76.2.517-524.2002
   CAPUTO SL, 2003, AIDS, V17, P531
   Cetinus SA, 2003, ENZYME MICROB TECH, V32, P889, DOI 10.1016/S0141-0229(03)00065-6
   Copland MJ, 2003, VACCINE, V21, P883, DOI 10.1016/S0264-410X(02)00536-4                                                   
   CZERKINSKY C, 1987, P NATL ACAD SCI USA, V84, P2449, DOI 10.1073/pnas.84.8.2449
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Dumais N, 2002, J INFECT DIS, V186, P1098, DOI 10.1086/344232
   ELSON CO, 1979, J EXP MED, V149, P632, DOI 10.1084/jem.149.3.632                                                           
   Foster N, 1998, VACCINE, V16, P536, DOI 10.1016/S0264-410X(97)00222-3
   Gutierro I, 2002, VACCINE, V21, P67, DOI 10.1016/S0264-410X(02)00435-8
   HARDING CV, 1994, J IMMUNOL, V153, P4925
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Imaoka K, 1998, J IMMUNOL, V161, P5952
   Jiang JQ, 2005, J VIROL, V79, P393, DOI 10.1128/JVI.79.1.393-400.2005
   Johansson EL, 1998, INFECT IMMUN, V66, P514
   Jung T, 2001, PHARMACEUT RES, V18, P352, DOI 10.1023/A:1011063232257                                                         
   Kang K, 2005, MACROMOL BIOSCI, V5, P344, DOI 10.1002/mabi.200400178
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kawamura M, 2005, J MED VIROL, V76, P7, DOI 10.1002/jmv.20317
   Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828                                                         
   MASCOLA JR, 2000, AIDS S, V14, P167
   Matsunaga Y, 2000, VACCINE, V19, P579, DOI 10.1016/S0264-410X(00)00120-1                                                   
   MATSUSAKI M, IN PRESS NANO LETT
   Mazzoli S, 1999, J INFECT DIS, V180, P871, DOI 10.1086/314934                                                                  
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Morris CB, 2000, VACCINE, V18, P1944, DOI 10.1016/S0264-410X(99)00447-8
   Nakaoka R, 1996, VACCINE, V14, P1251, DOI 10.1016/S0264-410X(96)00016-3
   OHAGAN DT, 2002, AIDS, V16, P115
   Reece JC, 2001, IMMUNOL CELL BIOL, V79, P255, DOI 10.1046/j.1440-1711.2001.01011.x                                                
   Staats HF, 1997, AIDS RES HUM RETROV, V13, P945, DOI 10.1089/aid.1997.13.945
   Staats HF, 2001, J IMMUNOL, V167, P5386, DOI 10.4049/jimmunol.167.9.5386                                                     
   Staats HF, 1996, J IMMUNOL, V157, P462
   SUTJIPTO S, 1990, J VIROL, V64, P2290
   Tabata Y, 1996, VACCINE, V14, P1677, DOI 10.1016/S0264-410X(96)00149-1
   Thiele L, 2003, BIOMATERIALS, V24, P1409, DOI 10.1016/S0142-9612(02)00525-2
   TOMMASO A, 1996, INFECT IMMUN, V64, P974
   van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7                                                   
   VanCott TC, 1998, J IMMUNOL, V160, P2000
   Wang X, 2005, IMMUNOL LETT, V98, P123, DOI 10.1016/j.imlet.2004.10.028
   Yoshida M, 2004, J BIOMED MATER RES A, V71A, P45, DOI 10.1002/jbm.a.30131
   Yoshino N, 2004, J IMMUNOL, V173, P6850, DOI 10.4049/jimmunol.173.11.6850                                                    
NR 49
TC 19
Z9 20
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 5
PY 2005
VL 109
IS 1-3
SI SI
BP 49
EP 61
DI 10.1016/j.jconrel.2005.09.014
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 000HA
UT WOS:000234450700007
PM 16256237
DA 2018-01-05
ER

PT J
AU Kleemann, E
   Neu, M
   Jekel, N
   Fink, L
   Schmehl, T
   Gessler, T
   Seeger, W
   Kissel, T
AF Kleemann, E
   Neu, M
   Jekel, N
   Fink, L
   Schmehl, T
   Gessler, T
   Seeger, W
   Kissel, T
TI Nano-carriers for DNA delivery to the lung based upon a TAT-derived
   peptide covalently coupled to PEG-PEI
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article; Proceedings Paper
CT 12th International Symposium on Recent Advances in Drug Delivery Systems
CY FEB 21-24, 2005
CL Salt Lake City, UT
SP Abbott Labs, Ind Technol Res Inst, Nitto Denko Corp, Samyang Corp, Shiseido Res Ctr, Watson Labs
DE pulmonary gene delivery; protein transduction domain; TAT;
   polyethylenimine; lung; PEG
ID PROTEIN TRANSDUCTION DOMAIN; AEROSOL GENE-THERAPY; ARGININE-RICH
   PEPTIDES; IN-VITRO; CELLULAR UPTAKE; TRANSFECTION EFFICIENCY;
   INTRACELLULAR DELIVERY; TRANSGENE EXPRESSION; POLYETHYLENE-GLYCOL;
   CYSTIC-FIBROSIS
AB Gene therapy aimed at the respiratory epithelium holds therapeutic potential for diseases such as cystic fibrosis and lung cancer. Polyethylenimine (PEI) has been utilized for gene delivery to the airways. In this study, we describe a new modification of PEI, in which an oligopeptide related to the protein transduction domain of HIV-1 TAT was covalently coupled to 25 kDa PEI (PEI) through a heterobifunctional polyethylenglycol (PEG) spacer resulting in a TAT-PEG-PEI conjugate. Improved DNA reporter gene complexation and protection was observed for small (similar to 90 nm) polyplexes as well as significantly improved stability against polyanions, Alveofact((R)), bronchial alveolar lining fluid and DNase. To determine polyplex toxicity in vitro, MTT assays were performed and, for in vivo testing, the mice bronchial alveolar lavage was investigated for total cell counts, quantity of neutrophils, total protein and TNF-alpha concentration. All parameters suggest significantly lower toxicity for TAT-PEG-PEI. Transfection efficiencies of both PEI and TAT-PEG-PEI polyplexes with DNA were studied under in vitro conditions (A549) and in mice after intratracheal instillation. While luciferase expression in A549 cells was much lower for TAT-PEG-PEI (0.2 ng/mg protein) than for PEI (2 ng/mg), significantly higher transfection efficiencies for TAT PEG-PEI were detected in mice. Reporter gene expression was distributed through bronchial and alveolar tissue. Thus, TAT-PEG-PEI represents a new approach to non-viral gene carriers for lung therapy, comprising protection for plasmid DNA, low toxicity and significantly enhanced transfection efficiency under in vivo conditions. (c) 2005 Elsevier B.V. All rights reserved.
C1 Univ Marburg, Dept Pharmaceut & Biopharm, D-35037 Marburg, Germany.
   UGLC, D-35392 Giessen, Germany.
RP Kissel, T (reprint author), Univ Marburg, Dept Pharmaceut & Biopharm, Ketzerbach 63, D-35037 Marburg, Germany.
EM Kissel@staff.uni-marburg.de
OI Seeger, Werner/0000-0003-1946-0894
CR Bragonzi A, 2000, GENE THER, V7, P1753, DOI 10.1038/sj.gt.3301282                                                           
   Bremner KH, 2004, BIOCONJUGATE CHEM, V15, P152, DOI 10.1021/bc034140k
   Dailey LA, 2004, J CONTROL RELEASE, V100, P425, DOI 10.1016/j.jconrel.2004.08.031
   Durr E, 2004, NAT BIOTECHNOL, V22, P985, DOI 10.1038/nbt993
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Ernst N, 1999, J GENE MED, V1, P331, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<331::AID-JGM60>3.0.CO;2-8                 
   Fernandex-Carneado J, 2005, J AM CHEM SOC, V127, P869, DOI 10.1021/ja044006q
   Ferrari S, 2002, ADV DRUG DELIVER REV, V54, P1373, DOI 10.1016/S0169-409X(02)00145-X
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142-9612(02)00445-3
   FISCHER D, 2000, BIOMATERIALS DRUG DE, P195
   Fretz MM, 2004, BBA-BIOMEMBRANES, V1665, P48, DOI 10.1016/j.bbamem.2004.06.022
   Funhoff AM, 2004, BIOCONJUGATE CHEM, V15, P1212, DOI 10.1021/bc049864q
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   Gautam A, 2000, MOL THER, V2, P63, DOI 10.1006/mthe.2000.0087
   Gautam A, 2003, MOL BIOTECHNOL, V23, P51, DOI 10.1385/MB:23:1:51
   Gautam A, 2001, MOL THER, V3, P551, DOI 10.1006/mthe.2001.0300
   Gautam A, 2001, GENE THER, V8, P254, DOI 10.1038/sj.gt.3301369
   Gill DR, 2004, CELL MOL LIFE SCI, V61, P355, DOI 10.1007/s00018-003-3317-z
   Godbey WT, 2000, J BIOMED MATER RES, V51, P321, DOI 10.1002/1097-4636(20000905)51:3<321::AID-JBM5>3.3.CO;2-I
   Griesenbach U, 2002, GENE THER, V9, P1344, DOI 10.1038/sj.gt.3301791
   Groneberg DA, 2003, RESP MED, V97, P382, DOI 10.1053/rmed.2002.1457
   Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680
   Hyndman L, 2004, J CONTROL RELEASE, V99, P435, DOI 10.1016/j.jconrel.2004.07.023
   Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018
   Kichler A, 2002, J CONTROL RELEASE, V81, P379, DOI 10.1016/S0168-3659(02)00080-9
   Kircheis R, 2001, J CONTROL RELEASE, V72, P165, DOI 10.1016/S0168-3659(01)00272-3                                                   
   Koping-Hoggard M, 2004, GENE THER, V11, P1441, DOI 10.1038/sj.gt.3302312
   Kunath K, 2003, J GENE MED, V5, P588, DOI 10.1002/jgm.382
   Kunath K, 2002, PHARMACEUT RES, V19, P810, DOI 10.1023/A:1016152831963
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Li L, 2002, BIOCONJUGATE CHEM, V13, P110, DOI 10.1021/bc015535b
   LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Manickam DS, 2005, J CONTROL RELEASE, V102, P293, DOI 10.1016/j.jconrel.2004.09.018
   McKenzie DL, 2000, J BIOL CHEM, V275, P9970, DOI 10.1074/jbc.275.14.9970
   McLachlan G, 2000, GENE THER, V7, P384, DOI 10.1038/sj.gt.3301097
   Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Ogris M, 2003, J CONTROL RELEASE, V91, P173, DOI 10.1016/S0168-3659(03)00230-X
   Ogris M, 1999, GENE THER, V6, P595, DOI 10.1038/sj.gt.3300900
   Petersen H, 2002, BIOMACROMOLECULES, V3, P926, DOI 10.1021/bm025539z
   Petersen H, 2002, BIOCONJUGATE CHEM, V13, P812, DOI 10.1021/bc0255135
   Petersen H, 2002, MACROMOLECULES, V35, P6867, DOI 10.1021/ma012060a
   Reschel T, 2002, J CONTROL RELEASE, V81, P201, DOI 10.1016/S0168-3659(02)00045-7
   Roesnecker J, 2003, J GENE MED, V5, P49, DOI 10.1002/jgm.291
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Rudolph C, 2002, BBA-GEN SUBJECTS, V1573, P75, DOI 10.1016/S0304-4165(02)00334-3
   Sagara K, 2002, J CONTROL RELEASE, V79, P271, DOI 10.1016/S0168-3659(01)00555-7
   Scheller A, 1999, J PEPT SCI, V5, P185, DOI 10.1002/(SICI)1099-1387(199904)5:4<185::AID-PSC184>3.0.CO;2-9
   Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689                                                        
   Siprashvili Z, 2003, HUM GENE THER, V14, P1225, DOI 10.1089/104303403767740768                                                      
   Sung SJ, 2003, BIOL PHARM BULL, V26, P492
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Trubetskoy VS, 1999, BIOCONJUGATE CHEM, V10, P624, DOI 10.1021/bc9801530                                                               
   Tung CH, 2003, ADV DRUG DELIVER REV, V55, P281, DOI 10.1016/S0169-409X(02)00183-7
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wagner E, 2004, PHARM RES, V21, P8, DOI 10.1023/B:PHAM.0000012146.04068.56                                              
NR 61
TC 163
Z9 175
U1 3
U2 55
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 5
PY 2005
VL 109
IS 1-3
SI SI
BP 299
EP 316
DI 10.1016/j.jconrel.2005.09.036
PG 18
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 000HA
UT WOS:000234450700028
PM 16298009
DA 2018-01-05
ER

PT J
AU Wabuyele, MB
   Vo-Dinh, T
AF Wabuyele, MB
   Vo-Dinh, T
TI Detection of human immunodeficiency virus type 1 DNA sequence using
   plasmonics nanoprobes
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID SURFACE-ENHANCED RAMAN; MOLECULAR BEACONS; SILVER ELECTRODE; P24
   ANTIGEN; PCR ASSAY; INFECTION; SCATTERING; RNA; PLASMA; PROBES
AB This paper describes the use of plasmonics-based nanoprobes that act as molecular sentinels for DNA diagnostics. The plasmonics nanoprobe comprises a metal nanoparticle and a stem-loop DNA molecule tagged with a Raman label. The nanoprobe utilizes the specificity and selectivity of the DNA hairpin probe sequence to detect a specific target DNA sequence of interest. In the absence of target DNA, the stem-loop configuration maintains the Raman label in proximity to the metal nanoparticle, inducing an intense surface-enhanced Raman scattering (SERS) effect that produces a strong Raman signal upon laser excitation. Upon hybridization of a complementary target DNA sequence to the nanoprobe, the stem-loop configuration is disrupted, causing the Raman label to physically separate from the metal nanoparticle, thus quenching the SERS signal. The usefulness and potential application of the plasmonics nanoprobe for diagnosis is demonstrated using the gag gene sequence of the human immunodeficiency virus type 1 (HIV-1). We successfully demonstrated the specificity and selectivity of the plasmonics nanoprobes to detect PCR amplicons of the HIV gene. The potential for combining the spectral selectivity and high sensitivity of the SERS process with inherent molecular specificity of DNA hairpins to diagnose molecular target sequences in homogeneous solutions is discussed.
C1 Oak Ridge Natl Lab, Ctr Adv Biomed Photon, Oak Ridge, TN 37831 USA.
RP Vo-Dinh, T (reprint author), Oak Ridge Natl Lab, Ctr Adv Biomed Photon, POB 2008, Oak Ridge, TN 37831 USA.
EM vodinht@ornl.gov
CR ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   Campion A, 1998, CHEM SOC REV, V27, P241, DOI 10.1039/a827241z                                                                
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Du H, 2005, J AM CHEM SOC, V127, P7932, DOI 10.1021/ja042482a
   Dubertret B, 2001, NAT BIOTECHNOL, V19, P365, DOI 10.1038/86762                                                                   
   Fan CH, 2003, P NATL ACAD SCI USA, V100, P9134, DOI 10.1073/pnas.1633515100
   Graham D, 2000, ANGEW CHEM INT EDIT, V39, P1061, DOI 10.1002/(SICI)1521-3773(20000317)39:6<1061::AID-ANIE1061>3.0.CO;2-9             
   HILDEBRANDT P, 1984, J PHYS CHEM-US, V88, P5935, DOI 10.1021/j150668a038
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6
   Jin RC, 2003, J AM CHEM SOC, V125, P1643, DOI 10.1021/ja021096v
   Kneipp K, 1998, APPL SPECTROSC, V52, P1493, DOI 10.1366/0003702981943059                                                        
   Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667
   LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983
   LEE PC, 1982, J PHYS CHEM-US, V86, P3391, DOI 10.1021/j100214a025                                                             
   Leone G, 1998, NUCLEIC ACIDS RES, V26, P2150, DOI 10.1093/nar/26.9.2150
   LIVAK KJ, 1995, PCR METH APPL, V4, P1
   Maxwell DJ, 2002, J AM CHEM SOC, V124, P9606, DOI 10.1021/ja025814p
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   MILES SA, 1993, NEW ENGL J MED, V328, P297, DOI 10.1056/NEJM199302043280501                                                     
   MULDER J, 1994, J CLIN MICROBIOL, V32, P292
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105
   Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003
   PANTALEO G, 1993, NEW ENGL J MED, V328, P327
   SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227
   SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460
   Schwartz SA, 1999, CLIN DIAGN LAB IMMUN, V6, P295
   Sutthent R, 2003, J CLIN MICROBIOL, V41, P1016, DOI 10.1128/JCM.41.3.1016-1022.2003
   Thelwell N, 2000, NUCLEIC ACIDS RES, V28, P3752, DOI 10.1093/nar/28.19.3752
   Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303
   *UNAIDS WHO, 2001, JOINT UN PROGR HIV A
   Vet JAM, 1999, P NATL ACAD SCI USA, V96, P6394, DOI 10.1073/pnas.96.11.6394
   Vo-Dinh T, 1998, TRAC-TREND ANAL CHEM, V17, P557, DOI 10.1016/S0165-9936(98)00069-7                                                   
   WOLKOW RA, 1987, J CHEM PHYS, V87, P5858, DOI 10.1063/1.453508
NR 34
TC 155
Z9 158
U1 3
U2 75
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD DEC 1
PY 2005
VL 77
IS 23
BP 7810
EP 7815
DI 10.1021/ac0514671
PG 6
WC Chemistry, Analytical
SC Chemistry
GA 991BA
UT WOS:000233785900049
PM 16316192
DA 2018-01-05
ER

PT J
AU Wiwanitkit, V
AF Wiwanitkit, V
TI HIV transmission from mother to child: an aspect on the placenta barrier
   at the nano-level
SO AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY
LA English
DT Letter
C1 Chulalongkorn Univ, Dept Lab Med, Fac Med, Bangkok, Thailand.
RP Wiwanitkit, V (reprint author), Chulalongkorn Univ, Dept Lab Med, Fac Med, Bangkok, Thailand.
CR CHALLIER JC, 1989, REPROD NUTR DEV, V29, P703, DOI 10.1051/rnd:19890609
   Schwartz DA, 2000, J INFECT DIS, V182, P1652, DOI 10.1086/317634
   Soilleux EJ, 2003, INT J BIOCHEM CELL B, V35, P283, DOI 10.1016/S1357-2725(02)00132-2
   Vidricaire G, 2004, M S-MED SCI, V20, P784, DOI 10.1051/medsci/2004208-9784
   Wabwire-Mangen F, 1999, J ACQ IMMUN DEF SYND, V22, P379
NR 5
TC 6
Z9 6
U1 0
U2 0
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0004-8666
J9 AUST NZ J OBSTET GYN
JI Aust. N. Z. J. Obstet. Gynaecol.
PD DEC
PY 2005
VL 45
IS 6
BP 539
EP 540
DI 10.1111/j.1479-828X.2005.00500.x
PG 3
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 987PY
UT WOS:000233531000025
PM 16401231
DA 2018-01-05
ER

PT J
AU Chellat, F
   Merhi, Y
   Moreau, A
   Yahia, L
AF Chellat, F
   Merhi, Y
   Moreau, A
   Yahia, L
TI Therapeutic potential of nanoparticulate systems for macrophage
   targeting
SO BIOMATERIALS
LA English
DT Review
DE review; macrophage targeting; nanoparticles; inflammatory diseases
ID EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SOLID LIPID NANOPARTICLES;
   TUMOR-NECROSIS-FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; EXPERIMENTAL
   AUTOIMMUNE ENCEPHALOMYELITIS; ANIONIC SUPERPARAMAGNETIC NANOPARTICLES;
   INTRACELLULAR LEISHMANIA-DONOVANI; PLASMA-PROTEIN ADSORPTION; ACUTE
   CORONARY SYNDROMES; CENTRAL-NERVOUS-SYSTEM
AB The use of non-viral nanoparticulate systems for the delivery of therapeutic agents is receiving considerable attention for medical and pharmaceutical applications. This increasing interest results from the fact that these systems can be designed to meet specific physicochemical requirements, and they display low toxic and immunogenic effects. Among potential cellular targets by drug-loaded nanoparticles, macrophages are considered because they play a central role in inflammation and they act as reservoirs for microorganisms that are involved with deadly infectious diseases. The most common and potent drugs used in macrophage-mediated diseases treatment often induce unwanted side effects, when applied as a free form, due to the necessity of high doses to induce a satisfactory effect. This could result in their systemic spreading, a lack of bioavailability at the desired sites, and a short half-life. Therefore, the use of drug-loaded nanoparticles represents a good alternative to avoid, or at least decrease, side effects and increase efficacy. In this manuscript, we present an overview of the usefulness of nanoparticles for macrophage-mediated therapies in particular. We discuss, though not exhaustively, the potential of therapeutic agent-loaded nanoparticles for some macrophage-mediated diseases. We also underline the most important parameters that affect the interaction mechanisms of the macrophages and the physicochemical aspects of the particulate systems that may influence their performance in macrophage-targeted therapies. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Ecole Polytech, Biomed Engn Inst, Montreal, PQ H3C 3A7, Canada.
   Univ Montreal, Lab Pathol Expt, Inst Cardiol Montreal, Montreal, PQ H1T 1C8, Canada.
   Hop St Justine, Ctr Rech, Lab Genet Mol Os & Malformat Squelett, Montreal, PQ H3T 1C5, Canada.
RP Chellat, F (reprint author), Ecole Polytech, Biomed Engn Inst, CP 6079,Succursale Ctr Ville, Montreal, PQ H3C 3A7, Canada.
EM Fatiha.Chellat@polymtl.ca; yahye.merhi@icm-mhi.org;
   Alain.moreau@recherche-ste-justine.qc.ca; Yahia@grbb.polymtl.ca
RI Mahapatra, Indrani/D-7506-2011; Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
CR AKHTAR S, 1991, NUCLEIC ACIDS RES, V19, P5551, DOI 10.1093/nar/19.20.5551
   ALLEN TM, 1994, TRENDS PHARMACOL SCI, V15, P215, DOI 10.1016/0165-6147(94)90314-X
   ALVING C R, 1988, Advanced Drug Delivery Reviews, V2, P107, DOI 10.1016/0169-409X(88)90007-5
   Andreesen R, 1998, J LEUKOCYTE BIOL, V64, P419
   Arnedo A, 2002, INT J PHARM, V244, P59, DOI 10.1016/S0378-5173(02)00300-9                                                   
   AUDRAN R, 1995, NUCL MED BIOL, V22, P817, DOI 10.1016/0969-8051(95)00013-N
   Avrameas A, 1996, EUR J IMMUNOL, V26, P394, DOI 10.1002/eji.1830260219
   Balland O, 1996, J ANTIMICROB CHEMOTH, V37, P105, DOI 10.1093/jac/37.1.105
   Bauer J, 1995, GLIA, V15, P437, DOI 10.1002/glia.440150407
   BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   BENEFRAIM S, 1994, MED ONCOL, V11, P7, DOI 10.1007/BF02990085
   Benveniste EN, 1997, J MOL MED-JMM, V75, P165, DOI 10.1007/s001090050101
   Berton M, 1999, EUR J PHARM SCI, V9, P163, DOI 10.1016/S0928-0987(99)00049-4
   BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.iy.07.040189.003205
   Billotey C, 2003, MAGNET RESON MED, V49, P646, DOI 10.1002/mrm.10418
   BLUNK T, 1993, ELECTROPHORESIS, V14, P1382, DOI 10.1002/elps.11501401214
   Bocca C, 1998, INT J PHARM, V175, P185, DOI 10.1016/S0378-5173(98)00282-8
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Brannon-Peppas L, 2004, ADV DRUG DELIVER REV, V56, P1649, DOI 10.1016/j.addr.2004.02.014
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   BROSNAN CF, 1981, J IMMUNOL, V126, P614
   Brus C, 2004, EUR J PHARM BIOPHARM, V57, P427, DOI 10.1016/j.ejph.2004.02.004
   Calvo P, 2002, EUR J NEUROSCI, V15, P1317, DOI 10.1046/j.1460-9568.2002.01967.x                                                
   Camner P, 2002, J APPL PHYSIOL, V92, P2608, DOI 10.1152/japplphysiol.01067.2001
   CHAVANY C, 1992, PHARMACEUT RES, V9, P441, DOI 10.1023/A:1015871809313
   Chellat F, 2005, BIOMATERIALS, V26, P961, DOI 10.1016/j.biomaterials.2004.04.006
   CHIA JKS, 1989, J INFECT DIS, V159, P113, DOI 10.1093/infdis/159.1.113                                                        
   Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006
   CHOKRI M, 1990, INT J IMMUNOL, V1, P79
   Chroneos Z, 1995, AM J PHYSIOL-LUNG C, V269, pL721
   CLARK RA, 1976, J CELL BIOL, V70, P719, DOI 10.1083/jcb.70.3.719
   CLEARY JD, 1992, ANTIMICROB AGENTS CH, V36, P977, DOI 10.1128/AAC.36.5.977                                                            
   Coester CJ, 2000, J MICROENCAPSUL, V17, P187
   COUVREUR P, 1979, J PHARM SCI, V68, P1521, DOI 10.1002/jps.2600681215                                                          
   COUVREUR P, 1988, CRIT REV THER DRUG, V5, P1
   Crooke ST, 2004, ANNU REV MED, V55, P61, DOI 10.1146/annurev.med.55.091902.104408
   Cruz T, 1997, PHARMACEUT RES, V14, P73, DOI 10.1023/A:1012059501947
   Cui ZG, 2004, PHARM RES, V21, P1018, DOI 10.1023/B:PHAM.0000029292.66792.4f
   Cui ZR, 2003, DRUG DEV IND PHARM, V29, P689, DOI 10.1081/DDC-120021318
   DAMGE C, 1988, DIABETES, V37, P246, DOI 10.2337/diabetes.37.2.246
   DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762
   DENIAU M, 1993, ANN PARASIT HUM COMP, V68, P34
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863
   East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7
   Egashira K, 2000, FASEB J, V14, P1974, DOI 10.1096/fj.00-0141com                                                           
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   ELFERINK JGR, 1985, INFLAMMATION, V9, P321, DOI 10.1007/BF00916280
   Espuelas MS, 2002, J DRUG TARGET, V10, P593, DOI 10.1080/1061186021000060738
   Fattal E, 1998, J CONTROL RELEASE, V53, P137, DOI 10.1016/S0168-3659(97)00246-0                                                   
   FELDMAN LJ, 1995, J AM COLL CARDIOL, V26, P826, DOI 10.1016/0735-1097(95)00235-V
   Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802
   Fidler I J, 1994, Adv Pharmacol, V30, P271, DOI 10.1016/S1054-3589(08)60177-5
   FIDLER IJ, 1974, CANCER RES, V34, P1074
   Fontana G, 2001, BIOMATERIALS, V22, P2857, DOI 10.1016/S0142-9612(01)00030-8                                                   
   FORESTIER F, 1992, J ANTIMICROB CHEMOTH, V30, P173, DOI 10.1093/jac/30.2.173
   FUSTER V, 1995, AM J CARDIOL, V76, P24
   GALLAGHER JE, 1987, AM REV RESPIR DIS, V135, P1345
   GASPAR R, 1992, ANN TROP MED PARASIT, V86, P41, DOI 10.1080/00034983.1992.11812629                                                  
   GASPAR R, 1992, PHARMACEUT RES, V9, P782, DOI 10.1023/A:1015807706530
   Gbadamosi JK, 2002, FEBS LETT, V532, P338, DOI 10.1016/S0014-5793(02)03710-9
   GELFAND JA, 1988, CLIN RES, V36, P456
   GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011                                                             
   Gessner A, 2000, INT J PHARM, V196, P245, DOI 10.1016/S0378-5173(99)00432-9
   Gibaud S, 1996, J PHARM SCI, V85, P944, DOI 10.1021/js960032d
   GIBAUD S, 1994, EUR J CANCER, V30A, P820, DOI 10.1016/0959-8049(94)90299-2
   Gibaud S., 1999, Annales Pharmaceutiques Francaises, V57, P324
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556                                                                
   Hartmann G, 1996, ANTISENSE NUCLEIC A, V6, P291, DOI 10.1089/oli.1.1996.6.291
   Hattori Y, 2004, BIOCHEM BIOPH RES CO, V317, P992, DOI 10.1016/j.bbrc.2004.03.141
   Hegyi L, 2001, J HEMATOTH STEM CELL, V10, P27, DOI 10.1089/152581601750098192
   HENRYTOULME N, 1995, BIOCHEM PHARMACOL, V50, P1135, DOI 10.1016/0006-2952(95)00226-P
   Hsu Cheng-Hsuan, 2003, AAPS PharmSciTech, V4, pE32
   HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025                                                          
   II M, 1988, J BIOCHEM-TOKYO, V104, P587
   ILLUM L, 1987, LIFE SCI, V40, P367, DOI 10.1016/0024-3205(87)90138-X
   Ito Takayuki, 2003, Current Drug Targets - Inflammation and Allergy, V2, P257, DOI 10.2174/1568010033484106
   JIANG YL, 1992, J IMMUNOL, V148, P2423
   Kakizawa Y, 2004, J CONTROL RELEASE, V97, P345, DOI 10.1016/j.jconrel.2004.03.031
   KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355
   KOBZIK L, 1995, J IMMUNOL, V155, P367
   KOLBBACHOFEN V, 1991, CARBOHYD RES, V213, P201, DOI 10.1016/S0008-6215(00)90609-8                                                   
   Kolodgie FD, 2002, CIRCULATION, V106, P1195, DOI 10.1161/01.CIR.0000032141.31476.15
   KOPFLER WP, 1994, CIRCULATION, V90, P1319
   KRAUSS JC, 1994, J IMMUNOL, V153, P1769
   Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077
   KRIEGER M, 1993, J BIOL CHEM, V268, P4569
   Kumar MNVR, 2004, EXPERT OPIN BIOL TH, V4, P1213, DOI 10.1517/14712598.4.8.1213                                                       
   Labhasetwar V, 1998, J PHARM SCI, V87, P1229, DOI 10.1021/js980021f
   Lambert G, 1998, BIOCHIMIE, V80, P969, DOI 10.1016/S0300-9084(99)80002-9
   Lambert G, 2001, INT J PHARM, V214, P13, DOI 10.1016/S0378-5173(00)00624-4
   LARGENT BL, 1984, J BIOL CHEM, V259, P1764
   LEEPERWOODFORD SK, 1991, AM REV RESPIR DIS, V143, P1076, DOI 10.1164/ajrccm/143.5_Pt_1.1076                                                  
   LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705                                                               
   Leonetti JP, 1990, BIOCONJUGATE CHEM, V1, P149, DOI 10.1021/bc00002a010
   LEROUX JC, 1995, EUR J PHARM BIOPHARM, V41, P14
   LEROUX JC, 1995, LIFE SCI, V57, P695, DOI 10.1016/0024-3205(95)00321-V                                                    
   LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553
   LEU D, 1984, J PHARM SCI, V73, P1433, DOI 10.1002/jps.2600731028
   Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683
   Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482
   Libby P, 2001, CIRCULATION, V104, P365
   Litzinger DC, 1996, BBA-BIOMEMBRANES, V1281, P139, DOI 10.1016/0005-2736(95)00268-5
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   Lobenberg R, 1996, AIDS RES HUM RETROV, V12, P1709, DOI 10.1089/aid.1996.12.1709
   LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474
   Lourenco C, 1996, INT J PHARM, V138, P1, DOI 10.1016/0378-5173(96)04486-9
   Lowery MM, 2003, ANN ALLERG ASTHMA IM, V91, P460, DOI 10.1016/S1081-1206(10)61514-1                                                   
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Mainardes RM, 2004, CURR DRUG TARGETS, V5, P449, DOI 10.2174/1389450043345407
   Mayne M, 1999, ANTISENSE NUCLEIC A, V9, P135, DOI 10.1089/oli.1.1999.9.135
   MCEVER RP, 1997, J CLIN INVEST, V100, P97
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Merodio M, 2000, J DRUG TARGET, V8, P289, DOI 10.3109/10611860008997907                                                       
   MISKO TP, 1995, J NEUROIMMUNOL, V61, P195, DOI 10.1016/0165-5728(95)00091-F                                                    
   Moghimi SM, 2003, PROG LIPID RES, V42, P463, DOI 10.1016/S0163-7827(03)00033-X
   Moghimi SM, 2001, PHARMACOL REV, V53, P283
   MORENO PR, 1994, CIRCULATION, V90, P775
   MORISHITA R, 1994, GENE, V149, P13, DOI 10.1016/0378-1119(94)90406-5
   Olbrich C, 2004, J PHARM PHARMACOL, V56, P883, DOI 10.1211/0022357023754
   Pack DW, 2000, BIOTECHNOL BIOENG, V67, P217, DOI 10.1002/(SICI)1097-0290(20000120)67:2<217::AID-BIT11>3.0.CO;2-Q
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com
   Peracchia MT, 1999, BIOMATERIALS, V20, P1269, DOI 10.1016/S0142-9612(99)00021-6
   PINTOALPHANDARY H, 1994, PHARMACEUT RES, V11, P38, DOI 10.1023/A:1018985308984                                                         
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   PRICER WE, 1971, J BIOL CHEM, V246, P4825
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   Rabinovich GA, 2000, MEM I OSWALDO CRUZ, V95, P225, DOI 10.1590/S0074-02762000000700038                                                 
   Raitakari OT, 2000, FREE RADICAL BIO MED, V28, P1100, DOI 10.1016/S0891-5849(00)00201-X                                                   
   Raynal I, 2004, INVEST RADIOL, V39, P56, DOI 10.1097/01.rli.0000101027.57021.28
   RENNO T, 1995, J IMMUNOL, V154, P944
   Rihova B, 2002, ADV DRUG DELIVER REV, V54, P653
   Rodrigues JM, 1995, INT J PARASITOL, V25, P1437, DOI 10.1016/0020-7519(95)00055-0
   RODRIGUES JM, 1994, TROP MED PARASITOL, V45, P223
   Rollins BJ, 1997, BLOOD, V90, P909
   ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1
   Roser M, 1998, EUR J PHARM BIOPHARM, V46, P255, DOI 10.1016/S0939-6411(98)00038-1
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207                                                     
   Saika T, 2004, CANCER GENE THER, V11, P317, DOI 10.1038/sj.cgt.7700709
   Sakuma S, 2002, INT J PHARM, V239, P185, DOI 10.1016/S0378-5173(02)00113-8
   Sarkar S, 2002, J DRUG TARGET, V10, P573, DOI 10.1080/106118021000072681
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Scholer N, 2002, INT J PHARM, V231, P167, DOI 10.1016/S0378-5173(01)00882-1
   Scholer N, 2000, INT J PHARM, V196, P235, DOI 10.1016/S0378-5173(99)00430-5                                                   
   SCHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460, DOI 10.1073/pnas.91.22.10460                                                        
   Skidan I. N., 2003, Antibiotiki i Khimioterapiya, V48, P23
   Soma CE, 2000, BIOMATERIALS, V21, P1
   STAHL P, 1980, CELL, V19, P207, DOI 10.1016/0092-8674(80)90402-X
   STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1
   Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   Sutterwala FS, 1996, J LEUKOCYTE BIOL, V59, P883
   TABATA Y, 1988, BIOMATERIALS, V9, P356, DOI 10.1016/0142-9612(88)90033-6
   Taylor MF, 1996, J BIOL CHEM, V271, P17445, DOI 10.1074/jbc.271.29.17445                                                        
   THOMAS ED, 1976, SCIENCE, V192, P1016, DOI 10.1126/science.775638
   Uwatoku T, 2003, CIRC RES, V92, pE62, DOI 10.1161/01.RES.0000069021.56380.E2
   Gillman CF, 1975, PHAGOCYTIC ENGULFMEN
   Vauthier C, 2003, ADV DRUG DELIVER REV, V55, P519, DOI 10.1016/S0169-409X(03)00041-3
   VERDUN C, 1990, CANCER CHEMOTH PHARM, V26, P13, DOI 10.1007/BF02940287
   WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934
   WARR GA, 1980, BIOCHEM BIOPH RES CO, V93, P737, DOI 10.1016/0006-291X(80)91139-0                                                    
   Wilhelm C, 2003, BIOMATERIALS, V24, P1001, DOI 10.1016/S0142-9612(02)00440-4
   Wilhelm C, 2002, LANGMUIR, V18, P8148, DOI 10.1021/la0257337
   Witting PK, 2000, FREE RADICAL BIO MED, V29, P295, DOI 10.1016/S0891-5849(00)00311-7
   Wolfert MA, 1996, GENE THER, V3, P269
   YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454
   Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191
   Yamamoto T, 2000, J IMMUNOL, V164, P6174, DOI 10.4049/jimmunol.164.12.6174                                                    
   Zambaux MF, 2000, BIOMATERIALS, V21, P975, DOI 10.1016/S0142-9612(99)00233-1
   Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493
   Zhang Q., 1996, Yaoxue Xuebao, V31, P375
   Zhang WD, 2005, NAT MED, V11, P56, DOI 10.1038/nm1174
   Zimmer A, 1999, METHODS, V18, P286, DOI 10.1006/meth.1999.0786
   Zobel HP, 2000, EUR J PHARM BIOPHARM, V49, P203, DOI 10.1016/S0939-6411(00)00080-1
   BAZILE D, 1991, Patent No. [8041, 08041]
NR 180
TC 156
Z9 158
U1 2
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2005
VL 26
IS 35
BP 7260
EP 7275
DI 10.1016/j.biomaterials.2005.05.044
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
SC Engineering; Materials Science
GA 962RP
UT WOS:000231750200007
PM 16023200
DA 2018-01-05
ER

PT J
AU Himmel, DM
   Das, K
   Clark, AD
   Hughes, SH
   Benjahad, A
   Oumouch, S
   Guillemont, J
   Coupa, S
   Poncelet, A
   Csoka, I
   Meyer, C
   Andries, K
   Nguyen, CH
   Grierson, DS
   Arnold, E
AF Himmel, DM
   Das, K
   Clark, AD
   Hughes, SH
   Benjahad, A
   Oumouch, S
   Guillemont, J
   Coupa, S
   Poncelet, A
   Csoka, I
   Meyer, C
   Andries, K
   Nguyen, CH
   Grierson, DS
   Arnold, E
TI Crystal structures for HIV-1 reverse transcriptase in complexes with
   three pyridinone derivatives: A new class of non-nucleoside inhibitors
   effective against a broad range of drug-resistant strains
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; TEMPLATE-PRIMER UTILIZATION; ANTIBODY FAB
   FRAGMENT; DOUBLE-STRANDED DNA; IN-VITRO EVALUATION; ANGSTROM RESOLUTION;
   WILD-TYPE; POSITIONAL ADAPTABILITY; CONFORMATIONAL-CHANGES; MUTANT
   STRAINS
AB In the treatment of AIDS, the efficacy of all drugs, including non-nucleoside inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT), has been limited by the rapid appearance of drug-resistant viruses. Lys103Asn, Tyr181Cys, and Tyr188Leu are some of the most common RT mutations that cause resistance to NNRTIs in the clinic. We report X-ray crystal structures for RT complexed with three different pyridinone derivatives, R157208, R165481, and R221239, at 2.95, 2.9, and 2.43 angstrom resolution, respectively. All three ligands exhibit nanomolar or subnanomolar inhibitory activity against wild-type RT, but varying activities against drug-resistant mutants. R165481 and R221239 differ from most NNRTIs in that binding does not involve significant contacts with Tyr181. These compounds strongly inhibit wild-type HIV-1 RT and drug-resistant variants, including Tyr181Cys and Lys103Asn RT. These properties result in part from an iodine atom on the pyridinone ring of both inhibitors that interacts with the main-chain carbonyl oxygen of Tyr188. An acrylonitrile substituent on R165481 substantially improves the activity of the compound against wild-type RT (and several mutants) and provides a way to generate novel inhibitors that could interact with conserved elements of HIV-1 RT at the polymerase catalytic site. In R221239, there is a flexible linker to a furan ring that permits interactions with Val106, Phe227, and Pro236. These contacts appear to enhance the inhibitory activity of R221239 against the HIV-1 strains that carry the Val106Ala, Tyr188Leu, and Phe227Cys mutations.
C1 Rutgers State Univ, CABM, Piscataway, NJ 08854 USA.
   Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.
   NCI, HIV Drug Resistance Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.
   Ctr Univ Orsay, Lab Pharmacochim, Sect Rech, UMR 176,CNRS,Inst Curie, F-91405 Orsay, France.
   Johnson & Johnson Pharmaceut Res & Dev, Dept Med Chem, Val De Reuil, France.
   Johnson & Johnson Pharmaceut Res & Dev, Virol Drug Discovery, B-2340 Beerse, Belgium.
RP Arnold, E (reprint author), Rutgers State Univ, CABM, Piscataway, NJ 08854 USA.
EM arnold@cabm.rutgers.edu
FU NIGMS NIH HHS [P01 GM 066671]; NIAID NIH HHS [F32 AI 060300, AI 27690]
CR Arnold E, 1996, Drug Des Discov, V13, P29
   Auffinger P, 2004, P NATL ACAD SCI USA, V101, P16789, DOI 10.1073/pnas.0407607101
   Benjahad A, 2005, J MED CHEM, V48, P1948, DOI 10.1021/jm0408621
   Benjahad A, 2004, J MED CHEM, V47, P5501, DOI 10.1021/jm0407658
   Benjahad A, 2003, BIOORG MED CHEM LETT, V13, P4309, DOI 10.1016/j.bmcl.2003.09.045
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Clark AD, 1995, METHOD ENZYMOL, V262, P171
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   COFFIN JM, 1997, RETROVIRUSES
   Das K, 2005, PROG BIOPHYS MOL BIO, V88, P209, DOI 10.1016/j.pbiomolbio.2004.07.001
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Ding J, 1997, STRUCTURE BASED DRUG, P41
   Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j                                                               
   Ghosh M, 2000, ACTA CRYSTALLOGR D, V56, P1085, DOI 10.1107/S0907444900008568
   Guillemont J, 2005, J MED CHEM, V48, P2072, DOI 10.1021/jm040838n
   HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3
   Hsiou Y, 1998, J MOL BIOL, V284, P313, DOI 10.1006/jmbi.1998.2171
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   JACQUES PS, 1994, J BIOL CHEM, V269, P26472
   Janssen PAJ, 2005, J MED CHEM, V48, P1901, DOI 10.1021/jm040840e
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   KRAULIS PJ, 1998, MOLSCRIPT 2 2 2
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597                                                       
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   OTWINOWSKI Z, 2001, CRYSTALLOGRAPHY BIOL, VF, P226
   Pelemans H, 2000, MOL PHARMACOL, V57, P954
   Ren J, 2005, TRENDS PHARMACOL SCI, V26, P4, DOI 10.1016/j.tips.2004.11.003
   Ren J, 2004, J MOL BIOL, V336, P569, DOI 10.1016/j.jmb.2003.12.055
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   Sarafianos SG, 2004, CURR OPIN STRUC BIOL, V14, P716, DOI 10.1016/j.sbi.2004.10.013
   Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449
   *SCHR LLC, 2004, MAESTR MOL MOD INT 6
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Udier-Blagovic M, 2003, BIOORG MED CHEM LETT, V13, P3337, DOI 10.1016/S0960-894X(03)00681-4
   Wang DP, 2001, BIOORG MED CHEM LETT, V11, P2799, DOI 10.1016/S0960-894X(01)00510-8
   Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581                                                        
   Wojtczak A, 1996, ACTA CRYSTALLOGR D, V52, P758, DOI 10.1107/S0907444996003046
   Yadav PNS, 1998, THEOCHEM-J MOL STRUC, V423, P101, DOI 10.1016/S0166-1280(96)04996-2                                                   
   YOUNG C, 2004, POVRAY 3 6
NR 56
TC 104
Z9 105
U1 0
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 1
PY 2005
VL 48
IS 24
BP 7582
EP 7591
DI 10.1021/jm0500323
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 989EE
UT WOS:000233654900008
PM 16302798
DA 2018-01-05
ER

PT J
AU Guo, PX
AF Guo, PX
TI RNA nanotechnology: Engineering, assembly and applications in detection,
   gene delivery and therapy
SO JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
LA English
DT Review
DE RNA; nanotechnology; self-assembly; RNA application; phi29 pRNA
ID BICOID MESSENGER-RNA; PHAGE PHI 29; ATOMIC-FORCE MICROSCOPY; DNA
   PACKAGING MOTOR; IN-VITRO SELECTION; RIBONUCLEASE-P RNA; CHEMICAL
   MODIFICATION INTERFERENCE; BACTERIOPHAGE-PHI-29 PROHEAD RNA;
   RECEPTOR-MEDIATED ENDOCYTOSIS; NUCLEAR MAGNETIC-RESONANCE
AB Biological macromolecules including DNA, RNA, and proteins, have intrinsic features that make W them potential building blocks for the bottom-up fabrication of nanodevices. RNA is unique in nanoscale fabrication due to its amazing diversity of function and structure. RNA molecules can be designed and manipulated with a level of simplicity characteristic of DNA while possessing versatility in structure and function similar to that of proteins. RNA molecules typically contain a large variety of single stranded loops suitable for inter- and intra-molecular interaction. These loops can serve as mounting dovetails obviating the need for external linking dowels in fabrication and assembly.
   The self-assembly of nanoparticles from RNA involves cooperative interaction of individual RNA molecules that spontaneously assemble in a predefined manner to form a larger two- or three-dimensional structure. Within the realm of self-assembly there are two main categories, namely template and non-template. Template assembly involves interaction of RNA molecules under the influence of specific external sequence, forces, or spatial constraints such as RNA transcription, hybridization, replication, annealing, molding, or replicas. In contrast, non-template assembly involves formation of a larger structure by individual components without the influence of external forces. Examples of non-template assembly are ligation, chemical conjugation, covalent linkage, and loop/loop interaction of RNA, especially the formation of RNA multimeric complexes. The best characterized RNA multiplier and the first to be described in RNA nanotechnological application is the motor pRNA of bacteriophage phi29 which form dimers, trimers, and hexamers, via hand-in-hand interaction. phi29 pRNA can be redesigned to form a variety of structures and shapes including twins, tetramers, rods, triangles, and 3D arrays several microns in size via interaction of programmed helical regions and loops. 3D RNA array formation requires a defined nucleotide number for twisting and a palindromic sequence. Such arrays are unusually stable and resistant to a wide range of temperatures, salt concentrations, and pH. Both the therapeutic siRNA or ribozyme and a receptor-binding RNA aptamer or other ligands have been engineered into individual pRNAs. Individual chimeric RNA building blocks harboring siRNA or other therapeutic molecules have been fabricated subsequently into a trimer through hand-in-hand interaction of the engineered right and left interlocking RNA loops. The incubation of these particles containing the receptor-binding aptamer or other ligands results in the binding and co-entry of trivalent therapeutic particles into cells. Such particles were subsequently shown to modulate the apoptosis of cancer cells in both cell cultures and animal trials. The use of such antigen-free 20-40 nm particles holds promise for the repeated long-term treatment of chronic diseases. Other potentially useful RNA molecules that form multimers include HIV RNA that contain kissing loop to form dimers, tecto-RNA that forms a "jigsaw puzzle," and the Drosophila bicoid mRNA that forms multimers; via "hand-by-arm" interactions.
   Applications of RNA molecules involving replication, molding, embossing, and other related techniques, have recently been described that allow the utilization of a variety of materials to enhance diversity and resolution of nanomaterials. It should eventually be possible to adapt RNA to facilitate construction of ordered, patterned, or pre-programmed arrays or superstructures. Given the potential for 3D fabrication, the chance to produce reversible self-assembly, and the ability of self-repair, editing and replication, RNA self-assembly will play an increasingly significant role in integrated biological nanofabrication. A random 100-nucleotide RNA library may exist in 1.6 x 10(60) varieties with multifarious structure to serve as a vital system for efficient fabrication, with a complexity and diversity far exceeding that of any current nanoscale system.
   This review covers the basic concepts of RNA structure and function, certain methods for the study of RNA structure, the approaches for engineering or fabricating RNA into nanoparticles or arrays, and special features of RNA molecules that form multimers. The most recent development in exploration of RNA nanoparticles for pathogen detection, drug/gene delivery, and therapeutic application is also introduced in this review.
C1 Purdue Univ, Purdue Canc Ctr, Dept Pathobiol, W Lafayette, IN 47906 USA.
   Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47906 USA.
RP Guo, PX (reprint author), Purdue Univ, Purdue Canc Ctr, Dept Pathobiol, W Lafayette, IN 47906 USA.
RI Guo, Peixuan/I-7184-2015
FU NIGMS NIH HHS [R01 GM059944, R01 GM059944-05A2, R01-GM59944]; NIBIB NIH
   HHS [R01 EB003730, R01 EB003730-01, R01-EB003730]
CR Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0
   Andersen ES, 2004, J BIOL CHEM, V279, P22243, DOI 10.1074/jbc.M314326200
   AYBACK P, 1993, J BIOCHEM BIOPH METH, V27, P229
   BABCOCK MS, 1994, J MOL BIOL, V237, P125, DOI 10.1006/jmbi.1994.1213
   BAILEY S, 1990, J BIOL CHEM, V265, P22365
   Baneyx G, 2002, P NATL ACAD SCI USA, V99, P5139, DOI 10.1073/pnas.072650799
   BAZINET C, 1988, BIOCHEMISTRY-US, V27, P1849, DOI 10.1021/bi00406a009
   BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013
   Berry RM, 2000, PHILOS T ROY SOC B, V355, P503, DOI 10.1098/rstb.2000.0591
   BLACK LW, 1995, BIOESSAYS, V17, P1025, DOI 10.1002/bies.950171206                                                          
   Bouvet P, 2001, Methods Mol Biol, V148, P603
   BRATTY J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P345, DOI 10.1016/0167-4781(93)90001-T
   Braun PV, 1996, NATURE, V380, P325, DOI 10.1038/380325a0                                                                
   Brereton HM, 2001, BBA-MOL CELL RES, V1540, P107, DOI 10.1016/S0167-4889(01)00124-0
   BROWNER MF, 1988, ANAL BIOCHEM, V168, P206, DOI 10.1016/0003-2697(88)90030-9                                                    
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999                                                         
   Brunel C, 2004, BIOCHIMIE, V86, P91, DOI 10.1016/j.biochi.2004.01.002
   BURGIN AB, 1990, EMBO J, V9, P4111
   BURKETT SL, 1996, CHEM COMMUN, V3, P321
   CAMMARANO P, 1982, EUR J BIOCHEM, V128, P297
   CANTOR CR, 1980, NUCLEIC ACIDS RES, V8, P1855, DOI 10.1093/nar/8.8.1855
   CARAZO JM, 1985, J MOL BIOL, V183, P79, DOI 10.1016/0022-2836(85)90282-7
   Carmichael GG, 2002, NATURE, V418, P379, DOI 10.1038/418379a
   CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x                                              
   CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551
   CHAN YNC, 1992, J AM CHEM SOC, V114, P7295
   Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021
   Chen CP, 1997, J VIROL, V71, P3864
   Chen CP, 2000, J BIOL CHEM, V275, P17510, DOI 10.1074/jbc.M909662199
   Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350
   Chen CP, 1997, J VIROL, V71, P495
   Chen T, 1997, J BIOMED MATER RES, V36, P190, DOI 10.1002/(SICI)1097-4636(199708)36:2<190::AID-JBM7>3.0.CO;2-F
   CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0
   Chworos A, 2004, SCIENCE, V306, P2068, DOI 10.1126/science.1104686
   CIESIOLKA J, 1995, RNA, V1, P538
   Clark SL, 2002, ELECTROPHORESIS, V23, P1335, DOI 10.1002/1522-2683(200205)23:9<1335::AID-ELPS1335>3.0.CO;2-E                     
   Clever JL, 1996, J VIROL, V70, P5902
   Coburn GA, 2002, J VIROL, V76, P9225, DOI 10.1128/JVI.76.18.9225-9231.2002
   COLEMAN J, 1985, NATURE, V315, P601, DOI 10.1038/315601a0
   Conrad RC, 1995, MOL DIVERS, V1, P69, DOI 10.1007/BF01715810
   CONWAY L, 1989, METHOD ENZYMOL, V180, P369
   Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2
   Craighead HG, 2000, SCIENCE, V290, P1532, DOI 10.1126/science.290.5496.1532                                                   
   CRUSE WBT, 1994, P NATL ACAD SCI USA, V91, P4160, DOI 10.1073/pnas.91.10.4160
   Davis JH, 2005, J MOL BIOL, V351, P371, DOI 10.1016/j.jmb.2005.05.069
   Demeshkina N, 2000, RNA, V6, P1727, DOI 10.1017/S1355838200000996
   Dujardin E, 2003, NANO LETT, V3, P413, DOI 10.1021/nl034004o
   EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109                                                          
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107                                                                
   ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0                                                                
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P2671, DOI 10.1093/nar/gkg350
   FEISS M, 1988, MOL GEN GENET, V212, P142, DOI 10.1007/BF00322457
   Fennimore AM, 2003, NATURE, V424, P408, DOI 10.1038/nature01823
   Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751                                                         
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   FORSTER AC, 1987, CELL, V50, P9, DOI 10.1016/0092-8674(87)90657-X
   Friedrich I, 2004, SEMIN CANCER BIOL, V14, P223, DOI 10.1016/j.semcancer.2004.04.001
   FUJISAWA H, 1991, VIROLOGY, V185, P788, DOI 10.1016/0042-6822(91)90550-U
   Furtig B, 2003, CHEMBIOCHEM, V4, P936, DOI 10.1002/cbic.200300700
   Gadi VK, 2003, J PHARMACOL EXP THER, V304, P1280, DOI 10.1124/jpet.102.044743
   Garver K, 1997, RNA, V3, P1068
   Garver K, 2000, J BIOL CHEM, V275, P2817, DOI 10.1074/jbc.275.4.2817                                                          
   Gates BD, 2005, CHEM REV, V105, P1171, DOI 10.1021/cr030076o
   GAUTHERET D, 1993, J MOL BIOL, V229, P1049, DOI 10.1006/jmbi.1993.1104                                                          
   GAUTHERET D, 1993, FASEB J, V7, P97
   Gerion D, 2002, J AM CHEM SOC, V124, P7070, DOI 10.1021/ja017822w
   Glotzer SC, 2004, SCIENCE, V306, P419, DOI 10.1126/science.1099988                                                         
   Gold L, 1995, Harvey Lect, V91, P47
   GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0                                                                
   Goldberger J, 2003, NATURE, V422, P599, DOI 10.1038/nature01551
   Goldsby RA, 2002, IMMUNOLOGY, P57
   GRIGORIEV D, 2003, ENCY NANOSCIENCE NAN, V1, P361
   Grimes S, 2002, ADV VIRUS RES, V58, P255, DOI 10.1016/S0065-3527(02)58007-6
   Guo PX, 2002, ACTA BIOCH BIOPH SIN, V34, P533
   GUO PX, 1994, SEMIN VIROL, V5, P1, DOI 10.1006/smvy.1994.1001                                                          
   GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081                                                          
   GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124                                                         
   Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0
   Guo PX, 2002, PROG NUCLEIC ACID RE, V72, P415, DOI 10.1016/S0079-6603(02)72076-X
   Guo SC, 2005, HUM GENE THER, V16, P1097, DOI 10.1089/hum.2005.16.1097
   Hampel A, 1998, PROG NUCLEIC ACID RE, V58, P1
   HAN WH, 1995, BIOCHEMISTRY-US, V34, P8215, DOI 10.1021/bi00026a001
   Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870
   Hansma HG, 2003, J MICROSC-OXFORD, V212, P273, DOI 10.1111/j.1365-2818.2003.01276.x
   HAO D, 2002, CLIN LUNG CANC, V4, P111, DOI 10.3816/CLC.2002.n.021
   Heath JR, 1996, J PHYS CHEM-US, V100, P3144, DOI 10.1021/jp951903v                                                               
   Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0                                                   
   Hess H., 2001, REV MOL BIOTECHNOL, V82, P67, DOI [10.1039/C005241H, DOI 10.1016/S1389-0352(01)00029-0]
   HIXSON SH, 1975, BIOCHEMISTRY-US, V14, P4251, DOI 10.1021/bi00690a016
   Hoeprich S, 2003, GENE THER, V10, P1258, DOI 10.1038/sj.gt.3302002
   Hoeprich S, 2002, J BIOL CHEM, V277, P20794, DOI 10.1074/jbc.M112061200
   Holbrook SR, 1997, BIOPOLYMERS, V44, P3
   HUI CF, 1985, P NATL ACAD SCI USA, V82, P1381, DOI 10.1073/pnas.82.5.1381
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Hyman P, 2002, P NATL ACAD SCI USA, V99, P8488, DOI 10.1073/pnas.132544299
   Inoue A, 2002, NAT CELL BIOL, V4, P302, DOI 10.1038/ncb774
   Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896
   JAEGER JA, 1993, ANNU REV BIOCHEM, V62, P255
   Jaeger L, 2000, ANGEW CHEM INT EDIT, V39, P2521, DOI 10.1002/1521-3773(20000717)39:14<2521::AID-ANIE2521>3.0.CO;2-P                  
   Jaeger L, 2001, NUCLEIC ACIDS RES, V29, P455, DOI 10.1093/nar/29.2.455
   JONES CR, 1974, P NATL ACAD SCI USA, V71, P4237, DOI 10.1073/pnas.71.10.4237
   Joshi P. J., 2003, Current Drug Targets - Infectious Disorders, V3, P383, DOI 10.2174/1568005033481060
   Jung HS, 2005, BIOTECHNOL LETT, V27, P567, DOI 10.1007/s10529-005-2883-6
   Kashani-Sabet M, 2002, J INVEST DERM SYMP P, V7, P76, DOI 10.1046/j.1523-1747.2002.19642.x
   Ke A, 2004, METHODS, V34, P408, DOI 10.1016/j.ymeth.2004.03.027
   KEARNS DR, 1974, J MOL BIOL, V87, P755, DOI 10.1016/0022-2836(74)90083-7                                                    
   Keren K, 2002, SCIENCE, V297, P72, DOI 10.1126/science.1071247                                                         
   Khaled A, 2005, NANO LETT, V5, P1797, DOI 10.1021/nl051264s
   KLUG SJ, 1994, MOL BIOL REP, V20, P97, DOI 10.1007/BF00996358
   KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221
   Kraus E, 1998, J IMMUNOL, V160, P5209
   LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955
   LEE CS, 1995, J VIROL, V69, P5018
   LEE CS, 1994, VIROLOGY, V202, P1039, DOI 10.1006/viro.1994.1434                                                          
   LEE RJ, 1994, J BIOL CHEM, V269, P3198
   Lee SW, 2002, SCIENCE, V296, P892, DOI 10.1126/science.1068054
   Leva S, 2002, CHEM BIOL, V9, P351, DOI 10.1016/S1074-5521(02)00111-4
   Li HW, 2002, SCIENCE, V296, P1319, DOI 10.1126/science.1070948
   Lindell M, 2002, RNA, V8, P534, DOI 10.1017/S1355838201020416
   Ma YL, 1996, J VIROL, V70, P5083
   MADAIO MP, 1984, J IMMUNOL, V132, P872
   Mao CB, 2003, P NATL ACAD SCI USA, V100, P6946, DOI 10.1073/pnas.0832310100
   Mao CD, 1999, J AM CHEM SOC, V121, P5437, DOI 10.1021/ja9900398                                                               
   Mao CD, 2000, NATURE, V407, P493
   MARCINIEC T, 1989, ACTA BIOCHIM POL, V36, P123
   Mariadason JM, 2003, CANCER RES, V63, P8791
   Marshall KA, 2000, METHOD ENZYMOL, V318, P193
   Massire C, 1998, J MOL GRAPH MODEL, V16, P197, DOI 10.1016/S1093-3263(98)80004-1
   Mat-Arip Y, 2001, J BIOL CHEM, V276, P32575, DOI 10.1074/jbc.M100045200
   Mathias CJ, 1996, J NUCL MED, V37, P1003
   McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   MIURA K, 1983, BIOCHIM BIOPHYS ACTA, V739, P281, DOI 10.1016/0167-4781(83)90102-1
   MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9
   Mohammad T, 1999, BIOORG MED CHEM LETT, V9, P1703, DOI 10.1016/S0960-894X(99)00265-6
   Moll D, 2002, P NATL ACAD SCI USA, V99, P14646, DOI 10.1073/pnas.232299399
   MONIA BP, 1993, J BIOL CHEM, V268, P14514
   Moore SD, 2002, CURR BIOL, V12, pR96, DOI 10.1016/S0960-9822(02)00670-X
   Motte L, 1996, ADV MATER, V8, P1018, DOI 10.1002/adma.19960081218
   MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335                                                   
   Niemeyer CM, 2002, TRENDS BIOTECHNOL, V20, P395, DOI 10.1016/S0167-7799(02)02022-X
   NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143
   Nulf CJ, 2002, NUCLEIC ACIDS RES, V30, P2782, DOI 10.1093/nar/gkf389                                                              
   OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802
   OSTER G, 2003, NATURE, V396, P279
   PACE NR, 1989, GENE, V82, P65, DOI 10.1016/0378-1119(89)90031-0                                                    
   PACE NR, 1995, J BACTERIOL, V177, P1919, DOI 10.1128/jb.177.8.1919-1928.1995                                                 
   Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096                                                          
   PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569
   PLEIJ CWA, 1989, METHOD ENZYMOL, V180, P289
   PRATS AC, 1990, J VIROL, V64, P774
   QUARLESS SA, 1985, ANAL BIOCHEM, V147, P296, DOI 10.1016/0003-2697(85)90275-1                                                    
   REID BR, 1981, ANNU REV BIOCHEM, V50, P969, DOI 10.1146/annurev.bi.50.070181.004541
   REID RJD, 1994, J BIOL CHEM, V269, P18656
   REID RJD, 1994, J BIOL CHEM, V269, P9084
   REID RJD, 1994, J BIOL CHEM, V269, P5157
   RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428
   Ryther RCC, 2005, GENE THER, V12, P5, DOI 10.1038/sj.gt.3302356
   Sablin EP, 2001, CURR OPIN STRUC BIOL, V11, P716, DOI 10.1016/S0959-440X(01)00265-2                                                   
   SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573                                                         
   Schmidt OG, 2001, NATURE, V410, P168, DOI 10.1038/35065525                                                                
   Scott WG, 1998, CURR OPIN STRUC BIOL, V8, P720, DOI 10.1016/S0959-440X(98)80091-2
   Seeman NC, 2002, P NATL ACAD SCI USA, V99, P6451, DOI 10.1073/pnas.221458298
   Serwer P, 2003, J STRUCT BIOL, V141, P179, DOI 10.1016/S1047-8477(02)00628-7
   Shenton W, 1997, NATURE, V389, P585
   Shi JF, 1997, ANGEW CHEM INT EDIT, V36, P111, DOI 10.1002/anie.199701111                                                          
   Shu D, 2003, J NANOSCI NANOTECHNO, V3, P295, DOI 10.1166/jnn.2003.160
   Shu D, 2003, J BIOL CHEM, V278, P7119, DOI 10.1074/jbc.M209895200
   Shu D, 2004, NANO LETT, V4, P1717, DOI [10.1021/nl0494497, 10.1021/nl04994497]
   Shu D, 2003, J VIROL METHODS, V115, P19
   SHU D, 2004, UNPUB
   Soong RK, 2000, SCIENCE, V290, P1555, DOI 10.1126/science.290.5496.1555                                                   
   Soukup GA, 1999, TRENDS BIOTECHNOL, V17, P469, DOI 10.1016/S0167-7799(99)01383-9                                                   
   Spatz JP, 1996, ADV MATER, V8, P337, DOI 10.1002/adma.19960080411
   STEPHENSON EC, 1992, CURR TOP DEV BIOL, V26, P23, DOI 10.1016/S0070-2153(08)60438-X                                                   
   STERN S, 1988, METHOD ENZYMOL, V164, P481
   Strobel SA, 1999, CURR OPIN STRUC BIOL, V9, P346, DOI 10.1016/S0959-440X(99)80046-3
   STUDNICKA GM, 1978, NUCLEIC ACIDS RES, V5, P3365, DOI 10.1093/nar/5.9.3365                                                            
   Torresi J, 1999, Expert Opin Investig Drugs, V8, P289, DOI 10.1517/13543784.8.3.289
   Trottier M, 2000, RNA, V6, P1257, DOI 10.1017/S1355838200992501
   Trottier M, 1997, J VIROL, V71, P487
   Trottier M, 1996, J VIROL, V70, P55
   Trottier M, 1997, NUCL ACIDS S SER, V36, P187
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Tullius TD, 2005, CURR OPIN CHEM BIOL, V9, P127, DOI 10.1016/j.cbpa.2005.02.009
   TYC K, 1992, NUCLEIC ACIDS RES, V20, P5375, DOI 10.1093/nar/20.20.5375
   VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875                                                       
   Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973
   VOSSMEYER T, 1995, SCIENCE, V267, P1476, DOI 10.1126/science.267.5203.1476
   Wagner C, 2004, J BIOL CHEM, V279, P4560, DOI 10.1074/jbc.M306511200
   Wagner C, 2001, J MOL BIOL, V313, P511, DOI 10.1006/jmbi.2001.5057
   Walter NG, 2001, BIOPOLYMERS, V61, P224
   Wang C, 1998, ACTA BIOCH BIOPH SIN, V30, P402
   WANG XD, 1989, P NATL ACAD SCI USA, V86, P7795, DOI 10.1073/pnas.86.20.7795
   Warner MG, 2003, NAT MATER, V2, P272, DOI 10.1038/nmat853
   WASSARMAN DA, 1993, MOL BIOL REP, V17, P143, DOI 10.1007/BF00996222                                                              
   WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506
   WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8
   WICHITWECHKARN J, 1992, J MOL BIOL, V223, P991, DOI 10.1016/0022-2836(92)90257-K
   Yan H, 2002, NATURE, V415, P62, DOI 10.1038/415062a
   Yan H, 2003, P NATL ACAD SCI USA, V100, P8103, DOI 10.1073/pnas.1032954100
   YAP LP, 1995, RNA, V1, P418
   Yeakley JM, 2002, NAT BIOTECHNOL, V20, P353, DOI 10.1038/nbt0402-353
   Yildiz A, 2003, SCIENCE, V300, P2061, DOI 10.1126/science.1084398
   Zandonella C, 2003, NATURE, V423, P10, DOI 10.1038/423010a
   Zhang CL, 1995, RNA, V1, P1041
   ZHANG CL, 1995, VIROLOGY, V207, P442, DOI 10.1006/viro.1995.1103                                                          
   ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267                                                          
   ZHANG CL, 1995, VIROLOGY, V211, P568, DOI 10.1006/viro.1995.1439                                                          
   Zhang CL, 1997, RNA, V3, P315
   Zhang F, 1998, J BIOL CHEM, V273, P2947, DOI 10.1074/jbc.273.5.2947
   Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9
   Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048
   Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695
   ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181
NR 216
TC 106
Z9 112
U1 6
U2 72
PU AMER SCIENTIFIC PUBLISHERS
PI STEVENSON RANCH
PA 25650 NORTH LEWIS WAY, STEVENSON RANCH, CA 91381-1439 USA
SN 1533-4880
J9 J NANOSCI NANOTECHNO
JI J. Nanosci. Nanotechnol.
PD DEC
PY 2005
VL 5
IS 12
BP 1964
EP 1982
DI 10.1166/jnn.2005.446
PG 19
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 992WK
UT WOS:000233914500004
PM 16430131
OA green_accepted
DA 2018-01-05
ER

PT J
AU Bayer, TS
   Booth, LN
   Knudsen, SM
   Ellington, AD
AF Bayer, TS
   Booth, LN
   Knudsen, SM
   Ellington, AD
TI Arginine-rich motifs present multiple interfaces for specific binding by
   RNA
SO RNA-A PUBLICATION OF THE RNA SOCIETY
LA English
DT Article
DE aptamer; arginine-rich motif; ARM; in vitro selection; peptide;
   specificity
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO SELECTION; MAJOR GROOVE;
   ALPHA-HELIX; AUTOMATED SELECTION; TAT PROTEINS; PEPTIDE; COMPLEX; REV;
   RECOGNITION
AB A number of proteins containing arginine-rich motifs (ARMs) are known to bind RNA and are involved in regulating RNA processing in viruses and cells. Using automated selection methods we have generated a number of aptamers against ARM peptides from various natural proteins. Aptamers bind tightly to their cognate ARMs, with K-d values in the nanomolar range, and frequently show no propensity to bind to other ARMs or even to single amino acid variants of the cognate ARM. However, at least some anti-ARM aptamers can cross-recognize a limited set of other ARMs, just as natural RNA-binding sites have been shown to exhibit so-called "chameleonism." We expand upon the number of examples of cross-recognition and, using mutational and circular dichroism (CD) analyses, demonstrate that there are multiple mechanisms by which RNA ligands can cross-recognize ARMs. These studies support a model in which individual arginine residues govern binding to an RNA ligand, and the inherent flexibility of the peptide backbone may make it possible for "semi-specific" recognition of a discrete set of RNAS by a discrete set of ARM peptides and proteins.
C1 Univ Texas, Dept Chem & Biochem, Inst Cell & Mol Biol, Austin, TX 78712 USA.
   CALTECH, Div Biol, Pasadena, CA 91125 USA.
RP Ellington, AD (reprint author), Univ Texas, Dept Chem & Biochem, Inst Cell & Mol Biol, Austin, TX 78712 USA.
EM andy.ellington@mail.utexas.edu
CR Austin RJ, 2002, J AM CHEM SOC, V124, P10966, DOI 10.1021/ja026610b
   Barrick JE, 2001, P NATL ACAD SCI USA, V98, P12374, DOI 10.1073/pnas.221467798
   BASKERVILLE S, 1995, J VIROL, V69, P7559
   Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547
   Berova N., 2000, CIRCULAR DICHROISM P
   Cox JC, 1998, BIOTECHNOL PROGR, V14, P845, DOI 10.1021/bp980097h
   Cox JC, 2001, BIOORGAN MED CHEM, V9, P2525, DOI 10.1016/S0968-0896(01)00028-1                                                   
   Cox JC, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf107
   Cox JC, 2002, COMB CHEM HIGH T SCR, V5, P289
   Das C, 2003, BIOPOLYMERS, V70, P80, DOI 10.1002/bip.10429
   ELINGTON AD, 1995, NUCL ACIDS S SER, V33, P156
   Ellington AD, 1996, NAT STRUCT BIOL, V3, P981, DOI 10.1038/nsb1296-981
   FELBER B K, 1989, New Biologist, V1, P318
   Frankel AD, 2000, CURR OPIN STRUC BIOL, V10, P332, DOI 10.1016/S0959-440X(00)00092-0
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   GILLIGAN TJ, 1976, BIOPHYS CHEM, V4, P55, DOI 10.1016/0301-4622(76)80007-5
   GIVER L, 1993, NUCLEIC ACIDS RES, V21, P5509, DOI 10.1093/nar/21.23.5509
   Harada K, 1996, NATURE, V380, P175, DOI 10.1038/380175a0
   Hemmerich P, 1997, EUR J BIOCHEM, V245, P549, DOI 10.1111/j.1432-1033.1997.00549.x
   Jiang F, 1999, STRUCT FOLD DES, V7, P1461, DOI 10.1016/S0969-2126(00)88337-9                                                   
   LATO SM, 1995, CHEM BIOL, V2, P291, DOI 10.1016/1074-5521(95)90048-9                                                    
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700                                                          
   PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Smith CA, 1998, BIOCHEMISTRY-US, V37, P10808, DOI 10.1021/bi980382+
   Smith CA, 2000, MOL CELL, V6, P1067, DOI 10.1016/S1097-2765(00)00105-2
   Smith CA, 2000, METHOD ENZYMOL, V318, P423
   SOLOMIN L, 1990, J VIROL, V64, P6010
   SU L, 1997, BIOCHEMISTRY-US, V36, P12772
   TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282
   TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025
   TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4
   TAO JS, 1993, P NATL ACAD SCI USA, V90, P1571, DOI 10.1073/pnas.90.4.1571
   TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931                                                          
   UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145
   Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8
   Xu W, 1996, P NATL ACAD SCI USA, V93, P7475, DOI 10.1073/pnas.93.15.7475
   Ye XM, 1999, CHEM BIOL, V6, P657, DOI 10.1016/S1074-5521(99)80117-3
   Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026
NR 39
TC 64
Z9 66
U1 2
U2 8
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI WOODBURY
PA 500 SUNNYSIDE BLVD, WOODBURY, NY 11797-2924 USA
SN 1355-8382
J9 RNA
JI RNA-Publ. RNA Soc.
PD DEC
PY 2005
VL 11
IS 12
BP 1848
EP 1857
DI 10.1261/rna.2167605
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 990QS
UT WOS:000233758900012
PM 16314457
OA gold
DA 2018-01-05
ER

PT J
AU Akagi, T
   Kaneko, T
   Kida, T
   Akashi, M
AF Akagi, T
   Kaneko, T
   Kida, T
   Akashi, M
TI Preparation and characterization of biodegradable nanoparticles based on
   poly(gamma-glutamic acid) with L-phenylalanine as a protein carrier
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE poly(gamma-glutamic acid); biodegradation; nanoparticles; amphiphilic;
   encapsulation
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; IMMOBILIZED POLYSTYRENE
   NANOSPHERES; SELF-ASSEMBLED NANOPARTICLES; IN-VITRO RELEASE;
   DRUG-DELIVERY; HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES;
   GRAFT-COPOLYMERS; ANTIBODY-RESPONSE; PEPTIDE DELIVERY
AB The objective of the present study was to prepare nanoparticles composed of poly(gamma-glutamic acid) (gamma-PGA) and (L)-phenylalanine ethylester ((L)-PAE) in order to evaluate the possibility of using these nanoparticles as protein carriers. Novel amphiphilic graft copolymers composed of gamma-PGA as the hydrophilic backbone and L-PAE as the hydrophobic segment were successfully synthesized by grafting L-PAE to gamma-PGA using water-soluble carbodiimide (WSC). Due to their amphiphilic properties, the gamma-PGA-graft-(L)-PAE copolymers were able to form nanoparticles. The size of the gamma-PGA nanoparticles was measured by photon correlation spectroscopy (PCs) and showed a monodispersed size distribution with a mean diameter ranging from 150 to 200 nm. The solvents selected to prepare the gamma-PGA nanoparticles by a precipitation and dialysis method affected the particle size distribution. To evaluate the feasibility of vehicles for these proteins, we prepared protein-loaded gamma-PGA nanoparticles by surface immobilization and encapsulation methods. Ovalbumin (OVA) was used as a model protein and was immobilized onto the gamma-PGA nanoparticles or encapsulated into the inner core of these nanoparticles. Moreover, these OVA-encapsulated gamma-PGA nanoparticles could be preserved by freeze-drying process. The results of cytotoxicity tests showed that the gamma-PGA and gamma-PGA nanoparticles did not cause any relevant cell damage. It is expected that biodegradable gamma-PGA nanoparticles can immobilize proteins, peptides, plasmid DNA and drugs onto their surfaces and/or into the nanoparticles. These nanoparticles are potentially useful in pharmaceutical and biomedical applications. (c) 2005 Elsevier B.V. All rights reserved.
C1 Osaka Univ, Dept Appl Chem, Grad Sch Engn, Suita, Osaka 5650871, Japan.
   Japan Sci & Technol Agcy, JST, CREST, Tokyo, Japan.
RP Akashi, M (reprint author), Osaka Univ, Dept Appl Chem, Grad Sch Engn, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
EM akashi@chem.eng.osaka-u.ac.jp
CR Akagi T, 2005, MACROMOL BIOSCI, V5, P598, DOI 10.1002/mabi.200500036
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Akiyoshi K, 1998, J CONTROL RELEASE, V54, P313, DOI 10.1016/S0168-3659(98)00017-0
   AKIYOSHI K, 1993, MACROMOLECULES, V26, P3062, DOI 10.1021/ma00064a011                                                             
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833                                                         
   Chen CW, 1999, CHEM MATER, V11, P1381, DOI 10.1021/cm9900047                                                               
   Feng SS, 2001, J CONTROL RELEASE, V71, P53, DOI 10.1016/S0168-3659(00)00364-3
   Gref R, 2002, MACROMOLECULES, V35, P9861, DOI 10.1021/ma021132a
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1                                                   
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Jaturanpinyo M, 2004, BIOCONJUGATE CHEM, V15, P344, DOI 10.1021/bc034149m
   Jung SW, 2003, INT J PHARM, V254, P109, DOI 10.1016/S0378-5173(03)00006-1
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kesuo F., 1996, J ENVIRON POLYM DEGR, V4, P253
   King EC, 1998, J POLYM SCI POL CHEM, V36, P1995, DOI 10.1002/(SICI)1099-0518(19980915)36:12<1995::AID-POLA4>3.0.CO;2-N               
   Kishida A, 1998, J BIOACT COMPAT POL, V13, P270, DOI 10.1177/088391159801300403                                                      
   KUBOTA H, 1993, BIOSCI BIOTECH BIOCH, V57, P1212, DOI 10.1271/bbb.57.1212
   Leonard M, 2004, J CONTROL RELEASE, V98, P395, DOI 10.1016/j.jconrel.2004.05.009
   Li XH, 2000, J APPL POLYM SCI, V78, P140, DOI 10.1002/1097-4628(20001003)78:1<140::AID-APP180>3.0.CO;2-P                      
   Liu XM, 2004, BIOMATERIALS, V25, P2619, DOI 10.1016/j.biomaterials.2003.09.028
   Matsusaki M, 2002, BIOCONJUGATE CHEM, V13, P23, DOI 10.1021/bc010008d
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Na K, 2000, J CONTROL RELEASE, V69, P225, DOI 10.1016/S0168-3659(00)00256-X                                                   
   Na K, 2003, EUR J PHARM SCI, V18, P165, DOI 10.1016/S0928-0987(02)00257-9
   Obst M, 2004, BIOMACROMOLECULES, V5, P1166, DOI 10.1021/bm049949u
   OHAGAN DT, 1994, INT J PHARM, V103, P37, DOI 10.1016/0378-5173(94)90201-1
   Oppermann FB, 1998, POLYM DEGRAD STABIL, V59, P337, DOI 10.1016/S0141-3910(97)00175-4                                                   
   Panyam J, 2003, J CONTROL RELEASE, V92, P173, DOI 10.1016/S0168-3659(03)00328-6
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Park JH, 2004, J CONTROL RELEASE, V95, P579, DOI 10.1016/j.jconrel.2003.12.020
   PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4                                                    
   Quellec P, 1998, J BIOMED MATER RES, V42, P45, DOI 10.1002/(SICI)1097-4636(199810)42:1<45::AID-JBM7>3.0.CO;2-O
   Ryu JG, 2000, INT J PHARM, V200, P231, DOI 10.1016/S0378-5173(00)00392-6
   Sah H, 1999, J CONTROL RELEASE, V58, P143, DOI 10.1016/S0168-3659(98)00148-5
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   Serizawa T, 2000, COLLOID SURFACE A, V169, P95, DOI 10.1016/S0927-7757(00)00421-0                                                   
   Shimokuri T, 2004, MACROMOL BIOSCI, V4, P407, DOI 10.1002/mabi.200300073
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Zhang LF, 1996, J AM CHEM SOC, V118, P3168, DOI 10.1021/ja953709s                                                               
NR 42
TC 122
Z9 126
U1 3
U2 36
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD NOV 28
PY 2005
VL 108
IS 2-3
BP 226
EP 236
DI 10.1016/j.jconrel.2005.08.003
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 992IW
UT WOS:000233878600003
PM 16125267
DA 2018-01-05
ER

PT J
AU Baba, M
   Takashima, K
   Miyake, H
   Kanzaki, N
   Teshima, K
   Wang, X
   Shiraishi, M
   Iizawa, Y
AF Baba, M
   Takashima, K
   Miyake, H
   Kanzaki, N
   Teshima, K
   Wang, X
   Shiraishi, M
   Iizawa, Y
TI TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1
   infection in vitro and has favorable pharmacokinetics in humans
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID CHEMOKINE RECEPTOR CCR5; SOCIETY-USA PANEL; SMALL-MOLECULE; HIV-1
   INFECTION; ANTIRETROVIRAL THERAPY; HIGHLY POTENT; DISEASE; ENTRY; AIDS;
   INDIVIDUALS
AB The first small-molecule CCR5 antagonist, TAK-779, could not be developed as an anti-human immunodeficiency virus type (anti-HIV-1) agent because of its poor oral bioavailability. TAK-652 is an orally bioavailable TAK-779 derivative with potent anti-HIV-1 activity. TAK-652 inhibited the binding of RANTES (regulated on activation, normal T-cell expressed and secreted), macrophage inflammatory protein l alpha (MIP-1 alpha), and NHP-1 beta to CCR5-expressing cells at nanomolar concentrations. TAK-652 could also suppress the binding of monocyte chemotactic protein 1 (MCP-1) to CCR2b-expressing cells. However, its inhibitory effect on ligand binding to other chemokine receptors was limited. TAK-652 was active against CCR5-using (R5) HIV-1 but totally inactive against CXCR4-using (X4) HIV-1. The compound was active against R5 HIV-1 clinical isolates containing reverse transcriptase and protease inhibitor-resistant mutations, with a mean 50% effective concentration (EC50) and EC90 of 0.061 and 0.25 nM, respectively. In addition, recombinant R5 viruses carrying different subtype (A to G) envelope proteins were equally susceptible to TAK-652. A single oral administration of TAK-652 up to 100 mg was safe and well tolerated in humans. The compound displayed favorable pharmacokinetics, and its plasma concentration was 7.2 ng/ml (9.1 nM) even 24 h after the administration of 25 mg. Thus, TAK-652 is a promising candidate as a novel entry inhibitor of HIV-1.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
   Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Osaka 5328686, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, 8-35-1,Sakuragaoka, Kagoshima 8908544, Japan.
EM baba@m.kufm.kagoshima-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   Baba M, 2000, AIDS RES HUM RETROV, V16, P935, DOI 10.1089/08892220050058344                                                       
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621                                                           
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497
   Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697
   Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597                                                                  
   Kuhmann SE, 2004, J VIROL, V78, P2790, DOI 10.1128/JVI.78.6.2790-2807.2004
   Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617
   Li S, 1999, J VIROL, V73, P9741
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Maeda K, 2004, J VIROL, V78, P8654, DOI 10.1128/JVI.78.16.8654-8662.2004
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   Moore JP, 2004, AIDS RES HUM RETROV, V20, P111, DOI 10.1089/088922204322749567
   Moore RD, 1999, AIDS, V13, P1933, DOI 10.1097/00002030-199910010-00017                                                
   PATELLA F, 1998, NEW ENGL J MED, V338, P853
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398                                                          
   Takashima K, 2001, ANTIMICROB AGENTS CH, V45, P3538, DOI 10.1128/AAC.45.12.3538-3543.2001
   Takashima K, 2005, ANTIMICROB AGENTS CH, V49, P3474, DOI 10.1128/AAC.49.8.3474-3482.2005
   Trkola A, 2001, J VIROL, V75, P579, DOI 10.1128/JVI.75.2.579-588.2001
   Trkola A, 2002, P NATL ACAD SCI USA, V99, P395, DOI 10.1073/pnas.012519099                                                          
   Tuttle DL, 2002, AIDS RES HUM RETROV, V18, P353, DOI 10.1089/088922202753519133
   Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373                                                          
   Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251
NR 28
TC 71
Z9 80
U1 1
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2005
VL 49
IS 11
BP 4584
EP 4591
DI 10.1128/AAC.49.11.4584-4591.2005
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 980LV
UT WOS:000233020900021
PM 16251299
OA gold
DA 2018-01-05
ER

PT J
AU Burnouf, T
   Radosevich, M
   Goubran, HA
   Willkommen, H
AF Burnouf, T
   Radosevich, M
   Goubran, HA
   Willkommen, H
TI Place of nanofiltration for assuring viral safety of biologicals
SO CURRENT NANOSCIENCE
LA English
DT Review
DE nanofiltration; viral filtration; biopharmaceuticals; virus; prions
ID FACTOR-IX CONCENTRATE; PURITY FACTOR-IX; WEST-NILE-VIRUS;
   HUMAN-IMMUNOGLOBULIN PRODUCTS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   SOLVENT-DETERGENT TREATMENT; LARGE-SCALE PREPARATION; HUMAN-PLASMA;
   INTRAVENOUS IMMUNOGLOBULIN; BLOOD PRODUCTS
AB Viruses are nanometer size organisms (range from 18 to 250 nm) that can potentially contaminate the feedstocks from animal or human origins used to manufacture biopharmaceutical products. Various measures are taken to ensure the optimal viral safety of this class of products. Selection and screening of starting materials play an important role in safeguarding from the introduction of viruses into the downstream processing but they have limits in specificity and sensitivity. Purification methods of protein biopharmaceutical products may also contribute to viral reduction, but since viruses exhibit a wide range of biochemical characteristics and resistance to physico-chemical treatments, complete elimination of infectious agents is not guaranteed. Therefore, the viral safety of animal derived biopharmaceutical products is well recognized to rely largely upon the use of deliberately introduced and validated viral inactivation and/or removal steps. A major progress in viral safety has been made recently by the development and availability of biocompatible viral filtration (also known as nanofiltration) systems using membranes of a pore size as small as 15 nm; these systems are specifically designed to allow, depending upon membrane used, typically over 4 to 6 logs of virus removal under conditions ensuring good protein permeability and recovery. Validation studies and production experience throughout the world have demonstrated that viral nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all biological products. This review analyzes the virus risks of biopharmaceutical products (human plasma derivatives, horse and sheep plasma-derived products, recombinant proteins and monoclonal antibodies), the various viral inactivation methods used at present, and the increasing role that viral nanofiltration is playing in assuring the safety of biopharmaceutical products.
C1 Human Plasma Prod Serv, F-59800 Lille, France.
   Cairo Univ, Dept Internal Med, Cairo, Egypt.
   Regulatory Affairs & Biol Safety Consulting, Erzhausen, Germany.
RP Burnouf, T (reprint author), Human Plasma Prod Serv, 18 Rue St Jacques, F-59800 Lille, France.
EM tburnou@attglobal.net; radosev@nordnet.fr
CR Aguzzi A, 2004, LANCET, V363, P411, DOI 10.1016/S0140-6736(04)15520-7                                                   
   Allain JP, 2002, TRANSFUSION MED, V12, P275, DOI 10.1046/j.1365-3148.2002.00386.x                                                
   Berting A, 2005, J MED VIROL, V75, P603, DOI 10.1002/jmv.20299
   Blumel J, 2002, TRANSFUSION, V42, P1473, DOI 10.1046/j.1537-2995.2002.00221.x                                                
   Bonn D, 2004, LANCET INFECT DIS, V4, P65, DOI 10.1016/S1473-3099(04)00912-0                                                   
   Bos OJM, 1998, BIOLOGICALS, V26, P267, DOI 10.1006/biol.1998.0148
   Bridonneau P, 1996, VOX SANG, V70, P203, DOI 10.1111/j.1423-0410.1996.tb01327.x                                              
   Brorson K, 2004, DEV BIOLOGICALS, V118, P17
   Brorson K, 2003, BIOTECHNOL BIOENG, V82, P321, DOI 10.1002/bit.10574
   Brorson K, 2002, BIOTECHNOL BIOENG, V80, P257, DOI 10.1002/bit.10366
   Brough H, 2002, BIOTECHNOL PROGR, V18, P782, DOI 10.1021/bp010193+
   Brown P, 2004, LANCET NEUROL, V3, P203, DOI 10.1016/S1474-4422(04)00702-1                                                   
   Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057
   BURNOUF T, 1987, VOX SANG, V52, P291, DOI 10.1111/j.1423-0410.1987.tb04895.x                                              
   Burnouf T, 2004, BIOLOGICALS, V32, P115, DOI 10.1016/j.biologicals.2004.07.001
   BURNOUF T, 1995, J CHROMATOGR B, V664, P3, DOI 10.1016/0378-4347(94)00532-A
   BURNOUF T, 1992, BIOLOGICALS, V20, P91, DOI 10.1016/S1045-1056(05)80056-9
   BURNOUF T, 1989, VOX SANG, V57, P225, DOI 10.1111/j.1423-0410.1989.tb00832.x                                              
   Burnouf T, 2003, VOX SANG, V84, P111, DOI 10.1046/j.1423-0410.2003.00265.x
   Burnouf T, 2003, HAEMOPHILIA, V9, P24, DOI 10.1046/j.1365-2516.2003.00701.x
   BURNOUF T, 1991, VOX SANG, V60, P8, DOI 10.1111/j.1423-0410.1991.tb00864.x                                              
   Burnouf T, 2000, BLOOD REV, V14, P94, DOI 10.1054/blre.2000.0129                                                          
   BURNOUF T, 1993, DEV BIOL STAND, V81, P199
   BURNOUFRADOSEVICH M, 1992, TRANSFUSION, V32, P861, DOI 10.1046/j.1537-2995.1992.32993110761.x                                          
   BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x                                              
   BURNOUFRADOSEVICH M, 1995, TRANSFUS CLIN BIOL, V2, P167, DOI 10.1016/S1246-7820(05)80044-8
   Cameron-Smith R, 2000, BIOLOGICALS, V28, P169, DOI 10.1006/biol.2000.0254
   CARTER J, 2003, BIOPROCESS INT, V1, P52
   Celis P, 2004, DEV BIOLOGICALS, V118, P3
   Chamberland ME, 2001, EMERG INFECT DIS, V7, P552, DOI 10.3201/eid0703.010331                                                          
   Chang CE, 2000, PREP BIOCHEM BIOTECH, V30, P177, DOI 10.1080/10826060008544957
   *CHMP, 2003, CPMPBWP179302 EUR ME
   *CHMP, 2004, CHMPBWP287902REV1
   *CHMP, 2004, PMPBWPCPMP513603 CHM
   CHTOUROU S, 2000, PLAN WORKSH JAP FOR, P91
   Chudy M, 1999, J MED VIROL, V57, P91, DOI 10.1002/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L
   CPMP, 1996, CPMPBWPCPMP513603 EM
   *CPMP, 2001, CPMPBWP26995 EUR AG
   *CPMP, 2002, CPMP NOT GUID PROD Q
   *CPMP ICH, 1997, CPMPICH29595 EUR MED
   Denton A, 2004, 7 PLAN WORKSH 2004 E
   Dichtelmuller H, 2002, BIOLOGICALS, V30, P135, DOI 10.1006/biol.2002.0332
   Eibl J, 1996, BIOLOGICALS, V24, P285, DOI 10.1006/biol.1996.0036
   Elombo FK, 2000, BIOL PHARM BULL, V23, P1406
   *EMEA, 2002, EMEACVMP74300
   Farrugia A, 2002, HAEMOPHILIA, V8, P230, DOI 10.1046/j.1365-2516.2002.00618.x
   Farrugia A, 2002, HAEMOPHILIA, V8, P236, DOI 10.1046/j.1365-2516.2002.00596.x                                                
   Farshid M, 2004, DEV BIOLOGICALS, V118, P11
   FELDMAN PA, 1994, BLOOD COAGUL FIBRIN, V5, P939, DOI 10.1097/00001721-199412000-00010
   Fischer G, 2001, TRANSFUS MED REV, V15, P27, DOI 10.1053/tmrv.2001.25376
   Foster PR, 2000, VOX SANG, V78, P86, DOI 10.1159/000031156
   Gregori L, 2004, BIOLOGICALS, V32, P1, DOI 10.1016/j.biologicals.2003.08.004
   Grieb T, 2002, BIOLOGICALS, V30, P207, DOI 10.1006/biol.2002.0330
   GUERRIER L, 1995, J CHROMATOGR B, V664, P119, DOI 10.1016/0378-4347(94)00363-A
   Guy JS, 2000, J CLIN MICROBIOL, V38, P4523
   HAMALAINEN E, 1992, VOX SANG, V63, P6
   HILFENHAUS J, 1987, J BIOL STAND, V15, P251, DOI 10.1016/0092-1157(87)90028-X
   Hilleman MR, 1998, DEV BIOL STAND, V94, P183
   HIRASAKI T, 1994, POLYM J, V26, P1244, DOI 10.1295/polymj.26.1244                                                          
   HOFFER L, 1995, J CHROMATOGR B, V669, P187, DOI 10.1016/0378-4347(95)00107-T
   Hong F, 1998, SEMIN HEMATOL, V35, P9
   Horowitz B, 1991, Biotechnology, V19, P417
   HOROWITZ B, 1993, DEV BIOL STAND, V81, P147
   Horowitz B, 1998, VOX SANG, V74, P203, DOI 10.1111/j.1423-0410.1998.tb05473.x                                              
   *ICH, 1998, ICH VIR SAF EV BIOT
   *ICTV, 2002, ICTVDB UN VIR DAT VE
   Jakubik JJ, 2004, HAEMOPHILIA, V10, P69, DOI 10.1046/j.1365-2516.2003.00847.x                                                
   Joch C, 2003, CARDIOVASC SURG, V11, P23, DOI 10.1016/S0967-2109(03)00068-1
   Johnston A, 2000, BIOLOGICALS, V28, P129, DOI 10.1006/biol.1999.0242
   KERNER B, 1995, BLOOD COAGUL FIBRIN, V6, pS15, DOI 10.1097/00001721-199506002-00004                                                
   Korneyeva M, 2002, BIOLOGICALS, V30, P153, DOI 10.1006/biol.2002.0334
   Kreil TR, 2003, TRANSFUSION, V43, P1023, DOI 10.1046/j.1537-2995.2003.00496.x
   Laub R, 2002, PATHOL BIOL, V50, P339, DOI 10.1016/S0369-8114(02)00303-6
   Lebing W, 2003, VOX SANG, V84, P193, DOI 10.1046/j.1423-0410.2003.00285.x                                                
   LEMON SM, 1995, BLOOD COAGUL FIBRIN, V6, pS20, DOI 10.1097/00001721-199506002-00005                                                
   Marzo A, 2002, ARZNEIMITTEL-FORSCH, V52, P187
   Mazurier C, 2004, VOX SANG, V86, P100, DOI 10.1111/j.0042-9007.2004.00398.x                                                
   McLean RG, 2002, CURR TOP MICROBIOL, V267, P271
   MCOMISH F, 1993, J CLIN MICROBIOL, V31, P323
   Morgenthaler JJ, 2001, TRANSFUS MED REV, V15, P224, DOI 10.1053/tmrv.2001.24590
   Morrica A, 2003, BIOLOGICALS, V31, P165, DOI 10.1016/S1045-1056(03)00035-6
   NG PK, 1985, THROMB RES, V39, P439, DOI 10.1016/0049-3848(85)90167-7                                                    
   NOWAK T, 1993, DEV BIOL STAND, V81, P169
   OGrady J, 1996, DEV BIOL STAND, V88, P319
   Omar A, 2002, TRANSFUSION, V42, P1005, DOI 10.1046/j.1537-2995.2002.00145.x
   Omar A, 1996, TRANSFUSION, V36, P866, DOI 10.1046/j.1537-2995.1996.361097017171.x
   PEJAUDIER L, 1987, VOX SANG, V52, P1, DOI 10.1111/j.1423-0410.1987.tb02979.x                                              
   PIET MPJ, 1990, TRANSFUSION, V30, P591, DOI 10.1046/j.1537-2995.1990.30790385516.x
   POULLE M, 1994, BLOOD COAGUL FIBRIN, V5, P543
   Radosevich M, 2000, HEMATOL ONCOL CLIN N, V14, P459, DOI 10.1016/S0889-8588(05)70145-3
   Radosevich M, 2003, J CHROMATOGR B, V790, P199, DOI 10.1016/S1570-0232(03)00091-6
   REID KG, 1988, VOX SANG, V55, P75, DOI 10.1111/j.1423-0410.1988.tb05140.x                                              
   Romisch J, 1996, BEITR INFUS, V33, P220
   Roth WK, 2001, TRANSFUS CLIN BIOL, V8, P282, DOI 10.1016/S1246-7820(01)00115-X                                                   
   Schmidt I, 2001, VOX SANG, V81, P228, DOI 10.1046/j.1423-0410.2001.00120.x
   Schulman S, 1999, HAEMOPHILIA, V5, P96, DOI 10.1046/j.1365-2516.1999.00284.x
   Shah G, 1999, Dev Biol Stand, V99, P17
   Shepherd AJ, 2003, BIOLOGICALS, V31, P251, DOI 10.1016/S1045-1056(03)00065-4
   Tateishi J, 2001, BIOLOGICALS, V29, P17, DOI 10.1006/biol.2001.0269
   Tateishi Jun, 1993, Membrane, V18, P357
   Teitel JM, 2000, ANN MED, V32, P485, DOI 10.3109/07853890009002024
   Theakston R. D. G., 2003, Toxicon, V41, P541, DOI 10.1016/S0041-0101(02)00393-8
   Tomokiyo K, 2003, VOX SANG, V84, P54, DOI 10.1046/j.1423-0410.2003.00247.x
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   Van Holten RW, 2002, VOX SANG, V83, P227, DOI 10.1046/j.1423-0410.2002.00224.x
   van Reis R, 2001, CURR OPIN BIOTECH, V12, P208, DOI 10.1016/S0958-1669(00)00201-9
   VANDAMME E, 2004, 7 PLAN WORKSH 2004 E
   *WHO, 2003, WHO GUID VIR IN REM
   Wolf HH, 2003, VOX SANG, V84, P45, DOI 10.1046/j.1423-0410.2003.00255.x
   Wurm FM, 2004, NAT BIOTECHNOL, V22, P1393, DOI 10.1038/nbt1026
   Yokoyama T, 2004, VOX SANG, V86, P225, DOI 10.1111/j.0042-9007.2004.00515.x
   2005, BIG PICTURE BOOK VIR
NR 112
TC 24
Z9 26
U1 0
U2 24
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
J9 CURR NANOSCI
JI Curr. Nanosci.
PD NOV
PY 2005
VL 1
IS 3
BP 189
EP 201
DI 10.2174/157341305774642894                                              
          
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA 992PA
UT WOS:000233894900002
DA 2018-01-05
ER

PT J
AU Kuo, YC
   Chung, CY
AF Kuo, YC
   Chung, CY
TI Transport of zidovudine- and lamivuldine-loaded polybutylcyanoacrylate
   and methylmethacrylate-sulfopropylmethacrylate nanoparticles across the
   in vitro blood-brain barrier: Characteristics of the drug-delivery
   system
SO JOURNAL OF THE CHINESE INSTITUTE OF CHEMICAL ENGINEERS
LA English
DT Article; Proceedings Paper
CT 10th Annual Conference on Biochemical Engineering
CY JUN 24-25, 2005
CL Taipei, TAIWAN
DE blood-brain barrier; zidovudine; lamivudine; polybutylcyanoacryl ate;
   methylmethacrylate-sulfopropylmethacrylate; nanoparticle
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POLY(BUTYL CYANOACRYLATE) NANOPARTICLES;
   COPOLYMER NANOPARTICLES; ENDOTHELIAL-CELLS; PHYSICOCHEMICAL
   CHARACTERIZATION; BODY DISTRIBUTION; TISSUE-CULTURE; SURFACE-CHARGE;
   RAT-BRAIN; PERMEABILITY
AB Transport study of zidovudine (AZT) and lamivudine (3TC) loaded on polyburylcyanoacrylate (PBCA) and methylmethacrylate-sulfopropylmethacrylate (MMA-SPM) nanoparticles (NPs) across the in vitro blood-brain barrier (BBB) model system was presented. Through primary culture, confluent monolayer of bovine brain-microvascular enclothelial cells (BBMECs) with the feature of cellular homogeneity and tight intercellular junction was demonstrated by immunocytochemical fluorescent method. Besides, for the colloidal drug-carrier system, average diameters of the two nearly monodispersed PBCA and MMA-SPM nanospheres were, respectively, about 92 nm and 78 nm. The amount of AZT and 3TC across the current BBMEC monolayer in carrier-incorporated system was much higher than that in non-carrier system, suggesting sufficient amelioration in drug transport by employing the NP carriers for brain-targeting delivery. Comparing PBCA NPs with MMA-SPM NPs, the amount of drug (AZT and 3TC) across the in vitro BBB system for the former was in excess of 1.5 times that for the latter.
C1 Natl Chung Cheng Univ, Dept Chem Engn, Chiayi 621, Taiwan.
RP Kuo, YC (reprint author), Natl Chung Cheng Univ, Dept Chem Engn, Chiayi 621, Taiwan.
CR Alyautdin RN, 1998, J MICROENCAPSUL, V15, P67, DOI 10.3109/02652049809006836
   AUDUS KL, 1986, PHARMACEUT RES, V3, P81, DOI 10.1023/A:1016337202335
   Betz A L, 1980, Adv Exp Med Biol, V131, P5
   BOWMAN PD, 1983, ANN NEUROL, V14, P396, DOI 10.1002/ana.410140403                                                           
   BOWMAN PD, 1981, IN VITRO CELL DEV B, V17, P353
   Bridges EG, 1996, BIOCHEM PHARMACOL, V51, P731, DOI 10.1016/0006-2952(96)00056-1                                                    
   COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P733, DOI 10.1128/AAC.36.4.733                                                            
   DEBAULT LE, 1979, IN VITRO CELL DEV B, V15, P473
   GELPERIAN SE, 2000, 3 WORLD M APV APGI B, P441
   Gelperina SE, 2002, TOXICOL LETT, V126, P131, DOI 10.1016/S0378-4274(01)00456-8
   Glynn SL, 1998, J PHARM SCI, V87, P306, DOI 10.1021/js970291i
   Gummerloch M. K., 1992, HDB EXPT PHARM, V103, P525
   HARDEBO JE, 1985, ACTA PHYSIOL SCAND, V125, P495, DOI 10.1111/j.1748-1716.1985.tb07746.x
   Hillier B, 1996, URBAN DES INT, V1, P41, DOI DOI 10.1057/UDI.1996.5
   Hoffmann F, 1997, INT J PHARM, V157, P189, DOI 10.1016/S0378-5173(97)00242-1                                                   
   Katlama C, 1996, AIDS, V10 Suppl A, pS135, DOI 10.1097/00002030-199601001-00019
   KREUTER J, 1976, J PHARM SCI, V65, P1624, DOI 10.1002/jps.2600651115                                                          
   KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J
   KREUTER J, 1983, PHARM ACTA HELV, V58, P196
   Kreutzer HJ, 2000, ACTA MOZARTIANA, V47, P65
   Kuo YC, 2005, INT J PHARM, V290, P161, DOI 10.1016/j.ijpharm.2004.11.025
   Langer K, 1996, INT J PHARM, V137, P67, DOI 10.1016/0378-5173(96)89589-5
   Langer K, 1997, INT J PHARM, V158, P219, DOI 10.1016/S0378-5173(97)00255-X                                                   
   Lipton SA, 1998, ANNU REV PHARMACOL, V38, P159, DOI 10.1146/annurev.pharmtox.38.1.159
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   MASEREEUW R, 1994, PHARMACEUT RES, V11, P324, DOI 10.1023/A:1018932213953
   MERESSE S, 1989, J NEUROCHEM, V53, P1363, DOI 10.1111/j.1471-4159.1989.tb08526.x
   Otis KW, 2001, J PHARMACOL TOXICOL, V45, P71, DOI 10.1016/S1056-8719(01)00120-4
   PANULA P, 1978, EXPERIENTIA, V34, P95, DOI 10.1007/BF01921925
   PHILLIPS P, 1979, J ANAT, V129, P261
   SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974
   Schroeder U, 1998, J PHARM SCI, V87, P1305, DOI 10.1021/js980084y
   Schroeder U, 2000, LIFE SCI, V66, P495, DOI 10.1016/S0024-3205(99)00619-0
   Simon VA, 2001, J CHROMATOGR A, V913, P447, DOI 10.1016/S0021-9673(00)01092-X                                                   
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   vanAsperen J, 1997, J PHARM SCI, V86, P881, DOI 10.1021/js9701364                                                               
   Weyermann J, 2004, EUR J PHARM BIOPHARM, V58, P25, DOI 10.1016/j.ejpb.2004.02.011
   Wu DA, 1998, BRAIN RES, V791, P313, DOI 10.1016/S0006-8993(98)00139-5
   YARCHOAN R, 1986, LANCET, V1, P575
   Yazdanian M, 1999, J PHARM SCI, V88, P950, DOI 10.1021/js990174i                                                               
NR 40
TC 21
Z9 21
U1 2
U2 5
PU CHINESE INST CHEMICAL ENGINEER
PI TAIPEI
PA NATL TSING HUA UNIV, HSINCHU, DEPT CHEMICAL ENGINEERING, TAIPEI 300,
   TAIWAN
SN 0368-1653
J9 J CHIN INST CHEM ENG
JI J. Chin. Inst. Chem. Eng.
PD NOV
PY 2005
VL 36
IS 6
BP 627
EP 638
PG 12
WC Engineering, Chemical
SC Engineering
GA 008LO
UT WOS:000235042400010
DA 2018-01-05
ER

PT J
AU Matsusaki, M
   Larsson, K
   Akagi, T
   Lindstedt, M
   Akashi, M
   Borrebaeck, CAK
AF Matsusaki, M
   Larsson, K
   Akagi, T
   Lindstedt, M
   Akashi, M
   Borrebaeck, CAK
TI Nanosphere induced gene expression in human dendritic cells
SO NANO LETTERS
LA English
DT Article
ID TOLL-LIKE RECEPTORS; INACTIVATED HIV-1-CAPTURING NANOSPHERES; INTRANASAL
   IMMUNIZATION; HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES;
   ANTIBODY-RESPONSE; GRAFT-COPOLYMERS; INNATE IMMUNITY; T-CELLS;
   MATURATION
AB The molecular mechanisms of nanosphere-induced mucosal immunization are important to decipher, since this can form the basis for novel approaches in, e.g., nasal vaccination. In this study, we have investigated the effect of nanospheres as antigen carriers on immature human dendritic cells. The results clearly indicate that tetanus toxoid immobilized nanospheres have a direct effect on human monocyte derived dendritic cells and induce a specific transcriptional profile involving genes crucial for phagocytosis and a protective immune response.
C1 Lund Univ, Dept Immunotechnol, SE-22007 Lund, Sweden.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Osaka, Japan.
   CREST, Osaka, Japan.
   CREST, Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Tokyo, Japan.
RP Borrebaeck, CAK (reprint author), Lund Univ, Dept Immunotechnol, POB 7031, SE-22007 Lund, Sweden.
EM carl.borrebaeck@immun.lth.se
RI Lindstedt, Malin/A-3855-2009; Matsusaki, Michiya/E-2476-2011
OI Lindstedt, Malin/0000-0001-9136-1087; Matsusaki,
   Michiya/0000-0003-4294-9313
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818
   Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749
   BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213
   Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7
   CROFT M, 1992, J EXP MED, V176, P1431, DOI 10.1084/jem.176.5.1431
   El Mezgueldi M, 2002, J BIOL CHEM, V277, P21514, DOI 10.1074/jbc.M200713200
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Gauzzi MC, 2002, J IMMUNOL, V169, P3038, DOI 10.4049/jimmunol.169.6.3038                                                     
   HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559
   Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870                                                    
   Kaneko T, 2004, J BIOMAT SCI-POLYM E, V15, P661, DOI 10.1163/156856204323046915
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Lindstedt M, 2002, INT IMMUNOL, V14, P1203, DOI 10.1093/intimm/dxf082                                                           
   Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104
   MACATONIA SE, 1995, J IMMUNOL, V154, P5071
   Mason JM, 2004, J IMMUNOL, V173, P4561, DOI 10.4049/jimmunol.173.7.4561                                                     
   Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moschella F, 2001, BRIT J HAEMATOL, V114, P444, DOI 10.1046/j.1365-2141.2001.02953.x                                                
   Nishimoto Norihiro, 2000, Annals of the Rheumatic Diseases, V59, pi21, DOI 10.1136/ard.59.suppl_1.i21
   Parker LC, 2004, J IMMUNOL, V172, P4977, DOI 10.4049/jimmunol.172.8.4977                                                     
   Patel DD, 2001, CLIN IMMUNOL, V99, P43, DOI 10.1006/clim.2000.4997
   Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   van der Flier A, 2002, J CELL BIOL, V156, P361, DOI 10.1083/jcb.200103037
   Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249                                                      
NR 32
TC 17
Z9 18
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD NOV
PY 2005
VL 5
IS 11
BP 2168
EP 2173
DI 10.1021/nl050541s
PG 6
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 986WZ
UT WOS:000233481700011
PM 16277447
DA 2018-01-05
ER

PT J
AU Pereira de Oliveira, M
   Garcion, E
   Venisse, N
   BenoIt, JP
   Couet, W
   Olivier, JC
AF Pereira de Oliveira, M
   Garcion, E
   Venisse, N
   BenoIt, JP
   Couet, W
   Olivier, JC
TI Tissue distribution of indinavir administered as solid lipid nanocapsule
   formulation in mdr1a (+/+) and mdr1a (-/-) CF-1 mice
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE CF-1 mice; indinavir; P-glycoprotein; solid lipid nanocapsule; Solutol
   (R) HS15
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV PROTEASE INHIBITORS;
   RESISTANCE-MODIFICATION AGENTS; FATTY-ACID DIESTERS; MALE WISTAR RATS;
   P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; SOLUTOL HS-15; CREMOPHOR-EL; HUMAN
   PLASMA
AB Purpose. Due to protease inhibitor (PI) efflux transport by P-glycoprotein (P-gp), insufficient PI concentrations result in low ongoing HIV replication in the so-called virus sanctuaries (brain and testes). The aim of the present study was to evaluate indinavir-loaded nanocapsules (Ind-LNC) including Solutol(R) HS15, an excipient reported to possess in vitro P-gp inhibiting properties, as a means to improve indinavir distribution into brain and testes of mice.
   Methods. Normal mdr1a (+/+) or P-gp-deficient mdr1a (-/-) CF-1 mice were dosed with Ind-LNC (10 mg indinavir/kg, i.v.). At 30 min postadministration, indinavir was determined in plasma, brain, testes, as well as in kidneys, liver, and heart by LC-MS/MS, and tissue/plasma concentration ratios were calculated. Results were compared with those of control groups that received an indinavir solution (Ind-Sol).
   Results. Using Ind-Sol, ratios were 21.3- and 3.3-fold higher in brains and testes of mdr1a (-/-) mice than of mdr1a (+/+) mice, respectively, whereas in the other organs ratios were not significantly different between the two substrains. When Ind-LNC was used, a similar [mdr1a (-/-) vs. mdr1a (+/+) mice] trend was observed. Moreover, ratios were found to be significantly increased (1.9-fold increase in average) in most organs (brain and testes in particular) with Ind-LNC compared to Ind-Sol, regardless of the substrain used.
   Conclusions. In agreement with previous works, P-gp governs at least in part indinavir uptake into brain and testes. LNC formulation increased indinavir uptake in brain and testes by mechanisms other than, or additional to, P-gp inhibition.
C1 Fac Med & Pharm, EA Pharmacol Medicaments Antiinfect 3809, F-86022 Poitiers, France.
   INSERM, U646, F-49100 Angers, France.
   CHU Poitiers, Fac Med & Pharm, Lab Pharmacocinet, F-86022 Poitiers, France.
RP Olivier, JC (reprint author), Fac Med & Pharm, EA Pharmacol Medicaments Antiinfect 3809, Pole Biol Sante,40 Av Recteur Pineau, F-86022 Poitiers, France.
EM jean.christophe.olivier@univ.poitiers.fr
RI GARCION, Emmanuel/K-5417-2015; Benoit, Jean-Pierre/K-4387-2015
OI GARCION, Emmanuel/0000-0003-0887-272X; Couet,
   William/0000-0002-7116-8965; Venisse, Nicolas/0000-0002-7466-6388;
   Olivier, Jean Christphe/0000-0002-9116-4400
CR Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Bittner B, 2003, EUR J PHARM BIOPHARM, V56, P143, DOI 10.1016/S0939-6411(03)00041-9
   Bittner B, 2003, BIOPHARM DRUG DISPOS, V24, P173, DOI 10.1002/bdd.353
   Buckingham LE, 1996, INT J CANCER, V65, P74
   BUCKINGHAM LE, 1995, INT J CANCER, V62, P436, DOI 10.1002/ijc.2910620413
   Bush JA, 2002, CARCINOGENESIS, V23, P1603, DOI 10.1093/carcin/23.10.1603                                                       
   Buszello K, 2000, EUR J PHARM BIOPHARM, V49, P143, DOI 10.1016/S0939-6411(99)00081-8
   Cahouet A, 2002, INT J PHARM, V242, P367, DOI 10.1016/S0378-5173(02)00218-1
   Chi JD, 2002, J PHARMACEUT BIOMED, V30, P675, DOI 10.1016/S0731-7085(02)00357-6
   CHONG ASF, 1993, CANCER IMMUNOL IMMUN, V36, P133, DOI 10.1007/BF01754414
   Choo EF, 2000, DRUG METAB DISPOS, V28, P655
   Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958
   COON JS, 1991, CANCER RES, V51, P897
   CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695
   CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346                                                            
   de Lange ECM, 2004, ADV DRUG DELIVER REV, V56, P1793, DOI 10.1016/j.addr.2004.07.009
   DUDEJA PK, 1995, ARCH BIOCHEM BIOPHYS, V319, P309, DOI 10.1006/abbi.1995.1298
   Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1
   Gonzalez RCB, 2004, BIOPHARM DRUG DISPOS, V25, P37, DOI 10.1002/bdd.383
   HOLASH JA, 1993, P NATL ACAD SCI USA, V90, P11069, DOI 10.1073/pnas.90.23.11069
   Huisman MT, 2002, AIDS, V16, P2295, DOI 10.1097/00002030-200211220-00009
   Jodoin J, 2003, J NEUROCHEM, V87, P1010, DOI 10.1046/j.1471-4159.2003.02081.x
   Kepler TB, 1998, P NATL ACAD SCI USA, V95, P11514, DOI 10.1073/pnas.95.20.11514
   Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269
   Kolson DL, 1998, ADV VIRUS RES, V50, P1, DOI 10.1016/S0065-3527(08)60804-0
   Komarov PG, 1996, INT J CANCER, V68, P245, DOI 10.1002/(SICI)1097-0215(19961009)68:2<245::AID-IJC18>3.0.CO;2-9
   Lankas GR, 1997, TOXICOL APPL PHARM, V143, P357, DOI 10.1006/taap.1996.8086                                                          
   Lewis JS, 1997, CLIN THER, V19, P187, DOI 10.1016/S0149-2918(97)80110-5
   Li LLY, 2002, J PHARMACOL EXP THER, V301, P586, DOI 10.1124/jpet.301.2.586
   Lin JH, 2004, DRUGS TODAY, V40, P5, DOI 10.1358/dot.2004.40.1.799434                                                    
   Lockman PR, 2003, PHARMACEUT RES, V20, P705, DOI 10.1023/A:1023492015851
   Melaine N, 2002, BIOL REPROD, V67, P1699, DOI 10.1095/biolreprod.102.003558
   Mizuno N, 2003, PHARMACOL REV, V55, P425, DOI 10.1124/pr.55.3.1
   Pippert TR, 2001, J BIOCHEM MOL TOXIC, V15, P83, DOI 10.1002/jbt.3                                                                   
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Rosati A, 2003, DEV GROWTH DIFFER, V45, P377
   Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028
   Schuetz EG, 2000, MOL PHARMACOL, V57, P188
   THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735
   TSE FLS, 1995, PHARMACOKINETICS REG, P281
   van Asperen J, 1999, BRIT J CANCER, V79, P108, DOI 10.1038/sj.bjc.6690019                                                          
   van Heeswijk RPG, 1998, J CHROMATOGR B, V719, P159, DOI 10.1016/S0378-4347(98)00392-2                                                   
   Vonarbourg A, 2005, ELECTROPHORESIS, V26, P2066, DOI 10.1002/elps.200410145
   WOODBURN K, 1995, INT J BIOCHEM CELL B, V27, P693, DOI 10.1016/1357-2725(95)00030-S
   Wu EY, 1997, J CHROMATOGR B, V695, P373, DOI 10.1016/S0378-4347(97)00193-X
   Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502                                                     
   HEURTAULT B, 2000, Patent No. 0002688
NR 47
TC 5
Z9 5
U1 0
U2 3
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD NOV
PY 2005
VL 22
IS 11
BP 1898
EP 1905
DI 10.1007/s11095-005-7147-6
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 977QY
UT WOS:000232819500013
PM 16132350
DA 2018-01-05
ER

PT J
AU Embrey, MW
   Wai, JS
   Funk, TW
   Homnick, CF
   Perlow, DS
   Young, SD
   Vacca, JP
   Hazuda, DJ
   Felock, PJ
   Stillmock, KA
   Witmer, MV
   Moyer, G
   Schleif, WA
   Gabryelski, LJ
   Jin, LX
   Chen, IW
   Ellis, JD
   Wong, BK
   Lin, JH
   Leonard, YM
   Tsou, NN
   Zhuang, LH
AF Embrey, MW
   Wai, JS
   Funk, TW
   Homnick, CF
   Perlow, DS
   Young, SD
   Vacca, JP
   Hazuda, DJ
   Felock, PJ
   Stillmock, KA
   Witmer, MV
   Moyer, G
   Schleif, WA
   Gabryelski, LJ
   Jin, LX
   Chen, IW
   Ellis, JD
   Wong, BK
   Lin, JH
   Leonard, YM
   Tsou, NN
   Zhuang, LH
TI A series of 5-(5,6)-dihydrouracil substituted
   8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide
   inhibitors of HIV-1 integrase and viral replication in cells
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV-1 integrase inhibitors; naphthyridine
AB Introduction of a 5,6-dihydrouracil functionality in the 5-position of N-(4-fluorobenzyl)-8-hydroxy-[1,6]naphthyridine-7-carboxamide I led to a series of highly active HIV-1 integrase inhibitors. These compounds displayed low nanomolar activity in inhibiting both the strand transfer process of HIV-1 integrase and viral replication in cells. Compound 11 is a 150-fold more potent antiviral agent than 1, with a CIC95 of 40 nM in the presence of human serum. It displays good pharmacokinetics when dosed in rats and dogs. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA.
   Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA.
   Merck Res Labs, Dept Vaccine & Biol Res, West Point, PA 19486 USA.
   Merck Res Labs, Dept Drug Metab & Pharmacol, West Point, PA 19486 USA.
   Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA.
RP Embrey, MW (reprint author), Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA.
EM mark_embrey@merck.com
CR Anthony NJ, 2004, CURR TOP MED CHEM, V4, P979, DOI 10.2174/1568026043388448
   Chiu TK, 2004, CURR TOP MED CHEM, V4, P965, DOI 10.2174/1568026043388547
   Hazuda DJ, 1997, J VIROL, V71, P7005
   Hazuda DJ, 2004, P NATL ACAD SCI USA, V101, P11233, DOI 10.1073/pnas.0402357101
   LEE CK, 1991, B KOR CHEM SOC, V12, P343
   Littke AF, 2001, J AM CHEM SOC, V123, P6989, DOI 10.1021/ja010988c
   Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660
   SAITO I, 1986, J ORG CHEM, V51, P5148, DOI 10.1021/jo00376a018
   Stevenson TM, 1996, TETRAHEDRON LETT, V37, P8375, DOI 10.1016/0040-4039(96)01934-X                                                    
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Wai JS, 2000, J MED CHEM, V43, P4923, DOI 10.1021/jm000176b
   Zhuang LC, 2003, J MED CHEM, V46, P453, DOI 10.1021/jm025553u
   Anthony N.J., 2002, <IT>PCT Int. Appl.</IT>, P434, Patent No. [WO 0230930 A2 20020418, 0230930]
NR 13
TC 41
Z9 44
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD OCT 15
PY 2005
VL 15
IS 20
BP 4550
EP 4554
DI 10.1016/j.bmcl.2005.06.105
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 965FU
UT WOS:000231936700031
PM 16102965
DA 2018-01-05
ER

PT J
AU Ersmark, K
   Nervall, M
   Hamelink, E
   Janka, LK
   Clemente, JC
   Dunn, BM
   Blackman, MJ
   Samuelsson, B
   Aqvist, J
   Hallberg, A
AF Ersmark, K
   Nervall, M
   Hamelink, E
   Janka, LK
   Clemente, JC
   Dunn, BM
   Blackman, MJ
   Samuelsson, B
   Aqvist, J
   Hallberg, A
TI Synthesis of malarial plasmepsin inhibitors and prediction of binding
   modes by molecular dynamics simulations
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PARASITE PLASMODIUM-FALCIPARUM; HIV-1 PROTEASE INHIBITORS; FREE-ENERGY
   CALCULATIONS; ASPARTIC PROTEASE; POTENT INHIBITORS; FOOD VACUOLE;
   ACTIVE-SITE; HEMOGLOBIN DEGRADATION; COMBINATORIAL LIBRARY; CYSTEINE
   PROTEASE
AB A series of inhibitors of the malarial aspartic proteases Plm I and II have been synthesized with L-mannitol as precursor. These inhibitors are characterized by either a diacylhydrazine or a five-membered oxadiazole ring replacing backbone amide functionalities. Molecular dynamics simulations were applied in the design process. The computationally predicted Plm II K-i values were generally in excellent agreement with the biological results. The diacylhydrazine was found to be superior over the oxadiazole as an amide bond replacement in the Plm I and II inhibitors studied. An extensive flexibility of the S2 ' pocket was captured by the simulations predicting the binding mode of the unsymmetrical inhibitors. Plm I and II inhibitors with single digit nanomolar K-i values devoid of inhibitory activity toward human Cat D were identified. One compound, lacking amide bonds, was found to be Plm IV selective and very potent, with a K-i value of 35 nM.
C1 Univ Uppsala, BMC, Dept Med Chem, S-75123 Uppsala, Sweden.
   Uppsala Univ, Dept Cell & Mol Biol, S-75124 Uppsala, Sweden.
   Natl Inst Med Res, Div Parasitol, London NWI 1AA, England.
   Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
RP Hallberg, A (reprint author), Univ Uppsala, BMC, Dept Med Chem, Box 574, S-75123 Uppsala, Sweden.
EM Anders.Hallberg@orgfarm.uu.se
FU Medical Research Council [MC_U117532063]
CR AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385
   Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6
   Asojo OA, 2002, ACTA CRYSTALLOGR D, V58, P2001, DOI 10.1107/S0907444902014695
   Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099
   Berry C, 2000, Curr Opin Drug Discov Devel, V3, P624
   Bjelic S, 2004, BIOCHEMISTRY-US, V43, P14521, DOI 10.1021/bi048252q
   Boss C, 2003, CURR MED CHEM, V10, P883, DOI 10.2174/0929867033457674
   Brain CT, 1999, TETRAHEDRON LETT, V40, P3275, DOI 10.1016/S0040-4039(99)00382-2                                                   
   BREMAN J, 2001, AM J TROP MED HYG, V64
   Carroll CD, 1998, BIOORG MED CHEM LETT, V8, P2315, DOI 10.1016/S0960-894X(98)00419-3
   Carroll CD, 1998, BIOORG MED CHEM LETT, V8, P3203, DOI 10.1016/S0960-894X(98)00554-X
   Chen XQ, 2003, ANNU REP MED CHEM, V38, P333, DOI 10.1016/S0065-7743(03)38033-9
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2
   COPELAND RA, 1996, ENZYMES PRACTICAL IN
   Cornell WD, 1996, J AM CHEM SOC, V118, P2309, DOI 10.1021/ja955032e                                                               
   Dahlgren A, 2003, BIOORGAN MED CHEM, V11, P3423, DOI 10.1016/S0968-0896(03)00312-2
   Dame JB, 2003, MOL BIOCHEM PARASIT, V130, P1, DOI 10.1016/S0166-6851(03)00137-3
   Dolle RE, 2000, J COMB CHEM, V2, P716, DOI 10.1021/cc000052k
   Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411
   Ersmark K, 2004, J MED CHEM, V47, P110, DOI 10.1021/jm030933g
   Ersmark K, 2003, BIOORGAN MED CHEM, V11, P3723, DOI 10.1016/S0968-0896(03)00339-0
   FRISCH MJ, 1998, GAUSSIAN 98 REV
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Giannis A., 1993, ANGEW CHEM, V105, P1303
   GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140
   GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961
   Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t
   HENICHART JP, 1977, J HETEROCYCLIC CHEM, V14, P615, DOI 10.1002/jhet.5570140416                                                         
   Hulten J, 1997, J MED CHEM, V40, P885, DOI 10.1021/jm960728j                                                               
   Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001
   Johansson PO, 2004, J MED CHEM, V47, P3353, DOI 10.1021/jm031106i
   KING G, 1989, J CHEM PHYS, V91, P3647, DOI 10.1063/1.456845
   Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997
   Larhed M, 2002, ACCOUNTS CHEM RES, V35, P717, DOI 10.1021/ar010074v
   Larhed M, 1996, TETRAHEDRON LETT, V37, P8219, DOI 10.1016/0040-4039(96)01872-2                                                    
   LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997
   Li T, 2004, MOL BIOCHEM PARASIT, V135, P101, DOI 10.1016/j.molbiopara.2004.01.010
   Liu J, 2005, J BIOL CHEM, V280, P1432, DOI 10.1074/jbc.M409740200
   Marelius J, 1998, INT J QUANTUM CHEM, V69, P77, DOI 10.1002/(SICI)1097-461X(1998)69:1<77::AID-QUA10>3.3.CO;2-2
   Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(98)80006-5
   Moon RP, 1997, EUR J BIOCHEM, V244, P552, DOI 10.1111/j.1432-1033.1997.00552.x
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   NARDI D, 1971, J MED CHEM, V14, P635
   Netherton MR, 2001, ORG LETT, V3, P4295, DOI 10.1021/ol016971g
   Nezami A, 2003, BIOCHEMISTRY-US, V42, P8459, DOI 10.1021/bi034131z
   Nezami A, 2002, INT J PARASITOL, V32, P1669, DOI 10.1016/S0020-7519(02)00196-0
   Nezami A, 2002, BIOCHEMISTRY-US, V41, P2273, DOI 10.1021/bi0117549
   Noteberg D, 2003, J MED CHEM, V46, P734, DOI 10.1021/jm020951i
   Noteberg D, 2003, J COMB CHEM, V5, P456, DOI 10.1021/cc0301014
   Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8                                                   
   Omara-Opyene AL, 2004, J BIOL CHEM, V279, P54088, DOI 10.1074/jbc.M409605200
   Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090
   Oscarsson K, 2003, BIOORGAN MED CHEM, V11, P1235, DOI 10.1016/S0968-0896(02)00643-0
   Oscarsson K, 2003, BIOORGAN MED CHEM, V11, P1107, DOI 10.1016/S0968-0896(02)00535-7
   Patani GA, 1996, CHEM REV, V96, P3147, DOI 10.1021/cr950066q                                                               
   Prata JV, 2002, J CHEM SOC PERK T 1, P513, DOI 10.1039/b110414d
   ROSENTHAL PJ, 1995, EXP PARASITOL, V80, P272, DOI 10.1006/expr.1995.1033
   SALAS F, 1995, INFECT IMMUN, V63, P2120
   Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200
   Shirts MR, 2003, J CHEM PHYS, V119, P5740, DOI 10.1063/1.1587119
   Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481
   Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034
   van Gunsteren W.F., 1987, GRONINGEN MOL SIMULA
   Westling J, 1999, PROTEIN SCI, V8, P2001, DOI 10.1110/ps.8.10.2001                                                            
   Wongsrichanalai C, 2002, LANCET INFECT DIS, V2, P209, DOI 10.1016/S1473-3099(02)00239-6
   Wyatt DM, 2002, FEBS LETT, V513, P159, DOI 10.1016/S0014-5793(02)02241-X
NR 67
TC 55
Z9 58
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 22
PY 2005
VL 48
IS 19
BP 6090
EP 6106
DI 10.1021/jm0504631
PG 17
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 967GS
UT WOS:000232080200021
PM 16162010
DA 2018-01-05
ER

PT J
AU You, CC
   De, M
   Han, G
   Rotello, VM
AF You, CC
   De, M
   Han, G
   Rotello, VM
TI Tunable inhibition and denaturation of alpha-chymotrypsin with amino
   acid-functionalized gold nanoparticles
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID SELF-ASSEMBLED MONOLAYERS; PROTEIN-PROTEIN INTERACTIONS; SURFACE
   RECOGNITION; CLUSTER MOLECULES; BUILDING-BLOCKS; MIXED MONOLAYER; HIV-1
   PROTEASE; RECEPTORS; PEPTIDE; BINDING
AB Water-soluble gold nanoparticles bearing diverse L-amino acid terminals have been fabricated to probe the effect of receptor surface on protein surface binding. The interaction of these nanoparticles with a-chymotrypsin (ChT) was investigated by activity assay, gel electrophoresis, zeta-potential, circular dichroism, and fluorescence spectroscopy. The results show that both electrostatic and hydrophobic interactions between the hydrophobic patches of receptors and the protein contribute to the stability of the complex. The microscopic binding constants for these receptor-protein systems are 10(6)-10(7) M-1, with the capacity of the nanoparticle receptors to bind proteins determined by both their surface area and their surface charge density. Furthermore, it is found that the hydrophilic side chains destabilize the ChT structure through either competitive hydrogen bonding or breakage of salt bridges, whereas denaturation was much slower with hydrophobic amino acid side chains. Significantly, correlation between the hydrophobicity index of amino acid side chains and the binding affinity and denaturation rates was observed.
C1 Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
RP Rotello, VM (reprint author), Univ Massachusetts, Dept Chem, 710 N Pleasant St, Amherst, MA 01003 USA.
EM rotello@chem.umass.edu
RI han, gang/B-7274-2013
OI han, gang/0000-0002-2300-5862
FU NIGMS NIH HHS [GM 59249]
CR BLOW DM, 1976, ACCOUNTS CHEM RES, V9, P145, DOI 10.1021/ar50100a004                                                             
   Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843
   Branden C., 1999, INTRO PROTEIN STRUCT
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Burgess K, 2001, ACCOUNTS CHEM RES, V34, P826, DOI 10.1021/ar9901523
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   CHOTHIA C, 1984, ANNU REV BIOCHEM, V53, P537
   Coppola G. M., 1987, ASYMMETRIC SYNTHESIS
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Ernst JT, 2003, ANGEW CHEM INT EDIT, V42, P535, DOI 10.1002/anie.200390154                                                          
   Fairlie DP, 1998, CURR MED CHEM, V5, P29
   Fazal MA, 2001, J AM CHEM SOC, V123, P6283, DOI 10.1021/ja003193z
   Fischer NO, 2003, J AM CHEM SOC, V125, P13387, DOI 10.1021/ja0352505
   Fischer NO, 2002, P NATL ACAD SCI USA, V99, P5018, DOI 10.1073/pnas.082644099
   Gadek TR, 2003, BIOCHEM PHARMACOL, V65, P1, DOI 10.1016/S0006-2952(02)01479-X
   GREENE TW, 1999, PROTECTIVE GROUPS OR
   Groves K, 2004, J AM CHEM SOC, V126, P12833, DOI 10.1021/ja0317731
   Hamuro Y, 1997, ANGEW CHEM INT EDIT, V36, P2680, DOI 10.1002/anie.199726801                                                          
   Harris J.M., 1992, POLYETHYLENE GLYCOL
   Herrwerth S, 2003, J AM CHEM SOC, V125, P9359, DOI 10.1021/ja034820y
   Hong R, 2004, J AM CHEM SOC, V126, P739, DOI 10.1021/ja037470o
   Hong R, 2004, J AM CHEM SOC, V126, P13572, DOI 10.1021/ja0461163
   Hostetler MJ, 1998, LANGMUIR, V14, P17, DOI 10.1021/la970588w                                                               
   Hostetler MJ, 1996, J AM CHEM SOC, V118, P4212, DOI 10.1021/ja960198g                                                               
   Hostetler MJ, 1999, LANGMUIR, V15, P3782, DOI 10.1021/la981598f                                                               
   Houseman BT, 1998, J ORG CHEM, V63, P7552, DOI 10.1021/jo981113s                                                               
   Hu JQ, 2004, J AM CHEM SOC, V126, P9470, DOI 10.1021/ja049738x
   Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13
   Kane RS, 2003, LANGMUIR, V19, P2388, DOI 10.1021/la020737x
   Katz E, 2004, ANGEW CHEM INT EDIT, V43, P6042, DOI 10.1002/anie.200400651
   Kirby BJ, 2004, ELECTROPHORESIS, V25, P187, DOI 10.1002/elps.200305754
   Ladokhin AS, 2000, ENCY ANAL CHEM, P5762
   Leung DK, 2000, P NATL ACAD SCI USA, V97, P5050, DOI 10.1073/pnas.97.10.5050                                                         
   Li XM, 2004, J MATER CHEM, V14, P2954, DOI 10.1039/b406037g
   Li Z, 2005, ANGEW CHEM INT EDIT, V44, P123, DOI 10.1002/anie.200460715
   Lijnzaad P, 1997, PROTEINS, V28, P333
   Lo Conte L, 1999, J MOL BIOL, V285, P2177
   Lu XF, 2004, CHEM COMMUN, P1522, DOI 10.1039/b403105a
   McIntosh CM, 2001, J AM CHEM SOC, V123, P7626, DOI 10.1021/ja015556g
   Monera OD, 1995, J PEPT SCI, V1, P319, DOI 10.1002/psc.310010507
   Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+
   Nath N, 2001, J AM CHEM SOC, V123, P8197, DOI 10.1021/ja015585r
   Nissink JWM, 1999, APPL SPECTROSC, V53, P33, DOI 10.1366/0003702991945425                                                        
   Park HS, 1999, J AM CHEM SOC, V121, P8, DOI 10.1021/ja981504o                                                               
   Pasquato L, 2004, J MATER CHEM, V14, P3481, DOI 10.1039/b410476e
   Peczuh MW, 2000, CHEM REV, V100, P2479, DOI 10.1021/cr9900026
   Pengo P, 2005, J AM CHEM SOC, V127, P1616, DOI 10.1021/ja043547c
   Pengo P, 2003, LANGMUIR, V19, P2521, DOI 10.1021/la025982v
   Perrin D. D., 1988, PURIFICATION LAB CHE
   Raschke G, 2003, NANO LETT, V3, P935, DOI 10.1021/nl034223+
   Redl FX, 2004, J AM CHEM SOC, V126, P14583, DOI 10.1021/ja046808r
   Roberts C, 1998, J AM CHEM SOC, V120, P6548, DOI 10.1021/ja972467o                                                               
   Sastry M, 2002, ACCOUNTS CHEM RES, V35, P847, DOI 10.1021/ar010094x
   Schaaff TG, 1998, J PHYS CHEM B, V102, P10643, DOI 10.1021/jp9830528
   Shenhar R, 2003, ACCOUNTS CHEM RES, V36, P549, DOI 10.1021/ar020083j
   Shultz MD, 2004, J AM CHEM SOC, V126, P9886, DOI 10.1021/ja048139n
   Shultz MD, 1999, BIOORG MED CHEM LETT, V9, P2431, DOI 10.1016/S0960-894X(99)00400-X                                                   
   Skaff H, 2004, J AM CHEM SOC, V126, P11322, DOI 10.1021/ja047260r
   Stavens KB, 1999, LANGMUIR, V15, P8337, DOI 10.1021/la9911786                                                               
   Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h                                                               
   Templeton AC, 1998, J AM CHEM SOC, V120, P4845, DOI 10.1021/ja980177h                                                               
   Templeton AC, 2000, ACCOUNTS CHEM RES, V33, P27, DOI 10.1021/ar9602664
   Toogood PL, 2002, J MED CHEM, V45, P1543, DOI 10.1021/jm010468s
   TSUKADA H, 1985, J MOL BIOL, V184, P703, DOI 10.1016/0022-2836(85)90314-6                                                    
   Turro NJ, 2002, NANO LETT, V2, P325, DOI 10.1021/n10202861
   Verma A, 2005, CHEM COMMUN, P303, DOI 10.1039/b410889b
   Verma A, 2004, J AM CHEM SOC, V126, P10806, DOI 10.1021/ja047719h
   Wang GL, 2002, ANAL CHEM, V74, P4320, DOI 10.1021/ac0257804
   WILSON AJ, 2003, J AM CHEM SOC, V125, P440
   Wilson R, 2003, CHEM COMMUN, P108, DOI 10.1039/b208170a
   Witt D, 2004, CURR ORG CHEM, V8, P1763, DOI 10.2174/1385272043369421                                                        
   Wroblowski B, 1997, PROTEIN ENG, V10, P1163, DOI 10.1093/protein/10.10.1163
   WU HL, 1981, P NATL ACAD SCI-BIOL, V78, P4118, DOI 10.1073/pnas.78.7.4118
   Zheng M, 2004, J AM CHEM SOC, V126, P12047, DOI 10.1021/ja047029d
   Zheng M, 2003, J AM CHEM SOC, V125, P7790, DOI 10.1021/ja0350278
   Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j                                                               
NR 76
TC 180
Z9 184
U1 3
U2 80
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD SEP 21
PY 2005
VL 127
IS 37
BP 12873
EP 12881
DI 10.1021/ja0512881
PG 9
WC Chemistry, Multidisciplinary
SC Chemistry
GA 965CY
UT WOS:000231928800043
PM 16159281
DA 2018-01-05
ER

PT J
AU Bianchi, E
   Finotto, M
   Ingallinella, P
   Hrin, R
   Carella, AV
   Hou, XS
   Schleif, WA
   Miller, MD
   Geleziunas, R
   Pessi, A
AF Bianchi, E
   Finotto, M
   Ingallinella, P
   Hrin, R
   Carella, AV
   Hou, XS
   Schleif, WA
   Miller, MD
   Geleziunas, R
   Pessi, A
TI Covalent stabilization of coiled coils of the HIV gp41 N region yields
   extremely potent and broad inhibitors of viral infection
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE fusion inhibitor
ID IMMUNODEFICIENCY-VIRUS TYPE-1; MONOCLONAL-ANTIBODY; PEPTIDE INHIBITOR;
   ATOMIC-STRUCTURE; MEMBRANE-FUSION; VACCINE DESIGN; CORE STRUCTURE;
   CELL-FUSION; ENTRY; ENFUVIRTIDE
AB Peptides from the N-heptad repeat region of the HIV gp41 protein can inhibit viral fusion, but their potency is limited by a low tendency to form a trimeric coiled-coil. Accordingly, stabilization of N peptides by fusion with the stable coiled-coil IZ yields nanomolar inhibitors [Eckert, D. M. & Kim, P. S. (2001) Proc. Natl. Acad. Sci. USA 98, 11187-11192]. Because the antiviral potency of IZN17 is limited by self-association equilibrium, we covalently stabilized the peptide by using interchain disulfide bonds. The resulting covalent trimer, (CCIZN17)(3), has an extraordinary thermodynamic stability that translates into unprecedented antiviral potency: (CCIZN17)3 (1) inhibits fusion in a cell-cell fusion assay (IC50 = 260 pM); (ii) is the most potent fusion inhibitor described to date (IC50 = 40-380 pM) in a single-cycle infectivity assay against HIVHXB2, HIVNL4-3, and HIVMN-1; (iii) efficiently neutralizes acute viral infection in peripheral blood mononuclear cells; and (iv) displays a broad antiviral profile, being able to neutralize 100 % of a large panel of HIV isolates, including R5, X4, and R5/X4 strains. In all of these assays, the potency of N-peptide inhibitor (CCIZN17)(3) was equal to or more than the C-peptide inhibitor in clinical use, DP178 (also known as Enfuvirtide and Fuzeon). More importantly, we show that the two inhibitors, which have different targets in gp41, synergize when used in combination. These features make (CCIZN17)(3) an attractive lead to develop as an antiviral drug, alone or in combination with DP178, as well as a promising immunogen to elicit a fusion-blocking neutralizing antibody response.
C1 Ist Ric Biol Mol P Angeletti, Dept Mol & Cell Biol, I-00040 Pomezia, Italy.
   Merck Res Labs, West Point, PA 19486 USA.
RP Bianchi, E (reprint author), Ist Ric Biol Mol P Angeletti, Dept Mol & Cell Biol, Via Pontina Km 30-600, I-00040 Pomezia, Italy.
EM elisabetta_bianchi@merck.com
CR Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200
   Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   CHARNEAU P, 1992, J VIROL, V66, P2814
   Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Derdeyn CA, 2001, J VIROL, V75, P8605, DOI 10.1128/JVI.75.18.8605-8614.2001
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214                                                          
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35
   Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5
   Joyce JG, 2002, J BIOL CHEM, V277, P45811, DOI 10.1074/jbc.M205862200
   LaBonte J, 2003, NAT REV DRUG DISCOV, V2, P345, DOI 10.1038/nrd1091
   Lineberger JE, 2002, J VIROL, V76, P3522, DOI 10.1128/JVI.76.7.3522-3533.2002
   Liu SW, 2004, CURR PHARM DESIGN, V10, P1827, DOI 10.2174/1381612043384466
   Louis JM, 2003, J BIOL CHEM, V278, P20278, DOI 10.1074/jbc.M301627200
   Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   Miller MD, 2004, DRUG RESIST UPDATE, V7, P89, DOI 10.1016/j.drup.2004.03.003
   Naicker KP, 2004, BIOORGAN MED CHEM, V12, P1215, DOI 10.1016/j.bmc.2003.11.006
   Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399
   Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Sundaram R, 2004, J BIOL CHEM, V279, P24141, DOI 10.1074/jbc.M313210200
   Suzuki K, 1998, PROTEIN ENG, V11, P1051, DOI 10.1093/protein/11.11.1051                                                      
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676                                                        
   WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
NR 36
TC 84
Z9 92
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 6
PY 2005
VL 102
IS 36
BP 12903
EP 12908
DI 10.1073/pnas.0502449102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 962FP
UT WOS:000231716700047
PM 16129831
OA gold
DA 2018-01-05
ER

PT J
AU Reynolds, F
   Weissleder, R
   Josephson, L
AF Reynolds, F
   Weissleder, R
   Josephson, L
TI Protamine as an efficient membrane-translocating peptide
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID ARGININE-RICH PEPTIDES; HIV-1 TAT PROTEIN; CELL-PENETRATING PEPTIDES;
   INTRACELLULAR DELIVERY; TRANSDUCTION DOMAINS; NANOPARTICLES; SURFACE;
   DNA; INTERNALIZATION; CONJUGATION
AB Protamine, a mixture of positively charged proteins from salmon roe used in diverse pharmaceutical applications, was reacted with the N-hydroxysuccinimide ester of tetramethylrhodamine to yield tetramethylrhodamine-labeled protamines (Pro(Rh)) containing one mole of fluorochrome per mole of protein. The internalization of tetramethylrhodamine-labeled protamine (Pro(Rh)) and the fluorescein-labeled tat peptide (Tat(Fl)) showed a similar dependence on time and concentration. Pro(Rh) and Tat(Fl) showed strong nuclear localizations, evident with both live cells and fixed cells costained with DAPI, a nuclear stain. The loss of fluorescence when cells were loaded with Pro(Rh) or Tat(Fl) was similar, further supporting a strong similarity between these two materials. Finally, when Pro(Ph) was covalently attached to the amino-CLIO nanoparticle, the cellular uptake of the nanoparticle was greatly enhanced. All experiments were performed with HeLa and CaCo-2 cells with similar results. These observations imply that protamine, a protein in regular clinical use, might be used for the design of novel membrane translocating/nuclear localizing pharmaceuticals whose development was initiated with other membrane-translocating peptides. In addition, the fluorescent protamines developed here might be used to further our understanding of this important pharmaceutical.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02129 USA.
RP Josephson, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02129 USA.
EM ljosephson@partners.org
OI /0000-0003-0828-4143
FU NIBIB NIH HHS [R01 EB004626, R01-EB00662]
CR BRANGE J, 1992, ACTA PHARM NORDICA, V4, P149
   Brange J, 1997, Pharm Biotechnol, V10, P343
   Carr JA, 1999, J CARDIOVASC SURG, V40, P659
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383
   Fuentes-Mascorro G, 2000, ARCH ANDROLOGY, V45, P215
   Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ
   Josephson L, 2001, ANGEW CHEM INT EDIT, V40, P3204, DOI 10.1002/1521-3773(20010903)40:17<3204::AID-ANIE3204>3.0.CO;2-H                  
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Koch AM, 2005, CHEMBIOCHEM, V6, P337, DOI 10.1002/cbic.200400174
   Koch AM, 2003, BIOCONJUGATE CHEM, V14, P1115, DOI 10.1021/bc034123v
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   MANN DA, 1991, EMBO J, V10, P1733
   Meistrich ML, 2003, CHROMOSOMA, V111, P483, DOI 10.1007/s00412-002-0227-z
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Reynolds F, 2005, ANAL CHEM, V77, P814, DOI 10.1021/ac049307x
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Snyder EL, 2001, CURR OPIN MOL THER, V3, P147
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 31
TC 68
Z9 71
U1 2
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD SEP-OCT
PY 2005
VL 16
IS 5
BP 1240
EP 1245
DI 10.1021/bc0501451
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 967CX
UT WOS:000232070200027
PM 16173804
DA 2018-01-05
ER

PT J
AU Reineke, TM
   Grinstaff, MW
AF Reineke, TM
   Grinstaff, MW
TI Designer materials for nucleic acid delivery
SO MRS BULLETIN
LA English
DT Article
DE DNA; gene delivery; lipid; lipoplex; liposome; nonviral vector; nucleic
   acid delivery; peptide; polyplex; RNA; viral vector
ID GENE-THERAPY; VIRAL VECTORS; DNA DELIVERY; SYSTEMS
AB The Human Genome Project continues to reveal the genetic basis for numerous acquired and inherited diseases ranging from cancer, HIV, and heart disease to muscular dystrophy and hemophilia. With this wealth of information, the ability to design patient-specific drugs that alter the cellular machinery at the genetic level in a way that controls or treats a specific disease will increasingly become a reality. Designing nucleic acid drugs as well as engineering novel delivery vehicles that encapsulate and effectively transport genetic materials into cells provides an opportunity to enhance the understanding of disease mechanisms and may help treat or cure these diseases. This issue of MRS Bulletin on "Designer Materials for Nucleic Acid Delivery" explores the diverse materials-polymers, lipids, nanoparticles, biocompatible scaffolds, and engineered peptides-that are being evaluated for the intracellular delivery of nucleic acids. These synthetic delivery systems are actively being investigated for many research purposes that range from gene-based therapy, genetic vaccine, and RNA interference to gene function and cellular signaling studies. This area is currently being pursued by a broad group of academic, clinical, and industrial researchers at both the fundamental and applied level, motivated by the widespread implications for human health. In this introductory article, we provide a general tutorial to gene-based therapies and a brief overview of the many areas of materials research that are currently making a tremendous impact on this interdisciplinary field. We conclude with a discussion of the future challenges that materials researchers face in developing viable nucleic acid delivery vehicles.
C1 Univ Cincinnati, Cincinnati, OH 45221 USA.
   Boston Univ, Boston, MA 02215 USA.
RP Reineke, TM (reprint author), Univ Cincinnati, Cincinnati, OH 45221 USA.
EM Theresa.Reineke@uc.edu; mgrin@bu.edu
RI Grinstaff, Mark/U-2829-2017
OI Grinstaff, Mark/0000-0002-5453-3668
CR Anderson WF, 1998, NATURE, V392, P25
   BEHR JP, 1993, ACCOUNTS CHEM RES, V26, P274, DOI 10.1021/ar00029a008                                                             
   Davis ME, 2002, CURR OPIN BIOTECH, V13, P128, DOI 10.1016/S0958-1669(02)00294-X
   Felgner PL, 1997, SCI AM, V276, P102, DOI 10.1038/scientificamerican0697-102                                              
   HUANG L, 1999, NONVIRAL VECTORS GEN, P442
   Kabanov A, 1998, SELF ASSEMBLING COMP
   Kay MA, 1997, P NATL ACAD SCI USA, V94, P12744, DOI 10.1073/pnas.94.24.12744                                                        
   Liu YM, 2005, J AM CHEM SOC, V127, P3004, DOI 10.1021/ja0436446                                                               
   Liu YM, 2004, J AM CHEM SOC, V126, P7422, DOI 10.1021/ja049831l
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   Marshall E, 2000, SCIENCE, V287, P565
   Miller A. D., 1998, ANGEW CHEM INT EDIT, V37, P1768, DOI 10.1002/(SICI)1521-3773(19980803)37:13/14
   Prata CAH, 2004, J AM CHEM SOC, V126, P12196, DOI 10.1021/ja0474906
   Robbins PD, 1998, TRENDS BIOTECHNOL, V16, P35, DOI 10.1016/S0167-7799(97)01137-2
   SMITH AE, 1995, ANNU REV MICROBIOL, V49, P807
   STRYER L, 1995, BIOCHEMISTRY-US, P1064
   Wang JK, 1998, J MED CHEM, V41, P2207, DOI 10.1021/jm950802i
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
NR 18
TC 16
Z9 16
U1 4
U2 8
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0883-7694
J9 MRS BULL
JI MRS Bull.
PD SEP
PY 2005
VL 30
IS 9
BP 635
EP 639
DI 10.1557/mrs2005.189                                                     
          
PG 5
WC Materials Science, Multidisciplinary; Physics, Applied
SC Materials Science; Physics
GA 966CF
UT WOS:000231996500014
OA gold
DA 2018-01-05
ER

PT J
AU Stricher, F
   Martin, L
   Barthe, P
   Pogenberg, V
   Mechulam, A
   Menez, A
   Roumestand, C
   Veas, F
   Royer, C
   Vita, C
AF Stricher, F
   Martin, L
   Barthe, P
   Pogenberg, V
   Mechulam, A
   Menez, A
   Roumestand, C
   Veas, F
   Royer, C
   Vita, C
TI A high-throughput fluorescence polarization assay specific to the CD4
   binding site of HIV-1 glycoproteins based on a fluorescein-labelled CD4
   mimic
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE CD4 binding; drug discovery; fluorescence polarization; HIV inhibitors;
   protein-protein interaction; threedimensional structure
ID GP120 ENVELOPE GLYCOPROTEIN; VIRUS TYPE-1 GP120; ENTRY INHIBITORS;
   FORCE-FIELD; RECEPTOR; COMPLEX; FUSION; ACIDS; NMR; CONFORMATIONS
AB The three-dimensional structure of CD4M33, a mimic of the host-cell receptor-antigen CD4 and a powerful inhibitor of CD4-gp120 (viral envelope glycoprotein 120) interaction and HIV-1 entry into cells [Martin, Stricher, Misse, Sironi, Pugniere, Barthe, Prado-Gotor, Freulon, Magne, Roumestand et al. (2003) Nat. Biotechnol. 21, 71-76], was solved by (1)H-NMR and its structure was modelled in its complex with gp120. In this complex, CD4M33 binds in a CD4-like mode and inserts its unnatural and prominent Bip(23) (biphenylalanine-23) side-chain into the gp120 interior 'Phe(43) cavity', thus filling its volume. CD4M33 was specifically labelled with fluorescein and shown by fluorescence anisotropy to bind to different gp120 glycoproteins with dissociation constants in the nanomolar range. Fluorescent CD4M33 was also used in a miniaturized 384-well-plate assay to study direct binding to a large panel of gp120 glycoproteins and in a competition assay to study binding of CD4 or other ligands targeting the CD4 binding site of gp120. Furthermore, by using the fluorescently labelled CD4M33 and the [Phe(23)]M33 mutant, which possesses a natural Phe(23) residue and thus cannot penetrate the gp120 Phe(43) cavity, we show that a recently discovered small-molecule-entry inhibitor, BMS-378806, does not target the CD4 binding site nor the Phe(43) cavity of gp120. The fluorescently labelled CD4M33 mimic, its mutants and their derivatives represent useful tools with which to discover new molecules which target the CD4 binding site and/or the phe(41) cavity of gp120 glycoproteins in a high-throughput fluorescence-polarization assay and to characterize their mechanism of action.
C1 CEA Saclay, Dept Prot Engn & Res, F-91191 Gif Sur Yvette, France.
   Fac Pharm Montpellier, Struct Biochem Ctr, Montpellier, France.
   CNRS, IRD, Retroviral & Mol Immunol Lab, F-34094 Montpellier, France.
RP Vita, C (reprint author), CEA Saclay, Dept Prot Engn & Res, F-91191 Gif Sur Yvette, France.
EM claudio.vita@cea.fr
RI Royer, Catherine/E-5266-2016; Pogenberg, Vivian/A-3463-2012
OI Royer, Catherine/0000-0002-2670-3391; Pogenberg,
   Vivian/0000-0002-1021-6804
CR Blair WS, 2000, DRUG DISCOV TODAY, V5, P183, DOI 10.1016/S1359-6446(00)01484-7
   CARDIN AD, 1991, J BIOL CHEM, V266, P13355
   Case D. A., 1997, AMBER 5
   CHAABIHI H, 1993, J VIROL, V67, P2664
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   Dandliker W B, 1981, Methods Enzymol, V74 Pt C, P3
   De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842                                                        
   DEMARIA S, 1995, AIDS RES HUM RETROV, V11, P127, DOI 10.1089/aid.1995.11.127
   Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284
   Guo Q, 2003, J VIROL, V77, P10528, DOI 10.1016/JVI.77.19.10528-10536.2003
   Huang CC, 2005, STRUCTURE, V13, P755, DOI 10.1016/j.str.2005.03.006
   KOLLMAN P, 1997, COMP SIM BIOMOL SYST, V3, P83
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026                                                            
   Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100
   Madani N, 2004, J VIROL, V78, P3742, DOI 10.1128/JVI.78.7.3742-3752.2004
   Martin L, 2000, TETRAHEDRON, V56, P9451, DOI 10.1016/S0040-4020(00)00829-2
   Martin L, 2003, NAT BIOTECHNOL, V21, P71, DOI 10.1038/nbt768
   Meanwell NA, 2003, CURR OPIN DRUG DI DE, V6, P451
   Misse D, 1998, J VIROL, V72, P7280
   Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Ono M, 1997, NAT BIOTECHNOL, V15, P343, DOI 10.1038/nbt0497-343
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   Pons JL, 1996, J BIOMOL NMR, V8, P445, DOI 10.1007/BF00228146
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Roumestand C, 1999, MAGN RESON CHEM, V37, P451, DOI 10.1002/(SICI)1097-458X(199907)37:7<451::AID-MRC487>3.0.CO;2-U                  
   ROYER CA, 1993, ANAL BIOCHEM, V210, P91, DOI 10.1006/abio.1993.1155
   ROYER CA, 1992, METHOD ENZYMOL, V210, P481
   ROYER CA, 1990, ANAL BIOCHEM, V191, P287, DOI 10.1016/0003-2697(90)90221-T
   RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0                                                                
   Si ZH, 2004, P NATL ACAD SCI USA, V101, P5036, DOI 10.1073/pnas.0307953101
   Sundberg EJ, 2000, BIOCHEMISTRY-US, V39, P15375, DOI 10.1021/bi000704l
   Vita C, 1999, P NATL ACAD SCI USA, V96, P13091, DOI 10.1073/pnas.96.23.13091
   Wang T, 2003, J MED CHEM, V46, P4236, DOI 10.1021/jm034082o
   Wodak SJ, 2003, ADV PROTEIN CHEM, V61, P9
   WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2
   Wuthrich K, 1986, NMR PROTEINS NUCL AC
   Xiang SH, 2002, J VIROL, V76, P9888, DOI 10.1128/JVI.76.19.9888-9899.2002
NR 41
TC 17
Z9 19
U1 0
U2 5
PU PORTLAND PRESS LTD
PI LONDON
PA THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND
SN 0264-6021
J9 BIOCHEM J
JI Biochem. J.
PD AUG 15
PY 2005
VL 390
BP 29
EP 39
DI 10.1042/BJ20041953
PN 1
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 959BV
UT WOS:000231492800004
PM 15836438
OA gold
DA 2018-01-05
ER

PT J
AU Williams, DC
   Lee, JY
   Cai, ML
   Bewley, CA
   Clore, GM
AF Williams, DC
   Lee, JY
   Cai, ML
   Bewley, CA
   Clore, GM
TI Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL
   free and bound to Man(3)GlcNAc(2) - Structural basis for specificity and
   high-affinity binding to the core pentasaccharide from N-linked
   oligomannoside
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID MACROMOLECULAR STRUCTURE DETERMINATION; ENVELOPE GLYCOPROTEIN GP120;
   CYANOVIRIN-N; INACTIVATING PROTEIN; NMR; ALIGNMENT; ANTIBODY;
   OLIGOSACCHARIDES; CRYSTALLOGRAPHY; MATRICES
AB The cyanobacterial protein MVL inhibits HIV-1 envelope-mediated cell fusion at nanomolar concentrations by binding to high mannose N-linked carbohydrate on the surface of the envelope glycoprotein gp120. Although a number of other carbohydrate-binding proteins have been shown to inhibit HIV-1 envelope-mediated cell fusion, the specificity of MVL is unique in that its minimal target comprises the Man alpha(136)Man beta(1 -> 4)GlcNAc beta(1 -> 4) GlcNAc tetrasaccharide core of oligomannosides. We have solved the crystal structures of MVL free and bound to the pentasaccharide Man(3)GlcNAc(2) at 1.9- and 1.8-angstrom resolution, respectively. MVL is a homodimer stabilized by an extensive intermolecular interface between monomers. Each monomer contains two structurally homologous domains with high sequence similarity connected by a short five-amino acid residue linker. Intriguingly, a water-filled channel is observed between the two monomers. Residual dipolar coupling measurements indicate that the structure of the MVL dimer in solution is identical to that in the crystal. Man(3)GlcNAc(2) binds to a preformed cleft at the distal end of each domain such that a total of four independent carbohydrate molecules associate with each homodimer. The binding cleft provides shape complementarity, including the presence of a deep hydrophobic hole that accommodates the N-acetyl methyl at the reducing end of the carbohydrate, and specificity arises from 7-8 intermolecular hydrogen bonds. The structures of MVL and the MVL-Man(3)GlcNAc(2) complex further our understanding of the molecular basis of high affinity and specificity in protein-carbohydrate recognition.
C1 NIDDK, Phys Chem Lab, NIH, Bethesda, MD 20892 USA.
   NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.
   NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Clore, GM (reprint author), NIDDK, Phys Chem Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.
EM mariusc@intra.niddk.nih.gov
RI Clore, G. Marius/A-3511-2008
OI Clore, G. Marius/0000-0003-3809-1027
FU Intramural NIH HHS
CR Bax A, 2001, METHOD ENZYMOL, V339, P127, DOI 10.1016/S0076-6879(01)39313-8                                                   
   Bewley CA, 2002, J MOL BIOL, V322, P881, DOI 10.1016/S0022-2836(02)00842-2
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   BEWLEY CA, 2001, STRUCTURE CAMB, V10, P931
   BEWLEY CA, 2004, J MOL BIOL, V338, P901
   Botos I, 2005, PROG BIOPHYS MOL BIO, V88, P233, DOI 10.1016/j.pbiomolbio.2004.05.001
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Calarese DA, 2003, SCIENCE, V300, P2065, DOI 10.1126/science.1083182
   CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240
   CLORE BM, 1999, J AM CHEM SOC, V126, P2923
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883                                                        
   HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489
   Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290                                                       
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h
   Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300
   Taylor G, 2003, ACTA CRYSTALLOGR D, V59, P1881, DOI 10.1107/S0907444903017815
   Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6
   Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Williams DC, 2004, J BIOL CHEM, V279, P1449, DOI 10.1074/jbc.M309790200
   Wormald MR, 2002, CHEM REV, V102, P371, DOI 10.1021/cr990368i
   Yamaguchi M, 1999, BIOCHEM BIOPH RES CO, V265, P703, DOI 10.1006/bbrc.1999.1749
   Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908                                                               
   [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760
NR 36
TC 44
Z9 46
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 12
PY 2005
VL 280
IS 32
BP 29269
EP 29276
DI 10.1074/jbc.M504642200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 952QT
UT WOS:000231021300057
PM 15937331
OA gold
DA 2018-01-05
ER

PT J
AU Sherrill, RG
   Furfine, ES
   Hazen, RJ
   Miller, JF
   Reynolds, DJ
   Sammond, DM
   Spaltenstein, A
   Wheelan, P
   Wright, LL
AF Sherrill, RG
   Furfine, ES
   Hazen, RJ
   Miller, JF
   Reynolds, DJ
   Sammond, DM
   Spaltenstein, A
   Wheelan, P
   Wright, LL
TI Synthesis and antiviral activities of novel
   N-alkoxy-arylsulfonamide-based HIV protease inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HIV protease
ID SERIES
AB A series of novel N-alkoxy-arylsulfonamide HIV protease inhibitors with low picomolar enzyme activity and single digit nanomolar antiviral activity is disclosed. (c) 2005 Elsevier Ltd. All rights reserved.
C1 GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.
RP Sherrill, RG (reprint author), GlaxoSmithKline, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
EM ron.g.sherrill@gsk.com
CR Chen P, 1997, TETRAHEDRON LETT, V38, P3175, DOI 10.1016/S0040-4039(97)00605-9
   DALUGE SM, 1994, ANTIMICROB AGENTS CH, V38, P1590, DOI 10.1128/AAC.38.7.1590                                                           
   Gatell J M, 2001, J HIV Ther, V6, P95
   Ghosh AK, 1998, J ORG CHEM, V63, P6146, DOI 10.1021/jo980159i                                                               
   Girijavallabhan V M, 1994, Bioorg Med Chem, V2, P1075, DOI 10.1016/S0968-0896(00)82057-X
   GROCHOWSKI E, 1976, SYNTHESIS-STUTTGART, P682
   Kim BM, 2001, ORG LETT, V3, P2349, DOI 10.1021/ol016147s
   KIM JN, 1992, SYNTHETIC COMMUN, V22, P1427, DOI 10.1080/00397919208021609                                                       
   Miller JF, 2004, BIOORG MED CHEM LETT, V14, P959, DOI 10.1016/j.bmc.2003.12.008
   Randolph JT, 2004, CURR TOP MED CHEM, V4, P1079, DOI 10.2174/1568026043388330                                                        
   Sham HL, 1998, ANTIMICROB AGENTS CH, V42, P3218
   THOMPSON WJ, 1992, J MED CHEM, V35, P1685, DOI 10.1021/jm00088a003                                                             
   TOJA E, 1991, EUR J MED CHEM, V26, P403, DOI 10.1016/0223-5234(91)90101-R
   TOTH MV, 1990, INT J PEPT PROT RES, V36, P544
   Xu ZM, 2002, ORG PROCESS RES DEV, V6, P323, DOI 10.1021/op025504r
   AIKINS JA, 1988, Patent No. 254577
NR 16
TC 8
Z9 9
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 1
PY 2005
VL 15
IS 15
BP 3560
EP 3564
DI 10.1016/j.bmcl.2005.05.101
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 947FC
UT WOS:000230627800018
PM 15975788
DA 2018-01-05
ER

PT J
AU Zhao, AJ
   Yao, P
   Kang, CS
   Yuan, XB
   Chang, J
   Pu, PY
AF Zhao, AJ
   Yao, P
   Kang, CS
   Yuan, XB
   Chang, J
   Pu, PY
TI Synthesis and characterization of tat-mediated O-CMC magnetic
   nanoparticles having anticancer function
SO JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS
LA English
DT Article
DE nanoparticles; O-carboxylmethylated chitosan; polymer; carrier; peptide;
   tumor; cytotoxicity
ID CHITOSAN
AB This paper describes a new formulation of magnetic nanoparticles coated by a novel polymer matrix - O-carboxylmethylated chitosan (O-CMC) as drug/gene carrier. The O-CMC magnetic nanoparticles were derivatized with a peptide sequence from the HIV-tat protein to improve the translocational property and cellar uptake of the nanoparticles. To evaluate the O-MNPs-tat as drug carriers, MTX was incorporated as a model drug and MTX-loaded O-MNPs-tat with an average diameter of 45-60 nm were prepared and characterized by TEM, AFM and VSM. The cytotoxicity of MTX-loaded O-MNPs-tat was investigated with U-937 tumor cells. The results showed that the MTX-loaded O-MNPs-tat retained significant antitumor toxicity; additionally, sustained release of MTX from O-CMC nanoparticles was observed in vitro, suggesting that the tat-O-MNPs could be a novel magnetic targeting carrier. (c) 2005 Elsevier B.V. All rights reserved.
C1 Tianjin Univ, Sch Mat Sci & Engn, Inst Nanobiotechnol, Tianjin 300072, Peoples R China.
   Tianjin Med Univ, Gen Hosp, Tianjin 300072, Peoples R China.
RP Chang, J (reprint author), Tianjin Univ, Sch Mat Sci & Engn, Inst Nanobiotechnol, Tianjin 300072, Peoples R China.
EM jinchang@tju.edu.cu; pupeiyu33@hotmail.com
CR Begona C. G., 1997, INT J PHARMACEUT, V148, P231
   CHANG J, 1996, CHIN J BIOMED ENG, V15, P354
   CHANG J, 1996, CHIN J BIOMED ENG, V15, P97
   CHOLY JH, 1994, MATER LETT, V19, P257
   DESHPANDE D, 1994, PHARMACEUT RES, V11, P1121, DOI 10.1023/A:1018980630675
   FRICKER J, 2001, DTT, V6
   Hafeli U, 2001, J MAGN MAGN MATER, V225, P73, DOI 10.1016/S0304-8853(00)01230-0
   Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ, P56
   Liu XF, 2001, J APPL POLYM SCI, V79, P1324
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Pulfer SK, 1997, SCIENTIFIC AND CLINICAL APPLICATIONS OF MAGNETIC CARRIERS, P445
   Xie WM, 2002, CARBOHYD POLYM, V50, P35, DOI 10.1016/S0144-8617(01)00370-8                                                   
NR 12
TC 20
Z9 21
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-8853
J9 J MAGN MAGN MATER
JI J. Magn. Magn. Mater.
PD AUG
PY 2005
VL 295
IS 1
BP 37
EP 43
DI 10.1016/j.jmmm.2004.12.044
PG 7
WC Materials Science, Multidisciplinary; Physics, Condensed Matter
SC Materials Science; Physics
GA 947HT
UT WOS:000230634700005
DA 2018-01-05
ER

PT J
AU Wannberg, J
   Kaiser, NFK
   Vrang, L
   Samuelsson, B
   Larhed, M
   Hallberg, A
AF Wannberg, J
   Kaiser, NFK
   Vrang, L
   Samuelsson, B
   Larhed, M
   Hallberg, A
TI High-speed synthesis of potent C-2-symmetric HIV-1 protease inhibitors
   by in-situ aminocarbonylations
SO JOURNAL OF COMBINATORIAL CHEMISTRY
LA English
DT Article
ID CARBON-MONOXIDE; AIR; RESISTANCE; CONVENIENT; CATALYSIS; CHEMISTRY;
   MORTALITY; DESIGN
AB Two novel series of C-2-symmetric HIV-1 protease inhibitors were synthesized by microwave-promoted, palladium-catalyzed aminocarbonylations of the o-iodo- and m-bromobenzyloxy P1/P1' substituted core structures. Molybdenum hexacarbonyl was used as a convenient solid source of carbon monoxide in these transformations. After the initial high-speed library generation, biological testing identified highly active HIV-1 protease inhibitors. Selected ortho- and meta-decorated inhibitors were subsequently resynthesized on a larger scale and retested for their affinity toward HIV-1 protease, showing micromolar to low nanomolar inhibition. The discovery of highly active inhibitors containing large phenyl amide ortho substituents in the P1/P1' positions indicates that larger groups than previously believed are tolerated in this part of the S1/S1' pocket.
C1 Uppsala Univ, Dept Med Chem, BMC, SE-75123 Uppsala, Sweden.
   Medivir AB, SE-14144 Huddinge, Sweden.
RP Hallberg, A (reprint author), Uppsala Univ, Dept Med Chem, BMC, Box 574, SE-75123 Uppsala, Sweden.
EM anders.hallberg@orgfarm.uu.se
CR Alterman M, 1999, J MED CHEM, V42, P3835, DOI 10.1021/jm9910371                                                               
   Alterman M, 1998, J MED CHEM, V41, P3782, DOI 10.1021/jm970777b                                                               
   Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195
   Danielson H, 1998, ADV EXP MED BIOL, V436, P99
   Ersmark K, 2004, CURR OPIN DRUG DISC, V7, P417
   Fellay J, 2001, LANCET, V358, P1322, DOI 10.1016/S0140-6736(01)06413-3
   Herrero MA, 2004, SYNLETT, P2335, DOI 10.1055/s-2004-832837
   HERRMANN WA, 1995, ANGEW CHEM INT EDIT, V34, P1844, DOI 10.1002/anie.199518441                                                          
   Joint United Nations Programme on HIV/ AIDS (UNAIDS), 2004, REP GLOB AIDS EP
   Kaiser NFK, 2002, J COMB CHEM, V4, P109, DOI 10.1021/cc010085f
   Kappe CO, 2004, ANGEW CHEM INT EDIT, V43, P6250, DOI 10.1002/anie.200400655
   Larhed M, 2002, ACCOUNTS CHEM RES, V35, P717, DOI 10.1021/ar010074v
   Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2
   Morimoto T, 2004, ANGEW CHEM INT EDIT, V43, P5580, DOI 10.1002/anie.200301736
   Netherton MR, 2001, ORG LETT, V3, P4295, DOI 10.1021/ol016971g
   Nillroth U, 1997, ANTIMICROB AGENTS CH, V41, P2383
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Wannberg J, 2003, J ORG CHEM, V68, P5750, DOI 10.1021/jo034382d
   WANNBERG J, 2005, IN PRESS COMB CHEM, V7
NR 19
TC 33
Z9 33
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1520-4766
J9 J COMB CHEM
JI J. Comb. Chem.
PD JUL-AUG
PY 2005
VL 7
IS 4
BP 611
EP 617
DI 10.1021/cc050016r
PG 7
WC Chemistry, Applied; Chemistry, Medicinal; Chemistry, Multidisciplinary
SC Chemistry; Pharmacology & Pharmacy
GA 945VA
UT WOS:000230529200019
PM 16004505
DA 2018-01-05
ER

PT J
AU McCarthy, TD
   Karellas, P
   Henderson, SA
   Giannis, M
   O'Keefe, DF
   Heery, G
   Paull, JRA
   Matthews, BR
   Holan, G
AF McCarthy, Tom D.
   Karellas, Peter
   Henderson, Scott A.
   Giannis, Michael
   O'Keefe, David F.
   Heery, Graharn
   Paull, Jeremy R. A.
   Matthews, Barry R.
   Holan, George
TI Dendrimers as drugs: Discovery and preclinical and clinical development
   of dendrimer-based microbicides for HIV and STI prevention
SO MOLECULAR PHARMACEUTICS
LA English
DT Review
DE nanoscale; nanotechnology; chemical diversity; molecular diversity;
   dendrimer; SPL7013; VivaGel; antiviral; HIV; HSV-2; microbicide
AB Starpharma focuses on the use of dendrimers as drugs in their own right, in contrast to dendrimers as drug delivery vehicles or diagnostics. This contextual review describes how dendrimers offer a unique platform for exploring chemical diversity on the nanoscale and how the production of dendrimer libraries covering a diverse array of macromolecular structures can be used in drug discovery and development. Using Starpharma's work on the prevention of HIV and sexually transmitted infections (STIs) through the development of microbicide candidates as an example, the process from which SPL7013 emerged as a development candidate is described. Following a range of preclinical studies, Starpharma submitted an investigational new drug application (IND) for SPL7013 gel (VivaGel) to the United States Food and Drug Administration (FDA) in June 2003, the first such submission for a dendrimer-based drug. The first clinical trial under this IND was completed in 2004.
C1 [McCarthy, Tom D.; Karellas, Peter; Henderson, Scott A.; Giannis, Michael; O'Keefe, David F.; Heery, Graharn; Paull, Jeremy R. A.; Matthews, Barry R.; Holan, George] Starpharma Pty Ltd, Melbourne, Vic 3004, Australia.
EM tom.mccarthy@starpharma.com
CR Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003
   Boas U, 2004, CHEM SOC REV, V33, P43, DOI 10.1039/b309043b
   Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000
   Brouwer AJ, 2001, EUR J ORG CHEM, P1903
   Choi S. K., 2004, SYNTHETIC MULTIVALEN
   COLLINGER MJ, 2002, CURR OPIN CHEM BIOL, V6, P742
   D'Cruz OJ, 2004, CURR PHARM DESIGN, V10, P315, DOI 10.2174/1381612043386374
   Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004
   Frechet J., 2001, DENDRIMERS OTHER DEN
   Gong YH, 2002, ANTIVIR RES, V55, P319, DOI 10.1016/S0166-3542(02)00054-2
   Ihre H, 2001, J AM CHEM SOC, V123, P5908, DOI 10.1021/ja010524e
   Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207
   Kirkpatrick P, 2004, NATURE, V432, P823, DOI 10.1038/432823a
   Kobayashi Hisataka, 2003, Mol Imaging, V2, P1, DOI 10.1162/153535003765276237
   Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Newkome GR, 1998, ANGEW CHEM INT EDIT, V37, P307, DOI 10.1002/(SICI)1521-3773(19980216)37:3<307::AID-ANIE307>3.0.CO;2-L               
   Sun CZ, 2003, BIOORGAN MED CHEM, V11, P1761, DOI 10.1016/S0968-0896(03)00057-9
   Turpin JA, 2002, EXPERT OPIN INV DRUG, V11, P1077, DOI 10.1517/13543784.11.8.1077                                                      
   Witvrouw M, 2000, MOL PHARMACOL, V58, P1100
   Wu G, 2004, BIOCONJUGATE CHEM, V15, P185, DOI 10.1021/bc0341674
   MATHEWS BR, 2002, Patent No. 02079299
   Ross M B, 2001, US Patent, Patent No. [6,190,650BI, 6190650]
   [Anonymous], UNPUB
NR 24
TC 195
Z9 202
U1 0
U2 37
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL-AUG
PY 2005
VL 2
IS 4
BP 312
EP 318
DI 10.1021/mp050023q
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA V52JD
UT WOS:000203538900008
PM 16053334
DA 2018-01-05
ER

PT J
AU Vives, RR
   Imberty, A
   Sattentau, QJ
   Lortat-Jacob, H
AF Vives, RR
   Imberty, A
   Sattentau, QJ
   Lortat-Jacob, H
TI Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor
   binding site
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR-BINDING; CONFORMATIONAL-CHANGES;
   TYPE-1 ATTACHMENT; PROTEOGLYCANS; MECHANISM; CELLS; GLYCOSAMINOGLYCANS;
   CHEMOKINES; INFECTION
AB Human immunodeficiency virus (HIV) attachment to host cells is a multi-step process that involves interaction of the viral envelope gp120 with the primary receptor CD4 and coreceptors. HIV gp120 also binds to other cell surface components, including heparan sulfate (HS), a sulfated polysaccharide whose wide interactive properties are exploited by many pathogens for attachment and concentration at the cell surface. To analyze the structural features of gp120 binding to HS, we used soluble CD4 to constrain gp120 in a specific conformation. We first found that CD4 induced conformational change of gp120, dramatically increasing binding to HS. We then showed that HS binding interface on gp120 comprised, in addition to the well characterized V3 loop, a CD4-induced epitope. This epitope is efficiently targeted by nanomolar concentrations of size-defined heparin/ HS- derived oligosaccharides. Because this domain of the protein also constitutes the binding site for the viral coreceptors, these results support an implication of HS at late stages of the virus- cell attachment process and suggest potential therapeutic applications.
C1 Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct, F-38027 Grenoble, France.
   CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France.
   Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
RP Lortat-Jacob, H (reprint author), Univ Grenoble 1, CNRS, Commissariat Energie Atom, Inst Biol Struct, 41 Rue Horowitz, F-38027 Grenoble, France.
EM Hugues.Lortat-Jacob@ibs.fr
RI Vives, Romain/I-9372-2012
OI Imberty, Anne/0000-0001-6825-9527
CR Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003
   Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729                                                
   Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6                                                   
   Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327
   Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7
   CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804
   Cros S, 1997, BIOORGAN MED CHEM, V5, P1301, DOI 10.1016/S0968-0896(97)00087-4                                                   
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   Hsu STD, 2004, PROTEINS, V55, P582, DOI 10.1002/prot.20061
   Imberty A., 1999, PERSPECTIVES STRUCTU, P392
   KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0
   Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000
   Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5                                                   
   Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699
   Mikhailov D, 1997, BIOCHEM J, V328, P51, DOI 10.1042/bj3280051                                                               
   Mondor I, 1998, J VIROL, V72, P3623
   Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060                                                                
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8
   Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x                                              
   OLSON ST, 1992, J BIOL CHEM, V267, P12528
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   RODERIQUEZ G, 1995, J VIROL, V69, P2233
   Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200                                                          
   Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001
   SATTENTAU QJ, 1993, J VIROL, V67, P7383
   Sharon M, 2003, STRUCTURE, V11, P225, DOI 10.1016/S0969-2126(03)00011-X
   Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1                                                   
   Stanfield RL, 2004, STRUCTURE, V12, P193, DOI 10.1016/j.str.2004.01.003
   Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959
   *TRIP INC, 1997, SYBYL VERS 6 4
   Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2
   Vives RR, 2004, J BIOL CHEM, V279, P54327, DOI 10.1074/jbc.M409760200
   Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i
   Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58
   WYATT R, 1995, J VIROL, V69, P5723
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002
NR 42
TC 84
Z9 86
U1 0
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 3
PY 2005
VL 280
IS 22
BP 21353
EP 21357
DI 10.1074/jbc.M500911200
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 930TA
UT WOS:000229438800054
PM 15797855
OA gold
DA 2018-01-05
ER

PT J
AU Ranise, A
   Spallarossa, A
   Cesarini, S
   Bondavalli, F
   Schenone, S
   Bruno, O
   Menozzi, G
   Fossa, P
   Mosti, L
   La Colla, M
   Sanna, G
   Murreddu, M
   Collu, G
   Busonera, B
   Marongiu, ME
   Pani, A
   La Colla, P
   Loddo, R
AF Ranise, A
   Spallarossa, A
   Cesarini, S
   Bondavalli, F
   Schenone, S
   Bruno, O
   Menozzi, G
   Fossa, P
   Mosti, L
   La Colla, M
   Sanna, G
   Murreddu, M
   Collu, G
   Busonera, B
   Marongiu, ME
   Pani, A
   La Colla, P
   Loddo, R
TI Structure-based design, parallel synthesis, structure-activity
   relationship, and molecular modeling studies of thiocarbamates, new
   potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of
   phenethylthiazolylthiourea derivatives
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PETT ANALOGS; RESISTANCE MUTATIONS;
   DRUG-RESISTANT; RT-INHIBITORS; WILD-TYPE; BIOLOGICAL EVALUATION;
   THIOUREA COMPOUNDS; ANTIVIRAL ACTIVITY; EFAVIRENZ DMP-266
AB In this paper we describe our structure-based ligand design, synthetic strategy, and structure-activity relationship (SAR) studies that led to the identification of thiocarbamates (TCs), a novel class of non-nucleoside reverse transcriptase inhibitors (NNRTIs), isosteres of phenethylthiazolylthiourea (PETT) derivatives. Assuming as a lead compound O-[2-(phthalimido)ethyl]-phenylthiocarbamate 12, one of the precursors of the previously described acylthiocarbamates (Ranise, A.; et al. J. Med. Chem. 2003, 46, 768-781), two targeted solution-phase TC libraries were prepared by parallel synthesis. The lead optimization strategy led to para-substituted TCs 31, 33, 34, 39, 40, 41, 44, 45, and 50, which were active against wild-type HIV-1 in MT-4-based assays at nanomolar concentrations (EC50 range: 0.04-0.01 mu M). The most potent congener 50 (EC50 = 0.01 mu M) bears a methyl group at position 4 of the phthalimide moiety and a nitro group at the para position of the N-phenyl ring. Most of the TCs showed good selectivity indices, since no cytotoxic effect was detected at concentrations as high as 100 mu M. TCs 31, 37, 39, 40, and 44 significantly reduced the multiplication of the Y181C mutant, but they were inactive against K103R and K103N + Y181C mutants. Nevertheless, the fold increase in resistance of 41 was not greater than that of efavirenz against the K103R mutant in enzyme assays. The docking model predictions were consistent with in vitro biological assays of the anti-HIV-1 activity of the TCs and related compounds synthesized.
C1 Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy.
   Univ Cagliari, Dipartimento Sci & Tecnol Biomed, Sez Microbiol & Virol Gen & Biotecnol Microb, I-09042 Monserrato, Italy.
RP Ranise, A (reprint author), Univ Genoa, Dipartimento Sci Farmaceut, Viale Benedetto XV 3, I-16132 Genoa, Italy.
EM ranise@unige.it; placolla@unica.it
RI Pani, Alessandra/B-7831-2011; La Colla , Paolo /B-8587-2011; Loddo,
   Roberta/B-9038-2011
OI Pani, Alessandra/0000-0002-0437-2499; Sanna,
   Giuseppina/0000-0002-3999-4263
CR An HY, 2000, CHEM REV, V100, P3311, DOI 10.1021/cr990014r
   Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   Artico M, 1996, FARMACO, V51, P305
   Balzarini J, 1996, MOL PHARMACOL, V50, P394
   Balzarini J, 2004, CURR TOP MED CHEM, V4, P921, DOI 10.2174/1568026043388420                                                        
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Campiani G, 1999, J MED CHEM, V42, P4462, DOI 10.1021/jm990150o                                                               
   Campiani G, 2000, ANTIVIR CHEM CHEMOTH, V11, P141, DOI 10.1177/095632020001100206                                                      
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CHAMBERLAIN SD, 1994, J MED CHEM, V37, P1371, DOI 10.1021/jm00035a018
   Das K, 2004, J MED CHEM, V47, P2550, DOI 10.1021/jm030558s
   DASETTIMO A, 1981, EUR J MED CHEM, V16, P59
   De Clercq E, 2004, CHEM BIODIVERS, V1, P44, DOI 10.1002/cbdv.200490012                                                          
   De Clercq E, 2001, FARMACO, V56, P3, DOI 10.1016/S0014-827X(01)01007-2                                                   
   De Clercq E, 1998, COLLECT CZECH CHEM C, V63, P449, DOI 10.1135/cccc19980449                                                            
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   De Clercq E, 1994, EXPERT OPIN INV DRUG, V3, P253
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   Dong YH, 2000, BIOORG MED CHEM LETT, V10, P87, DOI 10.1016/S0960-894X(99)00581-8                                                   
   DROBNICA L, 1977, CHEM CYANATES THEIR, P116
   Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1                                                   
   Hogberg M, 1999, J MED CHEM, V42, P4150, DOI 10.1021/jm990095j
   Hogberg M, 2000, BIOORG MED CHEM LETT, V10, P265, DOI 10.1016/S0960-894X(99)00675-7
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 1998, J MOL BIOL, V284, P313, DOI 10.1006/jmbi.1998.2171
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   Kauffman S, 1999, CURR OPIN CHEM BIOL, V3, P256, DOI 10.1016/S1367-5931(99)80040-4                                                   
   KLEIM JP, 1993, ANTIMICROB AGENTS CH, V37, P1659, DOI 10.1128/AAC.37.8.1659                                                           
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Lindberg J, 2002, EUR J BIOCHEM, V269, P1670, DOI 10.1046/j.1432-1327.2002.02811.x
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   Mager P P, 1996, Drug Des Discov, V14, P241
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   PECK RM, 1962, J ORG CHEM, V27, P2677, DOI 10.1021/jo01054a532                                                             
   Pedersen OS, 1999, ANTIVIR CHEM CHEMOTH, V10, P285, DOI 10.1177/095632029901000601                                                      
   Pedersen OS, 2000, SYNTHESIS-STUTTGART, P479
   Ranise A, 2003, J MED CHEM, V46, P768, DOI 10.1021/jm0209984
   Ren J, 2000, STRUCTURE, V8, P1089, DOI 10.1016/S0969-2126(00)00513-X                                                   
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Ren JS, 1999, J MED CHEM, V42, P3845, DOI 10.1021/jm990275t                                                               
   Ren JS, 2000, J BIOL CHEM, V275, P5633, DOI 10.1074/jbc.275.8.5633
   RICHMAN DD, 1994, J VIROL, V68, P1660
   Sahlberg C, 1998, BIOORG MED CHEM LETT, V8, P1511, DOI 10.1016/S0960-894X(98)00249-2
   Schinazi R. F., 1997, International Antiviral News, V5, P129
   STRICKLEY RG, 1993, PHARMACEUT RES, V10, P1076, DOI 10.1023/A:1018935311304                                                         
   Tachedjian Gilda, 2003, Curr Opin Investig Drugs, V4, P966
   Tanaka K, 2000, CHEM REV, V100, P1025, DOI 10.1021/cr940089p                                                               
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   TERRETT NK, 1995, TETRAHEDRON, V51, P8135, DOI 10.1016/0040-4020(95)00467-M
   Tucker TJ, 1996, METHOD ENZYMOL, V275, P440
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Venkatachalam TK, 2000, BIOORG MED CHEM LETT, V10, P2071, DOI 10.1016/S0960-894X(00)00398-X
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   WALTER W, 1967, ANGEW CHEM INT EDIT, V6, P281, DOI 10.1002/anie.196702811                                                          
   Weller H. N., 1999, MOL DIVERS, V4, P47
   WERMUTH CG, 2003, PRACTICE MEDICINAL C, P76
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
NR 64
TC 36
Z9 37
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 2
PY 2005
VL 48
IS 11
BP 3858
EP 3873
DI 10.1021/jm049252r
PG 16
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 930UX
UT WOS:000229443700024
PM 15916438
DA 2018-01-05
ER

PT J
AU Santra, S
   Dutta, D
   Moudgil, BM
AF Santra, S
   Dutta, D
   Moudgil, BM
TI Functional dye-doped silica nanoparticles for bioimaging, diagnostics
   and therapeutics
SO FOOD AND BIOPRODUCTS PROCESSING
LA English
DT Article; Proceedings Paper
CT 7th World Congress of Chemical Engineering
CY JUL 10-14, 2005
CL Glasgow, SCOTLAND
DE dye-doped nanoparticles; fluorescence; TAT; folate; cancer
ID HUMAN IMMUNODEFICIENCY VIRUS; CELL-PENETRATING PEPTIDES; TAT-PEPTIDE;
   IN-VIVO; FOLATE RECEPTOR; PROTEIN TRANSDUCTION; T-CELLS; DELIVERY; DRUG;
   CONJUGATION
AB his paper describes the design, synthesis and biological application of dye-doped silica nanoparticles (DDSNs). About 80 nm size monodisperse FITC (fluorescein isothiocyanate) doped silica nanoparticles were synthesized using water-in-oil (W/O) microemulsion method. The DDSN surface was then modified to attach amine functional groups. The complete synthesis of amine modified DDSNs was carried out in a single pot at room temperature. To demonstrate bioimaging applications, DDSNs were modified with TAT (a cell penetrating peptide, CPP) and folic acid (a vitamin, also called folate). TAT conjugated DDSNs were treated with A-549 cells and an effective labelling was observed. Folate conjugated DDSNs were targeted to two types of cells, human lung adenocarcinoma (A-549) and human dermal fibroblast cells. A-549 cells over express folate receptors and as expected, an extensive labelling was observed with A-549 cells when compared with normal fibroblast cells. Laser scanning confocal images clearly showed that folate conjugated DDSNs were internalized by A-549 cells.
C1 Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA.
   Univ Florida, Particle Engn Res Ctr, Gainesville, FL 32611 USA.
RP Moudgil, BM (reprint author), Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32611 USA.
EM bmoudgil@erc.ufl.edu
CR ANTONY AC, 1992, BLOOD, V79, P2807
   Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Evans CO, 2003, CANCER RES, V63, P4218
   FRANK B, 1894, BER DEUT BOT GES, V12, P8
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hayflick L, 2000, BRIT J CANCER, V83, P841, DOI 10.1054/bjoc.2000.1296
   Holm BA, 2002, MOL CRYST LIQ CRYST, V374, P589, DOI 10.1080/10587250210466
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   Kranz DR, 1998, J CONTROL RELEASE, V53, P77, DOI 10.1016/S0168-3659(97)00239-3
   LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572
   Leamon CP, 2001, DRUG DISCOV TODAY, V6, P44, DOI 10.1016/S1359-6446(00)01594-4
   Levchenko TS, 2003, METHOD ENZYMOL, V372, P339
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Qhobosheane M, 2001, ANALYST, V126, P1274, DOI 10.1039/b101489g                                                                
   ROSS JF, 1994, CANCER, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S
   Rund LA, 1999, INT J CANCER, V83, P141, DOI 10.1002/(SICI)1097-0215(19990924)83:1<141::AID-IJC24>3.0.CO;2-0
   Santra S, 2004, J NANOSCI NANOTECHNO, V4, P590, DOI 10.1166/jnn.2004.017
   Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+
   Santra S, 2001, J BIOMED OPT, V6, P160, DOI 10.1117/1.1353590
   SANTRA S, 2004, CHEM COMMUN, V24, P2810
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Sokolov K, 2003, TECHNOL CANCER RES T, V2, P491, DOI 10.1177/153303460300200602                                                      
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2
   Sudimack J, 2000, ADV DRUG DELIVER REV, V41, P147, DOI 10.1016/S0169-409X(99)00062-9                                                   
   Tan WH, 2004, MED RES REV, V24, P621, DOI 10.1002/med.20003
   Tapec R, 2002, J NANOSCI NANOTECHNO, V2, P405, DOI 10.1166/jnn.2002.114
   Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797
   Torchilin VP, 2003, CURR PROTEIN PEPT SC, V4, P133, DOI 10.2174/1389203033487298
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 39
TC 33
Z9 34
U1 0
U2 21
PU INST CHEMICAL ENGINEERS
PI RUGBY
PA 165-189 RAILWAY TERRACE, DAVIS BLDG, RUGBY CV21 3HQ, ENGLAND
SN 0960-3085
J9 FOOD BIOPROD PROCESS
JI Food Bioprod. Process.
PD JUN
PY 2005
VL 83
IS C2
BP 136
EP 140
DI 10.1205/fbp.04400
PG 5
WC Biotechnology & Applied Microbiology; Engineering, Chemical; Food
   Science & Technology
SC Biotechnology & Applied Microbiology; Engineering; Food Science &
   Technology
GA 944ZA
UT WOS:000230468600008
DA 2018-01-05
ER

PT J
AU Anarbaev, RO
   Khodyreva, SN
   Zakharenko, AL
   Rechkunova, NI
   Lavrik, OI
AF Anarbaev, RO
   Khodyreva, SN
   Zakharenko, AL
   Rechkunova, NI
   Lavrik, OI
TI DNA polymerase activity in water-structured and confined environment of
   reverse micelles
SO JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC
LA English
DT Article
DE DNA polymerase; enzymatic nucleic acids synthesis; reverse micelles
ID IN-OIL MICROEMULSIONS; KLENOW FRAGMENT; KINETIC MECHANISM;
   ESCHERICHIA-COLI; TRANSCRIPTASE; SOLUBILIZATION; PROTEINS; DYNAMICS;
   FIDELITY; INSIGHTS
AB DNA polymerases are the key enzymes of DNA replication and repair. These proteins in living cells are functioning not as isolated entities but in multiprotein complexes, and their work are carefully regulated. The main factors determining the enzyme activity are the structure and dynamics of 'biological' water. Reverse micelles (nano-sized water droplets dispersed in a continuous oil phase) are the simple model systems where the structure and dynamics of water are controlled. In this work, the activities and processivity of Klenow fragment of E. coli DNA polymerase 1, thermostable Tte DNA polymerase, and HIV-1 reverse transcriptase are investigated as a function of the water pool size. Klenow fragment was more active on poly(rA)-oligo(dT) in reverse micelles compared with the water buffer with activity being increased upon increasing water content. Tte polymerase was more active at low water content. HIV-1 reverse transcriptase revealed comparable activity and processivity on poly(rA)-oligo(dT) in the water buffer and reverse micelles at water content of 15-40%. Thus, the polymerase activity appears in certain range of water concentration and depends on the local polarity determining the protein 'expansion', microviscosity inside nano-droplets determining the enzyme dynamics, and nucleic acid hydration degree. (c) 2005 Published by Elsevier B.V.
C1 Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Div, Novosibirsk 630090, Russia.
RP Anarbaev, RO (reprint author), Russian Acad Sci, Inst Chem Biol & Fundamental Med, Siberian Div, Prospect Lavrentiev 8, Novosibirsk 630090, Russia.
EM anarbaev@niboch.nsc.ru
RI Anarbaev, Rashid/G-8485-2013; Lavrik, Olga /G-4641-2013; Rechkunova,
   Nadezda /G-5093-2013; Khodyreva, Svetlana/G-4659-2013
CR Akishev AG, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1298
   Anarbaev RO, 1998, BBA-PROTEIN STRUCT M, V1384, P315, DOI 10.1016/S0167-4838(98)00025-9
   Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0
   BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987
   Bryant RG, 1996, ANNU REV BIOPH BIOM, V25, P29, DOI 10.1146/annurev.bb.25.060196.000333                                             
   CARERI G, 1980, NATURE, V284, P572, DOI 10.1038/284572a0
   DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002
   de Gomez-Puyou MT, 1998, CRIT REV BIOCHEM MOL, V33, P53, DOI 10.1080/10409239891204170                                                       
   Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208
   Doublie S, 1999, STRUCT FOLD DES, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3
   Franks F, 2002, BIOPHYS CHEM, V96, P117, DOI 10.1016/S0301-4622(02)00014-5                                                   
   HERMANN T, 1994, NUCLEIC ACIDS RES, V22, P4625, DOI 10.1093/nar/22.22.4625
   Hermann T, 1996, EUR J BIOCHEM, V242, P98, DOI 10.1111/j.1432-1033.1996.0098r.x                                                
   HIZI A, 1988, P NATL ACAD SCI USA, V85, P1218, DOI 10.1073/pnas.85.4.1218
   Hottiger M, 1996, BIOL CHEM H-S, V377, P97
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Huibers PDT, 1997, LANGMUIR, V13, P5762, DOI 10.1021/la962108r                                                               
   Israelachvili J, 1997, P NATL ACAD SCI USA, V94, P8378, DOI 10.1073/pnas.94.16.8378
   Jaenicke R, 2000, J BIOTECHNOL, V79, P193, DOI 10.1016/S0168-1656(00)00236-4
   KATI WM, 1992, J BIOL CHEM, V267, P25988
   Kew Y, 1998, J BIOL CHEM, V273, P7529, DOI 10.1074/jbc.273.13.7529
   Klibanov AM, 2001, NATURE, V409, P241, DOI 10.1038/35051719
   KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264
   KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012
   Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514
   LUISI PL, 1986, CRIT REV BIOCHEM MOL, V20, P409, DOI 10.3109/10409238609081999
   LUISI PL, 1988, BIOCHIM BIOPHYS ACTA, V947, P209, DOI 10.1016/0304-4157(88)90025-1
   Makarov V, 2002, ACCOUNTS CHEM RES, V35, P376, DOI 10.1021/ar0100273
   MARTINEK K, 1986, EUR J BIOCHEM, V155, P453, DOI 10.1111/j.1432-1033.1986.tb09512.x
   MARTINEK K, 1989, BIOCHIM BIOPHYS ACTA, V981, P161, DOI 10.1016/0005-2736(89)90024-2
   Nazario LMM, 1996, LANGMUIR, V12, P6326, DOI 10.1021/la960687u                                                               
   Nazario LMM, 2000, LANGMUIR, V16, P5892, DOI 10.1021/la991674u
   Oldfield C, 1994, Biotechnol Genet Eng Rev, V12, P255
   OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0
   PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006
   Rosen M.J., 1989, SURFACTANTS INTERFAC
   Shinoda K, 1986, EMULSIONS SOLUBILIZA
   Soares CM, 2003, BIOPHYS J, V84, P1628, DOI 10.1016/S0006-3495(03)74972-8                                                   
   Stamatis H, 1999, BIOTECHNOL ADV, V17, P293, DOI 10.1016/S0734-9750(99)00007-5
   ZAKS A, 1988, J BIOL CHEM, V263, P8017
NR 40
TC 6
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1381-1177
J9 J MOL CATAL B-ENZYM
JI J. Mol. Catal. B-Enzym.
PD MAY 3
PY 2005
VL 33
IS 1-2
BP 29
EP 34
DI 10.1016/j.molcatb.2005.01.004
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Physical
SC Biochemistry & Molecular Biology; Chemistry
GA 930CU
UT WOS:000229394200005
DA 2018-01-05
ER

PT J
AU Kawamura, M
   Wang, X
   Uto, T
   Sato, K
   Ueno, M
   Akagi, T
   Hiraishi, K
   Matsuyama, T
   Akashi, M
   Baba, M
AF Kawamura, M
   Wang, X
   Uto, T
   Sato, K
   Ueno, M
   Akagi, T
   Hiraishi, K
   Matsuyama, T
   Akashi, M
   Baba, M
TI Induction of dendritic cell-mediated immune responses against HIV-1 by
   antigen-capturing nanospheres in mice
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE nanospheres; vaccine; HIV-1; CTL; dendritic cells
ID SIMIAN IMMUNODEFICIENCY VIRUS; INACTIVATED HIV-1-CAPTURING NANOSPHERES;
   IMMOBILIZED POLYSTYRENE NANOSPHERES; CYTOTOXIC T-LYMPHOCYTES; INTRANASAL
   IMMUNIZATION; LYMPH-NODES; INTRAVAGINAL INOCULATION; SERONEGATIVE
   PARTNERS; MUCOSAL IMMUNIZATION; ANTIBODY-RESPONSE
AB Prophylactic vaccines, designed to elicit potent humoral and cellular immune responses to human immunodeficiency virus type 1 (HIV-1) antigens in mucosa, are the important approach to the protection of individuals against HIV-1 infection, since HIV-1 transmission is largely a result of sexual contact. In this study, a novel strategy has been developed to induce HIV-1-specific immune responses, which involves inactivated HIV-1-caputring concanavalin A (Con A)-immobilized nanospheres (HIV-NS) and their interaction with bone marrow (BM)-derived dendritic cells. HIV-NS were taken up by dendritic cells via cytoskeleton-clepenclent but mannosebinding site-independent phagocytosis. Serial stimulations to unprimed T-cells with HIV-1 gp120-capturing NS-pulsed dendritic cells could induce antigen-specific T-cell response. Intranasal administration of fluorescein isothiocyanate-labeled nanospheres(NS) in mice proved that the particles were taken up into pulmonary dendritic cells. Analysis of mice receiving intranasal immunizations with HIV-NS revealed that the mice efficiently induced the antibodies against HIV-1 in the genital tract and specific cytotoxic T-cells in the spleen. These results suggest that the use of HIV-1-NS may provide a novel and promising approach for the induction of humoral and cellular immune responses to HIV-1. (c) 2005 Wiley-Liss, Inc.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Immunol & Med Zool, Kagoshima 8908544, Japan.
   Immunores Labs Co Ltd, Takasaki, Gumma, Japan.
   Kagoshima Univ, Fac Engn, Dept Chem Engn & Appl Chem, Kagoshima 8908544, Japan.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka, Japan.
   Japan Sci & Technol Corp, CREST, Tokyo, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, 8-35-1,Sakuragaoka, Kagoshima 8908544, Japan.
EM baba@m.kufm.kagoshima-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667
   Balmelli C, 2002, J VIROL, V76, P12596, DOI 10.1128/JVI.76.24.12596-12602.2002
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709
   Beyrer C, 1999, J INFECT DIS, V179, P59, DOI 10.1086/314556
   Biragyn A, 2002, BLOOD, V100, P1153, DOI 10.1182/blood-2002-01-0086                                                      
   Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X
   Crotty S, 2001, J VIROL, V75, P7435, DOI 10.1128/JVI.75.16.7435-7452.2001
   DEVITO C, 2000, J IMMUNOL, V14, P1917
   Fuller DH, 2002, J VIROL, V76, P3309, DOI 10.1128/JVI.76.7.3309-3317.2002
   Golding B, 2002, VACCINE, V20, P1445, DOI 10.1016/S0264-410X(01)00477-7
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Horner AA, 2001, J IMMUNOL, V167, P1584, DOI 10.4049/jimmunol.167.3.1584                                                     
   Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000
   Kato H, 2000, VACCINE, V18, P1151, DOI 10.1016/S0264-410X(99)00385-0                                                   
   Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004
   Kaul R, 2000, J IMMUNOL, V164, P1602, DOI 10.4049/jimmunol.164.3.1602                                                     
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   LAMM ME, 1995, APMIS, V103, P241, DOI 10.1111/j.1699-0463.1995.tb01101.x                                              
   Larsson M, 2002, AIDS, V16, P1319, DOI 10.1097/00002030-200207050-00003                                                
   Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875
   Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114
   LORI F, 1992, J VIROL, V66, P5553
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Mazzoli S, 1999, J INFECT DIS, V180, P871, DOI 10.1086/314934                                                                  
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   Morris CB, 2000, VACCINE, V18, P1944, DOI 10.1016/S0264-410X(99)00447-8
   Okada E, 1997, J IMMUNOL, V159, P3638
   Porgador A, 1997, J IMMUNOL, V158, P834
   Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4
   Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712
   Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215
   Vermaelen KY, 2001, J EXP MED, V193, P51, DOI 10.1084/jem.193.1.51                                                            
   Vremec D, 1997, J IMMUNOL, V159, P565
   Yoshizawa I, 2001, VACCINE, V19, P2995, DOI 10.1016/S0264-410X(00)00539-9                                                   
NR 39
TC 17
Z9 17
U1 0
U2 2
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD MAY
PY 2005
VL 76
IS 1
BP 7
EP 15
DI 10.1002/jmv.20317
PG 9
WC Virology
SC Virology
GA 912AN
UT WOS:000228049600002
PM 15778965
DA 2018-01-05
ER

PT J
AU Sommer, AP
AF Sommer, AP
TI Primordial proteins and HIV - Part II
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Letter
DE nanobacteria; primordial proteins; calcium phosphate; transfection; RNA;
   DNA; HIV
ID MODEL SIMULATION; LIVING NANOVESICLES; POSSIBLE PROVENANCE;
   NERVE-FIBERS; NANOBACTERIA; LIGHT; BIOMINERALIZATION; SUFFOCATION;
   REPLICATION; RNA
AB Nanobacteria are suspected to be responsible for a number of diseases, i.e., kidney stones, heart disease, ovarian cancer, peripheral neuropathy, and reduced bone mineral density. Being protected by a mineral shell consisting of apatite, the nanovesicles can enter eukaryotic cells. Depending on the host's stress level, nanobacteria may carry a substantial layer of a protein based slime, instrumental in collecting calcium phosphate from the environment. Calcium phosphate is known to mediate the uptake of nucleic acids by eukaryotic cells. Surprisingly, a pathogenic effect of nanobacteria in HIV can be derived primarily from the trafficking of calcium phosphate in HIV infected cells, performed by primordial proteins. The inescapable conclusion is that nanobacteria could promote genetic diversity in HIV.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Abbott A, 1999, NATURE, V401, P105, DOI 10.1038/43525
   Akerman KK, 1997, P SOC PHOTO-OPT INS, V3111, P436, DOI 10.1117/12.278798
   Cisar JO, 2000, P NATL ACAD SCI USA, V97, P11511, DOI 10.1073/pnas.97.21.11511
   DAI LL, 2005, IN PRESS LANGMUIR
   De Lucca FL, 2001, MOL CELL BIOCHEM, V228, P9, DOI 10.1023/A:1013305708539
   GODFARB DS, 2004, NEPHRON PHYSL, V98, P48
   GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3
   Hogan J, 2004, NEW SCI
   Hudelist G, 2004, HISTOPATHOLOGY, V45, P633, DOI 10.1111/j.1365-2559.2004.02030.x                                                
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   KLEINSCHMIDT AM, 1990, P NATL ACAD SCI USA, V87, P1283, DOI 10.1073/pnas.87.4.1283
   Lal RB, 2005, INDIAN J MED RES, V121, P287
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   SABELNIKOV AG, 1994, PROG BIOPHYS MOL BIO, V62, P119, DOI 10.1016/0079-6107(94)90009-4                                                    
   Sommer AP, 2005, J PROTEOME RES, V4, P633, DOI 10.1021/pr049795p
   Sommer AP, 2005, J PROTEOME RES, V4, P180, DOI 10.1021/pr0498382
   Sommer AP, 2005, CRYST GROWTH DES, V5, P21, DOI 10.1021/cg049812n
   Sommer AP, 2004, J PROTEOME RES, V3, P1296, DOI 10.1021/pr049861n
   Sommer AP, 2004, INT J ANTIMICROB AG, V24, P548, DOI 10.1016/j.ijantimicag.2004.09.006
   Sommer AP, 2004, J PROTEOME RES, V3, P1086, DOI 10.1021/pr049935v
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2004, J PROTEOME RES, V3, P667, DOI 10.1021/pr034122c
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   Sommer AP, 2002, J PROTEOME RES, V1, P111, DOI 10.1021/pr025501t
   STORM AJ, 2005, IN PRESS NANO LETT
   WainHobson S, 1997, NATURE, V387, P123, DOI 10.1038/387123a0
NR 32
TC 3
Z9 3
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAY-JUN
PY 2005
VL 4
IS 3
BP 1022
EP 1024
DI 10.1021/pr050064e
PG 3
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 936VB
UT WOS:000229882400041
PM 15952752
DA 2018-01-05
ER

PT J
AU Chou, SH
   Chin, KH
   Wang, AHJ
AF Chou, SH
   Chin, KH
   Wang, AHJ
TI DNA aptamers as potential anti-HIV agents
SO TRENDS IN BIOCHEMICAL SCIENCES
LA English
DT Article
ID TETRAD-FORMING OLIGONUCLEOTIDES; G-QUADRUPLEX; TELOMERIC DNA; INTEGRASE;
   INHIBITORS
AB Guanine (G)-rich DNA sequences can adopt stable G-quadruplex structures by G-tetrad hydrogen-bonding and hydrophobic stacking. Recently, it has been shown that a DNA sequence forms an aptamer (termed 93del) and adopts a novel dimeric quadruplex folding topology in K+ solution. This aptamer exhibits anti-HIV1 integrase activity in the nanomolar range in vitro. A docking-based model of the 93del-integrase complex positions the DNA aptamer within a channel of the tetrameric integrase. This mutual fitting blocks several catalytic amino acid residues that are essential for integrase function, and accounts for the anti-HIV1 activity of the 93del aptamer.
C1 Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan.
   Acad Sinica, Inst Biol Chem, Nankang, Taiwan.
RP Chou, SH (reprint author), Natl Chung Hsing Univ, Inst Biochem, Taichung 40227, Taiwan.
EM shchou@nchu.edu.tw
OI CHOU, Shan-Ho/0000-0002-5202-8238
CR Ambrus A, 2005, BIOCHEMISTRY-US, V44, P2048, DOI 10.1021/bi048242p
   Chou SH, 2003, NUCLEIC ACIDS RES, V31, P2461, DOI 10.1093/nar/gkg367
   Crnugelj M, 2003, J AM CHEM SOC, V125, P7866, DOI 10.1021/ja0348694
   Dapic V, 2003, NUCLEIC ACIDS RES, V31, P2097, DOI 10.1093/nar/gkg316
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950
   GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Jing NJ, 2002, BIOCHEMISTRY-US, V41, P5397, DOI 10.1021/bi0120401
   Kim MY, 2002, J AM CHEM SOC, V124, P2098, DOI 10.1021/ja017308q
   Neidle S, 2003, CURR OPIN STRUC BIOL, V13, P275, DOI 10.1016/S0959-440X(03)00072-1
   PADMANABHAN K, 1993, J BIOL CHEM, V268, P17651
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Patel D. J., 1999, OXFORD HDB NUCL ACID, P390
   Phan AT, 2005, P NATL ACAD SCI USA, V102, P634, DOI 10.1073/pnas.0406278102
   Shafer RH, 2001, BIOPOLYMERS, V56, P209
   Siddiqui-Jain A, 2002, P NATL ACAD SCI USA, V99, P11593, DOI 10.1073/pnas.182256799
   Zhang N, 2001, J MOL BIOL, V311, P1063, DOI 10.1006/jmbi.2001.4916
NR 19
TC 52
Z9 54
U1 0
U2 9
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0968-0004
J9 TRENDS BIOCHEM SCI
JI Trends Biochem.Sci.
PD MAY
PY 2005
VL 30
IS 5
BP 231
EP 234
DI 10.1016/j.tibs.2005.03.004
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 931DP
UT WOS:000229466300005
PM 15896739
DA 2018-01-05
ER

PT J
AU Wang, X
   Uto, T
   Sato, K
   Ide, K
   Akagi, T
   Okamoto, M
   Kaneko, T
   Akashi, M
   Baba, M
AF Wang, X
   Uto, T
   Sato, K
   Ide, K
   Akagi, T
   Okamoto, M
   Kaneko, T
   Akashi, M
   Baba, M
TI Potent activation of antigen-specific T cells by antigen-loaded
   nanospheres
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE polystyrene; nanotechnology; dendritic cell; maturation; vaccine; HIV-1
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; REGULATORY DENDRITIC CELLS; MHC
   CLASS-I; BONE-MARROW; MICROSPHERES; IMMUNIZATION; DELIVERY; MUCOSAL;
   MICE; MICROPARTICLES
AB Polystyrene nanospheres (NS) were found to be efficiently taken up by murine antigen-presenting cells (APC), especially bone marrow-derived dendritic cells (DC). in vitro and in vivo. The efficiency of NS uptake was not affected by the maturation state of DC. Both immature and mature DC had similar ability to take up NS in a dose- and time-dependent manner. Uptake and intracellular localization of NS was clearly demonstrated by confocal laser microscopy, using NS with fluorescence. DC could efficiently take up ovalbumin (OVA), when loaded on the surface of NS (OVA-NS). Consequently, OVA-NS-pulsed DC activated antigen-specific interferon (IFN)-gamma-producing T cells much more strongly than OVA-pulsed DC in vitro. These results suggest that NS can be used as an efficient antigen delivery system to DC for a variety of vaccines. such as an anti-human immunodeficiency virus type I vaccine. (c) 2004 Elsevier B.V. All rights reserved.
C1 Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Immunol & Med Zool, Kagoshima 8908544, Japan.
   Kagoshima Univ, Fac Engn, Dept Appl Chem & Chem Engn, Kagoshima 8900065, Japan.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka 5650871, Japan.
   Japan Sci & Technol Corp, CREST, Tokyo 1500002, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8908544, Japan.
EM baba@m.kufm.kagoshima-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030
   ELDRIDGE JH, 1991, MOL IMMUNOL, V28, P287, DOI 10.1016/0161-5890(91)90076-V
   ESOUSA CR, 1993, J EXP MED, V178, P509
   Harshyne LA, 2001, J IMMUNOL, V166, P3717, DOI 10.4049/jimmunol.166.6.3717                                                     
   Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163                                                         
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828                                                         
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Lutz MB, 1997, J IMMUNOL, V159, P3707
   MALOY KJ, 1994, IMMUNOLOGY, V81, P661
   Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4
   Men Y, 1999, VACCINE, V17, P1047, DOI 10.1016/S0264-410X(98)00321-1
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   OHagan DT, 1996, J ANAT, V189, P477
   PAPPO J, 1991, IMMUNOLOGY, V73, P277
   Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153                                                             
   Raychaudhuri S, 1998, NAT BIOTECHNOL, V16, P1025
   Sato K, 2003, IMMUNITY, V18, P367, DOI 10.1016/S1074-7613(03)00055-4
   Sato K, 2003, BLOOD, V101, P3581, DOI 10.1182/blood-2002-09-2712
   SCHEICHER C, 1995, EUR J IMMUNOL, V25, P1566, DOI 10.1002/eji.1830250615
   Scheicher C, 1995, ADV EXP MED BIOL, V378, P253
   Shen ZH, 1997, J IMMUNOL, V158, P2723
   STEINMAN RM, 1995, J EXP MED, V182, P283, DOI 10.1084/jem.182.2.283                                                           
   Thiele L, 2001, J CONTROL RELEASE, V76, P59, DOI 10.1016/S0168-3659(01)00412-6
   Walter E, 2001, J CONTROL RELEASE, V76, P149, DOI 10.1016/S0168-3659(01)00413-8                                                   
NR 29
TC 30
Z9 31
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD APR 15
PY 2005
VL 98
IS 1
BP 123
EP 130
DI 10.1016/j.imlet.2004.10.028
PG 8
WC Immunology
SC Immunology
GA 916TS
UT WOS:000228409700015
PM 15790517
DA 2018-01-05
ER

PT J
AU Saunders, NA
   Alexander, S
   Tatt, I
AF Saunders, NA
   Alexander, S
   Tatt, I
TI env gene typing of human immunodeficiency virus type 1 strains on
   electronic microarrays
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
ID HETERODUPLEX MOBILITY ASSAY; HIV-1 SUBTYPES; DNA HYBRIDIZATION;
   RECOMBINANT FORMS; FACTOR-V; ARRAY; SUSCEPTIBILITY; TRANSMISSION;
   RESISTANCE; MUTATIONS
AB The NanoChip system was used for subtyping human immunodeficiency virus type I (HIV-1) strains using probes complementary to the V1 region of the env gene. Probes for six subtypes (A to D, F, and G) and two circulating recombinant forms (AG and AE) of HIV-1 group M were included. The specificity of these oligonucleotides had been evaluated previously in a DNA enzyme immunoassay. Samples from 112 patient sera were used as templates in a nested reverse transcription-PCR to produce amplicons that were applied to the array. The array was then hybridized successively to pairs of oligonucleotide probes. The strains were assigned a subtype on the basis of their probe hybridization patterns. One strain gave a contradictory pattern and was designated as untypeable by the NanoChip assay. Eighty-eight strains gave hybridization patterns that allowed a correct subtype designation to be made by the NanoChip assay compared to either the sequence or the heteroduplex mobility assay (HMA)-determined subtypes. Thirteen strains that reacted with the subtype A probe (SA2) were incorrectly assigned to subtype A, or to one of the related circulating recombinant types (NE or AG), on the basis of reactions with probe SAE1 or SAG1. The results indicate that these oligonucleotides have relatively low specificities. The probe subtypes of three strains matched the subtypes determined for the gag and pol genes but not the env gene, suggesting that a recombination event may have occurred within the env gene. Overall, the NanoChip assay gave results comparable to those for HMA and sequencing and provides a convenient and cost-effective means by which to subtype HIV-1.
C1 GPBU, Ctr Infect, HPA, London NW9 5HT, England.
   Ctr Infect, Sexually Transmitted Bacteria Lab, London, England.
   Ctr Infect, Sexually Transmitted & Blood Borne Virus Lab, London, England.
RP Saunders, NA (reprint author), GPBU, Ctr Infect, HPA, 61 Colindale Ave, London NW9 5HT, England.
EM nick.saunders@hpa.org.uk
CR Alaeus A, 1997, AIDS, V11, P199, DOI 10.1097/00002030-199702000-00010
   Apetrei C, 1998, J VIROL, V72, P3534
   Barlow KL, 1997, J CLIN MICROBIOL, V35, P2846
   Barlow KL, 2001, AIDS RES HUM RETROV, V17, P467, DOI 10.1089/088922201750102607
   Belda FJ, 1997, J ACQ IMMUN DEF SYND, V16, P218, DOI 10.1097/00042560-199711010-00012                                                
   BOOM R, 1990, J CLIN MICROBIOL, V28, P495
   Clewley JP, 1996, LANCET, V347, P1487, DOI 10.1016/S0140-6736(96)91724-9                                                   
   Couturier E, 2000, AIDS, V14, P289, DOI 10.1097/00002030-200002180-00011
   DELWART EL, 1995, PCR METH APPL, V4, pS202
   Descamps D, 1998, AIDS, V12, P1109
   Edman CF, 2000, J INVEST MED, V48, P93
   Erali M, 2003, CLIN CHEM, V49, P732, DOI 10.1373/49.5.732                                                                
   Ewalt KL, 2001, ANAL BIOCHEM, V289, P162, DOI 10.1006/abio.2000.4927
   Heller MJ, 2000, ELECTROPHORESIS, V21, P157, DOI 10.1002/(SICI)1522-2683(20000101)21:1<157::AID-ELPS157>3.3.CO;2-5
   KUNANUSONT C, 1995, LANCET, V345, P1078
   Perez-Alvarez L, 2001, J HUMAN VIROL, V4, P35
   Plantier JC, 2002, J CLIN MICROBIOL, V40, P1010, DOI 10.1128/JCM.40.3.1010-1022.2002
   Robertson DL, 2000, SCIENCE, V288, P55
   Santacroce R, 2002, CLIN CHEM, V48, P2124
   Schrijver I, 2003, AM J CLIN PATHOL, V119, P490, DOI 10.1309/3VTR7TL2X7TXL0XY
   Sosnowski R, 2002, PSYCHIATR GENET, V12, P181, DOI 10.1097/00041444-200212000-00001
   Tatt ID, 2004, JAIDS-J ACQ IMM DEF, V36, P1092, DOI 10.1097/00126334-200408150-00013                                                
   Tatt ID, 2001, AIDS, V15, pS59, DOI 10.1097/00002030-200100005-00009                                                
   Tatt ID, 2000, J VIROL METHODS, V87, P41, DOI 10.1016/S0166-0934(00)00146-4                                                   
   Thistlethwaite WA, 2003, J MOL DIAGN, V5, P121, DOI 10.1016/S1525-1578(10)60461-8                                                   
   Trask SA, 2002, J VIROL, V76, P397, DOI 10.1128/JVI.76.1.397-405.2002
   Westin L, 2001, J CLIN MICROBIOL, V39, P1097, DOI 10.1128/JCM.39.3.1097-1104.2001
   Yirrell DI, 1997, BRIT MED J, V314, P1446, DOI 10.1136/bmj.314.7092.1446                                                       
   Yirrell DL, 1999, SEX TRANSM INFECT, V75, P392, DOI 10.1136/sti.75.6.392                                                            
NR 29
TC 1
Z9 2
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD APR
PY 2005
VL 43
IS 4
BP 1910
EP 1916
DI 10.1128/JCM.43.4.1910-1916.2005
PG 7
WC Microbiology
SC Microbiology
GA 916RS
UT WOS:000228404100060
PM 15815017
OA gold
DA 2018-01-05
ER

PT J
AU Snyder, GA
   Ford, J
   Torabi-Parizi, P
   Arthos, JA
   Schuck, P
   Colonna, M
   Sun, PD
AF Snyder, GA
   Ford, J
   Torabi-Parizi, P
   Arthos, JA
   Schuck, P
   Colonna, M
   Sun, PD
TI Characterization of DC-SIGN/R interaction with human immunodeficiency
   virus type 1 gp120 and ICAM molecules favors the receptor's role as an
   antigen-capturing rather than an adhesion receptor
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID C-TYPE LECTIN; ENDOTHELIAL-CELLS; ANTIBODY 2G12;
   CARBOHYDRATE-RECOGNITION; SELECTIVE RECOGNITION; GLYCOPROTEIN GP120;
   MANNOSE RECEPTOR; EBOLA-VIRUS; T-CELLS; BINDING
AB The dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin binding receptor (DC-SIGN) was shown to bind human immunodeficiency virus type 1 (HIV-1) viral envelope protein gp120 and proposed to function as a Trojan horse to enhance trans-virus infection to host T cells. To better understand the mechanism by which DC-SIGN and DC-SIGNR selectively bind HIV-1 gp120, we constructed a series of deletion mutations in the repeat regions of both receptors. Different truncated receptors exist in different oligomeric forms. The carbohydrate binding domain without any repeats was monomeric, whereas the full extracellular receptors existed as tetramers. All reconstituted receptors retained their ability to bind gp120. The dissociation constant, however, differed drastically from micromolar values for the monomeric receptors to nanomolar values for the tetrameric receptors, suggesting that the repeat region of these receptors contributes to the avidity of gp120 binding. Such oligomerization may provide a mechanism for the receptor to selectively recognize pathogens containing multiple high-mannose-concentration carbohydrates. In contrast, the receptors bound to ICAMs with submicromolar affinities that are similar to those of two nonspecific cell surface glycoproteins, Fc gamma RIIb and Fc gamma RIII, and the oligomerization of DC-SIGNR resulted in no increase in binding affinity to ICAM-3. These findings suggest that DC-SIGN may not discriminate other cell surface glycoproteins from ICAM-3 binding. The pH dependence in DC-SIGN binding to gp120 showed that the receptor retained high-affinity gp120 binding at neutral pH but lost gp120 binding at pH 5, suggesting a release mechanism of HIV in the acidic endosomal compartment by DC-SIGN. Our work contradicts the function of DC-SIGN as a Trojan horse to facilitate HIV-1 infection; rather, it supports the function of DC-SIGN/R (a designation referring to both DC-SIGN and DC-SIGNR) as an antigen-capturing receptor.
C1 NIAID, Immunogenet Lab, Struct Immunol Sect, NIH, Rockville, MD 20852 USA.
   NIAID, Immunogenet Lab, NIH, Rockville, MD 20852 USA.
   NIH, Off Director, Off Res Serv, Div Bioengn & Phys Sci, Bethesda, MD 20892 USA.
   Emory Univ, Dept Med, Atlanta, GA 30322 USA.
   Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
RP Sun, PD (reprint author), NIAID, Immunogenet Lab, Struct Immunol Sect, NIH, Twinbrook 2,12441 Parklawn Dr, Rockville, MD 20852 USA.
EM psun@nih.gov
OI Colonna, Marco/0000-0001-5222-4987; Schuck, Peter/0000-0002-8859-6966
CR Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002
   Bashirova AA, 2003, J VIROL, V77, P217, DOI 10.1128/JVI.77.1.217-227.2003
   Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671
   BEAVIL RL, 1995, IMMUNOLOGY, V84, P202
   CURTIS BM, 1992, P NATL ACAD SCI USA, V89, P8356, DOI 10.1073/pnas.89.17.8356                                                         
   DIERKS SE, 1993, J IMMUNOL, V150, P2372
   Engering A, 2002, J IMMUNOL, V168, P2118, DOI 10.4049/jimmunol.168.5.2118                                                     
   Feinberg H, 2001, SCIENCE, V294, P2163, DOI 10.1126/science.1066371
   Frison N, 2003, J BIOL CHEM, V278, P23922, DOI 10.1074/jbc.M302483200
   Geijtenbeek TBH, 2002, J BIOL CHEM, V277, P11314, DOI 10.1074/jbc.M111532200
   Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229
   Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7
   Geijtenbeek TBH, 2000, CELL, V100, P575, DOI 10.1016/S0092-8674(00)80693-5                                                   
   JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R
   Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P90
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Lin G, 2003, J VIROL, V77, P1337, DOI 10.1128/JVI.77.2.1337-1346.2003
   Mitchell DA, 2001, J BIOL CHEM, V276, P28939, DOI 10.1074/jbc.M104565200                                                          
   Park CG, 2001, INT IMMUNOL, V13, P1283, DOI 10.1093/intimm/13.10.1283
   Piguet V, 2002, J INVEST DERMATOL, V119, P365, DOI 10.1046/j.1523-1747.2002.01840.x                                                
   Pohlmann S, 2001, J VIROL, V75, P10523, DOI 10.1128/JVI.75.21.10523-10526.2001
   Pohlmann S, 2001, P NATL ACAD SCI USA, V98, P2670, DOI 10.1073/pnas.051631398
   Radaev S, 2002, MOL IMMUNOL, V38, P1073, DOI 10.1016/S0161-5890(02)00036-6
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Schjetne KW, 2002, INT IMMUNOL, V14, P1423, DOI 10.1093/intimm/dxf110                                                           
   Simmons G, 2003, VIROLOGY, V305, P115, DOI 10.1006/viro.2002.1730
   Soilleux EJ, 2000, J IMMUNOL, V165, P2937, DOI 10.4049/jimmunol.165.6.2937                                                     
   TAYLOR ME, 1992, J BIOL CHEM, V267, P1719
   Trkola A, 1996, J VIROL, V70, P1100
   Turville SG, 2001, BLOOD, V98, P2482, DOI 10.1182/blood.V98.8.2482
   Turville SG, 2002, NAT IMMUNOL, V3, P975, DOI 10.1038/ni841
NR 32
TC 59
Z9 64
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD APR
PY 2005
VL 79
IS 8
BP 4589
EP 4598
DI 10.1128/JVI.79.8.4589-4598.2005
PG 10
WC Virology
SC Virology
GA 912JJ
UT WOS:000228073700004
PM 15795245
OA gold
DA 2018-01-05
ER

PT J
AU Kolb, G
   Reigadas, S
   Boiziau, C
   van Aerschot, A
   Arzumanov, A
   Gait, MJ
   Herdewijn, P
   Toulme, JJ
AF Kolb, G
   Reigadas, S
   Boiziau, C
   van Aerschot, A
   Arzumanov, A
   Gait, MJ
   Herdewijn, P
   Toulme, JJ
TI Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1
   TAR RNA
SO BIOCHEMISTRY
LA English
DT Article
ID IN-VITRO SELECTION; DEPENDENT TRANSACTIVATION; MEDIATED TRANSCRIPTION;
   TRANS-ACTIVATION; DNA APTAMERS; OLIGONUCLEOTIDES; INHIBITION; BINDING;
   OLIGORIBONUCLEOTIDES; RECOGNITION
AB The transactivation responsive element (TAR) plays a crucial role in the transcription of the HIV-1 genome upon specific binding of the viral protein Tat and cellular proteins. We have previously identified a RNA hairpin aptamer forming a stable and specific kissing complex with TAR RNA (Duconge, F., and Toulme, J. J. (1999) RNA 5, 1605-1614). We chemically modified this aptamer with hexitol nucleic acid (HNA) residues. We demonstrate that a fully HNA-modified aptamer is a poor ligand but, in contrast, mixmers containing both HNA and unmodified RNA nucleotides display interesting properties. Two HNA-RNA mixmers bind to TAR with an equilibrium dissociation constant in the low-nanomolar range and show a reduced nuclease sensitivity. In addition, they show a moderate dependence on magnesium ions for binding to TAR. These HNA-RNA mixmers are able to inhibit transactivation of transcription in an in vitro assay.
C1 Univ Bordeaux 2, INSERM, U386, F-33076 Bordeaux, France.
   Rega Inst, Med Chem Lab, B-3000 Louvain, Belgium.
   MRC, Mol Biol Lab, Cambridge CB2 2QH, England.
   Inst Europeen Chim & Biol, F-33607 Pessac, France.
RP Toulme, JJ (reprint author), Univ Bordeaux 2, INSERM, U386, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM jean-jacques.toulme@bordeaux.inserm.fr
OI Toulme, Jean-jacques/0000-0002-8432-5034
CR Arzumanov A, 2001, NUCLEOS NUCLEOT NUCL, V20, P471, DOI 10.1081/NCN-100002321
   Arzumanov A, 2003, OLIGONUCLEOTIDES, V13, P435, DOI 10.1089/154545703322860762
   Arzumanov A, 2001, BIOCHEMISTRY-US, V40, P14645, DOI 10.1021/bi011279e
   Beaurain F, 2003, NUCLEIC ACIDS RES, V31, P4275, DOI 10.1093/nar/gkg467
   BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169
   Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730
   Brody E.N., 2000, REV MOL BIOTECHNOL, V74, P5, DOI DOI 10.1016/S1389-0352(99)00004-5
   CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128
   Darfeuille F, 2004, NUCLEIC ACIDS RES, V32, P3101, DOI 10.1093/nar/gkh636
   Darfeuille F, 2002, P NATL ACAD SCI USA, V99, P9709, DOI 10.1073/pnas.122247199
   Darfeuille F, 2002, BIOCHEMISTRY-US, V41, P12186, DOI 10.1021/bi025974d
   Darfeuille F, 2001, NUCLEOS NUCLEOT NUCL, V20, P441, DOI 10.1081/NCN-100002318                                                           
   Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487
   DeBouvere B, 1997, LIEBIGS ANN-RECL, P1453
   Declercq R, 2002, J AM CHEM SOC, V124, P928, DOI 10.1021/ja016570w
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   Froeyen M., 2002, Current Topics in Medicinal Chemistry, V2, P1123, DOI 10.2174/1568026023393200
   Hamma T, 2003, BIOORG MED CHEM LETT, V13, P1845, DOI 10.1016/S0960-894X(03)00323-8
   Hendrix C, 1997, CHEM-EUR J, V3, P110, DOI 10.1002/chem.19970030118                                                        
   Holmes SC, 2003, NUCLEIC ACIDS RES, V31, P2759, DOI 10.1093/nar/gkg384
   ISEL C, 1999, EMBO J, V18, P1048
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Lescrinier E, 2000, CHEM BIOL, V7, P719, DOI 10.1016/S1074-5521(00)00017-X                                                   
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   Lund LH, 2003, J GEN VIROL, V84, P603, DOI 10.1099/vir.0.18645-0
   Marchand C, 1996, BIOCHEMISTRY-US, V35, P5022, DOI 10.1021/bi952908l                                                               
   Patel D J, 2000, J Biotechnol, V74, P39
   ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365
   Sekkal D, 2002, ANTISENSE NUCLEIC A, V12, P265, DOI 10.1089/108729002320351584
   Tamilarasu N, 2001, BIOORG MED CHEM LETT, V11, P505, DOI 10.1016/S0960-894X(00)00709-5
   Tassew N, 2003, ORG BIOMOL CHEM, V1, P3268, DOI 10.1039/b307620m
   Toulme JJ, 2000, CURR OPIN MOL THER, V2, P318
   Van Aerschot A, 2001, NUCLEIC ACIDS RES, V29, P4187, DOI 10.1093/nar/29.20.4187
   Vandermeeren M, 2000, BIOCHEM PHARMACOL, V59, P655, DOI 10.1016/S0006-2952(99)00367-6                                                   
NR 35
TC 27
Z9 28
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 1
PY 2005
VL 44
IS 8
BP 2926
EP 2933
DI 10.1021/bi048393s
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 900ZJ
UT WOS:000227252500020
PM 15723535
DA 2018-01-05
ER

PT J
AU Sommer, AP
   Pavlath, AE
AF Sommer, AP
   Pavlath, AE
TI Primordial proteins and HIV
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Letter
DE nanobacteria; primordial proteins; slime; calcium phosphate; RNA; DNA;
   HIV
ID KIDNEY-STONE FORMATION; NANOBACTERIA; NANOPARTICLES; BIOSYSTEMS; PIECES;
   GENES; CELL; RNA
AB Primordial proteins regulate the response of nanobacteria to variations in their environment and reinforce existing pathogenic potentials. By analyzing specific response patterns, we predicted the prevalence of nanobacteria in HIV-and in the atmosphere. A current clinical study indicates the identification of a possibly giant nanobacterial reservoir in Africa: A significant fraction of a test group (40 HIV-infected mothers and 13 babies) was infected with nanobacteria. Concurrently, a multitude of 80-300 nm nanovesicles, apparently nanobacteria, were detected in the atmosphere of the Earth. Nanobacterial infections in HIV are possibly comparable to the twin epidemics HIV and tuberculosis. Models inspired by proteomics recommend methods to inactivate nanobacteria (and other slime-producing bacteria) in the body.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Amiel C, 2004, J BONE MINER RES, V19, P402, DOI 10.1359/JBMR.0301246
   BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0                                                                
   Ciftcioglu N, 1999, KIDNEY INT, V56, P1893, DOI 10.1046/j.1523-1755.1999.00755.x
   CIFTCIOGLU N, 2001, 101 GEN M AM SOC MIC
   De Lucca FL, 2001, MOL CELL BIOCHEM, V228, P9, DOI 10.1023/A:1013305708539
   GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0                                                                
   GLESBY M, 2003, J CLIN INFECT DIS S2, V37, pS91
   Javaux EJ, 2003, ORIGINS LIFE EVOL B, V33, P75, DOI 10.1023/A:1023992712071
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   Kim BH, 2004, APPL MICROBIOL BIOT, V63, P672, DOI 10.1007/s00253-003-1412-6
   KLEINSCHMIDT AM, 1990, P NATL ACAD SCI USA, V87, P1283, DOI 10.1073/pnas.87.4.1283
   LASKIN A, 2003, SCIENCE, V30, P340
   Maniscalco Benedict S., 2004, Pathophysiology, V11, P95, DOI 10.1016/j.pathophys.2004.06.001
   Marvin D. A., 2003, FIBRE DIFFRACTION RE, V11, P87
   McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   Rietmeijer FJM, 1997, J GEOPHYS RES-PLANET, V102, P6621, DOI 10.1029/96JE03989
   SABELNIKOV AG, 1994, PROG BIOPHYS MOL BIO, V62, P119, DOI 10.1016/0079-6107(94)90009-4                                                    
   Sommer AP, 2004, J PROTEOME RES, V3, P1296, DOI 10.1021/pr049861n
   Sommer AP, 2004, INT J ANTIMICROB AG, V24, P548, DOI 10.1016/j.ijantimicag.2004.09.006
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2002, CRYST GROWTH DES, V2, P563, DOI 10.1021/cg0255725
   SOMMER AP, 2005, PROTEOME RES, V4, P180
   Toon OB, 2003, NATURE, V424, P623, DOI 10.1038/424623a
   Vigano Alessandra, 2004, Expert Opin Drug Saf, V3, P199
   Wainwright M, 2004, MICROBIOL-SGM, V150, P756, DOI 10.1099/mic.0.26907-0
   Wolynes PG, 1996, P NATL ACAD SCI USA, V93, P14249, DOI 10.1073/pnas.93.25.14249
NR 35
TC 8
Z9 8
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAR-APR
PY 2005
VL 4
IS 2
BP 633
EP 636
DI 10.1021/pr049795p
PG 4
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 916YE
UT WOS:000228421900052
PM 15822945
DA 2018-01-05
ER

PT J
AU Rezacova, P
   Brynda, J
   Lescar, J
   Fabry, M
   Horejsi, M
   Sieglova, I
   Sedlacek, J
   Bentley, GA
AF Rezacova, P
   Brynda, J
   Lescar, J
   Fabry, M
   Horejsi, M
   Sieglova, I
   Sedlacek, J
   Bentley, GA
TI Crystal structure of a cross-reaction complex between an anti-HIV-1
   protease antibody and an HIV-2 protease peptide
SO JOURNAL OF STRUCTURAL BIOLOGY
LA English
DT Article
DE single-chain Fv fragment; peptide complex; HIV protease; crystal
   structure; antibody cross-reactivity
ID MONOCLONAL-ANTIBODY; INHIBITION; PROTEINS; INTERFACES
AB The monoclonal antibody 1696, elicited by HIV-1 protease, inhibits the activity of both HIV-1 and HIV-2 proteases with inhibition constants in the low nanomolar range. The antibody cross-reacts with peptides derived from the N-terminal region of both proteases. The crystal Structure of the recombinant single-chain Fv fragment of 1696 complexed with an N-terminal peptide from the HIV-2 protease has been determined at 1.88 Angstrom resolution. Interactions of the peptide with scFvl 696 are compared with the previousy reported Structure of scFv1696 in complex with the corresponding peptide from H1 V-1 protease. The origin of cross-reactivity of mAbI 696 with HIV proteases is discussed. (C) 2004 published by Elsevier Inc.
C1 Acad Sci Czech Republ, Inst Mol Genet, Dept Recombinant Express & Struct Biol, Prague 16637 6, Czech Republic.
   Nanyang Technol Univ, Sch Biol Sci, Singapore 637551, Singapore.
   Inst Pasteur, Dept Biol Struct & Chim, URA 2185 CNRS, Unite Immunol Struct, F-75724 Paris, France.
RP Rezacova, P (reprint author), Acad Sci Czech Republ, Inst Mol Genet, Dept Recombinant Express & Struct Biol, Flemingovo Nam 2, Prague 16637 6, Czech Republic.
EM rezacova@img.cas.cz
RI Brynda, Jiri/G-2760-2014; Maloy Rezacova, Pavlina/G-3600-2014; Sedlacek,
   Juraj/G-3606-2014; Fabry, Milan/G-3602-2014; Bentley, Graham/B-3623-2011
CR BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Craig L, 1998, J MOL BIOL, V281, P183, DOI 10.1006/jmbi.1998.1907
   Creighton T. E., 1993, PROTEINS STRUCTURES, P141
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071                                                       
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879                                                         
   JOHNSON S, 1991, METHOD ENZYMOL, V203, P88
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   Kurucz I, 1995, MOL IMMUNOL, V32, P1443, DOI 10.1016/0161-5890(95)00105-0
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648
   Lescar J, 1997, J MOL BIOL, V267, P1207, DOI 10.1006/jmbi.1997.0950
   Lescar J, 2003, ACTA CRYSTALLOGR D, V59, P955, DOI 10.1107/S0907444903003597
   Lescar J, 1996, PROTEIN SCI, V5, P966
   Lescar J, 1999, PROTEIN SCI, V8, P2686
   MILNERWHITE EJ, 1988, J MOL BIOL, V204, P777, DOI 10.1016/0022-2836(88)90368-3
   Nair DT, 2000, J IMMUNOL, V165, P6949, DOI 10.4049/jimmunol.165.12.6949                                                    
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597                                                       
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Rezacova P, 2002, J MOL RECOGNIT, V15, P272, DOI 10.1002/jmr.587
   Rezacova P, 2001, STRUCTURE, V9, P887, DOI 10.1016/S0969-2126(01)00654-2                                                   
   WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7                                                   
NR 25
TC 8
Z9 8
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1047-8477
J9 J STRUCT BIOL
JI J. Struct. Biol.
PD MAR
PY 2005
VL 149
IS 3
BP 332
EP 337
DI 10.1016/j.jsb.2004.11.009
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 902YY
UT WOS:000227393800012
PM 15721587
DA 2018-01-05
ER

PT J
AU Winum, JY
   Scozzafava, A
   Montero, JL
   Supuran, CT
AF Winum, JY
   Scozzafava, A
   Montero, JL
   Supuran, CT
TI Sulfamates and their therapeutic potential
SO MEDICINAL RESEARCH REVIEWS
LA English
DT Review
DE antibiotic; anti-cancer drug; anti-convulsant; anti-obesity drug;
   anti-viral agent; avasimibe; carbonic anhydrase inhibitor; COUMATE;
   EMATE; steroid sulfatase inhibitor; sulfamate; sulfamic acid; topiramate
ID CARBONIC-ANHYDRASE INHIBITORS; STEROID SULFATASE INHIBITORS;
   TRANSFER-RNA-SYNTHETASES; CYTOSOLIC ISOZYME-I; ANTI-HIV AGENTS;
   5'-DIPHOSPHATE GLUCOSE ANALOGS; SITE-DIRECTED INHIBITION; ACYL
   TRANSFERASE ACAT; BREAST-CANCER CELLS; ESTRONE SULFATASE
AB Starting from the very simple molecule sulfamic acid, O-substituted-, N-substituted-, or di-/tri-substituted sulfamates may be obtained, which show specific biological activities which were or started to be exploited for the design of many types of therapeutic agents. Among them, sulfamate inhibitors of aminoacyl-tRNA synthetases (aaRSs) were recently reported, constituting completely new classes of antibiotics, useful in the fight of drug-resistant infections. Anti-viral agents incorporating sulfamate moieties have also been obtained, with at least two types of such derivatives investigated: the nucleoside/nucleotide human immunodeficiency virus (HIV) reverse transcriptase inhibitors, and the HIV protease inhibitors (PIs). In the increasing armamentarium of anti-cancer drugs, the sulfamates occupy a special position, with at least two important targets evidenced so far: the steroid sulfatases (STSs) and the carbonic anhydrases (CAs). An impressing number of inhibitors of STSs of the sulfamate type have been reported in the last years, with several compounds, such as 667COUMATE among others, progressing to clinical trials for the treatment of hormone-dependent tumors (breast and prostate cancers). This field is rapidly evolving, with many types of new inhibitors being constantly reported and designed in such a way as to increase their anti-tumor properties, and decrease undesired features (for example, estrogenicity, a problem encountered with the first generation such inhibitors, such as EMATE). Among the many isozymes of CAs, at least two, CA IX and CA XII, are highly overexpressed in tumors, being generally absent in the normal tissues. Inhibition of turner-associated CAs was hypothesized to lead to novel therapeutic approaches for the treatment of cancer. Many sulfamates act as very potent (low nanomolar) CA inhibitors. The X-ray crystal structure of the best-studied isozyme, CA II, with three sulfamates (sulfamic acid, topiramate, and EMATE) has recently been reported, which allowed for a rationale drug design of new inhibitors. Indeed, low nanomolar CA IX inhibitors of the sulfamate type have been reported, although such compounds also act as efficient inhibitors of isozymes CA I and II, which are not associated with tumors. A large number of anti-convulsant sulfamates have been described, with one such compound, topiramate, being widely used clinically as anti-epileptic drug. By taking into consideration a side effect of topiramate, an anti-epileptic drug leading to weight loss in some patients, it has recently been proposed to use this drug and related sulfamates for the treatment of obesity. The rationale of this use is based on the inhibition of the mitochondrial CA isozyme, CAV, involved in lipogenesis. Some sulfamates were also shown to possess potent inhibitory activity against acyl coenzyme A:cholesterol acyltransferase, an enzyme involved in cholesterol metabolism. One such agent, avasimibe, is in advanced clinical trials for the treatment of hyperlipidemia and atherosclerosis. Thus, the sulfamate moiety offers very attractive possibilities for the drug design of various pharmacological agents, which are on one hand due to the relative ease with which such compounds are synthesized, and on the other one, due to the fact that biological activity of most of them is impressive. (C) 2004 Wiley Periodicals, Inc. Med Res Rev, 25, No. 2, 186-228, 2005.
C1 Univ Montpellier 2, Chim Biomol Lab, UMR 5032, Ecole Natl Super Chim Montpellier, F-34296 Montpellier, France.
   Univ Florence, Dipartimento Chim, Chim Bioorgan Lab, I-50019 Sesto Fiorentino, Italy.
RP Winum, JY (reprint author), Univ Montpellier 2, Chim Biomol Lab, UMR 5032, Ecole Natl Super Chim Montpellier, 8 Rue Ecole Normale, F-34296 Montpellier, France.
EM winumj@univ-montp2.fr; claudiu.supuran@unifi.it
RI WINUM, Jean-Yves/P-3387-2016; Supuran, Claudiu/A-5151-2008
OI WINUM, Jean-Yves/0000-0003-3197-3414; Scozzafava,
   Andrea/0000-0001-5020-3322
CR Abbate F, 2004, BIOORG MED CHEM LETT, V14, P217, DOI 10.1016/j.bmcl.2003.09.062
   Abbate F, 2002, J MED CHEM, V45, P3583, DOI 10.1021/jm011131t
   Abbate F, 2004, BIOORG MED CHEM LETT, V14, P231, DOI 10.1016/j.bmcl.2003.09.064
   Ahmed S, 2002, BIOORG MED CHEM LETT, V12, P1343, DOI 10.1016/S0960-894X(02)00170-1
   Ahmed S, 2002, BIOORG MED CHEM LETT, V12, P1279, DOI 10.1016/S0960-894X(02)00137-3
   Ahmed S, 2002, CURR MED CHEM, V9, P263, DOI 10.2174/0929867023371210                                                        
   Ahmed S, 2001, BIOORG MED CHEM LETT, V11, P2525, DOI 10.1016/S0960-894X(01)00482-6                                                   
   Ahmed S, 2001, BIOORG MED CHEM LETT, V11, P899, DOI 10.1016/S0960-894X(01)00087-7
   Ahmed S, 2001, BIOORG MED CHEM LETT, V11, P841, DOI 10.1016/S0960-894X(01)00086-5
   Antel J, 2004, CRC ENZYM INHIB SER, P45
   Aribi AM, 2002, EPILEPSY RES, V49, P143, DOI 10.1016/S0920-1211(02)00019-0
   BARBARO G, 2004, IN PRESS CURR PHARM
   BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224
   Bilban M, 2000, BIOORG MED CHEM LETT, V10, P967, DOI 10.1016/S0960-894X(00)00144-X
   BLOCH A, 1971, BIOCHEMISTRY-US, V10, P4394, DOI 10.1021/bi00800a007
   Briganti F, 1996, EUR J MED CHEM, V31, P1001, DOI 10.1016/S0223-5234(97)86179-X                                                   
   Brown MJB, 2000, BIOCHEMISTRY-US, V39, P6003, DOI 10.1021/bi000148v                                                               
   Brown P, 1999, BIOORGAN MED CHEM, V7, P2473, DOI 10.1016/S0968-0896(99)00192-3                                                   
   Brust P, 2002, APPL RADIAT ISOTOPES, V57, P687, DOI 10.1016/S0969-8043(02)00184-7                                                   
   Burnett John R, 2002, Curr Opin Investig Drugs, V3, P1328
   CAMARASA MJ, 1985, J MED CHEM, V28, P40, DOI 10.1021/jm00379a010
   Casini A, 2003, BIOORG MED CHEM LETT, V13, P841, DOI 10.1016/S0960-894X(03)00029-5
   Chu GH, 1999, BIOORG MED CHEM LETT, V9, P141, DOI 10.1016/S0960-894X(98)00707-0
   Ciobanu LC, 2003, J COMB CHEM, V5, P429, DOI 10.1021/cc020115u
   Ciobanu LC, 2002, J STEROID BIOCHEM, V80, P339, DOI 10.1016/S0960-0760(02)00024-9
   Ciobanu LC, 1999, J MED CHEM, V42, P2280, DOI 10.1021/jm980677l                                                               
   De Clercq E, 2002, MED RES REV, V22, P531
   De Clercq E, 2002, MINI-REV MED CHEM, V2, P163, DOI 10.2174/1389557024605474
   De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703
   Dodgson SJ, 2000, EPILEPSIA, V41, P35
   Elger W, 1995, J STEROID BIOCHEM, V55, P395, DOI 10.1016/0960-0760(95)00214-6                                                    
   Fakhoury T, 2002, EPILEPSY BEHAV, V3, P185, DOI 10.1006/ebeh.2002.0339
   FERNANDEZRESA P, 1986, EUR J MED CHEM, V21, P245
   FIANDOR J, 1986, EUR J MED CHEM, V22, P59
   Fischer DS, 2003, J STEROID BIOCHEM, V84, P343, DOI 10.1016/S0960-0760(03)00048-7
   Fischer DS, 2003, BIOORGAN MED CHEM, V11, P1685, DOI 10.1016/S0968-0896(03)00042-7
   Forrest AK, 2000, BIOORG MED CHEM LETT, V10, P1871, DOI 10.1016/S0960-894X(00)00360-7
   Gibbs JW, 2000, EPILEPSIA, V41, pS10
   Golob T, 2002, BIOORGAN MED CHEM, V10, P3941, DOI 10.1016/S0968-0896(02)00306-1
   Gordon A, 1999, AM J PSYCHIAT, V156, P968
   Guay DRP, 2003, EXPERT OPIN PHARMACO, V4, P1259, DOI 10.1517/14656566.4.8.1259
   Heacock D, 1996, BIOORG CHEM, V24, P273, DOI 10.1006/bioo.1996.0025
   Hejaz HAM, 1999, J MED CHEM, V42, P3188, DOI 10.1021/jm980717l
   Hernandez-Guzman FG, 2003, J BIOL CHEM, V278, P22989, DOI 10.1074/jbc.M211497200
   Herrero AI, 2002, NEUROPHARMACOLOGY, V42, P210, DOI 10.1016/S0028-3908(01)00171-X
   Ho YT, 2003, BIOCHEM BIOPH RES CO, V305, P909, DOI 10.1016/S0006-291X(03)00865-9
   Hoffmann R, 2000, EUR J DERMATOL, V10, P319
   HOWARTH NM, 1994, J MED CHEM, V37, P219, DOI 10.1021/jm00028a002
   Ilies MA, 2004, BIOORGAN MED CHEM, V12, P2717, DOI 10.1016/j.bmc.2004.03.008
   ISONO K, 1984, J ANTIBIOT, V37, P670, DOI 10.7164/antibiotics.37.670                                                      
   JENNINGS JL, 1992, J CHEM SOC P1, V1, P2197
   KINI GD, 1990, J MED CHEM, V33, P44, DOI 10.1021/jm00163a008                                                             
   Kolli A, 1999, J STEROID BIOCHEM, V68, P31, DOI 10.1016/S0960-0760(98)00159-9                                                   
   Kuo RL, 2002, J ENDOUROL, V16, P229, DOI 10.1089/089277902753752188
   Kuzniecky R, 2002, NEUROLOGY, V58, P368, DOI 10.1212/WNL.58.3.368                                                            
   Lane TW, 2000, P NATL ACAD SCI USA, V97, P4627, DOI 10.1073/pnas.090091397                                                          
   Lee HT, 1996, J MED CHEM, V39, P5031, DOI 10.1021/jm960674d
   Lee J, 2003, BIOORG MED CHEM LETT, V13, P1087, DOI 10.1016/S0960-894X(03)00020-9
   Lehtonen J, 2004, J BIOL CHEM, V279, P2719, DOI 10.1074/jbc.M308984200
   Li PK, 1996, J STEROID BIOCHEM, V59, P41, DOI 10.1016/S0960-0760(96)00093-3
   Li PK, 1998, STEROIDS, V63, P425, DOI 10.1016/S0039-128X(98)00044-0
   LLAVERIAS G, 2003, CARDIOVASC DRUG REV, V1, P33
   LO YS, 1992, J MED CHEM, V35, P4790, DOI 10.1021/jm00104a003                                                             
   LYNCH CJ, 1995, BIOCHEM J, V310, P197, DOI 10.1042/bj3100197                                                               
   Malini B, 2000, J STEROID BIOCHEM, V75, P253, DOI 10.1016/S0960-0760(00)00178-3
   MARYANOFF BE, 1987, J MED CHEM, V30, P880, DOI 10.1021/jm00388a023                                                             
   Maryanoff BE, 1998, J MED CHEM, V41, P1315, DOI 10.1021/jm970790w
   Masereel B, 2002, J MED CHEM, V45, P312, DOI 10.1021/jm0109199
   Mastrolorenzo A, 2001, EXPERT OPIN THER PAT, V11, P1245, DOI 10.1517/13543776.11.8.1245                                                      
   McLean MJ, 2000, EPILEPSIA, V41, pS21, DOI 10.1111/j.1528-1157.2000.tb06043.x
   MONTERO RR, 2002, REV NEUROL, V34, P101
   NOLAN JC, 1990, J PHARM PHARMACOL, V42, P533, DOI 10.1111/j.2042-7158.1990.tb07053.x                                              
   Nussbaumer P, 2003, J MED CHEM, V46, P5091, DOI 10.1021/jm030926s
   Nussbaumer P, 2003, EXPERT OPIN THER PAT, V13, P605, DOI 10.1517/13543776.13.5.605
   Nussbaumer P, 2002, BIOORG MED CHEM LETT, V12, P2093, DOI 10.1016/S0960-894X(02)00381-5
   Nussbaumer P, 2002, J MED CHEM, V45, P4310, DOI 10.1021/jm020878w
   Okada M, 2003, J STEROID BIOCHEM, V87, P141, DOI 10.1016/j/jsbmb.2003.07.005
   OSADA H, 1985, ANTIMICROB AGENTS CH, V27, P230, DOI 10.1128/AAC.27.2.230                                                            
   Pastorekova S, 2004, J ENZYM INHIB MED CH, V19, P199, DOI 10.1080/14756360410001689540
   PASTOREKOVA S, 2004, CARBONIC ANHYDRASE I, P253
   Patel CK, 2004, BIOORG MED CHEM LETT, V14, P605, DOI 10.1016/j.bmcl.2003.11.067
   Patel CK, 2003, BIOCHEM BIOPH RES CO, V307, P778, DOI 10.1016/S0006-291X(03)01258-0
   Perez-Molina Jose A, 2002, HIV Clin Trials, V3, P279, DOI 10.1310/3Q91-YT2D-BUT4-8HN6
   Perucca E, 1997, PHARMACOL RES, V35, P241, DOI 10.1006/phrs.1997.0124
   PETERSON EM, 1992, J MED CHEM, V35, P3991, DOI 10.1021/jm00100a003
   Picard F, 2000, OBES RES, V8, P656, DOI 10.1038/oby.2000.84                                                             
   Poirier D, 1999, EXPERT OPIN THER PAT, V9, P1083, DOI 10.1517/13543776.9.8.1083                                                       
   Prasad JVNV, 1999, BIOORG MED CHEM LETT, V9, P2217
   Purohit A, 1998, J STEROID BIOCHEM, V64, P269, DOI 10.1016/S0960-0760(97)00196-9                                                   
   Purohit A, 2003, J STEROID BIOCHEM, V86, P423, DOI 10.1016/S0960-0760(03)00353-4
   Purohit A, 2001, MOL CELL ENDOCRINOL, V171, P129, DOI 10.1016/S0303-7207(00)00428-7
   Recacha R, 2002, BIOCHEM J, V361, P437, DOI 10.1042/0264-6021:3610437                                                       
   Reed JE, 2004, BIOCHEM BIOPH RES CO, V317, P169, DOI 10.1016/j.bbrc.2004.03.023
   Reis J, 2002, EPILEPSIA, V43, P1149, DOI 10.1046/j.1528-1157.2002.09902.x                                                
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Rodig H, 2002, APPL RADIAT ISOTOPES, V56, P773, DOI 10.1016/S0969-8043(02)00060-X
   Rosenfeld WE, 1997, CLIN THER, V19, P1294, DOI 10.1016/S0149-2918(97)80006-9                                                   
   SAITO T, 2004, J STEROID BIOCHEM, P167
   Schimmel P, 1998, FASEB J, V12, P1599
   Schreiner EP, 2003, BIOORG MED CHEM LETT, V13, P4313, DOI 10.1016/j.bmcl.2003.09.050
   Scozzafava A, 2002, J ENZYM INHIB MED CH, V17, P69, DOI 10.1080/14756360290024227
   Scozzafava A, 2003, CURR MED CHEM, V10, P925, DOI 10.2174/0929867033457647                                                        
   SHANK RP, 1994, EPILEPSIA, V35, P450, DOI 10.1111/j.1528-1157.1994.tb02459.x
   SHUMAN DA, 1970, J AM CHEM SOC, V92, P3434, DOI 10.1021/ja00714a035                                                             
   Sills GJ, 2000, EPILEPSIA, V41, pS30, DOI 10.1111/j.1528-1157.2000.tb06046.x
   Skradski S, 2000, EPILEPSIA, V41, pS45
   SLISKOVIC DR, 1994, J MED CHEM, V37, P560, DOI 10.1021/jm00031a002
   Smith HJ, 2001, EXPERT OPIN THER PAT, V11, P789, DOI 10.1517/13543776.11.5.789                                                       
   So AKC, 2004, J BACTERIOL, V186, P623, DOI 10.1128/JB.186.3.623-630.2004
   Spillane WJ, 1996, FOOD CHEM, V56, P255, DOI 10.1016/0308-8146(96)00022-2
   Stringer JL, 2000, EPILEPSY RES, V40, P147, DOI 10.1016/S0920-1211(00)00118-2
   Suitters AJ, 1997, IMMUNOLOGY, V91, P314, DOI 10.1046/j.1365-2567.1997.00254.x                                                
   Supuran CT, 2003, MED RES REV, V23, P535, DOI 10.1002/med.10047
   Supuran CT, 2004, MINI-REV MED CHEM, V4, P189, DOI 10.2174/1389557043487402                                                        
   Supuran CT, 2003, EXPERT OPIN INV DRUG, V12, P283, DOI 10.1517/13543784.12.2.283
   Supuran CT, 2000, EXPERT OPIN THER PAT, V10, P575, DOI 10.1517/13543776.10.5.575                                                       
   Supuran CT, 2002, EXPERT OPIN THER PAT, V12, P217, DOI 10.1517/13543776.12.2.217                                                       
   Supuran CT, 2003, EXPERT OPIN THER PAT, V13, P1545, DOI 10.1517/13543776.13.10.1545
   Supuran CT, 2003, MED RES REV, V23, P146, DOI 10.1002/med.10025
   Supuran CT, 2004, CRC ENZYM INHIB SER, P1, DOI 10.1201/9780203475300.ch1
   Suzuki RN, 2003, J STEROID BIOCHEM, V84, P269, DOI 10.1016/S0960-0760(03)00035-9
   TAKAHASHI E, 1982, J ANTIBIOT, V35, P939, DOI 10.7164/antibiotics.35.939                                                      
   Taverna S, 1999, J PHARMACOL EXP THER, V288, P960
   THOMAS S O, 1956, Antibiot Annu, P716
   Tripp BC, 2004, J BIOL CHEM, V279, P6683, DOI 10.1074/jbc.M311648200
   UEDA H, 1991, BIOCHIM BIOPHYS ACTA, V1080, P126, DOI 10.1016/0167-4838(91)90138-P
   Vicker N, 2003, BIOORG MED CHEM LETT, V13, P863, DOI 10.1016/S0960-894X(03)00009-X
   Vince R, 1995, NUCLEOS NUCLEOT, V14, P2051, DOI 10.1080/15257779508010723
   VONDERHAAR F, 1981, ANGEW CHEM INT EDIT, V20, P217, DOI 10.1002/anie.198102173                                                          
   Vullo D, 2004, J MED CHEM, V47, P1272, DOI 10.1021/jm031057+
   WALSH DA, 1990, J MED CHEM, V33, P2068, DOI 10.1021/jm00170a003
   Weber A, 2004, J MED CHEM, V47, P550, DOI 10.1021/jm030912m
   Winum JY, 2003, J MED CHEM, V46, P5471, DOI 10.1021/jm030911u
   Winum JY, 2003, J MED CHEM, V46, P2197, DOI 10.1021/jm021124k
   Wolf OT, 1999, BRAIN RES REV, V30, P264, DOI 10.1016/S0165-0173(99)00021-1                                                   
   Woo LWL, 2000, CHEM BIOL, V7, P773, DOI 10.1016/S1074-5521(00)00023-5
   Woo LWL, 1996, J MED CHEM, V39, P1349, DOI 10.1021/jm950931z
   Woo LWL, 2003, J MED CHEM, V46, P3193, DOI 10.1021/jm034033b
   Yu XY, 1999, BIOORG MED CHEM LETT, V9, P375, DOI 10.1016/S0960-894X(98)00738-0
   Zullino DF, 2003, J CLIN PSYCHIAT, V64, P219, DOI 10.4088/JCP.v64n0215f                                                           
   Hill J. M., 1998, U.S.A. Patent, Patent No. [5,726,195, 5726195]
   SOLVAY PHARM, 2002, Patent No. 0207821
   LO YS, 1990, Patent No. 403185EP
NR 143
TC 131
Z9 134
U1 0
U2 18
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0198-6325
J9 MED RES REV
JI Med. Res. Rev.
PD MAR
PY 2005
VL 25
IS 2
BP 186
EP 228
DI 10.1002/med.20021
PG 43
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 898NT
UT WOS:000227084200003
PM 15478125
DA 2018-01-05
ER

PT J
AU Fittipaldi, A
   Giacca, M
AF Fittipaldi, A
   Giacca, M
TI Transcellular protein transduction using the Tat protein of HIV-1
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE encocytosis; human immunodeficiency virus type I (HIV-1); lipid rafts;
   protein transduction; transactivation
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE
   PROTEOGLYCANS; CELL-PENETRATING PEPTIDES; ISCHEMIC BRAIN INJURY;
   AMINO-ACID-SEQUENCE; RNA-POLYMERASE-II; NF-KAPPA-B; IN-VIVO; BASIC
   DOMAIN
AB The Tat protein of HIV-1 is a powerful transactivator of gene expression. By interacting with a structured RNA sequence at the 5' end of the viral mRNA, it promotes the remodeling of chromatin and the recruitment of processive RNA polymerase complexes at the viral promoter. In addition to these transcriptional functions, a short amino acid motif, highly enriched in basic amino acids, promotes the export of the protein from the expressing cells. Once in the extracellular environment, the same basic domain of Tat binds to cell surface heparan sulfate proteoglycans; through this interaction, the protein is internalized by a variety of different cell types. Cellular internalization of Tat and Tat fusion proteins requires the integrity of cell membrane lipid rafts and mainly occurs through caveolar endocytosis. The Tat basic domain, when attached to large protein cargos, also mediates their efficient cellular internalization and can be thus utilized for transcellular protein transduction. This property has already been successfully exploited for the delivery of heterologous proteins, nanoparticles, liposomes, phage and viral vectors, and plasmid DNA. The biological significance of intercellular Tat trafficking in the context of viral infection still remains elusive. (C) 2004 Elsevier B.V All rights reserved.
C1 Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy.
   Scuola Normale Super Pisa, Mol Biol Lab, Pisa, Italy.
RP Giacca, M (reprint author), Int Ctr Genet Engn & Biotechnol, Mol Med Lab, Padriciano 99, I-34012 Trieste, Italy.
EM giacca@icgeb.org
RI Giacca, Mauro/J-9287-2016
OI Giacca, Mauro/0000-0003-2927-7225
FU Telethon [GGP02278]
CR ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838
   Albini A, 1996, ONCOGENE, V12, P289
   Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153
   Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371
   Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199
   Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299
   BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0
   Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898
   Benmerah A, 1999, J CELL SCI, V112, P1303
   Bomsel M, 1997, NAT MED, V3, P42, DOI 10.1038/nm0197-42                                                               
   BONIFACI N, 1995, AIDS, V9, P995, DOI 10.1097/00002030-199509000-00003
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   Cheng F, 2002, J BIOL CHEM, V277, P44431, DOI 10.1074/jbc.M205241200
   CHIRMULE N, 1995, J VIROL, V69, P492
   Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200
   Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003                                                
   Crumpacker CS, 1996, NEW ENGL J MED, V335, P721, DOI 10.1056/NEJM199609053351007                                                     
   Datta K, 2001, CANCER RES, V61, P1768
   DAVID G, 1993, FASEB J, V7, P1023
   Demarchi F, 1999, J VIROL, V73, P7080
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0
   ENSOLI B, 1993, J VIROL, V67, P277
   Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655                                                         
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FRANSSON L, 1995, GLYCOBIOLOGY, V5, P407, DOI 10.1093/glycob/5.4.407
   Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Greene WC, 2002, NAT MED, V8, P673, DOI 10.1038/nm0702-673
   Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7
   Hakansson S, 2003, BIOCHEMISTRY-US, V42, P8999, DOI 10.1021/bi020715+
   Hakansson S, 2001, PROTEIN SCI, V10, P2138, DOI 10.1110/ps.23401                                                                
   HOFMAN FM, 1994, J NEUROIMMUNOL, V54, P19, DOI 10.1016/0165-5728(94)90226-7
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Inagaki K, 2003, CIRCULATION, V108, P2304, DOI 10.1161/01.CIR.0000101682.24138.36
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   JEANG KT, 1993, J VIROL, V67, P6224
   Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587                                                     
   Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071
   KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0
   Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951
   Lafrenie RM, 1997, J IMMUNOL, V159, P4077
   LAPPI DA, 1994, J BIOL CHEM, V269, P12552
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760
   Liu NQ, 2002, J VIROL, V76, P6689, DOI 10.1128/JVI.76.13.6689-6700.2002
   LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365
   Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631
   LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365                                                              
   MACCARANA M, 1993, J BIOL CHEM, V268, P23898
   Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777
   MANN DA, 1991, EMBO J, V10, P1733
   Marcello A, 2004, GENE, V326, P1, DOI 10.1016/j.gene.2003.10.018
   Marcello A, 2001, IUBMB LIFE, V51, P175, DOI 10.1080/152165401753544241
   Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519
   Mitola S, 1997, BLOOD, V90, P1365
   Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10
   NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87
   Nath A, 1996, J VIROL, V70, P1475
   Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529
   Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9                                                   
   OPALENIK SR, 1995, J BIOL CHEM, V270, P17457, DOI 10.1074/jbc.270.29.17457                                                        
   ORLANDI PA, 1993, J BIOL CHEM, V268, P12010
   Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0
   Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539
   PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673
   POCSIK E, 1992, LYMPHOKINE CYTOK RES, V11, P317
   Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x                                              
   PURI RK, 1992, CANCER RES, V52, P3787
   PURVIS SF, 1992, CELL IMMUNOL, V144, P32, DOI 10.1016/0008-8749(92)90223-C                                                    
   RESNICK L, 1988, NEUROLOGY, V38, P9, DOI 10.1212/WNL.38.1.9                                                              
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369
   Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Rusnati M, 1997, MOL BIOL CELL, V8, P2449, DOI 10.1091/mbc.8.12.2449                                                           
   SABATIER JM, 1991, J VIROL, V65, P961
   Sacchetti A, 2001, J CELL BIOCHEM, P117
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961
   Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511                                                
   Schmitz A, 2000, J CELL BIOL, V148, P1203, DOI 10.1083/jcb.148.6.1203
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Sosnowski BA, 1996, J BIOL CHEM, V271, P33647, DOI 10.1074/jbc.271.52.33647                                                        
   Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487
   Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325                                                            
   SUBRAMANYAM M, 1993, J IMMUNOL, V150, P2544
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Tasciotti E, 2003, CANCER GENE THER, V10, P64, DOI 10.1038/sj.cgt.7700526
   TAYLOR JP, 1992, P NATL ACAD SCI USA, V89, P9617, DOI 10.1073/pnas.89.20.9617
   Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   VERDIN E, 1993, EMBO J, V12, P3249
   VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368
   Veschambre P, 1997, J GEN VIROL, V78, P2235, DOI 10.1099/0022-1317-78-9-2235                                                     
   VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang HY, 2002, J CLIN INVEST, V109, P1463, DOI 10.1172/JCI200215399
   Watson K, 1999, BIOCHEM PHARMACOL, V57, P775, DOI 10.1016/S0006-2952(98)00352-9
   WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WESTENDORP MO, 1994, J VIROL, V68, P4177
   WUBAER F, 1995, P NATL ACAD SCI USA, V92, P7153, DOI 10.1073/pnas.92.16.7153
   Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242                                                                   
   Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466
   YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451
   ZAULI G, 1993, CANCER RES, V53, P4481
   ZAULI G, 1992, BLOOD, V80, P3036
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
NR 124
TC 84
Z9 88
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD FEB 28
PY 2005
VL 57
IS 4
BP 597
EP 608
DI 10.1016/j.addr.2004.10.011
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 905LT
UT WOS:000227570500009
PM 15722166
DA 2018-01-05
ER

PT J
AU Gupta, B
   Levchenko, TS
   Torchilin, VP
AF Gupta, B
   Levchenko, TS
   Torchilin, VP
TI Intracellular delivery of large molecules and small particles by
   cell-penetrating proteins and peptides
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE intracellular delivery; cell-penetrating peptides; fusion proteins; gene
   delivery; toxins; imaging agents; particles; liposomes
ID HIV-1 TAT PROTEIN; HUMAN-IMMUNODEFICIENCY-VIRUS; OVARIAN-CARCINOMA
   CELLS; ARGININE-RICH PEPTIDES; ISCHEMIC BRAIN INJURY; METAL-LINKED
   DIMER; NF-KAPPA-B; IN-VIVO; MAMMALIAN-CELLS; TRANSDUCTION DOMAIN
AB Cell-penetrating peptides (CPPs) have been used to overcome the lipophilic barrier of the cellular membranes and deliver large molecules and even small particles inside the cell for their biological actions. CPPs are being used to deliver inside cell a large variety of cargoes such as proteins, DNA, antibodies, contrast (imaging) agents, toxins, and nanoparticular drug carriers including liposomes. In this paper, we have reviewed the delivery of different molecules and particles mediated by TAT, Antp, VP22, and other CPPs as well as potential applications of these delivery systems in different areas of vaccine development, cancer immunotherapy, gene delivery, and cellular imaging. (c) 2004 Elsevier B.V All rights reserved.
C1 Northeastern Univ, Dept Pharmaceut Sci, Bouve Coll Hlth Sci, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Bouve Coll Hlth Sci, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
CR Aints A, 2001, GENE THER, V8, P1051, DOI 10.1038/sj.gt.3301493
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   ARNHEITER H, 1988, EMBO J, V7, P1315
   Asoh S, 2002, P NATL ACAD SCI USA, V99, P17107, DOI 10.1073/pnas.262460299
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   Cao GD, 2002, J NEUROSCI, V22, P5423
   Caron NJ, 2004, BIOCHEM BIOPH RES CO, V319, P12, DOI 10.1016/j.bbrc.2004.04.180
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
   Cochet O, 1998, CANCER RES, V58, P1170
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Derer Wolfgang, 2002, FASEB Journal, V16, P132
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Dolgilevich S, 2002, BIOCHEM BIOPH RES CO, V299, P505, DOI 10.1016/S0006-291X(02)02664-5
   Duguid JG, 1998, BIOPHYS J, V74, P2802, DOI 10.1016/S0006-3495(98)77987-1                                                   
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elliott G, 1998, J VIROL, V72, P6448
   Embury J, 2001, DIABETES, V50, P1706, DOI 10.2337/diabetes.50.8.1706                                                      
   Falnes PO, 2001, BIOCHEMISTRY-US, V40, P4349, DOI 10.1021/bi002443l
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944
   FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397                                                         
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487
   Gorodetsky R, 2004, J CONTROL RELEASE, V95, P477, DOI 10.1016/j.jconrel.2003.12.023
   Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gustafsson AB, 2002, CIRCULATION, V106, P735, DOI 10.1161/01.CIR.0000023943.50821.F7
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Hashida H, 2004, BRIT J CANCER, V90, P1252, DOI 10.1038/sj.bjc.6601680
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Jin LH, 2001, FREE RADICAL BIO MED, V31, P1509, DOI 10.1016/S0891-5849(01)00734-1
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kabouridis PS, 2002, J IMMUNOL, V169, P2587, DOI 10.4049/jimmunol.169.5.2587                                                     
   Kaufman CL, 2003, TRANSPLANTATION, V76, P1043, DOI 10.1097/01.TP.0000090164.42732.47
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kwon HY, 2000, FEBS LETT, V485, P163, DOI 10.1016/S0014-5793(00)02215-8
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Levchenko TS, 2003, METHOD ENZYMOL, V372, P339
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Liu C, 2001, J GENE MED, V3, P145, DOI 10.1002/jgm.164
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   MANN DA, 1991, EMBO J, V10, P1733
   Marty C, 2004, CELL MOL LIFE SCI, V61, P1785, DOI 10.1007/s00018-004-4166-0
   Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137
   Mie M, 2003, BIOCHEM BIOPH RES CO, V310, P730, DOI 10.1016/j.bbrc.2003.09.071
   Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2
   Moy P, 1996, MOL BIOTECHNOL, V6, P105, DOI 10.1007/BF02740767                                                              
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307
   Nori A, 2003, J CONTROL RELEASE, V91, P53, DOI 10.1016/S0168-3659(03)00213-X
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154                                                           
   Park J, 2002, J GEN VIROL, V83, P1173, DOI 10.1099/0022-1317-83-5-1173                                                     
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523
   ROEDER GE, 2004, APPL BIOCH, V40, P157
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   RUBEN S, 1989, J VIROL, V63, P1
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Shen HM, 2004, HUM GENE THER, V15, P415, DOI 10.1089/104303404322959560
   Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393                                                     
   SIOMI H, 1990, J VIROL, V64, P1803
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   Snyder EL, 2001, CURR OPIN MOL THER, V3, P147
   Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2
   STRAUBINGER RM, 1985, FEBS LETT, V179, P148, DOI 10.1016/0014-5793(85)80210-6                                                    
   Suzuki K, 2004, J MOL CELL CARDIOL, V36, P603, DOI 10.1016/j.yjmcc.2004.01.007
   Tasciotti E, 2003, CANCER GENE THER, V10, P64, DOI 10.1038/sj.cgt.7700526
   Tkachenko AG, 2004, BIOCONJUGATE CHEM, V15, P482, DOI 10.1021/bc034189q
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2003, CURR PROTEIN PEPT SC, V4, P133, DOI 10.2174/1389203033487298
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Varga CM, 2000, BIOTECHNOL BIOENG, V70, P593, DOI 10.1002/1097-0290(20001220)70:6<593::AID-BIT1>3.0.CO;2-N
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508
   VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang HY, 2002, J CLIN INVEST, V109, P1463, DOI 10.1172/JCI200215399
   WEEKS BS, 1993, J BIOL CHEM, V268, P5279
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   Wheeler DS, 2003, BIOCHEM BIOPH RES CO, V301, P54, DOI 10.1016/S0006-291X(02)02986-8
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474
   Yang YH, 2002, FEBS LETT, V532, P36, DOI 10.1016/S0014-5793(02)03624-4
   Yoon HY, 2002, NEUROCHEM INT, V41, P37, DOI 10.1016/S0197-0186(01)00138-3
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   Zavaglia D, 2003, MOL THER, V8, P840, DOI 10.1016/S1525-0016(03)00278-8
   Zavaglia D, 2003, GENE THER, V10, P314, DOI 10.1038/sj.gt.3301904
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 122
TC 422
Z9 454
U1 12
U2 197
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD FEB 28
PY 2005
VL 57
IS 4
BP 637
EP 651
DI 10.1016/j.addr.2004.10.007
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 905LT
UT WOS:000227570500011
PM 15722168
DA 2018-01-05
ER

PT J
AU Liu, ZH
   Li, MY
   Cui, DF
   Fei, J
AF Liu, ZH
   Li, MY
   Cui, DF
   Fei, J
TI Macro-branched cell-penetrating peptide design for gene delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE macro-branched peptide; HIV-1 tat; gene delivery; dendrimer; non-viral
   vector
ID HIV-1 TAT PROTEIN; IN-VIVO; TRANSFECTION EFFICIENCY; MOLECULAR-WEIGHT;
   DNA COMPLEXES; VECTOR; POLYETHYLENIMINE; NANOPARTICLES; CYTOTOXICITY;
   TRANSDUCTION
AB Many kinds of macromolecular compounds that comprise a series of branches around an inner core have been made and showed some promises as DNA- and drug-delivery systems. In this study, a method for peptide polymer design having macro-branched peptide structure was adapted and it was applied for plasmid DNA delivery for the first time; acryloyl chloride was used by introducing the double bond into the N-terminal of HIV-1 tat (47-57, YGRKKRRQRRR). After being cleaved from resin, it was transformed to a polymer which possesses a poly-propionyl core matrix with tat branches and was named polytat by radical polymerization. After further separation and purification by Sephadex G150, polytat P1, polytat P2 and polytat P3 were acquired and the average molecular weight of the different macromolecules are 240, 178 and 82 kDa. We found that all these compounds complexed with plasmid DNA and showed significant transfection capabilities in a variety of mammalian cell lines, but acrylyl-tat or tat alone showed no significant transfection capability. Further study showed that polytat could be applied for plasmid DNA delivery for cell lines even with serum by endocytosis-mediated pathways. (C) 2004 Elsevier B.V. All rights reserved.
C1 Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
   Chinese Acad Sci, Grad Sch, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Beijing 100864, Peoples R China.
RP Fei, J (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
EM jfei@sibs.ac.cn
CR Cristiano Richard J, 2002, Surg Oncol Clin N Am, V11, P697, DOI 10.1016/S1055-3207(02)00022-4
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Fischer D, 1999, PHARMACEUT RES, V16, P1273, DOI 10.1023/A:1014861900478
   Harris JD, 1996, TRENDS GENET, V12, P400, DOI 10.1016/0168-9525(96)40031-2
   Kimura T., 2001, NUCL ACIDS RES S, V1, P203
   Kunath K, 2003, J GENE MED, V5, P588, DOI 10.1002/jgm.382
   Lee H, 2002, J CONTROL RELEASE, V79, P283, DOI 10.1016/S0168-3659(02)00002-0
   Lee TKW, 2001, INT J CANCER, V93, P393, DOI 10.1002/ijc.1340
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li MY, 2000, ACTA BIOCH BIOPH SIN, V32, P665
   Liu ZH, 2003, J IMMUNOL METHODS, V281, P17, DOI 10.1016/S0022-1759(03)00264-3
   Lollo CP, 2000, CURR OPIN MOL THER, V2, P136
   Mahato RI, 1999, J DRUG TARGET, V7, P249, DOI 10.3109/10611869909085509                                                       
   Mannisto M, 2002, J CONTROL RELEASE, V83, P169, DOI 10.1016/S0168-3659(02)00178-5
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   OBrienSimpson NM, 1997, J AM CHEM SOC, V119, P1183, DOI 10.1021/ja962707k                                                               
   Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101                                                       
   Rhaese S, 2003, J CONTROL RELEASE, V92, P199, DOI 10.1016/S0168-3659(03)00302-X
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Sadler Kristen, 2002, J Biotechnol, V90, P195
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Stiriba SE, 2002, ANGEW CHEM INT EDIT, V41, P1329, DOI 10.1002/1521-3773(20020415)41:8<1329::AID-ANIE1329>3.0.CO;2-P
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   TAXMAN DJ, 1993, ANAL BIOCHEM, V213, P97, DOI 10.1006/abio.1993.1391
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255                                                         
   WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410
   Wolfert MA, 1996, GENE THER, V3, P269
NR 32
TC 36
Z9 45
U1 2
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD FEB 16
PY 2005
VL 102
IS 3
BP 699
EP 710
DI 10.1016/j.jconrel.2004.10.013
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 899LS
UT WOS:000227146500016
PM 15681091
DA 2018-01-05
ER

PT J
AU Shi, F
   Zhang, QH
   Gu, YL
   Deng, YQ
AF Shi, F
   Zhang, QH
   Gu, YL
   Deng, YQ
TI Silica gel confined ionic liquid plus metal complexes for oxygen-free
   carbonylation of amines and nitrobenzene to ureas
SO ADVANCED SYNTHESIS & CATALYSIS
LA English
DT Article
DE amines; carbonylation; ionic liquids; nitrobenzene; phosgene-free
ID HIV PROTEASE INHIBITORS; OXIDATIVE CARBONYLATION; CATALYZED
   CARBONYLATION; CYCLIC UREAS; DIPHENYLUREA FORMATION; MOLTEN-SALTS;
   ANILINE; DERIVATIVES; TRIPHENYLPHOSPHINE; HYDROGENATION
AB A new kind of silica gel confined ionic liquid containing a metal complex as heterogenized catalysts was prepared for the carbonylation of amines and nitrobenzene without molecular oxygen to afford the corresponding ureas with greatly enhanced catalytic activity (TOF exceeded 11000mol.mol(-1). h(-1)), with a much lower amount of ionic liquids being needed, with easy catalyst separation and possible reusability, and avoidance of the using of explosive CO + O-2 gas mixtures. Such an enhancement in catalytic activity may be derived from the effect of a high concentration of ionic liquid containing a metal complex due to the confinement into the nanopores or cavities of the silica gel matrix.
C1 Chinese Acad Sci, Lanzhou Inst Chem Phys, Ctr Green Chem & Catalysis, Lanzhou 730000, Peoples R China.
RP Deng, YQ (reprint author), Chinese Acad Sci, Lanzhou Inst Chem Phys, Ctr Green Chem & Catalysis, Lanzhou 730000, Peoples R China.
EM ydeng@ns.lzb.ac.cn
RI Zhang, Qinghua/K-4474-2013
OI Zhang, Qinghua/0000-0002-4162-7155
CR Aresta M., 1969, INORG CHIM ACTA, V3, P227
   Bonhote P, 1996, INORG CHEM, V35, P1168, DOI 10.1021/ic951325x                                                               
   CENINI S, 1987, ASPECTS HOMOGENEOUS, V6
   DIETER KM, 1988, J AM CHEM SOC, V110, P2722, DOI 10.1021/ja00217a004                                                             
   DOMBEK BD, 1977, J ORGANOMET CHEM, V134, P203, DOI 10.1016/S0022-328X(00)81420-5                                                   
   Dupont J, 2002, CHEM REV, V102, P3667, DOI 10.1021/cr010338r
   ELAIWI A, 1995, J CHEM SOC DALTON, P3467, DOI 10.1039/dt9950003467                                                            
   GABRIELE R, 2003, CHEM COMMUN, P486
   Giannoccaro P, 2000, J MOL CATAL A-CHEM, V157, P131, DOI 10.1016/S1381-1169(99)00425-2                                                   
   GUPTE SP, 1988, J CATAL, V114, P246, DOI 10.1016/0021-9517(88)90028-0                                                    
   GUPTE SP, 1997, J MOL CATAL A-CHEM, V122, P103
   Ichikawa M, 2000, PLATIN MET REV, V44, P3
   Islam SM, 1999, J MOL CATAL A-CHEM, V142, P169, DOI 10.1016/S1381-1169(98)00295-7                                                   
   ITATANI H, 1967, J AM OIL CHEM SOC, V44, P147, DOI 10.1007/BF02558176
   Kim HS, 1998, J CATAL, V176, P264, DOI 10.1006/jcat.1998.2074                                                          
   Kim HS, 2002, ANGEW CHEM INT EDIT, V41, P4300, DOI 10.1002/1521-3773(20021115)41:22<4300::AID-ANIE4300>3.0.CO;2-V                  
   Kim HS, 1999, J CATAL, V184, P526, DOI 10.1006/jcat.1999.2458                                                          
   Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   Ling G, 2003, J MOL CATAL A-CHEM, V202, P23, DOI 10.1016/S1381-1169(03)00188-2
   McCusker JE, 2000, J ORG CHEM, V65, P5216, DOI 10.1021/jo000364+
   Mehnert CP, 2002, J AM CHEM SOC, V124, P12932, DOI 10.1021/ja0279242
   Mehnert CP, 2002, CHEM COMMUN, P3010, DOI 10.1039/b210214e
   Mukherjee DK, 2003, J MOL CATAL A-CHEM, V193, P41, DOI 10.1016/S1381-1169(02)00458-2                                                   
   Mukherjee DK, 2002, J CATAL, V210, P255, DOI 10.1006/jcat.2002.3665
   Nanbu N, 2003, ELECTROCHEM COMMUN, V5, P383, DOI 10.1016/S1388-2481(03)00073-0
   ORLANDI M, 1996, J MOL CATAL, V111, P281
   Qian F, 2002, J ORG CHEM, V67, P4086, DOI 10.1021/jo0109319
   Ragaini F, 1999, ORGANOMETALLICS, V18, P4925, DOI 10.1021/om990578l                                                               
   Shi F, 2003, J CATAL, V219, P372, DOI 10.1016/S0021-9517(03)00198-2
   Shi F, 2003, ANGEW CHEM INT EDIT, V42, P3257, DOI 10.1002/anie.200351098
   Shi F, 2002, J CATAL, V211, P548, DOI 10.1006/jcat.2002.3772
   Shi F, 2001, TETRAHEDRON LETT, V42, P2161, DOI 10.1016/S0040-4039(01)00124-1
   STEPHENSON TA, 1966, J INORG NUCL CHEM, V28, P945, DOI 10.1016/0022-1902(66)80191-4                                                    
   TAIT S, 1984, INORG CHEM, V23, P4352, DOI 10.1021/ic00193a049                                                             
   VALKENBERG MH, 2002, GREEN CHEM, P88
   VENANZI LM, 1958, J CHEM SOC, P719, DOI 10.1039/jr9580000719                                                            
   vonGeldern TW, 1996, J MED CHEM, V39, P968, DOI 10.1021/jm950592+
   Wasserscheid P, 2000, ANGEW CHEM INT EDIT, V39, P3772, DOI 10.1002/1521-3773(20001103)39:21<3772::AID-ANIE3772>3.0.CO;2-5                  
   Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t                                                               
   GRATE JH, 1986, Patent No. 4629804
NR 41
TC 34
Z9 36
U1 0
U2 15
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 1615-4150
J9 ADV SYNTH CATAL
JI Adv. Synth. Catal.
PD FEB
PY 2005
VL 347
IS 2-3
BP 225
EP 230
DI 10.1002/adsc.200404242                                                  
          
PG 6
WC Chemistry, Applied; Chemistry, Organic
SC Chemistry
GA 903GS
UT WOS:000227414500003
DA 2018-01-05
ER

PT J
AU Colleluori, DM
   Tien, D
   Kang, FR
   Pagliei, T
   Kuss, R
   McCormick, T
   Watson, K
   McFadden, K
   Chaiken, I
   Buckheit, RW
   Romano, JW
AF Colleluori, DM
   Tien, D
   Kang, FR
   Pagliei, T
   Kuss, R
   McCormick, T
   Watson, K
   McFadden, K
   Chaiken, I
   Buckheit, RW
   Romano, JW
TI Expression, purification, and characterization of recombinant
   cyanovirin-N for vaginal anti-HIV microbicide development
SO PROTEIN EXPRESSION AND PURIFICATION
LA English
DT Article
DE cyanovirin-N; CV-N; microbicide; HIV; anti-HIV; cyanobacteria
ID DOMAIN-SWAPPED DIMER; INACTIVATING PROTEIN; RELATIVE ORIENTATION;
   DIPOLAR COUPLINGS; CYANOBACTERIUM
AB Cyanovirin-N (CV-N) is a prokaryotic protein under development as a topical anti-HIV microbicide. an urgent and necessary approach to prevent HIV transmission in at-risk populations worldwide. We have expressed recombinant CV-N as inclusion bodies in the cytoplasm of Escherichia coli. A purification scheme has been developed that exploits the physicochemical properties of this protein, in particular its stability in a harsh inclusion body purification scheme. Under the conditions developed. this system yields 140 mg of highly purified CV-N per liter of high-density cell culture, which represents a 14-fold increase over the best recombinant CV-N yield reported to date. This purification scheme results in monomeric CV-N as analyzed by SDS-PAGE, isoelectric focusing, and reverse phase- and size exclusion-HPLC. This recombinantly expressed and refolded CV-N, binds to gp120 with nanomollar affinity and retains its potent anti-HIV activities in cell-based assays. The expression and purification system described herein provides a better means for the mass production of CV-N for further microbicide development. (C) 2004 Published by Elsevier Inc.
C1 Biosyn Inc, Huntingdon Valley, PA 19006 USA.
   ImQuest Biosci Inc, Frederick, MD 21704 USA.
   Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19102 USA.
RP Colleluori, DM (reprint author), Biosyn Inc, 1800 Byberry Rd,Bldg 13, Huntingdon Valley, PA 19006 USA.
EM colleluori@biosyn-inc.com
FU NIAID NIH HHS [U19-AI051650-02]
CR Barrientos LG, 2002, STRUCTURE, V10, P673, DOI 10.1016/S0969-2126(02)00758-X                                                   
   Barrientos LG, 2001, J BIOMOL NMR, V19, P289, DOI 10.1023/A:1011292919947
   Bewley CA, 2000, J AM CHEM SOC, V122, P6009, DOI 10.1021/ja000858o
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200
   BOYD MR, 1997, ANTIMICROB AGENTS CH, V41, P223
   Buckheit RW, 2001, ANTIMICROB AGENTS CH, V45, P393, DOI 10.1128/AAC.45.2.393-400.2001
   Clore GM, 2002, J MAGN RESON, V154, P329, DOI 10.1006/jmre.2001.2489
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   Gustafson KR, 1997, BIOCHEM BIOPH RES CO, V238, P223, DOI 10.1006/bbrc.1997.7203
   Mori T, 1997, BIOCHEM BIOPH RES CO, V238, P218, DOI 10.1006/bbrc.1997.7202
   Mori T, 2002, PROTEIN EXPRES PURIF, V26, P42, DOI 10.1016/S1046-5928(02)00513-2
   Mori T, 1998, PROTEIN EXPRES PURIF, V12, P151, DOI 10.1006/prep.1997.0838
   RIESENBERG D, 1990, APPL MICROBIOL BIOT, V34, P77
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
NR 16
TC 35
Z9 47
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-5928
J9 PROTEIN EXPRES PURIF
JI Protein Expr. Purif.
PD FEB
PY 2005
VL 39
IS 2
BP 229
EP 236
DI 10.1016/j.pep.2004.10.009
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Biotechnology & Applied Microbiology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 889IP
UT WOS:000226437000013
PM 15642474
DA 2018-01-05
ER

PT J
AU Tao, L
   Lin, L
   Hong, Z
   Long, J
AF Tao, L
   Lin, L
   Hong, Z
   Long, J
TI DNA and RNA sensor
SO SCIENCE IN CHINA SERIES B-CHEMISTRY
LA English
DT Review
DE DNA detection; biosensor; immobilization of DNA; hybridization of DNA;
   nanoparticle
ID QUARTZ-CRYSTAL MICROBALANCE; HIV-1 TAR RNA; ELECTROGENERATED
   CHEMILUMINESCENT DETECTION; ALKANEBISPHOSPHONATE THIN-FILM;
   HYBRIDIZATION DETECTION; GOLD NANOPARTICLES; WAVE BIOSENSOR; PEPTIDE;
   IMMOBILIZATION; BINDING
AB This review summarizes recent advances in DNA sensor. Major areas of DNA sensor covered in this review include immobilization methods of DNA, general techniques of DNA detection and application of nanoparticles in DNA sensor.
C1 Chinese Acad Sci, Inst Chem, Key Lab Colloid & Interface, Ctr Mol Sci, Beijing 100080, Peoples R China.
RP Long, J (reprint author), Chinese Acad Sci, Inst Chem, Key Lab Colloid & Interface, Ctr Mol Sci, Beijing 100080, Peoples R China.
EM jianging@public.bta.net.cn
CR Aich P, 2002, J BIOMOL STRUCT DYN, V20, P93, DOI 10.1080/07391102.2002.10506826                                                  
   Bier FF, 1997, SENSOR ACTUAT B-CHEM, V38, P78, DOI 10.1016/S0925-4005(97)80174-8
   Blonder R, 1997, J AM CHEM SOC, V119, P10467, DOI 10.1021/ja971980z                                                               
   Bueno GJ, 2003, BIOORGAN MED CHEM, V11, P87
   Caruso F, 1997, SENSOR ACTUAT B-CHEM, V41, P189, DOI 10.1016/S0925-4005(97)80294-8
   Caruso F, 1997, ANAL CHEM, V69, P2043, DOI 10.1021/ac961220r
   Cater M. T., 1989, J AM CHEM SOC, V111, P8901
   CLARK LC, 1956, T AM SOC ART INT ORG, V2, P41
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Furtado LM, 1999, ANAL CHEM, V71, P1167, DOI 10.1021/ac980880o
   Garbesi A, 1998, NUCLEIC ACIDS RES, V26, P2886, DOI 10.1093/nar/26.12.2886
   Gelus N, 1999, BIOORGAN MED CHEM, V7, P1075, DOI 10.1016/S0968-0896(99)00030-9                                                   
   GRAHAM CR, 1992, BIOSENS BIOELECTRON, V7, P487, DOI 10.1016/0956-5663(92)80005-V
   HASHIMOTO K, 1993, SUPRAMOL CHEM, V2, P265
   KAM J, 1999, J MOL BIOL, V293, P235
   Kleinjung F, 1997, ANAL CHIM ACTA, V350, P51, DOI 10.1016/S0003-2670(97)00192-X
   LEE JS, 1993, BIOCHEM CELL BIOL, V71, P162, DOI 10.1139/o93-026                                                                 
   Lin L, 2000, COLLOID SURFACE A, V175, P11, DOI 10.1016/S0927-7757(00)00459-3                                                   
   LIN L, 1999, AMPHIPHILES INTERFAC, pA50
   刘盛辉, 1996, 分析化学, V24, P1301
   Liu T, 2002, BIOCHEM BIOPH RES CO, V295, P14, DOI 10.1016/S0006-291X(02)00628-9
   Liu T, 2002, LANGMUIR, V18, P5624, DOI 10.1021/la015765e
   LIVACHE T, 1994, NUCLEIC ACIDS RES, V22, P2915, DOI 10.1093/nar/22.15.2915
   Lohr M, 2003, BIOCHEM BIOPH RES CO, V300, P609, DOI 10.1016/S0006-291X(02)02903-0
   Marrazza G, 1999, BIOSENS BIOELECTRON, V14, P43, DOI 10.1016/S0956-5663(98)00102-X
   Mazzola LT, 1999, BIOPHYS J, V76, P2922, DOI 10.1016/S0006-3495(99)77447-3
   MEI HY, 1995, BIOORG MED CHEM LETT, V5, P2755, DOI 10.1016/0960-894X(95)00467-8
   MILLAN KM, 1994, ANAL CHEM, V66, P2943, DOI 10.1021/ac00090a023                                                             
   Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0
   Moser I, 1997, BIOSENS BIOELECTRON, V12, P729, DOI 10.1016/S0956-5663(97)00040-7
   NANNESS JV, 1991, NUCLEIC ACIDS RES, V19, P3345
   Nicolini C, 1997, BIOSENS BIOELECTRON, V12, P613, DOI 10.1016/S0956-5663(96)00080-2
   Okahata Y, 1998, ANAL CHEM, V70, P1288, DOI 10.1021/ac970584w
   OKAHATA Y, 1992, J AM CHEM SOC, V114, P8299, DOI 10.1021/ja00047a056
   Palanti S, 1996, ANAL LETT, V29, P2309
   PIUNNO PAE, 1994, ANAL CHIM ACTA, V288, P205, DOI 10.1016/0003-2670(93)E0611-A
   Schwergold C, 2002, TETRAHEDRON, V58, P5675, DOI 10.1016/S0040-4020(02)00527-6                                                   
   SU HB, 1993, ANALYST, V118, P309, DOI 10.1039/an9931800309
   Tamilarasu N, 2000, BIOORG MED CHEM LETT, V10, P971, DOI 10.1016/S0960-894X(00)00140-2                                                   
   Tassew N, 2003, BIOPHYS CHEM, V106, P241, DOI 10.1016/S0301-4622(03)00155-8
   Thiel AJ, 1997, ANAL CHEM, V69, P4948, DOI 10.1021/ac9708001                                                               
   Wang J, 1997, ANAL CHEM, V69, P5200, DOI 10.1021/ac9706077                                                               
   Wang J, 1998, ANAL CHIM ACTA, V375, P197, DOI 10.1016/S0003-2670(98)00503-0                                                   
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0
   WATTS HJ, 1995, ANAL CHEM, V67, P4283, DOI 10.1021/ac00119a013                                                             
   Wilson EK, 1998, CHEM ENG NEWS, V76, P47, DOI 10.1021/cen-v076n021.p047                                                       
   Wyszko E, 2001, INT J BIOL MACROMOL, V28, P373, DOI 10.1016/S0141-8130(01)00138-6                                                   
   Xiao CD, 1998, THIN SOLID FILMS, V327, P647, DOI 10.1016/S0040-6090(98)00732-9
   XU XH, 1995, J AM CHEM SOC, V117, P2627, DOI 10.1021/ja00114a027                                                             
   XU XH, 1994, J AM CHEM SOC, V116, P8386, DOI 10.1021/ja00097a064
   YAMAGUCHI S, 1993, ANAL CHEM, V65, P1925, DOI 10.1021/ac00062a019
   Yang MS, 1997, ANAL CHIM ACTA, V346, P259
   Yang MS, 1998, CHEM LETT, P257, DOI 10.1246/cl.1998.257                                                             
   Zhao H, 2004, BIOCHEM BIOPH RES CO, V320, P95, DOI 10.1016/j.bbrc.2004.05.148
   Zhao H, 2004, FEBS LETT, V563, P241, DOI 10.1016/S0014-5793(04)00284-4
   Zhao H, 2003, BIOCHEM BIOPH RES CO, V312, P351, DOI 10.1016/j.bbrc.2003.10.134
   Zhou XC, 2000, CHEM COMMUN, P953, DOI 10.1039/b001737j                                                                
NR 58
TC 2
Z9 2
U1 1
U2 28
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1006-9291
J9 SCI CHINA SER B
JI Sci. China Ser. B-Chem.
PD FEB
PY 2005
VL 48
IS 1
BP 1
EP 10
DI 10.1360/03yb0151
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA 913YC
UT WOS:000228190500001
DA 2018-01-05
ER

PT J
AU Chong, CSW
   Cao, M
   Wong, WW
   Fischer, KP
   Addison, WR
   Kwon, GS
   Tyrrell, DL
   Samuel, J
AF Chong, CSW
   Cao, M
   Wong, WW
   Fischer, KP
   Addison, WR
   Kwon, GS
   Tyrrell, DL
   Samuel, J
TI Enhancement of T helper type 1 immune responses against hepatitis B
   virus core antigen by PLGA nanoparticle vaccine delivery
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE hepatitis B; nanoparticles; PLGA; monophosphoryl lipid A; vaccines
ID MONOPHOSPHORYL-LIPID-A; RECOMBINANT HIV PROTEIN; MACROPHAGES IN-VITRO;
   DENDRITIC CELLS; BIODEGRADABLE MICROPARTICLES; IMMUNOLOGICAL EVALUATION;
   THERAPEUTIC VACCINATION; ACID) MICROSPHERES; DNA VACCINE; INFECTION
AB Currently, there is a need for therapeutic vaccines that are effective in inducing robust T helper type 1 (Th1) immune responses capable of mediating viral clearance in chronic hepatitis B infection. Hepatitis B therapeutic vaccines were designed and formulated by loading the hepatitis B core antigen (HBcAg) into poly(D,L-lactic-acid-co-glycolic acid) (PLGA) nanoparticles with or without monophospholipid A (MPLA), a Th1-favoring immunomodulator. These particles were around 300 nm in diameter, spherical in shape and had approximately 50% HBcAg encapsulation efficiency. A single immunization with a vaccine formulation containing (MPLA+HBcAg) coformulated in PLGA nanoparticles induced a stronger Th1 cellular immune response with a predominant interferon-gamma (IFN-gamma) profile than those induced by HBcAg alone, free (HBcAg+MPLA) simple mixture or HBcAg-loaded nanoparticles in a murine model. More importantly, the level of HBcAg-specific IFN-gamma production could be increased further significantly by a booster immunization with the (HBcAg+MPLA)-loaded nanoparticles. In summary, these results demonstrated that codelivery of HBcAg and MPLA in PLGA nanoparticles promoted HBcAg-specific Th1 immune responses with IFN-gamma production. These findings suggest that appropriate design of the vaccine formulation and careful planning of the immunization schedule are important in the successful development of effective HBV therapeutic vaccines. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada.
   Univ Alberta, Fac Med & Dent, Edmonton, AB T6G 2S2, Canada.
   Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA.
RP Samuel, J (reprint author), Univ Alberta, Fac Pharm & Pharmaceut Sci, Dent Pharm Bldg,3118 Edmonton, Edmonton, AB T6G 2N8, Canada.
EM jsamuel@pharmacy.ualberta.ca
RI Kwon, Glen/A-1919-2014
CR Agrawal S, 2003, J IMMUNOL, V171, P4984, DOI 10.4049/jimmunol.171.10.4984                                                    
   Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609
   ALONSO MJ, 1993, PHARMACEUT RES, V10, P945, DOI 10.1023/A:1018942118148
   Audran R, 2003, VACCINE, V21, P1250, DOI 10.1016/S0264-410X(02)00521-2                                                   
   Baldridge JR, 2004, EXPERT OPIN BIOL TH, V4, P1129, DOI 10.1517/14712598.4.7.1129
   Baldridge JR, 1999, METHODS, V19, P103, DOI 10.1006/meth.1999.0834                                                          
   BEASLEY RP, 1983, J INFECT DIS, V147, P185, DOI 10.1093/infdis/147.2.185                                                        
   Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731                                                                 
   Cochet O, 1998, IMMUNOLOGICAL TECHNI
   Couillin I, 1999, J INFECT DIS, V180, P1756
   Couillin I, 1999, J INFECT DIS, V180, P15, DOI 10.1086/314828                                                                  
   Cui ZR, 2002, INT J PHARM, V238, P229, DOI 10.1016/S0378-5173(02)00079-0
   Diwan Manish, 2004, Current Drug Delivery, V1, P405, DOI 10.2174/1567201043334597
   ELDRIDGE JH, 1993, SEMIN HEMATOL, V30, P16
   ELDRIDGE JH, 1991, INFECT IMMUN, V59, P2978
   Evans JT, 2004, VACCINE, V22, P1964, DOI 10.1016/j.vaccine.2003.10.035
   FERRARI C, 1990, J IMMUNOL, V145, P3442
   FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
   Hagen SR, 1997, J CHROMATOGR A, V767, P53, DOI 10.1016/S0021-9673(97)00041-1
   HORA MS, 1990, PHARMACEUT RES, V7, P1190, DOI 10.1023/A:1015948829632                                                         
   Hu JF, 1997, ONCOGENE, V15, P2795, DOI 10.1038/sj.onc.1201444                                                          
   Ishikawa T, 1998, J IMMUNOL, V161, P5842
   Jiang ZH, 2003, CURR MED CHEM, V10, P1423, DOI 10.2174/0929867033457340                                                        
   Jiang ZH, 2002, TETRAHEDRON, V58, P8833, DOI 10.1016/S0040-4020(02)01067-0
   Jiang ZH, 2002, BIOORG MED CHEM LETT, V12, P2193, DOI 10.1016/S0960-894X(02)00362-1
   Jung T, 2002, INT J PHARM, V234, P75, DOI 10.1016/S0378-5173(01)00957-7                                                   
   Kuhober A, 1996, J IMMUNOL, V156, P3687
   Lau GKK, 2002, GASTROENTEROLOGY, V122, P614, DOI 10.1053/gast.2002.31887
   Livingston BD, 1999, J IMMUNOL, V162, P3088
   Lohr HF, 1998, LIVER, V18, P405
   Lore K, 2003, J IMMUNOL, V171, P4320, DOI 10.4049/jimmunol.171.8.4320                                                     
   Lutsiak MEC, 2002, PHARM RES-DORDR, V19, P1480, DOI 10.1023/A:1020452531828                                                         
   Maini MK, 1999, GASTROENTEROLOGY, V117, P1386, DOI 10.1016/S0016-5085(99)70289-1
   Maini MK, 1999, IMMUNOL TODAY, V20, P262, DOI 10.1016/S0167-5699(99)01472-3
   Milich DR, 1997, J VIROL, V71, P2192
   MILICH DR, 1987, NATURE, V329, P547, DOI 10.1038/329547a0
   MONDELLI MU, 1990, SPRINGER SEMIN IMMUN, V12, P25
   Moore A, 1999, VACCINE, V17, P2517, DOI 10.1016/S0264-410X(99)00062-6                                                   
   Moore A, 1995, VACCINE, V13, P1741, DOI 10.1016/0264-410X(95)00184-3                                                    
   MORTON RE, 1992, ANAL BIOCHEM, V204, P332, DOI 10.1016/0003-2697(92)90248-6
   Newman KD, 1998, J PHARM SCI, V87, P1421, DOI 10.1021/js980070s
   Newman KD, 1998, J CONTROL RELEASE, V54, P49, DOI 10.1016/S0168-3659(97)00142-9                                                   
   Nixon DF, 1996, VACCINE, V14, P1523, DOI 10.1016/S0264-410X(96)00099-0
   OGAWA Y, 1988, CHEM PHARM BULL, V36, P1095
   OHAGAN DT, 1993, VACCINE, V11, P965, DOI 10.1016/0264-410X(93)90387-D
   OKADA H, 1995, CRIT REV THER DRUG, V12, P1
   Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231
   Penna A, 1997, HEPATOLOGY, V25, P1022, DOI 10.1002/hep.510250438                                                           
   Periti P, 2002, CLIN PHARMACOKINET, V41, P485, DOI 10.2165/00003088-200241070-00003
   PERRILLO RP, 1989, SEMIN LIVER DIS, V9, P240, DOI 10.1055/s-2008-1040517
   Pol S, 2001, J HEPATOL, V34, P917, DOI 10.1016/S0168-8278(01)00028-9                                                   
   Raghuvanshi RS, 2002, INT J PHARM, V245, P109, DOI 10.1016/S0378-5173(02)00342-3
   Raghuvanshi RS, 2002, DRUG DELIV, V9, P113, DOI 10.1080/10426500290095557
   Reed SG, 2003, TUBERCULOSIS, V83, P213, DOI 10.1016/S1472-9792(02)00080-X
   Rehermann B, 1996, J CLIN INVEST, V97, P1655, DOI 10.1172/JCI118592
   Rogers PR, 1999, J IMMUNOL, V163, P1205
   Senturk H, 2002, J GASTROEN HEPATOL, V17, P72, DOI 10.1046/j.1440-1746.2002.02652.x                                                
   Shi L, 2002, J PHARM SCI, V91, P1019, DOI 10.1002/jps.10042
   Siegel F, 2001, J VIROL, V75, P5036, DOI 10.1128/JVI.75.11.5036-5042.2001
   STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503                                                     
   Sun HF, 2003, VACCINE, V21, P849, DOI 10.1016/S0264-410X(02)00531-5                                                   
   Thermet A, 2003, VACCINE, V21, P659, DOI 10.1016/S0264-410X(02)00575-3                                                   
   Todt J, 2000, J IMMUNOL, V164, P4037, DOI 10.4049/jimmunol.164.8.4037                                                     
   Triyatni M, 1998, J VIROL, V72, P84
   Uchida T, 1998, PHARMACEUT RES, V15, P1708, DOI 10.1023/A:1011904627929                                                         
   Ulrich J T, 1995, Pharm Biotechnol, V6, P495
   Venkataprasad N, 1999, VACCINE, V17, P1814, DOI 10.1016/S0264-410X(98)00372-7                                                   
   VORDERMEIER HM, 1995, VACCINE, V13, P1576, DOI 10.1016/0264-410X(95)00084-E
   Walker KB, 1998, DEV BIOL STAND, V92, P259
   Webster GJM, 2004, J VIROL, V78, P5707, DOI 10.1128/JVI.78.11.5707-5719.2004
NR 70
TC 106
Z9 114
U1 2
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD JAN 20
PY 2005
VL 102
IS 1
BP 85
EP 99
DI 10.1016/j.jconrel.2004.09.014
PG 15
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 892CR
UT WOS:000226627800008
PM 15653136
DA 2018-01-05
ER

PT J
AU Phan, AT
   Kuryavyi, V
   Ma, JB
   Faure, A
   Andreola, ML
   Patel, DJ
AF Phan, AT
   Kuryavyi, V
   Ma, JB
   Faure, A
   Andreola, ML
   Patel, DJ
TI An interlocked dimeric parallel-stranded DNA quadruplex: A potent
   inhibitor of HIV-1 integrase
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE dimeric quadruplex; DNA aptamer
ID TETRAD-FORMING OLIGONUCLEOTIDES; HUMAN-IMMUNODEFICIENCY-VIRUS;
   THROUGH-BOND CORRELATION; C-MYC PROMOTER; QUARTET STRUCTURES;
   CRYSTAL-STRUCTURE; TERMINAL DOMAINS; BINDING DOMAIN; TRIPLET REPEAT;
   NUCLEIC-ACIDS
AB We report on the NMR-based solution structure of the 93del d(GGGGTGGGAGGAGGGT) aptamer, a potent nanomolar inhibitor of HIV-1 integrase. This guanine-rich DNA sequence adopts an unusually stable dimeric quadruplex architecture in K+ solution. Within each 16-nt monomer subunit, which contains one A(.)(G(.)G(.)G(.)G) pentad sandwiched between two G(.)G(.)G(.)G tetrads, all G-stretches are parallel, and all guanines are anti with the exception of G1, which is syn. Dinner formation is achieved through mutual pairing of G1 of one monomer, with G2, G6, and G13 of the other monomer, to complete G(.)G(.)G(.)G tetrad formation. There are three single-nucleotide clouble-chain-reversal loops within each monomer fold, such that the first (T5) and third (A12) loops bridge three G-tetrad layers, whereas the second (A9) loop bridges two G-tetrad layers and participates in A(.)(G(.)G(.)G(.)G) pentad formation. Results of NMR and of integrase inhibition assays on loop-modified sequences allowed us to propose a strategy toward the potential design of improved HIV-1 integrase inhibitors. Finally, we propose a model, based on molecular docking approaches, for positioning the 93del dimeric DNA quadruplex within a basic channel/canyon formed between subunits of a dimer of dimers of HIV-1 integrase.
C1 Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA.
   Univ Bordeaux 2, CNRS, UMR 5097, F-33076 Bordeaux, France.
   Inst Federat Rech 66 Pathol Infect & Canc, F-33076 Bordeaux, France.
RP Patel, DJ (reprint author), Mem Sloan Kettering Canc Ctr, Struct Biol Program, New York, NY 10021 USA.
EM pateld@mskcc.org
RI Phan, Anh Tuan/A-3673-2010
OI Phan, Anh Tuan/0000-0002-4970-3861
FU NIGMS NIH HHS [R01 GM034504, GM34504, P41 GM066354, GM66354]
CR BALAGURUMOORTHY P, 1992, NUCLEIC ACIDS RES, V20, P4061, DOI 10.1093/nar/20.15.4061
   Brunger A. T., 1992, XPLOR SYSTEM XRAY CR
   Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567
   Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297                                                          
   Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484
   CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845                                                         
   Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200
   Dapic V, 2003, NUCLEIC ACIDS RES, V31, P2097, DOI 10.1093/nar/gkg316
   de Soultrait VR, 2002, J MOL BIOL, V324, P195, DOI 10.1016/S0022-2836(02)01064-1
   EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807                                                             
   Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150                                                         
   Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712                                                         
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 1997, J BIOMOL STRUCT DYN, V15, P573, DOI 10.1080/07391102.1997.10508967                                                  
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195
   Kettani A, 2000, J MOL BIOL, V297, P627, DOI 10.1006/jmbi.2000.3524
   Kettani A, 2000, J MOL BIOL, V301, P129, DOI 10.1006/jmbi.2000.3932
   KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644
   Kuryavyi V, 2001, J MOL BIOL, V310, P181, DOI 10.1006/jmbi.2001.4759
   KURYAVYI VV, 1996, P 9 CONV BIOM STRUCT, P81
   Matsugami A, 2001, J MOL BIOL, V313, P255, DOI 10.1006/jmbi.2001.5047
   Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u
   Neamati N, 2000, Adv Pharmacol, V49, P147
   Parkinson GN, 2002, NATURE, V417, P876, DOI 10.1038/nature755
   Phan AT, 2004, J AM CHEM SOC, V126, P8710, DOI 10.1021/ja048805k
   Phan AT, 2003, J AM CHEM SOC, V125, P15021, DOI 10.1021/ja037616j
   Phan AT, 2002, J AM CHEM SOC, V124, P1160, DOI 10.1021/ja011977m
   Phan AT, 2001, J MAGN RESON, V153, P223, DOI 10.1006/jmre.2001.2445
   Phan AT, 2000, J BIOMOL NMR, V16, P175, DOI 10.1023/A:1008355231085
   Phan AT, 2001, METHOD ENZYMOL, V338, P341
   RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9
   Seenisamy J, 2004, J AM CHEM SOC, V126, P8702, DOI 10.1021/ja040022b
   SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0                                                                
   Tarrago-Litvak L, 2002, CURR PHARM DESIGN, V8, P595, DOI 10.2174/1381612024607162
   Vakser IA, 1996, BIOPOLYMERS, V39, P455, DOI 10.1002/(SICI)1097-0282(199609)39:3<455::AID-BIP16>3.3.CO;2-8
   Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333
   WANG Y, 1994, STRUCTURE, V2, P1141, DOI 10.1016/S0969-2126(94)00117-0                                                   
   Zhang N, 2001, J MOL BIOL, V311, P1063, DOI 10.1006/jmbi.2001.4916
NR 39
TC 161
Z9 163
U1 0
U2 32
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 18
PY 2005
VL 102
IS 3
BP 634
EP 639
DI 10.1073/pnas.0406278102
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 889IF
UT WOS:000226436000022
PM 15637158
OA gold
DA 2018-01-05
ER

PT J
AU Imamura, S
   Nishikawa, Y
   Ichikawa, T
   Hattori, T
   Matsushita, Y
   Hashiguchi, S
   Kanzaki, N
   Iizawa, Y
   Baba, M
   Sugihara, Y
AF Imamura, S
   Nishikawa, Y
   Ichikawa, T
   Hattori, T
   Matsushita, Y
   Hashiguchi, S
   Kanzaki, N
   Iizawa, Y
   Baba, M
   Sugihara, Y
TI CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological
   evaluation of piperidine-4-carboxamide derivatives
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE CCR5 antagonist; chemokine; HIV-1; piperidine-4-carboxamide
ID DISEASE PROGRESSION; HIV-1 INFECTION; SMALL-MOLECULE; GENE; INDIVIDUALS;
   POTENT; AIDS
AB Replacement of the 5-oxopyrrolidin-3-yl fragment in the previously reported lead structure with a 1-acetylpiperidin-4-yl group led to the discovery of a novel series of potent CCR5 antagonists. Introduction of small hydrophobic substituents on the central phenyl ring increased the binding affinity, providing low to sub-nanomolar CCR5 antagonists. The selected compound 11f showed excellent antiviral activity against CCR5-using HIV-1 replication in human peripheral blood mononuclear cells (EC50 = 0.59 nM) and an acceptable pharmacokinetic profile in dogs. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Yodogawa Ku, Osaka 5328686, Japan.
   Kagoshima Univ, Grad Sch Med & Dent Sci, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima, Japan.
RP Imamura, S (reprint author), Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Yodogawa Ku, 2-17-85 Jusohnmachi, Osaka 5328686, Japan.
EM imamura_shin-ichi@takeda.co.jp
RI Baba, Masanori/G-3867-2011
CR Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   BROWN RW, 1991, J ORG CHEM, V56, P4974, DOI 10.1021/jo00016a032
   CHESNEY A, 1990, SYNTHETIC COMMUN, V20, P3167, DOI 10.1080/00397919008051542
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621                                                           
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   DUNCAN RL, 1970, J MED CHEM, V13, P1, DOI 10.1021/jm00295a001                                                             
   Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0
   HUFFMAN CW, 1958, J ORG CHEM, V23, P727, DOI 10.1021/jo01099a023                                                             
   Imamura S, 2004, CHEM PHARM BULL, V52, P63, DOI 10.1248/cpb.52.63
   Imamura S, 2004, BIOORGAN MED CHEM, V12, P2295, DOI 10.1016/j.bmc.2004.02.004
   Kazmierski W, 2003, BIOORGAN MED CHEM, V11, P2663, DOI 10.1016/S0968-0868(03)00161-5
   LIU T, 1996, CELL, V86, P367
   Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   *UNAIDS WHO, 2003, AIDS EP UPD 2003
   Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222
   BIGGE CF, 1997, Patent No. 9723216
NR 19
TC 31
Z9 34
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JAN 17
PY 2005
VL 13
IS 2
BP 397
EP 416
DI 10.1016/j.bmc.2004.10.013
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 887ZK
UT WOS:000226343800010
PM 15598561
DA 2018-01-05
ER

PT J
AU Ziegler, A
   Nervi, P
   Durrenberger, M
   Seelig, J
AF Ziegler, A
   Nervi, P
   Durrenberger, M
   Seelig, J
TI The cationic cell-penetrating peptide Cpp(TAT) derived from the HIV-1
   protein TAT is rapidly transported into living fibroblasts: Optical,
   biophysical, and metabolic evidence
SO BIOCHEMISTRY
LA English
DT Article
ID HEPARAN-SULFATE PROTEOGLYCANS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   ARGININE-RICH PEPTIDES; TRANSDUCTION DOMAINS; BINDING MECHANISM;
   MAMMALIAN-CELLS; PLASMA-MEMBRANE; DELIVERY; SURFACE; INTERNALIZATION
AB Cell-penetratin peptides (CPPs) are cationic peptides which, when linked to genes, proteins, or nanoparticles, facilitate the transport of these entities across the cell membrane. Despite their potential use for gene transfer and drug delivery, the mode of action of CPPs is still mysterious. It has even been argued that the observed transport across the cell membrane is an artifact caused by chemical fixation of the cells, a common preparation method for microscopic observation. Here we have synthesized a fluorescent derivative of the HIV-1 TAT protein transduction domain [Fg-CPPTAT(PTD)] and have observed its uptake into nonfixated living fibroblasts with time-lapse confocal microscopy, eliminating the need for fixation. We observe that Fg-CPPTAT(PTD) enters the cytoplasm and nucleus of nonfixated fibroblasts within seconds, arguing against the suggested artifact of cell fixation. Using differential interference contrast microscopy, dense aggregates are detected on the cell surface. Several observations suggest that these 4 aggregates consist of Fg-CPPTAT(PTD) bound to membrane-associated heparan sulfate (HS). The aggregates arow in parallel with Fg-CPPTAT(PTD) uptake and are detected only on fibroblasts showing, Fg-CPPTAT(PTD) uptake. These observations resemble earlier reports of "capping" of cell surface molecules combined with a polarized endocytotic flow. Enzymatic removal of extracellular HS reduced the rate of both Fg-CPPTAT(PTD) uptake and aggregate formation, demonstrating that HS is involved in the uptake mechanism. The functionality of the fibroblasts during the CPP uptake was investigated with a cytosensor microphysiometer measuring the extracellular acidification rate (ECAR). Short exposures (2.5 min) to the CPP reduced the ECAR which was, however, reversible upon reperfusion with buffer only. In contrast, no recovery to baseline values was observed after repeated exposures to the CPP, suggesting that the CPP is toxic in long-term applications.
C1 Univ Basel, Dept Biophys Chem, CH-4056 Basel, Switzerland.
   Univ Basel, Biozentrum, Ctr Microscopy, CH-4056 Basel, Switzerland.
RP Seelig, J (reprint author), Univ Basel, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.
EM joachim.seelig@unibas.ch
CR Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8
   Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X
   CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228
   Dehio C, 1998, EXP CELL RES, V242, P528, DOI 10.1006/excr.1998.4116
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   EFTNIK MR, 1981, ANAL BIOCHEM, V114, P199
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FEDARKO NS, 1989, J CELL PHYSIOL, V139, P287, DOI 10.1002/jcp.1041390210
   FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587
   Fischer R, 2004, J BIOL CHEM, V279, P12625, DOI 10.1074/jbc.M311461200
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GRIFFIN CC, 1995, CARBOHYD RES, V276, P183, DOI 10.1016/0008-6215(95)00166-Q
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Ho A, 2001, CANCER RES, V61, P474
   ISHIHARA M, 1986, J BIOL CHEM, V261, P3575
   KRAEMER PM, 1972, J CELL BIOL, V55, P713, DOI 10.1083/jcb.55.3.713
   Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1
   Landwojtowicz E, 2002, BIOCHEMISTRY-US, V41, P8050, DOI 10.1021/bi025720s
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026                                                             
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   MANN DA, 1991, EMBO J, V10, P1733
   Martinho RG, 1996, MOL BIOL CELL, V7, P1771
   Maxfield F R, 1987, Adv Exp Med Biol, V225, P189
   MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   MORAD N, 1984, BIOCHIM BIOPHYS ACTA, V801, P117, DOI 10.1016/0304-4165(84)90219-8                                                    
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nath A, 1996, J VIROL, V70, P1475
   Nomarski G., 1955, J PHYS RADIUM, V16, P9
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   RYSER HJP, 1965, SCIENCE, V150, P501, DOI 10.1126/science.150.3695.501
   RYSER HJP, 1968, SCIENCE, V159, P390, DOI 10.1126/science.159.3813.390
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schulz JG, 1998, EUR J NEUROSCI, V10, P2085, DOI 10.1046/j.1460-9568.1998.00220.x
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   SHEN WC, 1978, P NATL ACAD SCI USA, V75, P1872, DOI 10.1073/pnas.75.4.1872
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Tumova S, 1999, BIOCHEM J, V337, P471, DOI 10.1042/0264-6021:3370471
   TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553                                                               
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   Ziegler A, 2004, BIOPHYS J, V86, P254, DOI 10.1016/S0006-3495(04)74101-6                                                   
   Ziegler A, 2003, BIOCHEMISTRY-US, V42, P9185, DOI 10.1021/bi0346805
NR 57
TC 173
Z9 179
U1 0
U2 23
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD JAN 11
PY 2005
VL 44
IS 1
BP 138
EP 148
DI 10.1021/bi0491604
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 886GJ
UT WOS:000226214600016
PM 15628854
DA 2018-01-05
ER

PT J
AU Torchilin, VP
AF Torchilin, VP
TI Fluorescence microscopy to follow the targeting of liposomes and
   micelles to cells and their intracellular fate
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE fluorescence microscopy; confocal microscopy; micelles; liposomes; cell
   targeting; internalization
ID HUMAN-IMMUNODEFICIENCY-VIRUS; VIVO PROTEIN TRANSDUCTION; TAT-FUSION
   PROTEINS; VITAMIN-K; IN-VIVO; MENADIONE 2-METHYL-1,4-NAPHTHOQUINONE;
   CELLULAR UPTAKE; GENE DELIVERY; ANTINUCLEAR AUTOANTIBODIES; MAGNETIC
   NANOPARTICLES
AB Fluorescence microscopy may provide important information regarding interactions between nanoparticulate drugs carriers, such as liposomes and micelles, with target cells as well as their intracellular fate. Current paper describes various applications of fluorescence microscopy to investigate specific targeting of antibody-modified drug carriers to cancer cells. The enhanced antibody-mediated targeting of drug-loaded immunomicelles confirmed by fluorescence microscopy resulted in enhanced cancer cell killing compared to free drug or drug-loaded nontargeted micelles. Fluorescence microscopy was also used to prove the endosomal escape of properly assembled polymeric micelles (based on polyethylene glycol-phosphatidylethanolamine conjugate, PEG-PE) containing various additives destabilizing the endosomal membrane. When loaded with the anticancer drug (paclitaxel or vitamin K3), such micelles demonstrate increased cytotoxicity. Fluorescence microscopy was also applied to investigate the capture of cell-penetrating TAT peptide-modified liposomes by various cells and stability and intracellular trafficking of captured TAT-liposomes inside cells. It was also used to confirm the successful transfection of cells with TAT-liposomes bearing the plasmid encoding for the Green Fluorescent Protein (GFP). (C) 2004 Elsevier B.V. All rights reserved.
C1 Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
CR Almofti MR, 2003, ARCH BIOCHEM BIOPHYS, V410, P246, DOI 10.1016/S0003-9861(02)00725-7
   BLUME G, 1993, BIOCHIM BIOPHYS ACTA, V1149, P180, DOI 10.1016/0005-2736(93)90039-3
   BROWN PC, 1991, ARCH BIOCHEM BIOPHYS, V285, P187, DOI 10.1016/0003-9861(91)90348-M
   Carr BI, 2002, J CELL PHYSIOL, V193, P263, DOI 10.1002/jcp.10171
   Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699                                                        
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   Francis G.E., 2000, DRUG TARGETING STRAT
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2002, INT J PHARM, V245, P1, DOI 10.1016/S0378-5173(02)00337-X
   GABIZON AA, 1995, ADV DRUG DELIVER REV, V16, P285, DOI 10.1016/0169-409X(95)00030-B                                                    
   GANT TW, 1988, CHEM-BIOL INTERACT, V65, P157, DOI 10.1016/0009-2797(88)90052-X                                                    
   Gao Z, 2003, J DRUG TARGET, V11, P87, DOI 10.1080/1061186031000138623
   Gao ZG, 2002, NANO LETT, V2, P979, DOI 10.1021/nl025604a
   Gius DR, 1999, CANCER RES, V59, P2577
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hafez IM, 2001, GENE THER, V8, P1188, DOI 10.1038/sj.gt.3301506
   IAKOUBOV L, 1995, IMMUNOL LETT, V47, P147, DOI 10.1016/0165-2478(95)00066-E
   Iakoubov LZ, 1998, CANCER DETECT PREV, V22, P470, DOI 10.1046/j.1525-1500.1998.00055.x                                                
   Iakoubov LZ, 1997, ONCOL RES, V9, P439
   Jain RK, 1999, ANNU REV BIOMED ENG, V1, P241, DOI 10.1146/annurev.bioeng.1.1.241                                                  
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kaiser S, 2001, J VASC RES, V38, P133, DOI 10.1159/000051040                                                               
   KWON GS, 1995, ADV DRUG DELIVER REV, V16, P295, DOI 10.1016/0169-409X(95)00031-2                                                    
   Lasic D, 1995, STEALTH LIPOSOMES
   LASIC DD, 1993, LIPOSOMES PHYSICS AP
   Lee HJ, 2001, BIOCONJUGATE CHEM, V12, P995, DOI 10.1021/bc0155061
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lukyanov AN, 2004, J CONTROL RELEASE, V94, P187, DOI 10.1016/j.jconrel.2003.10.008
   Lukyanov AN, 2002, PHARMACEUT RES, V19, P1424, DOI 10.1023/A:1020488012264
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   MANN DA, 1991, EMBO J, V10, P1733
   Markovits J, 2003, LIFE SCI, V72, P2769, DOI 10.1016/S0024-3205(03)00188-7
   Ni RZ, 1998, J BIOL CHEM, V273, P9906, DOI 10.1074/jbc.273.16.9906
   NISHIKAWA Y, 1995, J BIOL CHEM, V270, P28304
   NUTTER LM, 1992, J BIOL CHEM, V267, P2474
   NUTTER LM, 1991, BIOCHEM PHARMACOL, V41, P1283, DOI 10.1016/0006-2952(91)90099-Q                                                    
   Ota T, 2002, ANTICANCER RES, V22, P4049
   PALMER TN, 1984, BIOCHIM BIOPHYS ACTA, V797, P363, DOI 10.1016/0304-4165(84)90258-7
   Park J, 2002, J GEN VIROL, V83, P1173, DOI 10.1099/0022-1317-83-5-1173                                                     
   Plank C, 1998, ADV DRUG DELIVER REV, V34, P21, DOI 10.1016/S0169-409X(98)00005-2                                                   
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   SENIOR JH, 1987, CRIT REV THER DRUG, V3, P123
   Shen HM, 2004, HUM GENE THER, V15, P415, DOI 10.1089/104303404322959560
   Snyder EL, 2004, PHARM RES, V21, P389, DOI 10.1023/B:PHAM.0000019289.61978.f5
   THOR H, 1982, J BIOL CHEM, V257, P2419
   Torchilin V P, 1985, Crit Rev Ther Drug Carrier Syst, V2, P65
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P6039, DOI 10.1073/pnas.0931428100
   Torchilin VP, 2000, EUR J PHARM SCI, V11, pS81, DOI 10.1016/S0928-0987(00)00166-4
   TORCHILIN VP, 1992, FASEB J, V6, P2716
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   Torchilin VP, 1996, BBA-BIOMEMBRANES, V1279, P75, DOI 10.1016/0005-2736(95)00248-0
   TORCHILIN VP, 2000, CONTROLLED DRUG DELI, P297
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   TRUBETSKOY VS, 1995, ADV DRUG DELIVER REV, V16, P311, DOI 10.1016/0169-409X(95)00032-3
   Trubetskoy VS, 1996, STP PHARMA SCI, V6, P79
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   VERHOEF K, 1993, ANAL BIOCHEM, V210, P210, DOI 10.1006/abio.1993.1176
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wang JP, 2004, INT J PHARM, V272, P129, DOI 10.1016/j.ijpharm.2003.12.011
   Weissig V, 1998, J LIPOSOME RES, V8, P391, DOI 10.3109/08982109809035542
   Weissig V, 1998, PHARMACEUT RES, V15, P1552, DOI 10.1023/A:1011951016118                                                         
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   YUAN F, 1995, CANCER RES, V55, P3752
   Zaro JL, 2003, BIOCHEM BIOPH RES CO, V307, P241, DOI 10.1016/S006-291X(03)01167-7
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 76
TC 94
Z9 101
U1 2
U2 46
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD JAN 2
PY 2005
VL 57
IS 1
BP 95
EP 109
DI 10.1016/j.addr.2004.06.002
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 872JK
UT WOS:000225203300007
PM 15518923
DA 2018-01-05
ER

PT B
AU Valdivia-Granda, W
   Keating, CD
   Kann, M
   Beresford, R
   Kelley, SO
AF Valdivia-Granda, W
   Keating, CD
   Kann, M
   Beresford, R
   Kelley, SO
BE Badawy, W
   Moussa, W
TI Detection of encephalic and hemorrhagic viruses: Integration of micro-
   and nano-fabrication with computational tools
SO 2005 INTERNATIONAL CONFERENCE ON MEMS, NANO AND SMART SYSTEMS,
   PROCEEDINGS
LA English
DT Proceedings Paper
CT International Conference on MEMS, NANO and Smart Systems
CY JUL 24-27, 2005
CL Banff, CANADA
SP IEEE CAS TE BioCAs, IEEE Circuit & Syst Soc
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE TRANSCRIPTION-PCR; NANOPARTICLE
   PROBES; DENGUE VIRUS; ELECTRICAL DETECTION; BUILDING-BLOCKS; DNA
   MICROARRAYS; HEPATITIS-B; GENOMIC DNA; QUANTUM-DOT
AB This document present an overview or the use of microarray technology, quantum dots, nanowires and carbon nanotubes to detect pathogens, in particular encephalic and hemorrhagic viruses. The relevance and challenges in the development of detection nanosystems and their integration with computational analysis tools and viral evolutionary genomics techniques are highlighted.
CR Afonso CL, 2004, J VIROL, V78, P1858, DOI 10.1128/JVI.78.4.1858.1864.2004
   Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0
   Bacarese-Hamilton Tito, 2004, Methods Mol Biol, V264, P271
   Bao YP, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni017
   Batista WC, 2001, VIRUS RES, V75, P35, DOI 10.1016/S0168-1702(01)00222-2
   Bengtsson H, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-177
   Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013
   Bukh J, 1997, VIROLOGY, V229, P429, DOI 10.1006/viro.1997.8461
   Cai H, 2003, ANAL BIOANAL CHEM, V375, P287, DOI 10.1007/s00216-002-1652-9
   Cherkasova E, 2003, P NATL ACAD SCI USA, V100, P9398, DOI 10.1073/pnas.1633511100
   Cho NH, 2003, AM J OBSTET GYNECOL, V188, P56, DOI 10.1067/mob.2003.120
   Cui Y, 2001, SCIENCE, V291, P851, DOI 10.1126/science.291.5505.851
   Cui Y, 2001, SCIENCE, V293, P1289, DOI 10.1126/science.1062711
   Drosten C, 2002, J CLIN MICROBIOL, V40, P2323, DOI 10.1128/JCM.40.7.2323-2330.2002
   Duburcq X, 2004, BIOCONJUGATE CHEM, V15, P307, DOI 10.1021/bc034226d
   Gardner SN, 2003, J CLIN MICROBIOL, V41, P2417, DOI 10.1128/JCM.41.6.2417-2427.2003
   Gerion D, 2003, ANAL CHEM, V75, P4766, DOI 10.1021/ac034482j
   Gould EA, 2003, ADV VIRUS RES, V59, P277, DOI 10.1016/S0065-3527(03)59008-X
   Greenham NC, 1996, PHYS REV B, V54, P17628, DOI 10.1103/PhysRevB.54.17628
   He H., 2003, ENCY NANOSCIENCE NAN, VX, P1
   HENCHAL EA, 1991, AM J TROP MED HYG, V45, P418, DOI 10.4269/ajtmh.1991.45.418                                                       
   Hunt AR, 2002, J CLIN MICROBIOL, V40, P2023, DOI 10.1128/JCM.40.6.2023-2030.2002
   Jianrong Chen, 2004, Biotechnol Adv, V22, P505, DOI 10.1016/j.biotechadv.2004.03.004
   Johnson AJ, 2000, J CLIN MICROBIOL, V38, P1827
   Keating CD, 2003, ADV MATER, V15, P451, DOI 10.1002/adma.200390105                                                          
   Korn EL, 2004, BIOTECHNIQUES, V36, P960
   Laassri M, 2003, J VIROL METHODS, V112, P67, DOI 10.1016/S0166-0934(03)00193-9
   Lacoste TD, 2000, P NATL ACAD SCI USA, V97, P9461, DOI 10.1073/pnas.170286097
   Li JP, 2001, J CLIN MICROBIOL, V39, P696, DOI 10.1128/JCM.39.2.696-704.2001
   Liang RQ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni019
   Lovmar L, 2003, J CLIN MICROBIOL, V41, P5153, DOI 10.1128/JCM.41.11.5153-5158.2003
   Ludwig B, 2003, INTERVIROLOGY, V46, P71, DOI 10.1159/000069749
   Meiyu Fang, 1997, Microbiology and Immunology, V41, P209
   Mezzasoma L, 2002, CLIN CHEM, V48, P121
   Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137                                                    
   Niemeyer C. M., 2004, NANOBIOTECHNOLOGY CO
   Nordstrom H, 2004, J MED VIROL, V72, P646, DOI 10.1002/jmv.20041
   Osaki F, 2004, J AM CHEM SOC, V126, P6520, DOI 10.1021/ja048792a
   Papin JF, 2004, J CLIN MICROBIOL, V42, P1511, DOI 10.1128/JCM.42.4.1511-1518.2004
   Park SJ, 2002, SCIENCE, V295, P1503, DOI 10.1126/science.1067003
   Patolsky F, 2004, P NATL ACAD SCI USA, V101, P14017, DOI 10.1073/pnas.0406159101
   Pena SRN, 2002, J AM CHEM SOC, V124, P7314, DOI 10.1021/ja0177915
   Perez JM, 2003, J AM CHEM SOC, V125, P10192, DOI 10.1021/ja036409g
   Perrin A, 2003, ANAL BIOCHEM, V322, P148, DOI 10.1016/j.ab.2003.08.002
   Reynes JM, 2003, J CLIN MICROBIOL, V41, P3864, DOI 10.1128/JCM.41.8.3864-3867.2003
   Scaramozzino N, 2001, J CLIN MICROBIOL, V39, P1922, DOI 10.1128/JCM.39.5.1922-1927.2001
   Stears RL, 2003, NAT MED, V9, P140, DOI 10.1038/nm0103-140
   Storch GA, 2000, CLIN INFECT DIS, V31, P739, DOI 10.1086/314015
   Storhoff JJ, 2004, BIOSENS BIOELECTRON, V19, P875, DOI 10.1016/j.bios.2003.08.014
   Striebel Hans-Martin, 2003, Current Pharmaceutical Biotechnology, V4, P401, DOI 10.2174/1389201033377274
   Taton TA, 2000, SCIENCE, V289, P1757, DOI 10.1126/science.289.5485.1757
   Twiddy SS, 2003, INFECT GENET EVOL, V3, P87, DOI 10.1016/S1567-1348(02)00153-3
   Wang D, 2003, PLOS BIOL, V1, P257, DOI 10.1371/journal.pbio.0000002
   Wong CW, 2004, GENOME RES, V14, P398, DOI 10.1101/gr.2141004
   Yamagishi J, 2003, ARCH VIROL, V148, P587, DOI 10.1007/s00705-002-0922-3
   Zhao Wei, 2003, Hepatobiliary Pancreat Dis Int, V2, P234
NR 56
TC 1
Z9 1
U1 0
U2 0
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-2398-6
PY 2005
BP 411
EP 417
DI 10.1109/ICMENS.2005.40
PG 7
WC Engineering, Electrical & Electronic; Engineering, Mechanical;
   Instruments & Instrumentation
SC Engineering; Instruments & Instrumentation
GA BDO07
UT WOS:000234540800111
DA 2018-01-05
ER

PT J
AU Webster, A
   Compton, SJ
   Aylott, JW
AF Webster, A
   Compton, SJ
   Aylott, JW
TI Optical calcium sensors: development of a generic method for their
   introduction to the cell using conjugated cell penetrating peptides
SO ANALYST
LA English
DT Article
ID SINGLE LIVING CELLS; RAT C6 GLIOMA; PEBBLE SENSORS; CHEMICAL-ANALYSIS;
   TAT PEPTIDE; INTRACELLULAR DELIVERY; NANOSENSORS; PROTEIN;
   NANOPARTICLES; MECHANISM
AB Probes Encapsulated By Biologically Localised Embedding (PEBBLEs) are optical sensors with nanometer dimensions fabricated by microemulsion polymerisation. The most beneficial characteristic of these sensors is the protection offered by the sensor matrix which decreases interaction between the fluorophore and the cell. These sensors have been introduced to the cell by a number of methods; however this paper discusses the development of a generic method to facilitate inclusion of this type of sensor in the cell by a simple incubation step. This was achieved by covalent linkage of a synthetic Cell Penetrating Peptide (CPP) based on the Human Immunodeficiency Virus (HIV)- 1 Tat, to the external sensor matrix. Calcium sensors were used to demonstrate this approach to incorporate the sensors within the cell. Characterisation revealed the calcium sensors were approximately 30 +/- 7 nm in diameter with a slightly negative zeta potential. The sensors demonstrated a linear range of 0 - 50 muM with negligible interference from a range of cellular ions and protein. Leaching of entrapped dyes from the calcium sensors was determined as 3% in a 24 h period, while photobleaching of the entrapped dye was minimal over a 40 min period. The sensors ability to cross the cell membrane using the covalently attached synthetic Tat peptide is demonstrated. Cellular inclusion of the sensors occurred within a 30 min incubation period.
C1 Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England.
   Univ Hull, Dept Chem, Kingston Upon Hull HU6 7RX, N Humberside, England.
   Castle Hill Hosp, Cottingham HU16 5JQ, Yorks, England.
RP Aylott, JW (reprint author), Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England.
EM a.webster@chem.hull.ac.uk; s.j.compton@hull.ac.uk;
   Jon.Aylott@nottingham.ac.uk
RI Aylott, Jonathan/D-2237-2009
OI Aylott, Jonathan/0000-0003-1520-5490
CR Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Brasuel M, 2001, ANAL CHEM, V73, P2221, DOI 10.1021/ac0012041
   CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   Clark HA, 1999, ANAL CHEM, V71, P4831, DOI 10.1021/ac990629o
   Clark HA, 1998, SENSOR ACTUAT B-CHEM, V51, P12, DOI 10.1016/S0925-4005(98)00212-3
   Clark HA, 1999, ANAL CHEM, V71, P4837, DOI 10.1021/ac990630n                                                               
   DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699                                                        
   Haugland R. P., 2001, HDB FLUORESCENT PROB
   Irvine RF, 2003, NAT REV MOL CELL BIO, V4, P586, DOI 10.1038/nrm1152
   Joliot A, 2004, NAT CELL BIOL, V6, P189, DOI 10.1038/ncb0304-189
   Lee SK, 1999, ANAL BIOCHEM, V273, P186, DOI 10.1006/abio.1999.4212                                                          
   Leifert JA, 2003, MOL THER, V8, P13, DOI 10.1016/S1525-0016(03)00151-5
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760
   LUNDBERG P, 2003, J MOL RECOGNIT, P227
   Orlov SN, 2003, CELL CALCIUM, V34, P511, DOI 10.1016/S0143-4160(03)00125-8
   Rottingen JA, 2000, ACTA PHYSIOL SCAND, V169, P203
   Rudolf R, 2003, NAT REV MOL CELL BIO, V4, P579, DOI 10.1038/nrm1153
   Shriver-Lake LC, 2002, ANAL CHIM ACTA, V470, P71, DOI 10.1016/S0003-2670(02)00540-8
   Thoren PEG, 2004, BIOCHEMISTRY-US, V43, P3471, DOI 10.1021/bi0360049
   Tung CH, 2003, ADV DRUG DELIVER REV, V55, P281, DOI 10.1016/S0169-409X(02)00183-7
   van Nieuwenhuyzen W, 1998, FETT-LIPID, V100, P282
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Xu H, 2002, ANALYST, V127, P1471, DOI 10.1039/b202782h
   Xu H, 2001, ANAL CHEM, V73, P4124, DOI 10.1021/ac0102718
   Zhang J, 2002, NAT REV MOL CELL BIO, V3, P906, DOI 10.1038/nrm976
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 30
TC 33
Z9 33
U1 0
U2 6
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 0003-2654
J9 ANALYST
JI Analyst
PY 2005
VL 130
IS 2
BP 163
EP 170
DI 10.1039/b413725f
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 890BE
UT WOS:000226485900008
PM 15665969
DA 2018-01-05
ER

PT J
AU Linder, V
   Sia, SK
   Whitesides, GM
AF Linder, V
   Sia, SK
   Whitesides, GM
TI Reagent-loaded cartridges for valveless and automated fluid delivery in
   microfluidic devices
SO ANALYTICAL CHEMISTRY
LA English
DT Article
ID IMMUNOSORBENT-ASSAY; IMMUNOASSAY; MICROCHIP; POLY(DIMETHYLSILOXANE);
   SYSTEM; CHIPS; IMMUNOGLOBULIN; NETWORKS; STANDARD
AB An important problem in the life sciences and in health care is simple and rapid detection of biomarkers. Although microfluidic devices are potentially useful in addressing this problem, current techniques for automating fluid delivery-which include valves and electro-osmosis-require sophisticated microfabrication of the chip, bulky instrumentation, or both. In this paper, we describe a simple and reliable technique for storing and delivering a sequence of reagents to a microfluidic device. The technique is low-cost, requires minimal user intervention, and can be performed in resource-poor settings (e.g., outside of a laboratory) in the absence of electricity and computer-controlled equipment. In this method, cartridges made of commercially available tubing are filled by sequentially injecting plugs of reagents separated by air spacers. The air spacers prevent the reagents from mixing with each other during cartridge preparation, storage, and usage. As an example, we used this "plug-in cartridge" technology to complete a solid-phase immunoassay in a microchannel in 2 min with low-nanomolar sensitivity and demonstrate the diagnosis of HIV in 13 min.
C1 Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
RP Whitesides, GM (reprint author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.
EM gwhitesides@gmwgroup.harvard.edu
FU NIGMS NIH HHS [GM 51559]
CR Acharya T, 2003, NAT BIOTECHNOL, V21, P1434, DOI 10.1038/nbt1203-1434
   Auroux PA, 2002, ANAL CHEM, V74, P2637, DOI 10.1021/ac020239t
   Bernard A, 2001, ANAL CHEM, V73, P8, DOI 10.1021/ac0008845
   Crowe JH, 1998, ANNU REV PHYSIOL, V60, P73, DOI 10.1146/annurev.physiol.60.1.73
   Dodge A, 2001, ANAL CHEM, V73, P3400, DOI 10.1021/ac0015366
   Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z
   Fuerstman MJ, 2003, LANGMUIR, V19, P4714, DOI 10.1021/la030054x
   Hatch A, 2001, NAT BIOTECHNOL, V19, P461, DOI 10.1038/88135
   Hayes MA, 2001, ANAL CHEM, V73, P5896, DOI 10.1021/ac0104680
   Jiang XY, 2003, J AM CHEM SOC, V125, P5294, DOI 10.1021/ja034566
   Juncker D, 2002, ANAL CHEM, V74, P6139, DOI 10.1021/ac0261449
   Lenehan CE, 2002, ANALYST, V127, P997, DOI 10.1039/b106791p
   Linder V, 2002, ELECTROPHORESIS, V23, P740, DOI 10.1002/1522-2683(200203)23:5<740::AID-ELPS740>3.0.CO;2-7
   Linder V, 2001, ANAL CHEM, V73, P4181, DOI 10.1021/ac010421e
   Obeid PJ, 2003, ANAL CHEM, V75, P288, DOI 10.1021/ac0260239
   Rossier JS, 2001, LAB CHIP, V1, P153, DOI 10.1039/b104772h
   Ruzicka J., 1988, FLOW INJECTION ANAL
   Sato K, 2001, ANAL CHEM, V73, P1213, DOI 10.1021/ac000991z
   Sato K, 2000, ANAL CHEM, V72, P1144, DOI 10.1021/ac991151r                                                               
   Sia SK, 2003, ELECTROPHORESIS, V24, P3563, DOI 10.1002/elps.200305584
   Sia SK, 2004, ANGEW CHEM INT EDIT, V43, P498, DOI 10.1002/anie.200353016
   Song H, 2003, ANGEW CHEM INT EDIT, V42, P768, DOI 10.1002/anie.200390203                                                          
   Sundberg SA, 2000, CURR OPIN BIOTECH, V11, P47, DOI 10.1016/S0958-1669(99)00051-8
   Sundberg S. A., 2000, DRUG DISCOV TODAY, V5, P92
   Unger MA, 2000, SCIENCE, V288, P113, DOI 10.1126/science.288.5463.113
   Varmus H, 2003, SCIENCE, V302, P398, DOI 10.1126/science.1091769                                                         
   Verpoorte E, 2002, ELECTROPHORESIS, V23, P677, DOI 10.1002/1522-2683(200203)23:5<677::AID-ELPS677>3.0.CO;2-8
   Yakovleva J, 2002, ANAL CHEM, V74, P2994, DOI 10.1021/ac015645b
   [Anonymous], 2003, HDB CHEM PHYS
NR 29
TC 120
Z9 121
U1 2
U2 46
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0003-2700
J9 ANAL CHEM
JI Anal. Chem.
PD JAN 1
PY 2005
VL 77
IS 1
BP 64
EP 71
DI 10.1021/ac049071x
PG 8
WC Chemistry, Analytical
SC Chemistry
GA 885XS
UT WOS:000226191200016
PM 15623279
DA 2018-01-05
ER

PT J
AU Prasad, KK
   Purohit, CS
   Jain, A
   Sankararamakrishnan, R
   Verma, S
AF Prasad, KK
   Purohit, CS
   Jain, A
   Sankararamakrishnan, R
   Verma, S
TI Enforcing solution phase nanoscopic aggregation in a palindromic
   tripeptide
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID CRYSTAL-STRUCTURE; V3 LOOP; PEPTIDE; HIV-1; CONJUGATE; NANOTUBES;
   MOTIFS; TYPE-1
AB C-terminal dimerization of a tripeptide palindrome afforded fibrillation in solution through an assembly probably driven by hydrogen bonding and hydrophobic contributions; such an approach provides an expeditious entry into fabrication of fibrillating peptides from non-fibrillating peptide sequences.
C1 Indian Inst Technol, Dept Chem, Kanpur 208016, Uttar Pradesh, India.
   Indian Inst Technol, Dept Biol Sci & Bioengn, Kanpur 208016, Uttar Pradesh, India.
RP Verma, S (reprint author), Indian Inst Technol, Dept Chem, Kanpur 208016, Uttar Pradesh, India.
EM sverma@iitk.ac.in
RI Jain, Alok/F-6051-2012
OI , Alok/0000-0002-7365-7455; Sankararamakrishnan,
   Ramasubbu/0000-0002-8527-5614
CR AGGELL A, 1997, NATURE, V286, P259
   Catasti P, 1996, J BIOL CHEM, V271, P8236, DOI 10.1074/jbc.271.14.8236                                                         
   Chakraborty TK, 2002, J ORG CHEM, V67, P2093, DOI 10.1021/jo010937y
   de la Paz ML, 2002, P NATL ACAD SCI USA, V99, P16052, DOI 10.1073/pnas.252340199
   Djalali R, 2003, J AM CHEM SOC, V125, P5873, DOI 10.1021/ja0299598
   Fisk JD, 2001, J AM CHEM SOC, V123, P343, DOI 10.1021/ja002493d
   GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253                                                         
   GUNASEKARAN K, 1995, INT J PEPT PROT RES, V46, P359
   Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187                                                         
   LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685                                                         
   Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045                                                           
   Madhavaiah C, 2004, BIOORGAN MED CHEM, V12, P5973, DOI 10.1016/j.bmc.2004.08.018
   Madhavaiah C, 2004, CHEM COMMUN, P638, DOI 10.1039/b316793c
   Madhavaiah C, 2003, BIOORG MED CHEM LETT, V13, P923, DOI 10.1016/S0960-894X(02)01068-5
   Madhavaiah C, 2001, BIOCONJUGATE CHEM, V12, P855, DOI 10.1021/bc000140y
   Nowick JS, 2000, J AM CHEM SOC, V122, P7654, DOI 10.1021/ja001142w
   Qiu W, 2001, TETRAHEDRON LETT, V42, P145, DOI 10.1016/S0040-4039(00)01864-5                                                   
   Ranganathan D, 2001, CHEM COMMUN, P273, DOI 10.1039/b009532j                                                                
   Reches M, 2003, SCIENCE, V300, P625, DOI 10.1126/science.1082387                                                         
   Su J, 2001, J HUMAN VIROL, V4, P1
   Su J, 2000, AIDS RES HUM RETROV, V16, P37, DOI 10.1089/088922200309584
   Zhao XJ, 2004, TRENDS BIOTECHNOL, V22, P470, DOI 10.1016/j.tibech.2004.07.011
NR 22
TC 11
Z9 11
U1 0
U2 3
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2005
IS 20
BP 2564
EP 2566
DI 10.1039/b500654f
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 926YR
UT WOS:000229160100008
PM 15900327
DA 2018-01-05
ER

PT J
AU Sun, RWY
   Chen, R
   Chung, NPY
   Ho, CM
   Lin, CLS
   Che, CM
AF Sun, RWY
   Chen, R
   Chung, NPY
   Ho, CM
   Lin, CLS
   Che, CM
TI Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective
   activities toward HIV-1 infected cells
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID REVERSE-TRANSCRIPTASE; GOLD NANOPARTICLES; INHIBITION; PLATINUM
AB Silver nanoparticles fabricated in Hepes buffer exhibit potent cytoprotective and post-infected anti-HIV-1 activities toward Hut/CCR5 cells.
C1 Univ Hong Kong, Dept Surg, Med Ctr, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China.
   Univ Hong Kong, Open Lab Chem Biol, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China.
RP Lin, CLS (reprint author), Univ Hong Kong, Dept Surg, Med Ctr, Queen Mary Hosp, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.
EM cmche@hku.hk
RI Sun, Raymond/D-3165-2009; Ho, Chi Ming/D-3089-2009; Ho,
   Daniel/A-4740-2010; Chen, Rong/E-9474-2011
OI Chen, Rong/0000-0003-1455-5093
CR Che CM, 2003, CHEM COMMUN, P1718, DOI 10.1039/b303294a
   EBERLE J, 1992, J VIROL METHODS, V40, P347, DOI 10.1016/0166-0934(92)90092-R
   El-Sayed MA, 2004, ACCOUNTS CHEM RES, V37, P326, DOI 10.1021/ar020204f
   Elechiguerra JL, 2005, J NANOBIOTECHNOL, V3, P1, DOI DOI 10.1186/1477-3155-3-6
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Esumi K, 2000, LANGMUIR, V16, P2604, DOI 10.1021/1a991291w
   HITSUYA H, 1990, SCIENCE, V249, P1533
   Ho CM, 2004, ANGEW CHEM INT EDIT, V43, P3303, DOI 10.1002/anie.200453703
   Lang HF, 2003, J AM CHEM SOC, V125, P14832, DOI 10.1021/ja0364120
   LEWIS LN, 1993, CHEM REV, V93, P2693, DOI 10.1021/cr00024a006                                                             
   Mafune F, 2000, J PHYS CHEM B, V104, P8333, DOI 10.1021/jp001803b
   MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nicewarner-Pena SR, 2001, SCIENCE, V294, P137, DOI 10.1126/science.294.5540.137                                                    
   Raveendran P, 2003, J AM CHEM SOC, V125, P13940, DOI 10.1021/ja029267j
   Shen XC, 2003, SCI CHINA SER B, V46, P387, DOI 10.1360/02yb0062
   SONG SY, 2005, CHEM COMMUN, P3544
   Sun RWY, 2004, CHEMBIOCHEM, V5, P1293, DOI 10.1002/cbic.200300773
   Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229
   Trkola A, 1998, J VIROL, V72, P396
   Wright JB, 1999, AM J INFECT CONTROL, V27, P344, DOI 10.1016/S0196-6553(99)70055-6
   Xie H, 2003, ANAL CHEM, V75, P5797, DOI 10.1021/ac034578d
NR 22
TC 213
Z9 223
U1 0
U2 36
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PY 2005
IS 40
BP 5059
EP 5061
DI 10.1039/b510984a
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 972WG
UT WOS:000232483300015
PM 16220170
DA 2018-01-05
ER

PT J
AU Bramwell, VW
   Perrie, Y
AF Bramwell, VW
   Perrie, Y
TI Particulate delivery systems for vaccines
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE PLGA; liposome; DNA; niosome; adjuvant; ISCOM; vaccine; Mycobacterium
   tuberculosis; HIV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; B SURFACE-ANTIGEN;
   MYCOBACTERIUM-TUBERCULOSIS INFECTION; CHITOSAN-DNA NANOPARTICLES;
   T-LYMPHOCYTE RESPONSES; NITRIC-OXIDE SYNTHASE; BIODEGRADABLE
   POLY(LACTIDE-CO-GLYCOLIDE) MICROSPHERES; POLYACRYL STARCH
   MICROPARTICLES; CELLULAR IMMUNE-RESPONSES; IN-VIVO ELECTROPORATION
AB This review focuses on the use of particulate delivery systems for the purposes of immunization. This includes poly(lactide-co-glycolide) (PLGA), ISCOMs, liposomes, niosomes, virosomes, chitosan, and other biodegradable polymers. These systems are evaluated in terms of their use as carriers for protein subunit and DNA vaccines. There is an extensive focus on recent literature, the understanding of biological interactions, and relation of this to our present understanding of immunological mechanisms of action. In addition, there is consideration of formulation techniques including emulsification, solvent diffusion, DNA complexation, and entrapment. The diversity of formulation strategies presented is a testament to the exponential growth and interest in the area of vaccine delivery systems. A case study for the application of particulate vaccine carriers is assessed in terms of vaccine development and recent insights into the possible design and application of vaccines against two of the most important pathogens that threaten mankind and for which there is a significant need: Mycobacterium tuberculosis and human immunodeficiency virus. This review addresses the rationale for the use of particulate delivery systems in vaccine design in the context of the diversity of carriers for DNA- and protein-based vaccines and their potential for application in terms of the critical need for effective vaccines.
C1 Aston Univ, Sch Life & Hlth Sci, Med Res Unit, Birmingham B4 7ET, W Midlands, England.
RP Perrie, Y (reprint author), Aston Univ, Sch Life & Hlth Sci, Med Res Unit, Birmingham B4 7ET, W Midlands, England.
EM y.perrie@aston.ac.uk
CR Aaron L, 2004, CLIN MICROBIOL INFEC, V10, P388, DOI 10.1111/j.1469-0691.2004.00758.x
   Abboushi N, 2004, J IMMUNOL, V173, P3193, DOI 10.4049/jimmunol.173.5.3193                                                     
   Agger EM, 2002, VACCINE, V21, P7, DOI 10.1016/S0264-410X(02)00447-4
   Ahmad S, 2004, SCAND J IMMUNOL, V60, P382, DOI 10.1111/j.0300-9475.2004.01490.x                                                
   Akbar Sk. Md. Fazle, 2004, Current Drug Targets - Infectious Disorders, V4, P93, DOI 10.2174/1568005043340885
   Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4
   Al-Attiyah R, 2004, CLIN EXP IMMUNOL, V138, P139, DOI 10.1111/j.1365-2249.2004.02609.x
   ALLISON AC, 1974, NATURE, V252, P252, DOI 10.1038/252252a0
   Alpar HO, 2005, ADV DRUG DELIVER REV, V57, P411, DOI 10.1016/j.addr.2004.09.004
   Alpar HO, 2002, CRIT REV THER DRUG, V19, P307, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i45.20
   Alpar HO, 2001, ADV DRUG DELIVER REV, V51, P173, DOI 10.1016/S0169-409X(01)00166-1
   ALPAR HO, 1996, P INT S CONTR REL BI, V23, P861
   ALPER CA, 1995, EXP CLIN IMMUNOGENET, V12, P171
   ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5                                                    
   ANDERSEN P, 1994, INFECT IMMUN, V62, P2536
   Andre S, 1998, J VIROL, V72, P1497
   Anwer K, 2004, J DRUG TARGET, V12, P215, DOI 10.1080/10611860410001724468
   Atuah KN, 2003, J MICROENCAPSUL, V20, P387, DOI 10.1080/0265204031000093041
   AZMIN MN, 1985, J PHARM PHARMACOL, V37, P237, DOI 10.1111/j.2042-7158.1985.tb05051.x                                              
   Bachmann MF, 1998, J IMMUNOL, V161, P5791
   BAILLIE AJ, 1985, J PHARM PHARMACOL, V37, P863, DOI 10.1111/j.2042-7158.1985.tb04990.x                                              
   Baldwin S. L., 1999, Tubercle and Lung Disease, V79, P251, DOI 10.1054/tuld.1998.0196
   Barnet SW, 2001, J VIROL, V75, P5526, DOI 10.1128/JVI.75.12.5526-5540.2001                                                
   Bartholdy C, 2004, J GEN VIROL, V85, P3017, DOI 10.1099/vir.0.80098-0
   Baud D, 2004, INFECT IMMUN, V72, P750, DOI 10.1128/IAI.72.2.750-756.2004
   Baudner BC, 2003, VACCINE, V21, P3837, DOI 10.1016/S0264-410X(03)00305-0
   Baylor NW, 2002, VACCINE, V20, pS18, DOI 10.1016/S0264-410X(02)00166-4                                                   
   Behr MA, 2002, LANCET INFECT DIS, V2, P86, DOI 10.1016/S1473-3099(02)00182-2                                                   
   Biedermann T, 2001, NAT IMMUNOL, V2, P1054, DOI 10.1038/ni725
   Bivas-Benita M, 2004, J CONTROL RELEASE, V100, P145, DOI 10.1016/j.jconrel.2004.08.008
   Bivas-Benita M, 2004, VACCINE, V22, P1609, DOI 10.1016/j.vaccine.2003.09.044
   Blessing T, 1998, P NATL ACAD SCI USA, V95, P1427, DOI 10.1073/pnas.95.4.1427
   Blom AG, 2004, VACCINE, V23, P743, DOI 10.1016/j.vaccine.2004.07.021
   Bondanza A, 2004, J EXP MED, V200, P1157, DOI 10.1084/jem.20040327
   Bouchemal K, 2004, INT J PHARM, V280, P241, DOI 10.1016/j.ijpharm.2004.05.016
   Bouchemal K, 2004, INT J PHARM, V269, P89, DOI 10.1016/j.ijpharm.2003.09.025
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Bramwell V W, 2003, J Drug Target, V11, P525
   Bramwell VW, 2002, IMMUNOLOGY, V106, P412, DOI 10.1046/j.1365-2567.2002.01448.x                                                
   Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000
   Brewer JM, 1998, J IMMUNOL, V161, P4000
   BREWER JM, 1992, IMMUNOLOGY, V75, P570
   Brewer TF, 2000, CLIN INFECT DIS, V31, pS64, DOI 10.1086/314072                                                                  
   Brownlie A, 2004, INT J PHARM, V274, P41, DOI 10.1016/j.ijpharm.2003.12.029
   Brunel F, 1999, VACCINE, V17, P2192, DOI 10.1016/S0264-410X(98)00492-7
   CALDERON C, 1994, J EXP MED, V180, P945, DOI 10.1084/jem.180.3.945
   Capecchi B, 2004, CURR ISSUES MOL BIOL, V6, P17
   Caputo A, 2004, VACCINE, V22, P2910, DOI 10.1016/j.vaccine.2003.12.025
   Carcaboso AM, 2004, PHARM RES, V21, P121, DOI 10.1023/B:PHAM.0000012159.20895.5b
   Chambers MA, 2004, VACCINE, V22, P1063, DOI 10.1016/j.vaccine.2003.05.002
   Chedid MG, 1997, HUM IMMUNOL, V58, P42, DOI 10.1016/S0198-8859(97)00209-7
   Chen Dexiang, 2002, Expert Rev Vaccines, V1, P265, DOI 10.1586/14760584.1.3.265
   Chen X, 2004, J IMMUNOL, V173, P2985, DOI 10.4049/jimmunol.173.5.2985                                                     
   Chen XQ, 2001, J MICROENCAPSUL, V18, P637
   Chew JL, 2003, VACCINE, V21, P2720, DOI 10.1016/S0264-410X(03)00228-7
   Chow YH, 1997, J VIROL, V71, P169
   CLEMENS JD, 1992, JAMA-J AM MED ASSOC, V267, P673, DOI 10.1001/jama.267.5.673
   Clements CJ, 2002, VACCINE, V20, pS24, DOI 10.1016/S0264-410X(02)00168-8
   Cohen J, 2003, SCIENCE, V299, P1290, DOI 10.1126/science.299.5611.1290
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Comanducci M, 2002, J EXP MED, V195, P1445, DOI 10.1084/jem.20020407
   Coombes AGA, 1998, BIOMATERIALS, V19, P1073, DOI 10.1016/S0142-9612(98)00035-0
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   Corbeil S, 2000, VACCINE, V18, P2817, DOI 10.1016/S0264-410X(00)00078-5
   Cosma A, 2003, VACCINE, V22, P21, DOI 10.1016/S0264-410X(03)00538-3
   Cui ZR, 2003, CRIT REV THER DRUG, V20, P103, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10                                   
   Cusi MG, 2000, VIROLOGY, V277, P111, DOI 10.1006/viro.2000.0605
   Dailey LA, 2005, J CONTROL RELEASE, V101, P137, DOI 10.1016/j.jconrel.2004.09.03
   Dale CJ, 2004, VACCINE, V23, P188, DOI 10.1016/j.vaccine.2004.05.024
   Dao DN, 2004, INFECT IMMUN, V72, P2067, DOI 10.1128/IAI.72.4.2067-2074.2004
   Datta M, 1999, INDIAN J MED RES, V110, P56
   DAVIS D, 1987, IMMUNOLOGY, V61, P229
   Dawson M, 2004, BIOTECHNOL PROGR, V20, P851, DOI 10.1021/bp0342553
   de Jonge MI, 2004, VACCINE, V22, P4021, DOI 10.1016/j.vaccine.2004.03.047
   DEGLING L, 1995, VACCINE, V13, P629, DOI 10.1016/0264-410X(94)00031-H                                                    
   Demissie A, 2004, J IMMUNOL, V172, P6938, DOI 10.4049/jimmunol.172.11.6938                                                    
   Denis-Mize KS, 2003, CELL IMMUNOL, V225, P12, DOI 10.1016/j.cellimm.2003.09.003
   Dentico P, 2002, VACCINE, V20, P3725, DOI 10.1016/S0264-410X(02)00356-0                                                   
   Dietrich G, 2003, INT J MED MICROBIOL, V292, P441, DOI 10.1078/1438-4221-00227
   Diwan M, 2001, J CONTROL RELEASE, V73, P233, DOI 10.1016/S0168-3659(01)00292-9
   Diwan Manish, 2003, J Drug Target, V11, P495
   DOAN LX, 2004, REV MED VIROL, V15, P75
   Duclos P, 2004, VACCINE, V22, P2059, DOI 10.1016/j.vaccine.2004.01.010
   Duclos P, 2001, DRUG SAFETY, V24, P1105, DOI 10.2165/00002018-200124150-00002
   Eckstein M, 1997, VACCINE, V15, P220, DOI 10.1016/S0264-410X(96)00137-5
   EGAN MA, 1995, J INFECT DIS, V171, P1623, DOI 10.1093/infdis/171.6.1623                                                       
   ELSTAD MR, 1991, AM J RESP CELL MOL, V4, P148, DOI 10.1165/ajrcmb/4.2.148                                                          
   Endresz V, 1999, VACCINE, V17, P50, DOI 10.1016/S0264-410X(98)00145-5
   Engler OB, 2004, VACCINE, V23, P58, DOI 10.1016/j.vaccine.2004.05.009
   Eyles JE, 2003, J CONTROL RELEASE, V86, P25, DOI 10.1016/S0168-3659(02)00296-1                                                   
   Eyles JE, 2001, VACCINE, V19, P4732, DOI 10.1016/S0264-410X(01)00220-1                                                   
   Falo LD, 1999, P ASSOC AM PHYSICIAN, V111, P211
   Fearon K, 2003, EUR J IMMUNOL, V33, P2114, DOI 10.1002/eji.200323948
   Feltquate DM, 1997, J IMMUNOL, V158, P2278
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9                                                   
   Fitzpatrick M, 2004, BRIT MED BULL, V69, P143, DOI 10.1093/bmb/ldh002
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Freitas S, 2004, J CONTROL RELEASE, V95, P185, DOI 10.1016/j.jconrel.2003.11.005
   FYNAN EF, 1993, DNA CELL BIOL, V12, P785, DOI 10.1089/dna.1993.12.785
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Galindo-Rodriguez S, 2004, PHARM RES, V21, P1428, DOI 10.1023/B:PHAM.0000036917.75634.be
   GARCON N, 1988, IMMUNOLOGY, V64, P743
   Garmory Helen S, 2003, J Drug Target, V11, P471
   Gautherot I, 2002, IMMUNOGENETICS, V54, P635, DOI 10.1007/s00251-002-0510-4
   Goh SL, 2004, BIOCONJUGATE CHEM, V15, P467, DOI 10.1021/bc034159n
   GREGORIADIS G, 1993, BIOCHIM BIOPHYS ACTA, V1147, P185, DOI 10.1016/0005-2736(93)90003-I
   Gregoriadis G, 1999, METHODS, V19, P156, DOI 10.1006/meth.1999.0841
   GREGORIADIS G, 1987, VACCINE, V5, P145, DOI 10.1016/0264-410X(87)90063-6
   Grundner C, 2004, VIROLOGY, V330, P233, DOI 10.1016/j.virol.2004.08.037
   Gursel M, 1997, IMMUNOL LETT, V55, P161, DOI 10.1016/S0165-2478(97)02699-0
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Hagglund S, 2004, VACCINE, V23, P646, DOI 10.1016/j.vaccine.2004.07.006
   Haining WN, 2004, J IMMUNOL, V173, P2578, DOI 10.4049/jimmunol.173.4.2578                                                     
   HANAFUSA S, 1995, CLIN ORTHOP RELAT R, P262
   Hanke T, 1998, J GEN VIROL, V79, P83, DOI 10.1099/0022-1317-79-1-83                                                       
   Hanke T, 1998, VACCINE, V16, P439, DOI 10.1016/S0264-410X(97)00226-0
   Hasegawa H, 2005, J MED VIROL, V75, P130, DOI 10.1002/jmv.20247
   Hassan Y, 1996, VACCINE, V14, P1581, DOI 10.1016/S0264-410X(96)00155-7
   Hattori Y, 2004, BIOCHEM BIOPH RES CO, V317, P992, DOI 10.1016/j.bbrc.2004.03.141
   He B, 2004, J IMMUNOL, V173, P4479, DOI 10.4049/jimmunol.173.7.4479                                                     
   Heller R, 1996, FEBS LETT, V389, P225, DOI 10.1016/0014-5793(96)00590-X
   Henke A, 2004, ANTIVIR RES, V64, P131, DOI 10.1016/j.antivirial.2004.06.009
   Holten-Andersen L, 2004, INFECT IMMUN, V72, P1608, DOI 10.1128/IAI.72.3.1608-1617.2004
   Homhuan A, 2004, EUR J PHARM SCI, V22, P459, DOI 10.1016/j.ejps.2004.05.005
   HORWITZ MA, 1995, P NATL ACAD SCI USA, V92, P1530, DOI 10.1073/pnas.92.5.1530                                                          
   Hovanessian AG, 2004, IMMUNITY, V21, P617, DOI 10.1016/j.immuni.2004.08.015
   Huang DB, 2004, J INFECTION, V49, P179, DOI 10.1016/j.jinf.2004.05.018
   Huang Y, 2004, J VIROL, V78, P12557, DOI 10.1128/JVI.78.22.12557-12565.2004
   Huang Y, 2003, VACCINE, V21, P2500, DOI 10.1016/S0264-410X(03)00044-6
   HUNT LA, 1988, J VIROL, V62, P3014
   Hussain Iftikhar, 2003, Current Drug Targets - Inflammation and Allergy, V2, P199, DOI 10.2174/1568010033484151
   Iqbal M, 2003, VACCINE, V21, P1478, DOI 10.1016/S0264-410X(02)00662-X
   IRVINE B, 2004, BRIT MED J, V329, pC979
   Jabbal-Gill I, 1999, VACCINE, V18, P238, DOI 10.1016/S0264-410X(99)00195-4
   Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X                                                   
   Jiao XM, 2004, J GEN VIROL, V85, P1545, DOI 10.1099/vir.0.79896-0
   Jilek S, 2004, EUR J PHARM BIOPHARM, V58, P491, DOI 10.1016/j.ejpb.2004.03.038
   Jilek S, 2004, J ALLERGY CLIN IMMUN, V114, P943, DOI 10.1016/j.jaci.2004.05.065
   Jilek S, 2004, PHARM RES, V21, P1240, DOI 10.1023/B:PHAM.0000033012.16152.5d                                              
   JISKOOT W, 1986, PHARM WEEKBLAD, V8, P259, DOI 10.1007/BF01960070                                                              
   Jobmann M, 2002, INT J PHARM, V242, P213, DOI 10.1016/S0378-5173(02)00160-6                                                   
   Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6
   Juffermans NP, 2000, AM J RESP CRIT CARE, V162, P486, DOI 10.1164/ajrccm.162.2.9911009                                                    
   Kadowaki S, 2000, VACCINE, V18, P2779, DOI 10.1016/S0264-410X(00)00087-6
   KAHL LP, 1989, J IMMUNOL, V142, P4441
   Kai E, 2004, PHARM RES, V21, P838, DOI 10.1023/B:PHAM.0000026437.32238.6f
   Kapusta J, 1999, FASEB J, V13, P1796
   Karpenko LI, 2004, VACCINE, V22, P1692, DOI 10.1016/j.vaccine.2003.09.050
   Kaur R, 2004, VACCINE, V22, P2776, DOI 10.1016/j.vaccine.2004.01.040
   Kawakami S, 2000, GENE THER, V7, P292, DOI 10.1038/sj.gt.3301089
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   Kenney Richard T, 2003, Expert Rev Vaccines, V2, P167
   Kent SJ, 1998, J VIROL, V72, P10180
   Kersten GFA, 2003, VACCINE, V21, P915, DOI 10.1016/S0264-410X(02)00540-6
   Kirby C J, 1984, J Microencapsul, V1, P33, DOI 10.3109/02652048409031535
   Kompella UB, 2001, CRIT REV THER DRUG, V18, P173
   KREUTER J, 1983, J PHARM SCI, V72, P1146, DOI 10.1002/jps.2600721009                                                          
   Kuo JHS, 2004, J PHARM PHARMACOL, V56, P27, DOI 10.1211/0022357022494
   Labrijn AF, 2003, J VIROL, V77, P10557, DOI 10.1128/JVI.77.19.10557-10565.2003
   Langer R, 1997, PHARMACEUT RES, V14, P840, DOI 10.1023/A:1012131329148
   Letvin NL, 2002, J CLIN INVEST, V110, P15, DOI 10.1172/JCI200215985
   Li BW, 2004, FILARIA J, V3, P1
   Li JR, 2003, VIRUS RES, V98, P63, DOI 10.1016/j.virusres.2003.08.017
   Li WM, 2001, VACCINE, V20, P148, DOI 10.1016/S0264-410X(01)00277-8
   Lima KM, 2003, GENE THER, V10, P678, DOI 10.1038/sj.gt.3301908
   Lima VMF, 2001, INFECT IMMUN, V69, P5305, DOI 10.1128/IAI.69.9.5305-5312.2001                                                 
   Lisowska K, 2003, ARCH IMMUNOL THER EX, V51, P367
   Little SR, 2004, P NATL ACAD SCI USA, V101, P9534, DOI 10.1079/pnas.0403549101
   Locher CP, 2004, DNA CELL BIOL, V23, P107, DOI 10.1089/104454904322759911                                                      
   Lombry C, 2004, PHARM RES, V21, P127, DOI 10.1023/B:PHAM.0000012160.00222.55
   Lomotan EA, 1997, VACCINE, V15, P1959, DOI 10.1016/S0264-410X(97)00108-4
   Ludewig B, 2000, VACCINE, V19, P23, DOI 10.1016/S0264-410X(00)00163-8
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168-3659(98)00097-2
   Mader D, 2000, VACCINE, V18, P1110, DOI 10.1016/S0264-410X(99)00373-4
   Mandal B, 2004, INT J PHARM, V269, P259, DOI 10.1016/j.ijpharm.2003.09.023
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Mao HQ, 1996, P INT S CONTROL REL, V23, P401
   MATSUSUE Y, 1995, CLIN ORTHOP RELAT R, P246
   Matzelle MM, 2004, BIOMATERIALS, V25, P295, DOI 10.1016/S0142-9612(03)00531-3
   Mazzaccaro RJ, 1996, P NATL ACAD SCI USA, V93, P11786, DOI 10.1073/pnas.93.21.11786                                                        
   McKenzie BS, 2004, INT IMMUNOL, V16, P1613, DOI 10.1093/intimm/dxh163
   Men Y, 1999, VACCINE, V17, P1047, DOI 10.1016/S0264-410X(98)00321-1
   Mesa C, 2004, IMMUNOL CELL BIOL, V82, P644, DOI 10.1111/j.1440-1711.2004.01279.x
   MIETHKE T, 1988, EUR J IMMUNOL, V18, P767, DOI 10.1002/eji.1830180517
   MILICH DR, 1988, IMMUNOL TODAY, V9, P380, DOI 10.1016/0167-5699(88)91239-X
   MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028
   Mischler R, 2002, VACCINE, V20, pB17, DOI 10.1016/S0264-410X(02)00512-1
   Mok H, 2005, MOL THER, V11, P66, DOI 10.1016/j.ymthe.2004.09.015                                                     
   Mollenkopf HJ, 2004, VACCINE, V22, P2690, DOI 10.1016/j.vaccine.2004.05.005
   Morein B, 2004, ADV DRUG DELIVER REV, V56, P1367, DOI 10.1016/j.addr.2004.02.004
   MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Moschos SA, 2004, IMMUNOL CELL BIOL, V82, P628, DOI 10.1111/j.1440-1711.2004.01280.x
   Moser Christian, 2003, Expert Rev Vaccines, V2, P189, DOI 10.1586/14760584.2.2.189
   Mumper R., 1995, P INT S CONTR REL BI, P178
   Murdan S, 1999, EUR J PHARM SCI, V8, P177, DOI 10.1016/S0928-0987(99)00014-7                                                   
   Murillo M, 2002, J CONTROL RELEASE, V85, P237, DOI 10.1016/S0168-3659(02)00276-6
   Nahde T, 2001, J GENE MED, V3, P353, DOI 10.1002/jgm.203                                                                 
   Nardin EH, 2004, INFECT IMMUN, V72, P6519, DOI [10.1128/IAI.72.11.6519-6527.2004, 10.1128/IAI.72.11.6519-6529.2004]
   Nicol F, 2002, GENE THER, V9, P1351, DOI 10.1038/sj.gt.3301806
   Nishi T, 1996, CANCER RES, V56, P1050
   NIWA T, 1994, J PHARM SCI, V83, P727, DOI 10.1002/jps.2600830527
   Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7
   O'Hagan DT, 2004, VACCINE, V23, P672, DOI 10.1016/j.vaccine.2004.06.037
   OHASHI Y, 1993, BIOCHEM BIOPH RES CO, V195, P1314, DOI 10.1006/bbrc.1993.2187
   Olsen AW, 2003, IMMUNOL LETT, V85, P207, DOI 10.1016/S0165-2478(02)00232-8
   Olsen AW, 2004, INFECT IMMUN, V72, P6148, DOI 10.1128/IAI.72.10.6148-6150.2004
   Oriss TB, 1999, J IMMUNOL, V162, P1999
   Otten G, 2003, J VIROL, V77, P6087, DOI 10.1128/JVI.77.10.6087-6092.2003
   Palmer GA, 2004, J VIROL, V78, P1101, DOI 10.1128/JVI.78.3.1101-1108.2004
   Pantaleo G, 2004, NAT MED, V10, P806, DOI 10.1038/nm0804-806
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   PARANT M, 1977, J INFECT DIS, V135, P771, DOI 10.1093/infdis/135.5.771                                                        
   Parmar MM, 1999, BBA-BIOMEMBRANES, V1421, P77, DOI 10.1016/S0005-2736(99)00118-2
   Peachman KK, 2003, METHODS, V31, P232, DOI 10.1016/S1046-2023(03)00137-3
   Pearse MJ, 2005, ADV DRUG DELIVER REV, V57, P465, DOI 10.1016/j.addr.2004.09.006
   Perrie Y, 2003, J Drug Target, V11, P555
   Perrie Y, 2004, INT J PHARM, V284, P31, DOI 10.1016/j.ijpharm.2004.07.012
   Perrie Y, 2002, J LIPOSOME RES, V12, P185, DOI 10.1081/LPR-120004792
   Perrie Y, 2000, BBA-GEN SUBJECTS, V1475, P125, DOI 10.1016/S0304-4165(00)00055-6
   Perrie Y, 2001, VACCINE, V19, P3301, DOI 10.1016/S0264-410X(00)00432-1
   Peyre M, 2004, J CONTROL RELEASE, V99, P345, DOI 10.1016/j.jconrel.2004.07.014
   Peyre M, 2004, VACCINE, V22, P2430, DOI 10.1016/j.vaccine.2003.11.068
   Prange R, 1999, VACCINE, V17, P617, DOI 10.1016/S0264-410X(98)00243-6
   Rainczuk A, 2004, INFECT IMMUN, V72, P5565, DOI 10.1128/IAI.72.10.5565-5573.2004
   REDFIELD RR, 1987, NEW ENGL J MED, V316, P673, DOI 10.1056/NEJM198703123161106
   Regnstrom K, 2003, GENE THER, V10, P1575, DOI 10.1038/sj.gt.3302054
   Rimmelzwaan GF, 2000, VACCINE, V19, P1180, DOI 10.1016/S0264-410X(00)00310-8                                                   
   Rocha CD, 2004, INT MICROBIOL, V7, P83
   Romoren K, 2004, FISH SHELLFISH IMMUN, V16, P251, DOI 10.1016/S1050-4648(03)00083-4
   Rook GAW, 2004, TRENDS IMMUNOL, V25, P483, DOI 10.1016/j.it.2004.06.005
   Roth A, 2004, BIOCONJUGATE CHEM, V15, P541, DOI 10.1021/bc034184t
   Roy K, 1999, NAT MED, V5, P387
   Russell DG, 2002, J CELL BIOL, V158, P421, DOI 10.1083/jcb.200205034
   SABIN AB, 1992, P NATL ACAD SCI USA, V89, P8852, DOI 10.1073/pnas.89.18.8852
   Sacksteder KA, 2002, EXPERT OPIN BIOL TH, V2, P741
   SALAZAR M, 1995, IMMUNOGENETICS, V41, P366, DOI 10.1007/BF00163994
   Santra S, 2004, P NATL ACAD SCI USA, V101, P11088, DOI 10.1073/pnas.0401954101
   Scanga CA, 2000, J EXP MED, V192, P347, DOI 10.1084/jem.192.3.347
   Schijns VEJC, 2003, VACCINE, V21, P829, DOI 10.1016/S0264-410X(02)00527-3
   Schirmbeck R, 2001, J IMMUNOL, V166, P1405, DOI 10.4049/jimmunol.166.2.1405                                                     
   Schmitt HJ, 2003, VACCINE, V21, P3653, DOI 10.1016/S0264-410X(03)00389-X
   Schoen C, 2004, INT J MED MICROBIOL, V294, P319, DOI 10.1016/j.ijmm.2004.03.001
   Scholl I, 2004, CLIN EXP ALLERGY, V34, P315, DOI 10.1111/j.1365-2222.2004.01884.x
   SCHROIT AJ, 1982, CANCER RES, V42, P161
   Schwach G, 2003, EUR J PHARM BIOPHARM, V56, P327, DOI 10.1016/S0939-6411(03)000096-1
   SCHWARZ D, 1984, BIOCHEM BIOPH RES CO, V121, P118, DOI 10.1016/0006-291X(84)90695-8                                                    
   Senel S, 2004, ADV DRUG DELIVER REV, V56, P1467, DOI 10.1016/j.addr.2004.02.007
   Sesardic D, 2004, VACCINE, V22, P2452, DOI 10.1016/j.vaccine.2003.11.071
   Sette AD, 2001, J IMMUNOL, V166, P1389, DOI 10.4049/jimmunol.166.2.1389                                                     
   Shephard MJ, 2003, RES VET SCI, V74, P187, DOI 10.1016/S0034-5288(02)00180-7
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Skapenko A, 2004, J IMMUNOL, V172, P6427, DOI 10.4049/jimmunol.172.10.6427                                                    
   Sonnenberg MG, 1997, INFECT IMMUN, V65, P4515
   Spiers ID, 2000, J PHARM PHARMACOL, V52, P1195, DOI 10.1211/0022357001777324
   Staib Caroline, 2004, Methods Mol Biol, V269, P77
   Standley SM, 2004, BIOCONJUGATE CHEM, V15, P1281, DOI 10.1021/bc049956f
   STIENEKER F, 1991, AIDS, V5, P431, DOI 10.1097/00002030-199104000-00012                                                
   Storni T, 2004, J IMMUNOL, V172, P1777, DOI 10.4049/jimmunol.172.3.1777                                                     
   Sun HF, 2003, VACCINE, V21, P849, DOI 10.1016/S0264-410X(02)00531-5                                                   
   Sun XL, 2002, VACCINE, V20, P1466, DOI 10.1016/S0264-410X(01)00476-5
   Takeda S, 2004, CLIN IMMUNOL, V112, P92, DOI 10.1016/j.clim.2004.04.001
   Tamber H, 2005, ADV DRUG DELIVER REV, V57, P357, DOI 10.1016/j.addr.2004.09.002
   TAN L, 1991, ASIAN PAC J ALLERGY, V9, P21
   Tanghe A, 2000, INFECT IMMUN, V68, P3854, DOI 10.1128/IAI.68.7.3854-3860.2000                                                 
   TARTAGLIA J, 1992, VIROLOGY, V188, P217, DOI 10.1016/0042-6822(92)90752-B
   Tartour E, 2002, VACCINE, V20, pA32, DOI 10.1016/S0264-410X(02)00385-7
   TENU JP, 1995, BIOCHEM BIOPH RES CO, V208, P295, DOI 10.1006/bbrc.1995.1337
   Tharanathan RN, 2003, CRIT REV FOOD SCI, V43, P61, DOI 10.1080/10408690390826455
   Thiele L, 2001, J CONTROL RELEASE, V76, P59, DOI 10.1016/S0168-3659(01)00412-6
   Tischer BK, 2002, J GEN VIROL, V83, P2367, DOI 10.1099/0022-1317-83-10-2367                                                    
   TITOMIROV AV, 1991, BIOCHIM BIOPHYS ACTA, V1088, P131, DOI 10.1016/0167-4781(91)90162-F                                                    
   Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x
   Tree JA, 2004, VACCINE, V22, P2438, DOI 10.1016/j.vaccine.2003.11.069
   Tucker TJ, 2004, BRIT MED J, V329, P454, DOI 10.1136/bmj.329.7463.454                                                        
   Turner J, 2000, INFECT IMMUN, V68, P1706, DOI 10.1128/IAI.68.3.1706-1709.2000
   Van der Lubben IM, 2002, J DRUG TARGET, V10, P449, DOI 10.1080/1061186021000038319
   Vandervoort J, 2001, PHARMAZIE, V56, P484
   Vanrompay D, 2001, IMMUNOLOGY, V103, P106, DOI 10.1046/j.1365-2567.2001.01215.x
   VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705                                                        
   Vila A, 2004, J AEROSOL MED, V17, P174, DOI 10.1089/0894268041457183
   VORDERMEIER HM, 1995, VACCINE, V13, P1576, DOI 10.1016/0264-410X(95)00084-E
   Waeckerle-Men Y, 2004, J IMMUNOL METHODS, V287, P109, DOI 10.1016/j.jim.2004.01.010
   Walter E, 1999, J CONTROL RELEASE, V61, P361, DOI 10.1016/S0168-3659(99)00151-0                                                   
   Walter F, 2004, BIOCHEM BIOPH RES CO, V315, P281, DOI 10.1016/j.bbrc.2004.01.057
   Wang SW, 2004, AIDS RES HUM RETROV, V20, P846, DOI 10.1089/0889222041725253                                                        
   Warzecha H, 2003, J VIROL, V77, P8702, DOI 10.1128/JVI.77.16.8702-8711.2003
   Weir NA, 2004, P I MECH ENG H, V218, P307, DOI 10.1243/0954411041932782
   Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635                                                     
   Wikingsson LD, 2002, VACCINE, V20, P3355, DOI 10.1016/S0264-410X(02)00288-8
   WYATT R, 1993, J VIROL, V67, P4557
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Xin Ke-Qin, 2002, Biological Procedures Online, V3, P91, DOI 10.1251/bpo27
   Xin KQ, 2001, HUM GENE THER, V12, P1047, DOI 10.1089/104303401750214276                                                      
   Xu W, 2004, VACCINE, V22, P3603, DOI 10.1016/j.vaccine.2004.03.033
   Yang ZJ, 2004, CANCER RES, V64, P6673, DOI 10.1158/0008-5472.CAN-04-1822
   Yoshida M, 2004, J BIOMED MATER RES A, V71A, P45, DOI 10.1002/jbm.a.30131
   YOSHIOKA T, 1995, J DRUG TARGET, V2, P533, DOI 10.3109/10611869509015924                                                       
   YOUNG D, 1986, INFECT IMMUN, V54, P177
   Young KR, 2004, VIROLOGY, V327, P262, DOI 10.1016/j.virol.2004.07.009
   Yu ZS, 2002, EUR J PHARM BIOPHARM, V54, P221, DOI 10.1016/S0939-6411(02)00050-4
   Yu ZS, 2004, EUR J PHARM BIOPHARM, V58, P529, DOI 10.1016/j.ejpb.2004.04.018
   Zhang L, 2004, BIOELECTROCHEMISTRY, V63, P369, DOI 10.1016/j.bioelechem.2003.11.011
   Zhao W, 2004, CHINESE MED J-PEKING, V117, P1217
   Zheng BJ, 2002, EUR J IMMUNOL, V32, P3294, DOI 10.1002/1521-4141(200211)32:11<3294::AID-IMMU3294>3.0.CO;2-D
   Zhu XJ, 1997, J IMMUNOL, V158, P5921
   Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x                                              
   Zucchelli S, 2000, J VIROL, V74, P11598, DOI 10.1128/JVI.74.24.11598-11607.2000
   ZUR MJ, 2000, J VIROL, V74, P2628
NR 309
TC 66
Z9 68
U1 0
U2 20
PU BEGELL HOUSE INC
PI NEW YORK
PA 145 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-4863
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 2005
VL 22
IS 2
BP 151
EP 214
DI 10.1615/CritRevTherDrugCarrierSyst.v22.i2.20
PG 64
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 921AT
UT WOS:000228737300002
PM 15862111
DA 2018-01-05
ER

PT J
AU Sommer, AP
   Cehreli, M
   Akca, K
   Sirin, T
   Piskin, E
AF Sommer, AP
   Cehreli, M
   Akca, K
   Sirin, T
   Piskin, E
TI Superadhesion: Attachment of nanobacteria to tissues - Model simulation
SO CRYSTAL GROWTH & DESIGN
LA English
DT Editorial Material
ID KIDNEY-STONE FORMATION; PRIMORDIAL BIOSYSTEMS; LIVING NANOVESICLES;
   CALCIFICATION; LIGHT; NANOSPHERES; HIV; REPLICATION; GROWTH; NERVE
AB Adhesion is common in the bacterial world and is partially mediated by slime. Nanobacteria (NB) seem to attach by slime as well as by the protecting nanocrystalline apatite shell, securing their survival in hostile milieus. Identification of NB in the human heart has brought the particles into the focus of material scientists. In view of the size distribution of the apatite nanovesicles (80-300 nm), simulation of their interaction with tissues can be performed via nanosuspensions and mirror-polished titanium substrates. Due to its wide biocompatibility, titanium is an ideal body tissue substitute. Here we show in a model simulation that the apatite nanovesicles are likely to perform also an anchoring function, specific to the mineral apatite. Anchoring may prevent solitary NB from elimination from the body, and enforce existing toxic potentials. The capacity of the apatite nanoparticles to bind to tissues in aqueous liquids, and the pronounced tendency of NB to form mineralized biofilms, indicate that NB could affect intracardiac fluid forces. Adhesion and protection represent a unique combination, which may stimulate the design of novel drug release systems based on apatite nanovesicles.
C1 Univ Ulm, Dept Biomat, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
   Hacettepe Univ, Fac Dent, Dept Prosthodont, TR-06100 Ankara, Turkey.
   Hacettepe Univ, Dept Chem Engn, TR-06532 Ankara, Turkey.
   Bioengn Div, TR-06532 Ankara, Turkey.
   BIYOMUH, TUBITAK, Ctr Excellence, TR-06532 Ankara, Turkey.
RP Sommer, AP (reprint author), Univ Ulm, Dept Biomat, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
CR Albrektsson T, 1982, ADV BIOMATER, P167
   Branemark R, 2001, J REHABIL RES DEV, V38, P175
   Cehreli MC, 2003, CLIN ORAL IMPLAN RES, V14, P269, DOI 10.1034/j.1600-0501.2003.140303.x                                               
   Ciftcioglu N, 1999, KIDNEY INT, V56, P1893, DOI 10.1046/j.1523-1755.1999.00755.x
   Deegan RD, 2000, PHYS REV E, V62, P756, DOI 10.1103/PhysRevE.62.756
   Deegan RD, 1997, NATURE, V389, P827, DOI 10.1038/39827                                                                   
   DENKOV ND, 1993, NATURE, V361, P26, DOI 10.1038/361026a0                                                                
   Farzaneh-Far A, 2001, HEART, V85, P13, DOI 10.1136/heart.85.1.13
   GLESBY M, 2003, J CLIN INFECT DIS S2, V37, pS91
   Hove JR, 2003, NATURE, V421, P172, DOI 10.1038/nature01282
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   KALIMO H, 1981, MUSCLE NERVE, V4, P228, DOI 10.1002/mus.880040310
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   KING RHM, 1988, NEUROPATH APPL NEURO, V14, P105, DOI 10.1111/j.1365-2990.1988.tb00874.x                                              
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   Mofid MM, 1997, PLAST RECONSTR SURG, V100, P14, DOI 10.1097/00006534-199707000-00003                                                
   Nicolson T, 2004, CRYST GROWTH DES, V4, P667, DOI 10.1021/cg0499010
   PAETAU A, 1976, ACTA NEUROPATHOL, V36, P185, DOI 10.1007/BF00685280                                                              
   RUCKENSTEIN E, 1976, J THEOR BIOL, V58, P439, DOI 10.1016/S0022-5193(76)80130-0
   RUCKENSTEIN E, 1977, J THEOR BIOL, V66, P147, DOI 10.1016/0022-5193(77)90317-4
   Sommer AP, 2004, J PHYS CHEM B, V108, P8, DOI 10.1021/jp0363747
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2004, J PROTEOME RES, V3, P667, DOI 10.1021/pr034122c
   Sommer AP, 2004, J PHYS CHEM B, V108, P8096, DOI 10.1021/jp0487049
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2003, NANO LETT, V3, P573, DOI 10.1021/nl0258269
   Sommer AP, 2003, NANO LETT, V3, P321, DOI 10.1021/nl025940r
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   Sommer AP, 2002, CRYST GROWTH DES, V2, P563, DOI 10.1021/cg0255725
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   Sommer AP, 2002, J PROTEOME RES, V1, P111, DOI 10.1021/pr025501t
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   SOMMER AP, J PROTEOME RES
   Thomas J, 2003, JAIDS-J ACQ IMM DEF, V33, P281, DOI 10.1097/00126334-200307010-00001                                                
   WILLIAMS DF, 1982, BIOCOMPATIBILITY CLI, V1, P10
   Yanagisawa T, 2004, J NEUROSURG, V100, P146, DOI 10.3171/jns.2004.100.1.0146
   Bell SJD, 2002, US Patent, Patent No. [6,355,271, 6355271]
NR 42
TC 10
Z9 10
U1 1
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1528-7483
J9 CRYST GROWTH DES
JI Cryst. Growth Des.
PD JAN-FEB
PY 2005
VL 5
IS 1
BP 21
EP 23
DI 10.1021/cg049812n
PG 3
WC Chemistry, Multidisciplinary; Crystallography; Materials Science,
   Multidisciplinary
SC Chemistry; Crystallography; Materials Science
GA 885ZU
UT WOS:000226196700003
DA 2018-01-05
ER

PT J
AU Silvestri, R
   Artico, M
AF Silvestri, R
   Artico, M
TI Indolyl aryl Sulfones (IASs): Development of highly potent NNRTIs active
   against wt-HIV-1 and clinically relevant drug resistant mutants
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE AIDS; HIV-1; reverse transcriptase; NNRTI; indolyl aryl sulfones
ID REVERSE-TRANSCRIPTASE INHIBITORS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   4,5,6,7-TETRAHYDRO-5-METHYLIMIDAZO<4,5,1-JK><1,4>BENZODIAZEPIN-2(1H)-ONE
   TIBO DERIVATIVES; ANTI-HIV ACTIVITY; STRUCTURE-BASED DESIGN;
   NONNUCLEOSIDE INHIBITORS; ANTI-HIV-1 ACTIVITY; OXATHIIN CARBOXANILIDE;
   WILD-TYPE; 3,4-DIHYDRO-2-ALKOXY-6-BENZYL-4-OXOPYRIMIDINES DABOS
AB Indolyl aryl sulfones (IASs) are a potent class of NNRTIs developed from L-737,126, a lead agent discovered by Merck AG. IAS derivatives are endowed with inhibitory activities against wt HIV-1 in the low nanomolar concentration range. Introduction of two methyl groups at positions 3 and 5 of the phenyl ring of the aryl sulfonyl moiety furnished IAS derivatives such as 5-chloro- or 5-bromo-3-[(3,5-dimethylphenyl)sulfonyl]indole-2-carboxyamide, which showed very potent and selective anti-HIV-1 activity against some mutants carrying NNRTI resistant mutations at positions 103 and 181 of the reverse transcriptase. IAS derivatives bearing 2-hydroxyethylcarboxyamide or 2-hydroxyethy1carboxyhydrazide groups at position 2 of the indole nucleus were more active than L-737,126 against the K103N-Y181C double mutant. A great improvement of antiviral activity against wt HIV-1 and resistant mutants was obtained by coupling 1-3 simple amino acids, such as glycine and alanine, in sequence, with the 3-[(3,5dimethylphenyl)sulfonyl]-1H-indole-2-carbonyl moiety. The transformation of the chain terminus into amide or hydrazide, produced short peptides with high selectivity and potent activity against wt HIV-1, and the viral mutants Y181C, K103N-Y181C and EFVR. IAS having two halogen atoms at the indole showed potent inhibitory activity against the Y181C and the EFVR resistant mutant strains. In particular, the introduction of a fluorine atom at position 4 of the indole ring notably contributed to improve the antiviral activities against both wt and the related resistant mutants. 5Nitro-IASs were highly active against wt HIV-1 and exhibited low cytotoxicity. Experimental data highlighted the class IAS derivatives as promising candidates for clinical trials.
C1 Univ Roma La Sapienza, Fdn Cenci Bolognetti, Dipartimento Studi Farmaceut, Inst Pasteur, I-00185 Rome, Italy.
RP Silvestri, R (reprint author), Univ Roma La Sapienza, Fdn Cenci Bolognetti, Dipartimento Studi Farmaceut, Inst Pasteur, Box36,Roma62,Piazzale A Moro 5, I-00185 Rome, Italy.
EM romano.silvestri@uniroma1.it
OI Silvestri, Romano/0000-0003-2489-0178
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1239
   Artico M, 1996, BIOORGAN MED CHEM, V4, P837, DOI 10.1016/0968-0896(96)00075-2                                                    
   ARTICO M, 1993, ANTIVIR CHEM CHEMOTH, V4, P361, DOI 10.1177/095632029300400608                                                      
   Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   ARTICO M, 1995, ARCH PHARM, V328, P223, DOI 10.1002/ardp.19953280304
   Artico M, 2000, J MED CHEM, V43, P1886, DOI 10.1021/jm9901125
   Artico M, 1996, J MED CHEM, V39, P522, DOI 10.1021/jm950568w
   Artico M, 1996, FARMACO, V51, P305
   ATKINSON JG, 1988, SYNTHESIS-STUTTGART, P480
   BACHELER L, 1998, 12 WORLD AIDS C GEN
   BALZARINI J, 1995, ANTIVIR RES, V27, P219, DOI 10.1016/0166-3542(95)00006-8
   BARRISH JC, 1993, ANN PROGR MED CHEM, V28, pCH14
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   BOTTA M, 1992, EUR J MED CHEM, V27, P251, DOI 10.1016/0223-5234(92)90009-P
   BRESLIN HJ, 1995, J MED CHEM, V38, P771, DOI 10.1021/jm00005a005
   BROKOW G, 1999, ANTIMICROB AGENTS CH, V43, P259
   Buckheit RW, 1997, ANTIMICROB AGENTS CH, V41, P831
   Buckheit RW, 1996, ANTIVIR CHEM CHEMOTH, V7, P243, DOI 10.1177/095632029600700504                                                      
   BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718                                                          
   Campiani G, 2002, CURR PHARM DESIGN, V8, P615, DOI 10.2174/1381612024607207                                                        
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Chan JH, 2001, J MED CHEM, V44, P1866, DOI 10.1021/jm0004906
   CHEN M, 1999, BIOORG MED CHEM LETT, V9, P1593
   Chen RX, 2004, CURR PHARM DESIGN, V10, P4065, DOI 10.2174/1381612043382404
   Cocuzza AJ, 2001, BIOORG MED CHEM LETT, V11, P1177, DOI 10.1016/S0960-894X(01)00192-5
   Corbett JW, 2000, BIOORG MED CHEM LETT, V10, P193, DOI 10.1016/S0960-894X(99)00672-1                                                   
   Corbett JW, 2000, J MED CHEM, V43, P2019, DOI 10.1021/jm990580e                                                               
   Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1
   Corbett JW, 1999, ANTIMICROB AGENTS CH, V43, P2893
   Corbett JW, 2001, BIOORG MED CHEM LETT, V11, P309, DOI 10.1016/S0960-894X(00)00662-4                                                   
   De Clercq E, 2002, MINI-REV MED CHEM, V2, P163, DOI 10.2174/1389557024605474
   De Clercq E, 1998, COLLECT CZECH CHEM C, V63, P449, DOI 10.1135/cccc19980449                                                            
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   DECAT A, 1963, J ORG CHEM, V28, P3426
   DeClercq E, 1995, FARMACO, V50, P735
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1990, TRENDS PHARMACOL SCI, V11, P1298
   Freimuth WW, 1996, ADV EXP MED BIOL, V394, P279
   Fujiwara M, 1999, ANTIVIR CHEM CHEMOTH, V10, P315, DOI 10.1177/095632029901000602                                                      
   Genin MJ, 1996, J MED CHEM, V39, P5267, DOI 10.1021/jm960269m
   Graul A., 1998, Drugs of the Future, V23, P133, DOI 10.1358/dof.1998.023.02.445974
   GUIDA WC, 1980, J ORG CHEM, V45, P3172, DOI 10.1021/jo01304a006                                                             
   Hahn HC, 2000, ARCH PHARM RES, V23, P315, DOI 10.1007/BF02975440                                                              
   Hajos Gyorgy, 2000, Drugs of the Future, V25, P47, DOI 10.1358/dof.2000.025.01.858638
   HANASAKI Y, 1995, J MED CHEM, V38, P2038, DOI 10.1021/jm00012a002
   HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045
   HO W, 1995, J MED CHEM, V38, P794, DOI 10.1021/jm00005a006
   Hoetelmans RMW, 1999, ANTIVIR THER, V4, P29
   Ijichi K, 1996, ANTIVIR RES, V31, P87, DOI 10.1016/0166-3542(96)00950-3
   Imamichi T, 2004, CURR PHARM DESIGN, V10, P4039, DOI 10.2174/1381612043382440                                                        
   Jung M, 2000, CURR MED CHEM, V7, P649, DOI 10.2174/0929867003374822                                                        
   Kelly TA, 1997, J MED CHEM, V40, P2430, DOI 10.1021/jm960837y                                                               
   KELLY TA, 1995, J MED CHEM, V38, P4839, DOI 10.1021/jm00024a011
   KETCHA DM, 1985, J ORG CHEM, V50, P5451, DOI 10.1021/jo00350a001                                                             
   King RW, 2002, ANTIMICROB AGENTS CH, V46, P1640, DOI 10.1128/AAC.46.6.1640-1646.2002
   Klunder JM, 1998, J MED CHEM, V41, P2960, DOI 10.1021/jm9707028
   KLUNDER JM, 1992, J MED CHEM, V35, P1887, DOI 10.1021/jm00088a027                                                             
   KUKLA MJ, 1991, J MED CHEM, V34, P3187, DOI 10.1021/jm00115a007
   KUKLA MJ, 1991, J MED CHEM, V34, P746, DOI 10.1021/jm00106a040
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   MAI A, 1995, J MED CHEM, V38, P3258, DOI 10.1021/jm00017a010
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   MASSA S, 1995, ANTIVIR CHEM CHEMOTH, V6, P1
   MCMAHON JB, 1993, ANTIMICROB AGENTS CH, V37, P754, DOI 10.1128/AAC.37.4.754                                                            
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   NEAMATI N, 1997, DRUG DISCOV TODAY, V2, P261
   Patel M, 1999, BIOORG MED CHEM LETT, V9, P3221, DOI 10.1016/S0960-894X(99)00565-X
   Pedersen OS, 1999, ANTIVIR CHEM CHEMOTH, V10, P285, DOI 10.1177/095632029901000601                                                      
   Pereira CF, 2004, CURR PHARM DESIGN, V10, P4005, DOI 10.2174/1381612043382459                                                        
   PROUDFOOT JR, 1995, J MED CHEM, V38, P1406, DOI 10.1021/jm00008a019
   PROUDFOOT JR, 1995, J MED CHEM, V38, P4830, DOI 10.1021/jm00024a010
   Ren JS, 2000, J BIOL CHEM, V275, P5633, DOI 10.1074/jbc.275.8.5633
   Robinson B., 1982, FISCHER INDOLE SYNTH
   ROMERO DL, 1994, J MED CHEM, V37, P999, DOI 10.1021/jm00033a018
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   Romero DL, 1996, J MED CHEM, V39, P3769, DOI 10.1021/jm960158n
   Sbardella G, 2001, ANTIVIR CHEM CHEMOTH, V12, P37, DOI 10.1177/095632020101200102                                                      
   Silvestri R, 2000, BIOORG MED CHEM LETT, V10, P253, DOI 10.1016/S0960-894X(99)00664-2
   Silvestri R, 2004, ARKIVOC, P26
   Silvestri R, 2003, J MED CHEM, V46, P2482, DOI 10.1021/jm0211063
   Silvestri R, 2002, J MED CHEM, V45, P1567, DOI 10.1021/jm010904a
   Silvestri R, 1996, FARMACO, V51, P425
   SILVESTRI R, 2004, IN PRESS J MED CHEM
   SILVESTRI R, 2002, ORG PREP PROCED INT, V34, P507
   SPENCE RA, 1995, SCIENCE, V267, P988, DOI 10.1126/science.7532321                                                         
   Stephens CE, 2001, BIOORGAN MED CHEM, V9, P1123, DOI 10.1016/S0968-0896(00)00333-3                                                   
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   TUCKER TJ, 1994, J MED CHEM, V37, P2437, DOI 10.1021/jm00041a023
   TURCKER TJ, 1996, METHOD ENZYMOL, V275, P440
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   *UNAIDS, 2002, UNAIDS REP GLOV HIV
   Vandamme AM, 1998, ANTIVIR CHEM CHEMOTH, V9, P187, DOI 10.1177/095632029800900301                                                      
   Venkatachalam TK, 2001, BIOORG MED CHEM LETT, V11, P523, DOI 10.1016/S0960-894X(01)00011-7
   Venkatachalam TK, 2000, ANTIVIR CHEM CHEMOTH, V11, P329, DOI 10.1177/095632020001100503                                                      
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
   YOUNG SD, 1995, BIOORG MED CHEM LETT, V5, P491, DOI 10.1016/0960-894X(95)00059-3                                                    
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   LACOLLA P, 2002, Patent No. 60401915
   ARTICO M, 1995, Patent No. 000812
   Williams T. A, 1992, Patent Application EP, Patent No. [0 530 907 A1, 0530907]
   Williams T. A, 1994, Patent Application WO, Patent No. [94/19321 A1, 9419321, WO9419321]
   ARTICO M, 1996, Patent No. 9633171
   LACOLLA P, 2002, Patent No. 10122252
NR 106
TC 19
Z9 21
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2005
VL 11
IS 29
BP 3779
EP 3806
DI 10.2174/138161205774580624                                              
          
PG 28
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 977YO
UT WOS:000232839600006
PM 16305512
DA 2018-01-05
ER

PT J
AU Sparnacci, K
   Laus, M
   Tondelli, L
   Bernardi, C
   Magnani, L
   Corticelli, F
   Marchisio, M
   Ensoli, B
   Castaldello, A
   Caputo, A
AF Sparnacci, K
   Laus, M
   Tondelli, L
   Bernardi, C
   Magnani, L
   Corticelli, F
   Marchisio, M
   Ensoli, B
   Castaldello, A
   Caputo, A
TI Core-shell microspheres by dispersion polymerization as promising
   delivery systems for proteins
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article
DE core-shell microspheres; dispersion polymerization; protein; vaccine;
   delivery
ID TAT-BASED VACCINES; DRUG-DELIVERY; ANIONIC MICROPARTICLES;
   METHYL-METHACRYLATE; CYNOMOLGUS MONKEYS; INTERACTION FORCES; HIV-1;
   SURFACE; RELEASE; NANOPARTICLES
AB Functional poly(methyl methacrylate) core-shell microspheres were prepared by dispersion polymerization. An appropriate selection of experimental parameters and in particular of the initiator and stabilizer amount and of the medium solvency power allowed a monodisperse sample as large as 600 nm to be prepared. To this purpose, low initiator concentration, high steric stabilizer amount and a low solvency power medium were employed. The microspheres present a core-shell structure in which the outer shell is constituted by the steric stabilizer which affords carboxylic groups able to interact with basic proteins, such as trypsin, whose adsorption is essentially driven by the carboxylic group density in the microsphere shell. Finally, fluorescent microspheres were prepared for biodistribution studies and shown to be readily taken up by the cells both in vitro and in vivo. These results suggest that these microspheres are promising delivery systems for the development of novel protein-based vaccines.
C1 Univ Piemonte Orinetale, Dept Environm & Life Sci, INSTM, I-15100 Alessandria, Italy.
   CNR, ISOF, I-40129 Bologna, Italy.
   CNR, IMM, I-40129 Bologna, Italy.
   Univ Ferrara, Dept Morphol & Embriol, I-44100 Ferrara, Italy.
   Ist Super Sanita, I-00161 Rome, Italy.
   Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35122 Padua, Italy.
RP Laus, M (reprint author), Univ Piemonte Orinetale, Dept Environm & Life Sci, INSTM, Spalto Marengo 33, I-15100 Alessandria, Italy.
EM laus@mfn.unipmn.it; tondelli@isof.cnr.it
RI Sparnacci, Katia/C-1138-2009; Ensoli, Barbara/J-9169-2016; tondelli,
   luisa/C-1414-2012
OI Sparnacci, Katia/0000-0003-2102-9649; Ensoli,
   Barbara/0000-0002-0545-8737; tondelli, luisa/0000-0002-3971-3361; Laus,
   Michele/0000-0002-4296-3732; Marchisio, Marco/0000-0003-3058-3422
CR ALONSO MJ, 1994, VACCINE, V12, P299, DOI 10.1016/0264-410X(94)90092-2
   Baldwin SP, 1998, ADV DRUG DELIVER REV, V33, P71, DOI 10.1016/S0169-409X(98)00021-0                                                   
   BARRET KEJ, 1975, DISPERSION POLYM ORG
   BARRETT KEJ, 1969, J POLYM SCI A1, V7, P2621, DOI 10.1002/pol.1969.150070913                                                      
   Bhalgat MK, 1998, J IMMUNOL METHODS, V219, P57, DOI 10.1016/S0022-1759(98)00121-5
   Bickel U, 2001, ADV DRUG DELIVER REV, V46, P247, DOI 10.1016/S0169-409X(00)00139-3
   Cafaro A, 1999, NAT MED, V5, P643
   Caputo A, 2004, CURR HIV RES, V2, P357, DOI 10.2174/1570162043350986
   CHEN SA, 1985, J POLYM SCI POL CHEM, V23, P2615, DOI 10.1002/pol.1985.170231005                                                      
   Couvreur P, 1997, ADV DRUG DELIVER REV, V28, P85, DOI 10.1016/S0169-409X(97)00052-5                                                   
   Crotts G, 1997, J CONTROL RELEASE, V44, P123, DOI 10.1016/S0168-3659(96)01511-8
   Fanales-Belasio E, 2002, DNA CELL BIOL, V21, P599, DOI 10.1089/104454902760330138                                                      
   Hanes J, 1997, ADV DRUG DELIVER REV, V28, P97, DOI 10.1016/S0169-409X(97)00053-7                                                   
   HEDLEY ML, 2000, EXPERT OPIN BIOL TH, V13, P906
   Hunter R. J., 1981, ZETA POTENTIAL COLLO
   Johansen P, 2000, EUR J PHARM BIOPHARM, V50, P129, DOI 10.1016/S0939-6411(00)00079-5
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   KOBAYASHI S, 1992, MAKROMOL CHEM, V193, P2355
   Kompella UB, 2001, ADV DRUG DELIVER REV, V46, P211, DOI 10.1016/S0169-409X(00)00137-X                                                   
   KREUTER J, 1976, J PHARM SCI, V65, P1624, DOI 10.1002/jps.2600651115                                                          
   KREUTER J, 1979, J PHARM SCI, V68, P1443, DOI 10.1002/jps.2600681129
   KREUTER J, 1983, J PHARM SCI, V72, P1146, DOI 10.1002/jps.2600721009                                                          
   Langer R, 2000, ACCOUNTS CHEM RES, V33, P94, DOI 10.1021/ar9800993
   Laus M, 1996, POLYMER, V37, P343, DOI 10.1016/0032-3861(96)81108-6                                                    
   Laus M, 2001, J CONTROL RELEASE, V72, P280
   LOVELL PA, 1997, EMULSION POLYM EMULS, P743
   Maggiorella MT, 2004, VACCINE, V22, P3258, DOI 10.1016/j.vaccine.2004.03.009
   Neri LM, 1997, MICROSC RES TECHNIQ, V36, P179, DOI 10.1002/(SICI)1097-0029(19970201)36:3<179::AID-JEMT6>3.0.CO;2-K
   O'Hagan DT, 1998, ADV DRUG DELIVER REV, V32, P225, DOI 10.1016/S0169-409X(98)00012-X                                                   
   OBER CK, 1987, J POLYM SCI POL CHEM, V25, P1395, DOI 10.1002/pola.1987.080250516                                                     
   SHEN S, 1993, J POLYM SCI POL CHEM, V31, P1393, DOI 10.1002/pola.1993.080310606                                                     
   Singh M, 2004, J PHARM SCI-US, V93, P273, DOI 10.1002/jps.10538
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/S0168-3659(00)00339-4                                                   
   Sparnacci K, 2002, MACROMOL CHEM PHYSIC, V203, P1364, DOI 10.1002/1521-3935(200207)203:10/11<1364::AID-MACP1364>3.0.CO;2-6                
   Uchida T, 1996, CHEM PHARM BULL, V44, P235
   van de Weert M, 2000, PHARMACEUT RES, V17, P1159, DOI 10.1023/A:1026498209874                                                         
   WIECHELMAN KJ, 1988, ANAL BIOCHEM, V175, P231, DOI 10.1016/0003-2697(88)90383-1
   Yasuda M, 2001, MACROMOLECULES, V34, P3261, DOI 10.1021/ma001690u
   Yoon JY, 1996, J COLLOID INTERF SCI, V177, P613, DOI 10.1006/jcis.1996.0075                                                          
   Yoon JY, 1999, COLLOID SURFACE A, V153, P413, DOI 10.1016/S0927-7757(98)00533-0                                                   
   ENSOLI B, 2003, Patent No. 032356245
NR 42
TC 20
Z9 22
U1 0
U2 12
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 2005
VL 16
IS 12
BP 1557
EP 1574
DI 10.1163/156856205774576673
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 991UZ
UT WOS:000233840900006
PM 16366337
DA 2018-01-05
ER

PT J
AU Haim, H
   Steiner, I
   Panet, A
AF Haim, H
   Steiner, I
   Panet, A
TI Synchronized infection of cell cultures by magnetically controlled virus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID RETROVIRAL VECTORS; GENE-TRANSFER; IN-VIVO; LENTIVIRAL VECTOR; PACKAGING
   SYSTEM; ADSORPTION; EXPRESSION; DELIVERY; RECEPTOR; BINDING
AB To override the diffusion-limited adsorption step of viral infection, we magnetically synchronized cell attachment. Human immunodeficiency virus type 1-based lentivirus preparations were rendered magnetically reactive by association with magnetite nanoparticles, 50 nm in diameter. Application of a magnetic field resulted in immediate redistribution of the viral inoculum to the cell-associated state and completion of the productive adsorption process within 1 min. Independent of adsorption time, viral concentration, and diffusion rate, infection subsequently progressed by the receptor-mediated entry mechanism. Synchronization of this rate-limiting step of infection may now be applied to analyze isolated events in the viral replication sequence.
C1 Hebrew Univ Jerusalem, Fac Med, Dept Virol, Hadassah Med Sch, IL-91120 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Hadassah Med Sch, Lab Neurovirol, Dept Neurol, Jerusalem, Israel.
RP Haim, H (reprint author), Hebrew Univ Jerusalem, Fac Med, Dept Virol, Hadassah Med Sch, IL-91120 Jerusalem, Israel.
EM hhaim@md.huji.ac.il
CR Alian A, 2002, J VIROL METHODS, V105, P1, DOI 10.1016/S0166-0934(02)00022-8
   ALLISON AC, 1960, BIOCHIM BIOPHYS ACTA, V40, P400, DOI 10.1016/0006-3002(60)91380-9
   Andreadis S, 2000, J VIROL, V74, P3431, DOI 10.1128/JVI.74.7.3431-3431.2000
   Axelrod B. N., 1999, J FORENSIC NEUROPSYC, V1, P15
   Blumenzweig I, 2002, BIOCHEM BIOPH RES CO, V292, P832, DOI 10.1006/bbrc.2002.6732
   BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033
   Chuck AS, 1996, HUM GENE THER, V7, P1527, DOI 10.1089/hum.1996.7.13-1527
   Davies MJ, 1997, APPL BIOCHEM BIOTECH, V68, P95, DOI 10.1007/BF02785983
   Davis HE, 2002, BIOPHYS CHEM, V97, P159, DOI 10.1016/S0301-4622(02)00057-1                                                   
   Dull T, 1998, J VIROL, V72, P8463
   Hamaguchi I, 2000, J VIROL, V74, P10778, DOI 10.1128/JVI.74.22.10778-10784.2000
   HARDINGHAM JE, 1995, MOL MED, V1, P789
   Higashikawa F, 2001, VIROLOGY, V280, P124, DOI 10.1006/viro.2000.0743
   Hughes C, 2001, MOL THER, V3, P623, DOI 10.1006/mthe.2001.0268
   LANDAU NR, 1992, J VIROL, V66, P5110
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lubbe AS, 2001, J SURG RES, V95, P200, DOI 10.1006/jsre.2000.6030
   Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382
   NICOSIA RF, 1994, IN VITRO CELL DEV-AN, V30A, P394
   O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000                                              
   Rouzina I, 1996, J PHYS CHEM-US, V100, P9977, DOI 10.1021/jp960458g                                                               
   Scherer F, 2002, GENE THER, V9, P102, DOI 10.1038/sj/gt/3301624
   Seisenberger G, 2001, SCIENCE, V294, P1929, DOI 10.1126/science.1064103                                                         
   Sharma S, 2000, J VIROL, V74, P10790, DOI 10.1128/JVI.74.22.10790-10795.2000
   Spitzer D, 2003, J VIROL, V77, P6070, DOI 10.1128/JVI.77.10.6070-6075.2003
   WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0                                                                
   Wu JZ, 1998, P NATL ACAD SCI USA, V95, P15169, DOI 10.1073/pnas.95.26.15169
   YU H, 1995, J VIROL, V69, P6557
   Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871
NR 29
TC 35
Z9 35
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 2005
VL 79
IS 1
BP 622
EP 625
DI 10.1128/JVI.79.1.622-625.2005
PG 4
WC Virology
SC Virology
GA 881YF
UT WOS:000225904700061
PM 15596857
OA gold
DA 2018-01-05
ER

PT J
AU Rawal, BD
   Pretorius, AM
AF Rawal, BD
   Pretorius, AM
TI "Nanobacterium sanguineum" - Is it a new life-form insearch of human
   ailment or commensal: Overview of its transmissibility and chemical
   means of intervention
SO MEDICAL HYPOTHESES
LA English
DT Article
ID KIDNEY-STONE FORMATION; TO-CHILD TRANSMISSION; VERTICAL TRANSMISSION;
   PSEUDOMONAS-AERUGINOSA; HIV-1; CALCIFICATION; INHIBITION; PREVENTION;
   TYPE-1; ACID
AB Morphological, cultural, and immuno-histochemical characteristics of "Nanobacterium sanguineum" (NB) described in the literature are reviewed. NB is reported to be a motile, Gram negative organism that divides by binary fission within a calcium-coated slimy shell; this yeast-like shell replicates by budding. It measures between 20 and 200 nm with a unique structure containing 16S ribosomal RNA. NB has been observed by electron microscopy in coronary artery plaques (CAD) and in kidney stones (KS) found in renal diseases. On the basis of supportive literature, we suggest that NB is not only present in the human body but also has auxiliary association with human ailments without a specific etiological role; anti-NB antibody has been detected in subjects with calcified lesions and inflammation in diverse ailments including choriodecidual inflammation in pregnancy, ovarian cancers, arthritis and even Alzheimer's disease. More recent report on the detection and vertical transmission of NB antigen and anti-NB antibody in HIV-infected mothers supports the view that NB might be an important opportunistic infective agent contributing to HIV pathology; we note that the presence of viable and transmitting NB was not studied and suggest further studies to establish vertical transmission of NB in HIV-infected persons. On the basis of the foregoing we suggest that NB possibly exacerbates human ailments and raise the question: Is NB a new life-form in search of human ailment or a commensal organism? Recognizing the presence of NB in the human body, we discuss clinical trials, reported in the literature relevant to its eradication, with a rectal suppository containing very high amounts of disodium EDTA and tetracycline. We suggest that tetracycline in this formulation acted in combination with EDTA, more as a chelating agent than an antibiotic; oxytetracycline- a non-chelating form of tetracycline-does not inhibit or kill NB. Evaluation of anti-NB effect of orally administrabte and potentially safer as well as therapeutically more acceptable chelating agent -ascorbic acid, acting alone or in combination with antibiotics-that eradicates another slime forming bacterium Pseudomonas aeruginosa - in children with cystic fibrosis, is suggested. (c) 2005 Elsevier Ltd. All rights reserved.
C1 HARIS, San Diego, CA 92129 USA.
   Univ Free State, Dept Med Microbiol, Natl Hlth Lab Serv, Bloemfontein, South Africa.
RP Rawal, BD (reprint author), HARIS, San Diego, CA 92129 USA.
EM bhupatrawal@yahoo.com
CR Brenner BG, 2000, ANN NY ACAD SCI, V918, P9
   Chen F, 2000, AM J HEALTH-SYST PH, V57, P1616
   Ciftcioglu N, 2005, KIDNEY INT, V67, P483, DOI 10.1111/j.1523-1755.2005.67105.x                                                
   Ciftcioglu N, 1999, KIDNEY INT, V56, P1893, DOI 10.1046/j.1523-1755.1999.00755.x
   Ciftcioglu N, 2002, ANTIMICROB AGENTS CH, V46, P2077, DOI 10.1128/AAC.46.7.2007-2086.2002
   CONTE VA, 2001, ARCH ESPAN UROL, V54, P855
   COUTSOUDIS A, 2000, 13 INT AIDS C JUL 9
   Dabis F, 2000, HEALTH POLICY PLANN, V15, P34, DOI 10.1093/heapol/15.1.34
   Ea Hang-Korng, 2004, Curr Rheumatol Rep, V6, P221, DOI 10.1007/s11926-004-0072-6
   Friedland R P, 1990, Int Psychogeriatr, V2, P36
   Grosch-Worner I, 2000, AIDS, V14, P2903
   Hjelle JT, 2000, KIDNEY INT, V57, P2360, DOI 10.1046/j.1523-1755.2000.00096.x                                                
   Kajander EO, 2003, UROL RES, V31, P47, DOI 10.1007/s002440-003-0304-7
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   Khurana C, 2003, AM HEART J, V145, P724, DOI 10.1067/mhj.2003.99
   Kumar Arun, 2003, Nepal Med Coll J, V5, P102
   Maniscalco Benedict S., 2004, Pathophysiology, V11, P95, DOI 10.1016/j.pathophys.2004.06.001
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   Mofenson Lynne M, 2003, Semin Pediatr Infect Dis, V14, P295, DOI 10.1053/j.spid.2003.09.003
   MULHALL D, 2005, CALCIUM BOMB NANOBAC, P26
   Noack B, 2001, J PERIODONTOL, V72, P1221, DOI 10.1902/jop.2000.72.9.1221                                                      
   Pretorius AM, 2004, HIV MED, V5, P391, DOI 10.1111/j.1468-1293.2004.00242.x
   RAWAL BD, 1971, APPL MICROBIOL, V21, P367
   RAWAL BD, 1974, MED J AUSTRALIA, V1, P169
   RAWAL BD, 1974, IRCS MED SCI, V2, P1670
   Regensberg L, 2000, S AFR MED J, V90, P1093
   Scarlatti G, 2004, AIDS REV, V6, P67
   Sedivy R, 2003, APMIS, V111, P951, DOI 10.1034/j.1600-0463.2003.1111006.x
   Shoskes DA, 2005, J UROLOGY, V173, P474, DOI 10.1097/01.ju.0000150062.60633.b2
   Vermund Sten H, 2004, Top HIV Med, V12, P130
   Wen Y, 2005, CHINESE MED J-PEKING, V118, P421
NR 31
TC 5
Z9 5
U1 1
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2005
VL 65
IS 6
BP 1062
EP 1066
DI 10.1016/j.mehy.2005.06.024
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 978HY
UT WOS:000232865400012
PM 16122881
DA 2018-01-05
ER

PT S
AU Bachis, A
   Mocchetti, I
AF Bachis, A
   Mocchetti, I
BE Slikker, W
   Andrews, RJ
   Trembly, B
TI Brain-derived neurotrophic factor is neuroprotective against human
   immunodeficiency virus-1 envelope proteins
SO NEUROPROTECTIVE AGENTS
SE ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article; Proceedings Paper
CT 7th International Conference on Neuroprotective Agents
CY NOV 14-19, 2004
CL Pacific Grove, CA
SP Cent Arkansas Chapter SIGMA XI, Natl Ctr Toxicol Res, FDA, US EPA
DE AIDS; apoptosis; BDNF; caspase-3; gp120BaL; gp120IIIB; neuroprotection;
   RANTES
ID CHEMOKINE RECEPTOR CXCR4; METHYL-D-ASPARTATE; NEURONAL APOPTOSIS; HIV-1
   INFECTION; DOPAMINERGIC-NEURONS; GP120 NEUROTOXICITY; NERVOUS-SYSTEM;
   CELL-DEATH; RAT-BRAIN; IN-VIVO
AB Human immunodeficiency virus type 1 (HIV-1)-positive patients in the late phase of infection develop AIDS dementia complex, an array of neurological complications that include extrapyramidal symptoms, cognitive impairments, and psychiatric disturbances. Brains of these patients exhibit brain injury. The HIV-1 envelope glycoprotein 120 (gp120) has been suggested to be a causal agent of neuronal loss; however, several strains of gp120 exist during the infection and the relative neurotoxic potential of each strain is presently unknown. Using cultured cerebellar granule neurons, we determined whether two strains of gp120, gp120IIIB and gp120BaL, which bind to CXCR4 and CCR5 chemokine receptors, respectively, induce cell death. Apoptotic cell death and activated caspase-3 were evident within a few hours in neurons exposed to low nanomolar concentrations of either gp120IIIB or gp120BaL. However, the neurotoxic effect of gp120IIIB was more rapid and occurred at lower concentrations than that of gp120BaL, suggesting that cerebellar granule cells may be more sensitive to apoptotic signals activated by the CXCR4 receptor. The neurotrophin brain-derived neurotrophic factor (BDNF) has been shown to block neuronal apoptosis. Therefore, we examined whether BDNF protects against both strains of gp120. Preexposure of cerebellar granule cells to BDNF prior to both gp120s decreased apoptosis and consequently enhanced their survival. These findings underlie the rationale for exploring the ability of BDNF to reduce HIV-1-mediated neuronal cell death in vivo.
C1 Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA.
RP Mocchetti, I (reprint author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,Room EP04,Box 571464, Washington, DC 20057 USA.
EM moccheti@georgetown.edu
FU NINDS NIH HHS [NS047977, NS040670]
CR Acquas E, 2004, NEUROTOX RES, V5, P605
   ALTAR CA, 1992, P NATL ACAD SCI USA, V89, P11347, DOI 10.1073/pnas.89.23.11347
   Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606
   AYLWARD EH, 1995, AM J PSYCHIAT, V152, P987
   Bachis A, 2004, J NEUROSCI RES, V75, P75, DOI 10.1002/jnr.10826
   Bachis A, 2003, J NEUROSCI, V23, P5715
   Bachis Alessia, 2002, Neurotox Res, V4, P225, DOI 10.1080/10298420290015836
   BAGETTA G, 1995, BIOCHEM BIOPH RES CO, V211, P130, DOI 10.1006/bbrc.1995.1787
   Banisadr G, 2002, EUR J NEUROSCI, V16, P1661, DOI 10.1046/j.1460-9568.2002.02237.x
   Bansal AK, 2000, BRAIN RES, V879, P42, DOI 10.1016/S0006-8993(00)02725-6
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490                                                                   
   Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009
   Corasaniti MT, 1998, BIOCHEM PHARMACOL, V56, P153, DOI 10.1016/S0006-2952(98)00044-6                                                   
   Corasaniti MT, 2001, J NEUROCHEM, V79, P1
   DALPAN GJ, 1992, NEUROLOGY, V42, P2125, DOI 10.1212/WNL.42.11.2125                                                          
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   Dreyer EB, 1995, EUR J NEUROSCI, V7, P2502, DOI 10.1111/j.1460-9568.1995.tb01048.x
   Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8
   EVERALL IP, 1995, NAT MED, V1, P1174, DOI 10.1038/nm1195-1174
   Gelbard Harris A., 1995, Current Opinion in Pediatrics, V7, P655
   Han BH, 2000, NEUROBIOL DIS, V7, P38
   He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0
   Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1
   Hoffman TL, 2000, P NATL ACAD SCI USA, V97, P11215, DOI 10.1073/pnas.190274097                                                          
   HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0
   James HJ, 1999, NEUROPATH APPL NEURO, V25, P380
   Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212
   Klein RS, 1999, J IMMUNOL, V163, P1636
   Kolson DL, 2002, CLIN LAB MED, V22, P703, DOI 10.1016/S0272-2712(02)00009-4
   LINDHOLM D, 1993, EUR J NEUROSCI, V5, P1455, DOI 10.1111/j.1460-9568.1993.tb00213.x
   LopezVillegas D, 1997, P NATL ACAD SCI USA, V94, P9854, DOI 10.1073/pnas.94.18.9854
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   Maragos WF, 2003, TAT NEUROSCIENCE, V117, P43
   Marini AM, 1998, J BIOL CHEM, V273, P29394, DOI 10.1074/jbc.273.45.29394                                                        
   Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618
   McArthur JC, 2003, J NEUROVIROL, V9, P205, DOI 10.1080/13550280390194109
   Meucci O, 1996, J NEUROSCI, V16, P4080
   Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500                                                        
   Mocchetti Italo, 2004, Critical Reviews in Neurobiology, V16, P51, DOI 10.1615/CritRevNeurobiol.v16.i12.50
   Neuenburg JK, 2002, JAIDS, V31, P171, DOI 10.1097/01.QAI.0000030047.72209.D3
   Ramirez SH, 2001, J NEUROCHEM, V78, P874, DOI 10.1046/j.1471-4159.2001.00467.x                                                
   REICHARDT LF, 2001, NEUROTROPHIC FACTORS
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Stout JC, 1998, ARCH NEUROL-CHICAGO, V55, P161, DOI 10.1001/archneur.55.2.161                                                       
   THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593                                                    
   Toggas SM, 1996, CURR TOP MICROBIOL, V206, P223
   van der Meer P, 2000, EXP MOL PATHOL, V69, P192, DOI 10.1006/exmp.2000.2336
   WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613
   Zheng JL, 1999, J NEUROIMMUNOL, V98, P185, DOI 10.1016/S0165-5728(99)00049-1
NR 52
TC 27
Z9 29
U1 0
U2 2
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-578-8
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2005
VL 1053
BP 247
EP 257
DI 10.1196/annals.1344.022
PG 11
WC Multidisciplinary Sciences; Clinical Neurology; Neurosciences;
   Pharmacology & Pharmacy
SC Science & Technology - Other Topics; Neurosciences & Neurology;
   Pharmacology & Pharmacy
GA BDR63
UT WOS:000235109800027
PM 16179530
DA 2018-01-05
ER

PT J
AU Silverman, SK
AF Silverman, SK
TI In vitro selection, characterization, and application of deoxyribozymes
   that cleave RNA
SO NUCLEIC ACIDS RESEARCH
LA English
DT Review
ID SINGLE-STRANDED-DNA; SEQUENCE-SPECIFIC CLEAVAGE; HIV-1 GENE-EXPRESSION;
   DIVALENT METAL-IONS; CATALYTIC DNA; MESSENGER-RNA; GOLD NANOPARTICLES;
   BOND FORMATION; NUCLEIC-ACIDS; COLORIMETRIC BIOSENSOR
AB Over the last decade, many catalytically active DNA molecules (deoxyribozymes; DNA enzymes) have been identified by in vitro selection from random-sequence DNA pools. This article focuses on deoxyribozymes that cleave RNA substrates. The first DNA enzyme was reported in 1994 and cleaves an RNA linkage. Since that time, many other RNA-cleaving deoxyribozymes have been identified. Most but not all of these deoxyribozymes require a divalent metal ion cofactor such as Mg2+ to catalyze attack by a specific RNA 2'-hydroxyl group on the adjacent phosphodiester linkage, forming a 2',3'-cyclic phosphate and a 5'-hydroxyl group. Several deoxyribozymes that cleave RNA have utility for in vitro RNA biochemistry. Some DNA enzymes have been applied in vivo to degrade mRNAs, and others have been engineered into sensors. The practical impact of RNA-cleaving deoxyribozymes should continue to increase as additional applications are developed.
C1 Univ Illinois, Dept Chem, Urbana, IL 61801 USA.
RP Silverman, SK (reprint author), Univ Illinois, Dept Chem, 600 S Mathews Ave, Urbana, IL 61801 USA.
EM scott@scs.uiuc.edu
OI Silverman, Scott/0000-0001-8166-3460
CR Achenbach JC, 2005, ANAL CHIM ACTA, V534, P41, DOI 10.1016/j.aca.2004.03.080
   Achenbach JC, 2004, CURR PHARM BIOTECHNO, V5, P321, DOI 10.2174/1389201043376751
   Achenbach TV, 2003, CHEMBIOCHEM, V4, P928, DOI 10.1002/cbic.200300708
   Ackermann JM, 2005, BIOCHEMISTRY-US, V44, P2143, DOI 10.1021/bi047918d
   Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905
   Beaudry A, 2000, CHEM BIOL, V7, P323, DOI 10.1016/S1074-5521(00)00110-1
   Bell MA, 2002, BIOCHEMISTRY-US, V41, P15327, DOI 10.1021/bi0267386
   Bergman NH, 2000, BIOCHEMISTRY-US, V39, P3115, DOI 10.1021/bi992654u                                                               
   Bonaccio M, 2004, NUCLEIC ACIDS RES, V32, P916, DOI 10.1093/nar/gkh250
   Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0
   BREAKER RR, 1995, CHEM BIOL, V2, P655, DOI 10.1016/1074-5521(95)90028-4
   Brown AK, 2003, BIOCHEMISTRY-US, V42, P7152, DOI 10.1021/bi027332w
   Cairns M J, 2000, Nucleic Acids Res, V28, pE9, DOI 10.1093/nar/28.3.e9
   Cairns MJ, 2003, NUCLEIC ACIDS RES, V31, P2883, DOI 10.1093/nar/gkg378
   Cairns MJ, 1999, NAT BIOTECHNOL, V17, P480
   Cairns MJ, 2002, CURR DRUG TARGETS, V3, P269, DOI 10.2174/1389450023347722                                                        
   Carrigan MA, 2004, BIOCHEMISTRY-US, V43, P11446, DOI 10.1021/bi049898l
   Cech TR, 2000, SCIENCE, V289, P878, DOI 10.1126/science.289.5481.878                                                    
   CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771
   Chen F, 2004, NUCLEIC ACIDS RES, V32, P2336, DOI 10.1093/nar/gkh547
   Chen Y, 2004, ANGEW CHEM INT EDIT, V43, P3554, DOI 10.1002/anie.200453779
   Chen Y, 2003, GENE THER, V10, P1776, DOI 10.1038/sj.gt.3302068
   Chen Y, 2003, BIOTECHNIQUES, V34, P167
   Chen Y, 2000, ANTISENSE NUCLEIC A, V10, P415, DOI 10.1089/oli.1.2000.10.415
   Cheong HK, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh081
   Chu VT, 2001, EMBO J, V20, P6866, DOI 10.1093/emboj/20.23.6866
   Chu VT, 1998, RNA, V4, P1186, DOI 10.1017/S1355838298980724
   Cieslak M, 2003, J BIOL CHEM, V278, P47987, DOI 10.1074/jbc.M300504200
   Coleman TM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh007
   Collins CA, 2000, NAT STRUCT BIOL, V7, P850
   Conn MM, 1996, J AM CHEM SOC, V118, P7012, DOI 10.1021/ja961249c                                                               
   Cruz RPG, 2004, CHEM BIOL, V11, P57, DOI 10.1016/j.chembiol.2003.12.012
   Curtis EA, 2001, RNA, V7, P546, DOI 10.1017/S1355838201002357
   DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013
   DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011                                                             
   Dass CR, 2002, ANTISENSE NUCLEIC A, V12, P289, DOI 10.1089/108729002761381276
   Datta HJ, 2001, NUCLEIC ACIDS RES, V29, P5140, DOI 10.1093/nar/29.24.5140
   Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Emilsson GM, 2002, CELL MOL LIFE SCI, V59, P596, DOI 10.1007/s00018-002-8452-4
   Fahmy RG, 2004, NUCLEIC ACIDS RES, V32, P2281, DOI 10.1093/nar/gkh543
   Faulhammer D, 1997, J MOL BIOL, V269, P188, DOI 10.1006/jmbi.1997.1036
   Faulhammer D, 1996, ANGEW CHEM INT EDIT, V35, P2837, DOI 10.1002/anie.199628371                                                          
   Feldman AR, 2001, J MOL BIOL, V313, P283, DOI 10.1006/jmbi.2001.5058
   Flynn-Charlebois A, 2003, J AM CHEM SOC, V125, P2444, DOI 10.1021/ja028774y
   GESTELAND RF, RNA WORLD
   Geyer CR, 1997, CHEM BIOL, V4, P579, DOI 10.1016/S1074-5521(97)90244-1
   Geyer CR, 1998, J MOL BIOL, V275, P483, DOI 10.1006/jmbi.1997.1475
   GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0                                                                
   Gugliotti LA, 2004, SCIENCE, V304, P850, DOI 10.1126/science.1095678
   He QC, 2002, BIOMACROMOLECULES, V3, P69, DOI 10.1021/bm010095c
   Hiley SL, 2002, EMBO J, V21, P4691, DOI 10.1093/emboj/cdf462
   Hjiantoniou E, 2003, BIOCHEM BIOPH RES CO, V300, P178, DOI 10.1016/S0006-291X(02)02804-8
   Hoadley KA, 2005, BIOCHEMISTRY-US, V44, P9217, DOI 10.1021/bi05046g
   Ismagilov RF, 2003, ANGEW CHEM INT EDIT, V42, P4130, DOI 10.1002/anie.200301660
   Johnson AK, 2005, BIOCHEMISTRY-US, V44, P10702, DOI 10.1021/bi0504815
   Joyce GF, 2004, ANNU REV BIOCHEM, V73, P791, DOI 10.1146/annurev.biochem.73.011303.073717
   JOYCE GF, 2001, METHOD ENZYMOL, V3401, P503
   Kabuli Majid, 2004, Hematol J, V5, P426, DOI 10.1038/sj.thj.6200535
   Khachigian LM, 2002, CURR OPIN MOL THER, V4, P119
   Kierzek E, 2005, NUCLEIC ACIDS RES, V33, P5082, DOI 10.1093/nar/gki789
   Kohler U, 1999, J MOL BIOL, V285, P1935, DOI 10.1006/jmbi.1998.2447
   Konforti BB, 1998, EMBO J, V17, P7105, DOI 10.1093/emboj/17.23.7105                                                        
   Kubo T, 2005, BIOORG MED CHEM LETT, V15, P167, DOI 10.1016/j.bmcl.2004.10.009
   Kurreck J, 2002, J BIOL CHEM, V277, P7099, DOI 10.1074/jbc.M107206200
   Lermer L, 2002, J AM CHEM SOC, V124, P9960, DOI 10.1021/ja0205075
   Li J, 2000, J AM CHEM SOC, V122, P10466, DOI 10.1021/ja0021316
   Li J, 2000, NUCLEIC ACIDS RES, V28, P481, DOI 10.1093/nar/28.2.481
   Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p                                                               
   Li YF, 1996, NAT STRUCT BIOL, V3, P743, DOI 10.1038/nsb0996-743                                                             
   Liu J, 2005, J AM CHEM SOC, V127, P12677, DOI 10.1021/ja053567u
   Liu JW, 2003, J AM CHEM SOC, V125, P6642, DOI 10.1021/ja034775u
   Liu JW, 2004, ANAL CHEM, V76, P1627, DOI 10.1021/ac0351769
   Liu JW, 2004, J AM CHEM SOC, V126, P12298, DOI 10.1021/ja046628h
   Liu JW, 2004, CHEM MATER, V16, P3231, DOI 10.1021/cm049453j
   Liu JW, 2002, J AM CHEM SOC, V124, P15208, DOI 10.1021/ja027647z
   Liu JW, 2003, ANAL CHEM, V75, P6666, DOI 10.1021/AC034924r
   Liu Y, 2004, J MOL BIOL, V341, P887, DOI 10.1016/j.jmb.2004.06.060
   Liu ZJ, 2003, J AM CHEM SOC, V125, P7539, DOI 10.1021/ja035208+
   Lu Y, 2003, BIOSENS BIOELECTRON, V18, P529, DOI 10.1016/S0956-5663(03)00013-7
   Lu Y, 2002, CHEM-EUR J, V8, P4589
   Mei SHJ, 2003, J AM CHEM SOC, V125, P412, DOI 10.1021/ja0281232
   Mitchell A, 2004, NUCLEIC ACIDS RES, V32, P3065, DOI 10.1093/nar/gkh626
   Murray JB, 1998, CHEM BIOL, V5, P587, DOI 10.1016/S1074-5521(98)90116-8                                                   
   Nowakowski J, 1999, ACTA CRYSTALLOGR D, V55, P1885, DOI 10.1107/S0907444999010550
   Nowakowski J, 1999, NAT STRUCT BIOL, V6, P151
   Nunamaker EA, 2003, AM J PHYSIOL-HEART C, V285, pH2240, DOI 10.1152/ajpheart.00350.2003
   Nutiu R, 2004, CHEM-EUR J, V10, P1868, DOI 10.1002/cheem.200305470
   O'Rear JL, 2001, RNA, V7, P537, DOI 10.1017/S1355838201002461                                                       
   Ohbayashi T, 2005, ORG BIOMOL CHEM, V3, P2463, DOI 10.1039/b504330a
   Okumoto Y, 2002, BIOCHEMISTRY-US, V41, P2769, DOI 10.1021/bi011909c
   Okumoto Y, 2000, J INORG BIOCHEM, V82, P189, DOI 10.1016/S0162-0134(00)00159-8                                                   
   Opalinska JB, 2002, NAT REV DRUG DISCOV, V1, P503, DOI 10.1038/nrd837
   Ordoukhanian P, 2002, J AM CHEM SOC, V124, P12499, DOI 10.1021/ja027467p
   Ota N, 1998, NUCLEIC ACIDS RES, V26, P3385, DOI 10.1093/nar/26.14.3385                                                          
   PAN T, 1994, BIOCHEMISTRY-US, V33, P9561, DOI 10.1021/bi00198a023
   Pan WH, 2001, RNA, V7, P610, DOI 10.1017/S1355838201001595
   Peracchi A, 2005, J MOL BIOL, V352, P783, DOI 10.1016/j.jmb.2005.07.059
   Peracchi A, 2005, CHEMBIOCHEM, V6, P1316, DOI 10.1002/cbic.200500098
   Peracchi A, 2000, J BIOL CHEM, V275, P11693, DOI 10.1074/jbc.275.16.11693
   Perreault DM, 1997, ANGEW CHEM INT EDIT, V36, P432, DOI 10.1002/anie.199704321                                                          
   Perrin DM, 2001, J AM CHEM SOC, V123, P1556, DOI 10.1021/ja003290s
   Phylactou LA, 2000, ADV DRUG DELIVER REV, V44, P97, DOI 10.1016/S0169-409X(00)00088-0
   PRUDENT JR, 1994, SCIENCE, V264, P1924
   Pun SH, 2004, CANCER BIOL THER, V3, P641, DOI 10.4161/cbt.3.7.918                                                             
   Purtha WE, 2005, J AM CHEM SOC, V127, P13124, DOI 10.1021/ja0533702
   Pyle AM, 2000, METHOD ENZYMOL, V317, P140
   PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142
   Rhode BM, 2003, RNA, V9, P1542, DOI 10.1261/rna.5175703
   Roth A, 1998, P NATL ACAD SCI USA, V95, P6027, DOI 10.1073/pnas.95.11.6027                                                         
   Salehi-Ashtiani K, 2001, NATURE, V414, P82, DOI 10.1038/35102081
   Santoro SW, 2000, J AM CHEM SOC, V122, P2433, DOI 10.1021/ja993688s                                                               
   Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221
   Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262                                                          
   Schubert S, 2003, NUCLEIC ACIDS RES, V31, P5982, DOI 10.1093/nar/gkg791
   Schubert S, 2004, CURR DRUG TARGETS, V5, P667, DOI 10.2174/1389450043345092
   Schubert S, 2004, J MOL BIOL, V339, P355, DOI 10.1016/j.jmb.2004.03.064
   Seetharaman S, 2001, NAT BIOTECHNOL, V19, P336, DOI 10.1038/86723                                                                   
   Serganov A, 2005, NAT STRUCT MOL BIOL, V12, P218, DOI 10.1038/nsmb906
   SHEN Y, 2005, BIOCHEMISTRY-US, V44, P5328
   Sidorov AV, 2004, NUCLEIC ACIDS RES, V32, P1591, DOI 10.1093/nar/gkh326
   Silverman SK, 2004, ORG BIOMOL CHEM, V2, P2701, DOI 10.1039/b411910j
   Silverman SK, 2004, RNA, V10, P731, DOI 10.1261/rna.5247704
   Sioud Mouldy, 2004, Methods Mol Biol, V252, P1
   Sioud Mouldy, 2001, Current Molecular Medicine (Hilversum), V1, P575, DOI 10.2174/1566524013363366
   Soukup GA, 1999, RNA, V5, P1308, DOI 10.1017/S1355838299990891
   Sriram B, 2000, BIOCHEM J, V352, P667, DOI 10.1042/0264-6021:3520667
   Steele David, 2003, Am J Pharmacogenomics, V3, P131, DOI 10.2165/00129785-200303020-00006
   Stojanovic MN, 2002, J AM CHEM SOC, V124, P3555, DOI 10.1021/ja016756v
   Stojanovic MN, 2000, NUCLEIC ACIDS RES, V28, P2915, DOI 10.1093/nar/28.15.2915
   Stojanovic MN, 2005, J AM CHEM SOC, V127, P6914, DOI 10.1021/ja0430003a
   Stojanovic MN, 2003, J AM CHEM SOC, V125, P6673, DOI 10.1021/ja0296632
   Stojanovic MN, 2003, NAT BIOTECHNOL, V21, P1069, DOI 10.1038/nbt862
   Suenaga H, 2005, APPL ENVIRON MICROB, V71, P4879, DOI 10.1128/AEM.71.8.4879-4884.2005
   Suga H, 1998, BIOCHEMISTRY-US, V37, P10118, DOI 10.1021/bi980432a
   SUGIMOTO N, 1995, BIOCHEMISTRY-US, V34, P11211, DOI 10.1021/bi00035a029                                                             
   Sugimoto N, 1999, J CHEM SOC PERK T 2, P1381, DOI 10.1039/a901461f                                                                
   Sun LQ, 2000, PHARMACOL REV, V52, P325
   Swearingen CB, 2005, ANAL CHEM, V77, P442, DOI 10.1021/ac0401016
   Takahashi H, 2004, FEBS LETT, V560, P69, DOI 10.1016/S0014-5793(04)00073-0
   Tan XX, 2004, BIOCHEMISTRY-US, V43, P1111, DOI 10.1021/bi035164h
   Ting R, 2004, J AM CHEM SOC, V126, P12720, DOI 10.1021/ja046964y
   Todd AV, 2000, CLIN CHEM, V46, P625
   Travascio P, 1998, CHEM BIOL, V5, P505, DOI 10.1016/S1074-5521(98)90006-0
   Trulzsch B, 2004, J NEUROCHEM, V88, P257, DOI 10.1046/j.1471-4159.2003.02153.x
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Unwalla H, 2001, ANTIVIR RES, V51, P127, DOI 10.1016/S0166-3542(01)00144-9
   Vester B, 2004, BIOCHEM SOC T, V32, P37, DOI 10.1042/BST0320037
   Villa T, 2002, CELL, V109, P149, DOI 10.1016/S0092-8674(02)00726-2
   Wang DY, 2002, J MOL BIOL, V318, P33, DOI 10.1016/S0022-2836(02)00046-3
   Wang DY, 2002, NUCLEIC ACIDS RES, V30, P1735, DOI 10.1093/nar/30.8.1735
   Wang DY, 2001, J MOL BIOL, V310, P723, DOI 10.1006/jmbi.2001.4811
   Wang YM, 2005, ANGEW CHEM INT EDIT, V44, P5863, DOI 10.1002/anie.200501643
   Wang YM, 2005, BIOCHEMISTRY-US, V44, P3017, DOI 10.1021/bi0478291
   Watanabe T, 2000, ADV DRUG DELIVER REV, V44, P109, DOI 10.1016/S0169-409X(00)00089-2                                                   
   Wecker M, 1996, RNA, V2, P982
   WILSON C, 1995, NATURE, V374, P777, DOI 10.1038/374777a0                                                                
   Wilson DS, 1999, ANNU REV BIOCHEM, V68, P611, DOI 10.1146/annurev.biochem.68.1.611
   Wu YP, 1999, HUM GENE THER, V10, P2847, DOI 10.1089/10430349950016573                                                       
   Xiang GS, 2004, J EXP MED, V200, P1657, DOI 10.1084/jem.20040221
   YARUS M, 1993, FASEB J, V7, P31
   Yen LS, 1999, ANN NEUROL, V46, P366, DOI 10.1002/1531-8249(199909)46:3<366::AID-ANA12>3.0.CO;2-D
   Zaborowska Z, 2005, FEBS LETT, V579, P554, DOI 10.1016/j.febslet.2004.12.008
   Zhang BL, 1997, NATURE, V390, P96
   Zhang L, 2002, CANCER RES, V62, P5463
NR 165
TC 151
Z9 157
U1 2
U2 28
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PY 2005
VL 33
IS 19
BP 6151
EP 6163
DI 10.1093/nar/gki930
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 987BR
UT WOS:000233493900016
PM 16286368
OA gold
DA 2018-01-05
ER

PT S
AU Przybyl-Einstein, G
   Moratin, H
   Garcia, E
AF Przybyl-Einstein, G
   Moratin, H
   Garcia, E
BE Bartels, KE
   Bass, LA
   DeRiese, WTW
   Gregory, KW
   Hirschberg, H
   Katzir, A
   Kollias, N
   Madsen, SJ
   Malek, RS
   McNallyHeintzelman, KM
   Tate, LP
   Trowers, EA
   Wong, BJF
TI G. Einstein matrix and nano biophotonic treatment
SO Photonic Therapeutics and Diagnostics
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Photonic Therapeutics and Diagnostics
CY JAN 22-25, 2005
CL San Jose, CA
SP SPIE
AB The publication is presenting the Einstein Matrix Treatment Method and initial results for blood borne diseases on example of hepatitis, HIV and arthritis. The initial research was conducted at Einstein Clinical Laboratories S.A. on limited funds. The treatment and method is strongly recommended for specific viruses bacteria in blood home diseases but also for treatment of none specific viruses and bacteria in emergency treatments as SARS or ANTHRAX to safe life of the human. In the past years the Individual's Safety is in jeopardy by natural viral infections as well as by engineering cultured viruses and bacteria. Viruses mutate and become more resistant to current known medical treatment, in many cases partially efficient. This event required new testing method to investigate the possibility of treatments and to create new vaccine for non-specific viral and bacteria or viruses infections that causes death to thousands adults and children. The authors present in this paper the possibility of treatment of the non-specific viral, bacterial infections of the blood in human body. This treatment has safe procedure and no known side effect up to this time for patients that were treated at Einstein Clinical Laboratories SA.
C1 Thammasat Univ, SIIT, Pathum Thani, Thailand.
RP Przybyl-Einstein, G (reprint author), Thammasat Univ, SIIT, Pathum Thani, Thailand.
CR ARUTIUNOV A, 1988, MED TEKNIKA, V1, P48
   BAKLYKOVA SN, 1994, TERAPEVTICHESKII ARC, V66, P12
   BARGER G, 1950, MED PHYS, V2, P132
   Barrett HA, 1940, MED CLIN N AM, V24, P723
   Barrett H.A., 1943, AM J SURG, V61, P42
   BEDNARSKII AS, 1995, AKUSH GINEKOL, V6, P18
   BELOUSSOV L, 2000, P 2 A GURWITSCH C AD
   BERDICHEVSKY MY, 1991, ZH NEVROPATOL PSIKH, V91, P75
NR 8
TC 0
Z9 0
U1 0
U2 0
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-5659-4
J9 P SOC PHOTO-OPT INS
PY 2005
VL 5686
BP 398
EP 406
DI 10.1117/12.593318
PG 9
WC Engineering, Biomedical; Optics
SC Engineering; Optics
GA BCI71
UT WOS:000229607700056
DA 2018-01-05
ER

PT J
AU Meagher, KL
   Carlson, HA
AF Meagher, KL
   Carlson, HA
TI Solvation influences flap collapse in HIV-1 protease
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE molecular dynamics simulation; AMBER; cavity water; system setup;
   protein flexibility; calculation
ID MOLECULAR-DYNAMICS; DRUG-RESISTANCE; SIMULATION; RELAXATION; INHIBITORS;
   PROTEINS
AB HIV-1 protease (HIVp) is an important target for the development of therapies to treat AIDS and is one of the classic examples of structure-based drug design. The flap region of HIVp is known to be highly flexible and undergoes a large conformational change upon binding a ligand. Accurately modeling the inherent flexibility of the HIVp system is critical for developing new methods for structure-based drug design. We report several 3-ns molecular dynamics simulations investigating the role of solvation in HIVp flap rearrangement. Using an unliganded crystal structure of HIVp, other groups have observed flap reorganization on the nanosecond time-scale. We have also observed rapid, initial flap movement, but we propose that it may be caused by system setup. The initial solvation. of the system creates vacuum regions around the protein that may encourage large conformational deformities. By reducing the vacuum space created by the solvation. routine, the observed flap collapse is attenuated. Also, a more thorough equilibration procedure preserves a more stable protein conformation over the course of the simulation. (C) 2004 Wiley-Liss, Inc.
C1 Univ Michigan, Coll Pharm, Dept Med Chem, Ann Arbor, MI 48109 USA.
RP Carlson, HA (reprint author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.
EM carlsonh@umich.edu
OI Carlson, Heather/0000-0002-7495-1699
FU NIGMS NIH HHS [GM07767, GM65372]
CR Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Boden D, 1998, ANTIMICROB AGENTS CH, V42, P2775
   Case DA, 2002, ACCOUNTS CHEM RES, V35, P325, DOI 10.1021/ar010020l
   CASE DA, 1996, AMBER 6
   *CHEM COMP GROUP I, 2001, MOL OP ENV
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Freedberg DI, 2002, PROTEIN SCI, V11, P221, DOI 10.1110/ps.33202
   Garcia AE, 2002, P NATL ACAD SCI USA, V99, P2782, DOI 10.1073/pnas.042496899
   HARTE WE, 1990, P NATL ACAD SCI USA, V87, P8864, DOI 10.1073/pnas.87.22.8864
   Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Perryman AL, 2004, PROTEIN SCI, V13, P1108, DOI 10.1110/ps.03468904
   Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27
   Rick SW, 1998, PROTEINS, V32, P7, DOI 10.1002/(SICI)1097-0134(19980701)32:1<7::AID-PROT3>3.0.CO;2-K
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f                                                               
   Scott WRP, 2000, STRUCTURE, V8, P1259, DOI 10.1016/S0969-2126(00)00537-2                                                   
   Simmerling C, 2002, J AM CHEM SOC, V124, P11258, DOI 10.1021/ja0273851
   SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Wlodawer A, 2000, BBA-PROTEIN STRUCT M, V1477, P16, DOI 10.1016/S0167-4838(99)00267-8
   YORK DM, 1993, BIOCHEMISTRY-US, V32, P1443, DOI 10.1021/bi00057a007
NR 25
TC 66
Z9 66
U1 0
U2 3
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-3585
J9 PROTEINS
JI Proteins
PD JAN 1
PY 2005
VL 58
IS 1
BP 119
EP 125
DI 10.1002/prot.20274
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 881YI
UT WOS:000225905000013
PM 15521062
DA 2018-01-05
ER

PT J
AU Jaafar, FM
   Attoui, H
   Bahar, MW
   Siebold, C
   Sutton, G
   Mertens, PPC
   De Micco, P
   Stuart, DI
   Grimes, JM
   De Lamballerie, X
AF Jaafar, FM
   Attoui, H
   Bahar, MW
   Siebold, C
   Sutton, G
   Mertens, PPC
   De Micco, P
   Stuart, DI
   Grimes, JM
   De Lamballerie, X
TI The structure and function of the outer coat protein VP9 of Banna virus
SO STRUCTURE
LA English
DT Article
ID NANOLITRE CRYSTALLIZATION EXPERIMENTS; INFECTIOUS SUBVIRION PARTICLES;
   ELECTRON-DENSITY MAPS; MEMBRANE-FUSION; CRYOELECTRON MICROSCOPY; GENUS
   SEADORNAVIRUS; FAMILY REOVIRIDAE; RECEPTOR-BINDING; CAPSID PROTEIN;
   DSRNA VIRUSES
AB Banna virus (BAV: genus Seadornavirus, family Reoviridae) has a double-shelled morphology similar to rotavirus and bluetongue virus. The structure of BAV outer-capsid protein VP9 was determined by X-ray crystallography at 2.6 Angstrom resolution, revealing a trimeric molecule, held together by an N-terminal helical bundle, reminiscent of coiled-coil structures found in fusion-active proteins such as HIV gp41. The major domain of VP9 contains stacked P sheets with marked structural similarities to the receptor binding protein VP8 of rotavirus. Anti-VP9 antibodies neutralize viral infectivity, and, remarkably, pretreatment of cells with trimeric VP9 increased viral infectivity, indicating that VP9 is involved in virus attachment to cell surface and subsequent internalization. Sequence similarities were also detected between BAV VP10 and VP5 portion of rotavirus VP4, suggesting that the receptor binding and internalization apparatus, which is a single gene product activated by proteoloysis in rotavirus, is the product of two separate genome segments in BAV.
C1 Univ Mediterranee, EFS Alpes Mediterranee, Unite Virus Emergents EA3292, F-13005 Marseille, France.
   Univ Mediterranee, Fac Med, F-13005 Marseille, France.
   Univ Oxford, Div Struct Biol, Oxford OX3 7BN, England.
   Pirbright Lab, Inst Anim Hlth, Woking GU24 0NF, Surrey, England.
RP Attoui, H (reprint author), Univ Mediterranee, EFS Alpes Mediterranee, Unite Virus Emergents EA3292, 27 Bd Jean Moulin, F-13005 Marseille, France.
EM h-attoui-ets-ap@gulliver.fr; jonathan@strubi.ox.ac.uk
OI Mertens, Peter/0000-0002-3438-3738
CR ALLISON SL, 1995, J VIROL, V69, P695
   Attoui H, 2000, J GEN VIROL, V81, P1507, DOI 10.1099/0022-1317-81-6-1507                                                     
   Attoui H, 2002, ARCH VIROL, V147, P533, DOI 10.1007/s007050200005
   Baker TS, 1999, MICROBIOL MOL BIOL R, V63, P862
   Bamford DH, 2001, CURR OPIN STRUC BIOL, V11, P107, DOI 10.1016/S0959-440X(00)00177-9                                                   
   Bressanelli S, 2004, EMBO J, V23, P728, DOI 10.1038/sj.emboj.7600064
   Brown J, 2003, J APPL CRYSTALLOGR, V36, P315, DOI 10.1107/S0021889803002012
   BROWN SE, 1993, VIROLOGY, V196, P363, DOI 10.1006/viro.1993.1490
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   BURROUGHS JN, 1994, J GEN VIROL, V75, P1849, DOI 10.1099/0022-1317-75-8-1849
   Chandran K, 2001, J VIROL, V75, P5335, DOI 10.1128/JVI.75.11.5335-5342.2001
   Chang GJ, 1999, TAIWAN J MATH, V3, P73
   Charpilienne A, 1997, J GEN VIROL, V78, P1367, DOI 10.1099/0022-1317-78-6-1367                                                     
   Chen BQ, 1996, CHINESE MED J-PEKING, V109, P13
   Denisova E, 1999, J VIROL, V73, P3147
   Dormitzer PR, 2000, VIROLOGY, V277, P420, DOI 10.1006/viro.2000.0625
   Dormitzer PR, 2002, EMBO J, V21, P885, DOI 10.1093/emboj/21.5.885                                                          
   DORMITZER PR, 2003, 8 INT S DOUBL STRAND
   Dowling W, 2000, J VIROL, V74, P6368, DOI 10.1128/JVI.74.14.6368-6376.2000
   Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363
   ESTES MK, 2001, FIELDS VIROLOGY, P1747
   Forzan M, 2004, P NATL ACAD SCI USA, V101, P2100, DOI 10.1073/pnas.0306448101
   Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543
   Golantsova NE, 2004, J VIROL, V78, P2037, DOI 10.1128/JVI.78.4.2037-2044.2004
   Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305                                                 
   Grande A, 2000, VIROLOGY, V274, P367, DOI 10.1006/viro.2000.0473
   Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694
   HASSAN SH, 1999, J VIROL, V75, P8356
   HASSAN Y, 2001, P RSTGC 2001 INT C, V5, P75
   Hill CL, 1999, NAT STRUCT BIOL, V6, P565, DOI 10.1038/9347
   Jaafar FM, 2004, J VIROL METHODS, V116, P55, DOI 10.1016/j.jviromet.2003.10.010
   Jane-Valbuena J, 1999, J VIROL, V73, P2963
   JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   Li Q., 1992, ENDEMIC DIS B, V7, P77
   MENDEZ E, 1993, J VIROL, V67, P5253
   Mertens P, 2004, VIRUS RES, V101, P3, DOI 10.1016/j.virusres.2003.12.002
   MERTENS PPC, 2004, VIRUS TAXONOMY, P447
   MERTENS PPC, 2000, VIRUS TAXONOMY, P395
   MURPHY FA, 1968, VIROLOGY, V35, P28, DOI 10.1016/0042-6822(68)90302-4
   NIBERT ML, 1995, J VIROL, V69, P5057
   Nibert ML, 2001, FIELDS VIROLOGY, P1679
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   PRASAD BVV, 1990, NATURE, V343, P476, DOI 10.1038/343476a0                                                                
   RUGGERI FM, 1991, J VIROL, V65, P2211
   Schoehn G, 1997, VIROLOGY, V235, P191, DOI 10.1006/viro.1997.8685
   Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531
   STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9
   SUZUKI H, 1993, J GEN VIROL, V74, P2015, DOI 10.1099/0022-1317-74-9-2015
   Terwilliger TC, 2003, ACTA CRYSTALLOGR D, V59, P1174, DOI 10.1107/S0907444903009922
   Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839                                                       
   Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072
   Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997
   Xu PuTing, 1990, Chinese Journal of Virology, V6, P27
   Zarate S, 2000, J VIROL, V74, P593, DOI 10.1128/JVI.74.2.593-599.2000
   Zhu YF, 1997, J VIROL, V71, P8899
   [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760
NR 60
TC 15
Z9 18
U1 0
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA
SN 0969-2126
J9 STRUCTURE
JI Structure
PD JAN
PY 2005
VL 13
IS 1
BP 17
EP 28
DI 10.1016/j.str.2004.10.017
PG 12
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 893SW
UT WOS:000226740500005
PM 15642258
OA gold
DA 2018-01-05
ER

PT J
AU Ahn, KS
   Ou, W
   Silver, J
AF Ahn, KS
   Ou, W
   Silver, J
TI Inhibition of certain strains of HIV-1 by cell surface polyanions in the
   form of cholesterol-labeled oligonucleotides
SO VIROLOGY
LA English
DT Article
DE cholesterol-labeled oligonucleotides; virus entry; membrane fusion;
   HIV-1; electrostatic interaction
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HEPARAN-SULFATE PROTEOGLYCAN; GP120
   ENVELOPE GLYCOPROTEIN; DEXTRAN SULFATE; V3 LOOP; T-CELLS; INITIAL
   INTERACTION; TYPE-1 ATTACHMENT; PLASMA-MEMBRANE; INFECTION
AB Cholesterol-labeled oligonucleotides were found several years ago to inhibit HIV-1 in tissue culture at nanomolar concentrations. We present evidence that this is mainly due to an electrostatic interaction between polyanionic oligonucleotide concentrated at the cell surface and a positively charged region in the V3 loop of the HIV-1 envelope protein. When added to tissue culture, cholesterol-labeled oligonucleotides became concentrated at the plasma membrane and potently inhibited virus entry and cell fusion mediated by the envelope protein of some X4 strains of HIV-1, but had little effect on fusion mediated by R5 strains of HIV-1, amphotropic MLV envelope protein, or VSV-G protein. Noncholesterol-labeled oligonucleotides did not bind to the cell surface or inhibit fusion. The pattern of susceptibility to cholesterol-labeled oligonucleotides among HIV-1 strains was the same as reported for nonmembrane-associating polyanions such as dextran sulfate, but the cholesterol-labeled oligonucleotides were effective at lower concentrations. Substitution of a basic 33 amino acid V3 loop sequence from the envelope protein of a resistant strain into a susceptible strain made the envelope protein resistant to inhibition. Inhibition by cholesterol-labeled oligonucleotides was abrogated by the polycation DEAE-dextran. Cholesterol-labeled oligonucleotides bound to nonraft regions of the plasma membrane and did not inhibit HIV virus binding to cells. Many infectious agents first associate with target cells via relatively nonspecific charge interactions; our data suggest that molecules that combine a membrane-targeting motif with multiple negative charges might be useful to modify these interactions. Published by Elsevier Inc.
C1 NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.
RP Silver, J (reprint author), NIAID, Mol Microbiol Lab, NIH, Bldg 4,Room 336, Bethesda, MD 20892 USA.
EM jsilver@nih.gov
OI Silver, Jonathan/0000-0001-9231-6368
CR AGARWAL S, 1989, P NATL ACAD SCI USA, V86, P7790
   AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295
   BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132                                                         
   Baldwin CE, 2003, CURR MED CHEM, V10, P1633, DOI 10.2174/0929867033457124                                                        
   Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8
   Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571
   CALLAHAN LN, 1991, J VIROL, V65, P1543
   Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866
   Chung CS, 1998, J VIROL, V72, P1577
   Cocchi F, 1996, NAT MED, V2, P1244, DOI 10.1038/nm1196-1244                                                             
   COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   Demaria S, 1996, AIDS RES HUM RETROV, V12, P281, DOI 10.1089/aid.1996.12.281
   Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000
   FAROOQUI F, 1991, BIOCONJUGATE CHEM, V2, P422, DOI 10.1021/bc00012a007
   FELSER JM, 1989, VIROLOGY, V170, P566, DOI 10.1016/0042-6822(89)90448-0
   FLYNN SJ, 1995, J VIROL, V69, P834
   FOUCHIER RAM, 1992, J VIROL, V66, P3183
   HARRIS CC, 1994, CANCER EPIDEM BIOMAR, V3, P1
   HE JL, 1995, J VIROL, V69, P6705
   Hoffman TL, 1999, MOL MEMBR BIOL, V16, P57, DOI 10.1080/096876899294760                                                         
   Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359
   HWANG SS, 1992, SCIENCE, V257, P535, DOI 10.1126/science.1636088
   Ibrahim J, 1999, VIRUS RES, V60, P159, DOI 10.1016/S0168-1702(99)00018-0
   ITO M, 1987, ANTIVIR RES, V7, P361, DOI 10.1016/0166-3542(87)90018-0
   Kayman SC, 1999, J VIROL, V73, P1802
   Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002
   KRIEG AM, 1993, P NATL ACAD SCI USA, V90, P1048, DOI 10.1073/pnas.90.3.1048                                                          
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025
   MCCLURE MO, 1992, AIDS RES HUM RETROV, V8, P19, DOI 10.1089/aid.1992.8.19
   MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480
   Mondor I, 1998, J VIROL, V72, P3623
   Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000
   Ohshiro Y, 1996, MICROBIOL IMMUNOL, V40, P827, DOI 10.1111/j.1348-0421.1996.tb01148.x                                              
   PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167
   Platt EJ, 1998, J VIROL, V72, P2855
   Popik W, 2002, J VIROL, V76, P4709, DOI 10.1128/JVI.76.10.4709-4722.2002
   Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997
   Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763
   RODRIGUEZ G, 1995, J VIROL, V69, P2233
   Roos JW, 2000, VIROLOGY, V273, P307, DOI 10.1006/viro.2000.0431
   Saphire ACS, 1999, EMBO J, V18, P6771, DOI 10.1093/emboj/18.23.6771
   SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3
   Spenlehauer C, 2001, VIROLOGY, V280, P292, DOI 10.1006/viro.2000.0780
   STEIN CA, 1991, BIOCHEMISTRY-US, V30, P2439, DOI 10.1021/bi00223a020
   Summerford C, 1998, J VIROL, V72, P1438
   Thomas M, 2003, APPL MICROBIOL BIOT, V62, P27, DOI 10.1007/s00253-003-1321-8
   Trkola A, 1999, J VIROL, V73, P8966
   Vodicka MA, 1997, VIROLOGY, V233, P193, DOI 10.1006/viro.1997.8606
   Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002
   WUDUNN D, 1989, J VIROL, V63, P52
   Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002
NR 53
TC 8
Z9 9
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD DEC 5
PY 2004
VL 330
IS 1
BP 50
EP 61
DI 10.1016/j.virol.2004.09.010
PG 12
WC Virology
SC Virology
GA 872GL
UT WOS:000225195600006
PM 15527833
OA gold
DA 2018-01-05
ER

PT J
AU Sommer, AP
   Wickramasinghe, NC
AF Sommer, AP
   Wickramasinghe, NC
TI Keeping nanobacterial infections at bay during space travel
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Editorial Material
DE nanobacteria; astronauts; HIV; bone mineral density; primordial
   biosystems
ID LIVING NANOVESICLES; PRIMORDIAL BIOSYSTEMS; MODEL SIMULATION;
   NERVE-FIBERS; SUFFOCATION; HIV
AB In January 2004, President George W. Bush unveiled plans to send astronauts to the Moon in 2015 and shortly thereafter to Mars. With the prospect of manned exploration of the planets drawing ever closer, the new discipline of Space Medicine is destined to come to the fore. Moreover, investigations of how human beings function under space conditions could provide important new insights into fundamental questions of human physiology and disease. We draw attention here to one such instance of a disease process that can be provoked by extended periods of exposure to low gravity. (C) 2004 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
   Univ Wales Coll Cardiff, Cardiff Ctr Astrobiol, Cardiff CF10 3DY, S Glam, Wales.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   Maniscalco Benedict S., 2004, Pathophysiology, V11, P95, DOI 10.1016/j.pathophys.2004.06.001
   MILLER VM, 2004, AM J PHYSIOL-HEART C, V287, P1115
   Sommer AP, 2004, J PROTEOME RES, V3, P1086, DOI 10.1021/pr049935v
   Sommer AP, 2004, J PROTEOME RES, V3, P670, DOI 10.1021/pr049978b
   Sommer AP, 2004, J PROTEOME RES, V3, P667, DOI 10.1021/pr034122c
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   SOMMER AP, IN PRESS CRYST GROWT
   SOMMER AP, IN PRESS J PROTEOME
   Vico L, 2000, LANCET, V355, P1607, DOI 10.1016/S0140-6736(00)02217-0
NR 15
TC 5
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-8579
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD DEC
PY 2004
VL 24
IS 6
BP 548
EP 549
DI 10.1016/j.ijantimicag.2004.09.006
PG 2
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA 882FX
UT WOS:000225925600003
PM 15555875
DA 2018-01-05
ER

PT J
AU Chen, XF
   Weber, IT
   Harrison, RW
AF Chen, XF
   Weber, IT
   Harrison, RW
TI Molecular dynamics simulations of 14 HIV protease mutants in complexes
   with indinavir
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE drug resistance; aspartic protease; structural flexibility; inhibition;
   interaction energy
ID DRUG-RESISTANT MUTANTS; REVERSE-TRANSCRIPTASE; CROSS-RESISTANCE;
   MECHANICS CALCULATIONS; MULTIDRUG-RESISTANCE; INHIBITOR; MUTATIONS;
   FLAP; SITE; FLEXIBILITY
AB The molecular mechanisms of HIV drug resistance were studied using molecular dynamics simulations of HIV-1 protease complexes with the clinical inhibitor indinavir. One nanosecond molecular dynamics simulations were run for solvated complexes of indinavir with wild type protease, a control variant and 12 drug resistant mutants. The quality of the simulations was assessed by comparison with crystallographic and inhibition data. Molecular mechanisms that contribute to drug resistance include structural stability and affinity for inhibitor. The mutants showed a range of structural variation from 70 to 140% of the wild type protease. The protease affinity for indinavir was estimated by calculating the averaged molecular mechanics interaction energy. A correlation coefficient of 0.96 was obtained with observed inhibition constants for wild type and four mutants. Based on this good agreement, the trends in binding were predicted for the other mutants and discussed in relation to the clinical data for indinavir resistance.
C1 Georgia State Univ, Dept Biol, Mol Basis Dis Program, Atlanta, GA 30302 USA.
   Georgia State Univ, Dept Comp Sci, Mol Basis Dis Program, Atlanta, GA 30302 USA.
RP Weber, IT (reprint author), Georgia State Univ, Dept Biol, Mol Basis Dis Program, POB 4010, Atlanta, GA 30302 USA.
EM iweber@gsu.edu
OI Harrison, Robert/0000-0003-2449-1214
FU NIGMS NIH HHS [R01 GM062920, GM065762, GM62920]
CR Bagossi P, 1999, J MOL MODEL, V5, P143, DOI 10.1007/s008940050114                                                           
   Brown AJL, 1999, AIDS RES HUM RETROV, V15, P247, DOI 10.1089/088922299311420                                                         
   CHEN Z, 1995, J BIOL CHEM, V270, P433
   CHEN ZG, 1994, J BIOL CHEM, V269, P26344
   COLLINS JR, 1995, NAT STRUCT BIOL, V2, P334, DOI 10.1038/nsb0495-334
   Condra JH, 1996, J VIROL, V70, P8270
   GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002
   GUSTCHINA A, 1990, FEBS LETT, V269, P269, DOI 10.1016/0014-5793(90)81171-J
   HARRISON RW, 1994, PROTEIN ENG, V7, P1353, DOI 10.1093/protein/7.11.1353
   HARRISON RW, 1993, J COMPUT CHEM, V14, P1112, DOI 10.1002/jcc.540140912                                                           
   Harrison RW, 1999, J MATH CHEM, V26, P125, DOI 10.1023/A:1019181811090                                                         
   Harrison R.W., 2003, P INT C COMP SCI ITS, P77
   Hertogs K, 2000, AIDS, V14, P1203, DOI 10.1097/00002030-200006160-00018
   Jenwitheesuk Ekachai, 2003, BMC Struct Biol, V3, P2, DOI 10.1186/1472-6807-3-2
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   King NM, 2002, PROTEIN SCI, V11, P418, DOI 10.1110/ps.25502
   Liu HY, 1996, J MOL BIOL, V261, P454, DOI 10.1006/jmbi.1996.0476
   Mahalingam B, 1999, EUR J BIOCHEM, V263, P238, DOI 10.1046/j.1432-1327.1999.00514.x
   Munshi S, 2000, ACTA CRYSTALLOGR D, V56, P381, DOI 10.1107/S0907444900000469
   Muzammil S, 2003, BIOCHEMISTRY-US, V42, P631, DOI 10.1021/bi027019u
   Ohtaka H, 2003, BIOCHEMISTRY-US, V42, P13659, DOI 10.1021/bi0350405
   Olsen DB, 1999, J BIOL CHEM, V274, P23699, DOI 10.1074/jbc.274.34.23699                                                        
   Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702
   Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P298, DOI 10.1093/nar/gkg100
   SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5                                                   
   Scott WRP, 2000, STRUCTURE, V8, P1259, DOI 10.1016/S0969-2126(00)00537-2                                                   
   Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008
   Shafer RW, 2002, CLIN MICROBIOL REV, V15, P247, DOI 10.1128/CMR.15.2.247-277.2002
   Shafer RW, 1999, J VIROL, V73, P6197
   Tamalet C, 2000, J MED VIROL, V61, P181, DOI 10.1002/(SICI)1096-9071(200006)61:2<181::AID-JMV2>3.0.CO;2-T
   Trylska J, 2004, PROTEIN SCI, V13, P513, DOI 10.1110/ps.03372304
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Vergne L, 2000, J CLIN MICROBIOL, V38, P3919
   Wang W, 2001, P NATL ACAD SCI USA, V98, P14937, DOI 10.1073/pnas.251265598
   Weber IT, 1996, PROTEIN ENG, V9, P679, DOI 10.1093/protein/9.8.679
   Weber IT, 1999, PROTEIN ENG, V12, P469, DOI 10.1093/protein/12.6.469
   Weber IT, 1997, PROTEIN SCI, V6, P2365
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   Zoete V, 2002, J MOL BIOL, V315, P21, DOI 10.1006/jmbi.2001.5173
NR 39
TC 31
Z9 31
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0948-5023
J9 J MOL MODEL
JI J. Mol. Model.
PD DEC
PY 2004
VL 10
IS 5-6
BP 373
EP 381
DI 10.1007/s00894-004-0205-x
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA 884OY
UT WOS:000226096100008
PM 15597206
DA 2018-01-05
ER

PT J
AU Golebiowski, J
   Antonczak, S
   Fernandez-Carmona, J
   Condom, R
   Cabrol-Bass, D
AF Golebiowski, J
   Antonczak, S
   Fernandez-Carmona, J
   Condom, R
   Cabrol-Bass, D
TI Closing loop base pairs in RNA loop-loop complexes: structural behavior,
   interaction energy and solvation analysis through molecular dynamics
   simulations
SO JOURNAL OF MOLECULAR MODELING
LA English
DT Article
DE RNA; molecular dynamics; mismatch; energy; simulation
ID KISSING HAIRPIN COMPLEX; CONTINUUM SOLVENT MODEL; COLE1 ROM PROTEIN;
   CRYSTAL-STRUCTURE; RIBOSOMAL-RNA; ION-BINDING; CONFORMATIONAL-ANALYSIS;
   APTAMER COMPLEX; INTERNAL LOOPS; MAJOR GROOVE
AB Nanosecond molecular dynamics using the Ewald summation method have been performed to elucidate the structural and energetic role of the closing base pair in loop-loop RNA duplexes neutralized by Mg2+ counterions in aqueous phases. Mismatches GA, CU and Watson-Crick GC base pairs have been considered for closing the loop of an RNA in complementary interaction with HIV-1 TAR. The simulations reveal that the mismatch GA base, mediated by a water molecule, leads to a complex that presents the best compromise between flexibility and energetic contributions. The mismatch CU base pair, in spite of the presence of an inserted water molecule, is too short to achieve a tight interaction at the closing-loop junction and seems to force TAR to reorganize upon binding. An energetic analysis has allowed us to quantify the strength of the interactions of the closing and the loop-loop pairs throughout the simulations. Although the water-mediated GA closing base pair presents an interaction energy similar to that found on fully geometry-optimized structure, the water-mediated CU closing base pair energy interaction reaches less than half the optimal value.
C1 Univ Nice, Lab Aromes Synth Interact, Fac Sci, F-06108 Nice 2, France.
   Univ Nice, Lab Chim Bioorgan, CNRS, UMR 6001, F-06108 Nice, France.
RP Golebiowski, J (reprint author), Univ Nice, Lab Aromes Synth Interact, Fac Sci, F-06108 Nice 2, France.
EM jerome.golebiowski@unice.fr
CR Auffinger P, 2000, J MOL BIOL, V300, P1113, DOI 10.1006/jmbi.2000.3894
   Auffinger P, 1997, J MOL BIOL, V269, P326, DOI 10.1006/jmbi.1997.1022                                                          
   Auffinger P, 2001, BIOPOLYMERS, V56, P266
   Auffinger P, 2001, J MOL BIOL, V305, P1057, DOI 10.1006/jmbi.2000.4360
   Beaurain F, 2003, OLIGONUCLEOTIDES, V13, P501, DOI 10.1089/154545703322860816
   Beaurain F, 2003, NUCLEIC ACIDS RES, V31, P4275, DOI 10.1093/nar/gkg467
   BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220
   Brandl M, 1999, J AM CHEM SOC, V121, P2605, DOI 10.1021/ja9829923                                                               
   Brandl M, 2000, J PHYS CHEM A, V104, P11177, DOI 10.1021/jp002022d
   CASE DA, 1999, AMBER 6 0
   CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705                                                         
   Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021
   Cheatham TE, 2001, BIOPOLYMERS, V56, P232
   Correll CC, 1997, CELL, V91, P705, DOI 10.1016/S0092-8674(00)80457-2
   CULLEN BR, 1994, INFECT AGENT DIS, V3, P68
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   EGUCHI Y, 1991, J MOL BIOL, V220, P831, DOI 10.1016/0022-2836(91)90356-B
   EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Ennifar E, 1999, STRUCT FOLD DES, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7
   Fan P, 1996, J MOL BIOL, V258, P480, DOI 10.1006/jmbi.1996.0263                                                          
   FRISCH MJ, 1998, GAUSSIAN 98
   GAO YG, 1995, BIOPHYS J, V69, P559, DOI 10.1016/S0006-3495(95)79929-5                                                   
   Garriga J, 1998, ONCOGENE, V17, P3093, DOI 10.1038/sj.onc.1202548                                                          
   Golebiowski J, 2004, J MOL MODEL, V10, P60, DOI 10.1007/s00894-003-0170-9
   GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275
   Gresh N, 2003, J PHYS CHEM B, V107, P8669, DOI 10.1021/jp022659s
   HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983
   Hobza P, 1997, J COMPUT CHEM, V18, P1136, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1136::AID-JCC3>3.0.CO;2-S
   Hobza P, 1999, CHEM REV, V99, P3247, DOI 10.1021/cr9800255                                                               
   Ivanov D, 1999, J MOL BIOL, V288, P41, DOI 10.1006/jmbi.1999.2663
   Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593                                                          
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483                                                  
   Leontis NB, 1998, Q REV BIOPHYS, V31, P399, DOI 10.1017/S0033583599003479
   Lodmell JS, 2001, J MOL BIOL, V311, P475, DOI 10.1006/jmbi.2001.4879
   Okimoto N, 2000, J AM CHEM SOC, V122, P5613, DOI 10.1021/ja9929178
   PATTABIRAN N, 2002, J BIOMOL STRUCT DYN, V20, P311
   Reblova K, 2003, NUCLEIC ACIDS RES, V31, P6942, DOI 10.1093/nar/gkg880
   Reblova K, 2003, BIOPHYS J, V84, P3564, DOI 10.1016/S0006-3495(03)75089-9                                                   
   Rudisser S, 2000, J MOL BIOL, V295, P1211, DOI 10.1006/jmbi.1999.3421
   SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021
   Schneider C, 2001, J MOL BIOL, V305, P659, DOI 10.1006/jmbi.2000.4338
   Schroeder SJ, 2001, BIOCHEMISTRY-US, V40, P11509, DOI 10.1021/bi010489o
   SERRA MJ, 1993, NUCLEIC ACIDS RES, V21, P3845, DOI 10.1093/nar/21.16.3845
   SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581
   Tanaka Y, 1999, NUCLEIC ACIDS RES, V27, P949, DOI 10.1093/nar/27.4.949
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   WESTHOF E, 2000, STRUCTURE, V8, P55
   WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013
   Wu M, 1996, BIOCHEMISTRY-US, V35, P9677, DOI 10.1021/bi960133q
   Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026
   Zacharias M, 1999, J MOL BIOL, V289, P261, DOI 10.1006/jmbi.1999.2760                                                          
   Zacharias M, 2001, BIOPHYS J, V80, P2350, DOI 10.1016/S0006-3495(01)76205-4                                                   
   Zacharias M, 2000, CURR OPIN STRUC BIOL, V10, P311, DOI 10.1016/S0959-440X(00)00089-0                                                   
NR 58
TC 8
Z9 9
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0948-5023
J9 J MOL MODEL
JI J. Mol. Model.
PD DEC
PY 2004
VL 10
IS 5-6
BP 408
EP 417
DI 10.1007/s00894-004-0216-7
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Chemistry; Computer
   Science
GA 884OY
UT WOS:000226096100012
PM 15597210
DA 2018-01-05
ER

PT J
AU Temiz, NA
   Meirovitch, E
   Bahar, I
AF Temiz, NA
   Meirovitch, E
   Bahar, I
TI Escherichia coli adenylate kinase dynamics: Comparison of elastic
   network model modes with mode-coupling N-15-NMR relaxation data
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE Gaussian network model; slowly relaxing; Local Structure; collective
   modes; conformational changes
ID MAGNETIC-RESONANCE RELAXATION; HIV-1 REVERSE-TRANSCRIPTASE; N-H BOND;
   PROTEIN DYNAMICS; NMR RELAXATION; MOLECULAR-DYNAMICS; DOMAIN MOTIONS;
   CLOSED CONFORMATION; BACKBONE DYNAMICS; TRYPSIN-INHIBITOR
AB The dynamics of adenylate kinase of Escherichia coli (AKeco) and its complex with the inhibitor APA, are characterized by correlating the theoretical results obtained with the Gaussian Network Model (GNM) and the anisotropic network model (ANM) with the order parameters and correlation times obtained with Slowly Relaxing Local Structure (SRLS) analysis of N-15-NMR relaxation data. The AMPbd and LID domains of AKeco execute in solution large amplitude motions associated with the catalytic reaction Mg+2*ATP + AMP --> Mg+2* ADP + ADP. Two sets of correlation times and order parameters were determined by NMR/SRLS for AKeco, attributed to slow (nanoseconds) motions with correlation time tau(perpendicular to) and low order parameters, and fast (picoseconds) motions with correlation time tau(parallel to) and high order parameters. The structural connotation of these patterns is examined herein by subjecting AKeco and AKeco*AP(5)A to GNM analysis, which yields the dynamic spectrum in terms of slow and fast modes. The low/high NMR order parameters correlate with the slow/fast modes of the backbone elucidated with GNM. Likewise, tau(parallel to) and are associated with fast and slow GNM modes, respectively. Catalysis-related domain motion of AMPbd and LID in AKeco, occurring per NMR with correlation timer tau(perpendicular to), is associated with the first and second collective slow (global) GNM modes. The ANM-predicted deformations of the unliganded enzyme conform to the functional reconfiguration induced by ligand-binding, indicating the structural disposition (or potential) of the enzyme to bind its substrates. It is shown that NMR/SRLS and GNM/ANM analyses can be advantageously synthesized to provide insights into the molecular mechanisms that control biological function. (C) 2004 Wiley-Liss, Inc.
C1 Univ Pittsburgh, Ctr Computat Biol & Bioinformat, Dept Biochem & Mol Genet, Sch Med, Pittsburgh, PA 15261 USA.
   Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.
RP Bahar, I (reprint author), Univ Pittsburgh, Ctr Computat Biol & Bioinformat, Dept Biochem & Mol Genet, Sch Med, Pittsburgh, PA 15261 USA.
EM bahar@pitt.edu
FU NIGMS NIH HHS [P20 GM065805]; PHS HHS [065805-01A1]
CR ABELE U, 1995, PROTEIN SCI, V4, P1262, DOI 10.1002/pro.5560040702                                                          
   Abragam A., 1961, PRINCIPLES NUCL MAGN
   Amedei A, 1993, PROTEINS, V17, P412
   Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X                                                   
   BAHAR I, 1994, ADV POLYM SCI, V116, P145, DOI 10.1007/BFb0080199
   Bahar I, 1999, J MOL BIOL, V285, P1023, DOI 10.1006/jmbi.1998.2371
   Bahar I, 1998, BIOCHEMISTRY-US, V37, P1067, DOI 10.1021/bi9720641                                                               
   Bahar I, 1999, BIOCHEMISTRY-US, V38, P3478, DOI 10.1021/bi982697v
   BAHAR I, 1992, MACROMOLECULES, V25, P6309, DOI 10.1021/ma00049a030                                                             
   Bahar I, 1999, REV CHEM ENG, V15, P319
   Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2
   BENNETT WS, 1984, CRC CR REV BIOCH MOL, V15, P291, DOI 10.3109/10409238409117796
   BERRY MB, 1994, PROTEINS, V19, P183, DOI 10.1002/prot.340190304
   BROOKS B, 1983, P NATL ACAD SCI-BIOL, V80, P6571, DOI 10.1073/pnas.80.21.6571                                                         
   CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070
   Delarue M, 2002, J MOL BIOL, V320, P1011, DOI 10.1016/S0022-2836(02)00562-4
   Doruker P, 2000, PROTEINS, V40, P512, DOI 10.1002/1097-0134(20000815)40:3<512::AID-PROT180>3.3.CO;2-D
   Doruker P, 2002, J COMPUT CHEM, V23, P119, DOI 10.1002/jcc.1160
   Elamrani S, 1996, PROTEINS, V25, P79, DOI 10.1002/(SICI)1097-0134(199605)25:1<79::AID-PROT6>3.3.CO;2-Z
   Elezgaray J, 1998, BIOPOLYMERS, V46, P493, DOI 10.1002/(SICI)1097-0282(199812)46:7<493::AID-BIP7>3.3.CO;2-J
   Freed J. H., 1976, SPIN LABELING THEORY
   Freed J. H., 1994, MOL DYNAMICS LIQUID, P271
   GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001
   GIBRAT JF, 1990, PROTEINS, V8, P258, DOI 10.1002/prot.340080308                                                          
   GO M, 1976, BIOPOLYMERS, V15, P1119, DOI 10.1002/bip.1976.360150608
   Haliloglu T, 1997, PHYS REV LETT, V79, P3090, DOI 10.1103/PhysRevLett.79.3090
   Haliloglu T, 1999, PROTEINS, V37, P654, DOI 10.1002/(SICI)1097-0134(19991201)37:4<654::AID-PROT15>3.0.CO;2-J
   Hinsen K, 1999, PROTEINS, V34, P369, DOI 10.1002/(SICI)1097-0134(19990215)34:3<369::AID-PROT9>3.0.CO;2-F
   Hinsen K, 1999, J CHEM PHYS, V111, P10766, DOI 10.1063/1.480441
   Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963                                                                   
   Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755
   Keskin O, 2002, PROTEINS, V49, P191, DOI 10.1002/prot.10205
   Keskin O, 2002, BIOCHEMISTRY-US, V41, P491, DOI 10.1021/bi011393x
   KESKIN O, 2002, BIOPHYS J, P663
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Kumar S, 2001, BIOPHYS J, V80, P2439, DOI 10.1016/S0006-3495(01)76213-3                                                   
   Kurkcuoglu O, 2004, POLYMER, V45, P649, DOI 10.1016/j.polymer.2003.10.071
   LEVITT M, 1985, J MOL BIOL, V181, P423, DOI 10.1016/0022-2836(85)90230-X                                                    
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   Meirovitch E, 2003, J PHYS CHEM B, V107, P9883, DOI 10.1021/jp030501h
   Meirovitch E, 2003, J PHYS CHEM B, V107, P9898, DOI 10.1021/jp030502+
   Ming D, 2002, P NATL ACAD SCI USA, V99, P8620, DOI 10.1073/pnas.082148899
   Ming DM, 2002, P NATL ACAD SCI USA, V99, P7895, DOI 10.1073/pnas.112222299
   Miron S, 2004, BIOCHEMISTRY-US, V43, P67, DOI 10.1021/bi0355995
   Miyazawa S, 1996, J MOL BIOL, V256, P623, DOI 10.1006/jmbi.1996.0114
   MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5
   Muller CW, 1996, STRUCTURE, V4, P147, DOI 10.1016/S0969-2126(96)00018-4
   MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522
   Noda L., 1973, ENZYMES, V8, P279
   Palmer AG, 2001, ANNU REV BIOPH BIOM, V30, P129, DOI 10.1146/annurev.biophys.30.1.129                                                
   PENG JW, 1994, METHOD ENZYMOL, V239, P563
   Pfeiffer S, 2001, J AM CHEM SOC, V123, P3021, DOI 10.1021/ja003117
   POLIMENO A, 1995, J PHYS CHEM-US, V99, P10995, DOI 10.1021/j100027a047                                                             
   Polimeno A., 1993, ADV CHEM PHYS, V83, P89
   Prompers JJ, 2001, J AM CHEM SOC, V123, P7305, DOI 10.1021/ja0107226
   RICHARD JP, 1978, J AM CHEM SOC, V100, P7757, DOI 10.1021/ja00492a069                                                             
   Schlauderer GJ, 1996, J MOL BIOL, V256, P223, DOI 10.1006/jmbi.1996.0080
   Shapiro YE, 2002, BIOCHEMISTRY-US, V41, P6271, DOI 10.1021/bi012132q
   Shapiro YE, 2000, BIOCHEMISTRY-US, V39, P6634, DOI 10.1021/bi992076b
   SHAPIRO YE, 2004, IN PRESS J PHYS CHEM
   Sinev MA, 1996, BIOCHEMISTRY-US, V35, P6425, DOI 10.1021/bi952687j
   Sinev MA, 1996, FEBS LETT, V397, P273, DOI 10.1016/S0014-5793(96)01195-7
   Tama F, 2000, PROTEINS, V41, P1
   Tama F, 2002, J MOL BIOL, V321, P297, DOI 10.1016/S0022-2836(02)00627-7
   Tama F, 2002, J MOL BIOL, V318, P733, DOI 10.1016/S0022-2836(02)00135-3
   Temiz NA, 2002, PROTEINS, V49, P61, DOI 10.1002/prot.10183
   Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905                                                     
   Tugarinov V, 2002, J MOL BIOL, V315, P155, DOI 10.1006/jmbi.2001.5231
   Tugarinov V, 2001, J AM CHEM SOC, V123, P3055, DOI 10.1021/ja003803v
   VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2
   WANG Y, 2004, IN PRESS J STRUCT BI
   Xu CY, 2003, J MOL BIOL, V333, P153, DOI 10.1016/j.jmb.2003.08.027
   Zhang FL, 2002, J AM CHEM SOC, V124, P12654, DOI 10.1021/ja027847a
   Zhang HJ, 1997, BIOCHEM BIOPH RES CO, V238, P382, DOI 10.1006/bbrc.1997.7301
   Zheng WJ, 2003, P NATL ACAD SCI USA, V100, P13253, DOI 10.1073/pnas.2235686100
NR 76
TC 67
Z9 68
U1 0
U2 4
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-3585
J9 PROTEINS
JI Proteins
PD NOV 15
PY 2004
VL 57
IS 3
BP 468
EP 480
DI 10.1002/prot.20226
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 863RC
UT WOS:000224578400004
PM 15382240
OA green_accepted
DA 2018-01-05
ER

PT J
AU Petrokova, H
   Duskova, J
   Dohnalek, J
   Skalova, T
   Vondrackova-Buchtelova, E
   Soucek, M
   Konvalinka, J
   Brynda, J
   Fabry, M
   Sedlacek, J
   Hasek, J
AF Petrokova, H
   Duskova, J
   Dohnalek, J
   Skalova, T
   Vondrackova-Buchtelova, E
   Soucek, M
   Konvalinka, J
   Brynda, J
   Fabry, M
   Sedlacek, J
   Hasek, J
TI Role of hydroxyl group and R/S configuration of isostere in binding
   properties of HIV-1 protease inhibitors
SO EUROPEAN JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE ethyleneamine inhibitor; HIV-1 protease; peptidomimetic inhibitor; X-ray
   structure
ID X-RAY-DIFFRACTION; HYDROXYETHYLAMINE ISOSTERE; COMPLEXES; MODE
AB The crystal structure of the complex between human immunodeficiency virus type 1 (HIV-1) protease and a peptidomimetic inhibitor of ethyleneamine type has been refined to R factor of 0.178 with diffraction limit 2.5 Angstrom. The peptidomimetic inhibitor Boc-Phe-Psi[CH2CH2NH]-Phe-Glu-Phe-NH2 (denoted here as OE) contains the ethyleneamine replacement of the scissile peptide bond. The inhibitor lacks the hydroxyl group which is believed to mimic tetrahedral transition state of proteolytic reaction and thus is suspected to be necessary for good properties of peptidomimetic HIV-1 protease inhibitors. Despite the missing hydroxyl group the inhibition constant of OE is 1.53 nM and it remains in the nanomolar range also towards several available mutants of HIV-1 protease. The inhibitor was found in the active site of protease in an extended conformation with a unique hydrogen bond pattern different from hydroxyethylene and hydroxyethylamine inhibitors. The isostere nitrogen forms a hydrogen bond to one catalytic aspartate only. The other aspartate forms two weak hydrogen bridges to the ethylene group of the isostere. A comparison with other inhibitors of this series containing isostere hydroxyl group in R or S configuration shows different ways of accommodation of inhibitor in the active site. Special attention is devoted to intermolecular contacts between neighbouring dimers responsible for mutual protein adhesion and for a special conformation of Met46 and Phe53 side chains not expected for free protein in water solution.
C1 Acad Sci Czech Republ, Inst Macromol Chem, CR-16206 Prague, Czech Republic.
   Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16206 Prague, Czech Republic.
   Acad Sci Czech Republ, Inst Mol Genet, CR-16206 Prague, Czech Republic.
RP Petrokova, H (reprint author), Acad Sci Czech Republ, Inst Macromol Chem, Heyrovskehonam 2, CR-16206 Prague, Czech Republic.
EM petrokova@imc.cas.cz
RI Skalova, Tereza/G-6422-2014; Fabry, Milan/G-3602-2014; Petrokova,
   Hana/H-2563-2014; Brynda, Jiri/G-2760-2014; Konvalinka, Jan/G-7518-2014;
   Sedlacek, Juraj/G-3606-2014; Dohnalek, Jan/G-3573-2014; Duskova,
   Jarmila/G-5922-2014; Hasek, Jindrich/G-3267-2014
OI Skalova, Tereza/0000-0003-3186-2431; Hasek,
   Jindrich/0000-0001-7973-1815; Konvalinka, Jan/0000-0003-0695-9266
CR Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890
   Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z                                                               
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Desiraju G.R., 1998, WEAK HYDROGEN BOND
   Dohnalek J, 2002, J MED CHEM, V45, P1432, DOI 10.1021/jm010979e
   Dohnalek J, 1998, GEN PHYSIOL BIOPHYS, V17, P9
   Dohnalek J, 2001, ACTA CRYSTALLOGR D, V57, P472, DOI 10.1107/S0907444900018928
   Garg R, 1999, CHEM REV, V99, P3525, DOI 10.1021/cr9703358                                                               
   Jones T. A., 1990, CRYSTALLOGRAPHIC MOD, P189
   Konvalinka J, 1997, EUR J BIOCHEM, V250, P559, DOI 10.1111/j.1432-1033.1997.0559a.x                                                
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m
   Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9
   Munshi S, 1998, ACTA CRYSTALLOGR D, V54, P1053, DOI 10.1107/S0907444998003588
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Rinnova M, 2000, ARCH BIOCHEM BIOPHYS, V382, P22, DOI 10.1006/abbi.2000.2017
   SKALOVA T, 2003, J MED CHEM, V6, P1636
   SOUCEK M, 1995, COLLECT CZECH CHEM C, V60, P693, DOI 10.1135/cccc19950693
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
NR 21
TC 7
Z9 8
U1 0
U2 1
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0014-2956
J9 EUR J BIOCHEM
JI Eur. J. Biochem.
PD NOV
PY 2004
VL 271
IS 22
BP 4451
EP 4461
DI 10.1111/j.1432-1033.2004.04384.x
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 873FC
UT WOS:000225264300011
PM 15560786
OA gold
DA 2018-01-05
ER

PT J
AU Pretorius, AM
   Sommer, AP
   Aho, KM
   Kajander, EO
AF Pretorius, AM
   Sommer, AP
   Aho, KM
   Kajander, EO
TI HIV and nanobacteria
SO HIV MEDICINE
LA English
DT Article
ID DISEASE
C1 Univ Orange Free State, Natl Hlth Lab Serv, Dept Med Microbiol, Sch Med,Fac Hlth Sci, ZA-9300 Bloemfontein, South Africa.
   Univ Ulm, Cent Inst Biomed Engn, Ulm, Germany.
   Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland.
RP Pretorius, AM (reprint author), Univ Orange Free State, Natl Hlth Lab Serv, Dept Med Microbiol, Sch Med,Fac Hlth Sci, ZA-9300 Bloemfontein, South Africa.
EM gnvramp.md@mail.uovs.ac.za
CR Ciftcioglu N, 2002, ANTIMICROB AGENTS CH, V46, P2077, DOI 10.1128/AAC.46.7.2007-2086.2002
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   Kajander EO, 2001, CURR OPIN NEPHROL HY, V10, P445, DOI 10.1097/00041552-200105000-00023                                                
   Khullar M, 2004, UROL RES, V32, P190, DOI 10.1007/s00240-004-0400-3
   Miller VM, 2004, AM J PHYSIOL-HEART C, V287, pH1115, DOI 10.1152/ajpheart.00075.2004
   Nadler RB, 2003, J UROLOGY, V169, P475, DOI 10.1097/01.ju.0000046021.43205.d6
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J CLIN LASER MED SUR, V21, P231, DOI 10.1089/104454703768247819
NR 10
TC 17
Z9 20
U1 0
U2 0
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1464-2662
J9 HIV MED
JI HIV Med.
PD NOV
PY 2004
VL 5
IS 6
BP 391
EP 393
DI 10.1111/j.1468-1293.2004.00242.x
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA 876VN
UT WOS:000225526700001
PM 15544689
OA gold
DA 2018-01-05
ER

PT J
AU Cutalo, JM
   Deterding, LJ
   Tomer, KB
AF Cutalo, JM
   Deterding, LJ
   Tomer, KB
TI Characterization of glycopeptides from HIV-I-SF2 gp120 by liquid
   chromatography mass spectrometry
SO JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; N-LINKED GLYCANS; MANNOSE-BINDING LECTIN;
   ENVELOPE GLYCOPROTEIN; CORECEPTOR USAGE; SIALIC-ACID; HIV TYPE-1; GP
   120; COMPLEX; OLIGOSACCHARIDES
AB Previously, we have characterized the HIV-I-SF2 gp120 glycopeptides using matrix-assisted laser desorption/ ionization mass spectrometry (MALDI/MS) and nanospray electrospray ionization (ESI). Although we characterized 25 of 26 consensus glycosylation sites, we could not obtain any information about the extent of sialylation of the complex glycans. Sialylation is known to alter the biological activity of some glycoproteins, e.g., infectivity of some human and nonhuman primate lentiviruses is reduced when the envelope glycoproteins are extensively sialylated, and thus, characterization of the extent of sialylation of complex glycoproteins is of biological interest. Since neither MALDI/MS nor nanospray ESI provided much information about sialylation, probably because of suppression effects inherent in these techniques, we utilized online nanocapillary high performance liquid chromatography (nHPLC) with ESI/MS to characterize the sites and extent of sialylation on gp120. Eight of the known 26 consensus glycosylation sites of HIV-I-SF2 gp120 were determined to be sialylated. Two of these sites were previously uncharacterized complex glycans. Thirteen high mannose sites were also determined. The heterogeneity of four of these sites had not been previously characterized. In addition, a peptide containing two consensus glycosylation sites, which had previously been determined to contain complex glycans, was also determined to be high mannose aswell. (J Am Soc Mass Spectrom 2004,15,1545-1555) (C) 2004 American Society for Mass Spectrometry.
C1 NIEHS, Struct Biol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA.
RP Tomer, KB (reprint author), NIEHS, Struct Biol Lab, NIH, Dept Hlth & Human Serv, 111 TW Alexander Dr,POB 12233,MD-F0-03, Res Triangle Pk, NC 27709 USA.
EM tomer@niehs.nih.gov
RI Tomer, Kenneth/E-8018-2013
FU NIEHS NIH HHS [Z01 ES050150-10]
CR Alberts B, 1989, MOL BIOL CELL, P405
   Biller M, 1998, J VIROL METHODS, V76, P87, DOI 10.1016/S0166-0934(98)00127-X
   Bolmstedt A, 1997, ARCH VIROL, V142, P2465, DOI 10.1007/s007050050255                                                           
   Bozue JA, 1999, J BIOL CHEM, V274, P4106, DOI 10.1074/jbc.274.7.4106
   EZKOWITZ RAB, 1989, J EXP MED, V169, P185
   Hart ML, 2002, AIDS RES HUM RETROV, V18, P1311, DOI 10.1089/088922202320886352                                                      
   HAURUM JS, 1993, AIDS, V7, P1307, DOI 10.1097/00002030-199310000-00002
   Hu HL, 1996, J VIROL, V70, P7462
   Jeyarajah S, 1998, J AM SOC MASS SPECTR, V9, P157, DOI 10.1016/S1044-0305(97)00247-X                                                   
   Kolchinsky P, 2001, J VIROL, V75, P3435, DOI 10.1128/JVI.75.7.3435-3443.2001
   Kuster B, 2001, PROTEOMICS, V1, P350
   Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Li Y, 2001, AIDS RES HUM RETROV, V17, P1473, DOI 10.1089/08892220152644179                                                       
   Luciw Paul A., 1996, P845
   LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47
   MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Polzer S, 2002, VIROLOGY, V304, P70, DOI 10.1006/viro.2002.1760
   Polzer S, 2001, GLYCOBIOLOGY, V11, P11, DOI 10.1093/glycob/11.1.11                                                          
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Saifuddin M, 2000, J GEN VIROL, V81, P949, DOI 10.1099/0022-1317-81-4-949                                                      
   Smith RE, 1998, AIDS RES HUM RETROV, V14, P851, DOI 10.1089/aid.1998.14.851
   WYATT R, 1995, J VIROL, V69, P5723
   ZHU X, 2000, BIOCHEMISTRY-US, V9, P11194
NR 25
TC 49
Z9 49
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1044-0305
J9 J AM SOC MASS SPECTR
JI J. Am. Soc. Mass Spectrom.
PD NOV
PY 2004
VL 15
IS 11
BP 1545
EP 1555
DI 10.1016/j.jasms.2004.07.008
PG 11
WC Biochemical Research Methods; Chemistry, Analytical; Chemistry,
   Physical; Spectroscopy
SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy
GA 868PM
UT WOS:000224925500003
PM 15519221
OA gold
DA 2018-01-05
ER

PT J
AU Benjahad, A
   Courte, K
   Guillemont, J
   Mabire, D
   Coupa, S
   Poncelet, A
   Csoka, I
   Andries, K
   Pauwels, R
   de Bethune, MP
   Monneret, C
   Bisagni, E
   Nguyen, CH
   Grierson, DS
AF Benjahad, A
   Courte, K
   Guillemont, J
   Mabire, D
   Coupa, S
   Poncelet, A
   Csoka, I
   Andries, K
   Pauwels, R
   de Bethune, MP
   Monneret, C
   Bisagni, E
   Nguyen, CH
   Grierson, DS
TI 4-Benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family
   of potent anti-HIV agents: Optimization and in vitro evaluation against
   clinically important HIV mutant strains
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; IMMUNODEFICIENCY-VIRUS TYPE-1;
   SELECTIVE ANTI-HIV-1 AGENTS; 2-PYRIDINONE DERIVATIVES; NONNUCLEOSIDE
   INHIBITORS; 1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE HEPT;
   ANTIRETROVIRAL THERAPY; ANTIVIRAL ACTIVITY; PYRIDINONE DERIVATIVES;
   RESISTANCE MUTATIONS
AB The 4-benzyl and 4-benzoyl-3-dimethylaminopyridinones 13 and 14 are representatives of a new class of highly potent non nucleoside type inhibitors of HIV-1 reverse transcriptase. To conduct SAR studies on these two lead compounds, 102 new analogues were prepared. Thirty-three compounds displayed nanomolar range activity in vitro against wild-type HIV-1, and among these, 18 were active against the 103N, Y181C, and Y188L mutant strains with IC50 values inferior to 1 muM. Evaluation of this group of analogues against an additional eight single [100I, 101E, 106A, 138K, 179E, 190A, 190S, 227C] and four double HIV mutant strains [100I + 103N, 101E + 103N, 103N + 181C, and 227L + 106A], which are often present in HIV infected patients, permitted the selection of eight compounds, 17x, 18b, 18c, 18f, 18g, 27, 30, and 42, which are globally more active than the lead molecules 13/14, emivirine and the currently used NNRTI, nevirapine. Further comparison of the 3'-CN-substituted benzoylpyridinone compound 18c, and the corresponding 3'-acrylonitrile-substituted analogue 30, to efavirenz, the reference molecule in anti-HIV therapy today, revealed that the pyridinone analogues displayed a superior inhibition profile in the in vitro cellular assay system. These results form a solid basis for continued optimization of the pyridinone series.
C1 Inst Curie, CNRS, UMR 176, Lab Pharmacochim,Sect Rech, F-91405 Orsay, France.
   Johnson&Johnson Pharmaceut Res & Dev, Dept Med Chem, Val De Reuil, France.
   Johnson&Johnson Pharmaceut Res & Dev, Virol Drug Discovery, B-2340 Beerse, Belgium.
   TIBOTEC, B-2800 Mechelen, Belgium.
RP Nguyen, CH (reprint author), Inst Curie, CNRS, UMR 176, Lab Pharmacochim,Sect Rech, Batiment 110,Ctr Univ, F-91405 Orsay, France.
EM chi.hung@curie.u-psud.fr
CR Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064                                                          
   Bastard JP, 2002, LANCET, V359, P1026, DOI 10.1016/S0140-6736(02)08094-7
   Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   Chan JH, 2001, J MED CHEM, V44, P1866, DOI 10.1021/jm0004906
   De Clercq E, 2000, REV MED VIROL, V10, P255, DOI 10.1002/1099-1654(200007/08)10:4<255::AID-RMV282>3.0.CO;2-6
   De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7
   De Clercq E, 2002, BBA-MOL BASIS DIS, V1587, P258, DOI 10.1016/S0925-4439(02)00089-3
   Deeks SG, 2001, J ACQ IMMUN DEF SYND, V26, pS25, DOI 10.1097/00126334-200103011-00004
   Dolle V, 2000, J MED CHEM, V43, P3949, DOI 10.1021/jm0009437
   Dolle V, 1997, TETRAHEDRON, V53, P12505, DOI 10.1016/S0040-4020(97)00771-0
   DOLLE V, 1995, J MED CHEM, V38, P4679, DOI 10.1021/jm00023a007
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   FLEMING FF, 2003, CHEM REV, V103, P2019
   FREEMAN G, 2003, 2 INT AIDS SOC C HIV
   GOLDMAN ME, 1993, ANTIMICROB AGENTS CH, V37, P947, DOI 10.1128/AAC.37.5.947                                                            
   Hajos Gyorgy, 2000, Drugs of the Future, V25, P47, DOI 10.1358/dof.2000.025.01.858638
   Hertogs K, 1998, ANTIMICROB AGENTS CH, V42, P269
   HOFFMAN JM, 1993, J MED CHEM, V36, P953, DOI 10.1021/jm00060a002
   HOFFMAN JM, 1992, J MED CHEM, V35, P3784, DOI 10.1021/jm00099a006
   HOFFMANN C, 2003, HIV MED 2003
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   Jain RG, 2001, ANTIVIR RES, V51, P151, DOI 10.1016/S0166-3542(01)00148-6
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   KELLY TA, NOVEL NONNUCLEOSIDE
   Kleim JP, 1997, VIROLOGY, V231, P112, DOI 10.1006/viro.1997.8513
   LARDER BA, 1994, J GEN VIROL, V75, P951, DOI 10.1099/0022-1317-75-5-951
   LARHED V, 1997, J ORG CHEM, V62, P7558
   Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002
   Ludovici DW, 2001, BIOORG MED CHEM LETT, V11, P2235, DOI 10.1016/S0960-894X(01)00412-7
   MARX T, 1992, LIEBIGS ANN CHEM, V3, P183
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PROUDFOOT PR, NOVEL NONNUCLEOSIDE
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   Ren JS, 2000, J BIOL CHEM, V275, P14316, DOI 10.1074/jbc.275.19.14316
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   RUIZ N, 2002, 9 C RETR OPP INF FEB
   SAARI WS, 1991, J MED CHEM, V34, P2922, DOI 10.1021/jm00113a036
   SAARI WS, 1992, J MED CHEM, V35, P3792, DOI 10.1021/jm00099a007
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   TANAKA H, 1992, J MED CHEM, V35, P337, DOI 10.1021/jm00080a020
   TANAKA H, 1991, J MED CHEM, V34, P1394, DOI 10.1021/jm00108a023
   TANAKA H, 1995, J MED CHEM, V38, P2860, DOI 10.1021/jm00015a008
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TANAKA H, 1992, J MED CHEM, V35, P4713, DOI 10.1021/jm00103a009
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   TAYLOR HM, 1987, J MED CHEM, V30, P1359, DOI 10.1021/jm00391a016
   Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6
   Ventura M, 1999, ARCH VIROL, V144, P513, DOI 10.1007/s007050050522
   WAI JS, 1993, J MED CHEM, V36, P249, DOI 10.1021/jm00054a009
   Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6                                                   
   BISAGNI E, 1997, Patent No. 9705113
   BISAGNI E, 1999, Patent No. 9955676
NR 56
TC 15
Z9 19
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD OCT 21
PY 2004
VL 47
IS 22
BP 5501
EP 5514
DI 10.1021/jm0407658
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 862MT
UT WOS:000224495700018
PM 15481987
DA 2018-01-05
ER

PT J
AU Balzarini, J
   Van Laethem, K
   Hatse, S
   Vermeire, K
   De Clercq, ER
   Peumans, W
   Van Damme, E
   Vandamme, AM
   Bohlmstedt, A
   Schols, D
AF Balzarini, J
   Van Laethem, K
   Hatse, S
   Vermeire, K
   De Clercq, ER
   Peumans, W
   Van Damme, E
   Vandamme, AM
   Bohlmstedt, A
   Schols, D
TI Profile of resistance of human immunodeficiency virus to
   mannose-specific plant lectins
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID ENVELOPE GLYCOPROTEIN GP120; HAMSTER OVARY CELLS; CYANOVIRIN-N;
   CARBOHYDRATE STRUCTURES; LINKED GLYCOSYLATION; INACTIVATING PROTEIN;
   DEXTRAN SULFATE; HIV-1 INFECTION; SMALL-MOLECULE; V3 LOOP
AB The mannose-specific plant lectins from the Amaryllidaceae family (e.g., Hippeastrum sp. hybrid and Galanthus nivalis) inhibit human immunodeficiency virus (HIV) infection of human lymphocytic, cells in the higher nanogram per milliliter range and suppress syncytium formation between persistently HIV type 1 (HIV-1)-infected cells and uninfected CD4(+) T cells. These lectins inhibit virus entry. When exposed to escalating concentrations of G. nivalis and Hippeastrum sp. hybrid agglutinin, a variety of HIV-1 (IIIB) strains were isolated after 20 to 40 subcultivations which showed a decreased sensitivity to the plant lectins. Several amino acid changes in the envelope glycoprotein gp120, but not in gp41, of the mutant virus isolates were observed. The vast majority of the amino acid changes occurred at the N glycosylation sites and at the S or T residues that are part of the N glycosylation motif. The degree of resistance to the plant lectins was invariably correlated with an increasing number of mutated glycosylation sites in gp120. The nature of these mutations was entirely different from that of mutations that are known to appear in HIV-1 gp120 under the pressure of other viral entry inhibitors such as dextran sulfate, bicyclams (i.e., AMD3100), and chicoric acid, which also explains the lack of cross-resistance of plant lectin-resistant viruses to any other HIV inhibitor including T-20 and the blue-green algae (cyanobacteria)-derived mannose-specific cyanovirin. The plant lectins represent a well-defined class of anti-HIV (microbicidal) drugs with a novel HIV drug resistance profile different from those of other existing anti-HIV drugs.
C1 Rega Inst, B-3000 Louvain, Belgium.
   Univ Hosp St Rafael, Louvain, Belgium.
   Dept Mol Biotechnol, Ghent, Belgium.
   Swedish Inst Infect Dis, Gothenburg, Sweden.
RP Balzarini, J (reprint author), Rega Inst, Minderbroederstr 10, B-3000 Louvain, Belgium.
EM jan.balzarini@rega.kuleuven.ac.be
RI Vandamme, Anne Mieke/I-4127-2012; Van Laethem, Kristel/R-6282-2016;
   Vermeire, Kurt/P-9992-2017; Schols, Dominique/S-9057-2017
OI Vandamme, Anne Mieke/0000-0002-6594-2766; Van Laethem,
   Kristel/0000-0001-6036-2271; Vermeire, Kurt/0000-0003-1123-1907; Schols,
   Dominique/0000-0003-3256-5850; Van Damme, Els/0000-0001-9848-766X
CR ARENDRUP M, 1993, J GEN VIROL, V74, P855, DOI 10.1099/0022-1317-74-5-855                                                      
   Arthos J, 2002, J BIOL CHEM, V277, P11456, DOI 10.1074/jbc.M111191200
   Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   BALZARINI J, 1993, VIROLOGY, V196, P576, DOI 10.1006/viro.1993.1513
   Balzarini J, 1996, MOL PHARMACOL, V49, P882
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   BALZARINI J, 1992, ANTIVIR RES, V18, P191, DOI 10.1016/0166-3542(92)90038-7                                                    
   BALZARINI J, IN PRESS ANTIMICROB
   Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   DeVreese K, 1996, J VIROL, V70, P689
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Este JA, 1997, MOL PHARMACOL, V52, P98
   GALLAHER WR, 1995, AIDS RES HUM RETROV, V11, P191, DOI 10.1089/aid.1995.11.191
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003                                                
   Hart ML, 2002, AIDS RES HUM RETROV, V18, P1311, DOI 10.1089/088922202320886352                                                      
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Losman B, 2001, AIDS RES HUM RETROV, V17, P1067, DOI 10.1089/088922201300343753
   Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Mizuochi T, 1988, Biomed Chromatogr, V2, P260
   O'Keefe BR, 2000, MOL PHARMACOL, V58, P982
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Olofsson S, 1998, SCAND J INFECT DIS, V30, P435
   Pluymers W, 2000, MOL PHARMACOL, V58, P641
   Pollakis G, 2001, J BIOL CHEM, V276, P13433, DOI 10.1074/jbc.M009779200                                                          
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   SCHOLS D, 1990, VIROLOGY, V175, P556, DOI 10.1016/0042-6822(90)90440-3
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Schonning K, 1996, J GEN VIROL, V77, P753, DOI 10.1099/0022-1317-77-4-753
   SPEAR TT, 2003, IMMUNOLOGY, V110, P80
   Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398                                                          
   Trkola A, 1996, J VIROL, V70, P1100
   Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897
   Van den Steen PE, 2000, TRENDS GLYCOSCI GLYC, V12, P35, DOI 10.4052/tigg.12.35                                                              
   VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52
   VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1                                                    
   VANDAMME EJM, 1998, HDB PLANT LECTNS PRO
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514
NR 47
TC 76
Z9 82
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD OCT
PY 2004
VL 78
IS 19
BP 10617
EP 10627
DI 10.1128/JVI.78.19.10617-10627.2004
PG 11
WC Virology
SC Virology
GA 855HP
UT WOS:000223964300044
PM 15367629
OA gold
DA 2018-01-05
ER

PT J
AU Lee, KB
   Kim, EY
   Mirkin, CA
   Wolinsky, SM
AF Lee, KB
   Kim, EY
   Mirkin, CA
   Wolinsky, SM
TI The use of nanoarrays for highly sensitive and selective detection of
   human immunodeficiency virus type 1 in plasma
SO NANO LETTERS
LA English
DT Article
ID DIP-PEN NANOLITHOGRAPHY; SCANNING PROBE LITHOGRAPHY; SELF-ASSEMBLED
   MONOLAYERS; SIZED PROTEIN-PATTERNS; FABRICATION; IMMOBILIZATION;
   NANOSTRUCTURES; SURFACES; ARRAYS; GOLD
AB Arrays of antibodies with well-defined feature size and spacing are necessary for developing highly sensitive and selective immunoassays to detect macromolecules in complex solutions. Here we report the application of nanometer-scale antibody array-based analysis to determine the presence of the human immunodeficiency virus type 1 (HIV-1) in blood samples. Dip-pen nanolithography (DPN) was used to generate nanoscale patterns of antibodies against the HIV-1 p24 antigen on a gold surface. Feature sizes were less than 100-nanometers, and the activity of the antibody was preserved. HIV-1 p24 antigen in plasma obtained directly from HIV-1-infected patients was hybridized to the antibody array in situ, and the bound protein was hybridized to a gold antibody-functionalized nanoparticle probe for signal enhancement. The nanoarray features in the three-component sandwich assay were confirmed by atomic force microscopy (AFM). Demonstration of measurable amounts of HIV-1 p24 antigen in plasma obtained from men with less than 50 copies of RNA per ml of plasma (corresponding to 0.025 pg per ml) illustrates that the nanoarray-based assay can exceed the limit of detection of conventional enzyme-linked immunosorbent assay (ELISA)based immunoassays (5 pg per ml of plasma) by more than 1000-fold.
C1 Northwestern Univ, Dept Chem, Evanston, IL USA.
   Northwestern Univ, Inst Nanotechnol, Evanston, IL USA.
   Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA.
RP Mirkin, CA (reprint author), Northwestern Univ, Dept Chem, 2145 Sheridan Rd, Evanston, IL USA.
EM camirkin@chem.northwestern.edu; s-wolinsky@northwestern.edu
RI Mirkin, Chad/E-3911-2010; Lee, Ki-Bum/G-7503-2015; Lee,
   KiBum/F-3702-2012; Wolinsky, Steven/B-2893-2012
OI Wolinsky, Steven/0000-0002-9625-6697
CR Agarwal G, 2003, J AM CHEM SOC, V125, P7408, DOI 10.1021/ja029856p
   Agarwal G, 2003, J AM CHEM SOC, V125, P580, DOI 10.1021/ja020471g
   Bruckbauer A, 2003, J AM CHEM SOC, V125, P9834, DOI 10.1021/ja035755v
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Emili AQ, 2000, NAT BIOTECHNOL, V18, P393
   Ginger DS, 2004, ANGEW CHEM INT EDIT, V43, P30, DOI 10.1002/anie.200300608
   Gu JH, 2004, J AM CHEM SOC, V126, P8098, DOI 10.1021/ja048405x
   Hyun J, 2004, J AM CHEM SOC, V126, P4770, DOI 10.1021/ja049956q
   Hyun J, 2002, NANO LETT, V2, P1203, DOI 10.1021/n10257364
   Johanson J, 2001, J VIROL METHODS, V95, P81, DOI 10.1016/S0166-0934(01)00297-X
   Jung H, 2003, J AM CHEM SOC, V125, P12096, DOI 10.1021/ja0363720
   Kenseth JR, 2001, LANGMUIR, V17, P4105, DOI 10.1021/la0100744
   Kramer S, 2003, CHEM REV, V103, P4367, DOI 10.1021/cr020704m
   Lee KB, 2002, SCIENCE, V295, P1702, DOI 10.1126/science.1067172
   Lee KB, 2003, J AM CHEM SOC, V125, P5588, DOI 10.1021/ja034236p
   Leopold MC, 2002, LANGMUIR, V18, P978, DOI 10.1021/la011683e
   Liu GY, 2002, P NATL ACAD SCI USA, V99, P5165, DOI 10.1073/pnas.072695699                                                          
   MacBeath G, 2000, SCIENCE, V289, P1760
   Noy A, 2002, NANO LETT, V2, P109, DOI 10.1021/nl010081c
   Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661
   Smith JC, 2003, NANO LETT, V3, P883, DOI 10.1021/nl025956h
   Steindl F, 1998, J IMMUNOL METHODS, V217, P143, DOI 10.1016/S0022-1759(98)00107-0                                                   
   Sun SQ, 2002, J AM CHEM SOC, V124, P2414, DOI 10.1021/ja017673h
   SUTHENT R, 2003, J CLIN MICROBIOL, V41, P1016
   Wadu-Mesthrige K, 1999, LANGMUIR, V15, P8580, DOI 10.1021/la991196n                                                               
   Wadu-Mesthrige K, 2001, BIOPHYS J, V80, P1891, DOI 10.1016/S0006-3495(01)76158-9                                                   
   Wilson DL, 2001, P NATL ACAD SCI USA, V98, P13660, DOI 10.1073/pnas.241323198                                                          
   Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191
NR 28
TC 177
Z9 183
U1 2
U2 70
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530-6984
J9 NANO LETT
JI Nano Lett.
PD OCT
PY 2004
VL 4
IS 10
BP 1869
EP 1872
DI 10.1021/nl049002y
PG 4
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 862TU
UT WOS:000224514800012
DA 2018-01-05
ER

PT J
AU Basu, MK
   Lala, S
AF Basu, MK
   Lala, S
TI Macrophage specific drug delivery in experimental leishmaniasis
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
ID LIPOSOMAL AMPHOTERICIN-B; EXPERIMENTAL VISCERAL LEISHMANIASIS;
   EXPERIMENTAL CUTANEOUS LEISHMANIASIS; HUMAN-IMMUNODEFICIENCY-VIRUS;
   SODIUM STIBOGLUCONATE; ANTILEISHMANIAL AGENT; IN-VIVO; INTRACELLULAR
   LEISHMANIA; ENCAPSULATED DRUGS; MURAMYL DIPEPTIDE
AB Macrophage-specific delivery systems are the subject of much interest nowadays, because of the fact that macrophages act as host cells for many parasites and bacteria, which give rise to outbreak of so many deadly diseases(eg. leishmaniasis, tuberculosis etc.) in humans. To combat these deadly diseases initially macrophage specific liposomal delivery system were thought of and tested in vivo against experimental leishmaniasis in hamsters using a series of indigenous or synthetic antileishmanial compounds and the results were critically discussed. In vitro testing was also done against macrophages infected with Leishmania donovani, the causative agent for visceral leishmaniasis. The common problem of liposome therapy being their larger size, stability and storage, non-ionic surfactant vesicles, niosomes were prepared, for their different drug distribution and release characteristics compared to liposomes. When tested in vivo, the retention capacity of niosomes was found to be higher than that of liposomes due to the absence of lipid molecules and their smaller size. Thus the therapeutic efficacy of certain antileishmanial compounds was found to be better than that in the liposomal form. The niosomes, being cheaper, less toxic, biodegradable and non-immunogenic, were considered for sometime as suitable alternatives to liposomes as drug carriers. Besides the advent of other classical drugs carriers(e.g. neoglycoproteins), the biggest challenge came from polymeric delivery vehicles, specially the polymeric nanoparticles which were made of cost effective biodegradable polymers and different natural polymers. Because of very small size and highly stable nature, use of nanoparticles as effective drug carriers has been explored in experimental leishmaniasis using a series of antileishmanial compounds, both of indigenous and synthetic origin. The feasibility of application in vivo, when tested for biological as well as for other physicochemical parameters, the polymeric nanoparticles have turned out to be the best and thus may be projected for effective use in the clinics.
C1 Indian Inst Chem Biol, Biomembrane Div, Kolkata 700032, W Bengal, India.
RP Basu, MK (reprint author), Indian Inst Chem Biol, Biomembrane Div, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.
EM biomembrane@iicb.res.in; mukulkbasu@yahoo.com
CR ADINOLFI LE, 1985, INFECT IMMUN, V48, P409
   Afrin F, 2000, J PARASITOL, V86, P730, DOI 10.2307/3284956
   Afrin F, 2002, INFECT IMMUN, V70, P6697, DOI 10.1128/IAI.70.12.6697-6706.2002
   AGARWAL AK, 2002, J DRUG TARGET, V10, P41
   AHMAD J, 1991, J BIOSCIENCE, V16, P217
   Alving C. R., 1982, Targeting of drugs. (NATO Advanced Study Institutes Series A, Vol. 47)., P337
   ALVING CR, 1978, P NATL ACAD SCI USA, V75, P2959, DOI 10.1073/pnas.75.6.2959
   ALVING CR, 1980, LIFE SCI, V26, P2231, DOI 10.1016/0024-3205(80)90207-6
   ALVING CR, 1983, PHARMACOL THERAPEUT, V22, P407, DOI 10.1016/0163-7258(83)90010-4
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3                                                   
   BAILLIE AJ, 1986, J PHARM PHARMACOL, V38, P502, DOI 10.1111/j.2042-7158.1986.tb04623.x                                              
   BAILLIE AJ, 1987, J PHARM PHARMACOL, V39, P832, DOI 10.1111/j.2042-7158.1987.tb05126.x                                              
   BANERJEE G, 1994, BIOCHEM MED METAB B, V53, P1, DOI 10.1006/bmmb.1994.1050
   Banerjee G, 1996, J ANTIMICROB CHEMOTH, V38, P145, DOI 10.1093/jac/38.1.145                                                            
   Banerjee G, 1998, ANTIMICROB AGENTS CH, V42, P348
   Basu M K, 1994, Biotechnol Genet Eng Rev, V12, P383
   BERMAN JD, 1986, ANTIMICROB AGENTS CH, V30, P847, DOI 10.1128/AAC.30.6.847                                                            
   BLACK CDV, 1977, T ROY SOC TROP MED H, V71, P550, DOI 10.1016/0035-9203(77)90155-9
   Bodhe P V, 1996, J Assoc Physicians India, V44, P222
   Carter KC, 1999, CLIN DIAGN LAB IMMUN, V6, P61
   CHAKRABORTY P, 1990, BIOCHEM BIOPH RES CO, V166, P404, DOI 10.1016/0006-291X(90)91959-V
   Chakraborty R, 1999, BIOCHEM J, V340, P393, DOI 10.1042/0264-6021:3400393                                                       
   CHOWDHURI G, 1997, BIOCHEM PHARMACOL, V53, P385
   CROFT SL, 1991, J ANTIMICROB CHEMOTH, V28, P111, DOI 10.1093/jac/28.suppl_B.111                                                      
   DAS N, 1990, BIOCHEM MED METAB B, V43, P133, DOI 10.1016/0885-4505(90)90018-V
   Dasgupta D, 2002, J BIOCHEM, V132, P23, DOI 10.1093/oxfordjournals.jbchem.a003194                                           
   DAVIDSON RN, 1991, LANCET, V337, P1061, DOI 10.1016/0140-6736(91)91708-3
   Davies CR, 2003, BRIT MED J, V326, P377, DOI 10.1136/bmj.326.7385.377
   DIMARTINO L, 1993, T ROY SOC TROP MED H, V87, P477, DOI 10.1016/0035-9203(93)90045-R                                                    
   DUTTA M, 1994, PARASITOLOGY, V109, P139, DOI 10.1017/S0031182000076253                                                       
   FOVSAI T, 1994, PARASITE, V1, P319
   Fusai T, 1997, PARASITE, V4, P133, DOI 10.1051/parasite/1997042133                                                     
   Gangneux JP, 1996, ANTIMICROB AGENTS CH, V40, P1214
   GURU PY, 1989, FEBS LETT, V245, P204, DOI 10.1016/0014-5793(89)80222-4                                                    
   HASHIM FA, 1995, T ROY SOC TROP MED H, V89, P440, DOI 10.1016/0035-9203(95)90048-9
   Hiremath Shobha Rani R., 1999, Indian Journal of Pharmaceutical Sciences, V61, P69
   HUNTER CA, 1988, J PHARM PHARMACOL, V40, P161, DOI 10.1111/j.2042-7158.1988.tb05210.x                                              
   KOLE L, 1994, BIOCHEM BIOPH RES CO, V200, P351, DOI 10.1006/bbrc.1994.1455
   Kole L, 1999, J INFECT DIS, V180, P811, DOI 10.1086/314929
   LAGUNA F, 1995, CLIN INFECT DIS, V21, P711, DOI 10.1093/clinids/21.3.711                                                        
   Lala S, 2003, INDIAN J BIOCHEM BIO, V40, P169
   LAZANAS MC, 1993, AIDS, V7, P1018, DOI 10.1097/00002030-199307000-00020                                                
   MAITRA AJN, 2000, J SURF SCI TECHNOL, V16, P316
   Medda S, 2003, J DRUG TARGET, V11, P123, DOI 10.1080/1061186031000119101
   MEDDA S, 1993, BIOTECHNOL APPL BIOC, V17, P37
   Medda S, 1999, J ANTIMICROB CHEMOTH, V44, P791, DOI 10.1093/jac/44.6.791
   Mishra M, 2001, BIOCHEM PHARMACOL, V62, P569, DOI 10.1016/S0006-2952(01)00695-5
   MUKHOPADHYAY A, 1989, SCIENCE, V244, P705, DOI 10.1126/science.2717947                                                         
   MURRAY HW, 1998, J INFECT DIS, V158, P1372
   NEW RRC, 1980, ACTA TROP, V37, P253
   NEW RRC, 1978, NATURE, V272, P55, DOI 10.1038/272055a0                                                                
   Raay B, 1999, INDIAN J BIOCHEM BIO, V36, P248
   RUSSELL DG, 1988, J IMMUNOL, V140, P1274
   Russo R, 1996, J INFECTION, V32, P133, DOI 10.1016/S0163-4453(96)91343-2                                                   
   Sarkar K, 1997, J IMMUNOL, V158, P5357
   Sarkar S, 2002, J DRUG TARGET, V10, P573, DOI 10.1080/106118021000072681
   SEAMAN J, 1995, CLIN INFECT DIS, V21, P188, DOI 10.1093/clinids/21.1.188                                                        
   Sinha J, 2002, DRUG DELIV, V9, P55, DOI 10.1080/107175402753413181                                                      
   Sinha J, 2000, DRUG DELIV, V7, P209
   SMITH OP, 1995, ARCH DIS CHILD, V73, P157, DOI 10.1136/adc.73.2.157                                                            
   Sundar S, 1996, J INFECT DIS, V173, P762, DOI 10.1093/infdis/173.3.762                                                        
   Sundar S, 2001, BRIT MED J, V323, P419, DOI 10.1136/bmj.323.7310.419
   Thakur CP, 1996, T ROY SOC TROP MED H, V90, P319, DOI 10.1016/S0035-9203(96)90271-0                                                   
   TORRECISNEROS J, 1994, CLIN INFECT DIS, V18, P1024, DOI 10.1093/clinids/18.6.1024                                                       
   TORRECISNEROS J, 1993, CLIN INFECT DIS, V17, P625, DOI 10.1093/clinids/17.4.625                                                        
   Yardley V, 1997, ANTIMICROB AGENTS CH, V41, P752
NR 66
TC 42
Z9 43
U1 1
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PD SEP
PY 2004
VL 4
IS 6
BP 681
EP 689
DI 10.2174/1566524043360186                                                
          
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 845CK
UT WOS:000223213100011
PM 15357216
DA 2018-01-05
ER

PT J
AU Trehin, R
   Merkle, HP
AF Trehin, R
   Merkle, HP
TI Chances and pitfalls of cell penetrating peptides for cellular drug
   delivery
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Review
DE cell penetrating peptides; cellular drug delivery; endocytosis;
   permeation; biological barriers; toxicity
ID HIV-1 TAT PROTEIN; HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION
   SEQUENCE; ARGININE-RICH PEPTIDES; EFFICIENT INTRACELLULAR DELIVERY;
   VECTOR-MEDIATED STRATEGY; VP22-GFP FUSION PROTEINS; POLY-L-ARGININE;
   BASIC DOMAIN; IN-VIVO
AB Over the past decade, several classes and/or prototypes of cell penetrating peptides (CPP) have been identified and investigated in multiple aspects. CPP represent peptides, which show the ability to cross the plasma membrane of mammalian cells, and may thus give rise to the intracellular delivery of problematic therapeutic cargos, such as peptides, proteins, oligonucleotides, plasmids and even nanometer-sized particles, which otherwise cannot cross the plasma membrane. Most of the currently recognized CPP are of cationic nature and derived from viral, insect or mammalian proteins endowed with membrane translocation properties. The exact mechanisms underlying the translocation of CPP across the cellular membrane are still poorly understood. However, several similarities in translocation can be found. Early studies on CPP translocation mechanisms tended to suggest that the internalization of these peptides was neither significantly inhibited by low temperature, depletion of the cellular adenosine triphosphate (ATP) pool, nor by inhibitors of endocytosis. Moreover, chemical modification of the peptide sequence, such as the synthesis of retro-, enantio- or retroenantio-analogs, appeared not to affect the internalization properties. Therefore, translocation was concluded to result from direct, physical transfer through the lipid bilayer of the cell membrane. Later studies, however, showed convincing evidence for the involvement of endocytosis as the dominating mechanism for cellular internalization. In addition to describing the general properties of the commonly recognized classes of CPP, in this review we will also point out some limitations and typical pitfalls of CPP as carriers for therapeutics. In particular we will comment on emerging discrepancies with the current dogma, on cell-to-cell variability, biological barrier permeability, metabolic fate, toxicity and immunogenicity of CPP. (C) 2004 Elsevier B.V. All rights reserved.
C1 Massachusetts Gen Hosp, CMIR, Charlestown, MA 02129 USA.
   Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
   Swiss Fed Inst Technol, Dept Chem & Appl Biosci, Zurich, Switzerland.
RP Trehin, R (reprint author), Massachusetts Gen Hosp, CMIR, 13th St,Bldg 149, Charlestown, MA 02129 USA.
EM rtrehin@partners.org
RI Merkle, Hans/A-4381-2014
CR Aints A, 1999, J GENE MED, V1, P275
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   ANDERSON DC, 1993, BIOCONJUGATE CHEM, V4, P10, DOI 10.1021/bc00019a002
   Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   Bayley H, 1999, NAT BIOTECHNOL, V17, P1066, DOI 10.1038/15050
   Belting M, 2003, TRENDS BIOCHEM SCI, V28, P145, DOI 10.1016/S0968-0004(03)00031-8
   BENJOUAD A, 1993, FEBS LETT, V319, P119, DOI 10.1016/0014-5793(93)80049-Z
   Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x
   Beven L, 1997, BBA-BIOMEMBRANES, V1329, P357, DOI 10.1016/S0005-2736(97)00130-2                                                   
   Bogoyevitch MA, 2002, DNA CELL BIOL, V21, P879, DOI 10.1089/104454902762053846                                                      
   Bolton SJ, 2000, EUR J NEUROSCI, V12, P2847, DOI 10.1046/j.1460-9568.2000.00171.x                                                
   Bonavia R, 2001, BIOCHEM BIOPH RES CO, V288, P301, DOI 10.1006/bbrc.2001.5743
   Bonfanti M, 1997, CANCER RES, V57, P1442
   BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275
   Brewis N, 2000, J VIROL, V74, P1051, DOI 10.1128/JVI.74.2.1051-1056.2000                                                 
   CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   CHAKRABARTI R, 1989, J BIOL CHEM, V264, P15494
   Chaloin L, 1998, BIOCHEM BIOPH RES CO, V243, P601, DOI 10.1006/bbrc.1997.8050
   Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993
   Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325
   CONNOR J, 1985, J CELL BIOL, V101, P582, DOI 10.1083/jcb.101.2.582
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Davidson BL, 2003, NAT REV NEUROSCI, V4, P353, DOI 10.1038/nrn1104
   Derer W, 1999, J MOL MED-JMM, V77, P609, DOI 10.1007/s001099900036                                                           
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Dilber MS, 1999, GENE THER, V6, P12, DOI 10.1038/sj.gt.3300838
   Drin G, 2003, J BIOL CHEM, V278, P31192, DOI 10.1074/jbc.M303938200
   Drin G, 2001, EUR J BIOCHEM, V268, P1304, DOI 10.1046/j.1432-1327.2001.01997.x
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850
   ELLIOTT GD, 1992, J GEN VIROL, V73, P723, DOI 10.1099/0022-1317-73-3-723
   Elmquist A, 2003, BIOL CHEM, V384, P387, DOI 10.1515/BC.2003.044                                                             
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Falnes PO, 2001, BIOCHEMISTRY-US, V40, P4349, DOI 10.1021/bi002443l
   Fang B, 1998, GENE THER, V5, P1420, DOI 10.1038/sj.gt.3300741                                                           
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Ferrari A, 2003, MOL THER, V8, P284, DOI 10.1016/S1525-0016(03)00122-9
   Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115
   Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x                                                
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   FOLDVARI M, 1991, J PHARM SCI, V80, P1020, DOI 10.1002/jps.2600801105                                                          
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Garcia-Echeverria C, 2001, BIOORG MED CHEM LETT, V11, P1363, DOI 10.1016/S0960-894X(01)00208-6
   GEHRING WJ, 1990, TRENDS GENET, V6, P323, DOI 10.1016/0168-9525(90)90253-3                                                    
   Gius DR, 1999, CANCER RES, V59, P2577
   GREEN J, 2003, TRENDS PHARMACOL SCI, V24, P213
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Han K, 2000, MOL CELLS, V10, P728, DOI 10.1007/s100590000036
   Ho A, 2001, CANCER RES, V61, P474
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Jia HY, 2001, BIOCHEM BIOPH RES CO, V283, P469, DOI 10.1006/bbrc.2001.4790
   JOLIOT AH, 1991, NEW BIOL, V3, P1121
   Koelle DM, 1998, J VIROL, V72, P7476
   Koppelhus U, 2002, ANTISENSE NUCLEIC A, V12, P51, DOI 10.1089/108729002760070795                                                      
   Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1
   Kuchler Karl, 1993, Trends in Cell Biology, V3, P421, DOI 10.1016/0962-8924(93)90030-5
   Kueltzo LA, 2000, EXPERT OPIN INV DRUG, V9, P2039, DOI 10.1517/13543784.9.9.2039
   Lai ZN, 2000, P NATL ACAD SCI USA, V97, P11297, DOI 10.1073/pnas.97.21.11297
   Lang S, 1998, PEPTIDES, V19, P599, DOI 10.1016/S0196-9781(97)00470-1
   LEAMON CP, 1991, P NATL ACAD SCI USA, V88, P5572, DOI 10.1073/pnas.88.13.5572
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   LEROUX I, 1995, FEBS LETT, V368, P311, DOI 10.1016/0014-5793(95)00681-X
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305                                                         
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Lindgren ME, 2004, BIOCHEM J, V377, P69, DOI 10.1042/BJ20030760
   Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819
   LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   Machova Z, 2002, CHEMBIOCHEM, V3, P672, DOI 10.1002/1439-7633(20020703)3:7<672::AID-CBIC672>3.0.CO;2-D
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   MANN DA, 1991, EMBO J, V10, P1733
   Mazel M, 2001, ANTI-CANCER DRUG, V12, P107, DOI 10.1097/00001813-200102000-00003                                                
   MELAN MA, 1992, J CELL SCI, V101, P731
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nath A, 1996, J VIROL, V70, P1475
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   ORTIZ D, 1987, MOL CELL BIOL, V7, P3012, DOI 10.1128/MCB.7.8.3012                                                            
   PEREZ F, 1992, J CELL SCI, V102, P717
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Pichon C, 1999, ANTISENSE NUCLEIC A, V9, P89, DOI 10.1089/oli.1.1999.9.89
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X
   Prochiantz A, 1999, ANN NY ACAD SCI, V886, P172, DOI 10.1111/j.1749-6632.1999.tb09410.x                                              
   RICHARD JP, 2003, J BIOL CHEM, V30, P585
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370                                                             
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Rousselle C, 2001, J PHARMACOL EXP THER, V296, P124
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027
   Rusnati M, 2001, J BIOL CHEM, V276, P22420, DOI 10.1074/jbc.M010779200
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   SANTANA A, 1993, AGENTS ACTIONS, V39, P104, DOI 10.1007/BF01998961
   Schmidt MC, 1998, BIOCHEMISTRY-US, V37, P16582, DOI 10.1021/bi981219h                                                               
   SchutzeRedelmeier MP, 1996, J IMMUNOL, V157, P650
   Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shahana S, 2002, MEDIAT INFLAMM, V11, P141, DOI 10.1080/09622935020138172
   SHELDON K, 1995, P NATL ACAD SCI USA, V92, P2056, DOI 10.1073/pnas.92.6.2056
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400                                                          
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Trehin R, 2004, PHARM RES, V21, P33, DOI 10.1023/B:PHAM.0000012149.83119.bf
   TREHIN R, 2004, THESIS ETH ZURICH
   Troy CM, 1996, J NEUROSCI, V16, P253
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Violini S, 2002, BIOCHEMISTRY-US, V41, P12652, DOI 10.1021/bi026097e
   Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   VIVES E, 1994, J VIROL, V68, P3343
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   WU GY, 1991, BIOTHERAPY, V3, P87, DOI 10.1007/BF02175102
   Wybranietz WA, 1999, J GENE MED, V1, P265
   Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184                                                         
NR 132
TC 149
Z9 160
U1 3
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0939-6411
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD SEP
PY 2004
VL 58
IS 2
BP 209
EP 223
DI 10.1016/j.ejpb.2004.02.018
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 849GQ
UT WOS:000223527100003
PM 15296950
DA 2018-01-05
ER

PT J
AU Sommer, AP
AF Sommer, AP
TI Suffocation of nerve fibers by living nanovesicles: A model simulation -
   Part II
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Letter
DE apatite; nanovesicles; nanobacteria; adhesion; peripheral neuropathy;
   diabetes; HIV
ID KIDNEY-STONE FORMATION; PRIMORDIAL BIOSYSTEMS; NANOBACTERIA; LIGHT;
   WATER; CELL; CALCIFICATION; NANOSPHERES
AB Nanobacteria may cause peripheral neuropathy by adhesion to the perineurium. This hypothesis receives support from five independent observations: (1) identification of perineurial apatite in diabetic patients with peripheral neuropathy, (2) massive presence of nanobacteria in a diabetic patient, (3) beneficial effect of lasers on peripheral neuropathy, (4) model simulation indicating that perineurial deposition and attachment of nanobacteria is encouraged by both their size and chemical nature, and (5) transient inhibition of neural function by apatite. Initial deposition of (stressed) nanobacteria is promoted by a slime thought to consist of proteins, calcium, and phosphate, and is most likely followed by an immobilization phase, mediated by a bioadhesive capacity of the apatite. Proteomics may hold the key to control both attachment processes.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Cehreli MC, 2003, CLIN ORAL IMPLAN RES, V14, P269, DOI 10.1034/j.1600-0501.2003.140303.x                                               
   Ciftcioglu N, 1999, KIDNEY INT, V56, P1893, DOI 10.1046/j.1523-1755.1999.00755.x
   Ciftcioglu N, 2002, ANTIMICROB AGENTS CH, V46, P2077, DOI 10.1128/AAC.46.7.2007-2086.2002
   Freund J, 1999, MICROSC RES TECHNIQ, V44, P327, DOI 10.1002/(SICI)1097-0029(19990301)44:5<327::AID-JEMT3>3.0.CO;2-E                 
   Ghosh S, 2003, SCIENCE, V299, P1042, DOI 10.1126/science.1079080
   Jelic TM, 2004, SOUTH MED J, V97, P194, DOI 10.1097/01.SMJ.0000077067.44311.F0
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   KHULLAR M, IN PRESS UROL RES
   Kim BH, 2004, APPL MICROBIOL BIOT, V63, P672, DOI 10.1007/s00253-003-1412-6
   KING RH, 1988, J NEUROPATHOL APPL N, V14, P105
   MARMUR A, IN PRESS LANGMUIR
   MOREY TE, IN PRESS NANOLETT
   PAETAU A, 1976, ACTA NEUROPATHOL, V36, P185, DOI 10.1007/BF00685280                                                              
   RASMUSSEN TE, 2002, J AM COLL CARDIOL S1, V39, P206
   RUCKENSTEIN E, 1976, J THEOR BIOL, V58, P439, DOI 10.1016/S0022-5193(76)80130-0
   RUCKENSTEIN E, 1977, J THEOR BIOL, V66, P147, DOI 10.1016/0022-5193(77)90317-4
   Ruoslahti E, 1999, NATURE, V397, P479, DOI 10.1038/17229                                                                   
   Sommer AP, 2004, J PHYS CHEM B, V108, P8, DOI 10.1021/jp0363747
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2003, NANO LETT, V3, P321, DOI 10.1021/nl025940r
   Sommer AP, 2003, NANO LETT, V3, P19, DOI 10.1021/nl025839m
   Sommer AP, 2002, CRYST GROWTH DES, V2, P563, DOI 10.1021/cg0255725
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   Sommer AP, 2002, J PROTEOME RES, V1, P111, DOI 10.1021/pr025501t
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   SOMMER AP, IN PRESS J PROTEOME
   SOMMER AP, 2001, J CLIN LASER MED SUR, V19, P112
   SOMMER AP, 2003, J CLIN LASER MED SUR, V21, P229
NR 31
TC 19
Z9 19
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD SEP-OCT
PY 2004
VL 3
IS 5
BP 1086
EP 1088
DI 10.1021/pr049935v
PG 3
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 865HR
UT WOS:000224693800022
PM 15473700
DA 2018-01-05
ER

PT J
AU Zhang, MY
   Xiao, XD
   Sidorov, IA
   Choudhry, V
   Cham, F
   Zhang, PF
   Bouma, P
   Zwick, M
   Choudhary, A
   Montefiori, DC
   Broder, CC
   Burton, DR
   Quinnan, GV
   Dimitrov, DS
AF Zhang, MY
   Xiao, XD
   Sidorov, IA
   Choudhry, V
   Cham, F
   Zhang, PF
   Bouma, P
   Zwick, M
   Choudhary, A
   Montefiori, DC
   Broder, CC
   Burton, DR
   Quinnan, GV
   Dimitrov, DS
TI Identification and characterization of a new cross-reactive human
   immunodeficiency virus type 1-neutralizing human monoclonal antibody
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID NEUTRALIZATION RESISTANCE PHENOTYPE; HIV-1 ENVELOPE GLYCOPROTEINS; PHAGE
   DISPLAY LIBRARIES; CD4 BINDING-SITE; CD4-BINDING SITE; PHASE-I;
   COMBINATORIAL LIBRARIES; PASSIVE-IMMUNIZATION; ANTIVIRAL ACTIVITY; HIGH
   INFECTIVITY
AB The identification and characterization of new human monoclonal antibodies (hMAbs) able to neutralize primary human immunodeficiency virus type 1 (HIV-1) isolates from different subtypes may help in our understanding of the mechanisms of virus entry and neutralization and in the development of entry inhibitors and vaccines. For enhanced selection of broadly cross-reactive antibodies, soluble HIV-1 envelope glycoproteins (Envs proteins) from two isolates complexed with two-domain soluble CD4 (sCD4) were alternated during panning of a phage-displayed human antibody library; these two Env proteins (89.6 and IIIB gp140s), and one additional Env (JR-FL gp120) alone and complexed with sCD4 were used for screening. An antibody with relatively long HCDR3 (17 residues), designated m14, was identified that bound to all antigens and neutralized heterologous HIV-1 isolates in multiple assay formats. Fab m14 potently neutralized selected well-characterized subtype B isolates, including JRCSF, 89.6, IIIB, and Yu2. Immunoglobulin G1 (IgG1) m14 was more potent than Fab m14 and neutralized 7 of 10 other clade B isolates; notably, although the potency was on average significantly lower than that of IgG1 b12, IgG1 m14 neutralized two of the isolates with significantly lower 50% inhibitory concentrations than did IgG1 b12. IgG1 m14 neutralized four of four selected clade C isolates with potency higher than that of IgG1 b12. It also neutralized 7 of 17 clade C isolates from southern Africa that were difficult to neutralize with other hMAbs and sCD4. IgG1 m14 neutralized four of seven primary HIV-1 isolates from other clades (A, D, E, and F) much more efficiently than did IgG1 b12; for the other three isolates, IgG b12 was much more potent. Fab m14 bound with high (nanomolar range) affinity to gp120 and gp140 from various isolates; its binding was reduced by soluble CD4 and antibodies recognizing the CD4 binding site (CD4bs) on gp120, and its footprint as defined by alanine-scanning mutagenesis overlaps that of b12. These results suggest that m14 is a novel CD4bs cross-reactive HIV-1-neutralizing antibody that exhibits a different inhibitory profile compared to the only known potent broadly neutralizing CD4bs human antibody, b12, and may have implications for our understanding of the mechanisms of immune evasion and for the development of inhibitors and vaccines.
C1 NCI, LECB, CCR, Human Immunivirol Grp, Ft Detrick, MD 21702 USA.
   NCI, SAIC Frederick Inc, Basic Res Program, Ft Detrick, MD 21702 USA.
   Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD USA.
   Uniformed Serv Univ Hlth Sci, Dept Prevent Med, Bethesda, MD USA.
   Scripps Res Inst, Dept Immunol, La Jolla, CA USA.
   Scripps Res Inst, Dept Biol Mol, La Jolla, CA USA.
   Duke Univ, Ctr Med, Dept Surg, Lab AIDS Vaccine Res & Dev, Durham, NC USA.
RP Dimitrov, DS (reprint author), NCI, LECB, CCR, Human Immunivirol Grp, Bldg 469,Rm 105,POB B,Miller Dr, Ft Detrick, MD 21702 USA.
EM dimitrov@ncifcrf.gov
OI Sidorov, Igor/0000-0001-6519-4983
FU NIAID NIH HHS [AI48380, AI48280, P01 AI048280, AI47438]; NCI NIH HHS
   [N01CO12400, N01-CO-12400]
CR Armbruster C, 2002, AIDS, V16, P227, DOI 10.1097/00002030-200201250-00012
   Baba TW, 2000, NAT MED, V6, P200
   BARBAS CF, 1993, J MOL BIOL, V230, P812, DOI 10.1006/jmbi.1993.1203
   BARBAS CF, 2001, PHAGE DISPLAY LAB MA
   Binley JM, 1996, AIDS RES HUM RETROV, V12, P911, DOI 10.1089/aid.1996.12.911
   Bouma P, 2003, J VIROL, V77, P8061, DOI 10.1128/JVI.77.14.8061-8071.2003
   Brandt SM, 2002, J BIOL CHEM, V277, P17291, DOI 10.1074/jbc.M108232200
   BUCHACHER A, 1994, AIDS RES HUM RETROV, V10, P359, DOI 10.1089/aid.1994.10.359
   Bures R, 2002, J VIROL, V76, P2233, DOI 10.1128/JVI.76.5.2233-2244.2002
   BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652
   BURTON DR, 1991, P NATL ACAD SCI USA, V88, P10134, DOI 10.1073/pnas.88.22.10134
   Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018
   Burton DR, 2002, NAT REV IMMUNOL, V2, P706, DOI 10.1038/nri891
   Burton DR, 1997, AIDS, V11, pS87
   Cavacini LA, 1998, AIDS RES HUM RETROV, V14, P545, DOI 10.1089/aid.1998.14.545
   Chow YH, 2002, BIOCHEMISTRY-US, V41, P7176, DOI 10.1021/bi025646d
   CONLEY AJ, 1994, J VIROL, V68, P6994
   Conley AJ, 1996, J VIROL, V70, P6751
   Ditzel HJ, 1997, J MOL BIOL, V267, P684, DOI 10.1006/jmbi.1997.0912
   Dong M, 2003, J VIROL, V77, P3119, DOI 10.1128/JVI.77.5.3119-3130.2003
   DSouza MP, 1997, J INFECT DIS, V175, P1056, DOI 10.1086/516443                                                                  
   DSOUZA MP, 1995, AIDS, V9, P867, DOI 10.1097/00002030-199508000-00006
   Ferrantelli F, 2002, VACCINE, V20, pA61, DOI 10.1016/S0264-410X(02)00389-4
   Ferrantelli F, 2003, AIDS, V17, P301, DOI [10.1097/00002030-200302140-00003, 10.1097/01.aids.0000050803.28043.96]
   Ferrantelli F, 2002, CURR OPIN IMMUNOL, V14, P495, DOI 10.1016/S0952-7915(02)00362-X                                                   
   GORNY MK, 1992, J VIROL, V66, P7538
   HO DD, 1991, J VIROL, V65, P489
   Jacobson JM, 2004, ANTIMICROB AGENTS CH, V48, P423, DOI 10.1128/AAC.48.2.423-429.2004
   Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698                                                                  
   Jeffs SA, 2002, J GEN VIROL, V83, P2723, DOI 10.1099/0022-1317-83-11-2723                                                    
   Kim YB, 2003, VIROLOGY, V305, P124, DOI 10.1006/viro.2002.1727
   LAAL S, 1994, J VIROL, V68, P4001
   Labrijn AF, 2003, J VIROL, V77, P10557, DOI 10.1128/JVI.77.19.10557-10565.2003
   Leavitt M, 2003, J VIROL, V77, P560, DOI 10.1128/JVI.77.1.560-570.2003
   Lorin C, 2004, J VIROL, V78, P146, DOI 10.1128/JVI.78.1.146-157.2004
   Lu S, 1998, AIDS RES HUM RETROV, V14, P151, DOI 10.1089/aid.1998.14.151
   Mascola JR, 1999, J VIROL, V73, P4009
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   MONTEFIORI DC, CURRENT PROTOCOLS IM
   Moore JP, 1996, J VIROL, V70, P1863
   Moulard M, 2002, P NATL ACAD SCI USA, V99, P6913, DOI 10.1073/pnas.102562599
   MUSTER T, 1993, J VIROL, V67, P6642
   Ndung'u T, 2001, J VIROL, V75, P4964, DOI 10.1128/JVI.75.11.4964-4972.2001
   Pantophlet R, 2003, J VIROL, V77, P642, DOI 10.1128/JVI.77.1.642-658.2003
   Park EJ, 1998, J VIROL, V72, P7099
   Park EJ, 1999, J VIROL, V73, P5707
   Park EJ, 2000, J VIROL, V74, P4183, DOI 10.1128/JVI.74.9.4183-4191.2000
   Parren PWHI, 1996, J VIROL, V70, P9046
   PARREN PWHI, 1995, AIDS, V9, pF1
   POSNER MR, 1991, J IMMUNOL, V146, P4325
   PURTSCHER M, 1994, AIDS RES HUM RETROV, V10, P1651, DOI 10.1089/aid.1994.10.1651
   Quinnan GV, 1999, AIDS RES HUM RETROV, V15, P561, DOI 10.1089/088922299311088
   ROBEN P, 1994, J VIROL, V68, P4821
   Ruprecht RM, 2003, VACCINE, V21, P3370, DOI 10.1016/S0264-410X(03)00335-9
   Safrit JT, 2004, JAIDS-J ACQ IMM DEF, V35, P169, DOI 10.1097/00126334-200402010-00012
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Stiegler G, 2003, J ANTIMICROB CHEMOTH, V51, P757, DOI 10.1093/jac/dkg172
   Stiegler G, 2002, AIDS, V16, P2019, DOI 10.1097/00002030-200210180-00006                                                
   Stiegler G, 2001, AIDS RES HUM RETROV, V17, P1757, DOI 10.1089/08892220152741450
   THALI M, 1992, J VIROL, V66, P5635
   THALI M, 1991, J VIROL, V65, P6188
   THALI M, 1993, J VIROL, V67, P3978
   TILLEY SA, 1991, RES VIROLOGY, V142, P247, DOI 10.1016/0923-2516(91)90010-Z
   Trkola A, 1996, J VIROL, V70, P1100
   Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   XU JY, 1991, J VIROL, V65, P4832
   Zhang MY, 2004, ANTIVIR RES, V61, P161, DOI 10.1016/j.antiviral.2003.09.009
   Zhang MY, 2004, J MOL BIOL, V335, P209, DOI 10.1016/j.jmb.2003.09.055
   Zhang MY, 2003, J IMMUNOL METHODS, V283, P17, DOI 10.1016/j.jim.2003.07.003
   Zhang PF, 1999, J VIROL, V73, P5225
   Zhang PF, 2002, J VIROL, V76, P644, DOI 10.1128/JVI.76.2.644-655.2002
   Zwick MB, 2003, J VIROL, V77, P5863, DOI 10.1128/JVI.77.10.5863-5876.2003
   Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001
NR 76
TC 68
Z9 74
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 2004
VL 78
IS 17
BP 9233
EP 9242
DI 10.1128/JVI.78.17.9233-9242.2004
PG 10
WC Virology
SC Virology
GA 847IT
UT WOS:000223386600027
PM 15308718
OA gold
DA 2018-01-05
ER

PT J
AU Rudolph, C
   Schillinger, U
   Ortiz, A
   Tabatt, K
   Plank, C
   Muller, RH
   Rosenecker, J
AF Rudolph, C
   Schillinger, U
   Ortiz, A
   Tabatt, K
   Plank, C
   Muller, RH
   Rosenecker, J
TI Application of novel solid lipid nanoparticle (SLN)-gene vector
   formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE aerosol; gene delivery; plasmid DNA; polyethylenimine; solid lipid
   nanoparticles; TAT
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CONTROLLED DRUG-DELIVERY; GENE DELIVERY;
   LINEAR POLYETHYLENIMINE; DNA COMPLEXES; PLASMID DNA; AEROSOL DELIVERY;
   SLN; POLYPLEXES; EXPRESSION
AB Purpose. To optimize gene delivery of SLN-based gene vectors by incorporation of a dimeric HIV-1 TAT peptide (TAT(2)) into SLN gene vectors.
   Methods. Plasmid DNA was complexed with two SLN preparations either with or without pre-compaction of DNA by TAT2, poly-L-arginine, or the mutant TAT(2)-M1. DNA complexed with polyethylenimine (PEI) served as a standard. Gene expression was analyzed upon transfection of bronchial epithelial cells in vitro and after intratracheal instillation or aerosol application to the lungs of mice in vivo. Stability of DNA was analyzed by agarose gel electrophoresis.
   Results. Incorporation of TAT(2) into SLN gene vectors induced an up to 100-fold sequence-dependent increase of gene expression as compared with the mutant TAT(2)-M1 and was 4- to 8-times higher as compared with PEI in vitro. In vivo application of TAT(2)-SLN gene vectors via jet nebulization increased SLN-based gene expression but was accompanied with DNA degradation. DNA degradation was not observed when an innovative device operating on the principle of a perforated vibrating membrane was used.
   Conclusions. Incorporation of TAT(2) into SLN gene vectors is suitable to optimize gene transfer in vitro. The use of a mild nebulization technology avoids DNA degradation and offers the opportunity for further studies in large animal models.
C1 Univ Munich, Dept Pediat, D-80337 Munich, Germany.
   Tech Univ Munich, Inst Expt Oncol & Therapy Res, D-81675 Munich, Germany.
   Free Univ Berlin, Dept Pharmaceut Technol Biopharm & Biotechnol, D-12169 Berlin, Germany.
RP Rudolph, C (reprint author), Univ Munich, Dept Pediat, D-80337 Munich, Germany.
RI Plank, Christian/F-9628-2011; Rudolph, Carsten/B-9379-2011
OI Plank, Christian/0000-0002-6072-4903
CR Bragonzi A, 2000, GENE THER, V7, P1753, DOI 10.1038/sj.gt.3301282                                                           
   Chesnoy S, 2000, ANNU REV BIOPH BIOM, V29, P27, DOI 10.1146/annurev.biophys.29.1.27
   Chollet P, 2002, J GENE MED, V4, P84, DOI 10.1002/jgm.237                                                                 
   Ciftci K, 2001, INT J PHARM, V218, P81, DOI 10.1016/S0378-5173(01)00623-8
   Densmore CL, 2000, MOL THER, V1, P180, DOI 10.1006/mthe.1999.0021
   Dingler A, 2002, J MICROENCAPSUL, V19, P11, DOI 10.1080/02652040010018056                                                       
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Finsinger D, 2000, GENE THER, V7, P1183, DOI 10.1038/sj.gt.3301227                                                           
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Freitas C, 1999, EUR J PHARM BIOPHARM, V47, P125, DOI 10.1016/S0939-6411(98)00074-5
   Gautam A, 2000, MOL THER, V2, P63, DOI 10.1006/mthe.2000.0087
   Gebhart CL, 2001, J CONTROL RELEASE, V73, P401, DOI 10.1016/S0168-3659(01)00357-1
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Merdan T, 2002, ADV DRUG DELIVER REV, V54, P715, DOI 10.1016/S0169-409X(02)00046-7
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Muller R.H., 2000, HDB PHARM CONTROLLED
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Olbrich C, 2001, J CONTROL RELEASE, V77, P345, DOI 10.1016/S0168-3659(01)00506-5
   Oupicky D, 2002, MOL THER, V5, P463, DOI 10.1006/mthe.2002.0568
   Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101                                                       
   Rudolph C, 2000, J GENE MED, V2, P269, DOI 10.1002/1521-2254(200007/08)2:4<269::AID-JGM112>3.0.CO;2-F                      
   Rudolph C, 2002, J GENE MED, V4, P66, DOI 10.1002/jgm.225                                                                 
   RUDOLPH C, 2003, J BIOL CHEM, V8, P8
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schwarz C, 1997, INT J PHARM, V157, P171, DOI 10.1016/S0378-5173(97)00222-6
   SCHWARZ C, 1994, J CONTROL RELEASE, V30, P83, DOI 10.1016/0168-3659(94)90047-7
   Tabatt K, 2004, EUR J PHARM BIOPHARM, V57, P155, DOI 10.1016/j.ejpb.2003.10.015
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Uduehi AN, 2001, MOL THER, V4, P52, DOI 10.1006/mthe.2001.0413                                                          
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187                                                                 
   ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997                                                        
   Zou SM, 2000, J GENE MED, V2, P128, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<128::AID-JGM95>3.0.CO;2-W                 
NR 33
TC 66
Z9 67
U1 1
U2 11
PU KLUWER ACADEMIC/PLENUM PUBL
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES
JI Pharm. Res.
PD SEP
PY 2004
VL 21
IS 9
BP 1662
EP 1669
DI 10.1023/B:PHAM.0000041463.56768.ec                                      
          
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 854QS
UT WOS:000223919000021
PM 15497694
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Mao, C
   Uckun, FM
AF Venkatachalam, TK
   Mao, C
   Uckun, FM
TI Effect of stereochemistry on the anti-HIV activity of chiral thiourea
   compounds
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POTENT NONNUCLEOSIDE INHIBITOR;
   REVERSE-TRANSCRIPTASE INHIBITORS; PHARMACOKINETIC FEATURES; TISSUE
   DISTRIBUTION; ANTIVIRAL PROTEIN; DRUG-RESISTANT; PETT COMPOUNDS; DESIGN;
   ANALOGS
AB Chiral derivatives of several substituted halopyridyl and thiazolyl PETT compounds were synthesized as non-nucleoside inhibitors of the reverse transcriptase (RT) enzyme (NNRTI) of the human immunodeficiency virus (HIV-1). Molecular modeling studies indicated that because of the asymmetric geometry of the NNRTI binding pocket, the R stereoisomers would fit the NNRTI binding pocket of the HIV-1 RT much better than the corresponding S stereoisomers, as reflected by their 10(4)-fold lower K-i values. The R stereoisomers of several PETT derivatives inhibited recombinant RT in vitro with lower IC50 values than their enantiomers. The active compounds were further evaluated for their ability to inhibit HIV-1 replication in human peripheral blood mononuclear cells (PBMC). All the R isomers once again showed potent anti-HIV activity and inhibited the replication of the HIV-1 strain HTLVIIIB in peripheral blood mononuclear cells (PBMC) at nanomolar concentrations whereas their enantiomers were substantially less potent. The lead compounds in the respective groups were further tested against the NNRTI-resistant HIV strains, A17 (Y181C mutant), and A17Var (YISIC+K103N mutant) and RT MDR (V106N). The results showed that the lead compounds were several logs more potent than the standard NNRTI nevirapine. Structure-activity relationship studies also revealed a preference for the pyridyl unit with halo substitutions primarily at 5-position demonstrating the importance of regiochemistry. Our data provides experimental evidence that the stereochemistry as well as regiochemistry of NNRTI can profoundly affect their anti-HIV activity. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Parker Hughes Inst, Dept Immunol, Roseville, MN 55113 USA.
   Parker Hughes Inst, Dept Chem, Roseville, MN 55113 USA.
   Parker Hughes Inst, Dept Biol Struct, Roseville, MN 55113 USA.
   Parker Hughes Inst, Dept Virol, Roseville, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Dept Immunol, 2699 Patton Rd, Roseville, MN 55113 USA.
EM fatih_uckun@ih.org
CR BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Chen CL, 1999, PHARMACEUT RES, V16, P1226, DOI 10.1023/A:1014814313681
   Chen CL, 2001, ARZNEIMITTEL-FORSCH, V51, P574
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DEEKS SG, 1998, AIDS CLIN R, P145
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   FRANCHETTI P, 1995, J MED CHEM, V38, P4007, DOI 10.1021/jm00020a015
   Goldschmidt R H, 1997, J Am Board Fam Pract, V10, P144
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Hajos Gyorgy, 2000, Drugs of the Future, V25, P47, DOI 10.1358/dof.2000.025.01.858638
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   SATCHER D, 1997, HIV AIDS SURVEILL RE, V9, P1
   SUDBECK EA, 1998, ANTIMICRO AGENTS CHE, V19, P225
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 23
TC 104
Z9 107
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD AUG 1
PY 2004
VL 12
IS 15
BP 4275
EP 4284
DI 10.1016/j.bmc.2004.04.050
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 840UZ
UT WOS:000222886700033
PM 15246104
DA 2018-01-05
ER

PT J
AU Chiu, YL
   Ali, A
   Chu, CY
   Cao, H
   Rana, TM
AF Chiu, YL
   Ali, A
   Chu, CY
   Cao, H
   Rana, TM
TI Visualizing a correlation between siRNA localization, cellular uptake,
   and RNAi in living cells
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID SMALL INTERFERING RNA; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 TAT PROTEIN;
   DOUBLE-STRANDED-RNA; MAMMALIAN-CELLS; GENE-EXPRESSION; IN-VIVO;
   PENETRATING PEPTIDES; UNNATURAL BIOPOLYMER; MEDIATED DELIVERY
AB RNA interference (RNAi) is the process by which short-interfering RNA (siRNA) target a specific mRNA for degradation through interactions with an RNA-induced silencing complex (RISC). Here, a clear correlation between siRNA localization, cellular uptake, and RNAi activity was discovered by delivering siRNA into cells using siRNA-TAT(47-57) peptide, siRNA-TAT(47-57)-derived oligocarbamate conjugates, or nanoparticles. For successful RNAi, the localization of siRNA was distinctly perinuclear, suggesting that siRNA is targeted to these regions for interactions with RISC to induce RNAi. siRNA sequence variation and the presence of the target mRNA apparently did not change the subcellular localization pattern of siRNA. Intriguingly, siRNA conjugated to TAT(47-57) peptide or TAT(47-57)-derived oligocarbamate resulted in efficient RNAi activity and perinuclear localization of siRNA that was distinctly different from nonconjugated free TAT peptide nucleolar localization. These results suggest that interactions with RISC dictate siRNA localization even when siRNA is conjugated to TAT(47-57) peptide.
C1 Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.
RP Rana, TM (reprint author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.
EM tariq.rana@umassmed.edu
OI CHU, CHIA-YING/0000-0003-1619-1975
FU NIAID NIH HHS [AI 41404, AI 43198]
CR Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698                                                          
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999                                                         
   Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703
   Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4
   Chiu YL, 2004, J VIROL, V78, P2517, DOI 10.1128/JVI.78.5.2517-2529.2004
   CHO CY, 1993, SCIENCE, V261, P1303, DOI 10.1126/science.7689747
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fittipaldi A, 2003, J BIOL CHEM, V278, P34141, DOI 10.1074/jbc.M303045200
   Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556                                                                
   Hammond SM, 2000, NATURE, V404, P293
   Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   IGNATOVICH IA, 2003, J BIOL CHEM, V478, P42625
   Kawasaki H, 2003, NUCLEIC ACIDS RES, V31, P700, DOI 10.1093/nar/gkg/158
   KLAJNERT B, 2001, ACTA BIOCHIM POL, V47, P199
   Lebleu B, 1996, TRENDS BIOTECHNOL, V14, P109, DOI 10.1016/0167-7799(96)30005-X
   Lee NS, 2002, NAT BIOTECHNOL, V20, P500, DOI 10.1038/nbt0502-500
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   MANN DA, 1991, EMBO J, V10, P1733
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908
   Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497
   Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2
   Moulton HM, 2003, ANTISENSE NUCLEIC A, V13, P31, DOI 10.1089/108729003764097322
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   NAKANISHI M, 2003, CURR PROTEIN PEPT SC, V4, P133
   Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5
   Ohki EC, 2001, J NEUROSCI METH, V112, P95, DOI 10.1016/S0165-0270(01)00441-1
   Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399
   Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505
   Potocky TB, 2003, J BIOL CHEM, V278, P50188, DOI 10.1074/jbc.M308719200
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Shen CX, 2003, FEBS LETT, V539, P111, DOI 10.1016/S0014-5793(03)00209-6
   Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Torchilin VP, 2003, CURR PROTEIN PEPT SC, V4, P133, DOI 10.2174/1389203033487298
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289                                                        
   Wang XL, 1997, J AM CHEM SOC, V119, P6444, DOI 10.1021/ja963895h                                                               
   Zeng Y, 2002, RNA, V8, P855, DOI 10.1017/S1355838202020071
NR 52
TC 260
Z9 274
U1 5
U2 38
PU CELL PRESS
PI CAMBRIDGE
PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD AUG
PY 2004
VL 11
IS 8
BP 1165
EP 1175
DI 10.1016/j.chembiol.2004.06.006
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 851VU
UT WOS:000223714900020
PM 15324818
OA gold
DA 2018-01-05
ER

PT J
AU Becker, ML
   Remsen, EE
   Pan, D
   Wooley, KL
AF Becker, ML
   Remsen, EE
   Pan, D
   Wooley, KL
TI Peptide-derivatized shell-cross-linked nanoparticles. 1. Synthesis and
   characterization
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID TRANSFER RADICAL POLYMERIZATION; HUMAN IMMUNODEFICIENCY VIRUS;
   TAT-FUSION PROTEINS; CELLULAR UPTAKE; NANOSTRUCTURED MATERIALS;
   MAMMALIAN-CELLS; TRANSDUCTION; DELIVERY; INTERNALIZATION; MACROMOLECULES
AB The conjugation of the protein transduction domain (PTD) from the HIV-1 Tat protein to shell-crosslinked (SCK) nanoparticles is reported as a method to facilitate cell surface binding and transduction of SCK nanoparticles. Attaching increasing numbers of peptide sequences to SCK nanoparticles in a global solution-state functionalization strategy has been devised as a method for increasing the efficiency of the cell-penetrating process. The numbers of peptides per SCK were controlled through stoichiometric balance and measured experimentally by two independent methods, UV-visible spectroscopy and phenylglyoxal analysis. PTD was conjugated in (0.005, 0.01, and 0.02) molar ratios, relative to the acrylic acid residues in the shell, to the SCK nanoparticles resulting in SCK populations possessing nominally 52, 104, and 210 (41, 83, and 202 as measured by phenylglyoxal analysis) PTD peptides per particle, respectively. The methodologies for the block copolymer and nanoparticle syntheses, peptide derivatization, and characterization of peptide-functionalized SCK nanoparticles are reported and the feasibility and efficiency of intracellular internalization of the respective SCKs were quantified.
C1 Washington Univ, Ctr Mat Innovat, St Louis, MO 63130 USA.
   Washington Univ, Dept Chem, St Louis, MO 63130 USA.
RP Wooley, KL (reprint author), Washington Univ, Ctr Mat Innovat, 1 Brookings Dr, St Louis, MO 63130 USA.
EM klwooley@artsci.wustl.edu
RI Wooley, Karen/D-4399-2015
OI Wooley, Karen/0000-0003-4086-384X; Pan, Dipanjan/0000-0003-0175-4704
FU NIGMS NIH HHS [5-T32-GM08785-02]; NCI NIH HHS [N01-CO-27103]
CR Beck B, 2001, NUTR NEUROSCI, V4, P39, DOI 10.1080/1028415X.2001.11747349                                                  
   Buetuen V, 1999, J AM CHEM SOC, V121, P4288
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173
   Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hawker CJ, 2001, CHEM REV, V101, P3661, DOI 10.1021/cr990119u
   Huang HY, 1997, J AM CHEM SOC, V119, P11653, DOI 10.1021/ja9717469                                                               
   Huang HY, 2001, MACROMOLECULES, V34, P547, DOI 10.1021/ma001003z
   Jairajpuri MA, 1998, BIOCHEMISTRY-US, V37, P10780, DOI 10.1021/bi980058e
   Jensen KD, 2003, J CONTROL RELEASE, V87, P89, DOI 10.1016/S0168-3659(02)00352-8
   Kao HM, 2001, MACROMOLECULES, V34, P544, DOI 10.1021/ma001429d
   Klok HA, 2001, ADV MATER, V13, P1217, DOI 10.1002/1521-4095(200108)13:16<1217::AID-ADMA1217>3.0.CO;2-D                    
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Liu SY, 2002, LANGMUIR, V18, P8350, DOI 10.1021/la020496t
   Ma QG, 2000, J POLYM SCI POL CHEM, V38, P4805, DOI 10.1002/1099-0518(200012)38:1+<4805::AID-POLA180>3.0.CO;2-O
   Mai JC, 2002, J BIOL CHEM, V277, P30208, DOI 10.1074/jbc.M204202200
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Matyjaszewski K, 2001, CHEM REV, V101, P2921, DOI 10.1021/cr940534g
   MILLER JF, 1991, J COLLOID INTERF SCI, V143, P532, DOI 10.1016/0021-9797(91)90286-H                                                    
   Murthy KS, 2001, CHEM COMMUN, P773
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Niesner U, 2002, BIOCONJUGATE CHEM, V13, P729, DOI 10.1021/bc025517+
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Remsen EE, 1999, MACROMOLECULES, V32, P3685, DOI 10.1021/ma981951o                                                               
   Sandhu KK, 2002, BIOCONJUGATE CHEM, V13, P3, DOI 10.1021/bc015545c
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   TAKAHASHI K, 1968, J BIOL CHEM, V243, P6171
   Thurmond KB, 1996, J AM CHEM SOC, V118, P7239, DOI 10.1021/ja961299h                                                               
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Vives E, 2003, J MOL RECOGNIT, V16, P265, DOI 10.1002/jmr.636
   Vives E, 2003, CURR PROTEIN PEPT SC, V4, P125, DOI 10.2174/1389203033487306
   Wadia JS, 2004, NAT MED, V10, P310, DOI 10.1038/nm996
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   WANG JS, 1995, J AM CHEM SOC, V117, P5614, DOI 10.1021/ja00125a035                                                             
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wooley KL, 2000, J POLYM SCI POL CHEM, V38, P1397, DOI 10.1002/(SICI)1099-0518(20000501)38:9<1397::AID-POLA1>3.0.CO;2-N                
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 39
TC 60
Z9 61
U1 1
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL-AUG
PY 2004
VL 15
IS 4
BP 699
EP 709
DI 10.1021/bc049946e
PG 11
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 840SW
UT WOS:000222880900005
PM 15264856
DA 2018-01-05
ER

PT J
AU Becker, ML
   Bailey, LO
   Wooley, KL
AF Becker, ML
   Bailey, LO
   Wooley, KL
TI Peptide-derivatized shell-cross-linked nanoparticles. 2.
   Biocompatibility evaluation
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID TUMOR-NECROSIS-FACTOR; HUMAN IMMUNODEFICIENCY VIRUS;
   POLYMERASE-CHAIN-REACTION; DRUG-DELIVERY; FACTOR-ALPHA; IN-VIVO;
   TRANSDUCTION; RNA; QUANTIFICATION; CELLS
AB The conjugation of the protein transduction domain (PTD) from the HIV-1 Tat protein to shell crosslinked (SCK) nanoparticles is a method to facilitate cell surface binding and transduction. In the previous report, the preparation, derivatization, and characterization of peptide-functionalized SCK nanoparticles were reported in detail. Following assembly, the constructs were evaluated in vitro and in vivo to obtain a preliminary biocompatibility assessment. The effects of SCK exposure on cell viability were evaluated using a metabolic 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and a fluorescent apoptosis assay. Furthermore, stages of apoptosis were quantified by flow cytometry. Although higher levels of peptide functionalization resulted in decreased metabolic function as measured by MTT assay, significant apoptosis was not observed below 500 mg/L for all the samples. To evaluate the potential immunogenic response of the peptide-derivatized constructs, a real-time polymerase chain reaction (RT-PCR) system that allows for the in vitro analysis and quantification of the cellular inflammatory responses tumor necrosis factor alpha (TNF-alpha) and interleukin-1 beta (IL1-beta) was utilized. The inflammatory response to the peptide-functionalized SCK nanoparticles as measured by RT-PCR show statistically significant increases in the levels of both TNF-alpha and IL1-beta relative to tissue culture polystyrene (TCPS). However, the measured cytokine levels did not preclude the further testing of SCKs in an in vivo mouse immunization protocol. In this limited assay, measured increases in immunoglobulin G (IgG) concentration in the sera were minimal with no specific interactions being isolated, and more importantly, none of the mice (>50) subjected to the three 100 mug immunization protocol have died. Additionally, no gross morphological changes were observed in postmortem organ histology examinations.
C1 Washington Univ, Ctr Mat Innovat, St Louis, MO 63130 USA.
   Washington Univ, Dept Chem, St Louis, MO 63130 USA.
   Natl Inst Stand & Technol, Div Polymers, Biomat Grp, Gaithersburg, MD 20899 USA.
RP Becker, ML (reprint author), Washington Univ, Ctr Mat Innovat, 1 Brookings Dr, St Louis, MO 63130 USA.
EM mlbecker@nist.gov; klwooley@artsci.wustl.edu
RI Delehanty, James/F-7454-2012; Wooley, Karen/D-4399-2015
OI Wooley, Karen/0000-0003-4086-384X
FU NCI NIH HHS [N01-CO-27103]
CR Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678                                                          
   BAILEY L, 2004, UNPUB J DENT RES
   Bailey LO, 2004, J BIOMED MATER RES A, V69A, P305, DOI 10.1002/jbm.a.20134
   Beerens A. M. J., 2003, Current Gene Therapy, V3, P486, DOI 10.2174/1566523034578258
   BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445                                             
   Bourke SL, 2003, ADV DRUG DELIVER REV, V55, P447, DOI 10.1016/S0169-409X(03)00038-3
   Brodbeck WG, 2003, J BIOMED MATER RES A, V64A, P320, DOI 10.1002/jbm.a.10425                                                             
   Bullok KE, 2002, BIOCONJUGATE CHEM, V13, P1226, DOI 10.1021/bc025573a
   Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169
   Cannon JG, 1998, MOL CELL BIOCHEM, V179, P159, DOI 10.1023/A:1006828425418
   Catelas I, 1998, J BIOMED MATER RES, V41, P600, DOI 10.1002/(SICI)1097-4636(19980915)41:4<600::AID-JBM12>3.0.CO;2-I
   Chapekar MS, 1996, J BIOMED MATER RES, V31, P251, DOI 10.1002/(SICI)1097-4636(199606)31:2<251::AID-JBM12>3.0.CO;2-O
   Dai ZH, 1999, CURR OPIN IMMUNOL, V11, P504, DOI 10.1016/S0952-7915(99)00008-4
   Duncan R, 2003, NAT REV DRUG DISCOV, V2, P347, DOI 10.1038/nrd1088
   Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Frechet JMJ, 2003, J POLYM SCI POL CHEM, V41, P3713, DOI 10.1002/pola.10952
   Funatogawa K, 1998, INFECT IMMUN, V66, P5792
   Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291
   Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   GUATELLI JC, 1989, CLIN MICROBIOL REV, V2, P217
   Haag R, 2004, ANGEW CHEM INT EDIT, V43, P278, DOI 10.1002/anie.200301694
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Hawker CJ, 2001, CHEM REV, V101, P3661, DOI 10.1021/cr990119u
   HUANG H, 1998, CHEM COMMUN, V13, P1415
   Hubbell JA, 2003, CURR OPIN BIOTECH, V14, P551, DOI 10.1016/j.copbio.2003.09.004
   Hubbell JA, 2003, SCIENCE, V300, P595, DOI 10.1126/science.1083625
   Illei GG, 2000, CURR OPIN IMMUNOL, V12, P712, DOI 10.1016/S0952-7915(00)00167-9
   Joralemon MJ, 2004, BIOMACROMOLECULES, V5, P903, DOI 10.1021/bm0344710
   JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025
   Kataoka K, 2001, ADV DRUG DELIVER REV, V47, P113, DOI 10.1016/S0169-409X(00)00124-1                                                   
   Kumar V, 1997, BASIC PATHOLOGY
   LIEFERT JA, 2002, GENE THER, V9, P1422
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Matyjaszewski K, 2001, CHEM REV, V101, P2921, DOI 10.1021/cr940534g
   MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035                                                          
   Morrison TB, 1998, BIOTECHNIQUES, V24, P954
   Moses MA, 2003, CANCER CELL, V4, P337, DOI 10.1016/S1535-6108(03)00276-9                                                   
   Murthy KS, 2003, J MATER CHEM, V13, P2785, DOI 10.1039/b304166b
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nishiyama N, 2003, CANCER RES, V63, P8977
   Oppenheim JJ, 2001, INT J HEMATOL, V74, P3, DOI 10.1007/BF02982543                                                              
   Pan D, 2003, CHEM COMMUN, P2400, DOI 10.1039/b307878g
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974
   Remsen EE, 1999, MACROMOLECULES, V32, P3685, DOI 10.1021/ma981951o                                                               
   Suzuki T, 2000, BIOTECHNIQUES, V29, P332
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   TANG LP, 1995, AM J CLIN PATHOL, V103, P466
   Thurmond KB, 1996, J AM CHEM SOC, V118, P7239, DOI 10.1021/ja961299h                                                               
   TIFFANY CW, 1989, FEBS LETT, V247, P189, DOI 10.1016/0014-5793(89)81331-6                                                    
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211
   Wadia JS, 2003, CURR PROTEIN PEPT SC, V4, P97, DOI 10.2174/1389203033487289                                                        
   Wadia JS, 2002, CURR OPIN BIOTECH, V13, P52, DOI 10.1016/S0958-1669(02)00284-7                                                   
   Wang T, 1999, ANAL BIOCHEM, V269, P198, DOI 10.1006/abio.1999.4022
   Wooley KL, 2000, J POLYM SCI POL CHEM, V38, P1397, DOI 10.1002/(SICI)1099-0518(20000501)38:9<1397::AID-POLA1>3.0.CO;2-N                
NR 58
TC 48
Z9 49
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL-AUG
PY 2004
VL 15
IS 4
BP 710
EP 717
DI 10.1021/bc049945m
PG 8
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 840SW
UT WOS:000222880900006
PM 15264857
DA 2018-01-05
ER

PT J
AU Miyake, A
   Akagi, T
   Enose, Y
   Ueno, M
   Kawamura, M
   Horiuchi, R
   Hiraishi, K
   Adachi, M
   Serizawa, T
   Narayan, O
   Akashi, M
   Baba, M
   Hayami, M
AF Miyake, A
   Akagi, T
   Enose, Y
   Ueno, M
   Kawamura, M
   Horiuchi, R
   Hiraishi, K
   Adachi, M
   Serizawa, T
   Narayan, O
   Akashi, M
   Baba, M
   Hayami, M
TI Induction of HIV-specific antibody response and protection against
   vaginal SHIV transmission by intranasal immunization with inactivated
   SHIV-capturing nanospheres in macaques
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE vaccine; intranasal immunization; mucosal immunity; SHIV; intravaginal
   challenge
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMOBILIZED POLYSTYRENE NANOSPHERES;
   LYMPH-NODE IMMUNIZATION; RHESUS MACAQUES; MUCOSAL IMMUNITY; AIDS
   VACCINE; HIV-1-CAPTURING NANOSPHERES; SERONEGATIVE PARTNERS; NASAL
   IMMUNIZATION; CELLULAR-IMMUNITY
AB We have previously reported that concanavalin A-immobilized polystyrene nanospheres (Con ANS) could efficiently capture HIV-1 particles and that intranasal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody response in mice. In this study, to evaluate the protective effect of immunization, each three macaques was intranasally immunized with Con A-NS or inactivated simian/human immunodeficiency virus KU-2-capturing nanospheres (SHIV-NS) and then intravaginally challenged with a pathogenic virus, SHIV KU-2. After a series of six immunizations, vaginal anti-HIV-1 gp120 IgA and IgG antibodies were detected in all SHIV-NS-immunized macaques. After intravaginal challenge, one of the three macaques in each of the Con A-NS- and SHIV-NS-immunized groups was infected. Plasma viral RNA load of infected macaque in SHIV-NS-immunized macaques was substantially less than that in unimmunized control macaque and reached below the detectable level. However, it could not be determined whether intranasal immunization with SHIV-NS is effective in giving complete protection against intravaginal challenge. To explore the effect of the SHIV-NS vaccine, the remaining non-infected macaques were rechallenged intravenously with SHIV KU-2. After intravenous challenge, all macaques became infected. However, SHIV-NS-immunized macaques had lower viral RNA loads and higher CD4(+) T cell counts than unimmunized control macaques. Plasma anti-HIV-1 gp120 IgA and IgG antibodies were induced more rapidly in the SHIV-NS-immunized macaques than in the controls. The rapid antibody responses having neutralizing activity might contribute to the clearance of the challenge virus. Thus, SHIV-NS-immunized macaques exhibited partial protection to vaginal and systemic challenges with SHIV KU-2. (C) 2004 Wiley-Liss, Inc.
C1 Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Lab Primate Model,Sakyo Ku, Kyoto 6068507, Japan.
   Japan Immunores Labs, Takasaki, Gumma, Japan.
   Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima, Japan.
   Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostruct & Adv Mat, Kagoshima 890, Japan.
   Univ Kansas, Ctr Med, Kansas City, KS USA.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka, Japan.
   Japan Sci & Technol Corp, CREST, Tokyo, Japan.
RP Hayami, M (reprint author), Kyoto Univ, Inst Virus Res, Expt Res Ctr Infect Dis, Lab Primate Model,Sakyo Ku, Kyoto 6068507, Japan.
EM mhayami@virus.kyoto-u.ae.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akahata W, 2003, J GEN VIROL, V84, P2237, DOI 10.1099/vir.0.19082.0
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320
   Bergmeier LA, 1998, AIDS, V12, P1139, DOI 10.1097/00002030-199810000-00005
   Bogers WMJM, 2000, AIDS, V14, pS141
   Buge SL, 1997, J VIROL, V71, P8531
   Chen XN, 2001, NAT MED, V7, P1225, DOI 10.1038/nm1101-1225
   Crotty S, 1999, J VIROL, V73, P9485
   Enose Y, 2002, VIROLOGY, V298, P306, DOI 10.1006/viro.2002.1440
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Igarashi T, 1997, J GEN VIROL, V78, P985, DOI 10.1099/0022-1317-78-5-985                                                      
   Imaoka K, 1998, J IMMUNOL, V161, P5952
   Joag SV, 1998, J MED PRIMATOL, V27, P59, DOI 10.1111/j.1600-0684.1998.tb00227.x                                              
   Joag SV, 1996, J VIROL, V70, P3189
   Joag SV, 1997, AIDS RES HUM RETROV, V13, P635, DOI 10.1089/aid.1997.13.635
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kuwata T, 2001, TRENDS MICROBIOL, V9, P475, DOI 10.1016/S0966-842X(01)02164-3
   KUWATA T, 1995, J GEN VIROL, V76, P2181, DOI 10.1099/0022-1317-76-9-2181                                                     
   Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767
   Lehner T, 2002, AIDS, V16, pS125, DOI 10.1097/00002030-200216004-00017
   LI J, 1992, J ACQ IMMUN DEF SYND, V5, P639
   Lo Caputo S, 2003, AIDS, V17, P531, DOI 10.1097/01.aids.0000050818.06065.1c
   Lu XS, 1998, AIDS, V12, P1, DOI 10.1097/00002030-199801000-00001
   Lu YC, 1996, J VIROL, V70, P3045
   MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576
   MASCALI G, 2000, MATH INDUST, V1, P174
   Mascola JR, 2000, NAT MED, V6, P207, DOI 10.1038/72318
   Mazzoli S, 1999, J INFECT DIS, V180, P871, DOI 10.1086/314934                                                                  
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   Miller CJ, 1999, J INFECT DIS, V179, pS413, DOI 10.1086/314795
   Nardelli-Haefliger D, 1999, J VIROL, V73, P9609
   Polacino P, 1999, J VIROL, V73, P3134
   Reimann KA, 1996, J VIROL, V70, P3198
   Reimann KA, 1996, J VIROL, V70, P6922
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Shinohara K, 1999, J GEN VIROL, V80, P1231
   Staats HF, 1997, AIDS RES HUM RETROV, V13, P945, DOI 10.1089/aid.1997.13.945
   Staats HF, 1996, J IMMUNOL, V157, P462
   Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183                                                         
   Ui M, 1999, VIROLOGY, V265, P252, DOI 10.1006/viro.1999.0049
   VONEGMOND M, 2001, TRENDS IMMUNOL, V22, P205
   Voss G, 2003, J VIROL, V77, P1049, DOI 10.1128/JVI.77.2.1049-1058.2003
   Zuercher AW, 2002, J IMMUNOL, V168, P1796, DOI 10.4049/jimmunol.168.4.1796                                                     
NR 45
TC 45
Z9 46
U1 0
U2 0
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD JUL
PY 2004
VL 73
IS 3
BP 368
EP 377
DI 10.1002/jmv.20100
PG 10
WC Virology
SC Virology
GA 824HQ
UT WOS:000221677700007
PM 15170630
DA 2018-01-05
ER

PT J
AU Cui, ZR
   Patel, J
   Tuzova, M
   Ray, P
   Phillips, R
   Woodward, JG
   Nath, A
   Mumper, RJ
AF Cui, ZR
   Patel, J
   Tuzova, M
   Ray, P
   Phillips, R
   Woodward, JG
   Nath, A
   Mumper, RJ
TI Strong T cell type-1 immune responses to HIV-1 Tat(1-72) protein-coated
   nanoparticles
SO VACCINE
LA English
DT Article
DE rodent; Th1/Th2 cells; AIDS; cytokines; vaccination; spleen and lymph
   nodes
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CLASS-I PRESENTATION; TAT PROTEIN;
   CYNOMOLGUS MONKEYS; CLONAL EXPANSION; LYMPHOCYTES; MACAQUES; PATHWAY;
   IMMUNIZATION; REPLICATION
AB A significant emphasis has been placed on the development of adjuvants and/or delivery systems to improve both antibody production and cell-mediated immune responses. We previously reported on a novel anionic nanoparticle, which led to enhanced humoral and T helper type-1 (Th1) biased immune responses in mice when coated with cationized model antigen. Tat (1-72) is a conserved regulatory HIV-1 protein. It was hypothesized that HIV vaccine strategies employing Tat (1-72) may be a promising approach. Although previous reports have suggested that Tat (1-86) may be immunosuppressive, it was demonstrated in this present study that Tat (1-72) was not immunosuppressive when co-administered to mice with ovalbumin (OVA). Tat (1-72) was coated on novel anionic nanoparticles. BALB/c mice were immunized with Tat (5 mug)-coated nanoparticles (15 mug) by subcutaneous injection on days 0 and 14. Antibody and cytokine release were determined on day 28 and compared to Tat (5 mug) adjuvanted with Alum (15 jig) as a Th2 control, Tat (5 mug) adjuvanted with Lipid A (50 jig) as a Th1 control. Immunization of BALB/c mice with Tat-coated nanoparticles resulted in antibody levels (IgG and IgM) comparable to those. elicited from Tat and Alum. However, Tat-coated nanoparticles led to a Th1 biased immune response. The IFN-gamma release from splenocytes with Tat-coated nanoparticles was comparable to that from mice immunized with Tat and Lipid A, and 3.3-fold greater than that from mice immunized with Tat and Alum. These studies warrant further investigation of these nanoparticles to enhance both antibody and cellular-based immune responses. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Kentucky, Coll Pharm, Ctr Pharmaceut Sci & Technol, Lexington, KY 40536 USA.
   Univ Kentucky, Dept Immunol & Mol Genet, Lexington, KY 40536 USA.
   Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA.
RP Mumper, RJ (reprint author), Univ Kentucky, Coll Pharm, Ctr Pharmaceut Sci & Technol, Lexington, KY 40536 USA.
EM rjmump2@email.uky.edu
RI Xu, Qingguo/C-1962-2014
OI Xu, Qingguo/0000-0003-3191-0771
FU NCRR NIH HHS [P20RR015592]; NIAID NIH HHS [AI051147]
CR Allen TM, 2002, J VIROL, V76, P4108, DOI 10.1128/JVI.76.8.4108-4112.2002
   BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0
   Cafaro A, 1999, NAT MED, V5, P643
   Cafaro A, 2001, VACCINE, V19, P2862, DOI 10.1016/S0264-410X(01)00002-0
   Caputo A, 1996, GENE THER, V3, P235
   Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   Cohen SS, 1999, P NATL ACAD SCI USA, V96, P10842, DOI 10.1073/pnas.96.19.10842                                                        
   Cui Z, 2002, J CONTROL RELEASE, V81, P173, DOI 10.1016/S0168-3659(02)00051-2
   Cui ZR, 2002, INT J PHARM, V238, P229, DOI 10.1016/S0378-5173(02)00079-0
   Cui ZR, 2002, PHARMACEUT RES, V19, P939, DOI 10.1023/A:1016402019380
   DEANGELIS RL, 1993, CLIN PERINATOL, V20, P697
   Dockrell DH, 1998, J CLIN INVEST, V101, P2394, DOI 10.1172/JCI1171
   Egan RM, 1996, J IMMUNOL, V157, P2262
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   FROEBEL KS, 1994, AIDS RES HUM RETROV, V10, pS83
   Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6
   Haughey NJ, 1999, J NEUROCHEM, V73, P1363, DOI 10.1046/j.1471-4159.1999.0731363.x
   Holden CP, 1999, NEUROSCIENCE, V91, P1369, DOI 10.1016/S0306-4522(98)00714-3                                                   
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   Kazzaz J, 2000, J CONTROL RELEASE, V67, P347, DOI 10.1016/S0168-3659(00)00226-1
   KEARNEY ER, 1995, J IMMUNOL, V155, P1032
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Kolesnitchenko V, 1997, J VIROL, V71, P9753
   KORBER B, 1997, HUMAN RETROVIRUSES A
   KOVACSOVICSBANKOWSKI M, 1993, P NATL ACAD SCI USA, V90, P4942, DOI 10.1073/pnas.90.11.4942
   KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629
   Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116
   LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549                                                         
   Ma MH, 1997, J VIROL, V71, P2495
   Moy P, 1996, MOL BIOTECHNOL, V6, P105, DOI 10.1007/BF02740767                                                              
   Nath A, 2000, ANN NEUROL, V47, P186, DOI 10.1002/1531-8249(200002)47:2<186::AID-ANA8>3.3.CO;2-V
   Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103
   Parham P, 2000, THE IMMUNE SYSTEM
   Pauza CD, 2000, P NATL ACAD SCI USA, V97, P3515, DOI 10.1073/pnas.070049797
   Re M. C., 1995, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V10, P408, DOI 10.1097/00042560-199512000-00003
   Rossi C, 1997, GENE THER, V4, P1261, DOI 10.1038/sj.gt.3300522
   Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5
   Silvera P, 2002, J VIROL, V76, P3800, DOI 10.1128/JVI.76.8.3800-3809.2002
   vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913                                                     
   VENET A, 1992, J IMMUNOL, V148, P2899
   VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795
   Wu MX, 1997, P NATL ACAD SCI USA, V94, P13832, DOI 10.1073/pnas.94.25.13832
   ZAULI G, 1993, CANCER RES, V53, P4481
NR 45
TC 42
Z9 45
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN 30
PY 2004
VL 22
IS 20
BP 2631
EP 2640
DI 10.1016/j.vaccine.2003.12.013
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 834LQ
UT WOS:000222413000016
PM 15193389
DA 2018-01-05
ER

PT J
AU Morein, B
   Hu, KF
   Abusugra, I
AF Morein, B
   Hu, KF
   Abusugra, I
TI Current status and potential application of ISCOMs in veterinary
   medicine
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE vaccine; antigen delivery system; adjuvant; Quillaja saponin
ID IMMUNE-STIMULATING COMPLEXES; RESPIRATORY SYNCYTIAL VIRUS; EQUINE
   HERPESVIRUS TYPE-2; SYSTEMIC ANTIBODY-RESPONSES; SURFACE-ANTIGENS
   ISCOMS; MUCOSAL DELIVERY-SYSTEM; IMMUNOSTIMULATING COMPLEXES;
   INFLUENZA-VIRUS; SUBUNIT VACCINE; IN-VIVO
AB The immune stimulating complex (ISCOM) is a 40 nm nanoparticle used as a delivery system for vaccine antigens, targeting the immune system both after parenteral and mucosal administration. The ISCOM is made up of saponin, lipids and antigen usually held together by hydrophobic interaction between these three components. The compulsory elements to form the ISCOM structure are cholesterol and saponin. When the antigen is omitted the ISCOM-MATRIX is formed. There are a number of saponins that can form ISCOMs, and many other substances (including antigens, targeting and immuno-modulating molecules) can be incorporated into the ISCOM provided they are hydrophobic or rendered to be hydrophobic. Thus, it is possible to create ISCOM particles with different properties. After parenteral immunisation of the ISCOM, the T cell response is first detected in the draining lymph node. Subsequently, the T cell response is localised to the spleen, while the B cell response is first found both in the draining lymph nodes and in the spleen. Up to 50 days later, the majority of the antibody producing cells is found in the bone marrow (BM). In contrast, antigens that have been adjuvanted in an oil emulsion, limit the T cell response to the draining lymph nodes while the B cell response is found in the draining lymph nodes and spleen, but not in the BM. The ISCOM efficiently evokes CD8+, MHC class I restricted T cell response. The deposit of antigens both to the endosomal vesicles and to the cytosol of antigen presenting cells (APCs) explains why both T helper cells (vesicles) and cytotoxic T lymphocytes (cytosol) are efficiently induced by ISCOMs. The T helper (Th) cell response is balanced in the sense that both Th I and Th2 cells are induced. Prominent IL-12 production by cells in the innate system is a characteristic reaction induced by ISCOMs, promoting the development of a strong Th I response. After mucosal administration by the intranasal or the intestinal routes, the ISCOM induces strong specific mucosal IgA responses in local and remote mucosal surfaces. Also T cell responses are evoked by the mucosal administration. A large number of experimental ISCOM vaccines have been tested and protection has been induced against a number of pathogens in various species including chronic and persistent infections exemplified by human immune deficiency virus I (HIV-1), and 2 (HIV-2) and simian immune deficiency virus (SIV) in primates, and various herpes virus infections in several species. In contrast to a conventional rabies virus vaccine the ISCOM rabies formulation protected mice after exposure to the virulent virus. Recently, experimental ISCOM vaccines were shown to efficiently induce immune response in newborns of murine and bovine species in the presence of maternal antibodies, while conventional vaccines have failed. ISCOM vaccines are on the market for horses and cattle and several other ISCOM vaccines are under development. Since the ISCOM and the ISCOM-MATRIX can be blended with live attenuated vaccine antigens without hampering the proliferation of the live vaccine antigens, it opens the possibility to use the ISCOM adjuvant system in a mixture of live and killed vaccine antigens. (C) 2004 Published by Elsevier B.V.
C1 ISCONOVA AB, S-75183 Uppsala, Sweden.
   Swedish Univ Agr Sci, Coll Vet Med, Sect Virol, Dept Vet Microbiol, S-75123 Uppsala, Sweden.
RP Morein, B (reprint author), ISCONOVA AB, Uppsala Sci Pk,Dag Hammarskjolds Vag 54A, S-75183 Uppsala, Sweden.
EM bror.morein@isconova.se
CR Abusugra I, 1997, VET IMMUNOL IMMUNOP, V59, P31, DOI 10.1016/S0165-2427(97)00067-6
   Abusugra I, 1999, FEMS IMMUNOL MED MIC, V23, P5, DOI 10.1016/S0928-8244(98)00111-4
   BELAK S, 1980, ZBL VET MED B, V27, P826
   BENNER R, 1981, IMMUNOBIOLOGY, V158, P225, DOI 10.1016/S0171-2985(81)80072-1                                                   
   BENNER R, 1981, CLIN EXP IMMUNOL, V46, P1
   BERGSTROMMOLLAOGLU M, 1992, SCAND J IMMUNOL, V36, P565, DOI 10.1111/j.1365-3083.1992.tb03225.x
   CARLSSON U, 1991, VACCINE, V9, P577, DOI 10.1016/0264-410X(91)90245-2
   Carol H, 1998, VET IMMUNOL IMMUNOP, V65, P29, DOI 10.1016/S0165-2427(98)00171-8
   Carol H, 1997, PARASITE IMMUNOL, V19, P197, DOI 10.1046/j.1365-3024.1997.d01-197.x
   CLAASSEN I, 1995, ADV EXP MED BIOL, V371, P1485
   Claassen IJTM, 1998, IMMUNOLOGY, V94, P455
   DALSGAARD K, 1978, ACTA VET SCAND S, V69, P1
   Davis D, 1997, VACCINE, V15, P1661, DOI 10.1016/S0264-410X(97)00084-4
   Ekstrom J, 1999, VACCINE, V17, P2690, DOI 10.1016/S0264-410X(99)00052-3
   FOSSUM C, 1990, CELL IMMUNOL, V129, P414, DOI 10.1016/0008-8749(90)90217-F
   Grdic D, 1999, EUR J IMMUNOL, V29, P1774, DOI 10.1002/(SICI)1521-4141(199906)29:06<1774::AID-IMMU1774>3.0.CO;2-1              
   Heeney JL, 1998, P NATL ACAD SCI USA, V95, P10803, DOI 10.1073/pnas.95.18.10803                                                        
   Heeney JL, 1998, J MED PRIMATOL, V27, P50, DOI 10.1111/j.1600-0684.1998.tb00226.x                                              
   Hoglund S, 1989, Subcell Biochem, V15, P39
   Hu KF, 1998, CLIN EXP IMMUNOL, V113, P235
   Hu KF, 1999, MED MICROBIOL IMMUN, V187, P191, DOI 10.1007/s004300050092
   Hu KF, 2001, FEMS IMMUNOL MED MIC, V31, P105
   Hu KF, 2001, ADV DRUG DELIVER REV, V51, P149, DOI 10.1016/S0169-409X(01)00165-X
   Johansson M, 1999, VACCINE, V17, P2894, DOI 10.1016/S0264-410X(99)00128-0
   JONES PD, 1988, SCAND J IMMUNOL, V27, P645, DOI 10.1111/j.1365-3083.1988.tb02397.x
   KENSIL CR, 1991, J IMMUNOL, V146, P431
   Lazorova L, 1996, AM J PHYSIOL-GASTR L, V270, pG554
   Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5
   LOVGREN K, 1990, CLIN EXP IMMUNOL, V82, P435
   LOVGREN K, 1987, J IMMUNOL METHODS, V98, P137, DOI 10.1016/0022-1759(87)90447-9
   Lovgren-Bengtsson K, 2000, METH MOLEC MED, V42, P239
   LYCKE N, 1986, IMMUNOLOGY, V59, P301
   MCNAMARA M, 1984, IMMUNOL REV, V79, P87, DOI 10.1111/j.1600-065X.1984.tb00488.x                                              
   Medzhitov R, 1999, COLD SPRING HARB SYM, V64, P429, DOI 10.1101/sqb.1999.64.429
   MERZA M, 1991, ARCH VIROL, V120, P219, DOI 10.1007/BF01310477                                                              
   Morein B, 1998, DEV BIOL STAND, V92, P33
   Morein B, 1991, Scand J Infect Dis Suppl, V80, P110
   Morein B, 1996, VET IMMUNOL IMMUNOP, V54, P373, DOI 10.1016/S0165-2427(96)05697-8
   MOREIN B, 1978, NATURE, V276, P715, DOI 10.1038/276715a0
   MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0
   MOREIN B, 1990, J IMMUNOL METHODS, V128, P177, DOI 10.1016/0022-1759(90)90208-D
   MOREIN B, 1999, NEW VACCINE TECHNOLO, P274
   MOWAT AM, 1993, IMMUNOLOGY, V80, P527
   Mowat AM, 1999, IMMUNOL LETT, V65, P133
   MOWAT AM, 1991, IMMUNOL TODAY, V12, P383, DOI 10.1016/0167-5699(91)90133-E
   MOWAT AM, 1994, IMMUNE STIMULATING C
   Mowat AMI, 2001, J IMMUNOL, V167, P3398, DOI 10.4049/jimmunol.167.6.3398                                                     
   Nordengrahn A, 1996, VET MICROBIOL, V51, P55, DOI 10.1016/0378-1135(96)00032-6
   OSTERHAUS A, 1992, AIDS RES HUM RETROV, V8, P1507
   OSTERHAUS A, 1989, VACCINE, V7, P137, DOI 10.1016/0264-410X(89)90053-4
   OSTERHAUS A, 1985, J IMMUNOL, V135, P591
   PALFI V, 1978, ZBL VET MED B, V25, P165
   Polakos NK, 2001, J IMMUNOL, V166, P3589, DOI 10.4049/jimmunol.166.5.3589                                                     
   PUTKONEN P, 1994, J ACQ IMMUN DEF SYND, V7, P551
   PYLE SW, 1989, VACCINE, V7, P465, DOI 10.1016/0264-410X(89)90164-3
   RAMON G., 1926, ANN INST PASTEUR, V40, P1
   Rimmelzwaan GF, 1999, VACCINE, V17, P1355, DOI 10.1016/S0264-410X(98)00390-9                                                   
   RONNBERG B, 1995, VACCINE, V13, P1375, DOI 10.1016/0264-410X(95)00105-A
   SCHEEPERS K, 1994, MED MICROBIOL IMMUN, V183, P265, DOI 10.1007/BF00198460
   Sjolander A, 1997, CELL IMMUNOL, V177, P69, DOI 10.1006/cimm.1997.1088
   Sjolander A, 1996, SCAND J IMMUNOL, V43, P164, DOI 10.1046/j.1365-3083.1996.d01-29.x
   SJOLANDER A, 1993, EXP PARASITOL, V76, P134, DOI 10.1006/expr.1993.1016                                                          
   Sjolander A, 1998, J LEUKOCYTE BIOL, V64, P713
   Sjolander A, 1997, VACCINE, V15, P1030, DOI 10.1016/S0264-410X(96)00288-5
   Smith RE, 1999, J IMMUNOL, V162, P5536
   SPEIJERS GJA, 1988, FUND APPL TOXICOL, V10, P425, DOI 10.1016/0272-0590(88)90288-6                                                    
   Sundquist BG, 1996, VACCINE, V14, P892, DOI 10.1016/0264-410X(95)00262-Y
   THAPAR MA, 1991, VACCINE, V9, P129, DOI 10.1016/0264-410X(91)90269-C
   TRUDEL M, 1988, VACCINE, V6, P525, DOI 10.1016/0264-410X(88)90105-3
   TRUDEL M, 1989, VACCINE, V7, P12, DOI 10.1016/0264-410X(89)90004-2
   TRUDEL M, 1992, VACCINE, V10, P107, DOI 10.1016/0264-410X(92)90026-G
   VANBINNENDIJK RS, 1992, J EXP MED, V176, P119, DOI 10.1084/jem.176.1.119                                                           
   VAZQUEZ MS, 2001, REV ALERGIA MEX, V48, P15
   Verschoor EJ, 1999, J VIROL, V73, P3292
   Villacres MC, 1998, CELL IMMUNOL, V185, P30, DOI 10.1006/cimm.1998.1278                                                          
   VILLACRESERIKSS.M, 1993, INDUCTION IMMUNE RES
   VILLACRESERIKSSON M, 1992, SCAND J IMMUNOL, V36, P421, DOI 10.1111/j.1365-3083.1992.tb02956.x
   VILLACRESERIKSSON M, 1993, CLIN EXP IMMUNOL, V93, P120
   VILLACRESERIKSSON M, 1995, CLIN EXP IMMUNOL, V102, P46
   VillacresEriksson M, 1997, CYTOKINE, V9, P73, DOI 10.1006/cyto.1996.0139
   VISSER IKG, 1992, VACCINE, V10, P435, DOI 10.1016/0264-410X(92)90390-6
   WATSON DL, 1992, MICROBIOL IMMUNOL, V36, P199, DOI 10.1111/j.1348-0421.1992.tb01657.x                                              
   WATSON DL, 1989, INFLAMMATION, V13, P641, DOI 10.1007/BF00914308
NR 83
TC 68
Z9 77
U1 2
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD JUN 23
PY 2004
VL 56
IS 10
BP 1367
EP 1382
DI 10.1016/j.addr.2004.02.004
PG 16
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 832QB
UT WOS:000222280900003
PM 15191787
DA 2018-01-05
ER

PT J
AU He, YP
   Chen, FN
   Sun, GF
   Wang, YP
   De Clercq, E
   Balzarini, J
   Pannecouque, C
AF He, YP
   Chen, FN
   Sun, GF
   Wang, YP
   De Clercq, E
   Balzarini, J
   Pannecouque, C
TI 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thiol-6(1-naphthylmethyl)
   pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors
   of S-DABO series
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; RESOLUTION;
   INFECTION; DELAVIRDINE; ANTIBODIES; NNRTIS; CELLS
AB The introduction of a beta-carbonyl group to the C-2 side chain of S-DABO led to the finding of a series of novel potent anti-HIV agent. Some derivatives proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentrations. Furthermore, the novel S-DABOs differ from the classical NNRTIs in that some compounds are active against both HIV-1 and HIV-2. They might interfere with another target or at least act on RT in a different way as compared to typical NNRTIs. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   Katholieke Univ Leuven, Med Res Inst, B-3000 Louvain, Belgium.
RP Chen, FN (reprint author), Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
EM rfchen@fudan.edu.cn
CR Adkins JC, 1998, DRUGS, V56, P1055, DOI 10.2165/00003495-199856060-00014                                                
   ARTICO M, 1993, ANTIVIR CHEM CHEMOTH, V4, P361, DOI 10.1177/095632029300400608                                                      
   Artico M, 2002, DRUG FUTURE, V27, P159, DOI 10.1358/dof.2002.027.02.653978                                                  
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   Bardsley-Elliot A, 2000, Paediatr Drugs, V2, P373, DOI 10.2165/00128072-200002050-00005
   Buckheit RW, 2001, ANTIMICROB AGENTS CH, V45, P393, DOI 10.1128/AAC.45.2.393-400.2001
   De Clercq E, 2000, REV MED VIROL, V10, P255, DOI 10.1002/1099-1654(200007/08)10:4<255::AID-RMV282>3.0.CO;2-6
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842                                                        
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   HANNICK SM, 1983, J ORG CHEM, V48, P3833, DOI 10.1021/jo00169a053
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mai A, 2001, J MED CHEM, V44, P2544, DOI 10.1021/jm010853h
   Meng G, 2003, CHEM PHARM BULL, V51, P779
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REY F, 1991, VIROLOGY, V181, P165, DOI 10.1016/0042-6822(91)90481-P
   REY F, 1987, J VIROL METHODS, V16, P239, DOI 10.1016/0166-0934(87)90008-5
   Scott LJ, 2000, DRUGS, V60, P1411, DOI 10.2165/00003495-200060060-00013
   Tran JQ, 2001, CLIN PHARMACOKINET, V40, P207, DOI 10.2165/00003088-200140030-00005
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
NR 22
TC 31
Z9 36
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 21
PY 2004
VL 14
IS 12
BP 3173
EP 3176
DI 10.1016/j.bmcl.2004.04.008
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 825RU
UT WOS:000221776800034
PM 15149669
DA 2018-01-05
ER

PT J
AU Kasson, PM
   Pande, VS
AF Kasson, PM
   Pande, VS
TI Molecular dynamics simulation of lipid reorientation at bilayer edges
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID MEMBRANE-FUSION; CONSTANT-TEMPERATURE; PHOSPHOLIPID-BILAYER;
   BOUNDARY-CONDITIONS; PHASE-TRANSITIONS; NMR RELAXATION; DEUTERIUM NMR;
   DIPALMITOYLPHOSPHATIDYLCHOLINE; CHOLESTEROL; PARAMETERS
AB Understanding cellular membrane processes is critical for the study of events such as viral entry, neurotransmitter exocytosis, and immune activation. Supported lipid bilayers are commonly used to model these membrane processes experimentally. Despite the relative simplicity of such a system, many important structural and dynamic parameters are not experimentally observable with current techniques. Computational approaches allow the development of a high-resolution model of bilayer processes. We have performed molecular dynamics simulations of dimyristoylphosphatidylcholine (DMPC) bilayers to model the creation of bilayer gaps-a common process in bilayer patterning-and to analyze their structure and dynamics. We propose a model for gap formation in which the bilayer edges form metastable micelle-like structures on a nanosecond timescale. Molecules near edges structurally resemble lipids in ungapped bilayers but undergo small-scale motions more rapidly. These data suggest that lipids may undergo rapid local rearrangements during membrane fusion, facilitating the formation of fusion intermediates thought key to the infection cycle of viruses such as influenza, Ebola, and HIV.
C1 Stanford Univ, Biophys Program, Stanford, CA 94305 USA.
   Stanford Univ, Med Sci Training Program, Stanford, CA 94305 USA.
   Stanford Univ, Dept Chem, Stanford, CA 94305 USA.
RP Pande, VS (reprint author), Stanford Univ, Biophys Program, Stanford, CA 94305 USA.
EM pande@stanford.edu
CR Aravanis AM, 2003, NATURE, V423, P643, DOI 10.1038/nature01686
   Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3                                                   
   BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7
   BODEN N, 1991, BIOCHEMISTRY-US, V30, P2146, DOI 10.1021/bi00222a019
   BROWN MF, 1983, P NATL ACAD SCI-BIOL, V80, P4325, DOI 10.1073/pnas.80.14.4325
   Colman PM, 2003, NAT REV MOL CELL BIO, V4, P309, DOI 10.1038/nrm1076
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   DELOOF H, 1991, BIOCHEMISTRY-US, V30, P2099, DOI 10.1021/bi00222a015
   DOULIEZ JP, 1995, BIOPHYS J, V68, P1727, DOI 10.1016/S0006-3495(95)80350-4                                                   
   EGBERTS E, 1994, EUR BIOPHYS J BIOPHY, V22, P423, DOI 10.1007/BF00180163
   ESSEX JW, 1994, PHILOS T ROY SOC B, V344, P239, DOI 10.1098/rstb.1994.0064                                                          
   Feller SE, 1996, BIOPHYS J, V71, P1350, DOI 10.1016/S0006-3495(96)79337-2                                                   
   Gandhi SP, 2003, NATURE, V423, P607, DOI 10.1038/nature01677
   Groves JT, 1997, SCIENCE, V275, P651, DOI 10.1126/science.275.5300.651
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695                                                        
   Hovis JS, 2000, LANGMUIR, V16, P894, DOI 10.1021/la991175t                                                               
   Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863                                                
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201
   Kam L, 2000, J AM CHEM SOC, V122, P12901, DOI 10.1021/ja0034038
   Koubi L, 2001, BIOPHYS J, V81, P3339, DOI 10.1016/S0006-3495(01)75967-X                                                   
   Koynova R, 1998, BBA-REV BIOMEMBRANES, V1376, P91, DOI 10.1016/S0304-4157(98)00006-9
   Kung LA, 2000, LANGMUIR, V16, P6773, DOI 10.1021/la000653t
   Moore PB, 2001, BIOPHYS J, V81, P2484, DOI 10.1016/S0006-3495(01)75894-8                                                   
   Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2
   Nelson MT, 1996, INT J SUPERCOMPUT AP, V10, P251, DOI 10.1177/109434209601000401
   Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061                                                                
   NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334                                                                
   PASTOR RW, 1988, J CHEM PHYS, V89, P1112, DOI 10.1063/1.455218                                                                
   PEARSON RH, 1979, NATURE, V281, P499, DOI 10.1038/281499a0                                                                
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SEELIG A, 1974, BIOCHEMISTRY-US, V13, P4839, DOI 10.1021/bi00720a024
   Smondyrev AM, 1999, BIOPHYS J, V77, P2075, DOI 10.1016/S0006-3495(99)77049-9                                                   
   Tamm LK, 2003, CURR OPIN STRUC BIOL, V13, P453, DOI 10.1016/S0959-440X(03)00107-6
   Tieleman DP, 1996, J CHEM PHYS, V105, P4871, DOI 10.1063/1.472323
   Trouard TP, 1999, J CHEM PHYS, V110, P8802, DOI 10.1063/1.478787
   Tu K, 1995, BIOPHYS J, V69, P2558, DOI 10.1016/S0006-3495(95)80126-8                                                   
   VANDERKOOI G, 1991, BIOCHEMISTRY-US, V30, P10760, DOI 10.1021/bi00108a022
   VANDERPLOEG P, 1982, J CHEM PHYS, V76, P3271, DOI 10.1063/1.443321
   VENABLE RM, 1993, SCIENCE, V262, P223, DOI 10.1126/science.8211140
   Yang L, 2002, SCIENCE, V297, P1877, DOI 10.1126/science.1074354
NR 41
TC 21
Z9 21
U1 0
U2 8
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD JUN
PY 2004
VL 86
IS 6
BP 3744
EP 3749
DI 10.1529/biophysj.103.029652
PG 6
WC Biophysics
SC Biophysics
GA 829GK
UT WOS:000222035200033
PM 15189870
OA gold
DA 2018-01-05
ER

PT J
AU Toulme, JJ
   Di Primo, C
   Boucard, D
AF Toulme, JJ
   Di Primo, C
   Boucard, D
TI Regulating eukaryotic gene expression with aptamers
SO FEBS LETTERS
LA English
DT Article; Proceedings Paper
CT 29th Congress of the Federation-of-European-Biochemical-Societies
CY 2004
CL Warsaw, POLAND
SP Federat European Biochem Soc
DE in vitro selection; RNA structure; viral RNA; surface plasmon resonance
ID IMMUNODEFICIENCY-VIRUS TYPE-1; DIMERIZATION INITIATION SITE;
   TAT-MEDIATED TRANSCRIPTION; LOOP-LOOP INTERACTIONS; RNA KISSING COMPLEX;
   IN-VITRO SELECTION; HIV-1 GENOMIC RNA; REVERSE-TRANSCRIPTASE;
   EXPONENTIAL ENRICHMENT; SYSTEMATIC EVOLUTION
AB Aptamers are RNA or DNA oligonucleotides identified within a randomly synthesized library, through an in vitro selection procedure. The selected candidates display a pre-determined property of interest with respect to a given target. Successful selection has been carried out against targts ranging from small (amino acids, antibiotics) to macro-molecules (proteins, nucleic acids). They generally show an affinity in the nanomolar range and a high specificity of target recognition. Interesting, aptamers selected against purified targets in the test tube retain properties within cells. RNA aptamers can be generated in situ from an appropriate DNA construct or delivered as nulcease-resisitant oligonucleotide analogues. For example, aptamers recognizing RNA stucture through loop-loop interactions modulate the trans-activation of in vitro transcription mediated by the TAR RNA element of human immunodeficiency virus type 1. Consequently, they constitute both exquisite tools for functional geomics analysis and promising prototyes of theurapeutic agents. Natural aptameric motifs have been identified within mRNA sequences, which upon binding to a metabolite control the expreesion of the encoded gene, which is generally involved in the biosynthesis of this particular metabolite. (C) 2004 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 Univ Victor Segalen, INSERM, European Inst Chem & Biol, U 386, Bordeaux, France.
RP Toulme, JJ (reprint author), INSERM, IECB, U 386, 2 Rue Robert Escarpit, F-33607 Pessac, France.
EM jean-jacques.toulme@bordeaux.inserm.fr
OI Di Primo, Carmelo/0000-0002-0509-8399; Toulme,
   Jean-jacques/0000-0002-8432-5034
CR Agrawal N, 2003, MICROBIOL MOL BIOL R, V67, P657, DOI 10.1128/MMBR.67.4.657-685.2003
   ANDEOLA ML, 2000, EUR J BIOCHEM, V267, P5032
   Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5                                                   
   Baskerville S, 1999, J VIROL, V73, P4962
   Beaurain F, 2003, NUCLEIC ACIDS RES, V31, P4275, DOI 10.1093/nar/gkg467
   Berkhout B, 2000, Adv Pharmacol, V48, P29
   Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730
   Bondensgaard K, 2000, CHEM-EUR J, V6, P2687, DOI 10.1002/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.3.CO;2-L
   Brody E.N., 2000, REV MOL BIOTECHNOL, V74, P5, DOI DOI 10.1016/S1389-0352(99)00004-5
   Brunel C, 2002, BIOCHIMIE, V84, P925, DOI 10.1016/S0300-9084(02)01401-3
   Casey BP, 2001, PROG NUCLEIC ACID RE, V67, P163, DOI 10.1016/S0079-6603(01)67028-4
   Cassiday LA, 2003, P NATL ACAD SCI USA, V100, P3930, DOI 10.1073/pnas.0736013100
   Chaloin L, 2002, NUCLEIC ACIDS RES, V30, P4001, DOI 10.1093/nar/gkf522
   Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021
   Collin D, 2000, NUCLEIC ACIDS RES, V28, P3386, DOI 10.1093/nar/28.17.3386                                                          
   Darfeuille F, 2002, P NATL ACAD SCI USA, V99, P9709, DOI 10.1073/pnas.122247199
   Darfeuille F, 2002, BIOCHEMISTRY-US, V41, P12186, DOI 10.1021/bi025974d
   Darfeuille F, 2001, NUCLEOS NUCLEOT NUCL, V20, P441, DOI 10.1081/NCN-100002318                                                           
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   Egli M, 2000, CELL MOL LIFE SCI, V57, P1440, DOI 10.1007/PL00000628
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   GRYAZNOV SM, 1995, P NATL ACAD SCI USA, V92, P5798, DOI 10.1073/pnas.92.13.5798
   HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V
   Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175
   JELLINEK D, 1995, BIOCHEMISTRY-US, V34, P11363, DOI 10.1021/bi00036a009
   Joshi P, 2002, J VIROL, V76, P6545, DOI 10.1128/JVI.76.13.6545-6557.2002
   Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Khati M, 2003, J VIROL, V77, P12692, DOI 10.1128/JVI.77.23.12692-12698.2003
   Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697                                                          
   Konopka K, 2000, GENE, V255, P235, DOI 10.1016/S0378-1119(00)00334-6
   Lee AJ, 1998, STRUCT FOLD DES, V6, P993, DOI 10.1016/S0969-2126(98)00101-4
   LIN Y, 1994, NUCLEIC ACIDS RES, V22, P5229, DOI 10.1093/nar/22.24.5229
   Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698
   Lodmell JS, 2001, J MOL BIOL, V311, P475, DOI 10.1006/jmbi.2001.4879
   MONIA BP, 1993, J BIOL CHEM, V268, P14514
   Mujeeb A, 1998, NAT STRUCT BIOL, V5, P432, DOI 10.1038/nsb0698-432
   Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s
   Nickens DG, 2003, RNA, V9, P1029, DOI 10.1261/rna.5550103
   NUDLERE, 2004, TRENDS BIOCH SCI, V29, P11
   Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572
   Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d
   Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6                
   Praseuth D, 1999, BBA-GENE STRUCT EXPR, V1489, P181, DOI 10.1016/S0167-4781(99)00149-9                                                   
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Rist MJ, 2001, NUCLEIC ACIDS RES, V29, P2401, DOI 10.1093/nar/29.11.2401
   Scarabino D, 1999, EMBO J, V18, P4571, DOI 10.1093/emboj/18.16.4571
   Shi H, 1999, P NATL ACAD SCI USA, V96, P10033, DOI 10.1073/pnas.96.18.10033
   Sudarsan N, 2003, RNA, V9, P644, DOI 10.1261/rna.5090103
   Suess B, 2003, NUCLEIC ACIDS RES, V31, P1853, DOI 10.1093/nar/gkg285
   Tomita N, 2002, CURR OPIN MOL THER, V4, P166
   Toulme JJ, 2000, CURR OPIN MOL THER, V2, P318
   Toulme JJ, 2001, PROG NUCLEIC ACID RE, V69, P1, DOI 10.1016/S0079-6603(01)69043-3
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Werstuck G, 1998, SCIENCE, V282, P296, DOI 10.1126/science.282.5387.296
   Winkler WC, 2002, P NATL ACAD SCI USA, V99, P15908, DOI 10.1073/pnas.212628899
   Yamamoto R, 2000, GENES CELLS, V5, P371, DOI 10.1046/j.1365-2443.2000.00330.x                                                
   Yamamoto R., 1998, GENE THER MOL BIOL, V1, P451
NR 62
TC 17
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD JUN 1
PY 2004
VL 567
IS 1
BP 55
EP 62
DI 10.1016/j.febslet.2004.03.111
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 827UB
UT WOS:000221925500010
PM 15165893
DA 2018-01-05
ER

PT J
AU Chanturiya, AN
   Basanez, G
   Schubert, U
   Henklein, P
   Yewdell, JW
   Zimmerberg, J
AF Chanturiya, AN
   Basanez, G
   Schubert, U
   Henklein, P
   Yewdell, JW
   Zimmerberg, J
TI PB1-F2, an influenza A virus-encoded proapoptotic mitochondrial protein,
   creates variably sized pores in planar lipid membranes
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID PHOSPHOLIPID-BILAYER MEMBRANES; FORMS ION CHANNELS; TERMINAL REGION;
   MECHANISM; CURVATURE; BREAKDOWN; BCL-X(L); VESICLES; PEPTIDE; FUSION
AB A frameshifted region of the influenza A virus PB1 gene encodes a novel protein, termed PB1-F2, a mitochondrial protein that can induce cell death. Many proapoptotic proteins are believed to act at the mitochondrial outer membrane to form an apoptotic pore with lipids. We studied the interaction of isolated, synthetic PB1-F2 (sPB1-F2) peptide with planar phospholipid bilayer membranes. The presence of nanomolar concentrations of peptide in the bathing solution induced a transmembrane conductance that increased in a potential-dependent manner. Positive potential on the side of protein addition resulted in a severalfold increase in the rate of change of membrane conductance. sPB1-F2-treated membranes became permeable to monovalent cations, chloride, and to a lesser extent, divalent ions. Despite various experimental conditions, we did not detect the distinctive conductance levels typical of large, stable pores, protein channels, or even pores that are partially proteinaceous. Rather, membrane conductance induced by sPB1-F2 fluctuated and visited almost all conductance values. sPB1-F2 also dramatically decreased bilayer stability in an electric field, consistent with a decrease in the line tension of a lipidic pore. Since similar membrane-destabilizing profiles are seen with proapoptotic proteins (e.g., Bax) and the cytoplasmic helix of human immunodeficiency virus gp41, we suggest that the basis for sPB1-F2-induced cell death may be the permeabilization and destabilization of mitochondrial membranes, leading to macromolecular leakage and apoptosis.
C1 NICHHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA.
   NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA.
   Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Hamburg, Germany.
   Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Erlangen, Germany.
   Humboldt Univ, Inst Biochem, Berlin, Germany.
   Univ Basque Country, Unidad Biofis, CSIC, Ctr Mixto, E-48080 Bilbao, Spain.
RP Zimmerberg, J (reprint author), NICHHD, Lab Cellular & Mol Biophys, NIH, Bldg 10,Room 10D14, Bethesda, MD 20892 USA.
EM joshz@helix.nih.gov
RI yewdell, jyewdell@nih.gov/A-1702-2012; Basanez, Gorka/L-9509-2014
OI Basanez, Gorka/0000-0002-7475-7861
CR ABIDOR IG, 1979, BIOELECTROCH BIOENER, V6, P37
   Barlett G.R., 1959, J BIOL CHEM, V234, P466
   Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200
   Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200
   Basanez G, 2001, J EXP MED, V193, pF11, DOI 10.1084/jem.193.4.F11
   Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492
   BASHFORD CL, 1986, J BIOL CHEM, V261, P9300
   BENZ R, 1979, J MEMBRANE BIOL, V48, P181, DOI 10.1007/BF01872858
   Bhakdi S, 1996, ARCH MICROBIOL, V165, P73, DOI 10.1007/s002030050300
   CHANTURIA AN, 1992, TOXICON, V30, P1059, DOI 10.1016/0041-0101(92)90051-6
   Chanturiya A, 1999, MOL MEMBR BIOL, V16, P89, DOI 10.1080/096876899294805                                                         
   CHANTURIYA AN, 1990, BIOL MEMBR, V4, P1251
   Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306
   CHERNOMORDIK L, 1995, BIOPHYS J, V69, P922, DOI 10.1016/S0006-3495(95)79966-0                                                   
   CHERNOMORDIK L, 1994, J VIROL, V68, P7115
   CHERNOMORDIK LV, 1989, ELECTROPORATION ELEC, P181
   CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W
   Duclohier H, 2001, J MEMBRANE BIOL, V184, P1, DOI 10.1007/s00232-001-0077-2
   Epand RM, 1998, BBA-REV BIOMEMBRANES, V1376, P353, DOI 10.1016/S0304-4157(98)00015-X                                                   
   Gibbs JS, 2003, J VIROL, V77, P7214, DOI 10.1128/JVI.77.13.7214-7224.2003
   Ladokhin AS, 2001, BBA-BIOMEMBRANES, V1514, P253, DOI 10.1016/S0005-2736(01)00382-0
   Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P11856, DOI 10.1021/bi980539y
   MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561
   MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0
   Piller SC, 1999, J VIROL, V73, P4230
   Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111
   SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C
   Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X                                                   
   SUKHAREV SI, 1992, BIOELECTROCH BIOENER, V9, P133
   ZIMMERBERG J, 1999, SCIENCE, V284, P1516
NR 30
TC 100
Z9 107
U1 0
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2004
VL 78
IS 12
BP 6304
EP 6312
DI 10.1128/JVI.78.12.6304-6312.2004
PG 9
WC Virology
SC Virology
GA 825QC
UT WOS:000221772000024
PM 15163724
OA gold
DA 2018-01-05
ER

PT J
AU Darfeuille, F
   Hansen, JB
   Orum, H
   Primo, CD
   Toulme, JJ
AF Darfeuille, F
   Hansen, JB
   Orum, H
   Primo, CD
   Toulme, JJ
TI LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA
   element of HIV-1
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID LOCKED NUCLEIC-ACIDS; ANTISENSE OLIGONUCLEOTIDES; KISSING COMPLEX;
   MEDIATED TRANSCRIPTION; SECONDARY STRUCTURE; TRANS-ACTIVATION; LNA;
   INHIBITION; DESIGN; NMR
AB One of the major limitations of the use of phosphodiester oligonucleotides in cells is their rapid degradation by nucleases. To date, several chemical modifications have been employed to overcome this issue but insufficient efficacy and/or specificity have limited their in vivo usefulness. In this work conformationally restricted nucleotides, locked nucleic acid (LNA), were investigated to design nuclease resistant aptamers targeted against the HIV-1 TAR RNA. LNA/DNA chimeras were synthesized from a shortened version of the hairpin RNA aptamer identified by in vitro selection against TAR. The results indicate that these modifications confer good protection towards nuclease digestion. Electrophoretic mobility shift assays, thermal denaturation monitored by UV-spectroscopy and surface plasmon resonance experiments identified LNA/DNA TAR ligands that bind to TAR with a dissociation constant in the low nanomolar range as the parent RNA aptamer. The crucial G, A residues that close the aptamer loop remain a key structural determinant for stable LNA/DNA chimera-TAR complexes. This work provides evidence that LNA modifications alternated with DNA can generate stable structured RNA mimics for interacting with folded RNA targets.
C1 Inst Europeen Chim & Biol, F-33607 Pessac, France.
   Univ Victor Segalen, INSERM, U386, F-33076 Bordeaux, France.
   Santaris Pharma AS, DK-2970 Copenhagen, Denmark.
RP Primo, CD (reprint author), Inst Europeen Chim & Biol, 2 Rue Escarpit, F-33607 Pessac, France.
EM c.diprimo@iecb.u-bordeaux.fr
RI Darfeuille, Fabien/M-3883-2014
OI Darfeuille, Fabien/0000-0003-1167-6113; Di Primo,
   Carmelo/0000-0002-0509-8399; Toulme, Jean-jacques/0000-0002-8432-5034
CR Arzumanov A, 2001, NUCLEOS NUCLEOT NUCL, V20, P471, DOI 10.1081/NCN-100002321
   Arzumanov A, 2001, BIOCHEMISTRY-US, V40, P14645, DOI 10.1021/bi011279e
   Beaurain F, 2003, NUCLEIC ACIDS RES, V31, P4275, DOI 10.1093/nar/gkg467
   Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035                                                       
   Berkhout B, 2000, Adv Pharmacol, V48, P29
   Blight KJ, 1997, J VIROL, V71, P7345
   Bondensgaard K, 2000, CHEM-EUR J, V6, P2687, DOI 10.1002/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.3.CO;2-L
   Braasch DA, 2002, NUCLEIC ACIDS RES, V30, P5160, DOI 10.1093/nar/gkf651
   Childs JL, 2002, P NATL ACAD SCI USA, V99, P11091, DOI 10.1073/pnas.172391199
   Christensen U, 2001, BIOCHEM J, V354, P481, DOI 10.1042/0264-6021:3540481                                                       
   Crinelli R, 2002, NUCLEIC ACIDS RES, V30, P2435, DOI 10.1093/nar/30.11.2435
   Darfeuille F, 2002, P NATL ACAD SCI USA, V99, P9709, DOI 10.1073/pnas.122247199
   Darfeuille F, 2002, BIOCHEMISTRY-US, V41, P12186, DOI 10.1021/bi025974d
   Du ZH, 2002, CHEM BIOL, V9, P707, DOI 10.1016/S1074-5521(02)00151-5
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   Egli M, 2000, CELL MOL LIFE SCI, V57, P1440, DOI 10.1007/PL00000628
   Elayadi A N, 2001, Curr Opin Investig Drugs, V2, P558
   Fluiter K, 2003, NUCLEIC ACIDS RES, V31, P953, DOI 10.1093/nar/gkg185
   Froeyen M., 2002, Current Topics in Medicinal Chemistry, V2, P1123, DOI 10.2174/1568026023393200
   Hamma T, 2003, ANTISENSE NUCLEIC A, V13, P19, DOI 10.1089/108729003764097313
   Hamma T, 2003, BIOORG MED CHEM LETT, V13, P1845, DOI 10.1016/S0960-894X(03)00323-8
   Hwang S, 2003, J BIOL CHEM, V278, P39092, DOI 10.1074/jbc.M301749200
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697                                                          
   Koshkin AA, 1998, J AM CHEM SOC, V120, P13252, DOI 10.1021/ja9822862                                                               
   Kurreck J, 2002, NUCLEIC ACIDS RES, V30, P1911, DOI 10.1093/nar/30.9.1911                                                           
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   Mouritzen P, 2003, EXPERT REV MOL DIAGN, V3, P27, DOI 10.1586/14737159.3.1.27                                                         
   Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725
   Orum H, 2001, CURR OPIN MOL THER, V3, P239
   Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572
   Patel D J, 2000, J Biotechnol, V74, P39
   Petersen M, 2002, J AM CHEM SOC, V124, P5974, DOI 10.1021/ja012288d
   Petersen M, 2000, J MOL RECOGNIT, V13, P44, DOI 10.1002/(SICI)1099-1352(200001/02)13:1<44::AID-JMR486>3.0.CO;2-6                
   Petersen M, 2003, TRENDS BIOTECHNOL, V21, P74, DOI 10.1016/S0167-7799(02)00038-0
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Reynolds JE, 1996, RNA, V2, P867
   Rist MJ, 2001, NUCLEIC ACIDS RES, V29, P2401, DOI 10.1093/nar/29.11.2401
   Sambrook J, 1989, MOL CLONING LAB MANU
   Toulme JJ, 2000, CURR OPIN MOL THER, V2, P318
   Vickers TA, 2000, NUCLEIC ACIDS RES, V28, P1340, DOI 10.1093/nar/28.6.1340                                                           
   Wahlestedt C, 2000, P NATL ACAD SCI USA, V97, P5633, DOI 10.1073/pnas.97.10.5633
NR 43
TC 60
Z9 63
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN
PY 2004
VL 32
IS 10
BP 3101
EP 3107
DI 10.1093/nar/gkh636
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 830JQ
UT WOS:000222118600022
PM 15181175
OA gold
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Uckun, FM
AF Venkatachalam, TK
   Uckun, FM
TI Regiospecific synthesis of 5-halo-substituted thiophene pyridyl thiourea
   compounds as non-nucleoside inhibitors of HIV-1 reverse transcriptase
SO SYNTHETIC COMMUNICATIONS
LA English
DT Article
DE thiourea compounds; non-nucleoside inhibitors; HIV-1; reverse
   transcriptase
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RATIONAL DESIGN; PETT COMPOUNDS;
   RESISTANT; ANALOGS
AB The regiospecific synthesis of 5-halothiophenethylamines and halosubstituted phenylethyl thioureas was accomplished with an overall yield of 45 - 60%. Condensation of t-boc protected 2-thiophenethylamine with N-halo succinamide in dimethylformamide furnished the desired halo-substituted thiophenethylamines. These thiophenethyl amines were further converted into biologically active thiourea compounds using thiocarbonyldiimidazole chemistry. Several of the halo-substituted thiophene pyridyl thiourea compounds inhibited HIV-1 reverse transcriptase (RT) at nanomolar concentrations.
C1 Drug Discovery Program, Parker Hughes Clin, Roseville, MN USA.
   Parker Hughes Inst, Dept Chem, Roseville, MN USA.
   Parker Hughes Inst, Dept Immunol, Roseville, MN USA.
   Parker Hughes Inst, Dept Virol, Roseville, MN USA.
RP Uckun, FM (reprint author), Drug Discovery Program, Parker Hughes Clin, 2699 Patton Rd, St Paul, MN 55113 USA.
EM fatih-uckun@ih.org
CR BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   KOOYMAN EC, 1963, PURE APPL CHEM, V7, P193
   Mao C, 1999, ANTIVIR CHEM CHEMOTH, V10, P233, DOI 10.1177/095632029901000502                                                      
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   MARCH J, 1992, ADV ORG CHEM, P515
   MARINO G, 1971, ADVANCES HETEROCYCLI, V13, P235
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   UCKUN FM, 2000, Patent No. 6124324
NR 10
TC 6
Z9 6
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0039-7911
J9 SYNTHETIC COMMUN
JI Synth. Commun.
PD JUN
PY 2004
VL 34
IS 13
BP 2451
EP 2461
DI 10.1081/SCC-120039499
PG 11
WC Chemistry, Organic
SC Chemistry
GA 845AE
UT WOS:000223207200017
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Uckun, FM
AF Venkatachalam, TK
   Uckun, FM
TI Synthesis of beta-fluorophenethyl halopyridyl thiourea compounds as
   non-nucleoside inhibitors of HIV-1 reverse transcriptase
SO SYNTHETIC COMMUNICATIONS
LA English
DT Article
DE beta-fluorophenethylamines; thiourea; HIV-1; reverse transcriptase
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POTENT INHIBITOR; ANTIVIRAL PROTEIN;
   DRUG-RESISTANT; PETT COMPOUNDS; DESIGN; ANALOGS
AB Synthesis of beta-fluorophenethylamines was accomplished in three steps with an overall yield of 50%. Condensation of beta-fluorophenethylamine hydrochloride with thiocarbonylimidazole derivative derived from halopyridyl amines in dimethylformamide furnished the desired thiourea compounds as crystalline solids. Several of the beta-fluorophenethyl thiourea compounds inhibited HIV-1 reverse transcriptase (RT) at nanomolar to low micromolar concentrations.
C1 Parker Hughes Clin, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Clin, Dept Chem, St Paul, MN 55113 USA.
   Parker Hughes Clin, Dept Virol, St Paul, MN 55113 USA.
   Parker Hughes Clin, Dept Immunol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Clin, Drug Discovery Program, 2699 Patton Rd, St Paul, MN 55113 USA.
EM fatih_uckun@ih.org
CR BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   Uckun FM, 2000, ANTIVIR CHEM CHEMOTH, V11, P135, DOI 10.1177/095632020001100205                                                      
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 11
TC 3
Z9 3
U1 0
U2 2
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0039-7911
J9 SYNTHETIC COMMUN
JI Synth. Commun.
PD JUN
PY 2004
VL 34
IS 13
BP 2463
EP 2472
DI 10.1081/SCC-120039500
PG 10
WC Chemistry, Organic
SC Chemistry
GA 845AE
UT WOS:000223207200018
DA 2018-01-05
ER

PT J
AU Dinauer, N
   Lochmann, D
   Demirhan, I
   Bouazzaoui, A
   Zimmer, A
   Chandra, A
   Kreuter, J
   von Briesen, H
AF Dinauer, N
   Lochmann, D
   Demirhan, I
   Bouazzaoui, A
   Zimmer, A
   Chandra, A
   Kreuter, J
   von Briesen, H
TI Intracellular tracking of protamine/antisense oligonucleotide
   nanoparticles and their inhibitory effect on HIV-1 transactivation
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE nanoparticles; antisense oligonucleotides; HIV-1; protamine;
   intracellular processing
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTISENSE OLIGONUCLEOTIDES;
   PHOSPHOROTHIOATE OLIGONUCLEOTIDE; DELIVERY; CELLS; DNA; TRANSLATION;
   CONDENSATION; MACROPHAGES; RECEPTOR
AB Membrane transport of antisense oligonucleotides (AS-ODN) is an inefficient process which requires special carriers for their intracellular delivery. We have developed a delivery system for AS-ODN and their phosphorothioate analogues (AS-PTO) directed against human immunodeficiency virus type I (HIV-1) tat mRNA for efficient transfection of HIV-1 target cells. Protamine was used to complex AS-ODN and AS-PTO to form nanoparticles with diameters of about 180 nm and surface charges in the range of -18 to +30 mV. Cellular uptake of these nanoparticles was significantly enhanced compared to naked oligonucleotides. A double labeling technique with fluorescently tagged prolamine and AS-ODN was used to follow the intracellular fate of the nanoparticles. Protamine/AS-ODN nanoparticles showed release of the antisense compound leading to specific inhibition of tat mediated HIV-1 transactivation. In contrast, protamine/AS-PTO complexes were stable over 72 h, and failed to release AS-PTO. These results demonstrate that protamine/AS-ODN nanoparticles are useful for future therapeutical application to inhibit viral gene expression. (C) 2004 Elsevier B.V. All rights reserved.
C1 Chemotherapeut Forschungsinst Georg Speyer Haus, Dept Virol & Cell Biol, D-60596 Frankfurt, Germany.
   Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany.
   Univ Frankfurt, Sch Med, Inst Transfus Med, D-60528 Frankfurt, Germany.
   Paul Ehrlich Inst, D-63225 Langen, Germany.
   Karl Franzens Univ Graz, Inst Pharmaceut Chem & Technol, A-8010 Graz, Austria.
   Univ Frankfurt, Sch Med, Inst Med Virol, D-60590 Frankfurt, Germany.
RP von Briesen, H (reprint author), Chemotherapeut Forschungsinst Georg Speyer Haus, Dept Virol & Cell Biol, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.
EM briesen@em.uni-frankfurt.de
RI Fachbereich14, Dekanat/C-8553-2015
OI Zimmer, Andreas/0000-0003-3127-287X
CR Akhtar S, 1997, INT J PHARM, V151, P57, DOI 10.1016/S0378-5173(97)04887-4                                                   
   Anazodo MI, 1995, GENE, V166, P227, DOI 10.1016/0378-1119(95)00582-X
   Antony T, 1998, J BIOCHEM BIOPH METH, V36, P75, DOI 10.1016/S0165-022X(97)00047-X
   Barratt G., 1999, PHARM TECHNOL EU JAN, P25
   Berne B.J., 2000, DYNAMIC LIGHT SCATTE
   Berton M, 2001, PHARMACEUT RES, V18, P1096, DOI 10.1023/A:1010962507273                                                         
   Brewer L, 2002, J BIOL CHEM, V277, P38895, DOI 10.1074/jbc.M204755200
   Brown-Driver V, 1999, ANTISENSE NUCLEIC A, V9, P145, DOI 10.1089/oli.1.1999.9.145                                                        
   Cleek RL, 1997, J CONTROL RELEASE, V48, P259, DOI 10.1016/S0168-3659(97)00052-7                                                   
   Coulson JM, 1996, MOL PHARMACOL, V50, P314
   Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543                                             
   CROUCH SPM, 1993, J IMMUNOL METHODS, V160, P81, DOI 10.1016/0022-1759(93)90011-U
   DEMIRHAN I, 1995, VIRUS GENES, V9, P113, DOI 10.1007/BF01702654
   Eisert V, 2001, VIROLOGY, V286, P31, DOI 10.1006/viro.2001.0940
   FINSY R, 1992, PART PART SYST CHAR, V9, P125, DOI 10.1002/ppsc.19920090117                                                        
   Freedland SJ, 1996, BIOCHEM MOL MED, V59, P144, DOI 10.1006/bmme.1996.0080                                                          
   Good L, 2003, CELL MOL LIFE SCI, V60, P854, DOI 10.1007/s00018-003-3045-4
   Ho SP, 1999, MOL BRAIN RES, V65, P23, DOI 10.1016/S0169-328X(98)00326-X
   Islam A, 2000, J DRUG TARGET, V7, P373
   JOHANSSON HE, 1994, NUCLEIC ACIDS RES, V22, P4591, DOI 10.1093/nar/22.22.4591
   Junghans M, 2001, BBA-PROTEIN STRUCT M, V1544, P177, DOI 10.1016/S0167-4838(00)00219-3
   Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8
   LEWIS KJ, 1995, J CONTROL RELEASE, V37, P173, DOI 10.1016/0168-3659(95)00100-M
   Opalinska Joanna B, 2002, Curr Opin Investig Drugs, V3, P928
   Pecora R, 2000, J NANOPART RES, V2, P123, DOI 10.1023/A:1010067107182                                                         
   Putney SD, 1999, ANTISENSE NUCLEIC A, V9, P451, DOI 10.1089/oli.1.1999.9.451
   Saito G, 2003, GENE THER, V10, P72, DOI 10.1038/sj.gt.3301859
   Stahel RA, 2003, LUNG CANCER-J IASLC, V41, pS81, DOI 10.1016/S0169-5002(03)00147-8
   Thierry AR, 2003, CURR OPIN MOL THER, V5, P133
   Vijayanathan V, 2002, BIOCHEMISTRY-US, V41, P14085, DOI 10.1021/bi0203987
   WEHLING K, 1976, NUCLEIC ACIDS RES, V3, P149, DOI 10.1093/nar/3.1.149                                                             
   WICKSTROM E, 1986, J BIOCHEM BIOPH METH, V13, P97, DOI 10.1016/0165-022X(86)90021-7
   Yamaguchi K, 1997, AIDS RES HUM RETROV, V13, P545, DOI 10.1089/aid.1997.13.545
NR 33
TC 29
Z9 30
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 18
PY 2004
VL 96
IS 3
BP 497
EP 507
DI 10.1016/j.jconrel.02.020
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 822XE
UT WOS:000221573200013
PM 15120905
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Mao, C
   Uckun, FM
AF Venkatachalam, TK
   Mao, C
   Uckun, FM
TI Effect of stereo and regiochemistry towards wild and multidrug resistant
   HIV-1 virus: viral potency of chiral PETT derivatives
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE HIV; multidrug resistance; non-nucleoside inhibitors; regiochemistry;
   stereochemistry; thiourea
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS;
   NONNUCLEOSIDE INHIBITORS; DRUG-RESISTANT; PHARMACOKINETIC FEATURES;
   TISSUE DISTRIBUTION; THIOUREA COMPOUNDS; ANTIVIRAL ACTIVITY; MAJOR
   DETERMINANT; DESIGN
AB Chiral derivatives of several substituted halopyridyl and thiazolyl PETT compounds were synthesized as non-nucleoside inhibitors of the reverse transcriptase (RT) enzyme of the human immunodeficiency virus (HIV- 1). Molecular modeling studies indicated that because of the asymmetric geometry of the non-nucleoside inhibitors (NNRTI) binding pocket, the 'R' stercoisomers would fit the NNRTI binding pocket of the HIV-1 RT much better than the corresponding 'S' stereoisomers, as reflected by their 10(4)-fold lower K-i values. The 'R' stereoisomers of several PETT derivatives inhibited the recombinant RT in vitro with lower IC50 values than their enantiomers. The active compounds were further evaluated for their ability to inhibit HIV-1 replication in human peripheral blood mononuclear cells (PBMCs). All the 'R' isomers again showed potent anti-HIV activity and inhibited the replication of the HIV-1 strains HTLVIIIB in PBMCs at nanomolar concentrations whereas their enantiomers were less potent. The lead compounds for the respective groups were further tested against A17 (NNRTI-resistant, Y181C mutant RT), and A17Var (NNI-resistant Y181C +/- K103N mutant RT) as well as multidrug resistant viral strains. The results indicated that the lead compounds were several logs more potent than the standard NNRTI drug nevirapine. Structure-activity relationship among the derivatives showed preference of pyridyl unit with halo substitutions primarily at 5-position demonstrating the importance of both the stereochemistry as well as regiochemistry. Our data provides experimental evidence that the stereochemistry and the regiochemistry of non-nucleoside inhibitors can profoundly affect their anti-HIV activity. (C) 2004 Elsevier Inc. All rights reserved.
C1 Parker Hughes Inst, Dept Chem Struct Biol & Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Dept Chem Struct Biol & Virol, 2657 Patton Rd, St Paul, MN 55113 USA.
EM fatih_uckun@ih.org
CR BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Blagovic M. U., 2003, J AM CHEM SOC, V125, P6016
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Chen CL, 1999, PHARMACEUT RES, V16, P1226, DOI 10.1023/A:1014814313681
   Chen CL, 2001, ARZNEIMITTEL-FORSCH, V51, P574
   Cohen J, 2002, SCIENCE, V296, P2320, DOI 10.1126/science.296.5577.2320                                                   
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   Deeks SG, 1999, J INFECT DIS, V179, P1375, DOI 10.1086/314775
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   FRANCHETTI P, 1995, J MED CHEM, V38, P4007, DOI 10.1021/jm00020a015
   Fujiwara T, 1998, ANTIMICROB AGENTS CH, V42, P1340
   Goldschmidt R H, 1997, J Am Board Fam Pract, V10, P144
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Hajos Gyorgy, 2000, Drugs of the Future, V25, P47, DOI 10.1358/dof.2000.025.01.858638
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   LODOVICI DW, 2001, BIOORG MED CHEM LETT, V11, P2235
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   SATCHER D, 1997, HIV AIDS SURVEILL RE, V9, P1
   SUDBECK EA, 1998, ANTIMICRO AGENTS CHE, V19, P225
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Venkatachalam TK, 2000, BIOORG MED CHEM LETT, V10, P2071, DOI 10.1016/S0960-894X(00)00398-X
   Venkatachalam TK, 2001, ANTIVIR CHEM CHEMOTH, V12, P213, DOI 10.1177/095632020101200402                                                      
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 31
TC 21
Z9 22
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAY 15
PY 2004
VL 67
IS 10
BP 1933
EP 1946
DI 10.1016/j.bcp.2004.01.019
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 822TJ
UT WOS:000221562900013
PM 15130770
DA 2018-01-05
ER

PT J
AU Micheletti, C
   Carloni, P
   Maritan, A
AF Micheletti, C
   Carloni, P
   Maritan, A
TI Accurate and efficient description of protein vibrational dynamics:
   Comparing molecular dynamics and Gaussian models
SO PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
LA English
DT Article
DE HIV-1 protease; molecular dynamics; Gaussian models for vibrational
   dynamics; drug-resistance; protein flexibility
ID MAGNETIC-RESONANCE RELAXATION; HINGE-BENDING MODE; HIV-1 PROTEASE;
   DRUG-RESISTANCE; CONFORMATIONAL FLUCTUATIONS; COLLECTIVE MOTIONS;
   TRYPSIN-INHIBITOR; SINGLE-PARAMETER; ENZYME FUNCTION; X-RAY
AB Current all-atom potential based molecular dynamics (MD) allows the identification of a protein's functional motions on a wide-range of timescales, up to few tens of nanoseconds. However, functional, large-scale motions of proteins may occur on a timescale currently not accessible by all-atom potential based MD. To avoid the massive computational effort required by this approach, several simplified schemes have been introduced. One of the most satisfactory is the Gaussian network approach based on the energy expansion in terms of the deviation of the protein backbone from its native configuration. Here, we consider an extension of this model that captures in a more realistic way the distribution of native interactions due to the introduction of effective side-chain centroids. Since their location is entirely determined by the protein backbone, the model is amenable to the same exact and computationally efficient treatment as previous simpler models. The ability of the model to describe the correlated motion of protein residues in thermodynamic equilibrium is established through a series of successful comparisons with an extensive (14 ns) MD simulation based on the AMBER potential of HIV-1 protease in complex with a peptide substrate. Thus, the model presented here emerges as a powerful tool to provide preliminary, fast yet accurate characterizations of protein near-native motion. (C) 2004 Wiley-Liss, Inc.
C1 Scuola Int Super Studi Avanzati, SISSA, I-34014 Trieste, Italy.
   INFM, I-34014 Trieste, Italy.
   Abdus Salam Int Ctr Theoret Phys, Trieste, Italy.
   Dipartimento Fis G Galilei, I-35131 Padua, Italy.
RP Micheletti, C (reprint author), Scuola Int Super Studi Avanzati, SISSA, Via Beirut 2-4, I-34014 Trieste, Italy.
EM michelet@sissa.it
RI Carloni, Paolo/H-8736-2013
CR Ala PJ, 1998, BIOCHEMISTRY-US, V37, P15042, DOI 10.1021/bi980386e                                                               
   Amadei A, 1999, PROTEINS, V36, P419, DOI 10.1002/(SICI)1097-0134(19990901)36:4<419::AID-PROT5>3.0.CO;2-U
   AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408
   Atilgan AR, 2001, BIOPHYS J, V80, P505, DOI 10.1016/S0006-3495(01)76033-X                                                   
   Bahar I, 1998, PHYS REV LETT, V80, P2733, DOI 10.1103/PhysRevLett.80.2733
   Bahar I, 1999, J MOL BIOL, V285, P1023, DOI 10.1006/jmbi.1998.2371
   Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2
   Boucher C, 1996, AIDS, V10, pS15
   BROOKS B, 1985, P NATL ACAD SCI USA, V82, P4995, DOI 10.1073/pnas.82.15.4995
   Brooks C. L., 1988, PROTEINS THEORETICAL
   Brown AJL, 1999, AIDS RES HUM RETROV, V15, P247, DOI 10.1089/088922299311420                                                         
   CASE DA, 1994, CURR OPIN STRUC BIOL, V4, P285, DOI 10.1016/S0959-440X(94)90321-2
   Chandrasekhar S, 1943, REV MOD PHYS, V15, P0001, DOI 10.1103/RevModPhys.15.1                                                         
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   Doruker P, 2000, PROTEINS, V40, P512, DOI 10.1002/1097-0134(20000815)40:3<512::AID-PROT180>3.3.CO;2-D
   Doruker P, 2002, INT J QUANTUM CHEM, V90, P822, DOI 10.1002/qua.955
   Doruker P, 2002, J COMPUT CHEM, V23, P119, DOI 10.1002/jcc.1160
   FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933                                                         
   GARCIA AE, 1992, PHYS REV LETT, V68, P2696, DOI 10.1103/PhysRevLett.68.2696                                                     
   Goldstein H., 1980, CLASSICAL MECH
   Gulnik S, 2000, VITAM HORM, V58, P213, DOI 10.1016/S0083-6729(00)58026-1
   Haliloglu T, 1999, PROTEINS, V37, P654, DOI 10.1002/(SICI)1097-0134(19991201)37:4<654::AID-PROT15>3.0.CO;2-J
   Halle B, 2002, P NATL ACAD SCI USA, V99, P1274, DOI 10.1073/pnas.032522499
   Hess B, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.031910
   Hinsen K, 1998, PROTEINS, V33, P417, DOI 10.1002/(SICI)1097-0134(19981115)33:3<417::AID-PROT10>3.0.CO;2-8
   HOBOHM U, 1994, PROTEIN SCI, V3, P522
   HORIUCHI T, 1991, PROTEINS, V10, P106, DOI 10.1002/prot.340100204                                                          
   Howard J, 2001, MECH MOTOR PROTEINS
   Jacobs DJ, 2001, PROTEINS, V44, P150, DOI 10.1002/prot.1081                                                               
   Karplus M, 2002, ACCOUNTS CHEM RES, V35, P321, DOI 10.1021/ar020082r
   Kurt N, 2003, PROTEINS, V51, P409, DOI 10.1002/prot.10350
   LEVITT M, 1985, J MOL BIOL, V181, P423, DOI 10.1016/0022-2836(85)90230-X                                                    
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   MARKOWITZ M, 1995, J VIROL, V69, P701
   MCCAMMON JA, 1976, NATURE, V262, P325, DOI 10.1038/262325a0
   Micheletti C, 2002, PROTEIN SCI, V11, P1878, DOI 10.1110/ps.3360102
   Micheletti C, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.088102
   Micheletti C, 2002, J MOL BIOL, V321, P909, DOI 10.1016/S0022-2836(02)00710-6
   Micheletti C, 2001, PROTEINS, V42, P422, DOI 10.1002/1097-0134(20010215)42:3<422::AID-PROT120>3.0.CO;2-2                     
   Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760
   NOGUTI T, 1982, NATURE, V296, P776, DOI 10.1038/296776a0
   Park B, 1996, J MOL BIOL, V258, P367, DOI 10.1006/jmbi.1996.0256
   PATRICK AK, 1996, ANTIMICROB AGENTS CH, V40, P292
   Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702
   Piana S, 2002, J MOL BIOL, V319, P567, DOI 10.1016/S0022-2836(02)00301-7
   PIANA S, 2003, IN PRESS REACTION ME
   Press WH, 1999, NUMERICAL RECIPES
   Reddy P, 1999, FORMULARY, V34, P567
   ROD TH, 2003, P NATL ACAD SCI USA, V100, P3954
   Settanni G, 2003, BIOPHYS J, V84, P2282, DOI 10.1016/S0006-3495(03)75034-6
   SWAMINATHAN S, 1982, BIOCHEMISTRY-US, V21, P5230, DOI 10.1021/bi00264a019
   TIRION MM, 1993, J MOL BIOL, V230, P186, DOI 10.1006/jmbi.1993.1135
   Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905                                                     
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
NR 55
TC 116
Z9 118
U1 0
U2 12
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0887-3585
J9 PROTEINS
JI Proteins
PD MAY 15
PY 2004
VL 55
IS 3
BP 635
EP 645
DI 10.1002/prot.20049
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 818ML
UT WOS:000221249100017
PM 15103627
DA 2018-01-05
ER

PT J
AU Tkachenko, AG
   Xie, H
   Liu, YL
   Coleman, D
   Ryan, J
   Glomm, WR
   Shipton, MK
   Franzen, S
   Feldheim, DL
AF Tkachenko, AG
   Xie, H
   Liu, YL
   Coleman, D
   Ryan, J
   Glomm, WR
   Shipton, MK
   Franzen, S
   Feldheim, DL
TI Cellular trajectories of peptide-modified gold particle complexes:
   Comparison of nuclear localization signals and peptide transduction
   domains
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID INTRACELLULAR DELIVERY; METABOLIC-INHIBITORS; PROTEIN TRANSDUCTION;
   PLASMA-MEMBRANE; TAT PEPTIDE; CELLS; TRANSPORT; TEMPERATURE; MECHANISM;
   CONTRAST
AB Gold nanoparticles modified with nuclear localization peptides were synthesized and evaluated for their subcellular distribution in HeLa human cervical epithelium cells, 3T3/NIH murine fibroblastoma cells, and HepG2 human hepatocarcinoma cells. Video-enhanced color differential interference contrast microscopy and transmission electron microscopy indicated that transport of nanoparticles into the cytoplasm and nucleus depends on peptide sequence and cell line. Recently, the ability of certain peptides, called protein transduction domains (PTDs), to transclocate cell and nuclear membranes in a receptor- and temperature-independent manner has been questioned (see for example, Lundberg, M.; Wikstrom, S.; Johansson, M. (2003) Mol. Ther. 8, 143-150). We have evaluated the cellular trajectory of gold nanoparticles carrying the PTD from HIV Tat protein. Our observations were that (1) the conjugates did not enter the nucleus of 3T3/NlH or HepG2 cells, and (2) cellular uptake of Tat PTD peptide-gold nanoparticle conjugates was temperature dependent, suggesting an endosomal pathway of uptake. Gold nanoparticles modified with the adenovirus nuclear localization signal and the integrin binding domain also entered cells via an energy-de pendent mechanism, but in contrast to the Tat PTD, these signals triggered nuclear uptake of nanoparticles in HeLa and HepG2 cell lines.
C1 N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
RP Franzen, S (reprint author), N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA.
EM stefan_franzen@ncsu.edu; dan_feldheim@ncsu.edu
RI Glomm, Wilhelm/E-5179-2012
FU NCI NIH HHS [CA 98194-01]
CR BAUDHUIN PV, 1989, COLLOIDAL GOLD PRINC, V2
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   DUNCAN R, 1978, BIOCHIM BIOPHYS ACTA, V544, P647, DOI 10.1016/0304-4165(78)90339-2                                                    
   Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623                                                          
   FELDHERR CM, 1992, P NATL ACAD SCI USA, V89, P11002, DOI 10.1073/pnas.89.22.11002
   FELDHERR CM, 1994, EXP CELL RES, V215, P206, DOI 10.1006/excr.1994.1333
   FELDHERR CM, 1993, EXP CELL RES, V205, P179, DOI 10.1006/excr.1993.1073
   FELDHERR CM, 1990, J CELL BIOL, V111, P1, DOI 10.1083/jcb.111.1.1                                                             
   Feldherr CM, 1999, J CELL SCI, V112, P2043
   GOODMAN S, 1989, COLLOIDAL GOLD PRINC, P369
   HART S, 1995, INTEGRIN MEDIATED GE, P101
   HOEFSMIT ECM, 1986, J MICROSC-OXFORD, V143, P161, DOI 10.1111/j.1365-2818.1986.tb02774.x                                              
   INOUE S, 1981, J CELL BIOL, V89, P346, DOI 10.1083/jcb.89.2.346
   Inoue S., 1997, VIDEO MICROSCOPY FUN, P741
   Kang SH, 1999, ANTISENSE NUCLEIC A, V9, P497, DOI 10.1089/oli.1.1999.9.497
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lundberg M, 2003, MOL THER, V8, P143, DOI 10.1016/S1525-0016(03)00135-7
   LUNDBERG M, 2002, BIOCHEM BIOPH RES CO, V22, P367
   Nagasaki T, 2003, BIOCONJUGATE CHEM, V14, P282, DOI 10.1021/bc025602h
   Nakai K, 2000, ADV PROTEIN CHEM, V54, P277, DOI 10.1016/S0065-3233(00)54009-1
   Nori A, 2003, BIOCONJUGATE CHEM, V14, P44, DOI 10.1021/bc0255900
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   SAISONBEHMOARAS E, 1995, TARGETING DRUGS, V5, P31
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Tkachenko AG, 2003, J AM CHEM SOC, V125, P4700, DOI 10.1021/ja0296935
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Xie H, 2003, ANAL CHEM, V75, P5797, DOI 10.1021/ac034578d
   Zauner W, 1997, EXP CELL RES, V232, P137, DOI 10.1006/excr.1997.3486
   Zhang F, 1999, GENE THER, V6, P171, DOI 10.1038/sj.gt.3300801
NR 32
TC 324
Z9 330
U1 1
U2 86
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD MAY-JUN
PY 2004
VL 15
IS 3
BP 482
EP 490
DI 10.1021/bc034189q
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 822TN
UT WOS:000221563300007
PM 15149175
DA 2018-01-05
ER

PT J
AU Sommer, AP
AF Sommer, AP
TI Suffocation of nerve fibers by living nanovesicles: A model simulation
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Letter
DE nanovesicles; nanoclay; self-assembly; perineurium; peripheral
   neuropathy; HIV
ID STONE FORMATION; NANOBACTERIA; LIGHT; CALCIFICATION; NANOSPHERES; HIV
AB A model using nanospheres to allow the simulation of the nonspecific interaction of nanobacteria (NB), one with another or with body tissues, is established. Depending primarily on their concentrations and stress levels, these apatite nanovesicles may nucleate thrombogenic conglomerates in blood, or self-assemble to dense nanoclay layers on surfaces in the body. Partial or total encapsulation of nerve fiber bundles by such mineral layers may interrupt the metabolic exchanges between the surrounded tissue and its immediate environment and may restrict signaling processes. The presented model could provide detailed insight into plaque formation triggered by NB, and the parameters encouraging it.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
CR Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   KALIMO H, 1981, MUSCLE NERVE, V4, P228, DOI 10.1002/mus.880040310
   KING RH, 1988, J NEUROPATHOL APPL N, V14, P105
   Klatt EC, 2003, ADV CARDIOL, V40, P23
   Nadler RB, 2003, J UROLOGY, V169, P475, DOI 10.1097/01.ju.0000046021.43205.d6
   Sommer AP, 2004, J PHYS CHEM B, V108, P8, DOI 10.1021/jp0363747
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, NANO LETT, V3, P573, DOI 10.1021/nl0258269
   Sommer AP, 2003, NANO LETT, V3, P321, DOI 10.1021/nl025940r
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   Sommer AP, 2002, CRYST GROWTH DES, V2, P563, DOI 10.1021/cg0255725
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   SOMMER AP, 2003, J CLIN LASER MED SUR, V21, P229
NR 14
TC 5
Z9 5
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAY-JUN
PY 2004
VL 3
IS 3
BP 667
EP 669
DI 10.1021/pr034122c
PG 3
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 829UK
UT WOS:000222075500040
PM 15253453
DA 2018-01-05
ER

PT J
AU Sommer, AP
AF Sommer, AP
TI Could reduced bone mineral densities in HIV be caused by nanobacteria?
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Letter
DE HIV; calcium phosphate; apatite; bone mineral density; nanobacteria
ID KIDNEY-STONE FORMATION; PRIMORDIAL BIOSYSTEMS; LIGHT
AB From the observations of different research groups reporting on reduced bone mineral density (BMD) and on a pronounced tendency for kidney stone formation, both in HIV-infected patients, and from results achieved in the treatment of severest peripheral neuropathy with lasers, it is concluded that nanobacteria (NB) could actively contribute to the reduction of BMD. A reduced BMD could primarily stem from NB, extracting calcium and phosphate from blood, affecting the calcium and phosphate homeostasis in humans.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
EM samoan@gmx.net
CR Akerman KK, 1997, P SOC PHOTO-OPT INS, V3111, P436, DOI 10.1117/12.278798
   BRUERA D, 2003, J ACQ IMMUN DEF SYND, V17, P1917
   Bushinsky DA, 2003, J CLIN INVEST, V111, P602, DOI 10.1172/JCI200318016
   Ciftcioglu N, 1999, KIDNEY INT, V56, P1893, DOI 10.1046/j.1523-1755.1999.00755.x
   GLESBY M, 2003, J CLIN INFECT DIS S2, V37, pS91
   Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274                                                         
   Nadler RB, 2003, J UROLOGY, V169, P475, DOI 10.1097/01.ju.0000046021.43205.d6
   PASHEV IG, 1991, TRENDS BIOCHEM SCI, V16, P323, DOI 10.1016/0968-0004(91)90133-G
   Sommer AP, 2004, CRYST GROWTH DES, V4, P45, DOI 10.1021/cg034121x
   Sommer AP, 2003, J PROTEOME RES, V2, P665, DOI 10.1021/pr0340633
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2003, NANO LETT, V3, P19, DOI 10.1021/nl025839m
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   Sommer AP, 2002, CRYST GROWTH DES, V2, P563, DOI 10.1021/cg0255725
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   SOMMER AP, IN PRESS J PROTEOME
   SOMMER AP, 2003, J CLIN LASER MED SUR, V21, P229
   Thomas J, 2003, JAIDS-J ACQ IMM DEF, V33, P281, DOI 10.1097/00126334-200307010-00001                                                
NR 20
TC 14
Z9 14
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAY-JUN
PY 2004
VL 3
IS 3
BP 670
EP 672
DI 10.1021/pr049978b
PG 3
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 829UK
UT WOS:000222075500041
PM 15253454
DA 2018-01-05
ER

PT J
AU Akashi, M
   Akagi, T
AF Akashi, M
   Akagi, T
TI Synthesis and clinical application to drug delivery system of
   core-corona type polymeric nanospheres
SO JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN
LA Japanese
DT Article
DE nanospheres; macromonomer; graft copolymer; drug delivery system;
   peptide; HIV-1; virus; vaccine
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; IMMOBILIZED POLYSTYRENE
   NANOSPHERES; POLY(ETHYLENE GLYCOL) MACROMONOMER; ORAL PEPTIDE DELIVERY;
   GRAFT-COPOLYMERS; HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES;
   SALMON-CALCITONIN; POLY(N-ISOPROPYLACRYLAMIDE) BRANCHES; SILVER
   NANOPARTICLES
AB Monodisperse polymeric nanospheres, which consist of hydrophobic core and hydrophilic corona on their surfaces, were prepared by the free radical dispersion copolymerization of bydrophobic monomers and hydrophilic macromonomers in a polar solvent. For example, copolymerization of meth acrylate-terminated poly(ethylene glycol) (PEG) macromonomers and styrene in ethanol/water mixture gives water dispersible PEG coated nanospheres with a mean diameter around 100-2000 nm. An electron spectroscopy for chemical analysis (ESCA), dynamic light scattering (DLS) and transmission electron microscopy (TEM) observation of ultrathin cross section embedded in a resin supported accumulation of PEG component at the surface of nanospheres. The core-corona type nanospheres can be widely applied to various technological and biomedical applications, because of their possible variety of chemical structure. These nanospheres were utilized as oral drug carriers for peptide drugs physically adsorbed on the nanosphere surfaces, and demonstrated to be useful carrier for incorporating highly water-soluble peptides. Moreover, lectin-immobilized nanospheres could efficiently capture HIV-1 particles and HIV-1-capturing nanospheres may have great potential as a prophylactic vaccine against HIV-1 infection through sexual intercourse.
C1 Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka 5650871, Japan.
RP Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Mol Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   AKASHI M, 1985, ANGEW MAKROMOL CHEM, V132, P81, DOI 10.1002/apmc.1985.051320107                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   AKASHI M, 1990, J APPL POLYM SCI, V39, P2027, DOI 10.1002/app.1990.070390917                                                      
   Bogers WMJM, 2000, AIDS, V14, pS141
   Chen CW, 1999, LANGMUIR, V15, P7998, DOI 10.1021/la9817462                                                               
   Chen CW, 1998, CHEM COMMUN, P831, DOI 10.1039/a800203g                                                                
   Chen CW, 1998, ADV MATER, V10, P1122, DOI 10.1002/(SICI)1521-4095(199810)10:14<1122::AID-ADMA1122>3.3.CO;2-E
   Chen CW, 1999, CHEM MATER, V11, P1381, DOI 10.1021/cm9900047                                                               
   Chen MQ, 1999, J POLYM SCI POL CHEM, V37, P2155, DOI 10.1002/(SICI)1099-0518(19990701)37:13<2155::AID-POLA31>3.0.CO;2-G              
   Chen MQ, 1999, POLYM ADVAN TECHNOL, V10, P120, DOI 10.1002/(SICI)1099-1581(199901/02)10:1/2<120::AID-PAT781>3.3.CO;2-7
   Chen MQ, 2001, CHEM LETT, P1306
   Clerici M, 2002, AIDS, V16, P1731, DOI 10.1097/00002030-200209060-00004
   GATTEGNO L, 1992, AIDS RES HUM RETROV, V8, P27, DOI 10.1089/aid.1992.8.27
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Kaneko T, 2004, MACROMOLECULES, V37, P501, DOI 10.1021/ma035276g
   Kaul R, 2000, J IMMUNOL, V164, P1602, DOI 10.4049/jimmunol.164.3.1602                                                     
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   MATSUSAKI M, 2004, CHEM LETT, V33, P398
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   MIYAKE A, IN PRESS J MED VIROL
   Sakuma S, 1999, INT J PHARM, V177, P161, DOI 10.1016/S0378-5173(98)00346-9
   Sakuma S, 1997, INT J PHARM, V159, P181, DOI 10.1016/S0378-5173(97)00284-6                                                   
   Sakuma S, 2002, J CONTROL RELEASE, V81, P281, DOI 10.1016/S0168-3659(02)00072-X                                                   
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   Sakuma S, 2002, INT J PHARM, V239, P185, DOI 10.1016/S0378-5173(02)00113-8
   Sakuma S, 2001, ADV DRUG DELIVER REV, V47, P21, DOI 10.1016/S0169-409X(00)00119-8
   Sakuma S, 1997, INT J PHARM, V158, P69, DOI 10.1016/S0378-5173(97)00247-0
   Serizawa T, 2000, COLLOID SURFACE A, V169, P95, DOI 10.1016/S0927-7757(00)00421-0                                                   
   Serizawa T, 1999, J BIOMAT SCI-POLYM E, V10, P391, DOI 10.1163/156856299X00441                                                         
   Serizawa T, 2000, MACROMOLECULES, V33, P1759, DOI 10.1021/ma9907486                                                               
   Serizawa T, 2001, BIOMACROMOLECULES, V2, P469, DOI 10.1021/bm000131s
   Uchida T, 1999, POLYM J, V31, P970, DOI 10.1295/polymj.31.970                                                           
NR 34
TC 0
Z9 0
U1 0
U2 3
PU SOC SYNTHETIC ORGANIC CHEM JPN
PI TOKYO
PA CHEMISTRY HALL, 1-5 KANDA-SURUGADAI, CHIYODA-KU, TOKYO, 101, JAPAN
SN 0037-9980
J9 J SYN ORG CHEM JPN
JI J. Synth. Org. Chem. Jpn.
PD MAY
PY 2004
VL 62
IS 5
BP 520
EP 528
DI 10.5059/yukigoseikyokaishi.62.520                                       
          
PG 9
WC Chemistry, Organic
SC Chemistry
GA 822NB
UT WOS:000221545800015
OA gold
DA 2018-01-05
ER

PT J
AU Kensinger, RD
   Yowler, BC
   Benesi, AJ
   Schengrund, CL
AF Kensinger, RD
   Yowler, BC
   Benesi, AJ
   Schengrund, CL
TI Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1
   gp120
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN GP120; GALACTOSYL
   CERAMIDE; REGIOSELECTIVE SULFATION; SIGNAL-TRANSDUCTION; LIPID RAFTS;
   DIBUTYLSTANNYLENE ACETALS; ANTI-HIV-1 ACTIVITY; BINDING-PROPERTIES;
   EPITHELIAL-CELLS
AB Multivalent neoglycoconjugates are valuable tools for studying carbohydrate-protein interactions. To study the interaction of HIV-1 gp120 with its reported alternate glycolipid receptors, galactosyl ceramide (GalCer) and sulfatide, galactose- and sulfated galactose-derivatized dendrimers were synthesized, analyzed as ligands for rgp120 by surface plasmon resonance, and tested for their ability to inhibit HIV-1 infection of CXCR4- and CCR5-expressing indicator cells. Four different series of glycodendrimers were made by amine coupling spacer-arm derivatized galactose residues, either sulfated or nonsulfated, to poly(propylenimine) dendrimers, generations 1-5. One series of glycodendrimers was prepared from the ceramide saccharide derivative of purified natural GalCer, and another was from chemically synthesized 3-(beta-D-galactopyranosylthio)propionic acid. Synthesis of 3-sulfogalactopyranosyl-derivatized dendrimers was accomplished using the novel compound, 3-(beta-D-3sulfogalactopyranosylthio)propionic acid. The fourth series was made by random sulfation of the 3-(beta-D-galactopyranosylthio)propionic acid functionalized dendrimers. Structures of the carbohydrate moieties were confirmed by NMR, and the average molecular weights and polydispersities of the different glycodendrimers were determined using MALDI-TOF MS. Surface plasmon resonance studies found that rgp120 IIIB bound to the derivatized dendrimers tested with nanomolar affinity, and to dextran sulfate with picomolar affinity. In vitro studies of the effectiveness of these compounds at inhibiting infection of U373-MAGI-CCR5 cells by HIV-1 Ba-L indicated that the sulfated glycodendrimers were better inhibitors than the nonsulfated glycodendrimers, but not as effective as dextran sulfate.
C1 Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.
   Penn State Univ, Dept Chem, University Pk, PA 16802 USA.
RP Schengrund, CL (reprint author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, 500 Univ Dr, Hershey, PA 17033 USA.
EM cxs8@psu.edu
FU NINDS NIH HHS [R01 NS40231, F31 NS11184-01]
CR Andre S, 1999, GLYCOBIOLOGY, V9, P1253, DOI 10.1093/glycob/9.11.1253                                                        
   Ashton PR, 1997, CHEM-EUR J, V3, P974, DOI 10.1002/chem.19970030620                                                        
   BEZOUSKA K, 2002, REV MOL BIOTECH, V90, P269, DOI DOI 10.1016/S1389-0352(01)00064-2
   BHAT S, 1991, P NATL ACAD SCI USA, V88, P7131, DOI 10.1073/pnas.88.16.7131
   BHAT S, 1993, AIDS RES HUM RETROV, V9, P175, DOI 10.1089/aid.1993.9.175
   BORMAN S, 2000, CHEM ENG NEWS, P48
   Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200
   CALLAHAN LN, 1991, J VIROL, V65, P1543
   Conboy JC, 2002, J AM CHEM SOC, V124, P968, DOI 10.1021/ja011225s
   COOK DG, 1994, VIROLOGY, V201, P206, DOI 10.1006/viro.1994.1287
   Dam TK, 2002, BIOCHEMISTRY-US, V41, P1359, DOI 10.1021/bi015829k
   DAVID S, 1985, TETRAHEDRON, V41, P643, DOI 10.1016/S0040-4020(01)96443-9                                                   
   Driguez H, 1997, TOP CURR CHEM, V187, P85
   DUBOIS G, 1980, ANAL BIOCHEM, V102, P313, DOI 10.1016/0003-2697(80)90159-1
   ELOFSSON M, 1991, TETRAHEDRON LETT, V32, P7613, DOI 10.1016/0040-4039(91)80548-K
   FANTINI J, 1993, P NATL ACAD SCI USA, V90, P2700, DOI 10.1073/pnas.90.7.2700
   Fantini J, 2000, METHOD ENZYMOL, V311, P626
   Fantini J, 1997, J BIOL CHEM, V272, P7245, DOI 10.1074/jbc.272.11.7245                                                         
   Faroux-Corlay B, 2001, J MED CHEM, V44, P2188, DOI 10.1021/jm0011124
   Faroux-Corlay B, 2000, CARBOHYD RES, V327, P223, DOI 10.1016/S0008-6215(00)00055-0                                                   
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Fivaz M, 1999, TRENDS CELL BIOL, V9, P212, DOI 10.1016/S0962-8924(99)01567-6
   Fulton DA, 2001, BIOCONJUGATE CHEM, V12, P655, DOI 10.1021/bc0100410
   FURUTA Y, 1994, P NATL ACAD SCI USA, V91, P12559, DOI 10.1073/pnas.91.26.12559
   GU YLR, 2001, ANGEW CHEM INT EDIT, V40, P29
   GUILBERT B, 1994, TETRAHEDRON-ASYMMETR, V5, P2163, DOI 10.1016/S0957-4166(00)86292-8                                                   
   GUILBERT B, 1994, TETRAHEDRON LETT, V35, P6563, DOI 10.1016/S0040-4039(00)78273-6                                                   
   Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177
   Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967
   Harder T, 2001, ADV IMMUNOL, V77, P45, DOI 10.1016/S0065-2776(01)77014-9
   HAROUSE JM, 1995, J VIROL, V69, P7383
   HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969
   Ikami T, 1997, J CARBOHYD CHEM, V16, P859, DOI 10.1080/07328309708006544                                                       
   Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404                                                           
   Kasahara K, 2000, GLYCOCONJUGATE J, V17, P153, DOI 10.1023/A:1026576804247
   Kawakami K, 1998, MICROBIOL IMMUNOL, V42, P697, DOI 10.1111/j.1348-0421.1998.tb02342.x                                              
   LaBell RY, 2002, BIOCONJUGATE CHEM, V13, P143, DOI 10.1021/bc015533r
   LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1
   LUBINEAU A, 1994, TETRAHEDRON LETT, V35, P8795, DOI 10.1016/S0040-4039(00)78500-5
   LUNDIN K, 1987, J IMMUNOL METHODS, V97, P93, DOI 10.1016/0022-1759(87)90110-4
   Lundquist JJ, 2002, CHEM REV, V102, P555, DOI 10.1021/cr000418f
   MANUSSON G, 1981, ACTA CHEM SCAND B, V35, P213
   McReynolds KD, 2002, BIOORGAN MED CHEM, V10, P625, DOI 10.1016/S0968-0896(01)00325-X
   Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7                                                   
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   Mylvaganam M, 2000, METHOD ENZYMOL, V312, P473
   Mylvaganam M, 1999, BIOCHEMISTRY-US, V38, P10885, DOI 10.1021/bi990669m
   Nishida Y, 2000, BIOMACROMOLECULES, V1, P68, DOI 10.1021/bm990011o
   Page D, 1997, BIOCONJUGATE CHEM, V8, P714, DOI 10.1021/bc970126u
   Peerlings HWI, 1998, EUR J ORG CHEM, P1879
   Poirot E, 2001, CARBOHYD RES, V330, P7, DOI 10.1016/S0008-6215(00)00265-2
   RADIN NS, 1974, LIPIDS, V9, P358, DOI 10.1007/BF02533114
   Reuter JD, 1999, BIOCONJUGATE CHEM, V10, P271, DOI 10.1021/bc980099n
   Rico-Lattes I, 1998, BIOCHIMIE, V80, P483, DOI 10.1016/S0300-9084(00)80015-2                                                   
   SCHENGRUND CL, 1989, J BIOL CHEM, V264, P13233
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408
   SMITH TW, 1987, NORC REPORTER, V1, P4
   Thompson JP, 1997, GLYCOCONJUGATE J, V14, P837, DOI 10.1023/A:1018590021762
   Turnbull WB, 2000, CHEMBIOCHEM, V1, P70, DOI 10.1002/1439-7633(20000703)1:1<70::AID-CBIC70>3.0.CO;2-L
   TURNBULL WB, 2002, REV MOL BIOTECHNOL, V90, P231
   Woller EK, 2001, BIOMACROMOLECULES, V2, P1052, DOI 10.1021/bm015560k
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   YAHI N, 1992, J VIROL, V66, P4848
   YAHI N, 1995, J VIROL, V69, P320
   Zanini D, 1998, J ORG CHEM, V63, P3486, DOI 10.1021/jo972061u                                                               
   ZHU H, 1998, AM SOC MASS SPECTROM, V9, P275
   ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453
NR 68
TC 56
Z9 58
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD MAR-APR
PY 2004
VL 15
IS 2
BP 349
EP 358
DI 10.1021/bc034156a
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 804FH
UT WOS:000220284100015
PM 15025531
DA 2018-01-05
ER

PT J
AU Uckun, FM
   Pendergrass, S
   Qazi, S
   Samuel, P
   Venkatachalam, K
AF Uckun, FM
   Pendergrass, S
   Qazi, S
   Samuel, P
   Venkatachalam, K
TI Phenyl phosphoramidate derivatives of stavuldine as anti-HIV agents with
   potent and selective in-vitro antiviral activity against adenovirus
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE HIV; phosphoramidates; stampidine; adenovirus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; DNA-REPLICATION;
   NUCLEOSIDE; METHOXYALANINYL; STAMPIDINE; INHIBITION; AIDS; METABOLISM;
   MECHANISM
AB Adenoviruses are responsible for a broad range of clinical diseases that may be associated with high mortality, including pneumonia, hepatitis, encephalitis. hemorrhagic cystitis, nephritis, and gastroenteritis in immunocompromised patients, including HIV-infected individuals. Here we report the identification of halo-substituted stavudine phenyl phosphoramidate derivatives as a new class of dual-function anti-HIV agents with potent and selective anti-adenovirus (ADV) activity. We examined the investigational stavudine phenyl phosphoramidate derivative stampidine and 12 structurally similar stavudine derivatives for anti-ADV activity. All 13 derivatives of stavudine, including stampidine. were substantially more potent than stavudine and inhibited ADV-induced plaque formation at nanomolar IC50 values. Compounds, with halo substitutions in the phenyl ring as well as the unsubstituted compound 607 were more potent than compounds with methoxy, methyl, or cyano substitutions. Compound 113 (stampidine) with a 4-Br substitution and compound 609 with a 4-Cl substitution were identified as the most potent lead anti-ADV agents. Compound 113/Stampidine inhibited ADV-induced plaque formation in skin fibroblasts in a concentration-dependent fashion with a mean ( +/-S.E.M.) IC50 value of 17 +/- 2 nM without any evidence of cytotoxicity even at 100 muM. Similarly, compound 609 inhibited ADV-induced plaque formation with an IC50 value of 27 +/- 3 nM. We next sought to determine if the lead compounds 113 and 609 can also inhibit other viruses. Both compounds exhibited potent anti-HIV activity at nanomolar concentrations. However, neither compound exhibited any antiviral activity against non-HIV viruses, including Cytomegalovirus (CMV), Type I or Type II herpes simplex viruses (HSV-1, HSV-2), enterovirus ECHO 30, or respiratory syncytial virus (RSV) (IC50 > 100 muM/[). The remarkable anti-ADV potency of the lead compounds stampidine and compound 609 warrants the further development of these promising new antiviral agents for possible clinical use in ADV infected patients. (C) 2003 Elsevier SAS. All rights reserved.
C1 Parker Hughes Inst, Dept Virol, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Immunol, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Bioinformat, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Pharmaceut Sci, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Chem, Drug Discovery Program, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Dept Virol, Drug Discovery Program, 2720 Patton Rd, St Paul, MN 55113 USA.
EM fatih_uckun@ih.org
CR ALLEN LB, 1978, J MED CHEM, V21, P742, DOI 10.1021/jm00206a005                                                             
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   Bhanthumkosol Damrong, 1998, Journal of the Medical Association of Thailand, V81, P214
   Carrigan Donald R., 1997, American Journal of Medicine, V102, P71, DOI 10.1016/S0002-9343(97)00015-6
   Chen CL, 2002, DRUG METAB DISPOS, V30, P1523, DOI 10.1124/dmd.30.12.1523
   De Clercq E, 1996, Verh K Acad Geneeskd Belg, V58, P19
   De Jong JC, 1999, J CLIN MICROBIOL, V37, P3940
   Dombrowski F, 1997, VIRCHOWS ARCH, V431, P469, DOI 10.1007/s004280050125
   Ghez D, 2000, AM J HEMATOL, V63, P32, DOI 10.1002/(SICI)1096-8652(200001)63:1<32::AID-AJH7>3.0.CO;2-X
   GREEN WR, 1994, CLIN INFECT DIS, V18, P989, DOI 10.1093/clinids/18.6.989                                                        
   Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984
   KHOO SH, 1995, J INFECT DIS, V172, P629, DOI 10.1093/infdis/172.3.629                                                        
   Maslo C, 1997, AM J RESP CRIT CARE, V156, P1263, DOI 10.1164/ajrccm.156.4.97-02028                                                   
   McIntee EJ, 1997, J MED CHEM, V40, P3323, DOI 10.1021/jm960694f
   Mentel R, 1997, ANTIVIR RES, V34, P113, DOI 10.1016/S0166-3542(97)01029-2
   Mentel R, 2000, MED MICROBIOL IMMUN, V189, P91, DOI 10.1007/s004300000046                                                           
   MUL YM, 1989, NUCLEIC ACIDS RES, V17, P8917, DOI 10.1093/nar/17.22.8917                                                          
   REEFSCHLAGER J, 1982, ANTIVIR RES, V2, P41, DOI 10.1016/0166-3542(82)90025-0
   Sabin Caroline A., 1999, Journal of Medical Virology, V58, P280, DOI 10.1002/(SICI)1096-9071(199907)58:3<280::AID-JMV14>3.0.CO;2-N
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Thompson M., 1999, J ENVIRON MONITOR, V1, P19
   Uckun FM, 2003, ARZNEIMITTEL-FORSCH, V53, P357
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3613, DOI 10.1128/AAC.46.11.3613-3616.2002
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3428, DOI 10.1128/AAC.46.11.3428-3436.2002
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   UCKUN FM, UNPUB
   VANDERVLIET PC, 1981, BIOCHEMISTRY-US, V20, P2628, DOI 10.1021/bi00512a041                                                             
   Venkatachalam TK, 1998, BIOORG MED CHEM LETT, V8, P3121, DOI 10.1016/S0960-894X(98)00547-2
   Vig R, 1998, ANTIVIR CHEM CHEMOTH, V9, P445
NR 29
TC 10
Z9 12
U1 0
U2 3
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAR
PY 2004
VL 39
IS 3
BP 225
EP 234
DI 10.1016/j.ejmech.2003.12.002
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 815UL
UT WOS:000221067100003
PM 15051170
DA 2018-01-05
ER

PT J
AU Le Saint, C
   Terreux, R
   Duval, D
   Durant, J
   Ettesse, H
   Dellamonica, P
   Guedj, R
   Vincent, JP
   Cupo, A
AF Le Saint, C
   Terreux, R
   Duval, D
   Durant, J
   Ettesse, H
   Dellamonica, P
   Guedj, R
   Vincent, JP
   Cupo, A
TI Determination of ddATP levels in human immunodeficiency virus-infected
   patients treated with dideoxyinosine
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; BLOOD MONONUCLEAR-CELLS; TANDEM
   MASS-SPECTROMETRY; INTRACELLULAR ZIDOVUDINE; ENZYME-IMMUNOASSAY; HUMAN
   PLASMA; CARTRIDGE RADIOIMMUNOASSAY; PHOSPHORYLATED ANABOLITES;
   SIMULTANEOUS QUANTITATION; LAMIVUDINE TRIPHOSPHATE
AB Clinical failures of the highly active antiretroviral therapy could result from inefficient intracellular concentrations of antiviral drugs. The determination of drug contents in target cells of each patient would be useful in clinical investigations and trials. The purpose of this work was to quantify the intracellular concentration of ddATP, the active metabolite of dideoxyinosine (ddI), in peripheral blood mommuclear cells (PBMCs) of human immunodeficiency virus (HIV)-infected patients treated with ddI. We have raised antibodies against ddA-citrate, a stable isostere of ddATP selected on the basis of its structural and electronic analogies with ddATP. The anti-ddA-citrate antibodies recognized ddATP and ddA with nanomolar affinities and cross-reacted neither with any of the nucleotide reverse transcriptase inhibitors used in HIV therapy nor with their phosphorylated metabolites. The three phosphorylated metabolites of ddI (ddAMP, ddADP, and ddATP) were purified by anion exchange chromatography and the amount of each metabolite was determined by radioimmunoassay with or without prior phosphatase treatment. The intracellular levels of the three ddI metabolites were measured both in an in vitro model and in PBMCs of HIV-infected patients under ddI treatment. The possibility to measure intracellular levels of ddATP from small blood samples of HIV-infected patients treated with ddI could be exploited to develop individual therapeutic monitoring.
C1 CNRS, Unite Mixte Rech 6097, Inst Pharmacol Mol & Cellulaire, Sophia Antipolis, France.
   Fac Sci, CNRS, Unite Mixte Rech 6001, Lab Chim Aromes Synth Interact, Nice, France.
   Fac Sci, CNRS, Unite Mixte Rech 6001, Chim Bioorgan Lab, Nice, France.
   CHU Archet, Serv Malad Infect, Nice, France.
RP Cupo, A (reprint author), CNRS, Unite Mixte Rech 6097, Inst Pharmacol Mol & Cellulaire, 660 Route Lucioles Valbonne, Sophia Antipolis, France.
EM cupo@ipmc.cnrs.fr
CR Agrofolio LA, 2001, NUCLEOS NUCLEOT NUCL, V20, P375, DOI 10.1081/NCN-100002309
   Akeb F, 2001, NUCLEOS NUCLEOT NUCL, V20, P243, DOI 10.1081/NCN-100002084
   Back D, 2002, AIDS, V16, pS5, DOI 10.1097/00002030-200203001-00002
   BACK D, 2000, BR J CLIN PHARM, V51, P301
   BACK DJ, 1992, BRIT J CLIN PHARMACO, V33, P319, DOI 10.1111/j.1365-2125.1992.tb04043.x                                              
   Becher F, 2003, J MASS SPECTROM, V38, P879, DOI 10.1002/jms.500
   Becher F, 2002, RAPID COMMUN MASS SP, V16, P555, DOI 10.1002/rcm.605
   Brody SR, 1997, INT J ANTIMICROB AG, V9, P131, DOI 10.1016/S0924-8579(97)00041-1
   Brossette T, 1999, NUCLEOS NUCLEOT, V18, P939, DOI 10.1080/15257779908041604
   Brossette T, 1999, TETRAHEDRON LETT, V40, P3391, DOI 10.1016/S0040-4039(99)00497-9
   Cahours X, 2001, J PHARMACEUT BIOMED, V26, P819, DOI 10.1016/S0731-7085(01)00457-5
   Cucumel K, 1996, PEPTIDES, V17, P973
   CUPO A, 1985, J NEUROIMMUNOL, V8, P57, DOI 10.1016/S0165-5728(85)80047-3                                                   
   DeRemer M, 1996, ANTIMICROB AGENTS CH, V40, P1331
   Dyatkina N, 1996, BIOORG MED CHEM LETT, V6, P2639, DOI 10.1016/S0960-894X(96)00482-9
   FERRUA B, 1994, J IMMUNOL METHODS, V176, P103, DOI 10.1016/0022-1759(94)90354-9
   Fletcher CV, 2000, AIDS, V14, P2137, DOI 10.1097/00002030-200009290-00010
   GAO WY, 1994, J BIOL CHEM, V269, P12633
   Goujon L, 1998, J IMMUNOL METHODS, V218, P19, DOI 10.1016/S0022-1759(98)00101-X                                                   
   HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0
   Kaul S, 1996, J PHARMACEUT BIOMED, V15, P165, DOI 10.1016/0731-7085(96)01839-0
   Kenney KB, 2000, J PHARMACEUT BIOMED, V22, P967, DOI 10.1016/S0731-7085(00)00248-X
   Kewn S, 1999, AIDS RES HUM RETROV, V15, P793, DOI 10.1089/088922299310692
   KNUPP CA, 1990, J CHROMATOGR-BIOMED, V533, P282, DOI 10.1016/S0378-4347(00)82215-X
   LABATAILLE P, 1995, BIOORG MED CHEM LETT, V5, P2315, DOI 10.1016/0960-894X(95)00401-E
   Moore JD, 2000, J AM SOC MASS SPECTR, V11, P1134, DOI 10.1016/S1044-0305(00)00178-1                                                   
   MUKHERJI E, 1994, ANTIMICROB AGENTS CH, V38, P1573, DOI 10.1128/AAC.38.7.1573                                                           
   Pereira AS, 2000, J CHROMATOGR B, V742, P173, DOI 10.1016/S0378-4347(00)00162-6
   Peter K, 1996, J PHARMACEUT BIOMED, V14, P491, DOI 10.1016/0731-7085(95)01649-X
   Pruvost A, 2001, RAPID COMMUN MASS SP, V15, P1401, DOI 10.1002/rcm.384
   RAY G, 1987, ANAL LETT, V20, P1815
   Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P2656
   Robbins BL, 1996, ANTIMICROB AGENTS CH, V40, P2651
   Rodriguez JF, 2000, ANTIMICROB AGENTS CH, V44, P3097, DOI 10.1128/AAC.44.11.3097-3100.2000
   SAADY M, 1995, J ORG CHEM, V60, P3685, DOI 10.1021/jo00117a019                                                             
   Sarasa M, 2000, J CHROMATOGR B, V746, P183, DOI 10.1016/S0378-4347(00)00324-8
   SOMMADOSSI JP, 1993, CLIN INFECT DIS, V16, P7
   Trowbridge D B, 1970, J Am Chem Soc, V92, P2181, DOI 10.1021/ja00710a090
   van Heeswijk RPG, 2002, THER DRUG MONIT, V24, P323, DOI 10.1097/01.FTD.0000014431.93381.7B
   Weaver R, 1996, BIOORG MED CHEM LETT, V6, P2405, DOI 10.1016/0960-894X(96)00444-1                                                    
   Weaver R, 1997, TETRAHEDRON, V53, P5537, DOI 10.1016/S0040-4020(97)00210-X                                                   
NR 41
TC 4
Z9 4
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2004
VL 48
IS 2
BP 589
EP 595
DI 10.1128/AAC.48.2.589-595.2004
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 768WC
UT WOS:000188592200032
PM 14742213
OA gold
DA 2018-01-05
ER

PT J
CA AnorMed, Inc
TI Chemokine receptor antagonists as HIV entry inhibitors
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Article
DE antiviral agents; CC chemokine receptor (CCR)5; chemokine receptor
   antagonists; CXC chemokine receptor (CXCR)4; heterocycles; HIV;
   piperidine
ID ANTIRETROVIRAL THERAPY; AGENTS; DISCOVERY; DRUGS; STATE
AB HIV infection represents a serious medical problem, successfully approached by the introduction of highly active antiretroviral therapy (HAART). The chemokine receptor antagonists targeting both the CXC chemokine receptor (CXCR)4 and CC chemokine receptor (CCR)5 co-receptors are presently under intense investigation, as some of the first generation of these compounds (AMD-3100 or TAK-779) showed potent antiviral activity in vitro and in vivo, but could not be developed for human use due to unacceptably high toxicity. In these three patents, AnorMed and AstraZeneca claim very interesting, improved compounds targeting these chemokine receptors, with efficacies in the low nanomolar range and apparently improved bioavailability.
CR Balzarini J, 2000, PHARMACOL THERAPEUT, V87, P175, DOI 10.1016/S0163-7258(00)00050-4
   Blair WS, 2000, DRUG DISCOV TODAY, V5, P183, DOI 10.1016/S1359-6446(00)01484-7
   De Clercq E, 2001, J PHARMACOL EXP THER, V297, P1
   De Clercq E, 2001, J CLIN VIROL, V22, P73, DOI 10.1016/S1386-6532(01)00167-6                                                   
   Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838                                       
   Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000
   Joly V., 2000, EUR J INTERN MED, V11, P301
   Kaufmann GR, 2000, CURR OPIN MICROBIOL, V3, P508, DOI 10.1016/S1369-5274(00)00131-4
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Mastrolorenzo A, 2001, EXPERT OPIN THER PAT, V11, P1245, DOI 10.1517/13543776.11.8.1245                                                      
   Ogden R. C, 2001, PROTEASE INHIBITORS
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Scozzafava A, 2002, J ENZYM INHIB MED CH, V17, P69, DOI 10.1080/14756360290024227
   Scozzafava A, 2003, CURR MED CHEM, V10, P925, DOI 10.2174/0929867033457647                                                        
   Scozzafava A, 2001, EXPERT OPIN THER PAT, V11, P765, DOI 10.1517/13543776.11.5.765                                                       
   Shiraishi M, 2000, J MED CHEM, V43, P2049, DOI 10.1021/jm9906264
   Tomaras Georgia D., 2001, Curr Infect Dis Rep, V3, P93, DOI 10.1007/s11908-001-0064-x
   Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6
NR 18
TC 0
Z9 0
U1 0
U2 0
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1354-3776
EI 1744-7674
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD FEB
PY 2004
VL 14
IS 2
BP 251
EP 255
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 774KM
UT WOS:000188978700007
DA 2018-01-05
ER

PT J
AU Thrall, JH
AF Thrall, JH
TI Nanotechnology and medicine
SO RADIOLOGY
LA English
DT Editorial Material
DE perspectives; radiology and radiologists, research; technology
   assessment
ID HIV-1 PROTEASE; GENE DELIVERY; NANOPARTICLES; SYSTEM; DNA; INHIBITORS;
   PLATFORM; THERAPY; BINDING; CANCER
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Thrall, JH (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, 14 Fruit St,MZ-FND 216, Boston, MA 02114 USA.
EM thrall.james@mgh.harvard.edu
CR ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651
   BINNIG G, 1982, HELV PHYS ACTA, V55, P726
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3                                                   
   Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0                                                   
   Cote GL, 2001, J NUTR, V131, p1596S
   Couvreur P, 2002, CRIT REV THER DRUG, V19, P99, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i2.10                                    
   Crommelin DJA, 2003, J CONTROL RELEASE, V87, P81, DOI 10.1016/S0168-3659(03)00014-2
   Du C, 1998, J BIOMED MATER RES, V42, P540, DOI 10.1002/(SICI)1097-4636(19981215)42:4<540::AID-JBM9>3.0.CO;2-2
   Freitas RA, 1999, NANOMEDICINE, P71
   FREITAS RA, 1999, NANOMEDICINE, P209
   Friedman SH, 1998, J MED CHEM, V41, P2424, DOI 10.1021/jm970689r
   Hansma HG, 2001, ANNU REV PHYS CHEM, V52, P71, DOI 10.1146/annurev.physchem.52.1.71                                                
   Harisinghani MG, 2003, NEW ENGL J MED, V348, P2491, DOI 10.1056/NEJMoa022749
   Kasianowicz JJ, 2002, DIS MARKERS, V18, P185, DOI 10.1155/2002/565204                                                             
   Kasili RM, 2002, J NANOSCI NANOTECHNO, V2, P653, DOI 10.1166/jnn.2002.155
   KROTO HW, 1985, NATURE, V318, P162, DOI 10.1038/318162a0                                                                
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   LEWIS LE, 2003, OUR SUPERSTRING UNIV, P1
   Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200
   Mahmood U, 2002, RADIOLOGY, V224, P446, DOI 10.1148/radiol.2242011589
   Majumdar A, 2002, DIS MARKERS, V18, P167, DOI 10.1155/2002/856032                                                             
   Mazzola L, 2003, NAT BIOTECHNOL, V21, P1137, DOI 10.1038/nbt1003-1137
   Mu L, 2003, J CONTROL RELEASE, V86, P33, DOI 10.1016/S0168-3659(02)00320-6
   Na K, 2002, PHARMACEUT RES, V19, P681, DOI 10.1023/A:1015370532543                                                         
   Ng HT, 2001, J NANOSCI NANOTECHNO, V1, P375, DOI 10.1166/jnn.2001.056
   Paull R, 2003, NAT BIOTECHNOL, V21, P1144, DOI 10.1038/nbt1003-1144
   Ratner M, 2003, NANOTECHNOLOGY, P11
   RATNER M, 2003, NANOTECHNOLOGY, P63
   Reynolds AR, 2003, TRENDS MOL MED, V9, P2, DOI 10.1016/S1471-4914(02)00004-7
   Roy I, 2003, J AM CHEM SOC, V125, P7860, DOI 10.1021/ja0343095
   Santhi K, 2002, DRUG DEV IND PHARM, V28, P1171, DOI 10.1081/DDC-120014584
   Schellenberger EA, 2002, ACAD RADIOL, V9, pS310, DOI 10.1016/S1076-6332(03)80212-X
   SHEN T, 1993, MAGNET RESON MED, V29, P599, DOI 10.1002/mrm.1910290504
   Wang XJ, 2002, BIOMATERIALS, V23, P4787, DOI 10.1016/S0142-9612(02)00229-6
   Weissleder R, 1999, NAT BIOTECHNOL, V17, P375, DOI 10.1038/7933                                                                    
   Wunderbaldinger P, 2002, ACAD RADIOL, V9, pS304, DOI 10.1016/S1076-6332(03)80210-6                                                   
   Xu L, 2002, HUM GENE THER, V13, P469, DOI 10.1089/10430340252792594
   Zhu ZW, 2003, BIOCHEMISTRY-US, V42, P1326, DOI 10.1021/bi020496s
   2000, BECON NAN NAN S REP
NR 39
TC 39
Z9 43
U1 0
U2 4
PU RADIOLOGICAL SOC NORTH AMERICA
PI OAK BROOK
PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA
SN 0033-8419
J9 RADIOLOGY
JI Radiology
PD FEB
PY 2004
VL 230
IS 2
BP 315
EP 318
DI 10.1148/radiol.2302031698
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 767QG
UT WOS:000188463700003
PM 14752175
DA 2018-01-05
ER

PT B
AU Akashi, M
   Akagi, T
   Kaneko, T
   Baba, M
   Hayami, M
AF Akashi, M
   Akagi, T
   Kaneko, T
   Baba, M
   Hayami, M
BE Badawy, W
   Moussa, W
TI Anti-retroviral vaccine using polymeric nanoparticles
SO 2004 INTERNATIONAL CONFERENCE ON MEMS, NANO AND SMART SYSTEMS,
   PROCEEDINGS
LA English
DT Proceedings Paper
CT International Conference on MEMS, NANO and Smart Systems
CY AUG 25-27, 2004
CL Banff, CANADA
SP Univ Alberta, Univ Calgary, Veeco, Syst Res Corp, Sun, iCORE, FEMLAB, Conventor, ANSYS, MEMSCAP, IntelliSense Software, Natl Inst Nanotechnol, ROI, Micronet R&D, taiho
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; IMMOBILIZED POLYSTYRENE
   NANOSPHERES; INTRANASAL IMMUNIZATION; ANTIBODY-RESPONSES; AIDS VACCINE;
   NASAL IMMUNIZATION; MUCOSAL IMMUNITY; RHESUS MACAQUES; VIRAL LOAD; VIRUS
AB We have previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and that intranasal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody response in mice. In this study, to evaluate the protective effect of immunization, each three macaques was intranasally immunized with Con A-NS or inactivated simian/human immunodeficiency virus KU-2-capturing nanospheres (SHIV-NS) and then intravaginally challenged with a pathogenic virus, SHIV KU-2. After a series of six immunizations, vaginal anti-HIV-1 gp120 IgA and IgG antibodies were detected in all SHIV-NS-immunized macaques. After intravaginal challenge, one of the three macaques in each of the Con A-NS- and SHIV-NS-immunized groups was infected. Plasma viral RNA load of infected macaque in SHIV-NS-immunized macaques was substantially less than that in unimmunized control macaque and reached below the detectable level. Thus, SHIV-NS-immunized macaques exhibited partial protection to vaginal challenges with SHIV KU-2.
C1 Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka 5650871, Japan.
RP Akashi, M (reprint author), Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka 5650871, Japan.
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915
   Belyakov IM, 2001, NAT MED, V7, P1320, DOI 10.1038/nm1201-1320
   Bogers WMJM, 2000, AIDS, V14, pS141
   Chen XN, 2001, NAT MED, V7, P1225, DOI 10.1038/nm1101-1225
   Enose Y, 2002, VIROLOGY, V298, P306, DOI 10.1006/viro.2002.1440
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Igarashi T, 1997, J GEN VIROL, V78, P985, DOI 10.1099/0022-1317-78-5-985                                                      
   Imaoka K, 1998, J IMMUNOL, V161, P5952
   Joag SV, 1997, AIDS RES HUM RETROV, V13, P635, DOI 10.1089/aid.1997.13.635
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kuwata T, 2001, TRENDS MICROBIOL, V9, P475, DOI 10.1016/S0966-842X(01)02164-3
   Lehner T, 2002, AIDS, V16, pS125, DOI 10.1097/00002030-200216004-00017
   Lo Caputo S, 2003, AIDS, V17, P531, DOI 10.1097/01.aids.0000050818.06065.1c
   Lu XS, 1998, AIDS, V12, P1, DOI 10.1097/00002030-199801000-00001
   MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576
   MASCOLA JR, 2000, AIDS S, V14, P167
   Mazzoli S, 1999, J INFECT DIS, V180, P871, DOI 10.1086/314934                                                                  
   Miyake A, 2004, J MED VIROL, V73, P368, DOI 10.1002/jmv.20100
   Nardelli-Haefliger D, 1999, J VIROL, V73, P9609
   Sakaue G, 2003, J IMMUNOL, V170, P495, DOI 10.4049/jimmunol.170.1.495                                                      
   Staats HF, 1997, AIDS RES HUM RETROV, V13, P945, DOI 10.1089/aid.1997.13.945
   Staats HF, 1996, J IMMUNOL, V157, P462
   Suryanarayana K, 1998, AIDS RES HUM RETROV, V14, P183, DOI 10.1089/aid.1998.14.183                                                         
   Ui M, 1999, VIROLOGY, V265, P252, DOI 10.1006/viro.1999.0049
   van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7                                                   
   Voss G, 2003, J VIROL, V77, P1049, DOI 10.1128/JVI.77.2.1049-1058.2003
NR 28
TC 0
Z9 0
U1 0
U2 2
PU IEEE COMPUTER SOC
PI LOS ALAMITOS
PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA
BN 0-7695-2189-4
PY 2004
BP 556
EP 562
DI 10.1109/ICMENS.2004.1509010
PG 7
WC Engineering, Electrical & Electronic; Engineering, Mechanical; Materials
   Science, Multidisciplinary
SC Engineering; Materials Science
GA BAW55
UT WOS:000223904500112
DA 2018-01-05
ER

PT J
AU Uckun, FM
   Pendergrass, S
   Qazi, S
   Venkatachalam, TK
AF Uckun, FM
   Pendergrass, S
   Qazi, S
   Venkatachalam, TK
TI In vitro activity of stampidine against primary clinical human
   immunodeficiency virus isolates
SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
LA English
DT Article
DE antiviral agents; CAS 217178-62-6; HI-113; stampidine, effect on HIV
   isolates, in vitro studies
ID REVERSE-TRANSCRIPTASE INHIBITORS; DRUG-RESISTANT HIV-1; ANTIRETROVIRAL
   THERAPY; GENOTYPIC RESISTANCE; HIV-1-INFECTED PATIENTS; VIROLOGICAL
   RESPONSE; COMBINATION THERAPY; ANTIVIRAL PROTEIN; NAIVE PATIENTS;
   SUBTYPE-C
AB The in vitro activity profile of stampidine (CAS 217178-62-6, STAMP) was examined against clinical isolates of HIV-1. In a side-by-side comparison against 10 zidovudine-sensitive clinical HIV-1 isolates, STAMP was 100-fold more potent than stavudine (CAS 3056-17-5) and twice as effective as zidovudine (CAS 30516-87-1). STAMP was also active against phenotypically and/or genotypically NRTI (nucleoside analog inhibitors of reverse transcriptase) -resistant HIV and inhibited the replication of 20 zidovudine-resistant clinical HIV-1 isolates with low nanomolar to subnanomolar IC50 values. Similarly, STAMP inhibited the replication of 9 genotypically NNRTI (non-nucleoside analog inhibitors of reverse transcriptase) -resistant clinical HIV-1 isolates (n = 9) with an average IC50 value of 11.2 +/- 6.5 nmol/L. The remarkable potency of STAMP against clinical HIV-1 isolates with NRTI- or NNRTI-resistance warrants the further development of this promising new antiviral agent.
C1 Parker Hughes Canc Ctr, Drug Discovery Program, Dept Virol, St Paul, MN 55113 USA.
   Parker Hughes Canc Ctr, Drug Discovery Program, Dept Bioinformat, St Paul, MN 55113 USA.
   Parker Hughes Canc Ctr, Drug Discovery Program, Dept Immunol, St Paul, MN 55113 USA.
   Parker Hughes Canc Ctr, Drug Discovery Program, Dept Chem, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Canc Ctr, Drug Discovery Program, Dept Virol, 2699 Patton Rd, St Paul, MN 55113 USA.
EM fatih_uckun@ih.org
CR Briones C, 2000, AIDS, V14, P1659, DOI 10.1097/00002030-200007280-00024                                                
   Chen CL, 2001, DRUG METAB DISPOS, V29, P1035
   Coakley EP, 2000, AIDS, V14, pF9, DOI 10.1097/00002030-200001280-00002
   Duwe S, 2001, J ACQ IMMUN DEF SYND, V26, P266, DOI 10.1097/00126334-200103010-00010                                                
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   Freedberg KA, 2001, NEW ENGL J MED, V344, P824, DOI 10.1056/NEJM200103153441108
   Gottlieb MS, 2001, NEW ENGL J MED, V344, P1788, DOI 10.1056/NEJM200106073442312                                                     
   Gutierrez F, 2000, MED CLIN-BARCELONA, V115, P401, DOI 10.1016/S0025-7753(00)71574-0                                                   
   Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210                                                          
   Izopet J, 1999, J MED VIROL, V59, P507, DOI 10.1002/(SICI)1096-9071(199912)59:4<507::AID-JMV14>3.3.CO;2-3
   JOHNSON VA, 1995, J INFECT DIS, V171, pS140, DOI 10.1093/infdis/171.Supplement_2.S140                                            
   Kuritzkes DR, 2000, J INFECT DIS, V181, P491, DOI 10.1086/315244
   Lin PF, 1999, ANTIVIR THER, V4, P21
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Miller MD, 2001, J ACQ IMMUN DEF SYND, V27, P450
   Miller V, 2000, AIDS, V14, P163, DOI 10.1097/00002030-200001280-00012
   O'Brien WA, 2000, CLIN INFECT DIS, V30, pS185, DOI 10.1086/313858                                                                  
   Palmer S, 1998, AIDS RES HUM RETROV, V14, P157, DOI 10.1089/aid.1998.14.157
   Palmer S, 2001, AIDS RES HUM RETROV, V17, P1167, DOI 10.1089/088922201316912772
   Palmer S, 1999, AIDS, V13, P661
   Picard V, 2001, J INFECT DIS, V184, P781, DOI 10.1086/323088                                                                  
   Pillay D, 2000, REV MED VIROL, V10, P231, DOI 10.1002/1099-1654(200007/08)10:4<231::AID-RMV290>3.3.CO;2-G
   Rana KZ, 1997, CLIN PHARMACOKINET, V33, P276, DOI 10.2165/00003088-199733040-00003                                                
   Rey D, 2001, J ACQ IMMUN DEF SYND, V27, P459
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Ross L, 2001, AIDS RES HUM RETROV, V17, P1107, DOI 10.1089/088922201316912718
   Rousseau MN, 2001, J ACQ IMMUN DEF SYND, V26, P36
   Salomon H, 2000, AIDS, V14, pF17, DOI 10.1097/00002030-200001280-00003                                                
   Sepkowitz KA, 2001, NEW ENGL J MED, V344, P1764, DOI 10.1056/NEJM200106073442306
   Shafer RW, 1999, BIOMED PHARMACOTHER, V53, P73, DOI 10.1016/S0753-3322(99)80063-8
   Shafer RW, 1997, J VIROL, V71, P5441
   Shulman NS, 2001, J ACQ IMMUN DEF SYND, V27, P377
   Starr SE, 1999, NEW ENGL J MED, V341, P1874, DOI 10.1056/NEJM199912163412502                                                     
   Suzuki K, 2001, AIDS RES HUM RETROV, V17, P1293, DOI 10.1089/088922201750461366
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3428, DOI 10.1128/AAC.46.11.3428-3436.2002
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Venkatachalam TK, 1998, BIOORG MED CHEM LETT, V8, P3121, DOI 10.1016/S0960-894X(98)00547-2
   Venturi G, 1999, EUR J CLIN MICROBIOL, V18, P274
   Vig R, 1998, ANTIVIR CHEM CHEMOTH, V9, P445
   Uckun F.M., 2000, US Patent, Patent No. [6030957, 6,030,957]
NR 40
TC 19
Z9 19
U1 0
U2 0
PU ECV-EDITIO CANTOR VERLAG MEDIZIN NATURWISSENSCHAFTEN
PI AULENDORF
PA BANDELSTOCKWEG 20, POSTFACH 1255, D-88322 AULENDORF, GERMANY
SN 0004-4172
J9 ARZNEIMITTEL-FORSCH
JI Arzneimittelforschung
PY 2004
VL 54
IS 1
BP 69
EP 77
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 772GD
UT WOS:000188832700011
PM 14979612
DA 2018-01-05
ER

PT J
AU Santra, S
   Yang, H
   Dutta, D
   Stanley, JT
   Holloway, PH
   Tan, WH
   Moudgil, BM
   Mericle, RA
AF Santra, S
   Yang, H
   Dutta, D
   Stanley, JT
   Holloway, PH
   Tan, WH
   Moudgil, BM
   Mericle, RA
TI TAT conjugated, FITC doped silica nanoparticles for bioimaging
   applications
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID HUMAN IMMUNODEFICIENCY VIRUS; CELL-PENETRATING PEPTIDES; PROTEIN
   TRANSDUCTION; DELIVERY; MICROEMULSION; ANTIBODIES; BINDING
AB Water-in-oil (w/o) microemulsion synthesis of 70 nm size monodisperse TAT ( a cell penetrating peptide, CPP) conjugated, FITC ( fluorescein isothiocyanate) doped silica nanoparticles (TAT-FSNPs) is reported; human lung adenocarcinoma (A549) cells ( in vitro) and rat brain tissue ( in vivo) were successfully labeled using TAT-FSNPs.
C1 Univ Florida, Dept Neurol Surg, Gainesville, FL 32610 USA.
   Univ Florida, Particle Engn Res Ctr, Gainesville, FL 32611 USA.
   Univ Florida, Dept Mat Sci & Engn, Gainesville, FL 32610 USA.
   Univ Florida, Dept Chem, Gainesville, FL 32611 USA.
RP Santra, S (reprint author), Univ Florida, Dept Neurol Surg, POB 100265, Gainesville, FL 32610 USA.
EM santra@neurosurgery.ufl.edu
RI Tan, Weihong/A-5412-2008
OI Tan, Weihong/0000-0002-8066-1524
FU NIGMS NIH HHS [GM 66137]
CR Arriagada FJ, 1999, J COLLOID INTERF SCI, V211, P210, DOI 10.1006/jcis.1998.5985                                                          
   Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Bhalgat MK, 1998, J IMMUNOL METHODS, V219, P57, DOI 10.1016/S0022-1759(98)00121-5
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hall M, 1999, ANAL BIOCHEM, V272, P165, DOI 10.1006/abio.1999.4155
   He XX, 2002, J NANOSCI NANOTECHNO, V2, P317, DOI 10.1166/jnn.2002.105
   Jarver P, 2004, DRUG DISCOV TODAY, V9, P395, DOI 10.1016/S1359-6446(04)03042-9                                                   
   LEVCHENKO TS, 2003, LIPOSOMES B, V372
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Moss DM, 2004, J PARASITOL, V90, P397, DOI 10.1645/GE-3267
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Santra S, 2001, LANGMUIR, V17, P2900, DOI 10.1021/la0008636
   Santra S, 2001, ANAL CHEM, V73, P4988, DOI 10.1021/ac010406+
   Santra S, 2001, J BIOMED OPT, V6, P160, DOI 10.1117/1.1353590
   Schroedter A, 2002, ANGEW CHEM INT EDIT, V41, P3218, DOI 10.1002/1521-3773(20020902)41:17<3218::AID-ANIE3218>3.0.CO;2-P
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2
   Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797
   Torchilin VP, 2003, CURR PROTEIN PEPT SC, V4, P133, DOI 10.2174/1389203033487298
   Zhao M, 2004, MED RES REV, V24, P1, DOI 10.1002/med.10056
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 28
TC 177
Z9 177
U1 5
U2 76
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2004
IS 24
BP 2810
EP 2811
DI 10.1039/b411916a
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 879JW
UT WOS:000225715100012
PM 15599418
DA 2018-01-05
ER

PT J
AU Fischer, NO
   Paulini, R
   Drechsler, U
   Rotello, VM
AF Fischer, NO
   Paulini, R
   Drechsler, U
   Rotello, VM
TI Light-induced inhibition of chymotrypsin using photocleavable monolayers
   on gold nanoparticles
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
ID PROTEIN-PROTEIN INTERACTIONS; SURFACE RECOGNITION; P-HYDROXYPHENACYL;
   HIV-1 PROTEASE; EXCITED-STATE; RECEPTORS; ANTAGONISTS; MOLECULES;
   CLUSTER; ROUTE
AB Positively charged gold nanoparticles featuring photocleavable units within their surrounding monolayer are switched from non-interacting species to inhibitors of chymotrypsin through UV irradiation.
C1 Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
   Univ Massachusetts, Program Mol & Cellular Biol, Amherst, MA 01003 USA.
RP Rotello, VM (reprint author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
EM rotello@chem.umass.edu
FU NIGMS NIH HHS [GM62998, GM 08515]
CR Ando H, 2001, NAT GENET, V28, P317, DOI 10.1038/ng583
   Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Burgess K, 2001, ACCOUNTS CHEM RES, V34, P826, DOI 10.1021/ar9901523
   Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X
   Conrad PG, 2000, J AM CHEM SOC, V122, P9346, DOI 10.1021/ja001134f
   Cruz FG, 2000, J AM CHEM SOC, V122, P8777, DOI 10.1021/ja001804h
   Curley K, 1999, CURR OPIN CHEM BIOL, V3, P84, DOI 10.1016/S1367-5931(99)80015-5                                                   
   Fazal MA, 2001, J AM CHEM SOC, V123, P6283, DOI 10.1021/ja003193z
   Fischer NO, 2003, J AM CHEM SOC, V125, P13387, DOI 10.1021/ja0352505
   Fischer NO, 2002, P NATL ACAD SCI USA, V99, P5018, DOI 10.1073/pnas.082644099
   Gadek TR, 2003, BIOCHEM PHARMACOL, V65, P1, DOI 10.1016/S0006-2952(02)01479-X
   Hong R, 2004, J AM CHEM SOC, V126, P739, DOI 10.1021/ja037470o
   Hostetler MJ, 1998, LANGMUIR, V14, P17, DOI 10.1021/la970588w                                                               
   Hu J, 2001, J AM CHEM SOC, V123, P1464, DOI 10.1021/ja003180l
   Kayitmazer AB, 2003, J PHYS CHEM B, V107, P8158, DOI 10.1021/jp034065a
   Nadassy K, 1999, BIOCHEMISTRY-US, V38, P1999, DOI 10.1021/bi982362d                                                               
   Park CH, 1997, J AM CHEM SOC, V119, P2453, DOI 10.1021/ja9635589                                                               
   Park HS, 1999, J AM CHEM SOC, V121, P8, DOI 10.1021/ja981504o                                                               
   Rutledge SE, 2003, J AM CHEM SOC, V125, P14336, DOI 10.1021/ja034508o
   Schramm HJ, 1999, BIOL CHEM, V380, P593, DOI 10.1515/BC.1999.076
   Strong LE, 1999, J AM CHEM SOC, V121, P6193, DOI 10.1021/ja990223t                                                               
   Toogood PL, 2002, J MED CHEM, V45, P1543, DOI 10.1021/jm010468s
   Zhang K, 1999, J AM CHEM SOC, V121, P5625, DOI 10.1021/ja984187u                                                               
   Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j                                                               
NR 25
TC 7
Z9 7
U1 0
U2 5
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
J9 CHEM COMMUN
JI Chem. Commun.
PY 2004
IS 24
BP 2866
EP 2867
DI 10.1039/b408972c
PG 2
WC Chemistry, Multidisciplinary
SC Chemistry
GA 879JW
UT WOS:000225715100040
PM 15599446
DA 2018-01-05
ER

PT J
AU Kaneko, T
   Shimomai, S
   Miyazaki, M
   Baba, M
   Akashi, M
AF Kaneko, T
   Shimomai, S
   Miyazaki, M
   Baba, M
   Akashi, M
TI IgG responses to intranasal immunization with cholera-toxin-immobilized
   polymeric nanospheres in mice
SO JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION
LA English
DT Article; Proceedings Paper
CT Symposium on Gels, Genes, Grafts and Giants held in Celebration of the
   70th Birthday of Allan Hoffman
CY DEC, 2002
CL Maui, HI
SP Univ Washington Engineered Biomat NSF Engn Res Ctr
DE polymeric nanospheres; surface immobilization; cholera toxin; vaccine;
   IgG response
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; POLYSTYRENE NANOSPHERES;
   HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES; COLLOIDAL CRYSTALS;
   GRAFT-COPOLYMERS; SURFACES; CAPTURE; VIRIONS; GP120
AB IgG responses to antigen-nanosphere hybrids were studied in mice. Cholera toxin (CT) was covalently immobilized onto the surface of polymeric nanospheres (NS) with a nanophase-separated structure consisting of a polystyrene core and a poly(methacrylic acid) graft corona. Reaction conditions favoring the dehydroxide condensation reaction of the amino group of the CT with the carboxyl group of NS effectively immobilized CT onto their surface. When CT-immobilized nanospheres (CT-NS) were suspended in aqueous solution and administrated to mice either intranasally or intramuscularly, serum IgG titers elevated with increasing time and reached a maximum level at 8 weeks after immunization. On the other hand, intranasal administration of CT alone induced an even higher serum IgG titer than that of CT-NS at 4 weeks. However, the titer gradually decreased thereafter. Thus, polymeric NS may be an effective substrate to covalently immobilize antigen on their surface, steadily inducing a high level of IgG production in response to the intranasal administration.
C1 Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostructured & Adv Mat, Kagoshima 8900065, Japan.
   JST, CREST, Kawaguchi, Saitama, Japan.
   Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Antiviral Chemotherapy, Kagoshima 8900065, Japan.
   Osaka Univ, Grad Sch Engn, Dept Mol Chem, Suita, Osaka 5650871, Japan.
RP Akashi, M (reprint author), Kagoshima Univ, Grad Sch Sci & Engn, Dept Nanostructured & Adv Mat, 1-21-40 Korimoto, Kagoshima 8900065, Japan.
EM akashi@chem.eng.osaka-u.ac.jp
RI Baba, Masanori/G-3867-2011
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Hayward RC, 2000, NATURE, V404, P56
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   OHANGAN D, 2001, J VIROL, V75, P9037
   OKUBO T, 1993, PROG POLYM SCI, V18, P481, DOI 10.1016/0079-6700(93)90015-5                                                    
   Rihova B, 2002, ADV DRUG DELIVER REV, V54, P653
   RIZA M, 1995, J POLYM SCI POL CHEM, V33, P1219, DOI 10.1002/pola.1995.080330804                                                     
   Serizawa T, 1997, CHEM LETT, P809, DOI 10.1246/cl.1997.809
   Uchida T, 2001, BIOMACROMOLECULES, V2, P1343, DOI 10.1021/bm0100413
NR 11
TC 2
Z9 3
U1 0
U2 1
PU VSP BV
PI ZEIST
PA PO BOX 346, 3700 AH ZEIST, NETHERLANDS
SN 0920-5063
J9 J BIOMAT SCI-POLYM E
JI J. Biomater. Sci.-Polym. Ed.
PY 2004
VL 15
IS 5
BP 661
EP 669
DI 10.1163/156856204323046915
PG 9
WC Engineering, Biomedical; Materials Science, Biomaterials; Polymer
   Science
SC Engineering; Materials Science; Polymer Science
GA 832QA
UT WOS:000222280800009
PM 15264666
DA 2018-01-05
ER

PT J
AU Hellgren, I
   Gorman, J
   Sylven, C
AF Hellgren, I
   Gorman, J
   Sylven, C
TI Factors controlling the efficiency of Tat-mediated plasmid DNA transfer
SO JOURNAL OF DRUG TARGETING
LA English
DT Article
DE Tat; non-viral; plasmid; chloroquine; gene transfer; DNA
ID CELL-PENETRATING PEPTIDES; NONVIRAL GENE DELIVERY; IN-VITRO; PROTEIN;
   HIV-1; VECTOR; INTERNALIZATION; ANTENNAPEDIA; COMPLEXES; THERAPY
AB Background: The polycationic nanopeptide RKKRRQRRR is a fragment of HIV-Tat protein known to be a transfection enhancer. Such factors control the transfection efficiency of plasmid DNA complexed with tat peptide. However, their actions are poorly understood.
   Methods and results: Several cell lines and primary cells were used in transfection experiments. The optimal charge ratio of plasmid to the branched 8Tat peptide was 1:8 for all cell lines and primary cells tested except primary human skin fibroblasts where it was 1:4. The conditions of complex formation (volume, DNA-peptide-solution mixing order and the nature of solution (HEPES, 0.15 M NaCl or 5% dextrose)) influenced transfection efficiency. Chloroquine increased the transgene expression 50-fold in HeLa cells but had little impact on Cos7 cells or 3T3 fibroblasts. The integrity of plasmid DNA in the presence of DNase I was shown to be dependent on the DNA/Tat ratio and the nature of the complex solvent. Complexes with -/+ charge ratio of 1:8 formulated in NaCl and dextrose provided high degree of DNA resistance towards nuclease degradation.
   Conclusions: The conditions of DNA-peptide complex formation and DNA/Tat ratio have significant impact on the level of transgene expression and degree of DNA protection from nuclease attack. The level of elevation of gene delivery in the presence of chloroquine varied considerably between different cells, indicating possible different mechanisms of plasmid-peptide internalisation and intracellular trafficking. The efficiency of branched 8Tat peptide as a plasmid DNA carrier varied between different cell types and have to be optimised for each application.
C1 Huddinge Univ Hosp, Karolinska Inst, Dept Cardiol, Stockholm, Sweden.
RP Hellgren, I (reprint author), NOVUM, Clin Res Ctr, Dept Cardiol, 5th Floor, S-14186 Huddinge, Sweden.
EM irina.hellgren@medhs.ki.se
CR Adami RC, 1998, J PHARM SCI, V87, P678, DOI 10.1021/js9800477
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Collins L, 2000, TRANSPLANTATION, V69, P1168, DOI 10.1097/00007890-200003270-00023
   Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200
   COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033                                                         
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   FINKEL T, 1995, FASEB J, V9, P843
   Fominaya J, 2000, J GENE MED, V2, P455, DOI 10.1002/1521-2254(200011/12)2:6<455::AID-JGM145>3.0.CO;2-O
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   Hellgren I, 2000, CELL MOL LIFE SCI, V57, P1326, DOI 10.1007/PL00000769                                                              
   Ignatovich IA, 2003, J BIOL CHEM, V278, P42625, DOI 10.1074/jbc.M301431200
   Isner JM, 2002, NATURE, V415, P234
   Kichler A, 1998, GENE THER, V5, P855, DOI 10.1038/sj.gt.3300658                                                           
   Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6                                                   
   NABEL EG, 1994, ANNU REV PHYSIOL, V56, P741
   Nakanishi M, 2003, CURR PROTEIN PEPT SC, V4, P141, DOI 10.2174/1389203033487234
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Park YJ, 2003, J GENE MED, V5, P700, DOI 10.1002/jgm.402
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/M211891200
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Siprashvili Z, 2003, HUM GENE THER, V14, P1225, DOI 10.1089/104303403767740768                                                      
   Thoren PEG, 2003, BIOCHEM BIOPH RES CO, V307, P100, DOI 10.1016/S0006-291X(03)01135-5
   Torchilin VP, 2003, P NATL ACAD SCI USA, V100, P1972, DOI 10.1073/pnas.0435906100
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Verma IM, 1997, NATURE, V389, P239, DOI 10.1038/38410                                                                   
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   White RE, 2003, J GENE MED, V5, P883, DOI 10.1002/jgm.420
   Wiethoff CM, 2003, J PHARM SCI, V92, P203, DOI 10.1002/jps.10286
   Yla-Herttuala S, 2003, NAT MED, V9, P694, DOI 10.1038/nm0603-694
   Zhang XH, 2001, HUM GENE THER, V12, P2179, DOI 10.1089/10430340152710522
NR 33
TC 26
Z9 29
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1061-186X
J9 J DRUG TARGET
JI J. Drug Target.
PD JAN
PY 2004
VL 12
IS 1
BP 39
EP 47
DI 10.1080/106118604200041403
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 815DW
UT WOS:000221024000005
PM 15203910
DA 2018-01-05
ER

PT J
AU Ersmark, K
   Feierberg, I
   Bjelic, S
   Hamelink, E
   Hackett, F
   Blackman, MJ
   Hulten, J
   Samuelsson, B
   Aqvist, J
   Hallberg, A
AF Ersmark, K
   Feierberg, I
   Bjelic, S
   Hamelink, E
   Hackett, F
   Blackman, MJ
   Hulten, J
   Samuelsson, B
   Aqvist, J
   Hallberg, A
TI Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and
   II devoid of cathepsin D inhibitory activity
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID RANGE ELECTROSTATIC INTERACTIONS; HIV-1 PROTEASE INHIBITORS; DRUG
   DISCOVERY; COMBINATORIAL LIBRARY; BINDING-AFFINITY; DESIGN; SIMULATIONS;
   MALARIA; IDENTIFICATION; PREDICTION
AB The hemoglobin-degrading aspartic proteases plasmepsin I (Plin I) and plasmepsin II (Plin II) of the malaria parasite Plasmodium falciparum have lately emerged as putative drug targets. A series of C-2-symmetric compounds encompassing the 1,2-dihydroxyethylene scaffold and a variety of elongated P1/P1' side chains were synthesized via microwave-assisted palladium-catalyzed coupling reactions. Binding affinity calculations with the linear interaction energy method and molecular dynamics simulations reproduced the experimental binding data obtained in a Plm II assay with very good accuracy. Bioactive conformations of the elongated P1/P1' chains were predicted and agreed essentially with a recent X-ray structure. The compounds exhibited picomolar to nanomolar inhibition constants for the plasmepsins and no measurable affinity to the human enzyme cathepsin D. Some of the compounds also demonstrated significant inhibition of parasite growth in cell culture. To the best of our knowledge, these plasmepsin inhibitors represent the most selective reported to date and constitute promising lead compounds for further optimization.
C1 Uppsala Univ, Dept Med Chem, BMC, SE-75123 Uppsala, Sweden.
   Uppsala Univ, Dept Cell & Mol Biol, BMC, SE-75124 Uppsala, Sweden.
   Natl Inst Med Res, Div Parasitol, London NW7 1AA, England.
   Medivir AB, SE-14144 Huddinge, Sweden.
RP Hallberg, A (reprint author), Uppsala Univ, Dept Med Chem, BMC, Box 574, SE-75123 Uppsala, Sweden.
EM Anders.Hallberg@orgfarm.uu.se
OI Bjelic, Sinisa/0000-0002-9300-614X
CR Alterman M, 1999, J MED CHEM, V42, P3835, DOI 10.1021/jm9910371                                                               
   Alterman M, 1998, J MED CHEM, V41, P3782, DOI 10.1021/jm970777b                                                               
   Aqvist J, 2002, ACCOUNTS CHEM RES, V35, P358, DOI 10.1021/ar010014p
   Aqvist J, 1996, J COMPUT CHEM, V17, P1587, DOI 10.1002/(SICI)1096-987X(19961115)17:14<1587::AID-JCC1>3.0.CO;2-H
   AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385
   Asojo OA, 2003, J MOL BIOL, V327, P173, DOI 10.1016/S0022-2836(03)00036-6
   Asojo OA, 2002, ACTA CRYSTALLOGR D, V58, P2001, DOI 10.1107/S0907444902014695
   Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099
   Berry C, 2000, Curr Opin Drug Discov Devel, V3, P624
   BLACKMAN MJ, 1994, METHOD CELL BIOL, V45, P213
   Brandsdal BO, 2001, PROTEIN SCI, V10, P1584, DOI 10.1110/ps.940101
   Breman JG, 2001, AM J TROP MED HYG, V64, P1
   Brik A, 2003, ORG BIOMOL CHEM, V1, P5, DOI 10.1039/b208248a
   Brinner KM, 2002, BIOORGAN MED CHEM, V10, P3649, DOI 10.1016/S0968-0896(02)00207-9
   Carroll CD, 1998, BIOORG MED CHEM LETT, V8, P2315, DOI 10.1016/S0960-894X(98)00419-3
   Carroll CD, 1998, BIOORG MED CHEM LETT, V8, P3203, DOI 10.1016/S0960-894X(98)00554-X
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   CHULAY JD, 1983, EXP PARASITOL, V55, P138, DOI 10.1016/0014-4894(83)90007-3
   Coombs GH, 2001, TRENDS PARASITOL, V17, P532, DOI 10.1016/S1471-4922(01)02037-2
   COPELAND RA, 1996, ENZYMES PRACTICALS I
   DAHLGREN A, 2003, MED CHEM, V11, P827
   Dolle RE, 2000, J COMB CHEM, V2, P716, DOI 10.1021/cc000052k
   Ersmark K, 2003, BIOORGAN MED CHEM, V11, P3723, DOI 10.1016/S0968-0896(03)00339-0
   Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97
   Graffner-Nordberg M, 2001, J MED CHEM, V44, P2391, DOI 10.1021/jm010856u
   Hansson T, 1998, J COMPUT AID MOL DES, V12, P27, DOI 10.1023/A:1007930623000
   Haque TS, 1999, J MED CHEM, V42, P1428, DOI 10.1021/jm980641t
   Herrmann WA, 1999, J ORGANOMET CHEM, V576, P23, DOI 10.1016/S0022-328X(98)01050-X                                                   
   Jiang SP, 2001, ANTIMICROB AGENTS CH, V45, P2577, DOI 10.1128/AAC.45.9.2577-2584.2001
   KING G, 1989, J CHEM PHYS, V91, P3647, DOI 10.1063/1.456845
   Larhed M, 2002, ACCOUNTS CHEM RES, V35, P717, DOI 10.1021/ar010074v
   Larhed M, 2001, DRUG DISCOV TODAY, V6, P406, DOI 10.1016/S1359-6446(01)01735-4
   LEE FS, 1992, J CHEM PHYS, V97, P3100, DOI 10.1063/1.462997
   Luzhkov VB, 2001, FEBS LETT, V495, P191, DOI 10.1016/S0014-5793(01)02381-X                                                   
   Marelius J, 1998, J MOL GRAPH MODEL, V16, P213, DOI 10.1016/S1093-3263(98)80006-5
   Marelius J, 1998, J COMPUT AID MOL DES, V12, P119, DOI 10.1023/A:1007929626986
   Moon RP, 1997, EUR J BIOCHEM, V244, P552, DOI 10.1111/j.1432-1033.1997.00552.x
   Nezami A, 2002, BIOCHEMISTRY-US, V41, P2273, DOI 10.1021/bi0117549
   Noteberg D, 2003, J MED CHEM, V46, P734, DOI 10.1021/jm020951i
   Noteberg D, 2003, J COMB CHEM, V5, P456, DOI 10.1021/cc0301014
   Oscarsson K, 2003, BIOORGAN MED CHEM, V11, P1235, DOI 10.1016/S0968-0896(02)00643-0
   Patil VJ, 1996, TETRAHEDRON LETT, V37, P1481, DOI 10.1016/0040-4039(96)00044-5                                                    
   Polt R, 1999, J ORG CHEM, V64, P6147, DOI 10.1021/jo9820115                                                               
   Radding JA, 1999, ANNU REP MED CHEM, V34, P159
   Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034
   Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865
   van Gunsteren W.F., 1987, GRONINGEN MOL SIMULA
   Werbovetz KA, 2000, CURR MED CHEM, V7, P835
NR 48
TC 89
Z9 89
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JAN 1
PY 2004
VL 47
IS 1
BP 110
EP 122
DI 10.1021/jm030933g
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 780BD
UT WOS:000189350400013
PM 14695825
DA 2018-01-05
ER

PT J
AU Watanabe, J
   Ishihara, K
AF Watanabe, J
   Ishihara, K
TI Highly efficient sequential enzymatic reaction on bio-conjugate
   phospholipid polymer nanoparticles
SO KOBUNSHI RONBUNSHU
LA Japanese
DT Article
DE nanoparticles; phospholipid polymer; bio-conjugation; enzymatic
   reaction; high sensitivity
ID INACTIVATED HIV-1-CAPTURING NANOSPHERES; PROTEIN ADSORPTION; WATER;
   PAPAIN; MICE
AB Bio-conjugate nanoparticles were prepared by combination of a phospholipid polymer shell and a polystyrene core. Active ester groups for bio-conjugation and phospholipid polar groups were incorporated into the phospholipid polymer backbone by using a novel active ester monomer and 2-methacryloyloxyethyl phosphorylcholine. The active ester groups and the phospholipid polar groups were located on the nanoparticle surface. The reaction of the active ester groups with enzyme was roughly 40% at 4degreesC and 25degreesC. The activity of the enzyme immobilized at 4degreesC was found to be higher than that immobilization at 25degreesC. For the sequential enzymatic reaction, choline oxidase and peroxidase were immobilized onto the nanoparticles. Choline chloride and tetramethyl benzidine were added as substrates to the nanoparticle suspension. The choline chloride was oxidized by the choline oxidase, and hydrogen peroxide was formed as a degradation product. The hydrogen peroxide was used for the subsequent enzymatic oxidation of tetramethyl benzidine. If hydrogen peroxide was free to diffuse between the choline oxidase and the peroxidase, a sequential enzymatic reaction would be observed. The enzymatic reaction on the nanoparticles was found to be significantly more efficient than that by the enzyme mixture. This result indicates that the diffusion of the degradation products and localization of immobilized enzymes are dominant factors for the reaction. The nanoparticles are thus promising materials for a high-sensitivity diagnosis carrier.
C1 Univ Tokyo, Grad Sch Engn, Dept Mat Engn, Bunkyo Ku, Tokyo 1138656, Japan.
RP Watanabe, J (reprint author), Univ Tokyo, Grad Sch Engn, Dept Mat Engn, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.
CR Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   Ishihara K, 1998, J BIOMED MATER RES, V39, P323, DOI 10.1002/(SICI)1097-4636(199802)39:2<323::AID-JBM21>3.0.CO;2-C
   Ishihara K, 1999, POLYM J, V31, P1231, DOI 10.1295/polymj.31.1231                                                          
   Ishihara K, 2002, ARTIF ORGANS, V26, P1014, DOI 10.1046/j.1525-1594.2002.07039.x                                                
   Ishihara K, 2000, SCI TECHNOL ADV MAT, V1, P131, DOI 10.1016/S1468-6996(00)00012-7
   ISHIHARA K, 1990, POLYM J, V22, P355, DOI 10.1295/polymj.22.355                                                           
   Kawaguchi H, 2000, PROG POLYM SCI, V25, P1171, DOI 10.1016/S0079-6700(00)00024-1                                                   
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Kitano H, 2003, LANGMUIR, V19, P10260, DOI 10.1021/la0349673
   Kitano H., 2000, J PHYS CHEM B, V104, P10425
   KNOPP D, 1995, ANAL CHIM ACTA, V311, P383, DOI 10.1016/0003-2670(95)00147-R                                                    
   Konno T, 2004, BIOMACROMOLECULES, V5, P342, DOI 10.1021/bm034356p
   Kurien BT, 2003, J IMMUNOL METHODS, V274, P1, DOI 10.1016/S0022-1759(02)00523-9
   Miyamoto D, 2004, J APPL POLYM SCI, V91, P827, DOI 10.1002/app.13226
   Miyamoto D, 2004, BIOMATERIALS, V25, P71, DOI 10.1016/S0142-9612(03)00474-5
   Oki A, 2001, ELECTROPHORESIS, V22, P341, DOI 10.1002/1522-2683(200101)22:2<341::AID-ELPS341>3.0.CO;2-W                       
   Park J, 2004, ANAL CHEM, V76, P2649, DOI 10.1021/ac035321i
   Shimizu N, 2000, NAT BIOTECHNOL, V18, P877, DOI 10.1038/78496                                                                   
   Whelan DM, 2000, HEART, V83, P338, DOI 10.1136/heart.83.3.338
   Yoneyama T, 2002, BIOMATERIALS, V23, P1455, DOI 10.1016/S0142-9612(01)00268-X
NR 20
TC 3
Z9 3
U1 0
U2 4
PU SOC POLYMER SCIENCE JAPAN
PI TOKYO
PA TSUKIJI DAISAN NAGAOKA BLDG, 2-4-2 TSUKIJI, CHUO-KU, TOKYO, 104, JAPAN
SN 0386-2186
J9 KOBUNSHI RONBUNSHU
JI Kobunshi Ronbunshu
PY 2004
VL 61
IS 10
BP 547
EP 554
DI 10.1295/koron.61.547                                                    
          
PG 8
WC Polymer Science
SC Polymer Science
GA 867WT
UT WOS:000224874200006
OA gold
DA 2018-01-05
ER

PT B
AU Mishra, NN
   Retterer, S
   Zieziulewicz, TJ
   Isaacson, M
   Szarowski, D
   Mousseau, DE
   Lawrence, DA
   Turner, JN
AF Mishra, NN
   Retterer, S
   Zieziulewicz, TJ
   Isaacson, M
   Szarowski, D
   Mousseau, DE
   Lawrence, DA
   Turner, JN
BE Laudon, M
   Romanowicz, B
TI Bio-impedance sensing device (BISD) for detection of human CD4(+) cells
SO NSTI NANOTECH 2004, VOL 1, TECHNICAL PROCEEDINGS
LA English
DT Proceedings Paper
CT Nanotechnology Conference and Trade Show (Nanotech 2004)
CY MAR 07-11, 2004
CL Boston, MA
SP Nano Sci & Technol Inst, Intel Corp, Motorola, Texas Instruments, Ciphergen Biosyst Inc, iMediasoft Grp, Frontier Carbon Corp, Veeco Instruments, Hitachi High Technologies Amer Inc, Racepoint Grp Inc, Int SEMATECH, FEI Co, Keithley, St Gobain High Performance Mat, Zyvex Corp, Accelrys, ANSYS Inc, Atomistix, PolyInsight, GA Dept Ind & Trade, Swiss Business Hub USA, Australian Govt, Invest Australia, State Bavaria, Germany, United States Off Econ Dev, m+w zander, Engis Corp, COMSOL, Engelhard Corp, Nanonex Inc, nanoTITAN, Tegal Corp, Umech Technologies, MEMSCAP, Swiss House Adv Res & Educ SHARE, Basel Area Business, Dev, Dev Econ Western Switzerland, Nanoworld AG, Nanosensors, Nanofair, Burns, Doane, Swecker & Mathis, LLP, Mintz Levin Cohn Ferris Glovsky & Popeo, PC, Jackson Walker LLP, Greater Zurich Area
DE microelectrode; CD4 cell biosensor; impedance; nanofabrication; human
   blood
ID BACTERIAL-GROWTH; IMPEDANCE; ATTACHMENT; CULTURE; AIDS
AB The aim of this work is to develop a small on-chip bioimpedance sensing device (BISD) to rapidly detect and quantify cells with a specific phenotype in a heterogeneous population of cells (e.g., human CD4(+) cells in blood, for monitoring HIV-infected individuals) using a minimal sample volume and minimal preparation. The transducers, gold/titanium microelectrodes (100x100mum and 80x80mum), have been fabricated on glass substrates. The microelectrode surface is non-covalently modified sequentially with protein G', human albumin, monoclonal anti-human CD4 antibody, and mouse IgG. The anti-human CD4 antibody binds CD4(+) cells present in human blood. The basic function of the microelectrodes was characterized using electrochemical cyclic voltammetry before and after protein G' deposition. The binding of biomolecules, protein G' and antibodies, as well as cells was detected by precisely measuring the electrical current, as a function of frequency (1-8 kHz), that flowed between the microelectrode and the much larger reference electrode. This current was measured using a specially designed very low-noise amplifier based on instrument-grade operational amplifiers. This measurement was plotted as impedance, using the constant-amplitude voltage applied between the two electrodes. We have conducted a series of AC impedance and output voltage measurements with various sizes of gold microelectrodes with adsorbed protein layers, as well as with the CD4(+) cells. When a sample of human peripheral blood mononuclear cells (PBMCs) was incubated on the biosensor, an increase in impedance was observed; this increase was due to the presence of CD4(+) cells, which cause a decrease in the current flow. Incubation of the captured cells with FITC-labeled antihuman CD4 antibody verified that all captured cells were CD4(+), demonstrating the selectivity of the BISD system. The BISD system is a promising tool for the detection of CD4(+) cells in HIV-infected individuals, and for the detection and quantification of antigen: antibody or receptor:ligand interactions.
C1 NYS Dept Hlth, Wadsworth Ctr, Albany, NY USA.
RP Mishra, NN (reprint author), NYS Dept Hlth, Wadsworth Ctr, Albany, NY USA.
RI Retterer, Scott/A-5256-2011
OI Retterer, Scott/0000-0001-8534-1979
CR BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   EDEN G, 1984, IEEE T BIO-MED ENG, V31, P193, DOI 10.1109/TBME.1984.325406
   Fauci A, 1998, HARRISONS PRINCIPLES, P1791
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   HAUSE LL, 1981, IEEE T BIO-MED ENG, V28, P403, DOI 10.1109/TBME.1981.324723                                                        
   Kim GH, 2003, BIOSENS BIOELECTRON, V18, P83, DOI 10.1016/S0956-5663(02)00142-2
   Ko KSC, 1998, J MICROBIOL METH, V34, P125, DOI 10.1016/S0167-7012(98)00083-9                                                   
   KOWOLENKO M, 1990, J IMMUNOL METHODS, V127, P71, DOI 10.1016/0022-1759(90)90342-S
   LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563
   MITRA P, 1991, BIOTECHNIQUES, V11, P504
   OKERBLOM M, 1912, ZENTRALBLATT BAKTE 1, V65, P382
   Parsons LB, 1926, J BACTERIOL, V11, P177
   Parsons LB, 1929, J AM CHEM SOC, V51, P166, DOI 10.1021/ja01376a019
   PAUL WE, 1999, IMMUNOPATHOGENESIS H, P1455
   POLLAK V, 1974, MED BIOL ENG, V12, P460, DOI 10.1007/BF02478602
   RICHARDS JCS, 1978, J PHYS E SCI INSTRUM, V11, P560, DOI 10.1088/0022-3735/11/6/017
   Stewart G N, 1899, J Exp Med, V4, P235, DOI 10.1084/jem.4.2.235
   UR A, 1970, NATURE, V226, P269, DOI 10.1038/226269a0                                                                
   Xiao C, 2002, ANAL CHEM, V74, P1333, DOI 10.1021/ac011104a
   CADY P, 1973, Patent No. 3743581
NR 20
TC 0
Z9 0
U1 0
U2 4
PU NANO SCIENCE & TECHNOLOGY INST
PI CAMBRIDGE
PA ONE KENDALL SQUARE, PMB 308, CAMBRIDGE, MA 02139 USA
BN 0-9728422-7-6
PY 2004
BP 228
EP 231
PG 4
WC Biotechnology & Applied Microbiology; Instruments & Instrumentation;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Instruments & Instrumentation;
   Materials Science
GA BAO45
UT WOS:000223073000061
DA 2018-01-05
ER

PT J
AU Stranix, BR
   Sauve, G
   Bouzide, A
   Cote, A
   Sevigny, G
   Yelle, J
AF Stranix, BR
   Sauve, G
   Bouzide, A
   Cote, A
   Sevigny, G
   Yelle, J
TI Lysine sulfonamides as novel HIV-protease inhibitors: Optimization of
   the N epsilon-acyl-phenyl spacer
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID ASSAY
AB A series of Nalpha-isobutyl-Nalpha-arylsulfonamido-(Nepsilon acyl) lysine and lysinol derivatives were prepared and evaluated as inhibitors of HIV protease and wild type virus. A simple original synthesis was devised to form Nalpha-(arylsulfonamide)-Nalpha-isobutyI lysine, which could be easily acylated with carboxylic acids at the NE position. A two-atom spacer was found to be optimal between this acyl group and a phenyl yielding compounds of sub-nanomolar potency on purified enzyme. (C) 2003 Elsevier Ltd. All rights reserved.
C1 Pharmacor Inc, Laval, PQ H7V 3S8, Canada.
RP Stranix, BR (reprint author), Procyon Biopharma Inc, 6100 Royalmount, Montreal, PQ H4P 2R2, Canada.
CR Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z                                                               
   Eron JJ, 2000, CLIN INFECT DIS, V30, pS160, DOI 10.1086/313853                                                                  
   HIEBERT CK, 1988, J MED CHEM, V31, P2022, DOI 10.1021/jm00118a029
   JAPOUR AJ, 1993, ANTIMICROB AGENTS CH, V37, P1095, DOI 10.1128/AAC.37.5.1095                                                           
   Marastoni M, 1998, ARZNEIMITTEL-FORSCH, V48, P709
   Marastoni M, 2000, ARZNEIMITTEL-FORSCH, V50, P564
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Rutenber EE, 1997, BIOORGAN MED CHEM, V5, P1311, DOI 10.1016/S0968-0896(97)00078-3                                                   
   SAUVE G, UNPUB
   Swanstrom R, 2000, PHARMACOL THERAPEUT, V86, P145, DOI 10.1016/S0163-7258(00)00037-1
   Tomasselli AG, 2000, BBA-PROTEIN STRUCT M, V1477, P189, DOI 10.1016/S0167-4838(99)00273-3
   VELLA S, 2000, HANDB EXP PHARM, V140, P23
   STRANIX BR, 2002, Patent No. 6506786
   STRANIX BR, 2002, Patent No. 06455587
NR 15
TC 15
Z9 15
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD DEC 15
PY 2003
VL 13
IS 24
BP 4289
EP 4292
DI 10.1016/j.bmcl.2003.09.058
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 750RF
UT WOS:000187010700006
PM 14643311
DA 2018-01-05
ER

PT J
AU Locher, CP
   Putnam, D
   Langer, R
   Witt, SA
   Ashlock, BM
   Levy, JA
AF Locher, CP
   Putnam, D
   Langer, R
   Witt, SA
   Ashlock, BM
   Levy, JA
TI Enhancement of a human immunodeficiency virus env DNA vaccine using a
   novel polycationic nanoparticle formulation
SO IMMUNOLOGY LETTERS
LA English
DT Article
DE adjuvant; antibodies; gene therapy; animal model; AIDS
ID GENE DELIVERY; SYSTEM; POTENT
AB In an effort to develop a more effective DNA immunization strategy for HIV, we synthesized an HIV-2 env DNA vaccine and delivered it in a novel polycationic adjuvant formulation that forms nanoparticles in solution and enhances protein expression. The polycationic adjuvant contained imidazole moieties to facilitate endosomal escape. Nanoparticles containing the DNA vaccine plasmid were formed by electrostatic condensation with the polycationic adjuvant. We hypothesized that this formulation would improve immune responses to the gp 140 env gene from HIV-2(UC2) by increasing the level of expressed antigen. We found that the nanoparticles were superior at inducing high levels of systemic antibody responses compared to naked DNA when delivered by the intradermal route in BALB/c mice. In addition, the nanoparticles induced higher levels of IgM, IgG, and IgA antibodies. These results suggest that nanoparticles may be an important adjuvant formulation to improve the effectiveness of genetic immunization and rationalize its use in the evaluation of vaccine candidates in non-human primate models for AIDS. (C) 2003 Elsevier B.V. All rights reserved.
C1 Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94143 USA.
   MIT, Dept Chem Engn, Cambridge, MA 02319 USA.
RP Locher, CP (reprint author), Maxygen Inc, Dept Vaccines, 515 Galveston Dr, Redwood City, CA 94063 USA.
EM christopher.locher@maxygen.com
OI Putnam, David/0000-0002-0794-4915
FU NIAID NIH HHS [AI-34704]; NIGMS NIH HHS [GM 26698]
CR Barnett SW, 1996, VIROLOGY, V222, P257, DOI 10.1006/viro.1996.0417
   FELGNER JH, 1994, J BIOL CHEM, V269, P2550
   Gregoriadis G, 1999, METHODS, V19, P156, DOI 10.1006/meth.1999.0841
   Hasan UA, 1999, J IMMUNOL METHODS, V229, P1, DOI 10.1016/S0022-1759(99)00104-0                                                   
   Illum L, 2001, ADV DRUG DELIVER REV, V51, P81, DOI 10.1016/S0169-409X(01)00171-5
   Locher CP, 2001, IMMUNOL REV, V183, P127, DOI 10.1034/j.1600-065x.2001.1830111.x                                              
   Mattner F, 2002, CANCER RES, V62, P1477
   Pouton CW, 2001, ADV DRUG DELIVER REV, V46, P187, DOI 10.1016/S0169-409X(00)00133-2                                                   
   Putnam D, 2001, P NATL ACAD SCI USA, V98, P1200, DOI 10.1073/pnas.031577698
   Robinson HL, 2002, NAT REV IMMUNOL, V2, P239, DOI 10.1038/nri776
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a                                                                 
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Ulmer JB, 1996, CURR OPIN IMMUNOL, V8, P531, DOI 10.1016/S0952-7915(96)80042-2
NR 13
TC 33
Z9 36
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
J9 IMMUNOL LETT
JI Immunol. Lett.
PD DEC 15
PY 2003
VL 90
IS 2-3
BP 67
EP 70
DI 10.1016/j.imlet.2003.02.001
PG 4
WC Immunology
SC Immunology
GA 763YB
UT WOS:000188127100001
PM 14687705
DA 2018-01-05
ER

PT J
AU Forne, I
   Carrascal, M
   Martinez-Lostao, L
   Abian, J
   Rodriguez-Sanchez, JL
   Juarez, C
AF Forne, I
   Carrascal, M
   Martinez-Lostao, L
   Abian, J
   Rodriguez-Sanchez, JL
   Juarez, C
TI Identification of the autoantigen HB as the barrier-to-autointegration
   factor
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DNA-BINDING PROTEIN; HIV TYPE-1 INTEGRATION; PREINTEGRATION COMPLEXES;
   POLYACRYLAMIDE-GELS; MASS-SPECTROMETRY; HISTONES H2A; AUTOANTIBODIES;
   BAF; ANTIBODIES; SCLERODERMA
AB The HB autoantigen, a 10- kDa DNA- binding protein recognized by autoantibodies only when bound to DNA, was identified by two- dimensional electrophoresis. Silver-stained protein spots corresponding to the antigen were excised from two- dimensional electrophoresis gels, digested with trypsin, and analyzed by matrix- assisted laser desorption/ ionization- reflectron time of flight and nano- electrospray ionization- ion trap/ mass spectrometry. Data base search identified the HB antigen as the barrier- to- autointegration factor, a cellular protein implicated in the cellular cycle that blocks autointegration and promotes intermolecular integration of retrovirus such as the Moloney murine leukemia and the human immunodeficiency type 1 virus. The physicochemical characteristics described for these proteins, their ability to bind double- stranded DNA but not single-stranded DNA, and their nuclear localization confirm that HB and barrier- to- autointegration factor are the same protein.
C1 Univ Autonoma Barcelona, Hosp Sant Pau, Dept Immunol, Barcelona 08025, Spain.
   CSIC, IDIBAPS, IIBB,Dept Expt Pathol, Struct & Biol Mass Spectrometry Unit, Barcelona, Spain.
RP Juarez, C (reprint author), Univ Autonoma Barcelona, Hosp Sant Pau, Dept Immunol, Avda Sant Antoni Maria Claret 167, Barcelona 08025, Spain.
RI Abian, Joaquin/M-1965-2014; Forne, Ignasi/B-3837-2016; Carrascal,
   Montserrat/M-1913-2014
OI Abian, Joaquin/0000-0003-2823-5429; Carrascal,
   Montserrat/0000-0002-0205-2176; Martinez-Lostao,
   Luis/0000-0003-3043-147X; Juarez, Candido/0000-0003-2235-9893
CR BUSTIN M, 1982, SCIENCE, V215, P1245, DOI 10.1126/science.6460317
   Cai M, 1998, NAT STRUCT BIOL, V5, P903, DOI 10.1038/2345
   Chen HM, 1998, P NATL ACAD SCI USA, V95, P15270, DOI 10.1073/pnas.95.26.15270
   Furukawa K, 1999, J CELL SCI, V112, P2485
   Haraguchi T, 2001, J CELL SCI, V114, P4575
   HARDIN JA, 1983, P NATL ACAD SCI-BIOL, V80, P7410, DOI 10.1073/pnas.80.24.7410
   Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200
   JUAREZ C, 1994, CLIN IMMUNOL IMMUNOP, V72, P248, DOI 10.1006/clin.1994.1138
   JUAREZ C, 1988, J IMMUNOL, V141, P3841
   Lee KK, 2001, J CELL SCI, V114, P4567
   Levin MC, 2002, NAT MED, V8, P509, DOI 10.1038/nm0502-509
   Lin CW, 2003, J VIROL, V77, P5030, DOI 10.1128/JVI.77.8.5030-5036.2003
   LOSMAN MJ, 1992, J IMMUNOL, V148, P1561
   MIMORI T, 1986, J BIOL CHEM, V261, P2274
   Monestier M, 1996, MOL IMMUNOL, V33, P89, DOI 10.1016/0161-5890(95)00115-8
   PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0                                                                
   Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9
   REKVIG OP, 1980, J EXP MED, V152, P1720, DOI 10.1084/jem.152.6.1720                                                          
   RODRIGUEZSANCHEZ JL, 1987, J IMMUNOL, V139, P2579
   SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910                                                         
   Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h                                                               
   Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754
   Suzuki Y, 2002, J VIROL, V76, P12376, DOI 10.1128/JVI.76.23.12376-12380.2002
   TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0                                                   
   TAN S, 1990, CELL, V62, P367, DOI 10.1016/0092-8674(90)90373-M
   Umland TC, 2000, BIOCHEMISTRY-US, V39, P9130, DOI 10.1021/bi000572w
   WALKER DH, 1986, ACTA TROP, V43, P175
   WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0
   Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0
   Zheng RL, 2000, P NATL ACAD SCI USA, V97, P8997, DOI 10.1073/pnas.150240197
NR 31
TC 12
Z9 12
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD DEC 12
PY 2003
VL 278
IS 50
BP 50641
EP 50644
DI 10.1074/jbc.M308531200
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 751LH
UT WOS:000187068200119
PM 14523012
OA gold
DA 2018-01-05
ER

PT J
AU Kotelnikova, RA
   Bogdanov, GN
   Frog, EC
   Kotelnikov, AI
   Shtolko, VN
   Romanova, VS
   Andreev, SM
   Kushch, AA
   Fedorova, NE
   Medzhidova, AA
   Miller, GG
AF Kotelnikova, RA
   Bogdanov, GN
   Frog, EC
   Kotelnikov, AI
   Shtolko, VN
   Romanova, VS
   Andreev, SM
   Kushch, AA
   Fedorova, NE
   Medzhidova, AA
   Miller, GG
TI Nanobionics of pharmacologically active derivatives of fullerene C-60
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE amino acid derivatives of fullerene C-60; cytomegalovirus; HIV; electron
   transfer; liposome; stereospecificity; peroxidation of lipids;
   phosphorescence quenching
ID ACID
AB The physical-chemical mechanisms of pharmacologic functioning of amino acid derivatives of fullerene C-60 (ADF) have been studied. ADF were shown to penetrate through the lipid bilayer of liposomes without destruction of membrane integrity. ADF are able to carry bivalent metal ions through phospholipid bilayer owing to the formation of complexes. It was shown that stereoisomers of ADF selectively penetrate into phospholipid membranes. In contrast to D-isomers, L-isomers penetrate through the phosphatidylcholine membrane into liposome interior. Stereospecific effect of ADF enantiomers was also observed in reaction of peroxidation of lipids. Besides that, ADF bring about a substantial increase in the catalytic activity of monoaminoxidases A and B. The directed intraprotein electron transfer was studied by creating a donor-acceptor pair in a water solution in the presence of ADF. To realize the intraprotein electron transfer, the model system was produced on the base of apomyoglobin by incorporating ADF (electron acceptor) into the heme pocket of protein instead of removed heme. It was established that the fullerene C-60 and its derivatives did not produce specific anti-C-60 antibodies, both IgG and IgE classes, while ADF themselves are efficient adjuvants, i.e. they increased the antibody response to poor antigens. Some ADF were found to inhibit the human immunodeficiency virus and human cytomegalovirus infection.
C1 Inst Problems Chem Phys RAS, Chernogolovka, Moscow Region, Russia.
   Inst Organoelement Cpds RAS, Moscow, Russia.
   NRC Inst Immunol, Moscow, Russia.
   Ivanovski Inst Virol RAMS, Moscow, Russia.
   Inst Epidemiol & Microbiol RAMS, Moscow, Russia.
RP Kotelnikova, RA (reprint author), Inst Problems Chem Phys RAS, Chernogolovka, Moscow Region, Russia.
RI Alexander, Kotelnikov/H-8685-2016
CR FRIEDMAN SH, 1993, J AM CHEM SOC, V115, P6506, DOI 10.1021/ja00068a005
   GORKIN V. Z., 1967, LIFE SCI, V6, P791, DOI 10.1016/0024-3205(67)90280-9
   Kotelnikova RA, 1996, FEBS LETT, V389, P111, DOI 10.1016/0014-5793(96)00537-6
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   ROMANOVA VS, 1994, RUSSIAN CHEM B, V6, P1090
   Slater T. F., 1972, FREE RADICAL MECH TI, P30
   TOKUYAMA H, 1993, J AM CHEM SOC, V115, P7918, DOI 10.1021/ja00070a064
NR 7
TC 24
Z9 24
U1 1
U2 4
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
J9 J NANOPART RES
JI J. Nanopart. Res.
PD DEC
PY 2003
VL 5
IS 5-6
BP 561
EP 566
DI 10.1023/B:NANO.0000006070.61144.93                                      
          
PG 6
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 748ZU
UT WOS:000186894800013
DA 2018-01-05
ER

PT J
AU Kim, WJ
   Sato, Y
   Akaike, T
   Maruyama, A
AF Kim, WJ
   Sato, Y
   Akaike, T
   Maruyama, A
TI Cationic comb-type copolymers for DNA analysis
SO NATURE MATERIALS
LA English
DT Article
ID HIV-1 NUCLEOCAPSID PROTEIN; NUCLEIC-ACID-CHAPERONE; STRAND EXCHANGE;
   POLY(L-LYSINE)-GRAFT-DEXTRAN COPOLYMER; PHYSIOLOGICAL PH; TRIPLEX;
   THERMODYNAMICS; HYBRIDIZATION; NANOPARTICLES; SPECIFICITY
AB Genetic diagnoses, such as single nucleotide polymorphism (SNP) typing, allow elucidation of gene-based physiological differences, such as susceptibility to diseases and response to drugs, among individuals. Many detection technologies, including allele-specific hybridization, allele-specific primer extension and oligonucleotide ligation, are being used to discriminate SNP alleles(1,2). These methods still have many unsolved practical issues(1-3). In general they require adequate and specific hybridizations of primer or probe DNAs with target DNAs. This frequently needs optimization of the probe/primer structures and operating conditions. In nature, highly homology-sensitive hybridization is assisted by a nucleic acid chaperone that reduces the energy barrier associated with breakage and reassociation of nucleic base pairs(4,5). Here we report a simple, quick, precise but enzyme-free method for SNP analysis. The method uses cationic comb-type copolymers (CCCs) producing high nucleic acid chaperone activities. A single-base mismatch in 20-mer DNA can be detected within a few minutes at ambient temperatures (25-37degreesC). Even without careful optimization processes, the method has the sensitivity to detect the mismatches causing subtle changes (DeltaT(m)approximate to1degreesC) in duplex thermal stability. CCCs may have various bioanalytical applications where precise hybridization of nucleic acids is needed.
C1 Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan.
   Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan.
RP Maruyama, A (reprint author), Tokyo Inst Technol, Dept Biomol Engn, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.
RI Kim, Won Jong/F-5348-2013
OI Maruyama, Atsushi/0000-0002-7495-2974
CR Bazemore LR, 1997, J BIOL CHEM, V272, P14672, DOI 10.1074/jbc.272.23.14672
   Boon EM, 2000, NAT BIOTECHNOL, V18, P1096, DOI 10.1038/80301
   Brennan M D, 2001, Am J Pharmacogenomics, V1, P295, DOI 10.2165/00129785-200101040-00006
   Cao YWC, 2002, SCIENCE, V297, P1536, DOI 10.1126/science.297.5586.1536
   Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610
   Chicurel M, 2001, NATURE, V412, P580, DOI 10.1038/35088146                                                                
   Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078
   Ferdous A, 1998, NUCLEIC ACIDS RES, V26, P3949, DOI 10.1093/nar/26.17.3949                                                          
   GOLDSTEIN JA, 1994, PHARMACOGENETICS, V4, P285, DOI 10.1097/00008571-199412000-00001
   Han MY, 2001, NAT BIOTECHNOL, V19, P631, DOI 10.1038/90228                                                                   
   Jenison R, 2001, NAT BIOTECHNOL, V19, P62, DOI 10.1038/83530
   Kajiyama T, 2003, GENOME RES, V13, P467, DOI 10.1101/gr.790603
   Kim WJ, 2002, J AM CHEM SOC, V124, P12676, DOI 10.1021/ja0272080
   Kim WJ, 2001, CHEM-EUR J, V7, P176, DOI 10.1002/1521-3765(20010105)7:1<176::AID-CHEM176>3.0.CO;2-M                      
   Kwok PY, 2001, ANNU REV GENOM HUM G, V2, P235, DOI 10.1146/annurev.genom.2.1.235                                                   
   Li QQ, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e5
   Maruyama A, 1997, BIOCONJUGATE CHEM, V8, P3, DOI 10.1021/bc960071g
   Mazumder A, 1998, NUCLEIC ACIDS RES, V26, P1996, DOI 10.1093/nar/26.8.1996
   Morais S, 1994, J BIOL CHEM, V269, P15419
   PANYUTIN IG, 1993, J MOL BIOL, V230, P413, DOI 10.1006/jmbi.1993.1159
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   Reynaldo LP, 2000, J MOL BIOL, V297, P511, DOI 10.1006/jmbi.2000.3573
   SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460
   Takahashi T, 2002, CHEMBIOCHEM, V3, P543, DOI 10.1002/1439-7633(20020603)3:6<543::AID-CBIC543>3.0.CO;2-R
   Torigoe H, 1999, J BIOL CHEM, V274, P6161, DOI 10.1074/jbc.274.10.6161
   TSUCHIHASHI Z, 1994, J VIROL, V68, P5863
   Urbaneja MA, 2002, J MOL BIOL, V318, P749, DOI 10.1016/S0022-2836(02)00043-8
   Wilson JF, 2001, NAT GENET, V29, P265, DOI 10.1038/ng761                                                                   
   Yang L, 2001, GENOME RES, V11, P1888
NR 29
TC 59
Z9 59
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-1122
J9 NAT MATER
JI Nat. Mater.
PD DEC
PY 2003
VL 2
IS 12
BP 815
EP 820
DI 10.1038/nmat1021
PG 6
WC Chemistry, Physical; Materials Science, Multidisciplinary; Physics,
   Applied; Physics, Condensed Matter
SC Chemistry; Materials Science; Physics
GA 748CC
UT WOS:000186843800019
PM 14634643
DA 2018-01-05
ER

PT J
AU Reblova, K
   Spackova, N
   Sponer, JE
   Koca, J
   Sponer, J
AF Reblova, K
   Spackova, N
   Sponer, JE
   Koca, J
   Sponer, J
TI Molecular dynamics simulations of RNA kissing-loop motifs reveal
   structural dynamics and formation of cation-binding pockets
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID DIMERIZATION INITIATION SITE; HIV-1 GENOMIC RNA; CRYSTAL-STRUCTURE;
   NUCLEIC-ACIDS; BASE-PAIRS; MAGNESIUM BINDING; VIRUS RNA; COMPLEX;
   ENERGY; DUPLEX
AB Explicit solvent molecular dynamics (MD) simulations were carried out for three RNA kissing-loop complexes. The theoretical structure of two base pairs (2 bp) complex of H3 stem-loop of Moloney murine leukemia virus agrees with the NMR structure with modest violations of few NMR restraints comparable to violations present in the NMR structure. In contrast to the NMR structure, however, MD shows relaxed intermolecular G-C base pairs. The core region of the kissing complex forms a cation-binding pocket with highly negative electrostatic potential. The pocket shows nanosecond-scale breathing motions coupled with oscillations of the whole molecule. Additional simulations were carried out for 6 bp kissing complexes of the DIS HIV-1 subtypes A and B. The simulated structures agree well with the X-ray data. The subtype B forms a novel four-base stack of bulged-out adenines. Both 6 bp kissing complexes have extended cation-binding pockets in their central parts. While the pocket of subtype A interacts with two hexacoordinated Mg2+ ions and one sodium ion, pocket of subtype B is filled with a string of three delocalized Na+ ions with residency times of individual cations 1-2 ns. The 6 bp complexes show breathing motions of the cation-binding pockets and loop major grooves.
C1 Acad Sci Czech Republ, Natl Ctr Biomol Res, Brno 61265, Czech Republic.
   Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic.
   Masaryk Univ, Natl Ctr Biomol Res, CS-61137 Brno, Czech Republic.
RP Sponer, J (reprint author), Acad Sci Czech Republ, Natl Ctr Biomol Res, Kralovopolska 135, Brno 61265, Czech Republic.
RI Reblova, Kamila/E-1359-2012; Koca, Jaroslav/E-4460-2012; Sponer,
   Judit/D-9918-2012; Sponer, Jiri/D-9467-2012
OI Koca, Jaroslav/0000-0002-2780-4901; 
CR Auffinger P, 1999, BIOPHYS J, V76, P50, DOI 10.1016/S0006-3495(99)77177-8                                                   
   Auffinger P, 2003, CHEM BIOL, V10, P551, DOI 10.1016/S1074-5521(03)00121-2
   Auffinger Pascal, 2000, Biopolymers, V56, P266, DOI 10.1002/1097-0282(2000)56:4<266::AID-BIP10027>3.0.CO;2-3
   Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905
   Beaurain F, 2003, NUCLEIC ACIDS RES, V31, P4275, DOI 10.1093/nar/gkg467
   BENDER W, 1976, CELL, V7, P595, DOI 10.1016/0092-8674(76)90210-5
   Cai L, 1998, NUCLEIC ACIDS RES, V26, P4696, DOI 10.1093/nar/26.20.4696
   Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021
   Clever JL, 1996, J VIROL, V70, P5902
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   Csaszar K, 2001, J MOL BIOL, V313, P1073, DOI 10.1006/jmbi.2001.5100
   De Tapia M, 1998, BIOCHEMISTRY-US, V37, P6077, DOI 10.1021/bi9800303
   Ennifar E, 1999, STRUCT FOLD DES, V7, P1439, DOI 10.1016/S0969-2126(00)80033-7
   Ennifar E, 2003, NUCLEIC ACIDS RES, V31, P2671, DOI 10.1093/nar/gkg350
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7                                                    
   Gilson M., 1998, J COMPUT CHEM, V9, P327
   Giudice E, 2002, ACCOUNTS CHEM RES, V35, P350, DOI 10.1021/ar010023y
   Guo JX, 2000, J BIOMOL STRUCT DYN, V18, P335, DOI 10.1080/07391102.2000.10506670                                                  
   Harris SA, 2001, J AM CHEM SOC, V123, P12658, DOI 10.1021/ja016233n
   Harvey SC, 1998, J COMPUT CHEM, V19, P726, DOI 10.1002/(SICI)1096-987X(199805)19:7<726::AID-JCC4>3.0.CO;2-S
   Hermann T, 1998, EUR BIOPHYS J BIOPHY, V27, P153, DOI 10.1007/s002490050121
   Hermann T, 1998, STRUCT FOLD DES, V6, P1303, DOI 10.1016/S0969-2126(98)00130-0
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5                                                    
   Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982
   Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697                                                          
   Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f                                                               
   Lee AJ, 1998, STRUCT FOLD DES, V6, P993, DOI 10.1016/S0969-2126(98)00101-4
   Lodmell JS, 2001, J MOL BIOL, V311, P475, DOI 10.1006/jmbi.2001.4879
   Luisi B, 1998, J MOL BIOL, V279, P1123, DOI 10.1006/jmbi.1998.1833
   Misra VK, 2002, J MOL BIOL, V317, P507, DOI 10.1006/jmbi.2002.5422
   Mujeeb A, 1998, NAT STRUCT BIOL, V5, P432, DOI 10.1038/nsb0698-432
   Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s
   Nagan MC, 1999, J AM CHEM SOC, V121, P7310, DOI 10.1021/ja9842565                                                               
   Nagan MC, 2000, NUCLEIC ACIDS RES, V28, P2527, DOI 10.1093/nar/28.13.2527
   Norberg J, 2002, ACCOUNTS CHEM RES, V35, P465, DOI 10.1021/ar010026a
   Pattabiraman N, 2002, J BIOMOL STRUCT DYN, V20, P397, DOI 10.1080/07391102.2002.10506858                                                  
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   Reblova K, 2003, BIOPHYS J, V84, P3564, DOI 10.1016/S0006-3495(03)75089-9                                                   
   ROSS WS, 1994, J AM CHEM SOC, V116, P6070, DOI 10.1021/ja00093a003
   Sarzynska J, 2000, BIOPHYS J, V79, P1213, DOI 10.1016/S0006-3495(00)76376-4                                                   
   Schneider C, 2001, J MOL BIOL, V305, P659, DOI 10.1006/jmbi.2000.4338
   Schneider C, 2000, J BIOMOL STRUCT DYN, V18, P345, DOI 10.1080/07391102.2000.10506671                                                  
   Spackova N, 2000, J AM CHEM SOC, V122, P7564, DOI 10.1021/ja000460s
   Sponer J, 2003, J MOL BIOL, V330, P967, DOI 10.1016/S0022-2836(03)00667-3
   Sponer J, 2000, J PHYS CHEM B, V104, P7535, DOI 10.1021/jp001711m
   TOUNEKTI N, 1992, J MOL BIOL, V223, P205, DOI 10.1016/0022-2836(92)90726-Z
   Vlieghe D, 1999, BIOCHEMISTRY-US, V38, P16443, DOI 10.1021/bi9907882
   WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433                                             
   WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8
   YORK DM, 1993, J CHEM PHYS, V99, P8345, DOI 10.1063/1.465608
NR 51
TC 50
Z9 52
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD DEC 1
PY 2003
VL 31
IS 23
BP 6942
EP 6952
DI 10.1093/nar/gkg880
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 747JY
UT WOS:000186802500032
PM 14627827
OA gold
DA 2018-01-05
ER

PT J
AU Fischer, NO
   Verma, A
   Goodman, CM
   Simard, JM
   Rotello, VM
AF Fischer, NO
   Verma, A
   Goodman, CM
   Simard, JM
   Rotello, VM
TI Reversible "irreversible" inhibition of chymotrypsin using nanoparticle
   receptors
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID PROTEIN-PROTEIN INTERACTIONS; GOLD CLUSTER MOLECULES;
   ALPHA-CHYMOTRYPSIN; RECOGNITION SITES; HIV-1 PROTEASE; FLUORESCENCE;
   ANTAGONISTS; LACTALBUMIN; MONOLAYERS; DYNAMICS
AB Anionically functionalized amphiphilic nanoparticles efficiently inhibit chymotrypsin through electrostatic binding followed by protein denaturation. We demonstrate the ability to disrupt this "irreversible" inhibition of chymotrypsin through modification of the nanoparticle surface using cationic surfactants. Up to 50% of original chymotrypsin activity is rescued upon long-chain surfactant addition. Dynamic light-scattering studies demonstrate that chymotrypsin is released from the nanoparticle surface. The conformation of the rescued chymotrypsin was characterized by fluorescence and fluorescence anisotropy, indicating that chymotrypsin regains a high degree of native structure upon surfactant addition.
C1 Univ Massachusetts, Program Mol & Cellular Biol, Amherst, MA 01003 USA.
   Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.
RP Rotello, VM (reprint author), Univ Massachusetts, Program Mol & Cellular Biol, Amherst, MA 01003 USA.
OI Goodman, Catherine/0000-0003-3415-8554
FU NIGMS NIH HHS [GM08515, GM 62998]
CR Boal AK, 2000, LANGMUIR, V16, P9527, DOI 10.1021/la0012384
   Boal AK, 2000, J AM CHEM SOC, V122, P734, DOI 10.1021/ja993900s                                                               
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Burgess K, 2001, ACCOUNTS CHEM RES, V34, P826, DOI 10.1021/ar9901523
   Calas M, 1997, J MED CHEM, V40, P3557, DOI 10.1021/jm9701886
   Capasso C, 1997, J MOL RECOGNIT, V10, P26, DOI 10.1002/(SICI)1099-1352(199701/02)10:1<26::AID-JMR351>3.0.CO;2-N
   Chakraborty S, 2001, BIOCHEMISTRY-US, V40, P7228, DOI 10.1021/bi010004w
   Chrunyk BA, 2000, BIOCHEMISTRY-US, V39, P7092, DOI 10.1021/bi000096+
   Cochran AG, 2000, CHEM BIOL, V7, pR85, DOI 10.1016/S1074-5521(00)00106-X
   Cruz FG, 2000, J AM CHEM SOC, V122, P8777, DOI 10.1021/ja001804h
   Davey TW, 1998, AUST J CHEM, V51, P581, DOI 10.1071/C98001                                                                  
   DESIE G, 1986, BIOCHEMISTRY-US, V25, P8301, DOI 10.1021/bi00373a026
   DOROVSKATARAN V, 1993, EUR J BIOCHEM, V218, P1013, DOI 10.1111/j.1432-1033.1993.tb18460.x
   Engel MFM, 2002, J BIOL CHEM, V277, P10922, DOI 10.1074/jbc.M106005200
   Fischer NO, 2002, P NATL ACAD SCI USA, V99, P5018, DOI 10.1073/pnas.082644099
   FORD WT, 1973, J ORG CHEM, V38, P3916, DOI 10.1021/jo00962a020                                                             
   Furuta T, 1999, P NATL ACAD SCI USA, V96, P1193, DOI 10.1073/pnas.96.4.1193
   Gadek TR, 2003, BIOCHEM PHARMACOL, V65, P1, DOI 10.1016/S0006-2952(02)01479-X
   Harvey AJ, 2001, BIOORG MED CHEM LETT, V11, P2441, DOI 10.1016/S0960-894X(01)00464-4
   Hayashi T, 1998, J AM CHEM SOC, V120, P4910, DOI 10.1021/ja9723951                                                               
   Hostetler MJ, 1998, LANGMUIR, V14, P17, DOI 10.1021/la970588w                                                               
   Hostetler MJ, 1996, J AM CHEM SOC, V118, P4212, DOI 10.1021/ja960198g                                                               
   Hostetler MJ, 1999, LANGMUIR, V15, P3782, DOI 10.1021/la981598f                                                               
   INGHAM KC, 1984, J BIOL CHEM, V259, P1901
   Koide A, 2002, P NATL ACAD SCI USA, V99, P1253, DOI 10.1073/pnas.032665299
   LAKOKHIN AS, 2000, ENCY ANAL CHEM, P5762
   Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P291
   Lopez-Fontan JL, 1999, PHYS CHEM CHEM PHYS, V1, P3583, DOI 10.1039/a903532j                                                                
   McIntosh CM, 2001, J AM CHEM SOC, V123, P7626, DOI 10.1021/ja015556g
   Nadassy K, 1999, BIOCHEMISTRY-US, V38, P1999, DOI 10.1021/bi982362d                                                               
   Park HS, 1999, J AM CHEM SOC, V121, P8, DOI 10.1021/ja981504o                                                               
   Peczuh MW, 2000, CHEM REV, V100, P2479, DOI 10.1021/cr9900026
   Schramm HJ, 1999, BIOL CHEM, V380, P593, DOI 10.1515/BC.1999.076
   SIMARD J, 2000, CHEM COMMUN, V19, P1943
   Spreti N, 2001, EUR J BIOCHEM, V268, P6491, DOI 10.1046/j.0014-2956.2001.02604.x
   Stavens KB, 1999, LANGMUIR, V15, P8337, DOI 10.1021/la9911786                                                               
   Strong LE, 1999, J AM CHEM SOC, V121, P6193, DOI 10.1021/ja990223t                                                               
   STRONG LE, 1998, J AM CHEM SOC, V120, P4910
   Tien J, 1997, LANGMUIR, V13, P5349, DOI 10.1021/la970454i                                                               
   Toogood PL, 2002, J MED CHEM, V45, P1543, DOI 10.1021/jm010468s
   Turoverov KK, 2002, BIOCHEMISTRY-US, V41, P1014, DOI 10.1021/bi015548c
   Veselovsky AV, 2002, J MOL RECOGNIT, V15, P405, DOI 10.1002/jmr.597
   ZHANG ZY, 1991, J BIOL CHEM, V266, P15591
   Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7                                                   
NR 44
TC 84
Z9 87
U1 1
U2 28
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD NOV 5
PY 2003
VL 125
IS 44
BP 13387
EP 13391
DI 10.1021/ja0352505
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 738LN
UT WOS:000186289300039
PM 14583034
DA 2018-01-05
ER

PT J
AU Sommer, AP
AF Sommer, AP
TI Peripheral neuropathy and light-preliminary report indicating prevalence
   of nanobacteria in HIV
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE peripheral neuropathy; nanobacteria; diabetes mellitus; HIV; AIDS
ID PRIMORDIAL BIOSYSTEMS; CALCIFICATION
AB Peripheral neuropathy is a common condition in HIV-positive patients and is often experienced in diabetes mellitus. The primary mechanism of the disease, which can considerably aggravate the patient's state, is unknown. The perineurium of patients with peripheral neuropathy is frequently enveloped by apatite. Nanobacteria (NB) are protectd by a mineral shell consisting of apatite. Light has been shown to elevate the vitality level of cells, and was predicted to inhibit deposition of stressed NB in the cardiovascular system. Results indicate that light can durably restore the condition of patients with severe peripheral neuropathy.
C1 Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
RP Sommer, AP (reprint author), Univ Ulm, Cent Inst Biomed Engn, D-89081 Ulm, Germany.
CR ALWATBAN FAH, 2002, NASA C PUBLICATION
   KALIMO H, 1981, MUSCLE NERVE, V4, P228, DOI 10.1002/mus.880040310
   Maniscalco BS, 2003, CIRCULATION, V107, pE74, DOI 10.1161/01.CIR.0000060812.21017.8A                                              
   MOOSER V, 2003, AIDS S, V1, pS65
   PAETAU A, 1976, ACTA NEUROPATHOL, V36, P185, DOI 10.1007/BF00685280                                                              
   Sommer AP, 2003, J PROTEOME RES, V2, P558, DOI 10.1021/pr034040o
   Sommer AP, 2003, J PROTEOME RES, V2, P441, DOI 10.1021/pr034005h
   Sommer AP, 2002, J CLIN LASER MED SUR, V20, P241, DOI 10.1089/10445470260420731
   Sommer AP, 2002, J PROTEOME RES, V1, P475, DOI 10.1021/pr0255396
   Sommer AP, 2001, J CLIN LASER MED SUR, V19, P29, DOI 10.1089/104454701750066910
   SOMMER AP, IN PRESS CRYST GROWT
   SOMMER AP, 2003, CLIN LASER MED SURG, V21, P229
   VITTECOQ D, 2003, AIDS S, V1, pS70
   Yoon HC, 2002, RADIOLOGY, V224, P236, DOI 10.1148/radiol.2241011191
NR 14
TC 23
Z9 23
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD NOV-DEC
PY 2003
VL 2
IS 6
BP 665
EP 666
DI 10.1021/pr0340633
PG 2
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 753GD
UT WOS:000187222900013
PM 14692462
DA 2018-01-05
ER

PT J
AU Console, S
   Marty, C
   Garcia-Echeverria, C
   Schwendener, R
   Ballmer-Hofer, K
AF Console, S
   Marty, C
   Garcia-Echeverria, C
   Schwendener, R
   Ballmer-Hofer, K
TI Antennapedia and HIV transactivator of transcription (TAT) "protein
   transduction domains" promote endocytosis of high molecular weight cargo
   upon binding to cell surface glycosaminoglycans
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID INTRACELLULAR DELIVERY; PENETRATING PEPTIDES; BASIC DOMAIN;
   INTERNALIZATION; LIPOSOMES; MEMBRANE; HEPARIN; OLIGOSACCHARIDES;
   PROTEOGLYCANS; BIOSYNTHESIS
AB Protein transduction domains (PTDs) are short basic peptide sequences present in many cellular and viral proteins that mediate translocation across cellular membranes. PTDs have become widely used as tools for the delivery of high M-r polypetides, polynucleotides, or nanoparticles to cells in culture; and even the transfer of cargo molecules to the tissue of live animals has been reported. These cell-permeable peptides are functional when fused in-frame to recombinant polypeptides or when chemically coupled to their cargo. The mechanism responsible for PTD-mediated membrane translocation is controversially discussed and may vary among the various PTDs reported in the literature. Thus direct physical interaction with membrane lipids resulting in vectorial delivery to cells has been proposed for the Antennapedia (Antp) PTD, whereas uptake by the retroviral TAT ( transactivator of transcription) protein PTD seems to require cell surface-expressed glycosaminoglycans. The view that PTD-mediated cellular uptake is energy-independent has been dismissed recently as an artifact resulting from fixation of cells. The data reported here agree with and further extend this work. They support the idea that certain PTDs promote cellular uptake via endocytosis and require the expression of negatively charged glycosaminoglycans on the surface of the target cells. Uptake of Antp PTD conjugates or peptide-derivatized liposomes was blocked by heparan sulfate proteoglycans, whereas TAT-mediated uptake was inhibited by both heparin and dextran sulfate. Mutant cells defective for glycosaminoglycan synthesis showed dramatically reduced Antp- or TAT-mediated transmembrane transport confirming the role of these complex polysaccharides in PTD-mediated cellular uptake. The fact that PTDs selectively interact with distinct glycosaminoglycan species has implications for therapeutic applications and may allow targeting of selective tissues that differ in their surface-expressed glycosaminoglycan patterns.
C1 Paul Scherrer Inst, CH-5232 Villigen, Switzerland.
   Novartis Pharma Inc, CH-4002 Basel, Switzerland.
RP Ballmer-Hofer, K (reprint author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.
CR Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197
   Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Garcia-Echeverria C, 2001, BIOORG MED CHEM LETT, V11, P1363, DOI 10.1016/S0960-894X(01)00208-6
   GarciaEcheverria C, 1997, LETT PEPT SCI, V4, P49
   GarciaEcheverria C, 1996, BIOORG MED CHEM LETT, V6, P229, DOI 10.1016/0960-894X(96)00009-1
   Hausser H, 1999, BIOCHEM J, V344, P827, DOI 10.1042/0264-6021:3440827
   Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1
   LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267                                                          
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   MANN DA, 1991, EMBO J, V10, P1733
   Marty C, 2002, BRIT J CANCER, V87, P106, DOI 10.1038/sj.bjc.660423
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Rusnati M, 2001, J BIOL CHEM, V276, P22420, DOI 10.1074/jbc.M010779200
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vollenweider F, 1998, J CELL BIOL, V142, P377, DOI 10.1083/jcb.142.2.377
NR 29
TC 305
Z9 315
U1 3
U2 26
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 12
PY 2003
VL 278
IS 37
BP 35109
EP 35114
DI 10.1074/jbc.M301726200
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 718UG
UT WOS:000185164400046
PM 12837762
OA gold
DA 2018-01-05
ER

PT J
AU Chen, X
   Yang, L
   Zhang, N
   Turpin, JA
   Buckheit, RW
   Osterling, C
   Oppenheim, JJ
   Howard, OMZ
AF Chen, X
   Yang, L
   Zhang, N
   Turpin, JA
   Buckheit, RW
   Osterling, C
   Oppenheim, JJ
   Howard, OMZ
TI Shikonin, a component of Chinese herbal medicine, inhibits chemokine
   receptor function and suppresses human immunodeficiency virus type 1
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ANTI-HIV ACTIVITY; CD8(+) T-CELLS; POTENT INHIBITION; CCR5 ANTAGONIST;
   SMALL-MOLECULE; RESISTANCE; RANTES; ENTRY; IDENTIFICATION; SPECIFICITY
AB Shikonin is a major component of zicao (purple gromwell, the dried root of Lithospermum erythrorhizon), a Chinese herbal medicine with various biological activities, including inhibition of human immunodeficiency virus (HIV) type 1 (HIV-1). G protein-coupled chemokine receptors are used by HIV-1 as coreceptors to enter the host cells. In this study, we assessed the effects of shikonin on chemokine receptor function and HIV-1 replication. The results showed that, at nanomolar concentrations, shikonin inhibited monocyte chemotaxis and calcium flux in response to a variety of CC chemokines (CCL2 [monocyte chemoattractant protein 1], CCL3 [macrophage inflammatory protein 1alpha], and CCL5 [regulated upon activation, normal T-cell expressed and secreted protein]), the CXC chemokine (CXCL12 [stromal cell-derived factor 1alpha]), and classic chemoattractants (formylmethionyl-leucine-phenylalanine and complement fraction C5a). Shikonin down-regulated surface expression of CCR5, a primary HIV-1 coreceptor, on macrophages to a greater degree than the other receptors (CCR1, CCR2, CXCR4, and the formyl peptide receptor) did. CCR5 mRNA expression was also down-regulated by the compound. Additionally, shikonin inhibited the replication of a multidrug-resistant strain and pediatric clinical isolates of HIV in human peripheral blood mononuclear cells, with 50% inhibitory concentrations (IC(50)s) ranging from 96 to 366 nM. Shikonin also effectively inhibited the replication of the HIV Ba-L isolate in monocytes/macrophages, with an IC50 of 470 nM. Our results suggest that the anti-HIV and anti-inflammatory activities of shikonin may be related to its interference with chemokine receptor expression and function. Therefore, shikonin, as a naturally occurring, low-molecular-weight pan-chemokine receptor inhibitor, constitutes a basis for the development of novel anti-HIV therapeutic agents.
C1 NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA.
   NCI, Basic Res Program, SAIC Frederick Inc, Frederick, MD 21702 USA.
   TherImmune Res Corp, Gaithersburg, MD 20879 USA.
   Howpin Int Consulting, Frederick, MD 21703 USA.
   So Res Inst, Infect Dis Res Dept, Frederick, MD 21701 USA.
RP Howard, OMZ (reprint author), NCI, Mol Immunoregulat Lab, BO Box B,Bldg 560 Rm 31-19, Frederick, MD 21702 USA.
RI Chen, Xin/I-6601-2015; Howard, O M Zack/B-6117-2012
OI Chen, Xin/0000-0002-2628-4027; Howard, O M Zack/0000-0002-0505-7052
FU PHS HHS [N01-C0-12400]; NCI NIH HHS [N01CO12400]
CR Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718                                                          
   BUCKHEIT RW, 1994, AIDS RES HUM RETROV, V10, P1497, DOI 10.1089/aid.1994.10.1497
   BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2
   Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381                                                          
   Chen DG, 2000, ACTA PETROL SIN, V16, P199
   Chen X, 2002, BIOCHEM PHARMACOL, V63, P533, DOI 10.1016/S0006-2952(01)00917-0
   Cheng KS, 2001, CHINESE J ASTRON AST, V1, P1, DOI 10.1088/1009-9271/1/1/1                                                         
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Cocchi F, 2000, P NATL ACAD SCI USA, V97, P13812, DOI 10.1073/pnas.240469997
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/0022-1759(80)90211-2
   Farber JM, 2002, P NATL ACAD SCI USA, V99, P1749, DOI 10.1073/pnas.042708299
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209
   GOODWIN CJ, 1995, J IMMUNOL METHODS, V179, P95, DOI 10.1016/0022-1759(94)00277-4
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Min XM, 2001, J WUHAN UNIV TECHNOL, V16, P57
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865                                                         
   Perera LP, 1998, P NATL ACAD SCI USA, V95, P14308, DOI 10.1073/pnas.95.24.14308
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599                                                          
   Sabroe I, 2000, J BIOL CHEM, V275, P25985, DOI 10.1074/jbc.M908864199
   Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   Stantchev TS, 2001, CYTOKINE GROWTH F R, V12, P219, DOI 10.1016/S1359-6101(00)00033-2                                                   
   Ueba N, 1993, Nihon Rinsho, V51 Suppl, P207
   Vassilios PP, 1999, ANGEW CHEM INT EDIT, V38, P270
   Wang JH, 1998, J VIROL, V72, P7642
   Wang JP, 1997, BIOCHEM PHARMACOL, V53, P1173, DOI 10.1016/S0006-2952(97)00098-1
   Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373                                                          
   YAMASAKI K, 1993, YAKUGAKU ZASSHI, V113, P818, DOI 10.1248/yakushi1947.113.11_818                                                  
NR 32
TC 111
Z9 123
U1 0
U2 7
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2003
VL 47
IS 9
BP 2810
EP 2816
DI 10.1128/AAC.47.9.2810-2816.2003
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 715TH
UT WOS:000184988000014
PM 12936978
OA gold
DA 2018-01-05
ER

PT J
AU McComsey, GA
   Morrow, JD
AF McComsey, GA
   Morrow, JD
TI Lipid oxidative markers are significantly increased in lipoatrophy but
   not in sustained asymptomatic hyperlactatemia
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE lipoatrophy; hyperlactatemia; mitochondrial toxicity; oxidative markers;
   oxidative stress; lipodystrophy
ID REVERSE-TRANSCRIPTASE INHIBITORS; MITOCHONDRIAL-DNA DEPLETION;
   HIV-INFECTED PATIENTS; IN-VIVO; SUBCUTANEOUS FAT; LACTIC-ACIDOSIS;
   OXIDANT STRESS; ADIPOSE-TISSUE; F-2-ISOPROSTANES; QUANTIFICATION
AB The exact mechanism of lipoatrophy remains unclear. One hypothesized mechanism is accumulation of reactive oxygen free radicals, which is possibly related to dysfunctional mitochondria. We evaluated plasma levels of F-2-isoprostanes-the most accurate method to measure oxidant stress in vivo-in a group of 59 nucleoside reverse transcriptase inhibitor treated HIV-1-infected subjects. All had serial measurements of venous lactate levels as well as clinical evaluations for assessment of lipoatrophy and symptoms of mitochondrial toxicity. Overall, 16 subjects had sustained hyperlactatemia (4 of whom were symptomatic) and 43 had serial normal lactate levels. We found a significant increase in circulating products of lipid peroxidation, F-2-isoprostanes (nanograms per milliliter), in subjects with lipoatrophy when compared with subjects without lipoatrophy (0.060 +/- 0.025 vs. 0.0420 +/- 0.02, respectively; P = 0.02). Interestingly, there was no significant difference in F-2-isoprostane levels (nanograms per milliliter) between patients with persistently normal lactate and those who exhibited a sustained asymptomatic hyperlactatemia (0.053 +/- 0.027 vs. 0.053 +/- 0.02 1, respectively; P > 0.05). This could be explained by the yet unclear significance of asymptomatic hyperlactatemia, even in a setting like ours, where lactate levels were measured with close attention to the method of collection and processing. In contrast, the 4 subjects with symptomatic hyperlactatemia/lactic acidosis had a significant increase in their F-2-isoprostanes compared with subjects with asymptomatic sustained hyperlactatemia (0.082 +/- 0.021 vs. 0.053 +/- 0.021, respectively; P < 0.05).
C1 Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA.
   Univ Hosp Cleveland, Cleveland, OH USA.
   Case Western Reserve Univ, Ctr AIDS Res, Cleveland, OH USA.
   Vanderbilt Univ, Ctr Med, Nashville, TN USA.
RP McComsey, GA (reprint author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, 11100 Euclid Ave, Cleveland, OH 44106 USA.
FU NIAID NIH HHS [AI-36219]; NIDDK NIH HHS [DK 48831]; NIGMS NIH HHS [GM
   15431]; NCI NIH HHS [CA 77839]
CR Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4
   Brinkman K, 2001, AIDS, V15, P795, DOI 10.1097/00002030-200104130-00016
   Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI 10.1097/01.QAI.0000017962.22053.0E
   de la Asuncion JG, 1998, J CLIN INVEST, V102, P4, DOI 10.1172/JCI1418
   Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288                                                       
   Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002                                                
   McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001                                                
   MCCOMSEY G, 2002, 42 INT C ANT AG CHEM
   MCCOMSEY G, 2001, 3 INT WORKSH ADV DRU
   Miller KD, 2000, ANN INTERN MED, V133, P192, DOI 10.7326/0003-4819-133-3-200008010-00010
   MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804
   Morrow JD, 1999, METHOD ENZYMOL, V300, P3
   MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383
   Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340
   MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143
   Moyle Graeme, 2002, AIDS Read, V12, P344
   NOLAN D, 2001, 8 EUR C CLIN ASP TRE
   PAULIK M, 2000, ANTIVIR THER, V5, P6
   PICCOLO G, 1991, J NEUROL SCI, V105, P57, DOI 10.1016/0022-510X(91)90118-Q
   Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6
   Saint-Marc T, 1999, AIDS, V13, P1659, DOI 10.1097/00002030-199909100-00009
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Walker UA, 2002, J ACQ IMMUN DEF SYND, V29, P117
   Wei YH, 2001, CHINESE J PHYSIOL, V44, P1
   Yamaguchi T, 2002, EUR J BIOCHEM, V269, P2782, DOI 10.1046/j.1432-1033.2002.02954.x
NR 27
TC 21
Z9 21
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2003
VL 34
IS 1
BP 45
EP 49
DI 10.1097/00126334-200309010-00006                                        
          
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 719YL
UT WOS:000185232600006
PM 14501792
OA gold
DA 2018-01-05
ER

PT J
AU Nolting, B
   Yu, JJ
   Liu, GY
   Cho, SJ
   Kauzlarich, S
   Gervay-Hague, J
AF Nolting, B
   Yu, JJ
   Liu, GY
   Cho, SJ
   Kauzlarich, S
   Gervay-Hague, J
TI Synthesis of gold glyconanoparticles and biological evaluation of
   recombinant Gp120 interactions
SO LANGMUIR
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 GP120; GALACTOSYL CERAMIDE;
   QUANTITATIVE MEASUREMENTS; AIDS PATIENTS; HUMAN SPERM; HTLV-III;
   BINDING; ANALOGS; INHIBITION
AB As part of our continuing efforts to study the molecular events involved in HIV recognition of mucosal membrane cells, we are studying the interactions of the HIV-associated glycoprotein gp120, with the cellular receptor GalCer. In this work, we report investigations of multivalent interactions of Au glyconanoparticles containing galactosyl and glucosyl headgroups with recombinant gp120. These particles were prepared from disulfides containing C-glycosides linked to triethylene glycol via an amide bond using a modification of the Brust method.(1) Results from transmission electron microscopy, atomic force microscopy, and UV-vis absorption spectroscopy data are consistent with an average particle diameter of 2 nm. Elemental analyses indicate that the average composition of the particles is 1.6:1 Au: carbohydrate. A biotin-NeutrAvidin adhesion assay was used to evaluate the relative ability of carbohydrate disulfides and Au glyconanopraticles to displace rgp120 from plate-bound GalCer. The data indicate that divalent disulfides were less than 12% as active as biotinylated GalCer, a water-soluble surrogate of GalCer. However, when these same carbohydrates were presented in a polyvalent display on gold, they were greater than 300 times more active than the disulfides and at least 20 times more active than biotinylated GalCer. These results collectively demonstrate the potential utility of polyvalent ligand arrays on nanoplatforms.
C1 Univ Calif Davis, Dept Chem, Davis, CA 95616 USA.
RP Gervay-Hague, J (reprint author), Univ Calif Davis, Dept Chem, 1 Shields Ave, Davis, CA 95616 USA.
RI Kauzlarich, Susan/H-1439-2011
CR ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290                                                         
   Badia A, 1996, LANGMUIR, V12, P1262, DOI 10.1021/la9510487                                                               
   Badia A, 1996, CHEM-EUR J, V2, P359, DOI 10.1002/chem.19960020318                                                        
   BARIN F, 1985, SCIENCE, V228, P1094, DOI 10.1126/science.2986291
   BEMILLER JN, 1990, CARBOHYD RES, V200, P111, DOI 10.1016/0008-6215(90)84186-X                                                    
   BERTOZZI CR, 1992, J AM CHEM SOC, V114, P10639, DOI 10.1021/ja00052a072                                                             
   Bhat AS, 2001, ORG LETT, V3, P2081, DOI 10.1021/ol0160405
   Brogi A, 1996, AIDS RES HUM RETROV, V12, P483, DOI 10.1089/aid.1996.12.483                                                         
   BROGI A, 1995, J SUBMICR CYTOL PATH, V27, P565
   BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801                                                            
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Choi SK, 1997, J AM CHEM SOC, V119, P4103, DOI 10.1021/ja963519x                                                               
   Conboy JC, 2002, J AM CHEM SOC, V124, P968, DOI 10.1021/ja011225s
   Conboy JC, 2000, ANGEW CHEM INT EDIT, V39, P2882, DOI 10.1002/1521-3773(20000818)39:16<2882::AID-ANIE2882>3.0.CO;2-M                  
   COXON B, 1963, J AM CHEM SOC, V85, P2637, DOI 10.1021/ja00900a026                                                             
   COXON B, 1964, J AM CHEM SOC, V86, P922, DOI 10.1021/ja01059a038                                                             
   de la Fuente J.M., 2001, ANGEW CHEM INT EDIT, V40, P2257, DOI DOI 10.1002/1521-3773(20010618)40:12
   Faroux-Corlay B, 2000, CARBOHYD RES, V327, P223, DOI 10.1016/S0008-6215(00)00055-0                                                   
   Gu YM, 2001, ANGEW CHEM INT EDIT, V40, P2320, DOI 10.1002/1521-3773(20010618)40:12<2320::AID-ANIE2320>3.0.CO;2-X                  
   HAROUSE JM, 1989, J VIROL, V63, P2527
   HAROUSE JM, 1991, SCIENCE, V253, P320, DOI 10.1126/science.1857969
   Hernaiz MJ, 2002, ANGEW CHEM INT EDIT, V41, P1554, DOI 10.1002/1521-3773(20020503)41:9<1554::AID-ANIE1554>3.0.CO;2-3
   Hostetler MJ, 1998, LANGMUIR, V14, P17, DOI 10.1021/la970588w                                                               
   HOUGH L, 1962, J CHEM SOC, P4633, DOI 10.1039/jr9620004633                                                            
   Houseman BT, 2002, TOP CURR CHEM, V218, P1
   KOPF J, 1989, CARBOHYD RES, V186, P1, DOI 10.1016/0008-6215(89)84001-7                                                    
   LaBell RY, 2002, BIOCONJUGATE CHEM, V13, P143, DOI 10.1021/bc015533r
   LAI W, 1993, CARBOHYD RES, V250, P185, DOI 10.1016/0008-6215(93)84165-3                                                    
   Liang R, 1997, P NATL ACAD SCI USA, V94, P10554, DOI 10.1073/pnas.94.20.10554
   Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4
   LIU GY, 1994, J CHEM PHYS, V101, P4301, DOI 10.1063/1.467479                                                                
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   MCALARNEY T, 1994, J NEUROSCI RES, V37, P453, DOI 10.1002/jnr.490370404
   MCKEATING JA, 1989, AIDS, V3, pS35, DOI 10.1097/00002030-198901001-00005                                                
   McReynolds KD, 1999, BIOCONJUGATE CHEM, V10, P1021, DOI 10.1021/bc990050x                                                               
   McReynolds KD, 2002, BIOORGAN MED CHEM, V10, P625, DOI 10.1016/S0968-0896(01)00325-X
   Mulvaney P, 1996, LANGMUIR, V12, P788, DOI 10.1021/la9502711                                                               
   PETRUS L, 1983, COLLECT CZECH CHEM C, V48, P1867, DOI 10.1135/cccc19831867                                                            
   PETRUS L, 1982, CHEM ZVESTI, V36, P103
   Rico-Lattes I, 1998, NEW J CHEM, V22, P451, DOI 10.1039/a709184b                                                                
   RICOLATTES I, 1995, NEW J CHEM, V19, P341
   Schaaff TG, 1997, J PHYS CHEM B, V101, P7885, DOI 10.1021/jp971438x
   Sigal GB, 1996, J AM CHEM SOC, V118, P3789, DOI 10.1021/ja953729u                                                               
   SOWDEN JC, 1961, J ORG CHEM, V26, P1974, DOI 10.1021/jo01065a069                                                             
   SOWDEN JC, 1964, J ORG CHEM, V29, P130, DOI 10.1021/jo01024a029                                                             
   SOWDEN JC, 1946, J AM CHEM SOC, V68, P1511, DOI 10.1021/ja01212a037                                                             
   STOIBER H, 1995, IMMUNOBIOLOGY, V193, P98, DOI 10.1016/S0171-2985(11)80158-0                                                   
   Terrill RH, 1995, J AM CHEM SOC, V117, P12537, DOI 10.1021/ja00155a017                                                             
   UNDERWOOD S, 1994, LANGMUIR, V10, P3427, DOI 10.1021/la00022a011                                                             
   Vezmar I, 1997, Z PHYS D ATOM MOL CL, V40, P147, DOI 10.1007/s004600050180
   YAHI N, 1992, J VIROL, V66, P4848
   PENADES S, Patent No. 0232404
NR 52
TC 56
Z9 62
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0743-7463
J9 LANGMUIR
JI Langmuir
PD AUG 5
PY 2003
VL 19
IS 16
BP 6465
EP 6473
DI 10.1021/la034414s
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Materials Science,
   Multidisciplinary
SC Chemistry; Materials Science
GA 707TU
UT WOS:000184526600020
DA 2018-01-05
ER

PT J
AU Joch, C
AF Joch, C
TI The safety of fibrin sealants
SO CARDIOVASCULAR SURGERY
LA English
DT Article
DE fibrin sealants; safety; isolation and purification; standards; adverse
   events; aprotinin; antifibrinolytic agents; biological products; drug
   contamination
ID FACTOR-VIII CONCENTRATE; DRY HEAT-TREATMENT; BLOOD PRODUCTS;
   SOLVENT-DETERGENT; VIRAL-INFECTIONS; BOVINE THROMBIN; PARVOVIRUS B19;
   CLINICAL USE; HEPATITIS-A; GLUE
AB Fibrin sealants are prepared from fibrinogen, thrombin and sometimes also factor XIII that have been purified from human plasma. Bovine aprotinin is also included in some preparations. Each of these components has the potential to carry blood-borne pathogens, albeit at a very low frequency. In order to minimize the risk of viral transmission from commercial fibrin sealants, plasma donations undergo a series of procedures that contribute to avoiding, inactivating and eliminating potential contaminants.
   The procedures for selection and screening of plasma donors, and the testing of donated plasma, incorporates highly sensitive molecular techniques (e.g. PCR testing) and contributes significantly to reducing the theoretical possibility of viral transmission. The starting material for bovine aprotinin is also carefully selected, and the manufacturing process rigorously assessed, to minimize the putative risk of transmission of bovine spongiform encephalopathies.
   The manufacturing process for commercial fibrin sealants comprises a range of procedures, including heat treatment (e.g. pasteurization, dry or vapor heating), filtration, solvent/detergent treatment, precipitation, pH treatment and chromatography. Some steps are an inherent part of the purification process and others (e.g. pasteurization, nanofiltration) are deliberately introduced to inactivate/eliminate potential pathogens.
   Current manufacturing processes provide a very high degree of safety for fibrin sealants. In 20 years of worldwide use, there have been no known cases of hepatitis or HIV transmission associated with the use of commercial fibrin sealants. (C) 2003 The International Society for Cardiovascular Surgery. Published by Elsevier Ltd. All rights reserved.
C1 Aventis Behring GmbH, Global Drug Surveillance, D-35002 Marburg, Germany.
RP Joch, C (reprint author), Aventis Behring GmbH, Global Drug Surveillance, POB 1230, D-35002 Marburg, Germany.
CR ALVING BM, 1995, TRANSFUSION, V35, P783, DOI 10.1046/j.1537-2995.1995.35996029166.x
   Alving BM, 1996, TRANSFUSION, V36, P845
   BANNINGER H, 1993, BRIT J HAEMATOL, V85, P528
   *BAXT HEALTHC CORP, 1998, 2 COMP FIBR SEAL VAP
   BERGUER R, 1991, J TRAUMA, V31, P408, DOI 10.1097/00005373-199103000-00018
   Cardoso MD, 1996, VOX SANG, V71, P184, DOI 10.1046/j.1423-0410.1996.7130184.x
   Christie RJ, 1997, SURGERY, V121, P708, DOI 10.1016/S0039-6060(97)90061-1
   *COMM PROPR MED PR, 1998, CPMPBWP26995 EMEA
   DARLING AJ, 1993, DEV BIOL STAND, V81, P221
   DESFORGES JF, 1995, JAMA-J AM MED ASSOC, V274, P1374
   Dichtelmuller H, 1996, BIOLOGICALS, V24, P125, DOI 10.1006/biol.1996.0016
   Dodd RY, 2000, ANN MED, V32, P469, DOI 10.3109/07853890009002022
   Erhardt A, 1996, J CLIN MICROBIOL, V34, P1885
   Foster PR, 2000, ANN MED, V32, P501, DOI 10.3109/07853890009002026
   Greenhalgh DG, 1999, J TRAUMA, V46, P433, DOI 10.1097/00005373-199903000-00014
   HILFENHAUS J, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1617
   Hilfenhaus J, 1997, TRANSFUSION, V37, P935, DOI 10.1046/j.1537-2995.1997.37997454021.x
   Hino M, 2000, BRIT J HAEMATOL, V108, P194, DOI 10.1046/j.1365-2141.2000.01818.x
   Holland PV, 1996, NEW ENGL J MED, V334, P1734, DOI 10.1056/NEJM199606273342609
   HOROWITZ B, 1993, DEV BIOL STAND, V81, P147
   Jackson MR, 1996, BLOOD COAGUL FIBRIN, V7, P737, DOI 10.1097/00001721-199611000-00001
   JOCH C, 1999, 9 WORLD C CARD THOR
   JOHNSON Z, 1995, INT J EPIDEMIOL, V24, P821, DOI 10.1093/ije/24.4.821
   KEDDA MA, 1995, HEPATOLOGY, V22, P1363, DOI 10.1016/0270-9139(95)90137-X
   Martinowitz U, 1997, THROMB HAEMOSTASIS, V78, P661
   *P EHRL I, 1995, BEK MASSN ABW ARZN V
   Radosevich M, 1997, VOX SANG, V72, P133, DOI 10.1046/j.1423-0410.1997.7230133.x
   Santagostino E, 1997, TRANSFUSION, V37, P517, DOI 10.1046/j.1537-2995.1997.37597293884.x
   Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601
   Smith MP, 1997, THROMB HAEMOSTASIS, V77, P406
   Tock B, 1998, HAEMOPHILIA, V4, P449, DOI 10.1046/j.1365-2516.1998.440449.x
NR 31
TC 42
Z9 45
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-2109
J9 CARDIOVASC SURG
JI Cardiovasc. Surg.
PD AUG
PY 2003
VL 11
SU 1
BP 23
EP 28
DI 10.1016/S0967-2109(03)00068-1
PG 6
WC Cardiac & Cardiovascular Systems; Surgery
SC Cardiovascular System & Cardiology; Surgery
GA 724YT
UT WOS:000185516400006
PM 12869985
DA 2018-01-05
ER

PT J
AU Sheu, E
   Rothman, S
   German, M
   Wang, XG
   Finer, M
   McMahon, BM
AF Sheu, E
   Rothman, S
   German, M
   Wang, XG
   Finer, M
   McMahon, BM
TI The Gene Pill (R) and its therapeutic applications
SO CURRENT OPINION IN MOLECULAR THERAPEUTICS
LA English
DT Article
DE DNA; gastrointestinal; gene therapy; oral administration; protein
   replacement
ID ENTERIC-COATED MICROSPHERES; CHITOSAN-DNA NANOPARTICLES; HIV ENVELOPE
   GLYCOPROTEIN; GENE DELIVERY; PLASMID DNA; BIODEGRADABLE MICROPARTICLES;
   CATIONIC LIPOSOMES; NUCLEAR IMPORT; IN-VIVO; PEPTIDE
AB Gene delivery represents a revolutionary therapeutic approach with the potential for sustained protein production by the human body, leading to a convenient and effective method for systemic delivery of protein drugs. In this review, advantages of an orally administered DNA formulation, Gene Pill(R), are presented. Unlike previously described DNA delivery approaches, the Gene Pill enables DNA delivery in a non-invasive manner, leading to the secretion of therapeutic proteins into a patient's blood, supplanting the need for injection of therapeutic protein products. The Gene Pill also has potential for the development of oral DNA vaccination through expression of protein antigens in the gut lymphoid tissue. This approach limits the biodistribution of the delivered DNA to the gut and retains all of the safety advantages of non-viral gene delivery, including repeat dosing. Development of an oral DNA formulation involves overcoming several challenges, including depurination by low pH in the stomach, enzymatic degradation by DNases in the gut, crossing the physical barrier imposed by the mucus layer, cell entry, intracellular trafficking and nuclear uptake. The advantages of the Gene Pill technology, as well as challenges for its development, are presented in this review.
C1 Genter Inc, Alameda, CA 94502 USA.
   Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP McMahon, BM (reprint author), Genter Inc, 1650 Harbor Bay Pkwy, Alameda, CA 94502 USA.
CR AHEARN A, 1999, GENE THER MOL BIOL, V4, P159
   Baluom M, 1997, INT J PHARM, V154, P235, DOI 10.1016/S0378-5173(97)00140-3
   Behr JP, 1996, M S-MED SCI, V12, P56
   Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3                                                   
   CLARK MA, 2002, VACCINE, V20, P208
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Fahr A, 2002, J LIPOSOME RES, V12, P37, DOI 10.1081/LPR-120004774
   FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413
   FLORENCE AT, 1995, J CONTROL RELEASE, V36, P39, DOI 10.1016/0168-3659(95)00059-H                                                    
   Fooks A R, 2000, Dev Biol (Basel), V104, P65
   Gomez-Vargas A, 2003, MOL THER, V7, pS457
   Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513
   Hagstrom JE, 1997, J CELL SCI, V110, P2323
   HART SL, 1995, GENE THER, V2, P552
   Hashida M, 2001, ADV DRUG DELIVER REV, V52, P187, DOI 10.1016/S0169-409X(01)00209-5                                                   
   Jones D H, 1997, Behring Inst Mitt, P220
   Jones DH, 1998, DEV BIOL STAND, V92, P149
   Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6
   JUNGINGER HE, 1990, ACTA PHARM TECHNOL, V36, P110
   Kamiya H, 2002, BIOCHEM BIOPH RES CO, V298, P591, DOI 10.1016/S0006-291X(02)02485-3                                                   
   Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093
   KLIPSTEIN FA, 1983, INFECT IMMUN, V39, P1000
   Kuo JHS, 2003, INT J PHARM, V257, P75, DOI 10.1016/S0378-5173(03)00107-8
   Lieber A, 2000, J VIROL, V74, P721, DOI 10.1128/JVI.74.2.721-734.2000                                                   
   LIN SY, 1991, J MICROENCAPSUL, V8, P317, DOI 10.3109/02652049109069558
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   LIU G, 2003, J BIOCH
   MAHARAJ I, 1984, J PHARM SCI, V73, P39, DOI 10.1002/jps.2600730110
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Mathiowitz E, 1997, NATURE, V386, P410, DOI 10.1038/386410a0
   Mathiowitz E, 2001, United States Patent, Patent No. [US 6262034 B1, 6262034]
   McKenzie DL, 2000, J BIOL CHEM, V275, P9970, DOI 10.1074/jbc.275.14.9970
   MORISHITA I, 1993, INT J PHARM, V91, P29, DOI 10.1016/0378-5173(93)90418-F
   Nchinda Godwin, 2002, BMC Biotechnol, V2, P12, DOI 10.1186/1472-6750-2-12
   Norris DA, 1998, ADV DRUG DELIVER REV, V34, P135, DOI 10.1016/S0169-409X(98)00037-4                                                   
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Pouton CW, 1998, ADV DRUG DELIVER REV, V34, P3, DOI 10.1016/S0169-409X(98)00048-9                                                   
   Prabha S, 2002, INT J PHARM, V244, P105, DOI 10.1016/S0378-5173(02)00315-0
   Robertson D, 2001, NAT BIOTECHNOL, V19, P604, DOI 10.1038/90188                                                                   
   Roy K, 1999, NAT MED, V5, P387
   Salman H, 2001, P NATL ACAD SCI USA, V98, P7247, DOI 10.1073/pnas.121067698
   Tagawa T, 2002, GENE THER, V9, P564, DOI 10.1038/sj.gt.3301686
   Walter E, 2001, J CONTROL RELEASE, V76, P149, DOI 10.1016/S0168-3659(01)00413-8                                                   
   Wang J, 2001, J AM CHEM SOC, V123, P9480, DOI 10.1021/ja016062m
   Wierzbicki A, 2002, VACCINE, V20, P1295, DOI 10.1016/S0264-410X(01)00480-7
   Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187                                                                 
   Wilke M, 1996, GENE THER, V3, P1133
   Yang YH, 2001, J PHARM SCI, V90, P2010, DOI 10.1002/jps.1152
   MATHIOWITZ E, 2000, Patent No. 6143211
   TRUONG VL, 2002, Patent No. 06410517
   JULES J, 2001, Patent No. 06248720
   GERMAN MS, 2001, Patent No. 06258789
   GERMAN MS, 2001, Patent No. 06225290
   ROY K, 1999, Patent No. 05972707
NR 55
TC 7
Z9 7
U1 0
U2 3
PU CURRENT DRUGS LTD
PI LONDON
PA MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1P 6LB, ENGLAND
SN 1464-8431
J9 CURR OPIN MOL THER
JI Curr. Opin. Mol. Ther.
PD AUG
PY 2003
VL 5
IS 4
BP 420
EP 427
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 718UP
UT WOS:000185165100013
PM 14513686
DA 2018-01-05
ER

PT J
AU Bocklandt, S
   Blumberg, PM
   Hamer, DH
AF Bocklandt, S
   Blumberg, PM
   Hamer, DH
TI Activation of latent HIV-1 expression by the potent anti-tumor promoter
   12-deoxyphorbol 13-phenylacetate
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE human immunodeficiency virus; phorbol ester; immunotoxin; anti-viral
   compounds
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN-KINASE-C; ACTIVE ANTIRETROVIRAL
   THERAPY; T-CELL ACTIVATION; CD-1 MOUSE SKIN; NF-KAPPA-B; PHORBOL ESTER;
   HIV-1-INFECTED PATIENTS; SIGNAL-TRANSDUCTION; IMMUNE-ACTIVATION
AB Agents that induce HIV-1 out of latency would be useful adjuvants for currently available anti-retroviral therapy. We report that nanomolar concentrations of 12-deoxyphorbol 13-phenylacetate (DPP), an anti-tumor-promoting phorbol ester originally isolated from a West African plant, induce the expression of HIV-1 in latently infected T cells and render them sensitive to killing by an immunotoxin targeted to the viral envelope glycoprotein. DPP also regulates an extensive series of genes under the control of protein kinase C, including several involved in T cell activation and cytoskeleton reorganization, and represses expression of the HIV-1 receptor CD4 and coreceptor CXCR4. DPP is 20-40-fold more potent than the related phorbol ester prostratin, probably due to its more lipophilic side chain structure. The combination of high potency and anti-tumor promoting activity make DPP an attractive candidate for the adjunctive therapy of persistent HIV-1 infection. Published by Elsevier B.V.
C1 NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA.
   NCI, Cellular Carcinogenesis & Tumor Promot Lab, Bethesda, MD 20892 USA.
RP Hamer, DH (reprint author), NCI, Biochem Lab, NIH, Bld 37 Rm 6002,9000 Rockville Pike, Bethesda, MD 20892 USA.
RI Hamer, Dean/L-1248-2015
OI Hamer, Dean/0000-0002-6211-5781
CR Bartlett JA, 2002, AIDS RES HUM RETROV, V18, P535, DOI 10.1089/088922202753747888                                                      
   Blankson JN, 2002, ANNU REV MED, V53, P557, DOI 10.1146/annurev.med.53.082901.104024
   BLUMBERG PM, 1994, PROG CLIN BIOL RES, V387, P3
   Bogi K, 1998, CANCER RES, V58, P1423
   Cao WS, 2002, AM J PHYSIOL-CELL PH, V283, pC327, DOI 10.1152/ajpcell.00442.2001
   CASHMORE A R, 1976, Tetrahedron Letters, V20, P1737
   Chew CS, 2000, J CELL SCI, V113, P2035
   Chun TW, 1998, J EXP MED, V188, P83, DOI 10.1084/jem.188.1.83
   Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958
   Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498
   Clamp A, 2002, ANTI-CANCER DRUG, V13, P673, DOI 10.1097/00001813-200208000-00001                                                
   CLOUSE KA, 1989, J IMMUNOL, V142, P431
   COBB MH, 1994, SEMIN CANCER BIOL, V5, P261
   Dybul M, 2002, J INFECT DIS, V185, P61, DOI 10.1086/338123                                                                  
   Eisen MB, 1999, METHOD ENZYMOL, V303, P179
   EVANS FJ, 1979, PAX ACTA PHARM TOXIC, V45, P181
   Fichter M, 1997, ONCOGENE, V14, P2817, DOI 10.1038/sj.onc.1201127
   FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365
   Fraser C, 2000, AIDS, V14, P659, DOI 10.1097/00002030-200004140-00005
   Gulakowski RJ, 1997, ANTIVIR RES, V33, P87, DOI 10.1016/S0166-3542(96)01004-2
   GUSTAFSON KR, 1992, J MED CHEM, V35, P1978, DOI 10.1021/jm00089a006
   HAN XM, 1992, J VIROL, V66, P4065
   HERGENHAHN M, 1984, J CANCER RES CLIN, V108, P98, DOI 10.1007/BF00390980
   Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073
   Ho DD, 1998, SCIENCE, V280, P1866, DOI 10.1126/science.280.5371.1866
   JAKOBOVITS A, 1990, EMBO J, V9, P1165
   Kagnoff MF, 1999, J INFECT DIS, V179, pS444, DOI 10.1086/314801                                                                  
   Kalams SA, 1999, J VIROL, V73, P6721
   Kanashiro CA, 1998, CLIN EXP PHARMACOL P, V25, P974, DOI 10.1111/j.1440-1681.1998.tb02170.x                                              
   Kelso A, 2002, INT IMMUNOL, V14, P605, DOI 10.1093/intimm/dxf028
   KIM CH, 1994, BIOCHEM BIOPH RES CO, V199, P292, DOI 10.1006/bbrc.1994.1227
   Kirchner J, 1999, J EXP MED, V190, P217, DOI 10.1084/jem.190.2.217
   Korin YD, 2002, J VIROL, V76, P8118, DOI 10.1128/JVI.76.16.8118-8123.2002
   Kulkosky J, 2001, BLOOD, V98, P3006, DOI 10.1182/blood.V98.10.3006
   Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350
   Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797
   Marquez VE, 1999, PHARMACOL THERAPEUT, V82, P251, DOI 10.1016/S0163-7258(98)00048-5
   Martinez-Picado J, 2002, AIDS, V16, P895, DOI 10.1097/00002030-200204120-00009
   Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X
   MCHUGH L, 2002, J BIOL CHEM
   NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0
   Nicoll SB, 2002, BIOCHEM BIOPH RES CO, V292, P819, DOI 10.1006/bbrc.2002.6697
   NISHIZUKA Y, 1995, FASEB J, V9, P484
   Ogg GS, 1999, J VIROL, V73, P797
   Pomerantz RJ, 2002, CLIN INFECT DIS, V34, P91, DOI 10.1086/338256
   Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012
   Rabinovich GA, 2002, TRENDS IMMUNOL, V23, P313, DOI 10.1016/S1471-4906(02)02232-9
   Roebuck KA, 1996, AIDS, V10, P819, DOI 10.1097/00002030-199607000-00004                                                
   ROSENBERG ZF, 1989, CLIN IMMUNOL IMMUNOP, V50, P149
   SCHMIDT RJ, 1980, ARCH TOXICOL, V44, P279, DOI 10.1007/BF00278035
   Seimiya M, 2003, INT J ONCOL, V22, P301
   Sonza S, 2001, AIDS PATIENT CARE ST, V15, P511, DOI 10.1089/108729101753205676                                                      
   Strair RK, 2002, CLIN CANCER RES, V8, P2512
   SZALLASI Z, 1993, CANCER RES, V53, P2507
   SZALLASI Z, 1992, CARCINOGENESIS, V13, P2161, DOI 10.1093/carcin/13.11.2161
   Van Praag RME, 2001, J CLIN IMMUNOL, V21, P218, DOI 10.1023/A:1011091300321
   WILLIAMSON EM, 1981, BIOCHEM PHARMACOL, V30, P2691, DOI 10.1016/0006-2952(81)90539-6                                                    
   Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981
   ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X
NR 59
TC 60
Z9 64
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-3542
J9 ANTIVIR RES
JI Antiviral Res.
PD JUL
PY 2003
VL 59
IS 2
BP 89
EP 98
DI 10.1016/S0166-3542(03)00034-2
PG 10
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 714DD
UT WOS:000184896300002
PM 12895692
DA 2018-01-05
ER

PT J
AU El-Brollosy, NR
   Pedersen, EB
   Nielsen, C
AF El-Brollosy, NR
   Pedersen, EB
   Nielsen, C
TI Synthesis of novel MKC-442 analogues with potent activities against
   HIV-1
SO ARCHIV DER PHARMAZIE
LA English
DT Article
DE non-nucleoside reverse transcriptase inhibitors; MKC-442 analogues;
   human immunodeficiency virus (HIV-1); HIV-1 mutants;
   alkenyloxymethyluracils
ID IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; NONNUCLEOSIDE
   INHIBITORS; ANTI-HIV-1 AGENTS; HTLV-III/LAV;
   1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE; DERIVATIVES; HEPT;
   INFECTIVITY; RESISTANCE
AB Bis(alken-1-yloxy)methanes 2 were synthesized by reacting 2-cyclohexenol, 3-cyclohexenylmethanol, cinnamyl alcohol and its (x-methyl analogue with dibromomethane. Condensation of 2 with 5,6-disubstituted uracil derivatives 1 resulted in the desired MKC-442 analogues 3-6. The most active compounds, N-1 cinnamyloxymethyl- and N-1 2-methyl-3-phenylallyloxymethyl substituted 5-ethyl-6-(3,5dimethylbenzyl)uracils (5b and 6b), showed activity against wild-type HIV-1 in the nanomolar range, and against Y181C and Y181C+K103N, mutant strains known to be resistant to MKC-442, in the micromolar range.
C1 Univ So Denmark, Nucl Acid Ctr, Dept Chem, DK-6230 Odense M, Denmark.
   Statens Serum Inst, Dept Virol, Retrovirus Lab, DK-2300 Copenhagen, Denmark.
RP Pedersen, EB (reprint author), Univ So Denmark, Nucl Acid Ctr, Dept Chem, Campusvej 55, DK-6230 Odense M, Denmark.
EM EBP@Chem.sdu.dk
OI Pedersen, Erik B./0000-0002-7917-2379
CR BABA M, 1995, NUCLEOS NUCLEOT, V14, P575, DOI 10.1080/15257779508012431
   BALZARINI J, 1993, MOL PHARMACOL, V44, P694
   Danel K, 1996, J MED CHEM, V39, P2427, DOI 10.1021/jm9600499
   DANEL K, 1995, SYNTHESIS-STUTTGART, P934
   El-Brollosy NR, 2002, J MED CHEM, V45, P5721, DOI 10.1021/jm020949r
   Hara H, 1997, AIDS RES HUM RETROV, V13, P695, DOI 10.1089/aid.1997.13.695                                                         
   HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081                                                         
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   KOHISTAEDT LA, 1992, SCIENCE, V256, P1783
   LARSEN JS, 2000, J CHEM SOC P1, V18, P3035
   Leonard J., 1995, ADV PRACTICAL ORGANI
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   MIYASAKA T, 1989, J MED CHEM, V32, P2507, DOI 10.1021/jm00132a002                                                             
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NAZARETYAN AK, 1985, J APPL CHEM-USSR+, V58, P2396
   NUNBERG JH, 1991, J VIROL, V65, P4887
   PEDERSEN EB, 1998, RUSS J HIV AIDS RELA, V2, P73
   Petersen L, 2001, SYNTHESIS-STUTTGART, P559
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   Szczech GM, 2000, ANTIMICROB AGENTS CH, V44, P123, DOI 10.1128/AAC.44.1.123-130.2000                                                   
   TANAKA H, 1995, J MED CHEM, V38, P2860, DOI 10.1021/jm00015a008
   VORBRUGGEN H, 1981, CHEM BER-RECL, V114, P1234, DOI 10.1002/cber.19811140404
   YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840                                                         
   MIYASAKA T, 1991, Patent No. 420763
   MIYASAKA T, 1991, Patent No. 449726
NR 29
TC 15
Z9 15
U1 0
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY
SN 0365-6233
J9 ARCH PHARM
JI Arch. Pharm.
PD JUL
PY 2003
VL 336
IS 4-5
BP 236
EP 241
DI 10.1002/ardp.200300742
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA 710AZ
UT WOS:000184659800006
PM 12916058
DA 2018-01-05
ER

PT J
AU Horiya, S
   Li, XG
   Kawai, G
   Saito, R
   Katoh, A
   Kobayashi, K
   Harada, K
AF Horiya, S
   Li, XG
   Kawai, G
   Saito, R
   Katoh, A
   Kobayashi, K
   Harada, K
TI RNA LEGO: Magnesium-dependent formation of specific RNA assemblies
   through kissing interactions
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID DIMERIZATION INITIATION SITE; HIV-1 GENOMIC RNA; LOOP-LOOP COMPLEX;
   TERTIARY INTERACTIONS; ANTISENSE RNA; STABLE DIMER; IN-VITRO; DNA;
   RIBOZYME; MODEL
AB The high affinity and specificity of nucleic acid base complementarity has been proven to be a powerful method for constructing specific molecular assemblies. On the other hand, recent structural studies of RNA have revealed the wide range of tertiary interactions utilized in RNA folding, which may potentially be used as tools for the design of specific macromolecular assemblies. Here, RNA building blocks containing two hairpin loops, based on the dimerization initiation site (DIS) of HIV RNA, connected by a short linker were used to construct large RNA assemblies through hairpin loop-loop ("kissing") interactions. We show that specific linear and circular assemblies can be constructed in a magnesium-dependent manner using several non-self-complementary loop-loop interactions designed in this study. These results show that the use of RNA tertiary interactions may broaden the reportoire of nucleic acid-based nanostructures.
C1 Tokyo Gakugei Univ, Dept Life Sci, Koganei, Tokyo 1848501, Japan.
   Chiba Inst Technol, Dept Ind Chem, Narashino, Chiba 2750016, Japan.
   Seikei Univ, Fac Engn, Dept Appl Chem, Musashino, Tokyo 1808633, Japan.
RP Harada, K (reprint author), Tokyo Gakugei Univ, Dept Life Sci, Koganei, Tokyo 1848501, Japan.
CR ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651
   Andersen AA, 2001, P NATL ACAD SCI USA, V98, P7730, DOI 10.1073/pnas.141039198
   Barbault F, 2002, J BIOMOL STRUCT DYN, V19, P649, DOI 10.1080/07391102.2002.10506771                                                  
   BATEY RT, 1999, ANGEW CHEM INT EDIT, V38, P2326
   Benenson Y, 2001, NATURE, V414, P430, DOI 10.1038/35106533
   BURKARD ME, 1999, RNA WORLD, P233
   CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046
   Dardel F, 1998, NUCLEIC ACIDS RES, V26, P3567, DOI 10.1093/nar/26.15.3567
   EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215
   Ennifar E, 2001, NAT STRUCT BIOL, V8, P1064, DOI 10.1038/nsb727                                                                  
   GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275
   Hermann T, 1999, J MOL BIOL, V294, P829, DOI 10.1006/jmbi.1999.3312
   Ikawa Y, 1997, NUCLEIC ACIDS RES, V25, P1761, DOI 10.1093/nar/25.9.1761
   Jaeger L, 2000, ANGEW CHEM INT EDIT, V39, P2521, DOI 10.1002/1521-3773(20000717)39:14<2521::AID-ANIE2521>3.0.CO;2-P                  
   Jaeger L, 2001, NUCLEIC ACIDS RES, V29, P455, DOI 10.1093/nar/29.2.455
   Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982
   KLUG A, 1983, ANGEW CHEM INT EDIT, V22, P565, DOI 10.1002/anie.198305653                                                          
   Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f                                                               
   Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0
   Li YF, 1999, CURR OPIN STRUC BIOL, V9, P315, DOI 10.1016/S0959-440X(99)80042-6
   Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698
   Mao CD, 1999, NATURE, V397, P144
   Mao CD, 2000, NATURE, V407, P493
   Mujeeb A, 1998, NAT STRUCT BIOL, V5, P432, DOI 10.1038/nsb0698-432
   Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686                                                        
   Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s
   Paillart JC, 1996, P NATL ACAD SCI USA, V93, P5572, DOI 10.1073/pnas.93.11.5572
   Seeman NC, 1999, TRENDS BIOTECHNOL, V17, P437, DOI 10.1016/S0167-7799(99)01360-8
   Seeman NC, 2002, P NATL ACAD SCI USA, V99, P6451, DOI 10.1073/pnas.221458298
   SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945
   Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P681, DOI 10.1093/oxfordjournals.jbchem.a022657                                           
   Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635
   Venczel EA, 1996, J MOL BIOL, V257, P219, DOI 10.1006/jmbi.1996.0157                                                          
   WAGNER EGH, 1994, ANNU REV MICROBIOL, V48, P713, DOI 10.1146/annurev.mi.48.100194.003433                                             
   Westhof E, 2000, STRUCT FOLD DES, V8, pR55, DOI 10.1016/S0969-2126(00)00112-X                                                   
   WESTHOF E, 1996, FOLD DES, V1, P78
   Xia TB, 1998, BIOCHEMISTRY-US, V37, P14719, DOI 10.1021/bi9809425                                                               
   Yan H, 2002, NATURE, V415, P62, DOI 10.1038/415062a
   Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524                                                                
   ZEILER BN, 1998, RNA STRUCTURE FUNCTI, P437
NR 40
TC 40
Z9 41
U1 0
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD JUL
PY 2003
VL 10
IS 7
BP 645
EP 654
DI 10.1016/S1074-5521(03)00146-7
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 705CF
UT WOS:000184378100011
PM 12890538
OA gold
DA 2018-01-05
ER

PT J
AU Chew, JL
   Wolfowicz, CB
   Mao, HQ
   Leong, KW
   Chua, KY
AF Chew, JL
   Wolfowicz, CB
   Mao, HQ
   Leong, KW
   Chua, KY
TI Chitosan nanoparticles containing plasmid DNA encoding house dust mite
   allergen, Der p 1 for oral vaccination in mice
SO VACCINE
LA English
DT Article
DE oral; chitosan nanoparticles; Der p 1
ID HIV ENVELOPE GLYCOPROTEIN; SYSTEMIC IMMUNE-RESPONSES; MURINE
   PEYERS-PATCHES; IN-VIVO UPTAKE; DER-P-I; GENE-TRANSFER;
   DERMATOPHAGOIDES-PTERONYSSINUS; BIODEGRADABLE MICROPARTICLES; MUCOSAL
   IMMUNIZATION; ANTIBODY-RESPONSES
AB Our previous studies indicated that intramuscular (i.m.) immunisation with full length Der p 1 cDNA induced significant humoral response to the left domain (approximately corresponding to amino acids 1-116) but not to the right domain (approximately corresponding to amino acids 117-222) of Der p I allergen. This study explored the use of chitosan-DNA nanoparticles for oral immunisation to induce immune responses specific to both the left and right domains of Der p 1. DNA constructs pDer p 1 (1-222) and pDer p 1 (114-222) were complexed with chitosan and delivered orally followed by an i.m. injection of pDer p 1 (1-222) 13 weeks later. Such approach has successfully primed Th1-skewed immune responses against both domains of Der p 1. This strategy could be further optimised for more efficacious gene vaccination for full length Der p 1. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Natl Univ Singapore, Fac Med, Dept Paediat, Singapore 119074, Singapore.
   Johns Hopkins Singapore, Tissue & Therapeut Engn Lab, Singapore 117597, Singapore.
   Natl Univ Singapore, Dept Mat Sci, Singapore 117543, Singapore.
   Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA.
RP Chua, KY (reprint author), Natl Univ Singapore, Fac Med, Dept Paediat, Lower Kent Ridge Rd, Singapore 119074, Singapore.
RI Leong, Kam/A-7270-2009; Mao, Hai-Quan/A-3350-2010
OI Leong, Kam/0000-0002-8133-4955; Mao, Hai-Quan/0000-0002-4262-9988
CR Beier R, 1998, AM J PHYSIOL-GASTR L, V275, pG130
   Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3                                                   
   Bowersock TL, 1999, VACCINE, V17, P1804, DOI 10.1016/S0264-410X(98)00437-X
   CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164
   Chen CJ, 1998, APPL PHYS LETT, V72, P7, DOI 10.1063/1.120629
   CHUA KY, 1992, J ALLERGY CLIN IMMUN, V89, P95, DOI 10.1016/S0091-6749(05)80045-4
   CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175
   Collins SP, 1996, CLIN EXP ALLERGY, V26, P36, DOI 10.1111/j.1365-2222.1996.tb00054.x
   Dodane V, 1999, INT J PHARM, V182, P21, DOI 10.1016/S0378-5173(99)00030-7                                                   
   Duchateau J, 1997, CLIN EXP ALLERGY, V27, P296
   ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E
   Eo SK, 2001, J IMMUNOL, V166, P5473, DOI 10.4049/jimmunol.166.9.5473                                                     
   Etchart N, 1997, J GEN VIROL, V78, P1577, DOI 10.1099/0022-1317-78-7-1577                                                     
   Ferrari F, 1997, FARMACO, V52, P493
   Filipovic-Grcic J, 2001, J MICROENCAPSUL, V18, P3, DOI 10.1080/026520401750038557                                                      
   GREENE WK, 1991, J IMMUNOL, V147, P3768
   Herrmann JE, 1999, VIROLOGY, V259, P148, DOI 10.1006/viro.1999.9751
   Hershberg RM, 2000, IMMUNOL TODAY, V21, P123, DOI 10.1016/S0167-5699(99)01575-3
   Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405
   Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540
   Huang SK, 1997, CURR OPIN IMMUNOL, V9, P800, DOI 10.1016/S0952-7915(97)80181-1
   Illum L, 1998, PHARMACEUT RES, V15, P1326
   Jarnicki AG, 2002, CLIN EXP ALLERGY, V32, P942, DOI 10.1046/j.1365-2745.2002.01407.x
   Jones DH, 1998, DEV BIOL STAND, V92, P149
   Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6
   Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093
   Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8                                                   
   Mathiowitz E, 1997, NATURE, V386, P410, DOI 10.1038/386410a0
   OBRIEN RM, 1994, J ALLERGY CLIN IMMUN, V93, P628, DOI 10.1016/S0091-6749(94)70074-5
   OHAGAN DT, 1993, VACCINE, V11, P149, DOI 10.1016/0264-410X(93)90011-L
   Ranaldi G, 2002, J NUTR BIOCHEM, V13, P157, DOI 10.1016/S0955-2863(01)00208-X
   Richardson SCW, 1999, INT J PHARMACEUT, V178, P231, DOI 10.1016/S0378-5173(98)00378-0
   Roy K, 1999, NAT MED, V5, P387
   Singh M, 2001, VACCINE, V20, P594, DOI 10.1016/S0264-410X(01)00321-8                                                   
   Singla AK, 2001, J PHARM PHARMACOL, V53, P1047, DOI 10.1211/0022357011776441                                                        
   Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4
   THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127, DOI 10.1159/000234488                                                               
   THOMAS WR, 1992, EXP APPL ACAROL, V16, P153, DOI 10.1007/BF01201498
   van der Lubben IM, 2001, EUR J PHARM SCI, V14, P201, DOI 10.1016/S0928-0987(01)00172-5                                                   
   van der Lubben IM, 2001, BIOMATERIALS, V22, P687, DOI 10.1016/S0142-9612(00)00231-3
   Van der Lubben IM, 2001, J DRUG TARGET, V9, P39, DOI 10.3109/10611860108995631                                                       
   Wierzbicki A, 2002, VACCINE, V20, P1295, DOI 10.1016/S0264-410X(01)00480-7
   Wikingsson LD, 2002, VACCINE, V20, P3355, DOI 10.1016/S0264-410X(02)00288-8
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   WOLFOWICZ CB, 2002, VACCINE, V21, P1195
   YSSEL H, 1992, J IMMUNOL, V148, P738
NR 46
TC 86
Z9 105
U1 2
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN 20
PY 2003
VL 21
IS 21-22
BP 2720
EP 2729
DI 10.1016/S0264-410X(03)00228-7
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 693GT
UT WOS:000183709300006
PM 12798609
DA 2018-01-05
ER

PT J
AU Silvestri, R
   De Martino, G
   La Regina, G
   Artico, M
   Massa, S
   Vargiu, L
   Mura, M
   Loi, AG
   Marceddu, T
   La Colla, P
AF Silvestri, R
   De Martino, G
   La Regina, G
   Artico, M
   Massa, S
   Vargiu, L
   Mura, M
   Loi, AG
   Marceddu, T
   La Colla, P
TI Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI
   resistance mutations: Synthesis and SAR studies
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS
AB The potent anti-HIV-1 activities of L-737,126 (2) and PAS sulfones prompted us to design and test against HIV-1 in acutely infected MT-4 cells a number of novel 1- and 3-benzenesulfonylindoles. Indoles belonging to the 1-benzenesulfonyl series were found poorly or totally inactive. On the contrary, some of the 3-benzenesulfonyl derivatives turned out to be as potent as 2, being endowed with potencies in the low nanomolar concentration range. In particular, (2-methylphenyl)sulfonyl (72) and (3-methylphenyl)sulfonyl (73) derivatives showed EC50 values of 1 nM. Introduction of two methyl groups at positions 3 and 5 of the phenyl ring of 2 furnished derivatives (80 and 83) which showed very potent and selective anti-HIV-1 activity not only against the wt strain, but also against mutants carrying NNRTI-resistant mutations at positions 103 and 181 of the reverse transcriptase gene.
C1 Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur, Fondazione Cenci Bolognetti, I-00185 Rome, Italy.
   Univ Siena, Dipartimento Farmaco Chimicotecnol, I-53100 Siena, Italy.
   Univ Cagliari, Cooperat Lab Idenix, I-09042 Monserrato, Cagliari, Italy.
   Univ Cagliari, Dipartimento Biol Sperimentale, I-09042 Monserrato, Cagliari, Italy.
RP Silvestri, R (reprint author), Univ Roma La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur, Fondazione Cenci Bolognetti, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM romano.silvestri@uniroma1.it; placolla@unica.it
RI De Martino, Maria Gabriella/I-2357-2012; La Regina, Giuseppe/I-2161-2012
OI La Regina, Giuseppe/0000-0003-3252-1161; Silvestri,
   Romano/0000-0003-2489-0178
CR ARTICO M, 1995, ARCH PHARM, V328, P223, DOI 10.1002/ardp.19953280304
   Artico M, 1996, J MED CHEM, V39, P522, DOI 10.1021/jm950568w
   Artico M, 1996, FARMACO, V51, P305
   ATKINSON JG, 1988, SYNTHESIS-STUTTGART, P480
   BEHFOROUZ M, 1969, J ORG CHEM, V34, P51, DOI 10.1021/jo00838a013                                                             
   Corbett JW, 2002, PROGR MED CHEM, V40, P63, DOI 10.1016/S0079-6468(08)70082-1
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   KANO S, 1981, J ORG CHEM, V46, P3856, DOI 10.1021/jo00332a019                                                             
   KETCHA DM, 1985, J ORG CHEM, V50, P5451, DOI 10.1021/jo00350a001                                                             
   MCMAHON JB, 1993, ANTIMICROB AGENTS CH, V37, P754, DOI 10.1128/AAC.37.4.754                                                            
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   SAULNIER MG, 1982, J ORG CHEM, V47, P757, DOI 10.1021/jo00344a001                                                             
   Silvestri R, 1998, ANTIVIR CHEM CHEMOTH, V9, P139, DOI 10.1177/095632029800900205                                                      
   SUNDBERG RJ, 1973, J ORG CHEM, V38, P3324, DOI 10.1021/jo00959a018                                                             
   TRAMONTANO E, 1992, BIOCHEM PHARMACOL, V43, P1371
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
   WILLIAMS TM, Patent No. 9419321
NR 17
TC 102
Z9 108
U1 1
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 5
PY 2003
VL 46
IS 12
BP 2482
EP 2493
DI 10.1021/jm0211063
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 684RM
UT WOS:000183220400024
PM 12773052
DA 2018-01-05
ER

PT J
AU Shen, LL
   Shen, JH
   Luo, XM
   Cheng, F
   Xu, YC
   Chen, KX
   Arnold, E
   Ding, JP
   Jiang, HL
AF Shen, LL
   Shen, JH
   Luo, XM
   Cheng, F
   Xu, YC
   Chen, KX
   Arnold, E
   Ding, JP
   Jiang, HL
TI Steered molecular dynamics simulation on the binding of NNRTI to HIV-1
   RT
SO BIOPHYSICAL JOURNAL
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS;
   DOUBLE-STRANDED DNA; DRUG-RESISTANCE; NONNUCLEOSIDE INHIBITORS; ANGSTROM
   RESOLUTION; CRYSTAL-STRUCTURE; UNBINDING FORCES; TYPE-1; MUTATIONS
AB HIV-1 reverse transcriptase (RT) is the primary target for anti-AIDS chemotherapy. Nonnucleoside RT inhibitors (NNRTIs) are very potent and most promising anti-AIDS drugs that specifically inhibit HIV-1 RT. The binding and unbinding processes of alpha-APA, an NNRTI, have been studied using nanosecond conventional molecular dynamics and steered molecular dynamics simulations. The simulation results show that the unbinding process of alpha-APA consists of three phases based on the position of alpha-APA in relation to the entrance of the binding pocket. When alpha-APA is bound in the binding pocket, the hydrophobic interactions between HIV-1 RT and alpha-APA dominate the binding; however, the hydrophilic interactions (both direct and water-bridged hydrogen bonds) also contribute to the stabilizing forces. Whereas Tyr-181 makes significant hydrophobic interactions with alpha-APA, Tyr-188 forms a strong hydrogen bond with the acylamino group (N14) of alpha-APA. These two residues have very flexible side chains and appear to act as two "flexible clamps" discouraging alpha-APA to dissociate from the binding pocket. At the pocket entrance, two relatively inflexible residues, Val-179 and Leu-100, gauge the openness of the entrance and form the bottleneck of the inhibitor-unbinding pathway. Two special water molecules at the pocket entrance appear to play important roles in inhibitor recognition of binding and unbinding. These water molecules form water bridges between the polar groups of the inhibitor and the residues around the entrance, and between the polar groups of the inhibitor themselves. The water-bridged interactions not only induce the inhibitor to adopt an energetically favorable conformation so the inhibitor can pass through the pocket entrance, but also stabilize the binding of the inhibitor in the pocket to prevent the inhibitor's dissociation. The complementary steered molecular dynamics and conventional molecular dynamics simulation results strongly support the hypothesis that NNRTIs inhibit HIV-1 RT polymerization activity by enlarging the DNA-binding cleft and restricting the flexibility and mobility of the p66 thumb subdomain that are believed to be essential during DNA translocation and polymerization.
C1 Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res,Ctr Drug Discovery & Desig, Shanghai 200031, Peoples R China.
   Chinese Acad Sci, Shanghai Inst Biol Sci, Key Lab Proteom, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China.
   Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.
   Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ 08854 USA.
RP Jiang, HL (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, State Key Lab Drug Res,Ctr Drug Discovery & Desig, Shanghai 200031, Peoples R China.
RI Cheng, Feng/A-9760-2009; Luo, Xiaomin/R-6203-2016
OI Cheng, Feng/0000-0003-3619-8090; Luo, Xiaomin/0000-0003-0426-3417
CR ANCHELL JA, 1998, NWCHEM VERSION 3 2 H
   Auwerx J, 2002, MOL PHARMACOL, V61, P400, DOI 10.1124/mol.61.2.400                                                            
   BALZARINI J, 1993, J VIROL, V67, P5353
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   BOYER PL, 1993, J VIROL, V67, P2412
   BOYER PL, 1992, J VIROL, V66, P7533
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   BROOKS CL, 1983, J CHEM PHYS, V79, P6312, DOI 10.1063/1.445724
   Buckheit RW, 2001, EXPERT OPIN INV DRUG, V10, P1423, DOI 10.1517/13543784.10.8.1423                                                      
   BYRNES VW, 1993, ANTIMICROB AGENTS CH, V37, P1576, DOI 10.1128/AAC.37.8.1576                                                           
   Campiani G, 2002, CURR PHARM DESIGN, V8, P615, DOI 10.2174/1381612024607207                                                        
   CHEN M, 2000, BIOCHEM PHARMACOL, V60, P1251
   CONDRA JH, 1992, ANTIMICROB AGENTS CH, V36, P1441, DOI 10.1128/AAC.36.7.1441                                                           
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7
   De Clercq E, 2002, NAT REV DRUG DISCOV, V1, P13, DOI 10.1038/nrd703
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   De Clercq E, 2001, CURR MED CHEM, V8, P1543, DOI 10.2174/0929867013371842                                                        
   DEBYSER Z, 1991, P NATL ACAD SCI USA, V88, P1451, DOI 10.1073/pnas.88.4.1451
   DECLERCQ E, 1994, BIOCHEM PHARMACOL, V47, P155, DOI 10.1016/0006-2952(94)90001-9                                                    
   DeClercq E, 1996, MED RES REV, V16, P125, DOI 10.1002/(SICI)1098-1128(199603)16:2<125::AID-MED1>3.0.CO;2-2
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Ding J, 1997, STRUCTURE BASED DRUG, P41
   Ding JP, 1998, J MOL BIOL, V284, P1095, DOI 10.1006/jmbi.1998.2208
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   EICHINGER M, 2000, WORKSH MOL DYN PAR C, P397
   EICHINGER M, 1996, ECOVIII VERSION 2 0
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   EVANS E, 1995, BIOPHYS J, V68, P2580, DOI 10.1016/S0006-3495(95)80441-8                                                   
   FRISCH MJ, 1998, GAUSSIAN 98
   Grubmuller H, 1996, SCIENCE, V271, P997, DOI 10.1126/science.271.5251.997
   Grubmuller H, 1996, SOLVATE PROGRAM CREA
   Gupta Satya P, 2002, Prog Drug Res, V58, P223
   Heymann B, 1999, CHEM PHYS LETT, V303, P1, DOI 10.1016/S0009-2614(99)00183-9
   Heymann B, 2001, BIOPHYS J, V81, P1295, DOI 10.1016/S0006-3495(01)75787-6                                                   
   Heymann B, 1999, CHEM PHYS LETT, V307, P425, DOI 10.1016/S0009-2614(99)00531-X
   Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3
   Hsiou Y, 1998, J MOL BIOL, V284, P313, DOI 10.1006/jmbi.1998.2171
   Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Isralewitz B, 1997, BIOPHYS J, V73, P2972, DOI 10.1016/S0006-3495(97)78326-7                                                   
   Isralewitz B, 2001, J MOL GRAPH MODEL, V19, P13, DOI 10.1016/S1093-3263(00)00133-9
   Izrailev S., 1998, LECT NOTES COMPUTATI, V4, P39
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   JAGER J, 1994, STRUCTURE, V2, P869, DOI 10.1016/S0969-2126(94)00087-5
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Kleim JP, 1999, J INFECT DIS, V179, P709, DOI 10.1086/314633                                                                  
   Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P208, DOI 10.1016/S0076-6879(97)77013-7
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Krammer A, 1999, P NATL ACAD SCI USA, V96, P1351, DOI 10.1073/pnas.96.4.1351
   Larder B A, 1993, REVERSE TRANSCRIPTAS, P205
   Lindberg J, 2002, EUR J BIOCHEM, V269, P1670, DOI 10.1046/j.1432-1327.2002.02811.x
   Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3                                                   
   Lu H, 1999, PROTEINS, V35, P453, DOI 10.1002/(SICI)1097-0134(19990601)35:4<453::AID-PROT9>3.3.CO;2-D
   Maga G, 2000, ANTIMICROB AGENTS CH, V44, P1186, DOI 10.1128/AAC.44.5.1186-1194.2000
   Marrink SJ, 1998, BIOPHYS J, V74, P931, DOI 10.1016/S0006-3495(98)74016-0                                                   
   Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061                                                                
   NUNBERG JH, 1991, J VIROL, V65, P4887
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PERDEW JP, 1992, PHYS REV B, V45, P13244, DOI 10.1103/PhysRevB.45.13244
   POPLE JA, 1988, CHEM PHYSLETT, V153, P503
   Ren J, 2001, J MOL BIOL, V312, P795, DOI 10.1006/jmbi.2001.4988
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207                                                           
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   Rubsamen-Waigmann H, 1999, ANTIVIR RES, V42, P15, DOI 10.1016/S0166-3542(99)00010-8
   SAEBO S, 1989, CHEM PHYS LETT, V154, P83, DOI 10.1016/0009-2614(89)87442-1                                                    
   Sala M, 1998, B I PASTEUR, V96, P49, DOI 10.1016/S0020-2452(98)80028-6
   SHIH CK, 1991, P NATL ACAD SCI USA, V88, P9878, DOI 10.1073/pnas.88.21.9878
   Stepaniants S, 1997, J MOL MODEL, V3, P473, DOI 10.1007/s008940050065                                                           
   SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335                                             
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   *TRIP INC, 1999, SYB VERS 6 5
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   WRIGGERS W, 1997, BIOPHYS J, V73, P1281
   WU JC, 1991, BIOCHEMISTRY-US, V30, P2022, DOI 10.1021/bi00222a003
NR 80
TC 61
Z9 68
U1 0
U2 9
PU BIOPHYSICAL SOCIETY
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0006-3495
J9 BIOPHYS J
JI Biophys. J.
PD JUN
PY 2003
VL 84
IS 6
BP 3547
EP 3563
DI 10.1016/S0006-3495(03)75088-7                                           
          
PG 17
WC Biophysics
SC Biophysics
GA 683CL
UT WOS:000183129800006
PM 12770866
OA gold
DA 2018-01-05
ER

PT J
AU Louis, JM
   Nesheiwat, I
   Chang, LC
   Clore, GM
   Bewley, CA
AF Louis, JM
   Nesheiwat, I
   Chang, LC
   Clore, GM
   Bewley, CA
TI Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41
   and antibodies directed against them are potent inhibitors of HIV
   envelope-mediated cell fusion
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PEPTIDE INHIBITOR; NEUTRALIZING
   ANTIBODIES; ACTIVE CONFORMATION; ANTIVIRAL ACTIVITY; ATOMIC-STRUCTURE;
   SIV GP41; ENTRY; GLYCOPROTEIN; GP120
AB We have engineered two soluble, covalently linked, trimeric polypeptides, N35(CCG)-N13 and N34(CCG) comprising only the internal trimeric coiled-coil of the ectodomain of HIV-1 gp41. Both trimers inhibit human immunodeficiency virus, type 1 ( HIV-1) envelope (Env)mediated cell fusion at nanomolar concentrations by targeting the exposed C-terminal region of the gp41 ectodomain in the prehairpin intermediate state. The IC50 values for N35(CCG)-N13 and N34(CCG) are similar to15 and similar to95 nM, respectively, in a quantitative vaccinia virus-based reporter gene assay for HIV-1 Env-mediated cell fusion using Env from the T cell tropic strain LAV. Polyclonal antibodies were raised against N35(CCG)-N13 and a tightly binding fraction of anti-N35(CCG)-N13 inhibits T cell and macrophage tropic HIV-1 Env- mediated cell fusion with respective IC50 values of similar to0.5 and similar to1.5 mug/ml at 37 degreesC. The tightly binding anti-N35(CCG)-N13 antibody fraction targets the exposed internal trimeric coiled-coil in the prehairpin intermediate state of gp41 in a manner analogous to peptides derived from the C region of the gp41 ectodomain. The potency of the tightly binding anti-N35(CCG)-N13 antibody fraction in the fusion assay is comparable with that of the broadly neutralizing monoclonal antibody 2G12. These results indicate that N35(CCG)-N13 is a potential anti-HIV therapeutic agent and represents a suitable immunogen for the generation of neutralizing monoclonal antibodies targeted to the internal trimeric coiled-coil of gp41. The data on the tightly binding anti-N35(CCG)-N13 antibody fraction demonstrate that the internal trimeric coiled-coil of gp41 in the prehairpin intermediate state is accessible to antibodies and that access is not restricted by either antibody size or the presence of a kinetic barrier.
C1 NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
   NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA.
RP Bewley, CA (reprint author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8,Rm 1A-02, Bethesda, MD 20892 USA.
RI Clore, G. Marius/A-3511-2008
OI Clore, G. Marius/0000-0003-3809-1027
CR Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200
   BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191
   BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   De Rosny E, 2001, J VIROL, V75, P8859, DOI 10.1128/JVI.75.18.8859-8863.2001
   Dimitrov DS, 1999, VIROLOGY, V259, P1, DOI 10.1006/viro.1999.9747
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898                                                          
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883                                                        
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002
   HARLOW E, 1988, ANTIBODIES LAB MANUA
   Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294                                                      
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368
   Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200                                                          
   Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200
   Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200
   Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134                                                         
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   MUNOZBARROSO L, 1998, J CELL BIOL, V140, P315
   NASHI LO, 1997, ANAL BIOCHEM, V253, P246
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000                                                   
   Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002
   Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002
   Stiegler G, 2002, AIDS, V16, P2019, DOI 10.1097/00002030-200210180-00006                                                
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   TRKOLA A, 1995, J VIROL, V69, P6609
   Trkola A, 1996, J VIROL, V70, P1100
   Vaitukaitis J L, 1981, Methods Enzymol, V73, P46
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
NR 37
TC 89
Z9 92
U1 2
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 30
PY 2003
VL 278
IS 22
BP 20278
EP 20285
DI 10.1074/jbc.M301627200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 682EH
UT WOS:000183078000090
PM 12654905
OA gold
DA 2018-01-05
ER

PT J
AU Yang, F
   Belitsky, JM
   Villanueva, RA
   Dervan, PB
   Roth, MJ
AF Yang, F
   Belitsky, JM
   Villanueva, RA
   Dervan, PB
   Roth, MJ
TI Inhibition of Moloney murine leukemia virus integration using polyamides
   targeting the long-terminal repeat sequences
SO BIOCHEMISTRY
LA English
DT Article
ID DNA MINOR-GROOVE; CENTER-DOT-A; RETROVIRAL INTEGRATION; HIV-1 INTEGRASE;
   VIRAL-DNA; BASE-PAIRS; SUBSTRATE-SPECIFICITY; HAIRPIN POLYAMIDES;
   ESCHERICHIA-COLI; STRUCTURAL BASIS
AB The retroviral integrase (IN) carries out the integration of the viral DNA into the host genome. Both IN and the DNA sequences at the viral long-terminal repeat (LTR) are required for the integration function. In this report, a series of minor groove binding hairpin polyamides targeting sequences within terminal inverted repeats of the Moloney murine leukemia virus (M-MuLV) LTR were synthesized, and their effects on integration were analyzed. Using cell-free in vitro integration assays, polyamides targeting the conserved CA dinucleotide with cognate sites closest to the terminal base pairs were effective at blocking 3' processing but not strand transfer. Polyamides which efficiently inhibited 3' processing and strand transfer targeted the LTR sequences through position 9. Polyamides that inhibited integration were effective at nanomolar concentrations and showed subnanomolar affinity for their cognate LTR sites. These studies highlight the role of minor groove interactions within the LTR termini for retroviral integration.
C1 Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.
   CALTECH, Dept Chem, Pasadena, CA 91125 USA.
RP Roth, MJ (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.
FU NCI NIH HHS [CA76545]; NIGMS NIH HHS [GM57148]
CR Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z                                                               
   Balakrishnan M, 1997, J VIROL, V71, P1025
   Belitsky JM, 2002, BIOORGAN MED CHEM, V10, P3313, DOI 10.1016/S0968-0896(02)00204-3
   Brown P. O., 1997, P161
   BUSHMAN FD, 1991, P NATL ACAD SCI USA, V88, P1339, DOI 10.1073/pnas.88.4.1339                                                          
   CARTEAU S, 1994, BIOCHEM PHARMACOL, V47, P1821, DOI 10.1016/0006-2952(94)90311-5
   CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573
   Chang AY, 2000, J AM CHEM SOC, V122, P4856, DOI 10.1021/ja994345x                                                               
   Chen HM, 1999, J BIOL CHEM, V274, P17358, DOI 10.1074/jbc.274.24.17358
   Chiang SY, 2000, J BIOL CHEM, V275, P24246, DOI 10.1074/jbc.M000820200
   Clairac R. P. L., 1997, J AM CHEM SOC, V119, P7909
   Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200
   CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y                                                    
   Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77
   Dervan PB, 1999, CURR OPIN CHEM BIOL, V3, P688, DOI 10.1016/S1367-5931(99)00027-7                                                   
   Dervan PB, 2001, BIOORGAN MED CHEM, V9, P2215, DOI 10.1016/S0968-0896(01)00262-0                                                   
   Dickinson LA, 1998, P NATL ACAD SCI USA, V95, P12890, DOI 10.1073/pnas.95.22.12890
   Ellervik U, 2000, J AM CHEM SOC, V122, P9354, DOI 10.1021/ja001692u
   Erlanson DA, 2000, P NATL ACAD SCI USA, V97, P9367, DOI 10.1073/pnas.97.17.9367
   Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397                                                          
   Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832
   FELKNER RH, 1992, J VIROL, V66, P4258
   FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399                                                          
   GAO K, 2001, EMBO J, V20, P3585
   Gottesfeld JM, 2000, GENE EXPRESSION, V9, P77
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Herman DM, 1998, J AM CHEM SOC, V120, P1382, DOI 10.1021/ja9737228                                                               
   Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836
   Hyde C. C., 1999, J MOL BIOL, V296, P535
   Janssen S, 2000, MOL CELL, V6, P1013, DOI 10.1016/S1097-2765(00)00100-3
   Janssen S, 2000, MOL CELL, V6, P999, DOI 10.1016/S1097-2765(00)00099-X                                                   
   JONSSON CB, 1993, J BIOL CHEM, V268, P1462
   JONSSON CB, 1993, J VIROL, V67, P5562
   Jonsson CB, 1996, J VIROL, V70, P4585
   Katz RA, 2001, J BIOL CHEM, V276, P34213, DOI 10.1074/jbc.M104632200
   KATZMAN M, 1989, J VIROL, V63, P5319
   Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3
   Kielkopf CL, 2000, J MOL BIOL, V295, P557, DOI 10.1006/jmbi.1999.3364                                                          
   Kielkopf CL, 1998, NAT STRUCT BIOL, V5, P104, DOI 10.1038/nsb0298-104
   Kielkopf CL, 1998, SCIENCE, V282, P111, DOI 10.1126/science.282.5386.111
   LAFEMINA RL, 1991, J VIROL, V65, P5624
   Marshall E, 2003, SCIENCE, V299, P320, DOI 10.1126/science.299.5605.320                                                    
   Miller MD, 2001, CURR OPIN MICROBIOL, V4, P535, DOI 10.1016/S1369-5274(00)00247-2
   Neamati N, 1998, MOL PHARMACOL, V54, P280
   Pilch DS, 1999, BIOCHEMISTRY-US, V38, P2143, DOI 10.1021/bi982628g
   Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1
   Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3
   PRUSS D, 1994, J BIOL CHEM, V269, P25031
   PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913
   PRYCIAK PM, 1992, P NATL ACAD SCI USA, V89, P9237, DOI 10.1073/pnas.89.19.9237
   PRYCIAK PM, 1992, EMBO J, V11, P291
   PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O
   Roe T, 1997, J VIROL, V71, P1334
   Ryabinin VA, 2000, EUR J MED CHEM, V35, P989, DOI 10.1016/S0223-5234(00)01181-8
   Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371
   SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119
   Singh IR, 1997, P NATL ACAD SCI USA, V94, P1304, DOI 10.1073/pnas.94.4.1304                                                          
   Swalley SE, 1999, J AM CHEM SOC, V121, P1113, DOI 10.1021/ja9830905                                                               
   Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0
   Trauger JW, 2001, METHOD ENZYMOL, V340, P450
   VINK C, 1991, J VIROL, V65, P4636
   Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333
   Wang T, 1999, BIOCHEMISTRY-US, V38, P3624, DOI 10.1021/bi982124i
   Wei SQ, 1997, EMBO J, V16, P7511, DOI 10.1093/emboj/16.24.7511
   Wurtz NR, 2000, CHEM BIOL, V7, P153, DOI 10.1016/S1074-5521(00)00085-5                                                   
   Yang F, 2001, J VIROL, V75, P9561, DOI 10.1128/JVI.75.20.9561-9570.2001
NR 66
TC 14
Z9 14
U1 0
U2 0
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAY 27
PY 2003
VL 42
IS 20
BP 6249
EP 6258
DI 10.1021/bi034177s
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 681EP
UT WOS:000183024200032
PM 12755629
DA 2018-01-05
ER

PT J
AU Mak, CC
   Brik, A
   Lerner, DL
   Elder, JH
   Morris, GM
   Olson, AJ
   Wong, CH
AF Mak, CC
   Brik, A
   Lerner, DL
   Elder, JH
   Morris, GM
   Olson, AJ
   Wong, CH
TI Design and synthesis of broad-based mono- and bi-cyclic inhibitors of
   FIV and HIV proteases
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
ID FELINE IMMUNODEFICIENCY VIRUS; PEPTIDOMIMETIC INHIBITORS; MOLECULAR
   RECOGNITION; FUTURE-PROSPECTS; TYPE-1 PROTEASE; DRUG DESIGN; IN-VITRO;
   IDENTIFICATION; PROTEINASE; PEPTIDES
AB Based on the substrate transition state and our strategy to tackle the problem of drug resistance, a series of HIV/FIV protease (HIV/FIV PR) monocyclic inhibitors incorporating a 15- or 17-membered macrocycle with an equivalent P3 or P3' group and a unique unnatural amino acid, (2R, 3S)-3-amino-2-hydroxy-4-phenylbutyric acid, have been designed and synthesized. In addition, based on the structure of TL3 with small P3/P3' group, we have synthesized two conformationally restricted bicyclic inhibitors containing the macrocycle, which mimic the P1/P1'-P3/P3' tripeptide [Phe-Val-Ala] of TL3. We have found that the contribution of the macrocycle in our monocyclic inhibitors is important to the overall activity, but the ring size does not affect the activity to a significant extent. Several inhibitors that were developed in this work, exhibit low nanomolar inhibitory activity against the wild-type HIV/FIV PR and found to be highly effective against some drug-resistant as well as TL3-resistant mutants of HIV PRs. Compound 15, in particular, is the most effective cyclic inhibitor in hand to inhibit FIV replication in tissue culture at a concentration of 1.0 mug/mL (1.2 muM). (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
RP Wong, CH (reprint author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
RI Brik, Ashraf/F-1583-2012
OI Morris, Garrett/0000-0003-1731-8405
CR ABBENANTE G, 1995, J AM CHEM SOC, V117, P10220, DOI 10.1021/ja00146a007                                                             
   Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z                                                               
   Bavetsias V, 1997, TETRAHEDRON, V53, P13383, DOI 10.1016/S0040-4020(97)00851-X
   BUDT KH, 1995, BIOORGAN MED CHEM, V3, P559, DOI 10.1016/0968-0896(95)00069-S
   Chen JJ, 1996, BIOORG MED CHEM LETT, V6, P435, DOI 10.1016/0960-894X(96)00034-0
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DeLucca GV, 1997, DRUG DISCOV TODAY, V2, P6, DOI 10.1016/S1359-6446(96)10048-9                                                   
   DeMico A, 1997, J ORG CHEM, V62, P6974, DOI 10.1021/jo971046m                                                               
   Dunn BM, 1999, BIOPOLYMERS, V51, P69, DOI 10.1002/(SICI)1097-0282(1999)51:1<69::AID-BIP8>3.0.CO;2-#                       
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553                                             
   ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523
   ERIKSON JW, 1997, BIOCH BIOPHY ACTA, V1339, P113
   Ettmayer P, 1996, J MED CHEM, V39, P3291, DOI 10.1021/jm950641i
   Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295
   GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002
   KEMPF DJ, 1993, J MED CHEM, V36, P320, DOI 10.1021/jm00055a003
   Kiso Y, 1999, BIOPOLYMERS, V51, P59, DOI 10.1002/(SICI)1097-0282(1999)51:1<59::AID-BIP7>3.0.CO;2-3
   KONRADI AW, 1992, J ORG CHEM, V57, P28, DOI 10.1021/jo00027a009                                                             
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   Lee T, 1998, P NATL ACAD SCI USA, V95, P939, DOI 10.1073/pnas.95.3.939                                                           
   Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m
   Li M, 2000, PROTEINS, V38, P29, DOI 10.1002/(SICI)1097-0134(20000101)38:1<29::AID-PROT4>3.0.CO;2-N
   LIM D, UNPUB
   Mak CC, 2001, BIOORG MED CHEM LETT, V11, P219, DOI 10.1016/S0960-894X(00)00641-7
   March DR, 1996, J AM CHEM SOC, V118, P3375, DOI 10.1021/ja953790z
   Martin JL, 1999, BIOCHEMISTRY-US, V38, P7978, DOI 10.1021/bi990174x
   Mimoto T, 1999, J MED CHEM, V42, P1789, DOI 10.1021/jm980637h
   Moyle G, 1996, DRUGS, V51, P701, DOI 10.2165/00003495-199651050-00001
   OTTO MJ, 1993, P NATL ACAD SCI USA, V90, P7543, DOI 10.1073/pnas.90.16.7543
   PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650
   PODLOGAR BL, 1994, J MED CHEM, V37, P3684, DOI 10.1021/jm00048a004
   Reid RC, 1996, J AM CHEM SOC, V118, P8511, DOI 10.1021/ja960433v                                                               
   Sakurai M, 1994, Bioorg Med Chem, V2, P807, DOI 10.1016/S0968-0896(00)82181-1
   Schinazi R. F., 1997, International Antiviral News, V5, P129
   SLEE DH, 1995, J AM CHEM SOC, V117, P11867, DOI 10.1021/ja00153a008                                                             
   SMITH RA, 1994, BIOORG MED CHEM LETT, V4, P2217, DOI 10.1016/S0960-894X(00)80074-8
   TAM TF, 1992, J MED CHEM, V35, P1318, DOI 10.1021/jm00085a020                                                             
   TYNDALL JDA, 1999, J MOL RECOGNIT, V12, P1
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Vacca JP, 1997, DRUG DISCOV TODAY, V2, P261, DOI 10.1016/S1359-6446(97)01053-2                                                   
   WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   Yuan Wei, 1993, Journal of Medicinal Chemistry, V36, P211, DOI 10.1021/jm00054a004
NR 45
TC 15
Z9 19
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAY 1
PY 2003
VL 11
IS 9
BP 2025
EP 2040
DI 10.1016/S0968-0896(03)00054-3
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 665CA
UT WOS:000182101000010
PM 12670654
DA 2018-01-05
ER

PT J
AU Tamamura, H
   Koh, Y
   Ueda, S
   Sasaki, Y
   Yamasaki, T
   Aoki, M
   Maeda, K
   Watai, Y
   Arikuni, H
   Otaka, A
   Mitsuya, H
   Fujii, N
AF Tamamura, H
   Koh, Y
   Ueda, S
   Sasaki, Y
   Yamasaki, T
   Aoki, M
   Maeda, K
   Watai, Y
   Arikuni, H
   Otaka, A
   Mitsuya, H
   Fujii, N
TI Reduction of peptide character of HIV protease inhibitors that exhibit
   nanomolar potency against multidrug resistant HIV-1 strains
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ORALLY BIOAVAILABLE INHIBITOR; STEREOSELECTIVE SYNTHESIS; DIPEPTIDE
   ISOSTERES; ACTIVE-SITE; DESIGN; DISCOVERY; ANALOGS; ENZYME; ACIDS
AB Novel HIV protease inhibitors containing a hydroxyethylamine dipeptide isostere as a transition state-mimic king structure were synthesized by combining substructures of known HIV protease inhibitors. Among them, TYA5 and TYB5 were proven to be not only potent enzyme inhibitors (K-i = 0.12 nM and 0.10 nM, respectively) but also strong anti-HIV agents (IC50 = 9.5 nM and 66 nM, respectively), even against viral strains with multidrug resistance. Furthermore, insertion of an (E)-alkene dipeptide isostere at the P-1-P-2 position of TYB5 led to development of a purely nonpeptidic protease inhibitor, TYB1 (K-i = 0.38 nM, IC50 = 160 nM).
C1 Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.
   Kumamoto Univ, Sch Med, Dept Internal Med 2, Kumamoto 8608556, Japan.
   SC biosci Corp, Yokohama Lab, Hodogaya Ku, Yokohama, Kanagawa 2400005, Japan.
   NCI, Div Clin Sci, Med Branch, Expt Retrovirol Sect,NIH, Bethesda, MD 20892 USA.
RP Tamamura, H (reprint author), Kyoto Univ, Grad Sch Pharmaceut Sci, Sakyo Ku, Kyoto 6068501, Japan.
EM tamamura@pharm.kyoto-u.ac.jp; nfujii@pharm.kyoto-u.ac.jp
CR BARRISH JC, 1994, J MED CHEM, V37, P1758, DOI 10.1021/jm00038a005
   GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   Jungheim LN, 1996, J MED CHEM, V39, P96, DOI 10.1021/jm950576c                                                               
   Kaldor SW, 1997, J MED CHEM, V40, P3979, DOI 10.1021/jm9704098
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   Kuwata H, 1998, BIOCHEM BIOPH RES CO, V245, P764, DOI 10.1006/bbrc.1998.8466
   Mimoto T, 1999, J MED CHEM, V42, P1789, DOI 10.1021/jm980637h
   Mitsuya H., 1999, TXB AIDS MED, P751
   PARKES KEB, 1994, J ORG CHEM, V59, P3656, DOI 10.1021/jo00092a026
   RICH DH, 1990, J MED CHEM, V33, P1285, DOI 10.1021/jm00167a003
   Rich DH, 2002, BIOPOLYMERS, V66, P115, DOI 10.1002/bip.10231
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   SHAM HL, 1993, J CHEM SOC CHEM COMM, P1052, DOI 10.1039/c39930001052                                                            
   Tamamura H, 1999, J CHEM SOC PERK T 1, P2983, DOI 10.1039/a904671b                                                                
   Tamamura H, 2002, BIOORG MED CHEM LETT, V12, P923, DOI 10.1016/S0960-894X(02)00041-0
   Tamamura H, 2002, J CHEM SOC PERK T 1, P577, DOI 10.1039/b200324b
   Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1258.2002
NR 21
TC 44
Z9 44
U1 1
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD APR 24
PY 2003
VL 46
IS 9
BP 1764
EP 1768
DI 10.1021/jm020537i
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 671WR
UT WOS:000182488300022
PM 12699395
DA 2018-01-05
ER

PT J
AU Fernandez-Botello, A
   Holy, A
   Moreno, V
   Sigel, H
AF Fernandez-Botello, A
   Holy, A
   Moreno, V
   Sigel, H
TI Stability and structure of binary and ternary metal ion complexes in
   aqueous solution of the quaternary 1-[2-(phosphonomethoxy)ethyl]
   derivative of 2,4-diaminopyrimidine (PMEDAPy(-)). Properties of an
   acyclic nucleotide analogue
SO POLYHEDRON
LA English
DT Article; Proceedings Paper
CT 13th Spanish Italian Congress on the Thermodynamics of Metal
   Complexes/29th Annual Congress of Gruppo-di-Termodinamica-dei-Complessi
CY JUN 02-06, 2002
CL SANTIAGO COMPOSTE, SPAIN
DE acidity constants; charge repulsion; phosphonate complexes; pyrimidine
   nucleotide analogue; stability constants; stacking interactions; ternary
   complexes
ID (2'-DEOXY)ADENOSINE 5'-TRIPHOSPHATE DATP(4-)/ATP(4-); NUCLEOSIDE
   PHOSPHONATE ANALOGS; HUMAN-IMMUNODEFICIENCY-VIRUS; D-RIBOSE
   5'-MONOPHOSPHATE; NUCLEIC-ACID POLYMERASES; MIXED-LIGAND COMPLEXES;
   9-<2-(PHOSPHONOMETHOXY)ETHYL>ADENINE PMEA; STACKING INTERACTIONS;
   BINDING-PROPERTIES; COORDINATING PROPERTIES
AB The acidity constants of the twofold protonated. quaternary 1-[2-(phosphonomethoxy)ethyl] derivative of 2,4-diaminopyrimidine, H-2(PMEDAPy)(+), were determined by potentiometric pH titrations in aqueous solution (25 degreesC; I = 0.1 M, NaNO3) and compared with the corresponding constants of also twofold protonated. O-phosphonatomethylcholine, H-2(PMCh)(+), an analogue of phosphocholine; the corresponding acidity constants are quite similar. By the same experimental method and under the same conditions the stability constants of the M(PMEDAPy)(+) complexes with the metal ions M2+ = Mg2+, Ca2+, Sr2+, Ba2+, Mn2+, Co2+, Ni2+, Cu2+, Zn2+ or Cd2+ and also of the mixed ligand complexes, Cu(Arm)(PMEDAPy)(+), where Arm = Bpy (2,2'-bipyridine) or Phen (1,10-phenanthroline), have also been determined. Application of the previously determined straight-line plots of log K-M(R-PO3)(M) versus pK(H(R-PO3))(H) for simple phosph(on)ate ligands, R-PO32-, where R represents a residue that does not affect complex formation, proves that the positively charged pyrimidinium residue somewhat inhibits, due to charge repulsion, complex formation with the -PO32- group. In fact, a comparison with previous results obtained for R-CH2CH2-O-CH2-PO32- (=PME-R2-) ligands (R is non-interacting) with the data obtained now for the binary complexes of PMEDAPy(-) shows that for all 10 divalent metal ions studied the inhibition amounts to Deltalog Delta(M/PMEDAPy) = 0.42+/-0.04. This 'constant' repulsive effect is evidence that in the M(PMEDAPy)(+) complexes the ether oxygen does not participate in complex formation; this is different in the M(PME-R) complexes, where five-membered chelates form in equilibrium, the extent being dependent on the kind of metal ion involved. The results for the mixed ligand Cu(Arm)(PMEDAPy)(+) complexes show a significant increase in complex stability of about 0.6 log unit (compared to the stability expected on the basis of the basicity of the phosphonate group), which is due to intramolecular stack formation between the aromatic ring systems of Phen or Bpy and the pyrimidinium moiety of PMEDAPy(-). The formation degree of the stacked isomer in the Cu(Arm)(PMEDAPy)(+) systems is on the order of 70%, though it is somewhat more pronounced with Phen than with Bpy. Comparisons with the Cu(Arm)(N) systems, where N = cytidine 5'-monophosphate (CMP2-) or 1-[2-(phosphonomethoxy)ethyl]cytosine (PMEC2-), reveal that the stacking properties of all three pyrimidine derivatives are similar. An explanation is offered why PMEDAPy(-) shows no biological activity compared to several other closely related acyclic nucleotide analogues, which have antiviral properties. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Univ Basel, Dept Chem, CH-4056 Basel, Switzerland.
   Univ Barcelona, Fac Chem, Dept Inorgan Chem, E-08028 Barcelona, Spain.
   Acad Sci Czech Republ, Inst Organ Chem & Biochem, CZ-16610 Prague, Czech Republic.
RP Sigel, H (reprint author), Univ Basel, Dept Chem, Spitalstr 51, CH-4056 Basel, Switzerland.
CR ANDEREGG G, 1963, HELV CHIM ACTA, V46, P2397, DOI 10.1002/hlca.19630460657                                                        
   Aoki K, 1996, MET IONS BIOL SYST, V32, P91
   BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W
   Birkus G, 1999, BIOCHEM PHARMACOL, V58, P487, DOI 10.1016/S0006-2952(99)00118-5
   Birkus G, 2001, COLLECT CZECH CHEM C, V66, P1698, DOI 10.1135/cccc20011698                                                            
   Blindauer CA, 1997, CHEM-EUR J, V3, P1526, DOI 10.1002/chem.19970030922                                                        
   Blindauer CA, 1999, J CHEM SOC DALTON, P3661, DOI 10.1039/a904838c                                                                
   Blindauer CA, 1999, COLLECT CZECH CHEM C, V64, P613, DOI 10.1135/cccc19990613                                                            
   BLINDAUER CA, 1998, THESIS U BASEL
   BLINDAUER CA, IN PRESS
   CHEN D, 1993, J CHEM SOC DALTON, P1537, DOI 10.1039/dt9930001537
   Crowley JD, 2000, MET IONS BIOL SYST, V37, P209
   De Clercq E, 1998, COLLECT CZECH CHEM C, V63, P480, DOI 10.1135/cccc19980480                                                            
   DECLERCQ E, 1987, ANTIVIR RES, V8, P261
   Fernandez-Botello A, 2002, INORG CHIM ACTA, V331, P109, DOI 10.1016/S0020-1693(01)00763-0                                                   
   FUKUDA Y, 1978, HELV CHIM ACTA, V61, P638, DOI 10.1002/hlca.19780610210                                                        
   Gomez-Coca Raquel B., 2000, Metal-Based Drugs, V7, P313, DOI 10.1155/MBD.2000.313
   Gomez-Coca RB, 2000, J CHEM SOC DALTON, P2077, DOI 10.1039/b001588l
   Gomez-Coca RB, 2001, J INORG BIOCHEM, V84, P39, DOI 10.1016/S0162-0134(00)00194-X
   Holy A, 2002, J MED CHEM, V45, P1918, DOI 10.1021/jm011095y
   Holy A, 1999, COLLECT CZECH CHEM C, V64, P242, DOI 10.1135/cccc19990242                                                            
   Holy A, 1999, J MED CHEM, V42, P2064, DOI 10.1021/jm9811256
   IRVING H, 1953, J CHEM SOC, P3192, DOI 10.1039/jr9530003192                                                            
   IRVING H, 1962, J CHEM SOC, P5222, DOI 10.1039/jr9620005222                                                            
   IRVING HM, 1967, ANAL CHIM ACTA, V38, P475, DOI 10.1016/S0003-2670(01)80616-4                                                   
   Kampf G, 2001, CHEM-EUR J, V7, P1899, DOI 10.1002/1521-3765(20010504)7:9<1899::AID-CHEM1899>3.0.CO;2-5
   Luth MS, 1999, J CHEM SOC DALTON, P357, DOI 10.1039/a808479c
   MALINIBALAKRISHNAN R, 1985, INORG CHEM, V24, P2067, DOI 10.1021/ic00207a022                                                             
   Martin RB, 1988, COMMENTS INORG CHEM, V6, P285
   MASSOUD SS, 1989, INORG CHIM ACTA, V159, P243
   MASSOUD SS, 1988, INORG CHEM, V27, P1447, DOI 10.1021/ic00281a030                                                             
   MASSOUD SS, 1990, EUR J BIOCHEM, V187, P387, DOI 10.1111/j.1432-1033.1990.tb15316.x
   MITCHELL PR, 1979, HELV CHIM ACTA, V62, P1723, DOI 10.1002/hlca.19790620605                                                        
   MITCHELL PR, 1978, J AM CHEM SOC, V100, P1564, DOI 10.1021/ja00473a039
   NAESENS L, 1989, EUR J CLIN MICROBIOL, V8, P1043, DOI 10.1007/BF01975167
   Naesens L, 1997, ANTIVIR CHEM CHEMOTH, V8, P1
   Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566
   PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580
   Saha A, 1996, J BIOL INORG CHEM, V1, P231, DOI 10.1007/s007750050048                                                           
   Sigel H, 2000, COORDIN CHEM REV, V200, P563, DOI 10.1016/S0010-8545(00)00307-6                                                   
   Sigel H, 1997, J INDIAN CHEM SOC, V74, P261
   SIGEL H, 1970, ACCOUNTS CHEM RES, V3, P201, DOI 10.1021/ar50030a004                                                             
   Sigel H, 1999, CHEM COMMUN, P743, DOI 10.1039/a901233h                                                                
   Sigel H, 1996, MET IONS BIOL SYST, V32, P135
   Sigel H, 1999, PURE APPL CHEM, V71, P1727, DOI 10.1351/pac199971091727                                                         
   SIGEL H, 1995, COORDIN CHEM REV, V144, P287, DOI 10.1016/0010-8545(95)01158-L                                                    
   Sigel H, 1999, J AM CHEM SOC, V121, P6248, DOI 10.1021/ja9904181                                                               
   SIGEL H, 1992, HELV CHIM ACTA, V75, P2634, DOI 10.1002/hlca.19920750817                                                        
   SIGEL H, 1991, ANAL CHIM ACTA, V255, P63, DOI 10.1016/0003-2670(91)85088-A                                                    
   SIGEL H, 1989, PURE APPL CHEM, V61, P923, DOI 10.1351/pac198961050923                                                         
   SIGEL H, 1975, ANGEW CHEM INT EDIT, V14, P394, DOI 10.1002/anie.197503941
   SIGEL H, 1993, CHEM SOC REV, V22, P255, DOI 10.1039/cs9932200255                                                            
   Sigel H., 1980, COORD CHEM, P27
   Sigel RKO, 2000, J BIOL INORG CHEM, V5, P287, DOI 10.1007/PL00010657
   Yamauchi O, 1996, MET IONS BIOL SYST, V32, P207
   Yamauchi O, 2002, J CHEM SOC DALTON, P3411, DOI 10.1039/b202385g
   Zhao J, 1996, INORG CHIM ACTA, V250, P185, DOI 10.1016/S0020-1693(96)05227-9                                                   
NR 57
TC 13
Z9 13
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-5387
J9 POLYHEDRON
JI Polyhedron
PD APR 15
PY 2003
VL 22
IS 8
BP 1067
EP 1076
DI 10.1016/S0277-5387(03)00093-7
PG 10
WC Chemistry, Inorganic & Nuclear; Crystallography
SC Chemistry; Crystallography
GA 671XB
UT WOS:000182489400006
DA 2018-01-05
ER

PT J
AU Torchilin, VP
   Levchenko, TS
AF Torchilin, VP
   Levchenko, TS
TI TAT-liposomes: A novel intracellular drug carrier
SO CURRENT PROTEIN & PEPTIDE SCIENCE
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CELL-PENETRATING PEPTIDES; PROTEIN
   TRANSDUCTION DOMAIN; IN-VIVO; MAMMALIAN-CELLS; GENE DELIVERY;
   ANTENNAPEDIA HOMEODOMAIN; RETINOBLASTOMA PROTEIN; MAGNETIC
   NANOPARTICLES; CATIONIC LIPOSOMES
AB TAT peptide was attached to the surface of plain and PEGylated liposomes. These TAT peptide-modified liposomes have been shown to translocate into a variety of normal and cancer cells if a non-hindered interaction between the cell surface and liposome-attached TAT peptide was made possible. TAT peptide-liposomes translocated into cells remain intact within first few hours as proved by a co-localization of fluorescent markers entrapped inside liposomes and incorporated into the liposomal membrane. After 2 hours liposomes had slowly migrating towards cell nuclei. Liposomes had completely disintegrated with their inner marker released by approximately 9 hours. TAT peptide-liposomes were made slightly cationic by adding up to 10 mol % of a cationic lipid (DOTAP). These slightly cationic liposomes were non-toxic towards cells, formed firm complexes with DNA (plasmid encoding for the formation of the Green Fluorescent Protein), and efficiently transfected a variety of cells. TAT peptide-liposomes can be considered as promising carriers for the non-endocytotic intracellular delivery of drugs and DNA.
C1 Northeastern Univ, Bouve Coll Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA.
RP Torchilin, VP (reprint author), Northeastern Univ, Bouve Coll Hlth Sci, Dept Pharmaceut Sci, Boston, MA 02115 USA.
EM v.torchilin@neu.edu
CR ALLEN TM, 1995, INT J CANCER, V62, P199, DOI 10.1002/ijc.2910620215
   Astriab-Fisher A, 2002, PHARMACEUT RES, V19, P744, DOI 10.1023/A:1016136328329                                                         
   Audouy S, 2000, J GENE MED, V2, P465, DOI 10.1002/1521-2254(200011/12)2:6<465::AID-JGM141>3.0.CO;2-Z                      
   BELTING M, 1999, BIOCHEM J, V342, P282
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Buchschacher GL, 2001, HUM GENE THER, V12, P1013, DOI 10.1089/104303401750214249
   Buvoli M, 2002, GENE THER, V9, P227, DOI 10.1038/sj/gt/3301640
   CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201
   Chang LJ, 2001, CURR OPIN MOL THER, V3, P468
   Clark PR, 1999, CURR OPIN MOL THER, V1, P158
   COLLINS D, 1987, CANCER RES, V47, P735
   DAVIS JC, 2001, GEN MED, V5, P409
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dokka S, 2000, PHARMACEUT RES, V17, P521, DOI 10.1023/A:1007504613351
   Dornburg R, 2000, Adv Pharmacol, V49, P229
   Duncan JE, 1997, HUM GENE THER, V8, P431, DOI 10.1089/hum.1997.8.4-431
   Egleton RD, 1997, PEPTIDES, V18, P1431, DOI 10.1016/S0196-9781(97)00242-8
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699                                                        
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Filion MC, 1997, BBA-BIOMEMBRANES, V1329, P345, DOI 10.1016/S0005-2736(97)00126-0
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Gius DR, 1999, CANCER RES, V59, P2577
   GOMESNAVARRO J, 2000, LANCET ONCOL, V1, P48
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Gregoriadis G., 1988, LIPOSOMES DRUG CARRI
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Ho A, 2001, CANCER RES, V61, P474
   JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   KAPTURCZAK MH, 2001, CURR MOL MED, V2, P245
   LASIC D, 1992, AM SCI, V80, P20
   LASIC DD, 1993, LIPOSOMES PHYSICS AP
   LASIC DD, 1998, MEDICAL APPL LIPOSOM
   Lee HJ, 2001, BIOCONJUGATE CHEM, V12, P995, DOI 10.1021/bc0155061
   LEVCHENKO T, 2002, P CONTR REL SOC 29 A, P484
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li Y, 2002, BIOCHEM BIOPH RES CO, V298, P439, DOI 10.1016/S0006-291X(02)02470-1
   LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027
   LUDUENA RF, 1981, BIOCHEMISTRY-US, V20, P4437, DOI 10.1021/bi00518a031                                                             
   MANN DA, 1991, EMBO J, V10, P1733
   McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008
   Niidome T, 2000, J PEPT SCI, V6, P271, DOI 10.1002/1099-1387(200006)6:6<271::AID-PSC249>3.3.CO;2-6                         
   Park J, 2002, J GEN VIROL, V83, P1173, DOI 10.1099/0022-1317-83-5-1173                                                     
   Pecher G, 2001, ANTICANCER RES, V21, P2591
   Plank C, 1998, ADV DRUG DELIVER REV, V34, P21, DOI 10.1016/S0169-409X(98)00005-2                                                   
   Plank C, 1996, HUM GENE THER, V7, P1437, DOI 10.1089/hum.1996.7.12-1437                                                      
   Pooga M, 1998, FASEB J, V12, P67
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Putnam AJ, 2001, AM J PHYSIOL-CELL PH, V280, pC556
   PUYAL C, 1995, EUR J BIOCHEM, V228, P697, DOI 10.1111/j.1432-1033.1995.0697m.x
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Scheller A, 2000, EUR J BIOCHEM, V267, P6043, DOI 10.1046/j.1432-1327.2000.01681.x
   Scheule RK, 1997, HUM GENE THER, V8, P689, DOI 10.1089/hum.1997.8.6-689                                                        
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   SEARLE PF, 2002, DRUG DELIVERY SYST S, V1, P5
   SENIOR JH, 1987, CRIT REV THER DRUG, V3, P123
   Snyder EL, 2001, CURR OPIN MOL THER, V3, P147
   Speert D.P., 1997, BEHRING I MITT, V98, P274
   STOVE J, 2000, OSTEOARTHR CARTILAGE, V10, P212
   Suzuki M., 2001, Current Molecular Medicine (Hilversum), V1, P67, DOI 10.2174/1566524013364086
   TORCHILIN VP, 1995, ADV DRUG DELIVER REV, V16, P141, DOI 10.1016/0169-409X(95)00022-Y                                                    
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2001, BBA-BIOMEMBRANES, V1511, P397, DOI 10.1016/S0005-2728(01)00165-7
   Torchilin V. P., 1993, J LIPOSOME RES, V3, P201
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v
   VERHOEF K, 1993, ANAL BIOCHEM, V210, P210, DOI 10.1006/abio.1993.1176
   VIOLINI S, 2002, BIOCHEMISTRY-US, V42, P12652
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X                                                   
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 79
TC 81
Z9 87
U1 1
U2 15
PU BENTHAM SCIENCE PUBL LTD
PI HILVERSUM
PA PO BOX 1673, 1200 BR HILVERSUM, NETHERLANDS
SN 1389-2037
J9 CURR PROTEIN PEPT SC
JI Curr. Protein Pept. Sci.
PD APR
PY 2003
VL 4
IS 2
BP 133
EP 140
DI 10.2174/1389203033487298
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 658CN
UT WOS:000181704200006
PM 12678852
DA 2018-01-05
ER

PT J
AU Hosfield, D
   Palan, J
   Hilgers, M
   Scheibe, D
   McRee, DE
   Stevens, RC
AF Hosfield, D
   Palan, J
   Hilgers, M
   Scheibe, D
   McRee, DE
   Stevens, RC
TI A fully integrated protein crystallization platform for small-molecule
   drug discovery
SO JOURNAL OF STRUCTURAL BIOLOGY
LA English
DT Article
DE crystallization; automation; protein structure; drug discovery; X-ray
ID STRUCTURE-BASED DESIGN; ORALLY BIOAVAILABLE INHIBITOR; RATIONAL DESIGN;
   HIV-1 PROTEASE; POTENT; CRYSTALLOGRAPHY; EXPRESSION; PROTEOMICS;
   CRYSTALS; MICROGRAVITY
AB Structure-based drug discovery in the pharmaceutical industry benefits from cost-efficient methodologies that quickly assess the feasibility of specific, often refractory, protein targets to form well-diffracting crystals. By tightly coupling construct and purification diversity with nanovolume crystallization, the Structural Biology Group at Syrrx has developed such a platform to support its small-molecule drug-discovery program. During the past 18 months of operation at Syrrx, the Structural Biology Group has executed several million crystallization and imaging trials on over 400 unique drug-discovery targets. Here, key components of the platform, as well as an analysis of some experimental results that allowed for platform optimization, will be described. (C) 2003 Elsevier Science (USA). All rights reserved.
C1 Syrrx Inc, San Diego, CA 92121 USA.
   Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Joint Ctr Struct Genom, La Jolla, CA 92037 USA.
RP McRee, DE (reprint author), Syrrx Inc, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.
OI Stevens, Raymond/0000-0002-4522-8725
CR Aronov AM, 2000, BIOCHEMISTRY-US, V39, P4684, DOI 10.1021/bi992555g
   Blundell TL, 2002, NAT REV DRUG DISCOV, V1, P45, DOI 10.1038/nrd706
   Brizuela L, 2001, MOL BIOCHEM PARASIT, V118, P155, DOI 10.1016/S0166-6851(01)00366-8
   Buchanan SG, 2002, CURR OPIN DRUG DISC, V5, P367
   Burley SK, 2002, ANNU REV GENOM HUM G, V3, P243, DOI 10.1146/annurev.genom.3.022502.103227
   Carotenuto L, 2002, MICROGRAVITY SCI TEC, V13, P14, DOI 10.1007/BF02872072                                                              
   Claverie JM, 2002, COMB CHEM HIGH T SCR, V5, P511
   Diller DJ, 1999, PROTEINS, V36, P526, DOI 10.1002/(SICI)1097-0134(19990901)36:4<526::AID-PROT16>3.3.CO;2-6
   Ding HT, 2002, ACTA CRYSTALLOGR D, V58, P2102, DOI 10.1107/S0907444902016359
   Edwards AM, 2000, NAT STRUCT BIOL, V7, P970, DOI 10.1038/80751
   Garman E, 1999, ACTA CRYSTALLOGR D, V55, P1641, DOI 10.1107/S0907444999008653                                                       
   Goodwill KE, 2001, DRUG DISCOV TODAY, V6, pS113
   Gussio R, 2000, ANTI-CANCER DRUG DES, V15, P53
   Hauel NH, 2002, J MED CHEM, V45, P1757, DOI 10.1021/jm0109513
   HENDRICKSON WA, 1990, EMBO J, V9, P1665
   HENDRICKSON WA, 1989, BASIC LIFE SCI, V51, P317
   Holz C, 2002, PROTEIN EXPRES PURIF, V25, P372, DOI 10.1016/S1046-5928(02)00029-3                                                   
   Kaldor SW, 1997, J MED CHEM, V40, P3979, DOI 10.1021/jm9704098
   Karain WI, 2002, ACTA CRYSTALLOGR D, V58, P1519, DOI 10.1107/S0907444902012751
   Kim CU, 1997, J AM CHEM SOC, V119, P681, DOI 10.1021/ja963036t
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   Klebe G, 2000, J MOL MED-JMM, V78, P269, DOI 10.1007/s001090000084                                                           
   Krupka HI, 2002, ACTA CRYSTALLOGR D, V58, P1523, DOI 10.1107/S090744490201435X
   Kuhn P, 2002, CURR OPIN CHEM BIOL, V6, P704, DOI 10.1016/S1367-5931(02)00361-7                                                   
   Lamzin VS, 2000, NAT STRUCT BIOL, V7, P978, DOI 10.1038/80763                                                                   
   Lesley SA, 2001, PROTEIN EXPRES PURIF, V22, P159, DOI 10.1006/prep.2001.1465
   Maignan Sebastien, 2001, Current Topics in Medicinal Chemistry, V1, P161, DOI 10.2174/1568026013395461
   Muchmore SW, 2000, STRUCTURE, V8, pR243, DOI 10.1016/S0969-2126(00)00535-9                                                   
   Neamati N, 2001, EXPERT OPIN INV DRUG, V10, P281, DOI 10.1517/13543784.10.2.281                                                       
   Ng JD, 2002, ACTA CRYSTALLOGR D, V58, P645, DOI 10.1107/S0907444902003177
   Possee RD, 1997, CURR OPIN BIOTECH, V8, P569, DOI 10.1016/S0958-1669(97)80030-4
   Rahuel J, 2000, CHEM BIOL, V7, P493, DOI 10.1016/S1074-5521(00)00134-4
   REICH SH, 1995, P NATL ACAD SCI USA, V92, P3298, DOI 10.1073/pnas.92.8.3298
   Rupp B, 2002, ACTA CRYSTALLOGR D, V58, P1514, DOI 10.1107/S0907444902014282
   Santarsiero BD, 2002, J APPL CRYSTALLOGR, V35, P278, DOI 10.1107/S0021889802001474
   Saraswathi NT, 2002, ACTA CRYSTALLOGR D, V58, P1162, DOI 10.1107/S0907444902007126
   Schmid MB, 2002, TRENDS MICROBIOL, V10, pS27, DOI 10.1016/S0966-842X(02)02443-5
   Schroder J, 2001, J MED CHEM, V44, P3231, DOI 10.1021/jm010887p
   Stevens RC, 2000, CURR OPIN STRUC BIOL, V10, P558, DOI 10.1016/S0959-440X(00)00131-7                                                   
   Stevens RC, 2001, SCIENCE, V293, P519, DOI 10.1126/science.293.5529.519                                                    
   Stewart L, 2002, DRUG DISCOV TODAY, V7, P187, DOI 10.1016/S1359-6446(01)02121-3
   Sugahara Mitsuaki, 2002, Tanpakushitsu Kakusan Koso, V47, P1026
   Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839                                                       
   THAISRIVONGS S, 1994, J MED CHEM, V37, P3200, DOI 10.1021/jm00046a002
   TRAKHANOV S, 1995, PROTEIN SCI, V4, P1914, DOI 10.1002/pro.5560040925                                                          
   Vekilov PG, 1999, ADV SPACE RES, V24, P1231, DOI 10.1016/S0273-1177(99)00725-5
   VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0
   WALKINSHAW MD, 1992, MED RES REV, V12, P317, DOI 10.1002/med.2610120403
   Waszkowycz B, 2002, CURR OPIN DRUG DI DE, V5, P407
   Yasutake Yoshiaki, 2002, Tanpakushitsu Kakusan Koso, V47, P1033
NR 50
TC 58
Z9 62
U1 0
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1047-8477
J9 J STRUCT BIOL
JI J. Struct. Biol.
PD APR
PY 2003
VL 142
IS 1
BP 207
EP 217
DI 10.1016/S1047-8477(03)00051-0
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 675TJ
UT WOS:000182711400019
PM 12718932
DA 2018-01-05
ER

PT J
AU Rudolph, C
   Plank, C
   Lausier, J
   Schillinger, U
   Muller, RH
   Rosenecker, J
AF Rudolph, C
   Plank, C
   Lausier, J
   Schillinger, U
   Muller, RH
   Rosenecker, J
TI Oligomers of the arginine-rich motif of the HIV-1 TAT protein are
   capable of transferring plasmid DNA into cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MEDIATED GENE-TRANSFER; IN-VIVO;
   INTRACELLULAR DELIVERY; MAMMALIAN-CELLS; EFFICIENT; LIPOSOMES; PEPTIDES;
   POLYETHYLENIMINE; TRANSDUCTION
AB We constructed multimers of the TAT-(47-57) peptide. This polycationic peptide is known to be a protein and particle transduction domain and at the same time to comprise a nuclear localization function. Here we show that oligomers of the TAT-(47-57) peptide compact plasmid DNA to nanometric particles and stabilize DNA toward nuclease degradation. At optimized vector compositions, these peptides mediated gene delivery to cells in culture 6-8-fold more efficiently than poly-L-arginine or the mutant TAT(2)-M1. When DNA was precompacted with TAT peptides and polyethyleneimine (PEI), Superfect, or LipofectAMINE was added, transfection efficiency was enhanced up to 390-fold compared with the standard vectors. As early as after 4 h of transfection, reporter gene expression mediated by TAT-containing complexes was higher than the 24-h transfection level achieved with a standard PEI transfection. When cells were cell cycle-arrested by serum starvation or aphidicolin, TAT-mediated transfection was 3-fold more efficient than a standard PEI transfection in proliferating cells. In primary nasal epithelial cells and upon intratracheal instillation in vivo, TAT-containing complexes were superior to standard PEI vectors. These data together with confocal imaging of TAT-DNA complexes in cells support the hypothesis that the TAT nuclear localization sequence function is involved in enhancing gene transfer.
C1 Univ Munich, Div Mol Pulmonol, Dept Pediat, D-80337 Munich, Germany.
   Tech Univ Munich, Inst Expt Oncol, D-81675 Munich, Germany.
   Free Univ Berlin, Inst Pharm, D-12169 Berlin, Germany.
RP Rosenecker, J (reprint author), Univ Munich, Div Mol Pulmonol, Dept Pediat, Lindwurm 2A, D-80337 Munich, Germany.
RI Rudolph, Carsten/B-9379-2011; Plank, Christian/F-9628-2011
OI Plank, Christian/0000-0002-6072-4903
CR Behr JP, 1997, CHIMIA, V51, P34
   Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102
   Chida K, 1998, BIOCHEM BIOPH RES CO, V249, P849, DOI 10.1006/bbrc.1998.9245                                                          
   COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033                                                         
   de Lima MCP, 1999, MOL MEMBR BIOL, V16, P103
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Escriou V, 2001, J GENE MED, V3, P179, DOI 10.1002/jgm.174
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   LEE KD, 1993, BIOCHEMISTRY-US, V32, P889, DOI 10.1021/bi00054a021
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   MANN DA, 1991, EMBO J, V10, P1733
   Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349
   Ogris M, 1998, GENE THER, V5, P1425, DOI 10.1038/sj.gt.3300745
   Plank C, 1999, HUM GENE THER, V10, P319, DOI 10.1089/10430349950019101                                                       
   PLANK C, 1994, J BIOL CHEM, V269, P12918
   Pollard H, 1998, J BIOL CHEM, V273, P7507, DOI 10.1074/jbc.273.13.7507
   Rudolph C, 2000, J GENE MED, V2, P269, DOI 10.1002/1521-2254(200007/08)2:4<269::AID-JGM112>3.0.CO;2-F                      
   Rudolph C, 2002, J GENE MED, V4, P66, DOI 10.1002/jgm.225                                                                 
   Schaffer DV, 2000, BIOTECHNOL BIOENG, V67, P598, DOI 10.1002/(SICI)1097-0290(20000305)67:5<598::AID-BIT10>3.0.CO;2-G                 
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Slepushkin VA, 1997, J BIOL CHEM, V272, P2382
   SOLOVEI I, IN PRESS METHODS MOL
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Truant R, 1999, MOL CELL BIOL, V19, P1210
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Ward CM, 2001, BLOOD, V97, P2221, DOI 10.1182/blood.V97.8.2221
   Wolfert MA, 1999, BIOCONJUGATE CHEM, V10, P993, DOI 10.1021/bc990025r
   ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997                                                        
NR 31
TC 196
Z9 204
U1 2
U2 26
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 28
PY 2003
VL 278
IS 13
BP 11411
EP 11418
DI 10.1074/M211891200
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 660VU
UT WOS:000181855400070
PM 12519756
DA 2018-01-05
ER

PT J
AU Oscarsson, K
   Lahmann, M
   Lindberg, J
   Kangasmetsa, J
   Unge, T
   Oscarson, S
   Hallberg, A
   Samuelsson, B
AF Oscarsson, K
   Lahmann, M
   Lindberg, J
   Kangasmetsa, J
   Unge, T
   Oscarson, S
   Hallberg, A
   Samuelsson, B
TI Design and synthesis of HIV-1 protease inhibitors. Novel tetrahydrofuran
   P2/P2 '-groups interacting with Asp29/30 of the HIV-1 protease.
   Determination of binding from X-ray crystal structure of inhibitor
   protease complex
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; DEFICIENCY SYNDROME AIDS;
   PROTEINASE-INHIBITORS; ANTIVIRAL ACTIVITY; NATURAL-PRODUCTS; POTENT;
   MATURATION; L-735,524; MODEL
AB A series of HIV-1 protease inhibitors having new tetrahydrofuran P2/P2' groups have been synthesised and tested for protease inhibition and antiviral activity. Six novel 4-aminotetrahydrofuran derivatives were prepared starting from commercially available isopropylidene-alpha-D-xylofuranose yielding six symmetrical and six unsymmetrical inhibitors. Promising sub nanomolar HIV-1 protease inhibitory activities were obtained. The X-ray crystal structure of the most potent inhibitor (23, K-i 0.25 nM) cocrystallised with HIV-1 protease is discussed and the binding compared with inhibitors 1a and 1b. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Stockholm Univ, Dept Organ Chem, Arrhenius Lab, S-10691 Stockholm, Sweden.
   Uppsala Univ, Dept Cell & Mol Biol, BMC, S-75124 Uppsala, Sweden.
   Medivir AB, S-14144 Huddinge, Sweden.
   Univ Uppsala, BMC, Dept Organ Pharmaceut Chem, S-75123 Uppsala, Sweden.
RP Samuelsson, B (reprint author), Stockholm Univ, Dept Organ Chem, Arrhenius Lab, Floor 6, S-10691 Stockholm, Sweden.
RI Lahmann, Martina/A-3090-2010
OI Lahmann, Martina/0000-0002-8513-1952; Oscarson,
   Stefan/0000-0002-8273-4918
CR Alterman M, 1998, J MED CHEM, V41, P3782, DOI 10.1021/jm970777b                                                               
   ANDERSSON H, UNPUB
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BOLON PJ, 1994, TETRAHEDRON, V50, P7747, DOI 10.1016/S0040-4020(01)85259-5
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   Ewing GJ, 1999, ORG LETT, V1, P635, DOI 10.1021/ol9901117                                                               
   GALLO RC, 1983, SCIENCE, V220, P865, DOI 10.1126/science.6601823                                                         
   Ghosh AK, 1998, SYNTHESIS-STUTTGART, P937
   GIULIANO RM, 1995, J ORG CHEM, V60, P202, DOI 10.1021/jo00106a035
   GOSH AK, 1998, BIOORG MED CHEM LETT, V8, P687
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001
   KALISH V, 1995, EUR J MED CHEM, V30, pS201
   KEMPF DJ, 1995, P NATL ACAD SCI USA, V92, P2484, DOI 10.1073/pnas.92.7.2484
   Kempf DJ, 1996, CURR PHARM DESIGN, V2, P225
   Kempf D. J., 1995, PERSPECT DRUG DISCOV, V2, P427
   MARKGREN PO, 1998, ASPARTIC PROTEINASES, P99
   MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486
   Mills JS, 1996, ANTIVIR CHEM CHEMOTH, V7, P281, DOI 10.1177/095632029600700601                                                      
   MITSUNOBU O, 1981, SYNTHESIS-STUTTGART, P1, DOI 10.1055/s-1981-29317                                                            
   Nillroth U, 1997, ANTIMICROB AGENTS CH, V41, P2383
   Oscarsson K, 2000, CAN J CHEM, V78, P829, DOI 10.1139/cjc-78-6-829                                                            
   OZOLS AM, 1980, SYNTHESIS-STUTTGART, P557
   PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0
   PENG C, 1989, J VIROL, V63, P2550
   Reddy P, 1999, FORMULARY, V34, P567
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   Rusconi S, 2002, EXPERT OPIN INV DRUG, V11, P387
   SEELMEIER S, 1988, P NATL ACAD SCI USA, V85, P6612, DOI 10.1073/pnas.85.18.6612
   Stoner EJ, 2000, ORG PROCESS RES DEV, V4, P264, DOI 10.1021/op990202j
   Turner Steve R., 2002, Current Medicinal Chemistry - Anti-Infective Agents, V1, P141, DOI 10.2174/1568012023354956
   VACCA JP, 1994, P NATL ACAD SCI USA, V91, P4096, DOI 10.1073/pnas.91.9.4096
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   Williamson A., 1851, LIEBIGS ANN CHEM, V77, P37, DOI DOI 10.1002/JLAC.18510770104
   WOLFROM ML, 1962, J ORG CHEM, V27, P1800, DOI 10.1021/jo01052a076                                                             
   YOUNG C, 1999, RAY TRACER POV RAY 3
   ZEMPLEN G, 1929, BER DTSCH CHEM GES, V62, P534
NR 37
TC 11
Z9 11
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAR 20
PY 2003
VL 11
IS 6
BP 1107
EP 1115
AR PII S0968-0896(02)00535-7
DI 10.1016/S0968-0896(02)00535-7
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 655CZ
UT WOS:000181534900033
PM 12614898
DA 2018-01-05
ER

PT J
AU Parolin, C
   Gatto, B
   Del Vecchio, C
   Pecere, T
   Tramontano, E
   Cecchetti, V
   Fravolini, A
   Masiero, S
   Palumbo, M
   Palu, G
AF Parolin, C
   Gatto, B
   Del Vecchio, C
   Pecere, T
   Tramontano, E
   Cecchetti, V
   Fravolini, A
   Masiero, S
   Palumbo, M
   Palu, G
TI New anti-human immunodeficiency virus type 1 6-aminoquinolones:
   Mechanism of action
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID ANTIRETROVIRAL THERAPY; HAMMERHEAD RIBOZYME; TAR RNA; ARYLPIPERAZINYL
   FLUOROQUINOLONES; QUINOLONE ANTIBACTERIALS; ANTIVIRAL ACTIVITY; LATENT
   RESERVOIR; ESCHERICHIA-COLI; HIV-1 INTEGRASE; DNA GYRASE
AB A 6-aminoquinolone derivative, WM5, which bears a methyl substituent at the N-1 position and a 4-(2-pyridyl)-1-piperazine moiety at position 7 of the bicyclic quinolone ring system, was previously shown to exhibit potent activity against replication of human immunodeficiency virus type 1 (HIV-1) in de novo-infected human lymphoblastoid cells (V. Cecchetti et al., J. Med. Chem. 43:3799-3802, 2000). In this report, we further investigated WM5's mechanism of antiviral activity. WM5 inhibited HIV-1 replication in acutely infected cells as well as in chronically infected cells. The 50% inhibitory concentrations were 0.60 +/- 0.06 and 0.85 +/- 0.05 muM, respectively. When the effects of WM5 on different steps of the virus life cycle were analyzed, the reverse transcriptase activity and the integrase and protease activities were not impaired. By using a transient trans-complementation assay to examine the activity of WM5 on the replicative potential of HIV-1 in a single round of infection, a sustained inhibition of Tat-mediated long terminal repeat (LTR)-driven transcription (>80% of controls) was obtained in the presence of 5 muM WM5. Interestingly, the aminoquinolone was found to efficiently complex TAR RNA, with a dissociation constant in the nanomolar range (19 +/- 0.6 nM). These data indicate that WM5 is a promising lead compound for the development of a new class of HIV-1 transcription inhibitors characterized by recognition of viral RNA target(s).
C1 Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Microbiol & Virol, I-35121 Padua, Italy.
   Univ Padua, Dept Pharmaceut Sci, I-35121 Padua, Italy.
   Univ Cagliari, Dept Expt Biol, I-09042 Cagliari, Italy.
   Univ Perugia, Dept Pharmaceut Chem & Technol, I-06123 Perugia, Italy.
RP Palu, G (reprint author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Sect Microbiol & Virol, Via A Gabelli 63, I-35121 Padua, Italy.
RI Tramontano, Enzo/B-4919-2012; Gatto, Barbara/B-1542-2013
OI Tramontano, Enzo/0000-0002-4849-0980; Gatto,
   Barbara/0000-0001-9465-6913; Cecchetti, Violetta/0000-0001-8558-7004;
   Palumbo, Manlio/0000-0002-3163-1564
CR ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   ANTONELLO C, 1993, EUR J MED CHEM, V28, P291, DOI 10.1016/0223-5234(93)90146-6
   Artico M, 1998, J MED CHEM, V41, P3948, DOI 10.1021/jm9707232
   Baba M, 1998, MOL PHARMACOL, V53, P1097
   Baba M, 1997, ANTIMICROB AGENTS CH, V41, P1250
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   Bassi GS, 1999, BIOCHEMISTRY-US, V38, P3345, DOI 10.1021/bi982985r
   BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45
   Cecchetti V, 2000, J MED CHEM, V43, P3799, DOI 10.1021/jm9903390
   Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193
   Cohen J, 1998, SCIENCE, V279, P1854, DOI 10.1126/science.279.5358.1854                                                   
   COLLMAN R, 1992, J VIROL, V66, P7517
   CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S
   CULLEN BR, 1987, METHOD ENZYMOL, V152, P684
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8                                                   
   FAUCI AS, 1984, ANN INTERN MED, V100, P92, DOI 10.7326/0003-4819-100-1-92
   FENG Y, 1996, SCIENCE, V272, P809
   Finzi D, 1999, NAT MED, V5, P512
   Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295
   GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936
   Gatto B, 1999, CURR PHARM DESIGN, V5, P195
   Hagihara M, 1999, BIOORG MED CHEM LETT, V9, P3063, DOI 10.1016/S0960-894X(99)00537-5
   HELSETH E, 1990, J VIROL, V64, P2416
   Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417
   Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984
   HUI JO, 1993, J PROTEIN CHEM, V12, P323, DOI 10.1007/BF01028194
   Hwang S, 1999, P NATL ACAD SCI USA, V96, P12997, DOI 10.1073/pnas.96.23.12997
   Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819
   Kashiwase H, 1999, CHEMOTHERAPY, V45, P48, DOI 10.1159/000007164                                                               
   Litovchick A, 2000, BIOCHEMISTRY-US, V39, P2838, DOI 10.1021/bi9917885
   Marshall A. G., 1978, BIOPHYSICAL CHEM, P70
   Maschera B, 1996, J BIOL CHEM, V271, P33231, DOI 10.1074/jbc.271.52.33231                                                        
   MASCHERA B, 1995, J VIROL, V69, P5431
   MOSSMANN T, 1983, J IMMUNOL METHODS, V65, P55
   Ohmine T, 2002, BIOORG MED CHEM LETT, V12, P739, DOI 10.1016/S0960-894X(02)00003-3
   Okamoto H, 2000, VIROLOGY, V272, P402, DOI 10.1006/viro.2000.0396
   Okamoto M, 1999, ANTIMICROB AGENTS CH, V43, P492
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PALU G, 1992, P NATL ACAD SCI USA, V89, P9671, DOI 10.1073/pnas.89.20.9671
   PALU G, 1991, EUR J CLIN MICROBIOL, V20, P350
   Palumbo M, 1993, Trends Microbiol, V1, P232, DOI 10.1016/0966-842X(93)90138-H
   PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577                                                                   
   RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0                                                                
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5                                                    
   Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065
   SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3886, DOI 10.1021/bi00435a039
   SHEN LL, 1989, BIOCHEMISTRY-US, V28, P3879, DOI 10.1021/bi00435a038
   SISSI C, 1998, BIOORGAN MED CHEM, V6, P1551
   TOTH MV, 1990, INT J PEPT PROT RES, V36, P544
   Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o                                                               
   VALISENA S, 1990, BIOCHEM PHARMACOL, V40, P431, DOI 10.1016/0006-2952(90)90540-2
   Witvrouw M, 1998, ANTIVIR CHEM CHEMOTH, V9, P403, DOI 10.1177/095632029800900504                                                      
   Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291
   ZACHARIAS M, 1995, J MOL BIOL, V247, P486, DOI 10.1006/jmbi.1995.0155
   ZACHARIAS M, 1995, P NATL ACAD SCI USA, V92, P6052, DOI 10.1073/pnas.92.13.6052
   Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101                                                     
   ZHOU QA, 1995, EMBO J, V14, P321
NR 60
TC 50
Z9 55
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAR
PY 2003
VL 47
IS 3
BP 889
EP 896
DI 10.1128/AAC.47.3.889-896.2003
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 649HR
UT WOS:000181202000009
PM 12604517
OA gold
DA 2018-01-05
ER

PT J
AU Hanna, DM
   Oakley, BA
   Stryker, GA
AF Hanna, DM
   Oakley, BA
   Stryker, GA
TI Using a system-on-a-chip Implantable device to filter circulating
   infected cells in blood or lymph
SO IEEE TRANSACTIONS ON NANOBIOSCIENCE
LA English
DT Article
DE biological microelectromechanical system; (bioMEMS); engineered
   antibodies; human immunodeficiency virus (HIV); system on a chip
ID SELF-ASSEMBLED MONOLAYERS; VLSI NEURAL-NETWORK; PATTERN-RECOGNITION;
   IN-VIVO; ELECTRICAL BREAKDOWN; CHEMOTHERAPY; MEMBRANES; PROTEINS;
   THERAPY; ELECTROPORATION
AB This paper describes a system on a chip (SoC) that makes use of nanoscale cellular adhesion mechanisms in an integrated electronic microsystem to filter infected cells from blood or lymph. An example of a human immunodeficiency virus-specific SoC is explored in depth. Such systems work in vivo, and blood and lymph are filtered on a continuous basis. With the intelligence on the chip, captured cells can be identified and lyzed, expelled, or otherwise acted upon. These types of systems transfer the burden of research from traditional chemotherapy to bioengineering and system design.
C1 Oakland Univ, Sch Engn & Comp Sci, Rochester, MI 48309 USA.
   Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
RP Oakley, BA (reprint author), Oakland Univ, Sch Engn & Comp Sci, Rochester, MI 48309 USA.
EM oakley@oakland.edu
FU NIBIB NIH HHS [R21 EB00672-01]
CR ARYA M, 2002, 2 JOINT EMBS BMES C
   Baraldi A, 1999, IEEE T SYST MAN CY B, V29, P778, DOI 10.1109/3477.809032
   Beach RD, 2001, IEEE T INSTRUM MEAS, V50, P716, DOI 10.1109/19.930445
   Beebe DJ, 2002, ANNU REV BIOMED ENG, V4, P261, DOI 10.1146/annurev.bioeng.4.112601.125916
   BEIU V, 1996, 5 INT C MICR NEUR NE
   BENZ R, 1980, BIOCHIM BIOPHYS ACTA, V597, P637, DOI 10.1016/0005-2736(80)90236-9
   BENZ R, 1981, BIOCHIM BIOPHYS ACTA, V640, P169, DOI 10.1016/0005-2736(81)90542-3
   BENZ R, 1980, J ELECTROANAL CHEM, V116, P723
   Bernard A, 2001, NAT BIOTECHNOL, V19, P866, DOI 10.1038/nbt0901-866
   BLAKESLEE D, 1999, HIV AIDS RESOURCE CT
   Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013
   CIACCIO EJ, 1994, IEEE ENG MED BIOL, V13, P129, DOI 10.1109/51.265792
   COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947
   COGGINS R, 1995, IEEE J SOLID-ST CIRC, V30, P542, DOI 10.1109/4.384167
   Coster HGL, 1999, AUST J PHYS, V52, P117, DOI 10.1071/P98088                                                                  
   Dawson SL, 1997, J MOL RECOGNIT, V10, P18, DOI 10.1002/(SICI)1099-1352(199701/02)10:1<18::AID-JMR349>3.3.CO;2-N
   DeBruin KA, 1999, BIOPHYS J, V77, P1213, DOI 10.1016/S0006-3495(99)76973-0                                                   
   Dickhaus H, 1996, IEEE ENG MED BIOL, V15, P103, DOI 10.1109/51.537066
   Dieleman JP, 2002, AIDS, V16, P737, DOI 10.1097/00002030-200203290-00009
   Efremov NM, 2000, IEEE T PLASMA SCI, V28, P224, DOI 10.1109/27.842908
   HANNA DM, 2003, THESIS OAKLAND U ROC
   HASKELL RE, 1998, 3 INT C APPL FUZZ SY
   Ho SY, 1996, CRIT REV BIOTECHNOL, V16, P349, DOI 10.3109/07388559609147426
   Jain AK, 2000, IEEE T PATTERN ANAL, V22, P4, DOI 10.1109/34.824819
   Kneller LR, 2001, BIOPHYS J, V80, P2248, DOI 10.1016/S0006-3495(01)76197-8                                                   
   KUMAR A, 1995, ACCOUNTS CHEM RES, V28, P219, DOI 10.1021/ar00053a003                                                             
   LEE SW, 1998, IEEE 11 INT WORKSH M
   Leong P. H. W., 1991, Proceedings. Computers in Cardiology (Cat. No.91CH3116-1), P189, DOI 10.1109/CIC.1991.169077
   Meinardi MT, 2000, CANCER TREAT REV, V26, P429, DOI 10.1053/ctrv.2000.0175
   MELVIN DG, 1997, 7 IEEE WORKSH NEUR N
   MIKLAVCIC D, 2000, 22 ANN EMBS INT C CH
   Montalvo AJ, 1997, IEEE J SOLID-ST CIRC, V32, P535, DOI 10.1109/4.563675
   Murakawa M, 2001, CELL DEATH DIFFER, V8, P298, DOI 10.1038/sj.cdd.4400811
   OAKLEY B, 2002, IEEE EMBS SPEC TOP C
   Oettle H, 2001, J CANCER RES CLIN, V127, P340, DOI 10.1007/s004320000193
   Paech V, 2002, ARCH INTERN MED, V162, P1197, DOI 10.1001/archinte.162.10.1197
   PAI RS, 2002, IEEE 2 JOINT EMBS BM
   Phillips KA, 1998, J CLIN ONCOL, V16, P3179, DOI 10.1200/JCO.1998.16.9.3179                                                      
   ROSEN RH, 2002, J PHARM PRACTICE, V15, P32
   SARKAR M, 2000, P IEEE INT C SYST MA, V4, P2878
   Schalkoff R. J, 1992, PATTERN RECOGNITION
   Service RF, 1999, SCIENCE, V283, P619, DOI 10.1126/science.283.5402.619
   SHAFFER K, 1990, P 5 IEEE INT S INT C, V1, P530
   SHARMA YD, 1991, INT J BIOCHEM, V23, P775, DOI 10.1016/0020-711X(91)90061-Q
   SIGSGAARD TC, 1998, DANISH MED B, V45, P456
   Sitzia J, 1995, INT J NURS STUD, V32, P580, DOI 10.1016/0020-7489(95)00022-8
   Soong RK, 2000, SCIENCE, V290, P1555, DOI 10.1126/science.290.5496.1555                                                   
   Spatz JP, 2002, ANGEW CHEM INT EDIT, V41, P3359, DOI 10.1002/1521-3773(20020916)41:18<3359::AID-ANIE3359>3.0.CO;2-Y                  
   SZIRANYI T, 1994, P 12 IAPR INT C PATT, V94, P381
   TEISSIE J, 1993, BIOPHYS J, V65, P409, DOI 10.1016/S0006-3495(93)81052-X                                                   
   Tullis R H, 2001, Am Clin Lab, V20, P22
   UNAIDS/WHO, 2002, REP GLOB HIV AIDS EP
   Vijayendran RA, 2001, ANAL CHEM, V73, P471, DOI 10.1021/ac000523p
   WEAVER JC, 2000, METHODS MOL BIOL ELE, V47
   Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919
   WILAMOWSKI BM, 1998, P 24 ANN C IEEE, V1, P52
   WISE KD, 2002, VLSI CIRCUITS DIG TE, P106
   Wit FWNM, 2002, J INFECT DIS, V186, P23, DOI 10.1086/341084                                                                  
   Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.3.CO;2-7
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
   CHERWONOGRODZKY JW, 1999, Patent No. 6436652
   KAWASE M, 1998, Patent No. 6182659
NR 62
TC 12
Z9 12
U1 2
U2 6
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855 USA
SN 1536-1241
J9 IEEE T NANOBIOSCI
JI IEEE Trans. Nanobiosci.
PD MAR
PY 2003
VL 2
IS 1
BP 6
EP 13
DI 10.1109/TNB.2003.810160
PG 8
WC Biochemical Research Methods; Nanoscience & Nanotechnology
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA 780QJ
UT WOS:000189392600002
PM 15382417
DA 2018-01-05
ER

PT J
AU Ranise, A
   Spallarossa, A
   Schenone, S
   Bruno, O
   Bondavalli, F
   Vargiu, L
   Marceddu, T
   Mura, M
   La Colla, P
   Pani, A
AF Ranise, A
   Spallarossa, A
   Schenone, S
   Bruno, O
   Bondavalli, F
   Vargiu, L
   Marceddu, T
   Mura, M
   La Colla, P
   Pani, A
TI Design, synthesis, SAR, and molecular modeling studies of
   acylthiocarbamates: A novel series of potent non-nucleoside HIV-1
   reverse transcriptase inhibitors structurally related to
   phenethylthiazolylthiourea derivatives
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; ANTIRETROVIRAL
   THERAPY; RESISTANCE MUTATIONS; CRYSTAL-STRUCTURES; PETT COMPOUNDS;
   ANALOGS; RESOLUTION; COMPLEX; MUTANTS
AB A novel series of potent, selective HIV-1 N-acylthiocarbamate (ATC) nonnucleoside reverse transcriptase inhibitors (NNRTIs) is described. The title compounds were synthesized through a highly convergent, one-pot procedure. In cell-based assays, the lead compound (17c) prevented the HIV-1 multiplication with an EC50 of 8 muM. The lead optimization strategy was developed by single or multiple modifications of the three molecular portions, in which 17c was notionally divided. Molecular modeling studies led to the synthesis of O-(2-phthalimidoethyl)-N-(p-substituted phenyl)-N-acylthiocarbamates, which showed in vitro activities against HIV-1 in the low nanomolar range. Nevertheless, the title compounds retained low potency against HIV-1 strains carrying mutations (K103R, Y181C, and K103N/Y181C) responsible for NNRTI resistance. The hypothetical docking model of RT/17c and RT/25c, derived from X-ray crystallographic structure of a PETT derivative in complex with HIV-1 RT, revealed that the model structures of ATCs do not approximate the NNRTI butterfly-like conformation. Analysis of these hypotetical complexes helps to rationalize some SARs and resistance data.
C1 Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy.
   Univ Cagliari, Cooperat Lab Idenix, I-09042 Monserrato, Cagliari, Italy.
   Univ Cagliari, Dipartimento Biol Sperimentale, I-09042 Monserrato, Cagliari, Italy.
RP Ranise, A (reprint author), Univ Genoa, Dipartimento Sci Farmaceut, Viale Benedetto XV 3, I-16132 Genoa, Italy.
EM ranise@unige.it; placolla@unica.it
RI Pani, Alessandra/B-7831-2011
OI Pani, Alessandra/0000-0002-0437-2499
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   Artico M, 1996, J MED CHEM, V39, P522, DOI 10.1021/jm950568w
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Campiani G, 2000, ANTIVIR CHEM CHEMOTH, V11, P141, DOI 10.1177/095632020001100206                                                      
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Casimiro-Garcia A, 1999, J MED CHEM, V42, P4861, DOI 10.1021/jm990343b
   *COL U, 1996, MACR MOD 5 5
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106
   De Clercq E, 2000, REV MED VIROL, V10, P255, DOI 10.1002/1099-1654(200007/08)10:4<255::AID-RMV282>3.0.CO;2-6
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102
   Goldman Mark E., 1993, P105
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   *IND U, AM1MOPAC QCPE PROGR
   JIRMAN J, 1987, COLLECT CZECH CHEM C, V52, P2474, DOI 10.1135/cccc19872474                                                            
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   KATZ RA, 1991, ANNU REV BIOCHEM, V60, P577
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KOLOCOURIS N, 1994, J MED CHEM, V37, P2896, DOI 10.1021/jm00044a010
   KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078
   Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002
   MAASS G, 1993, ANTIMICROB AGENTS CH, V37, P2612, DOI 10.1128/AAC.37.12.2612                                                          
   MELLORS JW, 1991, MOL PHARMACOL, V42, P446
   Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060                                                                
   Motakis D, 2002, ANTIMICROB AGENTS CH, V46, P1851, DOI 10.1128/AAC.46.6.1851-1856.2002
   Nanni Raymond G., 1993, Perspectives in Drug Discovery and Design, V1, P129, DOI 10.1007/BF02171659
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PEARSON RG, 1988, J AM CHEM SOC, V110, P7684, DOI 10.1021/ja00231a017                                                             
   Pedersen OS, 2000, SYNTHESIS-STUTTGART, P479
   RANISE A, 1994, FARMACO, V49, P551
   RANISE A, 1991, FARMACO, V46, P317
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m                                                               
   Ren JS, 1999, J MED CHEM, V42, P3845, DOI 10.1021/jm990275t                                                               
   Ren JS, 2000, J BIOL CHEM, V275, P5633, DOI 10.1074/jbc.275.8.5633
   RICHMAN D, 1991, P NATL ACAD SCI USA, V88, P11241, DOI 10.1073/pnas.88.24.11241
   RICHMAN DD, 1994, J VIROL, V68, P1660
   SCHAFER W, 1993, J MED CHEM, V36, P726, DOI 10.1021/jm00058a009
   SILICIANO RF, 1999, CURR INFECT DIS REP, V3, P298
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   SMITH BM, 2001, MARCHS ADV ORGANIC C, P1338
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Vamecq J., 1998, Life Sciences, V63, P267
   Van Derpoorten K, 1997, BIOMED PHARMACOTHER, V51, P464, DOI 10.1016/S0753-3322(97)82327-X
   Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6
   WALTER W, 1967, ANGEW CHEM INT EDIT, V6, P281, DOI 10.1002/anie.196702811                                                          
   Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6                                                   
   1999, IT HUNG POL JOINT M
   1995, 2 IT SPAN JOINT M ME
NR 55
TC 41
Z9 42
U1 0
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 27
PY 2003
VL 46
IS 5
BP 768
EP 781
DI 10.1021/jm0209984
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 647JY
UT WOS:000181090700015
PM 12593657
DA 2018-01-05
ER

PT J
AU Peyrottes, S
   Coussot, G
   Lefebvre, I
   Imbach, JL
   Gosselin, G
   Aubertin, AM
   Perigaud, C
AF Peyrottes, S
   Coussot, G
   Lefebvre, I
   Imbach, JL
   Gosselin, G
   Aubertin, AM
   Perigaud, C
TI S-acyl-2-thioethyl aryl phosphotriester derivatives of AZT: Synthesis,
   antiviral activity, and stability study
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PHOSPHATE-PROTECTING GROUPS; MONONUCLEOTIDE PRODRUGS; AMIDASE;
   HYDROLYSIS; PRONUCLEOTIDES; PURIFICATION; DELIVERY; ANALOGS; ESTERS
AB The synthesis, antiviral activity, and stability study of phosphotriester derivatives of 3'-azido2',3'-dideoxythymidine (AZT) bearing modified L-tyrosinyl residues are reported. These compounds were obtained via phosphoramidite (P-III) chemistry from the appropriate aryl precursors. All the derivatives were evaluated for their in vitro anti-HIV activity, and they appeared to be potent inhibitors of HIV-1 replication in various cell culture experiments, with EC50 values between the micro- and nanomolar range, especially in thymidine kinase deficient (TK-) cells, showing their ability to act as mononucleotide prodrugs. The proposed decomposition process of these mixed mononucleoside aryl phosphotriesters successively involves an esterase and a phosphodiesterase hydrolysis.
C1 Univ Montpellier 2, CNRS, UMII, UMR 5625, F-34095 Montpellier 05, France.
   Univ Strasbourg 1, Lab Virol,Fac Med, INSERM, Unite 74, F-67000 Strasbourg, France.
RP Perigaud, C (reprint author), Univ Montpellier 2, CNRS, UMII, UMR 5625, Case Courrier 008,Pl Eugene Bataillon, F-34095 Montpellier 05, France.
EM perigaud@univ-montp2.fr
CR Alvarez K, 1999, J ORG CHEM, V64, P6319, DOI 10.1021/jo990479h                                                               
   Balzarini J, 1999, MOL PHARMACOL, V56, P1354
   CLARKE PH, 1970, ADV MICROBIAL PHYSL, P179
   COREY EJ, 1972, J AM CHEM SOC, V94, P6190, DOI 10.1021/ja00772a043                                                             
   FENG XQ, 1992, J ORG CHEM, V57, P5811, DOI 10.1021/jo00048a005
   FORD H, 1991, J LIQ CHROMATOGR, V14, P3365, DOI 10.1080/01483919108049396
   GOSSELIN G, 1993, ANTIVIR RES, V22, P143, DOI 10.1016/0166-3542(93)90092-W
   HAMADA Y, 1987, J ORG CHEM, V52, P1252, DOI 10.1021/jo00383a014
   Hirrlinger B, 1996, J BACTERIOL, V178, P3501, DOI 10.1128/jb.178.12.3501-3507.1996                                                
   JAKOBY WB, 1964, J BIOL CHEM, V239, P1978
   KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030                                                             
   Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9                                                   
   KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x                                              
   Kotlova EK, 1999, BIOCHEMISTRY-MOSCOW+, V64, P384
   KUYLYEHESKIELY E, 1987, NUCLEIC ACIDS RES, V15, P1807, DOI 10.1093/nar/15.4.1807
   LEFEBVRE I, 1995, J MED CHEM, V38, P3941, DOI 10.1021/jm00020a007
   McKillop A, 1996, J CHEM SOC PERK T 1, P1385, DOI 10.1039/p19960001385                                                            
   Meier C, 2001, NUCLEOS NUCLEOT NUCL, V20, P307, DOI 10.1081/NCN-100002301
   Parang K, 2000, CURR MED CHEM, V7, P995, DOI 10.2174/0929867003374372                                                        
   Perigaud C, 1996, ANTIVIR CHEM CHEMOTH, V7, P338, DOI 10.1177/095632029600700607                                                      
   PERIGAUD C, 2000, BIOMEDICAL CHEM APPL, P115
   Peyrottes S, 2001, NUCLEOS NUCLEOT NUCL, V20, P315, DOI 10.1081/NCN-100002302
   Schlienger N, 1997, J ORG CHEM, V62, P7216, DOI 10.1021/jo9706638                                                               
   Schlienger N, 2000, J MED CHEM, V43, P4570, DOI 10.1021/jm000996o
   SCHON I, 1982, J CHEM SOC CHEM COMM, P639, DOI 10.1039/c39820000639
   SOAI K, 1984, B CHEM SOC JPN, V57, P1948, DOI 10.1246/bcsj.57.1948                                                            
   Sobkowska A, 1997, J ORG CHEM, V62, P4791, DOI 10.1021/jo962224z                                                               
   STEINKE D, 1990, ANGEW CHEM INT EDIT, V29, P1139, DOI 10.1002/anie.199011391                                                          
   Wagner CR, 2000, MED RES REV, V20, P417, DOI 10.1002/1098-1128(200011)20:6<417::AID-MED1>3.0.CO;2-Z                          
NR 29
TC 22
Z9 22
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD FEB 27
PY 2003
VL 46
IS 5
BP 782
EP 793
DI 10.1021/jm021016y
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 647JY
UT WOS:000181090700016
PM 12593658
DA 2018-01-05
ER

PT J
AU Tung, CH
   Weissleder, R
AF Tung, CH
   Weissleder, R
TI Arginine containing peptides as delivery vectors
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE membrane penetration; translocation; Tat; antennapedia; peptide;
   arginine
ID HIV-1 TAT PROTEIN; EFFICIENT INTRACELLULAR DELIVERY;
   NUCLEAR-LOCALIZATION SEQUENCE; HUMAN-IMMUNODEFICIENCY-VIRUS;
   MAMMALIAN-CELLS; IN-VIVO; MEMBRANE TRANSLOCATION; CELLULAR DELIVERY;
   FUSION PROTEINS; GENE-THERAPY
AB Recently several membrane translocalizational signals (MTS) have been identified and applied to various applications. These peptide signals, ranging between nine and 30 amino acid residues in length, have the capability of crossing plasma membrane, in addition to delivering other biological molecules into cells. To date, small molecules, peptides, proteins, oligonucleotides, plasmids and even nanometer-sized particles have been delivered. These MTS sequences vary from hydrophobic to purely hydrophilic, and, surprisingly, all of them are able to penetrate cellular membrane in an energy-independent pathway. Potentially, MTS could be used as delivery vectors for a number of therapeutic agents. In this review, we specifically focus on arginine-containing MTS, and their properties, characteristics, in vitro and in vivo applications are discussed in detail. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
RP Tung, CH (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, 149 13th St,Rm 5406, Charlestown, MA 02129 USA.
EM tung@helix.mgh.harvard.edu
OI Tung, Ching-Hsuan/0000-0001-6648-6195
CR ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Antopolsky M, 1999, BIOCONJUGATE CHEM, V10, P598, DOI 10.1021/bc980133y
   Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   Bayley H, 1999, NAT BIOTECHNOL, V17, P1066, DOI 10.1038/15050
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Bisland SK, 1999, BIOCONJUGATE CHEM, V10, P982, DOI 10.1021/bc990020u
   Bonfanti M, 1997, CANCER RES, V57, P1442
   CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   Chaloin L, 2001, BIOCONJUGATE CHEM, V12, P691, DOI 10.1021/bc000125t
   Chesnoy S, 2000, ANNU REV BIOPH BIOM, V29, P27, DOI 10.1146/annurev.biophys.29.1.27
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Drin G, 2001, BIOCHEMISTRY-US, V40, P1824, DOI 10.1021/bi002019k
   Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623                                                          
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elliott G, 1999, GENE THER, V6, P149, DOI 10.1038/sj.gt.3300850
   ENSOLI B, 1993, J VIROL, V67, P277
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Ferrari S, 1999, BBA-GENE STRUCT EXPR, V1447, P219, DOI 10.1016/S0167-4781(99)00153-0                                                   
   Fischer PM, 2001, BIOCONJUGATE CHEM, V12, P825, DOI 10.1021/bc0155115
   Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x                                                
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Friedler A, 2000, J BIOL CHEM, V275, P23783, DOI 10.1074/jbc.M002200200                                                          
   Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gius DR, 1999, CANCER RES, V59, P2577
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   Han K, 2001, MOL CELLS, V12, P267
   Han K, 2000, MOL CELLS, V10, P728, DOI 10.1007/s100590000036
   Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7                                                   
   Ho A, 2001, CANCER RES, V61, P474
   Hogemann D, 2002, BIOCONJUGATE CHEM, V13, P116, DOI 10.1021/bc015549h
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kown MH, 2001, TRANSPLANTATION, V71, P1542, DOI 10.1097/00007890-200106150-00010
   Kown MH, 2001, J THORAC CARDIOV SUR, V121, P971, DOI 10.1067/mtc.2001.112532
   Kueltzo LA, 2000, EXPERT OPIN INV DRUG, V9, P2039, DOI 10.1517/13543784.9.9.2039
   Langel U, 1996, REGUL PEPTIDES, V62, P47, DOI 10.1016/0167-0115(96)00002-X
   Langel U., 2002, CELL PENETRATING PEP
   Lee HJ, 2001, BIOCONJUGATE CHEM, V12, P995, DOI 10.1021/bc0155061
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819
   Mazel M, 2001, ANTI-CANCER DRUG, V12, P107, DOI 10.1097/00001813-200102000-00003                                                
   Mitchell DJ, 2000, J PEPT RES, V56, P318, DOI 10.1034/j.1399-3011.2000.00723.x                                                
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   PEPINSKY RB, 1994, DNA CELL BIOL, V13, P1011, DOI 10.1089/dna.1994.13.1011
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Pooga M, 1998, FASEB J, V12, P67
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3
   Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370                                                             
   Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456                                                        
   Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Schluesener HJ, 1996, J NEUROSCI RES, V46, P258, DOI 10.1002/(SICI)1097-4547(19961015)46:2<258::AID-JNR14>3.0.CO;2-Z
   Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Scully SP, 2000, CLIN ORTHOP RELAT R, pS55
   SHELDON K, 1995, P NATL ACAD SCI USA, V92, P2056, DOI 10.1073/pnas.92.6.2056
   Singh D, 1999, BIOCONJUGATE CHEM, V10, P745, DOI 10.1021/bc980131d
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400                                                          
   TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723
   Teramato S, 2000, LANCET, V355, P1911, DOI 10.1016/S0140-6736(05)73358-4                                                   
   THEODORE L, 1995, J NEUROSCI, V15, P7158
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Troy CM, 1996, J NEUROSCI, V16, P253
   Tung CH, 2002, BIOORGAN MED CHEM, V10, P3609, DOI 10.1016/S0968-0896(02)00248-1
   Uemura S, 2000, CIRCULATION, V102, P2629
   Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242                                                                   
   YANKULOV K, 1998, CURR BIOL, V8, P447
   Zhang LS, 1998, P NATL ACAD SCI USA, V95, P9184, DOI 10.1073/pnas.95.16.9184                                                         
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 90
TC 127
Z9 128
U1 3
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0169-409X
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD FEB 10
PY 2003
VL 55
IS 2
BP 281
EP 294
AR PII S0169-409X(02)00183-7
DI 10.1016/S0169-409X(02)00183-7
PG 14
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 652KK
UT WOS:000181378200007
PM 12564981
DA 2018-01-05
ER

PT J
AU Hamma, T
   Miller, PS
AF Hamma, T
   Miller, PS
TI Interactions of hairpin oligo-2 '-O-methylribonucleotides containing
   methylphosphonate linkages with HIV TAR RNA
SO ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TETRAHYMENA-THERMOPHILA RIBOZYME;
   ANTISENSE RNA; IN-VITRO; THERMODYNAMIC PARAMETERS; KINETIC DESCRIPTION;
   KISSING COMPLEX; GENE-EXPRESSION; ACTIVE-SITE; OLIGONUCLEOTIDES
AB Methylphosphonate-modified oligo-2'-O-methylribonucleotides 15-20 nucleotides (nt) in length were prepared whose sequences are complementary to the 5' and 3' sides of the upper hairpin of HIV trans-acting response element (TAR) RNA. These anti-TAR oligonucleotides (ODNs) form stable hairpins whose melting temperatures (T.) range from 55degreesC to 80degreesC. Despite their rather high thermal stabilities, the hairpin oligo-2'-O-methylribonucleotides formed very stable complexes with TAR RNA, with dissociation constants in the nanomolar concentration range at 37degreesC. The affinities of the hairpin oligomers for TAR RNA were influenced by the positions of the methylphosphonate linkages. The binding affinity was reduced approximately 17-fold by the presence of two methylphosphonate linkages in the TAR loop complementary region (TLCR) of the oligomer, whereas methylphosphonate linkages outside this region increased binding affinity approximately 3-fold. The configurations of the methylphosphonate linkages in the TLCR also affected binding affinity, with the RpRp isomer showing significantly higher binding than the SpSp isomer. In addition to serving as probes of the interactions between the oligomer and TAR RNA, the presence of the methylphosphonate linkages in combination with the hairpin structure increases the resistance of these oligomers to degradation by exonucleases found. in mammalian serum. The combination of high binding affinity and nuclease resistance of the hairpin ODNs containing methylphosphonate linkages suggests their potential utility as antisense compounds.
C1 Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.
RP Miller, PS (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.
EM pmiller@jhsph.edu
FU NIGMS NIH HHS [GM 57140]
CR ANTAO VP, 1992, NUCLEIC ACIDS RES, V20, P819, DOI 10.1093/nar/20.4.819
   Arzumanov A, 2001, NUCLEOS NUCLEOT NUCL, V20, P471, DOI 10.1081/NCN-100002321
   Arzumanov A, 2001, BIOCHEMISTRY-US, V40, P14645, DOI 10.1021/bi011279e
   Boulme F, 1998, NUCLEIC ACIDS RES, V26, P5492, DOI 10.1093/nar/26.23.5492
   BOWER M, 1987, NUCLEIC ACIDS RES, V15, P4915, DOI 10.1093/nar/15.12.4915
   CHACKO KK, 1983, NUCLEIC ACIDS RES, V11, P2801, DOI 10.1093/nar/11.9.2801
   CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705                                                         
   Darfeuille F, 2002, BIOCHEMISTRY-US, V41, P12186, DOI 10.1021/bi025974d
   Eckardt S, 1997, BIOCHEMISTRY-US, V36, P12711, DOI 10.1021/bi9707234
   ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560
   EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215
   Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880
   Engdahl HM, 1997, NUCLEIC ACIDS RES, V25, P3218, DOI 10.1093/nar/25.16.3218
   Field AK, 1999, CURR OPIN MOL THER, V1, P323
   FREIER SM, 1975, BIOCHEMISTRY-US, V14, P3310, DOI 10.1021/bi00686a004
   GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275
   Grosjean H., 1998, MODIFICATION EDITING, P113
   Hamma T, 1999, BIOCHEMISTRY-US, V38, P15333, DOI 10.1021/bi991962p                                                               
   Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s
   HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004
   HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003
   Huq I, 1999, BIOCHEMISTRY-US, V38, P5172, DOI 10.1021/bi982638h
   Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819
   JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441
   KEAN JM, 1994, NUCLEIC ACIDS RES, V22, P4497, DOI 10.1093/nar/22.21.4497                                                          
   Kim CH, 2000, P NATL ACAD SCI USA, V97, P9396, DOI 10.1073/pnas.170283697                                                          
   LAPIDOT A, 1995, FEBS LETT, V367, P33, DOI 10.1016/0014-5793(95)00514-A
   Laughrea M, 1996, BIOCHEMISTRY-US, V35, P9366, DOI 10.1021/bi960395s                                                               
   LESNIKOWSKI ZJ, 1990, NUCLEIC ACIDS RES, V18, P2109, DOI 10.1093/nar/18.8.2109
   Maksimenko AV, 1999, NUCLEOS NUCLEOT, V18, P2071, DOI 10.1080/07328319908044865
   MANN DA, 1996, MOL MED SCI, P1
   MARINO JP, 1995, SCIENCE, V268, P1448, DOI 10.1126/science.7539549
   Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700                                                          
   Mei HY, 1998, BIOCHEMISTRY-US, V37, P14204, DOI 10.1021/bi981308u                                                               
   Mestre B, 1999, BBA-GENE STRUCT EXPR, V1445, P86, DOI 10.1016/S0167-4781(99)00019-6
   MILLER PS, 1993, BIOCHEMISTRY-US, V32, P2999, DOI 10.1021/bi00063a010                                                             
   Miller PS, 1998, APPLIED ANTISENSE OLIGONUCLEOTIDE TECHNOLOGY, P3
   Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s
   MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117
   PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680
   PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Reynolds MA, 1996, NUCLEIC ACIDS RES, V24, P4584, DOI 10.1093/nar/24.22.4584
   Samani TD, 2001, ANTISENSE NUCLEIC A, V11, P129
   Tamilarasu N, 1999, J AM CHEM SOC, V121, P1597, DOI 10.1021/ja983822t                                                               
   Tamura Y, 1998, NUCLEOS NUCLEOT, V17, P269, DOI 10.1080/07328319808005175
   UHLENBECK OC, 1990, NATURE, V346, P613, DOI 10.1038/346613a0                                                                
   VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016                                                             
   VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359
   ZHANG RW, 1995, CLIN PHARMACOL THER, V58, P44, DOI 10.1016/0009-9236(95)90071-3
   Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11
NR 51
TC 7
Z9 7
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2906
J9 ANTISENSE NUCLEIC A
JI Antisense Nucleic Acid Drug Dev.
PD FEB
PY 2003
VL 13
IS 1
BP 19
EP 30
DI 10.1089/108729003764097313
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 661YK
UT WOS:000181917500004
PM 12691533
DA 2018-01-05
ER

PT J
AU Ullman, D
AF Ullman, D
TI Controlled clinical trials evaluating the homeopathic treatment of
   people with human immunodeficiency virus or acquired immune deficiency
   syndrome
SO JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE
LA English
DT Article
ID HIV-INFECTED PATIENTS; ALTERNATIVE THERAPIES; COMPLEMENTARY THERAPIES;
   HIV/AIDS; DILUTIONS; MEDICINE
AB Context: Homeopathic medicine developed significant popularity in the nineteenth century in the United States and Europe as a result of its successes treating the infectious disease epidemics during that era. Homeopathic medicine is a medical system that is specifically oriented to using nanopharmacologic and ultramolecular doses of medicines to strengthen a person's immune and defense system rather than directly attacking the microbial agents.
   Objectives: To review the literature referenced in MEDLINE(TM) and in nonindexed homeopathic journals for placebo-controlled clinical trials using homeopathic medicines to treat people with AIDS or who are human immunodeficiency virus (HIV)-positive and to consider a different theoretical and methodological approach to treating people with the viral infection.
   Findings: A total of five controlled clinical trials were identified. A double-blinded, placebo-controlled study was conducted on 50 asymptomatic HIV-positive subjects (stage II) and 50 subjects with persistent generalized lymphadenopathy (stage III) in whom individualized single-remedy homeopathic treatment was provided. A separate body of preliminary research was conducted using homeopathic doses of growth factors. Two randomized double-blinded, placebo-controlled studies were conducted with a total of 77 people with AIDS who used only natural therapies over a 8-16-week period. Two other studies were conducted over a 2.5-year period with 27 subjects in an open-label format.
   Settings: The first study was conducted by the Regional Research Institute for Homoeopathy in Mumbai, India, under the Central Council for Research in Homoeopathy, with the approval of the Ministry of Health and Family Welfare, Government of India. The second body of studies was conducted in clinic settings in California, Oregon, Arizona, Hawaii, New York, and Washington.
   Results: The first study found no statistically significant improvement in CD4 T-lymphocytes, but did find statistically significant pretest and post-test results in subjects with stage III AIDS, in CD4 (p = 0.008) and in CD8 (p = 0.04) counts. The second group of studies found specific physical, immunologic, neurologic, metabolic, and quality-of-life benefits, including improvements in lymphocyte counts and functions and reductions in HIV viral loads.
   Conclusions: As a result of the growing number of people with drug-resistant HIV infection taking structured treatment interruptions, homeopathic medicine may play a useful role as an adjunctive and/or alternative therapy.
C1 Homeopath Educ Serv, Berkeley, CA 94704 USA.
RP Ullman, D (reprint author), Homeopath Educ Serv, 2124 Kittredge St, Berkeley, CA 94704 USA.
CR Albrecht H, 1999, ALTERN THER HEALTH M, V5, P64
   ANDERSON W, 1993, AIDS, V7, P561, DOI 10.1097/00002030-199304000-00016
   BARTON SE, 1994, AIDS, V8, P561
   BASTIDE M, 1987, INT J IMMUNOTHER, V3, P191
   BERNARD C, 1947, PRINCIPLES EXPT MED, P160
   BISSUEL F, 1995, AIDS, V9, P407
   Blower SM, 2001, NAT MED, V7, P1016, DOI 10.1038/nm0901-1016                                                             
   BRADFORD T, 1900, LOGIC FIGURES COMP R
   BREWITT B, 2002, AIDS COMPLEMENTARY A, P20
   BREWITT B, 2002, AIDS COMPLEMENTARY A, P126
   BREWITT B, 2000, 13 INT AIDS C IT, P81
   BREWITT B, 1996, ALTERN THER, V2, P90
   BREWITT B, 1996, 11 INT AIDS C VANC B
   Carwein VL, 1997, AIDS PATIENT CARE ST, V11, P79, DOI 10.1089/apc.1997.11.79                                                          
   CASANOVA P, 1992, REV 3 ANN RANDOMIZED
   COULTER HL, 1975, DIVIDED LEGACY HIST, V2
   DAURAT V, 1988, BIOMED PHARMACOTHER, V42, P197
   DAVENAS E, 1987, EUR J PHARMACOL, V135, P313, DOI 10.1016/0014-2999(87)90680-7
   de Visser R, 2000, ALTERN THER HEALTH M, V6, P44
   DUBOS R, 1959, MIRAGE HLTH, P93
   Fairfield KM, 1998, ARCH INTERN MED, V158, P2257, DOI 10.1001/archinte.158.20.2257                                                    
   FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x                                              
   GARRETT L, 2001, HIV DRUGS LOSING POW
   GAUCHER C, 1993, BR HOMEOPATHIC J, V82, P155
   GIBSON RG, 1980, BRIT J CLIN PHARMACO, V9, P453, DOI 10.1111/j.1365-2125.1980.tb05840.x                                              
   Jonas W, 2001, NEUROREPORT, V12, P335, DOI 10.1097/00001756-200102120-00031
   Jonas WB, 1999, ALTERN THER HEALTH M, V5, P36
   Leary B, 1987, BR HOMEOPATHIC J, V76, P190
   Lee PDK, 1996, J CLIN ENDOCR METAB, V81, P2968, DOI 10.1210/jc.81.8.2968
   LINDE K, 1994, HUM EXP TOXICOL, V13, P481, DOI 10.1177/096032719401300706                                                      
   Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208                                                              
   Papp R, 1998, BR HOM J, V87, P69
   RASTOGI DP, 1993, CCRH Q B, V15, P1
   RICHMAN D, 2001, P INT C ANT AG CHEM
   Singh L.M., 1985, BRIT HOMOEOPATHIC J, V74, P168
   Singh N, 1996, ARCH INTERN MED, V156, P197, DOI 10.1001/archinte.156.2.197
   SINGH V, 1994, INT C AIDS AUG 7 12, V10, P218
   Sparber A, 2000, J ALTERN COMPLEM MED, V6, P415, DOI 10.1089/acm.2000.6.415
   STANDISH L, 2002, AIDS COMPLEMENTARY A, P115
   ULLMAN D, 1995, CONSUMERS GUIDE HOME
   Ullman D, 1991, DISCOVERING HOMEOPAT
   Voelker, 2000, JAMA, V284, P169, DOI 10.1001/jama.284.2.169-a
   Wolffers I, 1994, Ned Tijdschr Geneeskd, V138, P307
   Wootton JC, 2001, J ALTERN COMPLEM MED, V7, P371, DOI 10.1089/107555301750463251
NR 44
TC 6
Z9 6
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1075-5535
J9 J ALTERN COMPLEM MED
JI J. Altern. Complement Med.
PD FEB
PY 2003
VL 9
IS 1
BP 133
EP 141
DI 10.1089/107555303321223008
PG 9
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA 652VE
UT WOS:000181400900016
PM 12676041
DA 2018-01-05
ER

PT J
AU Akagi, T
   Kawamura, M
   Ueno, M
   Hiraishi, K
   Adachi, M
   Serizawa, T
   Akashi, M
   Baba, M
AF Akagi, T
   Kawamura, M
   Ueno, M
   Hiraishi, K
   Adachi, M
   Serizawa, T
   Akashi, M
   Baba, M
TI Mucosal immunization with inactivated HIV-1-capturing nanospheres
   induces a significant HIV-1-specific vaginal antibody response in mice
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE vaccine; mucosal IgA; estrous cycle; nasal immunization
ID SIMIAN IMMUNODEFICIENCY VIRUS; FEMALE GENITAL-TRACT; IMMOBILIZED
   POLYSTYRENE NANOSPHERES; INTRANASAL IMMUNIZATION; RHESUS MACAQUES; NASAL
   IMMUNIZATION; IMMUNE-RESPONSES; INTRAVAGINAL INOCULATION; NEUTRALIZING
   ANTIBODIES; SERONEGATIVE PARTNERS
AB Mucosal secretory IgA is considered to have an important role in the prevention of human immunodeficiency virus type 1 (HIV-1) transmission through sexual intercourse. Therefore, substances that induce HIV-1-specific IgA antibody in the genital tract may become promising candidates for prophylactic vaccine against HIV-1 infection. We have previously reported that concanavalin A-immobilized polystyrene nanospheres (Con A-NS) could efficiently capture HIV-1 particles and gp120 antigens on their surface and that intravaginal immunization with inactivated HIV-1-capturing nanospheres (HIV-NS) induced vaginal anti-HIV-1 IgA antibody in mice. In this study, various strategies for immunization with HIV-NS were undertaken to induce HIV-1-specific IgA response in the mouse genital tract. HIV-NS were administered intravaginally, orally, intranasally or intraperitoneally to mice. Progesterone treatment enhanced the anti-HIV-1 IgA response to intravaginal immunization significantly, but intranasal immunization with HIV-NS was more effective compared with other immunization routes in terms of vaginal IgA response. In addition, vaginal washes from intranasally immunized mice were capable of neutralizing HIV-1(IIIB). Thus, application of HIV-NS is a practical approach to promote HIV-1-specific IgA response by the vaginal mucosa in the mouse and intranasal appears to be an effective immunization route in this animal model. Intranasal immunization with HIV-NS should be further pursued for its potential as an HIV-1 prophylactic vaccine.
C1 Japan Immunores Labs, Takasaki, Gumma 3700021, Japan.
   Kagoshima Univ, Fac Med, Div Human Retroviruses, Ctr Chron Viral Dis, Kagoshima 890, Japan.
   Kagoshima Univ, Dept Appl Chem & Chem Engn, Fac Engn, Kagoshima 890, Japan.
RP Akagi, T (reprint author), Japan Immunores Labs, 351-1 Nishiyokote Cho, Takasaki, Gumma 3700021, Japan.
RI Baba, Masanori/G-3867-2011
CR Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257                                                    
   Balmelli C, 1998, J VIROL, V72, P8220
   Beyrer C, 1999, J INFECT DIS, V179, P59, DOI 10.1086/314556
   Buge SL, 1997, J VIROL, V71, P8531
   Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104
   CZERKINSKY C, 1987, P NATL ACAD SCI USA, V84, P2449, DOI 10.1073/pnas.84.8.2449
   Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170                                                     
   Devito C, 2000, AIDS, V14, P1917, DOI 10.1097/00002030-200009080-00006                                                
   DiTommaso A, 1996, INFECT IMMUN, V64, P974
   ELSON CO, 1979, J EXP MED, V149, P632, DOI 10.1084/jem.149.3.632                                                           
   Foster N, 1998, VACCINE, V16, P536, DOI 10.1016/S0264-410X(97)00222-3
   Gallichan WS, 1996, VIROLOGY, V224, P487, DOI 10.1006/viro.1996.0555                                                          
   Gallichan WS, 2001, J IMMUNOL, V166, P3451, DOI 10.4049/jimmunol.166.5.3451                                                     
   Ghys PD, 2000, AIDS, V14, P2603, DOI 10.1097/00002030-200011100-00025
   Giannasca PJ, 1997, INFECT IMMUN, V65, P4288
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Heritage PL, 1997, AM J RESP CRIT CARE, V156, P1256, DOI 10.1164/ajrccm.156.4.97-03017                                                   
   Hu JJ, 2000, J VIROL, V74, P6087, DOI 10.1128/JVI.74.13.6087-6095.2000
   Imaoka K, 1998, J IMMUNOL, V161, P5952
   JEMIOLO B, 1986, P NATL ACAD SCI USA, V83, P4576, DOI 10.1073/pnas.83.12.4576
   Johansson EL, 1998, INFECT IMMUN, V66, P514
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   King NJC, 1998, J IMMUNOL, V160, P1173
   Kurono Y, 1999, J INFECT DIS, V180, P122, DOI 10.1086/314827
   Lavelle EC, 2001, IMMUNOLOGY, V102, P77, DOI 10.1046/j.1365-2567.2001.01157.x
   Lehner T, 1996, NAT MED, V2, P767, DOI 10.1038/nm0796-767
   Letvin NL, 1998, SCIENCE, V280, P1875, DOI 10.1126/science.280.5371.1875
   Lu FX, 1999, INFECT IMMUN, V67, P6321
   MARX PA, 1993, SCIENCE, V260, P1323, DOI 10.1126/science.8493576
   MASCOLA JR, 2000, SCIENCE, V14, pS167
   Mazzoli S, 1999, J INFECT DIS, V180, P871, DOI 10.1086/314934                                                                  
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   Miller CJ, 1999, J INFECT DIS, V179, pS413, DOI 10.1086/314795
   MILMAN G, 1994, AIDS RES HUM RETROV, V10, P1305, DOI 10.1089/aid.1994.10.1305
   Nardelli-Haefliger D, 1999, J VIROL, V73, P9609
   PARR MB, 1990, J REPROD IMMUNOL, V17, P101, DOI 10.1016/0165-0378(90)90029-6
   PARR MB, 1994, LAB INVEST, V70, P369
   Renegar KB, 1998, J IMMUNOL, V160, P1219
   Sonoda Y, 1998, J IMMUNOL, V160, P6159
   Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215
   Staats HF, 1997, AIDS RES HUM RETROV, V13, P945, DOI 10.1089/aid.1997.13.945
   Staats HF, 1996, J IMMUNOL, V157, P462
   STANISZ AM, 1986, J IMMUNOL, V136, P152
   van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7                                                   
   VanCott TC, 1998, J IMMUNOL, V160, P2000
   Wu HY, 2000, INFECT IMMUN, V68, P5539, DOI 10.1128/IAI.68.10.5539-5545.2000
   Zinckgraf JW, 1999, J REPROD IMMUNOL, V45, P99
NR 48
TC 58
Z9 58
U1 0
U2 2
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD FEB
PY 2003
VL 69
IS 2
BP 163
EP 172
DI 10.1002/jmv.10279
PG 10
WC Virology
SC Virology
GA 631VU
UT WOS:000180188300001
PM 12683403
DA 2018-01-05
ER

PT J
AU Hidaka, K
   Kimura, T
   Hayashi, Y
   McDaniel, KF
   Dekhtyar, T
   Colletti, L
   Kiso, Y
AF Hidaka, K
   Kimura, T
   Hayashi, Y
   McDaniel, KF
   Dekhtyar, T
   Colletti, L
   Kiso, Y
TI Design and synthesis of pseudo-symmetric HIV protease inhibitors
   containing a novel hydroxymethylcarbonyl (HMC)-hydrazide isostere
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID VIRUS TYPE-1 PROTEASE; DIPEPTIDE; POTENT; ALLOPHENYLNORSTATINE; ANALOGS
AB Pseudo-symmetric HIV-1 protease inhibitors containing a novel HMC-hydrazide isostere as the transition-state mimic were designed and synthesized. Most of the synthetic compounds with varied structures at the P and P' sites around this core unit showed potent inhibitory activity against HIV-1 protease with nanomolar K-i values. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Kyoto Pharmaceut Univ, Dept Med Chem, Ctr Frontier Res Med Sci, Yamashima Ku, Kyoto 6078412, Japan.
   Abbott Labs, Global Pharmaceut Res & Dev, Antiviral Res, Abbott Pk, IL 60064 USA.
RP Kiso, Y (reprint author), Kyoto Pharmaceut Univ, Dept Med Chem, Ctr Frontier Res Med Sci, Yamashima Ku, Kyoto 6078412, Japan.
CR Bold G, 1998, J MED CHEM, V41, P3387, DOI 10.1021/jm970873c
   ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122
   Fassler A, 1996, J MED CHEM, V39, P3203, DOI 10.1021/jm960022p
   KEMPF DJ, 1991, ANTIMICROB AGENTS CH, V35, P2209, DOI 10.1128/AAC.35.11.2209                                                          
   KEMPF DJ, 1990, J MED CHEM, V33, P2687, DOI 10.1021/jm00172a002
   Kiso Y, 1998, J SYN ORG CHEM JPN, V56, P896, DOI 10.5059/yukigoseikyokaishi.56.896                                               
   Kiso Y, 1999, BIOPOLYMERS, V51, P59, DOI 10.1002/(SICI)1097-0282(1999)51:1<59::AID-BIP7>3.0.CO;2-3
   Kiso Y, 1998, ARCH PHARM, V331, P87, DOI 10.1002/(SICI)1521-4184(199803)331:3<87::AID-ARDP87>3.0.CO;2-H                  
   Kiso Y, 1996, BIOPOLYMERS, V40, P235, DOI 10.1002/(SICI)1097-0282(1996)40:2<235::AID-BIP3>3.0.CO;2-X
   Mimoto T, 1999, J MED CHEM, V42, P1789, DOI 10.1021/jm980637h
   Mimoto T, 1999, PEPTIDE SCIENCE - PRESENT AND FUTURE, P652
   MIMOTO T, 1991, CHEM PHARM BULL, V39, P3088
   MIMOTO T, 1992, CHEM PHARM BULL, V40, P2251
   Mimoto T, 2000, CHEM PHARM BULL, V48, P1310
   Sham HL, 1996, J MED CHEM, V39, P392, DOI 10.1021/jm9507183
   SHAM HL, 1993, J CHEM SOC CHEM COMM, P1052, DOI 10.1039/c39930001052                                                            
   TANAKA Y, 1999, 119 ANN M PHAR SOC 2, P172
   Yoshimura K, 1999, P NATL ACAD SCI USA, V96, P8675, DOI 10.1073/pnas.96.15.8675
   Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1258.2002
NR 19
TC 11
Z9 12
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JAN 6
PY 2003
VL 13
IS 1
BP 93
EP 96
AR PII S0960-894X(02)00848-X
DI 10.1016/S0960-894X(02)00848-X
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 629PL
UT WOS:000180058000019
PM 12467624
DA 2018-01-05
ER

PT B
AU Dubey, A
   Mavroidis, C
   Thornton, A
   Nikitczuk, K
   Yarmush, ML
AF Dubey, A
   Mavroidis, C
   Thornton, A
   Nikitczuk, K
   Yarmush, ML
GP IEEE
   IEEE
TI Viral protein linear (VPL) nano-actuators
SO 2003 THIRD IEEE CONFERENCE ON NANOTECHNOLOGY, VOLS ONE AND TWO,
   PROCEEDINGS
LA English
DT Proceedings Paper
CT 3rd IEEE Conference on Nanotechnology (IEEE-NANO 2003)
CY AUG 12-14, 2003
CL SAN FRANCISCO, CA
SP IEEE Nanotechnol Council, IEEE Reg 6 Western
ID DNA; MOTORS; HEMAGGLUTININ; MOLECULES; KINESIN; FORCE
AB A new nanoscale biomolecular motor is. There is a group of retroviruses whose envelope introduced: The Viral Protein Linear (VPL) Motor. The motor glycoproteins undergo such a conformational change, and is based on a conformational change observed in a family of hence, each one, in principle, is a candidate for the creation of viral envelope proteins when a virus attempts to infect a cell a different VPL motor. The most common of these are the by the process of membrane fusion. By developing similar Influenza Virus protein hemagglutinin (HA) and the Human proteins in vitro and subjecting them to appropriate conditions, Immunodeficienty Virus type 1 (HIV 1) protein gp41. We a similar conformational change can be observed and have selected the HA as the basis of our VPL motor. Our controlled. The conformational change produces a motion of approach it two-pronged - experimental characterization, and about 10 nm, making the VPL a basic linear actuator which computational modeling and simulation of VPL actuators. can be further interfaced with other organic/inorganic Once the individual motors are created and modeled, it will be nanoscale components such as DNA actuators and carbon possible to synthesize and control complex biomolecular nanotubes.
C1 Rutgers State Univ, Dept Mech & Aerosp Engn, Piscataway, NJ 08854 USA.
RP Dubey, A (reprint author), Rutgers State Univ, Dept Mech & Aerosp Engn, 98 Brett Rd, Piscataway, NJ 08854 USA.
CR BERG HC, 1974, NATURE, V249, P77, DOI 10.1038/249077a0                                                                
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Block SM, 1998, CELL, V93, P5, DOI 10.1016/S0092-8674(00)81138-1
   BROOKMAN RR, 1983, J ADOLESCENT HEALTH, V4, P187
   CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W
   Erickson HP, 1997, SCIENCE, V276, P1090, DOI 10.1126/science.276.5315.1090                                                   
   Hu J, 2002, NANO LETT, V2, P55, DOI 10.1021/nl0156336
   Kitamura K, 1999, NATURE, V397, P129
   Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N                 
   Mahadevan L, 2000, SCIENCE, V288, P95, DOI 10.1126/science.288.5463.95                                                     
   Mao CD, 1999, NATURE, V397, P144
   Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1
   Montemagno C, 1999, NANOTECHNOLOGY, V10, P225, DOI 10.1088/0957-4484/10/3/301
   SAUTER NK, 1989, BIOCHEMISTRY-US, V28, P8388, DOI 10.1021/bi00447a018
   Schalley CA, 2001, ACCOUNTS CHEM RES, V34, P465, DOI 10.1021/ar000179i
   SCHLITTER J, 1994, J MOL GRAPHICS, V12, P84, DOI 10.1016/0263-7855(94)80072-3                                                    
   Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111
   Seeman NC, 1998, ANNU REV BIOPH BIOM, V27, P225, DOI 10.1146/annurev.biophys.27.1.225                                                
   Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520
   SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Tobias I, 2000, PHYS REV E, V61, P747, DOI 10.1103/PhysRevE.61.747
   Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902                                                    
   WILSON IA, 1981, NATURE, V289, P377
   Yan H, 2002, NATURE, V415, P62, DOI 10.1038/415062a
   Yuqiu J., 1992, Nanotechnology, V3, P16, DOI 10.1088/0957-4484/3/1/004
   Yurke B, 2000, NATURE, V406, P605, DOI 10.1038/35020524                                                                
NR 27
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-7976-4
PY 2003
BP 140
EP 143
PG 4
WC Chemistry, Applied; Materials Science, Multidisciplinary; Physics,
   Applied
SC Chemistry; Materials Science; Physics
GA BX48B
UT WOS:000185389900037
DA 2018-01-05
ER

PT S
AU Stokes, DL
   Allain, LR
   Isola, N
   Vo-Dinh, T
AF Stokes, DL
   Allain, LR
   Isola, N
   Vo-Dinh, T
BE VoDinh, T
   Grundfest, WS
   Benaron, DA
   Cohn, GE
TI SERS gene probe for DNA diagnostics
SO ADVANCED BIOMEDICAL AND CLINICAL DIAGNOSTIC SYSTEMS
SE PROCEEDINGS OF THE SOCIETY OF PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
   (SPIE)
LA English
DT Proceedings Paper
CT Conference on Advanced Biomedical and Clinical Diagnostic Systems
CY JAN 26-28, 2003
CL SAN JOSE, CA
SP SPIE
DE SERS; gene probe; DNA sequencing; PCR; oligonucleotides; silver surface
   derivatization; SAMS; Rhodamine; cresyl fast violet; brilliant cresyl
   blue
ID ENHANCED RAMAN-SCATTERING; SINGLE-MOLECULE DETECTION; SILVER ELECTRODE;
   ISLAND FILMS; SURFACE; SPECTROSCOPY; GOLD; SPECTRA; DYE; PYRIDINE
AB We describe the development of a surface-enhanced Raman scattering gene (SERGen) probe technology for rapid screening for diseases and pathogens through DNA hybridization assays. The technology combines the use of gene probes labeled with SERS-active markers, and nanostructured metallic platforms for inducing the SERS effect. As a result, SERGen-based methods can offer the spectral selectivity and sensitivity of SERS as well as the molecular specificity of DNA sequence hybridization. Furthermore, these new probe s preclude the use of radioactive labels. As illustrated herein, SERGen probes have been used as primers in polymerase chain reaction (PCR) amplifications of specific DNA sequences, hence further boosting the sensitivity of the technology. We also describe several approaches to developing SERS-active DNA assay platforms, addressing the challenges of making the SERGen technology accessible and practical for clinical settings. The usefulness of the SERGen approach has been demonstrated in the detection of HIV, BRCA1 breast cancer, and BAX genes. There is great potential for the use of numerous SERGen probes for multiplexed detection of multiple biological targets.
C1 Oak Ridge Natl Lab, Life Sci Div, Adv Biomed Sci & Technol Grp, Oak Ridge, TN 37831 USA.
RP Vo-Dinh, T (reprint author), Oak Ridge Natl Lab, Life Sci Div, Adv Biomed Sci & Technol Grp, POB 2008, Oak Ridge, TN 37831 USA.
CR ALBRECHT MG, 1977, J AM CHEM SOC, V99, P5215, DOI 10.1021/ja00457a071                                                             
   BELLO JM, 1989, ANAL CHEM, V61, P1779, DOI 10.1021/ac00190a600                                                             
   BELLO JM, 1989, APPL SPECTROSC, V43, P1325, DOI 10.1366/0003702894204326
   Boncheva M, 1999, LANGMUIR, V15, P4317, DOI 10.1021/la981702t                                                               
   Burgess JD, 1997, LANGMUIR, V13, P3781, DOI 10.1021/la9700735                                                               
   Chang R. K., 1982, SURFACE ENHANCED RAM
   CHU BCF, 1983, NUCLEIC ACIDS RES, V11, P6513, DOI 10.1093/nar/11.18.6513
   Deckert V, 1998, ANAL CHEM, V70, P2646, DOI 10.1021/ac971304f
   ERVIN KM, 1980, J ELECTROANAL CHEM, V114, P179, DOI 10.1016/S0022-0728(80)80446-3
   FLEISCHMANN M, 1974, CHEM PHYS LETT, V26, P163, DOI 10.1016/0009-2614(74)85388-1                                                    
   Graham D, 1997, ANAL CHEM, V69, P4703, DOI 10.1021/ac970657b                                                               
   Haghighat P, 2000, ANTICANCER RES, V20, P1337
   Herne TM, 1997, J AM CHEM SOC, V119, P8916, DOI 10.1021/ja9719586                                                               
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   JEANMAIRE DL, 1977, J ELECTROANAL CHEM, V84, P1, DOI 10.1016/S0022-0728(77)80224-6
   JENNINGS C, 1984, ANAL CHEM, V56, P2033, DOI 10.1021/ac00276a012
   KERKER M, 1984, ACCOUNTS CHEM RES, V17, P271, DOI 10.1021/ar00104a002                                                             
   Kneipp K, 1999, CHEM REV, V99, P2957, DOI 10.1021/cr980133r                                                               
   Kneipp K, 1998, APPL SPECTROSC, V52, P175, DOI 10.1366/0003702981943275                                                        
   Kneipp K, 1997, PHYS REV LETT, V78, P1667, DOI 10.1103/PhysRevLett.78.1667
   MOSKOVITS M, 1985, REV MOD PHYS, V57, P783, DOI 10.1103/RevModPhys.57.783
   Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102
   POCKRAND I, 1984, SURFACE ENHANCED RAM
   SCHATZ GC, 1984, ACCOUNTS CHEM RES, V17, P370, DOI 10.1021/ar00106a005                                                             
   SEQUARIS JM, 1985, J COLLOID INTERF SCI, V105, P417, DOI 10.1016/0021-9797(85)90315-7
   SEQUARIS JML, 1987, ANAL CHEM, V59, P525, DOI 10.1021/ac00130a034
   Steel AB, 1998, ANAL CHEM, V70, P4670, DOI 10.1021/ac980037q                                                               
   Vo-Dinh T, 1998, TRAC-TREND ANAL CHEM, V17, P557, DOI 10.1016/S0165-9936(98)00069-7                                                   
   Vo-Dinh T, 2002, J RAMAN SPECTROSC, V33, P511, DOI 10.1002/jrs.883
   VO-DINH T, 1989, TALANTA, V36, P227, DOI 10.1016/0039-9140(89)80100-6
   VO-DINH T, 1994, ANAL CHEM, V66, P3379, DOI 10.1021/ac00092a014
   Vo-Dinh T, 1999, J RAMAN SPECTROSC, V30, P785, DOI 10.1002/(SICI)1097-4555(199909)30:9<785::AID-JRS450>3.0.CO;2-6
   VODINH T, 1995, PHOTONIC PROBES SURF
   WOKAUN A, 1984, SOLID STATE PHYS, V38, P223
   Yang MS, 1998, LANGMUIR, V14, P6121, DOI 10.1021/la980577i                                                               
   Zeisel D, 1998, CHEM PHYS LETT, V283, P381, DOI 10.1016/S0009-2614(97)01391-2
NR 36
TC 0
Z9 0
U1 0
U2 5
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
BN 0-8194-4758-7
J9 P SOC PHOTO-OPT INS
PY 2003
VL 4958
BP 98
EP 108
DI 10.1117/12.488679
PG 11
WC Computer Science, Interdisciplinary Applications; Medical Laboratory
   Technology; Medicine, Research & Experimental; Physics, Applied
SC Computer Science; Medical Laboratory Technology; Research & Experimental
   Medicine; Physics
GA BX38F
UT WOS:000185090600013
DA 2018-01-05
ER

PT J
AU Shenai, BR
   Lee, BJ
   Alvarez-Hernandez, A
   Chong, PY
   Emal, CD
   Neitz, RJ
   Roush, WR
   Rosenthal, PJ
AF Shenai, BR
   Lee, BJ
   Alvarez-Hernandez, A
   Chong, PY
   Emal, CD
   Neitz, RJ
   Roush, WR
   Rosenthal, PJ
TI Structure-activity relationships for inhibition of cysteine protease
   activity and development of Plasmodium falciparum by peptidyl vinyl
   sulfones
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID TRIFLUOROMETHYL KETONE INHIBITORS; ORAL BIOAVAILABILITY;
   BIOLOGICAL-ACTIVITY; HIV-1 PROTEASE; POTENT; PROTEINASE; DISCOVERY;
   SPECIFICITY; MALARIA; ESTERS
AB The Plasmodium falciparum cysteine proteases falcipain-2 and falcipain-3 appear to be required for hemoglobin hydrolysis by intraerythrocytic malaria parasites. Previous studies showed that peptidyl vinyl sulfone inhibitors of falcipain-2 blocked the development of P. falciparum in culture and exerted antimalarial effects in vivo. We now report the structure-activity relationships for inhibition of falcipain-2, falcipain-3, and parasite development by 39 new vinyl sulfone, vinyl sulfonate ester, and vinyl sulfonamide cysteine protease inhibitors. Levels of inhibition of falcipain-2 and falcipain-3 were generally similar, and many potent compounds were identified. Optimal antimalarial compounds, which inhibited P. falciparum development at low nanomolar concentrations, were phenyl vinyl sulfones, vinyl sulfonate esters, and vinyl sulfonamides with P-2 leucine moieties. Our results identify independent structural correlates of falcipain inhibition and antiparasitic activity and suggest that peptidyl vinyl sulfones have promise as antimalarial agents.
C1 Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA.
   Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
RP Shenai, BR (reprint author), Univ Calif San Francisco, Box 0811, San Francisco, CA 94143 USA.
FU NIAID NIH HHS [P01 AI035707, AI 35707, R29 AI035800, R56 AI035800, AI
   35800, R01 AI035800]
CR Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099
   Bold G, 1998, J MED CHEM, V41, P3387, DOI 10.1021/jm970873c
   Bromme D, 1996, BIOCHEM J, V315, P85
   Caffrey CR, 2001, MOL BIOCHEM PARASIT, V118, P61, DOI 10.1016/S0166-6851(01)00368-1
   CARRETERO JC, 1987, TETRAHEDRON, V43, P5125, DOI 10.1016/S0040-4020(01)87688-2                                                   
   Chatterjee S, 1997, J MED CHEM, V40, P3820, DOI 10.1021/jm970197e
   Cherney RJ, 1996, J ORG CHEM, V61, P2544, DOI 10.1021/jo951958t                                                               
   Edwards PD, 1997, J MED CHEM, V40, P1876, DOI 10.1021/jm960819g
   Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411
   ENDERS D, 2000, ORG SYNTH, V78, P169
   Feng DM, 1997, J MED CHEM, V40, P3726, DOI 10.1021/jm970493r
   Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97
   GENNARI C, 1994, ANGEW CHEM INT EDIT, V33, P2067, DOI 10.1002/anie.199420671                                                          
   HANZLIK RP, 1984, J MED CHEM, V27, P711, DOI 10.1021/jm00372a001
   Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697                                                          
   Kempf DJ, 1998, J MED CHEM, V41, P602, DOI 10.1021/jm970636+
   KLEINERT HD, 1992, SCIENCE, V257, P1940, DOI 10.1126/science.1411510
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   LIU S, 1992, J MED CHEM, V35, P1067, DOI 10.1021/jm00084a012
   MCKERROW JH, 1993, ANNU REV MICROBIOL, V47, P821, DOI 10.1146/annurev.micro.47.1.821
   MUSICKI B, 1991, TETRAHEDRON LETT, V32, P1267, DOI 10.1016/S0040-4039(00)79642-0
   Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8                                                   
   PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002                                                             
   REYNOLDS RC, 1992, J ORG CHEM, V57, P2983, DOI 10.1021/jo00037a003
   Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a
   Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600
   ROSENTHAL PJ, 1992, MOL BIOCHEM PARASIT, V51, P143, DOI 10.1016/0166-6851(92)90209-3                                                    
   ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766
   Rosenthal PJ, 2002, CURR OPIN HEMATOL, V9, P140, DOI 10.1097/00062752-200203000-00010
   ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262
   Roush WR, 2001, BIOORG MED CHEM LETT, V11, P2759, DOI 10.1016/S0960-894X(01)00566-2
   Roush WR, 1998, J AM CHEM SOC, V120, P10994, DOI 10.1021/ja981792o                                                               
   Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a
   Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8
   Scheidt KA, 1998, BIOORGAN MED CHEM, V6, P2477, DOI 10.1016/S0968-0896(98)80022-9
   Serveau C, 1996, BIOCHEM J, V313, P951, DOI 10.1042/bj3130951                                                               
   Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200
   Shenai BR, 2002, MOL BIOCHEM PARASIT, V122, P99, DOI 10.1016/S0166-6851(02)00075-0
   Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481
   Smith AB, 1997, J MED CHEM, V40, P2440, DOI 10.1021/jm970195u                                                               
   TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031                                                             
   Veale CA, 1997, J MED CHEM, V40, P3173, DOI 10.1021/jm970250z                                                               
NR 42
TC 123
Z9 124
U1 2
U2 18
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JAN
PY 2003
VL 47
IS 1
BP 154
EP 160
DI 10.1128/AAC.47.1.154-160.2003
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 631CL
UT WOS:000180149600024
PM 12499184
OA gold
DA 2018-01-05
ER

PT J
AU Daifuku, R
AF Daifuku, R
TI Stealth nucleosides - Mode of action and potential use in the treatment
   of viral diseases
SO BIODRUGS
LA English
DT Article
ID DEPENDENT RNA-POLYMERASE; REVERSE-TRANSCRIPTASE; LETHAL MUTAGENESIS;
   ANTIVIRAL ACTIVITY; ANTIRETROVIRAL THERAPY; ERROR CATASTROPHE;
   HEPATITIS-C; VIRUS; DNA; ZIDOVUDINE
AB Riboviruses and retroviruses have been shown to spontaneously mutate at an extraordinarily high rate. While this genetic diversity allows viral subpopulations to escape conventional antivirals, it also has a cost. Indeed, this high mutation rate results in the synthesis of many defective virions. Stealth nucleosides are nucleoside analogues that are designed to increase the already high spontaneous mutation rate of viruses to the point where the virus cannot further replicate, a process known as 'lethal mutagenesis'. Rather than causing chain termination and attempting to immediately halt viral replication, as with conventional nucleoside reverse transcriptase inhibitors (NRTI), stealth nucleosides are incorporated into the viral genome during replication and, by mispairing, cause mutations to the viral genome. These mutations affect all viral proteins and cumulatively, over a number of replication cycles, are lethal to the virus. There are two distinct stealth nucleoside platforms: DNA stealth nuclecisides and RNA stealth nucleosides. DNA stealth nuclecisides are currently being screened for activity against HIV and may have activity against hepatitis B virus and smallpox vir-us, with the clinical lead DNA stealth nucleoside demonstrating activity in the low nanomolar range. In addition, DNA stealth nucleosides have been shown to be able to effectively treat NRTI-resistant HIV strains in vitro, which is not surprising given that the two principal modes of resistance (low affinity of reverse transcriptase for a modified sugar or pyrophosphorolysis) should not be applicable to DNA stealth nucleosides. RNA stealth nucleosides are being developed for the treatment of ribovirus infections, and particularly hepatitis C virus infection. RNA stealth nuclecisides are selected for their broad spectrum of antiviral activity, and current lead RNA stealth nucleosides have potency in the same range as ribavirin.
C1 Koronis Pharmaceut, Redmond, WA 98052 USA.
RP Daifuku, R (reprint author), Koronis Pharmaceut, 12277 134th Court NE,Suite 110, Redmond, WA 98052 USA.
CR BHIVA Writing Committee BHIVA Executive Committee, 2000, HIV MED, V1, P76
   Bjelland S, 2001, MUTAT RES-DNA REPAIR, V486, P147, DOI 10.1016/S0921-8777(01)00085-4
   Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002
   Cameron CE, 2001, CURR OPIN INFECT DIS, V14, P757, DOI 10.1097/00001432-200112000-00015                                                
   Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602
   CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0
   Crotty S, 2000, NAT MED, V6, P1375
   Crotty S, 2001, P NATL ACAD SCI USA, V98, P6895, DOI 10.1073/pnas.111085598
   Deeks SG, 2001, J ACQ IMMUN DEF SYND, V26, pS25, DOI 10.1097/00126334-200103011-00004
   Drake JW, 1999, P NATL ACAD SCI USA, V96, P13910, DOI 10.1073/pnas.96.24.13910
   Eigen M, 2002, P NATL ACAD SCI USA, V99, P13374, DOI 10.1073/pnas.212514799
   FALKYTTER Y, 2002, ANN INTERN MED, V136, P288
   Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235
   GRANT RM, 9 C RETR OPP INF 200
   HERTOGS K, 2001, ROLE RESISTANCE TEST
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200
   KamathLoeb AS, 1997, EUR J BIOCHEM, V250, P492, DOI 10.1111/j.1432-1033.1997.0492a.x
   Karino N, 2001, NUCLEIC ACIDS RES, V29, P2456, DOI 10.1093/nar/29.12.2456
   LARDER BA, 1991, J VIROL, V65, P5232
   LI L, 2001, 41 INT C ANT AG CHEM, P238
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Loeb LA, 2000, AIDS RES HUM RETROV, V16, P1, DOI 10.1089/088922200309539
   Loeb LA, 1999, P NATL ACAD SCI USA, V96, P1492, DOI 10.1073/pnas.96.4.1492
   LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0                                                   
   Maag D, 2001, J BIOL CHEM, V276, P46094, DOI 10.1074/jbc.C100349200                                                          
   Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5
   Markland W, 2000, ANTIMICROB AGENTS CH, V44, P859, DOI 10.1128/AAC.44.4.859-866.2000
   Moriyama K, 2001, NUCLEOS NUCLEOT NUCL, V20, P1473, DOI 10.1081/NCN-100105242
   Murata-Kamiya N, 1999, NUCLEIC ACIDS RES, V27, P4385, DOI 10.1093/nar/27.22.4385                                                          
   Naeger LK, 2001, NUCLEOS NUCLEOT NUCL, V20, P635, DOI 10.1081/NCN-100002340                                                           
   PAILLARD F, 1990, EMBO J, V250, P492
   Pariente N, 2001, J VIROL, V75, P9723, DOI 10.1128/JVI.75.20.9723-9730.2001                                                
   Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095
   *SCHER CORP, 2002, PHYS DESK REF, P3140
   Shafer RW, 1998, ANN INTERN MED, V128, P906, DOI 10.7326/0003-4819-128-11-199806010-00008
   Sierra S, 2000, J VIROL, V74, P8316, DOI 10.1128/JVI.74.18.8316-8323.2000
   Sluis-Cremer N, 2000, CELL MOL LIFE SCI, V57, P1408, DOI 10.1007/PL00000626
   Smith KY, 2002, J INFECT DIS, V185, pS123, DOI 10.1086/340200
   Stone VE, 2001, CLIN INFECT DIS, V33, P865, DOI 10.1086/322698                                                                  
   Storer R, 1999, NUCLEOS NUCLEOT, V18, P203, DOI 10.1080/15257779908043068
   Stubbe J, 2001, TRENDS BIOCHEM SCI, V26, P93, DOI 10.1016/S0968-0004(00)01764-3                                                   
   VOLBERDING P, 1995, INFECT DIS S, V171, pS150
   Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154
   Zhang QM, 2000, J BIOL CHEM, V275, P35471, DOI 10.1074/jbc.M006125200
NR 45
TC 14
Z9 14
U1 0
U2 3
PU ADIS INTERNATIONAL LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW
   ZEALAND
SN 1173-8804
J9 BIODRUGS
JI Biodrugs
PY 2003
VL 17
IS 3
BP 169
EP 177
DI 10.2165/00063030-200317030-00003
PG 9
WC Oncology; Immunology; Pharmacology & Pharmacy
SC Oncology; Immunology; Pharmacology & Pharmacy
GA 687ZL
UT WOS:000183407200003
PM 12749753
DA 2018-01-05
ER

PT S
AU Osawa, E
AF Osawa, E
BE Uskokovic, DP
   Battiston, GA
   Milonjic, SK
   Rakovic, DI
TI Recent progress in the developmental research of fullerenes and
   nanotubes
SO CONTEMPORARY STUDIES IN ADVANCED MATERIALS AND PROCESSES: YUCOMAT IV
SE MATERIALS SCIENCE FORUM
LA English
DT Article; Proceedings Paper
CT 4th Yugoslav-Materials-Research-Society Conference
CY SEP 10-14, 2001
CL HERCEG NOVI, YUGOSLAVIA
SP Fed Republic Yugoslavia, Minist Dev, Sci & Environm, Republic Serbia, Minist Sci Technol
DE carbon nanotubes; fullerenes; medical applications; superdiamond
ID CARBON NANOTUBES; C60; DIAMOND
AB The most critical problem in the realization of industrial applications for fullerene carbons is not to find good uses, but rather to make breakthroughs in the methods of producing C-60 and single-walled carbon nanotubes at reasonable cost. Promising improvements are being made on the arc discharge and low-pressure combustion methods for the production Of C-60, and on the production of single-walled carbon nanotubes (HiPco process). Difficulties in the developments of flat panel display using field emission effects of carbon nanotubes are mentioned. Opportunities in the composites Of C-60 with polymers are referred. Research work on medicinal applications Of C-60 going on at a venture company is touched upon using an HIV protease inhibitor and a neuroprotector. Some of the three-dimensional polymers of C-60 obtained at high-temperature ultra-high-pressure treatment of C-60 crystals are harder than diamond. Structural chacteristics of these superdiamonds are discussed in relation to the origin of their hardness.
C1 NanoCarbon Res Inst, Chiba, Japan.
RP Osawa, E (reprint author), NanoCarbon Res Inst, Chiba, Japan.
CR Alekseev NI, 2001, TECH PHYS+, V46, P577, DOI 10.1134/1.1372949                                                               
   Alekseyev NI, 2001, TECH PHYS+, V46, P1247, DOI 10.1134/1.1412058
   ALEKSEYEV NI, 2001, TECH PHYS, V46, P638
   Chen QD, 2001, J PHYS CHEM B, V105, P618, DOI 10.1021/jp003385g
   COLBERT DT, 2001, PERSPECTIVES FULLERE, P3
   DAI L, 2001, PERSPECTIVES FULLERE, P93
   HOWARD JB, 1991, NATURE, V352, P139, DOI 10.1038/352139a0
   Lee NS, 2001, DIAM RELAT MATER, V10, P265, DOI 10.1016/S0925-9635(00)00478-7
   NOVGORODOVA MI, 1999, GEOCHEM INT, V37, P896
   OSAWA E, 1998, Q FULLERENES, V6, P28
   Ozawa M, 1999, FULLERENE SCI TECHN, V7, P387, DOI 10.1080/10641229909350289                                                       
   PEUSS P, 1993, CORE
   PROSERPIO DM, 1994, J AM CHEM SOC, V116, P9634, DOI 10.1021/ja00100a030                                                             
   RUOFF RS, 1991, APPL PHYS LETT, V59, P1553, DOI 10.1063/1.106280                                                                
   RUOFF RS, 1991, NATURE, V350, P663, DOI 10.1038/350663b0                                                                
   Verne Jules, 1864, JOURNEY CTR EARTH
   WANG Y, 1991, PHYS REV B, V44, P6562, DOI 10.1103/PhysRevB.44.6562
   WILSON SR, 2001, PERSPECTIVES FULLERE, P155
   2001, NIKKEI SHIMBUN  0914
   2001, NIKKEI SHIMBUN  0908
NR 20
TC 3
Z9 4
U1 0
U2 4
PU TRANS TECH PUBLICATIONS LTD
PI ZURICH-UETIKON
PA BRANDRAIN 6, CH-8707 ZURICH-UETIKON, SWITZERLAND
SN 0255-5476
BN 0-87849-904-0
J9 MATER SCI FORUM
PY 2003
VL 413
BP 1
EP 6
PG 6
WC Materials Science, Multidisciplinary
SC Materials Science
GA BW04X
UT WOS:000180730700001
DA 2018-01-05
ER

PT J
AU Cui, ZR
   Mumper, RJ
AF Cui, ZR
   Mumper, RJ
TI Microparticles and nanoparticles as delivery systems for DNA vaccines
SO CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LA English
DT Review
DE genetic vaccine; adjuvant; immunization; dendritic cell;
   polylactide-co-glycolide; microemulsion
ID MEDIATED IMMUNE-RESPONSES; HIV ENVELOPE GLYCOPROTEIN; FUSIGENIC VIRAL
   LIPOSOME; PLASMID DNA; CATIONIC MICROPARTICLES; GENETIC IMMUNIZATION;
   CALCIUM-PHOSPHATE; INFLUENZA-VIRUS; DENDRITIC CELLS; DRUG-DELIVERY
AB DNA vaccines, also referred to as genetic vaccines, are generating significant preclinical and clinical interest. It has been proven that the expression of an antigen or antigens from plasmid DNA (pDNA) may elicit both humoral and cellular immune responses. Therefore, DNA vaccines may have potential as new vaccines for important pathogens such as HIV, hepatitis C, tuberculosis, and malaria. However, the clinical results using "naked" pDNA have been disappointing in the breadth and depth of the immune response and the relatively high doses of pDNA needed to elicit a response. Clinical trials with the gene gun have been promising, but it is unclear whether this technology will be commercially viable. As a result, there exists a clear need for new vaccine delivery systems that can be administered at low doses to elicit strong humoral and cellular immune responses. One promising approach is the development of microparticles and nanoparticles as delivery systems for DNA vaccines. In this review, the application of microparticles and nanoparticles as DNA vaccine delivery systems will be critically reviewed with a primary focus on those systems that have generated in vivo immune responses.
C1 Univ Kentucky, Coll Pharm, Ctr Pharmaceut Sci & Technol, Lexington, KY 40536 USA.
RP Mumper, RJ (reprint author), Univ Kentucky, Coll Pharm, Ctr Pharmaceut Sci & Technol, Lexington, KY 40536 USA.
CR Abbas AK, 1997, CELLULAR MOL IMMUNOL
   Alpar HO, 2002, CRIT REV THER DRUG, V19, P307, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i45.20
   ALVING CR, 1991, J IMMUNOL METHODS, V140, P1, DOI 10.1016/0022-1759(91)90120-5                                                    
   Ando S, 1999, J PHARM SCI, V88, P126, DOI 10.1021/js9801687
   Baba TW, 1999, NAT MED, V5, P194
   Bacon A, 2002, J LIPOSOME RES, V12, P173, DOI 10.1081/LPR-120004791
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   BANGHAM AD, 1972, ANNU REV BIOCHEM, V41, P753, DOI 10.1146/annurev.bi.41.070172.003541
   Barnes AGC, 2000, CURR OPIN MOL THER, V2, P87
   Bramwell VW, 2002, IMMUNOLOGY, V106, P412, DOI 10.1046/j.1365-2567.2002.01448.x                                                
   Calarota S, 1998, LANCET, V351, P1320, DOI 10.1016/S0140-6736(97)09440-3
   CASTELLINO F, 1997, HUM IMMUNOL, V54, P156
   Chen SC, 1998, J VIROL, V72, P5757
   CLAASSEN E, 1992, RES IMMUNOL, V143, P478, DOI 10.1016/0923-2494(92)80057-R
   COLLINS PL, 1996, FIELD VIROLOGY
   Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555
   Correale P, 2001, EUR J CANCER, V37, P2097, DOI 10.1016/S0959-8049(01)00241-6
   Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1
   Cui Z, 2002, J CONTROL RELEASE, V81, P173, DOI 10.1016/S0168-3659(02)00051-2
   CUI Z, 2001, MOL THER, V3, pS352
   Cui ZG, 2003, PHARMACEUT RES, V20, P16, DOI 10.1023/A:1022234305600
   Cui ZR, 2003, J BIOTECHNOL, V102, P105, DOI 10.1016/S0168-1656(03)00029-4
   Cui ZR, 2003, EUR J PHARM BIOPHARM, V55, P11, DOI 10.1016/S0939-6411(02)00129-7
   Cui ZR, 2002, PHARMACEUT RES, V19, P939, DOI 10.1023/A:1016402019380
   Cui ZR, 2002, J PHARM PHARMACOL, V54, P1195, DOI 10.1211/002235702320402035                                                      
   Cui ZR, 2001, J CONTROL RELEASE, V75, P409, DOI 10.1016/S0168-3659(01)00407-2                                                   
   Cusi MG, 2000, VIROLOGY, V277, P111, DOI 10.1006/viro.2000.0605
   Denis-Mize KS, 2000, GENE THER, V7, P2105, DOI 10.1038/sj.gt.3301347                                                           
   DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233
   DUBENSKY TW, 1984, P NATL ACAD SCI-BIOL, V81, P7529, DOI 10.1073/pnas.81.23.7529
   Dzau VJ, 1996, P NATL ACAD SCI USA, V93, P11421, DOI 10.1073/pnas.93.21.11421                                                        
   Fan HR, 1999, NAT BIOTECHNOL, V17, P870
   Fooks A R, 2000, Dev Biol (Basel), V104, P65
   FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478
   Goto N, 1997, VACCINE, V15, P1364, DOI 10.1016/S0264-410X(97)00054-6
   Gould-Fogerite S, 1998, ADV DRUG DELIVER REV, V32, P273, DOI 10.1016/S0169-409X(98)00014-3
   GREGORIADIS G, 1990, IMMUNOL TODAY, V11, P89, DOI 10.1016/0167-5699(90)90034-7
   Gregoriadis G, 1997, FEBS LETT, V402, P107, DOI 10.1016/S0014-5793(96)01507-4
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   Haensler J, 1999, VACCINE, V17, P628, DOI 10.1016/S0264-410X(98)00242-4                                                   
   Harpin S, 1999, J GEN VIROL, V80, P3137, DOI 10.1099/0022-1317-80-12-3137                                                    
   Hawley AE, 1997, PHARMACEUT RES, V14, P657, DOI 10.1023/A:1012117531448
   Hawley AE, 1997, FEBS LETT, V400, P319, DOI 10.1016/S0014-5793(96)01408-1
   He Q, 2002, CLIN DIAGN LAB IMMUN, V9, P1021, DOI 10.1128/CDLI.9.5.1021-1024.2002
   He Q, 2000, CLIN DIAGN LAB IMMUN, V7, P899, DOI 10.1128/CDLI.7.6.899-903.2000                                                   
   HEATH AW, 1995, CACCINE DESIGN SUBUN
   Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365
   Herrmann JE, 1999, VIROLOGY, V259, P148, DOI 10.1006/viro.1999.9751
   Hilleman MR, 1998, VACCINE, V16, P778, DOI 10.1016/S0264-410X(97)00272-7                                                   
   Iqbal M, 2003, VACCINE, V21, P1478, DOI 10.1016/S0264-410X(02)00662-X
   Ishii N, 1997, AIDS RES HUM RETROV, V13, P1421, DOI 10.1089/aid.1997.13.1421
   Iwasaki A, 1997, J IMMUNOL, V159, P11
   Jones DH, 1998, DEV BIOL STAND, V92, P149
   Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6
   Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093
   Klavinskis LS, 1997, VACCINE, V15, P818, DOI 10.1016/S0264-410X(96)00278-2
   Klencke B, 2002, CLIN CANCER RES, V8, P1028
   KREUTER J, 1976, INFECT IMMUN, V13, P204
   KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0
   Kumar M, 2002, HUM GENE THER, V13, P1415, DOI 10.1089/10430340260185058
   Langer R., 1997, ADV DRUG DELIV REV, V28, P97
   Lanuti M, 2000, CANCER RES, V60, P2955
   LESINSKI SB, 2001, CURR DRUG TARGETS IN, V1, P325
   Liu MA, 1997, P NATL ACAD SCI USA, V94, P10496, DOI 10.1073/pnas.94.20.10496
   Lunsford L, 2000, J DRUG TARGET, V8, P39, DOI 10.3109/10611860009009208                                                       
   Luo YP, 2003, VACCINE, V21, P1938, DOI 10.1016/S0264-410X(02)00821-6
   Lycke N, 1997, RES IMMUNOL, V148, P504, DOI 10.1016/S0923-2494(98)80144-2
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168-3659(98)00097-2
   MALOY KJ, 1994, IMMUNOLOGY, V81, P661
   McKeever U, 2002, VACCINE, V20, P1524, DOI 10.1016/S0264-410X(01)00509-6
   Mittal SK, 2000, VACCINE, V19, P253, DOI 10.1016/S0264-410X(00)00170-5                                                   
   MOGHIMI SM, 1994, FEBS LETT, V344, P25, DOI 10.1016/0014-5793(94)00351-3
   Moreno J. M., 1999, J MED ECOL, V1, P49
   Moser CA, 1997, VACCINE, V15, P1767, DOI 10.1016/S0264-410X(97)00106-0
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Mumper RJ, 2003, J DISPER SCI TECHNOL, V24, P569, DOI 10.1081/DIS-120021814
   Mumper RJ, 2001, MOL BIOTECHNOL, V19, P79, DOI 10.1385/MB:19:1:079
   MUMPER RJ, 1995, P INT S CONTR REL BI
   Nixon DF, 1996, VACCINE, V14, P1523, DOI 10.1016/S0264-410X(96)00099-0
   O'Hagan D, 2001, J VIROL, V75, P9037, DOI 10.1128/JVI.75.19.9037-9043.2001
   O'Hagan DT, 2001, BIOMOL ENG, V18, P69, DOI 10.1016/S1389-0344(01)00101-0                                                   
   OCAMPO V, 2000, 3 ANN C VACC RES APR
   Okada E, 1997, J IMMUNOL, V159, P3638
   OKADA H, 1995, CRIT REV THER DRUG, V12, P1
   Okamoto T, 1997, GENE THER, V4, P969, DOI 10.1038/sj.gt.3300490
   OSTER CG, 2002, CATIONIC NANOPARTICL
   Ott G, 2002, J CONTROL RELEASE, V79, P1, DOI 10.1016/S0168-3659(01)00545-4
   OTT G, 2000, VACCINE ADJUVANTS
   Pachuk CJ, 2000, CURR OPIN MOL THER, V2, P188
   PAPAHADJOPOULOS D, 1975, BIOCHIM BIOPHYS ACTA, V394, P483, DOI 10.1016/0005-2736(75)90299-0                                                    
   Parham P, 2000, THE IMMUNE SYSTEM
   Perrie Y, 2002, J LIPOSOME RES, V12, P185, DOI 10.1081/LPR-120004792
   Perrie Y, 2001, VACCINE, V19, P3301, DOI 10.1016/S0264-410X(00)00432-1
   PLOTKIN SA, 1988, VACCINE
   Putney SD, 1998, NAT BIOTECHNOL, V16, P153, DOI 10.1038/nbt0298-153                                                             
   RAMON G., 1926, ANN INST PASTEUR, V40, P1
   Raychaudhuri S, 1998, NAT BIOTECHNOL, V16, P1025
   Roy K, 1999, NAT MED, V5, P387
   Roy K., 1997, P INT S CONTR REL BI, V24, P673
   Roy MJ, 2000, VACCINE, V19, P764, DOI 10.1016/S0264-410X(00)00302-9                                                   
   RUSSELJONES GJ, 2002, J CONTROL RELEASE, V65, P49
   Schijns VEJC, 2000, CURR OPIN IMMUNOL, V12, P456, DOI 10.1016/S0952-7915(00)00120-5
   Sha ZY, 1999, IMMUNOBIOLOGY, V200, P21, DOI 10.1016/S0171-2985(99)80030-8                                                   
   Shedlock DJ, 2000, J LEUKOCYTE BIOL, V68, P793
   Shi ZK, 1999, VACCINE, V17, P2136, DOI 10.1016/S0264-410X(98)00488-5
   Singh M, 2001, VACCINE, V20, P594, DOI 10.1016/S0264-410X(01)00321-8                                                   
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Singh M, 2001, PHARMACEUT RES, V18, P1476, DOI 10.1023/A:1012269226066
   Singh M, 1998, VACCINE, V16, P1822, DOI 10.1016/S0264-410X(98)00179-0
   STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271
   Takashima A, 1999, J LEUKOCYTE BIOL, V66, P350
   Tanaka M, 2002, MOL THER, V5, P291, DOI 10.1006/mthe.2002.0537
   TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0
   Tang DC, 1997, NATURE, V388, P729, DOI 10.1038/41917                                                                   
   Tischer BK, 2002, J GEN VIROL, V83, P2367, DOI 10.1099/0022-1317-83-10-2367                                                    
   Toda S, 1997, IMMUNOLOGY, V92, P111, DOI 10.1046/j.1365-2567.1997.00307.x
   Ulmer JB, 1999, VACCINE, V18, P18, DOI 10.1016/S0264-410X(99)00151-6
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   ULRICH JT, 1995, VACCINE DESIGN SUBUN
   van der Lubben IM, 2001, EUR J PHARM SCI, V14, P201, DOI 10.1016/S0928-0987(01)00172-5                                                   
   Walter E, 1999, J CONTROL RELEASE, V61, P361, DOI 10.1016/S0168-3659(99)00151-0                                                   
   Wang RB, 2001, P NATL ACAD SCI USA, V98, P10817, DOI 10.1073/pnas.181123498
   Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476
   Wierzbicki A, 2002, VACCINE, V20, P1295, DOI 10.1016/S0264-410X(01)00480-7
   WILL H, 1982, NATURE, V299, P740, DOI 10.1038/299740a0                                                                
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Wong JP, 2001, VACCINE, V19, P2461, DOI 10.1016/S0264-410X(00)00474-6                                                   
   Yang Y, 1996, IMMUNOL RES, V15, P208, DOI 10.1007/BF02918250
   Yokoyama M, 1996, FEMS IMMUNOL MED MIC, V14, P221, DOI 10.1111/j.1574-695X.1996.tb00290.x
   ZARIF L, 1997, CANC GENE THERAPY
   Zhou WZ, 1999, GENE THER, V6, P1768, DOI 10.1038/sj.gt.3300998                                                           
NR 131
TC 74
Z9 79
U1 1
U2 23
PU BEGELL HOUSE INC
PI NEW YORK
PA 145 MADISON AVE, NEW YORK, NY 10016 USA
SN 0743-4863
J9 CRIT REV THER DRUG
JI Crit. Rev. Ther. Drug Carr. Syst.
PY 2003
VL 20
IS 2-3
BP 103
EP 137
DI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10                           
          
PG 35
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 730KY
UT WOS:000185831000001
PM 14584521
DA 2018-01-05
ER

PT J
AU Lorenz, R
   Kienast, J
   Otto, U
   Egger, K
   Kiehl, M
   Schreiter, D
   Kwasny, H
   Haertel, S
   Barthels, M
AF Lorenz, R
   Kienast, J
   Otto, U
   Egger, K
   Kiehl, M
   Schreiter, D
   Kwasny, H
   Haertel, S
   Barthels, M
TI Efficacy and safety of a prothrombin complex concentrate with two
   virus-inactivation steps in patients with severe liver damage
SO EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
DE prothrombin complex concentrate; severe liver damage; surgery; bleeding
ID FRESH-FROZEN PLASMA; ORAL ANTICOAGULANT REVERSAL; COAGULATION;
   THROMBOGENICITY; DISEASE
AB Objective To evaluate the efficacy and safety of intravenous infusions of an improved prothrombin complex concentrate (PCC) formulation.
   Patients and methods Twenty-two adults with haemostatic defects due to severe liver disease (Quick's test < 50%), which required rapid haemostasis because of bleeding or before urgent surgery or invasive intervention. Laboratory follow-up, including the response and in-vivo recovery of the substituted coagulation factors II, VII, IX and X and protein C took place before, then 10 min, 30 min and 60 min after PCC substitution. Clinical efficacy (avoidance or cessation of bleeding) was assessed using a scale ranging from 'very good' to 'none'.
   Results Patients received a median PCC dose of 25.7 IU/kg. The response of factor IX and protein C was 1.2-1.4 (IU/dl)/(IU/kg), the in-vivo recovery was 49.7-57.4%, and the Quick's test increased from 39% to a maximum of 65%. Levels of activation markers of the coagulation system factor Vila, prothrombin fragment 1 + 2 and thrombin antithrombin complex (TAT) increased, but without evidence of any thromboembolic events. Clinical efficacy was judged as 'very good' in 76% of patients after the first (n = 21) treatment. There were no changes in serological status regarding transmission of HIV, hepatitis A virus, hepatitis B virus and hepatitis C virus. No PCC-related adverse reactions occurred.
   Conclusions The infusion of pasteurized, nanometrefiltered PCC is an effective, well-tolerated method of correcting prothrombin complex deficiency in patients with severe liver disease with haemorrhage, or before an urgent surgical or invasive diagnostic intervention. (C) 2003 Lippincott Williams Wilkins.
C1 Tech Univ Munich, Med Klin 2, Klinikum Rechts Isar, Munich, Germany.
   Univ Munster, Med Klin & Poliklin, D-4400 Munster, Germany.
   Univ Leipzig, Zentrum Chirurg, Leipzig, Germany.
   Aventis Behring GmbH, Marburg, Germany.
   Med Hochsch, Zentrum Innere Med & Dermatol, Abt Hamatol & Onkol, Hannover, Germany.
RP Lorenz, R (reprint author), Vogtland Klinikum Plauen, Med Klin, Roentgenstr 2, D-08529 Plauen, Germany.
CR BRAUNSTEIN AH, 1984, T FUSION, V24, P81
   CASPARI G, 1995, KOELN DTSCH ARZTE VE, V163, P181
   EWE K, 1981, DIGEST DIS SCI, V26, P388, DOI 10.1007/BF01313579
   FREDRIKSSON K, 1992, STROKE, V23, P972, DOI 10.1161/01.STR.23.7.972                                                         
   GAZZARD BG, 1975, GUT, V16, P621, DOI 10.1136/gut.16.8.621                                                            
   HAMPTON KK, 1991, BLOOD COAGUL FIBRIN, V2, P637, DOI 10.1097/00001721-199110000-00008
   Kohler M, 1998, THROMB HAEMOSTASIS, V80, P399
   LUSHER JM, 1991, SEMIN HEMATOL, V28, P3
   MAHAL AS, 1981, WESTERN J MED, V134, P11
   Makris M, 1997, THROMB HAEMOSTASIS, V77, P477
   MAMMEN EF, 1994, CLIN LAB MED, V14, P769
   MANNUCCI PM, 1976, LANCET, V2, P542
   Pindur G, 1999, SEMIN THROMB HEMOST, V25, P85, DOI 10.1055/s-2007-996429
   SILBERSTEIN LE, 1989, JAMA-J AM MED ASSOC, V262, P1993, DOI 10.1001/jama.262.14.1993                                                        
   Sonntag J, 1997, TRANSFUSION, V37, P798, DOI 10.1046/j.1537-2995.1997.37897424401.x
   Staudinger T, 1999, INTENS CARE MED, V25, P1105, DOI 10.1007/s001340051019                                                           
   TABERNER DA, 1976, BRIT MED J, V2, P83, DOI 10.1136/bmj.2.6027.83                                                           
NR 17
TC 56
Z9 61
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0954-691X
J9 EUR J GASTROEN HEPAT
JI Eur. J. Gastroenterol. Hepatol.
PD JAN
PY 2003
VL 15
IS 1
BP 15
EP 20
DI 10.1097/00042737-200301000-00004                                        
          
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 642HJ
UT WOS:000180797900004
PM 12544689
DA 2018-01-05
ER

PT J
AU Savarino, A
   Bensi, T
   Chiocchetti, A
   Bottarel, F
   Mesturini, R
   Ferrero, E
   Calosso, L
   Deaglio, S
   Ortolan, E
   Butto, S
   Cafaro, A
   Katada, T
   Ensoli, B
   Malavasi, F
   Dianzani, U
AF Savarino, A
   Bensi, T
   Chiocchetti, A
   Bottarel, F
   Mesturini, R
   Ferrero, E
   Calosso, L
   Deaglio, S
   Ortolan, E
   Butto, S
   Cafaro, A
   Katada, T
   Ensoli, B
   Malavasi, F
   Dianzani, U
TI Human CD38 interferes with HIV-1 fusion through a sequence homologous to
   the V3 loop of the viral envelope glycoprotein gp120.
SO FASEB JOURNAL
LA English
DT Article
DE CD4; leukocyte surface antigens; lentiviruses; lymphocytes; antiviral
   molecules
ID HUMAN-IMMUNODEFICIENCY-VIRUS; LYMPHOCYTE SURFACE MOLECULES; T-CELL
   ACTIVATION; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED CHILDREN; TYPE-1
   INFECTION; LIPID RAFTS; CD4; RECEPTOR; BINDING
AB CD38 is a progression marker in HIV-1 infection, it displays lateral association with CD4, and down-modulates gp120/CD4 binding. The aim of this study was to elucidate the mechanism behind the interplay between CD4, CD38, and HIV-1. We used mouse cell transfectants expressing human CD4 and either CD38 or other CD4-associated molecules to show that CD38 specifically inhibits gp120/CD4 binding. Human cell transfectants expressing truncated forms of CD38 and bioinformatic analysis were used to map the anti-HIV activity and show that it is concentrated in the membrane-proximal region. This region displayed significant sequence-similarity with the V3 loop of the HIV-1 gp120 glycoprotein. In line with this similarity, synthetic soluble peptides derived from this region reproduced the anti-HIV effects of full-length CD38 and inhibited HIV-1 and HIV-2 primary isolates from different subtypes and with different coreceptor use. A multiple-branched peptide construct presenting part of the sequence of the V3-like region potently and selectively inhibited HIV-1 replication in the nanomolar range. Conversely, a deletion in the V3-like region abrogated the anti-HIV-1 activity of CD38 and its lateral association with CD4. These findings may provide new insights into the early events of HIV-1 fusion and strategies to intervene.
C1 A Avogadro Univ Eastern Piedmont, Dept Med Sci, Immunol Lab, Interdisciplinary Res Ctr Autoimmune Dis, I-28100 Novara, Italy.
   Univ Turin, Dept Genet Biol & Biochem, Turin, Italy.
   Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo, Japan.
   Ist Super Sanita, Virol Lab, Div Retrovirol, I-00161 Rome, Italy.
RP Savarino, A (reprint author), A Avogadro Univ Eastern Piedmont, Dept Med Sci, Immunol Lab, Interdisciplinary Res Ctr Autoimmune Dis, Via Solaroli 17, I-28100 Novara, Italy.
EM asavarino@medscape.com
RI Ensoli, Barbara/J-9169-2016; Cafaro, Aurelio/K-5314-2016; Dianzani,
   Umberto/K-1952-2016
OI Ensoli, Barbara/0000-0002-0545-8737; ORTOLAN, Erika/0000-0003-2287-9020;
   MALAVASI, Fabio/0000-0002-1844-174X
CR Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   BENJOUAD A, 1995, VIROLOGY, V206, P457, DOI 10.1016/S0042-6822(95)80061-1
   Bragardo M, 1997, J IMMUNOL, V159, P1619
   Carbone J, 2000, AIDS, V14, P2823, DOI 10.1097/00002030-200012220-00003                                                
   Cesano A, 1998, J IMMUNOL, V160, P1106
   Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X
   CHOE H, 1996, CELL, V85, P135
   Denisova G, 1997, J IMMUNOL, V158, P1157
   Dettin M, 1997, BIOCHEM BIOPH RES CO, V241, P584, DOI 10.1006/bbrc.1997.7857
   DIANZANI U, 1995, EUR J IMMUNOL, V25, P1306, DOI 10.1002/eji.1830250526
   DIANZANI U, 1994, J IMMUNOL, V153, P952
   Feito MJ, 1997, INT IMMUNOL, V9, P1141, DOI 10.1093/intimm/9.8.1141                                                         
   Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660                                                                  
   Hammache D, 1998, J BIOL CHEM, V273, P7967, DOI 10.1074/jbc.273.14.7967
   HaraYokoyama M, 1996, J BIOL CHEM, V271, P12951, DOI 10.1074/jbc.271.22.12951                                                        
   Hoffman NG, 2002, J VIROL, V76, P3852, DOI 10.1128/JVI.76.8.3852-3864.2002
   Hoshino S, 1997, J IMMUNOL, V158, P741
   HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624
   Kaufmann GR, 2000, AIDS, V14, P2643, DOI 10.1097/00002030-200012010-00003
   Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Levy JA, 2001, TRENDS IMMUNOL, V22, P312, DOI 10.1016/S1471-4906(01)01925-1
   MALAVASI F, 1984, HUM IMMUNOL, V9, P9, DOI 10.1016/0198-8859(84)90003-X
   Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025
   Mehta K, 1996, FASEB J, V10, P1408
   Moir S, 1996, J VIROL, V70, P8019
   Morgenstern B, 1999, BIOINFORMATICS, V15, P211, DOI 10.1093/bioinformatics/15.3.211                                                 
   Munshi CB, 1997, METHOD ENZYMOL, V280, P318
   Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026                                                         
   Nardese V, 2001, NAT STRUCT BIOL, V8, P611, DOI 10.1038/89653
   POSNETT DN, 1988, J BIOL CHEM, V263, P1719
   Rabehi L, 1998, AIDS RES HUM RETROV, V14, P1605, DOI 10.1089/aid.1998.14.1605
   Resino S, 2001, CLIN EXP IMMUNOL, V125, P266, DOI 10.1046/j.1365-2249.2001.01612.x                                                
   Roussanov BV, 2000, AIDS, V14, P2715, DOI 10.1097/00002030-200012010-00011                                                
   Savarino A, 1999, FASEB J, V13, P2265
   Savarino A, 1999, CELL BIOCHEM FUNCT, V17, P47, DOI 10.1002/(SICI)1099-0844(199903)17:1<47::AID-CBF810>3.0.CO;2-V
   Savarino A, 2000, AIDS, V14, P1079, DOI 10.1097/00002030-200006160-00004
   Savarino A, 2001, AIDS, V15, P2221, DOI 10.1097/00002030-200111230-00002                                                
   Spina CA, 1997, J CLIN INVEST, V99, P1774, DOI 10.1172/JCI119342
   Su J, 2000, AIDS RES HUM RETROV, V16, P37, DOI 10.1089/088922200309584
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   Tilling R, 2002, AIDS, V16, P589, DOI 10.1097/00002030-200203080-00010
   TRUNEH A, 1991, J BIOL CHEM, V266, P5942
   Vigano A, 1998, LANCET, V352, P1905, DOI 10.1016/S0140-6736(05)60396-0
   WILCHEK M, 1990, METHOD ENZYMOL, V184, P1
   Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0
   Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   YAHI N, 1995, P NATL ACAD SCI USA, V92, P4867, DOI 10.1073/pnas.92.11.4867
   ZANOTTO C, 1995, VIROLOGY, V206, P807, DOI 10.1006/viro.1995.1003
   Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353
   Zubiaur M, 2002, J BIOL CHEM, V277, P13, DOI 10.1074/jbc.M107474200
   Zufferey R, 1998, J VIROL, V72, P9873
NR 53
TC 21
Z9 21
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD JAN
PY 2003
VL 17
IS 1
BP 461
EP +
DI 10.1096/fj.02-0512fje
PG 20
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 653TT
UT WOS:000181453700001
PM 12551845
DA 2018-01-05
ER

PT J
AU Burnouf, T
   Radosevich, M
AF Burnouf, T
   Radosevich, M
TI Nanofiltration of plasma-derived biopharmaceutical products
SO HAEMOPHILIA
LA English
DT Review
DE nanofiltration; plasma; prions; validation; viral safety; virus
ID CREUTZFELDT-JAKOB-DISEASE; FACTOR-IX CONCENTRATE; TRANSMISSIBLE
   SPONGIFORM ENCEPHALOPATHY; CLOTTING FACTOR CONCENTRATE; FACTOR-VIII
   CONCENTRATE; HUMAN PARVOVIRUS B19; HOLLOW FIBER BMM; PURITY FACTOR-IX;
   VIRUS REMOVAL; BLOOD COMPONENTS
AB This review presents the current status on the use and benefits of viral removal filtration systems - known as nanofiltration - in the manufacture of plasma-derived coagulation factor concentrates and other biopharmaceutical products from human blood origin.
   Nanofiltration of plasma products has been implemented at a production scale in the early 1990s to improve margin of viral safety, as a complement to the viral reduction treatments, such as solvent-detergent and heat treatments, already applied for the inactivation of human immunodeficiency virus, hepatitis B and hepatitis C virus. The main reason for the introduction of nanofiltration was the need to improve product safety against non-enveloped viruses and to provide a possible safeguard against new infectious agents potentially entering the human plasma pool.
   Nanofiltration has gained quick acceptance as it is a relatively simple manufacturing step that consists in filtering protein solution through membranes of a very small pore size (typically 15-40 nm) under conditions that retain viruses by a mechanism largely based on size exclusion. Recent large-scale experience throughout the world has now established that nanofiltration is a robust and reliable viral reduction technique that can be applied to essentially all plasma products. Many of the licensed plasma products are currently nanofiltered.
   The technology has major advantages as it is flexible and it may combine efficient and largely predictable removal of more than 4 to 6 logs of a wide range of viruses, with an absence of denaturing effect on plasma proteins. Compared with other viral reduction means, nanofiltration may be the only method to date permitting efficient removal of enveloped and non-enveloped viruses under conditions where 90-95% of protein activity is recovered. New data indicate that nanofiltration may also remove prions, opening new perspectives in the development and interest of this technique. Nanofiltration is increasingly becoming a routine step in the manufacture of biopharmaceutical products.
C1 Human Plasma Prod Serv, F-59800 Lille, France.
RP Burnouf, T (reprint author), Human Plasma Prod Serv, 18 Rue Saint Jacques, F-59800 Lille, France.
CR Abe H, 2000, ARTIF CELL BLOOD SUB, V28, P375, DOI 10.3109/10731190009118582                                                       
   AranhaCreado H, 1997, PDA J PHARM SCI TECH, V51, P119
   ARANHACREADO H, 1543 STR
   Aubin JT, 2000, VOX SANG, V78, P7, DOI 10.1159/000031142
   Azari M, 2000, BIOLOGICALS, V28, P81, DOI 10.1006/biol.2000.0246
   Blum M, 1998, BIOPHARM-APPL T BIO, V11, P28
   BORELDERLON A, 2000, 3 JOURN LFB BRUSS 12
   Brandwein H, 2000, Dev Biol (Basel), V102, P157
   Brown P, 1999, TRANSFUSION, V39, P1169, DOI 10.1046/j.1537-2995.1999.39111169.x                                             
   Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x
   Brown P, 2000, LANCET, V356, P955, DOI 10.1016/S0140-6736(00)02706-9
   Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057
   BUNCH C, 1999, 17 C INT SOC THROMB
   BUNCH C, 1999, PLAN WORKSH US 99 FO, P35
   Burnouf T, 1996, VOX SANG, V70, P235, DOI 10.1111/j.1423-0410.1996.tb01334.x                                              
   BURNOUF T, 1995, J CHROMATOGR B, V664, P3, DOI 10.1016/0378-4347(94)00532-A
   BURNOUF T, 1989, VOX SANG, V57, P225, DOI 10.1111/j.1423-0410.1989.tb00832.x                                              
   BURNOUF T, 1991, VOX SANG, V60, P8, DOI 10.1111/j.1423-0410.1991.tb00864.x                                              
   Burnouf T, 2001, J BIOCHEM BIOPH METH, V49, P575, DOI 10.1016/S0165-022X(01)00221-4
   Burnouf T, 2000, BLOOD REV, V14, P94, DOI 10.1054/blre.2000.0129                                                          
   BURNOUF T, 1993, DEV BIOL STAND, V81, P199
   BURNOUF T, 1994, ANIMAL CELL TECHNOLO, V6, P17
   BURNOUFRADOSEVICH M, 1992, TRANSFUSION, V32, P861, DOI 10.1046/j.1537-2995.1992.32993110761.x                                          
   BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x                                              
   BURNOUFRADOSEVICH M, 1992, VOX SANG, V62, P1, DOI 10.1111/j.1423-0410.1992.tb01159.x                                              
   Carter J, 2002, EUR J PARENTER SCI, V7, P72
   CHTOUROU S, 2000, PLAN WORKSH JAP FOR, P91
   Dichtelmuller H., 1998, PLAN WORKSH MEET EXC, P27
   Eibl J, 1996, BIOLOGICALS, V24, P285, DOI 10.1006/biol.1996.0036
   *FALL CORP, 1996, OMEGA VR TM VIR RED
   Farrugia A, 2002, HAEMOPHILIA, V8, P230, DOI 10.1046/j.1365-2516.2002.00618.x
   FELDMAN F, 1995, ACTA HAEMATOL-BASEL, V94, P25, DOI 10.1159/000204024                                                               
   Feldman P., 1998, PLAN WORKSH MEET EXC, P47
   Foster PR, 2000, VOX SANG, V78, P86, DOI 10.1159/000031156
   Golker CF, 1996, BIOLOGICALS, V24, P103
   Goudemand J, 1998, THROMB HAEMOSTASIS, V80, P919
   Graf E G, 1999, Dev Biol Stand, V99, P89
   Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X
   Hilton DA, 2002, BRIT MED J, V325, P633, DOI 10.1136/bmj.325.7365.633
   HOFFER L, 1995, J CHROMATOGR B, V669, P187, DOI 10.1016/0378-4347(95)00107-T
   Hong F, 1998, SEMIN HEMATOL, V35, P9
   HOROWITZ B, 2002, WHOBS011941
   Hughes B, 1996, DEV BIOL STAND, V88, P91
   Hunter N, 2002, Dev Biol (Basel), V108, P93
   IDE S, 2000, PLAN WORKSH JAP FOR
   Johnston A, 2000, BIOLOGICALS, V28, P129, DOI 10.1006/biol.1999.0242
   Josic D, 2000, THROMB RES, V100, P433, DOI 10.1016/S0049-3848(00)00339-X
   KURODA Y, 1983, INFECT IMMUN, V41, P154
   LEE DC, 2001, TRANSFUSION, V41, P433
   MACGREGOR I, 1999, THROMB HAEMOSTASIS, V82, P86
   MAENO H, 2000, PLAN WORKSH JAP FOR, P22
   MAENO H, 2000, PLAN WORKSH JAP FOR, P21
   MANABE S, 1987, POLYM J, V19, P391, DOI 10.1295/polymj.19.391                                                           
   MANABE S-C, 1989, Membrane, V14, P77
   Manabe SI, 1996, DEV BIOL STAND, V88, P81
   MANNUCCI PM, 1995, THROMB HAEMOSTASIS, V73, P737
   *MILL, 2001, VIR NFP FILT DAT SHE
   *MILL, 2002, VIR VIR APPL FILTR G
   *MILL, 1999, VIR NFP FILT DAT SHE
   NOWAK T, 1998, PLAN WORKSH MEET EXC, P16
   Oshima KH, 1998, VOX SANG, V75, P181, DOI 10.1159/000030984
   Over J., 1998, PLAN WORKSH MEET EXC, P5
   *PALL BIOPH, 2000, VAL GUID VG DV20 PAL
   Peerlinck K, 1997, THROMB HAEMOSTASIS, V77, P80
   PEJAUDIER L, 1987, VOX SANG, V52, P1, DOI 10.1111/j.1423-0410.1987.tb02979.x                                              
   POULLE M, 1994, BLOOD COAGUL FIBRIN, V5, P543
   PRICE H, 1999, PLAN WORKSH US 99 FO, P21
   Prowse C, 1997, VOX SANG, V72, P1, DOI 10.1046/j.1423-0410.1997.00001.x                                                
   Romisch J, 1996, BEITR INFUS, V33, P220
   ROSENDAAL FR, 1993, BLOOD, V81, P2180
   ROTHSCHILD F, 1999, 17 C INT SOC THROMB
   Schulman S, 1999, HAEMOPHILIA, V5, P96, DOI 10.1046/j.1365-2516.1999.00284.x
   SEKIGUCHI S, 1989, Membrane, V14, P253
   Soucie JM, 1998, TRANSFUSION, V38, P573, DOI 10.1046/j.1537-2995.1998.38698326337.x
   Stucki M, 1997, J CHROMATOGR B, V700, P241, DOI 10.1016/S0378-4347(97)00319-8
   SUOMELA H, 1998, PLAN WORKSH MEET EXC, P38
   Takeda Y, 2001, VOX SANG, V81, P266, DOI 10.1046/j.1423-0410.2001.00114.x
   Tateishi J, 2001, BIOLOGICALS, V29, P17, DOI 10.1006/biol.2001.0269
   Tateishi J, 1995, ANIMAL CELL TECHNOLOGY: DEVELOPMENTS TOWARDS THE 21ST CENTURY, P637
   TATEISHI J, 1985, LANCET, V2, P1299
   TATEISHI J, 1980, ACTA NEUROPATHOL, V51, P127, DOI 10.1007/BF00690454                                                              
   TATEISHI J, 1991, MICROBIOL IMMUNOL, V35, P163, DOI 10.1111/j.1348-0421.1991.tb01544.x                                              
   Tateishi Jun, 1993, Membrane, V18, P357
   Tolo H, 2001, J INTERF CYTOK RES, V21, P913, DOI 10.1089/107999001753289523
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   TSURUMI T, 1990, POLYM J, V22, P751, DOI 10.1295/polymj.22.751                                                           
   van Reis R, 2001, CURR OPIN BIOTECH, V12, P208, DOI 10.1016/S0958-1669(00)00201-9
   von Bonsdorff L, 2001, BIOLOGICALS, V29, P27, DOI 10.1006/biol.2001.0273
   Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9
   Will RG, 1998, VOX SANG, V75, P178, DOI 10.1046/j.1423-0410.1998.7530178.x
   YAMAGUCHI K, 1991, J ELECTRON MICROSC, V40, P337
   YAP PL, 1992, CLIN APPL INTRAVENOU, P43
   Yee TT, 1996, BRIT J HAEMATOL, V93, P457, DOI 10.1046/j.1365-2141.1996.5161062.x                                              
   YUNOKI M, 2000, PLAN WORKSH JAP FOR
NR 94
TC 116
Z9 125
U1 0
U2 39
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 1351-8216
J9 HAEMOPHILIA
JI Haemophilia
PD JAN
PY 2003
VL 9
IS 1
BP 24
EP 37
DI 10.1046/j.1365-2516.2003.00701.x
PG 14
WC Hematology
SC Hematology
GA 638ZA
UT WOS:000180602000002
PM 12558776
DA 2018-01-05
ER

PT J
AU MacKay, JA
   Szoka, FC
AF MacKay, JA
   Szoka, FC
TI HIV TAT protein transduction domain mediated cell binding and
   intracellular delivery of nanoparticles
SO JOURNAL OF DISPERSION SCIENCE AND TECHNOLOGY
LA English
DT Article
DE HIV; TAT; human immunodeficiency virus; trans-acting transcriptional
   activator; liposomel; nanoparticle; cationic; peptide; endocytosis;
   potocytosis; polymer; heparan sulfate proteoglycan; CLIO; cross-linked
   iron-oxide; pharmacokinetic
ID HEPARAN-SULFATE PROTEOGLYCANS; BIOLOGICALLY-ACTIVE PROTEINS; IN-VIVO;
   MAMMALIAN-CELLS; MEMBRANE TRANSLOCATION; MAGNETIC NANOPARTICLES;
   PENETRATING PEPTIDES; INTERNALIZATION; DNA; LIPOSOMES
AB Intracellular delivery of non-transported therapeutic agents has traditionally been thought possible only for low molecular weight (<500DA) hydrophobic molecules. Higher molecular weight agents including oligonucleotides, proteins, DNA, liposomes, and nanoparticles do not readily enter the cytoplasm. However, the human immunodeficiency virus (HIV) trans-acting transcriptional activator (TAT) protein enters the cytosol by way of an 11 amino acid cationic peptide (TATp). When this cationic sequence is attached to a variety of small pharmacological agents, including paramagnetic ions([1,2]) and proteins,([3-6]) they are delivered into cells. Further, TATp modification of large cargo, such as proteins, polymers, and nanoparticles, may enable them to internalize into cells as well. The size limitations for cargo delivered by a single TATp are currently undetermined, but multiple TATp attached to polymers, nanoparticles, liposomes, and phage can definitely mediate their internalization. This process appears to follow an endocytotic or potocytic pathway and does not directly transfer the cargo into the cytoplasm of the cell. Here we review recent publications in which multiple TATp have been attached to and resulted in the successful intracellular delivery of nanoparticles.
C1 Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Joint Grad Grp Bioengn, San Francisco, CA 94143 USA.
   Univ Calif Berkeley, Joint Grad Grp Bioengn, San Francisco, CA 94143 USA.
RP Szoka, FC (reprint author), Univ Calif San Francisco, Dept Biopharmaceut Sci, HSE 1145,513 Parnassus Ave, San Francisco, CA 94143 USA.
FU NIGMS NIH HHS [R01 GM061851, R01 GM061851-03]
CR BARRON LG, 1999, NONVIRAL VECTORS GEN, P229
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dodd CH, 2001, J IMMUNOL METHODS, V256, P89, DOI 10.1016/S0022-1759(01)00433-1
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173
   Huang SY, 1998, BIOCONJUGATE CHEM, V9, P612, DOI 10.1021/bc980038p
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Leifert JA, 2002, GENE THER, V9, P1422, DOI 10.1038/sj.gt.3301819
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lindsey ME, 2000, J COUNTRY MUSIC, V21, P3
   Liu JQ, 2001, BIOMACROMOLECULES, V2, P362, DOI 10.1021/bm015515c
   Lundberg M, 2002, BIOCHEM BIOPH RES CO, V291, P367, DOI 10.1006/bbrc.2002.6450
   Lundberg M, 2001, NAT BIOTECHNOL, V19, P713, DOI 10.1038/90741
   MANN DA, 1991, EMBO J, V10, P1733
   Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137
   Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Sandgren S, 2002, J BIOL CHEM, V277, P38877, DOI 10.1074/jbc.M205395200
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7                                                   
   Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI200113799
   Silhol M, 2002, EUR J BIOCHEM, V269, P494, DOI 10.1046/j.0014-2956.2001.02671.x                                                
   Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2
   Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Torchilin VP, 2002, CELL MOL BIOL LETT, V7, P265
   Tseng YL, 2002, MOL PHARMACOL, V62, P864, DOI 10.1124/mol.62.4.864
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Watson K, 1999, BIOCHEM PHARMACOL, V57, P775, DOI 10.1016/S0006-2952(98)00352-9
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wunderbaldinger P, 2002, BIOCONJUGATE CHEM, V13, P264, DOI 10.1021/bc015563u
   Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242                                                                   
   Zhao M, 2002, BIOCONJUGATE CHEM, V13, P840, DOI 10.1021/bc0255236
NR 40
TC 4
Z9 4
U1 0
U2 2
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 0193-2691
J9 J DISPER SCI TECHNOL
JI J. Dispersion Sci. Technol.
PY 2003
VL 24
IS 3-4
BP 465
EP 473
DI 10.1081/DIS-120021802
PG 9
WC Chemistry, Physical
SC Chemistry
GA 701NF
UT WOS:000184173100012
PM 20808712
DA 2018-01-05
ER

PT B
AU English, TJ
   Hammer, DA
AF English, TJ
   Hammer, DA
BE Reisman, S
   Foulds, R
   Mantilla, B
TI HIV viral docking: Model predictions for bond number and trajectory
SO PROCEEDINGS OF THE IEEE 29TH ANNUAL NORTHEAST BIOENGINEERING CONFERENCE
LA English
DT Proceedings Paper
CT IEEE 29th Annual Northeast Bioengineering Conference
CY MAR 22-23, 2003
CL NJ INST TECHNOL, NEWARK, NJ
SP Schering Plough, Becton Dickinson, Boston Sci, Reva Med, Vyteris, Whitaker Fdn, NJIT Pre Coll Programs, NJIT Student Senate, NJIT Grad Student Assoc
HO NJ INST TECHNOL
ID DISSOCIATION; SURFACES; CELLS
AB Viruses are nano-scale pathogenic particles. Understanding viral attachment is important to understand infectivity, disease transmission, and virus propagation throughout the host. A new simulation technique has been developed to study viral docking behavior - Brownian Adhesive Dynamics (BRAD). BRAD couples Brownian motion algorithms with adhesive dynamic models, and incorporates the effect of virus/cell geometry - an improvement over previous models. The method is extendable to any virus/cell system as well as nanoparticle adhesion systems. Current studies have focused on the HIV/CD4 cell system. Comparison of BRAD simulation predictions with those of previous models of viral docking has shown differences in steady state bond number and bond trajectory. This indicates that geometry of the system plays a significant role in the bonding behavior of viruses. Thus, it is shown that the equivalent site hypothesis is suspect.
C1 Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA.
RP English, TJ (reprint author), Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA.
CR Allen M. P., 1987, COMPUTER SIMULATIONS
   HAMMER DA, 1992, BIOPHYS J, V63, P35, DOI 10.1016/S0006-3495(92)81577-1                                                   
   Hlavacek WS, 1999, P NATL ACAD SCI USA, V96, P14681, DOI 10.1073/pnas.96.26.14681
   King MR, 2001, BIOPHYS J, V81, P799, DOI 10.1016/S0006-3495(01)75742-6                                                   
   Levine AJ, 1992, VIRUSES
   PERELSON AS, 1981, MATH BIOSCI, V53, P1, DOI 10.1016/0025-5564(81)90036-5
   Tees DFJ, 2001, J CHEM PHYS, V114, P7483, DOI 10.1063/1.1356030
   WICKHAM TJ, 1990, BIOPHYS J, V58, P1501, DOI 10.1016/S0006-3495(90)82495-4                                                   
NR 8
TC 0
Z9 0
U1 0
U2 0
PU IEEE
PI NEW YORK
PA 345 E 47TH ST, NEW YORK, NY 10017 USA
BN 0-7803-7767-2
PY 2003
BP 156
EP 157
PG 2
WC Computer Science, Artificial Intelligence; Engineering, Biomedical;
   Instruments & Instrumentation; Radiology, Nuclear Medicine & Medical
   Imaging
SC Computer Science; Engineering; Instruments & Instrumentation; Radiology,
   Nuclear Medicine & Medical Imaging
GA BX14C
UT WOS:000184414900076
DA 2018-01-05
ER

PT J
AU Bourinbaiar, AS
   Metadilogkul, O
   Jirathitikal, V
AF Bourinbaiar, AS
   Metadilogkul, O
   Jirathitikal, V
TI Mucosal AIDS vaccines
SO VIRAL IMMUNOLOGY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOTOXIC T-LYMPHOCYTES; INACTIVATED
   HIV-1-CAPTURING NANOSPHERES; BROADLY NEUTRALIZING ANTIBODIES;
   RESPIRATORY-TRACT INFECTIONS; HIV-ENVELOPE PROTEIN; IMMUNE-RESPONSES;
   SIMIAN IMMUNODEFICIENCY; DNA VACCINE; INTRANASAL IMMUNIZATION
AB Debates are still being waged over what is the best strategy for developing a potent AIDS vaccine. All the obvious approaches to making AIDS vaccines have been tried in the past two decades without much success. It is clear that new thinking and a revision of prevailing dogmas needs to be in place if we really want a vaccine. Conventional envelope-based antibody-inducing vaccines do not appear to hold promise, and broadly-neutralizing antibodies are now being searched as an alternative to the failed approach with subunit vaccines. The current consensus is that cellular immune responses, especially those mediated by CD8 cytotoxic/suppressor (CTL) and CD4 helper T lymphocytes, are needed to control HIV. Vaccines capable of inducing cell-mediated responses are, therefore, considered critical for controlling the spread of HIV. DNA-based vaccines triggering CTL reaction are currently thought to be an answer, but will they fulfill the promise? In the following paragraphs, a critical assessment of the state of the art will be provided in an attempt to analyze what we know and still don't know. The focus of this review is primarily on mucosal vaccines-a relatively new area in AIDS research. The update on V-1 Immunitor, the first mucosal AIDS vaccine available commercially, is provided within this context. Some of the reviewed concepts may be disputable, but without departure from the uninspiring consensus no substantial progress in the AIDS vaccine field can be envisioned.
C1 Immunitor Corp Co Ltd, Chachoengsao 24130, Thailand.
   Minist Publ Hlth, Rajavithi Gen Hosp, Occupat & Environm Med Assoc Thailand, Bangkok, Thailand.
RP Bourinbaiar, AS (reprint author), Immunitor Corp Co Ltd, 71 Moo 5,Bangpakong Ind Pk, Chachoengsao 24130, Thailand.
EM info@immunitor.com
CR ADA G, 1993, NATURE, V362, P212
   Akagi T, 2003, J MED VIROL, V69, P163, DOI 10.1002/jmv.10279
   AKERBLOM L, 1991, AIDS RES HUM RETROV, V7, P621, DOI 10.1089/aid.1991.7.621
   Amara RR, 2002, J VIROL, V76, P7625, DOI 10.1128/JVI.76.15.7625-7631.2002
   Ambrose Z, 2001, J VIROL, V75, P8589, DOI 10.1128/JVI.75.18.8589-8596.2001
   Bagarazzi ML, 1999, J INFECT DIS, V180, P1351, DOI 10.1086/314978                                                                  
   BELLON G, 1990, ANN PEDIATR-PARIS, V37, P535
   Belyakov IM, 2000, J IMMUNOL, V165, P6454, DOI 10.4049/jimmunol.165.11.6454                                                    
   Belyakov IM, 1998, J VIROL, V72, P8264
   Belyakov IM, 1998, P NATL ACAD SCI USA, V95, P1709, DOI 10.1073/pnas.95.4.1709
   BERGGREN RE, 1995, J ACQ IMMUN DEF SYND, V10, P489
   Bergmeier LA, 2002, ORAL DIS, V8, P63, DOI 10.1034/j.1601-0825.2002.00014.x
   Berman PW, 1997, J INFECT DIS, V176, P384, DOI 10.1086/514055                                                                  
   Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001
   BOLLINGER RC, 1993, AIDS RES HUM RETROV, V9, P1067, DOI 10.1089/aid.1993.9.1067
   Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X
   Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205
   Borsutzky S, 2003, EUR J IMMUNOL, V33, P1548, DOI 10.1002/eji.200323954
   Boura ALA, 1997, BRIT J PHARMACOL, V120, P162, DOI 10.1111/j.1476-5381.1997.tb06794.x                                              
   BOURINBAIAR A, 1989, LANCET, V1, P1019
   BOURINBAIAR AS, 1995, ADV EXP MED BIOL, V374, P71
   BOURINBAIAR AS, 1994, MED HYPOTHESES, V42, P43, DOI 10.1016/0306-9877(94)90034-5                                                    
   Bourinbaiar AS, 2003, CURR PHARM DESIGN, V9, P1419, DOI 10.2174/1381612033454685
   BOURINBAIAR AS, 1991, J ACQ IMMUN DEF SYND, V4, P56
   BOURINBAIAR AS, 1988, JPN J CANC RES
   Bradney CP, 2002, J VIROL, V76, P517, DOI 10.1128/JVI.76.2.517-524.2002
   BROWNING M, 1992, VACCINE, V10, P585, DOI 10.1016/0264-410X(92)90437-O
   Bruhl P, 1998, AIDS RES HUM RETROV, V14, P401, DOI 10.1089/aid.1998.14.401
   BUKAWA H, 1995, NAT MED, V1, P681, DOI 10.1038/nm0795-681                                                              
   Burnett MS, 2000, VACCINE, V19, P735, DOI 10.1016/S0264-410X(00)00303-0                                                   
   Caley IJ, 1997, J VIROL, V71, P3031
   Caputo A, 2002, VACCINE, V20, P2303, DOI 10.1016/S0264-410X(02)00099-3
   CARLSON JR, 1987, IMMUNOPATHOLOGY SMAL, P21
   CARR RI, 1987, CLIN IMMUNOL IMMUNOP, V42, P298, DOI 10.1016/0090-1229(87)90018-3
   Davis NL, 2002, IUBMB LIFE, V53, P209, DOI [10.1080/15216540212657, 10.1080/15216540290098945]
   Decroix N, 2002, SCAND J IMMUNOL, V56, P59, DOI 10.1046/j.1365-3083.2002.01113.x
   Decroix N, 2001, SCAND J IMMUNOL, V53, P401, DOI 10.1046/j.1365-3083.2001.00894.x
   Devico AL, 2002, VACCINE, V20, P1968, DOI 10.1016/S0264-410X(02)00080-4
   Devito C, 2002, J ACQ IMMUN DEF SYND, V30, P413, DOI 10.1097/01.QAI.0000021664.20213.5A
   Dumais N, 2002, J INFECT DIS, V186, P1098, DOI 10.1086/344232
   Durrani Z, 1998, J IMMUNOL METHODS, V220, P93, DOI 10.1016/S0022-1759(98)00145-8
   Enose Y, 2002, VIROLOGY, V298, P306, DOI 10.1006/viro.2002.1440
   Estrada A, 2000, COMP IMMUNOL MICROB, V23, P27, DOI 10.1016/S0147-9571(99)00020-X
   Evans DT, 2003, J VIROL, V77, P2400, DOI 10.1128/JVI.77.4.2400-2409.2003
   Evans TG, 2001, VACCINE, V19, P2080, DOI 10.1016/S0264-410X(00)00415-1
   Ferko B, 2001, J VIROL, V75, P8899, DOI 10.1128/JVI.75.19.8899-8908.2001
   Flynn JN, 2000, IMMUNOLOGY, V101, P120, DOI 10.1046/j.1365-2567.2000.00089.x
   Frey A, 1999, VACCINE, V17, P3007, DOI 10.1016/S0264-410X(99)00163-2                                                   
   Friedman RS, 2000, J VIROL, V74, P9987, DOI 10.1128/JVI.74.21.9987-9993.2000
   Fuerst T R, 1991, Biotechnol Ther, V2, P159
   Fuller DH, 2002, J VIROL, V76, P3309, DOI 10.1128/JVI.76.7.3309-3317.2002
   Fust G, 1997, PARASITOLOGY, V115, pS127
   Galea P, 1999, VACCINE, V17, P1700, DOI 10.1016/S0264-410X(98)00432-0                                                   
   GICQUEL B, 1994, DEV BIOL STAND, V82, P171
   Golding B, 2002, VACCINE, V20, P1445, DOI 10.1016/S0264-410X(01)00477-7
   Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212
   GOULDFOGERITE S, 1994, AIDS RES HUM RETROV, V10, pS99
   Habel A, 2000, Dev Biol (Basel), V104, P101
   Hamajima K, 1998, CLIN IMMUNOL IMMUNOP, V88, P205, DOI 10.1006/clin.1998.4566
   HARRER T, 1993, J ACQ IMMUN DEF SYND, V6, P865
   Heeney JL, 1998, J MED PRIMATOL, V27, P50, DOI 10.1111/j.1600-0684.1998.tb00226.x                                              
   Hinkula J, 1997, VACCINE, V15, P874, DOI 10.1016/S0264-410X(96)00257-5
   HOGLUND S, 1990, Viral Immunology, V3, P195, DOI 10.1089/vim.1990.3.195
   HOLMGREN J, 1992, IMMUNOBIOLOGY, V184, P157, DOI 10.1016/S0171-2985(11)80473-0                                                   
   HOMSY J, 1989, SCIENCE, V244, P1357, DOI 10.1126/science.2786647
   Hone DM, 2002, J HUMAN VIROL, V5, P17
   Horner AA, 2001, J IMMUNOL, V167, P1584, DOI 10.4049/jimmunol.167.3.1584                                                     
   HOWELL DM, 1987, J GEN VIROL, V68, P2899, DOI 10.1099/0022-1317-68-11-2899
   Ihata A, 1999, IMMUNOLOGY, V98, P436, DOI 10.1046/j.1365-2567.1999.00879.x
   Jirathitikal V, 2004, EUR J CLIN NUTR, V58, P110, DOI 10.1038/sj.ejcn.1601756
   Jirathitikal V, 2003, ELECTRON J BIOTECHN, V6, P76
   JIRATHITIKAL V, 2001, V 1 IMMUNITOR GRASS
   JIRATHITIKAL V, 2003, VACCINE, V21, P324
   Jirathitikal Vichai, 2002, HIV Clin Trials, V3, P21
   KAGNOFF MF, 1982, ANN NY ACAD SCI, V392, P248, DOI 10.1111/j.1749-6632.1982.tb36111.x                                              
   KAHN JO, 1995, J INFECT DIS, V171, P1343, DOI 10.1093/infdis/171.5.1343                                                       
   Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093
   Karpenko L. I., 2002, Voprosy Virusologii, V47, P25
   Kato H, 2000, VACCINE, V18, P1151, DOI 10.1016/S0264-410X(99)00385-0                                                   
   Kawahara M, 2002, CLIN IMMUNOL, V105, P326, DOI 10.1006/clim.2002.5292
   Kawamura M, 2002, J MED VIROL, V66, P291, DOI 10.1002/jmv.2144
   Klavinskis LS, 1997, VACCINE, V15, P818, DOI 10.1016/S0264-410X(96)00278-2
   KOBAYASHI N, 1989, BIOCHEM BIOPH RES CO, V165, P715, DOI 10.1016/S0006-291X(89)80025-7
   Kojima Y, 2002, VACCINE, V20, P2857, DOI 10.1016/S0264-410X(02)00238-4
   Krivorutchenko YL, 1997, VOP VIRUSOL+, V42, P34
   Kubota M, 1997, J IMMUNOL, V158, P5321
   Lagranderie M, 1998, AIDS RES HUM RETROV, V14, P1625, DOI 10.1089/aid.1998.14.1625
   Lambert JS, 1997, CLIN DIAGN LAB IMMUN, V4, P302
   Lambert JS, 2001, VACCINE, V19, P3033, DOI 10.1016/S0264-410X(01)00051-2
   LAMM ME, 1988, AM J KIDNEY DIS, V12, P384, DOI 10.1016/S0272-6386(88)80030-1                                                   
   LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775
   Lau GKK, 2002, GASTROENTEROLOGY, V122, P614, DOI 10.1053/gast.2002.31887
   Le Buanec H, 2001, BIOMED PHARMACOTHER, V55, P316, DOI 10.1016/S0753-3322(01)00073-7
   Lehner T, 2000, EUR J IMMUNOL, V30, P2245, DOI 10.1002/1521-4141(2000)30:8<2245::AID-IMMU2245>3.0.CO;2-7
   Lehner Thomas, 2000, AIDS Research and Human Retroviruses, V16, P309, DOI 10.1089/088922200309188
   Levine BL, 2002, NAT MED, V8, P47, DOI 10.1038/nm0102-47
   Lian TS, 1999, VACCINE, V18, P604, DOI 10.1016/S0264-410X(99)00315-1
   Lisziewicz J, 2003, VACCINE, V21, P620, DOI 10.1016/S0264-410X(02)00569-8
   Liu XS, 1998, VIROLOGY, V252, P39, DOI 10.1006/viro.1998.9442
   LOHMAN BL, 1994, J MED PRIMATOL, V23, P95, DOI 10.1111/j.1600-0684.1994.tb00108.x                                              
   Lopalco L, 2000, AIDS RES HUM RETROV, V16, P109, DOI 10.1089/088922200309458
   LOUIS E, 1999, INT ARCH ALLERGY IMM, V108, P19
   Lowell GH, 1997, J INFECT DIS, V175, P292, DOI 10.1093/infdis/175.2.292                                                        
   Lu Y, 1999, CLIN EXP IMMUNOL, V115, P335, DOI 10.1046/j.1365-2249.1999.00793.x                                                
   Lund A, 2001, VET DERMATOL, V12, P75, DOI 10.1046/j.1365-3164.2001.00218.x
   Lundholm P, 2002, VIRUS RES, V82, P141
   Maksyutov A. Z., 2002, Molekulyarnaya Biologiya (Moscow), V36, P447
   Mannino RJ, 1998, ADV DRUG DELIV REV, V32, P273
   Mantis NJ, 2001, VACCINE, V19, P3990, DOI 10.1016/S0264-410X(01)00115-3
   Mayer L, 2000, J PEDIATR GASTR NUTR, V30, pS4, DOI 10.1097/00005176-200001001-00002                                                
   McElrath MJ, 1996, P NATL ACAD SCI USA, V93, P3972, DOI 10.1073/pnas.93.9.3972
   Metadilogkul Orapun, 2002, HIV Clin Trials, V3, P258
   Meyer D, 1998, AIDS RES HUM RETROV, V14, P751, DOI 10.1089/aid.1998.14.751
   Moja P, 2000, J INFECT DIS, V181, P1607, DOI 10.1086/315420
   Moore A, 1999, VACCINE, V17, P2517, DOI 10.1016/S0264-410X(99)00062-6                                                   
   Morris CB, 2000, VACCINE, V18, P1944, DOI 10.1016/S0264-410X(99)00447-8
   Morris CB, 2001, VACCINE, V20, P12, DOI 10.1016/S0264-410X(01)00271-7                                                   
   MORROW CD, 1994, AIDS RES HUM RETROV, V10, pS61
   Mrsny RJ, 1999, VACCINE, V17, P1425, DOI 10.1016/S0264-410X(98)00380-6
   Neidleman JA, 2000, IMMUNOLOGY, V101, P154, DOI 10.1046/j.1365-2567.2000.00090.x
   NEWMAN MJ, 1992, AIDS RES HUM RETROV, V8, P1413
   OHAGAN DT, 1992, J GEN VIROL, V73, P2141, DOI 10.1099/0022-1317-73-8-2141
   Ott G, 2002, J CONTROL RELEASE, V79, P1, DOI 10.1016/S0168-3659(01)00545-4
   Pabst R, 1998, PATHOBIOLOGY, V66, P117, DOI 10.1159/000028006
   Pacheco SE, 2000, AIDS RES HUM RETROV, V16, P2009, DOI 10.1089/088922200750054747
   Pal R, 2002, J VIROL, V76, P292, DOI 10.1128/JVI.76.1.292-302.2002
   PAUPE J, 1990, ANN PEDIATR-PARIS, V37, P475
   PESONEN M, 1984, J CELL BIOL, V99, P796, DOI 10.1083/jcb.99.3.796
   PHILLIPS DM, 1992, VIROLOGY, V186, P261, DOI 10.1016/0042-6822(92)90080-9
   Rayevskaya MV, 2001, J VIROL, V75, P2786, DOI 10.1128/JVI.75.6.2786-2791.2001
   Richardson J, 2002, J GEN VIROL, V83, P2515, DOI 10.1099/0022-1317-83-10-2515                                                    
   Rizzardi GP, 2002, J BIOL REG HOMEOS AG, V16, P83
   ROBINSON WE, 1998, LANCET, V351, P790
   Rutishauser M, 1998, ADV THER, V15, P330
   SABIN AB, 1993, NATURE, V362, P212, DOI 10.1038/362212a0                                                                
   SAKAUE G, 2003, J IMMUNOL, V170, P4952
   Sasaki S, 1998, J VIROL, V72, P4931
   Sasaki S, 1998, INFECT IMMUN, V66, P823
   Schmidhammer S, 2002, UROLOGY, V60, P521, DOI 10.1016/S0090-4295(02)01767-3                                                   
   Serrano E, 1997, EUR ARCH OTO-RHINO-L, V254, P372, DOI 10.1007/BF01642553
   Singh M, 2001, VACCINE, V20, P594, DOI 10.1016/S0264-410X(01)00321-8                                                   
   SISKIND GW, 1966, J EXP MED, V124, P417, DOI 10.1084/jem.124.3.417                                                           
   Skinner GRB, 2000, CROAT MED J, V41, P378
   Sousa AE, 2002, J IMMUNOL, V169, P3400, DOI 10.4049/jimmunol.169.6.3400                                                     
   Spear GT, 2001, J ACQ IMMUN DEF SYND, V26, P103, DOI 10.1097/00126334-200102010-00001
   Spruth M, 1999, AIDS RES HUM RETROV, V15, P533, DOI 10.1089/088922299311051
   Staats HF, 1997, AIDS RES HUM RETROV, V13, P945, DOI 10.1089/aid.1997.13.945
   STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0                                                                
   SWAIN WF, 1997, BEHRING I MITT, V98, P73
   Takahashi I, 1999, JPEN-PARENTER ENTER, V23, pS7, DOI 10.1177/014860719902300503                                                      
   TARTAGLIA J, 1994, DEV BIOL STAND, V82, P125
   Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7
   Ullrich R, 1998, PATHOBIOLOGY, V66, P145, DOI 10.1159/000028012
   Vajdy M, 2001, J INFECT DIS, V184, P1613, DOI 10.1086/324581
   Vecino WH, 2002, IMMUNOL LETT, V82, P197, DOI 10.1016/S0165-2478(02)00043-3                                                   
   Voltan R, 2003, CURR MOL MED, V3, P273, DOI 10.2174/1566524033479816
   Waldman R H, 1975, Acta Endocrinol Suppl (Copenh), V194, P262
   WALKER RS, 1991, FAMILY EC REV, V4, P8
   Walther-Jallow L, 2001, J GEN VIROL, V82, P1601, DOI 10.1099/0022-1317-82-7-1601                                                     
   Wang B, 1997, VACCINE, V15, P821
   Wentworth P, 2002, SCIENCE, V298, P2195, DOI 10.1126/science.1077642
   Winchell JM, 1998, J INFECT DIS, V178, P850, DOI 10.1086/515341                                                                  
   Xin KQ, 2002, HUM GENE THER, V13, P1571, DOI 10.1089/10430340260201662
   YAO Q, 1932, VACCINE, V21, P638
   Yoshizawa I, 2001, VACCINE, V19, P2995, DOI 10.1016/S0264-410X(00)00539-9                                                   
NR 165
TC 13
Z9 15
U1 0
U2 2
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0882-8245
J9 VIRAL IMMUNOL
JI Viral Immunol.
PY 2003
VL 16
IS 4
BP 427
EP 445
DI 10.1089/088282403771926274
PG 19
WC Immunology; Virology
SC Immunology; Virology
GA 759UW
UT WOS:000187756100001
PM 14733732
DA 2018-01-05
ER

PT J
AU D'Cruz, OJ
   Venkatachalam, TK
   Mao, C
   Qazi, S
   Uckun, FM
AF D'Cruz, OJ
   Venkatachalam, TK
   Mao, C
   Qazi, S
   Uckun, FM
TI Structural requirements for potent anti-human immunodeficiency virus
   (HIV) and sperm-immobilizing activities of cyclohexenyl thiourea and
   urea non-nucleoside inhibitors of HIV-1 reverse transcriptase
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE sperm; sperm motility and transport; vagina
ID POKEWEED ANTIVIRAL PROTEIN; STRUCTURE-BASED DESIGN; ARYL PHOSPHATE
   DERIVATIVES; DUAL-FUNCTION SPERMICIDES; NONNUCLEOSIDE INHIBITORS;
   DRUG-RESISTANT;
   N-<2-(2,5-DIMETHOXYPHENYLETHYL)>-N'-<2-(5-BROMOPYRIDYL)>-THIOUREA
   HI-236; PHARMACOKINETIC FEATURES; THERAPEUTIC STRATEGIES; VAGINAL
   MICROBICIDE
AB The current pandemic of sexually transmitted human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) has created an urgent need for a new type of microbicide, one that is both a spermicide and a virucide. In a systematic effort to identify a non-detergent-type antiviral spermicide, we have rationally designed and synthesized a series of cyclohexenyl thiourea (CHET) nonnucleoside inhibitors (NNIs) of HIV-1 reverse transcriptase (RT) with sperm-immobilizing activity (SIA). To gain further insight into the structural requirements for the optimal activity of these dual-function NNIs, we compared the effects of thiazolyl, benzothiazolyl, and pyridyl ring substitutions and functionalization with electron-donating and electron-withdrawing groups as well as the importance of thiourea and urea moieties of 15 heterocyclic ring-substituted NNIs. RT activity and p24 antigen production in HIV-infected peripheral blood mononuclear cells were used as markers of viral replication. Computer-assisted sperm analysis was used for evaluating SIA of CHET compounds. The rabbit model was used for evaluation of in vivo mucosal toxicity and contraceptive activity of the lead NNIs. Three CHET-NNIs with a bromo, chloro, or methyl substitution at the 5 position of the pyridyl ring exhibited potent anti-HIV activity at nanomolar concentrations (IC50 = 35 nM) and SIA at micromolar concentrations (EC50 = 45-96 muM). The dual-function CHET-NNIs were potent inhibitors of drug-resistant HIV-1 strains with genotypic and phenotypic NNI resistance. Upon substitution of the sulfur atom of the thiourea moiety with an oxygen atom, the most striking difference noted was a 38-fold reduction in time required for 50% sperm immobilization (T-1/2). A quantitative structure-activity relationship (QSAR) analysis was used in deriving regression equations between 20 physicochemical properties and SIA of NNIs. QSAR analysis showed that the T-1/2 values positively correlated with values for molecular refractivity (r = 0.88), hydrophobicity (r = 0.72), atomic polarizability (r = 0.70), and principal moment of inertia (r = 0.63) of spermicidal NNIs. A stepwise multiple regression model to describe the relationship of T-1/2 values with these four regressors provided excellent predictability (r = 0.93). Exposure of semen to thiourea/urea NNIs either alone or in combination at the time of artificial insemination led to marked or complete inhibition of pregnancy in rabbits as assessed by the number of embryo implants versus corpora lutea on Day 8 of pregnancy. Repeated intravaginal application of a gel-microemulsion with and without 0.5%, 1%, and 2% CHET-NNI or its urea analog either alone or in combination did not induce mucosal toxicity. We hypothesize that the gain of spermicidal function by CHET-NNIs is due to their metabolic oxidation to urea analogs by sperm. Three reaction pathways are discussed. The extremely rapid SIA of the urea analog as well as the broad-spectrum anti-HIV activity of spermicidal CHET-NNIs together with their lack of mucosal toxicity and the marked ability to reduce in vivo fertility is particularly useful for the clinical development of a dual-function spermicidal microbicide. The cyclohexenyl pyridyl NNIs, especially N- [2-(1-cyclohexenyl) ethyl] N'-[2-(5-bromopyridyl)]-thiourea in combination with the urea analog, show unique clinical potential as anti-HIV spermicides aimed at curbing the sexual transmission of multidrug-resistant HIV-1 while providing effective fertility control for women.
C1 Parker Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Reprod Biol, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Bioinformat, St Paul, MN 55113 USA.
   Paradigm Pharmaceut LLC, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP D'Cruz, OJ (reprint author), Parker Hughes Inst, Drug Discovery Program, 2657 Patton Rd, St Paul, MN 55113 USA.
FU NICHD NIH HHS [HD 042884, HD 37357]
CR Albrecht MA, 2001, NEW ENGL J MED, V345, P398, DOI 10.1056/NEJM200108093450602
   BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0
   BROWN D, 2001, WASHINGTON POST 1219
   Centers for Disease Control and Prevention, 2000, HIV AIDS SURV REP, V12, P1
   Chen CL, 1999, PHARMACEUT RES, V16, P1226, DOI 10.1023/A:1014814313681
   Chen CL, 2001, ARZNEIMITTEL-FORSCH, V51, P574
   COOKSON C, 1993, BRIT MED J, V307, P1375
   CRANK G, 1992, J PHOTOCH PHOTOBIO A, V64, P263, DOI 10.1016/1010-6030(92)85001-B                                                    
   D'Cruz OJ, 2000, ANTI-CANCER DRUG, V11, P849, DOI 10.1097/00001813-200011000-00009                                                
   D'Cruz OJ, 2001, FERTIL STERIL, V75, P106, DOI 10.1016/S0015-0282(00)01665-4
   D'Cruz OJ, 1999, BIOL REPROD, V60, P1419, DOI 10.1095/biolreprod60.6.1419                                                     
   D'Cruz OJ, 1998, BIOL REPROD, V58, P1515, DOI 10.1095/biolreprod58.6.1515                                                     
   D'Cruz OJ, 1998, BIOL REPROD, V59, P503, DOI 10.1095/biolreprod59.3.503                                                      
   D'Cruz OJ, 2001, BIOL REPROD, V64, P51, DOI 10.1095/biolreprod64.1.51
   D'Cruz OJ, 2001, FERTIL STERIL, V75, P115, DOI 10.1016/S0015-0282(00)01636-8
   D'Cruz OJ, 2001, CONTRACEPTION, V64, P113, DOI 10.1016/S0010-7824(01)00233-5
   D'Cruz OJ, 2000, BIOL REPROD, V63, P196, DOI 10.1095/biolreprod63.1.196                                                      
   D'Cruz OJ, 2000, BIOL REPROD, V62, P37, DOI 10.1095/biolreprod62.1.37                                                       
   DCRUZ OJ, 2002, TOXICOL PATHOL, V30, P1
   De Clercq E, 2001, J CLIN VIROL, V22, P73, DOI 10.1016/S1386-6532(01)00167-6                                                   
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DEGEYTER C, 1988, HUM REPROD, V3, P948, DOI 10.1093/oxfordjournals.humrep.a136824                                           
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Dong YH, 2000, BIOORG MED CHEM LETT, V10, P87, DOI 10.1016/S0960-894X(99)00581-8                                                   
   ECSTEIN P, 1969, J REPROD FERTIL, V20, P85
   Gayle H, 2000, AIDS, V14, pS8
   Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006
   Hodge C E, 2001, Compend Contin Educ Dent, V22, P52
   *INT WORK GROUP VA, 1996, AIDS, V10
   Klunder JM, 1998, J MED CHEM, V41, P2960, DOI 10.1021/jm9707028
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KUKLA MJ, 1991, J MED CHEM, V34, P3187, DOI 10.1021/jm00115a007
   LANGE JMA, 1993, LANCET, V341, P1356
   Mao C, 1999, ANTIVIR CHEM CHEMOTH, V10, P233, DOI 10.1177/095632029901000502                                                      
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   Miles SA, 1997, J ACQ IMMUN DEF SYND, V16, pS1, DOI 10.1097/00042560-199701001-00001                                                
   MILES SA, 1997, IMMUNE DEFIC SYNDR H, V16, pS36
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   *NAT I ALL INF DIS, 2001, HIV INF WOM NAT I AL
   POTTS M, 1994, AM J PUBLIC HEALTH, V84, P890, DOI 10.2105/AJPH.84.6.890                                                           
   Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Rivers K, 2001, BETA, V14, P35
   ROGERS D, 1994, J CHEM INF COMP SCI, V34, P854, DOI 10.1021/ci00020a020                                                             
   Romero DL, 1996, J MED CHEM, V39, P3769, DOI 10.1021/jm960158n
   Sahlberg C, 1998, BIOORG MED CHEM LETT, V8, P1511, DOI 10.1016/S0960-894X(98)00249-2
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   Sudbeck EA, 1998, ANTIMICROB AGENTS CH, V42, P3225
   Susman E, 2002, LANCET, V359, P49, DOI 10.1016/S0140-6736(02)07249-5                                                   
   Uckun FM, 2000, ANTIVIR CHEM CHEMOTH, V11, P135, DOI 10.1177/095632020001100205                                                      
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Uckun FM, 1999, HUM REPROD UPDATE, V5, P506, DOI 10.1093/humupd/5.5.506                                                          
   UNAIDS, 2001, REP GLOB HIV AIDS EP
   Venkatachalam TK, 2000, BIOORG MED CHEM LETT, V10, P2071, DOI 10.1016/S0960-894X(00)00398-X
   Venkatachalam TK, 2001, ANTIVIR CHEM CHEMOTH, V12, P213, DOI 10.1177/095632020101200402                                                      
   Venkatachalam TK, 2001, BIOORG MED CHEM LETT, V11, P523, DOI 10.1016/S0960-894X(01)00011-7
   Venkatachalam TK, 2000, ANTIVIR CHEM CHEMOTH, V11, P329, DOI 10.1177/095632020001100503                                                      
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   ZARLING JM, 1991, INT J IMMUNOPHARMACO, V13, P63, DOI 10.1016/0192-0561(91)90126-R                                                    
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 66
TC 21
Z9 21
U1 0
U2 8
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1603 MONROE ST, MADISON, WI 53711-2021 USA
SN 0006-3363
J9 BIOL REPROD
JI Biol. Reprod.
PD DEC
PY 2002
VL 67
IS 6
BP 1959
EP 1974
DI 10.1095/biolreprod.102.006478
PG 16
WC Reproductive Biology
SC Reproductive Biology
GA 619JM
UT WOS:000179472900038
PM 12444075
OA gold
DA 2018-01-05
ER

PT J
AU Nam, YS
   Park, JY
   Han, SH
   Chang, IS
AF Nam, YS
   Park, JY
   Han, SH
   Chang, IS
TI Intracellular drug delivery using poly(D,L-lactide-co-glycolide)
   nanoparticles derivatized with a peptide from a transcriptional
   activator protein of HIV-1
SO BIOTECHNOLOGY LETTERS
LA English
DT Article
DE biodegradable polymer; conjugates; nanoparticles; protein transduction
   domain (PTD); Tat peptide
ID TOXICITY; THERAPY
AB Biodegradable poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles were derivatized with Tat(49-57) peptide, which is the protein transduction domain from the transcriptional activator Tat protein of human immunodeficiency virus type-1 (HIV-1). The Tat(49-57) peptide-modified PLGA nanoparticles, with a mean diameter of ca. 238 nm, was effectively adsorbed on to the membrane of HaCaT cells and delivered into the nuclei without cytotoxicity.
C1 Amore Pacific R&D Ctr, Yongin Si 449729, Gyounggi Do, South Korea.
RP Nam, YS (reprint author), Amore Pacific R&D Ctr, 314-1 Bora Ri, Yongin Si 449729, Gyounggi Do, South Korea.
RI Nam, Yoon Sung/G-2713-2011
OI Nam, Yoon Sung/0000-0002-7302-6928
CR Allen C, 1999, COLLOID SURFACE B, V16, P3, DOI 10.1016/S0927-7765(99)00058-2                                                   
   Bayley H, 1999, NAT BIOTECHNOL, V17, P1066, DOI 10.1038/15050
   BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7                                                    
   Cho CS, 1997, BIOMATERIALS, V18, P323, DOI 10.1016/S0142-9612(96)00138-X
   Dawson GF, 2000, PHARMACEUT RES, V17, P1420, DOI 10.1023/A:1007503123620
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Duzgunes N, 1999, ADV DRUG DELIVER REV, V40, P3, DOI 10.1016/S0169-409X(99)00037-X
   Lavasanifar A, 2002, J CONTROL RELEASE, V79, P165, DOI 10.1016/S0168-3659(01)00537-5                                                   
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Muller RH, 2001, ADV DRUG DELIVER REV, V47, P3, DOI 10.1016/S0169-409X(00)00118-6
   Nam YS, 1999, J MICROENCAPSUL, V16, P625
   Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   VIVES E, 1997, J BIOL CHEM, V272, P10699
   ZHANG LF, 1995, SCIENCE, V268, P1728, DOI 10.1126/science.268.5218.1728
NR 15
TC 26
Z9 26
U1 0
U2 3
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-5492
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD DEC
PY 2002
VL 24
IS 24
BP 2093
EP 2098
DI 10.1023/A:1021373731787
PG 6
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 622FR
UT WOS:000179636600013
DA 2018-01-05
ER

PT J
AU Bogoyevitch, MA
   Kendrick, TS
   Ng, DCH
   Barr, RK
AF Bogoyevitch, MA
   Kendrick, TS
   Ng, DCH
   Barr, RK
TI Taking the cell by stealth or storm? Protein Transduction Domains (PTDs)
   as versatile vectors for delivery
SO DNA AND CELL BIOLOGY
LA English
DT Review
ID EFFICIENT INTRACELLULAR DELIVERY; HUMAN IMMUNODEFICIENCY VIRUS; HIV-1
   TAT PROTEIN; NF-KAPPA-B; IN-VIVO; ANTENNAPEDIA HOMEODOMAIN; 3RD HELIX;
   PENETRATING PEPTIDES; CYCLE PROGRESSION; MAMMALIAN-CELLS
AB A cell delivery system is increasing in use in many areas of cell and molecular biology and bio-medicine. This system is based on a number of naturally occurring protein motifs and/or sequences which show the remarkable ability to rapidly cross the mammalian cell membrane without compromising its structure or function. These so-called Protein Transduction Domains (PTDs) offer unprecedented advantages for intracellular delivery. These advantages include, but are not limited to, their applicability to all cell types (no cell type has yet been described which is not transduced by these PTDs), and the range of cargoes that can be transduced (including peptides, small proteins, full-length enzymes, DNA oligomers, peptide-nucleic acid oligomers, liposomes, and magnetic nanoparticles). Furthermore, the PTDs have been demonstrated to be suitable for in vivo delivery including delivery across the blood brain barrier, and have been shown to cross the plasma membrane rapidly and enter the cytoplasm and nuclear regions of the cell. In this review, the general properties of the most commonly used PTDs are described. The strategies currently being undertaken also highlight that improvements in membrane transduction are possible despite our lack of understanding of the exact biochemical and/or physical mechanisms of transduction. Recent examples of the range of potential applications are also discussed.
C1 Univ Western Australia, Cell Signalling Lab, Sch Biomed & Chem Sci, Crawley, WA 6009, Australia.
   Western Australian Inst Med Res, Perth, WA 6000, Australia.
RP Bogoyevitch, MA (reprint author), Univ Western Australia, Cell Signalling Lab, Sch Biomed & Chem Sci, 35 Stirling Highway, Crawley, WA 6009, Australia.
EM marieb@cyllene.uwa.edu.au
RI Ng, Dominic/C-7291-2015
OI Ng, Dominic/0000-0003-4657-159X
CR Abu-Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200
   Adachi T, 1999, J IMMUNOL, V162, P1496
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   ARAP W, 1998, SCIENCE, V279, P323
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2                                                   
   Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x
   Bolton SJ, 2000, EUR J NEUROSCI, V12, P2847, DOI 10.1046/j.1460-9568.2000.00171.x                                                
   Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77                                                        
   Chatelin L, 1996, MECH DEVELOP, V55, P111, DOI 10.1016/0925-4773(95)00478-5                                                    
   Chen CM, 2001, NAT BIOTECHNOL, V19, P921, DOI 10.1038/nbt1001-921                                                             
   CHEN LL, 1995, ANAL BIOCHEM, V227, P168, DOI 10.1006/abio.1995.1267
   Craig R, 2001, J BIOL CHEM, V276, P37621, DOI 10.1074/jbc.M103276200
   Cussac D, 1999, FASEB J, V13, P31
   Derossi D, 1998, BIOCHEM BIOPH RES CO, V251, P148, DOI 10.1006/bbrc.1998.9444
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772
   Drin G, 2001, EUR J BIOCHEM, V268, P1304, DOI 10.1046/j.1432-1327.2001.01997.x
   Ellerby HM, 1999, NAT MED, V5, P1032
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316
   Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Fenton M, 1998, J IMMUNOL METHODS, V212, P41, DOI 10.1016/S0022-1759(97)00208-1
   Fischer PM, 2000, J PEPT RES, V55, P163, DOI 10.1034/j.1399-3011.2000.00163.x                                                
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fujimoto K, 2000, CANCER LETT, V159, P151, DOI 10.1016/S0304-3835(00)00536-X
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Gius DR, 1999, CANCER RES, V59, P2577
   GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0
   Hall H, 1996, CURR BIOL, V6, P580, DOI 10.1016/S0960-9822(02)00544-4                                                   
   Hallbrink M, 2001, BBA-BIOMEMBRANES, V1515, P101, DOI 10.1016/S0005-2736(01)00398-4
   Han K, 2000, MOL CELLS, V10, P728, DOI 10.1007/s100590000036
   Ho A, 2001, CANCER RES, V61, P474
   Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298
   Jo DW, 2001, NAT BIOTECHNOL, V19, P929, DOI 10.1038/nbt1001-929                                                             
   Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529
   Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8
   Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200
   Keller P, 2001, J EXP MED, V194, P581, DOI 10.1084/jem.194.5.581
   Leneuve P, 2001, BIOTECHNIQUES, V31, P1156
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255                                                        
   Lindberg M, 2001, BIOCHEMISTRY-US, V40, P3141, DOI 10.1021/bi0008985
   Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s
   Liu XY, 1996, P NATL ACAD SCI USA, V93, P11819, DOI 10.1073/pnas.93.21.11819
   Magzoub M, 2001, BBA-BIOMEMBRANES, V1512, P77, DOI 10.1016/S0005-2736(01)00304-2
   MANN DA, 1991, EMBO J, V10, P1733
   Mi ZB, 2000, MOL THER, V2, P339, DOI 10.1006/mthe.2000.0137
   Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173
   Morris MC, 1997, NUCLEIC ACIDS RES, V25, P2730, DOI 10.1093/nar/25.14.2730
   Muratovska A, 2001, ADV DRUG DELIVER REV, V49, P189, DOI 10.1016/S0169-409X(01)00134-X
   Nielsen PE, 1999, CURR OPIN STRUC BIOL, V9, P353, DOI 10.1016/S0959-440X(99)80047-5
   Oehlke J, 1998, BBA-BIOMEMBRANES, V1414, P127, DOI 10.1016/S0005-2736(98)00161-8
   Oehlke J, 1997, FEBS LETT, V415, P196, DOI 10.1016/S0014-5793(97)01123-X
   Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542
   Peck D, 1998, J CELL SCI, V111, P1595
   Persson D, 2001, FEBS LETT, V505, P307, DOI 10.1016/S0014-5793(01)02843-5                                                   
   Pescarolo MP, 2001, FASEB J, V15, P31
   Pooga M, 2001, BIOMOL ENG, V17, P183, DOI 10.1016/S1389-0344(01)00075-2                                                   
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje
   Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456                                                        
   Rousselle C, 2000, MOL PHARMACOL, V57, P679
   Saffell JL, 1997, NEURON, V18, P231, DOI 10.1016/S0896-6273(00)80264-0                                                   
   Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755
   Sauzeau V, 2001, CIRC RES, V88, P1102, DOI 10.1161/hh1101.092034                                                           
   Scheller A, 2000, EUR J BIOCHEM, V267, P6043, DOI 10.1046/j.1432-1327.2000.01681.x
   Scheller A, 1999, J PEPT SCI, V5, P185, DOI 10.1002/(SICI)1099-1387(199904)5:4<185::AID-PSC184>3.0.CO;2-9
   Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2                                                   
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SHELDON K, 1995, P NATL ACAD SCI USA, V92, P2056, DOI 10.1073/pnas.92.6.2056
   Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100                                                          
   Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295
   Sohal DS, 2001, CIRC RES, V89, P20, DOI 10.1161/hh1301.092687
   Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9                                                   
   THEODORE L, 1995, J NEUROSCI, V15, P7158
   Thoren PEG, 2000, FEBS LETT, V482, P265, DOI 10.1016/S0014-5793(00)02072-X
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635
   Troy CM, 1996, J NEUROSCI, V16, P253
   Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200                                                          
   Villa R, 2000, FEBS LETT, V473, P241, DOI 10.1016/S0014-5793(00)01540-4
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Wang J, 1999, MOL CELL BIOL, V19, P6217
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Williams JR, 1997, MECH COHES-FRICT MAT, V2, P223, DOI 10.1002/(SICI)1099-1484(199707)2:3<223::AID-CFM30>3.0.CO;2-F
   Zelphati O, 2001, J BIOL CHEM, V276, P35103, DOI 10.1074/jbc.M104920200
   ZHOU L, 2001, GENESIS, V31, P85
NR 91
TC 30
Z9 30
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD DEC
PY 2002
VL 21
IS 12
BP 879
EP 894
DI 10.1089/104454902762053846                                              
          
PG 16
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 632NR
UT WOS:000180229900004
PM 12573048
DA 2018-01-05
ER

PT J
AU de Soultrait, VR
   Lozach, PY
   Altmeyer, R
   Tarrago-Litvak, L
   Litvak, S
   Andreola, ML
AF de Soultrait, VR
   Lozach, PY
   Altmeyer, R
   Tarrago-Litvak, L
   Litvak, S
   Andreola, ML
TI DNA aptamers derived from HIV-1 RNase H inhibitors are strong
   anti-integrase agents
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE HIV-1; integrase; RNase H; aptamers; inhibitors
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TETRAD-FORMING OLIGONUCLEOTIDES; IN-VITRO;
   REVERSE-TRANSCRIPTASE; TYPE-1 INTEGRASE; STRAND TRANSFER;
   PHOSPHOROTHIOATE OLIGONUCLEOTIDES; BIOCHEMICAL-CHARACTERIZATION;
   RETROVIRAL INTEGRASE; CRYSTAL-STRUCTURE
AB HIV-1 integrase, the retroviral-encoded enzyme involved in the integration of the retrotranscribed viral genome into the host nuclear DNA is an attractive and still unexploited target. To date, very few inhibitors of this enzyme with a potential therapeutic value have been described. During the search for new HIV-1 targets, we recently described DNA oligodeoxynucleotide aptamers (ODN 93 and ODN 112) that are strong inhibitors of the RNase H activity associated with HIV-1 reverse transcriptase. The striking structural homology between RNase H and integrase led us to study the effect of the RNase H inhibitors on the integrase. Shorter DNA aptamers derived from ODNs 93 and 112 (ODNs 93del and 112del) were able to inhibit HIV-1 integrase in the nanomolar range. They had G-rich sequences able to form G-quartets stabilized by the presence of K+. The presence of these ions increased the inhibitory efficiency of these agents dramatically. Inhibition of enzymatic activities by ODN 93del and ODN 112del was observed in a cell-free assay system using a recombinant integrase and HIV-1 replication was abolished in infected human cells. Moreover, cell fusion assays showed that these agents do not block viral cell entry at concentrations where viral replication is stopped. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Victor Segalen Bordeaux 2, CNRS, UMR 5097, F-33076 Bordeaux, France.
   Virale Inst Pasteur, Immunol Unit, F-75724 Paris, France.
   Inst Fed Rech Pathol Infect, IFR 66, F-33076 Bordeaux, France.
RP Andreola, ML (reprint author), Univ Victor Segalen Bordeaux 2, CNRS, UMR 5097, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
RI Lozach, Pierre-Yves/H-7072-2015
OI Lozach, Pierre-Yves/0000-0002-9966-1452
CR Altmeyer R, 1999, VIROLOGY, V259, P314, DOI 10.1006/viro.1999.9780
   Andreola ML, 2001, BIOCHEMISTRY-US, V40, P10087, DOI 10.1021/bi0108599
   ANDREOLA ML, 1992, BIOCHIMIE, V75, P127
   Asante-Appiah E, 1997, ANTIVIR RES, V36, P139, DOI 10.1016/S0166-3542(97)00046-6
   Caumont A, 1999, FEBS LETT, V455, P154, DOI 10.1016/S0014-5793(99)00859-5
   CHANEL C, 2002, AIDS, V16, P3
   CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542
   Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297                                                          
   Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484
   CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845                                                         
   Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193
   DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186                                                         
   Dougan H, 2000, NUCL MED BIOL, V27, P289, DOI 10.1016/S0969-8051(99)00103-1
   Dufour E, 1999, J MOL BIOL, V285, P1339, DOI 10.1006/jmbi.1998.2430
   ELDIRANIDIAB R, 1992, FEBS LETT, V301, P23
   ENGELMAN A, 1995, J VIROL, V69, P2729
   ENGELMAN A, 1994, J VIROL, V68, P5911
   ENGLUND G, 1995, J VIROL, V69, P3216
   Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397                                                          
   Este JA, 1998, MOL PHARMACOL, V53, P340
   FESEN MR, 1994, BIOCHEM PHARMACOL, V48, P595, DOI 10.1016/0006-2952(94)90291-7
   Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040                                                        
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Jing NJ, 1998, J BIOL CHEM, V273, P34992, DOI 10.1074/jbc.273.52.34992                                                        
   Jing NJ, 2000, J BIOL CHEM, V275, P21460, DOI 10.1074/jbc.M001436200
   Leavitt AD, 1996, J VIROL, V70, P721
   Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b
   MACAYA RF, 1993, P NATL ACAD SCI USA, V90, P3745, DOI 10.1073/pnas.90.8.3745
   Marchand C, 2002, J BIOL CHEM, V277, P12596, DOI 10.1074/jbc.M110758200
   MAURY G, 1993, BIOCHIM BIOPHYS ACTA, V1216, P1, DOI 10.1016/0167-4781(93)90030-H
   Mazumder A, 1996, BIOCHEMISTRY-US, V35, P13762, DOI 10.1021/bi960541u
   MAZUMDER A, 1994, NUCLEIC ACIDS RES, V22, P1037, DOI 10.1093/nar/22.6.1037
   MORVAN F, 1993, J MED CHEM, V36, P280, DOI 10.1021/jm00054a013                                                             
   MOUSCADET JF, 1994, J BIOL CHEM, V269, P21635
   Ni HH, 2001, J MED CHEM, V44, P3043, DOI 10.1021/jm010205y
   OJWANG J, 1994, J ACQ IMMUN DEF SYND, V7, P560
   Parissi V, 2000, J MOL BIOL, V295, P755, DOI 10.1006/jmbi.1999.3416                                                          
   Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1
   Puras Lutzke Ramon A., 1995, Proceedings of the National Academy of Sciences of the United States of America, V92, P11456
   Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4                                                   
   ROCANCOURT D, 1990, J VIROL, V64, P2660
   SCHULTZE P, 1994, J MOL BIOL, V235, P1532, DOI 10.1006/jmbi.1994.1105
   Snasel J, 2001, EUR J BIOCHEM, V268, P980, DOI 10.1046/j.1432-1327.2001.01956.x
   Staropoli I, 2000, J BIOL CHEM, V275, P35137, DOI 10.1074/jbc.M003868200
   Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o                                                               
   Ventura M, 1999, ARCH VIROL, V144, P513, DOI 10.1007/s007050050522
   VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419
   YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3
   Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659                                                        
NR 49
TC 109
Z9 110
U1 0
U2 4
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD NOV 22
PY 2002
VL 324
IS 2
BP 195
EP 203
DI 10.1016/S0022-2836(02)01064-1
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 621JU
UT WOS:000179585900001
PM 12441099
DA 2018-01-05
ER

PT J
AU Barreca, ML
   Balzarini, J
   Chimirri, A
   De Clercq, E
   De Luca, L
   Holtje, HD
   Holtje, M
   Monforte, AM
   Monforte, P
   Pannecouque, C
   Rao, A
   Zappala, M
AF Barreca, ML
   Balzarini, J
   Chimirri, A
   De Clercq, E
   De Luca, L
   Holtje, HD
   Holtje, M
   Monforte, AM
   Monforte, P
   Pannecouque, C
   Rao, A
   Zappala, M
TI Design, synthesis, structure-activity relationships, and molecular
   modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV
   agents
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE; RT INHIBITORS; NONNUCLEOSIDE; DOCKING
AB Starting from 1H,3H-thiazolo[3,4-albenzimidazoles (TBZs), we performed the design, synthesis, and the structure-activity relationship studies of a series of 2,3-diaryl-1,3-thiazolidin-4-ones. Some derivatives proved to be highly effective in inhibiting HIV-1 replication at nanomolar concentrations with minimal cytotoxicity, thereby acting as nonnucleoside HIV-1 RT inhibitors (NNRTIs). Computational studies were used to delineate the ligand-RT interactions and to probe the binding of the ligands to HIV-1 RT.
C1 Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy.
   Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
   Univ Dusseldorf, Inst Pharmaceut Chem, D-4000 Dusseldorf, Germany.
RP Monforte, P (reprint author), Univ Messina, Dipartimento Farmacochim, Viale Annunziata, I-98168 Messina, Italy.
EM monforte@pharma.unime.it
RI De Luca, Laura/D-8532-2011
OI ZAPPALA', Maria/0000-0002-8942-797X; De Luca, Laura/0000-0003-0614-5713;
   Barreca, Maria Letizia/0000-0003-3530-5042
CR Barreca ML, 1999, BIOORGAN MED CHEM, V7, P2283, DOI 10.1016/S0968-0896(99)00181-9
   Barreca ML, 2001, BIOORG MED CHEM LETT, V11, P1793, DOI 10.1016/S0960-894X(01)00304-3
   Chimirri A, 1999, ANTIVIR CHEM CHEMOTH, V10, P211, DOI 10.1177/095632029901000405                                                      
   Chimirri A, 1998, ANTIVIR CHEM CHEMOTH, V9, P431, DOI 10.1177/095632029800900507                                                      
   Chimirri A, 1997, ANTIVIR CHEM CHEMOTH, V8, P363, DOI 10.1177/095632029700800409                                                      
   De Clercq E, 2000, REV MED VIROL, V10, P255, DOI 10.1002/1099-1654(200007/08)10:4<255::AID-RMV282>3.0.CO;2-6
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   Hajos Gyorgy, 2000, Drugs of the Future, V25, P47, DOI 10.1358/dof.2000.025.01.858638
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   SCHAFER W, 1993, J MED CHEM, V36, P726, DOI 10.1021/jm00058a009
NR 11
TC 153
Z9 160
U1 1
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 21
PY 2002
VL 45
IS 24
BP 5410
EP 5413
DI 10.1021/jm020977+
PG 4
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 617DC
UT WOS:000179344400024
PM 12431069
DA 2018-01-05
ER

PT J
AU Uckun, FM
   Pendergrass, S
   Venkatachalam, TK
   Qazi, S
   Richman, D
AF Uckun, FM
   Pendergrass, S
   Venkatachalam, TK
   Qazi, S
   Richman, D
TI Stampidine is a potent inhibitor of zidovudine- and nucleoside analog
   reverse transcriptase inhibitor-resistant primary clinical human
   immunodeficiency virus type 1 isolates with thymidine analog mutations
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID D4T-5'-<P-BROMOPHENYL METHOXYALANINYL PHOSPHATE>; ANTI-HIV EFFICACY;
   PHOSPHORAMIDATE DERIVATIVES; INTRACELLULAR METABOLISM; ANTIVIRAL
   PROTEIN; D4T; 2',3'-DIDEHYDRO-2',3'-DIDEOXYTHYMIDINE; AGENT
AB We report the antiretroviral activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine [STAMP]), a novel aryl phosphate derivative of stavudine, against primary clinical human immunodeficiency virus type 1 (HIV-1) isolates. STAMP inhibited each one of nine clinical HIV-1 isolates of non-B envelope subtype and 20 genotypically and phenotypically nucleoside analog reverse transcriptase inhibitor-resistant HIV-1 isolates at subnanomolar to low-nanomolar concentrations.
C1 Parker Hughes Inst, Drug Discovery Program, Dept Virol, St Paul, MN 55113 USA.
   Parker Hughes Inst, Drug Discovery Program, Dept Bioinformat, St Paul, MN 55113 USA.
   Parker Hughes Inst, Drug Discovery Program, Dept Immunol, St Paul, MN 55113 USA.
   Parker Hughes Inst, Drug Discovery Program, Dept Chem, St Paul, MN 55113 USA.
   Parker Hughes Ctr Clin Immunol, Roseville, MN USA.
   Univ Calif San Diego, Virol Sect, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   VA San Diego Healthcare Syst, La Jolla, CA USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Drug Discovery Program, Dept Virol, 2657 Patton Rd, St Paul, MN 55113 USA.
CR Balzarini J, 1996, MOL PHARMACOL, V50, P1207
   Balzarini J, 1996, P NATL ACAD SCI USA, V93, P7295, DOI 10.1073/pnas.93.14.7295                                                         
   BALZARINI J, 1989, J BIOL CHEM, V264, P6127
   Chen CL, 2001, DRUG METAB DISPOS, V29, P1035
   Duwe S, 2001, J ACQ IMMUN DEF SYND, V26, P266, DOI 10.1097/00126334-200103010-00010                                                
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   Hu DJ, 1996, JAMA-J AM MED ASSOC, V275, P210, DOI 10.1001/jama.275.3.210                                                          
   McGuigan C, 1997, ANTIVIR RES, V35, P195, DOI 10.1016/S0166-3542(97)00029-6
   McGuigan C, 1996, BIOORG MED CHEM LETT, V6, P1183, DOI 10.1016/0960-894X(96)00195-3                                                    
   McGuigan C, 1996, J MED CHEM, V39, P1748, DOI 10.1021/jm950605j
   Rey D, 2001, J ACQ IMMUN DEF SYND, V27, P459
   RICHMAN DD, 1993, CURRENT PROTOCOLS IM, P1
   UCKU FM, IN PRESS ANTIVIR CHE
   Uckun FM, 2002, ANTIMICROB AGENTS CH, V46, P3428, DOI 10.1128/AAC.46.11.3428-3436.2002
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   UCKUN FM, IN PRESS ARZEIMITTEL
   Venkatachalam TK, 1998, BIOORG MED CHEM LETT, V8, P3121, DOI 10.1016/S0960-894X(98)00547-2
   Vig R, 1998, ANTIVIR CHEM CHEMOTH, V9, P445
   Uckun F.M., 2000, US Patent, Patent No. [6030957, 6,030,957]
NR 19
TC 46
Z9 46
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD NOV
PY 2002
VL 46
IS 11
BP 3613
EP 3616
DI 10.1128/AAC.46.11.3613-3616.2002
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 606BK
UT WOS:000178712800041
PM 12384373
OA gold
DA 2018-01-05
ER

PT J
AU Sharma, V
   Piwnica-Worms, D
AF Sharma, V
   Piwnica-Worms, D
TI Molecular imaging of gene expression and protein function in vivo with
   PET and SPECT
SO JOURNAL OF MAGNETIC RESONANCE IMAGING
LA English
DT Review
DE positron emission tomography; single-photon emission computed
   tomography; reporter gene; thymidine kinase; P-glycoprotein;
   fluorodeoxyglucose; protein-protein interactions
ID POSITRON-EMISSION-TOMOGRAPHY; MEDIATED MULTIDRUG-RESISTANCE;
   RECEPTOR-POSITIVE TUMORS; P-GLYCOPROTEIN TRANSPORT; SODIUM-IODIDE
   SYMPORTER; VIRUS THYMIDINE KINASE; BLOOD-BRAIN-BARRIER; RADIOLABELED
   ANTIVIRAL DRUG; BREAST-CANCER PATIENTS; IN-VIVO
AB Molecular imaging is broadly defined as the characterization and measurement of biological processes in living animals, model systems, and humans at the cellular and molecular level using remote imaging detectors. One underlying premise of molecular imaging is that this emerging field is not defined by the imaging technologies that underpin acquisition of the final image per se, but rather is driven by the underlying biological questions. In practice, the choice of imaging modality and probe is usually reduced to choosing between high spatial resolution and high sensitivity to address a given biological system. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) inherently use image-enhancing agents (radiopharmaceuticals) that are synthesized at sufficiently high specific activity to enable use of tracer concentrations of the compound (picomolar to nanomolar) for detecting molecular signals while providing the desired levels of image contrast. The tracer technologies strategically provide high sensitivity for imaging small-capacity molecular systems in vivo (receptors, enzymes, transporters) at a cost of lower spatial resolution than other technologies. We review several significant PET and SPECT advances in imaging receptors (somatostatin receptor subtypes, neurotensin receptor subtypes, alpha(v)beta(3) integrin), enzymes (hexokinase, thymidine kinase), transporters (MDRI P-glycoprotein, sodium-iodide symporter), and permeation peptides (human immunodeficiency virus type 1 (HIV-1) Tat conjugates), as well as innovative reporter gene constructs (herpes simplex virus 1 thymidine kinase, somatostatin receptor subtype 2, cytosine deaminase) for imaging gene promoter activation and repression, signal transduction pathways, and protein-protein interactions in vivo.
C1 Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, St Louis, MO 63110 USA.
RP Piwnica-Worms, D (reprint author), Washington Univ, Sch Med, Mallinckrodt Inst Radiol, Mol Imaging Ctr, 510 S Kingshighway Blvd,Box 8225, St Louis, MO 63110 USA.
FU NCI NIH HHS [P50 CA94056]
CR Alauddin MM, 1998, NUCL MED BIOL, V25, P175, DOI 10.1016/S0969-8051(97)00160-1
   Allikmets R, 1998, CANCER RES, V58, P5337
   Aloj L, 1999, CANCER RES, V59, P4709
   Anderson CJ, 1999, CHEM REV, V99, P2219, DOI 10.1021/cr980451q                                                               
   Anderson CJ, 2001, J NUCL MED, V42, P213
   ANDERSON CJ, 1995, J NUCL MED, V36, P2315
   BAKKER WH, 1991, LIFE SCI, V49, P1583, DOI 10.1016/0024-3205(91)90052-D
   Ballinger J R, 1995, Q J Nucl Med, V39, P122
   Ballinger JR, 1997, J NUCL MED, V38, P1915
   Ballinger JR, 1996, J NUCL MED, V37, P1578
   BALLINGER JR, 1995, NUCL MED COMMUN, V16, P253, DOI 10.1097/00006231-199504000-00156
   Bangard M, 2000, EUR J NUCL MED, V27, P628, DOI 10.1007/s002590050556                                                           
   Barbarics E, 1998, CANCER RES, V58, P276
   BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V
   Bergmann R, 2002, NUCL MED BIOL, V29, P61, DOI 10.1016/S0969-8051(01)00284-0                                                   
   Bigott H. M., 2001, Journal of Labelled Compounds and Radiopharmaceuticals, V44, pS119
   Blankenberg FG, 1998, P NATL ACAD SCI USA, V95, P6349, DOI 10.1073/pnas.95.11.6349
   Blasberg RG, 1999, Q J NUCL MED, V43, P163
   Blauenstein P, 1999, EUR J NUCL MED, V26, P1197
   Blower PJ, 1998, TRANSIT METAL CHEM, V23, P109
   Boland A, 2000, CANCER RES, V60, P3484
   Bom H. S., 1997, Journal of Nuclear Medicine, V38, p240P
   BOSCH I, 1996, BIOCHIM BIOPHYS ACTA, V1288, P37
   Braun KM, 2000, NAT MED, V6, P320
   Breeman WAP, 1999, INT J CANCER, V81, P658, DOI 10.1002/(SICI)1097-0215(19990517)81:4<658::AID-IJC24>3.0.CO;2-P
   BROCKMANN J, 1995, J LABEL COMPDS RADIO, V37, P519
   BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X            
   Brown RS, 1996, J NUCL MED, V37, P1042
   BRUNS C, 1994, MOL CELL BIOL ASPECT, P138
   Buck AK, 2002, CANCER RES, V62, P3331
   CARRASCO N, 1993, BIOCHIM BIOPHYS ACTA, V1154, P65, DOI 10.1016/0304-4157(93)90017-I
   CARRAWAY R, 1973, J BIOL CHEM, V248, P6854
   Chalon P, 1996, FEBS LETT, V386, P91, DOI 10.1016/0014-5793(96)00397-3                                                    
   CHARZLIOANNOU A, 1999, J NUCL MED, V40, P1164
   Chaudhuri TR, 2001, GYNECOL ONCOL, V83, P432, DOI 10.1006/gyno.2001.6333
   Chavatte K, 1999, J LABELLED COMPD RAD, V42, P415
   Chavatte K, 2000, J LABELLED COMPD RAD, V43, P1227, DOI 10.1002/1099-1344(20001030)43:12<1227::AID-JLCR410>3.0.CO;2-D                   
   Chen CC, 1997, CLIN CANCER RES, V3, P545
   Chen WS, 2000, BIOCHEM PHARMACOL, V60, P413, DOI 10.1016/S0006-2952(00)00341-5
   CHRISTMA.D, 1972, P NATL ACAD SCI USA, V69, P988, DOI 10.1073/pnas.69.4.988                                                           
   Ciarmiello A, 1998, J CLIN ONCOL, V16, P1677, DOI 10.1200/JCO.1998.16.5.1677                                                      
   CLAVO AC, 1995, J NUCL MED, V36, P1625
   COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704                                                         
   Conti PS, 1999, J NUCL MED, V40, p83P
   CONTI PS, 1995, NUCL MED BIOL, V22, P783, DOI 10.1016/0969-8051(95)00017-R
   Cordobes MD, 1996, J NUCL MED, V37, P286
   Crankshaw CL, 1998, J NUCL MED, V39, P77
   Dantzig AH, 1996, CANCER RES, V56, P4171
   de Herder WW, 2002, CURR OPIN ONCOL, V14, P53, DOI 10.1097/00001622-200201000-00010
   DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602
   Decristoforo C, 2000, J NUCL MED, V41, P1114
   DeGrado TR, 2001, CANCER RES, V61, P110
   DelVecchio S, 1997, J NUCL MED, V38, P1348
   DelVecchio S, 1997, EUR J NUCL MED, V24, P150, DOI 10.1007/BF02439547                                                              
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Doubrovin M, 2001, P NATL ACAD SCI USA, V98, P9300, DOI 10.1073/pnas.161091198
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   DYSZLEWSKI M, 2001, MOL IMAGING, V1, P24
   Eckelman WC, 2002, INVEST RADIOL, V37, P101, DOI 10.1097/00004424-200203000-00001
   Ehlers RA, 2000, ANN SURG, V231, P838, DOI 10.1097/00000658-200006000-00008
   Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0                                                   
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213                                                                
   Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Flens MJ, 1996, AM J PATHOL, V148, P1237
   FORD JM, 1990, PHARMACOL REV, V42, P155
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   Fukumoto M, 1999, CANCER, V86, P1470, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1470::AID-CNCR13>3.0.CO;2-S
   Gambhir SS, 2000, P NATL ACAD SCI USA, V97, P2785, DOI 10.1073/pnas.97.6.2785
   Gambhir SS, 1999, P NATL ACAD SCI USA, V96, P2333, DOI 10.1073/pnas.96.5.2333
   Gambhir SS, 1999, NUCL MED BIOL, V26, P481, DOI 10.1016/S0969-8051(99)00021-9                                                   
   Garcia-Garayoa E, 2001, NUCL MED BIOL, V28, P75
   GAVERIAUX C, 1991, J CELL PHARM, V2, P225
   Germann UA, 1997, ANTI-CANCER DRUG, V8, P141, DOI 10.1097/00001813-199702000-00005
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125                                             
   Grasby PM, 2002, CLIN MED, V2, P67, DOI 10.7861/clinmedicine.2-1-67                                                     
   Green Leeta A, 2002, Mol Imaging Biol, V4, P71, DOI 10.1016/S1095-0397(01)00071-1
   GROS P, 1986, NATURE, V323, P728, DOI 10.1038/323728a0
   GUHLKE S, 1994, NUCL MED BIOL, V21, P819, DOI 10.1016/0969-8051(94)90161-9
   Haberkorn U, 1996, J NUCL MED, V37, P87
   Haberkorn U, 2001, EXP CLIN ENDOCR DIAB, V109, P60, DOI 10.1055/s-2001-11010                                                            
   HANANIA EG, 1995, GENE THER, V2, P279
   Hara T, 1997, J NUCL MED, V38, P842
   Hara T, 2002, J NUCL MED, V43, P187
   Haubner R, 2000, EUR J NUCL MED, V27, P283, DOI 10.1007/s002590050035                                                           
   Haubner R, 2001, J NUCL MED, V42, P326
   Hemminki A, 2002, J NATL CANCER I, V94, P741
   Hendrikse NH, 1998, BRIT J CANCER, V77, P353, DOI 10.1038/bjc.1998.57
   Hendrikse NH, 1999, CANCER RES, V59, P2411
   Hendrikse NH, 1999, EUR J NUCL MED, V26, P283, DOI 10.1007/s002590050390                                                           
   Henze M, 2001, J NUCL MED, V42, P1053
   HERMAN LW, 1995, J MED CHEM, V38, P2955, DOI 10.1021/jm00015a018
   HERSCHMAN H, 2000, ED BOOK SPRING 2000, P169
   Hoekstra CJ, 2000, EUR J NUCL MED, V27, P731, DOI 10.1007/s002590050570                                                           
   Hom RK, 1997, NUCL MED BIOL, V24, P485, DOI 10.1016/S0969-8051(97)00066-8                                                   
   Hospers GAP, 2000, CANCER RES, V60, P1488
   Huang M, 2001, CANCER GENE THER, V8, P612, DOI 10.1038/sj.cgt.7700354
   HYAFIL F, 1993, CANCER RES, V53, P4595
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Katz-Brull R, 2002, CANCER RES, V62, P1966
   Keppler D, 1997, BIOL CHEM, V378, P787
   Kiesewetter Dale O., 2001, Journal of Labelled Compounds and Radiopharmaceuticals, V44, pS903
   KITABGI P, 1985, Reviews in Clinical and Basic Pharmacology, V5, P397
   KITABGI P, 1976, J BIOL CHEM, V251, P7053
   Kostakoglu L, 1998, J NUCL MED, V39, P228
   Kostakoglu L, 1997, J NUCL MED, V38, P1003
   KRENNING EP, 1993, EUR J NUCL MED, V20, P716, DOI 10.1007/BF00181765                                                              
   KRENNING EP, 1992, J NUCL MED, V33, P652
   Krohn Kenneth A., 2001, Journal of Clinical Pharmacology, V41, p96S
   KUBOTA K, 1993, J NUCL MED, V34, P419
   KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5
   Kurihara A, 1999, BIOCONJUGATE CHEM, V10, P502, DOI 10.1021/bc980123x                                                               
   LARSON SM, 1980, RADIOLOGY, V134, P771, DOI 10.1148/radiology.134.3.6965545                                                 
   Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9                                                    
   Levchenko A, 2000, J NUCL MED, V41, P493
   Lewis JS, 2000, EUR J NUCL MED, V27, P638, DOI 10.1007/s002590050557                                                           
   LIANG Q, 2001, GENE THER, V19, P1490
   ListerJames J, 1997, J NUCL MED, V38, P105
   Liu S, 1999, CHEM REV, V99, P2235, DOI 10.1021/cr980436l                                                               
   LUKER G, 2001, MOL IMAGING, V1, P65
   Luker GD, 2001, ACAD RADIOL, V8, P4, DOI 10.1016/S1076-6332(03)80738-9                                                   
   Luker GD, 2002, P NATL ACAD SCI USA, V99, P6961, DOI 10.1073/pnas.092022399
   Luker GD, 1997, BIOCHEMISTRY-US, V36, P14218, DOI 10.1021/bi971931z
   Luker GD, 1997, J NUCL MED, V38, P369
   MacLaren DC, 1999, GENE THER, V6, P785, DOI 10.1038/sj.gt.3300877
   Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273                                                        
   Mazella J, 1996, J NEUROSCI, V16, P5613
   Miyake K, 1999, CANCER RES, V59, P8
   Mochizuki TA, 2001, J NUCL MED, V42, P1551
   Moon DH, 2001, NUCL MED BIOL, V28, P829
   Moscow JA, 1999, BLOOD, V94, P52
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Nagamachi S, 1999, CLIN NUCL MED, V24, P765, DOI 10.1097/00003072-199910000-00007                                                
   Narula J, 2001, NAT MED, V7, P1347, DOI 10.1038/nm1201-1347
   Newman MJ, 2000, CANCER RES, V60, P2964
   Ogura Y, 2000, RADIOLOGY, V214, P795, DOI 10.1148/radiology.214.3.r00mr34795                                              
   PACKARD A, 1998, P 215 AM CHEM SOC M
   Pardridge WM, 2002, NAT REV DRUG DISCOV, V1, P131, DOI 10.1038/nrd725
   Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183                                                          
   PATEL YC, 1982, SCIENCE, V217, P1155, DOI 10.1126/science.6126003                                                         
   Pearson DA, 1996, J MED CHEM, V39, P1361, DOI 10.1021/jm950111m
   Peck RA, 2001, J CLIN ONCOL, V19, P3130, DOI 10.1200/JCO.2001.19.12.3130                                                     
   Pennisi E, 2000, SCIENCE, V288, P2304, DOI 10.1126/science.288.5475.2304                                                   
   PERLMUTTER M, 1956, NEW ENGL J MED, V255, P61
   PIWNICAWORMS D, 1993, CANCER RES, V53, P977
   PIWNICAWORMS D, 1995, BIOCHEMISTRY-US, V34, P12210, DOI 10.1021/bi00038a015
   PIWNICAWORMS D, 1990, CIRCULATION, V82, P1826, DOI 10.1161/01.CIR.82.5.1826                                                        
   PIWNICAWORMS D, 2000, ED BOOK, P178
   PIWNICAWORMS D, IN PRESS MOL NUCL ME
   PODDA S, 1992, P NATL ACAD SCI USA, V89, P9676, DOI 10.1073/pnas.89.20.9676
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Polyakov V. R., 1999, Journal of Labelled Compounds and Radiopharmaceuticals, V42, pS4
   Ponomarev V, 2001, NEOPLASIA, V3, P480, DOI 10.1038/sj.neo.7900204
   Price DT, 2002, J UROLOGY, V168, P273, DOI 10.1016/S0022-5347(05)64906-3                                                   
   Rabindran SK, 1998, CANCER RES, V58, P5850
   Rao PS, 2001, NUCL MED BIOL, V28, P445, DOI 10.1016/S0969-8051(01)00205-0
   REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406
   REICHLIN S, 1983, NEW ENGL J MED, V309, P1556, DOI 10.1056/NEJM198312223092506
   REUBI JC, 1990, CANCER RES, V50, P5969
   REUBI JC, 1990, INT J CANCER, V46, P416, DOI 10.1002/ijc.2910460315
   REUBI JC, 1992, INT J CANCER, V50, P895, DOI 10.1002/ijc.2910500613
   Reubi JC, 1998, GUT, V42, P546, DOI 10.1136/gut.42.4.546                                                            
   REUBI JC, 1985, NEUROSCIENCE, V15, P1183, DOI 10.1016/0306-4522(85)90261-1                                                    
   SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217
   SAITO Y, 1982, SCIENCE, V217, P1151, DOI 10.1126/science.7112121
   SAITO Y, 1984, ANN NEUROL, V15, P548, DOI 10.1002/ana.410150607
   SCHEPER RJ, 1993, CANCER RES, V53, P1475
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Shao YP, 1997, PHYS MED BIOL, V42, P1965, DOI 10.1088/0031-9155/42/10/010
   Sharma V, 2000, CHEM BIOL, V7, P335, DOI 10.1016/S1074-5521(00)00111-3
   Sharma V, 1999, CHEM REV, V99, P2545, DOI 10.1021/cr980429x                                                               
   SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471
   Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337
   SMITHJONES PM, 1994, J NUCL MED, V35, P317
   SORRENTINO BP, 1992, SCIENCE, V257, P99, DOI 10.1126/science.1352414
   Spitzweg C, 2001, GENE THER, V8, P1524, DOI 10.1038/sj.gt.3301558
   SREEDHARAN SP, 1989, J BIOL CHEM, V264, P949
   STOLZ B, 1994, HORM METAB RES, V26, P452
   Tait JF, 2000, BIOCONJUGATE CHEM, V11, P918, DOI 10.1021/bc000059v
   Tavitian B, 1998, NAT MED, V4, P467, DOI 10.1038/nm0498-467
   Tazebay UH, 2000, NAT MED, V6, P871
   Tjuvajev JG, 1999, CANCER RES, V59, P5186
   Tomicic MT, 2001, CANCER RES, V61, P7399
   Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X                                                   
   Vallabhajosula S, 1996, J NUCL MED, V37, P1016
   VANDERBORGHT T, 1991, APPL RADIAT ISOTOPES, V42, P103
   VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3
   Virgolini I, 1996, NUCL MED BIOL, V23, P685, DOI 10.1016/0969-8051(96)00066-2                                                    
   Vita N, 1998, EUR J PHARMACOL, V360, P265, DOI 10.1016/S0014-2999(98)00678-5
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Vocero-Akbani AM, 1999, NAT MED, V5, P29
   Volkert WA, 1999, CHEM REV, V99, P2269, DOI 10.1021/cr9804386                                                               
   WAHL RL, 1991, CANCER, V67, P1544, DOI 10.1002/1097-0142(19910315)67:6<1544::AID-CNCR2820670614>3.0.CO;2-0
   WAHL RL, 1993, J CLIN ONCOL, V11, P2101, DOI 10.1200/JCO.1993.11.11.2101                                                     
   WARBURG O, 1931, METABOLISM TUMORS, P1
   Wester HJ, 1997, NUCL MED BIOL, V24, P275, DOI 10.1016/S0969-8051(97)00039-5                                                   
   Wu AM, 2000, P NATL ACAD SCI USA, V97, P8495, DOI 10.1073/pnas.150228297
   Younes M, 1996, CANCER RES, V56, P1164
   Yu YJ, 2000, NAT MED, V6, P933
   Zhang LQ, 2002, MOL THER, V5, P223, DOI 10.1006/mthe.2002.0551
   Zhou JS, 2001, J NUCL MED, V42, P1476
   Zinn KR, 2000, J NUCL MED, V41, P887
   Zweit J., 1997, Journal of Nuclear Medicine, V38, p133P
NR 206
TC 90
Z9 93
U1 1
U2 16
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1053-1807
J9 J MAGN RESON IMAGING
JI J. Magn. Reson. Imaging
PD OCT
PY 2002
VL 16
IS 4
BP 336
EP 351
DI 10.1002/jmri.10182
PG 16
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 601KV
UT WOS:000178445700003
PM 12353250
OA gold
DA 2018-01-05
ER

PT J
AU Van Holten, RW
   Ciavarella, D
   Oulundsen, G
   Harmon, F
   Riester, S
AF Van Holten, RW
   Ciavarella, D
   Oulundsen, G
   Harmon, F
   Riester, S
TI Incorporation of an additional viral-clearance step into a human
   immunoglobulin manufacturing process
SO VOX SANGUINIS
LA English
DT Article
DE immunoglobulin; nanofiltration; tangential flow; viral clearance
ID PROTEIN SOLUTIONS; VIRUS; REMOVAL; NANOFILTRATION; MEMBRANES
AB Background and Objectives Regulatory agencies have mandated that manufacturers of immunoglobulin products incorporate robust viral inactivation or removal steps into their purification processes. We evaluated the effectiveness of incorporating nanofiltration, a generic virus-clearance step, into an existing plasma-fractionation process for a human anti-D immunoglobulin product.
   Materials and Methods The nanofiltration process studied utilizes a 180 000-molecular weight composite membrane with well-defined pore distribution. To examine its viral-clearance capability, diluted anti-D immunoglobulin was spiked with high concentrations of human and animal model viruses and subjected to tangential-flow nanofiltration during scaled-down validation runs. Viral clearance by the membrane was determined by calculating log removal values in accordance with guidelines provided by US and European regulatory agencies.
   Results Nanofiltration removed viruses of varying sizes and physical characteristics. For the three non-enveloped viruses tested (porcine parvovirus, encephalomyocarditis virus and hepatitis A virus, sizes 18-30 nm), clearance was 3.3, 4.1 and > 5.1 log, respectively. For the three enveloped viruses (human immunodeficiency virus-1, bovine viral diarrhoea virus and pseudorabies virus, 50-200 nm), a substantial 5-log reduction was demonstrated. Product potency, purity and stability were unaffected.
   Conclusions Tangential-flow nanofiltration provides substantial virus-removal capabilities for immunoglobulin preparations.
C1 Orthoclin Diagnost Inc, Res & Dev, Raritan, NJ 08869 USA.
   Orthoclin Diagnost Inc, Med Affairs, Raritan, NJ USA.
   Millipore Corp, Bedford, MA 01730 USA.
RP Van Holten, RW (reprint author), Orthoclin Diagnost Inc, Res & Dev, 1001 US Highway 202, Raritan, NJ 08869 USA.
CR COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034
   Committee for Proprietary Medicinal Products The European Agency for the Evaluation of Medicinal Products, 1996, CPMPBWP26895 EUR AG
   Committee for Proprietary Medicinal Products The European Agency for the Evaluation of Medicinal Products, 2001, CPMPBWP26995 EUR AG
   DILEO AJ, 1991, NATURE, V351, P420, DOI 10.1038/351420a0                                                                
   DILEO AJ, 1993, BIOLOGICALS, V21, P275, DOI 10.1006/biol.1993.1085
   DILEO AJ, 1992, BIO-TECHNOL, V10, P182, DOI 10.1038/nbt0292-182                                                             
   Editorial, 1947, <IT>Lancet</IT>, Vii, P691, Patent No. 0798003
   FANE AG, 1985, DESALINATION, V53, P37, DOI 10.1016/0011-9164(85)85051-7                                                    
   HELENIUS A, 1975, BIOCHIM BIOPHYS ACTA, V415, P29, DOI 10.1016/0304-4157(75)90016-7
   HIRASAKI T, 1994, POLYM J, V26, P1244, DOI 10.1295/polymj.26.1244                                                          
   Losikoff A, 1999, GENET ENG NEWS, V19, P48
   ONCLEY JL, 1949, J AM CHEM SOC, V71, P541, DOI 10.1021/ja01170a048
   OSHHIMA KH, 1996, BIOLOGICALS, V24, P137
   Peterson J, 2000, VOX SANG, V78, P80, DOI 10.1159/000031155
   Phillips MW, 1996, BIOLOGICALS, V24, P243, DOI 10.1006/biol.1996.0033                                                          
   Scheiblauer H, 1996, CLIN THER, V18, P59, DOI 10.1016/S0149-2918(96)80196-2
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   1994, BUNDESANZEIGER, V84, P4742
   VANHOLTEN RW, 2000, Patent No. 6096872
NR 19
TC 11
Z9 13
U1 2
U2 5
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0042-9007
J9 VOX SANG
JI Vox Sang.
PD OCT
PY 2002
VL 83
IS 3
BP 227
EP 233
DI 10.1046/j.1423-0410.2002.00224.x
PG 7
WC Hematology
SC Hematology
GA 601YZ
UT WOS:000178478200006
PM 12366764
DA 2018-01-05
ER

PT J
AU Bewley, CA
   Kiyonaka, S
   Hamachi, I
AF Bewley, CA
   Kiyonaka, S
   Hamachi, I
TI Site-specific discrimination by cyanovirin-N for alpha-linked
   trisaccharides comprising the three arms of Man(8) and Man(9)
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE NMR; Man(8) D1D3 and Man(9); carbohydrate-binding proteins; HIV;
   isothermal titration calorimetry
ID VIRUS-INACTIVATING PROTEIN; GP120; BINDING; OLIGOSACCHARIDES; AFFINITY;
   CD4
AB Cyanovirin-N (CVN) is a novel cyanobacterial protein that selectively binds with nanomolar affinities the mammalian oligosaccharides Man(8) and Man(9). Consequently, CVN potently blocks HIV entry through highly avid carbohydrate-mediated interactions with the HIV-envelope glycoprotein gp120, and is under preclinical investigation as an anti-HIV microbicide. CVN contains two non-overlapping carbohydrate-binding sites that bind the disaccharide Manalpha(1-2)Manalpha (which represents the terminal disaccharide of all three arms of Man(9)) with low to sub-micromolar affinities. The solution structure of a 1:2 CVN:Manalpha(1-2)Manalpha complex revealed that CVN recognizes the stacked conformation of Manu(1-2)Manalpha through a deep hydrophilic-binding pocket on one side of the protein (site 2) and a semi-circular cleft on the other (site 1). With the prominent exception of the C1 hydroxyl group of the reducing mannopyranose ring, the bound disaccharide is positioned so that each hydroxyl group is involved in a direct or water-mediated hydrogen bond to the polar or charged side-chains comprising the binding pocket. Thus, to determine whether the next-most reducing mannopyranose ring will augment CVN affinity and selectivity, we have characterized by NMR and ITC the binding of CVN to three synthetic trisaccharides representing the full-length D1, D2 and D3 arms of mammalian oligomannosides. Our findings demonstrate that site 1 is able to discriminate between the three related trisaccharides methyl Manalpha(1-2)Manalpha(1-2)Man, m.ethyl Manalpha(1-2)Manalpha(1-3)Man and methyl Manalpha(1-2)Manalpha(1-6)Man with remarkable selectivity; and binds these trisaccharides with K-A values ranging from 8.1 x 10(3) M-1 to 6.6 x 10(6) M-1. Site 2 is less selective in that it binds all three trisaccharides with similar K-A values ranging from 1.7 to 3.7(+/-0.3) x 10(5) M-1, but overall binds these trimannosides with higher affinities than site 1. The diversity of pathogenic organisms that display alpha(1-2)-linked mannosides on their cell surfaces suggests a broad defensive role for CVN in its cyanobacterial source. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
   Kyushu Univ, Dept Chem & Biochem, Fukuoka 8128581, Japan.
RP Bewley, CA (reprint author), NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RI U-ID, Kyushu/C-5291-2016
CR Bertozzi CR, 2001, SCIENCE, V291, P2357, DOI 10.1126/science.1059820
   Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Chatterjee D, 2001, CELL MOL LIFE SCI, V58, P2018, DOI 10.1007/PL00000834
   Cutler JE, 2001, MED MYCOL, V39, P75, DOI 10.1080/744118877
   Dam TK, 2002, CHEM REV, V102, P387, DOI 10.1021/cr000401x
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   Esser MT, 1999, J VIROL, V73, P4360
   Garrido F, 1991, Semin Cancer Biol, V2, P3
   Hewitt MC, 2001, J ORG CHEM, V66, P4233, DOI 10.1021/jo015521z
   Kelley BS, 2002, J AM CHEM SOC, V124, P3210, DOI 10.1021/ja025537m
   SCHWARZ FP, 1993, J BIOL CHEM, V268, P7668
   Seeberger PH, 1997, J AM CHEM SOC, V119, P10064, DOI 10.1021/ja971640d                                                               
   Seeberger PH, 1998, ACCOUNTS CHEM RES, V31, P685, DOI 10.1021/ar9600648                                                               
   Shenoy SR, 2001, J PHARMACOL EXP THER, V297, P704
   Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x
   WOOTEN EW, 1990, EUR BIOPHYS J, V18, P139, DOI 10.1007/BF02427373
NR 21
TC 51
Z9 51
U1 0
U2 4
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD SEP 27
PY 2002
VL 322
IS 4
BP 881
EP 889
DI 10.1016/S0022-2836(02)00842-2
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 601YB
UT WOS:000178475900020
PM 12270721
DA 2018-01-05
ER

PT J
AU Reineke, U
   Ivascu, C
   Schlief, M
   Landgraf, C
   Gericke, S
   Zahn, G
   Herzel, H
   Volkmer-Engergt, R
   Schneider-Mergener, J
AF Reineke, U
   Ivascu, C
   Schlief, M
   Landgraf, C
   Gericke, S
   Zahn, G
   Herzel, H
   Volkmer-Engergt, R
   Schneider-Mergener, J
TI Identification of distinct antibody epitopes and mimotopes from a
   peptide array of 5520 randomly generated sequences
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE peptide library; peptide array; SPOT synthesis; epitope; mimotope;
   antibody; molecular recognition; molecular diversity
ID CELLULOSE MEMBRANE SUPPORTS; HIV-1 MONOCLONAL-ANTIBODY; COMBINATORIAL
   LIBRARIES; SPOT-SYNTHESIS; AMINO-ACID; BIOACTIVE PEPTIDES; PHAGE
   DISPLAY; FAB FRAGMENT; BINDING; PROTEIN
AB We used a relatively small library of 5520 randomly generated single 15-mer peptides prepared by SPOT synthesis as an array of 28.5 x 19.0 cm to identify epitopes for three distinct monoclonal antibodies, namely anti-p24 (human immunodeficiency virus (HIV)-1) monoclonal anibody (mab) CB4-1, anti-interleukin-10 (IL-10) mab CB/RS/13, and anti-transforming growth factor alpha (TGFalpha) mab Tab2. Initially identified peptide ligands mostly had very low affinities for the antibodies with dissociation constants around 10(-4) M. Subsequent identification of residues critical for the antibody interactions involved complete L-amino acid substitutional analyses. Several substitutions resulted in analogs with dissociation constants in the low micromolar and high nanomolar range. Specifically binding peptides with key residue patterns matching the wild-type epitopes were identified for all three antibodies. In addition, for antibody CB4-1 mimotopes that showed no homology to the known epitope were selected. Our results suggest that a very limited library diversity, although far from covering the entire sequence repertoire, can suffice to rapidly and economically select peptidic antibody epitopes and mimotopes. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Jerini AG, D-10115 Berlin, Germany.
   Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10117 Berlin, Germany.
   Humboldt Univ, Inst Biol, D-10115 Berlin, Germany.
RP Reineke, U (reprint author), Jerini AG, Invalidenstr 130, D-10115 Berlin, Germany.
CR Ast T, 1999, TETRAHEDRON LETT, V40, P4317, DOI 10.1016/S0040-4039(99)00775-3
   BARLOW DJ, 1986, NATURE, V322, P474
   BECKSICKINGER AG, 1996, COMBINATORIAL PEPTID, P79
   BOTTGER V, 2001, ANTIBODY ENG, P460
   DONG L, 1999, PEPTIDES 1998, P530
   Dottavio D, 1996, Methods Mol Biol, V66, P181
   Frank R, 1996, Methods Mol Biol, V66, P149
   FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X
   FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4                                                    
   FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x                                              
   FURKA A, 1996, COMBINATORIAL PEPTID, P111
   GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8                                                    
   GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7
   GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998
   GRUNOW R, 1990, Z KLIN MED, V45, P367
   Hahn M, 2001, J MOL BIOL, V314, P293, DOI 10.1006/jmbi.2001.5135
   HOEPRICH PD, 1989, J BIOL CHEM, V264, P19086
   Hoffmuller U, 2000, EMBO J, V19, P4866, DOI 10.1093/emboj/19.18.4866                                                        
   Hohne W E, 1993, Mol Immunol, V30, P1213, DOI 10.1016/0161-5890(93)90140-7
   HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0
   HOUGHTEN RA, 1992, BIOTECHNIQUES, V13, P412
   Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9
   Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7
   Kramer A, 1998, METH MOL B, V87, P25
   KRAMER A, 1993, PEPTIDE RES, V6, P314
   Kramer A, 1999, J PEPT RES, V54, P319, DOI 10.1034/j.1399-3011.1999.00108.x
   KRAMER A, 1995, MOL IMMUNOL, V32, P459, DOI 10.1016/0161-5890(95)00006-Z
   LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0
   LEBL M, 1995, BIOPOLYMERS, V37, P177, DOI 10.1002/bip.360370303
   MATTHEAKIS LC, 1994, P NATL ACAD SCI USA, V91, P9022, DOI 10.1073/pnas.91.19.9022                                                         
   PINILLA C, 1992, BIOTECHNIQUES, V13, P901
   PINILLA C, 1993, MOL IMMUNOL, V30, P577, DOI 10.1016/0161-5890(93)90032-7
   PINILLA C, 1996, COMBINATORIAL PEPTID, P139
   Prasad L, 1998, J MOL BIOL, V280, P829, DOI 10.1006/jmbi.1998.1888                                                          
   Reineke U, 1999, CURR TOP MICROBIOL, V243, P23
   Reineke U, 2001, CURR OPIN BIOTECH, V12, P59, DOI 10.1016/S0958-1669(00)00178-6                                                   
   REINEKE U, 2001, ANTIBODY ENG SPRINGE, P443
   Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297
   Sabat R, 1996, MOL IMMUNOL, V33, P1103, DOI 10.1016/S0161-5890(96)00072-7                                                   
   Scharn D, 2000, J COMB CHEM, V2, P361, DOI 10.1021/cc000012g
   Schneider-Mergener J., 1996, COMBINATORIAL LIB, P53
   SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028
   Scott JK, 2001, PHAGE DISPLAY LAB MA, P141
   Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d                                                               
   Valle M, 1999, PROTEIN SCI, V8, P883
   VANREGENMORTEL MHV, 1994, IMMUNOCHEMISTRY, P277
   Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T
NR 47
TC 65
Z9 68
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD SEP 1
PY 2002
VL 267
IS 1
BP 37
EP 51
AR PII S0022-1759(02)00139-4
DI 10.1016/S0022-1759(02)00139-4
PG 15
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 584EE
UT WOS:000177453600005
PM 12135799
DA 2018-01-05
ER

PT J
AU Rezacova, P
   Brynda, J
   Fabry, M
   Horejsi, M
   Stouracova, R
   Lescar, J
   Chitarra, V
   Riottot, MM
   Sedlacek, J
   Bentley, GA
AF Rezacova, P
   Brynda, J
   Fabry, M
   Horejsi, M
   Stouracova, R
   Lescar, J
   Chitarra, V
   Riottot, MM
   Sedlacek, J
   Bentley, GA
TI Inhibition of HIV protease by monoclonal antibodies
SO JOURNAL OF MOLECULAR RECOGNITION
LA English
DT Review
DE monoclonal antibodies; HIV protease; enzyme inhibition; crystal
   structure
ID CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; NEUTRALIZING ANTIBODY;
   INTERFACE PEPTIDES; COMPLEX; FAB; ENZYMES
AB The protease of HIV plays a critical role in the maturation of the infectious particles of the virus. The enzyme has therefore been extensively studied with the objective of developing therapeutics that inhibit viral proliferation. We have produced monoclonal antibodies specific for the HIV-1 protease, and selected those that, inhibit enzyme function for use as probes to study the enzyme's activity and as an eventual aid for the development of potential inhibitors targeted to regions other than the active site. We have characterized two such mAbs, F11.2.32 and 1696, which have inhibition constants in the low nanomolar range and which recognize epitopes from different regions of the protease. The crystal structures of the two antibodies, both in the free state as well as complexes with peptide fragments corresponding to their respective epitopes, have been solved. The structural analyses, taken together with other functional data on the antibodies, suggest mechanisms of protease inhibition by these antibodies. Copyright (C) 2002 John Wiley Sons, Ltd.
C1 Inst Pasteur, Unite Immunol Struct, CNRS URA 2185, F-75724 Paris 15, France.
   Acad Sci Czech Republ, Inst Mol Genet, Dept Gene Manipulat, Prague, Czech Republic.
   Sch Biol Sci, Singapore 637616, Singapore.
RP Bentley, GA (reprint author), Inst Pasteur, Unite Immunol Struct, CNRS URA 2185, 25 Rue Dr Roux, F-75724 Paris 15, France.
RI Bentley, Graham/B-3623-2011; Brynda, Jiri/G-2760-2014; Maloy Rezacova,
   Pavlina/G-3600-2014; Fabry, Milan/G-3602-2014; Sedlacek,
   Juraj/G-3606-2014
CR AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354
   BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003                                                          
   HOLZMAN TF, 1991, J BIOL CHEM, V266, P19217
   KABAT EA, 1991, SEQUENCES PROTEINS I
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Lescar J, 1997, J MOL BIOL, V267, P1207, DOI 10.1006/jmbi.1997.0950
   Lescar J, 1996, PROTEIN SCI, V5, P966
   Lescar J, 1999, PROTEIN SCI, V8, P2686
   Murali R, 1998, P NATL ACAD SCI USA, V95, P12562, DOI 10.1073/pnas.95.21.12562
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   RAO JKM, 1991, BIOCHEMISTRY-US, V30, P4667
   Rezacova P, 2001, STRUCTURE, V9, P887, DOI 10.1016/S0969-2126(01)00654-2                                                   
   Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0                                                    
   STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521
   STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S
   TORMO J, 1994, EMBO J, V13, P2247
   WIEN MW, 1995, NAT STRUCT BIOL, V2, P232, DOI 10.1038/nsb0395-232
   Williams J W, 1979, Methods Enzymol, V63, P437
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102
   ZHANG ZY, 1991, J BIOL CHEM, V266, P15591
   Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j                                                               
NR 23
TC 5
Z9 5
U1 0
U2 4
PU JOHN WILEY & SONS LTD
PI W SUSSEX
PA BAFFINS LANE CHICHESTER, W SUSSEX PO19 1UD, ENGLAND
SN 0952-3499
J9 J MOL RECOGNIT
JI J. Mol. Recognit.
PD SEP-OCT
PY 2002
VL 15
IS 5
BP 272
EP 276
DI 10.1002/jmr.587
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 619JK
UT WOS:000179472700006
PM 12447903
DA 2018-01-05
ER

PT J
AU Medinas, RJ
   Lambert, DM
   Tompkins, WA
AF Medinas, RJ
   Lambert, DM
   Tompkins, WA
TI C-terminal gp40 peptide analogs inhibit feline immunodeficiency virus:
   Cell fusion and virus spread
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID POTENT INHIBITORS; GLYCOPROTEIN; CATS; MECHANISM; TYPE-1; DOMAIN; CD4
AB The envelope glycoprotein of human immunodeficiency virus type I (HIV-1), gp160, is synthesized as a protein precursor that when proteolytically cleaved yields two subunits, gp120 and gp41. gp120 is the surface glycoprotein on HIV-1 responsible for binding to CD4, and gp41 is the transmembrane glycoprotein involved in the membrane fusion process. gp41 is divided into the N-terminal fusion peptide, the heptad repeat I (HRI) and HR2 regions, and the C-terminal transmembrane region, which are collectively responsible for virus fusion and entry into the cell. Synthetic peptides derived from the HR2 and HRI regions of HIV-1,,, have been shown to prevent virus-cell fusion and infection in vitro. In phase II clinical trials in HIV patients, data revealed that T20 has antiviral efficacy and is well tolerated. Similar results were obtained in vitro with HIV-2 and simian immunodeficiency virus, supporting the conservation of the gp41 ectodomain among lentiviruses. Feline immunodeficiency virus (FIV) infection in the cat has been used as a model to develop potential antivirals for HIV. To determine if synthetic gp40 analogs capable of inhibiting FIV infection could be identified, 15 overlapping 35-amino-acid peptides derived from the C-terminal HR2 domain of FIV gp40 were synthesized. These peptides were tested for efficacy against FIV in a syncytium-forming assay with FIV-infected CrFK cells and HeLa cells expressing the FIV receptor CXCR4. Several peptides exhibited activity at the nanogram level. Antiviral activity was confirmed by suppression of reverse transcriptase in a FIV feline CD4(+)-T-cell (FCD4-E) acute-infection assay. These data demonstrate that synthetic peptides derived from the HR2 domain of the FIV gp41 protein are effective inhibitors of FIV infection.
C1 N Carolina State Univ, Program Immunol, Raleigh, NC 27606 USA.
   Trimeris Inc, Durham, NC USA.
RP Tompkins, WA (reprint author), N Carolina State Univ, Program Immunol, 4700 Hillsborough St, Raleigh, NC 27606 USA.
FU NIAID NIH HHS [AI43858]
CR BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001
   CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   ENGLISH RV, 1993, J VIROL, V67, P5175
   Fields B. N., 1996, VIROLOGY
   HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189
   Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404                                                           
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186
   Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   MAKI N, 1992, ARCH VIROL, V123, P29, DOI 10.1007/BF01317136                                                              
   NOVOTNEY C, 1990, AIDS, V4, P1213, DOI 10.1097/00002030-199012000-00005
   PEDERSEN NC, 1987, SCIENCE, V235, P790, DOI 10.1126/science.3643650
   PHILLIPS TR, 1990, J VIROL, V64, P4605
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   TOMPKINS MB, 1991, J AM VET MED ASSOC, V199, P1311
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Willett BJ, 1997, J VIROL, V71, P6407
   YAMAMOTO JK, 1988, AM J VET RES, V49, P1246
   Yang JS, 1996, J VIROL, V70, P3011
NR 26
TC 22
Z9 23
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD SEP
PY 2002
VL 76
IS 18
BP 9079
EP 9086
DI 10.1128/JVI.76.18.9079-9086.2002
PG 8
WC Virology
SC Virology
GA 587TF
UT WOS:000177658500010
PM 12186891
OA gold
DA 2018-01-05
ER

PT J
AU Yang, LJ
   Beard, WA
   Wilson, SH
   Roux, B
   Broyde, S
   Schlick, T
AF Yang, LJ
   Beard, WA
   Wilson, SH
   Roux, B
   Broyde, S
   Schlick, T
TI Local deformations revealed by dynamics simulations of DNA polymerase
   beta with DNA mismatches at the primer terminus
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE dynamics simulations; DNA polymerase beta; opening; DNA mispairs; DNA
   extension
ID TARGETED MOLECULAR-DYNAMICS; HIV-1 REVERSE-TRANSCRIPTASE; I KLENOW
   FRAGMENT; REPLICATION FIDELITY; CONFORMATIONAL-CHANGES;
   CRYSTAL-STRUCTURES; KINETIC MECHANISM; NUCLEOTIDE INCORPORATION;
   BIOMOLECULAR DYNAMICS; CATALYTIC MECHANISM
AB Nanosecond dynamics simulations for DNA polymerase beta (pol beta)/DNA complexes with three mismatched base-pairs, namely GG, CA, or CC (primer/template) at the DNA polymerase active site, are performed to investigate the mechanism of polymerase opening and how the mispairs may affect the DNA extension step; these trajectories are compared to the behavior of a pol beta/DNA complex with the correct GC base-pair, and assessed with the aid of targeted molecular dynamics (TMD) simulations of all systems from the closed to the open enzyme state. DNA polymerase conformational changes (subdomain closing and opening) have been suggested to play a critical role in DNA synthesis fidelity, since these changes are associated with the formation of the substrate-binding pocket for the nascent base-pair. Here we observe different large C-terminal subdomain (thumb) opening motions in the simulations of pol beta with GC versus GG base-pairs. Whereas the conformation of pol beta in the former approaches the observed open state in the crystal structures, the enzyme in the latter does not. Analyses of the motions of active-site protein/ DNA residues help explain these differences. Interestingly, rotation of Arg258 toward Asp192, which coordinates both active-site metal ions in the closed "active" complex, occurs rapidly in the GG simulation. We have previously suggested that this rotation is a key slow step in the closed to open transition. TMD simulations also point to a unique pathway for Arg258 rotation in the GG mispair complex. Simulations of the mismatched systems also reveal distorted geometries in the active site of all the mispair complexes examined. The hierarchy of the distortions (GG > CC > CA) parallels the experimentally deduced inability of pol beta to extend these mispairs. Such local distortions would be expected to cause inefficient DNA extension and polymerase dissociation and thereby might lead to proofreading by an extrinsic exonuclease. Thus, our studies on the dynamics of pol beta opening in mismatch systems provide structural and dynamic insights to explain experimental results regarding inefficient DNA extension following misincorporation; these details shed light on how proofreading may be invoked by the abnormal active-site geometry. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 NYU, Dept Chem, New York, NY 10012 USA.
   NYU, Courant Inst Math Sci, New York, NY 10012 USA.
   Howard Hughes Med Inst, New York, NY 10012 USA.
   NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
   Cornell Univ, Dept Biochem, Weill Med Coll, New York, NY 10021 USA.
   NYU, Dept Biol, New York, NY 10003 USA.
RP Schlick, T (reprint author), NYU, Dept Chem, 251 Mercer St, New York, NY 10012 USA.
FU NCI NIH HHS [CA28038, CA75449]; NIGMS NIH HHS [R01 GM55164]
CR Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o                                                               
   Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079                                                               
   Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j
   Barth E, 1998, J CHEM PHYS, V109, P1633, DOI 10.1063/1.476737
   Barth E, 1998, J CHEM PHYS, V109, P1617, DOI 10.1063/1.476736
   Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141                                                        
   Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200
   Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3
   Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X
   BEESE LS, 1991, EMBO J, V10, P25
   BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   BRUNGER AT, 1988, PROTEINS, V4, P148, DOI 10.1002/prot.340040208
   CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007
   Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a                                                                 
   DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002
   Doublie S, 1998, NATURE, V391, P251
   Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4
   Doublie S, 1999, STRUCT FOLD DES, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3
   ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477
   ELBER R, 1990, J CHEM PHYS, V93, P4312, DOI 10.1063/1.458713                                                                
   Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0
   Ferrara P, 2000, PROTEINS, V39, P252, DOI 10.1002/(SICI)1097-0134(20000515)39:3<252::AID-PROT80>3.0.CO;2-3
   Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8
   Gilson M., 1987, J COMPUT CHEM, V9, P327
   GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792
   Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493                                                        
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345                                             
   KATI WM, 1992, J BIOL CHEM, V267, P25988
   Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+
   Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X
   KIEFER JR, 1998, NATURE, V391, P302
   KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0
   KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109
   Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1                                                  
   Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7
   Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0               
   Kosa JL, 1999, J BIOL CHEM, V274, P35866, DOI 10.1074/jbc.274.50.35866
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Kraynov VS, 1997, BIOCHEM J, V323, P103, DOI 10.1042/bj3230103                                                               
   Kruger P, 2001, PROTEIN SCI, V10, P798, DOI 10.1110/ps.40401                                                                
   KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057                                                             
   Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497
   KUNKEL TA, 1986, J BIOL CHEM, V261, P160
   Kunkel TA, 1998, NAT STRUCT BIOL, V5, P95, DOI 10.1038/nsb0298-95
   Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514
   Ma JP, 1997, P NATL ACAD SCI USA, V94, P11905, DOI 10.1073/pnas.94.22.11905
   MacKerell AD, 2000, J COMPUT CHEM, V21, P105, DOI 10.1002/(SICI)1096-987X(20000130)21:2<105::AID-JCC3>3.0.CO;2-P                  
   MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338
   OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0
   Osheroff WP, 1999, J BIOL CHEM, V274, P20749, DOI 10.1074/jbc.274.30.20749
   Osheroff WP, 2000, J BIOL CHEM, V275, P28033
   PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029
   Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d
   PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580
   Saenger W., 1984, PRINCIPLES NUCL ACID
   Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812
   Schlick T, 1997, ANNU REV BIOPH BIOM, V26, P181, DOI 10.1146/annurev.biophys.26.1.181
   SCHLICK T, 2001, STRUCTURE, V9, pF45
   Schlick T, 1992, REV COMPUTATIONAL CH, VIII, P1
   SCHLITTER J, 1994, J MOL GRAPHICS, V12, P84, DOI 10.1016/0263-7855(94)80072-3                                                    
   SCHLITTER J, 1993, MOL SIMULAT, V10, P291, DOI 10.1080/08927029308022170                                                       
   Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200                                                          
   STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445                                                         
   STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T
   Steitz TA, 1998, NATURE, V391, P231, DOI 10.1038/34542
   Suo ZC, 1998, J BIOL CHEM, V273, P27250, DOI 10.1074/jbc.273.42.27250                                                        
   Vande Berg Brian J., 2001, Journal of Biological Chemistry, V276, P3408, DOI 10.1074/jbc.M002884200
   WATSON JD, 1953, NATURE, V171, P964, DOI 10.1038/171964b0
   Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0                                                   
   WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030
   Yang LJ, 2002, J MOL BIOL, V317, P651, DOI 10.1006/jmbi.2002.5450
   Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4
   Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j
NR 76
TC 48
Z9 49
U1 2
U2 8
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD AUG 16
PY 2002
VL 321
IS 3
BP 459
EP 478
DI 10.1016/S0022-2836(02)00617-4
PG 20
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 589MC
UT WOS:000177761300007
PM 12162959
DA 2018-01-05
ER

PT J
AU Ghosh, AK
   Swanson, LM
   Liu, CF
   Hussain, KA
   Cho, H
   Walters, DE
   Holland, L
   Buthod, J
AF Ghosh, AK
   Swanson, LM
   Liu, CF
   Hussain, KA
   Cho, H
   Walters, DE
   Holland, L
   Buthod, J
TI Novel cyclourethane-derived HIV protease inhibitors: A ring-closing
   olefin metathesis based strategy
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID POTENT; ALKOXYCARBONYLATION; PROTEINASE; URETHANES; ISOSTERE; AMINES;
   DESIGN
AB A series of novel macrocyclic urethanes incorporating a (R)-hydroxyethylamine isostere was designed and synthesized. Ring size and substituent efffects have been investigated. Cyclourethanes containing 14- to 16-membered rings exhibited low nanomolar inhibitory potencies against HIV-1 protease. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Univ Illinois, Dept Chem, Chicago, IL 60607 USA.
   Finch Univ Hlth Sci Chicago Med Sch, Dept Biol Chem, N Chicago, IL 60064 USA.
   IIT, Res Inst, Dept Life Sci, Chicago, IL 60616 USA.
RP Ghosh, AK (reprint author), Univ Illinois, Dept Chem, 845 W Taylor St, Chicago, IL 60607 USA.
FU NIGMS NIH HHS [GM 53386]
CR Cihlar T, 2000, ANNU REP MED CHEM, V35, P177, DOI 10.1016/S0065-7743(00)35017-5
   CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S
   Dohnalek J, 2001, ACTA CRYSTALLOGR D, V57, P472, DOI 10.1107/S0907444900018928
   EVANS DA, 1982, J AM CHEM SOC, V104, P1737, DOI 10.1021/ja00370a050                                                             
   Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808                                                     
   Ghosh AK, 1998, BIOORG MED CHEM LETT, V8, P687, DOI 10.1016/S0960-894X(98)00098-5
   GHOSH AK, 1992, TETRAHEDRON LETT, V33, P2781, DOI 10.1016/S0040-4039(00)78856-3
   Ghosh AK, 1998, TETRAHEDRON LETT, V39, P1881, DOI 10.1016/S0040-4039(98)00153-1                                                   
   GHOSH AK, 1993, J MED CHEM, V36, P2300, DOI 10.1021/jm00068a006
   Ghosh AK, 1996, J MED CHEM, V39, P3278, DOI 10.1021/jm960128k
   GHOSH AK, 1993, J MED CHEM, V36, P292, DOI 10.1021/jm00054a015                                                             
   GHOSH AK, 2001, IL FARMACO, V56, P29
   Grubbs RH, 1998, TETRAHEDRON, V54, P4413, DOI 10.1016/S0040-4020(97)10427-6                                                   
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   Munshi S, 2000, ACTA CRYSTALLOGR D, V56, P381, DOI 10.1107/S0907444900000469
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   TOTH MV, 1990, INT J PEPT PROT RES, V36, P544
   Yoshimura K, 2002, J VIROL, V76, P1349, DOI 10.1128/JVI.76.3.1349-1258.2002
NR 18
TC 10
Z9 10
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 5
PY 2002
VL 12
IS 15
BP 1993
EP 1996
AR PII S0960-894X(02)00300-1
DI 10.1016/S0960-894X(02)00300-1
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 580FW
UT WOS:000177225400025
PM 12113826
DA 2018-01-05
ER

PT J
AU Darfeuille, F
   Arzumanov, A
   Gryaznov, S
   Gait, MJ
   Di Primo, C
   Toulme, JJ
AF Darfeuille, F
   Arzumanov, A
   Gryaznov, S
   Gait, MJ
   Di Primo, C
   Toulme, JJ
TI Loop-loop interaction of HIV-1 TAR RNA with N3 '-> P5 '
   deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated
   transcription
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID LONG TERMINAL REPEAT; VIRUS TYPE-1 TAT; TRANS-ACTIVATION; HIGH-AFFINITY;
   HAIRPIN LOOP; STEM-LOOP; PROTEIN; BINDING; COMPLEX; TRANSACTIVATION
AB A hairpin RNA aptamer has been identified by in vitro selection against the transactivation-responsive element (TAR) of HIV-1. A nuclease-resistant N3' --> P5' phosphoramidate isosequential analog of this aptamer also folds as a hairpin and forms with TAR a loop-loop "kissing" complex with a binding constant in the low nanomolar range as demonstrated by electrophoretic mobility-shift assays and surface plasmon resonance experiments. The key structural determinants, which contribute to the stability of the RNA aptamer-TAR complex, loop complementarity and the GA residues closing the aptamer loop, remain crucial for the N3' --> P5' aptamer-TAR complex. Moreover, the N3' --> P5' phosphoramidate aptamer specifically interferes with the binding of a peptide derived from the transactivator protein (Tat) peptide to TAR and selectively inhibits the Tat-mediated transcription in an in vitro assay, which marks this nuclease-resistant aptamer as a relevant candidate for experiments in cells.
C1 Univ Victor Segalen, Inst Natl Sante & Rech Med, U386, F-33076 Bordeaux, France.
   Inst Europeen Chim & Biol, F-33607 Pessac, France.
   MRC, Mol Biol Lab, Cambridge CB2 2QH, England.
   Geron Corp, Menlo Pk, CA 94025 USA.
RP Toulme, JJ (reprint author), Univ Victor Segalen, Inst Natl Sante & Rech Med, U386, F-33076 Bordeaux, France.
RI Darfeuille, Fabien/M-3883-2014
OI Darfeuille, Fabien/0000-0003-1167-6113; Toulme,
   Jean-jacques/0000-0002-8432-5034; Di Primo, Carmelo/0000-0002-0509-8399
CR ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   Arzumanov A, 2001, NUCLEOS NUCLEOT NUCL, V20, P471, DOI 10.1081/NCN-100002321
   Arzumanov A, 2001, BIOCHEMISTRY-US, V40, P14645, DOI 10.1021/bi011279e
   Arzumanov A, 2000, HELV CHIM ACTA, V83, P1424, DOI 10.1002/1522-2675(20000705)83:7<1424::AID-HLCA1424>3.0.CO;2-D                   
   Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791                                                         
   Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730
   Brody E N, 2000, J Biotechnol, V74, P5
   Chang KY, 1997, J MOL BIOL, V269, P52, DOI 10.1006/jmbi.1997.1021
   CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128
   Ding D, 1998, BIOCHEMISTRY-US, V37, P12082, DOI 10.1021/bi980711y                                                               
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0                                                                
   GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275
   Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548
   Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837
   Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982
   KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505
   Lapidot A, 2000, DRUG DEVELOP RES, V50, P502, DOI 10.1002/1098-2299(200007/08)50:3/4<502::AID-DDR34>3.0.CO;2-L
   Lee AJ, 1998, STRUCT FOLD DES, V6, P993, DOI 10.1016/S0969-2126(98)00101-4
   Mayhood T, 2000, BIOCHEMISTRY-US, V39, P11532, DOI 10.1021/bi000708q
   Mestre B, 1999, BBA-GENE STRUCT EXPR, V1445, P86, DOI 10.1016/S0167-4781(99)00019-6
   Nelson JS, 1997, J ORG CHEM, V62, P7278, DOI 10.1021/jo970801t                                                               
   Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206
   Schultz RG, 1996, NUCLEIC ACIDS RES, V24, P2966, DOI 10.1093/nar/24.15.2966                                                          
   SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547
   Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944
   Toulme JJ, 2001, PROG NUCLEIC ACID RE, V69, P1, DOI 10.1016/S0079-6603(01)69043-3
   Toulme JJ, 2001, NAT BIOTECHNOL, V19, P17, DOI 10.1038/83451                                                                   
   WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   Wilson WD, 2000, CURR MED CHEM, V7, P73, DOI 10.2174/0929867003375434                                                        
NR 34
TC 42
Z9 44
U1 0
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 23
PY 2002
VL 99
IS 15
BP 9709
EP 9714
DI 10.1073/pnas.122247199
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 577DG
UT WOS:000177042400022
PM 12105271
OA gold
DA 2018-01-05
ER

PT J
AU Zhao, M
   Kircher, MF
   Josephson, L
   Weissleder, R
AF Zhao, M
   Kircher, MF
   Josephson, L
   Weissleder, R
TI Differential conjugation of tat peptide to superparamagnetic
   nanoparticles and its effect on cellular uptake
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID MAMMALIAN-CELLS; DELIVERY; PROTEINS
AB Surface modification of superparamagnetic contrast agents with HIV-1 tat peptide has emerged as a promising means for intracellular magnetic labeling and noninvasive tracking of a large number of cell types with MRI. To achieve efficient intracellular delivery of the nanoparticles, we investigated the effect on cellular uptake of superparamagnetic iron oxide particles by varying the number of attached tat peptides. First, we report here a modified P2T method in measuring the numbers of surface attachments per particle through disulfide linkage. The method was shown to have desirable simplicity and reproducibility. With the P2T method as a tool, conjugates with progressively higher ratios of peptide-to-particle were synthesized. We were able to demonstrate that higher numbers of tat peptide facilitate the cellular uptake of iron oxide nanoparticles in a nonlinear fashion. Cells labeled with these optimized preparations were readily detectable by MR imaging. The increase in sensitivity could allow in vivo tracking of 100-fold lower cell concentration than currently described.
C1 Harvard Univ, Sch Med, Ctr Mol Imaging Res, Charlestown, MA 02169 USA.
RP Zhao, M (reprint author), Harvard Univ, Sch Med, Ctr Mol Imaging Res, Room 5404,Bldg 149,13th St, Charlestown, MA 02169 USA.
OI /0000-0003-0828-4143
FU NCI NIH HHS [T32 CA 79443, P50 CA86355]
CR Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   CARON NJ, 2001, MOL THER, V11, P301
   Efthymiadis A, 1998, J BIOL CHEM, V273, P1623, DOI 10.1074/jbc.273.3.1623                                                          
   Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Kim DT, 1997, J IMMUNOL, V159, P1666
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   NGO TT, 1986, J BIOCHEM BIOPH METH, V12, P349, DOI 10.1016/0165-022X(86)90072-2
   Schoepf U, 1998, BIOTECHNIQUES, V24, P642
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167                                                           
   Weissleder R, 1997, JMRI-J MAGN RESON IM, V7, P258, DOI 10.1002/jmri.1880070140                                                         
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
NR 14
TC 247
Z9 255
U1 0
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUL-AUG
PY 2002
VL 13
IS 4
BP 840
EP 844
DI 10.1021/bc0255236
PG 5
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 574VF
UT WOS:000176909700018
PM 12121140
DA 2018-01-05
ER

PT J
AU Morcock, DR
   Katakam, S
   Kane, BP
   Casas-Finet, JR
AF Morcock, DR
   Katakam, S
   Kane, BP
   Casas-Finet, JR
TI Fluorescence and nucleic acid binding properties of bovine leukemia
   virus nucleocapsid protein
SO BIOPHYSICAL CHEMISTRY
LA English
DT Article
DE bovine leukemia virus; nucleocapsid; zinc finger; fluorescence
ID HUMAN-IMMUNODEFICIENCY-VIRUS; ENCAPSIDATION SIGNAL; GAG GENE; RNA;
   TYPE-1; SEQUENCE; COMPLEX; HIV-1
AB We used the intrinsic fluorescence of bovine leukemia virus p12, a nucleocapsid protein with two tryptophan-containing zinc fingers (ZFs), to study its conformation and binding to single-stranded nucleic acids. Spectral emission maxima suggested solvent-exposed tryptophans. A peptide derived from ZF1 had a higher quantum yield and longer average lifetime (tau) than ZF2. BLV p12 tau and rotational correlation time were greater than ZF values, but all de-metallated sequences gave similar results. Apo p12 showed reduced fluorescence intensity, T and loss of secondary structure. DNA-binding affinity of p12 was in the nanomolar range, and decreased 14-fold after Zn++ ejection. Nucleobase preference of BLV p12 was different from the closely related HTLV-1 but similar to HIV-1 and SIV nucleocapsids, both phylogenetically distant. (C) 2002 Elsevier Science B.V All rights reserved.
C1 NCI, Frederick Canc Res & Dev Ctr, AIDS Vaccine Program, SAIC Frederick, Frederick, MD 21702 USA.
   Informax Inc, Bethesda, MD 20814 USA.
   Medimmune Inc, Gaithersburg, MD 20878 USA.
RP Morcock, DR (reprint author), NCI, Frederick Canc Res & Dev Ctr, AIDS Vaccine Program, SAIC Frederick, Bldg 535,5th Floor,POB B, Frederick, MD 21702 USA.
FU NCI NIH HHS [N01-CO-56000]
CR Cantor C.R., 1980, BIOPHYSICAL CHEM 1
   Chen XH, 2000, J BIOL INORG CHEM, V5, P93
   CLEVER J, 1995, J VIROL, V69, P2101
   COPELAND TD, 1983, FEBS LETT, V156, P37, DOI 10.1016/0014-5793(83)80243-9
   DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635
   GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403
   Gregoire CJ, 1997, J BIOL CHEM, V272, P25143, DOI 10.1074/jbc.272.40.25143                                                        
   HELENE C, 1981, CRC CR REV BIOCH MOL, V10, P213, DOI 10.3109/10409238109113600                                                       
   HENDERSON LE, 1985, J VIROL, V55, P778
   Jewell NA, 2000, J GEN VIROL, V81, P1889, DOI 10.1099/0022-1317-81-8-1889                                                     
   KATOH I, 1991, J VIROL, V65, P6845
   KELLY RC, 1976, J BIOL CHEM, V251, P7240
   LACZKO G, 1990, REV SCI INSTRUM, V61, P2331, DOI 10.1063/1.1141360
   Lakowicz J. R., 1983, PRINCIPLES FLUORESCE
   MANSKY LM, 1995, J VIROL, V69, P3282
   Mansky LM, 1998, J VIROL, V72, P3196
   MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X
   Morcock DR, 2000, BBA-PROTEIN STRUCT M, V1481, P381, DOI 10.1016/S0167-4838(00)00181-3
   Mougel M, 1996, J VIROL, V70, P5043
   OMICHINSKI JG, 1991, FEBS LETT, V292, P25, DOI 10.1016/0014-5793(91)80825-N
   RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X                                                   
   Rein A, 1998, TRENDS BIOCHEM SCI, V23, P297, DOI 10.1016/S0968-0004(98)01256-0
   RIZVI TA, 1993, J VIROL, V67, P2681
   SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011                                                          
   Urbaneja MA, 2000, J BIOL CHEM, V275, P10394, DOI 10.1074/jbc.275.14.10394                                                        
   Urbaneja MA, 1999, J MOL BIOL, V287, P59, DOI 10.1006/jmbi.1998.2521                                                          
   VOGT VM, 1998, RETROVIRUSES, P27
   Wu JQ, 1997, BIOCHEMISTRY-US, V36, P12506, DOI 10.1021/bi970676f
   Zeffman A, 2000, J MOL BIOL, V297, P877, DOI 10.1006/jmbi.2000.3611
NR 29
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-4622
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD JUN 19
PY 2002
VL 97
IS 2-3
BP 203
EP 212
AR PII S0301-4622(02)00070-4
DI 10.1016/S0301-4622(02)00070-4                                           
          
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA 564AY
UT WOS:000176292700009
PM 12050010
DA 2018-01-05
ER

PT J
AU Du, ZH
   Lind, KE
   James, TL
AF Du, ZH
   Lind, KE
   James, TL
TI Structure of TAR RNA complexed with a Tat-TAR interaction nanomolar
   inhibitor that was identified by computational screening
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1 TAR; PROTEIN; BINDING; STEM;
   TRANSACTIVATION; CONFORMATION; REVEALS; MODEL; BULGE
AB HIV-1 TAR RNA functions critically in viral replication by binding the transactivating regulatory protein Tat. We recently identified several compounds that experimentally inhibit the Tat-TAR interaction completely at a 100 nM concentration. We used computational screening of the 181,000-compound Available Chemicals Directory against the three-dimensional structure of TAR 11]. Here we report the NMR-derived structure of TAR complexed with acetylpromazine. This structure represents a new class of compounds with good bioavailability and low toxicity that bind with high affinity to TAR. NMR data unambiguously show that acetylpromazine binds only to the unique 5' bulge site to which the Tat protein binds. Specificity and affinity of binding are conferred primarily by a network of base stacking and hydrophobic interactions. Acetylpromazine alters the structure of free TAR less than Tat peptides and neomycin do.
C1 Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
RP James, TL (reprint author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
FU NCRR NIH HHS [RR01081]; NIAID NIH HHS [AI46967]
CR ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555
   CARROLL R, 1992, J VIROL, V66, P2000
   CORNELL WD, 1996, J AM CHEM SOC, V117, P5179
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   DELLING U, 1992, J VIROL, V66, P3018
   DINGWALL C, 1990, EMBO J, V9, P4145
   Du ZH, 1996, BIOCHEMISTRY-US, V35, P4187, DOI 10.1021/bi9527350                                                               
   Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200                                                          
   Filikov AV, 2000, J COMPUT AID MOL DES, V14, P593, DOI 10.1023/A:1008121029716                                                         
   Gallo K., 1989, MOL INTERACTIVE DISP
   GODDARD TD, 1998, SPARKY 3 0
   Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284
   HAUBER J, 1989, J VIROL, V63, P1181
   Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819
   Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0                                                   
   Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h
   MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51
   NIKONOWICZ EP, 1993, J MOL BIOL, V232, P1141, DOI 10.1006/jmbi.1993.1466
   PEARLMAN DA, 1995, AMBER 4 1
   PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097
   Saenger W., 1984, PRINCIPLES NUCL ACID
   SMALLCOMBE SH, 1993, J AM CHEM SOC, V115, P4776, DOI 10.1021/ja00064a043
   Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589
NR 23
TC 68
Z9 72
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD JUN
PY 2002
VL 9
IS 6
BP 707
EP 712
AR PII S1074-5521(02)00151-5
DI 10.1016/S1074-5521(02)00151-5
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 566GG
UT WOS:000176418100008
PM 12079782
DA 2018-01-05
ER

PT J
AU Furet, P
   Imbach, P
   Fuerst, P
   Lang, M
   Noorani, M
   Zimmermann, J
   Garcia-Echeverria, C
AF Furet, P
   Imbach, P
   Fuerst, P
   Lang, M
   Noorani, M
   Zimmermann, J
   Garcia-Echeverria, C
TI Structure-based optimisation of 2-aminobenzylstatine derivatives: Potent
   and selective inhibitors of the chymotrypsin-like activity of the human
   20S proteasome
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID 4-AMINO-3-HYDROXY-5-PHENYLPENTANOIC ACID; ANTICANCER AGENTS; HIV-1
   PROTEINASE; COMPLEX
AB We have identified 2-aminobenzylstatine derivatives that inhibit non-covalently the chymotrypsin-like activity of the human 20S proteasome. A structure-based optimisation approach has allowed us to improve the potency of this structural class of proteasome inhibitors from micromolar to nanomolar level. The new derivatives showed good selectivity against the trypsin-like and post-glutamyl-peptide hydrolytic activities of this enzyme. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 Novartis Pharma Inc, Oncol Res, CH-4002 Basel, Switzerland.
RP Furet, P (reprint author), Novartis Pharma Inc, Oncol Res, CH-4002 Basel, Switzerland.
CR Adams J, 1999, CANCER RES, V59, P2615
   Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515
   BILLICH A, 1995, ANTIVIR CHEM CHEMOTH, V6, P327, DOI 10.1177/095632029500600507                                                      
   Dou QP, 1999, DRUG RESIST UPDATE, V2, P215, DOI 10.1054/drup.1999.0095                                                          
   Dou QP, 2000, EXPERT OPIN THER PAT, V10, P1263, DOI 10.1517/13543776.10.8.1263                                                      
   Elliot P J, 1999, Curr Opin Drug Discov Devel, V2, P484
   Furet P, 2001, BIOORG MED CHEM LETT, V11, P1321, DOI 10.1016/S0960-894X(01)00206-2                                                   
   Garcia-Echeverria C, 2001, BIOORG MED CHEM LETT, V11, P1317, DOI 10.1016/S0960-894X(01)00205-0
   Groll M, 2001, J MOL BIOL, V311, P543, DOI 10.1006/jmbi.2001.4869
   Kalogeris T, 1999, Expert Opin Investig Drugs, V8, P1397, DOI 10.1517/13543784.8.9.1397
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Lehr P, 1996, J MED CHEM, V39, P2060, DOI 10.1021/jm9508696
   MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405
   Murray RZ, 2000, ANTI-CANCER DRUG, V11, P407, DOI 10.1097/00001813-200007000-00001
   ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022
   Rivett AJ, 2000, J PEPT SCI, V6, P478, DOI 10.1002/1099-1387(200009)6:9<478::AID-PSC285>3.0.CO;2-F                         
   SCHOLZ D, 1994, J MED CHEM, V37, P3079, DOI 10.1021/jm00045a013
   Tanaka K, 1998, J BIOCHEM-TOKYO, V123, P195
NR 18
TC 25
Z9 26
U1 1
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD MAY 20
PY 2002
VL 12
IS 10
BP 1331
EP 1334
AR PII S0960-894X(02)00178-6
DI 10.1016/S0960-894X(02)00178-6
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 552YX
UT WOS:000175648800002
PM 11992770
DA 2018-01-05
ER

PT J
AU Chang, LC
   Bewley, CA
AF Chang, LC
   Bewley, CA
TI Potent inhibition of HIV-1 fusion by cyanovirin-N requires only a single
   high affinity carbohydrate binding site: Characterization of low
   affinity carbohydrate binding site knockout mutants
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE HIV-1 viral entry; surface envelope glycoprotein gpl20; high mannose
   oligosaccharides; NMR; dipolar couplings
ID INACTIVATING PROTEIN; DIPOLAR COUPLINGS; GP120; CD4; CORECEPTOR;
   BLOCKING
AB Cyanovirin-N (CVN) is a novel cyanobacterial protein that potently inhibits viral entry by human immunodeficiency viruses (HIV) via high affinity carbohydrate-mediated binding to the surface envelope glycoprotein gp120. Bearing C-2 pseudo-symmetry, CVN contains two carbohydrate binding sites of differing affinities located at opposite ends of the protein. CVN selectively binds with nanomolar affinity the mammalian high mannose oligosaccharides oligomannose-8 D1D3 and oligomannose-9, which also govern binding to gp120. At nanomolar concentrations CVN binds these oligosaccharides only through its high affinity site, while at micromolar to millimolar concentrations the oligosaccharides are bound through both sites leading to divalent protein-carbohydrate interactions. Similarly, two modes of binding to gp120 can be envisioned where CVN either binds gp120 solely through the high affinity site, or binds divalently using both carbohydrate binding sites. To determine the role of the low affinity site in binding to gp120, we sought to design a variant of CVN that lacks the low affinity carbohydrate binding site but retains a fully functional high affinity site. Thus, we constructed a series of CVN mutants possessing cumulative mutations in the low affinity site only, and characterized by NMR the overall structure and carbohydrate binding ability of each of these mutants. We demonstrate that carbohydrate binding by the low affinity site is completely absent in two mutants bearing three or four mutations (namely, m3-CVN = Lys3Asn, Glu23Ile, Asn93Ala; and m4-CVN = Lys3Asn, Thr7Ala, Glu23Ile, Asn93Ala), while the high affinity site binds the high affinity ligand Manalpha(1-2)Manalpha with a K-d value equal to that measured for CVN. Using an HIV-1 cell fusion assay, we show that all of the mutants inhibit HIV-1 fusion with nearly identical IC50 values as wild-type CVN. We interpret these results as indicating that the low affinity carbohydrate binding site of CVN is not necessary for high affinity binding to gp120, and HIV-1 fusion can therefore be blocked by monovalent protein-carbohydrate interactions. (C) 2002 Elsevier Science Ltd. All rights reserved.
C1 NIDDKD, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Bewley, CA (reprint author), NIDDKD, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
CR Bewley CA, 2001, STRUCTURE, V9, P931, DOI 10.1016/S0969-2126(01)00653-0
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   BRUNGER AT, 1993, XPLOR SYSTEM XRAY CR
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k                                                               
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170
   Esser MT, 1999, J VIROL, V73, P4360
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754
   NUSSBAUM O, 1994, J VIROL, V68, P5411
   Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361
   Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h
   Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000                                                   
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
NR 19
TC 37
Z9 37
U1 0
U2 5
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD APR 19
PY 2002
VL 318
IS 1
BP 1
EP 8
DI 10.1016/S0022-2836(02)00045-1
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 548MY
UT WOS:000175392800001
PM 12054763
DA 2018-01-05
ER

PT J
AU Scozzafava, A
   Mastrolorenzo, A
   Supuran, CT
AF Scozzafava, A
   Mastrolorenzo, A
   Supuran, CT
TI Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents
SO JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
LA English
DT Review
DE antiviral agent; bicyclam; chemokino receptor; CCR5; CXCR4; HIV entry
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CARBONIC-ANHYDRASE INHIBITORS; IN-VIVO
   SELECTIVITY; CCR5 ANTAGONISTS; ANTI-HIV-1 AGENTS; POTENT; ENTRY;
   DISCOVERY; INFECTION; CXCR4
AB HIV entry within the cell involves the presence of at least two chemokine co-receptors, the CCR5 and CXCR4 receptors. Viral entry can be inhibited by the natural ligands for CXCR4, the CXC chemokine SDF-1 and CCR5, the CC chemokines RANTES, MIP-1alpha and MIP-1beta, respectively. Much research has been devoted ultimately to the development of small molecule chemokine antagonists that inhibit virus entry within the cell, and constitute in this way novel antiviral medications. The most potent and specific CXCR4 antagonists reported up to now are the bicyclam derivatives, which also potently block X4 HIV replication. One such compound, AMD3100 has proved to be a highly specific CXCR4 antagonist, which consistently blocks the outgrowth of all X4 HIV and dual-tropic (R5/X4) variants that use CXCR4 for entering the cells. From such bicyclam analogues, AMD3100 was selected as the clinical candidate, which, after initial Phase I studies, proceeded to Phase H trials, but unfortunately showed significant cardiac side effects which lead to its withdrawal from further development. The first nonpeptidic compound that interacts with CCR5, but not with CXCR4, is a quaternary ammonium derivative, TAK-779, which also shows potent but variable anti-HIV activity. A large number of potent CCR5 antagonists from several classes of polycyclic derivatives have been recently disclosed. Many such derivatives showed nanomolar binding affinity to the receptor, and at least one of them, the oxime-piperidine derivative SCH-351125 has progressed to clinical evaluation. The development of such agents for clinical use may constitute an additional approach for the treatment of HIV infection, in addition to the classical one involving reverse transcriptase and protease inhibitors.
C1 Univ Florence, Dipartimento Chim, Lab Chim Bioinorgan, I-50019 Florence, Italy.
   Univ Florence, Dipartimento Sci Dermatol, Ctr MTS, I-50121 Florence, Italy.
   Univ Florence, Lab Chim Inorgan Bioinorgan, I-50121 Florence, Italy.
RP Supuran, CT (reprint author), Univ Florence, Dipartimento Chim, Lab Chim Bioinorgan, Via Lastruccia 3,Rm 188, I-50019 Florence, Italy.
RI Supuran, Claudiu/A-5151-2008
OI Scozzafava, Andrea/0000-0001-5020-3322
CR Blair WS, 2000, DRUG DISCOV TODAY, V5, P183, DOI 10.1016/S1359-6446(00)01484-7
   Blanco J, 2000, ANTIMICROB AGENTS CH, V44, P51, DOI 10.1128/AAC.44.1.51-56.2000                                                     
   Cascieri MA, 2000, CURR OPIN CHEM BIOL, V4, P420, DOI 10.1016/S1367-5931(00)00113-7
   D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215
   De Clercq E, 2001, J PHARMACOL EXP THER, V297, P1
   De Clercq E, 2000, MOL PHARMACOL, V57, P833
   De Clercq Erik, 2001, Antiviral Chemistry and Chemotherapy, V12, P19
   Dong XN, 2001, IMMUNOL LETT, V75, P215, DOI 10.1016/S0165-2478(00)00302-3
   Dorn CP, 2001, BIOORG MED CHEM LETT, V11, P259, DOI 10.1016/S0960-894X(00)00637-5
   Dowd CS, 2001, J CHROMATOGR B, V753, P327, DOI 10.1016/S0378-4347(00)00567-3
   Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697
   Este J A, 2001, Curr Opin Investig Drugs, V2, P354
   Finke PE, 2001, BIOORG MED CHEM LETT, V11, P2475, DOI 10.1016/S0960-894X(01)00492-9
   Finke PE, 2001, BIOORG MED CHEM LETT, V11, P265, DOI 10.1016/S0960-894X(00)00639-9
   Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000
   HLAE JJ, 2001, BIOORG MED CHEM LETT, V11, P2741
   IKEMOTO T, 2001, TETRAHEDRON, V11, P1525
   Kim D, 2001, BIOORG MED CHEM LETT, V11, P3103, DOI 10.1016/S0960-894X(01)00655-2                                                   
   Kim D, 2001, BIOORG MED CHEM LETT, V11, P3099, DOI 10.1016/S0960-894X(01)00654-0
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Maeda K, 2001, J BIOL CHEM, V276, P35194, DOI 10.1074/jbc.M105670200
   Mastrolorenzo A, 2001, EXPERT OPIN THER PAT, V11, P1245, DOI 10.1517/13543776.11.8.1245                                                      
   Mori T, 2001, ANTIMICROB AGENTS CH, V45, P664, DOI 10.1128/AAC.45.3.664-672.2001
   Nabel GJ, 2001, NATURE, V410, P1002, DOI 10.1038/35073500
   Nagashima KA, 2001, J INFECT DIS, V183, P1121, DOI 10.1086/319284                                                                  
   Ogden R. C, 2001, PROTEASE INHIBITORS
   Palani A, 2001, J MED CHEM, V44, P3339, DOI 10.1021/jm015526o
   Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Scozzafava A, 2001, EXPERT OPIN THER PAT, V11, P765, DOI 10.1517/13543776.11.5.765                                                       
   Scozzafava A, 2000, J MED CHEM, V43, P292, DOI 10.1021/jm990479+                                                               
   Shiraishi M, 2000, J MED CHEM, V43, P2049, DOI 10.1021/jm9906264
   Stantchev TS, 2001, CYTOKINE GROWTH F R, V12, P219, DOI 10.1016/S1359-6101(00)00033-2                                                   
   Strizki JM, 2001, P NATL ACAD SCI USA, V98, P12718, DOI 10.1073/pnas.221375398                                                          
   Supuran CT, 2000, J ENZYM INHIB, V15, P381, DOI 10.1080/14756360009040695                                                       
   Tagat JR, 2001, BIOORG MED CHEM LETT, V11, P2143, DOI 10.1016/S0960-894X(01)00381-X                                                   
   Tagat JR, 2001, J MED CHEM, V44, P3343, DOI 10.1021/jm0155401
   Tamamura H, 2000, BIOORG MED CHEM LETT, V10, P2633, DOI 10.1016/S0960-894X(00)00535-7
   TOAMRAS GD, 2001, CURR INFECT DIS REP, V3, P93
   Weiss RA, 2001, NATURE, V410, P963, DOI 10.1038/35073632                                                                
   Willoughby CA, 2001, BIOORG MED CHEM LETT, V11, P3137, DOI 10.1016/S0960-894X(01)00652-7
NR 41
TC 50
Z9 52
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1475-6366
J9 J ENZYM INHIB MED CH
JI J. Enzym. Inhib. Med. Chem.
PD APR
PY 2002
VL 17
IS 2
BP 69
EP 76
DI 10.1080/14756360290024227
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 588LK
UT WOS:000177702800001
PM 12420752
DA 2018-01-05
ER

PT J
AU Kawamura, M
   Naito, T
   Ueno, M
   Akagi, T
   Hiraishi, K
   Takai, I
   Makino, M
   Serizawa, T
   Sugimura, K
   Akashi, M
   Baba, M
AF Kawamura, M
   Naito, T
   Ueno, M
   Akagi, T
   Hiraishi, K
   Takai, I
   Makino, M
   Serizawa, T
   Sugimura, K
   Akashi, M
   Baba, M
TI Induction of mucosal IgA following intravaginal administration of
   inactivated HIV-1-capturing nanospheres in mice
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE concanavalin A; vagina; prophylaxis; vaccine
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IMMOBILIZED POLYSTYRENE NANOSPHERES;
   EPITHELIAL-CELLS; HYDROPHOBIC BACKBONE; HYDROPHILIC BRANCHES; SECRETORY
   COMPONENT; GRAFT-COPOLYMERS; THERMAL INACTIVATION; SEX WORKERS; HIV-1
AB Concanavalin A-immobilized polystyrene nanospheres (Con A-NS) were developed for the HIV-1 vaccine capable of preventing sexual transmission. Con A-NS could capture efficiently HIV-1 irrespective of their cell tropism (R5 or X4). Furthermore, Con A-NS captured equally infectious and heat-inactivated HIV-1. Inactivated HIV-1-capturing Con A-NS (HIV-NS) were intra-vaginally administered to mice. Heat-in-activated HIV-1 alone and Con A-NS alone were also administered as control immunogens. Vaginal fluids were collected during and after immunization and analyzed for their anti-HIV-1 antibody levels. Although the anti-HIV-1 IgG antibody was undetectable in any groups, increased anti-HIV-1 IgA antibody response was identified in the vaginal fluids of immunized mice with HIV-NS. The vaginal fluids obtained from the HIV-NS-administered mice showed neutralizing activity against the immunizing HIV-1 strain. A marked difference in vaginal distribution was observed between HIV-NS and other immunogens, and the toxicity of Con A was reduced by conjugation with nanospheres. Thus, HIV-NS may have great potential as a prophylactic HIV-1 vaccine and should be examined further for its efficacy in non-human primates. (C) 2002 Wiley-Liss, Inc.
C1 Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Human Retroviruses, Kagoshima 8908520, Japan.
   Kagoshima Univ, Fac Engn, Dept Appl Chem & Chem Engn, Kagoshima 8908520, Japan.
   Kagoshima Univ, Fac Engn, Dept Bioengn, Kagoshima 890, Japan.
   Immunores Labs Co Ltd, Takasaki, Gumma, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Human Retroviruses, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
RI Baba, Masanori/G-3867-2011
CR *AIDS VACC EV GROU, 2000, AVEG HDB
   AKASHI M, 1989, J POLYM SCI POL CHEM, V27, P3521, DOI 10.1002/pola.1989.080271029                                                     
   Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   Baba M, 2000, AIDS RES HUM RETROV, V16, P935, DOI 10.1089/08892220050058344                                                       
   Beyrer C, 1999, J INFECT DIS, V179, P59, DOI 10.1086/314556
   Bomsel M, 1998, IMMUNITY, V9, P277, DOI 10.1016/S1074-7613(00)80610-X
   BRANDTZAEG P, 1978, SCAND J IMMUNOL, V8, P39, DOI 10.1111/j.1365-3083.1978.tb00494.x                                              
   *CASCADE COLL, 2000, LANCET, V355, P1158
   CRAGO SS, 1978, J EXP MED, V147, P1832, DOI 10.1084/jem.147.6.1832
   Devito C, 2000, J IMMUNOL, V165, P5170, DOI 10.4049/jimmunol.165.9.5170                                                     
   Gazzard B, 1999, Int J Clin Pract Suppl, V103, P45
   Grovit-Ferbas K, 2000, J VIROL, V74, P5802, DOI 10.1128/JVI.74.13.5802-5809.2000                                                
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004
   Klein M, 1999, VACCINE, V17, pS65, DOI 10.1016/S0264-410X(99)00236-4                                                   
   KUHN LC, 1979, J BIOL CHEM, V254, P1072
   LAMM ME, 1995, APMIS, V103, P241, DOI 10.1111/j.1699-0463.1995.tb01101.x                                              
   LEE VHL, 1990, ADV DRUG DELIV REV, V4, P171
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   MCDOUGAL JS, 1985, J CLIN INVEST, V76, P875, DOI 10.1172/JCI112045
   Miyoshi I., 1982, GANN MONOGR, V28, P219
   OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784                                                         
   PARR EL, 1992, VACCINE RES, V1, P221
   RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57
   Rosenthal K L, 1997, Semin Immunol, V9, P303, DOI 10.1006/smim.1997.0086
   Sakuma S, 1997, INT J PHARM, V149, P93, DOI 10.1016/S0378-5173(96)04861-2
   Sansone GR, 2000, J URBAN HEALTH, V77, P166, DOI 10.1007/BF02390528                                                              
   Schwarcz SK, 2000, AM J EPIDEMIOL, V152, P178, DOI 10.1093/aje/152.2.178                                                           
   Staats HF, 1996, J IMMUNOL, V157, P462
   TERSMETTE M, 1986, VOX SANG, V51, P239, DOI 10.1111/j.1423-0410.1986.tb01962.x                                              
   WINKELMAN L, 1989, CURR STUD HEMATOL BL, V56, P55
NR 31
TC 36
Z9 36
U1 0
U2 1
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0146-6615
J9 J MED VIROL
JI J. Med. Virol.
PD MAR
PY 2002
VL 66
IS 3
BP 291
EP 298
DI 10.1002/jmv.2144
PG 8
WC Virology
SC Virology
GA 514TU
UT WOS:000173457800001
PM 11793379
DA 2018-01-05
ER

PT J
AU Rajarathnam, K
AF Rajarathnam, K
TI Designing decoys for chemokine-chemokine receptor interaction
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE chemokine; chemokine receptor; structure; drug design; receptor decoy;
   antagonist
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; NMR SOLUTION STRUCTURE;
   NEUTROPHIL-ACTIVATING PEPTIDE-2; GROWTH-STIMULATORY ACTIVITY; N-TERMINAL
   PEPTIDES; CC-CHEMOKINE; CRYSTAL-STRUCTURE; FACTOR-I; VMIP-II; MONOMERIC
   INTERLEUKIN-8
AB Aberrant expression of chemokines and their receptors play causative roles in the pathophysiology of numerous autoimmune and inflammatory disease processes. Moreover, an integral step in HIV infection involves binding to chemokine receptors, and hence chemokines are intimately linked to HIV-related diseases. Therefore, chemokines and their receptors are excellent targets for developing drugs that are more specific and may be of benefit in the management of disease. Knowledge of the chemokine and chemokine receptor structures, and an understanding of the structural basis of their function are essential for structure-aided design of receptor decoys. Chemokine ligands bind their receptors with nanomolar (nM) affinity, and successful design of a small molecule antagonist should bind the receptor with similar high affinity and specificity. Chemokines bind receptors that belong to the 7-transmembrane class on leukocytes, and highly negatively charged proteoglycans that are present on the cell surface. Structure-function studies have identified regions in both the ligand and the receptor that mediate binding and activation. Structures of numerous chemokines have been solved though very little is known regarding receptor structures. This review will summarize the current knowledge on the structures, structure-function, and the efficacy of chemokine derivatives and functional domain peptides as antagonists, and discuss strategies for exploiting this information for designing decoys for inflammatory, autoimmune, and HIV-related diseases.
C1 Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.
   Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA.
RP Rajarathnam, K (reprint author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 5-138 Med Res Bldg, Galveston, TX 77555 USA.
CR Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675                                                
   BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502
   Blaszczyk J, 2000, BIOCHEMISTRY-US, V39, P14075, DOI 10.1021/bi0009340
   Burns JM, 1999, P NATL ACAD SCI USA, V96, P14499, DOI 10.1073/pnas.96.25.14499
   Cascieri MA, 2000, CURR OPIN CHEM BIOL, V4, P420, DOI 10.1016/S1367-5931(00)00113-7
   Chang TLY, 2002, J VIROL, V76, P2245, DOI 10.1128/JVI.76.5.2245-2254.2002
   CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005
   CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128
   CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075
   CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574
   CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703
   Clemons MJ, 1998, BLOOD, V92, P1532
   CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004
   Crump MP, 1999, PROTEIN SCI, V8, P2041, DOI 10.1110/ps.8.10.2041                                                            
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471
   Crump MP, 2001, FEBS LETT, V489, P171, DOI 10.1016/S0014-5793(00)02393-0                                                   
   Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077
   Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941
   Elisseeva EL, 2000, J BIOL CHEM, V275, P26799
   FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577
   Fernandez EJ, 2000, BIOCHEMISTRY-US, V39, P12837, DOI 10.1021/bi001166f
   GAYLE RB, 1993, J BIOL CHEM, V268, P7283
   GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631                                                           
   Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270
   HANZAWA H, 1994, FEBS LETT, V354, P207, DOI 10.1016/0014-5793(94)01081-1
   Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s
   Hoover DM, 2000, J BIOL CHEM, V275, P23187, DOI 10.1074/jbc.M002584200
   Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239
   Keizer DW, 2000, BIOCHEMISTRY-US, V39, P6053, DOI 10.1021/bi000089l                                                               
   KIM KS, 1994, J BIOL CHEM, V269, P32909
   Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1
   Kuloglu ES, 2001, BIOCHEMISTRY-US, V40, P12486, DOI 10.1021/bi011106p
   Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196
   Liwang AC, 1999, PROTEIN SCI, V8, P2270
   Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425                                                    
   LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838                                                         
   Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279
   Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64
   Luo ZW, 2000, BIOCHEMISTRY-US, V39, P13545, DOI 10.1021/bi000633q
   Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9                                                   
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706                                                     
   MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077                                                         
   Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j
   MAYO KH, 1995, BIOCHEMISTRY-US, V34, P11399, DOI 10.1021/bi00036a012
   Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497
   Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614
   Monteclaro FS, 1997, J BIOL CHEM, V272, P23186, DOI 10.1074/jbc.272.37.23186
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Nardese V, 2001, NAT STRUCT BIOL, V8, P611, DOI 10.1038/89653
   Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z
   Perez-Canadillas JM, 2001, J BIOL CHEM, V276, P28372, DOI 10.1074/jbc.M103121200
   PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8
   Power Christine A., 2001, Current Opinion in Pharmacology, V1, P417, DOI 10.1016/S1471-4892(01)00072-8
   Qian YQ, 1999, J MOL BIOL, V294, P1065, DOI 10.1006/jmbi.1999.3333
   Rajarathnam K, 1997, J BIOL CHEM, V272, P1725, DOI 10.1074/jbc.272.3.1725                                                          
   Rajarathnam K, 1997, METHOD ENZYMOL, V287, P89
   RAJARATHNAM K, 1995, BIOCHEMISTRY-US, V34, P12983, DOI 10.1021/bi00040a008
   RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420                                                         
   Rajarathnam K, 1999, BIOCHEMISTRY-US, V38, P7653, DOI 10.1021/bi990033v
   RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P6623, DOI 10.1021/bi00187a032
   Rajarathnam K, 1999, Dev Biol Stand, V97, P49
   Rajarathnam K, 2001, J BIOL CHEM, V276, P4909, DOI 10.1074/jbc.M005085200                                                          
   Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628
   Rollins BJ, 1997, BLOOD, V90, P909
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Saunders J, 1999, DRUG DISCOV TODAY, V4, P80, DOI 10.1016/S1359-6446(98)01280-X                                                   
   Schwarz MK, 1999, CURR OPIN CHEM BIOL, V3, P407, DOI 10.1016/S1367-5931(99)80061-1
   Shao WP, 1998, BIOCHEMISTRY-US, V37, P8303, DOI 10.1021/bi980112r
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   Skelton NJ, 1999, STRUCT FOLD DES, V7, P157, DOI 10.1016/S0969-2126(99)80022-7                                                   
   SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004
   Sticht H, 1999, BIOCHEMISTRY-US, V38, P5995, DOI 10.1021/bi990065i
   Trkola A, 1999, J VIROL, V73, P6370
   Vila-Coro AJ, 1999, FASEB J, V13, P1699
   Wilken J, 1999, CHEM BIOL, V6, P43, DOI 10.1016/S1074-5521(99)80019-2
   Ye JP, 2000, J BIOL CHEM, V275, P27250
   Ye JQ, 2001, BIOCHEMISTRY-US, V40, P7820, DOI 10.1021/bi010252s
   Zagorski J, 1997, J IMMUNOL, V159, P1059
   ZHANG XH, 1994, BIOCHEMISTRY-US, V33, P8361, DOI 10.1021/bi00193a025
   Zhou NM, 2000, BIOCHEMISTRY-US, V39, P3782, DOI 10.1021/bi992750v
NR 81
TC 21
Z9 22
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI HILVERSUM
PA PO BOX 1673, 1200 BR HILVERSUM, NETHERLANDS
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2002
VL 8
IS 24
BP 2159
EP 2169
DI 10.2174/1381612023393233
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 602GV
UT WOS:000178498300004
PM 12369860
DA 2018-01-05
ER

PT J
AU Silhol, M
   Tyagi, M
   Giacca, M
   Lebleu, B
   Vives, E
AF Silhol, M
   Tyagi, M
   Giacca, M
   Lebleu, B
   Vives, E
TI Different mechanisms for cellular internalization of the HIV-1
   Tat-derived cell penetrating peptide and recombinant proteins fused to
   Tat
SO EUROPEAN JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE Tat; cell penetrating peptide (CPP); cellular uptake; heparan sulfate
ID IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VIVO; ANTENNAPEDIA HOMEODOMAIN;
   PLASMA-MEMBRANE; 3RD HELIX; DELIVERY; INHIBITION; VITRO
AB Translocation through the plasma membrane is a major limiting step for the cellular delivery of macromolecules. A promising strategy to overcome this problem consists in the chemical conjugation (or fusion) to cell penetrating peptides (CPP) derived from proteins able to cross the plasma membrane. A large number of different cargo molecules such as oligonucleotides, peptides, peptide nucleic acids, proteins or even nanoparticles have been internalized in cells by this strategy. One of these translocating peptides was derived from the HIV-1 Tat protein. The mechanisms by which CPP enter cells remain unknown. Recently, convincing biochemical and genetic findings has established that the full-length Tat protein was internalized in cells via the ubiquitous heparan sulfate (HS) proteoglycans. We demonstrate here that the short Tat CPP is taken up by a route that does not involve the HS proteoglycans.
C1 Inst Genet Mol Montpellier, CNRS, UMR 5124, F-34033 Montpellier 1, France.
   Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy.
RP Vives, E (reprint author), Inst Genet Mol Montpellier, CNRS, UMR 5124, BP 5051,1919 Route Mende, F-34033 Montpellier 1, France.
RI Giacca, Mauro/J-9287-2016
OI Giacca, Mauro/0000-0003-2927-7225
CR ABUAMER Y, 2001, J BIOL CHEM, V14, P14
   ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919
   ANDERSON DC, 1993, BIOCHEM BIOPH RES CO, V194, P876, DOI 10.1006/bbrc.1993.1903
   Astriab-Fisher A, 2000, BIOCHEM PHARMACOL, V60, P83, DOI 10.1016/S0006-2952(00)00310-5
   BAYER P, 1995, J MOL BIOL, V247, P529, DOI 10.1016/S0022-2836(05)80133-0
   BERKHOUT B, 1989, J VIROL, V63, P5501
   Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77                                                        
   BRUGIDOU J, 1995, BIOCHEM BIOPH RES CO, V214, P685, DOI 10.1006/bbrc.1995.2340                                                          
   Caron NJ, 2001, MOL THER, V3, P310, DOI 10.1006/mthe.2001.0279
   CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985
   Demarchi F, 1999, J VIROL, V73, P7080
   DEROSSI D, 1994, J BIOL CHEM, V269, P10444
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dostmann WRG, 2000, P NATL ACAD SCI USA, V97, P14772, DOI 10.1073/pnas.97.26.14772
   DRIN G, 2001, AUR J BIOCH, V268, P1304
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Futaki S, 2001, J BIOL CHEM, V276, P5836, DOI 10.1074/jbc.M007540200                                                          
   Hughes J, 2000, METHOD ENZYMOL, V313, P342
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Li H, 2001, P NATL ACAD SCI USA, V98, P1267, DOI 10.1073/pnas.031461598
   Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Stein S, 1999, FEBS LETT, V458, P383, DOI 10.1016/S0014-5793(99)01186-2
   Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498
   Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200                                                          
   Vives E, 1997, LETT PEPT SCI, V4, P429, DOI 10.1023/A:1008850300184
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349
NR 29
TC 201
Z9 214
U1 1
U2 24
PU BLACKWELL PUBLISHING LTD
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND
SN 0014-2956
J9 EUR J BIOCHEM
JI Eur. J. Biochem.
PD JAN
PY 2002
VL 269
IS 2
BP 494
EP 501
DI 10.1046/j.0014-2956.2001.02671.x                                        
          
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 518DQ
UT WOS:000173651700010
PM 11856307
OA gold
DA 2018-01-05
ER

PT J
AU Rivas, L
   Sanchez-Cortes, S
   Garcia-Ramos, JV
AF Rivas, L
   Sanchez-Cortes, S
   Garcia-Ramos, JV
TI Raman structural study of thymine and its 2 '-deoxy-ribosyl derivatives
   in solid state, aqueous solution and when adsorbed on silver
   nanoparticles
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID MECHANICAL FORCE-FIELDS; NUCLEIC-ACID BASES; VIBRATIONAL-SPECTRA;
   SCATTERING SERS; SURFACE; SPECTROSCOPY; AZIDOTHYMIDINE; COLLOIDS
AB The structures of thymine, 2'-deoxythymidine (dT), 5'-thymidinemonophosphate (TMP) and the anti-HIV drug 3'-azido-3'-deoxythymidine (AZT) are studied in this work in solid state, aqueous solution and when these molecules are adsorbed on Ag colloids by means of Raman and surface-enhanced Raman spectroscopy (SERS). The presence of a ribosyl group in the thymine N(1) position induces a change in the electrodynamical properties of the corresponding nucleosides and nucleotides of this base resulting in a different adsorption on the metal. In addition, the presence of substituents such as phosphate in TMP and azido group in AZT influences significantly the conformation of these molecules in solid state, in aqueous solution and adsorbed on the metal surface, as well as the orientation that they adopt on the metal. The molecular conformation of these thymine derivatives has an important significance because of the relationship existing between structure and biological activity.
C1 CSIC, Inst Estructura Mat, E-28006 Madrid, Spain.
RP Sanchez-Cortes, S (reprint author), CSIC, Inst Estructura Mat, Serrano 121, E-28006 Madrid, Spain.
RI Garcia-Ramos, Jose /D-3153-2013; Sanchez-Cortes, Santiago/D-4673-2014
OI Garcia-Ramos, Jose /0000-0003-4179-5105; Sanchez-Cortes,
   Santiago/0000-0002-1081-4644
CR Aamouche A, 1997, J PHYS CHEM A, V101, P1808, DOI 10.1021/jp962318c                                                               
   Aroca R, 1999, VIB SPECTROSC, V19, P11, DOI 10.1016/S0924-2031(99)00003-X
   BEGLEY TP, 1994, ACCOUNTS CHEM RES, V27, P394, DOI 10.1021/ar00048a002                                                             
   CAMERMAN A, 1987, P NATL ACAD SCI USA, V84, P8239, DOI 10.1073/pnas.84.23.8239
   Creighton J. A., 1988, SPECTROSCOPY SURFACE
   DIJKSTRA S, 1991, J MOL STRUCT, V242, P283, DOI 10.1016/0022-2860(91)87142-5
   ERVIN KM, 1980, J ELECTROANAL CHEM, V114, P179, DOI 10.1016/S0022-0728(80)80446-3
   FLORIAN J, 1993, SPECTROCHIM ACTA A, V49, P921, DOI 10.1016/0584-8539(93)80211-R
   IZATT RM, 1971, CHEM REV, V71, P439, DOI 10.1021/cr60273a002
   KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019
   KOGLIN E, 1984, J MOL STRUCT, V114, P219, DOI 10.1016/0022-2860(84)87131-8
   LEE PC, 1982, J PHYS CHEM-US, V86, P3991
   LORD RC, 1967, SPECTROCHIM ACTA A-M, VA 23, P2551, DOI 10.1016/0584-8539(67)80149-1
   MOSKOVITS M, 1984, J PHYS CHEM-US, V88, P1293, DOI 10.1021/j150651a010                                                             
   NISHIMURA Y, 1986, SPECTROSCOPY BIOL SY, V13, P177
   OH WS, 1987, J RAMAN SPECTROSC, V18, P253, DOI 10.1002/jrs.1250180405
   OH WS, 1988, J RAMAN SPECTROSC, V19, P261, DOI 10.1002/jrs.1250190408
   OTTO C, 1986, J RAMAN SPECTROSC, V17, P289, DOI 10.1002/jrs.1250170311                                                          
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   Rivas L, 2002, J RAMAN SPECTROSC, V33, P6, DOI 10.1002/jrs.802                                                                 
   ROEY PV, 1989, P NATL ACAD SCI USA, V86, P3929
   SANCHEZCORTES S, 1990, J RAMAN SPECTROSC, V21, P679, DOI 10.1002/jrs.1250211008                                                          
   SANCHEZCORTES S, 1992, J RAMAN SPECTROSC, V23, P61, DOI 10.1002/jrs.1250230108
   SUH JS, 1986, J AM CHEM SOC, V108, P4711, DOI 10.1021/ja00276a005
   SUSI H, 1974, SPECTROCHIM ACTA A, VA 30, P1843, DOI 10.1016/0584-8539(74)80135-2                                                    
   THOMAS GJ, 1985, BIOPOLYMERS, V24, P1101, DOI 10.1002/bip.360240613
   THOMAS GJ, 1986, ADV SPECTROSC, V13, P233
   WIERZCHO.KL, 1965, J AM CHEM SOC, V87, P4621, DOI 10.1021/ja00948a039
   Zhang SL, 1998, J PHYS CHEM A, V102, P461, DOI 10.1021/jp972385m
NR 29
TC 23
Z9 23
U1 0
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD,, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2002
VL 4
IS 10
BP 1943
EP 1948
DI 10.1039/b110564g
PG 6
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 547HC
UT WOS:000175326100038
DA 2018-01-05
ER

PT J
AU Kalra, P
   Redd, TV
   Jayaram, B
AF Kalra, P
   Redd, TV
   Jayaram, B
TI Free energy component analysis for drug design: A case study of HIV-1
   protease-inhibitor binding
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MOLECULAR-DYNAMICS SIMULATIONS;
   DIHYDROFOLATE-REDUCTASE; ATOMIC CHARGES; FORCE-FIELD; SOLVATION;
   RESOLUTION; MODEL; DNA; COMPLEX
AB A theoretically rigorous and computationally tractable methodology for the prediction of the flee energies of binding of protein-ligand complexes is presented. The method formulated involves developing molecular dynamics trajectories of the enzyme, the inhibitor, and the complex, followed by a free energy component analysis that conveys information on the physicochemical forces driving the protein-ligand complex formation and enables an elucidation of drug design principles for a given receptor from a thermodynamic perspective. The complexes of HIV-1 protease with two peptidomimetic inhibitors were taken as illustrative cases. Four-nanosecond-level all-atom molecular dynamics simulations using explicit solvent without any restraints were carried out on the protease-inhibitor complexes and the free proteases, and the trajectories were analyzed via a thermodynamic cycle to calculate the binding free energies. The computed flee energies were seen to be in good accord with the reported data. It was noted that the net van der Waals and hydrophobic contributions were favorable to binding while the net electrostatics, entropies, and adaptation expense were unfavorable in these protease-inhibitor complexes. The hydrogen bond between the CH2OH group of the inhibitor at the scissile position and the catalytic aspartate was found to be favorable to binding. Various implicit solvent models were also considered and their shortcomings discussed. In addition, some plausible modifications to the inhibitor residues were attempted, which led to better binding affinities. The generality of the method and the transferability of the protocol with essentially no changes to any other protein-ligand system are emphasized.
C1 Indian Inst Technol, Dept Chem, New Delhi 110016, India.
   Indian Inst Technol, Dept Biochem Engn & Biotechnol, New Delhi 110016, India.
RP Jayaram, B (reprint author), Indian Inst Technol, Dept Chem, Hauz Khas, New Delhi 110016, India.
OI Jayaram, B/0000-0002-5495-2213
CR Ajay M.A., 1995, J MED CHEM, V38, P4953
   Altomare C, 1998, J MED CHEM, V41, P3812, DOI 10.1021/jm981005y
   AQVIST J, 1994, PROTEIN ENG, V7, P385, DOI 10.1093/protein/7.3.385
   ATKINS PW, 1990, PHYSICAL CHEM
   Bartlett JG, 1998, SCI AM, V279, P84, DOI 10.1038/scientificamerican0798-84                                               
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   Ben-Naim A., 1992, STAT THERMODYNAMICS
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243
   CIEPLAK P, 1993, J COMPUT AID MOL DES, P7291
   Clare BW, 1998, J MED CHEM, V41, P3845, DOI 10.1021/jm980144c                                                               
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   Dill KA, 1997, J BIOL CHEM, V272, P701, DOI 10.1074/jbc.272.2.701                                                           
   Dominy BN, 1999, PROTEINS, V36, P318, DOI 10.1002/(SICI)1097-0134(19990815)36:3<318::AID-PROT6>3.0.CO;2-K                 
   Erickson J.W., 1999, PROTEASES INFECT AGE, P1
   FERGUSON DM, 1991, J MED CHEM, V34, P2654, DOI 10.1021/jm00112a048                                                             
   Gilson MK, 1997, BIOPHYS J, V72, P1047, DOI 10.1016/S0006-3495(97)78756-3                                                   
   Hansson T, 1995, PROTEIN ENG, V8, P1137, DOI 10.1093/protein/8.11.1137
   Hawkins GD, 1996, J PHYS CHEM-US, V100, P19824, DOI 10.1021/jp961710n                                                               
   HAWKINS GD, 1995, CHEM PHYS LETT, V246, P246
   Hirst JD, 1996, J MED CHEM, V39, P3526, DOI 10.1021/jm960197z
   HOLLOWAY MK, 1995, J MED CHEM, V38, P305, DOI 10.1021/jm00002a012
   JANIN J, 1995, PROTEINS, V21, P30, DOI 10.1002/prot.340210105
   Janin J, 1995, PROG BIOPHYS MOL BIO, V64, P145, DOI 10.1016/S0079-6107(96)00001-6
   JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023
   Jayaram B, 1998, J AM CHEM SOC, V120, P10629, DOI 10.1021/ja981307p                                                               
   Jayaram B, 1999, J COMPUT PHYS, V151, P333, DOI 10.1006/jcph.1998.6173
   Jayaram B, 1996, ANNU REV BIOPH BIOM, V25, P367, DOI 10.1146/annurev.bb.25.060196.002055                                             
   Jayaram B, 1998, J CHEM PHYS, V109, P1465, DOI 10.1063/1.476697
   Jayaram B, 1998, J PHYS CHEM B, V102, P9571, DOI 10.1021/jp982007x                                                               
   Kalra P, 2000, INDIAN J CHEM A, V39, P262
   KALRA P, IN PRESS APPL BIOCH
   Kamath S, 1999, J BIOMOL STRUCT DYN, V16, P1239, DOI 10.1080/07391102.1999.10508331                                                  
   KOLLMAN P, 1993, CHEM REV, V93, P2395, DOI 10.1021/cr00023a004                                                             
   KOMBO DC, IN PRESS MOL SIMUL
   Kubinyi H, 1997, DRUG DISCOV TODAY, V2, P538, DOI 10.1016/S1359-6446(97)01084-2                                                   
   LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0                                                                
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   Lee CY, 1998, PROTEIN ENG, V11, P429, DOI 10.1093/protein/11.6.429                                                        
   MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031                                                       
   Massova I, 1999, J AM CHEM SOC, V121, P8133, DOI 10.1021/ja990935j                                                               
   MCKEEVER BM, 1989, J BIOL CHEM, V264, P1919
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0
   MISRA VK, 1995, P NATL ACAD SCI USA, V92, P4691, DOI 10.1073/pnas.92.10.4691
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   Ota N, 1999, PROTEINS, V37, P641, DOI 10.1002/(SICI)1097-0134(19991201)37:4<641::AID-PROT14>3.0.CO;2-W
   OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   Rao BG, 1996, PROTEIN ENG, V9, P767, DOI 10.1093/protein/9.9.767
   RAO BG, 1999, ACS S SERIES, V719
   REDDY MR, 1991, P NATL ACAD SCI USA, V88, P10287, DOI 10.1073/pnas.88.22.10287
   Reddy MR, 1998, J COMPUT CHEM, V19, P769, DOI 10.1002/(SICI)1096-987X(199805)19:7<769::AID-JCC7>3.0.CO;2-O                    
   SCHMIDT MW, 1993, J COMPUT CHEM, V14, P1347, DOI 10.1002/jcc.540141112
   Selassie CD, 1998, J MED CHEM, V41, P4261, DOI 10.1021/jm970776j                                                               
   Silva AM, 1996, J MOL BIOL, V255, P321, DOI 10.1006/jmbi.1996.0026
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038                                                             
   STRAATSMA TP, 1992, ANNU REV PHYS CHEM, V43, P407
   Van Gunsteren W. F, 1989, COMPUTER SIMULATION, P27
   VERKHIVKER G, 1995, PROTEIN ENG, V8, P677, DOI 10.1093/protein/8.7.677                                                         
   Wang JM, 2001, J AM CHEM SOC, V123, P5221, DOI 10.1021/ja003834q
   Wang W, 1999, PROTEINS, V34, P395, DOI 10.1002/(SICI)1097-0134(19990215)34:3<395::AID-PROT11>3.0.CO;2-4
   WARDE RC, 1992, J MOL BIOL, V225, P697
   WEBER IT, 1989, SCIENCE, V243, P928, DOI 10.1126/science.2537531                                                         
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
NR 65
TC 34
Z9 34
U1 1
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD DEC 6
PY 2001
VL 44
IS 25
BP 4325
EP 4338
DI 10.1021/jm010175z
PG 14
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 498DK
UT WOS:000172494400003
PM 11728180
DA 2018-01-05
ER

PT J
AU Chen, CA
   Sieburth, SM
   Glekas, A
   Hewitt, GW
   Trainor, GL
   Erickson-Viitanen, S
   Garber, SS
   Cordova, B
   Jeffry, S
   Klabe, RM
AF Chen, CA
   Sieburth, SM
   Glekas, A
   Hewitt, GW
   Trainor, GL
   Erickson-Viitanen, S
   Garber, SS
   Cordova, B
   Jeffry, S
   Klabe, RM
TI Drug design with a new transition state analog of the hydrated carbonyl:
   silicon-based inhibitors of the HIV protease
SO CHEMISTRY & BIOLOGY
LA English
DT Article
DE drug design; HIV; organosilane; protease inhibitor; silanediol
ID IMMUNODEFICIENCY-VIRUS PROTEASE; RAY CRYSTAL-STRUCTURE; CYCLIC UREA;
   OXIDATION; SYMMETRY; POTENCY; BINDING; ANTHRAX; ENZYME
AB Background: Silicon is the element most similar to carbon, and bioactive organosilanes have therefore been of longstanding interest. Design of bioactive organosilanes has often involved a systematic replacement of a bioactive molecule's stable carbon atoms with silicon. Silanediols, which are best known as unstable precursors of the robust and ubiquitous silicone polymers, have the potential to mimic an unstable carbon, the hydrated carbonyl. As a bioisostere of the tetrahedral intermediate of amide hydrolysis, a silanediol could act as a transition state analog inhibitor of protease enzymes.
   Results: Silanediol analogs of a carbinol-based inhibitor of the HIV protease were prepared as single enantiomers, with up to six stereogenic centers. As inhibitors of this aspartic protease, the silanediols were nearly equivalent to both their carbinol analogs and indinavir, a current treatment for AIDS, with low nanomolar K(i) values. IC(90) data from a cell culture assay mirrored the K(i) data, demonstrating that the silanediols can also cross cell membranes and deliver their antiviral effects.
   Conclusions: In their first evaluation as inhibitors of an aspartic protease, silanediol peptidomimetics have been found to be nearly as potent as currently available pharmaceutical agents, in enzyme and cell protection assays. These neutral, cell-permeable transition state analogs therefore provide a novel foundation for the design of therapeutic agents. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA.
   Bristol Myers Squibb Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA.
RP Sieburth, SM (reprint author), Temple Univ, Dept Chem, Beury Hall, Philadelphia, PA 19122 USA.
EM sieburth@astro.temple.edu
FU NHLBI NIH HHS [HL62390]
CR ABIKO A, 1986, TETRAHEDRON LETT, V27, P4537, DOI 10.1016/S0040-4039(00)84997-7                                                   
   BAILEY WF, 1990, J ORG CHEM, V55, P5404, DOI 10.1021/jo00306a021                                                             
   Bodanszky M, 1988, PEPTIDE CHEM PRACTIC
   BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061
   CORRIU RJP, 1979, J CHEM SOC CHEM COMM, P8, DOI 10.1039/c39790000008
   Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7
   Curley K, 1997, J AM CHEM SOC, V119, P1529, DOI 10.1021/ja9634942                                                               
   Cypryk M, 1997, J ORGANOMET CHEM, V545, P483, DOI 10.1016/S0022-328X(97)00374-4                                                   
   Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107                                                     
   Doring G, 1999, PEDIATR PULM, V28, P363, DOI 10.1002/(SICI)1099-0496(199911)28:5<363::AID-PPUL9>3.0.CO;2-#
   Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734
   Erickson J.W., 1999, PROTEASES INFECT AGE, P1
   ERICKSONVIITANEN S, 1994, ANTIMICROB AGENTS CH, V38, P1628, DOI 10.1128/AAC.38.7.1628                                                           
   GALARDY RE, 1985, BIOCHEM J, V226, P447, DOI 10.1042/bj2260447                                                               
   Hodge CN, 1996, CHEM BIOL, V3, P301, DOI 10.1016/S1074-5521(96)90110-6
   HOLLADAY MW, 1987, J MED CHEM, V30, P374, DOI 10.1021/jm00385a020
   KEMPF DJ, 1994, METHOD ENZYMOL, V241, P334
   Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m
   Lickiss P. D., 1995, ADV INORG CHEM, V42, P147, DOI DOI 10.1016/S0898-8838(08)60053-7
   NEGISHI E, 1990, J ORG CHEM, V55, P5406, DOI 10.1021/jo00306a022                                                             
   Olson RE, 1996, ANNU REP MED CHEM, V31, P327, DOI 10.1016/S0065-7743(08)60472-8
   OMURA K, 1978, TETRAHEDRON, V34, P1651, DOI 10.1016/0040-4020(78)80197-5                                                    
   Plosker GL, 1999, DRUGS, V58, P1165, DOI 10.2165/00003495-199958060-00011
   Ripka AS, 1998, CURR OPIN CHEM BIOL, V2, P441, DOI 10.1016/S1367-5931(98)80119-1
   Rosch L, 1993, ULLMANNS ENCY IND CH, P21
   Sieburth SM, 1998, ANGEW CHEM INT EDIT, V37, P812, DOI 10.1002/(SICI)1521-3773(19980403)37:6<812::AID-ANIE812>3.0.CO;2-I               
   Stark F.O., 1982, COMPREHENSIVE ORGANO, P305
   STARR JM, 1994, ACE INHIBITORS
   TAKUMA S, 1982, CHEM PHARM BULL, V30, P3147
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312                                                   
   VACCA JP, 1994, METHOD ENZYMOL, V241, P311
   Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735                                                    
   Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4                                                   
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
NR 34
TC 59
Z9 61
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD DEC
PY 2001
VL 8
IS 12
BP 1161
EP 1166
DI 10.1016/S1074-5521(01)00079-5                                           
          
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 519XH
UT WOS:000173750400005
PM 11755395
OA gold
DA 2018-01-05
ER

PT J
AU Kumar, A
   Shankar, S
   Kothekar, V
AF Kumar, A
   Shankar, S
   Kothekar, V
TI Computer aided study of ligand binding with catalytic domain of avian
   sarcoma virus integrase and its ligand binding loops.
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
ID HIV-1 INTEGRASE; ACTIVE-SITE; DIVALENT-CATIONS; IN-VITRO; RESIDUES;
   MULTIMERIZATION; IDENTIFICATION; SIMILARITY; INHIBITOR; LYSOZYME
AB We have carried out 1 nanosecond (ns) Molecular Dynamics (MD) simulations of the drug Y3 (4-acetylamino-5-hydroxynaphthalene-2, 7-disulfonic acid) complexed with catalytic domain of Avian sarcoma virus Integrase (ASV-IN), both in vacuum and in the presence of explicit solvent. Starting models were obtained on the basis of PDB co-ordinates (1A5X) of ASV-IN-Y3 complex, by Lubkowski et at [1]. Mn2+ cation was present in the active site. To neutralize the positive charge in the presence of explicit solvent, eight Cl- anions were added. Energy Minimization (EM) and MD simulations, for both the systems, were carried out using Sander's module of AMBER5.0 [2] with all atom force field. Analysis of ligand-protein interaction in both environments is discussed in the paper. We also carried out I ns MD simulation on two flexible loops - L1 (Gly54-Gln62) and L2 (Trp138-Met155) playing crucial role in interaction of IN with the drug [3], under differing environmental conditions (vacuum, aqueous and organic solvent methanol). Comparison of the conformational changes in the loops, monomer and dimer is presented in the paper. Our result's showed that the conformation of the loop region was closest to crystallographic data in case of monomer and constrained loops in aqueous environment. However, the dimer in vacuum was more stable than monomer. The beta sheet structure of the monomer in aqueous environment was unstable. Latter also took long time for equilibration. The box formed by loops L1 and L2 from two sub units IINA and INB) of the dimer satisfies prerequisites for ligand recognition site and seems to be the functional biological unit.
C1 All India Inst Med Sci, Dept Biotechnol, New Delhi 110029, India.
   All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
RP Kothekar, V (reprint author), All India Inst Med Sci, Dept Biophys, New Delhi 110029, India.
CR Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633                                                        
   BROWN PO, 1997, INTEGRATION RETROVIR, VJ, P161
   Bujacz G, 1996, FEBS LETT, V398, P175, DOI 10.1016/S0014-5793(96)01236-7
   Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161
   BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556
   Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3
   CASE DA, 1997, AMBER 5 0 ASSISTED M
   Chacko S, 1996, PROTEINS, V26, P55, DOI 10.1002/(SICI)1097-0134(199609)26:1<55::AID-PROT5>3.0.CO;2-F                    
   DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124
   ENGELMAN A, 1992, J VIROL, V66, P6361
   GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X
   Gilquin B, 2000, PROTEINS, V41, P58, DOI 10.1002/1097-0134(20001001)41:1<58::AID-PROT90>3.0.CO;2-3
   Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150                                                         
   Ibragimova GT, 1998, BIOPHYS J, V74, P2906, DOI 10.1016/S0006-3495(98)77997-4                                                   
   JACKS T, 1988, NATURE, V331, P280, DOI 10.1038/331280a0
   Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712                                                         
   KOLLMAN P, 1997, COMP SIM BIOMOL SYST, V3, P83
   KORADI R, 1997, MOLMOL MOL ANAL DISP
   Kothekar V, 2001, J MOL STRUC-THEOCHEM, V540, P35, DOI 10.1016/S0166-1280(00)00706-5                                                   
   KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331                                                           
   Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p
   Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o
   Lubkowski J, 1998, P NATL ACAD SCI USA, V95, P4831, DOI 10.1073/pnas.95.9.4831
   LUTZKE RA, 1998, J VIROL, V72, P841
   Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002
   POPLE JA, 1978, APPROXIMATE MOL ORBI
   SAYLE R, 1994, MOL VISUALISATION PR
   Sotriffer CA, 2000, J AM CHEM SOC, V122, P6136, DOI 10.1021/ja001152x
   Swanstrom R, 1997, SYNTHESIS ASSEMBLY P, P263
   Thomas M, 1997, TRENDS BIOTECHNOL, V15, P167, DOI 10.1016/S0167-7799(97)01016-0
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   VANGENT DC, 1993, NUCLEIC ACIDS RES, V21, P3373, DOI 10.1093/nar/21.15.3373
   Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659                                                        
NR 33
TC 1
Z9 1
U1 0
U2 1
PU ADENINE PRESS INC
PI GUILDERLAND
PA PO BOX 355/340, GUILDERLAND, NY 12084 USA
SN 0739-1102
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD DEC
PY 2001
VL 19
IS 3
BP 449
EP 458
DI 10.1080/07391102.2001.10506753                                          
          
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 513ZT
UT WOS:000173411900010
PM 11790143
DA 2018-01-05
ER

PT J
AU Mendez, S
   Fernandez-Perez, FJ
   Santin, N
   De la Fuente, C
   Cuquerella, M
   Gomez-Munoz, MT
   Alunda, JM
AF Mendez, S
   Fernandez-Perez, FJ
   Santin, N
   De la Fuente, C
   Cuquerella, M
   Gomez-Munoz, MT
   Alunda, JM
TI Correlation between in vitro and in vivo infectivity of Leishmania
   infantum clones
SO JOURNAL OF EUKARYOTIC MICROBIOLOGY
LA English
DT Article
DE canine leishmaniasis; clones; growth; hamsters; macrophages; protozoa;
   resistance; virulence; visceral leishmaniasis
ID HUMAN-IMMUNODEFICIENCY-VIRUS; IN-VITRO; PROMASTIGOTES; MACROPHAGES;
   DONOVANI; VIRULENT; SENSITIVITY; TROPISM; STRAINS; SPAIN
AB Eleven clones of a single strain of Leishmania infantum (NCAN/ES/88/ISS441, Doba) were analyzed for biological behavior in vivo and in vitro, Different clones showed differences in growth dependent upon the two culture media employed. All clones displayed only slight differences in H2O2 and NaNO2 sensitivity compared to the original strain, whereas in vitro infectivity For mouse peritoneal macrophages differed significantly among the clones. In vivo infections in hamsters correlated strongly with in vitro infectivity. The phenotypic differences found suggest a polyclonal structure fur the Leishmania infantum strain studied.
C1 Univ Complutense Madrid, Fac Vet, Dept Patol Anim Sanidad Anim 1, Madrid 28040, Spain.
   NIAID, NIH, Bethesda, MD 20892 USA.
RP Alunda, JM (reprint author), Univ Complutense Madrid, Fac Vet, Dept Patol Anim Sanidad Anim 1, Madrid 28040, Spain.
RI Gomez_Munoz, Maria Teresa/S-3800-2016
OI Gomez_Munoz, Maria Teresa/0000-0001-8104-845X
CR ABRANCHES P, 1991, J PARASITOL, V77, P557, DOI 10.2307/3283159                                                                 
   Alvar J, 1997, CLIN MICROBIOL REV, V10, P298
   ANGELICI MC, 1989, PARASITOLOGY, V99, P301, DOI 10.1017/S0031182000058996                                                       
   BADARO R, 1986, LANCET, V1, P647
   BUCHMULLERROUILLER Y, 1987, INFECT IMMUN, V55, P587
   Callahan HL, 1996, EXP PARASITOL, V84, P400, DOI 10.1006/expr.1996.0128
   CAPPAI R, 1994, PARASITOLOGY, V108, P397, DOI 10.1017/S0031182000075946                                                       
   CARRERA L, 1993, MED SCI RES, V21, P251
   CARRERA L, 1994, PARASITOL RES, V80, P203, DOI 10.1007/BF00932675
   Chakrabarty R, 1996, J PARASITOL, V82, P632, DOI 10.2307/3283790
   CHANNON JY, 1985, PARASITOLOGY, V91, P197, DOI 10.1017/S0031182000057309                                                       
   GOMES GS, 1996, FOLIA PARASIT, V43, P7
   GRADONI L, 1994, PARASITOL TODAY, V10, P264, DOI 10.1016/0169-4758(94)90142-2
   GRIMALDI G, 1982, INT J PARASITOL, V12, P185, DOI 10.1016/0020-7519(82)90015-7
   GRIMM F, 1991, PARASITOL RES, V77, P185, DOI 10.1007/BF00930856
   HANDMAN E, 1983, MOL BIOCHEM PARASIT, V7, P111, DOI 10.1016/0166-6851(83)90039-7
   HILL JO, 1983, J PARASITOL, V69, P1068, DOI 10.2307/3280865
   Hofman V, 2000, HUM PATHOL, V31, P75, DOI 10.1016/S0046-8177(00)80202-6
   KATAKURA K, 1986, Jikeikai Medical Journal, V33, P157
   Li J, 1997, EXP PARASITOL, V87, P47, DOI 10.1006/expr.1997.4183
   Lopez-Velez R, 1998, AM J TROP MED HYG, V58, P436, DOI 10.4269/ajtmh.1998.58.436                                                       
   MALLINSON DJ, 1989, INT J PARASITOL, V19, P647, DOI 10.1016/0020-7519(89)90043-X
   MAUEL J, 1991, J LEUKOCYTE BIOL, V49, P73
   Mendez S, 1999, PARASITOL RES, V85, P507, DOI 10.1007/s004360050587
   Mendez S, 1996, INT J PARASITOL, V26, P619, DOI 10.1016/0020-7519(96)00037-9
   Morillas F, 1996, PARASITOL RES, V82, P569, DOI 10.1007/s004360050164
   MURRAY PJ, 1990, EXP PARASITOL, V71, P294, DOI 10.1016/0014-4894(90)90034-A
   PACHECO RS, 1990, PARASITOLOGY, V100, P393, DOI 10.1017/S0031182000078677                                                       
   PAGES M, 1989, MOL BIOCHEM PARASIT, V36, P161, DOI 10.1016/0166-6851(89)90188-6
   PETERS W, 1986, LEISHMANIA, P7
   Rioux JA, 1986, LEISHMANIA TAXONOMIE, P439
   RUSSELL DG, 1990, IMMUNOL TODAY, V11, P74, DOI 10.1016/0167-5699(90)90029-9                                                    
   RUSSELL DG, 1989, IMMUNOL TODAY, V10, P328, DOI 10.1016/0167-5699(89)90188-6
   SYMONS FM, 1994, MOL BIOCHEM PARASIT, V67, P103, DOI 10.1016/0166-6851(94)90100-7
NR 34
TC 4
Z9 4
U1 0
U2 4
PU SOC PROTOZOOLOGISTS
PI LAWRENCE
PA 810 E 10TH ST, LAWRENCE, KS 66044 USA
SN 1066-5234
J9 J EUKARYOT MICROBIOL
JI J. Eukaryot. Microbiol.
PD NOV-DEC
PY 2001
VL 48
IS 6
BP 616
EP 621
DI 10.1111/j.1550-7408.2001.tb00200.x
PG 6
WC Microbiology
SC Microbiology
GA 516VB
UT WOS:000173576500002
PM 11831769
DA 2018-01-05
ER

PT J
AU Pereira, RD
AF Pereira, RD
TI Atomic force microscopy as a novel pharmacological tool
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Editorial Material
DE atomic force microscopy; biosensors; electrodes; penicillin; drugs; drug
   delivery; calcium blockers; nifedipine derivatives
ID OPTICAL BEAM DEFLECTION; TRANSCRIPTASE INHIBITORS NNRTIS; BONE
   ALKALINE-PHOSPHATASE; REACTION HEAT; REVERSE-TRANSCRIPTASE;
   SACCHAROMYCES-CEREVISIAE; CRYPTOCOCCUS-NEOFORMANS; SINGLE MOLECULES;
   AQUEOUS-SOLUTION; HIV-1 INFECTION
AB With the advent of the atomic force microscope (AFM), the study of biological samples has become more realistic becouse, in most cases, samples are not covered or fixed, which makes it possible to observe them while the cells are alive. This advantage of the AFM allowed the advent of a new invention: nanobiosensors using the cantilever (probe) of the AFM and, in this case, it is possible to observe the entering or exiting of specific molecules (including medications) from living cells. This is the smallest biosensor in the world, measuring about 100 mum long (about the width of a hair). Beyond sensing the area of interest with this biosensor, it is also possible to see the area and exactly what is occurring on it, in real time. This new tool will be very useful for several areas: molecular pharmacology, enzymology, physiology, molecular biology, biotechnology, biophysics, physical chemistry, analytical chemistry, and organic chemistry. This article discusses, mainly, the application of this new technique to the field pharmacology. (C) Elsevier Science Inc. All rights reserved
C1 Inst Biomed Sci, BR-13084480 Campinas, SP, Brazil.
RP Pereira, RD (reprint author), Inst Biomed Sci, Rua Jean Nassif Mokurzel 174, BR-13084480 Campinas, SP, Brazil.
CR BEEZER AE, 1986, INT J PHARM, V29, P237, DOI 10.1016/0378-5173(86)90121-3
   BEEZER AE, 1986, J CHEM SOC FARAD T 1, V82, P2863, DOI 10.1039/f19868202863                                                            
   BEEZER AE, 1986, J CHEM SOC FARAD T 1, V82, P2929, DOI 10.1039/f19868202929                                                            
   Ben-Arie A, 1999, EUR J OBSTET GYN R B, V86, P69, DOI 10.1016/S0301-2115(99)00054-8
   BERGERET G, 1997, HDB HETEROGENEOUS CA, V2, P460
   BESOMBES JL, 1995, ANAL CHIM ACTA, V311, P255, DOI 10.1016/0003-2670(94)00686-G
   BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930
   BRADY D, 1994, ENZYME MICROB TECH, V16, P633, DOI 10.1016/0141-0229(94)90131-7
   Cappella B, 1999, SURF SCI REP, V34, P1, DOI 10.1016/S0167-5729(99)00003-5
   Caruso CS, 1999, ANAL LETT, V32, P39, DOI 10.1080/00032719908542597
   De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   Forzani ES, 1997, J ELECTROANAL CHEM, V435, P77, DOI 10.1016/S0022-0728(97)00049-1                                                   
   Fritz J, 2000, SCIENCE, V288, P316, DOI 10.1126/science.288.5464.316                                                    
   Hasebe Y, 1995, TALANTA, V42, P2079, DOI 10.1016/0039-9140(95)01698-8                                                    
   Kasas S, 1997, INT J IMAG SYST TECH, V8, P151, DOI 10.1002/(SICI)1098-1098(1997)8:2<151::AID-IMA2>3.0.CO;2-9                       
   Lisdat F, 1998, ELECTROANAL, V10, P803, DOI 10.1002/(SICI)1521-4109(199809)10:12<803::AID-ELAN803>3.0.CO;2-3
   Lisdat F, 1997, BIOSENS BIOELECTRON, V12, P1199, DOI 10.1016/S0956-5663(97)00098-5
   Magnusson P, 1999, J BONE MINER RES, V14, P1926, DOI 10.1359/jbmr.1999.14.11.1926                                                    
   Magnusson P, 1998, CLIN CHEM, V44, P1621
   MOY VT, 1994, SCIENCE, V266, P257, DOI 10.1126/science.7939660
   Nie SM, 1997, ANNU REV BIOPH BIOM, V26, P567, DOI 10.1146/annurev.biophys.26.1.567                                                
   Pereira RD, 1998, J FERMENT BIOENG, V85, P302
   Pereira RD, 1996, APPL BIOCHEM BIOTECH, V59, P135, DOI 10.1007/BF02787815
   Pereira RD, 2000, FEBS LETT, V475, P43
   Pereira RD, 1998, CRIT REV BIOTECHNOL, V18, P25, DOI 10.1080/0738-859891224211
   PEREIRA RD, 1998, PROBE MICROSC, V1, P277
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   Shao ZF, 1996, ADV PHYS, V45, P1, DOI 10.1080/00018739600101467                                                       
   SHIELE F, 1988, CLIN CHEM, V34, P685
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   Ushiki T, 1996, ARCH HISTOL CYTOL, V59, P421
   VOLPE PLO, 1993, QUIM NOVA, V16, P49
   Wagner P, 1998, FEBS LETT, V430, P112, DOI 10.1016/S0014-5793(98)00614-0                                                   
   Williamson PR, 1998, J BACTERIOL, V180, P1570
   WILLIAMSON PR, 1994, J BACTERIOL, V176, P656, DOI 10.1128/jb.176.3.656-664.1994                                                   
   Wollenberger U, 1997, ELECTROANAL, V9, P366, DOI 10.1002/elan.1140090503                                                         
   WU XZ, 1994, MICROCHEM J, V49, P213, DOI 10.1006/mchj.1994.1030
   Wu XZ, 1996, ANAL LETT, V29, P1993
   WU XZ, 1995, ANAL CHIM ACTA, V316, P111, DOI 10.1016/0003-2670(95)00339-2                                                    
   WU XZ, 1995, ANAL CHIM ACTA, V299, P333, DOI 10.1016/0003-2670(94)00465-X
   Wu XZ, 1997, J PHYS CHEM B, V101, P1520, DOI 10.1021/jp961896q                                                               
   Zhu C, 2000, J BIOMECH, V33, P23, DOI 10.1016/S0021-9290(99)00163-3
NR 43
TC 34
Z9 35
U1 2
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD OCT 15
PY 2001
VL 62
IS 8
BP 975
EP 983
DI 10.1016/S0006-2952(01)00746-8
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 482XF
UT WOS:000171602000001
PM 11597567
DA 2018-01-05
ER

PT J
AU Dodd, CH
   Hsu, HC
   Chu, WJ
   Yang, PG
   Zhang, HG
   Mountz, JD
   Zinn, K
   Forder, J
   Josephson, L
   Weissleder, R
   Mountz, JM
   Mountz, JD
AF Dodd, CH
   Hsu, HC
   Chu, WJ
   Yang, PG
   Zhang, HG
   Mountz, JD
   Zinn, K
   Forder, J
   Josephson, L
   Weissleder, R
   Mountz, JM
   Mountz, JD
TI Normal T-cell response and in vivo magnetic resonance imaging of T cells
   loaded with HIV transactivator-peptide-derived superparamagnetic
   nanoparticles
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE rodent; T lymphocytes; cell trafficking; MRI, superparamagnetic iron
   oxide; homing; in vivo animal models
ID TAT PROTEIN; IN-VIVO; ADHESION MOLECULES; HIGH-RESOLUTION; APOPTOSIS;
   ACTIVATION; EXPRESSION; MICE; LYMPHOCYTES; ANTIGEN
AB The present study analyzed the feasibility of using magnetic resonance imaging (MRI) to monitor T-cell homing in vivo after loading T cells with superparamagnetic iron oxide (CLIO) nanoparticles derivatized with a peptide sequence from the transactivator protein (Tat) of HIV-1. T cells were isolated from C57BL/6 (B6) mice and loaded with 0, 400, 800, 1600, or 8000 ng/ml of FITC conjugated CLIO-Tat (FITC-CLIO-Tat). There was a dose-dependent uptake of FITC-CLIO-Tat by T cells. Stimulation of FITC-CLIO-Tat loaded T cells with anti-CD3 (0.1 mug/ml) plus IL-2 (5 ng/ml) elicited normal activation and activation-induced cell death (AICD) responses, and normal upregulation of CD69, ICAM-1 (CD54), L-selectin (CD62L), and Fas. The FITC-CLIO-Tat loaded T cells (3 X 10(7)) were transferred intravenously (i.v.) into B6 mice and the in vivo MRI of mice was acquired using a spin-echo pulse sequence at 4.7 T with a Bruker Biospec system. Homing of T cells into the spleen was observed by a decrease in MRI signal intensity within I It after the transfer, which remained decreased for 2-24 h after transfer. These homing data were confirmed by FACS analysis and biodistribution analysis using I-125-CLIO-Tat. Thus, T cells can be efficiently loaded with FITC-CLIO-Tat without interfering with their normal activation and AICD, or homing to the spleen, and the biodistribution of FITC-CLIO-Tat loaded T cells can be monitored in vivo over time by MRI. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Radiol, Ctr Nucl Imaging Res, Birmingham, AL 35294 USA.
   Univ Alabama, Dept Radiol, Div Nucl Med, Birmingham, AL 35294 USA.
   Birmingham Vet Adm Med Ctr, Birmingham, AL 35294 USA.
   Massachusetts Gen Hosp, Ctr Mol Imaging Res, Boston, MA 02129 USA.
RP Mountz, JD (reprint author), Univ Alabama, Dept Med, Div Rheumatol, 701 S 19th St,473 Lyons Harrison Res Bldg, Birmingham, AL 35294 USA.
OI Zinn, Kurt/0000-0001-7463-4741
FU NIA NIH HHS [R01 AG11653-6A2]; NIAID NIH HHS [R01 AI46990, R01 AI42900];
   NCI NIH HHS [CA 20408]; NIAMS NIH HHS [N01-AR-6-2224]
CR ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71
   Barillari G, 1999, J IMMUNOL, V163, P1929
   Bartz SR, 1999, J VIROL, V73, P1956
   Beyersdorff D, 2000, ROFO-FORTSCHR RONTG, V172, P504, DOI 10.1055/s-2000-3751                                                             
   BISELLI R, 1992, SCAND J IMMUNOL, V35, P439, DOI 10.1111/j.1365-3083.1992.tb02879.x
   Bradley LM, 1999, EUR J IMMUNOL, V29, P3273, DOI 10.1002/(SICI)1521-4141(199910)29:10<3273::AID-IMMU3273>3.0.CO;2-2              
   Braschi S, 2000, BIOCHEMISTRY-US, V39, P5441, DOI 10.1021/bi9919504
   Bulte JWM, 1996, ACAD RADIOL, V3, pS301, DOI 10.1016/S1076-6332(96)80564-2
   Carrithers MD, 2000, BRAIN, V123, P1092, DOI 10.1093/brain/123.6.1092                                                        
   De Becker G, 2000, INT IMMUNOL, V12, P807, DOI 10.1093/intimm/12.6.807
   Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1                                                   
   Elliott G, 1997, CELL, V88, P223, DOI 10.1016/S0092-8674(00)81843-7                                                   
   ETTINGER R, 1995, J IMMUNOL, V154, P4302
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x
   GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9
   Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365-2141.1999.01203.x                                                
   Hogemann D, 2000, BIOCONJUGATE CHEM, V11, P941, DOI 10.1021/bc000079x
   Ichikawa T, 1999, AM J ROENTGENOL, V173, P207, DOI 10.2214/ajr.173.1.10397128                                                      
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Lauzurica P, 2000, BLOOD, V95, P2312
   LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425                                                          
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Lopez-Hoyos M, 1999, IMMUNOLOGY, V97, P438, DOI 10.1046/j.1365-2567.1999.00794.x
   LOPEZCABRERA M, 1993, J EXP MED, V178, P537, DOI 10.1084/jem.178.2.537                                                           
   Mischiati C, 1999, AIDS, V13, P1637, DOI 10.1097/00002030-199909100-00006
   MOUNTZ JD, 1995, J IMMUNOL, V155, P4829
   OGIMOTO M, 1991, THYMUS, V17, P11
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Philpott NJ, 1996, BLOOD, V87, P2244
   Potsch C, 1999, EUR J IMMUNOL, V29, P3562, DOI 10.1002/(SICI)1521-4141(199911)29:11<3562::AID-IMMU3562>3.0.CO;2-R
   Reiss Y, 1998, EUR J IMMUNOL, V28, P3086, DOI 10.1002/(SICI)1521-4141(199810)28:10<3086::AID-IMMU3086>3.3.CO;2-Q
   Rusnati M, 2000, FASEB J, V14, P1917, DOI 10.1096/fj.99-0902com
   Sastry KJ, 1996, ONCOGENE, V13, P487
   Secchiero P, 2000, J IMMUNOL, V164, P4018, DOI 10.4049/jimmunol.164.8.4018                                                     
   SHEN T, 1993, MAGNET RESON MED, V29, P599, DOI 10.1002/mrm.1910290504
   SMITH CW, 1993, CAN J PHYSIOL PHARM, V71, P76, DOI 10.1139/y93-012                                                                 
   Sytwu HK, 1996, IMMUNITY, V5, P17, DOI 10.1016/S1074-7613(00)80306-4                                                   
   Tangemann K, 1998, J IMMUNOL, V161, P6330
   TANI Y, 1993, J IMMUNOL, V151, P7337
   VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9
   Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010                                                        
   Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219
   Wu MX, 1997, P NATL ACAD SCI USA, V94, P13832, DOI 10.1073/pnas.94.25.13832
   YEH TC, 1995, MAGNET RESON MED, V33, P200, DOI 10.1002/mrm.1910330209
   YONG K, 1990, BLOOD REV, V4, P211, DOI 10.1016/0268-960X(90)90001-9                                                    
   ZHOU T, 1991, J IMMUNOL, V147, P466
   Zhou T, 1996, J IMMUNOL, V156, P2661
   ZHOU T, 1995, J EXP MED, V182, P129, DOI 10.1084/jem.182.1.129
   ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502                                                         
NR 50
TC 171
Z9 183
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD OCT 1
PY 2001
VL 256
IS 1-2
BP 89
EP 105
DI 10.1016/S0022-1759(01)00433-1
PG 17
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 469WR
UT WOS:000170839500009
PM 11516758
DA 2018-01-05
ER

PT J
AU Rezacova, P
   Lescar, J
   Brynda, J
   Fabry, M
   Horejsi, M
   Sedlacek, J
   Bentley, GA
AF Rezacova, P
   Lescar, J
   Brynda, J
   Fabry, M
   Horejsi, M
   Sedlacek, J
   Bentley, GA
TI Structural basis of HIV-1 and HIV-2 protease inhibition by a monoclonal
   antibody
SO STRUCTURE
LA English
DT Article
DE single-chain Fv; cross-reactivity; HIV protease; dissociative enzyme
   inhibitor; inhibition kinetics; crystal structure
ID IMMUNODEFICIENCY-VIRUS PROTEASE; 3-DIMENSIONAL STRUCTURE;
   ESCHERICHIA-COLI; PROTEINS; ENZYME; BOND; INFECTIVITY; SPECIFICITY;
   COMPLEX; ERRORS
AB Background: Since the demonstration that the protease of the human immunodeficiency virus (HIV Pr) is essential in the viral life cycle, this enzyme has become one of the primary targets for antiviral drug design. The murine monoclonal antibody 1696 (mAb1696), produced by immunization with the HIV-1 protease, inhibits the catalytic activity of the enzyme of both the HIV-1 and HIV-2 isolates with inhibition constants in the low nanomolar range. The antibody cross-reacts with peptides that include the N terminus of the enzyme, a region that is highly conserved in sequence among different viral strains and that, furthermore, is crucial for homodimerization to the active enzymatic form.
   Results: We report here the crystal structure at 2.7 Angstrom resolution of a recombinant single-chain Fv fragment of mAb1696 as a complex with a cross-reactive peptide of the HIV-1 protease. The anti body-antigen interactions observed in this complex provide a structural basis for understanding the origin of the broad reactivity of mAb1696 for the HIV-1 and HIV-2 proteases and their respective N-terminal peptides.
   Conclusion: A possible mechanism of HIV-protease inhibition by mAb1696 is proposed that could help the design of inhibitors aimed at binding inactive monomeric species.
C1 Acad Sci Czech Republic, Inst Mol Genet, Dept Gene Manipulat, Prague 16637 6, Czech Republic.
   Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble, France.
   European Synchrotron Radiat Facil, F-38043 Grenoble, France.
   Inst Pasteur, Dept Immunol, CNRS, URA 1961 Unite Immunol Struct, F-75724 Paris 15, France.
RP Rezacova, P (reprint author), Acad Sci Czech Republic, Inst Mol Genet, Dept Gene Manipulat, Flemingovo nam 2, Prague 16637 6, Czech Republic.
EM rezacova@img.cas.cz; bentley@pasteur.fr
RI Bentley, Graham/B-3623-2011; Brynda, Jiri/G-2760-2014; Maloy Rezacova,
   Pavlina/G-3600-2014; Sedlacek, Juraj/G-3606-2014; Fabry,
   Milan/G-3602-2014
CR BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016
   BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003                                                          
   BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   Dall'Acqua W, 1998, CURR OPIN STRUC BIOL, V8, P443, DOI 10.1016/S0959-440X(98)80121-8
   DARKE PL, 1994, METHOD ENZYMOL, V241, P104
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071                                                       
   HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879                                                         
   JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430
   JOHNSON S, 1991, METHOD ENZYMOL, V203, P88
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KABAT EA, 1991, SEQUENCES PROTEINS I, pR16
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   Kurucz I, 1995, MOL IMMUNOL, V32, P1443, DOI 10.1016/0161-5890(95)00105-0
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   Lescar J, 1997, J MOL BIOL, V267, P1207, DOI 10.1006/jmbi.1997.0950
   Lescar J, 1996, PROTEIN SCI, V5, P966
   Lescar J, 1999, PROTEIN SCI, V8, P2686
   Louis JM, 1999, NAT STRUCT BIOL, V6, P868
   MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587
   MAJER P, 1993, ARCH BIOCHEM BIOPHYS, V304, P1, DOI 10.1006/abbi.1993.1314                                                          
   MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005
   MILNERWHITE EJ, 1988, J MOL BIOL, V204, P777, DOI 10.1016/0022-2836(88)90368-3
   Murali R, 1998, P NATL ACAD SCI USA, V95, P12562, DOI 10.1073/pnas.95.21.12562
   NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597                                                       
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   Otwinowski Z., 1997, METHODS ENZYMOL
   Rana KZ, 1999, PHARMACOTHERAPY, V19, P35, DOI 10.1592/phco.19.1.35.30513                                                      
   READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622                                                       
   RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293                                                         
   Rondon IJ, 1997, ANNU REV MICROBIOL, V51, P257, DOI 10.1146/annurev.micro.51.1.257                                                  
   ROSE JR, 1995, J VIROL, V69, P2751
   SCHRAMM HJ, 1991, BIOCHEM BIOPH RES CO, V179, P847, DOI 10.1016/0006-291X(91)91895-J
   STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S
   URBAN J, 1992, FEBS LETT, V298, P9, DOI 10.1016/0014-5793(92)80010-E
   Williams J W, 1979, Methods Enzymol, V63, P437
   Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760
NR 41
TC 18
Z9 19
U1 0
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0969-2126
EI 1878-4186
J9 STRUCTURE
JI Structure
PD OCT
PY 2001
VL 9
IS 10
BP 887
EP 895
DI 10.1016/S0969-2126(01)00654-2                                           
          
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 482XZ
UT WOS:000171603700003
PM 11591344
OA gold
DA 2018-01-05
ER

PT J
AU Bewley, CA
AF Bewley, CA
TI Solution structure of a cyanovirin-N : Man alpha 1-2Man alpha complex:
   Structural basis for high-affinity carbohydrate-mediated binding to
   gp120
SO STRUCTURE
LA English
DT Article
DE NMR; dipolar couplings; HIV fusion; viral entry; lectin; oligomannose
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INACTIVATING PROTEIN; CYANOVIRIN-N;
   ENVELOPE GLYCOPROTEIN; DIPOLAR COUPLINGS; NMR; TYPE-1; CD4;
   OLIGOSACCHARIDE; INHIBITION
AB Background: Cyanovirin-N (CVN) is a novel, 11 kDa cyanobacterial protein that potently inhibits viral entry by diverse strains of HIV through high-affinity carbohydrate-mediated interactions with the viral envelope glycoprotein gp120. CVN contains two symmetry-related carbohydrate binding sites of differing affinities that selectively bind to Man(8) D1 D3 and Man(9) with nanomolar affinities, the carbohydrates that also mediate CVN:gp120 binding. High-resolution structural studies of CVN in complex with a representative oligosaccharide are desirable for understanding the structural basis for this unprecedented specificity.
   Results: We have determined by multidimensional heteronuclear NMR spectroscopy the three-dimensional solution structure of CVN in complex with two equivalents of the disaccharide Man alpha1-2Man alpha, a high-affinity ligand which represents the terminal-accessible disaccharide present in Man(8) D1 D3 and Man(9). The structure reveals that the bound disaccharide adopts the stacked conformation, thereby explaining the selectivity for Mans D1 D3 and Man(9) over other oligomannose structures, and presents two novel carbohydrate binding sites that account for the differing affinities of the two sites. The high-affinity site comprises a deep pocket that nearly envelops the disaccharide, while the lower-affinity site comprises a semicircular cleft that partially surrounds the disaccharide. The similar to 40 Angstrom spacing of the two binding sites provides a simple model for CVN:gp120 binding.
   Conclusions: The CVN:Man alpha1-2Man alpha. complex provides the first high-resolution structure of a mannose-specific protein-carbohydrate complex with nanomolar affinity and presents a new carbohydrate binding motif, as well as a new class of carbohydrate binding protein, that facilitates divalent binding via a monomeric protein.
C1 NIDDKD, Lab Bioorgan Chem, NIH, Bethesda, MD 20892 USA.
RP Bewley, CA (reprint author), NIDDKD, Lab Bioorgan Chem, NIH, Bethesda, MD 20892 USA.
CR BAX A, 1994, METHOD ENZYMOL, V239, P79
   Bewley CA, 2000, J AM CHEM SOC, V122, P6009, DOI 10.1021/ja000858o
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Bewley CA, 2001, J AM CHEM SOC, V123, P1014, DOI 10.1021/ja005714o
   Biller M, 1998, J VIROL METHODS, V76, P87, DOI 10.1016/S0166-0934(98)00127-X
   Bolmstedt AJ, 2001, MOL PHARMACOL, V59, P949
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   BRUNGER AT, 1993, XPLOR SYSTEM XRAY CR
   CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Clore GM, 1999, J AM CHEM SOC, V121, P9008, DOI 10.1021/ja991789k                                                               
   Clore GM, 1998, P NATL ACAD SCI USA, V95, P5891, DOI 10.1073/pnas.95.11.5891
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3                                                   
   Esser MT, 1999, J VIROL, V73, P4360
   Garrido F, 1991, Semin Cancer Biol, V2, P3
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754
   Mori T, 2001, ANTIMICROB AGENTS CH, V45, P664, DOI 10.1128/AAC.45.3.664-672.2001
   Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972                                                           
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307
   O'Keefe BR, 2000, MOL PHARMACOL, V58, P982
   Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361
   Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h
   SCHWELTERS CD, 2001, IN PRESS J MAGN RESO
   Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300
   Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111
   Trkola A, 1996, J VIROL, V70, P1100
   Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635
   WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0
   WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3
   Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x
   WOOTEN EW, 1990, EUR BIOPHYS J, V18, P139, DOI 10.1007/BF02427373
   Wormald MR, 1999, STRUCTURE, V7, P155
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
   Zhu XG, 2000, BIOCHEMISTRY-US, V39, P11194, DOI 10.1021/bi000432m
NR 41
TC 107
Z9 110
U1 0
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA
SN 0969-2126
J9 STRUCTURE
JI Structure
PD OCT
PY 2001
VL 9
IS 10
BP 931
EP 940
DI 10.1016/S0969-2126(01)00653-0
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 482XZ
UT WOS:000171603700007
PM 11591348
OA gold
DA 2018-01-05
ER

PT J
AU Eckert, DM
   Kim, PS
AF Eckert, DM
   Kim, PS
TI Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide
   region
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID COILED-COIL; TRANSMEMBRANE GLYCOPROTEIN; SYNTHETIC PEPTIDE;
   CRYSTAL-STRUCTURE; ATOMIC-STRUCTURE; TYPE-1 GP41; VIRUS; FUSION; DOMAIN;
   REPLICATION
AB The HIV-1 gp41 envelope glycoprotein promotes fusion of the virus and cell membranes through the formation of a trimer-of-hairpins structure, in which the amino- and carboxyl-terminal regions of the gp41 ectodomain are brought together. Synthetic peptides derived from these two regions (called N and C peptides, respectively) inhibit HIV-1 entry. In contrast to C peptides, which inhibit in the nanomolar range, N peptides are weak inhibitors with IC50 values in the micromolar range. To test the hypothesis that the weak inhibition of N peptides results from their tendency to aggregate, we have constructed chimeric variants of the N-peptide region of gp41 in which soluble trimeric coiled coils are fused to portions of the gp41 N peptide. These molecules, which present the N peptide in a trimeric coiled-coil conformation, are remarkably more potent inhibitors than the N peptides themselves and likely target the carboxyl-terminal region of the gp41 ectodomain. The best inhibitors described here inhibit HIV-1 entry at nanomolar concentrations.
C1 MIT, Howard Hughes Med Inst, Whitehead Inst Biomed Res, Dept Biol, Cambridge, MA 02142 USA.
RP Kim, PS (reprint author), Merck & Co Inc, Merck Res Labs, 770 Sumneytown Pike, W Point, PA 19486 USA.
FU NIGMS NIH HHS [GM44162]
CR Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   CHEN BK, 1994, J VIROL, V68, P654
   CHEN CH, 1995, J VIROL, V69, P3771
   CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027                                                             
   Cole JL, 2001, BIOCHEMISTRY-US, V40, P5633, DOI 10.1021/bi010085w
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Eckert DM, 1998, J MOL BIOL, V284, P859, DOI 10.1006/jmbi.1998.2214                                                          
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777                                                
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   FIELDS C G, 1991, Peptide Research, V4, P95
   HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   KING DS, 1990, INT J PEPT PROT RES, V36, P255
   LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357
   Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200
   Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958                                                  
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134                                                         
   Rimsky LT, 1998, J VIROL, V72, P986
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Suzuki K, 1998, PROTEIN ENG, V11, P1051, DOI 10.1093/protein/11.11.1051                                                      
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weng YK, 1998, J VIROL, V72, P9676
   WILD C, 1993, AIDS RES HUM RETROV, V9, P1051, DOI 10.1089/aid.1993.9.1051
   WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
NR 31
TC 202
Z9 211
U1 1
U2 17
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 25
PY 2001
VL 98
IS 20
BP 11187
EP 11192
DI 10.1073/pnas.201392898                                                  
          
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 476PC
UT WOS:000171237100040
PM 11572974
OA gold
DA 2018-01-05
ER

PT J
AU Gate, L
   Vauthier, C
   Couvreur, P
   Tew, KD
   Tapiero, H
AF Gate, L
   Vauthier, C
   Couvreur, P
   Tew, KD
   Tapiero, H
TI Glutathione-loaded poly(isobutylcyanoacrylate) nanoparticles and
   liposomes: comparative effects in murine erythroleukaemia and
   macrophage-like cells
SO STP PHARMA SCIENCES
LA English
DT Article
DE glutathione; liposomes; poly(isobutylcyanoacrylate); friend leukaemia
   cells; macrophages
ID BRONCHOALVEOLAR LAVAGE FLUID; OXIDATIVE STRESS; REDUCED GLUTATHIONE;
   MONOETHYL ESTER; LIPID PEROXIDES; HIV-INFECTION; DIETHYL ESTER; IN-VIVO;
   MICE; REPERFUSION
AB Glutathione depletion has been related to various pathologies including cancer and neurological and cardiovascular diseases. Its bioavailability, is highly limited due to its poor cellular uptake and rapid turnover. In recent decades, various nanoparticular vectors have been developed to increase the bioavailability of therapeutic drugs. In the present work, glutathione (GSH) was loaded into poly(isobutylcyanoacrylates) (PiBCA), biodegradable nanoparticle vectors. These GSH-loaded particles were synthesized by dispersion polymerization in aqueous media. Although a considerable proportion of GSH (up to 50%) was loaded into these particles, no net increase in intracellular glutathione was observed in erythroleukaemia FLC or macrophage-like J774 cells unless previously treated with buthionine sulphoximine (BSO), a gamma-glutamyl cysteine synthetase inhibitor. Due to the non-efficacy of GSH-PiBCA particles, we incorporated GSH into liposomes [(soy phosphatidylcholine:cholesterol: dipalmitoyl phosphatidylglycerol (6:3: 1)] with an efficiency close to 25%. The glutathione content of BSO-depleted J774 cells could be restored when cells were exposed to GSH-loaded liposomes but increased beyond basal levels. These data suggest that GSH-loaded liposomes could be used to restore intracellular GSH in depleted cells, but did not influence GSH homeostasis under normal physiological conditions. The efficacy of this formulation tested in a clinical setting in patients with pathologies related to impaired cellular GSH levels has vet to be investigated.
C1 Univ Paris Sud, Lab Pharmacol Cellulaire & Mol, Fac Pharm, CNRS,UMR 8612, F-92296 Chatenay Malabry, France.
   Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA.
RP Tapiero, H (reprint author), Univ Paris Sud, Lab Pharmacol Cellulaire & Mol, Fac Pharm, CNRS,UMR 8612, 5 Rue Jean Baptiste Clement, F-92296 Chatenay Malabry, France.
RI COUVREUR, Patrick/G-4844-2011
OI COUVREUR, Patrick/0000-0001-7961-5443
CR AMANO J, 1994, J AM COLL SURGEONS, V179, P714
   ANDERSON ME, 1985, ARCH BIOCHEM BIOPHYS, V239, P538, DOI 10.1016/0003-9861(85)90723-4
   AW TY, 1991, CHEM-BIOL INTERACT, V80, P89, DOI 10.1016/0009-2797(91)90033-4
   CASTAGNA A, 1995, NEUROLOGY, V45, P1678, DOI 10.1212/WNL.45.9.1678                                                           
   Chattaraj SC, 1999, J CONTROL RELEASE, V58, P223, DOI 10.1016/S0168-3659(98)00161-8                                                   
   CHIANNILKULACHAI N, 1990, CANCER CHEMOTH PHARM, V26, P122, DOI 10.1007/BF02897257                                                              
   Couvreur P, 2000, J Pharm Belg, V55, P78
   Damge C, 1997, J PHARM SCI, V86, P1403, DOI 10.1021/js970124i
   DELEVE LD, 1991, PHARMACOL THERAPEUT, V52, P287, DOI 10.1016/0163-7258(91)90029-L
   DENEKE SM, 1989, AM J PHYSIOL, V257, pL163
   deVerdiere AC, 1997, BRIT J CANCER, V76, P198, DOI 10.1038/bjc.1997.362
   FernandezUrrusuno R, 1997, BIOMATERIALS, V18, P511, DOI 10.1016/S0142-9612(96)00178-0
   FLAGG EW, 1994, AM J EPIDEMIOL, V139, P453, DOI 10.1093/oxfordjournals.aje.a117028                                              
   FORMAN MB, 1988, CIRCULATION, V78, P202, DOI 10.1161/01.CIR.78.1.202                                                         
   Gate L, 1999, BIOMED PHARMACOTHER, V53, P169, DOI 10.1016/S0753-3322(99)80086-9
   GRANGIER JL, 1991, J CONTROL RELEASE, V15, P3, DOI 10.1016/0168-3659(91)90098-X                                                    
   GRATTAGLIANO I, 1995, J PHARMACOL EXP THER, V272, P484
   GRIGG J, 1993, ARCH DIS CHILD, V69, P49, DOI 10.1136/adc.69.1_Spec_No.49                                                     
   Harrington KJ, 2001, CLIN CANCER RES, V7, P243
   HOSHIDA S, 1994, J AM COLL CARDIOL, V24, P1391, DOI 10.1016/0735-1097(94)90125-2                                                    
   Isbir T, 2000, ANTICANCER RES, V20, P219
   Jenner P, 1996, PATHOL BIOL, V44, P57
   LEROY P, 1993, BIOMED CHROMATOGR, V7, P86, DOI 10.1002/bmc.1130070208
   LEVY EJ, 1993, P NATL ACAD SCI USA, V90, P9171, DOI 10.1073/pnas.90.19.9171
   Maytin M, 1999, Curr Atheroscler Rep, V1, P156, DOI 10.1007/s11883-999-0012-z
   MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004                                                
   MINHAS HS, 1995, BIOCHEM PHARMACOL, V49, P1475, DOI 10.1016/0006-2952(94)00518-Q
   Muggia F M, 2001, Curr Oncol Rep, V3, P156, DOI 10.1007/s11912-001-0016-5
   MULLER RH, 1990, BIOMATERIALS, V11, P590, DOI 10.1016/0142-9612(90)90084-4
   Navarro J, 1999, FREE RADICAL BIO MED, V26, P410, DOI 10.1016/S0891-5849(98)00213-5
   Peracchia MT, 1997, LIFE SCI, V61, P749, DOI 10.1016/S0024-3205(97)00539-0
   PINTOALPHANDARY H, 1995, J DRUG TARGET, V3, P167, DOI 10.3109/10611869509059216                                                       
   PLACHTA H, 1992, CLIN CHIM ACTA, V211, P101, DOI 10.1016/0009-8981(92)90109-4                                                    
   Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x                                            
   RIETVELD EC, 1988, PHARM WEEKBLAD, V10, P224
   SHIGESAWA T, 1992, J GASTROEN HEPATOL, V7, P7, DOI 10.1111/j.1440-1746.1992.tb00926.x
   SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461, DOI 10.1164/ajrccm/147.6_Pt_1.1461                                                  
   Staal FJT, 1998, EUR J CLIN INVEST, V28, P194
   Stella B, 2000, J PHARM SCI, V89, P1452, DOI 10.1002/1520-6017(200011)89:11<1452::AID-JPS8>3.0.CO;2-P
   WEINER N, 1994, J DRUG TARGET, V2, P405, DOI 10.3109/10611869408996816                                                       
   Yan T, 1999, BIOCHEM BIOPH RES CO, V257, P163, DOI 10.1006/bbrc.1999.0423
NR 41
TC 3
Z9 3
U1 0
U2 4
PU EDITIONS SANTE
PI PARIS
PA 47 RUE GALILEE, 75116 PARIS, FRANCE
SN 1157-1489
J9 STP PHARMA SCI
JI STP Pharma Sci.
PD SEP-OCT
PY 2001
VL 11
IS 5
BP 355
EP 361
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 510QB
UT WOS:000173217800006
DA 2018-01-05
ER

PT J
AU Chao, SH
   Price, DH
AF Chao, SH
   Price, DH
TI Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II
   transcription in vivo
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST-CARCINOMA CELLS; ELONGATION-FACTOR-B; HIV-1 TAT; KINASE
   INHIBITORS; CYCLIN T1; IN-VITRO; TRANSACTIVATION; PROTEIN; REPLICATION;
   PITALRE
AB Flavopiridol (L86-8275, HMR1275) is a cyclin-dependent kinase (Cdk) inhibitor in clinical trials as a cancer therapy that has been recently shown to block human immunodeficiency virus Tat transactivation and viral replication through inhibition of positive transcription elongation factor b (P-TEFb). Flavopiridol is the most potent P-TEFb inhibitor reported and the first Cdk inhibitor that is not competitive with ATP. We examined the ability of flavopiridol to inhibit P-TEFb (Cdk9/cyclin T1) phosphorylation of both RNA polymerase II and the large subunit of the 5, 6-dichloro-1-beta -D-ribofuranosyl-benzimidazole (DRB) sensitivity-inducing factor and found that the IC50 determined was directly related to the concentration of the enzyme. We concluded that the flavonoid associates with P-TEFb with 1:1 stoichiometry even at concentrations of enzyme in the low nanomolar range. These results indicate that the apparent lack of competition with ATP could be caused by a very tight binding of the drug. We developed a novel immobilized P-TEFb assay and demonstrated that the drug remains bound for minutes even in the presence of high salt. Flavopiridol remained bound in the presence of a 1000-fold excess of the commonly used inhibitor DRB, suggesting that the immobilized P-TEFb could be used in a simple screening assay that would allow the discovery or characterization of compounds with binding properties similar to flavopiridol. Finally, we compared the ability of flavopiridol and DRB to inhibit transcription in vivo using nuclear run-on assays and concluded that P-TEFb is required for transcription of most RNA polymerase II molecules in vivo.
C1 Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA.
   Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.
RP Price, DH (reprint author), Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA.
RI Price, David/F-6173-2010
FU NIGMS NIH HHS [GM35500]; NIAID NIH HHS [AI43691]
CR Bieniasz PD, 1999, MOL CELL BIOL, V19, P4592
   Carlson B, 1999, CANCER RES, V59, P4634
   Carlson BA, 1996, CANCER RES, V56, P2973
   Chang TC, 1997, BIOCHEM PHARMACOL, V53, P969, DOI 10.1016/S0006-2952(96)00868-4
   Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200                                                          
   DE AWJ, 1996, P NATL ACAD SCI USA, V93, P2735
   De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4
   Egyhazi E, 1996, CHROMOSOMA, V104, P422, DOI 10.1007/BF00352266
   Flores OL, 1999, P NATL ACAD SCI USA, V96, P7208, DOI 10.1073/pnas.96.13.7208
   Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527
   Fujinaga K, 1998, J VIROL, V72, P7154
   Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512
   Gold MO, 1998, J VIROL, V72, P4448
   Gray N, 1999, CURR MED CHEM, V6, P859
   Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533                                                    
   Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903                                                      
   Kim KS, 2000, J MED CHEM, V43, P4126, DOI 10.1021/jm000231g
   KIRN JB, 2001, J BIOL CHEM, V276, P12317
   LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742                                                          
   Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633
   MARCINIAK RA, 1991, EMBO J, V10, P4189
   Murthi KK, 2000, BIOORG MED CHEM LETT, V10, P1037, DOI 10.1016/S0960-894X(00)00156-6
   Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755
   Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200
   Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000
   REEDER RH, 1972, J MOL BIOL, V67, P433, DOI 10.1016/0022-2836(72)90461-5
   Senderowicz AM, 2000, J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376
   Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986                                                      
   Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944
   Toledo LM, 1999, CURR MED CHEM, V6, P775
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622
NR 32
TC 437
Z9 449
U1 2
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 24
PY 2001
VL 276
IS 34
BP 31793
EP 31799
DI 10.1074/jbc.M102306200
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 465WT
UT WOS:000170613500044
PM 11431468
OA gold
DA 2018-01-05
ER

PT J
AU Louis, JM
   Bewley, CA
   Clore, GM
AF Louis, JM
   Bewley, CA
   Clore, GM
TI Design and properties of N-CCG-gp41, a chimeric gp41 molecule with
   nanomolar HIV fusion inhibitory activity
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SIMIAN IMMUNODEFICIENCY VIRUS; 44 KDA ECTODOMAIN; ENVELOPE GLYCOPROTEIN;
   COILED-COIL; INACTIVATING PROTEIN; SECONDARY STRUCTURE;
   CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ATOMIC-STRUCTURE; CYANOVIRIN-N
AB The design and characterization of a chimeric protein, termed N-CCG-gp41, derived from the ectodomain of human immunodeficiency virus (HIV), type I gp41 is described. N-CCG-gp41 features an exposed trimeric coiled-coil comprising the N-terminal helices of the gp41 ectodomain. The trimeric coiled-coil is stabilized both by fusion to a minimal thermostable ectodomain of gp41 and by engineered intersubunit disulfide bonds. N(CCG)gp41 is shown to inhibit HIV envelope-mediated cell fusion at nanomolar concentrations with an IC., of 16.1 +/- 2.8 nM. It is proposed that N-CCG-gp41 targets the exposed C-terminal region of the gp41 ectodomain in its pre-hairpin intermediate state, thereby preventing the formation of the fusogenic form of the gp41 ectodomain, which comprises a highly stable trimer of hairpins arranged in a six-helix bundle. N-CCG-gp41 has potential as a therapeutic agent for the direct inhibition of HIV cell entry, as an anti-HIV vaccine, and as a component of a rapid throughput assay for screening for small molecule inhibitors of HIV envelope-mediated cell fusion. It is anticipated that antibodies raised against N-CCG-gp41 may target the trimeric coiled-coil of N-terminal helices of the gp41 ectodomain that is exposed in the pre-hairpin intermediate state in a manner analogous to peptides derived from the C-terminal helix of gp41 that are currently in clinical trials.
C1 NIDDK, Phys Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Clore, GM (reprint author), NIDDK, Phys Chem Lab, NIH, Bldg 5,Rm B1-301, Bethesda, MD 20892 USA.
RI Clore, G. Marius/A-3511-2008
OI Clore, G. Marius/0000-0003-3809-1027
CR ALEXANDER WA, 1992, J VIROL, V66, P2934
   ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383
   Bewley CA, 2001, J AM CHEM SOC, V123, P3892, DOI 10.1021/ja004040e
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004
   BRUNGER AT, 1993, X PLOR SYSTEM XRYA C
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Caffrey M, 1997, J MOL BIOL, V271, P819, DOI 10.1006/jmbi.1997.1217
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Farzan M, 1998, J VIROL, V72, P7620
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Ferrer M, 1999, NAT STRUCT BIOL, V6, P953
   FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883                                                        
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V159, P87, DOI 10.1016/0006-291X(89)92408-X                                                    
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134                                                         
   McMichael AJ, 1999, NAT MED, V5, P612, DOI 10.1038/9455                                                                    
   Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0
   PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x
   Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453
   Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000                                                   
   Schwieters CD, 2001, J MAGN RESON, V149, P239, DOI 10.1006/jmre.2001.2300
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weng YK, 1998, J VIROL, V72, P9676
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   WILD CT, 1992, P NATL ACAD SCI USA, V99, P10537
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
NR 34
TC 87
Z9 94
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 3
PY 2001
VL 276
IS 31
BP 29485
EP 29489
DI 10.1074/jbc.C100317200
PG 5
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 461BX
UT WOS:000170346000111
PM 11418583
OA gold
DA 2018-01-05
ER

PT J
AU Mai, A
   Sbardella, G
   Artico, M
   Ragno, R
   Massa, S
   Novellino, E
   Greco, G
   Lavecchia, A
   Musiu, C
   La Colla, M
   Murgioni, C
   La Colla, P
   Loddo, R
AF Mai, A
   Sbardella, G
   Artico, M
   Ragno, R
   Massa, S
   Novellino, E
   Greco, G
   Lavecchia, A
   Musiu, C
   La Colla, M
   Murgioni, C
   La Colla, P
   Loddo, R
TI Structure-based design, synthesis, and biological evaluation of
   conformationally restricted novel
   2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin
   -4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS;
   3,4-DIHYDRO-2-ALKOXY-6-BENZYL-4-OXOPYRIMIDINES DABOS; NONNUCLEOSIDE
   INHIBITOR; FORCE-FIELD; ANTI-HIV-1 ACTIVITY; MOLECULAR-DYNAMICS;
   CRYSTAL-STRUCTURES; PETT COMPOUNDS; TYPE-1; COMPLEX
AB 5-Alkyl-2-(alkylthio)-6-(2,6-difluorobenzyl)-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs, 2) have been recently described as a new class of human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) active at nanomolar concentrations (Mai, A. et al. J. Med. Chem. 1999, 42, 619-627). In pursuing our lead optimization efforts, we designed novel conformationally restricted S-DABOs, 3, featuring a methyl at the benzylic carbon (Y = Me) and at the pyrimidine 5-position (R = Me). Conformational analyses and docking simulations suggested that the presence of both methyls would significantly reduce conformational flexibility without compromising, in the R enantiomers, the capability of fitting into the RT non-nucleoside binding pocket. To develop structure-activity relationships, we prepared several congeners of type 3 belonging to the thymine (R = Me) and uracil (R = H) series, featuring various 2-alkylthio side chains (X = Me, i-Pr, n-Bu, i-Bu, s-Bu, c-pentyl, and c-hexyl) and aryl moieties different from the 2,6-difluorophenyl (Ar = phenyl, 2,6-dichlorophenyl, 1-naphthyl). Moreover, alpha -ethyl derivatives (Y = Et) were included in the synthetic project in addition to alpha -methyl derivatives (Y = Me). All of the new compounds were evaluated for their cytotoxicity and anti-HIV-1 activity in MT-4 cells, and some of them were assayed against highly purified recombinant wild-type HIV-1 RT using homopolymeric template primers. The results were expressed as CC50 (cytotoxicity), EC50 (anti-HIV-1 activity), SI (selectivity, given by the CC50/EC50 ratio), and IC50 (RT inhibitory activity) values. In the 2,6-difluorobenzylthymine (R = Me) series, methylation of the benzylic carbon improved anti-HIV-1 and RT inhibitory activities together with selectivity. Compound 3w (Ar = 2,6-F-2-Ph, R = Y = Me, X = c-pentyl) turned out the most potent and selective among the S-DABOs reported to date (CC50 > 200 muM, EC50 = 6 nM, IC50 = 5 nM, and SI > 33 333). Assays performed on the pure enantiomer (+)-3w, much more active than (-)-3w, yielded the following results: CC50 > 200 muM, EC50 = 2 nM, IC50 = 8 nM, and SI > 100 000, under conditions wherein MKC-442 was less active and selective (CC50 > 200 muM, EC50 = 30 nM, IC50 = 40 nM, SI > 6666). The 2,6-difluorophenylethylthymines (R = Me) were generally endowed with higher potency compared with the uracil counterparts (R = H). In the 2,6-difluorophenyl series the best and the least performant 2-alkylthio side chains were the 2-c-pentylthio and the 2-methylthio, respectively. When the methyl at the benzylic carbon was replaced by an ethyl, activity was retained or decreased slightly, thus suggesting that the dimensions of the cavity within the RT hosting this substituent would not be compatible with groups larger than ethyl. Aryl moieties different from the 2,6-difluorophenyl (phenyl, 1-naphthyl, 2,6-dichlorophenyl) were generally detrimental to activity, consistent with a favorable electronic effect exerted by the 2,6-fluorines on a putative charge-transfer interaction between the aromatic moieties of the inhibitor and Tyr188.
C1 Univ Rome La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, I-00185 Rome, Italy.
   Univ Rome La Sapienza, Dipartimento Studi Chim & Tecnol Sostanze Biologi, I-00185 Rome, Italy.
   Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
   Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy.
   Novirio Pharmaceut Inc, Boston, MA USA.
   Univ Cagliari, Sez Microbiol, Dipartimento Biol Sperimentale, I-09042 Cagliari, Italy.
RP Artico, M (reprint author), Univ Rome La Sapienza, Dipartimento Studi Farmaceut, Fdn Cenci Bolognetti, Ist Pasteur, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
RI Lavecchia, Antonio/P-9476-2017; Loddo, Roberta/B-9038-2011; Sbardella,
   Gianluca/E-2823-2010; La Colla , Paolo /B-8587-2011
OI Lavecchia, Antonio/0000-0002-2181-8026; Sbardella,
   Gianluca/0000-0003-0748-1145; Ragno, Rino/0000-0001-5399-975X; Mai,
   Antonello/0000-0001-9176-2382; Novellino, Ettore/0000-0002-2181-2142
CR ALLINGER NL, 1977, J AM CHEM SOC, V99, P8127, DOI 10.1021/ja00467a001                                                             
   ARTICO M, 1993, ANTIVIR CHEM CHEMOTH, V4, P361, DOI 10.1177/095632029300400608                                                      
   BABA M, 1989, BIOCHEM BIOPH RES CO, V165, P1375, DOI 10.1016/0006-291X(89)92756-3
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118                                                                
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   Das K, 1996, J MOL BIOL, V264, P1085, DOI 10.1006/jmbi.1996.0698
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   DECLERCQ E, 1990, TRENDS PHARMACOL SCI, V11, P198, DOI 10.1016/0165-6147(90)90115-O
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   HEAD JD, 1985, CHEM PHYS LETT, V122, P264, DOI 10.1016/0009-2614(85)80574-1
   Hogberg M, 1999, J MED CHEM, V42, P4150, DOI 10.1021/jm990095j
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   JonesHertzog DK, 1997, J MED CHEM, V40, P1539, DOI 10.1021/jm960684e
   KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.biochem.63.1.133
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mai A, 1999, J MED CHEM, V42, P619, DOI 10.1021/jm980260f
   MAI A, 1995, J MED CHEM, V38, P3258, DOI 10.1021/jm00017a010
   MASSA S, 1995, ANTIVIR CHEM CHEMOTH, V6, P1
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096                                                         
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   PEARLMAN DA, 1995, AMBER VERSION 4 1
   Quaglia MG, 2001, CHIRALITY, V13, P75, DOI 10.1002/1520-636X(2001)13:2<75::AID-CHIR1001>3.0.CO;2-W                         
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m                                                               
   RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402
   RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207                                                           
   ROMERO DL, 1991, P NATL ACAD SCI USA, V88, P8806, DOI 10.1073/pnas.88.19.8806                                                         
   Singh SB, 2000, J MED CHEM, V43, P1062, DOI 10.1021/jm990168z
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972                                                          
   TERASAKI T, 1988, J INFECT DIS, V158, P630, DOI 10.1093/infdis/158.3.630                                                        
   TRAMONTANO E, 1994, MICROBIOLOGICA, V17, P269
   *TRIP INC, SYB MOL MOD SYST VER
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   MOPAC VERSION 6 0
NR 48
TC 75
Z9 79
U1 1
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 2
PY 2001
VL 44
IS 16
BP 2544
EP 2554
DI 10.1021/jm010853h
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 457YZ
UT WOS:000170167700007
PM 11472208
DA 2018-01-05
ER

PT J
AU Berton, M
   Turelli, P
   Trono, D
   Stein, CA
   Allemann, E
   Gurny, R
AF Berton, M
   Turelli, P
   Trono, D
   Stein, CA
   Allemann, E
   Gurny, R
TI Inhibition of HIV-1 in cell culture by oligonucleotide-loaded
   nanoparticles
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE phosphorothioate oligonucleoticle; nanoparticle; drug delivery; HIV-1;
   reverse transcription
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANTISENSE OLIGONUCLEOTIDES; IN-VITRO;
   REVERSE-TRANSCRIPTASE; BIOLOGICAL-ACTIVITY; GENE-EXPRESSION; ADVANCED
   CANCER; DELIVERY; MECHANISMS; OLIGODEOXYNUCLEOTIDES
AB Purpose. To investigate the potential use of polymeric nanoparticles for the delivery of antisense oligonucleotides in HIV-1-infected cell cultures.
   Methods. Phosphorothioate oligonucleotides were encapsulated into poly (D,L-lactic acid) nanoparticles. Two models of infected cells were used to test the ability of nanoparticles to deliver them. HeLa P4-2 CD4+ cells, stably transfected with the P-galactosidase reporter gone, were first used to evaluate the activity of the oligonucleotides on a single-round infection cycle. The acutely infected lymphoid CEM cells were then used to evaluate the inhibition of the viral production of HIV-1 by the oligonucleotides.
   Results. The addition to infected CENT cells of nanoparticles containing gag antisense oligonucleotides in the nanomolar range led to strong inhibition of the viral production in a concentration-dependent manner. Similar results were previously observed in HeLa P4-2 CD4+ cells. Nanoparticle-entrapped random-order gag oligonucleotides had similar effects on reverse transcription. However, the reverse transcriptase activity of infected cells treated with nanomolar concentrations of free antisense and random oligonucleotides was not affected.
   Conclusions. These results suggest that poly (D,L-lactic acid) nanoparticles may have great potential as an efficient delivery system for oligonucleotides in HIV natural target cells, i.e., lymphocytic cells.
C1 Univ Geneva, Sch Pharm, CH-1211 Geneva, Switzerland.
   Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva, Switzerland.
   Columbia Univ Coll Phys & Surg, Dept Med & Pharmacol, New York, NY 10032 USA.
RP Berton, M (reprint author), Univ Geneva, Sch Pharm, CH-1211 Geneva, Switzerland.
CR Agrawal S, 1999, BBA-GENE STRUCT EXPR, V1489, P53, DOI 10.1016/S0167-4781(99)00141-4
   Anderson KP, 1996, ANTIMICROB AGENTS CH, V40, P2004
   Baker BF, 1999, BBA-GENE STRUCT EXPR, V1489, P3, DOI 10.1016/S0167-4781(99)00146-3                                                   
   Bennett CF, 1998, J DRUG TARGET, V5, P149, DOI 10.3109/10611869808995870                                                       
   Berton M, 1999, EUR J PHARM BIOPHARM, V47, P119, DOI 10.1016/S0939-6411(98)00064-2
   Berton M, 1999, EUR J PHARM SCI, V9, P163, DOI 10.1016/S0928-0987(99)00049-4
   BONGARTZ JP, 1994, NUCLEIC ACIDS RES, V22, P4681, DOI 10.1093/nar/22.22.4681                                                          
   CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542
   Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7                                                   
   Cunningham CC, 2000, CLIN CANCER RES, V6, P1626
   Deminie CA, 1996, ANTIMICROB AGENTS CH, V40, P1346
   Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825
   GOFF S, 1981, J VIROL, V38, P239
   Hughes D, 1996, DRUG DISCOV TODAY, V1, P404, DOI 10.1016/S1359-6446(96)80002-X                                                   
   Juliano RL, 1999, PHARMACEUT RES, V16, P494, DOI 10.1023/A:1011958726518
   Krieg AM, 1999, BBA-GENE STRUCT EXPR, V1489, P107, DOI 10.1016/S0167-4781(99)00147-5                                                   
   Lebedeva I, 2000, EUR J PHARM BIOPHARM, V50, P101, DOI 10.1016/S0939-6411(00)00088-6
   Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176
   Lewis KJ, 1998, J DRUG TARGET, V5, P291, DOI 10.3109/10611869808995882                                                       
   Mangasarian A, 1999, J VIROL, V73, P1964
   NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307
   Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586                                                     
   OJWANG J, 1994, J ACQ IMMUN DEF SYND, V7, P560
   Pichon C, 2000, NUCLEIC ACIDS RES, V28, P504, DOI 10.1093/nar/28.2.504                                                            
   Veal GJ, 1998, NUCLEIC ACIDS RES, V26, P5670, DOI 10.1093/nar/26.24.5670
   Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812                                                      
   Yamaguchi K, 1997, AIDS RES HUM RETROV, V13, P545, DOI 10.1089/aid.1997.13.545
   Yoo H, 1999, PHARMACEUT RES, V16, P1799, DOI 10.1023/A:1018926605871
   ZELPHATI O, 1994, NUCLEIC ACIDS RES, V22, P4307, DOI 10.1093/nar/22.20.4307
   Zobel HP, 2000, EUR J PHARM BIOPHARM, V49, P203, DOI 10.1016/S0939-6411(00)00080-1
NR 30
TC 28
Z9 31
U1 1
U2 7
PU KLUWER ACADEMIC/PLENUM PUBL
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARMACEUT RES
JI Pharm. Res.
PD AUG
PY 2001
VL 18
IS 8
BP 1096
EP 1101
DI 10.1023/A:1010962507273                                                 
          
PG 6
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 478RX
UT WOS:000171360100004
PM 11587479
DA 2018-01-05
ER

PT J
AU Barreca, ML
   Chimirri, A
   De Luca, L
   Monforte, AM
   Monforte, P
   Rao, A
   Zappala, M
   Balzarini, J
   De Clercq, E
   Pannecouque, C
   Witvrouw, M
AF Barreca, ML
   Chimirri, A
   De Luca, L
   Monforte, AM
   Monforte, P
   Rao, A
   Zappala, M
   Balzarini, J
   De Clercq, E
   Pannecouque, C
   Witvrouw, M
TI Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1
   agents
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; RT INHIBITORS; HIV ACTIVITY;
   IMMUNODEFICIENCY
AB Design, synthesis and anti-HIV activity of a series of 2,3-diaryl-1,3-thiazolidin-4-ones are reported. Some derivatives proved to be highly effective in inhibiting HIV-I replication at nanomolar concentrations thereby acting as non-nucleoside HIV-1 RT inhibitors (NNRTIs). SAR studies evidenced that the nature of the substituents at the 2 and 3 positions of the thiazolidinone nucleus largely influenced the in vitro anti-HIV activity of this new class of potent antiviral agents. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Univ Messina, Dipartimento Farmacochim, I-98168 Messina, Italy.
   Univ Magna Graecia Catanzaro, Dipartimento Sci Farmacobiol, I-88021 Roccelletta Di Borgia, CZ, Italy.
   Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Monforte, AM (reprint author), Univ Messina, Dipartimento Farmacochim, Viale Annunziata, I-98168 Messina, Italy.
RI De Luca, Laura/D-8532-2011
OI ZAPPALA', Maria/0000-0002-8942-797X; De Luca, Laura/0000-0003-0614-5713;
   Barreca, Maria Letizia/0000-0003-3530-5042
CR Barreca ML, 1999, BIOORGAN MED CHEM, V7, P2283, DOI 10.1016/S0968-0896(99)00181-9
   Chimirri A, 1999, ANTIVIR CHEM CHEMOTH, V10, P211, DOI 10.1177/095632029901000405                                                      
   CHIMIRRI A, 1991, FARMACO, V46, P925
   Chimirri A, 1998, ANTIVIR CHEM CHEMOTH, V9, P431, DOI 10.1177/095632029800900507                                                      
   Chimirri A, 1997, ANTIVIR CHEM CHEMOTH, V8, P363, DOI 10.1177/095632029700800409                                                      
   GRASSO S, 1988, FARMACO, V43, P851
   Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Tavel JA, 1999, CLIN INFECT DIS, V28, P643, DOI 10.1086/515179                                                                  
   Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354
   WITVROUW M, 1991, Antiviral Chemistry and Chemotherapy, V2, P171
NR 11
TC 184
Z9 191
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUL 9
PY 2001
VL 11
IS 13
BP 1793
EP 1796
DI 10.1016/S0960-894X(01)00304-3
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 446ZC
UT WOS:000169543200041
PM 11425562
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Mao, C
   Uckun, FM
AF Venkatachalam, TK
   Mao, C
   Uckun, FM
TI Stereochemistry as a major determinant of the anti-HIV activity of
   chiral naphthyl thiourea compounds
SO ANTIVIRAL CHEMISTRY & CHEMOTHERAPY
LA English
DT Article
DE HIV; thiourea; stereochemistry; non-nucleoside inhibitor
ID REVERSE-TRANSCRIPTASE INHIBITORS; HUMAN-IMMUNODEFICIENCY-VIRUS; POTENT
   NONNUCLEOSIDE INHIBITORS; STRUCTURE-BASED DESIGN; DRUG-RESISTANT;
   ANTIVIRAL PROTEIN; RATIONAL DESIGN; PETT COMPOUNDS; INFECTION; ANALOGS
AB Eleven chiral naphthyl thiourea (CNT) compounds were synthesized as non-nucleoside inhibitors (NNI) of the reverse transcriptase (RT) enzyme of HIV-1. Molecular modelling studies indicated that, because of the asymmetric geometry of the NNI binding pocket, the 'R' stereoisomers would fit the NNI binding pocket of the HIV-1 RT much better than the corresponding 'S' stereoisomers, as reflected by their 10(4)-fold lower K-i values. The 'R' stereoisomers of all 11 compounds inhibited the recombinant RT in vitro with lower IC50 values than their enantiomers. Of seven CNT compounds whose 'R' stereoisomers exhibited nanomolar IC50 values against recombinant RT, five were further evaluated for their ability to inhibit HIV-1 replication in human peripheral blood mononuclear cells (PBMC). All five 'R' stereoisomers were active anti-HIV agents and inhibited the replication of the HIV-1 strains HTLV-IIIB (NNI-sensitive), A17 (NNI-resistant, Y181C mutant RT) and A17Var (NNI-resistant, Y181C plus K103N mutant RT), as well as primary HIV-1 isolates from AIDS patients in human PBMC at nanomolar concentrations, whereas their enantiomers were inactive. The lead compounds, 1R and 5R, were 3 log more potent than the standard NNI drug nevirapine against the NNI-resistant HIV-1 strains. Our data establish the stereochemistry as a major determinant of the potency of this new class of NNI.
C1 Parker Hughes Inst, Drug Discovery Program, St Paul, MN USA.
   Parker Hughes Inst, Dept Chem, St Paul, MN USA.
   Parker Hughes Inst, Dept Biol Struct, St Paul, MN USA.
   Parker Hughes Inst, Dept Virol, St Paul, MN USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Drug Discovery Program, St Paul, MN USA.
CR BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Chen CL, 1999, PHARMACEUT RES, V16, P1226, DOI 10.1023/A:1014814313681
   CHEN CL, 2001, DRUG RES, V51, P574
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Mao C, 1999, ANTIVIR CHEM CHEMOTH, V10, P233, DOI 10.1177/095632029901000502                                                      
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   Uckun FM, 2000, ANTIVIR CHEM CHEMOTH, V11, P135, DOI 10.1177/095632020001100205                                                      
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Venkatachalam TK, 2000, BIOORG MED CHEM LETT, V10, P2071, DOI 10.1016/S0960-894X(00)00398-X
   Venkatachalam TK, 2001, BIOORG MED CHEM LETT, V11, P523, DOI 10.1016/S0960-894X(01)00011-7
   Venkatachalam TK, 2000, ANTIVIR CHEM CHEMOTH, V11, P329, DOI 10.1177/095632020001100503                                                      
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 22
TC 18
Z9 18
U1 0
U2 0
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 0956-3202
J9 ANTIVIR CHEM CHEMOTH
JI Antivir. Chem. Chemother.
PD JUL
PY 2001
VL 12
IS 4
BP 213
EP 221
DI 10.1177/095632020101200402                                              
          
PG 9
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
GA 559TH
UT WOS:000176041100002
PM 11771730
OA gold
DA 2018-01-05
ER

PT J
AU Coffey, VC
AF Coffey, VC
TI Biotechnology - Gold nanoshells may deliver drugs, detect HIV
SO LASER FOCUS WORLD
LA English
DT News Item
NR 0
TC 0
Z9 0
U1 0
U2 0
PU PENNWELL PUBL CO
PI NASHUA
PA 98 SPIT BROOK RD, NASHUA, NH 03062-2801 USA
SN 0740-2511
J9 LASER FOCUS WORLD
JI Laser Focus World
PD JUL
PY 2001
VL 37
IS 7
BP 46
EP +
PG 3
WC Optics
SC Optics
GA 451ZH
UT WOS:000169832300022
DA 2018-01-05
ER

PT J
AU Howorka, S
   Cheley, S
   Bayley, H
AF Howorka, S
   Cheley, S
   Bayley, H
TI Sequence-specific detection of individual DNA strands using engineered
   nanopores
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID PROTEIN PORE; POLYNUCLEOTIDE MOLECULES; POLYMER-CHAIN; SINGLE; CHANNEL;
   DISCRIMINATION; BIOSENSOR; TRANSPORT; MEMBRANES; ANALYTES
AB We describe biosensor elements that are capable of identifying individual DNA strands with single-base resolution. Each biosensor element consists of an individual DNA oligonucleotide covalently attached within the lumen of the cc-hemolysin (alpha HL) pore to form a "DNA-nanopore". The binding of single-stranded DNA (ssDNA) molecules to the tethered DNA strand causes changes in the ionic current flowing through a nanopore. On the basis of DNA duplex lifetimes. the DNA-nanopores are able to discriminate between individual DNA strands up to 30 nucleotides in length differing by a single base substitution. This was exemplified by the detection of a drug resistance-conferring mutation in the reverse transcriptase gene of HIV. In addition, the approach was used to sequence a complete codon in an individual DNA strand tethered to a nanopore.
C1 Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA.
   Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA.
RP Howorka, S (reprint author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, 440 Reynolds Med Bldg, College Stn, TX 77843 USA.
CR ABOULELA F, 1985, NUCLEIC ACIDS RES, V13, P4811, DOI 10.1093/nar/13.13.4811                                                          
   Akeson M, 1999, BIOPHYS J, V77, P3227, DOI 10.1016/S0006-3495(99)77153-5                                                   
   Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5
   Cheley S, 1999, PROTEIN SCI, V8, P1257, DOI 10.1110/ps.8.6.1257                                                             
   COREY DR, 1995, BIOCONJUGATE CHEM, V6, P93, DOI 10.1021/bc00031a011
   Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432
   EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740
   Gu LQ, 1999, NATURE, V398, P686
   Gu LQ, 2001, SCIENCE, V291, P636, DOI 10.1126/science.291.5504.636                                                    
   Henrickson SE, 2000, PHYS REV LETT, V85, P3057, DOI 10.1103/PhysRevLett.85.3057
   Howorka S, 2000, J AM CHEM SOC, V122, P2411, DOI 10.1021/ja993221h                                                               
   Hulteen JC, 1998, J AM CHEM SOC, V120, P6603, DOI 10.1021/ja980045o                                                               
   Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770                                                        
   Meller A, 2000, P NATL ACAD SCI USA, V97, P1079, DOI 10.1073/pnas.97.3.1079
   Movileanu L, 2000, NAT BIOTECHNOL, V18, P1091, DOI 10.1038/80295                                                                   
   Quake SR, 2000, SCIENCE, V290, P1536, DOI 10.1126/science.290.5496.1536
   RICHMAN DD, 1994, J VIROL, V68, P1660
   Rief M, 1999, NAT STRUCT BIOL, V6, P346
   Schmidt C, 2000, ANGEW CHEM INT EDIT, V39, P3137, DOI 10.1002/1521-3773(20000901)39:17<3137::AID-ANIE3137>3.0.CO;2-D                  
   SMITH SM, 1995, ENG APPL ARTIF INTEL, V8, P271, DOI 10.1016/0952-1976(95)00013-Q
   Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859
   Stora T, 1999, ANGEW CHEM INT EDIT, V38, P389, DOI 10.1002/(SICI)1521-3773(19990201)38:3<389::AID-ANIE389>3.0.CO;2-U               
   Strunz T, 1999, P NATL ACAD SCI USA, V96, P11277, DOI 10.1073/pnas.96.20.11277
   Vercoutere W, 2001, NAT BIOTECHNOL, V19, P248, DOI 10.1038/85696
NR 24
TC 492
Z9 500
U1 12
U2 174
PU NATURE AMERICA INC
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUL
PY 2001
VL 19
IS 7
BP 636
EP 639
DI 10.1038/90236
PG 4
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 449HA
UT WOS:000169677200018
PM 11433274
DA 2018-01-05
ER

PT J
AU Isalan, M
   Klug, A
   Choo, Y
AF Isalan, M
   Klug, A
   Choo, Y
TI A rapid, generally applicable method to engineer zinc fingers
   illustrated by targeting the HIV-1 promoter
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID DNA RECOGNITION; TRANSCRIPTION FACTORS; PROTEINS; SELECTION; DOMAINS;
   PHAGE; SEQUENCES; COMPLEX; DESIGN; CODE
AB DNA-binding domains with predetermined sequence specificity are engineered by selection of zinc finger modules using phage display, allowing the construction of customized transcription factors. Despite remarkable progress in this field. the available protein-engineering methods are deficient in many respects, thus hampering the applicability of the technique. Here we present a rapid and convenient method that can be used to design zinc finger proteins against a variety of DNA-binding sites. This is based on a pair of pre-made zinc finger phage-display libraries, which are used in parallel to select two DNA-binding domains each of which recognizes given 5 base pair sequences, and whose products are recombined to produce a single protein that recognizes a composite (9 base pair) site of predefined sequence. Engineering using this system can be completed in less than two weeks and yields proteins that bind sequence-specifically to DNA with K-d values in the nanomolar range. To illustrate the technique, we have selected seven different proteins to bind various regions of the human immunodeficiency virus 1 (HIV-1) promoter.
C1 MRC, Mol Biol Lab, Cambridge CB2 2QH, England.
RP Choo, Y (reprint author), Gendaq Ltd, 1-3 Burtonhole Lane, London NW7 1AD, England.
FU Medical Research Council [U.1051.04.011(78830), MC_U105184324]
CR Beerli RR, 2000, P NATL ACAD SCI USA, V97, P1495, DOI 10.1073/pnas.040552697
   CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11168, DOI 10.1073/pnas.91.23.11168                                                        
   Choo Y, 1998, NAT STRUCT BIOL, V5, P264, DOI 10.1038/nsb0498-264
   Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2
   CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0
   CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163
   CHOO Y, 1995, CURR OPIN BIOTECH, V6, P431, DOI 10.1016/0958-1669(95)80073-5
   Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X
   CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857
   Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133
   ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6
   Greisman HA, 1997, SCIENCE, V275, P657, DOI 10.1126/science.275.5300.657
   Isalan M, 1998, BIOCHEMISTRY-US, V37, P12026, DOI 10.1021/bi981358z                                                               
   Isalan M, 1997, P NATL ACAD SCI USA, V94, P5617, DOI 10.1073/pnas.94.11.5617
   Isalan M, 2000, J MOL BIOL, V295, P471, DOI 10.1006/jmbi.1999.3366                                                          
   JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004
   Kang JS, 2000, J BIOL CHEM, V275, P8742, DOI 10.1074/jbc.275.12.8742                                                         
   Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812
   KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3
   Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200
   Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525                                                         
   MILLER J, 1985, EMBO J, V4, P1609
   Moore M, 2001, P NATL ACAD SCI USA, V98, P1432, DOI 10.1073/pnas.98.4.1432
   Moore M, 2001, P NATL ACAD SCI USA, V98, P1437, DOI 10.1073/pnas.98.4.1437
   PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256
   REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274
   Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758
   Thiesen HJ, 1996, GENE EXPRESSION, V5, P229
   Wolfe SA, 1999, J MOL BIOL, V285, P1917, DOI 10.1006/jmbi.1998.2421
   WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344
   Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200
NR 31
TC 135
Z9 142
U1 2
U2 13
PU NATURE AMERICA INC
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUL
PY 2001
VL 19
IS 7
BP 656
EP 660
DI 10.1038/90264
PG 5
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 449HA
UT WOS:000169677200022
PM 11433278
OA green_accepted
DA 2018-01-05
ER

PT J
AU Rodriguez-Barrios, F
   Perez, C
   Lobaton, E
   Velazquez, S
   Chamorro, C
   San-Felix, A
   Perez-Perez, MJ
   Camarasa, MJ
   Pelemans, H
   Balzarini, J
   Gago, F
AF Rodriguez-Barrios, F
   Perez, C
   Lobaton, E
   Velazquez, S
   Chamorro, C
   San-Felix, A
   Perez-Perez, MJ
   Camarasa, MJ
   Pelemans, H
   Balzarini, J
   Gago, F
TI Identification of a putative binding site for [2 ',5
   '-bis-O-(tert-butyldimethylsilyl)beta-D-ribofuranosyl]-3 '-spiro-5 ''-(4
   ''-amino-1 '',2 ''-oxathiole-2 '',2 ''-dioxide)thymine (TSAO)
   derivatives at the p51-p66 interface of HIV-1 reverse transcriptase
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1;
   2,5-BIS-O-(TERT-BUTYLDIMETHYLSILYL)-3-SPIRO-5-(4-AMINO-1,2-OXATHIOLE-2,2
   -DIOXIDE TSAO; ANTI-HIV-1 ACTIVITY; NUCLEOSIDE ANALOGS; DRUG-RESISTANCE;
   P51 SUBUNIT; NONNUCLEOSIDE INHIBITORS; CONFORMATIONAL-CHANGES; AUTOMATED
   DOCKING; CHIMERIC HIV-1
AB A binding site for TSAO-m(3)T at the interface between the p66 and p51 subunits of HIV-1 reverse transcriptase (RT) and distinct from that of "classical" HIV-1 non-nucleoside inhibitors is proposed. The feasibility of the binding mode was assessed by carrying out nanosecond molecular dynamics simulations for the complexes of TSAO-m(3)T with reduced models of both the wildtype enzyme and a more sensitive R172A mutant. The molecular model is in agreement with a previous proposal, with known structure-activity and mutagenesis data for this unique class of inhibitors, and also with recent biochemical evidence indicating that TSAO analogues can affect enzyme dimerization. The relative importance of residues involved in dimer formation and TSAO-RT complex stabilization was assessed by a combination of surface area accessibility, molecular mechanics, and continuum electrostatics calculations. A structure-based modification introduced into the lead compound yielded a new derivative with improved antiviral activity.
C1 Univ Alcala de Henares, Dept Farmacol, E-28871 Alcala De Henares, Madrid, Spain.
   CSIC, Inst Quim Med, E-28006 Madrid, Spain.
   Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
RP Gago, F (reprint author), Univ Alcala de Henares, Dept Farmacol, E-28871 Alcala De Henares, Madrid, Spain.
EM federico.gago@uah.es
RI Gago, Federico/H-1004-2015; SAN-FELIX, ANA/G-5117-2015; Perez-Perez,
   Maria-Jesus/O-4580-2014; Velazquez, sonsoles/B-6339-2015; Camarasa,
   Maria-Jose/B-6340-2015
OI Gago, Federico/0000-0002-3071-4878; SAN-FELIX, ANA/0000-0003-4271-7598;
   Perez-Perez, Maria-Jesus/0000-0003-1336-7760; Velazquez,
   sonsoles/0000-0003-2209-1751; Camarasa, Maria-Jose/0000-0002-4978-6468
CR Alvarez R, 1998, ANTIVIR CHEM CHEMOTH, V9, P333
   Amacker M, 1998, J MOL BIOL, V278, P757, DOI 10.1006/jmbi.1998.1739
   Arion D, 1996, MOL PHARMACOL, V50, P1057
   BALZARINI J, 1993, MOL PHARMACOL, V43, P109
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   BALZARINI J, 1992, J BIOL CHEM, V267, P11831
   BALZARINI J, 1993, P NATL ACAD SCI USA, V90, P6952, DOI 10.1073/pnas.90.15.6952
   BALZARINI J, 1994, BIOCHEM BIOPH RES CO, V201, P1305, DOI 10.1006/bbrc.1994.1846                                                          
   BALZARINI J, 1993, MOL PHARMACOL, V44, P694
   Balzarini J, 1999, BIOCHEM PHARMACOL, V58, P1
   BASU A, 1992, BIOCHEM BIOPH RES CO, V183, P1131, DOI 10.1016/S0006-291X(05)80308-0
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004                                                             
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P61, DOI 10.1007/BF00124387
   Camarasa MJ, 2000, J CARBOHYD CHEM, V19, P451, DOI 10.1080/07328300008544093                                                       
   CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0
   CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   CZERNECKI S, 1993, NUCLEOS NUCLEOT, V12, P369, DOI 10.1080/07328319308017833
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DIVITA G, 1993, FEBS LETT, V324, P153, DOI 10.1016/0014-5793(93)81383-B
   Divita G, 1995, BIOCHEMISTRY-US, V34, P16337, DOI 10.1021/bi00050a014
   DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P302
   ESNOUF R, UNPUB
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   EVERBY MR, 1986, HETEROCYCLES, V24, P2871
   FOX JJ, 1960, J AM CHEM SOC, V82, P486, DOI 10.1021/ja01487a061                                                             
   Frisch M.J., 1995, GAUSSIAN 94 REVISION
   Garcia-Nieto R, 2000, J COMPUT AID MOL DES, V14, P147, DOI 10.1023/A:1008110924479
   GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002
   GUZIEC FS, 1990, TETRAHEDRON LETT, V31, P23, DOI 10.1016/S0040-4039(00)94324-7                                                   
   Harris D, 1998, BIOCHEMISTRY-US, V37, P5903, DOI 10.1021/bi9728452                                                               
   Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Hubbard SJ, 1993, NACCESS
   INGATE S, 1995, ANTIVIR RES, V27, P281, DOI 10.1016/0166-3542(95)00012-B                                                    
   IUPAC-IUB, 1983, EUR J BIOCHEM, V131, P9
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   JONCKHEERE H, 1994, J BIOL CHEM, V269, P25255
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Khurana JM, 1997, ORG PREP PROCED INT, V29, P1, DOI 10.1080/00304949709355171                                                       
   KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   LUENGO S, UNPUB
   Misra HS, 1998, J BIOL CHEM, V273, P9785, DOI 10.1074/jbc.273.16.9785                                                         
   *MOL SIM INC, 1998, INS 2 VERS 98
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Morris G. M., 1999, AUTODOCK AUTOMATED D
   ORTIZ AR, 1993, J MED CHEM, V36, P1866, DOI 10.1021/jm00065a010
   PALOMINO E, 1990, J MED CHEM, V33, P258, DOI 10.1021/jm00163a043
   PEARLMAN DA, 1995, AMBER VERSION 4 1
   Pelemans H, 1998, J BIOL CHEM, V273, P34234, DOI 10.1074/jbc.273.51.34234                                                        
   Pelemans H, 2001, VIROLOGY, V280, P97, DOI 10.1006/viro.2000.0742
   Perez C, 1998, J MED CHEM, V41, P836, DOI 10.1021/jm970535b
   PEREZPEREZ MJ, 1992, J MED CHEM, V35, P2988, DOI 10.1021/jm00094a009
   Ren JS, 1998, P NATL ACAD SCI USA, V95, P9518, DOI 10.1073/pnas.95.16.9518
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   SCHEIBYE S, 1978, B SOC CHIM BELG, V87, P229
   SCHINAZI RF, 2000, INT ANTIVIRAL NEWS, V8, P65
   Sluis-Cremer N, 2000, BIOCHEMISTRY-US, V39, P1427, DOI 10.1021/bi991682+                                                               
   Velazquez S, 1999, J MED CHEM, V42, P5188, DOI 10.1021/jm991092+
   Velazquez S, 1998, ANTIVIR CHEM CHEMOTH, V9, P481, DOI 10.1177/095632029800900604                                                      
   Velazquez S, 1998, J MED CHEM, V41, P4636, DOI 10.1021/jm980370m
   Velazquez S, 1999, NUCLEOS NUCLEOT, V18, P1029, DOI 10.1080/15257779908041640                                                       
   WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242
   WIGHTMAN R, 1973, COLLECT CZECH CHEM C, V38, P1381, DOI 10.1135/cccc19731381                                                            
NR 69
TC 56
Z9 58
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 7
PY 2001
VL 44
IS 12
BP 1853
EP 1865
DI 10.1021/jm001095i
PG 13
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 438HK
UT WOS:000169047400003
PM 11384232
DA 2018-01-05
ER

PT J
AU Chan, JH
   Hong, JS
   Hunter, RN
   Orr, GF
   Cowan, JR
   Sherman, DB
   Sparks, SM
   Reitter, BE
   Andrews, CW
   Hazen, RJ
   St Clair, M
   Boone, LR
   Ferris, RG
   Creech, KL
   Roberts, GB
   Short, SA
   Weaver, K
   Ott, RJ
   Ren, JS
   Hopkins, A
   Stuart, DI
   Stammers, DK
AF Chan, JH
   Hong, JS
   Hunter, RN
   Orr, GF
   Cowan, JR
   Sherman, DB
   Sparks, SM
   Reitter, BE
   Andrews, CW
   Hazen, RJ
   St Clair, M
   Boone, LR
   Ferris, RG
   Creech, KL
   Roberts, GB
   Short, SA
   Weaver, K
   Ott, RJ
   Ren, JS
   Hopkins, A
   Stuart, DI
   Stammers, DK
TI 2-amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse
   transcriptase inhibitors of HIV-1
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NONNUCLEOSIDE INHIBITOR; DATA-COLLECTION;
   ARYL SULFONES; TYPE-1; DESIGN; CRYSTALLOGRAPHY; COMBINATIONS;
   REPLICATION; RESOLUTION
AB series of 2-amino-5-arylthiobenzonitriles (1) was found to be active against HIV-1. Structural modifications led to the sulfoxides (2) and sulfones (3). The sulfoxides generally showed antiviral activity against HIV-1 similar to that of 1. The sulfones, however, were the most potent series of analogues, a number having activity against HIV-1 in the nanomolar range. Structural-activity relationship (SAR) studies suggested that a meta substituent, particularly a meta methyl substituent, invariably increased antiviral activities. However, optimal antiviral activities were manifested by compounds where both meta groups in the arylsulfonyl moiety were substituted and one of the substituents was a methyl group. Such a disubstitution led to compounds 3v, 3w, 3x, and 3y having IC50 values against HIV-1 in the low nanomolar range. When gauged for their broad-spectrum antiviral activity against key non-nucleoside reverse transcriptase inhibitor (NNRTI) related mutants, all the di-meta-substituted sulfones 3u-z and the 2-naphthyl analogue 3ee generally showed single-digit nanomolar activity against the V106A and P236L strains and submicromolar to low nanomolar activity against strains E138K, V108I, and Y188C. However, they showed a lack of activity against the K103N and Y181C mutant viruses. The elucidation of the X-ray crystal structure of the complex of 3v (739W94) in HIV-1 reverse transcriptase showed an overlap in the binding domain when compared with the complex of nevirapine in HIV-1 reverse transcriptase. The X-ray structure allowed for the rationalization of SAR data and potencies of the compounds against the mutants.
C1 Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA.
   Univ Oxford, Struct Biol Div, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
   Univ Oxford, Oxford Ctr Mol Sci, Oxford OX1 3QT, England.
RP Chan, JH (reprint author), Glaxo Wellcome Inc, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.
CR ARTICO M, 1995, ARCH PHARM, V328, P223, DOI 10.1002/ardp.19953280304
   Artico M, 2000, J MED CHEM, V43, P1886, DOI 10.1021/jm9901125
   Artico M, 1996, FARMACO, V51, P305
   ASHTON WT, 1973, J MED CHEM, V16, P1233, DOI 10.1021/jm00269a005
   BABA M, 1995, NUCLEOS NUCLEOT, V14, P575, DOI 10.1080/15257779508012431
   Bacheler LT, 2000, ANTIMICROB AGENTS CH, V44, P2475, DOI 10.1128/AAC.44.9.2475-2484.2000                                                 
   Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254
   Buckheit RW, 1996, ANTIVIR CHEM CHEMOTH, V7, P243, DOI 10.1177/095632029600700504                                                      
   CHAN JH, 1995, J MED CHEM, V38, P3608, DOI 10.1021/jm00018a021                                                             
   Corbett JW, 1999, ANTIMICROB AGENTS CH, V43, P2893
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1                                                   
   Esnouf RM, 1998, ACTA CRYSTALLOGR D, V54, P938, DOI 10.1107/S0907444998004284
   Freimuth WW, 1996, ADV EXP MED BIOL, V394, P279
   FRIEDMAN L, 1961, J ORG CHEM, V26, P2522, DOI 10.1021/jo01351a092                                                             
   Fujiwara T, 1998, ANTIMICROB AGENTS CH, V42, P1340
   FURMAN PA, 1998, USE MKC 442 COMB OTH
   HARVEY RJ, 1982, REV INFECT DIS, V4, P255
   Hogg RS, 1998, AIDS, V12, P279, DOI 10.1097/00002030-199803000-00005                                                
   Hopkins AL, 1999, J MED CHEM, V42, P4500, DOI 10.1021/jm990192c
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   HYNES JB, 1988, J HETEROCYCLIC CHEM, V25, P1173, DOI 10.1002/jhet.5570250425                                                         
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KELLAM P, 1994, ANTIMICROB AGENTS CH, V38, P23, DOI 10.1128/AAC.38.1.23                                                             
   KIMPTON J, 1992, J VIROL, V66, P2232
   MCMAHON JB, 1993, ANTIMICROB AGENTS CH, V37, P754, DOI 10.1128/AAC.37.4.754                                                            
   MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396                                                       
   MOEREMANS M, 1995, 4 INT WORKSH HIV DRU, P33
   Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930                                                         
   NEWMAN H, 1969, J ORG CHEM, V34, P1463, DOI 10.1021/jo01257a060                                                             
   Otwinowski Z., 1993, DATA COLLECTION PROC
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Ren JS, 2000, J BIOL CHEM, V275, P14316, DOI 10.1074/jbc.275.19.14316
   Richman D., 2000, PRACTICAL GUIDE HIV
   RICHMAN DD, 1992, AIDS RES HUM RETROV, V8, P1065, DOI 10.1089/aid.1992.8.1065
   SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U
   SCHINAZI RF, 1992, AIDS RES HUM RETROV, V8, P963, DOI 10.1089/aid.1992.8.963                                                          
   SCHINAZI RF, 2000, INT ANTIVIRAL NEWS, V8, P65
   Snyder HR, 1941, J AM CHEM SOC, V63, P3280, DOI 10.1021/ja01857a016                                                             
   STAMMERS DK, 1994, J MOL BIOL, V242, P586, DOI 10.1006/jmbi.1994.1604
   STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041                                                             
   STUART DI, 1993, CURR OPIN STRUC BIOL, V3, P737, DOI 10.1016/0959-440X(93)90057-R
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
   Wishka DG, 1998, J MED CHEM, V41, P1357, DOI 10.1021/jm9801049
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
NR 47
TC 76
Z9 80
U1 2
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD JUN 7
PY 2001
VL 44
IS 12
BP 1866
EP 1882
DI 10.1021/jm0004906
PG 17
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 438HK
UT WOS:000169047400004
PM 11384233
DA 2018-01-05
ER

PT J
AU Liu, JQ
   Zhang, Q
   Remsen, EE
   Wooley, KL
AF Liu, JQ
   Zhang, Q
   Remsen, EE
   Wooley, KL
TI Nanostructured materials designed for cell binding and transduction
SO BIOMACROMOLECULES
LA English
DT Article
ID CROSS-LINKED NANOPARTICLES; TARGETED DRUG-DELIVERY; BIOLOGICAL-SYSTEMS;
   PEPTIDE; NANOSPHERES; MICELLES; VEHICLES; POLYMERS; KNEDELS; MOUSE
AB The surface-functionalization of shell cross-linked (SCK) nanoparticles with the oligomeric peptide sequence YGRKKRRQRRR, the protein transduction domain (PTD) from the human immunodeficiency virus TAT protein, is described, and the cell binding interactions these nanobioconjugates exhibit are demonstrated. A convergent synthetic strategy was employed, whereby the SCK nanoparticles and the PTD were prepared independently and then coupled together during immobilization of the PTD component on a solid support. The SCK nanoparticles were prepared by the micellization of amphiphilic block copolymers of poly(epsilon-caprolactone-b-acrylic acid), followed by amidation-based cross-linking of the acrylic acid residues located within the micellar corona, The PTD sequence was constructed upon a solid support, from C-terminus to N-terminus, followed by extension with four glycine residues, leaving the amino chain end for subsequent coupling with remaining acrylic acid functionalities present on the surface of the SCK. Finally, cleavage from the solid support was performed, which also facilitated deprotection of the peptide side chain functionalities as well as hydrolysis of the poly(epsilon-caprolactone) segments composing the SCK core domain, to yield PTD-derivatized nanocage structures (PTD-nanocage). Covalent labeling of the SCK precursor with fluorescein-5-thiosemicarbazide provided fluorescently tagged PTD-nanocage nanobioconjugates to allow for their detection by fluorescence microscopy. The fluorescent PTD-nanocage bioconjugates were found to interact with CHO cells and HeLa cells, whereas the analogous structure lacking the PTD component did not. CHO cells bound with fluorescent PTD-nanocage bioconjugates were analyzed using flow cytometry and fluorescence activated cell sorting (FACS). Fluorescence confocal microscopy of isolated bioconjugate-bound CHO cells indicated that the bioconjugated nanoparticles were primarily located near the cell periphery; however, transduction of the nanoparticle into the cells also occurred.
C1 Washington Univ, Dept Chem, St Louis, MO 63130 USA.
RP Wooley, KL (reprint author), Washington Univ, Dept Chem, 1 Brookings Dr,CB1134, St Louis, MO 63130 USA.
RI Wooley, Karen/D-4399-2015; Liu, Jianquan/B-5740-2011
OI Wooley, Karen/0000-0003-4086-384X; Liu, Jianquan/0000-0002-4773-4250
CR Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Baugher AH, 1998, BIOPHYS J, V75, P2574, DOI 10.1016/S0006-3495(98)77702-1                                                   
   Bhorade R, 2000, BIOCONJUGATE CHEM, V11, P301, DOI 10.1021/bc990168d                                                               
   Cha JN, 2000, MATER RES SOC SYMP P, V599, P239
   Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2
   Duncan R, 1999, PHARM SCI TECHNOL TO, V2, P441, DOI DOI 10.1016/S1461-5347(99)00211-4
   DUNCAN R, 2000, ACS SYM SER, V752, P350
   Hermanson G. T., 1995, BIOCONJUGATE TECHNIQ
   Huang HY, 1999, J AM CHEM SOC, V121, P3805, DOI 10.1021/ja983610w                                                               
   Huang HY, 1997, J AM CHEM SOC, V119, P11653, DOI 10.1021/ja9717469                                                               
   Huang HY, 2001, MACROMOLECULES, V34, P547, DOI 10.1021/ma001003z
   KATAOKA K, 1993, J CONTROL RELEASE, V24, P119
   KATAOKA K, 1997, CONTROLLED DRUG DELI, P629
   Kiessling LL, 2000, ANNU REP MED CHEM, V35, P321, DOI 10.1016/S0065-7743(00)35030-8
   Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X
   Kono K, 1999, BIOCONJUGATE CHEM, V10, P1115, DOI 10.1021/bc990082k
   Langer R, 1998, NATURE, V392, P5
   Lewin M, 2000, NAT BIOTECHNOL, V18, P410
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   Percec V, 2000, BIOMACROMOLECULES, V1, P6, DOI 10.1021/bm005507g
   Piotti ME, 1999, J AM CHEM SOC, V121, P9471, DOI 10.1021/ja991879p                                                               
   Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y
   Reuter JD, 1999, BIOCONJUGATE CHEM, V10, P271, DOI 10.1021/bc980099n
   RINGSDORF G, 1987, Zhurnal Vsesoyuznogo Khimicheskogo Obshchestva Imeni D. I. Mendeleeva, V32, P487
   SCHOLES PD, 1997, CONTROLLED DRUG DELI, P629
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SEYMOUR LW, 1991, SELECT CANCER THER, V7, P59, DOI 10.1089/sct.1991.7.59
   Seymour L.W., 1987, J BIOACT COMPAT POLY, V2, P97
   STOCK RS, 1985, J POLYM SCI POL PHYS, V23, P1393, DOI 10.1002/pol.1985.180230707
   STUDELSKA DR, UNPUB
   Stupp SI, 2000, MRS BULL, V25, P42, DOI 10.1557/mrs2000.28                                                              
   Teng HB, 1999, J NEUROSCI, V19, P4855
   Thurmond KB, 1997, J AM CHEM SOC, V119, P6656, DOI 10.1021/ja9710520                                                               
   Thurmond KB, 1999, NUCLEIC ACIDS RES, V27, P2966, DOI 10.1093/nar/27.14.2966                                                          
   Veronese FM, 1999, FARMACO, V54, P497, DOI 10.1016/S0014-827X(99)00066-X
   Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003
   Wooley KL, 2000, J POLYM SCI POL CHEM, V38, P1397, DOI 10.1002/(SICI)1099-0518(20000501)38:9<1397::AID-POLA1>3.0.CO;2-N                
   Zhang Q, 2000, J AM CHEM SOC, V122, P3642, DOI 10.1021/ja993941o                                                               
NR 39
TC 123
Z9 125
U1 3
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525-7797
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD SUM
PY 2001
VL 2
IS 2
BP 362
EP 368
DI 10.1021/bm015515c
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA 528RF
UT WOS:000174256200005
PM 11749193
DA 2018-01-05
ER

PT J
AU Perlow, RA
   Broyde, S
AF Perlow, RA
   Broyde, S
TI Evading the proofreading machinery of a replicative DNA polymerase:
   Induction of a mutation by an environmental carcinogen
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Review
DE benzo[a]pyrene; DNA polymerase; mutagenesis; environmental carcinogen;
   molecular dynamics simulations
ID (+)-ANTI-BENZO<A>PYRENE DIOL EPOXIDE; POLYCYCLIC AROMATIC-HYDROCARBONS;
   IN-VITRO REPLICATION; GROOVE BINDING TRACK; VERTICAL-SCANNING
   MUTAGENESIS; HIV-1 REVERSE-TRANSCRIPTASE; TEMPLATE-PRIMER JUNCTION;
   SINGLE-TURNOVER KINETICS; ESCHERICHIA-COLI PLASMID; FREE-ENERGY ANALYSIS
AB DNA replication fidelity is dictated by DNA polymerase enzymes and associated proteins. When the template DNA is damaged by a carcinogen, the fidelity of DNA replication is sometimes compromized, allowing mispaired bases to persist and be incorporated into the DNA, resulting in a mutation. A key question in chemical carcinogenesis by metabolically activated polycyclic aromatic hydrocarbons (PAHs) is the nature of the interactions between the carcinogen-damaged DNA and the replicating polymerase protein that permits the mutagenic misincorporation to occur. PAHs are environmental carcinogens that, upon metabolic activation, can react with DNA to form bulky covalently linked combination molecules known as carcinogen-DNA adducts. Benzo[a]pyrene (BP) is a common PAH found in a wide range of material ingested by humans, including cigarette smoke, car exhaust, broiled meats and fish, and as a contaminant in other foods. BP is metabolically activated into several highly reactive intermediates, including the highly tumorigenic (+)-antibenzo[a]pyrene diol epoxide (BPDE). The primary product of the reaction of (+)-anti-BPDE with DNA, the (+)-trans-anti-benzo[a]pyrene diol epoxide-N-2-dG ((+)-ta-[BP]G) adduct, is the most mutagenic BP adduct in mammalian systems and primarily causes G-to-T transversion mutations, resulting from the mismatch of adenine with BP-damaged guanine during replication. In order to elucidate the structural characteristics and interactions between the DNA polymerase and carcinogen-damaged DNA that allow a misincorporation opposite a DNA lesion, we have modeled a (+)-ta-[BP]G adduct at a primer-template junction within the replicative phage T7 DNA polymerase containing an incoming dATP, the nucleotide most commonly mismatched with the (+)-ta-[BP]G adduct during replication. A one nanosecond molecular dynamics simulation, using AMBER 5.0, has been carried out, and the resultant trajectory analyzed. The modeling and simulation have revealed that a (+)-ta-[BP]G:A mismatch can be accommodated stably in the active site so that the fidelity mechanisms of the polymerase are evaded and the polymerase accepts the incoming mutagenic base. In this structure, the modified guanine base is in the syn conformation, with the BP moiety positioned in the major groove, without interfering with the normal protein-DNA interactions required for faithful polymerase function. This structure is stabilized by a hydrogen bond between the modified guanine base and dATP partner, hydrophobic interactions between the BP moiety and the polymerase, a hydrogen bond between the modified guanine base and the polymerase, and several hydrogen bonds between the BP moiety and polymerase side-chains. Moreover, the G:A mismatch in this system closely resembles the size and shape of a normal Watson-Crick pair. These features reveal how the polymerase proofreading machinery may be evaded in the presence of a mutagenic carcinogen-damaged DNA, so that a mismatch can be accommodated readily, allowing bypass of the adduct by the replicative T7 DNA polymerase. (C) 2001 Academic Press.
C1 NYU, Dept Biol, New York, NY 10003 USA.
RP Broyde, S (reprint author), NYU, Dept Biol, 100 Washington Sq E Room 1009M, New York, NY 10003 USA.
FU NCI NIH HHS [CA28038]
CR Alekseyev YO, 2000, BIOCHEMISTRY-US, V39, P10431, DOI 10.1021/bi000552u
   Alekseyev YO, 2001, BIOCHEMISTRY-US, V40, P2282, DOI 10.1021/bi002245u
   AQVIST J, 1990, J PHYS CHEM-US, V94, P8021
   Auffinger P, 1998, CURR OPIN STRUC BIOL, V8, P227, DOI 10.1016/S0959-440X(98)80044-4
   Barsky D, 1999, J BIOMOL STRUCT DYN, V16, P1119, DOI 10.1080/07391102.1999.10508321                                                  
   Baynton K, 2000, TRENDS BIOCHEM SCI, V25, P74, DOI 10.1016/S0968-0004(99)01524-8
   Beard WA, 1998, J BIOL CHEM, V273, P30435, DOI 10.1074/jbc.273.46.30435
   Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3
   Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194
   Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Beveridge DL, 2000, CURR OPIN STRUC BIOL, V10, P182, DOI 10.1016/S0959-440X(00)00076-2
   Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9
   BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358
   CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007
   Carrell CJ, 1997, CARCINOGENESIS, V18, P415, DOI 10.1093/carcin/18.2.415
   Case DA, 1999, AMBER 6
   Case D. A., 1997, AMBER 5 0
   CHARY P, 1995, J BIOL CHEM, V270, P4990, DOI 10.1074/jbc.270.10.4990                                                         
   CHARY P, 1995, NUCLEIC ACIDS RES, V23, P1398, DOI 10.1093/nar/23.8.1398
   CHEATHAM T, 1998, J BIOMOL STRUCT DYN, V16, P845
   Cheatham TE, 1998, J BIOMOL STRUCT DYN, V16, P265, DOI 10.1080/07391102.1998.10508245                                                  
   Cheatham TE, 2000, ANNU REV PHYS CHEM, V51, P435, DOI 10.1146/annurev.physchem.51.1.435                                               
   CONNEY AH, 1982, CANCER RES, V42, P4875
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002                                                             
   COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043
   COSMAN M, 1994, BIOCHEMISTRY-US, V33, P11507, DOI 10.1021/bi00204a013
   COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914
   DAHLBERG ME, 1991, BIOCHEMISTRY-US, V30, P4835, DOI 10.1021/bi00234a002
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430
   Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647
   Doublie S, 1998, NATURE, V391, P251
   Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4
   ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477
   EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039
   Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0
   Feng BB, 1997, BIOCHEMISTRY-US, V36, P13769, DOI 10.1021/bi970069s
   Fernandes A, 1998, BIOCHEMISTRY-US, V37, P10164, DOI 10.1021/bi980401f                                                               
   FOUNTAIN MA, 1995, BIOCHEMISTRY-US, V34, P3152, DOI 10.1021/bi00010a004
   Frieden M, 1999, ANGEW CHEM INT EDIT, V38, P3654
   Frisch M.J., 1995, GAUSSIAN 94 REVISION
   Garner RC, 1998, MUTAT RES-FUND MOL M, V402, P67
   Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418                                                               
   Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051                                                                
   GRIMMER G, 1993, POLYCYCLIC AROMATIC COMPOUNDS : SYNTHESIS, PROPERTIES, ANALYTICAL MEASUREMENTS, OCCURRENCE AND BIOLOGICAL EFFECTS, P31
   Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151
   Hanrahan CJ, 1997, CHEM RES TOXICOL, V10, P369, DOI 10.1021/tx9601925
   Harvey R. G., 1991, POLYCYCLIC AROMATIC
   HINGERTY BE, 1985, BIOPOLYMERS, V24, P427, DOI 10.1002/bip.360240302
   HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829
   HRUSZKEWYCZ A, 1992, CARCINOGENESIS, V13, P2347, DOI 10.1093/carcin/13.12.2347                                                       
   Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9                                                   
   Jayaram B, 1998, J AM CHEM SOC, V120, P10629, DOI 10.1021/ja981307p                                                               
   Jayaram B, 1999, J COMPUT PHYS, V151, P333, DOI 10.1006/jcph.1998.6173
   JELINSKY SA, 1995, BIOCHEMISTRY-US, V34, P13545, DOI 10.1021/bi00041a034
   JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345                                             
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869                                                                
   Keohavong P, 1998, DNA CELL BIOL, V17, P541, DOI 10.1089/dna.1998.17.541
   Kiefer JR, 1998, NATURE, V391, P304
   Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X
   KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7
   Kool ET, 2000, ANGEW CHEM INT EDIT, V39, P990, DOI 10.1002/(SICI)1521-3773(20000317)39:6<990::AID-ANIE990>3.0.CO;2-0               
   KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264
   Kozack RE, 1999, CARCINOGENESIS, V20, P95, DOI 10.1093/carcin/20.1.95
   KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057                                                             
   KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012
   Langouet S, 1997, BIOCHEMISTRY-US, V36, P6069, DOI 10.1021/bi962526v
   Latham GJ, 2000, J BIOL CHEM, V275, P15025, DOI 10.1074/jbc.M000279200
   Lenne-Samuel N, 2000, MOL MICROBIOL, V38, P299, DOI 10.1046/j.1365-2958.2000.02116.x                                                
   Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491
   Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514
   LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018
   Lipinski LJ, 1998, INT J ONCOL, V13, P269
   Lu XJ, 2000, J MOL BIOL, V300, P819, DOI 10.1006/jmbi.2000.3690
   MACKAY W, 1992, CARCINOGENESIS, V13, P1415, DOI 10.1093/carcin/13.8.1415
   Matray TJ, 1999, NATURE, V399, P704, DOI 10.1038/21453                                                                   
   Minamoto T, 1999, CARCINOGENESIS, V20, P519, DOI 10.1093/carcin/20.4.519
   Morales JC, 1999, J AM CHEM SOC, V121, P2323, DOI 10.1021/ja983502+
   Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925
   Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506
   Moriya M, 1996, BIOCHEMISTRY-US, V35, P16646, DOI 10.1021/bi9608875
   Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259
   NEIDLE S, 1981, CARCINOGENESIS, V2, P533, DOI 10.1093/carcin/2.6.533
   NEIDLE S, 1982, CANCER RES, V42, P3766
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566
   Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d
   PERRIN J, 1993, P 13 INT S POL AR HY
   Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2                                                   
   Ploch SA, 1998, TOXICOL APPL PHARM, V149, P90, DOI 10.1006/taap.1997.8359
   POLESKY AH, 1992, J BIOL CHEM, V267, P8417
   RODRIGUEZ H, 1993, CARCINOGENESIS, V14, P373, DOI 10.1093/carcin/14.3.373
   Saenger W., 1984, PRINCIPLES NUCL ACID
   Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449
   Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812
   SHARP KA, 1990, ANNU REV BIOPHYS BIO, V19, P301, DOI 10.1146/annurev.bb.19.060190.001505
   Shukla R, 1997, BIOCHEMISTRY-US, V36, P13263, DOI 10.1021/bi971195z                                                               
   Shukla R, 1997, BIOCHEMISTRY-US, V36, P10256, DOI 10.1021/bi970541+                                                               
   Shukla R, 1999, CARCINOGENESIS, V20, P261, DOI 10.1093/carcin/20.2.261                                                         
   Singh SB, 1998, BIOCHEMISTRY-US, V37, P878, DOI 10.1021/bi9720639                                                               
   SINGH SB, 1991, CANCER RES, V51, P3482
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043                                                             
   SLAGA TJ, 1979, CANCER RES, V39, P67
   SLOANE DL, 1988, NUCLEIC ACIDS RES, V16, P6465, DOI 10.1093/nar/16.14.6465                                                          
   Smith LE, 2000, J NATL CANCER I, V92, P803, DOI 10.1093/jnci/92.10.803
   Srinivasan J, 1998, J AM CHEM SOC, V120, P9401, DOI 10.1021/ja981844+                                                               
   Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395
   TABOR S, 1987, J BIOL CHEM, V262, P16212
   THRALL BD, 1992, CARCINOGENESIS, V13, P1529, DOI 10.1093/carcin/13.9.1529
   Topinka J, 1998, MUTAT RES-GEN TOX EN, V419, P91, DOI 10.1016/S1383-5718(98)00127-2                                                   
   Vande Berg Brian J., 2001, Journal of Biological Chemistry, V276, P3408, DOI 10.1074/jbc.M002884200
   Vineis P, 1999, MUTAT RES-REV MUTAT, V436, P185
   WEAST R, 1978, CRC HDB CHEM PHYSICS, pD230
   WEI, 1999, INT J ONCOL, V14, P509
   WEI SJC, 1993, CANCER RES, V53, P3294
   WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030
   Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191                                                          
   Wu XY, 1999, CHEM RES TOXICOL, V12, P895, DOI 10.1021/tx990108w
   Yang HY, 1999, MUTAT RES-FUND MOL M, V423, P23, DOI 10.1016/S0027-5107(98)00221-8
   Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138                                                          
NR 123
TC 34
Z9 34
U1 0
U2 7
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD JUN 1
PY 2001
VL 309
IS 2
BP 519
EP 536
DI 10.1006/jmbi.2001.4674
PG 18
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 442CB
UT WOS:000169266700014
PM 11371169
DA 2018-01-05
ER

PT J
AU Kuhelj, R
   Rizzo, CJ
   Chang, CH
   Jadhav, PK
   Towler, EM
   Korant, BD
AF Kuhelj, R
   Rizzo, CJ
   Chang, CH
   Jadhav, PK
   Towler, EM
   Korant, BD
TI Inhibition of human endogenous retrovirus-K10 protease in cell-free and
   cell-based assays
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS PROTEASE; TIGHT-BINDING INHIBITORS; CYCLIC UREA
   AMIDES; HIV PROTEASE; HERV-K; MOLECULAR RECOGNITION; TROPHOBLASTIC
   TUMORS; STRUCTURAL-ANALYSIS; DRUG-RESISTANCE; GERM-CELL
AB A full-length and C-terminally truncated version of human endogenous retrovirus (HERV)-K10 protease were expressed in Escherichia coli and purified to homogeneity. Both versions of the protease efficiently processed HERV-K10 Gag polyprotein substrate. HERV-K10 Gag was also cleaved by human immunodeficiency virus, type 1 (HIV-1) protease, although at different sites. To identify compounds that could inhibit protein processing dependent on the HERV-K10 protease, a series of cyclic ureas that had previously been shown to inhibit HIV-1 protease was tested. Several symmetric bisamides acted as very potent inhibitors of both the truncated and full-length form of HERV-K10 protease, in subnanomolar or nanomolar range, respectively. One. of the cyclic ureas, SD146, can inhibit the processing of in vitro translated HERV-K10 Gag polyprotein substrate by HERV-K10 protease. In addition, in virus-like particles isolated from the teratocarcinoma cell line NCCIT, there is significant accumulation of Gag and Gag-Pol precursors upon treatment with SD146, suggesting the compound efficiently blocks HERV-K Gag processing in cells. This is the first report of an inhibitor able to block cell-associated processing of Gag polypeptides of an endogenous retrovirus.
C1 Dupont Merck Pharmaceut Co, Dept Virol, Expt Stn E336 22, Wilmington, DE 19880 USA.
   Dupont Merck Pharmaceut Co, Dept Chem & Phys Sci, Expt Stn E336 22, Wilmington, DE 19880 USA.
   NCI, SAIC Frederick, Frederick Canc Res & Dev Ctr, Prot Chem Lab,NIH, Frederick, MD USA.
RP Korant, BD (reprint author), Dupont Merck Pharmaceut Co, Dept Virol, Expt Stn E336 22, POB 80336, Wilmington, DE 19880 USA.
EM bruce.d.korant@dupontpharma.com
CR Ala PJ, 1998, J BIOL CHEM, V273, P12325, DOI 10.1074/jbc.273.20.12325                                                        
   Ala PJ, 1998, BIOCHEMISTRY-US, V37, P15042, DOI 10.1021/bi980386e                                                               
   Ala PJ, 1997, BIOCHEMISTRY-US, V36, P1573, DOI 10.1021/bi962234u
   ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472
   Ausubel F., 1987, CURRENT PROTOCOLS MO
   Bing OHL, 1998, J MOL CELL CARDIOL, V30, P1257, DOI 10.1006/jmcc.1998.0723                                                          
   Boeke J. D., 1997, P343
   BOLLER K, 1993, VIROLOGY, V196, P349, DOI 10.1006/viro.1993.1487
   BRONSON DL, 1979, J NATL CANCER I, V63, P337
   CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7
   CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660
   De Lucca G V, 1998, Pharm Biotechnol, V11, P257
   ERICKSONVIITANEN S, 1994, ANTIMICROB AGENTS CH, V38, P1628, DOI 10.1128/AAC.38.7.1628                                                           
   Herbst H, 1998, APMIS, V106, P216, DOI 10.1111/j.1699-0463.1998.tb01338.x                                              
   Herbst H, 1996, AM J PATHOL, V149, P1727
   Jadhav PK, 1997, J MED CHEM, V40, P181, DOI 10.1021/jm960586t
   KAGEYAMA S, 1994, AIDS RES HUM RETROV, V10, P735, DOI 10.1089/aid.1994.10.735
   KING RW, 1995, ANTIVIR RES, V28, P13, DOI 10.1016/0166-3542(95)00033-I
   Klabe RM, 1998, BIOCHEMISTRY-US, V37, P8735, DOI 10.1021/bi972555l
   Knerr I, 1999, PEDIATR RES, V46, P57, DOI 10.1203/00006450-199907000-00010                                                
   KURTH R, 1980, ONCONAVIRUS SYTHETIS, P835
   Lam PYS, 1996, J MED CHEM, V39, P3514, DOI 10.1021/jm9602571
   LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812
   LAMBERT DM, 1992, ANTIMICROB AGENTS CH, V36, P982, DOI 10.1128/AAC.36.5.982                                                            
   Larsson E, 1998, SCAND J IMMUNOL, V48, P329
   LEIBMOSCH C, 1993, GENOMICS, V18, P261, DOI 10.1006/geno.1993.1464                                                          
   Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177
   LOWER R, 1993, P NATL ACAD SCI USA, V90, P4480, DOI 10.1073/pnas.90.10.4480
   LOWER R, 1993, VIROLOGY, V192, P501, DOI 10.1006/viro.1993.1066
   Mayer J, 1999, NAT GENET, V21, P257
   MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3
   MUELLERLANTZSCH N, 1993, AIDS RES HUM RETROV, V9, P343, DOI 10.1089/aid.1993.9.343
   ONO M, 1986, J VIROL, V60, P589
   PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120                                                          
   PADOW M, 2001, AIDS RES HUM RETROV, V16, P1973
   Patience C, 1996, J VIROL, V70, P2654
   RAYNER MM, 1994, ANTIMICROB AGENTS CH, V38, P1635, DOI 10.1128/AAC.38.7.1635                                                           
   Rodgers JD, 1998, BIOORG MED CHEM LETT, V8, P715, DOI 10.1016/S0960-894X(98)00118-8                                                   
   SAUTER M, 1995, J VIROL, V69, P414
   Schommer S, 1996, J GEN VIROL, V77, P375, DOI 10.1099/0022-1317-77-2-375                                                      
   Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571                                                         
   Taruscio D, 1996, TERATOLOGY, V54, P108
   Tonjes RR, 1996, J ACQ IMMUN DEF SYND, V13, pS261
   Tonjes RR, 1997, VIROLOGY, V233, P280, DOI 10.1006/viro.1997.8614
   Tonjes RR, 1999, J VIROL, V73, P9187
   Towler EM, 1998, BIOCHEMISTRY-US, V37, P17137, DOI 10.1021/bi9818927
   Tristem M, 2000, J VIROL, V74, P3715, DOI 10.1128/JVI.74.8.3715-3730.2000
   WONDRAK EM, 1991, FEBS LETT, V280, P347, DOI 10.1016/0014-5793(91)80328-Z
NR 48
TC 6
Z9 7
U1 0
U2 0
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 18
PY 2001
VL 276
IS 20
BP 16674
EP 16682
DI 10.1074/jbc.M008763200
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 432ZG
UT WOS:000168730400013
PM 11278433
OA gold
DA 2018-01-05
ER

PT J
AU Bewley, CA
   Otero-Quintero, S
AF Bewley, CA
   Otero-Quintero, S
TI The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate
   binding sites that selectively bind to man(8) D1D3 and Man(9) with
   nanomolar affinity: Implications for binding to the HIV envelope protein
   gp120
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; INACTIVATING PROTEIN; CONCANAVALIN-A;
   GLYCOPROTEIN GP120; VACCINIA VIRUS; TYPE-1; CD4; INHIBITION; COMPLEX;
   FUSION
AB Cyanovirin-N (CVN) is a monomeric II kDa cyanobacterial protein that potently inactivates diverse strains of human immunodeficiency virus (HIV) at the level of cell fusion by virtue of high affinity interactions with the surface envelope glycoprotein gp120. Several lines of evidence have suggested that CVN-gp120 interactions are in part mediated by N-linked complex carbohydrates present on gp120, but experimental evidence has been lacking. To this end we screened a comprehensive panel of carbohydrates which represent structurally the N-linked carbohydrates found on gp120 for their ability to inhibit the fusion-blocking activity of CVN in a quantitative HIV-1 envelope-mediated cell fusion assay. Our results show that CVN specifically recognizes with nanomolar affinity Man(9)GlcNAc(2) and the D1D3 isomer of ManpGlcNAc(2). Nonlinear least squares best fitting of titration data generated using the cell fusion assay show that CVN binds to gp120 with an equilibrium association constant (K-a) of 2.4 (+/- 0.1) x 10(7) M-1 and an apparent stoichiometry of 2 equiv of CVN per gp120, Man(8)GlcNAc(2) DID3 acts as a divalent ligand (2 CVN:I Man(8)) with a K-a of 5.4 (+/- 0.5) x 10(7) M-1, and Man(9)GlcNAc(2) functions as a trivalent ligand (3 CVN:1 Man(9)) with a K-a of 1.3 (+/- 0.3) x 10(8) M-1 Isothermal titration calorimetry experiments of CVN binding to Man(9)GlcNAc(2) at micromolar concentrations confirmed the nanomolar affinity (K-a = 1.5 (+/- 0.9) x 10(8) M-1), and the fitted data indicated a stoichiometry equal to approximately one (1 Man(9):1 CVN). The 1:1 stoichiometry at micromolar concentrations suggested that CVN has not only a high affinity binding site-relevant to the studies at nM concentrations-but a lower affinity site as well that facilitates cross-linking of CVN-oligomannose at micromolar concentrations or higher. The specificity of CVN for Man(8) D1D3 and Mans over the D1D2 isomer of Man(8) indicated that the minimum structure required for high affinity binding comprises Man alpha1 --> 2Man alpha. By following the H-1-N-15 correlation spectrum of N-15-Iabeled CVN upon titration with this disaccharide, we unambiguously demonstrate that CVN recognizes and binds to the disaccharide Man alpha1 --> 2Mana via two distinct binding sites of differing affinities located on opposite ends of the protein. The high affinity site has a K, of 7.2 (+/- 4) x 10(6) M(-)1 and the low affinity site a kj of 6.8 (+/- 4) x 10(5) RI-l as determined by isothermal titration calorimetry. Mapped surfaces of the carbohydrate binding sites are presented, and implications for binding to gp120 are discussed.
C1 NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Bewley, CA (reprint author), NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA.
CR ALEXANDER WA, 1992, J VIROL, V66, P2934
   Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828
   BEWLEY CA, 2000, J AM CHEM SOC, V122, P6069
   Biller M, 1998, J VIROL METHODS, V76, P87, DOI 10.1016/S0166-0934(98)00127-X
   BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863
   Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521
   Brewer C. F, 1996, CHEMTRACTS BIOCH MOL, V6, P165
   BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004
   Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572
   Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0
   CHANCE EM, 1978, R8775 AT EN RES EST
   Clore GM, 1983, COMPUTING BIOL SCI, P313
   CURTIS AR, 1980, R9352 UK AT EN RES E
   DEDRA D, 1992, VIROLOGY, V187, P377
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809                                                              
   Dey B, 2000, J VIROL, V74, P4562, DOI 10.1128/JVI.74.10.4562-4569.2000                                                
   Dimick SM, 1999, J AM CHEM SOC, V121, P10286, DOI 10.1021/ja991729e                                                               
   Douglas NW, 1997, J MOL BIOL, V273, P122, DOI 10.1006/jmbi.1997.1277
   Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3                                                   
   Esser MT, 1999, J VIROL, V73, P4360
   GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P                                                    
   Kiessling LL, 1996, CHEM BIOL, V3, P71, DOI 10.1016/S1074-5521(96)90280-X
   Koradi R., 1996, J MOL GRAPHICS, V14, P29
   Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   Mammen MS, 1998, ANGEW CHEM INT EDIT, V37, P2754, DOI DOI 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3
   MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P12602, DOI 10.1021/bi00165a009
   Mariner JM, 1998, BIOCHEM BIOPH RES CO, V248, P841, DOI 10.1006/bbrc.1998.9060
   Mori T, 1997, BIOCHEM BIOPH RES CO, V238, P218, DOI 10.1006/bbrc.1997.7202
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   NUSSBAUM O, 1994, J VIROL, V68, P5411
   O'Keefe BR, 2000, MOL PHARMACOL, V58, P982
   Page D, 1996, BIOORGAN MED CHEM, V4, P1949, DOI 10.1016/S0968-0896(96)00177-0                                                   
   Petrescu AJ, 1997, EMBO J, V16, P4302, DOI 10.1093/emboj/16.14.4302                                                        
   Quesenberry MS, 1997, BIOCHEMISTRY-US, V36, P2724, DOI 10.1021/bi9622635                                                               
   Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000                                                   
   SCHWARZ FP, 1993, J BIOL CHEM, V266, P24344
   Trkola A, 1996, J VIROL, V70, P1100
   WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0
   Woods RJ, 1998, EUR J BIOCHEM, V258, P372, DOI 10.1046/j.1432-1327.1998.2580372.x
   WOOTEN EW, 1990, EUR BIOPHYS J, V18, P139, DOI 10.1007/BF02427373
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yang F, 1999, J MOL BIOL, V288, P403, DOI 10.1006/jmbi.1999.2693
NR 44
TC 110
Z9 114
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAY 2
PY 2001
VL 123
IS 17
BP 3892
EP 3902
DI 10.1021/ja004040e
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 428CC
UT WOS:000168442700006
PM 11457139
DA 2018-01-05
ER

PT J
AU Zhang, HP
   Ford, H
   Roth, JS
   Kelley, JA
AF Zhang, HP
   Ford, H
   Roth, JS
   Kelley, JA
TI Evaluation of a fluorogenic derivatization method for the reversed-phase
   HPLC analysis of 2 '-beta-fluoro-2 ',3 '-dideoxyadenosine, a new
   anti-AIDS drug
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE high-performance liquid chromatography; 2 '-beta-fluoro-2 ',3
   '-dideoxyadenosine; lodenosine; fluorescence detection; nucleoside;
   chloroacetaldehyde derivatization
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN
   PLASMA; FLUORESCENCE DETECTION; ADENINE-NUCLEOTIDES; CHLOROACETALDEHYDE;
   ADENOSINE; INFECTION; HIV; PHARMACOKINETICS
AB High sensitivity (10(-7) to 10(-9) M) reversed-phase high-performance liquid chromatography (HPLC) analysis of adenine nucleosides acid nucleotides, especially in a biological matrix, is difficult using only ultraviolet detection. Derivatization coupled with fluorescence detection has been investigated as a means of enhancing sensitivity for the reversed-phase HPLC analysis of 2 '-beta -fluoro-2 ' ,3 ' -dideuxyadenosine (F-ddA), an experimental, acid-stable, anti-AIDS drug. The reaction of chloroacetaldehyde: with the adenine base has been employed to form fluorescent 1,N-6-etheno derivatives of F-ddA and 5 ' -deoxyadenosine, which is used as an internal standard. These derivatives give an analytically useful fluorescence emission at 416 nm after excitation at 230, 265, or 275 nm. Derivatization, fluorescence detection and reversed-phase chromatography have been optimized for the analysis of nanomolar concentrations of F-ddA in human plasma. This method has potential for the measurement of F-ddA at low concentration and in limited volume samples from in vivo biological studies. Q Published by Elsevier Science B.V.
C1 NCI, Med Chem Lab, Div Basic Sci, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA.
RP Roth, JS (reprint author), NIH, Lab Neurotoxicol, Bldg 10,Room 3D-42,MSC1262,10 Ctr Dr, Bethesda, MD 20892 USA.
CR BARRIO JR, 1972, BIOCHEM BIOPH RES CO, V46, P597, DOI 10.1016/S0006-291X(72)80181-5
   BIERNAT J, 1978, NUCLEIC ACIDS RES, V5, P789, DOI 10.1093/nar/5.3.789
   DAI F, 2000, ANAL BIOCH, V287
   DION HW, 1977, ANN NY ACAD SCI, V284, P21, DOI 10.1111/j.1749-6632.1977.tb21933.x                                              
   FAULDS D, 1992, DRUGS, V44, P94, DOI 10.2165/00003495-199244010-00008
   FORD H, 1991, J LIQ CHROMATOGR, V14, P3365, DOI 10.1080/01483919108049396
   Fujimori H, 1998, BIOL PHARM BULL, V21, P1348
   GAJEWSKA M, 1995, PHARMAZIE, V50, P459
   HARTMAN NR, 1991, CLIN PHARMACOL THER, V50, P278, DOI 10.1038/clpt.1991.137                                                           
   HAYASHI Y, 1982, CHEM PHARM BULL, V30, P4107
   HITCHCOCKK M J M, 1990, Antiviral Chemistry and Chemotherapy, V1, P319
   KEMENA A, 1991, CLIN CHIM ACTA, V200, P95, DOI 10.1016/0009-8981(91)90081-M
   KNUPP CA, 1993, EUR J CLIN PHARMACOL, V45, P409, DOI 10.1007/BF00315510                                                              
   MARQUEZ VE, 1987, BIOCHEM PHARMACOL, V36, P2719, DOI 10.1016/0006-2952(87)90254-1
   MARQUEZ VE, 1990, J MED CHEM, V33, P978, DOI 10.1021/jm00165a015                                                             
   MASOOD R, 1990, MOL PHARMACOL, V37, P590
   QUINNAN GV, 1986, TRANSFUSION, V26, P481, DOI 10.1046/j.1537-2995.1986.26587020131.x
   RAMOSSALAZAR A, 1985, ANAL BIOCHEM, V145, P9, DOI 10.1016/0003-2697(85)90319-7                                                    
   RICHARDSON JH, 1984, BIOSAFETY MICROBIOLO
   RILEY CM, 1990, J CHROMATOGR-BIOMED, V531, P295, DOI 10.1016/S0378-4347(00)82287-2
   Roth JS, 1998, J CHROMATOGR B, V712, P199, DOI 10.1016/S0378-4347(98)00144-3
   ROTHOLZ DA, 1995, ED TREATMENT CHILDRE, V18, P1
   Ruxrungtham K, 1996, ANTIMICROB AGENTS CH, V40, P2369
   SATTAR SA, 1991, REV INFECT DIS, V13, P430
   SCHRAM KH, 1990, METHOD BIOCHEM ANAL, P259
   Sparidans RW, 1999, J CHROMATOGR B, V736, P115, DOI 10.1016/S0378-4347(99)00447-8                                                   
   STRATFORD MRL, 1994, J CHROMATOGR B, V662, P15, DOI 10.1016/0378-4347(94)00389-0
   WERNER A, 1993, J CHROMATOGR-BIOMED, V618, P3, DOI 10.1016/0378-4347(93)80024-X
NR 28
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0731-7085
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD MAY
PY 2001
VL 25
IS 2
BP 285
EP 297
DI 10.1016/S0731-7085(00)00496-9
PG 13
WC Chemistry, Analytical; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 423YB
UT WOS:000168204400012
PM 11275436
DA 2018-01-05
ER

PT J
AU Vo-Dinh, T
   Cullum, BM
   Stokes, DL
AF Vo-Dinh, T
   Cullum, BM
   Stokes, DL
TI Nanosensors and biochips: frontiers in biomolecular diagnostics
SO SENSORS AND ACTUATORS B-CHEMICAL
LA English
DT Article; Proceedings Paper
CT 5th European Conference on Optical Chemical Sensors and Biosensors,
   Europt(r)ode V-Opt(r)ode 2000
CY APR 16-19, 2000
CL LYON, FRANCE
DE index; nanosensor; biosensor; nanotechnology; biochip; microchip;
   benzopyrene tetrol; HIV; cancer
ID FT-IR SPECTROMETRY; CAPILLARY ELECTROPHORESIS; GAS-CHROMATOGRAPHY;
   MASS-SPECTROMETRY; CHEMICAL SENSORS; BIOSENSORS; DNA; SEPARATION
AB In the past two decades, the biotechnology and medical fields have seen great advances in the development of novel technologies that open new horizons for identifying and quantifying biomolecules, and diagnosing diseases. This manuscript provides an overview of two of those important technologies, nanosensors and biochips. We describe various types of nanosensors and biochips that have been developed for biological and medical applications, along with significant advances achieved over the last several years in these technologies. Some applications of nanosensors, developed in our laboratory for single-cell analysis, and applications of biochips for biological sensing of pathogenic agents and medical diagnostics are described to illustrate the usefulness and potential of these technologies. (C) 2001 Elsevier Science B.V. Ah rights reserved.
C1 Oak Ridge Natl Lab, Adv Monitoring Dev Grp, Oak Ridge, TN 37831 USA.
RP Vo-Dinh, T (reprint author), Oak Ridge Natl Lab, Adv Monitoring Dev Grp, Bethel Valley Rd,MS-6101,POB 2008, Oak Ridge, TN 37831 USA.
EM vodinht@ornl.gov
CR Alarie JP, 1996, POLYCYCL AROMAT COMP, V8, P45, DOI 10.1080/10406639608048333                                                       
   ALLISON J, 1987, ANAL CHEM, V59, pA1072
   Barker SLR, 1998, ANAL CHEM, V70, P971, DOI 10.1021/ac970706k                                                               
   BETZIG E, 1993, SCIENCE, V262, P1422, DOI 10.1126/science.262.5138.1422
   Braguglia CM, 1998, CHEM BIOCHEM ENG Q, V12, P183
   CLARK LC, 1962, ANN NY ACAD SCI, V102, P29, DOI 10.1111/j.1749-6632.1962.tb13623.x
   Cordek J, 1999, ANAL CHEM, V71, P1529, DOI 10.1021/ac980850l                                                               
   Cullum BM, 2000, ANAL BIOCHEM, V277, P25, DOI 10.1006/abio.1999.4341                                                          
   CULLUM BM, 2000, IN PRESS TRENDS BIOT
   Deckert V, 1998, ANAL CHEM, V70, P2646, DOI 10.1021/ac971304f
   Dempsey E, 1997, ANAL CHIM ACTA, V346, P341
   DIAMOND D, 1998, CHEM BIOL SENSORS
   Dorrell N, 1998, GUT, V43, pA13
   FUJIMOTO C, 1992, ANAL CHEM, V64, pA476, DOI 10.1021/ac00032a001                                                             
   GRIFFITHS PR, 1986, ANAL CHEM, V58, P1349, DOI 10.1021/ac00126a002
   Hacia JG, 1998, NUCLEIC ACIDS RES, V26, P4975, DOI 10.1093/nar/26.21.4975                                                          
   Henry CM, 1999, ANAL CHEM, V71, p401A, DOI 10.1021/ac9904361
   Isola NR, 1998, ANAL CHEM, V70, P1352, DOI 10.1021/ac970901z
   Linhardt RJ, 1996, J CHROMATOGR A, V720, P323
   Lu JZ, 2000, FRESEN J ANAL CHEM, V366, P569, DOI 10.1007/s002160051552                                                           
   MARCH RE, 1992, INT J MASS SPECTROM, V118, P71, DOI 10.1016/0168-1176(92)85059-9                                                    
   Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C                  
   Nishi H, 1997, J CHROMATOGR A, V780, P243, DOI 10.1016/S0021-9673(97)00347-6                                                   
   NOBLE D, 1995, ANAL CHEM, V67, pA265
   Rosenzweig Z, 1996, ANAL CHEM, V68, P1408, DOI 10.1021/ac950864g
   Sarmini K, 1997, J CHROMATOGR A, V792, P3, DOI 10.1016/S0021-9673(97)00720-6
   Sasaki TA, 1999, J CHROMATOGR A, V842, P341, DOI 10.1016/S0021-9673(99)00445-8
   Singh-Gasson S, 1999, NAT BIOTECHNOL, V17, P974, DOI 10.1038/13664
   TAN WH, 1992, SCIENCE, V258, P778, DOI 10.1126/science.1439785
   Tess ME, 1999, J PHARMACEUT BIOMED, V19, P55, DOI 10.1016/S0731-7085(98)00129-0
   Tomlinson MJ, 1996, MASS SPECTROM REV, V15, P1, DOI 10.1002/(SICI)1098-2787(1996)15:1<1::AID-MAS1>3.0.CO;2-M
   TROMBERG BJ, 1987, ANAL CHEM, V59, P1226, DOI 10.1021/ac00135a033                                                             
   vanBreemen RB, 1996, ANAL CHEM, V68, pA299, DOI 10.1021/ac961911n                                                               
   Vo-Dinh T, 2000, NAT BIOTECHNOL, V18, P764, DOI 10.1038/77337                                                                   
   VO-DINH T, 1987, APPL SPECTROSC, V41, P735, DOI 10.1366/0003702874448076                                                        
   Vo-Dinh T, 1999, ANAL CHEM, V71, P358, DOI 10.1021/ac980043m                                                               
   VO-DINH T, 1994, ANAL CHEM, V66, P3379, DOI 10.1021/ac00092a014
   Vo-Dinh T, 1998, INSTRUM SCI TECHNOL, V26, P503, DOI 10.1080/10739149808000917                                                       
   VO-DINH T, 1986, APPL SPECTROSC, V40, P696, DOI 10.1366/0003702864508575                                                        
   Vo-Dinh T, 1998, SENSOR ACTUAT B-CHEM, V51, P52, DOI 10.1016/S0925-4005(98)00182-8
   Vo-Dinh T, 2000, FRESEN J ANAL CHEM, V366, P540, DOI 10.1007/s002160051549
   VODINH T, IN PRESS J NANOPARTI
   VODINH T, 1999, P 6 ANN BIOCH TECHN
   Wadkins RM, 1998, BIOSENS BIOELECTRON, V13, P407, DOI 10.1016/S0956-5663(97)00113-9
   Weetall HH, 1999, BIOSENS BIOELECTRON, V14, P237
   WOLFBEIS OS, FIBER OPTICS CHEM SE, P217
   Zeisel D, 1998, CHEM PHYS LETT, V283, P381, DOI 10.1016/S0009-2614(97)01391-2
NR 47
TC 149
Z9 154
U1 6
U2 48
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 0925-4005
J9 SENSOR ACTUAT B-CHEM
JI Sens. Actuator B-Chem.
PD APR 15
PY 2001
VL 74
IS 1-3
BP 2
EP 11
DI 10.1016/S0925-4005(00)00705-X
PG 10
WC Chemistry, Analytical; Electrochemistry; Instruments & Instrumentation
SC Chemistry; Electrochemistry; Instruments & Instrumentation
GA 424DW
UT WOS:000168217700002
DA 2018-01-05
ER

PT J
AU Reddy, BSP
   Sharma, SK
   Lown, JW
AF Reddy, BSP
   Sharma, SK
   Lown, JW
TI Recent developments in sequence selective minor groove DNA effectors
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
ID 1,2-TRANS-DISUBSTITUTED CYCLOPROPANE UNITS; MOLECULAR-DYNAMICS
   SIMULATION; ANTITUMOR DRUG TALLIMUSTINE; CROSS-LINKED LEXITROPSINS;
   SUBSTITUTED CBI ANALOGS; HUMAN TUMOR HELICASES; ALKYLATION SUBUNIT;
   CRYSTAL-STRUCTURE; FUNCTIONAL REACTIVITY; REDUCTIVE CYCLIZATION
AB DNA is a well characterized intracellular target but its large size and sequential nature make it an elusive target for selective drug action. Binding of low molecular weight ligands to DNA causes a wide variety of potential biological responses. In this respect the main consideration is given to recent developments in DNA sequence selective binding agents bearing conjugated effecters because of their potential application in diagnosis and treatment of cancers as well as in molecular biology. Recent progress in the development of cross linked lexitropsin oligopeptides and hairpins, which bind selectively to the minor groove of duplex DNA, is discussed. Bis-distamycins and related lexitropsins show inhibitory activity against HIV-I and HIV-2 integrases at low nanomolar concentrations. Benzoyl nitrogen mustard analogs of, lexitropsins are active against a variety of tumor models. Certain of the bis-benzimidazoles show altered DNA sequence preference and bind to DNA at 5'CG and TG sequences rather than at the preferred AT sites of the parent drug. A comparision of bifunctional bizelesin with monoalkylating adozelesin shows that it appears to have an increased sequence selectivity such that monoalkylating compounds react at more than one site but bizelesin reacts only at sites where there are two suitably positioned alkylation sites. Adozelesin, bizelesin and carzelesin are far more potent as cytotoxic agents than cisplatin or doxorubicin. A new class of 1,2,9,9a-tetrahydrocyclo-propa[c]benz[e]indole-4- one (CBI) analogs i.e., CBI-lexitropsin conjugates arising from the latter leads are also discussed. A number of cyclopropylpyrroloindole (CPI) and CBI-lexitropsin conjugates related to CC-1065 alkylate at the N3 position of adenine in the minor groove of DNA in a sequence specific manner, and also show cytotoxicities in the femtomolar range. The cross linking efficiency of PBD dimers is much greater than that of other cross linkers including cisplatin, and melphalan. A new class of PBD-lexitropsin conjugates is also discussed. Certain functional models of the bleomycins (BLMs) show outstanding DNA cleavage activity comparable with that of and positionally distinct from natural BLM.
C1 Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
RP Lown, JW (reprint author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
CR Atwell GJ, 1997, BIOORG MED CHEM LETT, V7, P1493, DOI 10.1016/S0960-894X(97)00259-X
   BARALDI PG, 1994, J MED CHEM, V37, P4329, DOI 10.1021/jm00051a009                                                             
   Baraldi PG, 1998, BIOORG MED CHEM LETT, V8, P3019, DOI 10.1016/S0960-894X(98)00544-7
   Baraldi PG, 1997, ANTI-CANCER DRUG DES, V12, P555
   BAUCHER NR, 1993, MOL PHARMACOL, V44, P1064
   BAUCHER NR, 1992, MOL PHARMACOL, V41, P993
   Bauer GB, 1997, NUCLEIC ACIDS RES, V25, P1211, DOI 10.1093/nar/25.6.1211
   BELLORINI M, 1995, NUCLEIC ACIDS RES, V23, P1657, DOI 10.1093/nar/23.10.1657
   BHUAYAN BK, 1982, CANCER RES, V42, P3532
   BOGER DL, 1995, J AM CHEM SOC, V117, P11647, DOI 10.1021/ja00152a004                                                             
   Boger DL, 1996, BIOORG MED CHEM LETT, V6, P659, DOI 10.1016/0960-894X(96)00093-5
   Boger DL, 1997, BIOORGAN MED CHEM, V5, P263, DOI 10.1016/S0968-0896(96)00238-6
   Boger DL, 1996, J ORG CHEM, V61, P1710, DOI 10.1021/jo952033g                                                               
   Boger DL, 1996, J ORG CHEM, V61, P4894, DOI 10.1021/jo9605298                                                               
   Boger DL, 1997, J ORG CHEM, V62, P8875, DOI 10.1021/jo971686p                                                               
   BOGER DL, 1995, BIOORGAN MED CHEM, V3, P1429, DOI 10.1016/0968-0896(95)00130-9                                                    
   Boger DL, 1996, J AM CHEM SOC, V118, P8860, DOI 10.1021/ja961888n                                                               
   Boger DL, 1997, BIOORGAN MED CHEM, V5, P233, DOI 10.1016/S0968-0896(96)00237-4                                                   
   Boger D.L., 1996, ANGEW CHEM INT EDIT, V35, P1439
   Boitte N, 1997, ANTI-CANCER DRUG DES, V12, P481
   BOSE DS, 1992, J CHEM SOC CHEM COMM, P1518, DOI 10.1039/c39920001518                                                            
   BOSE DS, 1992, TETRAHEDRON, V48, P751
   Boulouard M., 1998, Pharmacy and Pharmacology Communications, V4, P43
   BROGGINI M, 1995, NUCLEIC ACIDS RES, V23, P81, DOI 10.1093/nar/23.1.81
   Brooks N, 1997, BIOORGAN MED CHEM, V5, P1497, DOI 10.1016/S0968-0896(97)00096-5                                                   
   Burckhardt G, 1997, J BIOMOL STRUCT DYN, V15, P81, DOI 10.1080/07391102.1997.10508948                                                  
   Burger RM, 1998, CHEM REV, V98, P1153, DOI 10.1021/cr960438a                                                               
   Caneva RC, 1997, BBA-GENE STRUCT EXPR, V1353, P93, DOI 10.1016/S0167-4781(97)00091-2
   Chai SH, 1996, NUCLEIC ACIDS RES, V24, P282, DOI 10.1093/nar/24.2.282                                                            
   Chen FM, 1998, BIOCHEMISTRY-US, V37, P11143, DOI 10.1021/bi980950l
   CHEN YH, 1994, J AM CHEM SOC, V116, P6995, DOI 10.1021/ja00095a001                                                             
   Chen YH, 1996, J BIOMOL STRUCT DYN, V14, P341, DOI 10.1080/07391102.1996.10508129                                                  
   Christodoulopoulos G, 1998, CANCER RES, V58, P1789
   Ciucci A, 1996, NUCLEIC ACIDS RES, V24, P311, DOI 10.1093/nar/24.2.311
   Clark GR, 1997, NUCLEIC ACIDS RES, V25, P1510, DOI 10.1093/nar/25.8.1510
   Clark GR, 1996, NUCLEIC ACIDS RES, V24, P4882, DOI 10.1093/nar/24.24.4882
   Clark GR, 1996, BIOCHEMISTRY-US, V35, P13745, DOI 10.1021/bi960421m
   Damayanthi Y, 1999, J ORG CHEM, V64, P290, DOI 10.1021/jo9812072                                                               
   Dassonneville L, 1997, NUCLEIC ACIDS RES, V25, P4487, DOI 10.1093/nar/25.22.4487
   deCupis A, 1997, BRIT J PHARMACOL, V120, P537, DOI 10.1038/sj.bjp.0700937
   DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408
   DWYER TJ, 1993, J AM CHEM SOC, V115, P9900, DOI 10.1021/ja00075a005
   Farinas ET, 1995, P INDIAN AS-CHEM SCI, V107, P459
   Filipowsky ME, 1996, BIOCHEMISTRY-US, V35, P15397, DOI 10.1021/bi961604b                                                               
   FLUMER P, 1997, BIOCHEMISTRY-US, V36, P4367
   Fouchet S. J., 1998, TETRAHEDRON LETT, V39, P819
   FREDERICK CS, 1996, J AM CHEM SOC, V118, P5383
   FREGEAU NL, 1995, J AM CHEM SOC, V117, P8917, DOI 10.1021/ja00140a004                                                             
   FUKUDA Y, 1997, HETEROCYCLES, V45, P2306
   GEURGE JW, 1992, J BIOL CHEM, V27, P10683
   Ghirlanda G, 1998, LANGMUIR, V14, P1646, DOI 10.1021/la971156o                                                               
   Ghirlanda G, 1996, LANGMUIR, V12, P5188, DOI 10.1021/la960255j                                                               
   Gillard AC, 1995, J HETEROCYCLIC CHEM, V32, P1741, DOI 10.1002/jhet.5570320613                                                         
   Gillard AC, 1996, J HETEROCYCLIC CHEM, V33, P275, DOI 10.1002/jhet.5570330211                                                         
   Gillard AC, 1997, TETRAHEDRON LETT, V38, P2271, DOI 10.1016/S0040-4039(97)00359-6                                                   
   Guan LL, 1997, BIOCHEM BIOPH RES CO, V231, P94, DOI 10.1006/bbrc.1996.5908
   GUO DQ, 1993, ANTI-CANCER DRUG DES, V8, P369
   Gupta R, 1996, ANTI-CANCER DRUG DES, V11, P581
   HANKA LJ, 1978, J ANTIBIOT, V31, P1211, DOI 10.7164/antibiotics.31.1211                                                     
   Haq I, 1997, J MOL BIOL, V271, P244, DOI 10.1006/jmbi.1997.1170
   HARGPANHALLI RS, 1996, J MED CHEM, V39, P4804
   HECHT SM, 1986, ACCOUNTS CHEM RES, V19, P383, DOI 10.1021/ar00132a002                                                             
   Helissey P, 1996, ANTI-CANCER DRUG DES, V11, P527
   Henderson D, 1996, J MOL RECOGNIT, V9, P75, DOI 10.1002/(SICI)1099-1352(199603)9:2<75::AID-JMR247>3.0.CO;2-4
   HSIUNG LC, 1995, NEW METHODS DRUG RES, V4, P173
   HUANG L, 1993, BIOMED CHEM LETT, V39, P1751
   HUANG LR, 1995, CURR MED CHEM, V2, P543
   HUANG LR, 1995, BIOCONJUGATE CHEM, V6, P21, DOI 10.1021/bc00031a003
   HUANG LR, 1994, TETRAHEDRON LETT, V35, P5323, DOI 10.1016/S0040-4039(00)73490-3
   HUANG LR, 1995, BIOORGAN MED CHEM, V3, P647, DOI 10.1016/0968-0896(95)00058-O
   HURLEY LH, 1989, J MED CHEM, V32, P2027, DOI 10.1021/jm00129a001
   IIDA H, 1998, SYNTH ORGANIC CHEM, V1, P45
   Jia GF, 1998, HETEROCYCL COMMUN, V4, P557
   Jia GF, 1999, CHEM COMMUN, P119, DOI 10.1039/a807884j                                                                
   KAMAL A, 1993, BIOORG MED CHEM LETT, V3, P743, DOI 10.1016/S0960-894X(01)81266-X
   Kamal A, 1997, BIOORG MED CHEM LETT, V7, P1825, DOI 10.1016/S0960-894X(97)00314-4                                                   
   Kamal A, 1996, TETRAHEDRON LETT, V37, P6803, DOI 10.1016/S0040-4039(96)01484-0
   KOHN KW, 1968, BIOCHIM BIOPHYS ACTA, V155, P121, DOI 10.1016/0005-2787(68)90342-0
   KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8
   Lakowicz JR, 1997, BIOPHYS J, V72, P567, DOI 10.1016/S0006-3495(97)78696-X                                                   
   LANGLOIS N, 1989, HETEROCYCLES, V29, P1529, DOI 10.3987/COM-89-4990                                                             
   LIN CH, 1990, BIOCHEMISTRY-US, V29, P9503, DOI 10.1021/bi00493a002
   LIN CH, 1995, J MOL BIOL, V248, P162, DOI 10.1006/jmbi.1995.0209
   Ling L, 1997, HETEROCYCL COMMUN, V3, P405
   Lombardi P, 1997, PHARMACOL THERAPEUT, V76, P125, DOI 10.1016/S0163-7258(97)00095-8
   Lown J. William, 1994, Journal of Molecular Recognition, V7, P79, DOI 10.1002/jmr.300070205
   LOWN JW, 1993, CHEMTRACTS ORG CHEM, V6, P205
   Lukhtanov EA, 1997, NUCLEIC ACIDS RES, V25, P5077, DOI 10.1093/nar/25.24.5077                                                          
   MARCO P, 1997, EUR J PHARMACOL, V319, P317
   MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445
   MIYAMOTO M, 1977, J ANTIBIOT, V30, P340, DOI 10.7164/antibiotics.30.340                                                      
   MORI S, 1991, TETRAHEDRON, V47, P5051, DOI 10.1016/S0040-4020(01)80968-6
   MRKSICH M, 1994, J AM CHEM SOC, V116, P7983, DOI 10.1021/ja00097a004
   Muratake H, 1997, TETRAHEDRON LETT, V38, P7577, DOI 10.1016/S0040-4039(97)01786-3                                                   
   NOEGELI H, 1993, J BIOL CHEM, V268, P10386
   ONeil IA, 1997, SYNLETT, P75
   Park HJ, 1997, J AM CHEM SOC, V119, P629, DOI 10.1021/ja9632264                                                               
   PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723                                                         
   PELTON JG, 1990, J AM CHEM SOC, V112, P1393, DOI 10.1021/ja00160a016
   PLOUVIER B, 1995, ANTI-CANCER DRUG DES, V10, P155
   POVIRK LF, 1978, BIOCHIM BIOPHYS ACTA, V521, P126, DOI 10.1016/0005-2787(78)90255-1                                                    
   Prabhu KR, 1998, SYNLETT, P47, DOI 10.1055/s-1998-1057884                                                          
   Punt CJA, 1996, BRIT J CANCER, V73, P803, DOI 10.1038/bjc.1996.140
   RAO KE, 1992, TRENDS ORG CHEM, V3, P141
   Reddy BSP, 1999, PHARMACOL THERAPEUT, V84, P1, DOI 10.1016/S0163-7258(99)00021-2
   Robles J, 1996, J AM CHEM SOC, V118, P5820, DOI 10.1021/ja9608914                                                               
   Rossi R, 1996, ANTICANCER RES, V16, P3779
   SAUSVILLE EA, 1978, BIOCHEMISTRY-US, V17, P2746, DOI 10.1021/bi00607a008
   Singh AK, 1999, HETEROCYCL COMMUN, V5, P11
   Singh AK, 1998, SYNTHETIC COMMUN, V28, P4059, DOI 10.1080/00397919808004966
   Singh M. P., 1996, PROGR MED CHEM, P49
   SMITH CEB, 1998, NUCLEIC ACIDS RES, V26, P1660
   Soderlind KJ, 1999, ANTI-CANCER DRUG DES, V14, P19
   Sondhi SM, 1997, CURR MED CHEM, V4, P313
   SPINK N, 1994, NUCLEIC ACIDS RES, V22, P1607, DOI 10.1093/nar/22.9.1607
   Surovaya AN, 1997, J BIOMOL STRUCT DYN, V14, P595, DOI 10.1080/07391102.1997.10508159                                                  
   THURSTON DE, 1990, J CHEM SOC CHEM COMM, P874, DOI 10.1039/c39900000874                                                            
   Thurston DE, 1996, CHEM COMMUN, P563, DOI 10.1039/cc9960000563                                                            
   THURSTON DE, 1994, CHEM REV, V94, P433, DOI 10.1021/cr00026a006                                                             
   THURSTON DE, 1990, CHEM BRIT, V26, P767
   Trauger JW, 1998, ANGEW CHEM INT EDIT, V37, P1421, DOI 10.1002/(SICI)1521-3773(19980605)37:10<1421::AID-ANIE1421>3.3.CO;2-#
   UMEZAWA H, 1966, J ANTIBIOT, V19, P200
   Wang YQ, 1996, ANTI-CANCER DRUG DES, V11, P15
   Wiederholt K, 1996, J AM CHEM SOC, V118, P7055, DOI 10.1021/ja960948m                                                               
   WOOD AA, 1995, NUCLEIC ACIDS RES, V23, P3678, DOI 10.1093/nar/23.18.3678
   Wyatt MD, 1997, ANTI-CANCER DRUG DES, V12, P49
   WYATT MD, 1995, BIOCHEMISTRY-US, V34, P13034, DOI 10.1021/bi00040a014
   Xie GJ, 1996, J MED CHEM, V39, P1049, DOI 10.1021/jm950465d
   Yang YW, 1996, BIOCONJUGATE CHEM, V7, P670, DOI 10.1021/bc960065k
   Zhang XB, 1998, BIOCHEM BIOPH RES CO, V248, P18, DOI 10.1006/bbrc.1998.8906
   1997, Patent No. 9745411
   SUSUMU K, 1995, Patent No. 07238080
NR 132
TC 99
Z9 100
U1 1
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI HILVERSUM
PA PO BOX 1673, 1200 BR HILVERSUM, NETHERLANDS
SN 0929-8673
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD APR
PY 2001
VL 8
IS 5
BP 475
EP 508
PG 34
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 413YH
UT WOS:000167638800002
PM 11281837
DA 2018-01-05
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI A novel template for non-peptide CCR5 receptor antagonists
SO EXPERT OPINION ON THERAPEUTIC PATENTS
LA English
DT Article
DE CCR5 antagonist; chemokine; HIV-1; inflammation; RANTES; rheumatoid
   arthritis
ID SMALL-MOLECULE; POTENT
AB Potent non-peptide chemokine CCR5 receptor antagonists have been identified, based upon a 1(1-aroylpiperidin-4-yl)piperidine template previously employed in a series of muscarinic M-2 receptor antagonists. Two applications claim piperidinylpiperidine and piperidinylpiperazine derivatives, respectively, including compounds with low nanomolar affinity for the CCR5 receptor. Such compounds are claimed to be useful in the treatment of HIV infection and inflammatory diseases.
CR Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   BAROUDY B, 2000, 7 INT C RETR OPP INF
   BILLARD W, BIOORG MED CHEM LETT, V10, P2209
   Gabuzda D, 2000, J NEUROVIROL, V6, pS24
   Le Y, 1999, Forum (Genova), V9, P299
   Shiraishi M, 2000, J MED CHEM, V43, P2049, DOI 10.1021/jm9906264
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   STRIZKI J, 2000, CHEMOTACTIC CYTOKINE
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ASHLEY PUBLICATIONS LTD
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE FINCHLEY CENTRAL, LONDON N3 1QB,
   ENGLAND
SN 1354-3776
J9 EXPERT OPIN THER PAT
JI Expert Opin. Ther. Patents
PD APR
PY 2001
VL 11
IS 4
BP 697
EP 700
PG 4
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 419ZR
UT WOS:000167979900009
DA 2018-01-05
ER

PT J
AU Dembri, A
   Montisci, MJ
   Gantier, JC
   Chacun, H
   Ponchel, G
AF Dembri, A
   Montisci, MJ
   Gantier, JC
   Chacun, H
   Ponchel, G
TI Targeting of 3 '-azido 3 '-deoxythymidine (AZT)-loaded
   poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa
   and associated lymphoid tissues
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE poly(isohexylcyanoacrylate) nanoparticles; 3 '-azido 3 '-deoxythymidine
   (AZT); intestinal epithelium; lymphatic duct cannulation; Peyer's
   patches; gastrointestinal reservoir of HIV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BODY DISTRIBUTION; INFECTED PATIENTS;
   T-LYMPHOCYTES; M-CELLS; HIV; MICROPARTICLES; NANOPARTICLES;
   AZIDOTHYMIDINE; DRUG
AB Purpose. The aim of the study was to evaluate the capacity of poly(isohexylcyanoacrylate) nanospheres to concentrate 3'-azido 3'-deoxythymidine (AZT) in the intestinal epithelium and associated immunocompetent cells, which are known to be one of the major reservoirs of the human immunodeficiency virus (HIV).
   Methods. The tissue concentration of (3)H-radiolabeled AZT in the gastrointestinal (GI) tract was obtained 30 and 90 minutes after intragastric administration to rats at a dose of 0.25 mg AZT/100 g of body weight. The distribution along the intestine was determined. AZT concentrations in the lymph were obtained by lymphatic duct cannulation.
   Results. Unlike the solution, nanoparticles did concentrate AZT very efficiently in the intestinal mucosa, as well as in the Peyer's patches, and could simultaneously control the release of free AZT. Concentration in Peyer's patches was 4 times higher for nanoparticles, compared with the control solution. The tissue concentration was 30-45 muM, which was much higher than the reported IC(50) of AZT (0.06-1.36 muM) and was regularly distributed along the gastrointestinal tract.
   Conclusions. Nanoparticles have been shown to be efficient in concentrating AZT in the intestinal epithelium and gut-associated lymphoid tissues, supporting the view that these particles may represent a promising carrier to treat specifically the GI reservoir of HIV.
C1 Univ Paris 11, UMR 8612, F-92296 Chatenay Malabry, France.
RP Ponchel, G (reprint author), Univ Paris 11, UMR 8612, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.
EM gilles.ponchel@cep.u-psud.fr
OI GANTIER, Jean-Charles/0000-0003-2064-5693
CR AGGARWAL SK, 1990, J MED CHEM, V33, P1505, DOI 10.1021/jm00167a034
   Benatti U, 1996, BIOCHEM BIOPH RES CO, V220, P20, DOI 10.1006/bbrc.1996.0349
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Daluge SM, 1997, ANTIMICROB AGENTS CH, V41, P1082
   Desai MP, 1997, PHARMACEUT RES, V14, P1568, DOI 10.1023/A:1012126301290                                                         
   DURRER C, 1994, PHARMACEUT RES, V11, P680, DOI 10.1023/A:1018920128007
   EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0
   Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985                                                    
   HEISE C, 1991, GASTROENTEROLOGY, V100, P1521, DOI 10.1016/0016-5085(91)90648-5                                                    
   HERDEWIJN P, 1987, J MED CHEM, V30, P1270, DOI 10.1021/jm00391a003
   HODGES GM, 1995, DIGEST DIS SCI, V40, P967, DOI 10.1007/BF02064184
   JENKINS PG, 1994, INT J PHARM, V102, P261, DOI 10.1016/0378-5173(94)90064-7
   LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804                                                         
   Li XL, 1999, ADV DRUG DELIVER REV, V39, P81, DOI 10.1016/S0169-409X(99)00021-6                                                   
   Lobenberg R, 1997, EUR J PHARM BIOPHARM, V44, P127, DOI 10.1016/S0939-6411(97)00078-7
   Lobenberg R, 1998, J CONTROL RELEASE, V50, P21, DOI 10.1016/S0168-3659(97)00105-3
   MATHEWSON JJ, 1994, J INFECT DIS, V169, P614, DOI 10.1093/infdis/169.3.614                                                        
   MAYER HB, 1994, AIDS, V8, P1639, DOI 10.1097/00002030-199412000-00001
   NELSON JA, 1988, LANCET, V1, P259
   Neutra MR, 1999, J INFECT DIS, V179, pS441, DOI 10.1086/314800                                                                  
   OHagan DT, 1996, J ANAT, V189, P477
   PANTALEO G, 1991, P NATL ACAD SCI USA, V88, P9838, DOI 10.1073/pnas.88.21.9838                                                         
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   PHILLIPS NC, 1992, BLOOD, V79, P1137
   Ponchel G, 1997, EUR J PHARM BIOPHARM, V44, P25, DOI 10.1016/S0939-6411(97)00098-2
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SCHERER D, 1994, INT J PHARM, V101, P165, DOI 10.1016/0378-5173(94)90086-8
   SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524
   SMITH MW, 1995, EXP PHYSIOL, V80, P735, DOI 10.1113/expphysiol.1995.sp003882                                                
   WARSHAW AL, 1972, GUT, V13, P66, DOI 10.1136/gut.13.1.66
NR 30
TC 44
Z9 47
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
J9 PHARM RES-DORDR
JI Pharm. Res.
PD APR
PY 2001
VL 18
IS 4
BP 467
EP 473
DI 10.1023/A:1011050209986
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 448LY
UT WOS:000169629400008
PM 11451033
DA 2018-01-05
ER

PT J
AU Dodd, C
   Mountz, J
   Chu, WJ
   Josephson, L
   Zhang, HG
   Weissleder, R
   Mountz, JM
   Zinn, K
   Mountz, JD
   Hsu, HC
AF Dodd, C
   Mountz, J
   Chu, WJ
   Josephson, L
   Zhang, HG
   Weissleder, R
   Mountz, JM
   Zinn, K
   Mountz, JD
   Hsu, HC
TI In vivo magnetic resonance imaging (MRI) of T cells loaded with HIV
   transactivator (tat) peptide-derived super-paramagnetic nanoparticles.
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 Univ Alabama, Birmingham, AL 35294 USA.
   Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
   VAMC, Birmingham, AL 35233 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 8
PY 2001
VL 15
IS 5
BP A744
EP A744
PN 2
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 410TA
UT WOS:000167454200179
DA 2018-01-05
ER

PT J
AU Hsu, HC
   Dodd, C
   Chu, WJ
   Yang, PA
   Josephson, L
   Sun, SH
   Zhang, HG
   Weissleder, R
   Mountz, JD
AF Hsu, HC
   Dodd, C
   Chu, WJ
   Yang, PA
   Josephson, L
   Sun, SH
   Zhang, HG
   Weissleder, R
   Mountz, JD
TI Normal response of T cells loaded with HIV transactivator (tat)
   peptide-derived super-paramagnetic nanoparticles for magnetic resonance
   imaging (MRI).
SO FASEB JOURNAL
LA English
DT Meeting Abstract
C1 Univ Alabama, Birmingham, AL 35294 USA.
   Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
   Univ Alabama, Birmingham, AL 35233 USA.
   VAMC, Birmingham, AL 35233 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
J9 FASEB J
JI Faseb J.
PD MAR 7
PY 2001
VL 15
IS 4
BP A330
EP A330
PN 1
PG 1
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 410KA
UT WOS:000167438101888
DA 2018-01-05
ER

PT J
AU Reid, SL
   Parry, D
   Liu, HH
   Connolly, BA
AF Reid, SL
   Parry, D
   Liu, HH
   Connolly, BA
TI Binding and recognition of GATATC target sequences by the EcoRV
   restriction endonuclease: A study using fluorescent oligonucleotides and
   fluorescence polarization
SO BIOCHEMISTRY
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; SITE-DIRECTED MUTAGENESIS; FLANKING
   DNA-SEQUENCES; CRYSTAL-STRUCTURE; COGNATE DNA; ACTIVE-SITE; CARBOXYLATE
   RESIDUES; ANGSTROM RESOLUTION; PVUII ENDONUCLEASE; NONSPECIFIC DNA
AB Oligonucleotides labeled with hexachlorofluorescein (hex) have enabled the interaction of the restriction endonuclease EcoRV with DNA to be evaluated using fluorescence anisotropy. The sensitivity of hex allowed measurements at oligonucleotide concentrations as low as 1 nM, enabling K-D values in the low nanomolar range to be measured. Both direct titration, i.e., addition of increasing amounts of the endonuclease to hex-labeled oligonucleotides, and displacement titration, i.e., addition of unlabeled oligonucleotide to preformed hex-oligonucleotide/EcoRV endonuclease complexes, have been used for K-D determination. Displacement titration is the method of choice; artifacts due to any direct interaction of the enzyme with the dye are eliminated, and higher fluorescent-labeled oligonucleotide concentrations may be used, improving signal-to-noise ratio. Using this approach (with three different oligonucleotides) we found that the EcoRV restriction endonuclease showed a preference of between 1.5 and 6.5 for its GATATC target sequence at pH 7.5 and 100 mM NaCl, when the divalent cation Ca2+ is absent. As expected, both the presence of Ca2+ and a decrease in pH value stimulated the binding of specific sequences but had much less effect on nonspecific ones.
C1 Univ Newcastle Upon Tyne, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
RP Connolly, BA (reprint author), Univ Newcastle Upon Tyne, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
CR AGGARWAL AK, 1995, CURR OPIN STRUC BIOL, V5, P11, DOI 10.1016/0959-440X(95)80004-K
   AIKEN CR, 1991, J BIOL CHEM, V266, P19063
   ALVES J, 1995, BIOCHEMISTRY-US, V34, P11191, DOI 10.1021/bi00035a026
   ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469
   BOUGUELERET L, 1985, NUCLEIC ACIDS RES, V13, P3823, DOI 10.1093/nar/13.11.3823                                                          
   Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015
   CHENG XD, 1994, EMBO J, V13, P3927
   CONNOLLY BA, 1992, METHOD ENZYMOL, V211, P36
   CONNOLLY BA, 1991, OLIGONUCLEOTIDES ANA, P155
   DARCY A, 1985, J BIOL CHEM, V260, P1987
   Deibert M, 1999, EMBO J, V18, P5805, DOI 10.1093/emboj/18.21.5805
   Eftink MR, 1997, METHOD ENZYMOL, V278, P221
   Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027
   *ER SOFTW, 1992, GRAF VERS 3 09A
   Erskine SG, 1998, J MOL BIOL, V275, P759, DOI 10.1006/jmbi.1997.1517                                                          
   Gormley NA, 2000, J BIOL CHEM, V275, P6928, DOI 10.1074/jbc.275.10.6928
   GRASBY JA, 1992, BIOCHEMISTRY-US, V31, P7855, DOI 10.1021/bi00149a016
   GUTFREUND H, 1995, KINETICS LIFE SCI RE, P201
   HALFORD SE, 1980, BIOCHEM J, V191, P593, DOI 10.1042/bj1910593                                                               
   HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744                                                          
   Hill JJ, 1997, METHOD ENZYMOL, V278, P390
   Horton NC, 1998, J BIOL CHEM, V273, P21721, DOI 10.1074/jbc.273.34.21721
   Horton NC, 2000, J AM CHEM SOC, V122, P3314, DOI 10.1021/ja993719j
   Horton NC, 1998, P NATL ACAD SCI USA, V95, P13489, DOI 10.1073/pnas.95.23.13489
   JAMESON DM, 1995, METHOD ENZYMOL, V246, P283
   JELTSCH A, 1995, BIOCHEMISTRY-US, V34, P6239, DOI 10.1021/bi00018a028
   KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465
   KONG H, 1994, J BIOL CHEM, V269, P683
   KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036
   Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z
   Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11093, DOI 10.1021/bi963126a
   Lagunavicius A, 1997, BIOCHEMISTRY-US, V36, P11086, DOI 10.1021/bi963125i
   LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548
   LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428
   Martin AM, 1999, NAT STRUCT BIOL, V6, P269
   Martin AM, 1999, BIOCHEMISTRY-US, V38, P8430, DOI 10.1021/bi9905359
   MAURY G, 1993, BIOCHIM BIOPHYS ACTA, V1216, P1, DOI 10.1016/0167-4781(93)90030-H
   *MICR SCI SOFTW, 1995, SCI VERS 2
   MULLER B, 1991, BIOCHEMISTRY-US, V30, P3709, DOI 10.1021/bi00229a017                                                             
   Newman M, 1998, EMBO J, V17, P5466, DOI 10.1093/emboj/17.18.5466
   NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0
   NEWMAN M, 1995, SCIENCE, V269, P656, DOI 10.1126/science.7624794
   NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9902, DOI 10.1021/bi00494a021
   Perona JJ, 1997, J MOL BIOL, V273, P207, DOI 10.1006/jmbi.1997.1315
   Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x
   Powell LM, 1998, J MOL BIOL, V283, P947, DOI 10.1006/jmbi.1998.2142
   Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104
   SELENT U, 1992, BIOCHEMISTRY-US, V31, P4808, DOI 10.1021/bi00135a010
   SIKSNYS V, 1993, EUR J BIOCHEM, V217, P411, DOI 10.1111/j.1432-1033.1993.tb18260.x
   Skirgaila R, 1998, J MOL BIOL, V279, P473, DOI 10.1006/jmbi.1998.1803
   Skirgaila R, 1998, BIOL CHEM, V379, P595
   Stanford NP, 1999, J MOL BIOL, V288, P105, DOI 10.1006/jmbi.1999.2673
   SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004
   TAYLOR JD, 1989, BIOCHEMISTRY-US, V28, P6198, DOI 10.1021/bi00441a011
   TAYLOR JD, 1991, BIOCHEMISTRY-US, V30, P8743, DOI 10.1021/bi00100a005
   TAYLOR JD, 1992, BIOCHEMISTRY-US, V31, P90, DOI 10.1021/bi00116a014
   TERRY BJ, 1983, J BIOL CHEM, V258, P9820
   THIELKING V, 1992, BIOCHEMISTRY-US, V31, P3727, DOI 10.1021/bi00130a001
   Thorogood H, 1996, J BIOL CHEM, V271, P8855, DOI 10.1074/jbc.271.15.8855                                                         
   VENCLOVAS C, 1994, PROTEINS, V20, P279, DOI 10.1002/prot.340200308
   VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6082, DOI 10.1021/bi00141a018
   VERMOTE CLM, 1992, BIOCHEMISTRY-US, V31, P6089, DOI 10.1021/bi00141a019                                                             
   VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002
   Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446                                                                   
   Wenner JR, 1999, ANAL BIOCHEM, V268, P201, DOI 10.1006/abio.1998.3079
   WINKLER FK, 1993, EMBO J, V12, P1781
   WITHERS BE, 1995, J BIOL CHEM, V270, P6496, DOI 10.1074/jbc.270.12.6496                                                         
   XU SY, 1991, J BIOL CHEM, V266, P4425
   ZEBALA JA, 1992, J BIOL CHEM, V267, P8106
   ZEBALA JA, 1992, J BIOL CHEM, V267, P8097
NR 70
TC 62
Z9 62
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD FEB 27
PY 2001
VL 40
IS 8
BP 2484
EP 2494
DI 10.1021/bi001956p
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 404VA
UT WOS:000167121500020
PM 11327870
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Sudbeck, EA
   Mao, C
   Uckun, FM
AF Venkatachalam, TK
   Sudbeck, EA
   Mao, C
   Uckun, FM
TI Anti-HIV activity of aromatic and heterocyclic thiazolyl thiourea
   compounds
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; POTENT
   NONNUCLEOSIDE INHIBITORS; POKEWEED ANTIVIRAL PROTEIN; STRUCTURE-BASED
   DESIGN; RATIONAL DESIGN; PETT COMPOUNDS; RESISTANT; TYPE-1; COMPLEX
AB Several thiazolyl thiourea derivatives were designed and synthesized as non-nucleoside inhibitors (NNRTI) of HIV-1 reverse transcriptase. Six lead compounds were identified that showed subnanomolar IC50 values for the inhibition of HIV replication, were minimally toxic to human peripheral blood mononuclear cells (PBMC) with CC50 values ranging from 28 to >100 muM, and showed remarkably high selectivity indices ranging from 28,000 to >100,000. The most promising compound was N-[1-(1-furoylmethyl)]-N'-[2-(thiazolyl)]thiourea (compound 6), which showed potency against two NNRTI-resistant HIV-1 isolates (A17 and A17 variant) at nanomolar to low micromolar concentrations, exhibited much greater potency against both wild-type as well as NNRTI-resistant HIV-1 than nevirapine, delavirdine, HI-443, and HI-244, was minimally toxic to PBMC, and had a selectivity index of >100,000. The potency and minimal cytotoxicity of these aromatic/heterocyclic thiourea compounds suggest that they may be potentially useful as anti-AIDS drugs. (C) 2001 Published by Elsevier Science Ltd.
C1 Parker Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Hogberg M, 2000, BIOORG MED CHEM LETT, V10, P265, DOI 10.1016/S0960-894X(99)00675-7
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Mao C, 1999, ANTIVIR CHEM CHEMOTH, V10, P233, DOI 10.1177/095632029901000502                                                      
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Ren JS, 1998, BIOCHEMISTRY-US, V37, P14394, DOI 10.1021/bi981309m                                                               
   Ren JS, 2000, J BIOL CHEM, V275, P14316, DOI 10.1074/jbc.275.19.14316
   Ren JS, 2000, J BIOL CHEM, V275, P5633, DOI 10.1074/jbc.275.8.5633
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   Uckun FM, 2000, ANTIVIR CHEM CHEMOTH, V11, P135, DOI 10.1177/095632020001100205                                                      
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Venkatachalam TK, 2000, BIOORG MED CHEM LETT, V10, P2071, DOI 10.1016/S0960-894X(00)00398-X
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
   UCKUN FM, 2000, Patent No. 09338685
   UCKUN FM, 2000, Patent No. 09244677
   PARADIGM PHARM, 1999, Patent No. 5998411
NR 31
TC 59
Z9 59
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD FEB 26
PY 2001
VL 11
IS 4
BP 523
EP 528
DI 10.1016/S0960-894X(01)00011-7
PG 6
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 403BG
UT WOS:000167022200021
PM 11229762
DA 2018-01-05
ER

PT J
AU Kayser, O
AF Kayser, O
TI A new approach for targeting to Cryptosporidium parvum using
   mucoadhesive nanosuspensions: research and applications
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article; Proceedings Paper
CT 3rd European Workshop on Particulate Systems
CY APR 27-29, 2000
CL UTRECHT, NETHERLANDS
DE cryptosporidium; mucoadhesion; bioadhesion; bupravaquone; in vivo; in
   vitro; HIV; drug delivery; chitosan; nanosuspension
ID INFECTION; MICE
AB A new strategy to deliver antibiotics to the Cryptosporidium-infected gastrointestinal tract is presented. In an effort to augment the anticryptosporidial effect of clinically used drugs, mucoadhesive nanosuspensions were prepared. They have the ability to reside in the gastrointestinal tract for an extended period. The hydrogel contained bupravaquone nanosuspensions and an adhesive polymer (chitosan) powder dispersed in water. By the development of mucoadhesive nanosuspensions. a potential drug delivery system for poorly soluble drugs has been investigated to overcome bioavailability problems caused by the pathophysiological diarrhoeic situation in patients suffering from cryptosporidiosis. Adapting drug delivery systems to the situation of Cryptosporidium parvum infections in man allows increased retention times with a prolonged action at reduced elimination in the gastrointestinal tract. In this communication, in vivo data are presented to document the efficiency of bupravaquone formulated as mucoadhesive polymers to improve its activity against C. parvum. (C) 2001 Elsevier Science B.V. All rights reserved.
C1 Free Univ Berlin, Inst Pharm Pharmazeut Technol Biopharm & Biotechn, D-12169 Berlin, Germany.
RP Kayser, O (reprint author), Free Univ Berlin, Inst Pharm Pharmazeut Technol Biopharm & Biotechn, Kelchstr 31, D-12169 Berlin, Germany.
RI Kayser, Oliver/B-1431-2016
OI Kayser, Oliver/0000-0001-6131-2495
CR HARP JA, 1992, INFECT IMMUN, V60, P3509
   Hoepelman IM, 1996, INT J STD AIDS, V7, P28, DOI 10.1258/0956462961917285
   Jacobs C, 2001, INT J PHARM, V214, P3, DOI 10.1016/S0378-5173(00)00622-0
   JACOBS C, 2000, P INT S CONTR REL BI
   Laing RBS, 1999, J HOSP INFECT, V43, P179, DOI 10.1053/jhin.1999.0617
   Nelson SP, 1999, CLIN PEDIATR, V38, P367, DOI 10.1177/000992289903800609
   Smith NH, 1998, J INFECT DIS, V178, P900, DOI 10.1086/515352                                                                  
   Theodos CM, 1998, ANTIMICROB AGENTS CH, V42, P1959
   Uip D. E., 1998, Journal of Antimicrobial Chemotherapy, V41, P93, DOI 10.1093/jac/41.suppl_2.93
   Waters WR, 1996, INFECT IMMUN, V64, P1854
NR 10
TC 32
Z9 36
U1 1
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-5173
J9 INT J PHARM
JI Int. J. Pharm.
PD FEB 19
PY 2001
VL 214
IS 1-2
BP 83
EP 85
DI 10.1016/S0378-5173(00)00640-2
PG 3
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 403VC
UT WOS:000167062300017
PM 11282242
DA 2018-01-05
ER

PT J
AU Jacotot, E
   Ferri, KF
   El Hamel, C
   Brenner, C
   Druillennec, S
   Hoebeke, J
   Rustin, P
   Metivier, D
   Lenoir, C
   Geuskens, M
   Vieira, HLA
   Loeffler, M
   Belzacq, AS
   Briand, JP
   Zamzami, N
   Edelman, L
   Xie, ZH
   Reed, JC
   Roques, BP
   Kroemer, G
AF Jacotot, E
   Ferri, KF
   El Hamel, C
   Brenner, C
   Druillennec, S
   Hoebeke, J
   Rustin, P
   Metivier, D
   Lenoir, C
   Geuskens, M
   Vieira, HLA
   Loeffler, M
   Belzacq, AS
   Briand, JP
   Zamzami, N
   Edelman, L
   Xie, ZH
   Reed, JC
   Roques, BP
   Kroemer, G
TI Control of mitochondrial membrane permeabilization by adenine nucleotide
   translocator interacting with HIV-1 viral protein R and Bcl-2
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE ADP/ATP translocase; HIV; Vpr; mitochondria; Bcl-2
ID IMMUNODEFICIENCY-VIRUS TYPE-1; C-TERMINAL DOMAIN; DEPENDENT ANION
   CHANNEL; TRANSITION PORE; CELL-DEATH; FAMILY PROTEINS; CYTOCHROME-C;
   INHIBITS APOPTOSIS; ADP/ATP CARRIER; OUTER-MEMBRANE
AB Viral protein R (Vpr), an apoptogenic accessory protein encoded by HIV-1, induces mitochondrial membrane permeabilization (MMP) via a specific interaction with the permeability transition pore complex, which comprises the voltage-dependent anion channel (VDAC) in the outer membrane (OM) and the adenine nucleotide translocator (ANT) in the inner membrane. Here, we demonstrate that a synthetic Vpr-derived peptide (Vpr52-96) specifically binds to the intermembrane face of the ANT with an affinity in the nanomolar range. Taking advantage of this specific interaction, we determined the role of ANT in the control of MMP. In planar lipid bilayers, Vpr52-96 and purified ANT cooperatively form large conductance channels. This cooperative channel formation relies on a direct protein-protein interaction since it is abolished by the addition of a peptide corresponding to the Vpr binding site of ANT. When added to isolated mitochondria, Vpr52-96 uncouples the respiratory chain and induces a rapid inner MMP to protons and NADH. This inner MMP precedes outer MMP to cytochrome c. Vpr52-96-induced matrix swelling and inner MMP both are prevented by preincubation of purified mitochondria with recombinant Bcl-2 protein. In contrast to Konig's polyanion (PA10), a specific inhibitor of the VDAC, Bcl-2 fails to prevent Vpr52-96 from crossing the mitochondrial OM. Rather, Bcl-2 reduces the ANT-Vpr interaction, as determined by affinity purification and plasmon resonance studies. Concomitantly, Bcl-2 suppresses channel formation by the ANT-Vpr complex in synthetic membranes. In conclusion, both Vpr and Bcl-2 modulate MMP through a direct interaction with ANT.
C1 Inst Gustave Roussy, CNRS, UMR 1599, F-94805 Villejuif, France.
   Univ Paris 05, CNRS, UMR 860, INSERM,U266,Unite Pharmacochim Mol & Struct, F-75006 Paris, France.
   Univ Technol Compiegne, CNRS, UMR A6022, F-60205 Compiegne, France.
   CNRS, UPR 9021, Inst Biol Mol & Cellulaire Immunol & Chim Therape, F-67084 Strasbourg, France.
   Hop Necker Enfants Malad, INSERM, U393, Unite Rech Handicaps Genet Enfant, F-75015 Paris, France.
   Free Univ Brussels, B-1640 Rhode St Genese, Belgium.
   Inst Pasteur, Lab Technol Cellulaire, F-75015 Paris, France.
   Burnham Inst, La Jolla, CA 92037 USA.
RP Kroemer, G (reprint author), Inst Gustave Roussy, CNRS, UMR 1599, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.
RI Kroemer, Guido/B-4263-2013
OI Kroemer, Guido/0000-0002-9334-4405; Vieira, Helena/0000-0001-9415-3742
FU NIGMS NIH HHS [R01 GM060554]
CR Arunagiri C, 1997, APOPTOSIS, V2, P69, DOI 10.1023/A:1026487609215                                                         
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P493
   Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298
   BRULLEMANS M, 1994, EUR BIOPHYS J BIOPHY, V23, P39, DOI 10.1007/BF00192204
   Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v
   Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.3.CO;2-V
   Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690
   Ciminale V, 1999, ONCOGENE, V18, P4505, DOI 10.1038/sj.onc.1203047                                                          
   Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299
   Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233
   Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2
   Derfuss T, 1998, J VIROL, V72, P5897
   Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891
   Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880
   Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081
   Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1                                                  
   GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j                                                               
   Goldmacher VS, 1999, P NATL ACAD SCI USA, V96, P12536, DOI 10.1073/pnas.96.22.12536                                                        
   Gotow T, 2000, CELL DEATH DIFFER, V7, P666, DOI 10.1038/sj.cdd.4400694
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309                                                   
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215                                                          
   HANKE W, 1984, BIOELECTROCH BIOENER, V12, P329, DOI 10.1016/0302-4598(84)87013-0                                                    
   Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33
   Kichler A, 2000, J VIROL, V74, P5424, DOI 10.1128/JVI.74.12.5424-5431.2000                                                
   KLINGENBERG M, 1993, J BIOENERG BIOMEMBR, V25, P447, DOI 10.1007/BF01108402
   KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961
   Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809
   Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994                                                                   
   Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1                                                   
   LEVY DN, 1994, P NATL ACAD SCI USA, V91, P10873, DOI 10.1073/pnas.91.23.10873
   LU YL, 1993, J VIROL, V67, P6542
   MACREADIE IG, 1995, P NATL ACAD SCI USA, V92, P2770, DOI 10.1073/pnas.92.7.2770
   Macreadie IG, 1997, FEBS LETT, V410, P145, DOI 10.1016/S0014-5793(97)00542-5                                                   
   Marshall WL, 1999, J VIROL, V73, P5181
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027                                                   
   MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000                                                           
   Motoyama S, 1998, BIOCHEM BIOPH RES CO, V249, P628, DOI 10.1006/bbrc.1998.9205
   Muthumani K, 2000, DNA CELL BIOL, V19, P179, DOI 10.1089/104454900314564
   Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681
   Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111
   Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Rustin P, 1996, J BIOL CHEM, V271, P14785, DOI 10.1074/jbc.271.25.14785                                                        
   Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365                                                          
   Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381
   Shimizu S, 1999, NATURE, V399, P483
   Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100                                                          
   Singh SP, 2000, VIROLOGY, V268, P364, DOI 10.1006/viro.2000.0191
   Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406                                                        
   STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694                                                        
   Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000
   Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i                                                               
NR 57
TC 218
Z9 222
U1 0
U2 4
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD FEB 19
PY 2001
VL 193
IS 4
BP 509
EP 519
DI 10.1084/jem.193.4.509                                                   
          
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 404RR
UT WOS:000167114900011
PM 11181702
OA gold
DA 2018-01-05
ER

PT J
AU Root, MJ
   Kay, MS
   Kim, PS
AF Root, MJ
   Kay, MS
   Kim, PS
TI Protein design of an HIV-1 entry inhibitor
SO SCIENCE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; COILED-COIL; POTENT INHIBITORS; SYNTHETIC
   PEPTIDE; ENVELOPE GLYCOPROTEIN; ATOMIC-STRUCTURE; GP41; FUSION; DOMAIN;
   EPITOPE
AB Human immunodeficiency virus type-1 (HIV-1) membrane fusion is promoted by the formation of a trimer-of-hairpins structure that brings the amino- and carboxyl-terminal regions of the gp41 envelope glycoprotein ectodomain into close proximity. Peptides derived from the carboxyl-terminal region (called C-peptides) potently inhibit HIV-1 entry by binding to the gp41 amino-terminal region. To test the converse of this inhibitory strategy, we designed a small protein, denoted 5-Helix, that binds the C-peptide region of gp41. The 5-Helix protein displays potent (nanomolar) inhibitory activity against diverse HIV-1 variants and may serve as the basis for a new class of antiviral agents. The inhibitory activity of 5-Helix also suggests a strategy for generating an HIV-1 neutralizing antibody response that targets the carboxyl-terminal region of the gp41 ectodomain.
C1 MIT, Dept Biol, Whitehead Inst Biomed Res, Howard Hughes Med Inst, Cambridge, MA 02142 USA.
RP Kim, PS (reprint author), Merck Res Labs, 770 Sumneytown Pike, W Point, PA 19486 USA.
FU NIGMS NIH HHS [P01 GM56552]
CR ALEXANDER S, 1984, SCIENCE, V226, P1328, DOI 10.1126/science.6505693
   BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001
   CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613
   Chang KM, 1998, MICROSYST TECHNOL, V5, P93, DOI 10.1007/s005420050148                                                           
   Chen B., UNPUB
   CHEN BK, 1994, J VIROL, V68, P654
   D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215
   Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699                                                               
   Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5
   Eckhart L, 1996, J GEN VIROL, V77, P2001, DOI 10.1099/0022-1317-77-9-2001
   EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010
   Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276
   HUGHSON FM, 1997, CURR BIOL, V7, P565
   JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0                                                                
   Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293
   LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357
   Lambert DM, 1996, P NATL ACAD SCI USA, V93, P2186, DOI 10.1073/pnas.93.5.2186
   LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075
   Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315
   MUSTER T, 1994, J VIROL, V68, P4031
   MUSTER T, 1993, J VIROL, V67, P6642
   Purtscher M, 1996, AIDS, V10, P587, DOI 10.1097/00002030-199606000-00003
   RAPAPORT D, 1995, EMBO J, V14, P5524
   Rimsky LT, 1998, J VIROL, V72, P986
   ROOT MJ, UNPUB
   Singh M, 1999, J MOL BIOL, V290, P1031, DOI 10.1006/jmbi.1999.2796
   Sutton RB, 1998, NATURE, V395, P347
   Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   Weng YK, 1998, J VIROL, V72, P9676
   WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537
   WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770
   Yao QZ, 1996, VIROLOGY, V223, P103, DOI 10.1006/viro.1996.0459
   Zhao X, 2000, P NATL ACAD SCI USA, V97, P14172, DOI 10.1073/pnas.260499197                                                          
   PAI EF, 2000, Patent No. 0061618
NR 37
TC 314
Z9 332
U1 4
U2 23
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD FEB 2
PY 2001
VL 291
IS 5505
BP 884
EP 888
DI 10.1126/science.1057453
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 398TD
UT WOS:000166771700048
PM 11229405
DA 2018-01-05
ER

PT J
AU Aranha, H
AF Aranha, H
TI Viral clearance strategies for biopharmaceutical safety - Part 2:
   Filtration for viral clearance
SO BIOPHARM-THE APPLIED TECHNOLOGIES OF BIOPHARMACEUTICAL DEVELOPMENT
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MICROPOROUS MEMBRANE-FILTER; MAMMALIAN
   VIRUSES; PARVOVIRUS B19; FACTOR-VIII; FACTOR-IX; REMOVAL;
   NANOFILTRATION; HEMOPHILIACS; RETENTION
AB Because the definitive absence of viral presence is currently impossible to demonstrate, multiple overlapping virus clearance methodologies need to be incorporated into the manufacturing process. Filtration can be used either independently or as an adjunct to other methods. Knowing the factors that affect filtration and being able to identify critical parameters that influence the process will help when evaluating filtration as a strategy for virus removal.
C1 Pall Corp, Port Washington, NY 11050 USA.
RP Aranha, H (reprint author), Pall Corp, 25 Harbor Pk Dr, Port Washington, NY 11050 USA.
CR Abe H, 2000, ARTIF CELL BLOOD SUB, V28, P375, DOI 10.3109/10731190009118582                                                       
   ANAZAWA H, 1997, PHARM TECH JAPAN, V13, P951
   Aranha-Creado H, 1999, PDA J PHARM SCI TECH, V53, P75
   Aranha-Creado H, 1998, BIOLOGICALS, V26, P167, DOI 10.1006/biol.1998.0130                                                          
   AranhaCreado H, 1997, PDA J PHARM SCI TECH, V51, P119
   ARANHACREADO H, 1998, BIOTECHNOLOGY ISSUES
   AygorenPursun E, 1997, THROMB HAEMOSTASIS, V78, P1352
   BRANTLEY JD, 1997, PBBSTR28 PALL ULTR F
   BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x                                              
   Chudy M, 1999, J MED VIROL, V57, P91, DOI 10.1002/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L
   *CTR BIOL EV RES, 1999, VOL REC POOL PLASM S
   DARBY SC, 1995, NATURE, V377, P79, DOI 10.1038/377079a0                                                                
   DILEO AJ, 1993, BIOLOGICALS, V21, P275, DOI 10.1006/biol.1993.1085
   Eis-Hubinger AM, 1999, THROMB HAEMOSTASIS, V81, P476
   *GUID VIR SAF EV B, 1998, FED REGISTER, V63, P51074
   HAMAMOTO Y, 1989, VOX SANG, V56, P230, DOI 10.1111/j.1423-0410.1989.tb02034.x                                              
   HIEMSTRA H, 2000, EMEA C WORKSH VIR SA
   Johnston A, 2000, BIOLOGICALS, V28, P129, DOI 10.1006/biol.1999.0242
   Levy Richard V., 1998, P619
   LUTZ H, 2000, IBCS 2 ANN C BLOOD S
   MANNUCCI PM, 1995, THROMB HAEMOSTASIS, V73, P737
   *NOT GUID VIR VAL, 1996, CPMPBWP26895
   OGrady J, 1996, DEV BIOL STAND, V88, P319
   Oshima KH, 1996, BIOLOGICALS, V24, P137, DOI 10.1006/biol.1996.0018
   OSHIMA KH, 1994, ENVIRON TOXIC WATER, V9, P165, DOI 10.1002/tox.2530090302
   OSHIMA KH, 1995, J ACQ IMMUN DEF SYND, V8, P64
   OSHIMA KH, 1998, VOX SANG, V75, P185
   OSHIMA KH, 2000, WORKSH VIR CLEAR TES
   Osumi M, 1996, PDA J Pharm Sci Technol, V50, P30
   *PALL ULTR FILTR C, 1995, TRUDV50 PALL ULTR FI
   Pallak M. S., 1980, APPLIED SOCIAL PSYCH, P235
   Phillips MW, 1996, BIOLOGICALS, V24, P243, DOI 10.1006/biol.1996.0033                                                          
   Roberts P, 1997, J VIROL METHODS, V65, P27, DOI 10.1016/S0166-0934(96)02163-5
   Santagostino E, 1997, TRANSFUSION, V37, P517, DOI 10.1046/j.1537-2995.1997.37597293884.x
   SATO T, 1994, ANIMAL CELL TECHNOLOGY: BASIC & APPLIED ASPECTS, VOL 6, P517
   Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601
   SEKIGUCHI S, 1989, Membrane, V14, P253
   Shi LM, 1999, BIOLOGICALS, V27, P253, DOI 10.1006/biol.1999.0213
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   VARADARAJAN U, 2000, WORKSH VIR CLEAR TES
   WALTER JK, 1998, ACS S SERIES, V698
NR 41
TC 6
Z9 6
U1 1
U2 6
PU ADVANSTAR COMMUNICATIONS
PI DULUTH
PA 131 W FIRST ST, DULUTH, MN 55802 USA
SN 1040-8304
J9 BIOPHARM-APPL T BIO
JI Biopharm-Appl Technol. Biopharm. Dev.
PD FEB
PY 2001
VL 14
IS 2
BP 32
EP +
PG 8
WC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
SC Biotechnology & Applied Microbiology; Pharmacology & Pharmacy
GA 403BD
UT WOS:000167021900007
DA 2018-01-05
ER

PT J
AU Snasel, J
   Rejman, D
   Liboska, R
   Tocik, Z
   Ruml, T
   Rosenberg, I
   Pichova, I
AF Snasel, J
   Rejman, D
   Liboska, R
   Tocik, Z
   Ruml, T
   Rosenberg, I
   Pichova, I
TI Inhibition of HIV-1 integrase by modified oligonucleotides derived from
   U5 ' LTR
SO EUROPEAN JOURNAL OF BIOCHEMISTRY
LA English
DT Article
DE HIV-1 integrase; oligonucleotides; inhibition
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RETROVIRAL DNA INTEGRATION;
   PHOTO-CROSS-LINKING; STYRYLQUINOLINE DERIVATIVES; SUBSTRATE-SPECIFICITY;
   IN-VITRO; PROTEIN; BINDING; REPLICATION; RECOGNITION
AB Retroviral integrase catalyzes integration of double-stranded viral DNA into the host chromosome by a process that has become an attractive target for drug design. In the 3' processing reaction, two nucleotides are specifically cleaved from both 3' ends of viral DNA yielding a 5' phosphorylated dimer (pGT). The resulting recessed 3' hydroxy groups of adenosine provide the attachment sites to the host DNA in the strand transfer reaction. Here, we studied the effect of modified double-stranded oligonucleotides mimicking both the unprocessed (21-mer oligonucleotides) and 3' processed (19-mer oligonucleotides) U5 termini of proviral DNA on activities of HIV-1 integrase in vitro. The inhibitions of 3' processing and strand transfer reactions were studied using 21-mer oligonucleotides containing isopolar, nonisosteric, both conformationally flexible and restricted phosphonate inter-nucleotide linkages between the conservative AG of the sequence CAGT, and using a 21-mer oligonucleotide containing 2'-fluoroarabinofuranosyladenine. All modified 21-mer oligonucleotides competitively inhibited both reactions mediated by HIV-1 integrase with nanomolar IC50 values. Our studies with 19-mer oligonucleotides showed that modifications of the 3' hydroxyl significantly reduced the strand transfer reaction. The inhibition of integrase with 19-mer oligonucleotides terminated by (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine, 9-(2-phosphonomethoxyethyl)adenine, and adenosine showed that proper orientation of the 3' OH group and the presence of the furanose ring of adenosine significantly influence the strand transfer reaction.
C1 Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic.
   Inst Chem Technol, Dept Biochem & Microbiol, CR-16628 Prague, Czech Republic.
RP Pichova, I (reprint author), Acad Sci Czech Republ, Inst Organ Chem & Biochem, Flemingovo N 2, CR-16610 Prague 6, Czech Republic.
RI Rejman, Dominik/D-6901-2011; Liboska, Radek/I-5715-2014; Pichova,
   Iva/G-7917-2014; Rosenberg, Ivan/G-5602-2014
OI Snasel, Vaclav/0000-0002-9600-8319
CR Balakrishnan M, 1997, J VIROL, V71, P1025
   BALZARINI J, 1989, P NATL ACAD SCI USA, V86, P332, DOI 10.1073/pnas.86.1.332
   Balzarini J, 1998, CURR OPIN MICROBIOL, V1, P535, DOI 10.1016/S1369-5274(98)80086-6
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Caumont A, 1999, FEBS LETT, V455, P154, DOI 10.1016/S0014-5793(99)00859-5
   Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644                                                    
   Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7
   ENGELMAN A, 1993, EMBO J, V12, P3269
   Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832
   Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123                                                        
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c
   Heuer TS, 1997, BIOCHEMISTRY-US, V36, P10655, DOI 10.1021/bi970782h
   Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836
   Katzman M, 1996, J VIROL, V70, P9069
   Katzman M, 1999, ADV VIRUS RES, V52, P371, DOI 10.1016/S0065-3527(08)60307-3
   LAFEMINA RL, 1991, J VIROL, V65, P5624
   LEE SP, 1995, BIOCHEMISTRY-US, V34, P10215, DOI 10.1021/bi00032a015                                                             
   Lin ZW, 1999, J MED CHEM, V42, P1401, DOI 10.1021/jm980531m
   McDougall B, 1998, ANTIMICROB AGENTS CH, V42, P140
   Mekouar K, 1998, J MED CHEM, V41, P2846, DOI 10.1021/jm980043e
   Neamati N, 2000, Adv Pharmacol, V49, P147
   Ouali M, 2000, J MED CHEM, V43, P1949, DOI 10.1021/jm9911581                                                               
   PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025                                                           
   Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1
   Pommier Y, 1999, ADV VIRUS RES, V52, P427, DOI 10.1016/S0065-3527(08)60310-3
   SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119
   Taktakishvili M, 2000, BIOORG MED CHEM LETT, V10, P249, DOI 10.1016/S0960-894X(99)00677-0
   Tramontano E, 1998, BIOCHEMISTRY-US, V37, P7237, DOI 10.1021/bi972792o                                                               
   VANDENENT FMI, 1994, J VIROL, V68, P7825
   VANGENT DC, 1993, EMBO J, V12, P3261
   Vella S, 2000, ANTIVIR RES, V45, P1, DOI 10.1016/S0166-3542(99)00068-6
   VINK C, 1991, J VIROL, V65, P4636
   Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000                                              
   YOSHINAGA T, 1995, J VIROL, V69, P3233
   Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o                                                               
NR 36
TC 22
Z9 22
U1 0
U2 4
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0014-2956
J9 EUR J BIOCHEM
JI Eur. J. Biochem.
PD FEB
PY 2001
VL 268
IS 4
BP 980
EP 986
DI 10.1046/j.1432-1327.2001.01956.x
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 406WH
UT WOS:000167238800012
PM 11179964
OA gold
DA 2018-01-05
ER

PT J
AU Malhotra, U
   Holte, S
   Dutta, S
   Berrey, MM
   Delpit, E
   Koelle, DM
   Sette, A
   Corey, L
   McElrath, MJ
AF Malhotra, U
   Holte, S
   Dutta, S
   Berrey, MM
   Delpit, E
   Koelle, DM
   Sette, A
   Corey, L
   McElrath, MJ
TI Role for HLA class II molecules in HIV-1 suppression and cellular
   immunity following antiretroviral treatment
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID VIRUS TYPE-1 INFECTION; DR-BETA-CHAIN; HOMOSEXUAL MEN; DISEASE
   PROGRESSION; NATURAL INFECTION; HLA-DR13 ALLELES; PEPTIDE BINDING; MHC
   GENOTYPE; T-CELLS; IN-VIVO
AB HIV-1-infected patients treated early with combination antiretrovirals respond favorably, but not all maintain viral suppression and improved HIV-specific Th function. To understand if genetic factors contribute to this variation, we prospectively evaluated over 18 months 21 early-treated patients stratified by alleles of class II haplotypes. All seven subjects with the DRB1*13-DQB1*06 haplotype, but only 21% of other subjects, maintained virus suppression at every posttreatment measurement. Following HIV-1 p24 antigen stimulation, PBMCs from patients with this haplotype demonstrated higher mean lymphoproliferation and IFN-gamma secretion than did cells from patients with other haplotypes. Two DRB1*13-restricted Gag epitope regions were identified, a promiscuous one that bound its putative restriction element with nanomolar affinity, and another that mapped to a highly conserved region. These findings suggest that class II molecules, particularly the DRB1*13 haplotype, have an important impact on virologic and immunologic responses. The advantage of the haplotype may relate to selection of key HIV-1 Th1 epitopes in highly conserved regions with avid binding to class II molecules. Eliciting responses to the promiscuous epitope region may be beneficial in vaccine strategies.
C1 Epimmune, San Diego, CA USA.
   Univ Washington, Sch Med, Dept Lab Med, Seattle, WA USA.
   Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Program Biostat, Seattle, WA 98104 USA.
   Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
   Fred Hutchinson Canc Res Ctr, Div Clin Res, Program Infect Dis, Seattle, WA 98109 USA.
RP McElrath, MJ (reprint author), Fred Hutchinson Canc Res Ctr, Div Clin Res, Program Infect Dis, 1100 Fairview Ave N,D3-100, Seattle, WA 98109 USA.
RI Koelle, David/Q-6529-2016
OI Koelle, David/0000-0003-1255-9023
FU NIAID NIH HHS [AI-41535, AI-30731, P01 AI030731, AI-01411, P30 AI027757]
CR Adams SL, 1997, J ACQ IMMUN DEF SYND, V15, P257, DOI 10.1097/00042560-199708010-00002                                                
   APPLE RJ, 1994, NAT GENET, V6, P157, DOI 10.1038/ng0294-157
   Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112
   BERDOZ J, 1987, J IMMUNOL, V139, P1336
   BORROW P, 1994, J VIROL, V68, P6103
   Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748
   Chaturvedi P, 1996, INT IMMUNOL, V8, P745, DOI 10.1093/intimm/8.5.745                                                          
   Chen Y, 1997, HUM IMMUNOL, V55, P154, DOI 10.1016/S0198-8859(97)00092-X
   Cohen OJ, 1997, IMMUNOL REV, V159, P31, DOI 10.1111/j.1600-065X.1997.tb01005.x
   DAVENPORT MP, 1995, P NATL ACAD SCI USA, V92, P6567, DOI 10.1073/pnas.92.14.6567
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   DEMOTZ S, 1991, P NATL ACAD SCI USA, V88, P8730, DOI 10.1073/pnas.88.19.8730
   DEWAR RL, 1994, J INFECT DIS, V170, P1172, DOI 10.1093/infdis/170.5.1172                                                       
   FALK K, 1994, IMMUNOGENETICS, V39, P230
   Goulder PJR, 1996, AIDS RES HUM RETROV, V12, P1691, DOI 10.1089/aid.1996.12.1691
   Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410                                                                   
   HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240                                                             
   KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H
   Keet IPM, 1999, J INFECT DIS, V180, P299, DOI 10.1086/314862
   KOELLE DM, 1994, J VIROL, V68, P2803
   LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204
   Lederman MM, 1998, J INFECT DIS, V178, P70, DOI 10.1086/515591                                                                  
   LIPSITZ SR, 1994, BIOMETRICS, V50, P270, DOI 10.2307/2533218
   LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003
   Malhotra U, 2000, J INFECT DIS, V181, P121, DOI 10.1086/315202
   MARLOUBIAN M, 1994, J VIROL, V68, P8056
   McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0
   McNeil AJ, 1996, QJM-MON J ASSOC PHYS, V89, P177
   MIEDEMA F, 1988, J CLIN INVEST, V82, P1908, DOI 10.1172/JCI113809
   MURRAY JS, 1992, EUR J IMMUNOL, V22, P559, DOI 10.1002/eji.1830220239
   Musey LK, 1999, J INFECT DIS, V180, P278, DOI 10.1086/314868
   Nakamura Y, 1997, VACCINE, V15, P489, DOI 10.1016/S0264-410X(96)00224-1
   NISHINO Y, 1992, VACCINE, V10, P677, DOI 10.1016/0264-410X(92)90089-3
   PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569
   Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400
   Raboud JM, 1999, J INFECT DIS, V180, P1347, DOI 10.1086/314998
   Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008                                                
   Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447
   ROZEMULLER EH, 1995, TISSUE ANTIGENS, V45, P57, DOI 10.1111/j.1399-0039.1995.tb02415.x
   Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001
   Schountz T, 1996, J IMMUNOL, V157, P3893
   SCHRIER RD, 1989, J IMMUNOL, V142, P1166
   SHEARER GM, 1984, J CLIN INVEST, V74, P496, DOI 10.1172/JCI111447
   SIDNEY J, 1998, CURRENT PROTOCOLS IM, V18
   Sintasath DM, 1999, HUM IMMUNOL, V60, P1001, DOI 10.1016/S0198-8859(99)00085-3
   Southwood S, 1998, J IMMUNOL, V160, P3363
   THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604
   TISHON A, 1995, VIROLOGY, V212, P244, DOI 10.1006/viro.1995.1477
   VERRECK FA, 1996, IMMUNOGENETICS, V43, P292
   WAHREN B, 1989, J ACQ IMMUN DEF SYND, V2, P448
   WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603
   Wu SH, 1997, J IMMUNOL, V158, P3221
   ZEGER SL, 1994, BIOMETRICS, V50, P689, DOI 10.2307/2532783
NR 54
TC 87
Z9 90
U1 0
U2 3
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA
SN 0021-9738
J9 J CLIN INVEST
JI J. Clin. Invest.
PD FEB
PY 2001
VL 107
IS 4
BP 505
EP 517
DI 10.1172/JCI11275                                                        
          
PG 13
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 403YY
UT WOS:000167071700015
PM 11181650
OA gold
DA 2018-01-05
ER

PT J
AU Perez, A
   Probert, AW
   Wang, KKW
   Sharmeen, L
AF Perez, A
   Probert, AW
   Wang, KKW
   Sharmeen, L
TI Evaluation of HIV-1 Tat induced neurotoxicity in rat cortical cell
   culture
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE neuronal cell death; HIV-1; Tat; NMDA receptors
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RECEPTOR-MEDIATED NEUROTOXICITY;
   TRANSACTIVATING PROTEIN TAT; CENTRAL-NERVOUS-SYSTEM;
   NECROSIS-FACTOR-ALPHA; MAEDI-VISNA VIRUS; AIDS DEMENTIA; COAT PROTEIN;
   HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS
AB In a substantial number of cases, Human Immunodeficiency Virus type 1 (HIV-1) infection causes neuronal cell loss and leads to the development of AIDS associated dementia. Several studies have suggested that both host and viral factors contribute to neuronal loss. Here we studied the effect of HIV-1 Tat in primary rat neuronal cells as a model to understand mechanism of neuronal cell death. At nano molar concentration, recombinant Tat induced cell death in primary rat mixed cortical neurons. Tat could also induce uptake of calcium in primary rat cultures. When cells were incubated with NMDA receptor antagonists, MK-801 and D-CPP, cell death and Ca-45 uptake were inhibited. Under similar conditions non-NMDA antagonists, NBQX, DNQX and CNQX, and sodium channel antagonist, TTX, did not inhibit Tat induced neuronal cell death. In a similar way HIV associated products from in vitro HIV-1 infected cells induced neuronal cell death which was inhibited by NMDA receptor antagonist. Results presented in this paper suggest that activation of NMDA receptors by HIV-1 Tat is responsible for neuronal cell death in primary rat cortical neurons.
C1 Parke Davis Pharmaceut Res, Dept Infect Dis, Ann Arbor, MI 48105 USA.
   Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Ann Arbor, MI 48105 USA.
RP Sharmeen, L (reprint author), Parke Davis Pharmaceut Res, Dept Infect Dis, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.
OI Wang, Kevin/0000-0002-9343-6473
CR Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917
   Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153
   Albini A, 1998, J BIOL CHEM, V273, P15895, DOI 10.1074/jbc.273.26.15895
   BIRRELL GJ, 1993, NEUROPHARMACOLOGY, V32, P1351, DOI 10.1016/0028-3908(93)90030-7                                                    
   Bloom FE, 1997, J NEUROVIROL, V3, P102, DOI 10.3109/13550289709015800                                                       
   BUONAGURO L, 1992, J VIROL, V66, P7159
   Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385
   Conant K, 1998, P NATL ACAD SCI USA, V95, P3117, DOI 10.1073/pnas.95.6.3117
   Corasaniti MT, 1996, BIOCHEM BIOPH RES CO, V229, P299, DOI 10.1006/bbrc.1996.1796
   DIOP AG, 1994, NEUROSCI LETT, V165, P187, DOI 10.1016/0304-3940(94)90741-2
   DREYER E, 1997, EUR J NEUROSCI, V7, P2502
   EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502
   Ferrarese C, 1997, JAMA-J AM MED ASSOC, V277, P630, DOI 10.1001/jama.277.8.630
   Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303                                                        
   Fontana G, 1997, J NEUROSCI RES, V49, P732, DOI 10.1002/(SICI)1097-4547(19970915)49:6<732::AID-JNR7>3.0.CO;2-8
   FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944
   FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2
   HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093
   Haughey NJ, 1999, J NEUROCHEM, V73, P1363, DOI 10.1046/j.1471-4159.1999.0731363.x
   HAYMAN M, 1993, NEUROSCIENCE, V53, P1, DOI 10.1016/0306-4522(93)90278-N
   He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0
   HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909                                                         
   Ito M, 1998, AIDS RES HUM RETROV, V14, P845, DOI 10.1089/aid.1998.14.845
   Johnson RT, 1995, CURR TOP MICROBIOL, V202, P3
   Katsikis PD, 1997, INT IMMUNOL, V9, P835, DOI 10.1093/intimm/9.6.835
   KIMPTON J, 1992, J VIROL, V66, P2232
   Kirsch T, 1996, PROTEIN EXPRES PURIF, V8, P75, DOI 10.1006/prep.1996.0076
   Kruman II, 1998, EXP NEUROL, V154, P276, DOI 10.1006/exnr.1998.6958
   Lafrenie RM, 1996, J IMMUNOL, V157, P974
   Lafrenie RM, 1997, J IMMUNOL, V159, P4077
   Lavi E, 1998, J NEUROVIROL, V4, P301, DOI 10.3109/13550289809114531                                                       
   LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549                                                         
   Lipton SA, 1998, ANNU REV PHARMACOL, V38, P159, DOI 10.1146/annurev.pharmtox.38.1.159
   Lipton SA, 1996, BRAIN PATHOL, V6, P507, DOI 10.1111/j.1750-3639.1996.tb00879.x
   LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F                                                    
   Maccarrone M, 1998, BIOCHEM J, V333, P45, DOI 10.1042/bj3330045                                                               
   MAGNUSON DSK, 1995, ANN NEUROL, V37, P373, DOI 10.1002/ana.410370314
   MANN DA, 1991, EMBO J, V10, P1733
   Nath A, 1996, J VIROL, V70, P1475
   New DR, 1997, J NEUROVIROL, V3, P168, DOI 10.3109/13550289709015806                                                       
   New DR, 1998, J BIOL CHEM, V273, P17852, DOI 10.1074/jbc.273.28.17852                                                        
   Nishida K, 1996, J NEUROCHEM, V66, P433
   NOKTA MA, 1995, VIROLOGY, V208, P590, DOI 10.1006/viro.1995.1190
   PHILIPPON V, 1994, VIROLOGY, V205, P519, DOI 10.1006/viro.1994.1673
   PROBERT A, 1997, NEUROPHARMACOLOGY, V36, P1037
   Raber J, 1996, VIROLOGY, V226, P362, DOI 10.1006/viro.1996.0664
   SABATIER JM, 1991, J VIROL, V65, P961
   Sanders E, 1998, PHYS WORLD, V11, P12
   SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961
   SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405
   Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529                                                       
   STRIJBOS PJLM, 1995, NEUROSCI LETT, V197, P215, DOI 10.1016/0304-3940(95)11940-X
   Toggas SM, 1996, BRAIN RES, V706, P303, DOI 10.1016/0006-8993(95)01197-8
   USHIJIMA H, 1995, EUR J NEUROSCI, V7, P1353, DOI 10.1111/j.1460-9568.1995.tb01126.x
   Vitkovic L, 1995, CURR TOP MICROBIOL, V202, P105
   Wang P, 1999, NEUROSCIENCE, V88, P585, DOI 10.1016/S0306-4522(98)00242-5                                                   
   WESTENDORP MO, 1994, J VIROL, V68, P4177
   Zidovetzki R, 1998, AIDS RES HUM RETROV, V14, P825, DOI 10.1089/aid.1998.14.825
NR 58
TC 58
Z9 58
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD FEB
PY 2001
VL 7
IS 1
BP 1
EP 10
DI 10.1080/135502801300069575
PG 10
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 472QZ
UT WOS:000170997600002
PM 11519477
DA 2018-01-05
ER

PT J
AU Chekulayeva, MN
   Kurnasov, OV
   Shirokov, VA
   Spirin, AS
AF Chekulayeva, MN
   Kurnasov, OV
   Shirokov, VA
   Spirin, AS
TI Continuous-exchange cell-free protein-synthesizing system: Synthesis of
   HIV-1 antigen Nef
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE continuous-exchange cell-free (CECF) system; combined
   transcription/translation; green fluorescent protein; HIV-1 antigen Nef
ID GREEN FLUORESCENT PROTEIN; FREE TRANSLATION SYSTEM; GENE-EXPRESSION;
   PREPARATIVE-SCALE
AB HIV-1 antigen Nef, Green Fluorescent Protein (GFP), and the fusion protein GFP-Nef ("Green Fluorescent Nef") were synthesized in bacterial cell-free system with continuous supply of substrates and continuous removal of low-molecular-weight products through a dialysis membrane during incubation, the so-called continuous-exchange cell-free (CECF) system. The identity of synthesized proteins was confirmed by electrophoretic mobility, Western blotting, and GFP fluorescence. The system produced several nanomoles (hundreds of mug) of each protein per mi of the reaction mixture. Construction of GFP-fused proteins is considered as a general strategy for visualization and monitoring of cell-free production of the proteins that have no easily testable functions. (C) 2001 Academic Press.
C1 Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.
RP Chekulayeva, MN (reprint author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.
RI Shirokov, Vladimir/M-3740-2015; Spirin, Alexander/A-7307-2016
CR ADACHI A, 1999, INT J MOL MED, V4, P427
   BARANOV VI, 1993, METHOD ENZYMOL, V217, P123
   BARANOV VI, 1989, GENE, V84, P463, DOI 10.1016/0378-1119(89)90521-0
   CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295
   Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0
   DAVIS J, 1996, PROMEGA NOTES, V56, P14
   Kigawa T, 1999, FEBS LETT, V442, P15, DOI 10.1016/S0014-5793(98)01620-2
   Kim DM, 1996, BIOTECHNOL PROGR, V12, P645, DOI 10.1021/bp960052l                                                               
   Kolb VA, 1996, BIOTECHNOL LETT, V18, P1447, DOI 10.1007/BF00129353
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Madin K, 2000, P NATL ACAD SCI USA, V97, P559, DOI 10.1073/pnas.97.2.559
   Piguet V, 1999, REV MED VIROL, V9, P111
   SPIRIN AS, 1990, RIBOSOME, P56
   SPIRIN AS, 1988, SCIENCE, V242, P1162, DOI 10.1126/science.3055301
   SPIRIN AS, 1991, FRONTIERS BIOPROCESS, P31
   SPIRIN AS, 1991, RIBOSOME STRUCTURE F, P31
   ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411
   Alakhov J.B., 1995, U. S. Patent, Patent No. 5478730
NR 18
TC 12
Z9 15
U1 0
U2 1
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 26
PY 2001
VL 280
IS 3
BP 914
EP 917
DI 10.1006/bbrc.2000.4188
PG 4
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 397LN
UT WOS:000166697300052
PM 11162611
DA 2018-01-05
ER

PT J
AU Mak, CC
   Le, VD
   Lin, YC
   Elder, JH
   Wong, CH
AF Mak, CC
   Le, VD
   Lin, YC
   Elder, JH
   Wong, CH
TI Design, synthesis, and biological evaluation of HIV/FIV protease
   inhibitors incorporating a conformationally constrained macrocycle with
   a small P3 ' residue
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID FELINE IMMUNODEFICIENCY VIRUS; HIV-PROTEASE; FIV PROTEASE; DRUG DESIGN;
   PEPTIDES; ISOSTERE; BINDING
AB A series of norstatine-based HIV/FIV protease inhibitors incorporating a 15-membered macrocycle as a mimic of the tripeptide (Ala-Val-Phe), a motif with a small P3' residue effective against the FIV protease and the drug-resistant HIV proteases, has been synthesized. It was found that the macrocycle is important to the overall activity of the inhibitors. Certain inhibitors were developed expressing low nanomolar inhibitory activity against the HIV/FIV proteases and they are also effective against some drug-resistant as well as TL3-resistant HIV proteases. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA.
   Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
   Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
RP Wong, CH (reprint author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.
FU NIGMS NIH HHS [GM48870]
CR ABBENANTE G, 1995, J AM CHEM SOC, V117, P10220, DOI 10.1021/ja00146a007                                                             
   Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z                                                               
   Chen JJ, 1996, BIOORG MED CHEM LETT, V6, P435, DOI 10.1016/0960-894X(96)00034-0
   Dunn BM, 1999, BIOPOLYMERS, V51, P69, DOI 10.1002/(SICI)1097-0282(1999)51:1<69::AID-BIP8>3.0.CO;2-#                       
   ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523
   Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t
   Kiso Y, 1999, BIOPOLYMERS, V51, P59, DOI 10.1002/(SICI)1097-0282(1999)51:1<59::AID-BIP7>3.0.CO;2-3
   LE VD, UNPUB BIOORG MED CHE
   Lee T, 1998, P NATL ACAD SCI USA, V95, P939, DOI 10.1073/pnas.95.3.939                                                           
   Lee TY, 1999, J AM CHEM SOC, V121, P1145, DOI 10.1021/ja982893p                                                               
   Leung D, 2000, J MED CHEM, V43, P305, DOI 10.1021/jm990412m
   Li M, 2000, PROTEINS, V38, P29, DOI 10.1002/(SICI)1097-0134(20000101)38:1<29::AID-PROT4>3.0.CO;2-N
   March DR, 1996, J AM CHEM SOC, V118, P3375, DOI 10.1021/ja953790z
   Mimoto T, 1999, J MED CHEM, V42, P1789, DOI 10.1021/jm980637h
   Moyle G, 1996, DRUGS, V51, P701, DOI 10.2165/00003495-199651050-00001
   Munoz B, 1994, Bioorg Med Chem, V2, P1085, DOI 10.1016/S0968-0896(00)82058-1
   PODLOGAR BL, 1994, J MED CHEM, V37, P3684, DOI 10.1021/jm00048a004
   Reid RC, 1996, J AM CHEM SOC, V118, P8511, DOI 10.1021/ja960433v                                                               
   Sakurai M, 1994, Bioorg Med Chem, V2, P807, DOI 10.1016/S0968-0896(00)82181-1
   SLEE DH, 1995, J AM CHEM SOC, V117, P11867, DOI 10.1021/ja00153a008                                                             
   SMITH RA, 1994, BIOORG MED CHEM LETT, V4, P2217, DOI 10.1016/S0960-894X(00)80074-8
   TAM TF, 1992, J MED CHEM, V35, P1318, DOI 10.1021/jm00085a020                                                             
   WLODAWER A, 1995, NAT STRUCT BIOL, V2, P480, DOI 10.1038/nsb0695-480
   Yuan Wei, 1993, Journal of Medicinal Chemistry, V36, P211, DOI 10.1021/jm00054a004
NR 24
TC 13
Z9 13
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JAN 22
PY 2001
VL 11
IS 2
BP 219
EP 222
DI 10.1016/S0960-894X(00)00641-7
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 396QM
UT WOS:000166648100031
PM 11206463
DA 2018-01-05
ER

PT J
AU Ishima, R
   Louis, JM
   Torchia, DA
AF Ishima, R
   Louis, JM
   Torchia, DA
TI Characterization of two hydrophobic methyl clusters in HIV-1 protease by
   NMR spin relaxation in solution
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE retroviral protease; internal motion; protein; conformational change
ID MAGNETIC-RESONANCE RELAXATION; DRUG-RESISTANT MUTANTS; MODEL-FREE
   APPROACH; ROTATIONAL DIFFUSION; C-13 RELAXATION; MOLECULAR-BASIS;
   INHIBITORS; PROTEINS; MACROMOLECULES; FLEXIBILITY
AB Nearly 50 % of the amino acid residues of HIV-1 protease contain methyl side-chains, most of which appear to be organized into two clusters: the inner cluster that nearly surrounds the active site and the outer cluster that contains the hydrophobic core which stabilizes the inhibitor-free protease structure. NMR relaxation experiments sensitive to motions of methyl groups on the sub-nanosecond and the milli-microsecond timescales revealed flexible methyl groups in residues that link the two clusters, the methyl groups of L10, L23, V75, and L76. We hypothesize that flexibility at the junctions of these clusters allows the protease to minimize conformational changes upon drug-binding. The two-methyl cluster motif appears to be a common structural feature among retroviral proteases and may play a similar role throughout this family of enzymes. (C) 2001 Academic Press.
C1 Natl Inst Dent & Craniofacial REs, Struct Mol Biol Unit, NIH, Bethesda, MD 20892 USA.
   NIDDKD, Phys Chem Lab, NIH, Bethesda, MD 20892 USA.
RP Torchia, DA (reprint author), Natl Inst Dent & Craniofacial REs, Struct Mol Biol Unit, NIH, Bethesda, MD 20892 USA.
CR Ala PJ, 1997, BIOCHEMISTRY-US, V36, P1573, DOI 10.1021/bi962234u
   BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244
   Blunden S. J., 1990, HDB ENV CHEM E, V3, P1
   BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375                                                         
   Condra JH, 1998, HAEMOPHILIA, V4, P610, DOI 10.1046/j.1365-2516.1998.440610.x
   Erickson JW, 1999, AIDS, V13, pS189
   Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553                                             
   ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523
   Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5
   Ishima R, 1999, J AM CHEM SOC, V121, P11589, DOI 10.1021/ja992836b                                                               
   Kay LE, 1996, BIOCHEMISTRY-US, V35, P361, DOI 10.1021/bi9522312
   LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0                                                                
   Lee AL, 1997, J BIOMOL NMR, V9, P437, DOI 10.1023/A:1018311013338
   Lee AL, 2000, NAT STRUCT BIOL, V7, P72
   Lee LK, 1997, J BIOMOL NMR, V9, P287, DOI 10.1023/A:1018631009583
   LeMaster DM, 1996, J AM CHEM SOC, V118, P9255, DOI 10.1021/ja960877r                                                               
   LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010
   LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009
   LOUIS JM, 1994, P NATL ACAD SCI USA, V91, P7970, DOI 10.1073/pnas.91.17.7970
   Louis JM, 1999, NAT STRUCT BIOL, V6, P868
   LOUIS MJ, 2000, ADV PHARMACOL, V49, P111
   Luque I, 1998, BIOCHEMISTRY-US, V37, P5791, DOI 10.1021/bi9802521
   Mahalingam B, 1999, EUR J BIOCHEM, V263, P238, DOI 10.1046/j.1432-1327.1999.00514.x
   MUHANDIRAM DR, 1995, J AM CHEM SOC, V117, P11536, DOI 10.1021/ja00151a018                                                             
   NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274
   RAO JKM, 1991, BIOCHEMISTRY-US, V30, P4663, DOI 10.1021/bi00233a005
   Ridky TW, 1998, BIOCHEMISTRY-US, V37, P13835, DOI 10.1021/bi980612k                                                               
   SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2
   Tjandra N, 1996, J BIOMOL NMR, V8, P273, DOI 10.1007/BF00410326                                                              
   Walsh JC, 1998, AIDS, V12, P613, DOI 10.1097/00002030-199806000-00010
   Wand AJ, 1996, BIOCHEMISTRY-US, V35, P6116, DOI 10.1021/bi9530144
   Weber IT, 1997, EUR J BIOCHEM, V249, P523, DOI 10.1111/j.1432-1033.1997.00523.x
   Weber IT, 1999, PROTEIN ENG, V12, P469, DOI 10.1093/protein/12.6.469
   Winslow D L, 1995, AIDS, V9 Suppl A, pS183
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   Wondrak EM, 1996, J BIOL CHEM, V271, P4477
   Xie D, 1999, PROTEIN SCI, V8, P1702, DOI 10.1110/ps.8.8.1702                                                             
NR 37
TC 42
Z9 44
U1 0
U2 2
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
J9 J MOL BIOL
JI J. Mol. Biol.
PD JAN 19
PY 2001
VL 305
IS 3
BP 515
EP 521
DI 10.1006/jmbi.2000.4321
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 416BW
UT WOS:000167760800013
PM 11152609
DA 2018-01-05
ER

PT J
AU Miranda, LP
   Tao, T
   Jones, A
   Chernushevich, I
   Standing, KG
   Geczy, CL
   Alewood, PF
AF Miranda, LP
   Tao, T
   Jones, A
   Chernushevich, I
   Standing, KG
   Geczy, CL
   Alewood, PF
TI Total chemical synthesis and chemotactic activity of human S100A12
   (EN-RAGE)
SO FEBS LETTERS
LA English
DT Article
DE calcium; S100; chemotactic; solid-phase peptide synthesis; mass
   spectrometry; non-covalent interaction; zinc
ID CALCIUM-BINDING PROTEINS; PHASE PEPTIDE-SYNTHESIS; IONIZATION
   MASS-SPECTROMETRY; IN-SITU NEUTRALIZATION; PIG GRANULOCYTES; HIV-1
   PROTEASE; CALGRANULIN-C; EF-HANDS; IDENTIFICATION; COMPLEX
AB Human S100A12 (extracellular newly identified RAGE (receptor for advanced glycosylation end products)binding protein), a new member of the S100 family of EF-hand calcium-binding proteins, was chemically synthesised using highly optimised 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate/tert-butoxycarbonyl in situ neutralisation solid-phase chemistry. Circular dichroism studies indicated that CaCl(2) decreased the helical content by 27% whereas helicity was marginally increased by ZnCl(2). The propensity of S100A12 to dimerise was examined by electrospray ionisation time-of-flight mass spectrometry which clearly demonstrated the prevalence of the non-covalent homodimer (20 890 Da). Importantly, synthetic human S100A12 in the nanomolar range was chemotactic for neutrophils and macrophages in vitro. (C) 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
C1 Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
   Univ New S Wales, Sch Pathol, Cytokine Res Unit, Sydney, NSW 2052, Australia.
   Univ Manitoba, Dept Phys, Winnipeg, MB R3T 2N2, Canada.
RP Miranda, LP (reprint author), Carlsberg Lab, Dept Chem, Gamle Carlsberg Vej 10, Valby, Denmark.
EM les@crc.dk; p.alewood@mailbox.uq.edu.au
RI Standing, Kenneth/E-2416-2011
CR Alewood P, 1997, METHOD ENZYMOL, V289, P14
   Allen BG, 1996, BIOCHEM CELL BIOL, V74, P687, DOI 10.1139/o96-075                                                                 
   Brodersen DE, 1998, STRUCT FOLD DES, V6, P477, DOI 10.1016/S0969-2126(98)00049-5
   CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027                                                             
   Chernushevich IV, 1998, NATO ADV SCI I C-MAT, V510, P101
   CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281
   Cornish CJ, 1996, J CELL PHYSIOL, V166, P427, DOI 10.1002/(SICI)1097-4652(199602)166:2<427::AID-JCP21>3.0.CO;2-6
   DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629                                                         
   DellAngelica EC, 1996, INT J BIOCHEM CELL B, V28, P53, DOI 10.1016/1357-2725(95)00115-8
   DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929
   Drohat AC, 1996, BIOCHEMISTRY-US, V35, P11577, DOI 10.1021/bi9612226
   EDGEWORTH J, 1991, J BIOL CHEM, V266, P7706
   ENS W, 1998, NEW METHODS STUDY BI
   Fitzgerald MC, 1996, P NATL ACAD SCI USA, V93, P6851, DOI 10.1073/pnas.93.14.6851                                                         
   Hackeng TM, 1997, P NATL ACAD SCI USA, V94, P7845, DOI 10.1073/pnas.94.15.7845
   Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6                                                   
   Ilg EC, 1996, BIOCHEM BIOPH RES CO, V225, P146, DOI 10.1006/bbrc.1996.1144
   KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343
   KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521                                             
   Kordowska J, 1998, EUR J BIOCHEM, V253, P57, DOI 10.1046/j.1432-1327.1998.2530057.x
   KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467                                                       
   KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313
   Kretsinger RH, 1991, NOVEL CALCIUM BINDIN, P17
   LACKMANN M, 1992, J BIOL CHEM, V267, P7499
   LACKMANN M, 1993, J IMMUNOL, V150, P2981
   LAU W, 1995, J CLIN INVEST, V95, P1957, DOI 10.1172/JCI117879
   Loo JA, 1997, MASS SPECTROM REV, V16, P1
   LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x
   Marti T, 1996, BIOCHEM BIOPH RES CO, V221, P454, DOI 10.1006/bbrc.1996.0616
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025                                                             
   MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029
   ODINK K, 1987, NATURE, V330, P80, DOI 10.1038/330080a0
   POTTS BCM, 1995, NAT STRUCT BIOL, V2, P912
   Raftery MJ, 1998, J AM SOC MASS SPECTR, V9, P533, DOI 10.1016/S1044-0305(98)00020-8                                                   
   SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1
   Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7
   SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7
   SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180
   SOHNLE PG, 1991, J INFECT DIS, V163, P187, DOI 10.1093/infdis/163.1.187                                                        
   Sohnle PG, 1997, REV MED MICROBIOL, V8, P217
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673                                                          
   VALLEE BL, 1993, ACCOUNTS CHEM RES, V26, P543, DOI 10.1021/ar00034a005                                                             
   VERENTCHIKOV AN, 1994, ANAL CHEM, V66, P126, DOI 10.1021/ac00073a022
   WILKINSON PC, 1978, ADHESION LOCOMOTION, V50, P109
NR 44
TC 47
Z9 48
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-5793
J9 FEBS LETT
JI FEBS Lett.
PD JAN 12
PY 2001
VL 488
IS 1-2
BP 85
EP 90
DI 10.1016/S0014-5793(00)02392-9                                           
          
PG 6
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 396ZC
UT WOS:000166667400018
PM 11163801
OA gold
DA 2018-01-05
ER

PT J
AU Cinelli, RAG
   Ferrari, A
   Pellegrini, V
   Signorelli, A
   Tyagi, M
   Giacca, M
   Beltram, F
AF Cinelli, RAG
   Ferrari, A
   Pellegrini, V
   Signorelli, A
   Tyagi, M
   Giacca, M
   Beltram, F
TI Engineering single-molecule fluorescence dynamics for advanced
   biomolecular applications
SO AUSTRALIAN JOURNAL OF CHEMISTRY
LA English
DT Article
ID EXCITED-STATE DYNAMICS; INTRACELLULAR TRAFFICKING; STRUCTURAL BASIS;
   LIVING CELLS; PROTEIN GFP; HIV-1 TAT; GREEN; MUTANTS; SPECTROSCOPY;
   EXCITATION
AB The green fluorescent protein (GFP) of the Aequorea victoria jellyfish is a uniquely fluorescent label that is opening the way to advanced biomolecular studies. Fundamental processes on a nanoscopic scale can, in fact, be directly addressed by imaging and spectroscopy of GFP-tagged molecules. To this end, the design of labels with novel spectral and dynamic properties plays an important role to enhance GFP applicability. We investigated and engineered the fluorescence dynamics of two GFP mutants, the F64L/S65T and the F64L/S65T/T203Y, down to the single-molecule level in order to evaluate their suitability for a broad range of experimental systems. We shall argue that the first mutant is suitable for quantitative fluorescence microscopy and displays fluorescence almost unaffected by the environment, while the second offers the important additional advantage of undergoing photobleaching reversal after ultraviolet illumination. As a consequence, the latter mutant is a viable candidate for applications when prolonged imaging is required. As an example of novel possibilities provided by GFP technology, we shall show studies of HIV-1 Tat activity in cells and, in particular, we shall demonstrate Tat interaction with cyclin T1 by fluorescence-resonance energy transfer.
C1 INFM, NEST, I-56126 Pisa, Italy.
   Scuola Normale Super Pisa, I-56126 Pisa, Italy.
   Int Ctr Genet Engn & Biotechnol, Mol Med Lab, I-34012 Trieste, Italy.
RP Cinelli, RAG (reprint author), INFM, NEST, Piazza Cavalieri 7, I-56126 Pisa, Italy.
RI Giacca, Mauro/J-9287-2016; Beltram, Fabio/F-2920-2013; Ferrari,
   Aldo/H-5209-2012
OI Giacca, Mauro/0000-0003-2927-7225; Beltram, Fabio/0000-0002-6081-436X; 
CR Agranovich V., 1982, ELECT EXCITATION ENE
   BELTRAM F, 2000, NEW MUTANT GFP FLUOR
   Brejc K, 1997, P NATL ACAD SCI USA, V94, P2306, DOI 10.1073/pnas.94.6.2306
   CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295
   Chattoraj M, 1996, P NATL ACAD SCI USA, V93, P8362, DOI 10.1073/pnas.93.16.8362                                                         
   Cinelli RAG, 2000, PHOTOCHEM PHOTOBIOL, V71, P771, DOI 10.1562/0031-8655(2000)071<0771:TEGFPA>2.0.CO;2                                 
   CINELLI RAG, UNPUB
   Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0
   Creemers TMH, 1999, NAT STRUCT BIOL, V6, P557
   DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151
   Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048                                                                   
   Garcia-Parajo MF, 2000, P NATL ACAD SCI USA, V97, P7237, DOI 10.1073/pnas.97.13.7237
   Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683                                                   
   Haupts U, 1998, P NATL ACAD SCI USA, V95, P13573, DOI 10.1073/pnas.95.23.13573                                                        
   HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501                                                        
   HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0
   Jung G, 1998, BIOIMAGING, V6, P54, DOI 10.1002/1361-6374(199803)6:1<54::AID-BIO7>3.0.CO;2-8
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Kummer AD, 2000, J PHYS CHEM B, V104, P4791, DOI 10.1021/jp9942522                                                               
   Kummer AD, 1998, CHEM PHYS, V237, P183, DOI 10.1016/S0301-0104(98)00245-6
   Lee S, 1999, MOL CELL BIOL, V19, P1486
   Lippincott-Schwartz J, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P243
   MARCELLO, UNPUB
   Metha A.D., 1999, SCIENCE, V283, P1689
   Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670
   Ormo M, 1996, SCIENCE, V273, P1392
   Patterson GH, 1997, BIOPHYS J, V73, P2782, DOI 10.1016/S0006-3495(97)78307-3                                                   
   Peterman EJG, 1999, J PHYS CHEM A, V103, P10553, DOI 10.1021/jp991968o
   Pierce DW, 1997, NATURE, V388, P338, DOI 10.1038/41009
   Presley JF, 1997, NATURE, V389, P81
   Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763
   Stauber RH, 1998, VIROLOGY, V252, P126, DOI 10.1006/viro.1998.9400                                                          
   Stauber RH, 1998, VIROLOGY, V251, P38, DOI 10.1006/viro.1998.9295                                                          
   Wachter RM, 1998, STRUCT FOLD DES, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0                                                   
   Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3
   Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676
NR 36
TC 2
Z9 2
U1 0
U2 3
PU C S I R O PUBLISHING
PI COLLINGWOOD
PA 150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA
SN 0004-9425
J9 AUST J CHEM
JI Aust. J. Chem.
PY 2001
VL 54
IS 2
BP 107
EP 111
DI 10.1071/CH01050                                                         
          
PG 5
WC Chemistry, Multidisciplinary
SC Chemistry
GA 448MH
UT WOS:000169630300007
DA 2018-01-05
ER

PT J
AU Sonksen, CP
   Roepstorff, P
   Markgren, PO
   Danielson, UH
   Hamalainen, MD
   Jansson, O
AF Sonksen, CP
   Roepstorff, P
   Markgren, PO
   Danielson, UH
   Hamalainen, MD
   Jansson, O
TI Capture and analysis of low molecular weight ligands by surface plasmon
   resonance combined with mass spectrometry
SO EUROPEAN JOURNAL OF MASS SPECTROMETRY
LA English
DT Article
DE surface plasmon resonance; matrix-assisted laser desorption/ionization;
   electrospray ionization; HIV-1 protease inhibitors
ID BIOMOLECULAR INTERACTION ANALYSIS; OPTICAL BIOSENSOR TECHNOLOGY;
   KINETIC-ANALYSIS; INHIBITORS; PEPTIDES; BINDING; PROTEIN; BIA/MS
AB The combination of biomolecular interaction analysis (BIA) by surface plasmon resonance (SPR) and nano-electrospray ionization ion trap mass spectrometry (nanoESI-Ion Trap MS) as well as matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) is demonstrated for the binding of low molecular weight inhibitors (similar to 600 Da) to HIV-1 protease. Inhibitors were captured on sensor chips of a manual or an automated SPR biosensor, to which HIV-1 protease was immobilized. Compounds and buffer components that bound unspecifically to the sensor surface were removed and the inhibitors were eluted in a minimal volume (3 muL), between air bubbles, in order to prevent dispersion of analyte into buffer eluent. Molecular weights were subsequently determined by mass spectrometry, structural information was obtained by MALDI-ToF post-source decay as well as by electrospray ionization tandem mass spectrometry (MS/MS) analysis. Furthermore, competition experiments, using a mixture of different ligands, demonstrated that the peak intensities in the MALDI-ToF spectrum could be used for relative quantification of the amount of the different ligands bound to the immobilized target. Methodology for automated capture and elution of analytes was developed and evaluated.
C1 Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark.
   Univ Uppsala, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden.
   Biacore AB, S-75450 Uppsala, Sweden.
RP Roepstorff, P (reprint author), Univ So Denmark, Odense Univ, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Denmark.
RI Danielson, Helena/A-4217-2012
OI Danielson, Helena/0000-0003-2728-0340
CR DAVIES J, 1994, NANOBIOLOGY, V3, P5
   Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4
   JONSSON U, 1991, BIOTECHNIQUES, V11, P620
   Kampranis SC, 1999, BIOCHEMISTRY-US, V38, P1967, DOI 10.1021/bi982320p
   Karlsson R, 2000, ANAL BIOCHEM, V278, P1, DOI 10.1006/abio.1999.4406                                                          
   KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390
   KAUFMANN R, 1993, RAPID COMMUN MASS SP, V7, P902, DOI 10.1002/rcm.1290071010
   Krone JR, 1997, ANAL BIOCHEM, V244, P124, DOI 10.1006/abio.1996.9871
   LINDGREN M, UNPUB
   Malmqvist M, 1997, CURR OPIN CHEM BIOL, V1, P378, DOI 10.1016/S1367-5931(97)80077-4                                                   
   Malmqvist M, 1999, BIOCHEM SOC T, V27, P335, DOI 10.1042/bst0270335                                                              
   Markgren PO, 2000, ANAL BIOCHEM, V279, P71, DOI 10.1006/abio.1999.4467
   Markgren PO, 1998, ANAL BIOCHEM, V265, P340, DOI 10.1006/abio.1998.2927
   MARKGREN PO, UNPUB
   Myszka DG, 1999, J MOL RECOGNIT, V12, P390, DOI 10.1002/(SICI)1099-1352(199911/12)12:6<390::AID-JMR482>3.0.CO;2-8
   Nelson RW, 1999, ANAL CHEM, V71, P2858, DOI 10.1021/ac990089v                                                               
   Nelson RW, 1999, J MOL RECOGNIT, V12, P77, DOI 10.1002/(SICI)1099-1352(199903/04)12:2<77::AID-JMR448>3.0.CO;2-G
   Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3
   Sonksen CP, 1998, ANAL CHEM, V70, P2731, DOI 10.1021/ac9800457
   STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F
   SZABO A, 1995, CURR OPIN STRUC BIOL, V5, P699, DOI 10.1016/0959-440X(95)80064-6
NR 21
TC 14
Z9 15
U1 0
U2 6
PU IM PUBLICATIONS
PI W SUSSEX
PA 6 CHARLTON MILL, CHARLTON, CHICHESTER,, W SUSSEX PO18 0HY, ENGLAND
SN 1469-0667
J9 EUR J MASS SPECTROM
JI Eur. J. Mass Spectrom.
PY 2001
VL 7
IS 4-5
BP 385
EP 391
PG 7
WC Physics, Atomic, Molecular & Chemical; Spectroscopy
SC Physics; Spectroscopy
GA 506UT
UT WOS:000172990700013
DA 2018-01-05
ER

PT J
AU Trkola, A
   Ketas, TJ
   Nagashima, KA
   Zhao, L
   Cilliers, T
   Morris, L
   Moore, JP
   Maddon, PJ
   Olson, WC
AF Trkola, A
   Ketas, TJ
   Nagashima, KA
   Zhao, L
   Cilliers, T
   Morris, L
   Moore, JP
   Maddon, PJ
   Olson, WC
TI Potent, broad-spectrum inhibition of human immunodeficiency virus type 1
   by the CCR5 monoclonal antibody PRO 140
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID HIV-1 DISEASE PROGRESSION; CHEMOKINE RECEPTOR CCR5; SIGNAL-TRANSDUCTION;
   PRIMARY MACROPHAGES; CORECEPTOR USAGE; GP120 BINDING; IN-VITRO; T-CELLS;
   ANTI-HIV-1 ACTIVITY; DELETION ALLELE
AB CCR5 serves as a requisite fusion coreceptor for clinically relevant strains of human immunodeficiency virus type 1 (HIV-1) and provides a promising target for antiviral therapy. However, no study to date has examined whether monoclonal antibodies, small molecules, or other nonchemokine agents possess broad-spectrum activity against the major genetic subtypes of HIV-1. PRO 140 (PA14) is an anti-CCR5 monoclonal antibody that potently inhibits HIV-1 entry at concentrations that do not affect CCR5's chemokine receptor activity. In this study, PRO 140 was tested against a panel of primary HTV-1 isolates selected for their genotypic and geographic diversity. In quantitative assays of viral infectivity, PRO 140 was compared with RANTES, a natural CCR5 ligand that can inhibit HIV-1 entry by receptor downregulation as well as receptor blockade. Despite their divergent mechanisms of action and binding epitopes on CCR5, low nanomolar concentrations of both PRO 140 and RANTES inhibited infection of primary peripheral blood mononuclear cells (PBMC) by all CCR5-using (R5) viruses tested. This is consistent with there being a highly restricted pattern of CCR5 usage by R5 viruses. In addition, a panel of 25 subtype C South African R5 viruses were broadly inhibited by PRO 140, RANTES, and TAK-779, although similar to 30-fold-higher concentrations of the last compound were required. Interestingly, significant inhibition of a dualtropic subtype C virus was also observed. Whereas PRO 140 potently inhibited HIV-1 replication in both PBMC and primary macrophages, RANTES exhibited limited antiviral activity in macrophage cultures. Thus CCR5-targeting agents such as PRO 140 can demonstrate potent and genetic-subtype-independent anti-RIV-1 activity.
C1 Progen Pharmaceut Inc, Tarrytown, NY 10591 USA.
   Aaron Diamond AIDS Res Ctr, New York, NY USA.
   Natl Inst Virol, Johannesburg, South Africa.
RP Olson, WC (reprint author), Progen Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
OI , Lynn/0000-0003-3961-7828; Trkola, Alexandra/0000-0003-1013-876X
FU NIAID NIH HHS [R44 AI046871, R01 AI041420, R43 AI046871, AI46871,
   AI41420]
CR Abebe A, 1999, AIDS, V13, P1305, DOI 10.1097/00002030-199907300-00006
   Amzazi S, 1998, VIROLOGY, V252, P96, DOI 10.1006/viro.1998.9452
   ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0
   ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056
   Atchison RE, 1996, SCIENCE, V274, P1924, DOI 10.1126/science.274.5294.1924
   Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   BABA TW, 1995, SCIENCE, V267, P1820, DOI 10.1126/science.7892606
   Balotta C, 1997, AIDS, V11, pF67, DOI 10.1097/00002030-199710000-00001
   Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252
   Bjorndal A, 1999, AIDS RES HUM RETROV, V15, P647, DOI 10.1089/088922299310944                                                         
   Burns JM, 1999, P NATL ACAD SCI USA, V96, P14499, DOI 10.1073/pnas.96.25.14499
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621                                                           
   Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762                                                         
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Dragic T, 2000, P NATL ACAD SCI USA, V97, P5639, DOI 10.1073/pnas.090576697
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Dragic T, 1998, J VIROL, V72, P279
   Essex M, 1999, ADV VIRUS RES, V53, P71, DOI 10.1016/S0065-3527(08)60343-7
   Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854                                                         
   Farzan M, 1998, J VIROL, V72, P1160
   Genoud S, 1999, J VIROL, V73, P1645
   Glushakova S, 1999, J CLIN INVEST, V104, pR7, DOI 10.1172/JCI7403
   Gordon CJ, 1999, J VIROL, V73, P684
   Gosling J, 1997, P NATL ACAD SCI USA, V94, P5061, DOI 10.1073/pnas.94.10.5061
   Howard OMZ, 1998, J MED CHEM, V41, P2184, DOI 10.1021/jm9801253                                                               
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240                                                             
   Hung CS, 1999, J VIROL, V73, P8216
   Hung CS, 1999, VIROLOGY, V264, P278, DOI 10.1006/viro.1999.0013                                                          
   Husman AD, 1999, J IMMUNOL, V163, P4597
   Husman AMD, 1997, ANN INTERN MED, V127, P882, DOI 10.7326/0003-4819-127-10-199711150-00004
   Husman AMD, 1999, J INFECT DIS, V180, P1106
   Kinter A, 1998, P NATL ACAD SCI USA, V95, P11880, DOI 10.1073/pnas.95.20.11880
   Kostrikis LG, 1999, J VIROL, V73, P10264
   Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617
   Lee S, 2000, J VIROL, V74, P5016, DOI 10.1128/JVI.74.11.5016-5023.2000                                                
   Li S, 1999, J VIROL, V73, P9741
   Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215
   Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907                                                   
   McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0
   McKnight A, 1997, J VIROL, V71, P1692
   Menten P, 1999, J CLIN INVEST, V104, pR1, DOI 10.1172/JCI7318
   Michael NL, 1999, NAT MED, V5, P740, DOI 10.1038/10462                                                                   
   Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338
   Misrahi M, 1998, JAMA-J AM MED ASSOC, V279, P277, DOI 10.1001/jama.279.4.277
   Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341
   Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786
   OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1                                                   
   Olson WC, 1999, J VIROL, V73, P4145
   Oravecz T, 1996, J IMMUNOL, V157, P1329
   Oravecz T, 1997, J IMMUNOL, V159, P4587
   Ping LH, 1999, J VIROL, V73, P6271
   Platt EJ, 1998, J VIROL, V72, P2855
   Rabut GEE, 1998, J VIROL, V72, P3464
   Rizzuto C, 2000, AIDS RES HUM RETROV, V16, P741, DOI 10.1089/088922200308747
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959
   Stott EJ, 1996, J ANTIMICROB CHEMOTH, V37, P185, DOI 10.1093/jac/37.suppl_B.185                                                      
   Theodorou I, 1997, LANCET, V349, P1219
   Torre VS, 2000, J VIROL, V74, P4868, DOI 10.1128/JVI.74.10.4868-4876.2000                                                
   Trkola A, 1999, J VIROL, V73, P8966
   Trkola A, 1999, J VIROL, V73, P6370
   TRKOLA A, 1995, J VIROL, V69, P6609
   Trkola A, 1998, J VIROL, V72, P396
   Trkola A, 1998, J VIROL, V72, P1876
   Tscherning C, 1998, VIROLOGY, V241, P181, DOI 10.1006/viro.1997.8980                                                          
   Tuttle DL, 1998, J VIROL, V72, P4962
   Wagner L, 1998, NATURE, V391, P908, DOI 10.1038/36129
   Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681
   Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373                                                          
   Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496
   Yi YJ, 1998, J VIROL, V72, P772
   Ylisastigui L, 1998, AIDS, V12, P977, DOI 10.1097/00002030-199809000-00003
   Zhang YJ, 1998, J VIROL, V72, P9337
NR 78
TC 174
Z9 187
U1 0
U2 8
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JAN
PY 2001
VL 75
IS 2
BP 579
EP 588
DI 10.1128/JVI.75.2.579-588.2001                                           
          
PG 10
WC Virology
SC Virology
GA 385QK
UT WOS:000166015000003
PM 11134270
OA gold
DA 2018-01-05
ER

PT J
AU Akeb, F
   Creminon, C
   Grassi, J
   Guedj, R
   Duval, D
AF Akeb, F
   Creminon, C
   Grassi, J
   Guedj, R
   Duval, D
TI The production and evaluation of antibodies for enzyme immunoassay of
   AZTTP
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; ZIDOVUDINE
   PHOSPHORYLATION; INFECTED PATIENTS; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT;
   INTRACELLULAR PHOSPHORYLATION; CARTRIDGE RADIOIMMUNOASSAY;
   REVERSE-TRANSCRIPTASE; PLASMA-CONCENTRATIONS; COMPETITIVE ELISA
AB We describe the development of the first enzyme immunoassay for quantifying AZTTP that does not use of radioactive labeling. Anti-AZTTP antibodies were raised in rabbits by immunizing with an AZTTP-kelhoyle limpet hemocyanin (KLH) conjugate. Competitive immunoassays indicated a nanomolar sensitivity to AZTTP. One of the antisera produced was specific for AZTTP.
C1 Univ Nice, CNRS, Chim Bioorgan Lab, ESA 6001,Fac Sci, F-06108 Nice 2, France.
   CEA Saclay, Serv Pharmacol & Immunol, Direct Sci Vivant, F-91191 Gif Sur Yvette, France.
RP Duval, D (reprint author), Univ Nice, CNRS, Chim Bioorgan Lab, ESA 6001,Fac Sci, Parc Valrose, F-06108 Nice 2, France.
CR AHERNE GW, 1989, BIOCHEM SOC T, V17, P1052, DOI 10.1042/bst0171052                                                              
   Akeb F, 1999, NUCLEOS NUCLEOT, V18, P893, DOI 10.1080/15257779908041595
   AMER ES, 1992, BIOCHEM BIOPH RES CO, V188, P712
   Arts EJ, 1996, J VIROL, V70, P712
   Barry M, 1999, CLIN PHARMACOKINET, V36, P289, DOI 10.2165/00003088-199936040-00004
   Barry MG, 1996, AIDS, V10, P1361, DOI 10.1097/00002030-199610000-00008
   Brossette T, 1999, TETRAHEDRON LETT, V40, P3391, DOI 10.1016/S0040-4039(99)00497-9
   Darque A, 1999, ANTIMICROB AGENTS CH, V43, P2245
   FERRUA B, 1994, J IMMUNOL METHODS, V176, P103, DOI 10.1016/0022-1759(94)90354-9
   Ferrua B, 1996, J IMMUNOASSAY, V17, P175, DOI 10.1080/01971529608005787                                                       
   Fletcher CV, 1998, CLIN PHARMACOL THER, V64, P331, DOI 10.1016/S0009-9236(98)90182-5                                                   
   Font E, 1999, ANTIMICROB AGENTS CH, V43, P2964
   FURMAN PA, 1988, AM J MED, V85, P176
   Goujon L, 1998, J IMMUNOL METHODS, V218, P19, DOI 10.1016/S0022-1759(98)00101-X                                                   
   HALLORAN MJ, 1966, J IMMUNOL, V96, P373
   HEDAYA MA, 1988, CLIN CHEM, V34, P1565
   Hoetelmans LMW, 1996, CLIN PHARMACOKINET, V30, P314
   KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003
   KUSTER H, 1991, J INFECT DIS, V164, P773, DOI 10.1093/infdis/164.4.773                                                        
   LACROIX C, 1990, J CHROMATOGR-BIOMED, V525, P240, DOI 10.1016/S0378-4347(00)83399-X                                                   
   LUDWIG J, 1981, ACTA BIOCHIM BIOPHYS, V16, P131
   MASSOULIE J, 1976, EUR J BIOCHEM, V68, P531, DOI 10.1111/j.1432-1033.1976.tb10841.x
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MOORE JD, 2000, 7 C RETR OPP INF SAN
   Peter K, 1998, PHARMACEUT RES, V15, P819, DOI 10.1023/A:1011956011207
   Peter K, 1998, AIDS, V12, P1729
   PIALL EM, 1986, ANAL BIOCHEM, V154, P276, DOI 10.1016/0003-2697(86)90526-9
   PIALL EM, 1989, ANAL BIOCHEM, V177, P347, DOI 10.1016/0003-2697(89)90064-X
   PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003
   QUINN RP, 1989, J IMMUNOASSAY, V10, P177, DOI 10.1080/01971528908053235                                                       
   Robbins BL, 1998, ANTIMICROB AGENTS CH, V42, P2656
   Robbins BL, 1996, ANTIMICROB AGENTS CH, V40, P2651
   ROBBINS BL, 1994, ANTIMICROB AGENTS CH, V38, P115, DOI 10.1128/AAC.38.1.115                                                            
   Rodman JH, 1996, J INFECT DIS, V174, P490, DOI 10.1093/infdis/174.3.490                                                        
   Solas C, 1998, ANTIMICROB AGENTS CH, V42, P2989
   STRETCHER BN, 1994, AIDS, V8, P763, DOI 10.1097/00002030-199406000-00007
   STRETCHER BN, 1991, THER DRUG MONIT, V13, P325, DOI 10.1097/00007691-199107000-00008
   STRETCHER BN, 1994, ANTIMICROB AGENTS CH, V38, P1541, DOI 10.1128/AAC.38.7.1541                                                           
   TADEPALLI SM, 1990, J ACQ IMMUN DEF SYND, V3, P19
   TADEPALLI SM, 1990, CLIN CHEM, V36, P897
   TORNEVIK Y, 1995, BIOCHEM PHARMACOL, V49, P829, DOI 10.1016/0006-2952(94)00453-S
   Zhou XJ, 1996, ANTIMICROB AGENTS CH, V40, P1472
NR 42
TC 3
Z9 3
U1 0
U2 0
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 1525-7770
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PY 2001
VL 20
IS 3
BP 243
EP 250
DI 10.1081/NCN-100002084
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 453TR
UT WOS:000169933000006
PM 11393400
DA 2018-01-05
ER

PT J
AU Darfeuille, F
   Cazenave, C
   Gryaznov, S
   Duconge, F
   Di Primo, C
   Toulme, JJ
AF Darfeuille, F
   Cazenave, C
   Gryaznov, S
   Duconge, F
   Di Primo, C
   Toulme, JJ
TI RNA and N3 -> P5 ' kissing aptamers targeted to the trans-activation
   responsive (TAR) RNA of the human immunodeficiency virus-1
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Proceedings Paper
CT XIVth International Roundtable on Nucleosides, Nucleotides and their
   Biological Applications
CY SEP 10-14, 2000
CL SAN FRANCISCO, CALIFORNIA
ID DIMERIZATION INITIATION SITE; IN-VITRO SELECTION; HIV-1 GENOMIC RNA;
   LOOP-LOOP COMPLEX; ANTISENSE OLIGONUCLEOTIDES; HAIRPIN; PROTEIN; DNA;
   DETERMINANTS; SEQUENCE
AB We used in vitro selection to identify RNA aptamers able to selectively bind to the TAR RNA motif of HIV-1, an unperfect RNA hairpin involved in the transcription of the retroviral genome. We selected aptameric RNA hairpins giving rise to kissing complexes with TAR. The N3' --> P5' phosphoramidate variant of the aptamer bind to TAR with a Kd in the low nanomolar range. However, only the RNA-RNA loop-loop complex is recognized by the Rop protein of E. coli which is specific for kissing complexes.
C1 Univ Victor Segalen, INSERM, U386, F-33076 Bordeaux, France.
   Geron Corp, Menlo Pk, CA 94025 USA.
   CNRS, Inst Europeen Chim & Biol, F-33402 Talence, France.
   Univ Paris 11, INSERM, U334, F-91405 Orsay, France.
RP Toulme, JJ (reprint author), Univ Victor Segalen, INSERM, U386, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
RI Duconge, Frederic/C-6729-2012; Darfeuille, Fabien/M-3883-2014
OI Darfeuille, Fabien/0000-0003-1167-6113; Di Primo,
   Carmelo/0000-0002-0509-8399; Toulme, Jean-jacques/0000-0002-8432-5034
CR Aupeix K, 1999, FEBS LETT, V449, P169, DOI 10.1016/S0014-5793(99)00427-5                                                   
   Boiziau C, 1999, J BIOL CHEM, V274, P12730, DOI 10.1074/jbc.274.18.12730
   BROSSALINA E, 1993, J AM CHEM SOC, V115, P796, DOI 10.1021/ja00055a065                                                             
   CHEN JK, 1995, NUCLEIC ACIDS RES, V23, P2661, DOI 10.1093/nar/23.14.2661                                                          
   Comolli LR, 1998, NUCLEIC ACIDS RES, V26, P4688, DOI 10.1093/nar/26.20.4688
   Compagno D, 1999, J BIOL CHEM, V274, P8191, DOI 10.1074/jbc.274.12.8191                                                         
   Dardel F, 1998, NUCLEIC ACIDS RES, V26, P3567, DOI 10.1093/nar/26.15.3567
   Ding DY, 1996, NUCLEIC ACIDS RES, V24, P354, DOI 10.1093/nar/24.2.354
   Duconge F, 1999, RNA, V5, P1605, DOI 10.1017/S1355838299991318                                                       
   Duconge F, 2000, J BIOL CHEM, V275, P21287, DOI 10.1074/jbc.M002694200
   EGUCHI Y, 1990, CELL, V60, P199, DOI 10.1016/0092-8674(90)90736-X
   GREGORIAN RS, 1995, J MOL BIOL, V248, P968, DOI 10.1006/jmbi.1995.0275
   GROSJEAN H, 1976, J MOL BIOL, V103, P499, DOI 10.1016/0022-2836(76)90214-X
   GRYAZNOV SM, 1995, P NATL ACAD SCI USA, V92, P5798, DOI 10.1073/pnas.92.13.5798
   Gryaznov SM, 1999, BBA-GENE STRUCT EXPR, V1489, P131, DOI 10.1016/S0167-4781(99)00151-7
   Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593                                                          
   Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060
   Lee AJ, 1998, STRUCT FOLD DES, V6, P993, DOI 10.1016/S0969-2126(98)00101-4
   Mishra RK, 1996, P NATL ACAD SCI USA, V93, P10679, DOI 10.1073/pnas.93.20.10679
   MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209                                                         
   Paillart JC, 1997, J MOL BIOL, V270, P36, DOI 10.1006/jmbi.1997.1096                                                          
   Pascolo E, 1996, J BIOL CHEM, V271, P24187, DOI 10.1074/jbc.271.39.24187                                                        
   PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2                                                    
   Scarabino D, 1999, EMBO J, V18, P4571, DOI 10.1093/emboj/18.16.4571
   SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945
   TOMIZAWA JI, 1981, P NATL ACAD SCI-BIOL, V78, P6096, DOI 10.1073/pnas.78.10.6096
NR 26
TC 17
Z9 17
U1 0
U2 2
PU MARCEL DEKKER INC
PI NEW YORK
PA 270 MADISON AVE, NEW YORK, NY 10016 USA
SN 1525-7770
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PY 2001
VL 20
IS 4-7
BP 441
EP 449
DI 10.1081/NCN-100002318                                                   
          
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 467EY
UT WOS:000170690500021
PM 11563059
DA 2018-01-05
ER

PT J
AU Burdujan, R
   d'Angelo, J
   Desmaele, D
   Zouhiri, F
   Tauc, P
   Brochon, JC
   Auclair, C
   Mouscadet, JF
   Pernot, P
   Tfibel, F
   Enescu, M
   Fontaine-Aupart, MP
AF Burdujan, R
   d'Angelo, J
   Desmaele, D
   Zouhiri, F
   Tauc, P
   Brochon, JC
   Auclair, C
   Mouscadet, JF
   Pernot, P
   Tfibel, F
   Enescu, M
   Fontaine-Aupart, MP
TI Spectroscopy and photophysics of styrylquinoline-type HIV-1 integrase
   inhibitors and its oxidized forms studied by steady state and time
   resolved absorption and fluorescence
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID MAXIMUM-ENTROPY METHOD; CONFORMATIONAL EQUILIBRIUM; DERIVATIVES;
   REPLICATION; ACID; PAZELLIPTINE; TRIPLET; PROTON; CELLS
AB The geometric and electronic structure in solution of a new 2-styrylquinoline-type inhibitor of the HIV1-integrase was examined for the first time by following changes in the photophysical properties of the chromophore using steady state as well as time resolved absorption and fluorescence methods. The results obtained under different conditions of pH and solvent revealed that there are at least two rotamers in the ground state which exhibit different photophysical and photochemical properties. Picosecond fluorescence and absorption measurements gave evidence for a very short (similar to 20-30 ps) singlet excited state lifetime for one conformer and a much longer one for the other conformer, from a few hundreds of picoseconds up to nanoseconds, depending on the solvent characteristics. At physiological pH, the longer lived conformer can also undergo oxygen oxidation or photooxidation giving rise to the formation of the semiquinone radical and ultimately to a stable orthoquinone species. The role played by the singlet excited state of the rotamer on the photooxidation process is also detailed using picosecond and nanosecond absorption measurements.
C1 Univ Paris 11, CNRS, Photophys Mol Lab, UPR 3361, F-91405 Orsay, France.
   Univ Paris Sud, CNRS, Chim Organ Lab, Ctr Etud Pharmaceut,UPRES A8076, F-92296 Chatenay Malabry, France.
   ENS Cachan, Lab Biotechnol & Pharmacol Genet Appl, UMR 8532, F-92435 Cachan, France.
   Inst Gustave Roussy, CNRS, UMR 8532, Villejuif, France.
   Univ Paris 11, Chim Phys Lab, F-91405 Orsay, France.
RP Fontaine-Aupart, MP (reprint author), Univ Paris 11, CNRS, Photophys Mol Lab, UPR 3361, F-91405 Orsay, France.
RI PERNOT, Pascal/C-2643-2008
OI PERNOT, Pascal/0000-0001-8586-6222
CR ALFASSI ZB, 1985, J PHYS CHEM-US, V89, P3359, DOI 10.1021/j100261a040                                                             
   ALOISI GG, 1992, J CHEM SOC FARADAY T, V88, P2139, DOI 10.1039/ft9928802139                                                            
   BARDEZ E, 1994, J PHYS CHEM-US, V98, P2357, DOI 10.1021/j100060a025                                                             
   BENSASSON RV, 1993, EXCITED STATES FREE, P80
   BOSCA F, 1999, PHOTOCHEM PHOTOBIOL, V70, P653
   BROCHON JC, 1994, METHOD ENZYMOL, V240, P262
   *CHEM RUBB CO, HDB CHEM PHYS, pD86
   Denisov GS, 1997, J MOL STRUCT, V437, P153, DOI 10.1016/S0022-2860(97)00136-1
   Encinas S, 1998, PHOTOCHEM PHOTOBIOL, V68, P633, DOI 10.1111/j.1751-1097.1998.tb02522.x
   Enescu M, 1998, J PHYS CHEM B, V102, P3631, DOI 10.1021/jp980099k                                                               
   Fontaine-Aupart MP, 1999, PHOTOCHEM PHOTOBIOL, V70, P829
   GALIAZZO G, 1983, J PHOTOCHEM, V23, P149, DOI 10.1016/0047-2670(83)80057-4                                                    
   GENNARI G, 1986, J PHOTOCHEM, V35, P177, DOI 10.1016/0047-2670(86)85027-4                                                    
   GENNARI G, 1991, J MOL STRUCT, V249, P189, DOI 10.1016/0022-2860(91)85067-D                                                    
   Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646
   LIVESEY AK, 1987, BIOPHYS J, V52, P693, DOI 10.1016/S0006-3495(87)83264-2                                                   
   MAZZUCATO U, 1991, CHEM REV, V91, P1679, DOI 10.1021/cr00008a002                                                             
   MEECH SR, 1983, J PHOTOCHEM, V23, P193, DOI 10.1016/0047-2670(83)80061-6                                                    
   Mekouar K, 1998, J MED CHEM, V41, P2846, DOI 10.1021/jm980043e
   O'Connor D., 1984, TIME CORRELATED SING
   Ouali M, 2000, J MED CHEM, V43, P1949, DOI 10.1021/jm9911581                                                               
   PARKER CA, 1968, PHOTOLUMINESCENCE SO, pCH4
   SHIM SC, 1991, J PHOTOCH PHOTOBIO A, V56, P227
   Sortino S, 1999, PHOTOCHEM PHOTOBIOL, V69, P167, DOI 10.1111/j.1751-1097.1999.tb03270.x
   Spalletti A, 1999, PHYS CHEM CHEM PHYS, V1, P5623, DOI 10.1039/a906176b                                                                
   Wahl P., 1975, NEW TECHNIQUES BIOPH, V2, P233
   WALDECK DH, 1991, CHEM REV, V91, P415, DOI 10.1021/cr00003a007                                                             
   Wang SL, 1997, CHEM PHYS LETT, V268, P434, DOI 10.1016/S0009-2614(97)00236-4
   ZAMBONI R, 1992, J MED CHEM, V35, P3832, DOI 10.1021/jm00099a011
   Zouhiri F, 2000, J MED CHEM, V43, P1533, DOI 10.1021/jm990467o                                                               
   1933, TRAITE CHIMIE MINERA, P220
NR 31
TC 9
Z9 9
U1 0
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD,, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PY 2001
VL 3
IS 17
BP 3797
EP 3804
DI 10.1039/b102555b                                                        
          
PG 8
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA 471BW
UT WOS:000170907800050
DA 2018-01-05
ER

PT J
AU Denis-Mize, KS
   Dupuis, M
   MacKichan, ML
   Singh, M
   Doe, B
   O'Hagan, D
   Ulmer, JB
   Donnelly, JJ
   McDonald, DM
   Ott, G
AF Denis-Mize, KS
   Dupuis, M
   MacKichan, ML
   Singh, M
   Doe, B
   O'Hagan, D
   Ulmer, JB
   Donnelly, JJ
   McDonald, DM
   Ott, G
TI Plasmid DNA adsorbed onto cationic microparticles mediates target gene
   expression and antigen presentation by dendritic cells
SO GENE THERAPY
LA English
DT Article
DE DNA delivery; dendritic cells; cationic microparticles; DNA vaccines
ID THERAPEUTIC ANTITUMOR IMMUNITY; BONE-MARROW; LARGE NUMBERS; VACCINATION;
   RESPONSES; OLIGONUCLEOTIDES; NANOPARTICLES; MICROSPHERES; GENERATION;
   VACCINES
AB Dendritic cells (DC) play a key role in antigen presentation and activation of specific immunity. Much current research focuses on harnessing the potency of DC for vaccines, gene therapy, and cancer immunotherapy applications. However, DC are not readily transfected in vitro by traditional nonviral techniques. A novel DNA vaccine formulation was used to determine if DC are transfected in vitro. The formulation consists of plasmid DNA adsorbed on to cationic microparticles composed of the biodegradable polymer polylactide-co-glycolide (PLG) and the cationic surfactant, cetyltrimethylammonium bromide (CTAB). Using preparations of fluorescent-labeled plasmid DNA formulated on PLG-CTAB microparticles to study internalization by macrophages and dendritic cells in vitro and in vivo, we found that most, but not all, of the fluorescence was concentrated in endosomal compartments. Furthermore, uptake of plasmid DNA encoding HIV p55 gag adsorbed to PLG-CTAB microparticles by murine bone marrow-derived dendritic cells resulted in target gene expression, as detected by RT-PCR. The antigen was subsequently processed and presented, resulting in stimulation of an H-2k(d)-restricted, gag-specific T cell hybridoma. Activation of the hybridoma, detected by IL-2 production, was dose-dependent in the range of 0.1-20 mug DNA (10-2000 mug PLG) and was sustained up to 5 days after transfection. Thus, adsorption of plasmid DNA on PLG-CTAB microparticles provides a potentially useful nonviral approach for in vitro transfection of dendritic cells.
C1 Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.
   Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.
   Chiron Corp, Vaccines Res, Emeryville, CA 94608 USA.
RP Ott, G (reprint author), Chiron Corp, Vaccines Res, 4560 Horton St,M-S 4-3, Emeryville, CA 94608 USA.
FU NHLBI NIH HHS [HL24136]
CR Akbari O, 1999, J EXP MED, V189, P169, DOI 10.1084/jem.189.1.169
   Arthur JF, 1997, CANCER GENE THER, V4, P17
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   CHAVANY C, 1994, PHARMACEUT RES, V11, P1370, DOI 10.1023/A:1018923301967
   CIFTCI K, 1999, AAPS ANN M ABSTR ONL
   Doe B, 1996, AIDS, V10, P793, DOI 10.1097/00002030-199606001-00015
   Dupuis M, 2000, J IMMUNOL, V165, P2850, DOI 10.4049/jimmunol.165.5.2850                                                     
   Fattal E, 1998, J CONTROL RELEASE, V53, P137, DOI 10.1016/S0168-3659(97)00246-0                                                   
   Fields RC, 1998, P NATL ACAD SCI USA, V95, P9482, DOI 10.1073/pnas.95.16.9482
   Fields RC, 1998, J IMMUNOTHER, V21, P323, DOI 10.1097/00002371-199809000-00001                                                
   Fink DJ, 2000, GENE THER, V7, P115, DOI 10.1038/sj.gt.3301118                                                           
   Hedley ML, 1998, NAT MED, V4, P365, DOI 10.1038/nm0398-365
   INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693
   INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157
   Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5
   Luo D, 2000, NAT BIOTECHNOL, V18, P33
   MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297
   Melero I, 1999, GENE THER, V6, P1779, DOI 10.1038/sj.gt.3301010
   NEWMAN K, 1999, AAPS ANN M ABSTR ONL
   Paglia P, 1998, BLOOD, V92, P3172
   Paliard X, 1998, CELL IMMUNOL, V188, P73, DOI 10.1006/cimm.1998.1338                                                          
   Raychaudhuri S, 1998, NAT BIOTECHNOL, V16, P1025
   ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83                                                            
   SANDERSON S, 1994, INT IMMUNOL, V6, P369, DOI 10.1093/intimm/6.3.369
   Singh M, 1999, NAT BIOTECHNOL, V17, P1075, DOI 10.1038/15058
   Singh M, 2000, P NATL ACAD SCI USA, V97, P811, DOI 10.1073/pnas.97.2.811                                                           
   Song W, 1997, J EXP MED, V186, P1247, DOI 10.1084/jem.186.8.1247                                                          
   Specht JM, 1997, J EXP MED, V186, P1213, DOI 10.1084/jem.186.8.1213
   STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271
   Sundaresan P, 2000, J VIROL, V74, P3832, DOI 10.1128/JVI.74.8.3832-3841.2000
   TABATA Y, 1990, ADV POLYM SCI, V94, P107
   Thurner B, 1999, J IMMUNOL METHODS, V223, P1, DOI 10.1016/S0022-1759(98)00208-7
   Timmerman JM, 1999, ANNU REV MED, V50, P507
   VANTENDELOO V, 1988, GENE THER, V5, P700
   Wickham TJ, 2000, GENE THER, V7, P110, DOI 10.1038/sj.gt.3301115
   Zelphati O, 1999, HUM GENE THER, V10, P15, DOI 10.1089/10430349950019156
   zur Megede J, 2000, J VIROL, V74, P2628, DOI 10.1128/JVI.74.6.2628-2635.2000
NR 37
TC 132
Z9 144
U1 1
U2 18
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 0969-7128
J9 GENE THER
JI Gene Ther.
PD DEC
PY 2000
VL 7
IS 24
BP 2105
EP 2112
DI 10.1038/sj.gt.3301347                                                   
          
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 391CD
UT WOS:000166335800008
PM 11223992
OA gold
DA 2018-01-05
ER

PT J
AU Schlienger, N
   Peyrottes, S
   Kassem, T
   Imbach, JL
   Gosselin, G
   Aubertin, AM
   Perigaud, C
AF Schlienger, N
   Peyrottes, S
   Kassem, T
   Imbach, JL
   Gosselin, G
   Aubertin, AM
   Perigaud, C
TI S-acyl-2-thioethyl aryl phosphotriester derivatives as mononucleotide
   prodrugs
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID BLOOD-BRAIN-BARRIER; PHOSPHATE-PROTECTING GROUPS; AMINO-ACID-TRANSPORT;
   HIV-INFECTIONS; DELIVERY; PHOSPHODIESTERASE; PRONUCLEOTIDES; DESIGN
AB The synthesis and biological activities of phosphotriester derivatives of 3'-azido-2',3'-dideoxythymidine (AZT) bearing a phenyl group or L-tyrosinyl residues are reported. The target compounds were obtained via either P-V or p(III) chemistry from the appropriate aryl precursors. All the derivatives were evaluated for their in vitro anti-HIV activity, and they appeared to be potent inhibitors of HIV-1 replication in various cell culture experiments, with EC50 values between the micro- and nanomolar range. Furthermore, compounds incorporating an amino-and/or acid-substituted tyrosinyl residue demonstrated significant anti-HIV effects in thymidine kinase-deficient (TK-) cells showing their ability to act as mononucleotide prodrugs. The proposed decomposition process of these mixed mononucleoside aryl phosphotriesters may involve esterase activation followed by phosphodiesterase hydrolysis.
C1 Univ Montpellier 2, UMR 5625 CNRS, F-34095 Montpellier 05, France.
   Univ Strasbourg 1, Unite 74 INSERM, Fac Med, Virol Lab, F-67000 Strasbourg, France.
RP Perigaud, C (reprint author), Univ Montpellier 2, UMR 5625 CNRS, Cc 008,Pl E Bataillon, F-34095 Montpellier 05, France.
CR Alvarez K, 1999, J ORG CHEM, V64, P6319, DOI 10.1021/jo990479h                                                               
   Arzumanov AA, 1996, BIOORG KHIM+, V22, P777
   AUGUSTIJNS PF, 1999, PHARM SCI, V1
   Baldwin JE, 1996, TETRAHEDRON LETT, V37, P3761, DOI 10.1016/0040-4039(96)00676-4
   De Clercq E, 1998, COLLECT CZECH CHEM C, V63, P449, DOI 10.1135/cccc19980449                                                            
   De Clercq E, 1998, PURE APPL CHEM, V70, P567, DOI 10.1351/pac199870030567                                                         
   DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913                                                        
   Egron D, 1997, B SOC CHIM BELG, V106, P461
   FORD H, 1991, J LIQ CHROMATOGR, V14, P3365, DOI 10.1080/01483919108049396
   GAO WY, 1994, J BIOL CHEM, V269, P12633
   GREIG NH, 1987, CANCER RES, V47, P1571
   HAUGEN HF, 1977, CLIN CHEM, V23, P1531
   KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030                                                             
   Khorana HG, 1961, ENZYMES, V5, P79
   Krise JP, 1996, ADV DRUG DELIVER REV, V19, P287, DOI 10.1016/0169-409X(95)00111-J
   LANDT M, 1980, BIOCHEMISTRY-US, V19, P138, DOI 10.1021/bi00542a021
   LEFEBVRE I, 1995, J MED CHEM, V38, P3941, DOI 10.1021/jm00020a007
   Martin LT, 2000, NUCLEOS NUCLEOT NUCL, V19, P481, DOI 10.1080/15257770008033023                                                       
   MATHIAS LJ, 1979, SYNTHESIS-STUTTGART, P561
   Meier C, 1998, SYNLETT, P233
   OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629
   PERIGAUD C, 1996, ADV ANTIV D, V2, P147
   PERIGAUD C, 2000, BIOMEDICAL CHEM APPL, V5, P115
   PLACIDI L, 1998, ANTIVIR RES, V37, P87
   Schlienger N, 1997, J ORG CHEM, V62, P7216, DOI 10.1021/jo9706638                                                               
   Schlienger N, 1998, BIOORG MED CHEM LETT, V8, P3003, DOI 10.1016/S0960-894X(98)00535-6                                                   
   SHVESTS VI, 1968, J ORG KHIM USSR, V4, P942
   SMITH QR, 1987, J NEUROCHEM, V49, P1651, DOI 10.1111/j.1471-4159.1987.tb01039.x
   WALKER I, 1994, INT J PHARM, V104, P157, DOI 10.1016/0378-5173(94)90191-0                                                    
NR 29
TC 32
Z9 33
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 16
PY 2000
VL 43
IS 23
BP 4570
EP 4574
DI 10.1021/jm000996o
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 374HR
UT WOS:000165340200026
PM 11087582
DA 2018-01-05
ER

PT J
AU Mao, C
   Sudbeck, EA
   Venkatachalam, TK
   Uckun, FM
AF Mao, C
   Sudbeck, EA
   Venkatachalam, TK
   Uckun, FM
TI Structure-based drug design of non-nucleoside inhibitors for wild-type
   and drug-resistant: HIV reverse transcriptase
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Editorial Material
DE HIV; reverse transcriptase; non-nucleoside inhibitor; drug resistance;
   drug design; molecular modeling
ID HUMAN-IMMUNODEFICIENCY-VIRUS; POTENT NONNUCLEOSIDE INHIBITORS; S-DABO
   SERIES; HIGHLY POTENT; ANTI-HIV-1 ACTIVITY;
   1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE HEPT; 3-DIMENSIONAL
   STRUCTURE; OXATHIIN CARBOXANILIDE; THERAPEUTIC STRATEGIES; SELECTIVE
   INHIBITORS
AB The generation of anti-HIV agents using structure-based drug design methods has yielded a number of promising non-nucleoside inhibitors (NNIs) of HIV reverse transcriptase (RT). Recent successes in identifying potent NNIs are reviewed with an emphasis on the recent trend of utilizing a computer model of HIV RT to identify space in the NNI binding pocket that can be exploited by carefully chosen functional groups predicted to interact favorably with binding pocket residues. The NNI binding pocket model was used to design potent NNIs against both wild-type RT and drug resistant RT mutants. Molecular modeling and score functions were used to analyze how drug-resistant mutations would change the RT binding pocket shape, volume, and chemical make up, and how these changes could affect inhibitor binding. Modeling studies revealed that for an NNI of HIV RT to be active against RT mutants such as the especially problematic Y181C RT mutant, the following features are required: (a) the inhibitor should be highly potent against wild-type RT and therefore capable of tolerating a considerable activity loss against RT mutants (i.e. a picomolar-level inhibitor against wild-type RT may still be effective against RT mutants at nanomolar concentrations), (b) the inhibitor should maximize the occupancy in the Wing 2 region of the NNI binding site of RT, and (c) the inhibitor should contain functional groups that provide favorable chemical interactions with Wing 2 residues of wild-type as well as mutant RT. Our rationally designed NNI compounds HI-236, HI-240, HI-244, H-253, HI-443, and HI-445 combine these three features and outperform other anti-HIV agents examined. (C) 2000 Elsevier Science Inc.
C1 Parker Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Biol Struct, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Drug Discovery Program, 2665 Long Lake Rd, St Paul, MN 55113 USA.
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BABA M, 1992, ANTIVIR RES, V17, P245, DOI 10.1016/0166-3542(92)90021-V
   Balzarini J, 1995, Verh K Acad Geneeskd Belg, V57, P575
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   BOHM HJ, 1992, J COMPUT AID MOL DES, V6, P593, DOI 10.1007/BF00126217
   BOHM HJ, 1994, J COMPUT AID MOL DES, V8, P243, DOI 10.1007/BF00126743
   Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9
   Buckheit RW, 1997, ANTIMICROB AGENTS CH, V41, P831
   Buckheit RW, 1997, AIDS RES HUM RETROV, V13, P789, DOI 10.1089/aid.1997.13.789
   BUCKHEIT RW, 1995, ANTIMICROB AGENTS CH, V39, P2718, DOI 10.1128/AAC.39.12.2718                                                          
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170
   Danel K, 1997, ACTA CHEM SCAND, V51, P426, DOI 10.3891/acta.chem.scand.51-0426
   Danel K, 1998, J MED CHEM, V41, P191, DOI 10.1021/jm970443m
   Danel K, 1996, J MED CHEM, V39, P2427, DOI 10.1021/jm9600499
   De Clercq E, 1999, FARMACO, V54, P26, DOI 10.1016/S0014-827X(98)00103-7
   De Clercq E, 1998, ANTIVIR RES, V38, P153, DOI 10.1016/S0166-3542(98)00025-4
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   Deeks S G, 1997, AIDS Clin Rev, P145
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Font M, 1997, Drug Des Discov, V14, P305
   Fujiwara M, 1997, MICROBIOL IMMUNOL, V41, P301, DOI 10.1111/j.1348-0421.1997.tb01205.x                                              
   Goldschmidt R H, 1997, J Am Board Fam Pract, V10, P144
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006
   Heinisch G, 1997, ANTIVIR CHEM CHEMOTH, V8, P443, DOI 10.1177/095632029700800507                                                      
   Hirsch MS, 1998, JAMA-J AM MED ASSOC, V279, P1984, DOI 10.1001/jama.279.24.1984
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 1998, J MOL BIOL, V284, P313, DOI 10.1006/jmbi.1998.2171
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Jain AN, 1996, J COMPUT AID MOL DES, V10, P427, DOI 10.1007/BF00124474
   JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995                                                
   Kleim JP, 1996, P NATL ACAD SCI USA, V93, P34, DOI 10.1073/pnas.93.1.34
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   Kroeger Smith M B, 1995, Protein Sci, V4, P2203
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   Miles SA, 1997, J ACQ IMMUN DEF SYND, V16, pS1, DOI 10.1097/00042560-199701001-00001                                                
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   Pontikis R, 1997, J MED CHEM, V40, P1845, DOI 10.1021/jm960765a
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   ROMERO DL, 1993, J MED CHEM, V36, P1505, DOI 10.1021/jm00062a027
   Romero DL, 1996, J MED CHEM, V39, P3769, DOI 10.1021/jm960158n
   SATCHER D, 1997, HIV AIDS SURVEILL RE, V9, P1
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445                                                         
   Sudbeck EA, 1998, ANTIMICROB AGENTS CH, V42, P3225
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 63
TC 67
Z9 67
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV 1
PY 2000
VL 60
IS 9
BP 1251
EP 1265
DI 10.1016/S0006-2952(00)00408-1                                           
          
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 361BY
UT WOS:000089702900001
PM 11008119
DA 2018-01-05
ER

PT J
AU Andries, K
   de Bethune, MP
   Ludovici, DW
   Kukla, MJ
   Azijn, H
   Lewi, P
   Janssen, PAJ
   Pauwels, R
AF Andries, K
   de Bethune, MP
   Ludovici, DW
   Kukla, MJ
   Azijn, H
   Lewi, P
   Janssen, PAJ
   Pauwels, R
TI R165335-TMC125, a novel non nucleoside reverse transcriptase inhibitor
   (NNRTI) with nanomolar activity against NNRTI resistant HIV strains
SO AIDS
LA English
DT Meeting Abstract
C1 Janssen Res Fdn, B-2340 Beerse, Belgium.
   Tibotec, Mechelen, Belgium.
   Janssen Res Fdn, Spring House, PA 19477 USA.
   Janssen Res Fdn, Vosselaar, Belgium.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD OCT
PY 2000
VL 14
SU 4
MA PL45
BP S4
EP S5
PG 2
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 371RQ
UT WOS:000165192300013
DA 2018-01-05
ER

PT J
AU Rinnova, M
   Hradilek, M
   Barinka, C
   Weber, J
   Soucek, M
   Vondrasek, J
   Klimkait, T
   Konvalinka, J
AF Rinnova, M
   Hradilek, M
   Barinka, C
   Weber, J
   Soucek, M
   Vondrasek, J
   Klimkait, T
   Konvalinka, J
TI A picomolar inhibitor of resistant strains of human immunodeficiency
   virus protease identified by a combinatorial approach
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE HIV protease; combinatorial library; inhibitor testing; viral resistance
ID SOLID-PHASE SYNTHESIS; HIV PROTEINASE-INHIBITORS; RETROVIRAL
   PROTEINASES; RATIONAL DESIGN; LIBRARIES; SPECIFICITY; POTENT;
   ALLOPHENYLNORSTATINE; GENERATION; DISCOVERY
AB In order to identify inhibitors of various drug-resistant forms of the human immunodeficiency virus protease (HIV PR), we have designed and synthesized pseudopeptide libraries with a general structure Z-mimetic-Aa(1)-Aa(2)-NH2. Five different chemistries for peptide bond replacement have been employed and the resulting five individual sublibraries tested with the HIV PR and its drug-resistant mutants. Each mutant contains amino acid substitutions that have previously been shown to be associated with resistance to protease inhibitors, including Ritonavir, Indinavir, and Saquinavir, We have mapped the subsite preferences of resistant HIV PR species with the aim of selecting a pluripotent pharmaceutical lead. All of the enzyme species in this study manifest clear preference for an L-Glu residue in the P2' position. Slight, but significant, differences in P3' subsite specificity among individual resistant PR species have been documented. We have identified three compounds, combining the most favorable features of the inhibitor array, that exhibit low-nanomolar or picomolar K-i values for all three mutant PR species tested. (C) 2000 Academic Press.
C1 Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague 6, Czech Republic.
   Univ Basel, Inst Med Microbiol, Basel, Switzerland.
RP Konvalinka, J (reprint author), Acad Sci Czech Republ, Inst Organ Chem & Biochem, Flemingovo Nam 2, CR-16610 Prague 6, Czech Republic.
RI Barinka, Cyril/G-9803-2014; Weber, Jan/B-5405-2013; Konvalinka,
   Jan/G-7518-2014; Vondrasek, JIri/A-4244-2008; Klimkait,
   Thomas/A-1057-2008
OI Weber, Jan/0000-0002-2799-7352; Konvalinka, Jan/0000-0003-0695-9266
CR ADACHI A, 1986, J VIROL, V59, P284
   BARRET AJ, 1998, HDB PROTELYTIC ENZYM
   Berkhout B, 1999, J BIOMED SCI, V6, P298, DOI 10.1007/BF02253518
   Boross P, 1999, EUR J BIOCHEM, V264, P921, DOI 10.1046/j.1432-1327.1999.00687.x                                                
   DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170                                                               
   Dolle RE, 1998, MOL DIVERS, V3, P199, DOI 10.1023/A:1009699413828
   DORSEY BD, 1994, J MED CHEM, V37, P3443, DOI 10.1021/jm00047a001                                                             
   DREYER GB, 1989, P NATL ACAD SCI USA, V86, P9752, DOI 10.1073/pnas.86.24.9752
   DUNN BM, 1994, METHOD ENZYMOL, V241, P254
   Erickson JW, 1996, ANNU REV PHARMACOL, V36, P545, DOI 10.1146/annurev.pa.36.040196.002553                                             
   GRIFFITHS JT, 1992, BIOCHEMISTRY-US, V31, P5193, DOI 10.1021/bi00137a015
   HOBZA P, 2000, IN PRESS CHEM REV
   HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0
   HUI KY, 1993, FEBS LETT, V327, P355, DOI 10.1016/0014-5793(93)81020-Z
   Jiracek J, 1996, J BIOL CHEM, V271, P19606, DOI 10.1074/jbc.271.32.19606                                                        
   Kempf DJ, 1998, J MED CHEM, V41, P602, DOI 10.1021/jm970636+
   KICK EK, 1995, J MED CHEM, V38, P1427, DOI 10.1021/jm00009a002
   Konvalinka J, 1997, EUR J BIOCHEM, V250, P559, DOI 10.1111/j.1432-1033.1997.0559a.x                                                
   KONVALINKA J, 1995, EUR J BIOCHEM, V228, P191, DOI 10.1111/j.1432-1033.1995.0191o.x
   LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0
   MAJER P, 1993, ARCH BIOCHEM BIOPHYS, V304, P1, DOI 10.1006/abbi.1993.1314                                                          
   MELDAL M, 1994, P NATL ACAD SCI USA, V91, P3314, DOI 10.1073/pnas.91.8.3314                                                          
   Mimoto T, 1999, J MED CHEM, V42, P1789, DOI 10.1021/jm980637h
   MIMOTO T, 1991, CHEM PHARM BULL, V39, P3088
   OWENS RA, 1991, BIOCHEM BIOPH RES CO, V181, P402, DOI 10.1016/S0006-291X(05)81433-0
   POORMAN RA, 1991, J BIOL CHEM, V266, P14554
   RICHARDS AD, 1990, J BIOL CHEM, V265, P7733
   RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6
   Rinnova M, 1996, COLLECT CZECH CHEM C, V61, P171, DOI 10.1135/cccc19960171                                                            
   ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354
   SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X                                                   
   Schinazi R. F., 1997, International Antiviral News, V5, P129
   TOTH MV, 1990, INT J PEPT PROT RES, V36, P544
   URBAN J, 1992, FEBS LETT, V298, P9, DOI 10.1016/0014-5793(92)80010-E
   WANG GT, 1995, J MED CHEM, V38, P2995, DOI 10.1021/jm00016a001
   Weber J, 1997, ARCH BIOCHEM BIOPHYS, V341, P62, DOI 10.1006/abbi.1997.9945
   Williams J W, 1979, Methods Enzymol, V63, P437
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
NR 38
TC 16
Z9 16
U1 0
U2 5
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-9861
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD OCT 1
PY 2000
VL 382
IS 1
BP 22
EP 30
DI 10.1006/abbi.2000.2017
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 360VE
UT WOS:000089687400004
PM 11051093
DA 2018-01-05
ER

PT J
AU Anantharaman, V
   Moen, LK
AF Anantharaman, V
   Moen, LK
TI Effects of nucleoside analogs on native and site-directed mutants of
   HTLV type 1 reverse transcriptase
SO BIOORGANIC CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL LEUKEMIA; ESCHERICHIA-COLI;
   DRUG-RESISTANCE; RETROVIRUS HTLV; LYMPHOMA; HIV; COMBINATION;
   INHIBITION; FOSCARNET
AB A bacterial assay was developed for testing HTLV-1 reverse transcriptase sensitivity to common nucleoside analog inhibitors in an Escherichia coli strain characterized by a temperature sensitive PolI/RecA deletion phenotype. This genetic complementation assay exploits the ability of HTLV-1 reverse transcriptase to functionally replace these missing activities at nonpermissive temperatures. The four inhibitors tested, dideoxyinosine, dideoxyadenosine, deoxythymidine, and didehydrodeoxythymidine are well-known inhibitors of HIV reverse transcriptase. All except dideoxyadenosine showed a strong activity against HTLV-1 reverse transcriptase with ICS, in the nanomolar range. Sequence alignments were used to identify amino acid residues in HTLV-I reverse transcriptase, which correspond to those identified as important for drug-resistance in HIV reverse transcriptase. Mutations of some of these HTLV-I residues altered the ICS, for the inhibitors as expected, which suggests that these amino acids have a function in HTLV-1 reverse transcriptase similar to that of their homologs in HIV reverse transcriptase, (C) 2000 Academic Press.
C1 Old Dominion Univ, Dept Chem & Biochem, Norfolk, VA 23529 USA.
RP Moen, LK (reprint author), NIGMS, Off Sci Review, NIH, Bldg 45 Rm 1AS-13H, Bethesda, MD 20892 USA.
OI Anantharaman, Vivek/0000-0001-8395-0009
CR Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097/00042560-199600001-00028
   Bazarbachi A, 2000, LEUKEMIA, V14, P716, DOI 10.1038/sj.leu.2401742
   BRODER S, 1987, AIDS MODERN CONCEPTS, P303
   CHU CK, 1988, BIOCHEM PHARMACOL, V37, P3543, DOI 10.1016/0006-2952(88)90383-8
   GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056/NEJM199506293322603
   GOODY RS, 1991, FEBS LETT, V291, P1, DOI 10.1016/0014-5793(91)81089-Q
   GU ZX, 1992, J VIROL, V66, P7128
   GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275                                                            
   HERDEWIJN P, 1987, J MED CHEM, V30, P2131, DOI 10.1021/jm00394a034
   HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476
   Hollsberg P, 1999, MICROBIOL MOL BIOL R, V63, P308
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   IM GJ, 1993, BIOCHEM PHARMACOL, V46, P2307, DOI 10.1016/0006-2952(93)90622-4
   KIM B, 1995, P NATL ACAD SCI USA, V92, P684, DOI 10.1073/pnas.92.3.684
   Kim B, 1996, J BIOL CHEM, V271, P4872
   Kleim JP, 1996, P NATL ACAD SCI USA, V93, P34, DOI 10.1073/pnas.93.1.34
   KOPROWSKI H, 1985, NATURE, V318, P154, DOI 10.1038/318154a0
   LACEY SF, 1994, ANTIMICROB AGENTS CH, V38, P1428, DOI 10.1128/AAC.38.6.1428                                                           
   LIN TS, 1987, BIOCHEM PHARMACOL, V36, P2713
   Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561
   LLOYD RG, 1974, J BACTERIOL, V120, P407
   Matsushita K, 1999, LEUKEMIA LYMPHOMA, V36, P67, DOI 10.3109/10428199909145950                                                       
   MCEVOY GK, 1989, AHFS DRUG INFORMATIO, P502
   MELLORS JW, 1995, ANTIMICROB AGENTS CH, V39, P1087, DOI 10.1128/AAC.39.5.1087                                                           
   MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911
   NAM SH, 1993, J VIROL, V67, P196
   NYGAARD P, 1983, METABOLISM NUCLEOTID, P27
   Owen SM, 1998, J VIROL, V72, P5279
   POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0
   POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415                                                         
   PRASAD VR, 1991, P NATL ACAD SCI USA, V88, P11363, DOI 10.1073/pnas.88.24.11363
   RHO HM, 1981, VIROLOGY, V112, P355, DOI 10.1016/0042-6822(81)90642-5                                                    
   ROBERTGUROFF M, 1983, BLUT, V47, P1, DOI 10.1007/BF00321045
   SARIN PS, 1988, ANN NEUROL, V23, pS181, DOI 10.1002/ana.410230740
   SAUNDERS J, 1992, DRUG NEWS PERSPECT, V5, P153
   STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788                                                         
   TACHEDJIAN G, 1995, VIROLOGY, V212, P58, DOI 10.1006/viro.1995.1453                                                          
   TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9
   Takimoto Y, 1998, BRIT J HAEMATOL, V102, P876, DOI 10.1046/j.1365-2141.1998.0887d.x                                                
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673                                                          
   Trentin B, 1998, J VIROL, V72, P6504
   UCHIYAMA T, 1977, BLOOD, V50, P481
   Uike N, 1998, INTERNAL MED, V37, P411, DOI 10.2169/internalmedicine.37.411
   VRANG L, 1986, ANTIMICROB AGENTS CH, V29, P867, DOI 10.1128/AAC.29.5.867                                                            
   WEISS R, 1984, RNA TUMOR VIRUSES, P1244
   WEISS R, 1984, RNA TUMOR VIRUSES, P406
   WEISS RA, 1987, J CLIN PATHOL, V40, P1064, DOI 10.1136/jcp.40.9.1064                                                           
   YARCHOAN R, 1989, SCIENCE, V245, P412, DOI 10.1126/science.2502840                                                         
   Young Steven D., 1993, Perspectives in Drug Discovery and Design, V1, P181, DOI 10.1007/BF02171661
NR 50
TC 1
Z9 2
U1 0
U2 2
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0045-2068
J9 BIOORG CHEM
JI Bioorganic Chem.
PD OCT
PY 2000
VL 28
IS 5
BP 293
EP 305
DI 10.1006/bioo.2000.1181
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA 392AB
UT WOS:000166387500005
DA 2018-01-05
ER

PT J
AU Tyndall, JDA
   Reid, RC
   Tyssen, DP
   Jardine, DK
   Todd, B
   Passmore, M
   March, DR
   Pattenden, LK
   Bergman, DA
   Alewood, D
   Hu, SH
   Alewood, PF
   Birch, CJ
   Martin, JL
   Fairlie, DP
AF Tyndall, JDA
   Reid, RC
   Tyssen, DP
   Jardine, DK
   Todd, B
   Passmore, M
   March, DR
   Pattenden, LK
   Bergman, DA
   Alewood, D
   Hu, SH
   Alewood, PF
   Birch, CJ
   Martin, JL
   Fairlie, DP
TI Synthesis, stability, antiviral activity, and protease-bound structures
   of substrate-mimicking constrained macrocyclic inhibitors of HIV-1
   protease
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS INFECTION; ORALLY BIOAVAILABLE INHIBITOR;
   PEPTIDOMIMETIC INHIBITORS; KINETIC-PROPERTIES; CRYSTAL-STRUCTURE;
   BINDING MODE; DRUG-DESIGN; ENZYME; COMPLEX; ERRORS
AB Three new peptidomimetics (1-3) have been developed with highly stable and conformationally constrained macrocyclic components that replace tripeptide segments of protease substrates. Each compound inhibits both HIV-1 protease and viral replication (HIV-I, HIV-2) at nanomolar concentrations without cytotoxicity to uninfected cells below 10 mu M. Their activities against HIV-1 protease (K-i 1.7 nM (1), 0.6 nM (2), 0.3 nM (3)) are 1-2 orders of magnitude greater than their antiviral potencies against HIV-1-infected primary peripheral blood mononuclear cells (IC50 45 nM (1), 56 nM (2), 95 nM (3)) or HIV-1-infected MT2 cells (IC50 90 nM (1), 60 nM (2)), suggesting suboptimal cellular uptake. However their antiviral potencies are similar to those of indinavir and amprenavir under identical conditions. There were significant differences in their capacities to inhibit the replication of HIV-1 and HIV-2 in infected MT2 cells, 1 being ineffective against HIV-2 while 2 was equally effective against both virus types. Evidence is presented that 1 and 2 inhibit cleavage of the HIV-1 structural protein precursor Pr55(gag) to p24 in virions derived from chronically infected cells, consistent with inhibition of the viral protease in cells. Crystal structures refined to 1.75 Angstrom (1) and 1.85 Angstrom (2) for two of the macrocyclic inhibitors bound to HIV-1 protease establish structural mimicry of the tripeptides that the cycles were designed to imitate. Structural comparisons between protease-bound macrocyclic inhibitors, VX478 (amprenavir), and L-735,524 (indinavir) show that their common acyclic components share the same space in the active site of the enzyme and make identical interactions with enzyme residues. This substrate-mimicking minimalist approach to drug design could have benefits in the context of viral resistance, since mutations which induce inhibitor resistance may also be those which prevent substrate processing.
C1 Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.
   Victorian Infect Dis Ref Lab, Carlton S, Vic 3053, Australia.
   Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Herston, Qld 4029, Australia.
RP Birch, CJ (reprint author), Univ Queensland, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.
RI Fairlie, David/F-8865-2014; Reid, Robert/D-8041-2012; tyndall,
   joel/C-2803-2008
OI Reid, Robert/0000-0002-0829-239X; tyndall, joel/0000-0003-0783-1635;
   Fairlie, David/0000-0002-7856-8566; Martin, Jennifer
   L./0000-0002-9225-8863
CR ABBENANTE G, 1995, J AM CHEM SOC, V117, P10220, DOI 10.1021/ja00146a007                                                             
   BERGMAN DA, 1995, LETT PEPT SCI, V2, P99, DOI 10.1007/BF00128504
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352
   Brunger AT, 1992, XPLOR VERSION 3 1 MA
   BUKRINSKY MS, 1993, J VIROL, V67, P6387
   CHEN ZG, 1994, J BIOL CHEM, V269, P26344
   CONDRA J, 1995, NATURE, V375, P569
   Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X
   ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071                                                       
   EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T
   Evans S. V., 1993, J MOL GRAPHICS, V11, P127
   Fairlie DP, 2000, J MED CHEM, V43, P1271, DOI 10.1021/jm990315t
   HAHN BH, 1994, TXB AIDS MED, P21
   Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101
   Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0                                                                
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   Kempf DJ, 1996, CURR PHARM DESIGN, V2, P225
   KIM EE, 1995, J AM CHEM SOC, V117, P1181, DOI 10.1021/ja00108a056                                                             
   KROHN A, 1991, J MED CHEM, V34, P3340, DOI 10.1021/jm00115a028
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944                                                       
   LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161                                                       
   March DR, 1996, J AM CHEM SOC, V118, P3375, DOI 10.1021/ja953790z
   MARCH DR, 1996, DESIGNING NEW ANTIVI
   Martin JL, 1999, BIOCHEMISTRY-US, V38, P7978, DOI 10.1021/bi990174x
   MILDNER AM, 1994, BIOCHEMISTRY-US, V33, P9405, DOI 10.1021/bi00198a005
   Misson J, 1997, J CLIN PHARM THER, V22, P109, DOI 10.1111/j.1365-2710.1997.tb00004.x                                              
   NEATE EV, 1987, AUST NZ J MED, V17, P461, DOI 10.1111/j.1445-5994.1987.tb00096.x
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Palmer S, 1999, AIDS, V13, P661
   Reid RC, 1996, J AM CHEM SOC, V118, P8511, DOI 10.1021/ja960433v                                                               
   REID RC, 2000, UNPUB J ORG CHEM
   ROSE JR, 1993, J BIOL CHEM, V268, P11939
   SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7
   SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805
   TACHEDJIAN G, 1990, Antiviral Chemistry and Chemotherapy, V1, P131
   TYNDALL JDA, 1999, J MOL RECOGNIT, V12, P1
   Vondrasek J, 1997, NAT STRUCT BIOL, V4, P8, DOI 10.1038/nsb0197-8
   WEST ML, 1995, TRENDS PHARMACOL SCI, V16, P67, DOI 10.1016/S0165-6147(00)88980-4
   WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551                                             
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
NR 43
TC 52
Z9 53
U1 0
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 21
PY 2000
VL 43
IS 19
BP 3495
EP 3504
DI 10.1021/jm000013n                                                       
          
PG 10
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 356HD
UT WOS:000089437100006
PM 11000004
DA 2018-01-05
ER

PT J
AU Zhu, XG
   Borchers, C
   Bienstock, RJ
   Tomer, KB
AF Zhu, XG
   Borchers, C
   Bienstock, RJ
   Tomer, KB
TI Mass spectrometric characterization of the glycosylation pattern of
   HIV-gp120 expressed in CHO cells
SO BIOCHEMISTRY
LA English
DT Article
ID ENVELOPE GLYCOPROTEIN GP120; SITE-SPECIFIC CHARACTERIZATION; HAMSTER
   OVARY CELLS; N-LINKED GLYCANS; V3 LOOP; HIV-1 GP120; STRUCTURAL
   CHARACTERIZATION; OLIGOSACCHARIDE STRUCTURES; EXOGLYCOSIDASE DIGESTION;
   NEUTRALIZATION SITE
AB An analytical approach is reported for the characterization of the specific glycans found on highly glycosylated proteins based on a combination of specific proteolysis and deglycosylation combined with two different mass spectrometric approaches, matrix-assisted laser desorption/ionization mass spectrometry, and nanoelectrospray mass spectrometry/tandem mass spectrometry using a hybrid quadrupole-time-of-flight tandem mass spectrometer. The high resolution and mass accuracy of the mass spectrometric data obtained on the hybrid instrument combined with the high parent mass capabilities are shown to be extremely useful in the site-specific assignment of heterogeneous glycans. Using this methodology, 25 of 26 consensus glycosylation sites on HIV-1(SF2) gp120, expressed in Chinese hamster ovary cells, could be assigned. Good correlations between the relative abundances of members of heterogeneous series in the matrix-assisted laser desorption/ionization mass spectra and the nanoelectrospray mass spectra were observed, indicating that the mass spectrometric data reflected the actual abundances of the members of the series. These data were incorporated with molecular modeling based on the solved structure of a mutant truncated, highly deglycosylated gp120 to propose a structural model for the completely glycosylated form.
C1 NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
   NIEHS, Comp Sci Lab, NIH, Res Triangle Pk, NC 27709 USA.
RP Tomer, KB (reprint author), NIEHS, Struct Biol Lab, NIH, POB 12233,MD F0-03, Res Triangle Pk, NC 27709 USA.
RI Tomer, Kenneth/E-8018-2013
OI Bienstock, Rachelle/0000-0001-5228-3610
CR Biller M, 1998, J VIROL METHODS, V76, P87, DOI 10.1016/S0166-0934(98)00127-X
   BLACKBURN K, 1998, P 46 ASMS C MASS SPE, P219
   Borchers C, 1999, BIOCHEMISTRY-US, V38, P11734, DOI 10.1021/bi990935w
   CARR SA, 1993, PROTEIN SCI, V2, P183
   CONBOY JJ, 1992, J AM SOC MASS SPECTR, V3, P804, DOI 10.1016/1044-0305(92)80003-4
   EZKOWITZ RAB, 1989, J EXP MED, V169, P185
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Ghiara JB, 1997, J MOL BIOL, V266, P31, DOI 10.1006/jmbi.1996.0768
   GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253                                                         
   Ha SN, 1988, CARBOHYD RES, V180, P207, DOI 10.1016/0008-6215(88)80078-8
   HAGLER AT, 1974, J AM CHEM SOC, V96, P5319, DOI 10.1021/ja00824a004
   Hochleitner EO, 2000, J IMMUNOL, V164, P4156, DOI 10.4049/jimmunol.164.8.4156                                                     
   HOMANS SW, 1990, BIOCHEMISTRY-US, V29, P9110, DOI 10.1021/bi00491a003
   Hu HL, 1996, J VIROL, V70, P7462
   HUBERTY MC, 1993, ANAL CHEM, V65, P877
   HUDDLESTON MJ, 1993, ANAL CHEM, V65, P877, DOI 10.1021/ac00055a009
   HUNT LA, 1982, J VIROL METHODS, V4, P283, DOI 10.1016/0166-0934(82)90075-1
   Jeyarajah S, 1998, J AM SOC MASS SPECTR, V9, P157, DOI 10.1016/S1044-0305(97)00247-X                                                   
   Juhasz P, 1997, INT J MASS SPECTROM, V169, P217, DOI 10.1016/S0168-1176(97)00219-X
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602
   LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47
   MEDZIHRADSZKY KF, 1994, J AM SOC MASS SPECTR, V5, P350, DOI 10.1016/1044-0305(94)85050-X
   MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Nakayama EE, 1998, FEBS LETT, V426, P367, DOI 10.1016/S0014-5793(98)00375-5                                                   
   RahbekNielsen H, 1997, J MASS SPECTROM, V32, P948, DOI 10.1002/(SICI)1096-9888(199709)32:9<948::AID-JMS551>3.0.CO;2-C                  
   Reitter JN, 1998, NAT MED, V4, P679, DOI 10.1038/nm0698-679
   Saifuddin M, 2000, J GEN VIROL, V81, P949, DOI 10.1099/0022-1317-81-4-949                                                      
   SCHINDLER PA, 1995, PROTEIN SCI, V4, P791
   SETTINERI CA, 1994, TECHNIQUES IN PROTEIN CHEMISTRY V, P97
   Stanfield RL, 1999, STRUCT FOLD DES, V7, P131, DOI 10.1016/S0969-2126(99)80020-3
   Stimson E, 1999, BIOCHEMISTRY-US, V38, P4885, DOI 10.1021/bi982330q
   SUTTON CW, 1994, ANAL BIOCHEM, V218, P34, DOI 10.1006/abio.1994.1138
   Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0
   Tsarbopoulos A, 1997, INT J MASS SPECTROM, V169, P251, DOI 10.1016/S0168-1176(97)00222-X
   Valenzuela A, 1997, J VIROL, V71, P8289
   VRANKEN WF, 1995, FEBS LETT, V374, P117, DOI 10.1016/0014-5793(95)01086-T
   Vu HM, 1996, BIOCHEMISTRY-US, V35, P5158, DOI 10.1021/bi952665x
   Weliky DP, 1999, NAT STRUCT BIOL, V6, P141
   YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019                                                             
NR 43
TC 181
Z9 183
U1 0
U2 7
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD SEP 19
PY 2000
VL 39
IS 37
BP 11194
EP 11204
DI 10.1021/bi000432m
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 356GY
UT WOS:000089436600004
PM 10985765
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Sudbeck, EA
   Mao, C
   Uckun, FM
AF Venkatachalam, TK
   Sudbeck, EA
   Mao, C
   Uckun, FM
TI Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a
   major determinant of their potency as nonnucleoside inhibitors of HIV-1
   reverse transcriptase
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; STRUCTURE-BASED DESIGN; RATIONAL DESIGN;
   RESISTANT; DERIVATIVES
AB Chiral derivatives of two cyclohexylethyl halopyridyl thiourea compounds (HI-509 and HI-510), two alpha-methyl benzyl halopyridyl compounds (HI-511 and HI-512), and a cyclohexyl ethyl thiazolyl thiourea compound (HI-513) were synthesized as nonnucleoside inhibitors (NNI) of human immunodeficiency virus (HIV) reverse transcriptase (RT). The R stereoisomers of all five compounds inhibited the recombinant RT in vitro with 100-fold lower IC50 values. HI-509(R), HI-510(R), HI-511(R), HI-512(R) and HI-513(R) were active anti-HIV agents and inhibited HIV-1 replication in human peripheral blood mononuclear cells at nanomolar concentrations, whereas their enantiomers were inactive. Each of these five compounds was also active against NNI-resistant HIV-1 strains, with HI-511(R) being the most active agent. When tested against the NNI-resistant HIV-1 strain A17 with a Y181C mutation in RT, HI-511(R) was found to be 10,000-times more active than nevirapine, 5000-times more active than delavirdine, and 50-times more active than trovirdine. HI-511(R) inhibited the HIV-strain A17 variant, containing RT mutations Y181C plus K103N, with an IC50 value of 2.7 mu M, whereas the IC50 values of nevirapine, delavirdine, and trovirdine against this highly NNI-resistant HIV-1 strain were >100 mu M. (C) 2000 Elsevier Science Ltd. All rights reserved.
C1 Parker Hughes Inst, Dept Virol, St Paul, MN USA.
   Parker Hughes Inst, Dept Biol Struct, St Paul, MN USA.
   Parker Hughes Inst, Dept Chem, St Paul, MN USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Dept Virol, St Paul, MN USA.
CR Mao C, 1999, ANTIVIR CHEM CHEMOTH, V10, P233, DOI 10.1177/095632029901000502                                                      
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   Sudbeck EA, 1999, ACTA CRYSTALLOGR C, V55, P2122, DOI 10.1107/S0108270199012044                                                       
   Sudbeck EA, 1998, ANTIMICROB AGENTS CH, V42, P3225
   Uckun FM, 2000, ANTIVIR CHEM CHEMOTH, V11, P135, DOI 10.1177/095632020001100205                                                      
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   PARADIGM PHARM, 1999, Patent No. 5998411
NR 11
TC 42
Z9 42
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD SEP 18
PY 2000
VL 10
IS 18
BP 2071
EP 2074
DI 10.1016/S0960-894X(00)00398-X
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 360QZ
UT WOS:000089679900007
PM 10999473
DA 2018-01-05
ER

PT J
AU Taylor, SE
   Desbat, B
   Blaudez, D
   Jacobi, S
   Chi, LF
   Fuchs, H
   Schwarz, G
AF Taylor, SE
   Desbat, B
   Blaudez, D
   Jacobi, S
   Chi, LF
   Fuchs, H
   Schwarz, G
TI Structure of a fusion peptide analogue at the air-water interface,
   determined from surface activity, infrared spectroscopy and scanning
   force microscopy
SO BIOPHYSICAL CHEMISTRY
LA English
DT Article
DE HIV-1; molecular area; beta-turn; Langmuir monolayer; polarization
   modulated infrared reflection absorption spectroscopy; (PMIRRAS);
   brewster angle microscopy (BAM)
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIR/WATER INTERFACE; IR SPECTROSCOPY;
   BREWSTER-ANGLE; MONOLAYERS; REFLECTION; PROTEINS; LIPIDS
AB We have investigated a point mutant of the HIV-1 fusion peptide in a compressed monolayer at the air-water interface. A variety of surface sensitive techniques were applied to study structural features under conditions mimicking the hydrophobic/hydrophilic environment of a biomembrane. Possible partitioning into the aqueous bulk phase and molecular areas were examined by surface activity based mass conservation plots. This shows that the peptide is practically fully accumulated in the interface. Secondary structure and orientation was analyzed by means of polarized infrared reflectivity. Brewster angle microscopy and scanning force microscopy contributed nanostructural images. At low surface pressures the molecules form anti-parallel beta-sheets lying flat on the interface. Upon a moderate increase of the lateral pressure a flat beta-turn structure appears with inter- and intramolecular H-bonds. We also observed aggregates forming fingerprint-like structures with a diameter of approximately double the hydrophobic length of a beta-turn conformation. Beyond approximately 15 mN m(-1) the beta-turns straighten up. The lowest measured tilt angle was 45 degrees at 36 mN m(-1). (C) 2000 Published by Elsevier Science B.V. All rights reserved.
C1 Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland.
   Univ Bordeaux 1, Lab Physicochim Mol, F-33405 Talence, France.
   Univ Bordeaux 1, Ctr Phys Mol Opt & Hertzienne, F-33405 Talence, France.
   Univ Munster, Inst Phys, D-48149 Munster, Germany.
RP Schwarz, G (reprint author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.
RI Chi, Lifeng/A-1419-2015
CR BIRDI KS, 1983, COLLOID POLYM SCI, V261, P767, DOI 10.1007/BF01410951                                                              
   BLAUDEZ D, 1994, THIN SOLID FILMS, V242, P146, DOI 10.1016/0040-6090(94)90519-3
   BLAUDEZ D, 1993, APPL SPECTROSC, V47, P869, DOI 10.1366/0003702934415273                                                        
   Blaudez D, 1996, J CHEM SOC FARADAY T, V92, P525, DOI 10.1039/ft9969200525                                                            
   Chi LF, 2000, ADV MATER, V12, P25, DOI 10.1002/(SICI)1521-4095(200001)12:1<25::AID-ADMA25>3.0.CO;2-1
   Cornut I, 1996, BIOPHYS J, V70, P305, DOI 10.1016/S0006-3495(96)79571-1                                                   
   DHATHATHREYAN A, 1988, BIOCHIM BIOPHYS ACTA, V944, P265, DOI 10.1016/0005-2736(88)90440-3
   GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5                                                    
   Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0                                                   
   GOORMAGHTIGH E, 1994, SUBCELLULAR BIOCH, V23, P342
   HENON S, 1991, REV SCI INSTRUM, V62, P936, DOI 10.1063/1.1142032                                                               
   HONIG D, 1991, J PHYS CHEM-US, V95, P4590, DOI 10.1021/j100165a003
   Jacobi S, 1998, THIN SOLID FILMS, V327, P180, DOI 10.1016/S0040-6090(98)00624-5
   KUHN H, 1993, PHYSICAL METHODS C B, V9, P375
   Miyazawa T., 1967, POLY ALPHA AMINO ACI, P69
   SCHAAL H, 1995, J VIROL, V69, P3308
   SCHWARZ G, 1995, LANGMUIR, V11, P4341, DOI 10.1021/la00011a028                                                             
   Tamm LK, 1997, Q REV BIOPHYS, V30, P365, DOI 10.1017/S0033583597003375                                                       
   TAYLOR SE, 1997, BIOCHIM BIOPHYS ACTA, V1362, P257
   Wackerbauer G, 1996, BIOPHYS J, V71, P1422, DOI 10.1016/S0006-3495(96)79343-8                                                   
   Welzel PB, 1998, COLLOID SURFACE A, V144, P229, DOI 10.1016/S0927-7757(98)00649-9                                                   
   Zhong Q, 1993, SURF SCI LETT, V290, P688
NR 22
TC 16
Z9 16
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0301-4622
J9 BIOPHYS CHEM
JI Biophys. Chem.
PD SEP 15
PY 2000
VL 87
IS 1
BP 63
EP 72
DI 10.1016/S0301-4622(00)00182-4
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA 355MH
UT WOS:000089389100006
PM 11036970
DA 2018-01-05
ER

PT J
AU De Rocquigny, H
   Caneparo, A
   Dong, CZ
   Delaunay, T
   Roques, BP
AF De Rocquigny, H
   Caneparo, A
   Dong, CZ
   Delaunay, T
   Roques, BP
TI Generation of monoclonal antibodies specifically directed against the
   proximal zinc finger of HIV type 1 NCp7
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID NUCLEOCAPSID PROTEIN NCP7; IMMUNODEFICIENCY-VIRUS TYPE-1;
   REVERSE-TRANSCRIPTASE; ANNEALING ACTIVITIES; GAG PRECURSOR; IN-VITRO;
   RNA; VPR; BINDING; H-1-NMR
AB The HIV-1 NCp7 contains two spatially close zinc fingers, required for the production of infectious particles. To investigate in more detail the function of the zinc finger domain, monoclonal antibodies were generated with a cyclic analog of the NCp7 proximal zinc finger. This analog was shown to bind zinc ions and to preserve the highly folded structure of the native peptide (Dong C-Z et al.: J Am Chem Soc 1995; 117: 2726-2731). We report here two monoclonal antibodies (2B10 and 4D3), which are the first monoclonal antibodies directed against CCHC NCp7 zinc fingers. Dot-blot experiments revealed that a few nanograms of synthetic NCp7 can be detected on a nitrocellulose membrane. Whereas 2B10 appears specific for an epitope located in sequence 19-27 of NCp7, 4D3 appears to be structurally specific. Immunocomplex affinities were evaluated, using BIAcore technology, to be up to 1 and 10 nM, respectively, for 2B10 and 4D3 in 100 mM NaCl. These antibodies were able to recognize NCp7 in the Gag polyprotein precursor and were shown to immunoprecipitate NCp7 from a cell supernatant. Moreover, NCp7-Vpr interaction mediated by the zinc fingers is inhibited by 2B10, emphasizing the role of these domains in the protein-protein complex. These results indicate that 2B10 and 4D3 behave as useful tools for studying both NC protein functions during the course of virion morphogenesis and the role played by its zinc finger domain at various steps in the retroviral life cycle.
C1 UFR Sci Pharmaceut & Biol, CNRS, UMR 8600, INSERM,U266,Dept Pharmacochim Mol & Struct, F-75270 Paris 06, France.
   INRA Bordeaux, Pathol Vegetale Stn, F-33883 Villenave Dornon, France.
RP Roques, BP (reprint author), UFR Sci Pharmaceut & Biol, CNRS, UMR 8600, INSERM,U266,Dept Pharmacochim Mol & Struct, 4 Ave Observ, F-75270 Paris 06, France.
CR ARONOFF R, 1993, J VIROL, V67, P178
   BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409
   Boulanger P, 1996, CURR TOP MICROBIOL, V214, P237
   Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700
   CARRIERE C, 1995, J VIROL, V69, P2366
   DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753
   DEMENE H, 1994, J BIOMOL NMR, V4, P153, DOI 10.1007/BF00175244                                                              
   DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0
   DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472                                                         
   DONG CZ, 1995, J AM CHEM SOC, V117, P2726, DOI 10.1021/ja00115a007                                                             
   Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283                                                        
   Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0
   JULLIAN N, 1993, FEBS LETT, V331, P43
   KARPEL RL, 1987, J BIOL CHEM, V262, P4961
   Lee BM, 1998, J MOL BIOL, V279, P633, DOI 10.1006/jmbi.1998.1766
   Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781
   Li MS, 1996, BIOCHEM BIOPH RES CO, V218, P352, DOI 10.1006/bbrc.1996.0061
   MELY Y, 1994, BIOCHEMISTRY-US, V33, P12085, DOI 10.1021/bi00206a011
   Mely Y, 1996, BIOCHEMISTRY-US, V35, P5175, DOI 10.1021/bi952587d
   MORELLET N, 1992, EMBO J, V11, P3059
   MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6
   Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098
   PRATS AC, 1988, EMBO J, V7, P1777
   Remy E, 1998, J BIOL CHEM, V273, P4819, DOI 10.1074/jbc.273.9.4819                                                          
   Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8
   Selig L, 1999, J VIROL, V73, P592
   SOUTH TL, 1991, BIOCHEMISTRY-US, V30, P6342, DOI 10.1021/bi00239a036                                                             
   TANCHOU V, 1994, AIDS RES HUM RETROV, V10, P983, DOI 10.1089/aid.1994.10.983
   TANCHOU V, 1995, J GEN VIROL, V76, P2475
   Tung HYL, 1997, FEBS LETT, V401, P197, DOI 10.1016/S0014-5793(96)01470-6
NR 32
TC 4
Z9 4
U1 0
U2 1
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 0889-2229
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 2000
VL 16
IS 13
BP 1259
EP 1267
DI 10.1089/08892220050117023
PG 9
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 347HC
UT WOS:000088921400007
PM 10957723
DA 2018-01-05
ER

PT J
AU Venkatachalam, TK
   Sudbeck, EA
   Mao, C
   Uckun, FM
AF Venkatachalam, TK
   Sudbeck, EA
   Mao, C
   Uckun, FM
TI Piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thiourea
   compounds with potent anti-HIV activity
SO ANTIVIRAL CHEMISTRY & CHEMOTHERAPY
LA English
DT Article
DE HIV; reverse transcriptase; thiourea; non-nucleoside reverse
   transcriptase inhibitor
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE INHIBITORS; POKEWEED
   ANTIVIRAL PROTEIN; STRUCTURE-BASED DESIGN; NONNUCLEOSIDE INHIBITORS;
   RATIONAL DESIGN; RESISTANT; COMPLEX
AB Derivatives of piperidinylethyl, phenoxyethyl and fluoroethyl bromopyridyl thioureas were designed and synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs) of HIV-1 reverse transcriptase (RT). The anti-HIV activity of these compounds was examined by determining their ability to inhibit the replication of the HIV-1 strain HTLVIIIB in human peripheral blood mononuclear cells. The unsubstituted parent pyridyl thiourea compound N-[2-(1-piperidine)ethyl]-N'-[2-(pyridyl)] thiourea (1) exhibited no anti-HIV activity, even at 100 muM. However, the thiourea derivatives that contain a bromo- or chloro-substituted pyridyl group, compounds 2 and 5, inhibited HIV-1 replication at nanomolar concentrations. The addition of a methyl group onto the piperidine ring significantly altered the potency of these compounds; while methyl substitution at the 3-position of the piperidine ring reduced the activity, methyl substitution at the 2-position enhanced the anti-HIV activity. The IC50 value of the lead piperidinyl compound, N-[2-(2-methylpiperidinylethyl)]-N'-[2-(5-bromopyridyl)] thiourea (4) was <0.001 <mu>M. All three phenoxyethyl derivatives, including the unsubstituted parent phenoxyethyl pyridyl thiourea compound N-[2-(phenoxy)ethyl]N'-[2-(pyridyl)]thiourea (8) and the bromo-/chlorosubstituted phenoxyethyl halopyridyl thiourea compounds N-[2-(phenoxy)ethyl]-N'-[2-(5-chlorepyridyl)]thiourea (9) and N-[2-(phenoxy)ethyl]-N'-[2(5-bromopyridyl)]thiourea (10) exhibited potent anti-HIV activity with nanomolar IC50 values. The corresponding fluoroethyl halopyridyl thiourea compounds beta -fluouo[2-phenethyl]-N'[2-(5-chloropyridyl)]thiourea (11) and beta -fluoro[2-phenethyl]-N'[2(5-bromopyridyl)]thiourea (12) inhibited HIV-1 replication in PBMC with subnanomolar IC50 values and selectivity indices >30000. Compared to the corresponding phenoxyethyl thiourea compounds 9 and 10, these compounds were >4-5-fold more active as anti-HIV agents. Notably, the lead flourothiourea compounds 11 and 12 were both substantially more active against the NNRTI-resistant HIV strains RT-MDR (V106A) and A17 (Y181C) than nevirapine or delavirdine. Taken together, our results provide additional experimental evidence that the structural features of the 'linker unit' between the pyridyl and phenyl moieties and changes in the phenyl group of PETT-related thiourea compounds significantly affects their biological activity as NNRTIs of HIV-1 RT.
C1 Parker Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
CR BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   DEEKS SG, 1997, AIDS CLIN REV, V98, P145
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   Esnouf RM, 1997, P NATL ACAD SCI USA, V94, P3984, DOI 10.1073/pnas.94.8.3984
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Kroeger Smith M B, 1995, Protein Sci, V4, P2203
   Mao C, 1999, ANTIVIR CHEM CHEMOTH, V10, P233, DOI 10.1177/095632029901000502                                                      
   Mao C, 2000, BIOCHEM PHARMACOL, V60, P1251, DOI 10.1016/S0006-2952(00)00408-1                                                   
   Mao C, 1999, BIOORG MED CHEM LETT, V9, P1593, DOI 10.1016/S0960-894X(99)00235-8
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P3411, DOI 10.1016/S0960-894X(99)00624-1                                                   
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
NR 20
TC 11
Z9 11
U1 0
U2 2
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 0956-3202
J9 ANTIVIR CHEM CHEMOTH
JI Antivir. Chem. Chemother.
PD SEP
PY 2000
VL 11
IS 5
BP 329
EP 336
DI 10.1177/095632020001100503                                              
          
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
GA 383EQ
UT WOS:000165870500003
PM 11142631
OA gold
DA 2018-01-05
ER

PT J
AU Johnston, A
   MacGregor, A
   Borovec, S
   Hattarki, M
   Stuckly, K
   Anderson, D
   Goss, NH
   Oates, A
   Uren, E
AF Johnston, A
   MacGregor, A
   Borovec, S
   Hattarki, M
   Stuckly, K
   Anderson, D
   Goss, NH
   Oates, A
   Uren, E
TI Inactivation and clearance of viruses during the manufacture of high
   purity Factor IX
SO BIOLOGICALS
LA English
DT Article
DE virus inactivation; Factor IX; virus partitioning; nanofiltration
ID HEPATITIS-A VIRUS; HUMAN ALBUMIN; FACTOR-VIII; CHROMATOGRAPHIC REMOVAL;
   HEAT INACTIVATION; CONCENTRATE; NANOFILTRATION; FRACTIONATION; SAFETY
AB Haemophilia is a bleeding disorder characterised by a deficiency in Factor IX. Replacement therapy in the form of a Factor IX concentrate is a widely accepted practice. In this paper we describe a double virus inactivated chromatographic process for producing a high purity Factor IX product, MonoFIX(R)-VF. The process involves separation of the prothrombin complex by cryoprecipitation, fraction I precipitation and DEAE-cellulose adsorption, further ion-exchange chromatography of crude Factor IX, followed by solvent/detergent treatment. Heparin affinity chromatography is then used to further purify Factor IX. Final nanofiltration is sequential through 35 nm then 15 nm membrane filters. The principal virus inactivation/removal steps are solvent/detergent treatment and nanofiltration and the partitioning of relevant and model viruses provides further reduction in virus load through the production process.
   Solvent/detergent treatment was shown to achieve log reduction factors of 4.5 for HIV-1, 5.1 for Sindbis virus, 6.1 for vesicular stomatitis virus (VSV), 5.1 for bovine viral diarrhoea virus (BVDV) and 5.3 for pseudorabies virus (PRV), BVDV is a model for hepatitis C virus (HCV), and pseudorabies virus (PRV), like hepatitis B virus (HBV) is an enveloped DNA virus. Using scaled down models of the production process, we have also demonstrated the neutralization/partitioning of at least 6 logs of hepatitis A virus (HAV) during cryoprecipitation, Fraction I precipitation, and the DEAF adsorption and elution step, and a further 1.6 log reduction in HAV load as a result of heparin affinity chromatography The log reduction factors for HAV as a result of the second ion-exchange chromatography step and as a result of enhanced neutralisation associated with solvent/detergent treatment were not significant.
   Nanofiltration was shown to contribute a further log reduction factor of 6.7 for HAV and 5.8 for BVDV indicating that log reduction factors of this order would be obtained with other viruses of a similar or larger size, such as HIV, HBV and HCV.
   Overall, these studies indicate that MonoFIX(R)-VF is a product with an extremely high level of viral safety. (C) 2000 The International Association for Biologicals.
C1 CSL Ltd, Biplasma Div, Res & Dev, Broadmeadows, Vic 3047, Australia.
   Macfarlane Burnet Ctr Med Res, Melbourne, Vic, Australia.
RP Johnston, A (reprint author), CSL Ltd, Biplasma Div, Res & Dev, 189-209 Camp Rd, Broadmeadows, Vic 3047, Australia.
CR Adcock WL, 1998, BIOTECHNOL APPL BIOC, V28, P85
   Adcock WL, 1998, BIOTECHNOL APPL BIOC, V28, P169
   BEES WCH, 1989, C INSERM, V175, P207
   Borovec S, 1997, J VIROL METHODS, V68, P81, DOI 10.1016/S0166-0934(97)00107-9                                                   
   BURNOUF T, 1991, VOX SANG, V60, P8, DOI 10.1111/j.1423-0410.1991.tb00864.x                                              
   BURNOUF T, 1989, C INSERM, V175, P325
   BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x                                              
   Cameron R, 1997, BIOLOGICALS, V25, P391, DOI 10.1006/biol.1997.0115                                                          
   DILEO AJ, 1992, BIO-TECHNOL, V10, P182, DOI 10.1038/nbt0292-182                                                             
   Eibl J, 1996, BIOLOGICALS, V24, P285, DOI 10.1006/biol.1996.0036
   GORNALL AG, 1949, J BIOL CHEM, V177, P751
   GUST ID, 1988, HEPATITIS A, P41
   HAMAMOTO Y, 1989, VOX SANG, V56, P230, DOI 10.1111/j.1423-0410.1989.tb02034.x                                              
   HOFFER L, 1995, J CHROMATOGR B, V669, P187, DOI 10.1016/0378-4347(95)00107-T
   HOROWITZ B, 1989, CURR STUD HEMATOL BL, V56, P83
   LEMON SM, 1994, J MED VIROL, V43, P44, DOI 10.1002/jmv.1890430109                                                          
   LUSHER JM, 1991, SEMIN HEMATOL, V28, P3
   Ohmann H. B., 1990, Revue Scientifique et Technique - Office International des Epizooties, V9, P61
   Pehta JC, 1996, TRANSFUS MED REV, V10, P303, DOI 10.1016/S0887-7963(96)80006-X
   ROBERTS P, 1995, HAEMOPHILIA, V1, P19
   SCHWARZ TF, 1991, J MED VIROL, V35, P28, DOI 10.1002/jmv.1890350107
   SMITH PK, 1985, ANN BIOCH, V100, P201
   Soucie JM, 1998, TRANSFUSION, V38, P573, DOI 10.1046/j.1537-2995.1998.38698326337.x
   TOTH CS, 1988, RETENTION VIRAL CONT, pA1358
   VERMYLEN J, 1994, VOX SANG, V67, P8, DOI 10.1111/j.1423-0410.1994.tb01290.x                                              
   WELLS MA, 1986, TRANSFUSION, V26, P210, DOI 10.1046/j.1537-2995.1986.26286152919.x
   WHITE GC, 1977, BLOOD, V49, P159
NR 27
TC 21
Z9 24
U1 1
U2 8
PU ACADEMIC PRESS LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
J9 BIOLOGICALS
JI Biologicals
PD SEP
PY 2000
VL 28
IS 3
BP 129
EP 136
DI 10.1006/biol.1999.0242
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA 355MJ
UT WOS:000089389200001
PM 10964439
DA 2018-01-05
ER

PT J
AU Sabroe, I
   Peck, MJ
   Van Keulen, BJ
   Jorritsma, A
   Simmons, G
   Clapham, PR
   Williams, TJ
   Pease, JE
AF Sabroe, I
   Peck, MJ
   Van Keulen, BJ
   Jorritsma, A
   Simmons, G
   Clapham, PR
   Williams, TJ
   Pease, JE
TI A small molecule antagonist of chemokine receptors CCR1 and CCR3 -
   Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID GUINEA-PIG MODEL; ENDOTHELIAL-CELLS; EOTAXIN RECEPTOR; IN-VIVO;
   CHEMOATTRACTANT CYTOKINE; CROSS-DESENSITIZATION; CHEMOTACTIC CYTOKINES;
   MONOCLONAL-ANTIBODY; MESSENGER-RNA; BONE-MARROW
AB We describe a small molecule chemokine receptor antagonist, UCB35625 (the trans-isomer J113863 published by Banyu Pharmaceutical Co., patent WO98/04554), which is a potent, selective inhibitor of CCR1 and CCR3. Nanomolar concentrations of UCB35625 were sufficient to inhibit eosinophil shape change responses to MIP-1 alpha; MCP-4, and eotaxin, while greater concentrations could inhibit the chemokine induced internalization of both CCR1 and CCR3. UCB35625 also inhibited the CCR3-mediated entry of the human immunodeficiency virus-1 primary isolate 89.6 into the glial cell line, NP-2 (IC(50) = 57 nM). Chemotaxis of transfected cells expressing either CCR1 or CCR3 was inhibited by nanomolar concentrations of the compound (IC(50) values of CCR1-MIP-1 alpha = 9.6 nM, CCR3-eotaxin = 93.7 nM). However, competitive ligand binding assays on the same transfectants revealed that considerably larger concentrations of UCB35625 were needed for effective ligand displacement than were needed far the inhibition of receptor function. Thus, it appears that the compound may interact with a region present in both receptors that inhibits the conformational change necessary to initiate intracellular signaling. By virtue of its potency at the two major eosinophil chemokine receptors, UCB35625 is a prototypic therapy for the treatment of eosinophil-mediated inflammatory disorders, such as asthma and as an inhibitor of CCR3-mediated human immunodeficiency virus-1 entry.
C1 Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Div Biomed Sci, Sch Med, London SW7 2AZ, England.
   UCB, Pharma Res & Dev, B-1420 Braine Lalleud, Belgium.
   UCL, Sch Med, Wohl Vir Ctr, Dept Mol Pathol & Clin Biochem, London W1P 6DB, England.
RP Pease, JE (reprint author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Div Biomed Sci, Sch Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England.
EM j.pease@ic.ac.uk
RI Sabroe, Ian/I-5981-2013; Simmons, Graham/G-3523-2012
OI Sabroe, Ian/0000-0001-9750-8975; Simmons, Graham/0000-0002-9615-7023
CR Alam R, 1996, AM J RESP CRIT CARE, V153, P1398, DOI 10.1164/ajrccm.153.4.8616572                                                    
   Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027                                                         
   Alkhatib G, 1997, J BIOL CHEM, V272, P20420, DOI 10.1074/jbc.272.33.20420
   ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x                                              
   Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757                                                        
   BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   CLAPHAM PR, 1992, J VIROL, V66, P3531
   COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169
   COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491                                                        
   Dairaghi DJ, 1997, J BIOL CHEM, V272, P28206, DOI 10.1074/jbc.272.45.28206
   Elsner J, 2000, J BIOL CHEM, V275, P7787, DOI 10.1074/jbc.275.11.7787                                                         
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685, DOI 10.1164/ajrccm/138.3.685                                                        
   Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171                                                         
   Gao JL, 1996, BIOCHEM BIOPH RES CO, V223, P679, DOI 10.1006/bbrc.1996.0955
   Gura T, 1996, SCIENCE, V272, P954, DOI 10.1126/science.272.5264.954
   HASLETT C, 1985, AM J PATHOL, V119, P101
   He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0
   Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145
   Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687
   Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601
   JOSE PJ, 1994, BIOCHEM BIOPH RES CO, V205, P788, DOI 10.1006/bbrc.1994.2734                                                          
   JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881
   Li D, 1997, EUR RESPIR J, V10, P1946, DOI 10.1183/09031936.97.10091946
   Li L, 1999, J IMMUNOL, V162, P2477
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706                                                     
   MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461                                                          
   Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084                                                        
   NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A
   Olson WC, 1999, J VIROL, V73, P4145
   Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621
   Palframan RT, 1998, BLOOD, V91, P2240
   Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972
   Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456                                                               
   Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437
   POST TW, 1995, J IMMUNOL, V155, P5299
   Reeves JD, 2000, METH MOL B, V138, P209
   Rollins BJ, 1997, BLOOD, V90, P909
   ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489
   ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960
   Sabroe I, 1997, J IMMUNOL, V158, P1361
   Sabroe I, 1998, J IMMUNOL, V161, P6139
   Sabroe I, 1999, J IMMUNOL, V162, P2946
   Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005
   Shinkai A, 1999, J IMMUNOL, V163, P1602
   SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214
   Soda Y, 1999, BIOCHEM BIOPH RES CO, V258, P313, DOI 10.1006/bbrc.1999.0633
   SPRY CJF, 1992, IMMUNOL TODAY, V13, P384, DOI 10.1016/0167-5699(92)90085-L                                                    
   UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113                                                          
   Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624
   Venge P, 1988, AM REV RESPIR DIS, V138, P54
   Wang ZX, 1999, J BIOL CHEM, V274, P28413, DOI 10.1074/jbc.274.40.28413
   Williams CMM, 1998, IMMUNOGENETICS, V47, P178
   Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258
   Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252
   Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909
   NAYA A, 1998, Patent No. 9804554
NR 58
TC 172
Z9 177
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 25
PY 2000
VL 275
IS 34
BP 25985
EP 25992
DI 10.1074/jbc.M908864199
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 348RF
UT WOS:000088999700016
PM 10854442
OA gold
DA 2018-01-05
ER

PT J
AU De Jaeghere, F
   Allemann, E
   Kubel, F
   Galli, B
   Cozens, R
   Doelker, E
   Gurny, R
AF De Jaeghere, F
   Allemann, E
   Kubel, F
   Galli, B
   Cozens, R
   Doelker, E
   Gurny, R
TI Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor
   incorporated into pH-sensitive particles: effect of the particle size
   and nutritional state
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE HIV-1 protease inhibitor; poorly water-soluble drug; nanoparticle;
   microparticle; pH-sensitive particles; methacrylic acid copolymer; oral
   bioavailability
ID ACID) NANOPARTICLES; DRUG ABSORPTION; POTENTIAL ROLE; FOOD; POLYMERS;
   DOGS
AB The new chemical entity CGP 70726, a very poorly water-soluble HIV-1 protease inhibitor, was incorporated into pH-sensitive nanoparticles and microparticles made of the poly(methacrylic acid-co-ethylacrylate) copolymer Eudragit(R) L100-55. The particles were characterized in terms of morphology, size distribution, drug loading, production yield and dispersion state of the drug inside the polymeric matrices. Aqueous dispersions of the particles were administered orally to Beagle dogs against a suspension of free drug (control formulation) all at a dose of 100 mg/kg. Oral administration was conducted in the absence and presence of food. Plasma concentrations and pharmacokinetic parameters were determined within 8 h post-dose. While no measurable absorption of the drug resulted after administration of the control formulation, substantial systemic exposure to the compound was obtained with both kinds of pH-sensitive formulations. The selective release of CGP 70726 in a highly dispersed/amorphous state and creation of high concentrations close to its absorption site was thought to account for this positive result. The largest areas under the plasma concentration-time curve (AUC) were obtained in the fasted state, with slightly better performance of the microparticles over the nanoparticles, in both nutritional states (7.8+/-1.5 versus 5.8+/-0.8 mu mol.h/l in the fasted state; 4.4+/-1.4 versus 2.00+/-0.5 mu mol.h/l in the fed state). With these results, the potential of pH-sensitive particles for the oral delivery of HIV-1 protease inhibitors with low water solubility was confirmed. (C) 2000 Elsevier Science B.V. All rights reserved.
C1 Univ Geneva, Sch Pharm, CH-1211 Geneva 4, Switzerland.
   Univ Geneva, Crystallog Lab, CH-1211 Geneva, Switzerland.
   Novartis Pharma AG, CH-4002 Basel, Switzerland.
RP Gurny, R (reprint author), Univ Geneva, Sch Pharm, CH-1211 Geneva 4, Switzerland.
CR AHMED SM, 1991, INT J PHARM, V77, P247, DOI 10.1016/0378-5173(91)90323-G                                                    
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P13
   Attwood D., 1994, COLLOIDAL DRUG DELIV, V2, P31
   Charman WN, 1997, J PHARM SCI-US, V86, P269, DOI 10.1021/js960085v
   DEJAEGHERE F, 1998, P 2 WORLD M APGI APV, V2, P559
   DELABOURET A, 1995, DRUG DEV IND PHARM, V21, P229, DOI 10.3109/03639049509048106                                                       
   GANDER B, 1985, INT J PHARM, V27, P117, DOI 10.1016/0378-5173(85)90190-5
   Giunchedi P, 1996, J MICROENCAPSUL, V13, P89, DOI 10.3109/02652049609006805
   Kenyon CJ, 1998, PHARMACEUT RES, V15, P417, DOI 10.1023/A:1011972230829                                                         
   LANG M, 1993, ARCH PHARM, V326, P921, DOI 10.1002/ardp.19933261202                                                        
   LERK PC, 1993, INT J PHARM, V92, P197, DOI 10.1016/0378-5173(93)90280-S
   LEROUX JC, 1995, J PHARM SCI, V84, P1387, DOI 10.1002/jps.2600841202
   Leroux JC, 1996, PHARMACEUT RES, V13, P485, DOI 10.1023/A:1016073416332                                                         
   LEROUX JC, 1995, EUR J PHARM BIOPHARM, V41, P14
   LIVERSIDGE GG, 1995, INT J PHARM, V125, P91, DOI 10.1016/0378-5173(95)00122-Y
   Maa YF, 1998, J PHARM SCI, V87, P152, DOI 10.1021/js970308x
   Owusu-Ababio G, 1998, CLIN RES REGUL AFF, V15, P25, DOI 10.3109/10601339809048527                                                       
   QuintanarGuerrero D, 1996, INT J PHARM, V143, P133, DOI 10.1016/S0378-5173(96)04697-2
   ROBINS T, 1993, J ACQ IMMUN DEF SYND, V6, P162
   Saarinen-Savolainen P, 1997, INT J PHARM, V159, P27, DOI 10.1016/S0378-5173(97)00264-0
   WELLING PG, 1989, PHARMACOL THERAPEUT, V43, P425, DOI 10.1016/0163-7258(89)90019-3
NR 21
TC 48
Z9 49
U1 1
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
J9 J CONTROL RELEASE
JI J. Control. Release
PD AUG 10
PY 2000
VL 68
IS 2
BP 291
EP 298
DI 10.1016/S0168-3659(00)00272-8
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA 345TU
UT WOS:000088831900015
PM 10925137
DA 2018-01-05
ER

PT J
AU Astoul, CH
   Peumans, WJ
   Van Damme, EJM
   Rouge, P
AF Astoul, CH
   Peumans, WJ
   Van Damme, EJM
   Rouge, P
TI Accessibility of the high-mannose glycans of glycoprotein gp120 from
   human immunodeficiency virus type 1 probed by in vitro interaction with
   mannose-binding lectins
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE gp120; HIV-1; high-mannose glycans; mannose-binding lectins; interaction
ID IMMOBILIZED POLYSTYRENE NANOSPHERES; HAMSTER OVARY CELLS; N-LINKED
   GLYCANS; ENVELOPE GLYCOPROTEIN; PLANT-LECTINS; CARBOHYDRATE STRUCTURES;
   EPIPACTIS-HELLEBORINE; UNUSUAL SPECIFICITY; MOLECULAR-CLONING; CYMBIDIUM
   HYBRID
AB The direct interaction of mannose-specific plant lectins with gp120 of HIV-1 was studied by surface plasmon resonance. Inhibition experiments indicated that exposed high mannose type glycans play a key role in the interaction. Most of the lectins specifically accommodate outer alpha 1,2-, alpha 1,3-, or alpha 1,6-linked di- or trimannosides, and especially legume lectins, also interact with the trimannoside core of the complex type glycans. The unexpected affinity of some lectins towards gp120 presumably results from conformational differences in their binding sites. These results demonstrate that mannose-specific plant lectins are powerful tools to study the accessibility and elucidate the function of the gp120 glycans in the recognition and infection of the host cells by HIV-1. (C) 2000 Academic Press.
C1 CNRS, UMR 5089, Inst Pharmacol & Biol Struct, F-31077 Toulouse 4, France.
   Katholieke Univ Leuven, Lab Phytoathol & Plant Protect, B-3001 Louvain, Belgium.
RP Rouge, P (reprint author), CNRS, UMR 5089, Inst Pharmacol & Biol Struct, 205 Route Narbonne, F-31077 Toulouse 4, France.
RI Van Damme, Els/B-4410-2015
OI Van Damme, Els/0000-0001-9848-766X
CR Akashi M, 1998, BIOCONJUGATE CHEM, V9, P50, DOI 10.1021/bc970045y                                                               
   BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410                                                            
   BALZARINI J, 1992, ANTIVIR RES, V18, P191, DOI 10.1016/0166-3542(92)90038-7                                                    
   Barre A, 1996, PLANT PHYSIOL, V112, P1531, DOI 10.1104/pp.112.4.1531                                                           
   Biller M, 1998, J VIROL METHODS, V76, P87, DOI 10.1016/S0166-0934(98)00127-X
   Bourne Y, 1999, STRUCT FOLD DES, V7, P1473, DOI 10.1016/S0969-2126(00)88338-0
   BOURNE Y, 1992, J BIOL CHEM, V267, P197
   BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8
   CHRISPEELS MJ, 1991, PLANT CELL, V3, P1
   CORBEAU P, 1995, IMMUNOL LETT, V47, P141, DOI 10.1016/0165-2478(95)00047-9
   FAVERO J, 1994, GLYCOBIOLOGY, V4, P387, DOI 10.1093/glycob/4.4.387                                                          
   FENOUILLET E, 1994, TRENDS BIOCHEM SCI, V19, P65, DOI 10.1016/0968-0004(94)90034-5                                                    
   GEYER H, 1988, J BIOL CHEM, V263, P11760
   HAIGWOOD NL, 1990, VACCINES, V90, P313
   HAMMAR L, 1989, AIDS RES HUM RETROV, V5, P495, DOI 10.1089/aid.1989.5.495
   HANSEN EA, 1991, BIOMASS BIOENERG, V1, P1, DOI 10.1016/0961-9534(91)90046-F                                                    
   HANSEN JES, 1989, AIDS, V3, P635, DOI 10.1097/00002030-198910000-00003                                                
   Hayakawa T, 1998, J MED VIROL, V56, P327, DOI 10.1002/(SICI)1096-9071(199812)56:4<327::AID-JMV7>3.0.CO;2-A
   Hester G, 1996, J MOL BIOL, V262, P516, DOI 10.1006/jmbi.1996.0532
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LEONARD CK, 1990, J BIOL CHEM, V265, P10373
   LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563
   LIFSON J, 1986, J EXP MED, V164, P2101, DOI 10.1084/jem.164.6.2101
   MERKLE RK, 1991, ARCH BIOCHEM BIOPHYS, V290, P248, DOI 10.1016/0003-9861(91)90616-Q
   Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9
   MIZUOCHI T, 1990, J BIOL CHEM, V265, P8519
   MIZUOCHI T, 1988, BIOCHEM J, V254, P599, DOI 10.1042/bj2540599                                                               
   Naismith JH, 1996, J BIOL CHEM, V271, P972, DOI 10.1074/jbc.271.2.972                                                           
   NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407
   PEUMANS WJ, 1995, PLANT PHYSIOL, V109, P347, DOI 10.1104/pp.109.2.347
   Peumans WJ, 1997, GLYCOCONJUGATE J, V14, P259, DOI 10.1023/A:1018502107707                                                         
   RINI JM, 1993, J BIOL CHEM, V268, P10126
   ROBINSON WE, 1987, AIDS RES HUM RETROV, V3, P265, DOI 10.1089/aid.1987.3.265
   ROUGE P, 1984, PLANT SCI LETT, V37, P21, DOI 10.1016/0304-4211(84)90197-4
   ROUGE P, 1991, LECTIN REV, V1, P143
   SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227
   Sattentau QJ, 1998, STRUCT FOLD DES, V6, P945, DOI 10.1016/S0969-2126(98)00096-3
   SCANDELLA CJ, 1993, AIDS RES HUM RETROV, V9, P1233, DOI 10.1089/aid.1993.9.1233
   SHILATIFARD A, 1993, J VIROL, V67, P943
   Sjolander S, 1996, VIROLOGY, V215, P124, DOI 10.1006/viro.1996.0015
   Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2
   Van Damme EJM, 1999, EUR J BIOCHEM, V259, P135, DOI 10.1046/j.1432-1327.1999.00013.x
   Van Damme EJM, 1998, CRIT REV PLANT SCI, V17, P575
   VANDAMME EJM, 1994, EUR J BIOCHEM, V221, P769
   VANDAMME EJM, 1988, PHYSIOL PLANTARUM, V73, P52
   VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1                                                    
   VanDamme EJM, 1996, EUR J BIOCHEM, V235, P128
   Wright CS, 1996, STRUCTURE, V4, P1339, DOI 10.1016/S0969-2126(96)00141-4
NR 49
TC 16
Z9 18
U1 0
U2 0
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 2
PY 2000
VL 274
IS 2
BP 455
EP 460
DI 10.1006/bbrc.2000.3166
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 341LU
UT WOS:000088592500030
PM 10913359
DA 2018-01-05
ER

PT J
AU Gemignani, A
   Paudice, P
   Pittaluga, A
   Raiteri, M
AF Gemignani, A
   Paudice, P
   Pittaluga, A
   Raiteri, M
TI The HIV-1 coat protein gp120 and some of its fragments potently activate
   native cerebral NMDA receptors mediating neuropeptide release
SO EUROPEAN JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE gp120; HIV-1 envelope proteins; neuropeptide release; NMDA receptor
   subtypes; V3 loop fragments
ID D-ASPARTATE RECEPTORS; HUMAN-IMMUNODEFICIENCY-VIRUS; EXCITATORY
   AMINO-ACIDS; NORADRENALINE RELEASE; RAT STRIATUM; GABA RELEASE; ENVELOPE
   GLYCOPROTEIN; GLUTAMATE RECEPTORS; NEURONAL INJURY; CELL-CULTURES
AB The objective of this study was to investigate the effects of the HIV-1 envelope protein gp120 and its peptide fragments on the function of N-methyl-d-aspartate (NMDA) receptors mediating release of cholecystokinin (CCK) and somatostatin (SRIF). These are nonconventional NMDA receptors recently found to be activated by glycine or d-serine 'only'. The release of cholecystokinin-like immunoreactivity (CCK-LI) and of somatostatin-like immunoreactivity (SRIF-LI) elicited by 12 mm K(+) from superfused rat neocortex synaptosomes was potently increased by gp120, its cyclic V3 loop and the linear V3 sequence BRU-C-34-A, but not by RP-135 (a central portion of BRU-C-34-A). The EC(50) values of gp120 were 0.02 nm (CCK-LI release) and 0.01 nm (SRIF-LI release). The releasing effect of gp120 was prevented by blocking the glycine site or the ion channel of NMDA receptors, but not the glutamate recognition site; in addition, the gp120 effect was strongly inhibited by nanomolar concentrations of Zn(2+) ions and by low micromolar concentrations of ifenprodil. It is concluded that gp120 acts as a very potent agonist at the glycine site of NMDA receptors sited on CCK- and SRIF-releasing nerve endings; the protein is able to activate the receptor channel in the absence of glutamate. Gp120 activates the receptors through its V3 loop as peptide fragments related to V3 retain near-maximal activity. The sensitivity of the gp120 effect to both Zn(2+) and ifenprodil would not be incompatible with the idea that these NMDA receptors contain the triple subunit combination NR1/NR2A/NR2B.
C1 Dept Expt Med, Pharmacol & Toxicol Sect, I-16148 Genoa, Italy.
RP Raiteri, M (reprint author), Dept Expt Med, Pharmacol & Toxicol Sect, Viale Cembrano 4, I-16148 Genoa, Italy.
EM raiteri@pharmatox.unige.it
RI Pittaluga, Anna/C-5960-2008
CR BANDOPADHYAY R, 1991, NEUROPEPTIDES, V18, P159, DOI 10.1016/0143-4179(91)90108-U
   Beinfeld Margery C., 1995, P585
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475
   CODAZZI F, 1995, EUR J NEUROSCI, V7, P1333, DOI 10.1111/j.1460-9568.1995.tb01124.x
   CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X
   DAWBARN D, 1985, BRAIN RES, V340, P251, DOI 10.1016/0006-8993(85)90921-7
   DESCE JM, 1992, NEUROSCIENCE, V47, P333, DOI 10.1016/0306-4522(92)90249-2
   DREJER J, 1987, J NEUROSCI, V7, P2910
   FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741
   FINK K, 1990, EUR J PHARMACOL, V185, P115, DOI 10.1016/0014-2999(90)90219-V
   FINK K, 1995, N-S ARCH PHARMACOL, V352, P394
   Fontana G, 1997, J NEUROSCI RES, V49, P732, DOI 10.1002/(SICI)1097-4547(19970915)49:6<732::AID-JNR7>3.0.CO;2-8
   GALLI T, 1992, NEUROSCIENCE, V50, P769, DOI 10.1016/0306-4522(92)90203-E
   GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769
   Glass JD, 1996, ANNU REV NEUROSCI, V19, P1
   HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335                                             
   JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0                                                                
   KREBS MO, 1989, EUR J PHARMACOL, V166, P567, DOI 10.1016/0014-2999(89)90378-6                                                    
   KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0
   LANNUZEL A, 1995, EUR J NEUROSCI, V7, P2285, DOI 10.1111/j.1460-9568.1995.tb00649.x
   LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685                                                         
   LEVI G, 1993, P NATL ACAD SCI USA, V90, P1541, DOI 10.1073/pnas.90.4.1541
   LIPTON SA, 1994, INT REV NEUROBIOL, V36, P1, DOI 10.1016/S0074-7742(08)60301-3
   LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X
   LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F                                                    
   Luo JH, 1997, MOL PHARMACOL, V51, P79
   MOLINOFF PB, 1994, PROG BRAIN RES, V100, P39
   MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217                                                   
   MOORE JP, 1994, J VIROL, V68, P469
   MULLER WEG, 1992, EUR J PHARM-MOLEC PH, V226, P209, DOI 10.1016/0922-4106(92)90063-2
   Paoletti P, 1997, J NEUROSCI, V17, P5711
   Pattarini R, 1998, NEUROSCIENCE, V87, P147, DOI 10.1016/S0306-4522(98)00125-0
   Paudice P, 1998, EUR J NEUROSCI, V10, P2934, DOI 10.1046/j.1460-9568.1998.00302.x                                                
   PIN JP, 1989, J NEUROSCI, V9, P648
   Pittaluga A, 1996, AIDS, V10, P463, DOI 10.1097/00002030-199605000-00003
   PITTALUGA A, 1990, EUR J PHARMACOL, V191, P231, DOI 10.1016/0014-2999(90)94153-O
   PITTALUGA A, 1994, EUR J NEUROSCI, V6, P1743, DOI 10.1111/j.1460-9568.1994.tb00566.x                                              
   PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272
   RAITERI M, 1984, J PHARMACOL EXP THER, V231, P671
   RAITERI M, 1974, EUR J PHARMACOL, V25, P411, DOI 10.1016/0014-2999(74)90272-6                                                    
   REHFELD JF, 1978, J BIOL CHEM, V253, P4016
   Rubinow David R., 1995, P553
   RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198
   SAVIO T, 1993, J NEUROSCI RES, V34, P265, DOI 10.1002/jnr.490340303                                                           
   SCATTON B, 1982, NATURE, V297, P422, DOI 10.1038/297422a0
   SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0                                                                
   SWEETNAM PM, 1993, EUR J NEUROSCI, V5, P276, DOI 10.1111/j.1460-9568.1993.tb00494.x
   TAPIAARANCIBIA L, 1992, EUR J PHARM-MOLEC PH, V225, P253, DOI 10.1016/0922-4106(92)90027-S
   Wenzel A, 1995, NEUROREPORT, V7, P45, DOI 10.1097/00001756-199512290-00010
   WILLIAMS K, 1993, MOL PHARMACOL, V44, P851
   Wittekindt B, 2000, NEUROSCI LETT, V280, P151, DOI 10.1016/S0304-3940(00)00775-8
   Wu P, 1996, NEUROREPORT, V7, P1045, DOI 10.1097/00001756-199604100-00018
   YAKSH TL, 1989, ELLIS HOR S, P81
NR 54
TC 15
Z9 16
U1 0
U2 0
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0953-816X
J9 EUR J NEUROSCI
JI Eur. J. Neurosci.
PD AUG
PY 2000
VL 12
IS 8
BP 2839
EP 2846
DI 10.1046/j.1460-9568.2000.00172.x
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 349PP
UT WOS:000089055100018
PM 10971626
DA 2018-01-05
ER

PT J
AU D'Cruz, OJ
   Venkatachalam, TK
   Uckun, FM
AF D'Cruz, OJ
   Venkatachalam, TK
   Uckun, FM
TI Novel thiourea compounds as dual-function microbicides
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE sperm; sperm motility
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; POTENT
   NONNUCLEOSIDE INHIBITORS; POKEWEED ANTIVIRAL PROTEIN; ANTI-HIV; VAGINAL
   MICROBICIDE; ANTI-HIV-1 ACTIVITY; NONOXYNOL-9 USE; PETT COMPOUNDS;
   1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE HEPT
AB Sexually active women represent the fastest growing human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome risk group, In an effort to develop a vaginal microbicidal contraceptive potentially capable of preventing HIV transmission as well as providing fertility control, we previously reported the synthesis of novel nonnucleoside inhibitors (NNIs) of HIV-1 reverse transcriptase with sperm-immobilizing activity (SIA), To gain further insight into the structure-function relationship controlling these two properties of NNIs, we have rationally designed and synthesized 30 novel thiourea compounds and examined them for dual-function, anti-HIV and spermicidal activity. Twelve of the 30 thiourea compounds exhibited potent anti-HIV activity in the nanomolar range (IC50 = <1-9 nM), Nine of the 30 thiourea derivatives exhibited both anti-HIV and spermicidal activity. Among the phenyl ring-containing thioureas, the 2-fluoro (HI-240) -substituted and 2-chloro (HI-253) -substituted derivatives exhibited potent anti-HIV activity (IC50 = <1 nM) with SIA (EC50 = 70 mu M and 147 mu M). Among the alicyclic ring-containing thioureas, the 5-bromo (HI-346) and 5-chloro (HI-445) functionalized cyclohexenyl ring-substituted thioureas were the most potent dual-function spermicides (EC50 = 42 and 57 mu M), with anti-HIV activity at nanomolar range (IC50 = 3 nM). Unlike nonoxynol-9 (N-9), none of the potent dual-function thiourea compounds were cytotoxic to normal human vaginal, ectocervical, and endocervical epithelial cells at spermicidal concentrations. We conclude that as potent anti-HIV agents with SIA and reduced cytotoxicity when compared with N-9, the phenyl-substituted and cyclohexenyl-substituted thiourea derivatives, especially compounds HI-253 (N-[2-(2-chlorophenethyl)]-N'-[2-(5-bromopyridyl)-thiourea), HI-346 (N-[2(5-bromopyridinyl)]-N'-[2-(1-cyclohexenyl)ethyl-thiourea), and HI-445 (N-[2-(5-chloropyridinyl)]-N'-[2-(1-cyclohexenyl)ethylthiourea) show unique clinical potential to become the active ingredients of a vaginal contraceptive for women who are at high risk for acquiring HIV by heterosexual vaginal transmission.
C1 Parker Hughes Inst, Drug Discovery Program, Dept Reprod Biol, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
   Parker Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Parker Hughes Inst, Drug Discovery Program, Dept Reprod Biol, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BABA M, 1992, ANTIVIR RES, V17, P245, DOI 10.1016/0166-3542(92)90021-V
   BACCETTI B, 1994, J CELL BIOL, V127, P903, DOI 10.1083/jcb.127.4.903
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CELUM CL, 1996, HIV MANUAL, P120
   CHANTLER E, 1992, BRIT J FAMIL PLANNIN, V17, P118
   Cook RL, 1998, SEX TRANSM DIS, V25, P144, DOI 10.1097/00007435-199803000-00007                                                
   COOKSON C, 1993, BRIT MED J, V307, P1375
   D'Cruz OJ, 1999, MOL HUM REPROD, V5, P421, DOI 10.1093/molehr/5.5.421                                                          
   D'Cruz OJ, 1999, BIOL REPROD, V60, P1419, DOI 10.1095/biolreprod60.6.1419                                                     
   D'Cruz OJ, 1998, MOL HUM REPROD, V4, P683
   D'Cruz OJ, 1999, BIOL REPROD, V60, P435, DOI 10.1095/biolreprod60.2.435
   D'Cruz OJ, 1998, BIOL REPROD, V58, P1515, DOI 10.1095/biolreprod58.6.1515                                                     
   D'Cruz OJ, 1998, BIOL REPROD, V59, P503, DOI 10.1095/biolreprod59.3.503                                                      
   D'Cruz OJ, 1999, CONTRACEPTION, V59, P319, DOI 10.1016/S0010-7824(99)00041-4
   D'Cruz OJ, 2000, BIOL REPROD, V62, P37, DOI 10.1095/biolreprod62.1.37                                                       
   Danel K, 1998, J MED CHEM, V41, P191, DOI 10.1021/jm970443m
   Danel K, 1996, J MED CHEM, V39, P2427, DOI 10.1021/jm9600499
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Heinisch G, 1997, ANTIVIR CHEM CHEMOTH, V8, P443, DOI 10.1177/095632029700800507                                                      
   Hira SK, 1997, INT J STD AIDS, V8, P243, DOI 10.1258/0956462971919994
   Hogberg M, 1999, J MED CHEM, V42, P4150, DOI 10.1021/jm990095j
   HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64                                                           
   Hsiou Y, 1998, J MOL BIOL, V284, P313, DOI 10.1006/jmbi.1998.2171
   Jan ST, 1999, ANTIVIR CHEM CHEMOTH, V10, P39, DOI 10.1177/095632029901000105                                                      
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477                                                          
   LANGE JMA, 1993, LANCET, V341, P1356
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   MANN J, 1995, INFECT DIS CLIN N AM, P275
   Mao C, 1998, BIOORG MED CHEM LETT, V8, P2213, DOI 10.1016/S0960-894X(98)00384-9                                                   
   MAO C, 2000, IN PRESS BIOCH PHARM
   MATI JKG, 1995, INT J GYNECOL OBSTET, V48, P61
   MCGROARTY JA, 1990, CURR MICROBIOL, V21, P219, DOI 10.1007/BF02092159
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010
   OSBORN JE, 1991, SEX INFORMATION ED C, V19, P1
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   Pontikis R, 1997, J MED CHEM, V40, P1845, DOI 10.1021/jm960765a
   POTTS M, 1994, AM J PUBLIC HEALTH, V84, P890, DOI 10.2105/AJPH.84.6.890                                                           
   Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541                                                                  
   Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X
   REKART ML, 1992, J ACQ IMMUN DEF SYND, V5, P425
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   RODDY RE, 1993, INT J STD AIDS, V4, P165, DOI 10.1177/095646249300400308                                                      
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   ROMERO DL, 1993, J MED CHEM, V36, P1505, DOI 10.1021/jm00062a027
   Rosenstein IJ, 1998, J INFECT DIS, V177, P1386, DOI 10.1086/517820                                                                  
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   Stafford MK, 1998, J ACQ IMMUN DEF SYND, V17, P327, DOI 10.1097/00042560-199804010-00006                                                
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TRYPHONAS L, 1984, TOXICOL LETT, V20, P289, DOI 10.1016/0378-4274(84)90162-0
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Uckun FM, 1999, BIOORG MED CHEM LETT, V9, P2721, DOI 10.1016/S0960-894X(99)00460-6
   Uckun FM, 1999, HUM REPROD UPDATE, V5, P506, DOI 10.1093/humupd/5.5.506                                                          
   Venkatachalam TK, 2000, ANTIVIR CHEM CHEMOTH, V11, P31, DOI 10.1177/095632020001100103                                                      
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   WEIR SS, 1995, GENITOURIN MED, V71, P78
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
   1980, FED REG, V45, P82014
   1997, HIV AIDS SURVEILLANC, V8, P1
NR 70
TC 45
Z9 46
U1 0
U2 1
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1603 MONROE ST, MADISON, WI 53711-2021 USA
SN 0006-3363
J9 BIOL REPROD
JI Biol. Reprod.
PD JUL
PY 2000
VL 63
IS 1
BP 196
EP 205
DI 10.1095/biolreprod63.1.196                                              
          
PG 10
WC Reproductive Biology
SC Reproductive Biology
GA 327UP
UT WOS:000087812400028
PM 10859260
OA gold
DA 2018-01-05
ER

PT J
AU Lucas, SW
   Harding, MM
AF Lucas, SW
   Harding, MM
TI Detection of DNA via an ion channel switch biosensor
SO ANALYTICAL BIOCHEMISTRY
LA English
DT Article
DE DNA detection; ion channel biosensor; oligonucleotide; gramicidin;
   hybridization; streptavidin-biotin
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEIC-ACID HYBRIDIZATION;
   OLIGONUCLEOTIDE PROBE; RESPIRATORY SPECIMENS; SIGNAL AMPLIFICATION;
   DETECTION SYSTEMS; PCR; RNA; TECHNOLOGY; SEQUENCES
AB Detection of DNA by an ion channel switch biosensor has been demonstrated in a model system, using single-stranded oligonucleotide sequences of 52-84 bases in length. Two different biotinylated probes are bound, via streptavidin, either to the outer region of a gramicidin ion channel dimer or to an immobilized membrane component. The ion channels are switched off upon detection of DNA containing complementary epitopes to these probes, separated by a nonbinding region, at nanomolar levels. The DNA cross-links the ion channel to the immobilized species, preventing ions passing through the channel. Addition of DNase I after the target DNA has been added switches the ion channels on. The DNA response is dependent on the rate of hybridization of the individual probes to their complementary epitopes, as shown by using a single probe against DNA containing a repeat of the complementary epitope. These results were correlated with hybridization rates determined using surface plasmon resonance (BLAcore 2000), and with free energies of dimer formation for the probes. (C) 2000 Academic Press.
C1 Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.
RP Harding, MM (reprint author), Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia.
OI Harding, Margaret/0000-0003-1072-3870
CR Bains W, 1998, ANAL BIOCHEM, V260, P252, DOI 10.1006/abio.1998.2669
   BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189
   Bassam BJ, 1996, AUSTRALAS BIOTECHNOL, V6, P285
   Boncheva M, 1999, LANGMUIR, V15, P4317, DOI 10.1021/la981702t                                                               
   BROOKS JL, 1992, INT J FOOD MICROBIOL, V16, P303, DOI 10.1016/0168-1605(92)90032-X
   Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610
   CHU BCF, 1985, DNA-J MOLEC CELL BIO, V4, P327
   Collins ML, 1997, NUCLEIC ACIDS RES, V25, P2979, DOI 10.1093/nar/25.15.2979
   Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432
   DiDomenico N, 1996, CLIN CHEM, V42, P1915
   Edman CF, 1997, NUCLEIC ACIDS RES, V25, P4907, DOI 10.1093/nar/25.24.4907
   EHLERS S, 1994, EUR J CLIN MICROBIOL, V13, P827, DOI 10.1007/BF02111344
   GUESDON JL, 1992, J IMMUNOL METHODS, V150, P33, DOI 10.1016/0022-1759(92)90063-Y                                                    
   Hall DR, 1996, ANAL BIOCHEM, V235, P175, DOI 10.1006/abio.1996.0109
   HINTON JF, 1988, P 21 JER S QUANT CHE, P203
   Hwang SJ, 1996, J VIROL METHODS, V62, P123, DOI 10.1016/S0166-0934(96)02093-9
   IWEN PC, 1995, J CLIN MICROBIOL, V33, P2587
   Jensen KK, 1997, BIOCHEMISTRY-US, V36, P5072, DOI 10.1021/bi9627525                                                               
   Keller G.H., 1993, DNA PROBES
   Lee H. H., 1997, NUCL ACID AMPLIFICAT
   LEE LG, 1993, NUCLEIC ACIDS RES, V21, P3761, DOI 10.1093/nar/21.16.3761
   LIVAK KJ, 1995, PCR METH APPL, V4, P357
   McCreery T, 1997, MOL BIOTECHNOL, V7, P121, DOI 10.1007/BF02761747                                                              
   Nazarenko IA, 1997, NUCLEIC ACIDS RES, V25, P2516, DOI 10.1093/nar/25.12.2516                                                          
   NELSON NC, 1990, CLIN CHIM ACTA, V194, P73, DOI 10.1016/0009-8981(90)90304-B                                                    
   Niemeyer CM, 1998, BIOCONJUGATE CHEM, V9, P168, DOI 10.1021/bc970170+
   NILSSON P, 1995, ANAL BIOCHEM, V224, P400, DOI 10.1006/abio.1995.1057
   OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167
   Pfyffer GE, 1996, J CLIN MICROBIOL, V34, P834
   SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980
   URDEA MS, 1994, BIO-TECHNOL, V12, P926, DOI 10.1038/nbt0994-926                                                             
   WALKER GT, 1992, NUCLEIC ACIDS RES, V20, P1691, DOI 10.1093/nar/20.7.1691
   Wang J, 1999, BIOELECTROCH BIOENER, V48, P477, DOI 10.1016/S0302-4598(99)00003-3                                                   
   Wang J, 1998, ANAL CHIM ACTA, V375, P197, DOI 10.1016/S0003-2670(98)00503-0                                                   
   Wang J, 1996, ANAL CHEM, V68, P2629, DOI 10.1021/ac9602433                                                               
   WANG RF, 1991, APPL ENVIRON MICROB, V57, P3666
   WETMUR JG, 1968, J MOL BIOL, V31, P349, DOI 10.1016/0022-2836(68)90414-2
   WRIGHT AC, 1992, J CLIN MICROBIOL, V30, P2302
   Yeghiazarian T, 1998, J CLIN MICROBIOL, V36, P2096
   Yershov G, 1996, P NATL ACAD SCI USA, V93, P4913, DOI 10.1073/pnas.93.10.4913
   Zhu ZR, 1997, CYTOMETRY, V28, P206
NR 41
TC 25
Z9 27
U1 0
U2 9
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0003-2697
J9 ANAL BIOCHEM
JI Anal. Biochem.
PD JUN 15
PY 2000
VL 282
IS 1
BP 70
EP 79
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
   Chemistry, Analytical
SC Biochemistry & Molecular Biology; Chemistry
GA 327DE
UT WOS:000087777300010
DA 2018-01-05
ER

PT J
AU Fischer, WB
   Forrest, LR
   Smith, GR
   Sansom, MSP
AF Fischer, WB
   Forrest, LR
   Smith, GR
   Sansom, MSP
TI Transmembrane domains of viral ion channel proteins: A molecular
   dynamics simulation study
SO BIOPOLYMERS
LA English
DT Article
DE molecular dynamics simulation; viral ion channel; transmembrane
   alpha-helix; alpha-helix propensity; lipid bilayer; hydrophobic
   mismatch; hydrogen bonding
ID IMMUNODEFICIENCY-VIRUS TYPE-1; INFLUENZA-B VIRUS; VPU PROTEIN;
   MEMBRANE-PROTEIN; HYDROPHOBIC MISMATCH; SECONDARY STRUCTURE; NB PROTEIN;
   C VIRUS; PREDICTION; AMANTADINE
AB Nanosecond molecular dynamics simulations in a fully solvated phospholipid bilayer have been performed on single transmembrane alpha-helices from three putative ion channel proteins encoded by viruses: NB (from influenza B), CM2 (from influenza C), and Vpu (from HIV-1). alpha-Helix stability is maintained within a core region of ca. 28 residues for each protein. Helix perturbations are due either to unfavourable interactions of hydrophobic residues with the lipid headgroups or to the need of the termini Of short helices to extend into the surrounding interfacial environment in order to form H-bonds. The requirement of both ends of a helix to form favourable interactions with lipid headgroups and/or water may also lead to tilting and/or kinking of a transmembrane alpha-helix.. Residues that are generally viewed as poor helix formers in aqueous solution (e.g., Gly, ne, Val) do riot destabilize helices, if located within a helix that spans a lipid bilayer. However, helix/bilayer mismatch such that a helix ends abruptly within the bilayer core destabilizes the end of the helix, Especially in the presence of Gly and Aln residues. Hydrogen bonding of polar side-chains with the peptide backbone and with one another occurs when such residues are present within the bilayer core, thus minimizing the energetic cost of burying such side-chains. (C) 2000 John Wiley & Sons, Inc.
C1 Univ Oxford, Dept Biochem, Mol Biophys Lab, Oxford OX1 3QU, England.
RP Fischer, WB (reprint author), Univ Oxford, Dept Biochem, Mol Biophys Lab, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.
OI Fischer, Wolfgang/0000-0001-7753-1828; Sansom, Mark/0000-0001-6360-7959
CR Betakova T, 1996, J GEN VIROL, V77, P2689, DOI 10.1099/0022-1317-77-11-2689
   Brassard DL, 1996, VIROLOGY, V220, P350, DOI 10.1006/viro.1996.0323
   Brunger A. T., 1992, XPLOR VERSION 3 1 SY
   Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220                                                   
   Chizhmakov I, 1998, BIOPHYS J, V74, pA319
   Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495                                                  
   Coady MJ, 1998, VIROLOGY, V244, P39, DOI 10.1006/viro.1998.9087                                                          
   CSERZO M, 1994, J MOL BIOL, V243, P388, DOI 10.1006/jmbi.1994.1666
   Daura X, 1998, J MOL BIOL, V280, P925, DOI 10.1006/jmbi.1998.1885
   de Planque MRR, 1998, BIOCHEMISTRY-US, V37, P9333, DOI 10.1021/bi980233r
   DEBER CM, 1995, BIOPOLYMERS, V37, P295, DOI 10.1002/bip.360370503
   Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69
   Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740
   DUFF KC, 1994, VIROLOGY, V202, P287, DOI 10.1006/viro.1994.1345
   DUFF KC, 1992, FEBS LETT, V311, P256, DOI 10.1016/0014-5793(92)81114-2
   Ewart GD, 1996, J VIROL, V70, P7108
   Forrest LR, 1999, BIOPHYS J, V76, P1886, DOI 10.1016/S0006-3495(99)77347-9                                                   
   FRIBORG J, 1995, J ACQ IMMUN DEF SYND, V8, P10
   HAY AJ, 1985, EMBO J, V4, P3021
   Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N
   Hongo S, 1997, J VIROL, V71, P2786
   Hongo S, 1999, J VIROL, V73, P46
   JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   KERR ID, 1994, BIOPHYS J, V67, P1501, DOI 10.1016/S0006-3495(94)80624-1                                                   
   Koshi JM, 1999, PROTEINS, V34, P333, DOI 10.1002/(SICI)1097-0134(19990215)34:3<333::AID-PROT6>3.0.CO;2-2
   Kovacs FA, 1999, BIOPHYS J, V76, pA126
   Kukol A, 1999, J MOL BIOL, V286, P951, DOI 10.1006/jmbi.1998.2512
   Lamb RA, 1997, VIROLOGY, V229, P1, DOI 10.1006/viro.1997.8451                                                          
   LI SC, 1992, FEBS LETT, V311, P217, DOI 10.1016/0014-5793(92)81106-V
   MALDARELLI F, 1993, J VIROL, V67, P5056
   MOURITSEN OG, 1993, ANNU REV BIOPH BIOM, V22, P145, DOI 10.1146/annurev.bb.22.060193.001045                                             
   Paul M, 1998, J VIROL, V72, P1270
   Pekosz A, 1997, VIROLOGY, V237, P439, DOI 10.1006/viro.1997.8788
   PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220
   PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I                                                    
   POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001
   Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824                                                          
   Sansom MSP, 1998, BIOESSAYS, V20, P992, DOI 10.1002/(SICI)1521-1878(199812)20:12<992::AID-BIES5>3.0.CO;2-7                  
   SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C
   SANSOM MSP, 1993, Q REV BIOPHYS, V26, P365, DOI 10.1017/S0033583500002833                                                       
   Sansom MSP, 1998, CURR OPIN STRUC BIOL, V8, P237, DOI 10.1016/S0959-440X(98)80045-6                                                   
   Schubert U, 1996, FEBS LETT, V398, P12, DOI 10.1016/S0014-5793(96)01146-5
   SCHUBERT U, 1994, J VIROL, V68, P2260
   Schubert U, 1996, J VIROL, V70, P809
   Shimbo K, 1996, BIOPHYS J, V70, P1335, DOI 10.1016/S0006-3495(96)79690-X                                                   
   Sunstrom NA, 1996, J MEMBRANE BIOL, V150, P127, DOI 10.1007/s002329900037
   Tieleman DP, 1999, BIOPHYS J, V76, P40, DOI 10.1016/S0006-3495(99)77176-6                                                   
   Tieleman DP, 1999, BIOPHYS J, V76, P1757
   UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0                                                                
   VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C
   WANG C, 1993, J VIROL, V67, P5585
   Webb RJ, 1998, BIOCHEMISTRY-US, V37, P673, DOI 10.1021/bi972441+                                                               
NR 53
TC 28
Z9 28
U1 0
U2 1
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0006-3525
J9 BIOPOLYMERS
JI Biopolymers
PD JUN
PY 2000
VL 53
IS 7
BP 529
EP 538
DI 10.1002/(SICI)1097-0282(200006)53:7<529::AID-BIP1>3.0.CO;2-6            
          
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 306FU
UT WOS:000086587300001
PM 10766949
DA 2018-01-05
ER

PT J
AU Burnouf, T
   Radosevich, M
AF Burnouf, T
   Radosevich, M
TI Reducing the risk of infection from plasma products: specific
   preventative strategies
SO BLOOD REVIEWS
LA English
DT Review
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; FACTOR-VIII
   CONCENTRATE; FACTOR-IX CONCENTRATE; INTRAVENOUS IMMUNE GLOBULIN;
   CREUTZFELDT-JAKOB-DISEASE; CLOTTING FACTOR CONCENTRATE; COLD ETHANOL
   FRACTIONATION; LABILE BLOOD DERIVATIVES; HUMAN PARVOVIRUS B19
AB Collection and testing procedures of blood and plasma that are designed to exclude donations contaminated by viruses provide a solid foundation for the safety of all blood products. Plasma units may be collected from a selected donor population, contributing to the exclusion of individuals at risk of carrying infectious agents. Each blood/plasma unit is individually screened to exclude donations positive for a direct (e.g. viral antigen) or an indirect (e.g. anti-viral antibodies) viral marker. As infectious donations, if collected from donors in the testing window period, can still be introduced into manufacturing plasma pools, the production of pooled plasma products requires a specific approach that integrates additional viral reduction procedures. Prior to the large-pool processing, samples of each donation for fractionation are pooled ('mini-pool') and subjected to a nucleic acid amplification test (NAT) by, for example, the polymerase chain reaction (PCR) to detect viral genomes tin Europe: HCV RNA plasma pool testing is now mandatory). Any individual donation found PCR positive is discarded before the industrial pooling. The pool of eligible plasma donations (which may be 2000 litres or more) may be subjected to additional viral screening tests, and then undergoes a series of processing and purification steps that, for each product, comprise one or several reduction treatments to exclude HIV, HBV, HCV and other viruses. Viral inactivation treatments most commonly used are solvent-detergent incubation and heat treatment in liquid phase (pasteurization). Nanofiltration (viral elimination by filtration), as well as specific forms of dry-heat treatments, have gained interest as additional viral reduction steps coupled with established methods. Viral reduction steps have specific advantages and limits that should be carefully balanced with the risks of loss of protein activity and enhancement of epitope immunogenicity. Due to the combination of these overlapping strategies, viral transmission events of HIV, HBV, and HCV by plasma products have become very rare. Nevertheless, the vulnerability of the plasma supply to new infectious agents requires continuous vigilance so that rational and appropriate scientific countermeasures against emerging infectious risks can be implemented promptly. (C) 2000 Harcourt Publishers Ltd.
C1 HPPS, F-59800 Lille, France.
RP Burnouf, T (reprint author), HPPS, 18 Rue St Jacques, F-59800 Lille, France.
CR *AD HOC WORK PART, 1991, NOT GUID CPMP GUID V, P11
   Allain JP, 1998, VOX SANG, V74, P125, DOI 10.1111/j.1423-0410.1998.tb05409.x                                              
   ALTER HJ, 1994, VOX SANG, V67, P19, DOI 10.1111/j.1423-0410.1994.tb04539.x                                              
   Aubin JT, 2000, VOX SANG, V78, P7, DOI 10.1159/000031142
   Barbara JAJ, 1998, TRANSFUS SCI, V19, P3, DOI 10.1016/S0955-3886(98)00003-4                                                   
   Barrett PN, 1997, TRANSFUSION, V37, P215, DOI 10.1046/j.1537-2995.1997.37297203527.x
   BARROWCLIFFE TW, 1993, DEV BIOL STAND, V81, P125
   Biesert L, 1996, J MED VIROL, V48, P360, DOI 10.1002/(SICI)1096-9071(199604)48:4<360::AID-JMV10>3.0.CO;2-F                   
   Bos OJM, 1998, BIOLOGICALS, V26, P267, DOI 10.1006/biol.1998.0148
   BRACKMANN HH, 1988, LANCET, P967
   Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563                                                        
   Brown P, 1999, TRANSFUSION, V39, P1169, DOI 10.1046/j.1537-2995.1999.39111169.x                                             
   Burnouf T, 1996, VOX SANG, V70, P235, DOI 10.1111/j.1423-0410.1996.tb01334.x                                              
   Burnouf T, 1998, J CHROMATOGR B, V715, P65, DOI 10.1016/S0378-4347(98)00052-8
   BURNOUF T, 1995, J CHROMATOGR B, V664, P3, DOI 10.1016/0378-4347(94)00532-A
   BURNOUF T, 1992, BIOLOGICALS, V20, P91, DOI 10.1016/S1045-1056(05)80056-9
   BURNOUF T, 1993, DEV BIOL STAND, V81, P199
   BURNOUF T, 2000, TRANSFUSION SANGUINE, P153
   BURNOUF T, 1994, ANIMAL CELL TECHNOLO, V6, P17
   BURNOUF T, 2000, TRANSF TODAY, P9
   BURNOUF T, 1989, C INSERM, V175, P53
   BURNOUF T, 1989, C INSERM BIOTECHNOLO, V175, P373
   BURNOUFRADOSEVICH M, 1992, INFUSIONSTHERAPIE, V19, P91
   BURNOUFRADOSEVICH M, 1994, VOX SANG, V67, P132, DOI 10.1111/j.1423-0410.1994.tb01647.x                                              
   *CDC, 1988, MMWR-MORBID MORTAL W, V37, P441
   Chamberland M, 1998, INFECT DIS CLIN N AM, V12, P217, DOI 10.1016/S0891-5520(05)70419-0                                                   
   Chamberland ME, 1999, THROMB HAEMOSTASIS, V82, P494
   Chandra S, 1999, TRANSFUSION, V39, P249, DOI 10.1046/j.1537-2995.1999.39399219280.x
   Chang WSW, 1997, THROMB HAEMOSTASIS, V77, P323
   Chen BP, 1999, BLOOD, V94, P4333
   Chin S, 1997, PHOTOCHEM PHOTOBIOL, V65, P432, DOI 10.1111/j.1751-1097.1997.tb08584.x
   CHIN S, 1995, BLOOD, V86, P4431
   Chudy M, 1999, J MED VIROL, V57, P91, DOI 10.1002/(SICI)1096-9071(199902)57:2<91::AID-JMV1>3.0.CO;2-L
   *COMM EUR COM AD H, 1995, CONTR PART 2 STRUCT
   *CPMP, 1998, NOT GUID PLASM DER M
   *CPMP, 1999, NOT GUID MIN RISK TR
   *CPMP, 1999, PLASM DER MED PROD P
   CUTHBERTSON B, 1991, BLOOD SEPARATION PLA, P385
   De Filippi F, 1998, TRANSFUSION, V38, P307
   DICHTELMULLER H, 1993, BIOLOGICALS, V21, P259, DOI 10.1006/biol.1993.1083
   DIETRICH SL, 1990, VOX SANG, V59, P129, DOI 10.1111/j.1423-0410.1990.tb00846.x                                              
   Dodd RY, 1998, TRANSFUSION, V38, P221, DOI 10.1046/j.1537-2995.1998.38398222863.x                                          
   DODD RY, 1995, HEMATOL ONCOL CLIN N, V9, P137
   Dodd RY, 1996, CLIN EXP IMMUNOL, V104, P31
   EPSTEIN JS, 1990, ARCH PATHOL LAB MED, V114, P335
   FELDMAN P, 1991, BLOOD SEPARATION PLA, P341
   FELDMAN P, 1998, PLANOVA WORKSH AS CH
   Flanagan P, 1999, TRANSFUS MED REV, V13, P164, DOI 10.1016/S0887-7963(99)80030-3
   Foster Peter R., 1994, P207
   Foster PR, 2000, VOX SANG, V78, P86, DOI 10.1159/000031156
   Foster PR, 2000, TRANSFUS SCI, V22, P53, DOI 10.1016/S0955-3886(00)00011-4
   GELLIS SS, 1948, J CLIN INVEST, V27, P239, DOI 10.1172/JCI101939                                                               
   GONZALEZ A, 1995, HEPATOLOGY, V22, P4439
   Goto K, 1999, PEDIATR RES, V45, P128, DOI 10.1203/00006450-199901000-00021
   GOUBRAN HA, IN PRESS HEMOPHILIA
   Goudemand J, 1998, THROMB HAEMOSTASIS, V80, P919
   GOUDEMAND J, COMMUNICATION
   GRANDGEORGE M, 1996, QUALITY SAFETY PLASM, P81
   HAMALAINEN E, 1992, VOX SANG, V63, P6
   HAMAMOTO Y, 1989, VOX SANG, V56, P230, DOI 10.1111/j.1423-0410.1989.tb02034.x                                              
   HEIMBURGER N, 1989, CURR STUD HEMATOL BL, V56, P23
   HENIN Y, 1988, VOX SANG, V54, P78, DOI 10.1111/j.1423-0410.1988.tb01621.x                                              
   Hilfenhaus J, 1997, TRANSFUSION, V37, P935, DOI 10.1046/j.1537-2995.1997.37997454021.x
   HILFENHAUS J, 1986, VOX SANG, V50, P208, DOI 10.1111/j.1423-0410.1986.tb04882.x                                              
   HOFFER L, 1995, J CHROMATOGR B, V669, P187, DOI 10.1016/0378-4347(95)00107-T
   HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x
   HOROWITZ B, 1993, DEV BIOL STAND, V81, P147
   Horowitz B, 1998, VOX SANG, V74, P203, DOI 10.1111/j.1423-0410.1998.tb05473.x                                              
   Horowitz B, 1995, Curr Opin Hematol, V2, P484
   HOROWITZ B, 1985, TRANSFUSION, V25, P523, DOI 10.1046/j.1537-2995.1985.25686071423.x
   Hsu HY, 1997, HEPATOLOGY, V26, P786, DOI 10.1002/hep.510260336
   IKEDA H, 1990, Artificial Organs, V14, P259
   Inoue K, 1999, J HEPATOL, V30, P801, DOI 10.1016/S0168-8278(99)80132-9                                                   
   Jarvis LM, 1996, LANCET, V348, P1352, DOI 10.1016/S0140-6736(96)04041-X
   JOHANNSEN R, 1999, COAGULATION MED 21 C
   Jongerius JM, 1998, TRANSFUSION, V38, P56, DOI 10.1046/j.1537-2995.1998.38198141499.x
   Josic D, 1999, VOX SANG, V77, P90, DOI 10.1159/000056726                                                               
   KALLENBACH NR, 1989, CURR STUD HEMATOL BL, V56, P23
   KERNOFF PBA, 1987, BRIT J HAEMATOL, V67, P207, DOI 10.1111/j.1365-2141.1987.tb02328.x                                              
   KITAYAPORN D, 1994, TRANSFUSION, V34, P152, DOI 10.1046/j.1537-2995.1994.34294143945.x
   KLEIM JP, 1990, THROMB HAEMOSTASIS, V64, P336
   Larzul D, 1999, Dev Biol Stand, V99, P139
   LAURIAN Y, 1994, NOUV REV FR HEMATOL, V36, P449
   Lawlor E, 1999, VOX SANG, V76, P138
   Lee HH, 1998, VOX SANG, V74, P119, DOI 10.1111/j.1423-0410.1998.tb05408.x                                              
   Lefrere JJ, 1999, J VIROL METHODS, V80, P33, DOI 10.1016/S0166-0934(99)00028-2                                                   
   LUDLAM CA, 1997, BLOOD COAGUL FIBRIN, V8, P19
   LYON DJ, 1989, LANCET, V1, P1085
   MACGREGOR I, 1999, THROMB HAEMOSTASIS, V82, P86
   MACLEOD AJ, 1984, RES DISCLOSURES, V244, P380
   MANNUCCI PM, 1988, BRIT J HAEMATOL, V68, P427, DOI 10.1111/j.1365-2141.1988.tb04230.x
   MANNUCCI PM, 1990, THROMB HAEMOSTASIS, V64, P232
   MANNUCCI PM, 1994, LANCET, V343, P597, DOI 10.1016/S0140-6736(94)91548-2                                                   
   MCDOUGAL JS, 1985, J CLIN INVEST, V76, P875, DOI 10.1172/JCI112045
   MCLEAN C, 1999, TRANSF MED, V9, P47
   MORE JE, 1991, BLOOD SEPARATION PLA, P261
   MORGENTHALER JJ, 1993, DEV BIOL STAND, V81, P185
   MORGENTHALER JJ, 1994, C INSERM, V227, P221
   Murozuka T, 1999, VOX SANG, V76, P181
   NG PK, 1985, THROMB RES, V39, P439, DOI 10.1016/0049-3848(85)90167-7                                                    
   NOWAK T, 1993, DEV BIOL STAND, V81, P169
   OGrady J, 1996, DEV BIOL STAND, V88, P319
   OVER J, 1998, PLANOVA WORKSH AS CH
   PATTISON CP, 1976, AM J EPIDEMIOL, V103, P398
   Peerlinck K, 1997, THROMB HAEMOSTASIS, V77, P80
   Pisani G, 1999, BRIT J HAEMATOL, V106, P431, DOI 10.1046/j.1365-2141.1999.01568.x
   POULLE M, 1994, BLOOD COAGUL FIBRIN, V5, P543
   PRINCE AM, 1983, REV INFECT DIS, V5, P92
   Prowse C, 1997, VOX SANG, V72, P1, DOI 10.1046/j.1423-0410.1997.00001.x                                                
   Radosevich M, 1998, SEMIN THROMB HEMOST, V24, P157, DOI 10.1055/s-2007-995835
   Radosevich M, 2000, HEMATOL ONCOL CLIN N, V14, P459, DOI 10.1016/S0889-8588(05)70145-3
   Raut S, 1998, THROMB HAEMOSTASIS, V80, P624
   Rogers PM, 1997, VOX SANG, V72, P199, DOI 10.1046/j.1423-0410.1997.7240199.x                                              
   Romisch J, 1996, BEITR INFUS, V33, P220
   Roth WK, 1999, LANCET, V353, P359, DOI 10.1016/S0140-6736(98)06318-1                                                   
   Rousell RH, 1991, BLOOD SEPARATION PLA, P307
   RUBINSTEIN AI, 1989, VOX SANG, V57, P272, DOI 10.1111/j.1423-0410.1989.tb00841.x                                              
   Saldanha J, 1999, VOX SANG, V76, P163
   Santagostino E, 1997, TRANSFUSION, V37, P517, DOI 10.1046/j.1537-2995.1997.37597293884.x
   Scheiblauer H, 1996, CLIN THER, V18, P59, DOI 10.1016/S0149-2918(96)80196-2
   Scheidler A, 1998, BIOLOGICALS, V26, P135, DOI 10.1006/biol.1998.0125
   Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601
   Schulman S, 1999, HAEMOPHILIA, V5, P96, DOI 10.1046/j.1365-2516.1999.00284.x
   Simmonds F, 1998, BLOOD REV, V12, P171
   Simmonds P, 1998, LANCET, V352, P191, DOI 10.1016/S0140-6736(98)03056-6
   SMITH JK, 1988, LANCET, V2, P814
   Soucie JM, 1998, TRANSFUSION, V38, P573, DOI 10.1046/j.1537-2995.1998.38698326337.x
   STEPHAN W, 1989, C INSERM, V175, P391
   STUCKI M, 1997, J CHROMATOGR B, V700, P141
   SUOMELA H, 1998, PLANOVA WORKSH AS CH
   Tabor E, 1999, TRANSFUSION, V39, P912, DOI 10.1046/j.1537-2995.1999.39080912.x                                             
   Tabor E, 1999, TRANSFUSION, V39, P1160, DOI 10.1046/j.1537-2995.1999.39111160.x                                             
   Takano S, 1996, HEPATOLOGY, V23, P708, DOI 10.1053/jhep.1996.v23.pm0008666321
   TATEISHI J, 1997, ISBT C FRANKF
   TATEISHI J, 1993, MEMBRANE, V18, P101
   Taylor DM, 2000, VET J, V159, P10, DOI 10.1053/tvjl.1999.0406
   Troccoli NM, 1998, BIOLOGICALS, V26, P321, DOI 10.1006/biol.1998.0164
   Turner ML, 1998, BLOOD REV, V12, P255, DOI 10.1016/S0268-960X(98)90007-8
   Uhle C, 1997, BRIT J HAEMATOL, V99, P837, DOI 10.1046/j.1365-2141.1997.4883292.x
   *US DEP HHS FDA, 1999, FDA DOC REV PREC MEA
   Vrielink H, 1998, Curr Opin Hematol, V5, P396, DOI 10.1097/00062752-199811000-00008
   Ways JP, 1999, BIOTECHNOL APPL BIOC, V30, P257
   WELLS MA, 1986, TRANSFUSION, V26, P210, DOI 10.1046/j.1537-2995.1986.26286152919.x
   Willkommen H, 1999, Dev Biol Stand, V99, P131
   WINKELMAN L, 1986, THROMB RES, V43, P219, DOI 10.1016/0049-3848(86)90063-0
   YAMAGUCHI K, 1989, J ELECTRON MICROSC, V38, P259
   Yap PL, 1998, VOX SANG, V74, P131, DOI 10.1111/j.1423-0410.1998.tb05410.x                                              
   YAP PL, 1997, INTRAVENOUS IMMUNOGL, P67
   Yee TT, 1996, BRIT J HAEMATOL, V93, P457, DOI 10.1046/j.1365-2141.1996.5161062.x                                              
   YU MW, 1995, LANCET, V345, P1173, DOI 10.1016/S0140-6736(95)91002-6                                                   
   1996, MMWR MORB MORTAL WKL, V45, P1
NR 151
TC 114
Z9 118
U1 0
U2 8
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0268-960X
J9 BLOOD REV
JI Blood Rev.
PD JUN
PY 2000
VL 14
IS 2
BP 94
EP 110
DI 10.1054/blre.2000.0129                                                  
          
PG 17
WC Hematology
SC Hematology
GA 344BU
UT WOS:000088738400003
PM 11012252
DA 2018-01-05
ER

PT J
AU Barin, F
AF Barin, F
TI Viruses and prions: update on blood safety
SO TRANSFUSION CLINIQUE ET BIOLOGIQUE
LA French
DT Article
DE prion; transfusion; virus
ID PREVALENCE; INFECTION; DONORS; AIDS
AB The blood borne viruses must be separated into major and minor agents. Major viruses transmissible by blood transfusion are human immunodeficiency virus (HIV) and hepatitis B and C viruses (respectively HBV, HCV). The prevalence of virological markers in French blood donors has been continuously decreasing since the implementation of serological screening methods as soon as they were available. In 1998, the prevalences (per 10,000 donations) were 0.17 for antibody to HIV, 0.08 for antibody to human T-cell leukemia virus (HTLV), 2.23 for hepatitis B surface antigen (HBs Ag) and 2.52 for antibody to HCV. The values are, of course, higher in new donors when compared to regular donors: approximately five-fold for HIV, 50-fold for HCV and 300-fold for HBs Ag. The remaining major questions concern the residual risk due to infectious donations which could escape the preventive measures. It seems evident that the major risk is imputable mainly to donations collected during the window period. During the 1996-1998 period, the residual risk for HIV was 1 our of 1,350,000 donations, 0 for HTLV, 1 out of 375,000 for HCV, and 1 out of 220,000 Jor HBV. A few cases of "immunosilent" patients have been reported. They remain exceptional. The first data col lected after the implementation of nucleic acid technology (NAT) confirm the very low residual risk. The recent introduction of leukodepletion probably brought an important contribution to diminishing the risk of transmission of leucotropic viruses such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesviruses-6, -7 and -8, and HTLV.
   If the purification process of plasma-derived medicinal products including inactivation procedures makes it possible to be confident with the elimination of infectivity due to enveloped viruses, the detection of nucleic acid sequences derived from naked viruses in plasma pools such as parvovirus B19 or hepatitis A virus (HAV), and/or the introduction of a nanofiltration step during the purification process, when possible, may greatly contribute to their safety.
   The emergence of a new form of the Creutzfeldt-Jakob disease (nvCJD) introduces a new series of questions about the safely of blood products that, although the risks appear limited, are not yet resolved. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
C1 Inst Natl Transfus Sanguine, Unite Virol Transfusionnelle, F-75015 Paris, France.
   CHU Bretonneau, Virol Lab, F-37044 Tours, France.
RP Barin, F (reprint author), Inst Natl Transfus Sanguine, Unite Virol Transfusionnelle, 6 Rue Alexandre-Cabanel, F-75015 Paris, France.
CR Alter HJ, 1996, NEW ENGL J MED, V334, P1536, DOI 10.1056/NEJM199606063342310                                                     
   Barin F, 2000, TRANSFUS CLIN BIOL, V7, P79, DOI 10.1016/S1246-7820(00)88715-7                                                   
   BOWDEN RA, 1995, BLOOD, V86, P3598
   Busch MP, 1997, APPL MOL BIOL BLOOD, P123
   COUROUCE AM, 1999, SPECTRA BIOL, V18, P38
   Deslys JP, 1999, BIOFUTUR, P34
   Jordan J, 1998, VOX SANG, V75, P97, DOI 10.1046/j.1423-0410.1998.7520097.x
   Kopko P, 1999, TRANSFUSION, V39, P383, DOI 10.1046/j.1537-2995.1999.39499235670.x                                          
   LASMEZAS CI, 1997, RECHERCHE, V299, P46
   PETERSON J, 2000, IN PRESS VOX SANG
   Pillonel J, 1998, TRANSFUS CLIN BIOL, V5, P305, DOI 10.1016/S1246-7820(98)85001-5
   PILLONEL J, 1998, EUROSURVEILLANCE, V3, P76
   Rapicetta M, 1999, VOX SANG, V76, P192, DOI 10.1159/000031049
   ROTH WK, 1999, LANCET, V353, P259
   Schuttler CG, 2000, LANCET, V355, P41, DOI 10.1016/S0140-6736(99)04719-4
   Sullivan PS, 1999, AIDS, V13, P89, DOI 10.1097/00002030-199901140-00012                                                
   TARDIVEL R, 1999, 3 C NAT SEC TRANSF H
NR 17
TC 9
Z9 10
U1 0
U2 1
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 1246-7820
J9 TRANSFUS CLIN BIOL
JI Transfu. Clin. Biol.
PD JUN
PY 2000
VL 7
SU 1
BP 5S
EP 10S
DI 10.1016/S1246-7820(00)80009-9
PG 6
WC Hematology; Immunology
SC Hematology; Immunology
GA 341DU
UT WOS:000088576400001
PM 10919217
DA 2018-01-05
ER

PT J
AU Corbett, JW
   Ko, SS
   Rodgers, JD
   Gearhart, LA
   Magnus, NA
   Bacheler, LT
   Diamond, S
   Jeffrey, S
   Klabe, RM
   Cordova, BC
   Garber, S
   Logue, K
   Trainor, GL
   Anderson, PS
   Erickson-Viitanen, SK
AF Corbett, JW
   Ko, SS
   Rodgers, JD
   Gearhart, LA
   Magnus, NA
   Bacheler, LT
   Diamond, S
   Jeffrey, S
   Klabe, RM
   Cordova, BC
   Garber, S
   Logue, K
   Trainor, GL
   Anderson, PS
   Erickson-Viitanen, SK
TI Inhibition of clinically relevant mutant variants of HIV-1 by
   quinazolinone non-nucleoside reverse transcriptase inhibitors
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; NONNUCLEOSIDE INHIBITORS; EFAVIRENZ
   SUSTIVA(TM); DIRECTED LITHIATION; INFECTION; ANALOGS; CYCLIZATION;
   RESISTANCE; SELECTION; TYPE-1
AB A series of 4-alkenyl and 4-alkynyl-3,4-dihydro-4-(trifluoromethyl)-2-(1H)-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type-1 (HIV-1). The 4-alkenyl-3,4-dihydro-4-(trifluoromethyl) quinazolinones DPC 082 and DPC 083 and the 4-alkynyl-3,4-dihydro-4-(trifluoromethyl) (LK)-quinazolinones DPC 961 and DPC 963 were found to exhibit low nanomolar potency toward wild-type RF virus (IC90 = 2.0, 2.1, 2.0, and 1.3 nM, respectively) and various single and many multiple amino acid substituted HIV-1 mutant viruses.-The increased potency is combined with favorable plasma serum protein binding as demonstrated by improvements in the percent free drug in human plasma when compared to efavirenz: 3.0%, 2.0%, 1.5% 2.8%, and 0.2- 0.5% for DPC 082, DPC 083, DPC 961, DPC 963, and efavirenz, respectively.
C1 Dupont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA.
RP Corbett, JW (reprint author), Dupont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA.
CR BACHELER L, 1998, 12 WORLD AIDS C GEN
   BACHELER LT, 1994, ANTIVIR CHEM CHEMOTH, V5, P111, DOI 10.1177/095632029400500208                                                      
   Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064                                                          
   BACHELER LT, 1999, 39 INT C ANT AG CHEM
   BACHELER LT, 1999, 37 ANN M INF DES SOC
   BEAVER DJ, 1963, J MED CHEM, V6, P501, DOI 10.1021/jm00341a006
   BOGER DL, 1987, J ORG CHEM, V52, P1521, DOI 10.1021/jo00384a026
   Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78                                                           
   CLARK RD, 1982, J ORG CHEM, V47, P2804, DOI 10.1021/jo00135a031                                                             
   Corbett JW, 1999, ANTIMICROB AGENTS CH, V43, P2893
   CORBETT JW, 1998, 4 INT C DRUG THER HI
   EKHATO IV, 1994, J LABELLED COMPD RAD, V34, P505, DOI 10.1002/jlcr.2580340603
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Havlir DV, 1996, J VIROL, V70, P7894
   HIRSCH MS, 1998, AIDS, V12, P6
   HOUPIS IN, 1994, TETRAHEDRON LETT, V35, P6811, DOI 10.1016/0040-4039(94)85011-9
   Kahn JO, 1998, NEW ENGL J MED, V339, P33, DOI 10.1056/NEJM199807023390107
   KELLY TA, 1994, TETRAHEDRON LETT, V35, P9003, DOI 10.1016/0040-4039(94)88411-0                                                    
   Kleim JP, 1997, VIROLOGY, V231, P112, DOI 10.1006/viro.1997.8513
   KO SS, UNPUB SYNTHESIS BIOL
   LEVY JA, 1993, MICROBIOL REV, V57, P183
   MORALESRAMIREZ J, 1998, 38 INT C ANT AG CHEM
   Patel M, 1999, BIOORG MED CHEM LETT, V9, P3221, DOI 10.1016/S0960-894X(99)00565-X
   Patel M, 1999, BIOORG MED CHEM LETT, V9, P2805, DOI 10.1016/S0960-894X(99)00486-2
   SMALLHEER JM, 1993, ANTIVIR CHEM CHEMOTH, V4, P27, DOI 10.1177/095632029300400104                                                      
   Stanetty P, 1996, J ORG CHEM, V61, P5130, DOI 10.1021/jo960203z                                                               
   TUCKER TJ, 1994, J MED CHEM, V37, P2437, DOI 10.1021/jm00041a023
   Winslow DL, 1996, AIDS, V10, P1205, DOI 10.1097/00002030-199609000-00005                                                
NR 28
TC 193
Z9 196
U1 0
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 18
PY 2000
VL 43
IS 10
BP 2019
EP 2030
DI 10.1021/jm990580e                                                       
          
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 317KE
UT WOS:000087223900012
PM 10821714
DA 2018-01-05
ER

PT J
AU Aoki, S
   Kimura, E
AF Aoki, S
   Kimura, E
TI Highly selective recognition of thymidine mono- and diphosphate
   nucleotides in aqueous solution by ditopic receptors
   zinc(II)-bis(cyclen) complexes (cyclen 1,4,7,10-tetraazacyclododecane)
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; MACROCYCLIC POLYAMINE COMPLEXES; ZINC(II)
   COMPLEX; MOLECULAR RECOGNITION; METAL-COMPLEXES; LIQUID MEMBRANE;
   NEUTRAL PH; ANION RECEPTORS; TRANSPORT; PHOSPHATE
AB Highly selective and efficient recognition of thymidine and uridine nucleotides such as 3'-dTMP (thymidine 3'-monophosphate), 5'-dTMP (thymidine 5'-monophosphate), 2'-UMP (uridine 2'-monophosphate), 3'-UMP (uridine 3'-monophosphate), 5'-UMP (uridine 5'-monophosphate), 5'-dTDP (thymidine 5'-diphosphate), 5'-dTTP (thymidine 5'-triphosphate), AZTMP (3'-azido-3'-deoxythymidine 5'-monophosphate), and AZTDP (3'-azido-3'-deoxythymidine 5'-diphosphate) with ditopic dimeric zinc(II) complexes of macrocyclic 12-membered tetramines. meta- and para-xylyl-bis(Zn2+-cyclen)s (Zn2L4 and Zn2L5) (cyclen = 1,4,7,10-tetraazacyclododecane) has been studied by potentiometric pH titration, isothermal titration calorimetry, UV spectrophotometric titration, and NMR titration. The apparent 1:1 complexation constants for 5'-dTMP, K-app ( = [(Zn2L)-(S--OPO32-)]/[Zn2L](free)[S-OPO32-](free) (M-1)), where S- denotes the imide-deprotonated thymine part), with Zn2L4 or Zn2L5 determined by potentiometric pH titration showed a more stable complex with Zn2L5 (log K-app = 6.4) than with Zn2L4 (log K-app = 5.5) at pH 7.6 with I = 0.1 (NaNO3) and 25 degrees C. These values are mu ch greater than log K-app (K-app = [ZnL3 - dT(-)]/[ZnL3](free)[dT](free) (M-1)) Of 3.2 for a nucleoside thymidine (dT) complex with a monomeric Zn2+-benzylcyclen (ZnL3). The 1:1 complexation was confirmed by the FAB mass spectroscopic data for Zn2L with 3'- and 5'-dTMP. The combined data from the spectrophotometric UV titration and H-1 NMR measurements of 5'-dThlP and 5'-dTDP with Zn2L5 in D2O at pD 7.8 and 35 degrees C indicated that the terminal phosphate dianion interacted with one of the (Zn2+-cyclen)s and the imide anion of dT bound to the other Zn2+-cyclen.
C1 Hiroshima Univ, Fac Med, Dept Med Chem, Minami Ku, Hiroshima 7348551, Japan.
RP Kimura, E (reprint author), Hiroshima Univ, Fac Med, Dept Med Chem, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.
CR AGUILAR JA, 1995, J CHEM SOC CHEM COMM, P2237, DOI 10.1039/C39950002237                                                            
   Antonisse M. M. G., 1998, J CHEM SOC CHEM COMM, P443
   Aoki S, 1998, J AM CHEM SOC, V120, P10018, DOI 10.1021/ja9810888                                                               
   Aoki S, 1998, J AM CHEM SOC, V120, P10094, DOI 10.1021/ja981788c                                                               
   Bazzicalupi C, 1999, J AM CHEM SOC, V121, P6807, DOI 10.1021/ja983947y                                                               
   BENCINI A, 1997, J CHEM SOC P2, P775
   Berger M, 1999, J AM CHEM SOC, V121, P9986, DOI 10.1021/ja992028k                                                               
   Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887                                                         
   Bridger GJ, 1999, J MED CHEM, V42, P3971, DOI 10.1021/jm990211i                                                               
   Chrisstoffels LAJ, 1999, J AM CHEM SOC, V121, P10142, DOI 10.1021/ja991588g                                                               
   CUDIC P, 1995, J CHEM SOC CHEM COMM, P1073, DOI 10.1039/c39950001073
   DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286                                                         
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   DESLONGCHAMPS G, 1992, ANGEW CHEM INT EDIT, V31, P61, DOI 10.1002/anie.199200611
   FOX JJ, 1963, J ORG CHEM, V28, P936, DOI 10.1021/jo01039a014                                                             
   FREIRE E, 1990, ANAL CHEM, V62, pA950, DOI 10.1021/ac00217a002
   Fujioka H, 1996, HETEROCYCLES, V42, P775
   FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333
   GOSSELIN G, 1994, B I PASTEUR, V92, P181
   HORWITZ JP, 1964, J ORG CHEM, V29, P2076, DOI 10.1021/jo01030a546                                                             
   HORWITZ JP, 1962, J ORG CHEM, V27, P3300, DOI 10.1021/jo01056a502                                                             
   HOSSEINI MW, 1990, J AM CHEM SOC, V112, P3896, DOI 10.1021/ja00166a025
   HURYN DM, 1992, CHEM REV, V92, P1745, DOI 10.1021/cr00016a004                                                             
   INOUYE Y, 1995, ANTIVIR CHEM CHEMOTH, V6, P337, DOI 10.1177/095632029500600508                                                      
   INOUYE Y, 1994, BIOL PHARM BULL, V17, P243
   Inouye Y, 1996, BIOL PHARM BULL, V19, P456
   Iverson BL, 1996, J AM CHEM SOC, V118, P1608, DOI 10.1021/ja952961x                                                               
   KATO Y, 1994, J AM CHEM SOC, V116, P3279, DOI 10.1021/ja00087a013
   Kikuta E, 1999, J BIOL INORG CHEM, V4, P431, DOI 10.1007/s007750050329
   KIKUTA E, 1999, J AM CHEM SOC, V120, P5126
   Kimura E, 1997, PURE APPL CHEM, V69, P2187, DOI 10.1351/pac199769102187                                                         
   KIMURA E, 1982, J AM CHEM SOC, V104, P3182, DOI 10.1021/ja00375a042                                                             
   KIMURA E, 1990, J ORG CHEM, V55, P42, DOI 10.1021/jo00288a009
   Kimura E, 1997, J AM CHEM SOC, V119, P3068, DOI 10.1021/ja9640408                                                               
   Kimura E, 1999, CHEM-EUR J, V5, P3113, DOI 10.1002/(SICI)1521-3765(19991105)5:11<3113::AID-CHEM3113>3.0.CO;2-L             
   Kimura E, 1999, PERSP BIOIN, V4, P145
   KIMURA E, 1983, CHEM PHARM BULL, V31, P3264
   KIMURA E, 1985, CHEM PHARM BULL, V33, P655
   Kimura E, 1998, J BIOL INORG CHEM, V3, P259, DOI 10.1007/s007750050230                                                           
   Kimura E, 1996, MET IONS BIOL SYST, V33, P29
   Kimura E, 1996, J AM CHEM SOC, V118, P10963, DOI 10.1021/ja961789+                                                               
   KIMURA E, 1998, J CHEM SOC CHEM COMM, P1495
   KIMURA E, 1994, TRANSITION METALS SU, P245
   KIMURA E, 1999, BIOINORGANIC CATALYS, P33
   KNEELAND DM, 1993, J AM CHEM SOC, V115, P10042, DOI 10.1021/ja00075a021
   Koike T, 1996, CHEM-EUR J, V2, P617, DOI 10.1002/chem.19960020604                                                        
   KOIKE T, 1991, J AM CHEM SOC, V113, P8935, DOI 10.1021/ja00023a048
   KOIKE T, 1995, J AM CHEM SOC, V117, P1210, DOI 10.1021/ja00109a004                                                             
   Koike T, 1998, INORG CHIM ACTA, V270, P424, DOI 10.1016/S0020-1693(97)05998-7                                                   
   KOVACS T, 1988, TETRAHEDRON LETT, V29, P4525, DOI 10.1016/S0040-4039(00)80537-7
   Kral V, 1996, J AM CHEM SOC, V118, P1595, DOI 10.1021/ja9529605                                                               
   KRAL V, 1995, J CHEM SOC CHEM COMM, P2349
   KRAL V, 1992, J AM CHEM SOC, V114, P8704, DOI 10.1021/ja00048a056                                                             
   Lehn J., 1995, SUPRAMOLECULAR CHEM
   LI TY, 1993, J ORG CHEM, V58, P380, DOI 10.1021/jo00054a021
   LI TY, 1992, J ORG CHEM, V57, P3449, DOI 10.1021/jo00038a039
   LIAN LY, 1993, NMR MACROMOLECULES P, P153
   LIN TS, 1978, J MED CHEM, V21, P109, DOI 10.1021/jm00199a020
   Magnani M, 1996, P NATL ACAD SCI USA, V93, P4403, DOI 10.1073/pnas.93.9.4403
   Martell A.E., 1992, DETERMINATION USE ST
   Martell A. E., 1996, METAL COMPLEXES AQUE
   Martin J. C, 1989, NUCLEOTIDE ANALOGUES
   MERIGAN TCJ, 1999, TXB AIDS MED
   Niikura K, 1998, J AM CHEM SOC, V120, P8533, DOI 10.1021/ja980990c                                                               
   ODASHIMA K, 1997, ADV SUPR CH, V4, P211
   Odashima K., 1996, COMPREHENSIVE SUPRAM, V2, P143
   RICHMAN DD, 1987, J EXP MED, V166, P1144, DOI 10.1084/jem.166.4.1144
   Sakthivel K, 1998, ANGEW CHEM INT EDIT, V37, P2872, DOI 10.1002/(SICI)1521-3773(19981102)37:20<2872::AID-ANIE2872>3.3.CO;2-X
   Schmidtchen FP, 1997, CHEM REV, V97, P1609, DOI 10.1021/cr9603845                                                               
   Sessler JL, 1993, SUPRAMOL CHEM, V1, P209, DOI 10.1080/10610279308035164
   SHIONOYA M, 1994, J AM CHEM SOC, V116, P3848, DOI 10.1021/ja00088a021
   SHIONOYA M, 1993, J AM CHEM SOC, V115, P6730, DOI 10.1021/ja00068a033
   SHIONOYA M, 1994, J CHEM SOC CHEM COMM, P1747, DOI 10.1039/c39940001747                                                            
   SHIONOYA M, 1993, SUPRAMOL CHEM, V2, P173
   TABUSHI I, 1980, J AM CHEM SOC, V102, P1744, DOI 10.1021/ja00525a056
   TABUSHI I, 1981, J AM CHEM SOC, V103, P6152, DOI 10.1021/ja00410a029
   Teulade-Fichou MP, 1996, J CHEM SOC PERK T 2, P2169, DOI 10.1039/p29960002169                                                            
   WADSO I, 1997, CHEM SOC REV, P79
   Wong CH, 1998, J AM CHEM SOC, V120, P8319, DOI 10.1021/ja980826p                                                               
   ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748
NR 80
TC 114
Z9 116
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD MAY 17
PY 2000
VL 122
IS 19
BP 4542
EP 4548
DI 10.1021/ja994537s                                                       
          
PG 7
WC Chemistry, Multidisciplinary
SC Chemistry
GA 315MT
UT WOS:000087118100002
DA 2018-01-05
ER

PT J
AU Artico, M
   Silvestri, R
   Pagnozzi, E
   Bruno, B
   Novellino, E
   Greco, G
   Massa, S
   Ettorre, A
   Loi, AG
   Scintu, F
   La Colla, P
AF Artico, M
   Silvestri, R
   Pagnozzi, E
   Bruno, B
   Novellino, E
   Greco, G
   Massa, S
   Ettorre, A
   Loi, AG
   Scintu, F
   La Colla, P
TI Structure-based design, synthesis, and biological evaluation of navel
   pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase
   inhibitors active at nanomolar concentrations
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
AB Pyrrolyl aryl sulfones (PASs) have been recently reported as a new class of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) inhibitors acting at the non-nucleosicie binding site of this enzyme (Artico, M.; et al. J. Med. Chem. 1996, 39, 522-530). Compound 3, the most patent inhibitor within the series (EC50 = 0.14 mu M, IC50 = 0.4 mu M, and SI > 1429), was then selected as a lead compound for a synthetic project based on molecular modeling studies. Using the three-dimensional structure of RT cocrystallized with the alpha-APA derivative R95845, we derived a model of the RT/3 complex by taking into account previously developed structure-activity relationships. Inspection of this model and docking calculations on virtual compounds prompted the design of novel PAS derivatives and related analogues. Our computational approach proved to be effective in making qualitative predictions, that is in discriminating active versus inactive compounds. Among the compounds synthesized and tested, 20 was the most active one, with EC50 = 0.045 mu M, IC50 = 0.05 mu M, and SI = 5333. Compared with the lead 3, these values represent a 3- and 8-fold improvement in the cell-based and enzyme assays, respectively, together with the highest selectivity achieved so far in the PAS series.
C1 Univ Rome La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur Fdn Cenci Bolognetti, I-00185 Rome, Italy.
   Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy.
   Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
   Menarini Ric SpA, I-00040 Pomezia, Roma, Italy.
   Univ Cagliari, Sez Microbiol, Dipartimento Biol Sperimentale, I-09042 Cagliari, Italy.
RP Artico, M (reprint author), Univ Rome La Sapienza, Dipartimento Studi Farmaceut, Ist Pasteur Fdn Cenci Bolognetti, P A Moro 5,BOX 36,ROMA 62, I-00185 Rome, Italy.
RI La Colla , Paolo /B-8587-2011
OI Silvestri, Romano/0000-0003-2489-0178; Novellino,
   Ettore/0000-0002-2181-2142
CR ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249                                                       
   ARTICO M, 1995, ARCH PHARM, V328, P223, DOI 10.1002/ardp.19953280304
   Artico M, 1996, J MED CHEM, V39, P522, DOI 10.1021/jm950568w
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2                                                    
   HEAD JD, 1985, CHEM PHYS LETT, V122, P264, DOI 10.1016/0009-2614(85)80574-1
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   KRYSTEK SR, 1995, J MED CHEM, V38, P659, DOI 10.1021/jm00004a012
   MCMAHON JB, 1993, ANTIMICROB AGENTS CH, V37, P754, DOI 10.1128/AAC.37.4.754                                                            
   *MOL STRUCT CORP, 1989, TEXAN TEXRAY SINGL C
   PURCELL WP, 1967, J CHEM ENG DATA, V12, P235, DOI 10.1021/je60033a020                                                             
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   [Anonymous], SYBYL MOL MOD SYST V
   WILLIAMS TM, 1993, J MED CHEM, V36, P1291, DOI 10.1021/jm00061a022
NR 17
TC 76
Z9 79
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 4
PY 2000
VL 43
IS 9
BP 1886
EP 1891
DI 10.1021/jm9901125
PG 6
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 312XN
UT WOS:000086969400025
PM 10794705
DA 2018-01-05
ER

PT J
AU Cauchetier, E
   Paul, M
   Rivollet, D
   Fessi, H
   Astier, A
   Deniau, M
AF Cauchetier, E
   Paul, M
   Rivollet, D
   Fessi, H
   Astier, A
   Deniau, M
TI Therapeutic evaluation of free and liposome-encapsulated atovaquone in
   the treatment of murine leishmaniasis
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE atovaquone; effective doses; Leishmania infantum; liposomes; mouse model
ID VISCERAL LEISHMANIASIS; AMPHOTERICIN-B; LOADED NANOCAPSULES;
   HIV-INFECTION; NANOPARTICLES; DONOVANI; INFANTUM; MODEL; MICE;
   FORMULATION
AB The use of drug delivery systems may reduce the toxicity and improve the activity of anti-leishmanial compounds. The activity of atovaquone (ATV)-loaded liposomes was compared by determination of median effective doses (ED25 and ED50), with that of free ATV in a murine model of Visceral leishmaniasis induced by Leishmania infantum. On day 0, mice were infected intravenously with 4.10(7) promastigotes and treated via the tail vein on days 15, 17 and 19 by free drug in a DMSO/cremophor/water solution (0.2 to 1.6 mg/kg body weight) or by liposomal drug (0.04 to 0.32 mg/kg body weight). Mice were killed and livers and spleens were removed and weighed on day 21 p,i, and liver parasite burdens evaluated using the Stauber method. Effective doses were determined using the Hill representation relating the percentage of parasite suppression to the dose. Liposomal ATV was significantly more effective than the free drug in reducing liver parasites (61.6% of parasite suppression at a dose of 0.32 mg/kg vs 34.9% at a dose of 1.6mg/kg). Liposomal ATV was 23 times more active than the free drug (ED25 value = 0.02 +/- 0.01 mg/kg vs 0.46 +/- 0.15 mg/kg for free drug). It was not possible to obtain the ED5o for free ATV because the dose-response curve reached a plateau around 33% of parasite suppression. Conversely, the ED50 for liposomal ATV was 0.17 +/- 0.05 mg/kg. 100% efficacy of bound ATV could be obtained with a concentration of 1.77 +/- 0.35 mg/kg. A significant decrease in spleen weights was also observed reflecting a leishmanicidal activity of ATV. These results suggest that liposome loaded ATV is more efficacious than the free drug against Leishmania infantum in this murine model. (C) 2000 Australian Society for Parasitology Inc. Published by Elsevier Science Ltd. All rights reserved.
C1 CHU Henri Mondor, Serv Pharm, Lab Pharmacotech, AP HP, F-94010 Creteil, France.
   Univ Paris 12, Hop Henri Mondor, Parasitol Lab, AP HP, F-94010 Creteil, France.
   Univ Lyon 1, Fac Pharm Claude Bernard, F-69365 Lyon, France.
   Univ Nancy 1, Fac Pharm, EA 2399, F-54013 Nancy, France.
RP Cauchetier, E (reprint author), 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.
CR ALVING C R, 1986, Parasitology Today, V2, P101, DOI 10.1016/0169-4758(86)90039-6
   ALVING CR, 1983, PHARMACOL THERAPEUT, V22, P407, DOI 10.1016/0163-7258(83)90010-4
   BERMAN JD, 1986, AM J TROP MED HYG, V35, P297, DOI 10.4269/ajtmh.1986.35.297                                                       
   BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P119
   Bryceson A., 1987, The leishmaniases in biology and medicine. Volume II. Clinical aspects and control, P847
   CABIE A, 1992, PRESSE MED, V21, P1658
   CARTER KC, 1989, J PHARM PHARMACOL, V41, P87, DOI 10.1111/j.2042-7158.1989.tb06399.x                                              
   Cauchetier E, 1999, DRUG DEVELOP RES, V47, P155, DOI 10.1002/(SICI)1098-2299(199908)47:4<155::AID-DDR1>3.3.CO;2-W
   *CIOMS, 1985, GUID PRINC BIOM RES
   CROFT SL, 1991, J ANTIMICROB CHEMOTH, V28, P111, DOI 10.1093/jac/28.suppl_B.111                                                      
   CROFT SL, 1992, J ANTIMICROB CHEMOTH, V30, P827, DOI 10.1093/jac/30.6.827
   Dalencon F, 1997, INT J PHARM, V153, P127, DOI 10.1016/S0378-5173(97)00076-8                                                   
   DAVIDSON RN, 1994, Q J MED, V87, P75
   DEDET JP, 1995, PRESSE MED, V24, P1036
   Durand R, 1997, PARASITE, V4, P331, DOI 10.1051/parasite/1997044331                                                     
   Durand R, 1997, INT J PARASITOL, V27, P1361, DOI 10.1016/S0020-7519(97)00124-0
   Fusai T, 1995, Med Trop (Mars), V55, P73
   GASPAR R, 1992, ANN TROP MED PARASIT, V86, P41, DOI 10.1080/00034983.1992.11812629                                                  
   JERNIGAN JA, 1993, 33 INT C ANT AG CHEM, P257
   KIRSH R, 1987, ANN NY ACAD SCI, P141
   Murray HW, 1996, ANTIMICROB AGENTS CH, V40, P586
   NEW RRC, 1983, BIOL CELL, V47, P59
   Paul M, 1997, ANTIMICROB AGENTS CH, V41, P1731
   RODRIGUES JM, 1994, TROP MED PARASITOL, V45, P223
   Sordet F, 1998, PARASITE, V5, P223, DOI 10.1051/parasite/1998053223                                                     
   STAUBER LA, 1958, J PROTOZOOL, V5, P269, DOI 10.1111/j.1550-7408.1958.tb02565.x                                              
   VENIERJULIENNE MC, 1995, J DRUG TARGET, V3, P23, DOI 10.3109/10611869509015929
NR 27
TC 28
Z9 30
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD MAY
PY 2000
VL 30
IS 6
BP 777
EP 783
DI 10.1016/S0020-7519(00)00053-9
PG 7
WC Parasitology
SC Parasitology
GA 325EX
UT WOS:000087664300013
PM 10856513
DA 2018-01-05
ER

PT J
AU De Clercq, E
AF De Clercq, E
TI Inhibition of HIV infection by bicyclams, highly potent and specific
   CXCR4 antagonists
SO MOLECULAR PHARMACOLOGY
LA English
DT Review
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTOR CXCR4;
   PHENYLENEBIS(METHYLENE)-LINKED BIS-TETRAAZAMACROCYCLES; SMALL-MOLECULE
   INHIBITOR; CELL FUSION; SELECTIVE-INHIBITION; DERIVATIVE JM3100; FACTOR
   1-ALPHA; TYPE-1 ENTRY; IN-VIVO
AB The bicyclams represent a new entity of low-molecular weight molecules that inhibit human immunodeficiency virus (HIV) infection through a specific blockade of CXCR4 (fusin), the receptor for the CXC chemokine SDF-1 (soluble-derived factor), which is also used as coreceptor by T-lymphotropic HIV strains to enter their target cells. The bicyclam AMD3100 or 1,1'-[1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate, is able to block the CXCR4 receptor and to inhibit HIV replication at nanomolar concentrations while not being toxic to the host cells at 100,000-fold higher concentrations. It is the most specific and most potent CXCR4 antagonist that has been described to date.
C1 Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Div Virol & Chemotherapy, B-3000 Louvain, Belgium.
RP De Clercq, E (reprint author), Katholieke Univ Leuven, Rega Inst Med Res, Dept Microbiol & Immunol, Div Virol & Chemotherapy, Minderbroedersstr 10, B-3000 Louvain, Belgium.
CR Arakaki R, 1999, J VIROL, V73, P1719
   Berson JF, 1996, J VIROL, V70, P6288
   Blanco J, 2000, ANTIMICROB AGENTS CH, V44, P51, DOI 10.1128/AAC.44.1.51-56.2000                                                     
   Bridger GJ, 1996, J MED CHEM, V39, P109, DOI 10.1021/jm950584t
   Bridger GJ, 1999, J MED CHEM, V42, P3971, DOI 10.1021/jm990211i                                                               
   BRIDGER GJ, 1995, J MED CHEM, V38, P366, DOI 10.1021/jm00002a019
   Cammack N, 1999, ANTIVIR CHEM CHEMOTH, V10, P53, DOI 10.1177/095632029901000201                                                      
   Daelemans D, 2000, MOL PHARMACOL, V57, P116
   Datema R, 1996, ANTIMICROB AGENTS CH, V40, P750
   DE CLERCQ E, 1994, ANTIMICROB AGENTS CH, V38, P668, DOI 10.1128/AAC.38.4.668                                                            
   Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941
   DECLERCO E, 1992, P NATL ACAD SCI USA, V89, P5286, DOI 10.1073/pnas.89.12.5286                                                         
   DECLERCQ E, 1992, INT J IMMUNOTHER, V8, P115
   DECLERCQ E, 1995, CLIN MICROBIOL REV, V8, P200
   Dessolin J, 1999, J MED CHEM, V42, P229, DOI 10.1021/jm980358u                                                               
   DeVreese K, 1997, ANTIMICROB AGENTS CH, V41, P2616
   DeVreese K, 1996, ANTIVIR RES, V29, P209, DOI 10.1016/0166-3542(95)00837-3
   DeVreese K, 1996, J VIROL, V70, P689
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395
   Egberink HF, 1999, J VIROL, V73, P6346
   Este JA, 1996, ANTIVIR RES, V29, P297, DOI 10.1016/0166-3542(95)00936-1
   Este JA, 1999, MOL PHARMACOL, V55, P67
   Este JA, 1999, J VIROL, V73, P5577
   HENDRIX C, 1999, 6 C RET OPP INF 1999
   Howard OMZ, 1998, J MED CHEM, V41, P2184, DOI 10.1021/jm9801253                                                               
   JOAO HC, 1995, J MED CHEM, V38, P3865, DOI 10.1021/jm00019a017
   Labrosse B, 1998, J VIROL, V72, P6381
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706                                                     
   Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389
   Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451
   Schober A, 1997, MICROSYST TECHNOL, V4, P35, DOI 10.1007/s005420050089
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Schols D, 1998, J VIROL, V72, P4032
   Schols D, 1998, J GEN VIROL, V79, P2203, DOI 10.1099/0022-1317-79-9-2203                                                     
   Simmons G, 1998, J VIROL, V72, P8453
   Tamamura H, 1998, BIOORGAN MED CHEM, V6, P231, DOI 10.1016/S0968-0896(97)10037-2                                                   
   Yi YJ, 1999, J VIROL, V73, P7117
   Zhang YJ, 1999, J VIROL, V73, P3443
NR 39
TC 98
Z9 98
U1 0
U2 10
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD MAY
PY 2000
VL 57
IS 5
BP 833
EP 839
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 309HH
UT WOS:000086762100001
PM 10779364
DA 2018-01-05
ER

PT J
AU Delibrias, CC
   Fischer, EM
   Kazatchkine, MD
AF Delibrias, CC
   Fischer, EM
   Kazatchkine, MD
TI The enhancing role of complement in human immunodeficiency virus
   infection: Soluble recombinant CR1 (CD35) inhibits complement-mediated
   enhancement of infection of a CD4-positive T-cell line with human
   immunodeficiency virus-1
SO SCANDINAVIAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CLASSICAL PATHWAY; TYPE-1 INFECTION; OPSONIZED HIV; LYMPHOCYTES-T; CR-1
   CD35; RECEPTOR; CD21; PATHOGENESIS; EXPRESSION; ACTIVATION
AB The present study investigated the effect of soluble recombinant CR1 (srCR1, sCD35) on complement-dependent enhancement of human immunodeficiency virus-1 (HIV-1) infection in vitro. Cells of the human T-cell line HPB-ALL were infected with HIV-1 that had been preopsonized with normal human HIV-seronegative serum in the presence of srCR1. At nanomolar concentrations, srCR1 suppressed complement-dependent enhancement of infection of HPB-ALL cells in a dose-dependent manner. Under these conditions, infection was decreased to levels similar to those observed in cells infected with unopsonized virus. These observations provide further evidence to support the role of complement-dependent opsonization facilitating viral entry into target cells.
C1 Hop Broussais, INSERM, U430, F-75014 Paris, France.
   Univ Paris 06, Hop Broussais, F-75014 Paris, France.
RP Kazatchkine, MD (reprint author), Hop Broussais, INSERM, U430, 96 Rue Didot, F-75014 Paris, France.
CR BOYER V, 1991, J EXP MED, V173, P1151, DOI 10.1084/jem.173.5.1151                                                          
   DELIBRIAS CC, 1993, SCAND J IMMUNOL, V38, P183, DOI 10.1111/j.1365-3083.1993.tb01711.x
   DIERICH MP, 1993, IMMUNOL TODAY, V14, P435, DOI 10.1016/0167-5699(93)90246-H
   EBENBICHLER CF, 1991, J EXP MED, V174, P1417, DOI 10.1084/jem.174.6.1417                                                          
   FISCHER E, 1991, J IMMUNOL, V146, P865
   GRAS G, 1993, BLOOD, V81, P1808
   HAURUM JS, 1993, AIDS, V7, P1307, DOI 10.1097/00002030-199310000-00002
   IIDA K, 1981, J EXP MED, V153, P1138, DOI 10.1084/jem.153.5.1138                                                          
   JUNE RA, 1992, IMMUNOLOGY, V75, P59
   KALLI KR, 1994, SPRINGER SEMIN IMMUN, V15, P417, DOI 10.1007/BF01837368                                                              
   MEDOF ME, 1982, J EXP MED, V156, P1739, DOI 10.1084/jem.156.6.1739
   MONTEFIORI DC, 1993, J VIROL, V67, P2699
   Montefiori DC, 1997, SPRINGER SEMIN IMMUN, V18, P371, DOI 10.1007/BF00813504                                                              
   Mouhoub A, 1994, Clin Exp Immunol, V97 Suppl 2, P9
   ROBINSON WE, 1988, LANCET, V1, P790
   SENALDI G, 1990, J INFECT DIS, V162, P1227, DOI 10.1093/infdis/162.6.1227                                                       
   Speth C, 1997, IMMUNOL REV, V159, P49, DOI 10.1111/j.1600-065X.1997.tb01006.x                                              
   Tacnet-Delorme P, 1999, J IMMUNOL, V162, P4088
   THIEBLEMONT N, 1993, CLIN EXP IMMUNOL, V92, P106
   WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562
NR 20
TC 8
Z9 10
U1 0
U2 0
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0300-9475
J9 SCAND J IMMUNOL
JI Scand. J. Immunol.
PD MAY
PY 2000
VL 51
IS 5
BP 526
EP 529
PG 4
WC Immunology
SC Immunology
GA 308HC
UT WOS:000086703600014
PM 10792846
DA 2018-01-05
ER

PT J
AU Lewin, M
   Carlesso, N
   Tung, CH
   Tang, XW
   Cory, D
   Scadden, DT
   Weissleder, R
AF Lewin, M
   Carlesso, N
   Tung, CH
   Tang, XW
   Cory, D
   Scadden, DT
   Weissleder, R
TI Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking
   and recovery of progenitor cells
SO NATURE BIOTECHNOLOGY
LA English
DT Article
DE stem cells; CD34; neural progenitor cells; magnetic resonance; iron
   oxide; homing
ID HEMATOPOIETIC STEM-CELLS; IRON-OXIDE; BONE-MARROW; LYMPH-NODES; IN-VIVO;
   MICROSCOPY; PROTEIN; SUSCEPTIBILITY; MIGRATION; DELIVERY
AB The ability to track the distribution and differentiation of progenitor and stem cells by high-resolution in vivo imaging techniques would have significant clinical and research implications. We have developed a cell labeling approach using short HIV-Tat peptides to derivatize superparamagnetic nanoparticles. The particles are efficiently internalized into hematopoietic and neural progenitor cells in quantities up to 10-30 pg of superparamagnetic iron per cell. Iron incorporation did not affect cell viability, differentiation, or proliferation of CD34(+) cells. Following intravenous injection into immunodeficient mice, 4% of magnetically CD34(+) cells homed to bone marrow per gram of tissue, and single cells could be detected by magnetic resonance (MR) imaging in tissue samples. In addition, magnetically labeled cells that had homed to bone marrow could be recovered by magnetic separation columns. Localization and retrieval of cell populations in vivo enable detailed analysis of specific stem cell and organ interactions critical for advancing the therapeutic use of stem cells.
C1 Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
   Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA.
   MIT, Dept Nucl Engn, NMR Facil, Cambridge, MA 02139 USA.
RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Mol Imaging Res, Charlestown, MA 02129 USA.
OI Tung, Ching-Hsuan/0000-0001-6648-6195
FU NIAID NIH HHS [R01 AI/CA 46973]; NCI NIH HHS [R01 CA46973, R01 CA59649]
CR Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Avrameas A, 1998, P NATL ACAD SCI USA, V95, P5601, DOI 10.1073/pnas.95.10.5601
   Bulte JW, 1999, RADIOLOGY, V213P, P225
   Choi SM, 1997, INT J IMAG SYST TECH, V8, P263, DOI 10.1002/(SICI)1098-1098(1997)8:3<263::AID-IMA4>3.0.CO;2-8                       
   Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188                                                        
   Dodd SJ, 1999, BIOPHYS J, V76, P103, DOI 10.1016/S0006-3495(99)77182-1                                                   
   ENSOLI B, 1993, J VIROL, V67, P277
   FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664
   Frenette PS, 1998, P NATL ACAD SCI USA, V95, P14423, DOI 10.1073/pnas.95.24.14423
   HARDY CL, 1995, AM J MED SCI, V309, P260
   Harisinghani MG, 1999, AM J ROENTGENOL, V172, P1347, DOI 10.2214/ajr.172.5.10227514                                                      
   HAWRYLAK N, 1993, EXP NEUROL, V121, P181, DOI 10.1006/exnr.1993.1085
   Hendrikx PJ, 1996, EXP HEMATOL, V24, P129
   HOLT RW, 1994, JMRI-J MAGN RESON IM, V4, P809, DOI 10.1002/jmri.1880040612
   Jacobs RE, 1999, TRENDS CELL BIOL, V9, P73, DOI 10.1016/S0962-8924(98)01435-4                                                   
   JOHNSON GA, 1993, MAGN RESON QUART, V9, P1
   Josephson L, 1999, BIOCONJUGATE CHEM, V10, P186, DOI 10.1021/bc980125h
   Lanzkron SM, 1999, BLOOD, V93, P1916
   Lynch WP, 1999, J VIROL, V73, P6841
   MANN DA, 1991, EMBO J, V10, P1733
   MENGER MD, 1993, IMMUNOL TODAY, V14, P519, DOI 10.1016/0167-5699(93)90179-O
   Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682
   Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042
   Papayannopoulou T, 1997, ACTA HAEMATOL-BASEL, V97, P97
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Phelan A, 1998, NAT BIOTECHNOL, V16, P440, DOI 10.1038/nbt0598-440
   Rogers JM, 1998, MAGN RESON IMAGING, V16, P917, DOI 10.1016/S0730-725X(98)00090-3                                                   
   Safarik I, 1999, J CHROMATOGR B, V722, P33, DOI 10.1016/S0378-4347(98)00338-7                                                   
   Schoepf U, 1998, BIOTECHNIQUES, V24, P642
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SHEN T, 1993, MAGNET RESON MED, V29, P599, DOI 10.1002/mrm.1910290504
   von Andrian UH, 1998, CELL ADHES COMMUN, V6, P85
   WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167                                                           
   Weissleder R, 1997, JMRI-J MAGN RESON IM, V7, P258, DOI 10.1002/jmri.1880070140                                                         
   Weissleder Ralph, 2000, Nature Medicine, V6, P351, DOI 10.1038/73219
   Wiesmann A, 1999, EXP HEMATOL, V27, P946, DOI 10.1016/S0301-472X(99)00029-6
   Zandstra PW, 1997, P NATL ACAD SCI USA, V94, P4698, DOI 10.1073/pnas.94.9.4698
   Zanjani ED, 1999, BLOOD, V94, P2515
NR 38
TC 1351
Z9 1424
U1 14
U2 257
PU NATURE AMERICA INC
PI NEW YORK
PA 345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA
SN 1087-0156
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD APR
PY 2000
VL 18
IS 4
BP 410
EP 414
PG 5
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 303UY
UT WOS:000086444300023
PM 10748521
DA 2018-01-05
ER

PT J
AU Campiani, G
   Fabbrini, M
   Morelli, E
   Nacci, V
   Greco, G
   Novellino, E
   Maga, G
   Spadari, S
   Bergamini, A
   Faggioli, E
   Uccella, I
   Bolacchi, F
   Marini, S
   Coletta, M
   Fracasso, C
   Caccia, S
AF Campiani, G
   Fabbrini, M
   Morelli, E
   Nacci, V
   Greco, G
   Novellino, E
   Maga, G
   Spadari, S
   Bergamini, A
   Faggioli, E
   Uccella, I
   Bolacchi, F
   Marini, S
   Coletta, M
   Fracasso, C
   Caccia, S
TI Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and
   biological evaluation of novel quinoxalinylethylpyridylthioureas as
   potent antiviral agents
SO ANTIVIRAL CHEMISTRY & CHEMOTHERAPY
LA English
DT Article
DE HIV; non-nucleoside HIV-1 RT inhibitors; thioureas; QXPTs
ID 5-HT3 RECEPTOR AGONISTS; BLOOD-BRAIN-BARRIER; NONNUCLEOSIDE INHIBITORS;
   COLORIMETRIC ASSAY; PETT COMPOUNDS; DERIVATIVES; ANALOGS; SERIES; AIDS;
   CELLS
AB New heterocyclic derivatives of ethylpyridylthiourea, quinoxalinylethylpyridylthiourea (QXPT) and analogues, inhibited human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) activity and prevented HIV-1 cytopathogenicity in T4 lymphocytes. Several of these novel non-nucleoside RT inhibitors, with a substituted pyrroloquinoxalinone heteroaromatic skeleton, showed inhibitory activity against wild-type RT as well as against mutant RTs containing the single amino acid substitutions L100I, K103N, V106A, Y181I and Y188L that was much greater than other non-nucleoside inhibitors such as nevirapine. Maximum potency in enzymatic assays was achieved with a fluoropyrroloquinoxaline skeleton linked to the ethylpyridylthiourea moiety (FQXPT). In cell-based assays on different cell lines and on human monocyte-macrophages, 6-FQXPT exhibited EC50 values in the nanomolar range, with a promising selectivity index. Moreover, 6-FQXPT showed synergistic antiviral activity with zidovudine.
C1 Univ Salerno, Fac Farm, Dipartimento Sci Farmaceut, I-84084 Salerno, Italy.
   Univ Siena, Dipartimento Farmaco Chim Tecnol, I-53100 Siena, Italy.
   Univ Naples Federico II, Dipartimento Chim Farmaceut & Tossicol, I-80131 Naples, Italy.
   CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy.
   Univ Roma Tor Vergata, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy.
   Univ Roma Tor Vergata, Dipartimento Med Sperimentale & Sci Biochim, I-00133 Rome, Italy.
   Ist Ric Farmacol Mario Negri, I-20157 Milan, Italy.
RP Campiani, G (reprint author), Univ Salerno, Fac Farm, Dipartimento Sci Farmaceut, Via Ponte Don Melillo, I-84084 Salerno, Italy.
RI Marini, Stefano/B-1161-2012; Maga, Giovanni/C-5409-2009
OI Marini, Stefano/0000-0003-1299-6696; Maga, Giovanni/0000-0001-8092-1552;
   Novellino, Ettore/0000-0002-2181-2142
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   BERGAMINI A, 1992, J VIROL METHODS, V40, P275, DOI 10.1016/0166-0934(92)90086-S
   Campbell JP, 1996, IEEE T SPEECH AUDI P, V4, P1, DOI 10.1109/TSA.1996.481447                                                         
   Campiani G, 1999, J MED CHEM, V42, P4462, DOI 10.1021/jm990150o                                                               
   CAMPIANI G, 1993, J ORG CHEM, V58, P7660, DOI 10.1021/jo00079a008
   Campiani G, 1999, J MED CHEM, V42, P4362, DOI 10.1021/jm990151g
   Campiani G, 1997, J MED CHEM, V40, P3670, DOI 10.1021/jm970376w
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CARBONI B, 1987, TETRAHEDRON, V43, P1799, DOI 10.1016/S0040-4020(01)81491-5                                                   
   CHOU TC, 1976, J THEOR BIOL, V59, P253, DOI 10.1016/0022-5193(76)90169-7                                                    
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4                                                    
   CRETTON EM, 1991, MOL PHARMACOL, V39, P258
   DATRI S, 1986, INT J TISSUE REACT, V7, P383
   DAVEY DD, 1991, J MED CHEM, V34, P2671, DOI 10.1021/jm00113a002                                                             
   DECLERCQ E, 1990, TRENDS PHARMACOL SCI, V11, P198, DOI 10.1016/0165-6147(90)90115-O
   DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001
   GAO WY, 1994, J BIOL CHEM, V269, P12633
   GARTNER S, 1986, SCIENCE, V233, P1533
   GOLDMAN ME, 1991, P NATL ACAD SCI USA, V88, P6863, DOI 10.1073/pnas.88.15.6863
   HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045
   Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914
   KUMAR R, 1994, J MED CHEM, V37, P3554, DOI 10.1021/jm00047a013
   LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022                                                             
   Maga G, 1997, J MOL BIOL, V274, P738, DOI 10.1006/jmbi.1997.1427
   MAKINO K, 1987, HETEROCYCLES, V26, P1215, DOI 10.3987/R-1987-05-1215                                                          
   MCQUAID LA, 1992, J MED CHEM, V35, P3319, DOI 10.1021/jm00096a002
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   PERNO CF, 1988, J EXP MED, V168, P1111, DOI 10.1084/jem.168.3.1111
   POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935
   PORTEGIES P, 1995, LANCET, V346, P1244, DOI 10.1016/S0140-6736(95)91857-4
   Prunier H, 1997, J MED CHEM, V40, P1808, DOI 10.1021/jm960501o
   Reddy PY, 1997, J ORG CHEM, V62, P2652, DOI 10.1021/jo962202c                                                               
   RESNICK L, 1988, NEUROLOGY, V38, P9, DOI 10.1212/WNL.38.1.9                                                              
   RICHARDSON N, 1993, NEW STATESMAN SOC, V6, P37
   SANDSTROM E, 1993, DRUGS, V45, P488, DOI 10.2165/00003495-199345040-00002                                                
   SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891
   TERASAKI T, 1988, J INFECT DIS, V158, P630, DOI 10.1093/infdis/158.3.630                                                        
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   AKIRA M, 1974, Patent No. 129461
   AKIRA M, 1975, Patent No. 27877
NR 43
TC 14
Z9 16
U1 0
U2 2
PU INT MEDICAL PRESS
PI LONDON
PA 125 HIGH HOLBORN, LONDON WC1V 6QA, ENGLAND
SN 0956-3202
J9 ANTIVIR CHEM CHEMOTH
JI Antivir. Chem. Chemother.
PD MAR
PY 2000
VL 11
IS 2
BP 141
EP 155
DI 10.1177/095632020001100206                                              
          
PG 15
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Virology
GA 309RA
UT WOS:000086782000006
PM 10819438
OA gold
DA 2018-01-05
ER

PT J
AU David, L
   Luo, R
   Gilson, MK
AF David, L
   Luo, R
   Gilson, MK
TI Comparison of generalized born and Poisson models: Energetics and
   dynamics of HIV protease
SO JOURNAL OF COMPUTATIONAL CHEMISTRY
LA English
DT Article
DE generalized Born; Poisson equation; stochastic dynamics; HIV protease;
   implicit solvent models
ID CONTINUUM SOLVATION MODEL; BOUNDARY-ELEMENT METHOD; FREE-ENERGIES;
   BOLTZMANN EQUATION; MOLECULAR-DYNAMICS; ALANINE DIPEPTIDE; ELECTROSTATIC
   FORCES; BINDING; SOLVENT; SIMULATION
AB This study characterizes the accuracy of energies and forces computed with a generalized Born (GB) model and the distance-dependent dielectric (DDD) model with respect to detailed finite solutions of the Poisson equation (FDPE). Tests are done for a small molecule in solution and for HIV-1 protease with inhibitor, KNI-272. GB agrees well with FDPE for the small molecule, but less well for the protein system. The correlation between GB and FDPE energies is poorest in calculations of changes upon binding. Also, forces computed with the GB model are less accurate than energies. The DDD model is far less accurate than GB. Nanosecond stochastic dynamics simulations of HIV-1 protease with an empty active site are used to examine the consequence of the models for the conformational preferences of the active site. Interestingly, the active site flaps remain near their starting conformations in the FDPE and GB simulations but collapse into the active site in the DDD simulation. (C) 2000 John Wiley & Sons, Inc.
C1 NIST, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA.
RP Gilson, MK (reprint author), NIST, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.
RI Luo, Ray/I-6928-2012
OI Luo, Ray/0000-0002-6346-8271; David, Laurent/0000-0002-3354-400X
CR ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052                                                          
   BALDWIN ET, 1995, STRUCTURE, V3, P581, DOI 10.1016/S0969-2126(01)00192-7
   BROOKS BR, 1983, M J COMP CHEM, V4, P187
   CRAMER CJ, 1992, J COMPUT CHEM, V13, P1089, DOI 10.1002/jcc.540130907                                                           
   David L, 1999, J PHYS CHEM B, V103, P1031, DOI 10.1021/jp983675l                                                               
   DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2                                                    
   DAVIS ME, 1991, J COMPUT CHEM, V12, P909, DOI 10.1002/jcc.540120718
   Dominy BN, 1999, J PHYS CHEM B, V103, P3765, DOI 10.1021/jp984440c                                                               
   EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0
   Ghosh A, 1998, J PHYS CHEM B, V102, P10983, DOI 10.1021/jp982533o                                                               
   GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104
   GILSON MK, 1993, J PHYS CHEM-US, V97, P3591, DOI 10.1021/j100116a025                                                             
   GILSON MK, 1995, J COMPUT CHEM, V16, P1081, DOI 10.1002/jcc.540160904
   GILSON MK, 1985, J MOL BIOL, V183, P503
   GILSON MK, 1990, J COMPUT AID MOL DES, V5, P5
   Given JA, 1998, PROTEINS, V33, P475, DOI 10.1002/(SICI)1097-0134(19981201)33:4<475::AID-PROT3>3.3.CO;2-2
   HARTE WE, 1990, P NATL ACAD SCI USA, V87, P8864, DOI 10.1073/pnas.87.22.8864
   HAWKINS GD, 1995, CHEM PHYS LETT, V246, P122, DOI 10.1016/0009-2614(95)01082-K
   HOIJTINK GJ, 1956, RECL TRAV CHIM PAY B, V75, P487
   HYLAND LJ, 1991, BIOCHEMISTRY-US, V266, P24349
   Im W, 1998, COMPUT PHYS COMMUN, V111, P59, DOI 10.1016/S0010-4655(98)00016-2
   JANO I, 1965, CR HEBD ACAD SCI, V261, P103
   Jayaram B, 1998, J CHEM PHYS, V109, P1465, DOI 10.1063/1.476697
   KANG YK, 1988, J PHYS CHEM-US, V92, P4739, DOI 10.1021/j100327a036                                                             
   Kiso Y, 1996, BIOPOLYMERS, V40, P235, DOI 10.1002/(SICI)1097-0282(1996)40:2<235::AID-BIP3>3.0.CO;2-X
   Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N                 
   Luo R, 1998, J AM CHEM SOC, V120, P6138, DOI 10.1021/ja974307i                                                               
   Luo R, 1999, J PHYS CHEM B, V103, P727, DOI 10.1021/jp982715i                                                               
   Luo R, 1999, BIOPHYS CHEM, V78, P183, DOI 10.1016/S0301-4622(98)00229-4
   LUO R, UNPUB
   LUTY BA, 1992, J COMPUT CHEM, V13, P768, DOI 10.1002/jcc.540130610                                                           
   NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405                                                           
   PERADEJORDI F, 1963, CAH PHYS, V17, P393
   Qiu D, 1997, J PHYS CHEM A, V101, P3005, DOI 10.1021/jp961992r                                                               
   RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055
   Roux B, 1999, BIOPHYS CHEM, V78, P1, DOI 10.1016/S0301-4622(98)00226-9
   Schaefer M, 1998, J MOL BIOL, V284, P835, DOI 10.1006/jmbi.1998.2172                                                          
   SCHMIDT AB, 1994, MOL SIMULAT, V13, P347, DOI 10.1080/08927029408021998                                                       
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043                                                             
   Smart JL, 1997, J COMPUT CHEM, V18, P1750, DOI 10.1002/(SICI)1096-987X(19971115)18:14<1750::AID-JCC4>3.0.CO;2-J
   SMITH PE, 1994, J PHYS CHEM-US, V98, P9700, DOI 10.1021/j100090a002                                                             
   SPINELLI S, 1991, BIOCHIMIE, V73, P1391, DOI 10.1016/0300-9084(91)90169-2
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038                                                             
   STOUTEN PFW, 1993, MOL SIMULAT, V10, P97, DOI 10.1080/08927029308022161                                                       
   Stratton J A, 1941, ELECTROMAGNETIC THEO
   VAJDA S, 1994, BIOCHEMISTRY-US, V33, P13977, DOI 10.1021/bi00251a004                                                             
   Van Gunsteren WF, 1988, MOL SIMULAT, V1, P173, DOI 10.1080/08927028808080941
   VENABLE RM, 1993, PROTEINS, V15, P374, DOI 10.1002/prot.340150405
   Wan SZ, 1997, J COMPUT CHEM, V18, P1440, DOI 10.1002/(SICI)1096-987X(199709)18:12<1440::AID-JCC2>3.0.CO;2-J                  
   Wang YX, 1996, BIOCHEMISTRY-US, V35, P9945, DOI 10.1021/bi961268z
   WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8
   YOON BJ, 1990, J COMPUT CHEM, V11, P1080, DOI 10.1002/jcc.540110911                                                           
   YOU TJ, 1993, J COMPUT CHEM, V14, P484, DOI 10.1002/jcc.540140413
   ZAUHAR RJ, 1990, J COMPUT CHEM, V11, P603, DOI 10.1002/jcc.540110509
   ZAUHAR RJ, 1985, J MOL BIOL, V186, P815, DOI 10.1016/0022-2836(85)90399-7
NR 55
TC 84
Z9 84
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0192-8651
J9 J COMPUT CHEM
JI J. Comput. Chem.
PD MAR
PY 2000
VL 21
IS 4
BP 295
EP 309
DI 10.1002/(SICI)1096-987X(200003)21:4<295::AID-JCC5>3.3.CO;2-#
PG 15
WC Chemistry, Multidisciplinary
SC Chemistry
GA 283UD
UT WOS:000085293600005
DA 2018-01-05
ER

PT J
AU Coester, CJ
   Langer, K
   Von Briesen, H
   Kreuter, J
AF Coester, CJ
   Langer, K
   Von Briesen, H
   Kreuter, J
TI Gelatin nanoparticles by two step desolvation - a new preparation
   method, surface modifications and cell uptake
SO JOURNAL OF MICROENCAPSULATION
LA English
DT Article
DE nanoparticles; gelatin; macrophages; cell uptake
ID IN-VITRO; MACROPHAGES; SYSTEM; HIV
AB A new two-step desolvation method for manufacturing gelatin nanoparticles was developed. After the first desolvation step, the low molecular gelatin fractions present in the supernatant were removed by decanting. The high molecular fractions present in the sediment were redesolved and then desolvated again at pH 2.5 in the second step. The resulting particles can then be easily purified by centrifugation and redispersion. The different fractions obtained during the process were analysed by gel permeation chromatography (GPC). Based on these results, it can be concluded that the molecular weight of gelatin has a decisive influence on the stability of the manufactured gelatin nanoparticles. In addition, two fluorescent dyes (Texasred(R) and fluoresceinamine) were coupled to the nanoparticles for cell uptake studies. The fluorescent nanoparticles showed a high uptake into monocytes/macrophages.
C1 Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany.
   Georg Speyer Haus, Chemotherapeut Res Inst, D-60596 Frankfurt, Germany.
RP Kreuter, J (reprint author), Univ Frankfurt, Inst Pharmaceut Technol, D-60439 Frankfurt, Germany.
RI Fachbereich14, Dekanat/C-8553-2015
CR ANDREESEN R, 1983, J IMMUNOL METHODS, V56, P295, DOI 10.1016/S0022-1759(83)80019-2                                                   
   BENDER A, 1994, RES VIROLOGY, V145, P215, DOI 10.1016/S0923-2516(07)80025-2                                                   
   Bender AR, 1996, ANTIMICROB AGENTS CH, V40, P1467
   Hassig A, 1969, Bibl Haematol, V33, P1
   MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
   Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857
   Schafer V, 1994, Clin Diagn Virol, V1, P279, DOI 10.1016/0928-0197(94)90058-2
   SCHAFER V, 1992, PHARMACEUT RES, V9, P541, DOI 10.1023/A:1015852732512
   SCHWICK HG, 1969, BIBL HAEMATOL, V3, P111
NR 9
TC 205
Z9 210
U1 5
U2 57
PU TAYLOR & FRANCIS LTD
PI LONDON
PA 11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND
SN 0265-2048
J9 J MICROENCAPSUL
JI J. Microencapsul.
PD MAR-APR
PY 2000
VL 17
IS 2
BP 187
EP 193
PG 7
WC Chemistry, Applied; Engineering, Chemical; Pharmacology & Pharmacy
SC Chemistry; Engineering; Pharmacology & Pharmacy
GA 293VP
UT WOS:000085874300006
PM 10738694
DA 2018-01-05
ER

PT J
AU Murphy, PM
   Baggiolini, M
   Charo, IF
   Hebert, CA
   Horuk, R
   Matsushima, K
   Miller, LH
   Oppenheim, JJ
   Power, CA
AF Murphy, PM
   Baggiolini, M
   Charo, IF
   Hebert, CA
   Horuk, R
   Matsushima, K
   Miller, LH
   Oppenheim, JJ
   Power, CA
TI International union of pharmacology. XXII. Nomenclature for chemokine
   receptors
SO PHARMACOLOGICAL REVIEWS
LA English
DT Review
ID PROTEIN-COUPLED RECEPTOR; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA;
   MONOCYTE CHEMOATTRACTANT PROTEIN-1; SARCOMA-ASSOCIATED HERPESVIRUS;
   IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN INTERLEUKIN-8 RECEPTOR;
   HIGH-AFFINITY BINDING; HUMAN BETA-CHEMOKINE; NEUTROPHIL-ACTIVATING
   PEPTIDE-2; EOSINOPHIL EOTAXIN RECEPTOR
AB Chemokine receptors comprise a large family of seven transmembrane domain G protein-coupled receptors differentially expressed in diverse cell types. Biological activities have been most clearly defined in leukocytes, where chemokines coordinate development, differentiation, anatomic distribution, trafficking, and effector functions and thereby regulate innate and adaptive immune responses. Pharmacological analysis of chemokine receptors is at an early stage of development. Disease indications have been established in human immunodeficiency virus/acquired immune deficiency syndrome and in Plasmodium vivax malaria, due to exploitation of CCR5 and Duffy, respectively, by the pathogen for cell entry. Additional indications are emerging among inflammatory and immunologically mediated diseases, but selection of targets in this area still remains somewhat speculative. Small molecule antagonists with nanomolar affinity have been reported for 7 of the 18 known chemokine receptors but have not yet been studied in clinical trials. Virally encoded chemokine receptors, as well as chemokine agonists and antagonists, and chemokine scavengers have been identified in medically important poxviruses and herpesviruses, again underscoring the importance of the chemokine system in microbial pathogenesis and possibly identifying specific strategies for modulating chemokine action therapeutically. The purpose of this review is to update current concepts of the biology and pharmacology of the chemokine system, to summarize key information about each chemokine receptor, and to describe a widely accepted receptor nomenclature system, ratified by the International Union of Pharmacology, that is facilitating clear communication in this area.
C1 NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA.
   Univ Bern, Theodor Kocher Inst, Bern, Switzerland.
   Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA.
   Genentech Inc, S San Francisco, CA 94080 USA.
   Berlex Biosci, Dept Immunol, Richmond, CA USA.
   Univ Tokyo, Sch Med, Dept Mol Prevent Med, Bunkyo Ku, Tokyo 113, Japan.
   NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA.
   NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Div Basic Sci, Frederick, MD 21702 USA.
   Serono Pharmaceut Res Inst, Geneva, Switzerland.
RP Murphy, PM (reprint author), NIAID, Host Def Lab, NIH, Bldg 10,Room 11N113, Bethesda, MD 20892 USA.
CR Agostini C, 1998, J IMMUNOL, V161, P6413
   AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31
   Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545                                                        
   Ahuja SK, 1996, J BIOL CHEM, V271, P225, DOI 10.1074/jbc.271.1.225                                                           
   AHUJA SK, 1993, J BIOL CHEM, V268, P20691
   Albini A, 1998, P NATL ACAD SCI USA, V95, P13153, DOI 10.1073/pnas.95.22.13153
   ALBRECHT JC, 1992, J VIROL, V66, P5047
   Alcami A, 1998, J IMMUNOL, V160, P624
   Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139
   Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691
   Ansel KM, 1999, J EXP MED, V190, P1123, DOI 10.1084/jem.190.8.1123                                                          
   ArenzanaSeisdedos F, 1996, NATURE, V383, P400, DOI 10.1038/383400a0
   Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0
   Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893
   Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675                                                
   Baird JW, 1999, J BIOL CHEM, V274, P33496, DOI 10.1074/jbc.274.47.33496                                                        
   Bais C, 1998, NATURE, V392, P210, DOI 10.1038/32472                                                                   
   Bais C, 1998, NATURE, V391, P86
   BALDWIN JM, 1993, EMBO J, V12, P1693
   BARELLA L, 1995, BIOCHEM J, V309, P773, DOI 10.1042/bj3090773                                                               
   Bazan HA, 1998, J VIROL, V72, P4485
   Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0
   Beisser PS, 1998, J VIROL, V72, P2352
   BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123                                                        
   Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603
   Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657                                                
   Berger EA, 1998, NATURE, V391, P240, DOI 10.1038/34571
   Bernardini G, 1998, EUR J IMMUNOL, V28, P582, DOI 10.1002/(SICI)1521-4141(199802)28:02<582::AID-IMMU582>3.0.CO;2-A
   BIRKENBACH M, 1993, J VIROL, V67, P2209
   Blanpain C, 1999, BLOOD, V94, P1899
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925
   Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855                                                           
   Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195
   Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129
   Bonini JA, 1997, DNA CELL BIOL, V16, P1249, DOI 10.1089/dna.1997.16.1249
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551                                                         
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290
   BOZIC CR, 1994, J BIOL CHEM, V269, P29355
   Bridger GJ, 1999, J MED CHEM, V42, P3971, DOI 10.1021/jm990211i                                                               
   BROADDUS VC, 1994, J IMMUNOL, V152, P2960
   Broxmeyer HE, 1999, J EXP MED, V189, P1987, DOI 10.1084/jem.189.12.1987
   Broxmeyer HE, 1996, J EXP MED, V184, P1825, DOI 10.1084/jem.184.5.1825
   Broxmeyer HE, 1997, STEM CELLS, V15, P69, DOI 10.1002/stem.5530150811                                                         
   BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525
   CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519                                                         
   Camarda G, 1999, J VIROL, V73, P9843
   Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053
   Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495                                                                   
   Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381
   CAMPBELL JJ, 1999, J IMMUNOL, V163, P2160
   CAO JX, 1995, VIROLOGY, V209, P207, DOI 10.1006/viro.1995.1244
   Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118                                                          
   Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755
   CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752                                                          
   CHAUDHURI A, 1995, BLOOD, V85, P615
   Chaudhuri A, 1997, BLOOD, V89, P701
   CHAUDHURI A, 1993, P NATL ACAD SCI USA, V90, P10793, DOI 10.1073/pnas.90.22.10793
   CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835
   CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0
   Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110
   CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497
   Choe H, 1998, J VIROL, V72, P6113
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682
   CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703
   Clemons MJ, 1998, BLOOD, V92, P1532
   CLORE GM, 1995, FASEB J, V9, P57
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009
   COMBADIERE C, 1995, DNA CELL BIOL, V14, P673, DOI 10.1089/dna.1995.14.673
   Combadiere C, 1998, BIOCHEM BIOPH RES CO, V253, P728, DOI 10.1006/bbrc.1998.9849
   COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491                                                        
   Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147
   Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799
   COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639
   COULIN F, 1997, EUR J BIOCHEM, V248, P7
   Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996
   Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098
   Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447                                                           
   Daelemans D, 2000, MOL PHARMACOL, V57, P116
   Dairaghi DJ, 1997, J BIOL CHEM, V272, P28206, DOI 10.1074/jbc.272.45.28206
   Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569
   Damon I, 1998, P NATL ACAD SCI USA, V95, P6403, DOI 10.1073/pnas.95.11.6403
   Daniels GD, 1999, J LEUKOCYTE BIOL, V65, P684
   DARBONNE WC, 1991, J CLIN INVEST, V88, P1362, DOI 10.1172/JCI115442
   Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349
   DavisPoynter NJ, 1997, J VIROL, V71, P1521
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894                                                                   
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373
   Dilloo D, 1996, NAT MED, V2, P1090, DOI 10.1038/nm1096-1090
   DOBNER T, 1992, EUR J IMMUNOL, V22, P2795, DOI 10.1002/eji.1830221107
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8                                                   
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Dunstan CAN, 1996, J BIOL CHEM, V271, P32770, DOI 10.1074/jbc.271.51.32770                                                        
   Endres MJ, 1999, J EXP MED, V189, P1993, DOI 10.1084/jem.189.12.1993
   Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8
   Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2
   Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405
   Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x                                                
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Fleming P, 1999, J VIROL, V73, P6800
   Fong AM, 1998, J EXP MED, V188, P1413, DOI 10.1084/jem.188.8.1413                                                          
   Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171                                                         
   Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8
   FORSTER R, 1994, BLOOD, V84, P830
   Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5
   FOXMAN EF, 1997, J CELL BIOL, V139, P349
   Frade JMR, 1997, J IMMUNOL, V159, P5576
   Frodl R, 1998, J RECEPT SIGNAL TR R, V18, P321, DOI 10.3109/10799899809047750
   Gallo RC, 1999, P NATL ACAD SCI USA, V96, P8324, DOI 10.1073/pnas.96.15.8324
   Gao JL, 1996, BIOCHEM BIOPH RES CO, V223, P679, DOI 10.1006/bbrc.1996.0955
   GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494                                                        
   Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959
   GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421
   GAO JL, 1994, J BIOL CHEM, V269, P28539
   Gao W, 2000, J CLIN INVEST, V105, P35, DOI 10.1172/JCI8126                                                                 
   GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613
   Gerard C, 1997, J CLIN INVEST, V100, P2022, DOI 10.1172/JCI119734
   Gerard Craig, 1999, P41
   Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405                                                           
   Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801                                                           
   Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557                                                          
   Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X                                                   
   Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461
   Gerszten RE, 1999, NATURE, V398, P718
   Goila R, 1998, FEBS LETT, V436, P233, DOI 10.1016/S0014-5793(98)01137-5
   Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289
   Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682
   Gonzalo JA, 1999, J IMMUNOL, V163, P403
   Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624
   Goya I, 1998, J IMMUNOL, V160, P1975
   Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423
   GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433
   Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837
   Green SP, 1996, J BIOL CHEM, V271, P25400, DOI 10.1074/jbc.271.41.25400                                                        
   Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846
   Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2
   Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451
   Gunn MD, 1998, NATURE, V391, P799
   Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258
   Gupta SK, 1999, J IMMUNOL, V163, P2368
   Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282                                                          
   Gupta SK, 1998, BIOCHEM MOL BIOL INT, V44, P673
   Hadida F, 1998, J EXP MED, V188, P609, DOI 10.1084/jem.188.3.609
   HADLEY TJ, 1994, J CLIN INVEST, V94, P985, DOI 10.1172/JCI117465                                                               
   Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539                                                           
   HAMMOND MEW, 1995, J IMMUNOL, V155, P1428
   Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896
   HARRISON JK, 1994, NEUROSCI LETT, V169, P85, DOI 10.1016/0304-3940(94)90362-X
   Haskell CA, 1999, J BIOL CHEM, V274, P10053, DOI 10.1074/jbc.274.15.10053
   HAYASHI S, 1995, J IMMUNOL, V154, P814
   He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0
   Heath DB, 1997, J ROY ANTHROPOL INST, V3, P178, DOI 10.2307/3034391                                                                 
   HEBERT CA, 1991, J BIOL CHEM, V266, P18989
   HEESEN M, 1997, J IMMUNOL, V158, P261
   Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026
   Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687
   Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1
   HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472
   Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8                                                   
   Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1
   HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701
   HOMEY B, IN PRESS J IMMUNOL
   Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059
   HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X
   HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250                                                         
   Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386
   Horuk R, 1997, J IMMUNOL, V158, P2882
   Howard OMZ, 1998, J MED CHEM, V41, P2184, DOI 10.1021/jm9801253                                                               
   Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240                                                             
   Huffnagle GB, 1999, J IMMUNOL, V163, P4642
   Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601
   Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036
   Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764
   Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9
   Isegawa Y, 1998, J VIROL, V72, P6104
   Jenh CH, 1999, J IMMUNOL, V162, P3765
   Johnston B, 1999, J CLIN INVEST, V103, P1269, DOI 10.1172/JCI5208                                                                 
   Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682
   JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881
   KAISER E, 1993, EUR J IMMUNOL, V23, P2532, DOI 10.1002/eji.1830231023
   Kanbe K, 1999, VIROLOGY, V265, P264, DOI 10.1006/viro.1999.0036                                                          
   Kellermann SA, 1999, J IMMUNOL, V162, P3859
   KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732                                                         
   Kennedy KJ, 1998, J NEUROIMMUNOL, V92, P98, DOI 10.1016/S0165-5728(98)00187-8
   Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975                                                        
   Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725                                                         
   Kitayama J, 1998, J CLIN INVEST, V101, P2017, DOI 10.1172/JCI2688
   Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656
   Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8                                                   
   Kowalska MA, 1999, BRIT J HAEMATOL, V104, P220, DOI 10.1046/j.1365-2141.1999.01169.x                                                
   Krathwohl MD, 1997, P NATL ACAD SCI USA, V94, P9875, DOI 10.1073/pnas.94.18.9875
   Kuang YN, 1996, J BIOL CHEM, V271, P3975
   Kurihara T, 1996, J BIOL CHEM, V271, P11603, DOI 10.1074/jbc.271.20.11603                                                        
   Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   LaCasse RA, 1999, SCIENCE, V283, P357, DOI 10.1126/science.283.5400.357
   Lalani AS, 1999, CYTOKINE GROWTH F R, V10, P219, DOI 10.1016/S1359-6101(99)00018-0
   Lalani AS, 1999, SCIENCE, V286, P1968, DOI 10.1126/science.286.5446.1968                                                   
   Lalani AS, 1997, J VIROL, V71, P4356
   Lapham CK, 1999, NAT MED, V5, P303, DOI 10.1038/6523
   Lee B, 1998, J VIROL, V72, P7450
   LEE J, 1992, J BIOL CHEM, V267, P16283
   LEE J, 1995, J IMMUNOL, V155, P2158
   Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655
   Liao F, 1997, BIOCHEM BIOPH RES CO, V236, P212, DOI 10.1006/bbrc.1997.6936
   Liao F, 1997, GENOMICS, V40, P175, DOI 10.1006/geno.1996.4544
   Liao F, 1999, J IMMUNOL, V162, P186
   Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015
   Libert F, 1998, HUM MOL GENET, V7, P399, DOI 10.1093/hmg/7.3.399
   LINDLEY IJD, 1993, IMMUNOL TODAY, V14, P24
   Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922                                                         
   LIRA SA, 1994, J EXP MED, V180, P2039, DOI 10.1084/jem.180.6.2039
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Loetscher M, 1997, CURR BIOL, V7, P652, DOI 10.1016/S0960-9822(06)00292-2
   Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963
   Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W
   LOETSCHER P, 1994, FEBS LETT, V341, P187, DOI 10.1016/0014-5793(94)80454-0
   Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569
   Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279
   Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814                                                                   
   Lomize AL, 1999, J COMPUT AID MOL DES, V13, P325, DOI 10.1023/A:1008050821744                                                         
   Ludwig A, 1997, BLOOD, V90, P4588
   Luo H, 1997, GENOME RES, V7, P932, DOI 10.1101/gr.7.9.932                                                              
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706                                                     
   Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448
   MALLINSON G, 1995, BRIT J HAEMATOL, V90, P823, DOI 10.1111/j.1365-2141.1995.tb05202.x
   MARCUS RD, 1995, REV AM HIST, V23, P618
   Marshall E, 1998, EUR J CANCER, V34, P1023, DOI 10.1016/S0959-8049(97)10141-1
   Martin MP, 1998, SCIENCE, V282, P1907, DOI 10.1126/science.282.5395.1907                                                   
   MASSUNG RF, 1993, VIROLOGY, V197, P511, DOI 10.1006/viro.1993.1625                                                          
   MATSUSHIMA K, 1989, J EXP MED, V169, P1485, DOI 10.1084/jem.169.4.1485                                                          
   Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273
   McDermott DH, 1998, LANCET, V352, P866, DOI 10.1016/S0140-6736(98)04158-0
   Mellado M, 1999, NATURE, V400, P723, DOI 10.1038/23382                                                                   
   Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500                                                        
   Meyer A, 1996, J BIOL CHEM, V271, P14445, DOI 10.1074/jbc.271.24.14445                                                        
   Michael NL, 1998, J VIROL, V72, P6040
   MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213
   MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602
   Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101                                           
   Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084                                                        
   MOORE MW, 1995, SCIENCE, V269, P1591, DOI 10.1126/science.269.5230.1591                                                   
   Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470
   MOROHASHI H, 1995, J LEUKOCYTE BIOL, V57, P180
   MOSER B, 1991, J BIOL CHEM, V266, P10666
   Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389
   Murphy Philip M., 1996, Methods (Orlando), V10, P104, DOI 10.1006/meth.1996.0084
   MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7                                                    
   MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593
   MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716
   MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786                                                         
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Najakshin AM, 1999, EUR J IMMUNOL, V29, P375, DOI 10.1002/(SICI)1521-4141(199902)29:02<375::AID-IMMU375>3.3.CO;2-Y
   Napolitano M, 1996, J IMMUNOL, V157, P2759
   Nardelli B, 1999, J IMMUNOL, V162, P435
   NEOTE K, 1994, BLOOD, V84, P44
   NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A
   Ng HP, 1999, J MED CHEM, V42, P4680, DOI 10.1021/jm990316l
   Nibbs RJB, 1999, J BIOL CHEM, V274, P17478, DOI 10.1074/jbc.274.25.17478
   Nibbs RJB, 2000, J IMMUNOL, V164, P1488, DOI 10.4049/jimmunol.164.3.1488                                                     
   Nibbs RJB, 1997, J BIOL CHEM, V272, P12495, DOI 10.1074/jbc.272.19.12495
   Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078
   Nicholas J, 1996, J VIROL, V70, P5975
   Nilsson G, 1999, BLOOD, V93, P2791
   Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0
   Ochensberger B, 1999, EUR J IMMUNOL, V29, P11, DOI 10.1002/(SICI)1521-4141(199901)29:01<11::AID-IMMU11>3.0.CO;2-B                  
   Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267
   Olson WC, 1999, J VIROL, V73, P4145
   OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153                                             
   OPPENHEIM JJ, 2000, ROLE CHEMOTACTIC FAC
   Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865                                                         
   Owman C, 1998, P NATL ACAD SCI USA, V95, P9530, DOI 10.1073/pnas.95.16.9530
   Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695
   Palframan RT, 1998, BLOOD, V91, P2240
   PAN L, 1997, NATURE, V389, P1001
   Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491
   Pease JE, 1998, SEMIN IMMUNOL, V10, P169, DOI 10.1006/smim.1998.0129
   Pease JE, 1998, J BIOL CHEM, V273, P19972, DOI 10.1074/jbc.273.32.19972
   PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311                                                          
   Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845
   Penfold MET, 1999, P NATL ACAD SCI USA, V96, P9839, DOI 10.1073/pnas.96.17.9839
   Petering H, 1999, BLOOD, V93, P694
   Pleskoff O, 1998, J VIROL, V72, P6389
   Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874
   Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456                                                               
   POST TW, 1995, J IMMUNOL, V155, P5299
   POWER CA, 1995, CYTOKINE, V7, P479, DOI 10.1006/cyto.1995.0065                                                          
   Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825                                                           
   POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495                                                        
   Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599                                                          
   Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422
   Rabin RL, 1999, J IMMUNOL, V162, P3840
   Ransohoff RM, 1999, J NEUROIMMUNOL, V98, P57, DOI 10.1016/S0165-5728(99)00082-X
   Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161                                                        
   Reid S, 1999, BLOOD, V93, P1524
   Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949
   Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628
   Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251
   Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956
   Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785                                                           
   Rubbert A, 1998, J IMMUNOL, V160, P3933
   Rucker J, 1997, J VIROL, V71, P8999
   Ruiz ME, 1998, J IMMUNOL, V161, P4169
   Sabroe I, 1998, J IMMUNOL, V161, P6139
   Saederup N, 1999, P NATL ACAD SCI USA, V96, P10881, DOI 10.1073/pnas.96.19.10881
   Saeki H, 1999, J IMMUNOL, V162, P2472
   Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5
   Sallusto F, 1999, CURR TOP MICROBIOL, V246, P123
   Sallusto F, 1999, EUR J IMMUNOL, V29, P2037, DOI 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V
   Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875                                                           
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Samson M, 1996, GENOMICS, V36, P522, DOI 10.1006/geno.1996.0498
   Samson M, 1998, EUR J IMMUNOL, V28, P1689, DOI 10.1002/(SICI)1521-4141(199805)28:05<1689::AID-IMMU1689>3.0.CO;2-I
   Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g
   Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99
   SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0
   SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4                                                    
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Schwarz MK, 1999, CURR OPIN CHEM BIOL, V3, P407, DOI 10.1016/S1367-5931(99)80061-1
   SCHWEICKART VL, 1994, GENOMICS, V23, P643, DOI 10.1006/geno.1994.1553
   SCHWEICKART VL, 2000, IN PRESS J BIOL CHEM
   SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0                                                                
   Shimizu N, 2000, J VIROL, V74, P619, DOI 10.1128/JVI.74.2.619-626.2000
   Shinkai A, 1999, J IMMUNOL, V163, P1602
   SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730
   Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959
   Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205
   Sozzani S, 1999, J LEUKOCYTE BIOL, V66, P1
   Sozzani S, 1997, J IMMUNOL, V159, P1993
   Sozzani S, 1998, BLOOD, V92, P4036
   Sozzani S, 1998, J IMMUNOL, V161, P1083
   SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9
   Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1                                                   
   Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G
   Su SB, 1997, BLOOD, V90, P605
   Su SB, 1996, J LEUKOCYTE BIOL, V60, P658
   Suzuki G, 1999, J IMMUNOL, V162, P5981
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871
   TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4
   Tang HL, 1999, SCIENCE, V284, P819, DOI 10.1126/science.284.5415.819
   Tang T, 1998, DNA SEQUENCE, V9, P129, DOI 10.3109/10425179809072188
   TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023                                                         
   Tashiro K, 1999, METHOD ENZYMOL, V303, P479
   TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314
   THOMAS KM, 1991, J BIOL CHEM, V266, P14839
   THOMAS KM, 1990, J BIOL CHEM, V265, P20061
   Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165
   Topham PS, 1999, J CLIN INVEST, V104, P1549, DOI 10.1172/JCI7707                                                                 
   TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224
   Trentin L, 1999, J CLIN INVEST, V104, P115, DOI 10.1172/JCI7335                                                                 
   Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0
   Tsou CL, 1998, J EXP MED, V188, P603, DOI 10.1084/jem.188.3.603
   Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624
   Unger VM, 1997, NATURE, V389, P203
   VANHOUTTE PM, 1998, IUPHAR COMPENDIUM RE, P31
   VanSnick J, 1996, J IMMUNOL, V157, P2570
   Varona R, 1998, FEBS LETT, V440, P188, DOI 10.1016/S0014-5793(98)01450-1                                                   
   Vieira J, 1998, J VIROL, V72, P8158
   VIRGIN HW, 1997, J VIROL, V71, P5994
   Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147
   WALZ A, 1990, J EXP MED, V171, P449, DOI 10.1084/jem.171.2.449
   WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3
   WALZ DA, 1977, THROMB RES, V11, P893, DOI 10.1016/0049-3848(77)90117-7
   Wang JF, 1998, BLOOD, V92, P756
   Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173                                                                   
   Wells TNC, 1997, J LEUKOCYTE BIOL, V61, P545
   Weng YM, 1998, J BIOL CHEM, V273, P18288, DOI 10.1074/jbc.273.29.18288
   WHITE JK, 1994, GENOMICS, V24, P295, DOI 10.1006/geno.1994.1619
   White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095                                                        
   Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C              
   Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389
   WOLPE SD, 1989, FASEB J, V3, P2565
   Wong LM, 1997, J BIOL CHEM, V272, P1038, DOI 10.1074/jbc.272.2.1038                                                          
   Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373                                                          
   Wuyts A, 1997, BIOCHEMISTRY-US, V36, P2716, DOI 10.1021/bi961999z
   Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496
   Xu YN, 1999, AIDS RES HUM RETROV, V15, P419, DOI 10.1089/088922299311169                                                         
   Yanagihara S, 1998, J IMMUNOL, V161, P3096
   Yang AG, 1997, P NATL ACAD SCI USA, V94, P11567, DOI 10.1073/pnas.94.21.11567
   Yang D, 1999, J IMMUNOL, V163, P1737
   Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525                                                    
   Yang Y, 1998, BLOOD, V92, P3912
   Yoneyama H, 1998, J CLIN INVEST, V102, P1933, DOI 10.1172/JCI4619                                                                 
   Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118
   Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803
   Yoshida T, 1998, J BIOL CHEM, V273, P16551, DOI 10.1074/jbc.273.26.16551
   Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634
   YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233
   YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3
   Youn BS, 1999, BLOOD, V94, P2533
   Youn BS, 1997, J IMMUNOL, V159, P5201
   Yu CR, 2000, J IMMUNOL, V164, P1293, DOI 10.4049/jimmunol.164.3.1293                                                     
   Zaballos A, 1999, J IMMUNOL, V162, P5671
   Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241                                                          
   Zaitseva M, 1997, NAT MED, V3, P1369, DOI 10.1038/nm1297-1369                                                             
   Zaitseva MB, 1998, J IMMUNOL, V161, P3103
   Zhang LQ, 1998, J VIROL, V72, P5035
   Zhang SM, 1999, J IMMUNOL, V162, P4938
   Zhang YJ, 1998, J VIROL, V72, P9337
   Zhou YH, 1998, J IMMUNOL, V160, P4018
   Zimmerman PA, 1997, MOL MED, V3, P23
   ZIMMERMAN PA, 1999, IN PRESS P NATL ACAD
   Zingoni A, 1998, J IMMUNOL, V161, P547
   Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1
   Zou P, 1999, J VIROL, V73, P5926
   Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269
NR 422
TC 1392
Z9 1438
U1 5
U2 59
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0031-6997
J9 PHARMACOL REV
JI Pharmacol. Rev.
PD MAR
PY 2000
VL 52
IS 1
BP 145
EP 176
PG 32
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 291FJ
UT WOS:000085723200007
PM 10699158
DA 2018-01-05
ER

PT J
AU Caflisch, A
   Schramm, HJ
   Karplus, M
AF Caflisch, A
   Schramm, HJ
   Karplus, M
TI Design of dimerization inhibitors of HIV-1 aspartic proteinase: A
   computer-based combinatorial approach
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE de novo design; finite-difference Poisson-Boltzmann; HIV-1 aspartic
   proteinase; inhibitors of dimerization; MCSS; structure-based drug
   design
ID COPY SIMULTANEOUS SEARCH; VIRUS TYPE-1 PROTEASE; ACTIVE-SITE CLEFT;
   INTERFACE PEPTIDES; DRUG-RESISTANCE; LIGAND DESIGN; KINETIC
   CHARACTERIZATION; MOLECULAR-DYNAMICS; LEUCINE ZIPPER; BINDING-SITES
AB Inhibition of dimerization to the active form of the HIV-1 aspartic proteinase (HIV-1 PR) may be a way to decrease the probability of escape mutations for this viral protein. The Multiple Copy Simultaneous Search (MCSS) methodology was used to generate functionality maps for the dimerization interface of HIV-1 PR. The positions of the MCSS minima of 19 organic fragments, once postprocessed to take into account solvation effects, are in good agreement with experimental data on peptides that bind to the interface. The MCSS minima combined with an approach for computational combinatorial ligand design yielded a set of modified HIV-1 PR C-terminal peptides that are similar to known nanomolar inhibitors of HIV-1 PR dimerization. A number of N-substituted 2,5-diketopiperazines are predicted to be potential dimerization inhibitors of HIV-1 PR.
C1 Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland.
   Max Planck Inst Biochem, D-82152 Martinsried, Germany.
   Univ Strasbourg 1, Lab Chim Biophys, Inst Le Bel, F-6700 Strasbourg, France.
RP Caflisch, A (reprint author), Univ Zurich, Dept Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.
EM caflisch@bioc.unizh.ch
RI Caflisch, Amedeo/I-3459-2012
CR Ala PJ, 1997, BIOCHEMISTRY-US, V36, P1573, DOI 10.1021/bi962234u
   BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003                                                          
   BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244
   BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3                                                   
   Bouras A, 1999, J MED CHEM, V42, P957, DOI 10.1021/jm9803976                                                               
   Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010
   BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211
   BRUNGER AT, 1988, PROTEINS, V4, P148, DOI 10.1002/prot.340040208
   Caflisch A, 1996, J COMPUT AID MOL DES, V10, P372, DOI 10.1007/BF00124471
   Caflisch A, 1995, PERSPECT DRUG DISCOV, V3, P51, DOI 10.1007/BF02174467                                                              
   CAFLISCH A, 1993, J MED CHEM, V36, P2142, DOI 10.1021/jm00067a013                                                             
   Caflisch A., 1997, STRUCTURE BASED DRUG, P541
   CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0
   DARKE PL, 1994, BIOCHEMISTRY-US, V33, P98, DOI 10.1021/bi00167a013                                                             
   DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2                                                    
   ERICKSON JW, 1995, NAT STRUCT BIOL, V2, P523, DOI 10.1038/nsb0795-523
   Ermolieff J, 1997, BIOCHEMISTRY-US, V36, P12364, DOI 10.1021/bi971072e
   GELIN BR, 1975, P NATL ACAD SCI USA, V72, P2002, DOI 10.1073/pnas.72.6.2002
   GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104
   GRANT SK, 1992, BIOCHEMISTRY-US, V31, P9491, DOI 10.1021/bi00154a023
   Grootenhuis PDJ, 1996, J COMPUT AID MOL DES, V10, P1, DOI 10.1007/BF00124460
   GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002
   HERMANN RB, 1972, J PHYS CHEM-US, V76, P2754, DOI 10.1021/j100663a023                                                             
   Hoetelmans RMW, 1997, PHARM WORLD SCI, V19, P159, DOI 10.1023/A:1008629608556                                                         
   HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829
   JosephMcCarthy D, 1997, PROTEINS, V29, P32, DOI 10.1002/(SICI)1097-0134(199709)29:1<32::AID-PROT3>3.0.CO;2-H
   KLEBE G, 1994, J COMPUT AID MOL DES, V8, P751, DOI 10.1007/BF00124019
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X
   LOEB DD, 1989, NATURE, V340, P397, DOI 10.1038/340397a0
   LOUIS JM, 1989, BIOCHEM BIOPH RES CO, V164, P30, DOI 10.1016/0006-291X(89)91678-1                                                    
   MIRANKER A, 1991, PROTEINS, V11, P29, DOI 10.1002/prot.340110104
   Miranker A, 1995, PROTEINS, V23, P472, DOI 10.1002/prot.340230403                                                          
   Neria E, 1996, J CHEM PHYS, V105, P1902, DOI 10.1063/1.472061                                                                
   OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757
   OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029
   PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9                                                    
   Patick AK, 1997, ANTIMICROB AGENTS CH, V41, P2159
   Rayner MM, 1997, VIROLOGY, V236, P85, DOI 10.1006/viro.1997.8620
   Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5                                                    
   SARDANA VV, 1994, BIOCHEMISTRY-US, V33, P2004, DOI 10.1021/bi00174a005
   SCHRAMM HJ, 1991, BIOCHEM BIOPH RES CO, V179, P847, DOI 10.1016/0006-291X(91)91895-J
   SCHRAMM HJ, 1993, BIOCHEM BIOPH RES CO, V194, P595, DOI 10.1006/bbrc.1993.1863
   Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0                                                    
   SITKOFF D, 1994, J PHYS CHEM-US, V98, P1978, DOI 10.1021/j100058a043                                                             
   STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038                                                             
   VENABLE RM, 1993, PROTEINS, V15, P374, DOI 10.1002/prot.340150405
   WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8
   WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279
   ZHANG ZY, 1991, J BIOL CHEM, V266, P15591
   Zheng Q, 1996, BIOORGAN MED CHEM, V4, P631, DOI 10.1016/0968-0896(96)00056-9
   ZHENG Q, 1994, PROTEINS, V19, P324, DOI 10.1002/prot.340190407
   Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j                                                               
NR 56
TC 19
Z9 19
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD FEB
PY 2000
VL 14
IS 2
BP 161
EP 179
DI 10.1023/A:1008146201260                                                 
          
PG 19
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA 279EG
UT WOS:000085031000004
PM 10721504
DA 2018-01-05
ER

PT J
AU Corbett, JW
   Ko, SS
   Rodgers, JD
   Jeffrey, S
   Bacheler, LT
   Klabe, RM
   Diamond, S
   Lai, CM
   Rabel, SR
   Saye, JA
   Adams, SP
   Trainor, GL
   Anderson, PS
   Erickson-Viitanen, SK
AF Corbett, JW
   Ko, SS
   Rodgers, JD
   Jeffrey, S
   Bacheler, LT
   Klabe, RM
   Diamond, S
   Lai, CM
   Rabel, SR
   Saye, JA
   Adams, SP
   Trainor, GL
   Anderson, PS
   Erickson-Viitanen, SK
TI Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit
   clinically relevant mutant variants of human immunodeficiency virus type
   1
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HIV; SERIES
AB A research program targeted toward the identification of expanded-spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human immunodeficiency virus (HIV) and which maintain pharmacokinetics consistent with once-a-day dosing has resulted in the identification of the 4-cyclopropylalkynyl-4-trifluoromethyl-3,4-dihydro-2(1H)quinazolinones DPC 961 and DPC 963 and the 4-cyclopropylalkenyl-4-trifluoromethyl-3,4-dihydro-2(1H)quinazolinones DPC 082 and DPC 083 for clinical development. DPC 961, DPC 963, DPC 082, and DPC 083 all exhibit low-nanomolar potency toward wild-type virus, K103N and L1001 single-mutation variants, and many multiply amino acid-substituted HN type 1 mutants. This high degree of potency is combined with a high degree of oral bioavailability, as demonstrated in rhesus monkeys and chimpanzees, and,vith plasma serum protein binding that can result in significant free levels of drug.
C1 DuPont Pharmaceut Co, Expt Stn, Wilmington, DE 19880 USA.
RP Corbett, JW (reprint author), DuPont Pharmaceut Co, Expt Stn, E500-4403A,POB 80500, Wilmington, DE 19880 USA.
CR BACHELER L, 1998, 12 WORLD AIDS C
   BACHELER LT, 1994, ANTIVIR CHEM CHEMOTH, V5, P111, DOI 10.1177/095632029400500208                                                      
   Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064                                                          
   CORBETT JW, 1998, 4 INT C DRUG THER HI
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   Havlir DV, 1996, J VIROL, V70, P7894
   HIRSCH MS, 1998, AIDS, V12, P6
   Jadhav PK, 1997, J MED CHEM, V40, P181, DOI 10.1021/jm960586t
   Kleim JP, 1997, VIROLOGY, V231, P112, DOI 10.1006/viro.1997.8513
   MORALESRAMIREZ J, 1998, 38 INT C ANT AG CHEM, P394
   PATEL M, IN PRESS BIOORG MED
   SMALLHEER JM, 1993, ANTIVIR CHEM CHEMOTH, V4, P27, DOI 10.1177/095632029300400104                                                      
   TUCKER TJ, 1994, J MED CHEM, V37, P2437, DOI 10.1021/jm00041a023
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
NR 14
TC 107
Z9 117
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD DEC
PY 1999
VL 43
IS 12
BP 2893
EP 2897
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 261YE
UT WOS:000084037900012
PM 10582878
DA 2018-01-05
ER

PT J
AU Berton, M
   Allemann, E
   Stein, CA
   Gurny, R
AF Berton, M
   Allemann, E
   Stein, CA
   Gurny, R
TI Highly loaded nanoparticulate carrier using an hydrophobic antisense
   oligonucleotide complex
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE nanoparticle; antisense oligonucleotide; poly-(D,L-laclic acid); drug
   delivery; biodegradable polymer; HIV-1
ID POLYALKYLCYANOACRYLATE NANOPARTICLES; INTRACELLULAR DELIVERY;
   OLIGODEOXYNUCLEOTIDES; MECHANISM; VIRUS; REPLICATION; INHIBITION;
   LIPOSOMES; SYSTEMS; RELEASE
AB Antisense oligonucleotides, and particularly those with phosphorothioate backbones, have emerged as potential gene specific therapeutic agents and are currently undergoing evaluation in clinical trials for a variety of diseases. In the area of HIV-I therapeutics, targeting of oligonucleotides to infected cells, such as macrophages, would be highly desirable. The present study was designed to prepare and characterize oligonucleotide-loaded nanoparticles for this purpose. Due to their hydrophilic characteristics, oligonucleotides are difficult to entrap in polymeric particles. Here, the oligonucleotides were first complexed with cetyltrimethylammonium bromide. The oligonucleotide-loaded nanoparticles were prepared by the emulsification-diffusion method and subsequently purified. In comparison with previous studies, a high oligonucleotide-loading was achieved: 2.5, 5 and 10% oligonucleotide loading were assessed. If the initial oligonucleotide content was 4%, this method produced a final oligonucleotide loading of 1.9% with an entrapment efficiency of 47%. The integrity of the oligonucleotide and of the polymer, in the final freeze-dried product, was retained. (C) 1999 Elsevier Science B.V. All rights reserved.
C1 Univ Geneva, Sch Pharm, CH-1211 Geneva 4, Switzerland.
   Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA.
   Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY USA.
RP Gurny, R (reprint author), Univ Geneva, Sch Pharm, Quai E Ansermet, CH-1211 Geneva 4, Switzerland.
CR Akhtar S, 1997, INT J PHARM, V151, P57, DOI 10.1016/S0378-5173(97)04887-4                                                   
   Akhtar S, 1996, J ANTIMICROB CHEMOTH, V38, P159, DOI 10.1093/jac/38.2.159
   ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P13
   Benimetskaya L, 1998, NUCLEIC ACIDS RES, V26, P5310, DOI 10.1093/nar/26.23.5310                                                          
   Bennett CF, 1998, J DRUG TARGET, V5, P149, DOI 10.3109/10611869808995870                                                       
   Bennett CF, 1998, BIOCHEM PHARMACOL, V55, P9, DOI 10.1016/S0006-2952(97)00214-1
   Berton M, 1999, EUR J PHARM BIOPHARM, V47, P119, DOI 10.1016/S0939-6411(98)00064-2
   Berton M, 1997, BBA-MOL CELL RES, V1355, P7, DOI 10.1016/S0167-4889(96)00111-5
   CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255
   CHAVANY C, 1994, PHARMACEUT RES, V11, P1370, DOI 10.1023/A:1018923301967
   CHAVANY C, 1992, PHARMACEUT RES, V9, P441, DOI 10.1023/A:1015871809313
   COHEN S, 1991, PHARMACEUT RES, V8, P713, DOI 10.1023/A:1015841715384                                                         
   CROOKE ST, 1995, J DRUG TARGET, V3, P185, DOI 10.3109/10611869509015944
   DeLong R, 1997, J PHARM SCI, V86, P762, DOI 10.1021/js960409f                                                               
   Fattal E, 1998, J CONTROL RELEASE, V53, P137, DOI 10.1016/S0168-3659(97)00246-0                                                   
   HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V
   Hughes D., 1996, Journal of Veterinary Emergency & Critical Care, V6, P13
   LEROUX JC, 1995, EUR J PHARM BIOPHARM, V41, P14
   Lewis JG, 1996, P NATL ACAD SCI USA, V93, P3176, DOI 10.1073/pnas.93.8.3176
   LEWIS KJ, 1995, J CONTROL RELEASE, V37, P173, DOI 10.1016/0168-3659(95)00100-M
   LIU LS, 1992, MACROMOLECULES, V25, P123, DOI 10.1021/ma00027a020                                                             
   Lourenco C, 1996, INT J PHARM, V138, P1, DOI 10.1016/0378-5173(96)04486-9
   Mahato RI, 1997, PHARMACEUT RES, V14, P853, DOI 10.1023/A:1012187414126                                                         
   Nakanishi M, 1998, J CONTROL RELEASE, V54, P61, DOI 10.1016/S0168-3659(97)00220-4
   Narayanan Ramaswamy, 1996, Current Opinion in Oncology, V8, P509
   Oliveira M.C., 1997, J CONTROL RELEASE, V48, P179
   Reich G, 1998, EUR J PHARM BIOPHARM, V45, P165, DOI 10.1016/S0939-6411(97)00152-5
   Shaw DR, 1997, BIOCHEM PHARMACOL, V53, P1123, DOI 10.1016/S0006-2952(97)00091-9
   STEIN CA, 1994, ANTISENSE RES DEV, V4, P67
   Stein CA, 1996, TRENDS BIOTECHNOL, V14, P147, DOI 10.1016/0167-7799(96)20006-X
   STEIN CA, 1995, NAT MED, V1, P1119, DOI 10.1038/nm1195-1119
   Waelti ER, 1998, INT J CANCER, V77, P728, DOI 10.1002/(SICI)1097-0215(19980831)77:5<728::AID-IJC11>3.0.CO;2-Y
   ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280
   Zelphati O, 1996, PHARMACEUT RES, V13, P1367, DOI 10.1023/A:1016026101195                                                         
   ZELPHATI O, 1994, NUCLEIC ACIDS RES, V22, P4307, DOI 10.1093/nar/22.20.4307
   Zelphati O, 1996, J CONTROL RELEASE, V41, P99, DOI 10.1016/0168-3659(96)01361-2
   Zelphati O, 1996, P NATL ACAD SCI USA, V93, P11493, DOI 10.1073/pnas.93.21.11493
NR 37
TC 33
Z9 34
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928-0987
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD DEC
PY 1999
VL 9
IS 2
BP 163
EP 170
DI 10.1016/S0928-0987(99)00049-4
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 268HJ
UT WOS:000084408000007
PM 10620729
DA 2018-01-05
ER

PT J
AU Arrizabalaga, G
   Lehmann, I
AF Arrizabalaga, G
   Lehmann, I
TI A selective screen reveals discrete functional domains in Drosophila
   Nanos
SO GENETICS
LA English
DT Article
ID HIV-1 NUCLEOCAPSID PROTEIN; POSTERIOR MORPHOGEN NANOS; TRANSLATIONAL
   REGULATION; MESSENGER-RNA; ZINC-FINGER; EMBRYONIC POLARITY; DETERMINANT
   NANOS; BINDING DOMAIN; CELL-FORMATION; MATERNAL GENE
AB The Drosophila protein Nanos encodes an evolutionarily conserved protein with two zinc finger motifs. In the embryo, Nanos protein function is required for establishment of the anterior-posterior body pattern and for the migration of primordial germ cells. During oogenesis, Nanos protein is involved in the establishment and maintenance of germ-line stem cells and the differentiation of oocyte precursor cells. To establish proper embryonic patterning, Nanos acts as a translational regulator of hunchback RNA. Nanos' targets for germ cell migration and development are not known. Were, we describe a selective genetic screen aimed at isolating new nanos alleles. The molecular and genetic analysis of 68 new alleles has allowed us to identify amino acids critical for nanos function. This analysis shows that the CCHC motifs, which coordinate two metal ions, are essential for all known functions of Nanos protein. Furthermore, a region C-terminal to the zinc fingers seems to constitute a novel functional domain within the Nanos protein. This "tail region" of Nanos is required for abdomen formation and germ cell migration, but not for oogenesis.
C1 NYU, Med Ctr, Skirball Inst, Dev Genet Program,Sch Med,Howard Hughes Med Inst, New York, NY 10016 USA.
   MIT, Dept Biol, Cambridge, MA 02139 USA.
RP Lehmann, I (reprint author), NYU, Med Ctr, Skirball Inst, Dev Genet Program,Sch Med,Howard Hughes Med Inst, 540 1st Ave,4th Fl, New York, NY 10016 USA.
CR AHRINGER J, 1992, EMBO J, V11, P2303
   AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0
   Asaoka M, 1998, MECH DEVELOP, V78, P153, DOI 10.1016/S0925-4773(98)00164-6
   ASHBURNER M, 1989, DROSOPHILA LAB HDB, P299
   Bai CY, 1998, NUCLEIC ACIDS RES, V26, P1597, DOI 10.1093/nar/26.7.1597
   BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312
   Bhat KM, 1999, GENETICS, V151, P1479
   Chou TB, 1996, GENETICS, V144, P1673
   Curtis D, 1997, EMBO J, V16, P834, DOI 10.1093/emboj/16.4.834
   CURTIS D, 1995, DEVELOPMENT, V121, P1899
   Dahanukar A, 1996, GENE DEV, V10, P2610, DOI 10.1101/gad.10.20.2610
   DANNULL J, 1994, EMBO J, V13, P1525
   De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384                                                    
   EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N
   EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0
   Forbes A, 1998, DEVELOPMENT, V125, P679
   GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J
   Gavis ER, 1996, DEV BIOL, V176, P36, DOI 10.1006/dbio.1996.9996
   Gavis ER, 1996, DEVELOPMENT, V122, P2791
   GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0
   Heller A, 1998, MECH DEVELOP, V72, P169, DOI 10.1016/S0925-4773(98)00020-3
   HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0
   IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0                                                                
   Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0
   Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7                                                   
   LEHMANN R, 1988, DEVELOPMENT, V104, P17
   LEHMANN R, 1991, DEVELOPMENT, V112, P679
   LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2
   MACDONALD PM, 1992, DEVELOPMENT, V114, P221
   MOSQUERA L, 1993, DEVELOPMENT, V117, P377
   MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4                                                    
   OTTMANN M, 1995, J VIROL, V69, P1778
   Pilon M, 1997, DEVELOPMENT, V124, P1771
   PIRROTTA V, 1998, VECTORS SURVEY MOL C, P437
   RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787
   Sambrook J, 1989, MOL CLONING LAB MANU
   Smibert CA, 1996, GENE DEV, V10, P2600, DOI 10.1101/gad.10.20.2600
   Spradling A.C., 1986, DROSOPHILA PRACTICAL, P175
   STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0
   Subramaniam K, 1999, DEVELOPMENT, V126, P4861
   THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167
   WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K
   WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204                                                          
   WANG CI, 1995, THESIS MIT CAMBRIDGE
   WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9
   Wharton RP, 1998, MOL CELL, V1, P863, DOI 10.1016/S1097-2765(00)80085-4
   WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0
   Zamore PD, 1999, BIOCHEMISTRY-US, V38, P596, DOI 10.1021/bi982264s
   Zamore PD, 1997, RNA, V3, P1421
   Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297                                                                   
NR 50
TC 28
Z9 29
U1 0
U2 1
PU GENETICS
PI BALTIMORE
PA 428 EAST PRESTON ST, BALTIMORE, MD 21202 USA
SN 0016-6731
J9 GENETICS
JI Genetics
PD DEC
PY 1999
VL 153
IS 4
BP 1825
EP 1838
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA 262RB
UT WOS:000084079300029
PM 10581288
DA 2018-01-05
ER

PT J
AU Morris, MC
   Berducou, C
   Mery, J
   Heitz, F
   Divita, G
AF Morris, MC
   Berducou, C
   Mery, J
   Heitz, F
   Divita, G
TI The thumb domain of the P51-subunit is essential for activation of HIV
   reverse transcriptase
SO BIOCHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE;
   ESCHERICHIA-COLI; SUBUNIT BINDING; CROSS-LINKING; DNA-SYNTHESIS;
   DIMERIZATION; INHIBITORS; PEPTIDES
AB The biologically relevant and active form of human immunodeficiency virus reverse transcriptase is a heterodimer produced in a two-step dimerization process. Dimerization involves first the rapid association of the two subunits, followed by a slow conformational change yielding a fully active form. In the present study, we demonstrate that the interaction between the thumb domain of p51 and the RNase-H domain of p66 plays a major role in an essential conformational change required for proper folding of the primer/template and the tRNA-binding site, for maturation and for activation of heterodimeric reverse transcriptase, A synthetic peptide derived from the sequence within the thumb domain of p51, which forms the interface with the RNase-H domains of p66, binds heterodimeric reverse transcriptase with an apparent dissociation constant in the nanomolar range and selectively inhibits activation of heterodimeric reverse transcriptase with an inhibition constant of 1.2 mu M. A detailed study of the mechanism of inhibition reveals that this peptide does not require dissociation of heterodimeric RT for efficient inhibition and does not affect subunit association, but interferes with the conformational change required for activation of heterodimeric reverse transcriptase, resulting in a decrease in the affinity of reverse transcriptase for the tRNA and an increase in the stability of the primer/template/reverse transcriptase complex. We have previously proposed that the dimeric nature of reverse transcriptase represents an interesting target for the design of antiviral agents. On the basis of this work, we propose that the conformational changes involved in the activation of reverse transcriptase similarly represent an important target for the design of novel antiviral compounds,
C1 CNRS, UPR1086, Ctr Rech Biochim Macromol, F-34283 Montpellier 5, France.
RP Divita, G (reprint author), CNRS, UPR1086, Ctr Rech Biochim Macromol, 1919 Route Mende, F-34283 Montpellier 5, France.
RI MORRIS, May/J-5940-2016
OI MORRIS, May/0000-0001-8106-9728
CR Arts EJ, 1998, J BIOL CHEM, V273, P14523, DOI 10.1074/jbc.273.23.14523                                                        
   BAILLON JG, 1991, NEW BIOL, V3, P1015
   Baltimore D., 1970, NATURE, V226, P1211
   BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999
   Debyser Z, 1996, PROTEIN SCI, V5, P278
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DIVITA G, 1994, J BIOL CHEM, V269, P13080
   Divita G, 1995, BIOCHEMISTRY-US, V34, P16337, DOI 10.1021/bi00050a014
   DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042
   DIVITA G, 1995, J BIOL CHEM, V270, P28642, DOI 10.1074/jbc.270.48.28642                                                        
   Dufour E, 1999, J MOL BIOL, V285, P1339, DOI 10.1006/jmbi.1998.2430
   ESNOUF R, 1995, NAT STRUCT BIOL, V2, P303, DOI 10.1038/nsb0495-303
   GOEL R, 1993, BIOCHEMISTRY-US, V32, P13012, DOI 10.1021/bi00211a009
   Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669                                                   
   Isel C, 1999, EMBO J, V18, P1038, DOI 10.1093/emboj/18.4.1038
   JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320                                                         
   JACQUES PS, 1994, J BIOL CHEM, V269, P1388
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   LIGHTFOOTE MM, 1986, J VIROL, V60, P771
   MERLUZZI VJ, 1990, SCIENCE, V250, P1411, DOI 10.1126/science.1701568                                                         
   MERY J, 1993, INT J PEPT PROT RES, V42, P44
   MISHIMA Y, 1995, EMBO J, V14, P2679
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   MULLER B, 1989, J BIOL CHEM, V264, P13975
   MULLER B, 1991, J BIOL CHEM, V266, P14709
   MULLER B, 1991, BIOCHEMISTRY, V30
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   RESTLE T, 1990, J BIOL CHEM, V265, P8986
   RESTLE T, 1992, FEBS LETT, V300, P97, DOI 10.1016/0014-5793(92)80172-D                                                    
   RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222
   Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387
   VERONESE FD, 1986, SCIENCE, V231, P1289
   WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4
   WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242
   Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581                                                        
NR 36
TC 23
Z9 24
U1 0
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD NOV 16
PY 1999
VL 38
IS 46
BP 15097
EP 15103
DI 10.1021/bi9914558
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 259NF
UT WOS:000083899400005
PM 10563792
DA 2018-01-05
ER

PT J
AU Hawkins, V
   Shen, Q
   Chiueh, CC
AF Hawkins, V
   Shen, Q
   Chiueh, CC
TI Kynostatin and 17 beta-estradiol prevent the apoptotic death of human
   neuroblastoma cells exposed to HIV-1 protease
SO JOURNAL OF BIOMEDICAL SCIENCE
LA English
DT Article
DE AIDS dementia complex; antioxidants; apoptosis; cerebral atrophy; gp120;
   HIV-1 protease; human neuroblastoma cell; neuroprotection; protease
   inhibitor (KNI-272)
ID HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS DEMENTIA COMPLEX; OXIDATIVE STRESS;
   TYPE-1 PROTEASE; BRAIN; NEUROTOXICITY; PEPTIDE; LOCALIZATION;
   INHIBITORS; INFECTION
AB A significant number of adult male patients with acquired immunodeficiency syndrome develop cerebral atrophy and progressive brain disorders such as dementia complex and neuropsychiatric problems. Upon entering the brain via activated macrophages or microglias, the human immunodeficiency type 1 virus (HIV-1) may produce cytotoxic factors such as HIV-1 envelope protein (gp120) and protease, Owing to significant proteolysis of nonviral proteins, the protease derived from HIV-1 may be detrimental to brain cells and neurons. Our results revealed that HIV-1 protease, at nanomolar concentrations, was as potent as gp120 in causing neurotoxicity in human neuroblastoma neurotypic SH-SY5Y cells. As shown by the Oncor ApopTag staining procedure, HIV-1 protease significantly increased the number of apoptotic cells over the serum-free controls. Moreover, HIV-1 protease-induced neurotoxicity was blocked by a selective protease inhibitor, kynostatin (KNI-272), Antioxidants such as 17 beta-estradiol, melatonin, and S-nitrosoglutathione also prevented protease-induced neurotoxicity. These findings indicate that oxidative proteolysis may mediate HIV-1 protease-induced apoptosis and the degeneration of neurons and other brain cells. Centrally active protease inhibitors and antioxidants may play an important role in preventing cerebral atrophy and associated dementia complex caused by HIV-1.
C1 NIMH, Unit Neurodegenerat & Neuroprotect, Clin Sci Lab, NIH, Bethesda, MD 20892 USA.
   NIH, Bethesda, MD USA.
RP Chiueh, CC (reprint author), NIMH, Unit Neurodegenerat & Neuroprotect, Clin Sci Lab, NIH, 10-3D-41, Bethesda, MD 20892 USA.
CR ACHIM CL, 1994, J NEUROPATH EXP NEUR, V53, P284, DOI 10.1097/00005072-199405000-00010
   Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479
   BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0
   BRENNEMAN DE, 1994, ADV NEUROIMMUNOL, V4, P157, DOI 10.1016/S0960-5428(06)80252-4
   Carneiro RCG, 1998, NEUROSCIENCE, V82, P293
   CHIUEH CC, 1999, IN PRESS FREE RADIC
   CHUEH CC, 1999, FASEB J, V13, p6B134
   COROSANITI MT, 1996, BIOCHEM BIOPH RES CO, V229, P299
   DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153
   DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646
   Dubal DB, 1999, J NEUROSCI, V19, P6385
   Eves EM, 1996, J NEUROCHEM, V67, P1908
   FILLIT H, 1986, PSYCHONEUROENDOCRINO, V11, P337, DOI 10.1016/0306-4530(86)90019-3
   FRENKEL K, 1987, CARCINOGENESIS, V8, P1207, DOI 10.1093/carcin/8.9.1207
   GLASS JD, 1993, NEUROLOGY, V43, P2230, DOI 10.1212/WNL.43.11.2230                                                          
   GUSTCHINA A, 1994, PROTEIN ENG, V7, P309, DOI 10.1093/protein/7.3.309
   Kiso Y, 1996, BIOPOLYMERS, V40, P235, DOI 10.1002/(SICI)1097-0282(1996)40:2<235::AID-BIP3>3.0.CO;2-X
   KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686
   Kruse PF, 1973, TISSUE CULTURE METHO
   KURE K, 1990, AM J PATHOL, V136, P1085
   LEE SY, 1999, FASEB J, V13, pLB135
   Li YP, 1996, BRAIN RES, V738, P196, DOI 10.1016/S0006-8993(96)00733-0
   Masliah E, 1996, CRIT REV NEUROBIOL, V10, P57, DOI 10.1615/CritRevNeurobiol.v10.i1.30                                              
   MERRILL JE, 1991, FASEB J, V5, P2391
   NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603
   NAVIA MA, 1989, NATURE, V337, P615, DOI 10.1038/337615a0
   Persichini T, 1998, BIOCHEM BIOPH RES CO, V250, P575, DOI 10.1006/bbrc.1998.9350
   PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272
   Rauhala P, 1998, FASEB J, V12, P165
   RAUHALA P, IN PRESS P NY AC SCI
   ROSS RA, 1983, J NATL CANCER I, V71, P741
   Schulz Ruediger, 1996, Journal of Marine Biotechnology, V4, P16
   Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529                                                       
   SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336
   SMITHSWINTOSKY VL, 1995, J NEUROCHEM, V65, P1415
   Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571                                                         
   Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606
   TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548
   TOMASZEK TA, 1992, BIOCHEMISTRY-US, V31, P10153, DOI 10.1021/bi00157a003
   Vago L, 1990, Acta Neurol (Napoli), V12, P32
   WALLIN M, 1990, J GEN VIROL, V71, P1985, DOI 10.1099/0022-1317-71-9-1985
   Woolley CS, 1999, CURR OPIN NEUROBIOL, V9, P349, DOI 10.1016/S0959-4388(99)80051-8                                                   
NR 42
TC 8
Z9 9
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1021-7770
J9 J BIOMED SCI
JI J. Biomed. Sci.
PD NOV-DEC
PY 1999
VL 6
IS 6
BP 433
EP 438
DI 10.1159/000025419
PG 6
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 249VZ
UT WOS:000083355100009
PM 10545779
DA 2018-01-05
ER

PT J
AU Hogberg, M
   Sahlberg, C
   Engelhardt, P
   Noreen, R
   Kangasmetsa, J
   Johansson, NG
   Oberg, B
   Vrang, L
   Zhang, H
   Sahlberg, BL
   Unge, T
   Lovgren, S
   Fridborg, K
   Backbro, K
AF Hogberg, M
   Sahlberg, C
   Engelhardt, P
   Noreen, R
   Kangasmetsa, J
   Johansson, NG
   Oberg, B
   Vrang, L
   Zhang, H
   Sahlberg, BL
   Unge, T
   Lovgren, S
   Fridborg, K
   Backbro, K
TI Urea-PETT compounds as a new class of HIV-1 reverse transcriptase
   inhibitors. 3. Synthesis and further structure-activity relationship
   studies of PETT analogues
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; WILD-TYPE;
   POTENT; DERIVATIVES; REPLICATION; COMBINATION; NEVIRAPINE; DRUG;
   ZIDOVUDINE
AB The further development-of allosteric HIV-1 RT inhibitors in the urea analogue series of PETT (phenylethylthiazolylthiourea) derivatives is described here. The series includes derivatives with an ethyl linker (1-5) and racemic (6-16) and enantiomeric (17-20) cis-cyclopropane compounds. The antiviral activity was determined both at the RT level and in cell culture on both wild-type and mutant forms of HIV-1. Most compounds have anti-HIV-l activity on the wt in the nanomolar range. Resistant HIV-1 was selected in vitro for some of the compounds, and the time for resistant HIV-1 to develop was longer for urea-PETT compounds than it was for reference compounds. Preliminary pharmacokinetics in rats showed that compound 18 is orally bioavailable and penetrates well into the brain. The three-dimensional structure of complexes between HIV-1 RT and two enantiomeric compounds (17 and 18) have been determined. The structures show similar binding in the NNI binding pocket. The propionylphenyl moieties of both inhibitors show perfect-stacking to tyrosine residues 181 and 188. The cyclopropyl moiety of the (+)-enantiomer 18 exhibits optimal packing distances for the interactions with leucine residue 100 and valine residue 179.
C1 Medivir AB, S-14144 Huddinge, Sweden.
   Karolinska Inst, Ctr Microbiol & Tumor Biol, MTC, Stockholm, Sweden.
   Uppsala Univ, Dept Mol Biol, S-75124 Uppsala, Sweden.
RP Hogberg, M (reprint author), Medivir AB, Lunastigen 7, S-14144 Huddinge, Sweden.
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   Balzarini J, 1996, ANTIMICROB AGENTS CH, V40, P1454
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   Carr A, 1996, AIDS, V10, P635, DOI 10.1097/00002030-199606000-00009
   CHEESEMAN SH, 1993, ANTIMICROB AGENTS CH, V37, P178, DOI 10.1128/AAC.37.2.178                                                            
   Cushman M, 1996, J MED CHEM, V39, P3217, DOI 10.1021/jm960082v                                                               
   Davey RT, 1996, ANTIMICROB AGENTS CH, V40, P1657
   DEJONG MD, 1995, ANTIVIR RES, V29, P5
   EVANS DA, 1991, J AM CHEM SOC, V113, P726, DOI 10.1021/ja00002a080                                                             
   Fujiwara T, 1998, ANTIMICROB AGENTS CH, V42, P1340
   GEWIRTH D, 1995, SCALEPACK MANUAL
   GROB PM, 1992, AIDS RES HUM RETROV, V8, P145, DOI 10.1089/aid.1992.8.145
   HARGRAVE KD, 1991, J MED CHEM, V34, P2231, DOI 10.1021/jm00111a045
   Hirsch M. S., 1997, Antiviral Therapy, V2, P19
   JEFFREY S, 1999, 6 C RETR OPP INF CHI
   JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224
   KLEIM JP, 1995, ANTIMICROB AGENTS CH, V39, P2253, DOI 10.1128/AAC.39.10.2253                                                          
   KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399
   Lange J., 1997, Antiviral Therapy, V2, P71
   NOLAND WE, 1988, ORG SYNTH, V6, P739
   NOREEN R, 1993, 6 INT C ANT RES VEN
   Okamoto M, 1996, ANTIVIR RES, V31, P69, DOI 10.1016/0166-3542(96)00946-1
   OTWINOVSKI Z, HKL PROGRAM SUITE
   PAUWELS R, 1994, ANTIMICROB AGENTS CH, V38, P2863, DOI 10.1128/AAC.38.12.2863                                                          
   PAUWELS R, 1993, P NATL ACAD SCI USA, V90, P1711, DOI 10.1073/pnas.90.5.1711                                                          
   Richman D. D., 1997, Antiviral Therapy, V2, P41
   ROMERO DL, 1994, J MED CHEM, V37, P999, DOI 10.1021/jm00033a018
   Sahlberg C, 1998, BIOORG MED CHEM LETT, V8, P1511, DOI 10.1016/S0960-894X(98)00249-2
   Staszewski S, 1996, AIDS, V10, pF1, DOI 10.1097/00002030-199605000-00001
   WEISLOW OS, 1989, J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577
   YOUNG SD, 1995, ANTIMICROB AGENTS CH, V39, P2602, DOI 10.1128/AAC.39.12.2602                                                          
   ZHANG H, 1993, ANTIVIR CHEM CHEMOTH, V4, P301, DOI 10.1177/095632029300400506                                                      
   Zhang H, 1996, ANTIVIR CHEM CHEMOTH, V7, P221, DOI 10.1177/095632029600700501                                                      
   Zhang H, 1995, ANTIVIR RES, V28, P331, DOI 10.1016/0166-3542(95)00056-9                                                    
NR 36
TC 76
Z9 81
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
J9 J MED CHEM
JI J. Med. Chem.
PD OCT 7
PY 1999
VL 42
IS 20
BP 4150
EP 4160
DI 10.1021/jm990095j
PG 11
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA 244EV
UT WOS:000083039600015
PM 10514285
DA 2018-01-05
ER

PT J
AU Martyanov, IV
   Zakharova, OD
   Sottofattori, E
   Pyshnyi, DV
   Yurchenko, EY
   Babbi, P
   Mazzei, M
   Balbi, A
   Andreola, ML
   Litvak, S
   Tarrago-Litvak, L
   Nevinsky, GA
AF Martyanov, IV
   Zakharova, OD
   Sottofattori, E
   Pyshnyi, DV
   Yurchenko, EY
   Babbi, P
   Mazzei, M
   Balbi, A
   Andreola, ML
   Litvak, S
   Tarrago-Litvak, L
   Nevinsky, GA
TI Interaction of oligonucleotides conjugated to substituted chromones and
   coumarins with HIV-1 reverse transcriptase
SO ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT
LA English
DT Article
ID DNA-SYNTHESIS; FUNCTIONAL-ANALYSIS; PRIMER TRNA(LYS3); AFFINITY;
   COMPLEX; AGENTS; MONONUCLEOTIDES; 5'-DERIVATIVES; POLYMERASES;
   ACTIVATION
AB Ten different pyranone-related substituents (chromones or coumarins) were covalently linked to the 5' end of various oligonucleotides (ODN), The interaction of these compounds with human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) was analyzed, A different behavior was found to depend on the structure of the olgonucleotide derivatives. Some compounds activated the enzyme at relatively low concentrations (0.1-0.5 mu M), followed by an inhibition of the activity at higher concentrations (5-20 mu M), whereas others behave just as inhibitors. Because the presence of some coumarin or chromone derivatives conjugated to ODNs enhanced the interaction with the reverse transcriptase, we analyzed the capacity of such ODN derivatives to be used as primers. The introduction of substituent I, a chromone derivative, the 2-[(3-(aminopropyl)amino]-8-isopropyl-5-methyl-4-oxo-4H-1-benzopyran-3-carbaldehyde], and II, a coumarin derivative, the 1-(3-aminopropoxy)-2-ethyl-3H-naphto[2,1-b]pyran-3-one into the 5' end of a noncomplementary ODN allowed these compounds to be used as primers. In the case of complementary primers, the presence of conjugated derivatives enhanced the affinity with K-m values that were two to three orders of magnitude lower than that of a complementary primer of the same length. After addition of a ddT-unit to the 3'-terminal end of the ODN, some of these primers became very effective inhibitors of RT with Ki values in the nanomolar range.
C1 Univ Bordeaux 2, CNRS, EP 630, IRF Pathol Infect 66, F-33077 Bordeaux, France.
   Russian Acad Sci, Novosibirsk Bioorgan Chem Inst, Siberian Div, Novosibirsk 630090, Russia.
   Univ Genoa, Inst Pharmaceut Sci, I-16132 Genoa, Italy.
RP Nevinsky, GA (reprint author), Univ Bordeaux 2, CNRS, EP 630, IRF Pathol Infect 66, 1 Rue Camille St Saens, F-33077 Bordeaux, France.
RI Zakharova, Olga/G-6239-2013; Nevinsky, Georgy/E-6053-2012; Pyshnyi,
   Dmitriy/F-4729-2013
OI Zakharova, Olga/0000-0002-2054-561X; Pyshnyi,
   Dmitriy/0000-0002-2587-3719
CR ANDREOLA ML, 1993, BIOCHEMISTRY-US, V32, P3629, DOI 10.1021/bi00065a015                                                             
   ANDREOLA ML, 1992, J BIOL CHEM, V267, P19356
   ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0
   BALBI A, 1994, TETRAHEDRON, V50, P4009, DOI 10.1016/S0040-4020(01)89676-9
   Balbi A, 1997, BIOORGAN MED CHEM, V5, P1903, DOI 10.1016/S0968-0896(97)00127-2                                                   
   BUKHRASHVILI IS, 1989, BIOCHIM BIOPHYS ACTA, V1008, P102, DOI 10.1016/0167-4781(89)90175-9
   CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI, P260
   Divita G, 1995, BIOCHEMISTRY-US, V34, P16337, DOI 10.1021/bi00050a014
   KHODYREVA SN, 1993, MOL BIOL REP, V18, P43, DOI 10.1007/BF01006894
   Kolocheva TI, 1996, FEBS LETT, V399, P113, DOI 10.1016/S0014-5793(96)01298-7
   LITVAK S, 1994, TRENDS BIOCHEM SCI, V19, P114, DOI 10.1016/0968-0004(94)90203-8
   LOKHOVA IA, 1991, FEBS LETT, V281, P111, DOI 10.1016/0014-5793(91)80371-9
   Maniatis T., 1982, MOL CLONING LAB MANU
   Martyanov IV, 1998, BIOCHEM MOL BIOL INT, V45, P857
   NEVINSKII GA, 1995, MOL BIOL+, V29, P6
   NEVINSKY GA, 1992, EUR J BIOCHEM, V207, P351, DOI 10.1111/j.1432-1033.1992.tb17057.x
   NEVINSKY GA, 1990, BIOCHEMISTRY-US, V29, P1200, DOI 10.1021/bi00457a016
   NEVINSKY GA, 1989, FEBS LETT, V259, P166
   PODUST VN, 1990, MOL BIOL REP, V14, P247, DOI 10.1007/BF00429892
   SALLAFRANQUEANDREOLA ML, 1989, EUR J BIOCHEM, V184, P367, DOI 10.1111/j.1432-1033.1989.tb15028.x                                              
   SOTTOFATTORI E, 1995, TETRAHEDRON LETT, V36, P1131
   TOULEM JJ, 1986, P NATL ACAD SCI USA, V83, P1227, DOI 10.1073/pnas.83.5.1227
   VIWKSTROM E, 1991, PROSPECTS ANTISENCE
   VLASSOV VV, 1991, OLIGONUCLEOTIDES
   ZAKHAROVA OD, 1995, EUR J BIOCHEM, V233, P856, DOI 10.1111/j.1432-1033.1995.856_3.x                                                
   Zakharova OD, 1998, BIOCHEMISTRY-US, V37, P13343, DOI 10.1021/bi980239g                                                               
   ZAKHAROVA OD, 1995, FEBS LETT, V373, P255, DOI 10.1016/0014-5793(95)01056-K                                                    
   ZAKHAROVA OD, 1995, FEBS LETT, V361, P287, DOI 10.1016/0014-5793(95)00200-S
NR 28
TC 8
Z9 9
U1 0
U2 0
PU MARY ANN LIEBERT INC PUBL
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1087-2906
J9 ANTISENSE NUCLEIC A
JI Antisense Nucleic Acid Drug Dev.
PD OCT
PY 1999
VL 9
IS 5
BP 473
EP 480
DI 10.1089/oli.1.1999.9.473                                                
          
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA 250EZ
UT WOS:000083377200006
PM 10555155
DA 2018-01-05
ER

PT J
AU Rusnati, M
   Tulipano, G
   Spillmann, D
   Tanghetti, E
   Oreste, P
   Zoppetti, G
   Giacca, M
   Presta, M
AF Rusnati, M
   Tulipano, G
   Spillmann, D
   Tanghetti, E
   Oreste, P
   Zoppetti, G
   Giacca, M
   Presta, M
TI Multiple interactions of HIV-I tat protein with size-defined heparin
   oligosaccharides
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH-FACTOR; METAL-LINKED
   DIMER; TRANSGENIC MICE; KAPOSIS-SARCOMA; ENDOTHELIAL-CELLS; SULFATE;
   BINDING; TYPE-1; APOPTOSIS
AB Tat protein, a transactivating factor of the human immunodeficiency virus type I, acts also as an extracellular molecule. Heparin affects the bioavailability and biological activity of extracellular Tat (Rusnati, Prl., Coltrini, D., Oreste, P., Zoppetti, G., Albini, k, Noonan, D., D'Adda di Fagagna, F., Giacca, M., and Presta, M. (1997) J. Biol. Chem. 272, 11313-11320). Here, a series of homogeneously sized, H-3-labeled heparin fragments were evaluated for their capacity to hind to free glutathione S-transferase (GST)-Tat protein and to immobilized GST-Tat. Hexasaccharides represent the minimum sized heparin fragments able to interact with GST-Tat at physiological ionic strength. Also, the affinity of binding increases with increasing the molecular size of the oligosaccharides, with large fragments (greater than or equal to 18 saccharides) approaching the affinity of full-size heparin. 6-Mer heparin binds GST-Tat with a dissociation constant (K-d) equal to 0.7 +/- 0.4 mu M and a molar oligosaccharide:GST-Tat ratio of about 1:1. Interaction of GST-Tat with 22-mer or full-size heparin is consistent instead with two-component binding. At subsaturating concentrations, a single molecule of heparin interacts with 4-6 molecules of GST-Tat with high affinity K-d values in the nanomolar range of concentration at saturating concentrations, heparin binds GST-Tat with lower affinity (K-d, values in the micromolar range of concentration) and a molar oligosaccharide:GST-Tat ratio of about 1:1. In agreement with the binding data, a positive correlation exists between the size of heparin oligosaccharides and their capacity to inhibit cell internalization, long terminal repeat-transactivating activity of extracellular Tat in HL3T1 cells, and its mitogenic activity in murine adenocarcinoma T53 Tat-less cells.
   The data demonstrate that the modality of heparin-Tat interaction is strongly affected by the size of the saccharide chain. The possibility of establishing multiple interactions increases the affinity of large heparin fragments for Tat protein and the capacity of the glycosaminoglycan to modulate the biological activity of extracellular Tat.
C1 Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy.
   Glycores 2000, I-20100 Milan, Italy.
   Univ Uppsala, Ctr Biomed, Dept Med Biochem & Microbiol, Biochem Unit, S-75123 Uppsala, Sweden.
   Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy.
RP Presta, M (reprint author), Univ Brescia, Sch Med, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Via Valsabbina 19, I-25123 Brescia, Italy.
RI rusnati, marco/F-1168-2010; Giacca, Mauro/J-9287-2016; Presta,
   Marco/B-4345-2010
OI Giacca, Mauro/0000-0003-2927-7225; RUSNATI, Marco/0000-0001-9968-5908;
   PRESTA, Marco/0000-0002-4398-8376
CR ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838
   Albini A, 1996, ONCOGENE, V12, P289
   Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371
   ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037
   ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586                                                        
   BABA M, 1988, P NATL ACAD SCI USA, V85, P6132, DOI 10.1073/pnas.85.16.6132                                                         
   BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941
   CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039
   Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006
   COLTRINI D, 1993, EUR J BIOCHEM, V214, P51, DOI 10.1111/j.1432-1033.1993.tb17895.x
   CORALLINI A, 1993, CANCER RES, V53, P5569
   Corallini A, 1996, AIDS, V10, P701, DOI 10.1097/00002030-199606001-00003                                                
   Demarchi F, 1996, J VIROL, V70, P4427
   Dewhurst S, 1996, MOL MED TODAY, V2, P16, DOI 10.1016/1357-4310(96)88754-5
   ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0
   ENSOLI B, 1993, J VIROL, V67, P277
   Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116
   Feyzi E, 1997, J BIOL CHEM, V272, P5518, DOI 10.1074/jbc.272.9.5518                                                          
   Figueroa JE, 1999, BIOCHEM BIOPH RES CO, V254, P642, DOI 10.1006/bbrc.1998.9985                                                          
   FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944
   FRANKEL AD, 1988, P NATL ACAD SCI USA, V85, P6297, DOI 10.1073/pnas.85.17.6297
   GIBELLINI D, 1998, J IMMUNOL, V160, P3981
   GOLDSTEIN G, 1996, NAT MED, V1, P960
   GUIMOND S, 1993, J BIOL CHEM, V268, P23906
   Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s
   Howell AL, 1996, INT J CLIN LAB RES, V26, P124, DOI 10.1007/BF02592355                                                              
   ISHIHARA M, 1993, J BIOL CHEM, V268, P4675
   Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936                                                        
   LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549                                                         
   LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8
   LYON M, 1994, J BIOL CHEM, V269, P11216
   MACCARANA M, 1993, J BIOL CHEM, V268, P23898
   Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519
   Menegon A, 1997, BIOCHEM BIOPH RES CO, V238, P800, DOI 10.1006/bbrc.1997.7393                                                          
   Milani D, 1996, J BIOL CHEM, V271, P22961, DOI 10.1074/jbc.271.38.22961                                                        
   Milani D, 1998, AIDS, V12, P1275, DOI 10.1097/00002030-199811000-00008
   Mitola S, 1997, BLOOD, V90, P1365
   MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753
   NERLICH A, 1991, PATHOL RES PRACT, V187, P444, DOI 10.1016/S0344-0338(11)80005-1                                                   
   ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240                                                            
   Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027
   Rusnati M, 1997, J BIOL CHEM, V272, P11313
   Rusnati M, 1996, NONANTICOAGULANT ACTIONS OF GLYCOSAMINOGLYCANS, P171
   Sakata H, 1997, J BIOL CHEM, V272, P9457
   Sastry KJ, 1996, ONCOGENE, V13, P487
   SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x                                              
   Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487
   SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1                                                   
   Stringer SE, 1997, J BIOL CHEM, V272, P20508, DOI 10.1074/jbc.272.33.20508
   ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K
   VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0
   WALKER A, 1994, J BIOL CHEM, V269, P931
   WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0
   WRIGHT CM, 1986, SCIENCE, V234, P988, DOI 10.1126/science.3490693
   ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871                                                        
NR 55
TC 103
Z9 104
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 1
PY 1999
VL 274
IS 40
BP 28198
EP 28205
DI 10.1074/jbc.274.40.28198
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 241ZA
UT WOS:000082912700022
PM 10497173
OA gold
DA 2018-01-05
ER

PT J
AU Reddy, BSP
   Sondhi, SM
   Lown, JW
AF Reddy, BSP
   Sondhi, SM
   Lown, JW
TI Synthetic DNA minor groove-binding drugs
SO PHARMACOLOGY & THERAPEUTICS
LA English
DT Review
DE lexitropsins; Hoechst 33258; diarylamidine; berenil; pentamidine;
   CC-1065; pyrrolo[1,4]benzodiazepines
ID ELECTRIC LINEAR DICHROISM; INTERSTRAND CROSS-LINKING; ANTITUMOR
   ANTIBIOTIC CC-1065; SEQUENCE-SELECTIVE BINDING; BISQUATERNARY AMMONIUM
   HETEROCYCLES; PNEUMOCYSTIS-CARINII PNEUMONIA; NON-INTERCALATING
   ANTIBIOTICS; HUMAN-IMMUNODEFICIENCY-VIRUS; DIRECTED ALKYLATING-AGENTS;
   NUCLEAR-MAGNETIC-RESONANCE
AB In this review, both cationic and neutral synthetic ligands that bind in the minor groove of DNA are discussed. Certain bis-distamycins and related lexitropsins show activities against human immunodeficiency virus (HIV)-1 and HIV-2 at low nanomolar concentrations. DAPI binds strongly to AT-containing polymers and is located in the minor groove of DNA. DAPI intercalates in DNA sequences that do not contain at least three consecutive AT bp. Berenil can also exhibit intercalative, as well as minor groove binding, properties depending on sequence. Furan-containing analogues of berenil play an important role in their activities against Pneumocystis carinii and Cryptosporidium parvuam infections in vivo. Pt(II)-berenil conjugates show a good activity profile against HL60 and U-937 human leukemic cells. Pt-pentamidine shows higher antiproliferative activity against small cell lung, non-small cell lung, and melanoma cancer cell lines compared with many other tumor cell lines. trans-Butenamidine shows good anti-P. carinii activity in rats. Pentamidine is used against P. carinii pneumonia in individuals infected with HIV who are at high risk from this infection. A comparison of the cytotoxic potencies of adozelesin, bizelesin, carzelesin, cisplatin, and doxorubicin indicates that adozelesin is a potent analog of CC-1065. Naturally occurring pyrrolo[2,1-c][1,4]benzodiazepines such as anthramycin have a 2- to 3-bp sequence specificity, but a synthetic PBD dimer spans 6 bp, actively recognizing a central 5'-GATC sequence. The crosslinking efficiency of PBD dimers is much greater than that of other major groove crosslinkers, such as cisplatin, melphalan, etc. Neothramycin is used clinically for the treatment of superficial carcinoma of the bladder. (C) 1999 Elsevier Science Inc. All rights reserved.
C1 Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
   Univ Roorkee, Dept Chem, Roorkee 247667, Uttar Pradesh, India.
RP Lown, JW (reprint author), Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada.
CR ABUDAYA A, 1995, NUCLEIC ACIDS RES, V23, P3385, DOI 10.1093/nar/23.17.3385
   ADAMS EG, 1988, CANCER RES, V48, P109
   ADNET F, 1992, J BIOMOL STRUCT DYN, V10, P565, DOI 10.1080/07391102.1992.10508668                                                  
   ANIMATI F, 1995, J MED CHEM, V38, P1140, DOI 10.1021/jm00007a011
   ANLEZARK GM, 1995, BIOCHEM PHARMACOL, V50, P609, DOI 10.1016/0006-2952(95)00187-5
   ANNE J, 1980, ANTIMICROB AGENTS CH, V18, P231, DOI 10.1128/AAC.18.2.231                                                            
   ARIMA K, 1972, J ANTIBIOT, V25, P437, DOI 10.7164/antibiotics.25.437                                                      
   ARISTOFF PA, 1993, J MED CHEM, V36, P1956, DOI 10.1021/jm00066a004                                                             
   Ashley JN, 1942, J CHEM SOC, P103, DOI 10.1039/jr9420000103                                                            
   ATWELL GJ, 1995, BIOORGAN MED CHEM, V3, P679, DOI 10.1016/0968-0896(95)00049-M                                                    
   BAGULEY BC, 1982, MOL CELL BIOCHEM, V43, P167
   BAILLY C, 1994, J BIOMOL STRUCT DYN, V12, P173, DOI 10.1080/07391102.1994.10508095                                                  
   BAILLY C, 1994, MOL PHARMACOL, V46, P313
   BAILLY C, 1993, ANTI-CANCER DRUG DES, V8, P145
   BAILLY C, 1993, NUCLEIC ACIDS RES, V21, P3705, DOI 10.1093/nar/21.16.3705
   Bailly C, 1997, BIOCHEM J, V323, P23, DOI 10.1042/bj3230023                                                               
   BAILLY C, 1990, BIOCHEM BIOPH RES CO, V167, P798, DOI 10.1016/0006-291X(90)92096-I
   Bailly C, 1996, NUCLEIC ACIDS RES, V24, P1460, DOI 10.1093/nar/24.8.1460
   Bailly Christian, 1992, Journal of Molecular Recognition, V5, P155, DOI 10.1002/jmr.300050406
   Balzarini J, 1983, Invest New Drugs, V1, P103
   BARALDI PG, 1994, J MED CHEM, V37, P4329, DOI 10.1021/jm00051a009                                                             
   BARCELLONA ML, 1989, BIOCHIM BIOPHYS ACTA, V993, P174, DOI 10.1016/0304-4165(89)90160-8                                                    
   BARCELLONA ML, 1990, EUR BIOPHYS J, V17, P315
   BARCELO F, 1993, BIOPHYS CHEM, V47, P251, DOI 10.1016/0301-4622(93)80050-S                                                    
   BARKLEY MD, 1986, BIOCHEMISTRY-US, V25, P3021, DOI 10.1021/bi00358a043
   Bartulewicz D, 1995, Rocz Akad Med Bialymst, V40, P364
   BATES HM, 1969, CANCER RES, V29, P2195
   BATHINI Y, 1990, CHEM RES TOXICOL, V3, P268, DOI 10.1021/tx00015a013
   BEERMAN TA, 1992, BIOCHIM BIOPHYS ACTA, V1131, P53, DOI 10.1016/0167-4781(92)90098-K                                                    
   BELLORINI M, 1995, NUCLEIC ACIDS RES, V23, P1657, DOI 10.1093/nar/23.10.1657
   BHUYAN BK, 1992, CANCER CHEMOTH PHARM, V30, P348, DOI 10.1007/BF00689961
   BHUYAN BK, 1992, CANCER RES, V52, P5687
   BHUYAN BK, 1982, CANCER RES, V42, P3532
   Bielawski K, 1996, Rocz Akad Med Bialymst, V41, P293
   BLASKO A, 1993, P NATL ACAD SCI USA, V90, P10018, DOI 10.1073/pnas.90.21.10018
   Boger D L, 1993, Bioorg Med Chem, V1, P27, DOI 10.1016/S0968-0896(00)82100-8
   Boger D L, 1994, Bioorg Med Chem, V2, P115, DOI 10.1016/S0968-0896(00)82007-6
   BOGER DL, 1991, P NATL ACAD SCI USA, V88, P1431, DOI 10.1073/pnas.88.4.1431
   BOGER DL, 1991, J AM CHEM SOC, V113, P3980, DOI 10.1021/ja00010a046
   BOGER DL, 1995, P NATL ACAD SCI USA, V92, P3642, DOI 10.1073/pnas.92.9.3642
   BOGER DL, 1990, J AM CHEM SOC, V112, P4623, DOI 10.1021/ja00168a002
   Boger DL, 1997, BIOORGAN MED CHEM, V5, P263, DOI 10.1016/S0968-0896(96)00238-6
   BOGER DL, 1991, TETRAHEDRON, V47, P2661, DOI 10.1016/S0040-4020(01)81798-1
   BOGER DL, 1995, BIOORGAN MED CHEM, V3, P1429, DOI 10.1016/0968-0896(95)00130-9                                                    
   Boger DL, 1997, BIOORGAN MED CHEM, V5, P233, DOI 10.1016/S0968-0896(96)00237-4                                                   
   Boger DL, 1996, BIOORGAN MED CHEM, V4, P859, DOI 10.1016/0968-0896(96)00073-9
   Boitte N, 1997, ANTI-CANCER DRUG DES, V12, P481
   BOSE DS, 1992, J CHEM SOC CHEM COMM, P1518, DOI 10.1039/c39920001518                                                            
   BOSE DS, 1992, TETRAHEDRON, V48, P751
   BOSE DS, 1992, J AM CHEM SOC, V114, P4939, DOI 10.1021/ja00038a089                                                             
   BOURDOUXHE C, 1995, ANTI-CANCER DRUG DES, V10, P131
   BOUZIANE M, 1995, BIOCHEMISTRY-US, V34, P14051, DOI 10.1021/bi00043a010
   BOYD FL, 1990, BIOCHEMISTRY-US, V29, P2387, DOI 10.1021/bi00461a024
   BRAITHWAITE AW, 1980, BIOCHEMISTRY-US, V19, P1101, DOI 10.1021/bi00547a009
   BROGGINI M, 1995, NUCLEIC ACIDS RES, V23, P81, DOI 10.1093/nar/23.1.81
   BROWN DG, 1992, J MOL BIOL, V226, P481, DOI 10.1016/0022-2836(92)90962-J
   BROWN DG, 1990, EMBO J, V9, P1329
   Brown PM, 1996, J MOL BIOL, V262, P671, DOI 10.1006/jmbi.1996.0544
   BROWNE KA, 1993, J AM CHEM SOC, V115, P7072, DOI 10.1021/ja00069a003
   Buel Eric, 1993, Applied and Theoretical Electrophoresis, V3, P253
   BUMMA C, 1988, BIOCHEM PHARMACOL, V37, P1865, DOI 10.1016/0006-2952(88)90485-6                                                    
   CHAN K L, 1977, SMJ Singapore Medical Journal, V18, P81
   CHARI RVJ, 1995, CANCER RES, V55, P4079
   CHAUDHARY D, 1995, BIOCHEMISTRY-US, V34, P3438, DOI 10.1021/bi00010a036
   CHEATHAM S, 1988, J MED CHEM, V31, P583, DOI 10.1021/jm00398a016
   CHEN AY, 1993, P NATL ACAD SCI USA, V90, P8131, DOI 10.1073/pnas.90.17.8131
   CHEN FX, 1993, CARCINOGENESIS, V14, P935, DOI 10.1093/carcin/14.5.935                                                         
   CHEN SM, 1992, BIOCHEMISTRY-US, V31, P4406, DOI 10.1021/bi00133a004
   Chen YH, 1996, BIOCHEM BIOPH RES CO, V220, P213, DOI 10.1006/bbrc.1996.0383
   CHI HI, 1990, J INVEST DERMATOL, V95, P154, DOI 10.1111/1523-1747.ep12477921                                                    
   CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003
   Chiang SY, 1997, P NATL ACAD SCI USA, V94, P2811, DOI 10.1073/pnas.94.7.2811                                                          
   CIOMEI M, 1994, BIOCHEM PHARMACOL, V47, P295, DOI 10.1016/0006-2952(94)90020-5
   CIUCCI A, 1994, BIOCHEM PHARMACOL, V48, P1583, DOI 10.1016/0006-2952(94)90203-8
   CLANTON DJ, 1995, ANTIVIR RES, V27, P335, DOI 10.1016/0166-3542(95)00017-G
   Clark GR, 1997, NUCLEIC ACIDS RES, V25, P1510, DOI 10.1093/nar/25.8.1510
   Clark GR, 1996, NUCLEIC ACIDS RES, V24, P4882, DOI 10.1093/nar/24.24.4882
   Clark GR, 1996, BIOCHEMISTRY-US, V35, P13745, DOI 10.1021/bi960421m
   CLIFFE S, 1994, INT J RADIAT ONCOL, V29, P373, DOI 10.1016/0360-3016(94)90292-5                                                    
   Colson P, 1996, BIOPHYS CHEM, V58, P125, DOI 10.1016/0301-4622(95)00092-5
   COLSON P, 1995, J BIOMOL STRUCT DYN, V13, P351, DOI 10.1080/07391102.1995.10508845                                                  
   COMINGS DE, 1975, CHROMOSOMA, V52, P229, DOI 10.1007/BF00332113
   CONNORS TA, 1964, BIOCHEM PHARMACOL, V13, P395, DOI 10.1016/0006-2952(64)90158-3
   CONTE MR, 1995, EUR J BIOCHEM, V229, P433, DOI 10.1111/j.1432-1033.1995.0433k.x
   COREY M, 1992, J MED CHEM, V35, P431
   COTE S, 1993, ANTI-CANCER DRUG, V4, P327, DOI 10.1097/00001813-199306000-00006                                                
   DABROWIAK JC, 1990, CHEM PHYSICS DNA LIG, P143
   Dan O, 1971, LIEBIGS ANN CHEM, V749, P68
   deCupis A, 1997, BRIT J PHARMACOL, V120, P537, DOI 10.1038/sj.bjp.0700937
   DENISON L, 1992, INT J RADIAT BIOL, V61, P69, DOI 10.1080/09553009214550641
   DENISON L, 1992, INT J RADIAT BIOL, V61, P561
   DENNY WA, 1979, J MED CHEM, V22, P1234, DOI 10.1021/jm00196a016                                                             
   DENNY WA, 1979, J MED CHEM, V22, P134, DOI 10.1021/jm00188a005
   DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408
   Dickerson R.E., 1987, DNA LIGAND INTERACTI, P45
   Ding L, 1994, Acta Chem Scand, V48, P498, DOI 10.3891/acta.chem.scand.48-0498
   DING ZM, 1991, ANTI-CANCER DRUG DES, V6, P427
   DONKOR IO, 1995, J PHARM SCI, V84, P448, DOI 10.1002/jps.2600840412
   DOUGHERTY G, 1982, CRC CR REV BIOCH MOL, V12, P103, DOI 10.3109/10409238209108704                                                       
   DUBEY DD, 1983, EXP CELL RES, V149, P419, DOI 10.1016/0014-4827(83)90354-3
   DURAND M, 1994, BIOCHIMIE, V76, P181, DOI 10.1016/0300-9084(94)90011-6
   DURAND M, 1994, J BIOMOL STRUCT DYN, V11, P1191, DOI 10.1080/07391102.1994.10508063                                                  
   DUSCI LJ, 1987, THER DRUG MONIT, V9, P422, DOI 10.1097/00007691-198712000-00010                                                
   EBRA E, 1995, INT J CANCER, V62, P170
   EBRAHIMI SES, 1995, ANTI-CANCER DRUG DES, V10, P463
   EDWARDS KJ, 1992, BIOCHEMISTRY-US, V31, P7104, DOI 10.1021/bi00146a011
   EMBREY KJ, 1993, EUR J BIOCHEM, V211, P437, DOI 10.1111/j.1432-1033.1993.tb17569.x
   ENA J, 1994, CLIN INFECT DIS, V18, P901, DOI 10.1093/clinids/18.6.901                                                        
   ERICSSON O, 1990, THER DRUG MONIT, V12, P362, DOI 10.1097/00007691-199007000-00011                                                
   ERIKSSON S, 1993, BIOCHEMISTRY-US, V32, P2987, DOI 10.1021/bi00063a009
   Fagan PA, 1996, NUCLEIC ACIDS RES, V24, P1566, DOI 10.1093/nar/24.8.1566
   FAHRMANN JW, 1988, MICROBIOLOGICA, V11, P85
   FARMER JD, 1991, NUCLEIC ACIDS RES, V19, P899, DOI 10.1093/nar/19.4.899
   FEDE A, 1991, BIOCHEMISTRY-US, V30, P11377, DOI 10.1021/bi00112a004
   FEIGON J, 1984, J MED CHEM, V27, P450, DOI 10.1021/jm00370a007
   FERGUSON LR, 1995, MUTAT RES-FUND MOL M, V329, P19, DOI 10.1016/0027-5107(95)00013-9
   FERGUSON-SMITH M. A., 1962, CYTO GENETICS [BASEL], V1, P325, DOI 10.1159/000129743
   FINLAY GJ, 1990, EUR J CANCER, V26, P586, DOI 10.1016/0277-5379(90)90083-6
   FORROW SM, 1995, CHEM-BIOL INTERACT, V96, P125, DOI 10.1016/0009-2797(94)03577-U
   Fortsch I, 1996, J BIOMOL STRUCT DYN, V14, P317
   Foster B J, 1996, Invest New Drugs, V13, P321
   FOX KR, 1990, FEBS LETT, V266, P150, DOI 10.1016/0014-5793(90)81527-U                                                    
   FRITZSCHE H, 1993, NUCLEIC ACIDS RES, V21, P5085, DOI 10.1093/nar/21.22.5085
   GAO YG, 1993, BIOCHEMISTRY-US, V32, P9639, DOI 10.1021/bi00088a016
   GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021
   GAUZE G F, 1969, Antibiotiki (Moscow), V14, P963
   GEIERSTANGER BH, 1994, BIOCHEMISTRY-US, V33, P3055, DOI 10.1021/bi00176a039
   GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719                                                         
   Ghielmini M, 1997, BRIT J CANCER, V75, P878, DOI 10.1038/bjc.1997.155                                                            
   GIARTOSIO A, 1984, PHYSIOL CHEM PHYS, V16, P481
   Gillard AC, 1995, J HETEROCYCLIC CHEM, V32, P1741, DOI 10.1002/jhet.5570320613                                                         
   GLAUBIGER D, 1974, BIOCHIM BIOPHYS ACTA, V361, P303, DOI 10.1016/0005-2787(74)90373-6
   GLIKSON M, 1990, ISRAEL J MED SCI, V26, P588
   Gonzalez VM, 1996, J INORG BIOCHEM, V63, P57, DOI 10.1016/0162-0134(95)00175-1                                                    
   GOODSELL D, 1986, J MED CHEM, V29, P727, DOI 10.1021/jm00155a023
   Goodsell DS, 1995, BIOCHEMISTRY-US, V34, P16654, DOI 10.1021/bi00051a013
   GOODSELL DS, 1995, BIOCHEMISTRY-US, V34, P4983, DOI 10.1021/bi00015a009                                                             
   GOPALAKRISHNA K, 1987, FEBS LETT, V215, P95, DOI 10.1016/0014-5793(87)80120-5                                                    
   GOULAOUIC H, 1994, BIOCHEMISTRY-US, V33, P1412, DOI 10.1021/bi00172a018
   GRAVATT GL, 1994, J MED CHEM, V37, P4338, DOI 10.1021/jm00051a010
   GREENIDGE PA, 1993, MOL PHARMACOL, V43, P982
   GRESH N, 1984, MOL PHARMACOL, V25, P452
   Guan LL, 1997, BIOCHEM BIOPH RES CO, V231, P94, DOI 10.1006/bbrc.1996.5908
   Gupta R, 1996, ANTI-CANCER DRUG DES, V11, P581
   GUPTA R, 1995, ANTI-CANCER DRUG DES, V10, P25
   HAND IL, 1993, ANN NY ACAD SCI, V693, P300, DOI 10.1111/j.1749-6632.1993.tb26290.x
   HANKA LJ, 1978, J ANTIBIOT, V31, P1211, DOI 10.7164/antibiotics.31.1211                                                     
   HARA M, 1988, J ANTIBIOT, V41, P702, DOI 10.7164/antibiotics.41.702                                                      
   HARBACH PR, 1988, CANCER RES, V48, P32
   HARD T, 1990, PHOTOCHEM PHOTOBIOL, V51, P77, DOI 10.1111/j.1751-1097.1990.tb01686.x
   HARSHMAN KD, 1985, NUCLEIC ACIDS RES, V13, P4825, DOI 10.1093/nar/13.13.4825                                                          
   Hartley J A, 1995, Drug Des Discov, V12, P323
   HARTLEY JA, 1994, ANTI-CANCER DRUG DES, V9, P181
   HARWORTH IS, 1991, ANTI-CANCER DRUG DES, V6, P59
   Henichart JP, 1997, MOL PHARMACOL, V51, P448
   HERTZBERG RP, 1986, BIOCHEMISTRY-US, V25, P1249, DOI 10.1021/bi00354a009
   HIGHTOWER RD, 1993, CANCER INVEST, V11, P276, DOI 10.3109/07357909309024852
   HIGHTOWER RD, 1992, GYNECOL ONCOL, V47, P186, DOI 10.1016/0090-8258(92)90104-Q                                                    
   HOSCHLOWSKI JE, 1987, J ANTIBIOT, V40, P145
   HOUGHTON PJ, 1995, CANCER CHEMOTH PHARM, V36, P45
   HU S, 1992, EUR J BIOCHEM, V204, P31, DOI 10.1111/j.1432-1033.1992.tb16602.x
   HURLEY LH, 1986, ACCOUNTS CHEM RES, V19, P230, DOI 10.1021/ar00128a001                                                             
   HURLEY LH, 1988, BIOCHEMISTRY-US, V27, P3886, DOI 10.1021/bi00410a054
   HURLEY LH, 1977, BIOCHIM BIOPHYS ACTA, V475, P521, DOI 10.1016/0005-2787(77)90067-3
   HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915
   HURLEY LH, 1990, J AM CHEM SOC, V112, P4633, DOI 10.1021/ja00168a003
   HURLEY LH, 1980, BIOCHEM PHARMACOL, V29, P1307, DOI 10.1016/0006-2952(80)90291-9
   HURLEY LH, 1979, NATURE, V282, P529, DOI 10.1038/282529a0                                                                
   HURLEY LH, 1979, CANCER RES, V39, P3134
   HURLEY LH, 1977, J ANTIBIOT, V30, P349, DOI 10.7164/antibiotics.30.349                                                      
   ITOH J, 1988, J ANTIBIOT, V41, P1281, DOI 10.7164/antibiotics.41.1281                                                     
   JANSEN K, 1993, BIOCHEMISTRY-US, V32, P6605, DOI 10.1021/bi00077a013                                                             
   JENKINS TC, 1993, EUR J BIOCHEM, V213, P1175, DOI 10.1111/j.1432-1033.1993.tb17868.x                                              
   Jenkins TC, 1997, BBA-GENE STRUCT EXPR, V1350, P189, DOI 10.1016/S0167-4781(96)00160-1                                                   
   JEPPESEN C, 1989, EUR J BIOCHEM, V182, P437, DOI 10.1111/j.1432-1033.1989.tb14850.x                                              
   JIN R, 1988, P NATL ACAD SCI USA, V85, P8939, DOI 10.1073/pnas.85.23.8939
   JONES GB, 1990, ANTI-CANCER DRUG DES, V5, P249
   JORGENSON KF, 1988, J BIOMOL STRUCT DYN, V5, P1005, DOI 10.1080/07391102.1988.10506446                                                  
   KAMAL A, 1993, BIOORG MED CHEM LETT, V3, P743, DOI 10.1016/S0960-894X(01)81266-X
   KAMINSKY R, 1993, ACTA TROP, V54, P19, DOI 10.1016/0001-706X(93)90065-J
   KAPUSCINSKI J, 1995, BIOTECH HISTOCHEM, V70, P220, DOI 10.3109/10520299509108199
   KARLOVSKY P, 1991, ANAL BIOCHEM, V194, P192, DOI 10.1016/0003-2697(91)90167-R
   KATOUZIANSAFADI M, 1989, ANAL BIOCHEM, V176, P416, DOI 10.1016/0003-2697(89)90334-5
   Kayser K, 1996, ANAL QUANT CYTOL, V18, P115
   KENNARD O, 1991, ANGEW CHEM INT EDIT, V30, P1254, DOI 10.1002/anie.199112541
   Ketterle C, 1996, J BIOMOL STRUCT DYN, V13, P963, DOI 10.1080/07391102.1996.10508911                                                  
   Khokhlov D N, 1995, Mol Biol (Mosk), V29, P354
   KIM SK, 1993, BIOPOLYMERS, V33, P1677, DOI 10.1002/bip.360331105
   Kimura K, 1982, Gan To Kagaku Ryoho, V9, P924
   Kittler L, 1997, BIOCHEM MOL BIOL INT, V41, P143
   Kittler L, 1996, BIOCHEM MOL BIOL INT, V40, P263
   Kittler L, 1996, ANTI-CANCER DRUG DES, V11, P101
   KIZU R, 1993, BIOCHEMISTRY-US, V32, P8712, DOI 10.1021/bi00084a043
   KOHN KW, 1968, BIOCHIM BIOPHYS ACTA, V155, P121, DOI 10.1016/0005-2787(68)90342-0
   KONISHI M, 1984, J ANTIBIOT, V37, P200, DOI 10.7164/antibiotics.37.200                                                      
   KOPKA ML, 1994, BIOCHEMISTRY-US, V33, P13593, DOI 10.1021/bi00250a011
   Kopka ML, 1997, STRUCTURE, V5, P1033, DOI 10.1016/S0969-2126(97)00255-4
   KOZMYAN LI, 1977, ANTIBIOT MED BIOTEK, V22, P602
   KRISHNA KG, 1993, BIOPOLYMERS, V33, P1415, DOI 10.1002/bip.360330911
   KROES ACM, 1988, CANCER LETT, V41, P295, DOI 10.1016/0304-3835(88)90291-1
   KRUEGER WC, 1991, CHEM-BIOL INTERACT, V79, P265, DOI 10.1016/0009-2797(91)90109-K
   KRUGER WC, 1991, CHEM-BIOL INTERACT, V79, P137
   KRUGH TR, 1989, BIOCHEMISTRY-US, V28, P9988, DOI 10.1021/bi00452a017
   KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057
   KUBOTA Y, 1986, NUCL ACIDS S SER, V17, P219
   KUMAR S, 1990, J BIOMOL STRUCT DYN, V8, P331, DOI 10.1080/07391102.1990.10507809                                                  
   KUMAR S, 1992, J BIOMOL STRUCT DYN, V9, P853, DOI 10.1080/07391102.1992.10507963                                                  
   KUNIMOTO S, 1980, J ANTIBIOT, V33, P665, DOI 10.7164/antibiotics.33.665                                                      
   LAGE M, 1990, MED KLIN, V85, P255
   LANE AN, 1991, BIOCHEMISTRY-US, V30, P1372, DOI 10.1021/bi00219a030
   LANGLEY DR, 1987, J ORG CHEM, V52, P91, DOI 10.1021/jo00377a016
   LANGLOIS N, 1989, HETEROCYCLES, V29, P1529, DOI 10.3987/COM-89-4990                                                             
   LARSEN TA, 1989, J BIOMOL STRUCT DYN, V7, P477, DOI 10.1080/07391102.1989.10508505                                                  
   LAUGHTON CA, 1990, NUCLEIC ACIDS RES, V18, P4479, DOI 10.1093/nar/18.15.4479
   Laughton CA, 1996, BIOCHEMISTRY-US, V35, P5655, DOI 10.1021/bi952162r
   LAVERY R, 1986, J BIOMOL STRUCT DYN, V3, P1155, DOI 10.1080/07391102.1986.10508492                                                  
   LEE CS, 1991, CANCER RES, V51, P6586
   LEE CS, 1993, BIOCHEMISTRY-US, V32, P9108, DOI 10.1021/bi00086a015
   LEE CS, 1993, BIOCHEMISTRY-US, V32, P2592, DOI 10.1021/bi00061a017
   LEE CS, 1994, BIOCHEMISTRY-US, V33, P6024, DOI 10.1021/bi00185a043                                                             
   LEE M, 1994, J MED CHEM, V37, P1208, DOI 10.1021/jm00034a019
   LEE M, 1994, J MED CHEM, V37, P4073, DOI 10.1021/jm00050a003
   LEE M, 1993, BIOCHEMISTRY-US, V32, P4237, DOI 10.1021/bi00067a011
   Lemgruber W., 1965, J AM CHEM SOC, V87, P5793
   LEMGRUBER W, 1965, J AM CHEM SOC, V87, P5791
   LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1
   LEUPIN W, 1990, FEBS LETT, V263, P313, DOI 10.1016/0014-5793(90)81402-A                                                    
   LEUPIN W, 1986, BIOCHEMISTRY-US, V25, P5902, DOI 10.1021/bi00368a010                                                             
   Li H., 1982, CANCER RES, V42, P999
   LI LH, 1991, INVEST NEW DRUG, V9, P137
   LIBBY PR, 1992, BIOCHEM PHARMACOL, V44, P830, DOI 10.1016/0006-2952(92)90424-H
   LIN MS, 1977, CHROMOSOMA, V60, P15, DOI 10.1007/BF00330407
   LOONTIENS FG, 1990, BIOCHEMISTRY-US, V29, P9029, DOI 10.1021/bi00490a021
   LOONTIENS FG, 1991, BIOCHEMISTRY-US, V30, P182, DOI 10.1021/bi00215a027
   Lown J. William, 1994, Journal of Molecular Recognition, V7, P79, DOI 10.1002/jmr.300070205
   LOWN JW, 1979, BIOCHEM PHARMACOL, V28, P2017, DOI 10.1016/0006-2952(79)90218-1
   Lown J. W., 1997, ADV DNA SEQUENCE SPE, V3, P67
   LOWN JW, 1983, BIOCHEMISTRY-US, V27, P3886
   LU CP, 1995, PANCREAS, V11, P315, DOI 10.1097/00006676-199510000-00016
   LUCK G, 1987, J BIOMOL STRUCT DYN, V4, P1079, DOI 10.1080/07391102.1987.10507699                                                  
   Lukhtanov EA, 1996, NUCLEIC ACIDS RES, V24, P683, DOI 10.1093/nar/24.4.683
   LYNEN L, 1992, ANN SOC BELG MED TR, V72, P13
   Mariani M, 1992, EXS, V61, P455
   MARTIN DG, 1981, J ANTIBIOT, V34, P1119, DOI 10.7164/antibiotics.34.1119                                                     
   MARTIN RF, 1992, INT J RADIAT ONCOL, V23, P579, DOI 10.1016/0360-3016(92)90014-9                                                    
   MARTIN RF, 1994, INT J RADIAT BIOL, V66, P517, DOI 10.1080/09553009414551551
   MARUYAMA IN, 1978, J ANTIBIOT, V31, P761, DOI 10.7164/antibiotics.31.761                                                      
   MARUYAMA IN, 1981, J ANTIBIOT, V34, P427, DOI 10.7164/antibiotics.34.427                                                      
   Matesoi D, 1996, BIOCHEM MOL BIOL INT, V38, P123
   MATSUKUMA S, 1978, EXP CELL RES, V113, P453, DOI 10.1016/0014-4827(78)90390-7                                                    
   Matsuzawa Y., 1991, NUCL ACIDS S SER, V25, P131
   MCCONNAUGHIE AW, 1995, J MED CHEM, V38, P3488, DOI 10.1021/jm00018a009
   MCGOVREN JP, 1984, J ANTIBIOT, V37, P63, DOI 10.7164/antibiotics.37.63                                                       
   MCGOWAN PF, 1988, J HISTOCHEM CYTOCHEM, V36, P757, DOI 10.1177/36.7.2454985                                                            
   MCHUGH MM, 1989, BIOCHEM PHARMACOL, V38, P2323, DOI 10.1016/0006-2952(89)90472-3
   MCHUGH MM, 1990, BIOCHEM PHARMACOL, V39, P707, DOI 10.1016/0006-2952(90)90149-F
   MEYER JC, 1984, ARCH DERMATOL RES, V276, P52, DOI 10.1007/BF00412563
   MIKHAILOV M V, 1981, Molekulyarnaya Biologiya (Moscow), V15, P690
   MILDNER B, 1978, CANCER LETT, V4, P89, DOI 10.1016/S0304-3835(78)93687-X
   MISRA VK, 1994, J MOL BIOL, V238, P245, DOI 10.1006/jmbi.1994.1285                                                          
   MITCHELL MA, 1991, J AM CHEM SOC, V113, P8994, DOI 10.1021/ja00023a085                                                             
   MIYAMOTO M, 1977, J ANTIBIOT, V30, P340, DOI 10.7164/antibiotics.30.340                                                      
   MOHAMADI F, 1994, J MED CHEM, V37, P232, DOI 10.1021/jm00028a005
   MONROE TJ, 1993, CANCER RES, V53, P5690
   Montanari CA, 1996, J COMPUT AID MOL DES, V10, P67, DOI 10.1007/BF00124466
   Moon JH, 1996, BIOPOLYMERS, V38, P593, DOI 10.1002/(SICI)1097-0282(199605)38:5<593::AID-BIP5>3.0.CO;2-N
   MORI S, 1991, TETRAHEDRON, V47, P5051, DOI 10.1016/S0040-4020(01)80968-6
   Morikawa K., 1981, NUCL ACIDS RES S SER, V10, P85
   MORRISON I, 1990, J PHYS-CONDENS MAT, V2, P1
   MOUNTZOURIS JA, 1994, J MED CHEM, V37, P3132, DOI 10.1021/jm00045a019
   MOY BC, 1989, CANCER RES, V49, P1983
   MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586
   MUKHOPADHYAY R, 1995, INT J BIOCHEM CELL B, V27, P55, DOI 10.1016/1357-2725(95)93432-P
   Muller P.R., 1989, SCIENCE, V246, P780
   MURRAY V, 1988, J MOL BIOL, V201, P437, DOI 10.1016/0022-2836(88)90150-7
   MURRAY V, 1988, J MOL BIOL, V203, P63, DOI 10.1016/0022-2836(88)90091-5                                                    
   NAGUYEN HN, 1992, J CANC RES CLIN ONCO, V118, P515
   NAGUYEN HN, 1992, CANCER CHEMOTH PHARM, V30, P37
   NAIRN RS, 1982, J BIOCHEM BIOPH METH, V6, P95, DOI 10.1016/0165-022X(82)90055-0
   Neamati N, 1998, MOL PHARMACOL, V54, P280
   Nikolaev VA, 1996, J BIOMOL STRUCT DYN, V14, P31, DOI 10.1080/07391102.1996.10508927                                                  
   NORDEN B, 1976, BIOPHYS CHEM, V4, P191, DOI 10.1016/0301-4622(76)85009-0                                                    
   Norden Bengt, 1994, Journal of Molecular Recognition, V7, P141, DOI 10.1002/jmr.300070211
   NUNN CM, 1993, BIOCHEMISTRY-US, V32, P13838, DOI 10.1021/bi00213a012
   NUNN CM, 1995, J MED CHEM, V38, P2317, DOI 10.1021/jm00013a008
   NUNN CM, 1994, EUR J BIOCHEM, V226, P953, DOI 10.1111/j.1432-1033.1994.00953.x
   PALU G, 1987, BIOCHEM BIOPH RES CO, V145, P40, DOI 10.1016/0006-291X(87)91284-8
   Parkinson J, 1995, BIOCHEMISTRY-US, V34, P16240, DOI 10.1021/bi00050a002
   PARKINSON JA, 1994, BIOCHEMISTRY-US, V33, P8442, DOI 10.1021/bi00194a008
   PARKINSON JA, 1990, BIOCHEMISTRY-US, V29, P10181, DOI 10.1021/bi00496a005
   PAROLIN C, 1995, BIOCHEM BIOPH RES CO, V208, P332, DOI 10.1006/bbrc.1995.1342                                                          
   PASSADORE M, 1995, BIOCHEM J, V308, P513, DOI 10.1042/bj3080513                                                               
   PATEL DJ, 1979, ACCOUNTS CHEM RES, V12, P118, DOI 10.1021/ar50136a002                                                             
   PEARL LH, 1987, NUCLEIC ACIDS RES, V15, P3469, DOI 10.1093/nar/15.8.3469                                                           
   Pelucio Maria T., 1995, Journal of Emergency Medicine, V13, P633, DOI 10.1016/0736-4679(95)00068-L
   PEREZ JM, 1993, CHEM-BIOL INTERACT, V89, P61, DOI 10.1016/0009-2797(93)03199-5                                                    
   PETRUSEK RL, 1981, BIOCHEMISTRY-US, V20, P1111, DOI 10.1021/bi00508a011
   PEZZONI G, 1991, BRIT J CANCER, V64, P1047, DOI 10.1038/bjc.1991.463
   PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502
   PIERCE JR, 1993, BIOCHEMISTRY-US, V32, P7069, DOI 10.1021/bi00079a002
   Pilch D S, 1996, Drug Des Discov, V13, P115
   PILCH DS, 1995, BIOCHEMISTRY-US, V34, P9962, DOI 10.1021/bi00031a019
   Pilch DS, 1995, BIOCHEMISTRY-US, V34, P16107, DOI 10.1021/bi00049a026
   PILCH DS, 1994, P NATL ACAD SCI USA, V91, P9332, DOI 10.1073/pnas.91.20.9332
   PIMPINELLI S, 1976, CYTOGENET CELL GENET, V17, P114, DOI 10.1159/000130703
   PJURA PE, 1987, J MOL BIOL, V197, P257, DOI 10.1016/0022-2836(87)90123-9
   PLOUVIER B, 1995, ANTI-CANCER DRUG DES, V10, P155
   PLOUVIER B, 1994, BIOCONJUGATE CHEM, V5, P475, DOI 10.1021/bc00029a016
   POOT M, 1990, CELL STRUCT FUNCT, V15, P151, DOI 10.1247/csf.15.151                                                              
   PORTUGAL J, 1987, EUR J BIOCHEM, V167, P281, DOI 10.1111/j.1432-1033.1987.tb13334.x                                              
   PORTUGAL J, 1988, BIOCHIM BIOPHYS ACTA, V949, P158, DOI 10.1016/0167-4781(88)90079-6                                                    
   PORTUGAL J, 1994, FEBS LETT, V344, P136, DOI 10.1016/0014-5793(94)00363-7
   POWERS R, 1990, BIOCHEMISTRY-US, V29, P9994, DOI 10.1021/bi00494a033
   Punt CJA, 1996, BRIT J CANCER, V73, P803, DOI 10.1038/bjc.1996.140
   Puvvada MS, 1997, BIOCHEMISTRY-US, V36, P2478, DOI 10.1021/bi952490r
   QUINTANA JR, 1991, BIOCHEMISTRY-US, V30, P10294, DOI 10.1021/bi00106a030
   RAO KE, 1991, CHEM RES TOXICOL, V4, P661, DOI 10.1021/tx00024a011
   Reinert KE, 1996, J BIOMOL STRUCT DYN, V14, P245, DOI 10.1080/07391102.1996.10508115                                                  
   REINERT KE, 1995, J BIOMOL STRUCT DYN, V12, P847, DOI 10.1080/07391102.1995.10508780                                                  
   REMERS WA, 1986, J MED CHEM, V29, P2492, DOI 10.1021/jm00162a012
   REYNOLDS VL, 1986, J ANTIBIOT, V39, P319, DOI 10.7164/antibiotics.39.319                                                      
   REYNOLDS VL, 1985, BIOCHEMISTRY-US, V24, P6228, DOI 10.1021/bi00343a029
   ROCCHI A, 1979, CYTOGENET CELL GENET, V23, P250, DOI 10.1159/000131335
   ROSS CF, 1983, BIOCHIM BIOPHYS ACTA, V741, P230, DOI 10.1016/0167-4781(83)90063-5
   ROSS WC, 1961, BIOCHEM PHARMACOL, V8, P235, DOI 10.1016/0006-2952(61)90006-5
   Rossi R, 1996, ANTICANCER RES, V16, P3779
   Rydzewski JM, 1996, NUCLEIC ACIDS RES, V24, P1287, DOI 10.1093/nar/24.7.1287
   Samuelson Per, 1994, Journal of Molecular Recognition, V7, P233, DOI 10.1002/jmr.300070313
   SANSOM CE, 1990, ANTI-CANCER DRUG DES, V5, P243
   SAPSE AM, 1995, J BIOMOL STRUCT DYN, V12, P857, DOI 10.1080/07391102.1995.10508781                                                  
   SCHMITZ HU, 1995, Z NATURFORSCH C, V50, P263
   SCHMITZ HU, 1993, BIOPHYS CHEM, V48, P61, DOI 10.1016/0301-4622(93)80042-H
   SEAMAN FC, 1993, BIOCHEMISTRY-US, V32, P12577, DOI 10.1021/bi00210a005
   SEARLE MS, 1990, NUCLEIC ACIDS RES, V18, P3753, DOI 10.1093/nar/18.13.3753
   SESSA C, 1994, ANN ONCOL, V5, P901, DOI 10.1093/oxfordjournals.annonc.a058728                                           
   SHAMDAS GJ, 1994, ANTI-CANCER DRUG, V5, P10, DOI 10.1097/00001813-199402000-00002
   SHAPIRO TA, 1990, P NATL ACAD SCI USA, V87, P950, DOI 10.1073/pnas.87.3.950
   SHIMIZU K, 1982, J ANTIBIOT, V35, P972, DOI 10.7164/antibiotics.35.972                                                      
   SHIOIRI T, 1995, ANTI-CANCER DRUG DES, V10, P167
   SIDOROVA NY, 1995, BIOPOLYMERS, V35, P377, DOI 10.1002/bip.360350405
   SIDOROVA NY, 1995, J BIOMOL STRUCT DYN, V13, P367, DOI 10.1080/07391102.1995.10508846                                                  
   SINGH MP, 1992, CHEM RES TOXICOL, V5, P597, DOI 10.1021/tx00029a003
   Singh M. P., 1996, PROGR MED CHEM, P49
   SINHARAY S, 1977, NUCLEIC ACIDS RES, V4, P3829, DOI 10.1093/nar/4.11.3829
   SMELLIE M, 1994, BRIT J CANCER, V70, P48, DOI 10.1038/bjc.1994.248
   SMITH KS, 1995, CANCER CHEMOTH PHARM, V35, P471, DOI 10.1007/BF00686831
   SMITH PJ, 1989, MUTAT RES, V217, P163, DOI 10.1016/0921-8777(89)90068-2
   SOLA F, 1995, CANCER CHEMOTH PHARM, V36, P217, DOI 10.1007/BF00685849
   Sola F, 1992, EXS, V61, P459
   Sola F, 1995, INVAS METAST, V15, P222
   Sondhi SM, 1997, CURR MED CHEM, V4, P313
   SPIELMANN HP, 1995, NUCLEIC ACIDS RES, V23, P1576, DOI 10.1093/nar/23.9.1576
   SPINK N, 1994, NUCLEIC ACIDS RES, V22, P1607, DOI 10.1093/nar/22.9.1607
   SRIRAM M, 1992, EMBO J, V11, P225
   SRIRAM M, 1994, ANN NY ACAD SCI, V726, P18, DOI 10.1111/j.1749-6632.1994.tb52794.x                                              
   Stevenson S, 1989, Nurs Times, V85, P30
   STOKKE T, 1986, CYTOMETRY, V7, P227, DOI 10.1002/cyto.990070302
   STOKKE T, 1985, J HISTOCHEM CYTOCHEM, V33, P333, DOI 10.1177/33.4.2579998                                                            
   STORL K, 1993, FEBS LETT, V334, P49, DOI 10.1016/0014-5793(93)81678-S
   SUBRA F, 1993, BIOCHEM PHARMACOL, V45, P93, DOI 10.1016/0006-2952(93)90381-6                                                    
   SUGIYAMA H, 1993, TETRAHEDRON LETT, V34, P2179, DOI 10.1016/S0040-4039(00)60376-3
   SUN DY, 1993, CHEM RES TOXICOL, V6, P889, DOI 10.1021/tx00036a020
   Surovaya AN, 1997, J BIOMOL STRUCT DYN, V14, P595, DOI 10.1080/07391102.1997.10508159                                                  
   SWENSON DH, 1985, CHEM-BIOL INTERACT, V67, P199
   Tagliabue G, 1997, EUR J CANCER, V33, P284, DOI 10.1016/S0959-8049(96)00435-2                                                   
   TAKEUCHI T, 1976, J ANTIBIOT, V29, P93, DOI 10.7164/antibiotics.29.93                                                       
   TANIOUS FA, 1992, BIOCHEMISTRY-US, V31, P3103, DOI 10.1021/bi00127a010
   TENG M, 1988, NUCLEIC ACIDS RES, V16, P2671, DOI 10.1093/nar/16.6.2671
   THOMPSON AS, 1995, BIOCHEMISTRY-US, V34, P11005, DOI 10.1021/bi00035a006
   THURSTON DE, 1990, J CHEM SOC CHEM COMM, P874, DOI 10.1039/c39900000874                                                            
   THURSTON DE, 1990, SYNTHESIS-STUTTGART, P81
   TIDWELL RR, 1978, J MED CHEM, V21, P613, DOI 10.1021/jm00205a005
   TIJSSEN JPF, 1982, BIOCHIM BIOPHYS ACTA, V721, P394, DOI 10.1016/0167-4889(82)90094-5
   TOZUKA Z, 1983, J ANTIBIOT, V36, P1699, DOI 10.7164/antibiotics.36.1699                                                     
   TOZUKA Z, 1983, J ANTIBIOT, V36, P276, DOI 10.7164/antibiotics.36.276                                                      
   Trent JO, 1996, J MED CHEM, V39, P4554, DOI 10.1021/jm9604484
   Trotta E, 1996, J BIOL CHEM, V271, P27608, DOI 10.1074/jbc.271.44.27608                                                        
   TROTTA E, 1995, NUCLEIC ACIDS RES, V23, P1333, DOI 10.1093/nar/23.8.1333
   TROTTA E, 1993, J BIOL CHEM, V268, P3944
   Tsugaya M, 1986, Hinyokika Kiyo, V32, P1443
   Tuite E, 1997, EUR J BIOCHEM, V243, P482, DOI 10.1111/j.1432-1033.1997.0482a.x
   Turner PR, 1996, MUTAT RES-FUND MOL M, V355, P141, DOI 10.1016/0027-5107(96)00027-9
   UMETSKAYA VN, 1990, BIOFIZIKA+, V35, P399
   UMETSKAYA VN, 1991, BIOFIZIKA+, V36, P167
   VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470
   VEGA MC, 1994, EUR J BIOCHEM, V222, P721, DOI 10.1111/j.1432-1033.1994.tb18917.x
   VINOGRADOV AE, 1993, BIOTECH HISTOCHEM, V68, P265, DOI 10.3109/10520299309105628
   Volpe DA, 1996, CANCER CHEMOTH PHARM, V39, P143, DOI 10.1007/s002800050550                                                           
   WADE WS, 1993, BIOCHEMISTRY-US, V32, P11385, DOI 10.1021/bi00093a015
   WALKER DL, 1994, CANCER CHEMOTH PHARM, V34, P317, DOI 10.1007/s002800050148
   WALTON AR, 1991, ACTA CRYSTALLOGR B, V47, P771, DOI 10.1107/S0108768191004524                                                       
   WANG JJ, 1992, J MED CHEM, V35, P2995, DOI 10.1021/jm00094a010
   Wang YQ, 1996, ANTI-CANCER DRUG DES, V11, P15
   WANG YQ, 1993, J MED CHEM, V36, P4172, DOI 10.1021/jm00078a005                                                             
   Wang ZY, 1997, BIOCHEM PHARMACOL, V53, P309, DOI 10.1016/S0006-2952(96)00690-9
   WARPEHOSKI MA, 1988, J MED CHEM, V31, P590, DOI 10.1021/jm00398a017
   WEILAND KL, 1991, BIOCHEMISTRY-US, V30, P7559, DOI 10.1021/bi00244a027
   WILSON WD, 1993, BIOCHEMISTRY-US, V32, P4098, DOI 10.1021/bi00066a035
   WILSON WD, 1990, BIOCHEMISTRY-US, V29, P8452, DOI 10.1021/bi00488a036
   WILSON WR, 1994, INT J RADIAT ONCOL, V29, P323, DOI 10.1016/0360-3016(94)90283-6                                                    
   WITTUNG P, 1994, NUCLEIC ACIDS RES, V22, P5371, DOI 10.1093/nar/22.24.5371                                                          
   WONG SSC, 1994, BIOCHEM PHARMACOL, V47, P827, DOI 10.1016/0006-2952(94)90483-9
   WOOD AA, 1995, NUCLEIC ACIDS RES, V23, P3678, DOI 10.1093/nar/23.18.3678
   WOYNAROWSKI JM, 1989, BIOCHEMISTRY-US, V28, P3850, DOI 10.1021/bi00435a034                                                             
   WOYNAROWSKI JM, 1989, MOL PHARMACOL, V35, P177
   Wyatt MD, 1997, ANTI-CANCER DRUG DES, V12, P49
   WYATT MD, 1995, BIOCHEMISTRY-US, V34, P13034, DOI 10.1021/bi00040a014
   YAMAMOTO K, 1992, BIOCHEM BIOPH RES CO, V183, P292, DOI 10.1016/0006-291X(92)91642-4
   Yang YW, 1996, BIOCHEM BIOPH RES CO, V222, P764, DOI 10.1006/bbrc.1996.0818
   YOSHIDA M, 1990, BIOCHEMISTRY-US, V29, P6585, DOI 10.1021/bi00480a006
   YOSHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V188, P1274, DOI 10.1016/0006-291X(92)91369-2                                                    
   YOUNG FE, 1989, ARCH INTERN MED, V149, P2412, DOI 10.1001/archinte.149.11.2412                                                    
   ZAKRZEWSKA K, 1983, NUCLEIC ACIDS RES, V11, P8825, DOI 10.1093/nar/11.24.8825                                                          
   ZAKRZEWSKA K, 1984, NUCLEIC ACIDS RES, V12, P6559, DOI 10.1093/nar/12.16.6559                                                          
   ZIMMER C, 1992, ADV DNA SEQUENCE SPE, V1, P51
   ZSIDO TJ, 1992, BIOCHEM PHARMACOL, V43, P1817, DOI 10.1016/0006-2952(92)90715-U
NR 416
TC 175
Z9 177
U1 5
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7258
J9 PHARMACOL THERAPEUT
JI Pharmacol. Ther.
PD OCT
PY 1999
VL 84
IS 1
BP 1
EP 111
DI 10.1016/S0163-7258(99)00021-2
PG 111
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 239FJ
UT WOS:000082757900001
PM 10580832
DA 2018-01-05
ER

PT J
AU Huang, PL
   Sun, YT
   Chen, HC
   Kung, HF
   Huang, PL
   Lee-Huang, S
AF Huang, PL
   Sun, YT
   Chen, HC
   Kung, HF
   Huang, PL
   Lee-Huang, S
TI Proteolytic fragments of anti-HIV and anti-tumor proteins MAP30 and
   GAP31 are biologically active
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
ID POKEWEED ANTIVIRAL PROTEIN; RICIN-A-CHAIN; INHIBITION; ANGSTROM; GAP-31;
   DNA; REPLICATION; INFECTION; TYPE-1; MAP-30
AB We analyzed the structural and functional organization of anti-HIV and anti-tumor proteins MAP30 and GAP31 by limited proteolysis with endopeptidases Lys-C and Glu-C (V8), MAP30 and GAP31 are resistant to proteolytic digestion under conditions of as much as 5% (w/w) proteases. In the presence of 10% (w/w) protease, the central regions of the proteins are still. resistant to proteolysis, whereas the N- and C-termini are accessible. Peptide fragments were purified by FPLC on Superdex 75 columns, characterized by gel electrophoresis, identified by amino acid sequencing, and analyzed for anti-HIV, anti-tumor, and other biochemical activities. We report here that limited proteolysis yields biologically active fragments of both MAP30 and GAP31. These fragments are active against HIV-1 and tumor cells with EC(50)s in the sub-nanomolar ranges, 0.2-0.4 nM. At the dose levels used in the assays, little cytotoxicity to normal cells was observed. In addition, these fragments remain fully active in HIV-integrase inhibition and HIV-LTR topological inactivation, but not ribosome inactivation. These results demonstrate that the antiviral and anti-tumor activities of MAP30 and GAP31 are independent of ribosome inactivation activity. In addition, we demonstrate that portions of the N- and C-termini are not essential for antiviral and anti-tumor activities, but do appear to be required for ribosome inactivation. These results may provide novel strategies for rational design and targeted development of mimetic antiviral and anti-tumor therapeutics, (C) 1999 Academic Press.
C1 NYU, Sch Med, Dept Biochem, New York, NY 10016 USA.
   Amer Biosci, New York, NY 10021 USA.
   NICHHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA.
   Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong.
   Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Lee-Huang, S (reprint author), NYU, Sch Med, Dept Biochem, New York, NY 10016 USA.
FU NIAID NIH HHS [R01 AI-31343]
CR ARON GM, 1980, ANTIMICROB AGENTS CH, V17, P1032, DOI 10.1128/AAC.17.6.1032                                                           
   Chaddock JA, 1996, EUR J BIOCHEM, V235, P159, DOI 10.1111/j.1432-1033.1996.00159.x
   CORY AH, 1991, CANCER COMMUN, V3, P207
   Day PJ, 1996, BIOCHEMISTRY-US, V35, P11098, DOI 10.1021/bi960880n                                                               
   DRAPEAU GR, 1972, J BIOL CHEM, V247, P6720
   ELLIOTT BW, 1986, J BIOL CHEM, V261, P11258
   HUANG PL, 1992, BIOFACTORS, V4, P37
   HUSAIN J, 1994, FEBS LETT, V342, P154, DOI 10.1016/0014-5793(94)80491-5
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee-Huang S, 1999, P NATL ACAD SCI USA, V96, P2678, DOI 10.1073/pnas.96.6.2678
   LEEHUANG S, 1994, P NATL ACAD SCI USA, V91, P12208, DOI 10.1073/pnas.91.25.12208
   LEEHUANG S, 1991, FEBS LETT, V291, P139, DOI 10.1016/0014-5793(91)81122-O
   LEEHUANG S, 1990, FEBS LETT, V272, P12, DOI 10.1016/0014-5793(90)80438-O
   LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818                                                         
   LEEHUANG S, 1994, J MOL BIOL, V240, P92, DOI 10.1006/jmbi.1994.1421                                                          
   LEEHUANG S, 1992, NATURAL PRODUCTS AS ANTIVIRAL AGENTS, P153
   LEEHUANG S, 1999, IN PRESS MOL MED
   Li Jian Jun, 1998, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V17, pA23
   LI JJ, 1998, 13 INT C AIDS
   MLSNA D, 1993, PROTEIN SCI, V2, P429
   MONTFORT W, 1987, J BIOL CHEM, V262, P5398
   MONZINGO AF, 1993, J MOL BIOL, V233, P705, DOI 10.1006/jmbi.1993.1547
   RYBAK SM, 1994, INT J ONCOL, V5, P1171
   Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866
   WANG YX, 1999, IN PRESS PROTEIN SCI
   WONG SW, 1989, J BIOL CHEM, V264, P5924
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
   ZHOU KJ, 1994, PROTEINS, V19, P4, DOI 10.1002/prot.340190103
NR 28
TC 30
Z9 39
U1 0
U2 3
PU ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 7
PY 1999
VL 262
IS 3
BP 615
EP 623
DI 10.1006/bbrc.1999.1213                                                  
          
PG 9
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 235AH
UT WOS:000082516200010
PM 10471373
DA 2018-01-05
ER

PT J
AU Frey, A
   Mantis, N
   Kozlowski, PA
   Quayle, AJ
   Bajardi, A
   Perdomo, JJ
   Robey, FA
   Neutra, MR
AF Frey, A
   Mantis, N
   Kozlowski, PA
   Quayle, AJ
   Bajardi, A
   Perdomo, JJ
   Robey, FA
   Neutra, MR
TI Immunization of mice with peptomers covalently coupled to aluminum oxide
   nanoparticles
SO VACCINE
LA English
DT Article
DE adjuvant; antibodies; vaccine
ID IMMUNODEFICIENCY-VIRUS ENVELOPE; MUCOSAL IMMUNE-RESPONSES; T-CELL;
   PEPTIDE VACCINE; CHOLERA-TOXIN; TYPE-1 GP120; C4 DOMAIN;
   MONOCLONAL-ANTIBODIES; SYNTHETIC PEPTIDES; CD4-BINDING DOMAIN
AB Subunit vaccines generally require adjuvants to elicit immune responses, but adjuvants may alter the conformation of critical epitopes and reduce vaccine efficacy. We therefore tested an immunization strategy in which antigen is covalently coupled to aluminum oxide nanoparticles using a method that favors preservation of the native conformation. The test antigen consisted of "peptomers" (head-to-tail-linked peptide homopolymers) derived from the 4th conserved region (C4) of HIV-1 gp120 which is believed to be in an alpha-helical conformation prior to binding to CD4, Immune responses in mice to peptomer-nanoparticle conjugates were compared to responses elicited by free C4 peptide and C4 peptomers, with and without the hydrophilic adjuvant muramyl dipeptide (MDP). Highest peptomer-specific serum antibody responses were induced by peptomer-particles without MDP. Serum antibodies induced by peptomer-particles also showed highest reactivity towards recombinant, glycosylated gp120 and HIV-1 infected T cells. The results suggest that this novel vaccine approach could be useful for induction of immune responses against conformation-sensitive viral antigens without the need for additional adjuvants. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Childrens Hosp, GI Cell Biol Res Lab, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Fearing Res Lab, Boston, MA 02115 USA.
   Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.
RP Neutra, MR (reprint author), Childrens Hosp, GI Cell Biol Res Lab, 300 Longwood Ave,Enders 1220, Boston, MA 02115 USA.
OI Mantis, Nicholas/0000-0002-5083-8640
FU NICHD NIH HHS [HD17557]; NIDDK NIH HHS [DK34854]; NIAID NIH HHS
   [AI34757]
CR AHLERS JD, 1993, J IMMUNOL, V150, P5647
   Ahlers JD, 1997, P NATL ACAD SCI USA, V94, P10856, DOI 10.1073/pnas.94.20.10856
   BERZOFSKY JA, 1991, J CLIN INVEST, V88, P876, DOI 10.1172/JCI115389
   BORRASCUESTA F, 1988, EUR J IMMUNOL, V18, P199, DOI 10.1002/eji.1830180203
   BUKAWA H, 1995, NAT MED, V1, P681, DOI 10.1038/nm0795-681                                                              
   Burton DR, 1997, P NATL ACAD SCI USA, V94, P10018, DOI 10.1073/pnas.94.19.10018
   CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249
   CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0
   CORDONNIER A, 1989, NATURE, V340, P571, DOI 10.1038/340571a0
   DELGIUDICE G, 1986, J IMMUNOL, V137, P2952
   ELSON CO, 1984, J IMMUNOL, V133, P2892
   FEVRIER M, 1978, EUR J IMMUNOL, V8, P558, DOI 10.1002/eji.1830080804
   FRASERSMITH EB, 1982, INFECT IMMUN, V35, P105
   Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045
   Frey A, 1997, BIOCONJUGATE CHEM, V8, P424, DOI 10.1021/bc970036p
   Graf Von Stosch Andreas, 1995, Journal of Molecular Biology, V250, P507
   GUPTA RK, 1993, VACCINE, V11, P293, DOI 10.1016/0264-410X(93)90190-9
   GURGO C, 1988, VIROLOGY, V164, P531, DOI 10.1016/0042-6822(88)90568-5
   HANEBERG B, 1994, INFECT IMMUN, V62, P15
   HARMS J, 1979, J BIOMED MATER RES, V13, P67, DOI 10.1002/jbm.820130109                                                           
   HART MK, 1990, J IMMUNOL, V145, P2677
   HILLMAN K, 1991, CELL IMMUNOL, V134, P1, DOI 10.1016/0008-8749(91)90326-7
   HSIEH CS, 1995, J EXP MED, V181, P713, DOI 10.1084/jem.181.2.713
   KOZLOWSKI PA, 1994, AIDS RES HUM RETROV, V10, P813
   LASKY LA, 1987, CELL, V50, P975, DOI 10.1016/0092-8674(87)90524-1
   LYCKE N, 1986, IMMUNOLOGY, V59, P301
   MOORE JP, 1994, J VIROL, V68, P469
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   NAKAMURA GR, 1993, J VIROL, V67, P6179
   NARDELLI B, 1992, J IMMUNOL, V148, P914
   Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3
   Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275
   PALKER TJ, 1989, J IMMUNOL, V142, P3612
   REED J, 1991, BIOCHEMISTRY-US, V30, P4521, DOI 10.1021/bi00232a022
   Robey F A, 1994, Methods Mol Biol, V35, P73
   Robey FA, 1996, J BIOL CHEM, V271, P17990, DOI 10.1074/jbc.271.30.17990                                                        
   ROBEY FA, 1995, J BIOL CHEM, V270, P23918, DOI 10.1074/jbc.270.41.23918                                                        
   SCIBIENS.RJ, 1973, J IMMUNOL, V111, P114
   Staats HF, 1996, J IMMUNOL, V157, P462
   SUN NC, 1989, J VIROL, V63, P3579
   TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409
   Tijssen P, 1985, PRACTICE THEORY ENZY, P385
   UGOLEV AM, 1973, BIOCHIM BIOPHYS ACTA, V300, P105, DOI 10.1016/0304-4157(73)90001-4
   WARING R H, 1980, European Journal of Drug Metabolism and Pharmacokinetics, V5, P49
   WEISSBURG RP, 1995, PHARMACEUT RES, V12, P1439, DOI 10.1023/A:1016266916893
   WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673
   XUAMANO JC, 1993, J EXP MED, V178, P1309, DOI 10.1084/jem.178.4.1309
NR 47
TC 29
Z9 30
U1 1
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD AUG 6
PY 1999
VL 17
IS 23-24
BP 3007
EP 3019
DI 10.1016/S0264-410X(99)00163-2                                           
          
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 225KD
UT WOS:000081957300010
PM 10462236
DA 2018-01-05
ER

PT J
AU Schwarz, MK
   Wells, TNC
AF Schwarz, MK
   Wells, TNC
TI Interfering with chemokine networks - the hope for new therapeutics
SO CURRENT OPINION IN CHEMICAL BIOLOGY
LA English
DT Review
ID HIV-1 INFECTION; MICE LACKING; CC-CHEMOKINE; T-CELLS; AIRWAY
   HYPERRESPONSIVENESS; ALLERGIC INFLAMMATION; NEUTROPHIL MIGRATION; HUMAN
   INTERLEUKIN-8; REPERFUSION INJURY; RECEPTOR CXCR4
AB Chemokines are a large family of cytokines with a wide variety of biological actions. Originally, they were identified as controllers of the routine trafficking of immune cells, and directed migration of cells during inflammatory response from which they get their name, a contraction of chemotactic cytokines. They are now also known to be active in angiogenesis, embryonic development and infection by viruses such as HIV-1. Studies with antibodies, modified chemokine and transgenic mice suggest that chemokine receptor antagonists may be selective anti-inflammatory, antiviral or immunomodulatory agents. Small-molecule antagonists of seven of the receptors have been reported, some with potency in the low nanomolar range. These compounds are shown to be active in cell biology assays; the next step will be to determine their efficacy in animal models of disease.
C1 Ares Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland.
RP Schwarz, MK (reprint author), Ares Serono Int SA, Serono Pharmaceut Res Inst, 14 Chemin Aux, CH-1228 Geneva, Switzerland.
OI Wells, Timothy/0000-0001-9796-847X
CR Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716
   Alcami A, 1998, J IMMUNOL, V160, P624
   Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698                                                         
   Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873
   BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902
   Berger EA, 1997, AIDS, V11, pS3
   Bonecchi R, 1999, J IMMUNOL, V162, P474
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Bright C, 1998, BIOORG MED CHEM LETT, V8, P771, DOI 10.1016/S0960-894X(98)00094-8                                                   
   CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519                                                         
   CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005
   COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639
   Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009
   Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959
   Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521                                                        
   GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631                                                           
   Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131
   Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157                                                           
   Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045
   Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2
   Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687
   Holmes WE, 1991, SCIENCE, V253, P278, DOI 10.1126/science.1840701
   Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s
   Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6
   Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682
   Karpus WJ, 1997, J LEUKOCYTE BIOL, V62, P681
   Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o                                                               
   Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340
   LAPIERRE JM, 1998, 26 NAT MED CHEM S 1
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Lloyd GM, 1997, J EXP MED, V185, P1371
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706                                                     
   Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215
   Matsumoto T, 1997, J LEUKOCYTE BIOL, V62, P581
   McKinnon M, 1996, DRUG NEWS PERSPECT, V9, P389
   MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716
   Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0
   Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875
   Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z
   PLATERZYBERK C, 1997, IMMUNOL LETT, V57, P57
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599                                                          
   Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451
   RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420                                                         
   Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628
   ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150
   Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785                                                           
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Saunders J, 1999, DRUG DISCOV TODAY, V4, P80, DOI 10.1016/S1359-6446(98)01280-X                                                   
   SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   SCHWARZ MK, 1999, IN PRESS EXPT OPIN T, V9
   SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0                                                                
   SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150
   Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487
   Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261
   Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53
   Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4                                                   
   Wells TNC, 1997, CURR OPIN BIOTECH, V8, P741, DOI 10.1016/S0958-1669(97)80129-2
   White JH, 1998, NATURE, V396, P679
   White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095                                                        
   Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252
   Zagorski J, 1997, J IMMUNOL, V159, P1059
   Zhou YH, 1998, J IMMUNOL, V160, P4018
   WIDDOWSON KL, 1997, Patent No. 9749286
   NAYA A, 1998, Patent No. 9804554
   ZENECA GROUP PLC, 1999, Patent No. 09907351
   TAKEMOTO T, 1997, Patent No. 09169729
   WIDDOWSON KL, 1997, Patent No. 9749400
   WIDDOWSON KL, 1998, Patent No. 9832439
   HONDA S, 1997, Patent No. 09249570
   KATO K, 1997, Patent No. 9724325
   Connor D. T., 1998, [No title captured], Patent No. [WO 98/06703, 9806703]
   HONDA S, 1997, Patent No. 09255572
   SCHWENDER CF, 1998, Patent No. 9802151
   XIANG JN, 1998, Patent No. 9807418
   WIDDOWSON KL, 1996, Patent No. 9625157
   BRYAN DL, 1998, Patent No. 9806701
   WIDDOWSON KL, 1997, Patent No. 9749287
   1996, Patent No. 9618393
   HONDA S, 1997, Patent No. 09249566
   BRYAN DL, 1998, Patent No. 9806262
   BONDINELL WE, 1998, Patent No. 9830218
   SHIOTA T, 1997, Patent No. 9744329
   WIDDOWSON KL, 1997, Patent No. 9749680
NR 89
TC 25
Z9 27
U1 0
U2 0
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1367-5931
J9 CURR OPIN CHEM BIOL
JI Curr. Opin. Chem. Biol.
PD AUG
PY 1999
VL 3
IS 4
BP 407
EP 417
DI 10.1016/S1367-5931(99)80061-1
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 223XL
UT WOS:000081866800007
PM 10419853
DA 2018-01-05
ER

PT J
AU Cauchetier, E
   Fessi, H
   Boulard, Y
   Deniau, M
   Astier, A
   Paul, M
AF Cauchetier, E
   Fessi, H
   Boulard, Y
   Deniau, M
   Astier, A
   Paul, M
TI Preparation and physicochemical characterization of
   atovaquone-containing liposomes
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article
DE atovaquone; liposomes; physicochemical properties; adsorption
ID VISCERAL LEISHMANIASIS; AMPHOTERICIN-B; ENCAPSULATED DRUGS;
   HIV-INFECTION; NANOPARTICLES; PHOSPHOLIPIDS; MACROPHAGES; CARRIERS;
   DONOVANI; OPSONINS
AB This work describes the preparation and the physicochemical properties of atovaquone-loaded liposomes. It also describes drug release from the liposomes. As many factors can influence liposome stability, we studied several formulations, including different concentrations of atovaquone, phospholipids, and cholesterol. The effect of atovaquone (ATV) concentration was also evaluated. The high est binding percentage (100 +/- 2.5%) was obtained under alkaline conditions for a 2 mg/ml concentration of AN. The percentage of encapsulation decreased significantly when drug concentrations increased. Drug uptake (expressed per unit mass of phospholipids) was nonlinearly related to equilibrium ATV concentration. A Langmuir-type sorption was suggested (r = 0.978). in acidic or neutral buffer, the binding percentage reached 42.1 +/- 0.02%. The increase of phospholipids and cholesterol concentrations did not significantly improve the ATV binding yield for the lowest AN concentration. Conversely, ATV binding was significantly increased for the highest ATV concentration. All the formulations tested gave monodispersed liposomes with a mean diameter around 260 nm. The dilution (1/5-1/20) of liposomes in alkaline conditions induced a significant release of ATV (74% release). In acidic or neutral buffer no release was observed, suggesting an encapsulation process. (C) 1999 Wiley-Liss, Inc.
C1 CHU Henri Mondor, Serv Pharm, Lab Pharmacotech, F-94010 Creteil, France.
   Fac Pharm Claude Bernard, Lyon, France.
   Museum Natl Hist Nat, Lab Biol Parasitaire Protistol & Helminthol, F-75231 Paris, France.
   Univ H Poincare, Lab Pharm Clin, Nancy, France.
RP Cauchetier, E (reprint author), CHU Henri Mondor, Serv Pharm, Lab Pharmacotech, F-94010 Creteil, France.
CR ALVING C R, 1986, Parasitology Today, V2, P101, DOI 10.1016/0169-4758(86)90039-6
   ALVING CR, 1978, P NATL ACAD SCI USA, V75, P2959, DOI 10.1073/pnas.75.6.2959
   ALVING CR, 1983, PHARMACOL THERAPEUT, V22, P407, DOI 10.1016/0163-7258(83)90010-4
   ANTOINE JC, 1995, PATHOL BIOL, V43, P215
   BADARO R, 1994, J INFECT DIS, V170, P413, DOI 10.1093/infdis/170.2.413                                                        
   BAKKERWOUDENBERG IAJM, 1994, J DRUG TARGET, V2, P363, DOI 10.3109/10611869408996811                                                       
   BARTLETT GR, 1959, J BIOL CHEM, V234, P466
   Bryceson A., 1987, The leishmaniases in biology and medicine. Volume II. Clinical aspects and control, P847
   *BURR WELLC, 1992, MEPR PACK INS
   CABIE A, 1992, PRESSE MED, V21, P1658
   COUVREUR P, 1979, J PHARM PHARMACOL, V31, P331, DOI 10.1111/j.2042-7158.1979.tb13510.x                                              
   CROFT SL, 1992, J ANTIMICROB CHEMOTH, V30, P827, DOI 10.1093/jac/30.6.827
   CZURYLO EA, 1993, BIOCHEM J, V291, P403, DOI 10.1042/bj2910403                                                               
   DAVIDSON RN, 1994, Q J MED, V87, P75
   DAVIDSON RN, 1991, LANCET, V337, P1061, DOI 10.1016/0140-6736(91)91708-3
   deChasteigner S, 1996, DRUG DEVELOP RES, V38, P125, DOI 10.1002/(SICI)1098-2299(199606)38:2<125::AID-DDR7>3.0.CO;2-L
   DEDET JP, 1995, PRESSE MED, V24, P1036
   DUPLESSIS J, 1986, INT J PHARM, V34, P173, DOI 10.1016/0378-5173(86)90026-8                                                    
   DUPLESSIS J, 1988, INT J PHARM, V46, P177, DOI 10.1016/0378-5173(88)90024-5                                                    
   Durand R, 1997, INT J PARASITOL, V27, P1361, DOI 10.1016/S0020-7519(97)00124-0
   GONDAL JA, 1989, ANTIMICROB AGENTS CH, V33, P1544, DOI 10.1128/AAC.33.9.1544                                                           
   HARASHIMA H, 1993, PHARMACEUT RES, V10, P606, DOI 10.1023/A:1018918623658
   HWANG KJ, 1983, LIPOSOMES BIOPHYSICS, P109
   ILLUM L, 1986, INT J PHARM, V30, P17, DOI 10.1016/0378-5173(86)90131-6
   JERNIGAN JA, 1993, 33 INT C ANT AG CHEM, P257
   KIRBY C, 1980, BIOCHEM J, V186, P591, DOI 10.1042/bj1860591                                                               
   OLLIARO PL, 1993, PARASITOL TODAY, V9, P323, DOI 10.1016/0169-4758(93)90231-4
   PATEL HM, 1992, CRIT REV THER DRUG, V9, P39
   Paul M, 1998, DRUG DEVELOP RES, V43, P98, DOI 10.1002/(SICI)1098-2299(199802)43:2<98::AID-DDR2>3.0.CO;2-K                     
   PUISIEUX F, 1985, FORMES PHARM NOUVELL, P467
   RODRIGUES JM, 1994, TROP MED PARASITOL, V45, P223
   SENIOR JH, 1987, CRIT REV THER DRUG, V3, P123
   TOCANNE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P111, DOI 10.1016/0304-4157(90)90005-W                                                    
   Vemuri S, 1995, Pharm Acta Helv, V70, P95, DOI 10.1016/0031-6865(95)00010-7
   WISSNER A, 1990, TETRAHEDRON COMPUT M, V3, P63
   ZOGRAFI G, 1995, REMINGTON SCI PRACTI, P249
   STAINMESS F, 1989, Patent No. 4018571
NR 37
TC 11
Z9 11
U1 0
U2 3
PU WILEY-LISS
PI NEW YORK
PA DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 0272-4391
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
PD AUG
PY 1999
VL 47
IS 4
BP 155
EP 161
DI 10.1002/(SICI)1098-2299(199908)47:4<155::AID-DDR1>3.3.CO;2-W
PG 7
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 239WN
UT WOS:000082793000001
DA 2018-01-05
ER

PT J
AU Bertini, R
   Howard, OMZ
   Dong, HF
   Oppenheim, JJ
   Bizzarri, C
   Sergi, R
   Caselli, G
   Pagliei, S
   Romines, B
   Wilshire, JA
   Mengozzi, M
   Nakamura, H
   Yodoi, J
   Pekkari, K
   Gurunath, R
   Holmgren, A
   Herzenberg, LA
   Herzenberg, LA
   Ghezzi, P
AF Bertini, R
   Howard, OMZ
   Dong, HF
   Oppenheim, JJ
   Bizzarri, C
   Sergi, R
   Caselli, G
   Pagliei, S
   Romines, B
   Wilshire, JA
   Mengozzi, M
   Nakamura, H
   Yodoi, J
   Pekkari, K
   Gurunath, R
   Holmgren, A
   Herzenberg, LA
   Herzenberg, LA
   Ghezzi, P
TI Thioredoxin, a redox enzyme released in infection and inflammation, is a
   unique chemoattractant for neutrophils, monocytes, and T cells
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE chemotaxis; thioredoxin; HTLV-1; migration
ID LEUKEMIA-DERIVED FACTOR; ACQUIRED IMMUNODEFICIENCY SYNDROME; HTLV-I;
   LYMPHADENOPATHY SYNDROME; EXPRESSION; PROTEIN; MIGRATION; LINES;
   IDENTIFICATION; GLUTAREDOXIN
AB Thioredoxin (Trx) is a ubiquitous intracellular protein disulfide oxidoreductase with a CXXC active site that can be released by various cell types upon activation. We show here that Trx is chemotactic for monocytes, polymorphonuclear leukocytes, and T lymphocytes, both in vitro in the standard micro Boyden chamber migration assay and in vivo in the mouse air pouch model. The potency of the chemotactic action of Tn: for all leukocyte populations is in the nanomolar range, comparable with that of known chemokines. However, Trx does not increase intracellular Ca2+ and its activity is not inhibited by pertussis toxin. Thus, the chemotactic action of Trx differs from that of known chemokines in that it is G protein independent. Mutation of the active site cysteines resulted in loss of chemotactic activity, suggesting that the latter is mediated by the enzyme activity of Trx. Trx also accounted for part of the chemotactic activity released by human T lymphotropic virus (HTLV)-1-infected cells, which was inhibited by incubation with anti-Trx antibody. Since Trx production is induced by oxidants, it represents a link between oxidative stress and inflammation that is of particular interest because circulating Tn: levels are elevated in inflammatory diseases and HIV infection.
C1 Stanford Univ, Dept Genet, Sch Med, Sch Med, Stanford, CA 94305 USA.
   Dompe Res Ctr, I-67100 Laquila, Italy.
   NCI, Frederick Canc Res & Dev Ctr, Mol Immunoregulat Lab, Frederick, MD 21702 USA.
   Consorzio Biolaq, I-67100 Laquila, Italy.
   Kyoto Univ, Inst Virus Res, Dept Biol Responses, Kyoto 606, Japan.
   Karolinska Inst, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.
RP Ghezzi, P (reprint author), Stanford Univ, Dept Genet, Sch Med, Sch Med, B-007,300 Pasteur Dr, Stanford, CA 94305 USA.
RI Howard, O M Zack/B-6117-2012; Ramanathan, Gurunath/B-4757-2011
OI Howard, O M Zack/0000-0002-0505-7052; Ramanathan,
   Gurunath/0000-0003-4627-1677
FU NCI NIH HHS [N01-CO-56000, CA42509]
CR Anderson MT, 1998, CYTOMETRY, V33, P435, DOI 10.1002/(SICI)1097-0320(19981201)33:4<435::AID-CYTO7>3.0.CO;2-1
   Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495                                                        
   BERTINI R, 1995, AIDS RES HUM RETROV, V11, P155, DOI 10.1089/aid.1995.11.155
   BIGUET C, 1994, J BIOL CHEM, V269, P28865
   BIZZARRI C, 1995, BLOOD, V86, P2388
   Brandolini L, 1996, J LEUKOCYTE BIOL, V59, P427
   Buetler TM, 1998, HEPATOLOGY, V28, P1551, DOI 10.1002/hep.510280615
   Chertov O, 1996, J BIOL CHEM, V271, P2935, DOI 10.1074/jbc.271.6.2935                                                          
   Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751
   DECOTTIGNIES P, 1990, ARCH BIOCHEM BIOPHYS, V280, P112, DOI 10.1016/0003-9861(90)90525-4
   ENDOH M, 1993, BIOCHEM BIOPH RES CO, V192, P760, DOI 10.1006/bbrc.1993.1479
   ERICSON ML, 1992, LYMPHOKINE CYTOK RES, V11, P201
   FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/0022-1759(80)90211-2
   Gallegos A, 1996, CANCER RES, V56, P5765
   GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643
   GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206
   HECHTMAN DH, 1991, J IMMUNOL, V147, P883
   HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237
   HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199
   HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283
   HOLMGREN A, 1989, J BIOL CHEM, V264, P13963
   HORI K, 1993, J IMMUNOL, V151, P5624
   Kuang YN, 1996, J BIOL CHEM, V271, P3975
   LAZZARIN A, 1986, CLIN EXP IMMUNOL, V65, P105
   LIPPOLDT A, 1995, J NEUROSCI, V15, P6747
   Maurice MM, 1997, J IMMUNOL, V158, P1458
   Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2                                                   
   NAKAMURA H, 1994, IMMUNOL LETT, V42, P213, DOI 10.1016/0165-2478(94)90090-6                                                    
   NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8
   Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603                                                          
   Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351                                                
   POLI G, 1985, CLIN EXP IMMUNOL, V62, P136
   REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023                                                             
   Roederer M, 1997, CYTOMETRY, V29, P328, DOI 10.1002/(SICI)1097-0320(19971201)29:4<328::AID-CYTO10>3.0.CO;2-W
   ROMANO M, 1997, MED INFLAMM, V6, P1
   RUBARTELLI A, 1995, CANCER RES, V55, P675
   RUBARTELLI A, 1992, J BIOL CHEM, V267, P24161
   RUTLEDGE BJ, 1995, J IMMUNOL, V155, P4838
   SACHI Y, 1995, IMMUNOL LETT, V44, P189, DOI 10.1016/0165-2478(95)00213-O
   SAGGIORO D, 1991, AIDS RES HUM RETROV, V7, P571, DOI 10.1089/aid.1991.7.571
   Sahaf B, 1997, EXP CELL RES, V236, P181, DOI 10.1006/excr.1997.3699
   Sasada T, 1996, J CLIN INVEST, V97, P2268, DOI 10.1172/JCI118668
   Schenk H, 1996, J IMMUNOL, V156, P765
   SILBERSTEIN DS, 1993, J BIOL CHEM, V268, P9138
   SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450                                                               
   TAGAYA Y, 1989, EMBO J, V8, P757
   TAGAYA Y, 1989, J EXP MED, V13, P2244
   TESHIGAWARA K, 1985, J MOL CELL IMMUNOL, V2, P17
   TOMIMOTO H, 1993, BRAIN RES, V625, P1, DOI 10.1016/0006-8993(93)90130-F
   WAKASUGI N, 1990, P NATL ACAD SCI USA, V87, P8282, DOI 10.1073/pnas.87.21.8282
   Wollman EE, 1997, BIOCHEM BIOPH RES CO, V230, P602, DOI 10.1006/bbrc.1996.6015
   WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840
   YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K
   YODOI J, 1991, ADV CANCER RES, V57, P381, DOI 10.1016/S0065-230X(08)61004-0
NR 54
TC 234
Z9 239
U1 0
U2 10
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD JUN 7
PY 1999
VL 189
IS 11
BP 1783
EP 1789
DI 10.1084/jem.189.11.1783                                                 
          
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 206BB
UT WOS:000080855200012
PM 10359582
OA gold
DA 2018-01-05
ER

PT J
AU D'Cruz, OJ
   Uckun, FM
AF D'Cruz, OJ
   Uckun, FM
TI Novel derivatives of phenethyl-5-bromopyridylthiourea and
   dihydroalkoxybenzyl-oxopyrimidine are dual-function spermicides with
   potent anti-human immunodeficiency virus activity
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
ID HIV-1 REVERSE-TRANSCRIPTASE; POKEWEED ANTIVIRAL PROTEIN; S-DABO SERIES;
   NONNUCLEOSIDE INHIBITORS; ANTI-HIV-1 ACTIVITY; NONOXYNOL-9 USE;
   1-<(2-HYDROXYETHOXY)METHYL>-6-(PHENYLTHIO)THYMINE HEPT;
   SELECTIVE-INHIBITION; THIOUREA DERIVATIVES; PETT COMPOUNDS
AB Sexually active women represent the fastest growing HIV/AIDS (human immunodeficiency virus/acquired immunodeficiency syndrome) risk group. In an effort to develop a vaginal microbicidal contraceptive potentially capable of preventing HIV transmission as well as providing fertility control, we have synthesized novel non-nucleoside inhibitors (NNIs) of HIV-1 reverse transcriptase (RT) and examined them for dual-function anti-HIV and spermicidal activity. Structure-based drug design by use of a computer docking procedure for the NNI binding pocket generated from nine RT-NNI crystal structures led to tbe synthesis of three novel NNIs: N-[2-(2,5-dimethoxyphenethyl)]N'- [2-(5-bromopyridyl)]-thiourea (D-PBT); N-[2-(2-fluorophenethyl)]-N'-[2-(5-bromopyridyl)]-thiourea (F-PBT); and 5-isopropyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-one (S-DABO). The anti-HIV activity of these NNIs was compared with that of trovirdine and virucidal/spermicide, nonoxynol-9 (N-9), by measuring viral RT activity and p24 antigen production as markers of viral replication using HTLVIIIB-infected human peripheral blood mononuclear cells (PBMCs). The effects on sperm motion kinematics and sperm membrane integrity were examined by computer-assisted sperm analysis and by confocal laser scanning microscopy (CLSM), respectively. The growth-inhibitory effects of NNI versus N-9 against normal human ectocervical and endocervical epithelial cells were tested using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay. All three NNIs were potent inhibitors of purified recombinant HIV RT and abrogated HIV replication in PBMCs at nanomolar concentrations (IC50 < 1 nM) when compared with N-9 or trovirdine (IC50 values of 2.2 mu M and 0.007 mu M, respectively). Two NNIs, F-PBT and S-DABO, also exhibited concentration- and time-dependent spermicidal activity. The drug concentration required to inhibit sperm motility by 50% (EC50 values) for the lead compound F-PBT versus N-9 was 147 mu M and 81 mu M, respectively. Sperm-immobilizing activity induced by F-PBT and S-DABO was rapid (t(1/2) = 7-13 min) and irreversible. Unlike that of N-9, spermicidal activity of F-PBT and S-DABO was not accompanied by loss of acrosomal membrane as detected by fluorescent-lectin binding assay and CLSM. Whereas N-9 was cytotoxic to normal human ectocervical and endocervical cells at spermicidal doses, both F-PBT and S-DABO were selectively spermicidal. We conclude that as potent anti-HIV agents with spermicidal activity and reduced cytotoxicity, F-PBT and S-DABO show unique clinical potential to become the active ingredients of a vaginal contraceptive for women who are at high risk for acquiring HIV by heterosexual vaginal transmission.
C1 Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Hughes Inst, Dept Reprod Biol, St Paul, MN 55113 USA.
   Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Hughes Inst, Drug Discovery Program, 2665 Long Lake Rd,Suite 330, Roseville, MN 55113 USA.
CR AHGREN C, 1995, ANTIMICROB AGENTS CH, V39, P1329, DOI 10.1128/AAC.39.6.1329                                                           
   BABA M, 1992, ANTIVIR RES, V17, P245, DOI 10.1016/0166-3542(92)90021-V
   BALZARINI J, 1992, P NATL ACAD SCI USA, V89, P4392, DOI 10.1073/pnas.89.10.4392
   BELL FW, 1995, J MED CHEM, V38, P4929, DOI 10.1021/jm00025a010
   BIRD KD, 1991, AIDS, V55, P791
   BOSWORTH N, 1989, NATURE, V341, P167, DOI 10.1038/341167a0
   Cantrell AS, 1996, J MED CHEM, V39, P4261, DOI 10.1021/jm950639r
   CELUM CL, 1996, HIV MANUAL, P120
   CHANTLER E, 1992, BRIT J FAMIL PLANNIN, V17, P118
   CIOOK RL, 1998, SEX TRANSM DIS, V25, P144
   D'Cruz OJ, 1998, BIOL REPROD, V58, P1515, DOI 10.1095/biolreprod58.6.1515                                                     
   D'Cruz OJ, 1998, BIOL REPROD, V59, P503, DOI 10.1095/biolreprod59.3.503                                                      
   Danel K, 1998, J MED CHEM, V41, P191, DOI 10.1021/jm970443m
   Danel K, 1996, J MED CHEM, V39, P2427, DOI 10.1021/jm9600499
   DCruz OJ, 1996, BIOL REPROD, V54, P1217, DOI 10.1095/biolreprod54.6.1217                                                     
   DECLERCQ E, 1992, AIDS RES HUM RETROV, V8, P119, DOI 10.1089/aid.1992.8.119                                                          
   DING J, 1995, STRUCTURE, V3, P365, DOI 10.1016/S0969-2126(01)00168-X
   DING JP, 1995, NAT STRUCT BIOL, V2, P407, DOI 10.1038/nsb0595-407
   ERICE A, 1993, ANTIMICROB AGENTS CH, V37, P835, DOI 10.1128/AAC.37.4.835                                                            
   FELDBLUM PJ, 1988, JAMA-J AM MED ASSOC, V259, P2851
   FELDBLUM PJ, 1988, AM J PUBLIC HEALTH, V78, P52, DOI 10.2105/AJPH.78.1.52
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Heinisch G, 1997, ANTIVIR CHEM CHEMOTH, V8, P443, DOI 10.1177/095632029700800507                                                      
   Hira SK, 1997, INT J STD AIDS, V8, P243, DOI 10.1258/0956462971919994
   HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64                                                           
   Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x
   Hsiou Y, 1998, J MOL BIOL, V284, P313, DOI 10.1006/jmbi.1998.2171
   KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403
   KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477                                                          
   Mai A, 1997, J MED CHEM, V40, P1447, DOI 10.1021/jm960802y
   MANN J, 1995, INFECT DIS CLIN N AM, P275
   MCGROARTY JA, 1990, CURR MICROBIOL, V21, P219, DOI 10.1007/BF02092159
   MITSUYA H, 1990, SCIENCE, V249, P1533, DOI 10.1126/science.1699273
   Narla RK, 1998, CLIN CANCER RES, V4, P1405
   NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010
   OSBORN JE, 1991, SEX INFORMATION ED C, V19, P1
   PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0
   PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001
   Pontikis R, 1997, J MED CHEM, V40, P1845, DOI 10.1021/jm960765a
   Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541                                                                  
   REKART ML, 1992, J ACQ IMMUN DEF SYND, V5, P425
   REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293
   REN JS, 1995, STRUCTURE, V3, P915, DOI 10.1016/S0969-2126(01)00226-X
   RODDY RE, 1993, INT J STD AIDS, V4, P165, DOI 10.1177/095646249300400308                                                      
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   ROMERO DL, 1993, J MED CHEM, V36, P1505, DOI 10.1021/jm00062a027
   Rosenstein IJ, 1998, J INFECT DIS, V177, P1386, DOI 10.1086/517820                                                                  
   SCHILL WB, 1981, ANDROLOGIA, V13, P42
   SMERDON SJ, 1994, P NATL ACAD SCI USA, V91, P3911, DOI 10.1073/pnas.91.9.3911
   Stafford MK, 1998, J ACQ IMMUN DEF SYND, V17, P327, DOI 10.1097/00042560-199804010-00006                                                
   TANAKA H, 1991, J MED CHEM, V34, P349, DOI 10.1021/jm00105a055
   TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665                                                          
   TRYPHONAS L, 1984, TOXICOL LETT, V20, P289, DOI 10.1016/0378-4274(84)90162-0
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Vig R, 1998, BIOORG MED CHEM LETT, V8, P1461, DOI 10.1016/S0960-894X(98)00250-9
   Vig R, 1998, BIOORGAN MED CHEM, V6, P1789, DOI 10.1016/S0968-0896(98)00108-4
   WEIR SS, 1995, GENITOURIN MED, V71, P78
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   WILBORN WH, 1983, FERTIL STERIL, V39, P717
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
   1980, FED REG, V45, P82014
NR 62
TC 36
Z9 37
U1 0
U2 0
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1603 MONROE ST, MADISON, WI 53711-2021 USA
SN 0006-3363
J9 BIOL REPROD
JI Biol. Reprod.
PD JUN
PY 1999
VL 60
IS 6
BP 1419
EP 1428
DI 10.1095/biolreprod60.6.1419                                             
          
PG 10
WC Reproductive Biology
SC Reproductive Biology
GA 198YN
UT WOS:000080452300022
PM 10330101
OA gold
DA 2018-01-05
ER

PT J
AU Tossi, A
   Antcheva, N
   Benedetti, F
   Norbedo, S
   Miertus, S
   Romeo, D
AF Tossi, A
   Antcheva, N
   Benedetti, F
   Norbedo, S
   Miertus, S
   Romeo, D
TI Flexible synthesis of symmetric and nonsymmetric HIV-1 protease
   inhibitors based on all-S-diaminodiol isosteres
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
ID STEREOCONTROLLED SYNTHESIS; ASPARTIC PROTEASE; DIOLS; HOE/BAY-793;
   ALCOHOLS; DESIGN
AB C-2 symmetric and non-Symmetric pseudopeptide inhibitors of HIV-1 protease, containing a S,S,S,S-diaminodiol isostere have been obtained by a synthetic strategy designed to couple a high degree of stereochemical control with complete flexibility in the choice of residues in the central core and flanking chains. Using this approach, inhibitors with IC50 values in the low nanomolar range were assembled From readily available aminoacids and carboxylic acids, chosen with the aid of molecular modelling.
C1 Univ Trieste, Dept Biochem Biophys & Macromol Chem, I-34127 Trieste, Italy.
   Univ Trieste, Dept Chem Sci, I-34127 Trieste, Italy.
   UNIDO, Int Ctr Sci & High Technol, I-34012 Trieste, Italy.
RI Benedetti, Fabio/G-4787-2012
OI Benedetti, Fabio/0000-0002-8773-7413; Tossi,
   Alessandro/0000-0001-9087-5764; Miertus, Stanislav/0000-0001-6766-4571
CR Babine RE, 1997, CHEM REV, V97, P1359, DOI 10.1021/cr960370z                                                               
   Benedetti F, 1998, TETRAHEDRON LETT, V39, P7971, DOI 10.1016/S0040-4039(98)01733-X                                                   
   Benedetti F, 1997, J ORG CHEM, V62, P9348, DOI 10.1021/jo971202p                                                               
   BUDT KH, 1995, BIOORGAN MED CHEM, V3, P559, DOI 10.1016/0968-0896(95)00069-S
   CHENERA B, 1991, BIOORG MED CHEM LETT, V1, P219, DOI 10.1016/S0960-894X(00)80256-5
   GHOSH AK, 1991, TETRAHEDRON LETT, V32, P5729
   Gurjar MK, 1997, TETRAHEDRON, V53, P4769, DOI 10.1016/S0040-4020(97)00160-9                                                   
   KANG SH, 1996, J CHEM SOC CHEM COMM, P355
   KEMPF DJ, 1992, J ORG CHEM, V57, P5692, DOI 10.1021/jo00047a023                                                             
   KONRADI AW, 1992, J ORG CHEM, V57, P28, DOI 10.1021/jo00027a009                                                             
   LangeSavage G, 1997, EUR J BIOCHEM, V248, P313, DOI 10.1111/j.1432-1033.1997.00313.x
   MASCHERA B, 1995, J VIROL, V69, P5431
   Miertus S, 1996, CHEM PHYS, V204, P173, DOI 10.1016/0301-0104(95)00363-0                                                    
   Mitin YV, 1996, INT J PEPT PROT RES, V48, P374
   Tossi A, 1995, PEPTIDE RES, V8, P328
NR 15
TC 7
Z9 7
U1 0
U2 0
PU BENTHAM SCIENCE PUBL BV
PI HILVERSUM
PA PO BOX 1673, 1200 BR HILVERSUM, NETHERLANDS
SN 0929-8665
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PD JUN
PY 1999
VL 6
IS 3
BP 145
EP 148
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 213ZQ
UT WOS:000081303500005
DA 2018-01-05
ER

PT J
AU Baba, M
   Nishimura, O
   Kanzaki, N
   Okamoto, M
   Sawada, H
   Iizawa, Y
   Shiraishi, M
   Aramaki, Y
   Okonogi, K
   Ogawa, Y
   Meguro, K
   Fujino, M
AF Baba, M
   Nishimura, O
   Kanzaki, N
   Okamoto, M
   Sawada, H
   Iizawa, Y
   Shiraishi, M
   Aramaki, Y
   Okonogi, K
   Ogawa, Y
   Meguro, K
   Fujino, M
TI A small-molecule, nonpeptide CCR5 antagonist with highly potent and
   selective anti-HIV-1 activity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CHEMOKINE RECEPTORS CCR3; HIV-1 INFECTION;
   BIOLOGICAL PHENOTYPE; DISEASE PROGRESSION; CORECEPTOR USAGE; CELL-LINE;
   TYPE-1; RANTES; INHIBITION
AB The beta-chemokine receptor CCR5 is considered to be an attractive target for inhibition of macrophage-tropic (CCR5-using or R5) HIV-1 replication because individuals having a nonfunctional receptor (a homozygous 32-bp deletion in the CCR5 coding region) are apparently normal but resistant to infection with R5 HIV-1. In this study, we found that TAK-779, a nonpeptide compound with a small molecular weight (M-r 531.13), antagonized the binding of RANTES (regulated on activation, normal T cell expressed and secreted) to CCR5-expressing Chinese hamster ovary cells and blocked CCR5-mediated Ca2+ signaling at nanomolar concentrations. The inhibition of beta-chemokine receptors by TAK-779 appeared to be specific to CCR5 because the compound antagonized CCR2b to a lesser extent but did not affect CCR1, CCR3, or CCR4. Consequently, TAK-779 displayed highly potent and selective inhibition of R5 HIV-I replication without showing any cytotoxicity to the host cells. The compound inhibited the replication of R5 HIV-1 clinical isolates as well as a laboratory strain at a concentration of 1.6-3.7 nM in peripheral blood mononuclear cells, though it was totally inactive against T-cell line-tropic (CXCR4-using or X4) HIV-1.
C1 Kagoshima Univ, Div Human Retroviruses, Ctr Chron Viral Dis, Fac Med, Kagoshima 8908520, Japan.
   Takeda Chem Ind Ltd, Div Pharmaceut Res, Osaka 5328686, Japan.
RP Baba, M (reprint author), Kagoshima Univ, Div Human Retroviruses, Ctr Chron Viral Dis, Fac Med, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
RI Baba, Masanori/G-3867-2011
CR Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955
   BABA M, 1991, P NATL ACAD SCI USA, V88, P2356, DOI 10.1073/pnas.88.6.2356
   Bjorndal A, 1997, J VIROL, V71, P7478
   Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78                                                           
   Chackerian B, 1997, J VIROL, V71, P3932
   CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
   Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6
   COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811
   Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621                                                           
   Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145
   Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0
   Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072                                                              
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8                                                   
   Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0
   Ghorpade A, 1998, J VIROL, V72, P3351
   Havlir DV, 1996, ANN INTERN MED, V124, P984, DOI 10.7326/0003-4819-124-11-199606010-00006
   He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0
   Hesselgesser J, 1998, J IMMUNOL, V160, P877
   KIMPTON J, 1992, J VIROL, V66, P2232
   Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706                                                     
   Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215
   Miyoshi I., 1982, GANN MONOGR, V28, P219
   PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6
   Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599                                                          
   Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161                                                        
   RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968                                                        
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g
   Scarlatti G, 1997, NAT MED, V3, P1259, DOI 10.1038/nm1197-1259                                                             
   Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383
   Schols D, 1998, J VIROL, V72, P4032
   SCHUITEMAKER H, 1992, J VIROL, V66, P1354
   Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276
   Wu LJ, 1997, J EXP MED, V186, P1373, DOI 10.1084/jem.186.8.1373                                                          
NR 35
TC 638
Z9 658
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 11
PY 1999
VL 96
IS 10
BP 5698
EP 5703
DI 10.1073/pnas.96.10.5698                                                 
          
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 195JG
UT WOS:000080246500069
PM 10318947
OA gold
DA 2018-01-05
ER

PT J
AU Schramm, HJ
   de Rosny, E
   Reboud-Ravaux, M
   Buttner, J
   Dick, A
   Schramm, W
AF Schramm, HJ
   de Rosny, E
   Reboud-Ravaux, M
   Buttner, J
   Dick, A
   Schramm, W
TI Lipopeptides as dimerization inhibitors of HIV-1 protease
SO BIOLOGICAL CHEMISTRY
LA English
DT Article
DE AIDS; dimerization inhibitors; HIV-1 protease; lipopeptides; modified
   peptides
ID PROTEINASE-INHIBITOR; INTERFACE PEPTIDES; DESIGN
AB In AIDS therapy, attempts have been made to inhibit the virus-encoded enzymes, e.g, HIV-1 protease, using active site-directed inhibitors. This approach is questionable, however, due to virus mutations and the high toxicity of the drugs, An alternative method to inhibit the dimeric HIV protease is the targeting of the interface region of the protease subunits in order to prevent subunit dimerization and enzyme activity, This approach should be less prone to inactivation by mutation, A list of improved 'dimerization inhibitors' of HIV-1 protease is presented. The main structural features are a short 'interface' peptide segment, including non-natural amino acids, and an aliphatic N-terminal blocking group. The high inhibitory power of some of the lipopeptides [e.g, palmitoyl-Tyr-Glu-Leu-OH, palmitoyl-Tyr-Glu-(L-thyronine)-OH, palmitoyl-Tyr-Glu-(L-biphenyl-alanine)-OH] with low nanomolar K-i values in the enzyme test suggests that mimetics with good bio-availability can be derived for AIDS therapy.
C1 Max Planck Inst Biochem, D-82152 Martinsried, Germany.
   Univ Paris 06, Inst Jacques Monod, F-75251 Paris, France.
   Univ Paris 07, Inst Jacques Monod, F-75251 Paris, France.
   Univ Munich, Univ Klinikum Innenstadt, D-80336 Munich, Germany.
RP Schramm, HJ (reprint author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.
CR BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003                                                          
   BILLICH A, 1990, BIOL CHEM H-S, V371, P265, DOI 10.1515/bchm3.1990.371.1.265
   Bouras A, 1999, J MED CHEM, V42, P957, DOI 10.1021/jm9803976                                                               
   Fan XD, 1998, J AM CHEM SOC, V120, P8893, DOI 10.1021/ja981306x                                                               
   Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808                                                     
   FRANCISKOVICH J, 1993, BIOORG MED CHEM LETT, V3, P765, DOI 10.1016/S0960-894X(01)81271-3
   Klimkait Thomas, 1996, Antiviral Research, V30, pA33
   MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161
   RICHARDS AD, 1990, J BIOL CHEM, V265, P7733
   SCHRAMM HJ, 1991, BIOCHEM BIOPH RES CO, V179, P847, DOI 10.1016/0006-291X(91)91895-J
   Schramm HJ, 1996, ANTIVIR RES, V30, P155, DOI 10.1016/0166-3542(96)00940-0                                                    
   SCHULZE AJ, 1992, BIOCHEMISTRY-US, V31, P7560, DOI 10.1021/bi00148a017
   Uhlikova T, 1996, BIOCHEM BIOPH RES CO, V222, P38, DOI 10.1006/bbrc.1996.0694
   Wlodawer A, 1998, ANNU REV BIOPH BIOM, V27, P249, DOI 10.1146/annurev.biophys.27.1.249                                                
   ZHANG ZY, 1991, J BIOL CHEM, V266, P15591
   Zutshi R, 1997, J AM CHEM SOC, V119, P4841, DOI 10.1021/ja962496j                                                               
   Zutshi R, 1998, CURR OPIN CHEM BIOL, V2, P62, DOI 10.1016/S1367-5931(98)80036-7                                                   
NR 17
TC 50
Z9 51
U1 0
U2 2
PU WALTER DE GRUYTER & CO
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1431-6730
J9 BIOL CHEM
JI Biol. Chem.
PD MAY
PY 1999
VL 380
IS 5
BP 593
EP 596
DI 10.1515/BC.1999.076
PG 4
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 202FJ
UT WOS:000080641200011
PM 10384967
DA 2018-01-05
ER

PT J
AU D'Cruz, OJ
   Shih, MJ
   Yiv, SH
   Chen, CL
   Uckun, FM
AF D'Cruz, OJ
   Shih, MJ
   Yiv, SH
   Chen, CL
   Uckun, FM
TI Synthesis, characterization and preclinical formulation of a dual-action
   phenyl phosphate derivative of bromo-methoxy zidovudine (compound
   WHI-07) with potent anti-HIV and spermicidal activities
SO MOLECULAR HUMAN REPRODUCTION
LA English
DT Article; Proceedings Paper
CT XVI World Congress on Fertility and Sterility / 54th Annual Meeting of
   the American-Society-for-Reproductive-Medicine
CY OCT 03-09, 1998
CL SAN FRANCISCO, CALIFORNIA
SP Amer Soc Reprod Med, Int Federat Fertil & Steril
DE contraceptives; HIV; microbicide; spermicide; ZDV
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; VAGINAL
   MICROBICIDE; NONOXYNOL-9 USE; CONTRACEPTIVE SPONGE; ANTIVIRAL PROTEIN;
   TRANSMISSION; INFECTION; 3'-AZIDO-3'-DEOXYTHYMIDINE; DIASTEREOMERS
AB In a systematic effort to develop a microbicide contraceptive capable of preventing transmission of human immunodeficiency virus (HIV), as well as providing fertility control, we have previously identified novel phenyl phosphate derivatives of zidovudine (ZDV) with 5-halo 6-alkoxy substitutions in the thymine ring and halo substitution in the phenyl moiety respectively. Here, we describe the synthesis, characterization, and successful preclinical formulation of our lead compound, 5-bromo-6-methoxy-3'-azidothymidine-5'-(p-bromophenyl) methoxyalaninyl phosphate (WHI-07), which exhibits potent anti-HIV and sperm immobilizing activities. The anti-HIV activity of WHI-07 was tested by measuring viral p24 antigen production and reverse transcriptase activity as markers of viral replication in HIV-1 infected human peripheral blood mononuclear cells (PBMC). WHI-07 inhibited replication of HIV in a concentration-dependent fashion with nanomolar IC50 values. The effects of WHI-07 on human sperm motion kinematics were analysed by computer-assisted sperm analysis (CASA), and its effects on sperm membrane integrity were examined by confocal laser scanning microscopy (CLSM), and high-resolution low-voltage scanning electron microscopy (HR-LVSEM). WHI-07 caused cessation of sperm motility in a concentration- and time-dependent fashion, The in-vitro cytotoxicities of WHI-07 and nonoxynol-9 (N-9) were compared using normal human ectocervical and endocervical epithelial cells by the MTT cell viability assay. Unlike N-9, WHI-07 had no effect upon sperm plasma and acrosomal membrane integrity. N-9 was cytotoxic to normal human ectocervical and endocervical cells at spermicidal doses, whereas WHI-07 was selectively spermicidal. The in-vivo vaginal absorption and vaginal toxicity of 2% gel-microemulsion of WHI-07 was studied in the rabbit model. The sperm immobilizing activity of WHI-07 was 18-fold more potent than that of N-9. Over a 10 day period, there was no irritation or local toxicity to the vaginal epithelia or systemic absorption of WHI-07. Therefore, as a potent anti-HIV agent with spermicidal activity, and lack of mucosal toxicity, WHI-07 may have the clinical potential to become the active ingredient of a vaginal contraceptive for women who are at high risk for acquiring HIV by heterosexual vaginal transmission.
C1 Hughes Inst, Drug Discovery Program, St Paul, MN 55113 USA.
   Hughes Inst, Dept Reprod Biol, St Paul, MN 55113 USA.
   Hughes Inst, Dept Chem, St Paul, MN 55113 USA.
   Hughes Inst, Dept Pharmacol, St Paul, MN 55113 USA.
   Hughes Inst, Dept Virol, St Paul, MN 55113 USA.
RP Uckun, FM (reprint author), Hughes Inst, Drug Discovery Program, 2665 Long Lake Rd,Suite 330, St Paul, MN 55113 USA.
CR AUGENBRAUN MH, 1994, INFECT DIS CLIN N AM, V8, P439
   BIRD KD, 1991, AIDS, V55, P791
   CELUM CL, 1996, HIV MANUAL, P120
   CHANTLER E, 1992, BRIT J FAMIL PLANNIN, V17, P118
   COOKSON C, 1993, BRIT MED J, V307, P1375
   D'Cruz OJ, 1998, BIOL REPROD, V58, P1515, DOI 10.1095/biolreprod58.6.1515                                                     
   D'Cruz OJ, 1998, BIOL REPROD, V59, P503, DOI 10.1095/biolreprod59.3.503                                                      
   DCruz OJ, 1996, BIOL REPROD, V54, P1217, DOI 10.1095/biolreprod54.6.1217                                                     
   DCRUZ OJ, 1998, ADV REPROD, V1, P101
   Eccleston GM, 1992, ENCY PHARM TECHNOLOG, V9, P375
   ECKSTEIN P, 1969, J REPROD FERTIL, V20, P85
   Elias CJ, 1997, CONTRACEPTION, V56, P387, DOI 10.1016/S0010-7824(97)00176-5
   Elias CJ, 1996, AIDS, V10, pS43
   ERLANDSEN SL, 1989, SCANNING, V11, P169, DOI 10.1002/sca.4950110403                                                          
   FELDBLUM PJ, 1988, JAMA-J AM MED ASSOC, V259, P2851
   FELDBLUM PJ, 1988, AM J PUBLIC HEALTH, V78, P52, DOI 10.2105/AJPH.78.1.52
   HICKS DR, 1985, LANCET, V2, P1422
   Hira SK, 1997, INT J STD AIDS, V8, P243, DOI 10.1258/0956462971919994
   HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710                                                     
   KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477                                                          
   KUMAR R, 1994, J MED CHEM, V37, P4297, DOI 10.1021/jm00051a006
   LINDSAY MK, 1996, ADV OBS GYN, V3, P3
   MAKULOWICH GS, 1997, AIDS PATIENT CARE ST, V11, P200
   MANN J, 1995, INFECT DIS CLIN N AM, P275
   MARTINDALE, 1996, ROYAL PHARM SOC GREA, P1216
   MCCLURE M O, 1991, Antiviral Chemistry and Chemotherapy, V2, P149
   MCGUIGAN C, 1993, J MED CHEM, V36, P1048, DOI 10.1021/jm00060a013
   MCGUIGAN C, 1993, BIOORG MED CHEM LETT, V3, P1207, DOI 10.1016/S0960-894X(00)80316-9
   MILLER CJ, 1995, 9 INT C ANT RES SANT
   MITSUYA H, 1987, NATURE, V325, P773, DOI 10.1038/325773a0
   NIRUTHISARD S, 1991, SEX TRANSM DIS, V18, P176, DOI 10.1097/00007435-199107000-00010
   OSBORN JE, 1991, SEX INFORMATION ED C, V19, P1
   PearcePratt R, 1996, BIOL REPROD, V54, P173, DOI 10.1095/biolreprod54.1.173
   Phillips David M., 1994, Trends in Microbiology, V2, P454, DOI 10.1016/0966-842X(94)90804-4
   PHILLIPS DM, 1994, AIDS, V8, P719, DOI 10.1097/00002030-199406000-00001
   POLSKY B, 1988, LANCET, V1, P1456
   POTTS M, 1994, AM J PUBLIC HEALTH, V84, P890, DOI 10.2105/AJPH.84.6.890                                                           
   Quayle AJ, 1997, J INFECT DIS, V176, P960, DOI 10.1086/516541                                                                  
   REKART ML, 1992, J ACQ IMMUN DEF SYND, V5, P425
   RITSCHEL WA, 1993, METHOD FIND EXP CLIN, V13, P205
   RODDY RE, 1993, INT J STD AIDS, V4, P165, DOI 10.1177/095646249300400308                                                      
   Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803
   Rosenstein IJ, 1998, J INFECT DIS, V177, P1386, DOI 10.1086/517820                                                                  
   Rowe PM, 1997, LANCET, V349, P1074, DOI 10.1016/S0140-6736(05)62299-4
   Sander F. V., 1941, HUM FERTIL, V6, P134
   SCHILL WB, 1981, ANDROLOGIA, V13, P42
   Silver J, 1997, AIDS PATIENT CARE ST, V11, P367, DOI 10.1089/apc.1997.11.367                                                         
   Stafford MK, 1997, J ACQ IMMUN DEF SYND, V14, P213, DOI 10.1097/00042560-199703010-00003                                                
   Stafford MK, 1998, J ACQ IMMUN DEF SYND, V17, P327, DOI 10.1097/00042560-199804010-00006                                                
   Steinbrook LD, 1997, NEW ENGL J MED, V337, P779
   TRUSSELL J, 1987, STUD FAMILY PLANN, V18, P237, DOI 10.2307/1966856                                                                 
   TRYPHONAS L, 1984, TOXICOL LETT, V20, P289, DOI 10.1016/0378-4274(84)90162-0
   Uckun FM, 1998, CLIN CANCER RES, V4, P901
   Uckun FM, 1998, ANTIMICROB AGENTS CH, V42, P383
   Vig R, 1998, ANTIVIR CHEM CHEMOTH, V9, P439
   Vig R, 1998, ANTIVIR CHEM CHEMOTH, V9, P445
   Wang LL, 1996, J MED CHEM, V39, P826, DOI 10.1021/jm9408326
   WEIR SS, 1995, GENITOURIN MED, V71, P78
   WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571                                                         
   YANAGIMACHI R, 1988, PHYSL REPRODUCTION, V1, P135
   ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0
   1980, FED REG, V45, P84014
NR 62
TC 41
Z9 41
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1360-9947
J9 MOL HUM REPROD
JI Mol. Hum. Reprod.
PD MAY
PY 1999
VL 5
IS 5
BP 421
EP 432
DI 10.1093/molehr/5.5.421                                                  
          
PG 12
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA 193FJ
UT WOS:000080125000006
PM 10338365
OA gold
DA 2018-01-05
ER

PT J
AU Bencheikh, M
   Bentsman, G
   Sarkissian, N
   Canki, M
   Volsky, DJ
AF Bencheikh, M
   Bentsman, G
   Sarkissian, N
   Canki, M
   Volsky, DJ
TI Replication of different clones of human immunodeficiency virus type 1
   in primary fetal human astroyctes: enhancement of viral gene expression
   by Nef
SO JOURNAL OF NEUROVIROLOGY
LA English
DT Article
DE HIV-1 tropism; DNA transfection; neuropathogenesis; AIDS
ID HUMAN GLIAL-CELLS; INFECTIOUS MOLECULAR CLONES; HIGHLY CYTOPATHIC
   STRAIN; CENTRAL-NERVOUS-SYSTEM; AIDS DEMENTIA COMPLEX; HIV-1 INFECTION;
   NEURAL CELLS; HUMAN-BRAIN; PRODUCTIVE INFECTION; NUCLEOTIDE-SEQUENCE
AB Dementia is a common complication of AIDS which is associated with human immunodeficiency virus type 1 (HIV-1) infection of brain macrophages and microglia. Recent studies have shown that astrocytes are also infected in the brain but HIV-1 replication in these cells is restricted. To determine Virus specificity of this restriction we tested the expression of 15 HIV-1 molecular clones in primary human fetal astrocytes by infection and DNA transfection. Infection with cell-free viruses was poorly productive and revealed no clone-specific differences. In contrast, transfected cells produced transiently high levels of HIV-1 p24 core antigen, up to 50 nanograms per mi culture supernatant, and nanogram levels of p24 were detected 3-4 weeks after transfection of some viral clones. The average peak expression of HIV-1 in astrocytes varied as a function of viral clone used by a factor of 15 but the differences and the subsequent virus spread did not correlate with the tropism of the viral clones to T cells or macrophages. Functional vif, vpu, and vpr genes were dispensable for virus replication from transfected DNA, but intact nef provided a detectable enhancement of early viral gene expression and promoted maintenance of HIV-1 infection. We conclude that primary astrocytes present no fundamental barriers to moderate expression of different strains of HIV-1 and that the presence of functional Nef is advantageous to virus infection in these cells.
C1 Columbia Univ, St Lukes Roosevelt Hosp Ctr, Mol Virol Lab, New York, NY USA.
RP Volsky, DJ (reprint author), Columbia Univ, St Lukes Roosevelt Hosp Ctr, Mol Virol Lab, New York, NY USA.
FU NINDS NIH HHS [P01-NS-31492, P01 NS031492]
CR ADACHI A, 1986, J VIROL, V59, P284
   Ausubel FM, 1989, CURRENT PROTOCOLS MO
   BAGASRA O, 1992, J VIROL, V66, P7522
   BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494
   Canki M, 1997, J NEUROVIROL, V3, P10, DOI 10.3109/13550289709015788                                                       
   CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526
   CHESEBRO B, 1990, J VIROL, V64, P215
   CHIODI F, 1987, J VIROL, V61, P1244
   Chowdhury IH, 1996, J VIROL, V70, P5336
   CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0
   Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929
   COLLMAN R, 1992, J VIROL, V66, P7517
   CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016                                                          
   DEWHURST S, 1987, J VIROL, V61, P3774
   GABUZDA DH, 1994, J ACQ IMMUN DEF SYND, V7, P908
   GENDELMAN HE, 1988, J EXP MED, V167, P1428, DOI 10.1084/jem.167.4.1428
   HAROUSE JM, 1989, J VIROL, V63, P2527
   HATCH WC, 1994, AIDS RES HUM RETROV, V10, P1597, DOI 10.1089/aid.1994.10.1597                                                        
   He JL, 1997, P NATL ACAD SCI USA, V94, P3954, DOI 10.1073/pnas.94.8.3954
   He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0
   KUNSCH C, 1989, VIROLOGY, V171, P715
   LI YX, 1991, J VIROL, V65, P3973
   Lipton S, 1995, NEW ENGL J MED, V233, P934
   Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4
   MIZRACHI Y, 1991, B I PASTEUR, V89, P81
   NATH A, 1995, J NEUROPATH EXP NEUR, V54, P320, DOI 10.1097/00005072-199505000-00005
   NEUMANN M, 1995, J VIROL, V69, P2159
   NUSSBAUM O, 1994, J VIROL, V68, P5411
   PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272
   RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004                                                
   SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474                                                     
   SAKAI K, 1991, J VIROL, V65, P5765
   SAKAI K, 1988, J VIROL, V62, P4078
   SHAHABUDDIN M, 1992, PATHOBIOLOGY, V60, P195, DOI 10.1159/000163723
   Shahabuddin M, 1996, J VIROL, V70, P7992
   SHARER LR, 1992, J NEUROPATH EXP NEUR, V51, P3, DOI 10.1097/00005072-199201000-00002
   SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449                                                         
   SIMM M, 1995, J VIROL, V69, P4582
   Sova P, 1997, BIOCHEM BIOPH RES CO, V240, P257, DOI 10.1006/bbrc.1997.7518                                                          
   SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1
   SRINIVASAN A, 1988, ARCH VIROL, V99, P135, DOI 10.1007/BF01311031                                                              
   SRINIVASAN A, 1987, GENE, V52, P71, DOI 10.1016/0378-1119(87)90396-9                                                    
   STOLER MH, 1986, JAMA-J AM MED ASSOC, V256, P2360, DOI 10.1001/jama.256.17.2360
   Takahashi K, 1996, ANN NEUROL, V39, P705, DOI 10.1002/ana.410390606
   TILLMANN M, 1994, ADV NEUROIMMUNOL, V4, P305, DOI 10.1016/S0960-5428(06)80271-8                                                   
   TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481                                                     
   TORNATORE C, 1994, J VIROL, V68, P93
   TORNATORE C, 1991, J VIROL, V65, P6094
   TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2                                                    
   VOLSKY B, 1992, VIROLOGY, V186, P303, DOI 10.1016/0042-6822(92)90086-5
   VOLSKY DJ, 1992, MOL NEUROVIROLOGY
   VONSCHWEDLER U, 1993, J VIROL, V67, P4945
   WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097
NR 53
TC 39
Z9 39
U1 0
U2 0
PU STOCKTON PRESS
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 1355-0284
J9 J NEUROVIROL
JI J. Neurovirol.
PD APR
PY 1999
VL 5
IS 2
BP 115
EP 124
DI 10.3109/13550289909021993
PG 10
WC Neurosciences; Virology
SC Neurosciences & Neurology; Virology
GA 188FH
UT WOS:000079835800001
PM 10321975
DA 2018-01-05
ER

PT J
AU Sanchez-Alavez, M
   Navarro, L
   Diaz-Ruiz, O
   Galicia-Castillo, O
   Sanchez-Narvaez, F
   Murillo-Rodriguez, E
   Gomez-Chavarin, M
   Rivero-Palomero, M
   Prospero-Garcia, O
AF Sanchez-Alavez, M
   Navarro, L
   Diaz-Ruiz, O
   Galicia-Castillo, O
   Sanchez-Narvaez, F
   Murillo-Rodriguez, E
   Gomez-Chavarin, M
   Rivero-Palomero, M
   Prospero-Garcia, O
TI Molecular aspects of dementia associated with AIDS.
SO SALUD MENTAL
LA Spanish
DT Article
DE HIV; gp120; citokines; animal model; glutamate
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CENTRAL-NERVOUS-SYSTEM; SUPPRESSING HIV
   REPLICATION; IMMUNE-DEFICIENCY SYNDROME; CHEMOKINE RECEPTOR GENE; COAT
   PROTEIN GP120; TRANSGENIC MICE; ENVELOPE GLYCOPROTEIN; BETA-CHEMOKINES;
   NEURONAL INJURY
AB A variety of neuropsychiatric disorders have been described in 20 to 30 % of the patients suffering of acquired immunodeficiency syndrome (AIDS). Due to the fact that neurons are not directly infected with the human immunodeficiency virus (HIV), the pathophysiological manifestations of the AIDS-related dementia complex (ADC) could be mediated through indirect mechanisms. The envelope glycoprotein 120 (gp120) derived from HIV seems to play an important role in the development of ADC. A number of experiments have shown that a nanomolar concentration of gp120 derived from HIV produces neuronal dead in vivo, and picomolar concentration kills neurons in vitro. Recent data suggest that in order to induce neuronal damage the citokines and CD4+ receptor play an important role in the activation of intracellular events that lead to an increase of intracellular Ca++ through the NMDA receptors, consequently triggering intracellular events and apoptosis. Understanding the mechanism causing neuronal damage at molecular and behavioral level, very likely will provide clues for treatment and prevention of this clinical entity. In this review we include the development of animal models which are useful to study the mechanisms of AIDS related dementia complex.
C1 Univ Nacl Autonoma Mexico, Fac Med, Dept Fisiol, Grp Neurociencias, Mexico City 04510, DF, Mexico.
RP Prospero-Garcia, O (reprint author), Univ Nacl Autonoma Mexico, Fac Med, Dept Fisiol, Grp Neurociencias, Apdo Postal 70-250, Mexico City 04510, DF, Mexico.
RI Navarro, Luz/A-4983-2013; Diaz-Ruiz, Oscar/F-3162-2010
OI Sanchez-Alavez, Manuel/0000-0002-8164-8452
CR ATKINSON JH, 1988, ARCH GEN PSYCHIAT, V45, P859
   Bagetta G, 1998, BIOCHEM BIOPH RES CO, V244, P819, DOI 10.1006/bbrc.1998.8321                                                          
   Balter M, 1996, SCIENCE, V272, P1740, DOI 10.1126/science.272.5269.1740                                                   
   BALTIMORE D, 1989, NEW ENGL J MED, V132, P1673
   BELMAN AL, 1988, AM J DIS CHILD, V142, P29, DOI 10.1001/archpedi.1988.02150010039017                                            
   Bencherif B, 1998, AIDS, V12, P233
   BENOS DJ, 1994, J BIOL CHEM, V269, P13811
   Benveniste EN, 1995, FASEB J, V9, P1577
   BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0
   Cho MW, 1998, J VIROL, V72, P2509
   CHRYSIKOPOULOS HS, 1990, RADIOLOGY, V175, P185, DOI 10.1148/radiology.175.1.2315479                                                 
   Clapham PR, 1997, TRENDS CELL BIOL, V7, P264, DOI 10.1016/S0962-8924(97)01075-1                                                   
   Cocchi F, 1996, SCIENCE, V274, P1394, DOI 10.1126/science.274.5291.1394                                                   
   Darko DF, 1996, SRS B, V2, P43
   Demaria S, 1996, AIDS RES HUM RETROV, V12, P281, DOI 10.1089/aid.1996.12.281
   DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013
   DiStefano M, 1996, AIDS RES HUM RETROV, V12, P471, DOI 10.1089/aid.1996.12.471
   Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8                                                   
   EPSTEIN LG, 1988, ANN NEUROL S, V23, P519
   EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2
   Farnarier G, 1990, Electroencephalogr Clin Neurophysiol Suppl, V41, P355
   FOUCHIER RAM, 1992, J VIROL, V66, P3183
   GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389
   GLOWA JR, 1992, BRAIN RES, V570, P49, DOI 10.1016/0006-8993(92)90562-N
   GRANT I, 1987, ANN INTERN MED, V107, P828, DOI 10.7326/0003-4819-107-6-828
   GREENE WC, 1991, NEW ENGL J MED, V324, P308
   Gurwitz D, 1998, MOL MED TODAY, V4, P196, DOI 10.1016/S1357-4310(98)01254-4
   Henriksen SJ, 1995, CURR TOP MICROBIOL, V202, P167
   HENRIKSEN SJ, 1995, CURRENT TOPICS MICRO, V202
   Hoffman T L, 1998, AIDS, V12 Suppl A, pS17
   ISHIDA T, 1989, J AM VET MED ASSOC, V194, P221
   JASSEN RS, 1989, NEUROLOGY, V39, P119
   JOHNSON RT, 1988, FASEB J, V2, P2970
   KAY DG, 1991, P NATL ACAD SCI USA, V88, P1281, DOI 10.1073/pnas.88.4.1281
   KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735
   KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228                                                              
   Krucker T, 1998, NEUROSCIENCE, V83, P691, DOI 10.1016/S0306-4522(97)00413-2
   Kubicki S, 1988, HIV NERVOUS SYSTEM, P97
   Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405
   LACKNER AA, 1991, AM J PATHOL, V139, P609
   LANG W, 1989, J ACQ IMMUN DEF SYND, V2, P63
   LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E
   LEVI G, 1993, P NATL ACAD SCI USA, V90, P1541, DOI 10.1073/pnas.90.4.1541
   Lipton SA, 1998, ANNU REV PHARMACOL, V38, P159, DOI 10.1146/annurev.pharmtox.38.1.159
   LIPTON SA, 1995, NEW ENGL J MED, V332, P934, DOI 10.1056/NEJM199504063321407                                                     
   LIPTON SA, 1991, ANN NEUROL, V30, P110, DOI 10.1002/ana.410300121
   Mackewicz CE, 1996, SCIENCE, V274, P1393, DOI 10.1126/science.274.5291.1393
   MAINI CL, 1990, NUCL MED COMMUN, V11, P639, DOI 10.1097/00006231-199009000-00007
   MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003
   MOELLER AA, 1991, J ACQ IMMUN DEF SYND, V4, P1000
   NAVIA BA, 1986, ANN NEUROL, V19, P525, DOI 10.1002/ana.410190603
   NORMAN SE, 1992, SLEEP, V15, P150, DOI 10.1093/sleep/15.2.150                                                          
   OPP MR, 1996, AM J PHYSIOL, V270, P12963
   OZTURK GE, 1987, J CLIN IMMUNOL, V7, P130, DOI 10.1007/BF00916007
   PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0
   Persons JB, 1995, IN SESSION-PSYCHOTH, V1, P1
   PHILLIPS TR, 1994, J GEN VIROL, V75, P979, DOI 10.1099/0022-1317-75-5-979
   PHILLIPS TR, 1996, J NEUROVIROL, V2, P338
   POWER C, 1994, J VIROL, V68, P4643
   POWER C, 1995, CAN J NEUROL SCI, V22, P92, DOI 10.1017/S0317167100040154                                                       
   PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272
   PRICE RW, 1994, HIV AIDS BRAIN
   PROSPEROGARCIA O, 1994, P NATL ACAD SCI USA, V91, P12947, DOI 10.1073/pnas.91.26.12947                                                        
   Pulliam L, 1997, LANCET, V349, P692, DOI 10.1016/S0140-6736(96)10178-1
   Pulliam L, 1996, AIDS, V10, P1495, DOI 10.1097/00002030-199611000-00006                                                
   Raport CJ, 1996, J LEUKOCYTE BIOL, V59, P18
   RATNER L, 1992, AIDS RES HUM RETROV, V8, P165, DOI 10.1089/aid.1992.8.165
   ROYAL W, 1991, NEUROLOGY, V41, P1905, DOI 10.1212/WNL.41.12.1905                                                          
   Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625
   Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0
   SEIHEAN D, 1993, NEUROLOGY, V43, P1492
   SMITH T, 1990, AIDS, V4, P589, DOI 10.1097/00002030-199006000-00017
   SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404
   STANLEY J, 1997, J NEUROVIROL, V3, P283
   THOMAS FP, 1994, J VIROL, V68, P7099
   TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0
   TSOUKAS CM, 1995, ROLE SURROGATE MARKE
   WARNER CG, 1993, SCI AM, V269, P100
   WESSELINGH SL, 1996, CYTOKINES CNS, P287
   WIEGAND M, 1991, ACTA NEUROL SCAND, V83, P141, DOI 10.1111/j.1600-0404.1991.tb04664.x                                              
   Wiley CA, 1998, BRAIN PATHOL, V8, P277
   WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613
   WOLKINSKY SM, 1989, ANN INTERN MED, V111, P961
   Yoshioka M, 1995, ADV NEUROIMMUNOL, V5, P335, DOI 10.1016/0960-5428(95)00012-Q
NR 84
TC 1
Z9 1
U1 0
U2 0
PU INST MEX PSIQUIATRIA
PI MEXICO CITY
PA CALZ MEXICO-XOCHIMILCO #101, MEXICO CITY 22 DF, MEXICO
SN 0185-3325
J9 SALUD MENT
JI Salud Ment.
PD APR
PY 1999
VL 22
IS 2
BP 49
EP 65
PG 17
WC Psychiatry
SC Psychiatry
GA 206RA
UT WOS:000080891800006
DA 2018-01-05
ER

PT J
AU Lebruska, LL
   Maher, LJ
AF Lebruska, LL
   Maher, LJ
TI Selection and characterization of an RNA decoy for transcription factor
   NF-kappa B
SO BIOCHEMISTRY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; LIGANDS; DNA;
   EXPRESSION; ACTIVATION; BINDING; CELLS; OLIGONUCLEOTIDES; PSEUDOKNOTS
AB Despite their chemical similarity, DNA and RNA sequences typically adopt very different structures within cells and are recognized by different proteins. However, a few interesting examples of proteins with dual specificity for DNA and RNA have previously been noted. These observations raise the possibility that RNA surrogates might be identified for many transcription factors that normally bind DNA. As an initial test of this novel concept, we used in vitro selection to isolate a small RNA aptamer that binds with nanomolar affinity to human transcription factor NF-kappa B, a key regulator of inflammation, HIV-1 gene expression, and apoptosis. Selected RNAs contain a 31-nucleotide core domain that was shown by mutation and deletion analyses to be necessary and sufficient for NF-kappa B binding. Neither DNA nor 2'-O-methyl RNA analogues of the aptamer bound NF-kappa B. The results of competition experiments demonstrate that binding of the RNA aptamer blocks the ability of NF-kappa B to bind duplex DNA. Expression of this aptamer structure within heterologous nuclear RNA transcripts may provide a new strategy to inhibit NF-kappa B function in vivo. Aptamers that inhibit transcription factors might be useful in a variety of applications.
C1 Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
RP Maher, LJ (reprint author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Guggenheim 16,200 1st St SW, Rochester, MN 55905 USA.
EM maher@mayo.edu
FU NIGMS NIH HHS [GM47814, GM54411, GM20070]
CR ABELSON JN, 1996, METHODS ENZYMOLOGY
   Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782                                                    
   BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444
   BINKLEY J, 1995, NUCLEIC ACIDS RES, V23, P3198, DOI 10.1093/nar/23.16.3198
   Burke DH, 1996, J MOL BIOL, V264, P650, DOI 10.1006/jmbi.1996.0667
   Chen FE, 1998, NATURE, V391, P410
   CHEN H, 1994, BIOCHEMISTRY-US, V33, P8746, DOI 10.1021/bi00195a016                                                             
   Coleman TA, 1997, PROTEIN EXPRES PURIF, V9, P40, DOI 10.1006/prep.1996.0670
   Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0
   ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0                                                                
   FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775                                                             
   GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581                                                        
   Gold L, 1997, P NATL ACAD SCI USA, V94, P59, DOI 10.1073/pnas.94.1.59
   HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901
   Huang Z, 1996, NUCLEIC ACIDS RES, V24, P4360, DOI 10.1093/nar/24.21.4360                                                          
   JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706
   JAEGER JA, 1990, METHOD ENZYMOL, V183, P281
   JUKER M, 1989, SCIENCE, V244, P48
   KITAJIMA I, 1992, SCIENCE, V258, P1972
   KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412                                                          
   Makarov SS, 1997, GENE THER, V4, P846, DOI 10.1038/sj.gt.3300461
   Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812
   Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894                                                              
   MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0
   NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0
   NIEUWLANDT D, 1995, BIOCHEMISTRY-US, V34, P5651, DOI 10.1021/bi00016a041
   PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R
   Rickwood D., 1982, GEL ELECTROPHORESIS
   RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0                                                                
   Sambrook J, 1989, MOL CLONING LAB MANU
   SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6
   Sharma HW, 1996, ANTICANCER RES, V16, P61
   Soukup GA, 1996, J MOL BIOL, V259, P216, DOI 10.1006/jmbi.1996.0314
   TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988                                                         
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723
   Yoo S, 1998, BIOCHEMISTRY-US, V37, P1336, DOI 10.1021/bi972100w
NR 38
TC 81
Z9 88
U1 0
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 9
PY 1999
VL 38
IS 10
BP 3168
EP 3174
DI 10.1021/bi982515x                                                       
          
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 175JE
UT WOS:000079089300036
PM 10074372
DA 2018-01-05
ER

EF